Unnamed: 0,nct_id,downcase_mesh_term,official_title,brief_title,all_conditions,study_first_submitted_date,primary_completion_date,completion_date,enrollment,observational_model,intervention_model,time_perspective,study_type,overall_status,study_phases,funded_bys,sponsors_name,investigators,intervention_types,location,minimum_age_num,maximum_age_num,category_age,category,sub_category,URL
0,NCT00001159,hypothyroidism,Evaluation of Patients With Thyroid Function Disorders,Evaluation of Patients With Thyroid Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,2500.0,Case-Only,,Retrospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00001159
1,NCT00001159,graves disease,Evaluation of Patients With Thyroid Function Disorders,Evaluation of Patients With Thyroid Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,2500.0,Case-Only,,Retrospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00001159
2,NCT00001159,goiter,Evaluation of Patients With Thyroid Function Disorders,Evaluation of Patients With Thyroid Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,2500.0,Case-Only,,Retrospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00001159
3,NCT00001159,hyperthyroidism,Evaluation of Patients With Thyroid Function Disorders,Evaluation of Patients With Thyroid Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,2500.0,Case-Only,,Retrospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00001159
4,NCT00001160,"adenocarcinoma, follicular",Studies on Thyroid Nodules and Thyroid Cancer,Studies on Tumors of the Thyroid,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,1999-11-03,,,2500.0,Case-Only,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00001160
5,NCT00001160,"thyroid cancer, papillary",Studies on Thyroid Nodules and Thyroid Cancer,Studies on Tumors of the Thyroid,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,1999-11-03,,,2500.0,Case-Only,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00001160
8,NCT00001242,pseudopseudohypoparathyroidism,Studies of States With Resistance to Vitamin D and Parathyroid Hormone,Studies of States With Resistance to Vitamin D and Parathyroid Hormone,Hypocalcemia|Osteomalacia|Pseudohypoparathyroidism|Pseudopseudohpoparathyroidism|Rickets,1999-11-03,,,3000.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,2.0,100.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00001242
9,NCT00001277,hyperparathyroidism,Studies of Hyperparathyroidism and Related Disorders,Studies of Elevated Parathyroid Activity,Hypercalcemia|Hyperparathyroidism|MEN1|Multiple Endocrine Neoplasia|Parathyroid Neoplasm,1999-11-03,2020-03-11,2020-12-23,1553.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,2.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00001277
10,NCT00001277,parathyroid neoplasms,Studies of Hyperparathyroidism and Related Disorders,Studies of Elevated Parathyroid Activity,Hypercalcemia|Hyperparathyroidism|MEN1|Multiple Endocrine Neoplasia|Parathyroid Neoplasm,1999-11-03,2020-03-11,2020-12-23,1553.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,2.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00001277
13,NCT00001304,hypoparathyroidism,Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34,Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34,Hypoparathyroidism,1999-11-03,2014-03-31,2014-04-30,27.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,17.0,69.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00001304
14,NCT00001394,parathyroid neoplasms,Use of Hypocalcemic Intraarterial Infusion Into the Thyroid/Parathyroid Bed to Localize Occult Parathyroid Adenomas,Using X-Ray Dye to Locate Hidden Parathyroid Tumors,Parathyroid Neoplasms,1999-11-03,,2005-07-31,150.0,,,,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00001394
16,NCT00001730,hypothyroidism,A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal,Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,Hypothyroidism|Thyroid Neoplasms,1999-11-03,,2000-04-30,20.0,,,,Interventional,Completed,Phase 4,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00001730
17,NCT00001730,thyroid neoplasms,A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal,Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,Hypothyroidism|Thyroid Neoplasms,1999-11-03,,2000-04-30,20.0,,,,Interventional,Completed,Phase 4,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00001730
18,NCT00004048,thyroid neoplasms,Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin,Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer,Head and Neck Cancer,1999-12-10,2002-05-31,2002-05-31,30.0,,,,Interventional,Completed,Phase 1/Phase 2,Garden State Cancer Center at the Center for Molecular Medicine and Immunology,Garden State Cancer Center at the Center for Molecular Medicine and Immunology,Garden State Cancer Center|St. Joseph's Hospital and Medical Center,Biological|Drug|Procedure|Procedure|Radiation|Radiation,United States,16.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00004048
21,NCT00004074,parathyroid neoplasms,A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00004074
22,NCT00004074,"adenocarcinoma, follicular",A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00004074
23,NCT00004074,"thyroid carcinoma, anaplastic",A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00004074
24,NCT00004074,"thyroid cancer, papillary",A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00004074
25,NCT00004089,thyroid neoplasms,A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer,Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer,Head and Neck Cancer,1999-12-10,2002-04-30,2002-04-30,,,,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"Robert H. Lurie Comprehensive Cancer Center, Northwestern University|University of Illinois at Chicago|University of Chicago Cancer Research Center",Biological|Drug|Drug|Drug|Procedure|Radiation,United States,15.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00004089
27,NCT00004340,hyperparathyroidism,,Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis,End Stage Renal Disease|Renal Osteodystrophy,1999-10-18,,,109.0,,,,Interventional,Completed,Phase 2,National Center for Research Resources (NCRR),"National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Los Angeles",University of California Los Angeles School of Medicine,Drug|Drug,United States,1.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004340
30,NCT00004351,hypoparathyroidism,,Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes,Angelman Syndrome|Chromosome Abnormalities|DiGeorge Syndrome|Prader-Willi Syndrome|Shprintzen Syndrome|Smith-Magenis Syndrome|Williams Syndrome,1999-10-18,,,20.0,,,,Observational,Completed,,Office of Rare Diseases (ORD),Baylor College of Medicine|National Institute of Neurological Disorders and Stroke (NINDS),Baylor College of Medicine,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004351
31,NCT00004361,hypoparathyroidism,,Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects,"Conotruncal Cardiac Defects|Heart Defects, Congenital|Hypoparathyroidism|Pulmonary Atresia|Pulmonary Valve Stenosis|Tetralogy of Fallot",1999-10-18,,,150.0,,,,Observational,Completed,,Office of Rare Diseases (ORD),Ann & Robert H Lurie Children's Hospital of Chicago|National Center for Research Resources (NCRR),,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004361
33,NCT00004660,goiter,Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Graves' Disease,2000-02-24,1998-01-31,1998-01-31,42.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic,Radiation|Radiation,United States,30.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00004660
34,NCT00004660,graves disease,Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Graves' Disease,2000-02-24,1998-01-31,1998-01-31,42.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic,Radiation|Radiation,United States,30.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00004660
35,NCT00004660,graves ophthalmopathy,Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Graves' Disease,2000-02-24,1998-01-31,1998-01-31,42.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic,Radiation|Radiation,United States,30.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00004660
36,NCT00004660,hyperthyroidism,Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Graves' Disease,2000-02-24,1998-01-31,1998-01-31,42.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic,Radiation|Radiation,United States,30.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00004660
38,NCT00004661,pseudohypoparathyroidism,,Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism,Pseudohypoparathyroidism,2000-02-24,,,20.0,,,,Observational,Completed,,Office of Rare Diseases (ORD),"National Center for Research Resources (NCRR)|University of California, Los Angeles",,,,12.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004661
39,NCT00004843,hyperparathyroidism,A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic,A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic Primary Hyperparathyroidism,Hyperparathyroidism,2000-02-24,1999-03-30,1999-03-30,53.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Henry Ford Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,Procedure|Other,,50.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004843
42,NCT00005102,hypoparathyroidism,Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome,Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome,"Abnormalities, Multiple|Chromosome Abnormalities|Conotruncal Cardiac Defects|DiGeorge Syndrome|Shprintzen Syndrome",2000-04-06,,,11.0,Natural History,,,Observational,Unknown status,,National Center for Research Resources (NCRR),Children's Hospital of Philadelphia|National Center for Research Resources (NCRR),Children's Hospital of Philadelphia,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00005102
43,NCT00005184,hypothyroidism,,Immunogenetic Factors of Coronary Heart Disease,Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Heart Diseases|Hypertension|Hypothyroidism|Obesity,2000-05-25,,1989-11-30,,,,,Observational,Completed,,"National Heart, Lung, and Blood Institute (NHLBI)","National Heart, Lung, and Blood Institute (NHLBI)",,,,0.0,100.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00005184
44,NCT00006329,hyperparathyroidism,,Comparison of Two Methods of Parathyroidectomy for Primary Hyperparathyroidism,Hyperparathyroidism,2000-10-04,,,,,,,Interventional,Completed,Phase 2/Phase 3,National Center for Research Resources (NCRR),National Center for Research Resources (NCRR),"Univ. of Michigan Hosp, Dept. of Surgery",Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00006329
48,NCT00037193,hyperparathyroidism,Acute Regulation of Parathyroid Hormone by Dietary Phosphate,Acute Regulation of Parathyroid Hormone by Dietary Phosphate,Secondary Hyperparathyroidism,2002-05-16,,,,Defined Population,,Prospective,Observational,Completed,,National Center for Research Resources (NCRR),National Center for Research Resources (NCRR),Washington University Medical School,,United States,21.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00037193
49,NCT00037518,parathyroid neoplasms,An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.,A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer,Hyperparathyroidism|Parathyroid Neoplasms,2002-05-17,,,46.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00037518
50,NCT00037518,hyperparathyroidism,An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.,A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer,Hyperparathyroidism|Parathyroid Neoplasms,2002-05-17,,,46.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00037518
53,NCT00037635,hyperparathyroidism,A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis,A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients,End Stage Renal Disease|Secondary Hyperparathyroidism,2002-05-17,2003-03-31,2003-03-31,400.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00037635
56,NCT00042432,hyperparathyroidism,A Study of an Investigational Medication for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients,Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients,Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2002-07-29,2003-03-31,2003-08-31,54.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00042432
59,NCT00042653,hyperparathyroidism,"A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis)",A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis,End Stage Renal Disease|Secondary Hyperparathyroidism,2002-08-02,2003-07-31,2003-07-31,380.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00042653
64,NCT00053547,hyperparathyroidism,Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis,Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis,End Stage Renal Disease|Secondary Hyperparathyroidism,2003-01-30,,,28.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Stanford University Medical Center|Miami Children's Hospital|The Children's Hospital of Buffalo|Texas Children's Hospital|University of Texas at Houston|Medical College of Wisconsin,Drug,United States,2.0,20.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00053547
65,NCT00060242,"thyroid carcinoma, anaplastic",Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid,Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer,Head and Neck Cancer,2003-05-06,2007-02-28,2008-01-31,26.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Case Comprehensive Cancer Center,Case Comprehensive Cancer Center|National Cancer Institute (NCI),"Josephine Ford Cancer Center at Henry Ford Hospital|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center|Hillman Cancer Center at University of Pittsburgh Cancer Institute",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00060242
66,NCT00061906,thyroid neoplasms,Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma,Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer,Head and Neck Cancer,2003-06-05,2006-06-30,2006-06-30,25.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Ohio State University Comprehensive Cancer Center,Ohio State University Comprehensive Cancer Center,Ohio State University Comrehensive Cancer Center|University of Texas - MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00061906
67,NCT00068497,"thyroid cancer, papillary","Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,40.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00068497
70,NCT00068497,"adenocarcinoma, follicular","Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,40.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00068497
71,NCT00068497,"thyroid carcinoma, anaplastic","Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,40.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00068497
72,NCT00068497,parathyroid neoplasms,"Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,40.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00068497
73,NCT00073710,hyperparathyroidism,"A Phase IV, Single-Center, Active-Controlled Cross-Over Pilot Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium",Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium,Chronic Kidney Disease|Secondary Hyperparathyroidism,2003-12-03,,,30.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Creighton University,Drug|Procedure|Drug,United States,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00073710
76,NCT00077103,"thyroid carcinoma, anaplastic",Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation],Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer,Head and Neck Cancer,2004-02-10,2007-02-28,2007-12-31,4.0,,Single Group Assignment,,Interventional,Terminated,Phase 1/Phase 2,Case Comprehensive Cancer Center,Case Comprehensive Cancer Center|National Cancer Institute (NCI),"Josephine Ford Cancer Center at Henry Ford Hospital|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center|Hillman Cancer Center at University of Pittsburgh Cancer Institute",Biological|Biological|Drug|Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00077103
78,NCT00080574,thyroid neoplasms,The Effects of Thyroid Hormone on Cytochrome P450 and P-Glycoprotein Activity in Thyroid Cancer Patients,The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients,Thyroid Cancer,2004-04-07,,2005-11-30,20.0,,,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00080574
79,NCT00085293,"thyroid cancer, papillary",Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine,Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2004-06-10,2014-01-31,2014-05-31,12.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Colorado at Denver|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center,Drug|Radiation|Biological|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00085293
81,NCT00085293,"adenocarcinoma, follicular",Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine,Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2004-06-10,2014-01-31,2014-05-31,12.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Colorado at Denver|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center,Drug|Radiation|Biological|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00085293
82,NCT00094055,thyroid neoplasms,Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131 I Treatment,Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer,Thyroid Neoplasms,2004-10-08,2009-01-31,2009-01-31,60.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Pfizer,Pfizer,Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00094055
83,NCT00094237,hypothyroidism,Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke,Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke,Cardiovascular Diseases|Cerebrovascular Accident|Heart Diseases|Hypothyroidism|Myocardial Infarction,2004-10-15,2007-07-31,2007-07-31,3200.0,Cohort,,Prospective,Observational,Completed,,"University of North Carolina, Chapel Hill","National Heart, Lung, and Blood Institute (NHLBI)|University of North Carolina, Chapel Hill",,,,50.0,79.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00094237
86,NCT00094484,hyperparathyroidism,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis",Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis,Chronic Kidney Disease|Kidney Disease,2004-10-19,,,400.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00094484
87,NCT00095693,"adenocarcinoma, follicular",Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-11-05,2005-08-31,2011-12-31,25.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug|Other|Other|Radiation|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00095693
89,NCT00095693,"thyroid cancer, papillary",Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-11-05,2005-08-31,2011-12-31,25.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug|Other|Other|Radiation|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00095693
90,NCT00095693,"thyroid carcinoma, anaplastic",Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-11-05,2005-08-31,2011-12-31,25.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug|Other|Other|Radiation|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00095693
91,NCT00095836,thyroid neoplasms,A Phase II Study of ZD 1839 (IRESSA) in Patients With Advanced Thyroid Cancer,Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy,Head and Neck Cancer,2004-11-09,2011-03-31,2011-03-31,27.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Massachusetts General Hospital,AstraZeneca|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Massachusetts General Hospital|National Cancer Institute (NCI),Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00095836
92,NCT00098345,thyroid neoplasms,"An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.",Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer,Thyroid Cancer,2004-12-07,2008-02-29,2017-04-19,40.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,France|United States,18.0,130.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00098345
93,NCT00098813,"adenocarcinoma, follicular","A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma",Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-12-08,2009-08-31,2009-08-31,20.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center at Suffolk,Drug|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00098813
95,NCT00098813,"thyroid cancer, papillary","A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma",Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-12-08,2009-08-31,2009-08-31,20.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center at Suffolk,Drug|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00098813
96,NCT00098852,thyroid neoplasms,A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer,Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer,Head and Neck Cancer,2004-12-08,2010-06-30,,25.0,,,,Interventional,Unknown status,Phase 2,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Helen Diller Family Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00098852
97,NCT00100828,thyroid neoplasms,Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer,Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer,Head and Neck Cancer,2005-01-06,2008-11-30,2008-11-30,6.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|University of Michigan Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00100828
98,NCT00103155,thyroid neoplasms,Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study,Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer,Head and Neck Cancer,2005-02-07,,,,,,,Interventional,Unknown status,Phase 1,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Comprehensive Cancer Center,Procedure|Procedure,United States,21.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00103155
99,NCT00104871,"thyroid cancer, papillary",A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma,Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2005-03-03,2010-05-31,2014-04-30,24.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"University of Colorado at Denver Health Sciences Center|Lombardi Comprehensive Cancer Center at Georgetown University|Emory University|Massachusetts General Hospital Cancer Center|Dana-Farber Harvard Cancer Center|Cleveland Clinic Foundation|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00104871
101,NCT00104871,"adenocarcinoma, follicular",A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma,Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2005-03-03,2010-05-31,2014-04-30,24.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"University of Colorado at Denver Health Sciences Center|Lombardi Comprehensive Cancer Center at Georgetown University|Emory University|Massachusetts General Hospital Cancer Center|Dana-Farber Harvard Cancer Center|Cleveland Clinic Foundation|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00104871
103,NCT00105274,hypoparathyroidism,Intermediate Phenotype and Genetic Mechanisms for Psychosis and Cognitive Disturbance in 22q11.2-Hemideletion Syndrome,Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study,22q11.2 Syndrome|DiGeorge Syndrome|Velocardiofacial Syndrome,2005-03-10,,2010-02-02,,,,,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Mental Health (NIMH),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,50.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00105274
104,NCT00108394,hyperparathyroidism,Osteopenia and Renal Osteodystrophy: Evaluation and Management,Osteopenia and Renal Osteodystrophy: Evaluation and Management,Osteopenia|Renal Osteodystrophy,2005-04-14,,2007-09-30,,,Parallel Assignment,,Interventional,Completed,Phase 4,VA Office of Research and Development,US Department of Veterans Affairs,VA Puget Sound Health Care System,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00108394
108,NCT00110929,hyperparathyroidism,A Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens Are Used in Subjects With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD),Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD),End Stage Renal Disease,2005-05-16,,,850.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00110929
110,NCT00111735,hypothyroidism,"What is the Optimal Serum TSH Concentration During Thyroxine Treatment for Primary Hypothyroidism? Effects of Fine Titration of Thyroxine Dosage on Wellbeing, Quality of Life and Cognitive Function",Thyroxine Titration Study,Hypothyroidism,2005-05-24,,2005-03-31,55.0,,Crossover Assignment,,Interventional,Unknown status,Phase 4,Sir Charles Gairdner Hospital,Sir Charles Gairdner Hospital,Sir Charles Gairdner Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00111735
111,NCT00115739,thyroid neoplasms,Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer,Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma,Thyroid Cancer,2005-06-23,2008-05-31,2010-08-31,11.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,University of Michigan Rogel Cancer Center,University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00115739
112,NCT00115895,thyroid neoplasms,Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq,The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy,Thyroid Neoplasms,2005-06-26,2004-10-31,2020-09-30,160.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,University of Helsinki,Helsinki University Central Hospital|University of Helsinki,"Helsinki University Central Hospital, Department of Oncology",Drug,Finland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00115895
113,NCT00117052,hyperparathyroidism,SENSOR: Study to InvestigatE Cinacalcet TreatmeNt in Haemodialysis Patients With SecOndary HyperparathyRoidism,SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism,End Stage Renal Disease|Secondary Hyperparathyroidism,2005-06-30,2005-11-30,2006-02-28,673.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00117052
116,NCT00118248,"thyroid cancer, papillary",A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma,Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-07-08,2009-08-31,2012-04-30,41.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00118248
118,NCT00118248,"adenocarcinoma, follicular",A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma,Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-07-08,2009-08-31,2012-04-30,41.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00118248
119,NCT00121628,thyroid neoplasms,"A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer","A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer",Thyroid Cancer,2005-07-12,2006-11-30,2010-10-31,184.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00121628
120,NCT00123461,hyperparathyroidism,"A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT).","Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism",Chronic Renal Insufficiency|Renal Failure|Secondary Hyperparathyroidism,2005-07-21,2007-10-31,2007-10-31,70.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company","AKDHC Medical Research Services|UCLA Diabetes Reseach Center|Apex Research of Riverside|George Washington University Hospital|Discovery Medical Research Group|Nephrology Associates|Georgia Kidney Associates, Inc.|Michigan Kidney Consultants, P.C.|Twin Cities Clinical Research|Montefiore Medical Center|University of Rochester Medical Center|Wake Nephrology Associates, PA|Wake Forest University School of Medicine|Altru Health System Research Center|DaVita Lewiston Dialysis Center|Temple University|Virginia Commonwealth University|Instituto Renal del Este|Jose Cangiano, MD",Drug,Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00123461
123,NCT00123760,thyroid neoplasms,"A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer",Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer,Brain Neoplasms|Colorectal Neoplasms|Lung Neoplasms|Lymphoma|Thyroid Neoplasms,2005-07-22,2008-12-31,2008-12-31,10838.0,,Single Group Assignment,,Interventional,Completed,Phase 2/Phase 3,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Cross Cancer Institute,Cross Cancer Institute,Procedure,Canada,15.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00123760
124,NCT00124527,thyroid neoplasms,Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer,Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer,Thyroid Cancer,2005-07-26,2006-08-31,2006-08-31,35.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Eisai Inc.,Eisai Inc.,,Drug,Argentina|France|Peru|Russian Federation|Ukraine|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00124527
126,NCT00126568,"thyroid carcinoma, anaplastic",Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2005-08-02,2011-09-30,2011-09-30,20.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Case Western Reserve University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00126568
127,NCT00132431,hyperparathyroidism,Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism,START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism,Chronic Kidney Disease|Kidney Disease|Secondary Hyperparathyroidism,2005-08-19,,2005-07-31,300.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00132431
131,NCT00134043,"thyroid cancer, papillary",Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma,Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-08-22,2009-03-31,2009-03-31,19.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00134043
132,NCT00134043,"adenocarcinoma, follicular",Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma,Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-08-22,2009-03-31,2009-03-31,19.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00134043
134,NCT00135304,hyperparathyroidism,ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone,ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2005-08-24,2006-10-31,2006-12-31,170.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00135304
136,NCT00144079,thyroid neoplasms,Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma,Multicenter Study Differentiated Thyroid Carcinoma,Thyroid Neoplasms,2005-09-01,,2010-01-31,500.0,,Parallel Assignment,,Interventional,Completed,Phase 3,University Hospital Muenster,"Deutsche Krebshilfe e.V., Bonn (Germany)|University Hospital Muenster","Department of Nuclear Medicine|Department of Nuclear Medicine, Wien University Hospital|Department of Nuclear Medicine, University Halle-Wittenberg|Department of Nuclear medicine, Saarland University|Department of Nuclear Medicine, Cologne University|Department of Nuclear Medicine, Mnster University Hospital|Department of Nuclear Medicine, Katharinen-Hospital|Department of Nuclear Medicine, Helios-Klinikum Wuppertal|Department of Nuclear Medicine, Wrzburg University|Department of Nuclear Medicine, Zrich University Hospital",Procedure,Austria|Germany|Switzerland,18.0,69.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00144079
137,NCT00145366,graves disease,"Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.","rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter",Benign Nontoxic and Toxic Goiter|Graves' Disease,2005-09-02,,2005-07-31,110.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00145366
138,NCT00145366,hyperthyroidism,"Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.","rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter",Benign Nontoxic and Toxic Goiter|Graves' Disease,2005-09-02,,2005-07-31,110.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00145366
139,NCT00145366,goiter,"Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.","rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter",Benign Nontoxic and Toxic Goiter|Graves' Disease,2005-09-02,,2005-07-31,110.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00145366
140,NCT00147433,hypothyroidism,Are IQs Low in Offspring of Euthyroid Women With Low T4?,The Effect of Thyroid Hormone Levels in Pregnant Women on the Intelligence Quotient (IQ) of Their Children,Child Development Disorders|Pregnancy|Subclinical Hypothyroidism,2005-09-02,,2008-11-30,5000.0,Case-Control,,Other,Observational,Unknown status,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Foundation for Blood Research,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00147433
141,NCT00148213,thyroid neoplasms,Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma,Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma,Thyroid Neoplasms,2005-09-06,,2005-06-30,100.0,,,Other,Observational,Completed,,University Hospital Muenster,"Nichols Institute Diagnostika GmbH, Bad Vilbel, Germany|University Hospital Muenster","Department of Nuclear Medicine, Mnster University Hospital",,Germany,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00148213
142,NCT00150111,hyperthyroidism,B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease,Rituximab in the Treatment of Graves' Disease,Graves Disease|Thyroid Associated Ophthalmopathy,2005-09-06,,2006-10-31,20.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital|Department of Hematology, Odense University Hospital",Drug|Drug|Biological,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00150111
143,NCT00150111,graves disease,B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease,Rituximab in the Treatment of Graves' Disease,Graves Disease|Thyroid Associated Ophthalmopathy,2005-09-06,,2006-10-31,20.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital|Department of Hematology, Odense University Hospital",Drug|Drug|Biological,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00150111
144,NCT00150111,graves ophthalmopathy,B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease,Rituximab in the Treatment of Graves' Disease,Graves Disease|Thyroid Associated Ophthalmopathy,2005-09-06,,2006-10-31,20.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital|Department of Hematology, Odense University Hospital",Drug|Drug|Biological,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00150111
145,NCT00150111,goiter,B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease,Rituximab in the Treatment of Graves' Disease,Graves Disease|Thyroid Associated Ophthalmopathy,2005-09-06,,2006-10-31,20.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital|Department of Hematology, Odense University Hospital",Drug|Drug|Biological,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00150111
147,NCT00150124,graves disease,The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism,Block-replacement Therapy During Radioiodine Therapy,Graves' Disease|Toxic Nodular Goitre,2005-09-06,2008-12-31,2009-03-31,100.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Odense University Hospital,Steen Bonnema,"Department of Endocrinology, Odense University Hospital",Drug|Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00150124
148,NCT00150124,"goiter, nodular",The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism,Block-replacement Therapy During Radioiodine Therapy,Graves' Disease|Toxic Nodular Goitre,2005-09-06,2008-12-31,2009-03-31,100.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Odense University Hospital,Steen Bonnema,"Department of Endocrinology, Odense University Hospital",Drug|Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00150124
149,NCT00150124,hyperthyroidism,The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism,Block-replacement Therapy During Radioiodine Therapy,Graves' Disease|Toxic Nodular Goitre,2005-09-06,2008-12-31,2009-03-31,100.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Odense University Hospital,Steen Bonnema,"Department of Endocrinology, Odense University Hospital",Drug|Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00150124
150,NCT00150137,hyperthyroidism,The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism,Antithyroid Drugs During Radioiodine Therapy,Graves Disease|Toxic Nodular Goitre,2005-09-06,,2004-12-31,80.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00150137
152,NCT00150137,goiter,The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism,Antithyroid Drugs During Radioiodine Therapy,Graves Disease|Toxic Nodular Goitre,2005-09-06,,2004-12-31,80.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00150137
153,NCT00150137,graves disease,The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism,Antithyroid Drugs During Radioiodine Therapy,Graves Disease|Toxic Nodular Goitre,2005-09-06,,2004-12-31,80.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00150137
154,NCT00150150,thyroid neoplasms,Ultrasound Guided Interstitial Laser Photocoagulation on Benign Thyroid Nodules,Laser Therapy of Benign Thyroid Nodules,Benign Solitary Solid|Cystic Thyroid Nodules,2005-09-06,,2006-03-31,70.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Procedure,Denmark,20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00150150
155,NCT00150150,thyroid nodule,Ultrasound Guided Interstitial Laser Photocoagulation on Benign Thyroid Nodules,Laser Therapy of Benign Thyroid Nodules,Benign Solitary Solid|Cystic Thyroid Nodules,2005-09-06,,2006-03-31,70.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Procedure,Denmark,20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00150150
156,NCT00151723,hyperthyroidism,"Subclinical Hyperthyroidism ""To Treat or Not to Treat?"" A Dutch Multicenter Trial",Does Radioiodine Treatment Prevent Atrial Fibrillation and Bone Loss in Endogenous Subclinical Hyperthyroidism?,Hyperthyroidism,2005-09-08,,,200.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Radboud University Medical Center,Radboud University Medical Center,Academical Medical Centre Amsterdam|Martini Ziekenhuis Groningen|University Hospital Groningen|Radboud University Medical Centre Nijmegen|Maxima Medisch Centrum,Procedure,Netherlands,40.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00151723
157,NCT00161109,hypoparathyroidism,Genetics and Psychopathology in the 22q11 Deletion Syndrome,Genetics and Psychopathology in the 22q11 Deletion Syndrome,Chromosome 22q11.2 Deletion Syndrome,2005-09-08,,2012-10-31,175.0,Defined Population,,Prospective,Observational,Unknown status,,UMC Utrecht,Children's Hospital of Philadelphia|Netherlands Brain Foundation|UMC Utrecht,"Children's Hospital of Philadelphia, Dpt of Genetics and Dpt of Child and Adolescent Psychiatry|UMC Utrecht, Dpt of Child and Adolescent Psychiatry",,Netherlands|United States,8.0,20.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00161109
160,NCT00169806,hyperparathyroidism,Randall's Plaques: Pathogenesis and Relationship to Nephrolithiasis,Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis,Cystinuria|Hypercalciuria|Hyperparathyroidism|Nephrocalcinosis|Renal Calculi,2005-09-12,2025-12-31,2025-12-31,600.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Indiana Kidney Stone Institute,Indiana Kidney Stone Institute|Indiana University School of Medicine|University of Chicago,IU Health Methodist Hospital,Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00169806
161,NCT00174057,graves ophthalmopathy,,"The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy",Graves' Ophthalmopathy,2005-09-13,,2006-07-31,50.0,Case-Control,,Other,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shu Lang Liao,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00174057
162,NCT00174057,goiter,,"The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy",Graves' Ophthalmopathy,2005-09-13,,2006-07-31,50.0,Case-Control,,Other,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shu Lang Liao,,Taiwan,20.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00174057
163,NCT00174057,hyperthyroidism,,"The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy",Graves' Ophthalmopathy,2005-09-13,,2006-07-31,50.0,Case-Control,,Other,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shu Lang Liao,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00174057
164,NCT00174057,graves disease,,"The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy",Graves' Ophthalmopathy,2005-09-13,,2006-07-31,50.0,Case-Control,,Other,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shu Lang Liao,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00174057
166,NCT00175149,hyperparathyroidism,"The Efficacy of 1,25 Dihydroxycholecalciferol on the Cardiovascular System in Patients With Renal Dysfunction",Active Vitamin D Effect on Left Ventricular Hypertrophy,Chronic Kidney Disease|Left Ventricular Hypertrophy|Secondary Hyperparathyroidism,2005-09-11,2008-12-31,2008-12-31,24.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,University of Aarhus,Per Ivarsen,"Department of Renal Medicne C, Skejby Hospital",Drug,Denmark,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00175149
168,NCT00176748,thyroid neoplasms,Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment,Treatment for Patients With Metastatic Thyroid Cancer,Thyroid Cancer,2005-09-09,2006-08-31,2009-06-30,3.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Michigan Rogel Cancer Center,Pfizer|University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00176748
169,NCT00181168,thyroid neoplasms,Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-differentiated Epithelial Thyroid Cancer,Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer,Thyroid Cancer,2005-09-12,2003-09-30,2003-09-30,63.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Johns Hopkins University,"Genzyme, a Sanofi Company|Gustave Roussy, Cancer Campus, Grand Paris|Johns Hopkins University|M.D. Anderson Cancer Center",Johns Hopkins Division of Endocrinology & Metabolism|M.D. Anderson Cancer Center|Institute Gustave Roussy,Drug,France|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00181168
171,NCT00189501,hyperparathyroidism,"A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)","A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)",Nephrology,2005-09-12,,,1000.0,,,Prospective,Observational,Completed,,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00189501
173,NCT00196729,thyroid neoplasms,"A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State",Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration,Thyroid Neoplasms,2005-09-13,,2003-09-30,63.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Sanofi,"Genzyme, a Sanofi Company",,Drug,,20.0,68.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00196729
174,NCT00205348,hypothyroidism,Swallowing Function Before and After Surgery for Thyroid Goiter,Swallowing Function Before and After Surgery for Thyroid Goiter,Hypothyroidism,2005-09-13,2009-01-31,2009-01-31,146.0,Case-Only,,Prospective,Observational,Completed,,"University of Wisconsin, Madison","University of Wisconsin, Madison",,,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00205348
175,NCT00206375,hypothyroidism,Concomitant Use of Growth Hormone and GnRH Agonist in Adolescent Patients With Acquired Hypothyroidism,Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism,Hypothyroidism,2005-09-13,2011-09-30,2011-11-30,16.0,,Single Group Assignment,,Interventional,Terminated,Phase 4,Baylor College of Medicine,Baylor College of Medicine|Eli Lilly and Company|TAP Pharmaceutical Products Inc.,Baylor college of Medicine,Drug|Drug,United States,8.0,17.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00206375
177,NCT00209235,pseudopseudohypoparathyroidism,Natural History Study of Albright Hereditary Osteodystrophy: Includes Substudies on Effects of Growth Hormone in Patients With Pseudohypoparathyroidism Type 1a and Cognitive & Behavioral Studies in Albright Hereditary Osteodystrophy,"Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments",Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1A,2005-09-13,2026-10-31,2027-12-31,600.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Connecticut Children's Medical Center,"Connecticut Children's Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Johns Hopkins University|UConn Health",Connecticut Children's Medical Center,Behavioral,United States,2.0,89.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00209235
178,NCT00211939,hyperparathyroidism,CARE-2 (Calcium Acetate (PhosLo)/Sevelamer(Renagel) Evaluation Study 2),CARE-2 (Calcium Acetate [PhosLo]/Sevelamer[Renagel] Evaluation Study 2) for Heart Calcification in Dialysis Patients,"Arteriosclerosis|Calcinosis|Hyperparathyroidism, Secondary",2005-09-13,2006-12-31,2007-03-31,203.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Nabi Biopharmaceuticals,Nabi Biopharmaceuticals,University of Texas Health Sciences Center,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00211939
181,NCT00213720,hyperthyroidism,Place de l'Iode RadioActif Dans l'HyperThyrodiE Sub-clinique (PIRHATES)/ Evaluation of the Interest of Subclinical Hyperthyroidism Treatment,Treatment of Subclinical Hyperthyroidism,Atrial Fibrillation|Subclinical Hyperthyroidism,2005-09-13,2019-11-30,2020-01-31,145.0,Cohort,,Prospective,Observational,Terminated,,"University Hospital, Strasbourg, France","University Hospital, Strasbourg, France",Patrick Roger|Philippe Thiblot|Jean-Marcel Brun|Jean-Louis Wemeau|Marie-Pierre Teissier|Jacques Orgiazzi|Bernard Conte-Delvox|CH de Montbrison|Jacques Bringer|Marc Klein|Michel Rodier|Laurence Leenhardt|Richard Marechaud|Brigitte Delemer|Claire Schvartz|Jean-Marc Kuhn|Bruno Estour|Centre Paul Strauss|Hopitaux Universitaires de Strasbourg|Philippe Caron|Pierre Lecomte,,France,50.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00213720
182,NCT00215605,thyroid neoplasms,A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies,Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies,Cancer|Lymphoma|Thyroid Carcinoma,2005-09-20,2011-04-30,2012-07-31,85.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Exelixis,Exelixis,University of Chicago|Johns Hopkins University|Memorial Sloan Kettering Cancer Center|Fox Chase Cancer Center|Univ. of Texas MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00215605
183,NCT00223158,thyroid neoplasms,L-T3 Preparation for I131 Whole Body Scintigraphy: A Randomized Controlled Trial,Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer,Thyroid Cancer,2005-09-19,2005-05-31,2005-05-31,70.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Universit de Sherbrooke,Patrice Perron|Theramed co.,Centre Hospitalier Universitaire de Sherbrooke,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00223158
184,NCT00230802,hypothyroidism,Thyroid Hormone Dose Adjustments During Pregnancy in Women With Primary Hypothyroidism.,Thyroid Hormone Dose Adjustment in Pregnancy,Hypothyroidism|Pregnancy,2005-09-29,2010-07-31,2010-07-31,48.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital|Harvard Medical School (HMS and HSDM),Brigham and Women's Hospital,Drug|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00230802
185,NCT00251316,thyroid neoplasms,The Effects of Lithium Carbonate on Low Dose Radioiodine Ablation in Early Thyroid Cancer Treatment,Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer,Differentiated Thyroid Carcinoma|Thyroid Cancer,2005-11-09,2011-12-31,2011-12-31,34.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00251316
188,NCT00257920,hyperparathyroidism,"A Phase 4, Single-Center, Open-Label, Randomized, Active-Controlled, Cross-over Pilot Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar Injection and Hectorol Injection, on Intestinal Absorption of Calcium in CKD Stage 5 Subjects on Hemodialysis",A Study of Zemplar Injection and Hectorol Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease,"Chronic Kidney Disease, Stage 5|Secondary Hyperparathyroidism",2005-11-22,2008-01-31,,41.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,,Drug|Drug,United States,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00257920
191,NCT00261950,hyperparathyroidism,Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease,Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease,Secondary Hyperparathyroidism,2005-12-02,2011-05-31,2011-05-31,110.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,"Belgium|Czech Republic|Hungary|Italy|Macedonia, The Former Yugoslav Republic of|Poland|Portugal|Spain|Switzerland|Turkey|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00261950
194,NCT00271427,"thyroiditis, autoimmune",Selenium Treatment in Autoimmune Thyroiditis: Long Term Follow-Up With Variable Doses,Selenium Treatment in Autoimmune Thyroiditis (AIT),Autoimmune Thyroiditis|Hashimotos Thyroiditis,2005-12-30,,2005-08-31,100.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Ege University,Ege University,"Dep. of Nuc. Med., Ege University Faculty of Medicine.",Drug,Turkey,15.0,70.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT00271427
196,NCT00275171,"goiter, nodular","The Effect of 0.1 mg Recombinant Human Thyrotropin (rhTSH) on Thyroid Radioiodine-uptake and the Degree of Goiter Reduction Following 131I-therapy, in Patients With Benign Non-toxic Nodular Goiter. A Randomized, Double-blind, Placebo-controlled Trial.","rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter",Nodular Goiter,2006-01-09,2009-04-30,2009-09-30,90.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Odense University Hospital,Steen Bonnema,Odense University Hospital,Drug|Drug|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00275171
198,NCT00277589,goiter,"TSH-adapted Therapy in a Large Randomized, Observer-blind, Placebo-controlled, Prospective Treatment Study of Patients With Nodular Goiter",LISA-study : Levothyroxin in Nodular Goiter,"Goiter, Nodular",2006-01-13,2008-12-31,2008-12-31,1024.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sanofi,Sanofi,Sanofi-Aventis Administrative Office,Drug|Drug|Drug|Drug,Germany,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00277589
199,NCT00278005,hypoparathyroidism,Incidence of Infection in the Patient With DiGeorge Syndrome Following Surgery for Congenital Heart Disease,Infection in DiGeorge Following CHD Surgery,Congenital Heart Defects|DiGeorge Syndrome,2006-01-13,2008-03-31,2008-03-31,400.0,,,Retrospective,Observational,Terminated,,Children's Healthcare of Atlanta,Children's Healthcare of Atlanta,Children's Healthcare of Atlanta,,United States,0.0,15.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00278005
201,NCT00279721,thyroid neoplasms,Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.,Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.,Thyroid Neoplasms,2006-01-18,2010-06-30,2010-06-30,40.0,,Single Group Assignment,,Interventional,Completed,Phase 2,AHS Cancer Control Alberta,Alberta Health Services,,Procedure,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00279721
203,NCT00280852,"thyroid carcinoma, anaplastic",A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer,Review of Multimodality Management of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2006-01-20,2006-06-30,2006-06-30,5.0,,,Retrospective,Observational,Completed,,AHS Cancer Control Alberta,Alberta Health Services,Tom Baker Cancer Centre,,Canada,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00280852
206,NCT00285467,hyperparathyroidism,Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in CKD,Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease,Renal Osteodystrophy,2006-01-31,2009-12-31,2009-12-31,55.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Indiana University,Indiana University School of Medicine,Indiana University School of Medicine,Drug|Drug,United States,18.0,82.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00285467
207,NCT00287144,hypothyroidism,Observations of Leng Term Effects From Post Partum Thyroiditis.,Post Partum Thyroiditis 2: Long Term Observations,Hypothyroidism,2006-02-02,2015-12-31,2016-12-31,0.0,Cohort,,Retrospective,Observational,Withdrawn,,Sykehuset Telemark,Sykehuset Telemark,Sykehuset Telemark HF,,Norway,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00287144
209,NCT00287144,thyroiditis,Observations of Leng Term Effects From Post Partum Thyroiditis.,Post Partum Thyroiditis 2: Long Term Observations,Hypothyroidism,2006-02-02,2015-12-31,2016-12-31,0.0,Cohort,,Retrospective,Observational,Withdrawn,,Sykehuset Telemark,Sykehuset Telemark,Sykehuset Telemark HF,,Norway,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT00287144
210,NCT00287144,postpartum thyroiditis,Observations of Leng Term Effects From Post Partum Thyroiditis.,Post Partum Thyroiditis 2: Long Term Observations,Hypothyroidism,2006-02-02,2015-12-31,2016-12-31,0.0,Cohort,,Retrospective,Observational,Withdrawn,,Sykehuset Telemark,Sykehuset Telemark,Sykehuset Telemark HF,,Norway,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Other thyroiditis,https://clinicaltrials.gov/ct2/show/NCT00287144
212,NCT00287287,"adenocarcinoma, follicular",Phase II Trial of REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas,REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas,Thyroid Neoplasms,2006-02-03,2010-07-06,2010-07-06,25.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Kentucky,Celgene Corporation|Kenneth Ain,University of Kentucky Markey Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00287287
213,NCT00288522,goiter,"A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.",Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment,Thyroid-Associated Ophthalmopathy,2006-02-07,2007-04-30,2007-04-30,5.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Ipsen,Ipsen,Hospital General d'Alacant,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00288522
214,NCT00288522,hyperthyroidism,"A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.",Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment,Thyroid-Associated Ophthalmopathy,2006-02-07,2007-04-30,2007-04-30,5.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Ipsen,Ipsen,Hospital General d'Alacant,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00288522
215,NCT00288522,graves disease,"A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.",Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment,Thyroid-Associated Ophthalmopathy,2006-02-07,2007-04-30,2007-04-30,5.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Ipsen,Ipsen,Hospital General d'Alacant,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00288522
216,NCT00288522,graves ophthalmopathy,"A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.",Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment,Thyroid-Associated Ophthalmopathy,2006-02-07,2007-04-30,2007-04-30,5.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Ipsen,Ipsen,Hospital General d'Alacant,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00288522
218,NCT00288873,hyperparathyroidism,Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity,Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity,Obesity|Secondary Hyperparathyroidism|Vitamin D Deficiency,2006-02-06,2007-07-31,2007-07-31,60.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Weill Medical College of Cornell University,Weill Medical College of Cornell University,Weill Cornell Medical College,Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00288873
220,NCT00295763,thyroid neoplasms,Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method.,"A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.",Differentiated Thyroid Cancer,2006-02-22,2006-07-31,2006-09-30,61.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Sanofi,"Genzyme, a Sanofi Company",University of Colorado Health Sciences Centre|Johns Hopkins University|Ohio State University|MD Anderson Cancer Centre|LHRI Research Services|Centre Rene Huguenin|Institut Gustave Roussy|University of Wurzburg|University of Pisa,Drug,Canada|France|Germany|Italy|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00295763
221,NCT00297297,thyroid nodule,"Preoperative Selection of Solitary Solid Cold Thyroid Nodules - A Prospective Study on the Value of Sonography, Cytology, Immunostaining and Molecular Profiling",Improved Preoperative Selection of Cold Thyroid Nodules,Thyroid Nodules,2006-02-27,,2011-03-31,100.0,Case-Only,,Prospective,Observational,Unknown status,,Herlev Hospital,Herlev Hospital,"Outpatient clinic of The Department of Endocrinology, Herlev University Hospital",Other,Denmark,20.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00297297
222,NCT00297297,thyroid neoplasms,"Preoperative Selection of Solitary Solid Cold Thyroid Nodules - A Prospective Study on the Value of Sonography, Cytology, Immunostaining and Molecular Profiling",Improved Preoperative Selection of Cold Thyroid Nodules,Thyroid Nodules,2006-02-27,,2011-03-31,100.0,Case-Only,,Prospective,Observational,Unknown status,,Herlev Hospital,Herlev Hospital,"Outpatient clinic of The Department of Endocrinology, Herlev University Hospital",Other,Denmark,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00297297
224,NCT00307840,hyperparathyroidism,Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism,Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2006-03-27,,2005-07-31,,,Parallel Assignment,,Interventional,Completed,Phase 4,Papageorgiou General Hospital,Papageorgiou General Hospital,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00307840
226,NCT00316823,thyroid neoplasms,Gene Expression Analysis in Thyroid Nodule FNA Samples,Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules,Head and Neck Cancer,2006-04-19,2009-12-31,,400.0,,,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Helen Diller Family Comprehensive Cancer Center,Genetic|Genetic|Genetic|Other|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00316823
227,NCT00316823,thyroid nodule,Gene Expression Analysis in Thyroid Nodule FNA Samples,Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules,Head and Neck Cancer,2006-04-19,2009-12-31,,400.0,,,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Helen Diller Family Comprehensive Cancer Center,Genetic|Genetic|Genetic|Other|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00316823
228,NCT00322322,hyperthyroidism,Early Administration of L-carnitine in Hemodialysis Patients: Double Blind Randomized Trial Versus Placebo,Early Administration of L-carnitine in Hemodialysis Patients,Complication of Hemodialysis|Hyperthyroidism Treated or Under Control,2006-05-03,2010-06-30,2010-06-30,110.0,,Factorial Assignment,,Interventional,Completed,Phase 3,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,"Assistance Publique Hopitaux de Paris|HOPITAL LA PITIE SALPETRIERE, service de Nphrologie",Drug,France,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00322322
230,NCT00325104,hyperparathyroidism,Cinacalcet Actions in Familial Primary Hyperparathyroidism,Cinacalcet to Treat Familial Primary Hyperparathyroidism,Familial Primary Hyperparathyroidism|Hypercalcemia,2006-05-11,,2007-03-31,25.0,,,,Interventional,Completed,Phase 3,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00325104
232,NCT00335062,graves disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,Graves' Disease,2006-06-06,2010-02-28,2010-02-28,19.0,Cohort,,Prospective,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Childrens' Hospital Boston,,United States,2.0,21.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00335062
233,NCT00335062,goiter,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,Graves' Disease,2006-06-06,2010-02-28,2010-02-28,19.0,Cohort,,Prospective,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Childrens' Hospital Boston,,United States,2.0,21.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00335062
234,NCT00335062,hyperthyroidism,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,Graves' Disease,2006-06-06,2010-02-28,2010-02-28,19.0,Cohort,,Prospective,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Childrens' Hospital Boston,,United States,2.0,21.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00335062
235,NCT00336102,hypothyroidism,Thyroid Function & Breast Cancer: A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed With Breast Cancer and the Magnitude of Change in Thyroid Function Post-Chemotherapy,Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers,Breast Cancer|Fatigue|Hypothyroidism,2006-06-08,2015-06-30,2015-06-30,541.0,Case-Control,,Prospective,Observational,Completed,,University of South Florida,National Cancer Institute (NCI)|University of South Florida,"CCOP - Western Regional, Arizona|North Colorado Medical Center|McKee Medical Center|Cancer Centers of Central Florida, PA|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida|Northeast Georgia Cancer Care, LLC - Medical Oncology|Medical College of Georgia Cancer Center|MBCCOP - Medical College of Georgia Cancer Center|Saint Anthony's Hospital at Saint Anthony's Health Center|Good Samaritan Regional Health Center|MBCCOP - LSU Health Sciences Center|Feist-Weiller Cancer Center at Louisiana State University Health Sciences|CCOP - Beaumont|William Beaumont Hospital - Royal Oak Campus|William Beaumont Hospital - Troy Campus|MeritCare Bemidji|Southeast Cancer Center|Saint Francis Medical Center|David C. Pratt Cancer Center at St. John's Mercy|St. John's Regional Health Center|CCOP - Cancer Research for the Ozarks|Hulston Cancer Center at Cox Medical Center South|CCOP - St. Louis-Cape Girardeau|Newark Beth Israel Medical Center|MBCCOP - Our Lady of Mercy Comprehensive Cancer Center|Our Lady of Mercy Medical Center Comprehensive Cancer Center|Mission Hospitals - Memorial Campus|Rutherford Internal Medicine Associates, PA|CCOP - Southeast Cancer Control Consortium|Southeastern Medical Oncology Center - Goldsboro|Moses Cone Regional Cancer Center at Wesley Long Community Hospital|Pardee Memorial Hospital|Iredell Memorial Hospital|Southeastern Medical Oncology Center - Wilson|Forsyth Regional Cancer Center at Forsyth Medical Center|CCOP - MeritCare Hospital|Roger Maris Cancer Center at MeritCare Hospital|AnMed Cancer Center|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center|CCOP - Scott and White Hospital|Scott and White Cancer Institute",Other|Procedure|Procedure,United States,20.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00336102
236,NCT00339716,thyroid neoplasms,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident,Non-Cancer Thyroid Disease|Non Thyroid Cancer|Thyroid Cancer,2006-06-19,2020-03-11,2020-03-11,19456.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Republican Resear ch Center for Radiation Medicine and Human Ecology|Ministry of Health Republic of Belarus,,Belarus,30.0,51.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00339716
237,NCT00341094,thyroid neoplasms,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Diseases in Ukraine Following the Chernobyl Accident,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Ukraine Following the Chernobyl Accident,Non-Cancer Thyroid Disease|Non Thyroid Cancer|Thyroid Cancer,2006-06-19,2020-10-08,2020-10-08,23143.0,Cohort,,Retrospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"Research Institute of Endocrinology and Metabolism, Kiev, Ukraine",,Ukraine,18.0,48.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00341094
238,NCT00341185,thyroid neoplasms,Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing,Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing,Thyroid Cancer,2006-06-19,,2016-11-18,2997.0,Cohort,,Retrospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Semipalatinsk State Medical Academy,,Kazakhstan,63.0,71.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00341185
239,NCT00342407,thyroid neoplasms,The Incidence of Breast and Other Cancers Among Female Flight Attendants,The Incidence of Breast and Other Cancers Among Female Flight Attendants,Breast Cancer|Melanoma|Non-Melanoma Skin Cancer|Thyroid Cancer,2006-06-19,2005-12-31,2020-04-09,6093.0,Case-Only,,Other,Observational,Completed,,National Institutes of Health Clinical Center (CC),Centers for Disease Control and Prevention|National Cancer Institute (NCI)|National Institute for Occupational Safety and Health (NIOSH/CDC),National Institute for Occupational Safety and Health (NIOSH),,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00342407
240,NCT00342446,thyroid neoplasms,Follow-Up Study of Women Evaluated and Treated for Infertility,A Follow-up Study of Women Evaluated and Treated for Infertility,"Breast Cancer|Colorectal Cancer, Melanoma|Endometrial Cancer|Ovarian Cancer|Thyroid Cancer",2006-06-19,,,12193.0,Cohort,,Prospective,Observational,Active not recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Columbia University,,United States,44.0,88.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00342446
241,NCT00342641,thyroid neoplasms,Associations of Hematologic Malignancies and Thyroid Cancer With HCV Infection Among US Military Veterans,Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers,Hepatitis C Virus,2006-06-19,,2011-12-13,815000.0,,,,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Houston Veterans AFfairs Medical Center,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00342641
242,NCT00345839,hyperparathyroidism,EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events,E.V.O.L.V.E. Trial: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events,Chronic Kidney Disease|Secondary Hyperparathyroidism,2006-06-27,2012-04-10,2012-04-10,3883.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00345839
245,NCT00348413,goiter,"Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.",Thyroid Treatment Trial,Graves Ophthalmopathy,2006-07-03,2008-07-31,2008-07-31,80.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Singapore National Eye Centre,International Stem Cell Forum|Singapore National Eye Centre,Singapore National Centre,Drug,Singapore,21.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00348413
246,NCT00348413,graves ophthalmopathy,"Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.",Thyroid Treatment Trial,Graves Ophthalmopathy,2006-07-03,2008-07-31,2008-07-31,80.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Singapore National Eye Centre,International Stem Cell Forum|Singapore National Eye Centre,Singapore National Centre,Drug,Singapore,21.0,60.0,[18-65],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00348413
247,NCT00348413,graves disease,"Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.",Thyroid Treatment Trial,Graves Ophthalmopathy,2006-07-03,2008-07-31,2008-07-31,80.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Singapore National Eye Centre,International Stem Cell Forum|Singapore National Eye Centre,Singapore National Centre,Drug,Singapore,21.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00348413
248,NCT00348413,hyperthyroidism,"Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.",Thyroid Treatment Trial,Graves Ophthalmopathy,2006-07-03,2008-07-31,2008-07-31,80.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Singapore National Eye Centre,International Stem Cell Forum|Singapore National Eye Centre,Singapore National Centre,Drug,Singapore,21.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00348413
249,NCT00352170,hyperparathyroidism,Calcium and Vitamin D Malnutrition in Elderly Women,Calcium and Vitamin D Malnutrition in Elderly Women,Osteoporosis|Secondary Hyperparathyroidism,2006-07-12,2005-07-31,2005-07-31,1180.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Creighton University,Creighton University|GlaxoSmithKline,,Dietary Supplement|Dietary Supplement|Dietary Supplement,,55.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00352170
252,NCT00354523,thyroid neoplasms,A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma,Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma,Solid Tumor|Thyroid Cancer,2006-07-18,2006-11-30,2013-08-31,21.0,,Single Group Assignment,,Interventional,Terminated,Phase 1/Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|Novartis Pharmaceuticals,UT MD Anderson Cancer Center,Drug|Drug|Drug,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00354523
253,NCT00356512,hypoparathyroidism,Physiologic Regulation of FGF-23,Physiologic Regulation of FGF-23,Hypoparathyroidism,2006-07-25,2009-09-02,,20.0,,,,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Dental and Craniofacial Research (NIDCR),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00356512
255,NCT00358956,thyroid neoplasms,"A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer",A Study To Assess ZD6474 (ZACTIMA) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer,Thyroid Cancer,2006-07-28,2008-01-31,2014-05-31,19.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Australia|Canada|Italy|Netherlands|Romania|Spain|Switzerland|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00358956
256,NCT00359385,hyperparathyroidism,The Effects of Alendronate After Cure of Primary Hyperparathyroidism,The Effects of Alendronate After Cure of Primary Hyperparathyroidism,Hyperparathyroidism,2006-08-01,2009-09-30,2009-09-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,Columbia University,Columbia University|Merck Sharp & Dohme LLC,CUMC,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00359385
259,NCT00360074,hypothyroidism,"A Randomised, Controlled, Crossover Study: Treatment With Thyroxin Compared to Thyroxin + Triiodothyronin in Patients With Secondary Hypothyroidism",Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation,Hyperlipidemias|Hypopituitarism|Secondary Hypothyroidism,2006-08-02,,2007-04-30,25.0,,Crossover Assignment,,Interventional,Completed,Phase 4,University Hospital Freiburg,University Hospital Freiburg,"University Hospital Freiburg, Department of Medicine",Drug,Germany,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00360074
261,NCT00364234,hyperparathyroidism,Low Magnitute Mechanical Stimuli Effects on Bone Structure in ESRD,Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD,Renal Osteodystrophy,2006-08-14,2007-09-30,2007-09-30,30.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Childen's Hospital of Philadelphia,Device,United States,21.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00364234
263,NCT00373711,thyroid neoplasms,"Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection","Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA",Thyroid Cancer,2006-09-06,,,100.0,Cohort,,Prospective,Observational,Withdrawn,,Stanford University,Stanford University,,Drug|Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00373711
265,NCT00374595,hyperparathyroidism,Vascular Risk After Kidney Transplantation,Vascular Risk After Kidney Transplantation,Cardiovascular Disease|Chronic Kidney Disease|Diabetes|Hyperparathyroidism|Vitamin D Deficiency,2006-09-08,2019-03-29,2019-04-30,342.0,Other,,Prospective,Observational,Unknown status,,University of Nebraska,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Nebraska,University of Nebraska Medical Center,,United States,19.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00374595
268,NCT00374712,hyperparathyroidism,Study of Klotho Gene Polymorphisms in the Regulation of Serum Phosphate Levels in Hemodialysis Patients,Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia,Chronic Kidney Disease|End Stage Renal Disease|Hyperphosphatemia|Renal Osteodystrophy,2005-09-12,,2007-11-30,40.0,,,Prospective,Observational,Terminated,,Assistance Publique - Hpitaux de Paris,"Assistance Publique - Hpitaux de Paris|Institut National de la Sant Et de la Recherche Mdicale, France",Clinique de l'Orangerie - Service de Nphrologie et Dialyse,,France,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00374712
270,NCT00377312,hyperparathyroidism,Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone(1-34): Effects on Bone Formation,7 Day Continuous Parathyroid Hormone IV Infusion,"Bone Diseases, Endocrine|Hyperparathyroidism|Osteoporosis",2006-09-14,2007-12-31,2007-12-31,11.0,,Single Group Assignment,,Interventional,Completed,Early Phase 1,University of Pittsburgh,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh,University of Pittsburgh Medical Center,Drug,United States,24.0,35.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00377312
272,NCT00379899,hyperparathyroidism,A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis,ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis,Calcification|Cardiovascular Disease|Chronic Kidney Disease|Chronic Renal Failure|Coronary Artery Calcification|End Stage Renal Disease|Hyperparathyroidism|Kidney Disease|Nephrology|Secondary Hyperparathyroidism|Vascular Calcification,2006-09-21,2009-05-31,2009-11-30,360.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00379899
274,NCT00381641,"adenocarcinoma, follicular","Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers",Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery,Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2006-09-26,2016-12-31,,63.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|Duly Health and Care Joliet|Loyola University Medical Center|Illinois CancerCare-Peoria|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Northern Indiana Cancer Research Consortium|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Oncology Care Associates PLLC|Mercy Hospital Saint Louis|M D Anderson Cancer Center|Medical College of Wisconsin,Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00381641
276,NCT00381641,"thyroid cancer, papillary","Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers",Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery,Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2006-09-26,2016-12-31,,63.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|Duly Health and Care Joliet|Loyola University Medical Center|Illinois CancerCare-Peoria|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Northern Indiana Cancer Research Consortium|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Oncology Care Associates PLLC|Mercy Hospital Saint Louis|M D Anderson Cancer Center|Medical College of Wisconsin,Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00381641
277,NCT00385983,thyroid nodule,Total Thyroidectomy With Harmonic Scalpel Versus Standard Surgery. Open Multicentric Randomized Controlled Trial,Total Thyroidectomy With Harmonic Scalpel,Goiter|Thyroid Neoplasm|Thyroid Nodule,2006-10-10,,,280.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Brazilian Society of Head and Neck Surgery,Brazilian Society of Head and Neck Surgery|Johnson & Johnson,Hospital Araujo Jorge|Hospital Erasto Gaertner|Instituto Nacional de Cancer INCA|Hospital do Cancer de Natal|Hospital do Cancer AC Camargo|Hospital Heliopolis|Hospital Sao Paulo-UNIFESP|Instituto Arnaldo Vieira de Carvalho|Santa Casa de Misericordia,Device,Brazil,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00385983
278,NCT00385983,thyroid neoplasms,Total Thyroidectomy With Harmonic Scalpel Versus Standard Surgery. Open Multicentric Randomized Controlled Trial,Total Thyroidectomy With Harmonic Scalpel,Goiter|Thyroid Neoplasm|Thyroid Nodule,2006-10-10,,,280.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Brazilian Society of Head and Neck Surgery,Brazilian Society of Head and Neck Surgery|Johnson & Johnson,Hospital Araujo Jorge|Hospital Erasto Gaertner|Instituto Nacional de Cancer INCA|Hospital do Cancer de Natal|Hospital do Cancer AC Camargo|Hospital Heliopolis|Hospital Sao Paulo-UNIFESP|Instituto Arnaldo Vieira de Carvalho|Santa Casa de Misericordia,Device,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00385983
279,NCT00388297,hypothyroidism,A Randomized Trial of Thyroxine Therapy for Subclinical Hypothyroidism or Hypothyroxinemia Diagnosed During Pregnancy,Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy,Hypothyroxinemia|Pregnancy|Subclinical Hypothyroidism,2006-10-12,2015-08-31,2015-10-31,1203.0,,Single Group Assignment,,Interventional,Completed,Phase 3,The George Washington University Biostatistics Center,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Neurological Disorders and Stroke (NINDS)|The George Washington University Biostatistics Center,University of Alabama - Birmingham|Northwestern University|Wayne State University|Columbia University|University of North Carolina - Chapel Hill|Case Western University|Ohio State University|Oregon Health & Sciences University|University of Pittsburgh Magee Womens Hospital|Brown University|University of Texas - Southwest|University of Texas Medical Branch - Galveston|University of Texas-Houston|University of Utah Medical Center,Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00388297
280,NCT00389441,thyroid neoplasms,A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer,Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer,Thyroid Neoplasms,2006-10-16,2012-09-30,2012-09-30,52.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Pfizer,Pfizer,Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site,Drug,Canada|China|Czech Republic|India|Italy|Poland|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00389441
281,NCT00390325,thyroid neoplasms,Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer",Hereditary Thyroid Gland Medullary Carcinoma|Locally Advanced Thyroid Gland Medullary Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Recurrent Thyroid Gland Medullary Carcinoma|Sporadic Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7,2006-10-18,2017-01-30,,21.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Washington University School of Medicine|Duke University Medical Center|Ohio State University Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00390325
283,NCT00395538,hypoparathyroidism,Effects of PTH Replacement on Bone in Hypoparathyroidism,Effects of PTH Replacement on Bone in Hypoparathyroidism,DiGeorge Syndrome|Hypoparathyroidism,2006-11-02,2017-09-30,2017-10-04,46.0,,Single Group Assignment,,Interventional,Terminated,Phase 3,National Institutes of Health Clinical Center (CC),National Institute of Dental and Craniofacial Research (NIDCR),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00395538
284,NCT00395902,hyperparathyroidism,A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients,Post Transplant Study,Hyperparathyroidism|Kidney Tansplant|Secondary Hyperparathyroidism,2006-11-02,,,50.0,,,Retrospective,Observational,Completed,,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00395902
288,NCT00397475,hyperparathyroidism,Evaluation of Colecalciferol Substitution in Dialysis Patients,Evaluation of Colecalciferol Substitution in Dialysis Patients,"Hyperparathyroidism, Secondary|RENAL INSUFFICIENCY, CHRONIC",2006-11-07,,2007-03-31,50.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"University Hospital, Saarland","University Hospital, Saarland","University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension",Drug,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00397475
290,NCT00400465,goiter,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,116.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00400465
291,NCT00400465,graves disease,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,116.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00400465
292,NCT00400465,thyroid nodule,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,116.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00400465
293,NCT00400465,thyroid neoplasms,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,116.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00400465
294,NCT00400465,hyperthyroidism,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,116.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00400465
296,NCT00403390,congenital hypothyroidism,Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism,Generic vs. Name-Brand Levothyroxine,Congenital Hypothyroidism|Hypothyroidism,2006-11-21,2009-12-31,2010-03-31,34.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Boston Children's Hospital,Boston Children's Hospital,Children's Hospital Boston,Drug|Drug,United States,3.0,18.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00403390
297,NCT00403598,parathyroid diseases,,Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders,Osteitis Deformans|Osteoporosis|Parathyroid Diseases,2006-11-23,,,,,,Other,Observational,Unknown status,,Sheba Medical Center,Ben-Gurion University of the Negev|Sheba Medical Center,"Sheba Medical Center, Tel Hashomer",,Israel,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT00403598
298,NCT00405405,thyroid neoplasms,A Phase I Study of the Combination of Chemoradiotherapy With Biologic Therapy for Advanced Head and Neck Cancer,Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer,Head and Neck Cancer|Melanoma|Parotid Gland Cancer|Stage IV Head and Neck Cancer|Thyroid Gland Cancer,2006-11-29,2010-06-30,2010-06-30,13.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Thomas Jefferson University,"Genentech, Inc.|Sidney Kimmel Cancer Center at Thomas Jefferson University",Thomas Jefferson University,Drug|Drug|Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00405405
299,NCT00410761,thyroid neoplasms,"An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer",An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer,Thyroid Cancer,2006-12-06,2009-07-31,2022-12-31,437.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Sanofi,"Genzyme, a Sanofi Company",Investigational Site Number 3|Investigational Site Number 8|Investigational Site Number 9|Investigational Site Number 11|Investigational Site Number 15|Investigational Site Number 18|Investigational Site Number 17|Investigational Site Number 2|Investigational Site Number 7|Investigational Site Number 14|Investigational Site Number 10|Investigational Site Number 6|Investigational Site Number 22|Investigational Site Number 19|Investigational Site Number 13|Investigational Site Number 21|Investigational Site Number 1001|Investigational Site Number 1901|Investigational Site Number 1101|Investigational Site Number 1102|Investigational Site Number 2301|Investigational Site Number 2302|Investigational Site Number 1203|Investigational Site Number 1202|Investigational Site Number 1201|Investigational Site Number 1204|Investigational Site Number 1205|Investigational Site Number 3601|Investigational Site Number 2701|Investigational Site Number 2802|Investigational Site Number 2803|Investigational Site Number 2801|Investigational Site Number 2002|Investigational Site Number 2001|Investigational Site Number 2005|Investigational Site Number 1601|Investigational Site Number 1401|Investigational Site Number 1402|Investigational Site Number 2506|Investigational Site Number 2502|Investigational Site Number 2503|Investigational Site Number 2501|Investigational Site Number 2505|Investigational Site Number 2504|Investigational Site Number 1501|Investigational Site Number 2403|Investigational Site Number 2402|Investigational Site Number 2404|Investigational Site Number 2902|Investigational Site Number 2901|Investigational Site Number 1701|Investigational Site Number 1702|Investigational Site Number 1703|Investigational Site Number 2602|Investigational Site Number 2601|Investigational Site Number 1801|Investigational Site Number 3301|Investigational Site Number 3402|Investigational Site Number 3401|Investigational Site Number 3003|Investigational Site Number 3001|Investigational Site Number 3002|Investigational Site Number 3102|Investigational Site Number 3101|Investigational Site Number 2101|Investigational Site Number 2102,Drug,"Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|France|Germany|Hungary|India|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00410761
300,NCT00415233,thyroid neoplasms,"Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO]",High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer,Head and Neck Cancer,2006-12-20,2011-06-30,2025-07-31,438.0,,Factorial Assignment,,Interventional,Active not recruiting,Phase 3,"University College, London","University College, London",Sussex Cancer Centre at Royal Sussex County Hospital|Addenbrooke's Hospital|Kent and Canterbury Hospital|Castle Hill Hospital|Derbyshire Royal Infirmary|Royal Devon and Exeter Hospital|Gloucestershire Royal Hospital|St. Luke's Cancer Centre at Royal Surrey County Hospital|Ipswich Hospital|Leeds Cancer Centre at St. James's University Hospital|Leicester Royal Infirmary|Guy's Hospital|Royal Marsden - London|Maidstone Hospital|Christie Hospital|James Cook University Hospital|Newcastle Upon Tyne Hospitals NHS Trust|Northampton General Hospital|Mount Vernon Cancer Centre at Mount Vernon Hospital|Norfolk and Norwich University Hospital|Dorset Cancer Centre|Cancer Research Centre at Weston Park Hospital|University Hospital of North Staffordshire|Velindre Cancer Center at Velindre Hospital|Glan Clwyd Hospital,Biological|Radiation,United Kingdom,16.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00415233
302,NCT00415584,hyperparathyroidism,"Cinacalcet for Treatment of Persistent Secondary Hyperparathyroidism in Renal Transplant Recipients: Effect on Renal Function, Serum Calcium and Bone Histomorphometry",Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients,Hypercalcemia|Secondary Hyperparathyroidism,2006-12-21,2009-11-30,2009-11-30,18.0,,Single Group Assignment,,Interventional,Terminated,Phase 1/Phase 2,Montefiore Medical Center,Montefiore Medical Center,Montefiore Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00415584
304,NCT00416949,thyroid neoplasms,Dose-Response in Radionuclide Therapy of Thyroid Cancer,Iodine I 131 in Treating Patients With Thyroid Cancer,Head and Neck Cancer,2006-12-27,2009-10-31,2009-10-31,9.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Device,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00416949
305,NCT00417612,hyperparathyroidism,The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH),Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets,"Hyperparathyroidism|Hypophosphatemia, Familial",2006-12-28,2012-08-31,2012-08-31,33.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Yale University,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yale University,Yale University School of Medicine,Drug|Other,United States,9.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00417612
308,NCT00418600,hyperparathyroidism,"A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol Capsules When Converting From Hectorol Injection for the Treatment of SHPT in Stage 5 CKD Subjects on Hemodialysis","A Phase 4, Conversion Study of Hectorol Injection to Hectorol Capsules in Stage 5 CKD Patients on Dialysis",Secondary Hyperparathyroidism,2007-01-03,2007-06-30,2007-08-31,36.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company",,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00418600
310,NCT00424151,goiter,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,2007-01-17,2009-03-31,2009-03-31,12.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,"Silkiss, Rona Z., M.D., FACS","Coleman, Morton M.D.|Lauer, Simeon, M.D.|Reier, Alice M.D.|Silkiss, Rona Z., M.D., FACS","Rona Z. Silkiss, MD, FACS|Simeon A. Lauer, MD",Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00424151
311,NCT00424151,graves disease,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,2007-01-17,2009-03-31,2009-03-31,12.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,"Silkiss, Rona Z., M.D., FACS","Coleman, Morton M.D.|Lauer, Simeon, M.D.|Reier, Alice M.D.|Silkiss, Rona Z., M.D., FACS","Rona Z. Silkiss, MD, FACS|Simeon A. Lauer, MD",Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00424151
312,NCT00424151,graves ophthalmopathy,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,2007-01-17,2009-03-31,2009-03-31,12.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,"Silkiss, Rona Z., M.D., FACS","Coleman, Morton M.D.|Lauer, Simeon, M.D.|Reier, Alice M.D.|Silkiss, Rona Z., M.D., FACS","Rona Z. Silkiss, MD, FACS|Simeon A. Lauer, MD",Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00424151
313,NCT00424151,hyperthyroidism,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,2007-01-17,2009-03-31,2009-03-31,12.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,"Silkiss, Rona Z., M.D., FACS","Coleman, Morton M.D.|Lauer, Simeon, M.D.|Reier, Alice M.D.|Silkiss, Rona Z., M.D., FACS","Rona Z. Silkiss, MD, FACS|Simeon A. Lauer, MD",Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00424151
314,NCT00430547,goiter,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Graves' Ophthalmopathy,2007-02-01,,2006-01-31,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Barwon Health,"Barwon Health|National Health and Medical Research Council, Australia|University of Melbourne",Barwon Health - The Geelong Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00430547
315,NCT00430547,graves disease,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Graves' Ophthalmopathy,2007-02-01,,2006-01-31,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Barwon Health,"Barwon Health|National Health and Medical Research Council, Australia|University of Melbourne",Barwon Health - The Geelong Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00430547
316,NCT00430547,graves ophthalmopathy,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Graves' Ophthalmopathy,2007-02-01,,2006-01-31,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Barwon Health,"Barwon Health|National Health and Medical Research Council, Australia|University of Melbourne",Barwon Health - The Geelong Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00430547
317,NCT00430547,hyperthyroidism,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Graves' Ophthalmopathy,2007-02-01,,2006-01-31,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Barwon Health,"Barwon Health|National Health and Medical Research Council, Australia|University of Melbourne",Barwon Health - The Geelong Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00430547
319,NCT00431496,hyperparathyroidism,A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management,A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD),Anemia|Secondary Hyperparathyroidism,2007-02-01,2009-06-30,2009-10-31,71.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00431496
321,NCT00432146,hyperthyroidism,Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease,Effect of Lugol's Solution in the Patients With Graves' Disease,Graves Disease,2007-02-05,,2006-09-30,36.0,,,Prospective,Observational,Completed,,Istanbul University,Istanbul University,,Drug,,14.0,61.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00432146
322,NCT00432146,goiter,Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease,Effect of Lugol's Solution in the Patients With Graves' Disease,Graves Disease,2007-02-05,,2006-09-30,36.0,,,Prospective,Observational,Completed,,Istanbul University,Istanbul University,,Drug,,14.0,61.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00432146
323,NCT00432146,graves disease,Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease,Effect of Lugol's Solution in the Patients With Graves' Disease,Graves Disease,2007-02-05,,2006-09-30,36.0,,,Prospective,Observational,Completed,,Istanbul University,Istanbul University,,Drug,,14.0,61.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00432146
326,NCT00432939,hyperparathyroidism,Primary Hyperparathyroidism: Non-classical Manifestations,Primary Hyperparathyroidism: Non-classical Manifestations,Primary Hyperparathyroidism,2007-02-06,2009-11-30,2012-12-31,58.0,Cohort,,Prospective,Observational,Completed,,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Metabolic Bone Diseases Unit,,United States,50.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00432939
327,NCT00435851,thyroid neoplasms,Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl,Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients,Thyroid Cancer,2007-02-15,,,950.0,,Factorial Assignment,,Interventional,Unknown status,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France",Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00435851
328,NCT00437931,hyperthyroidism,,Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction,Hyperthyroidism|Subclinical Hypothyroidism|Thyroid Dysfunction,2007-02-19,2008-02-29,2008-02-29,60.0,Case-Control,,Prospective,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel","Haemek Medical Center, Department of Radiology",,Israel,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00437931
329,NCT00437931,hypothyroidism,,Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction,Hyperthyroidism|Subclinical Hypothyroidism|Thyroid Dysfunction,2007-02-19,2008-02-29,2008-02-29,60.0,Case-Control,,Prospective,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel","Haemek Medical Center, Department of Radiology",,Israel,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00437931
330,NCT00439127,thyroid neoplasms,Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma?,OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation,Differentiated Thyroid Carcinoma,2007-02-22,,2007-01-31,28.0,Defined Population,,Other,Observational,Completed,,Oncology Institute of Southern Switzerland,Oncology Institute of Southern Switzerland,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00439127
331,NCT00439478,thyroid neoplasms,The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer,Dental Safety Profile of High-Dose Radioiodine Therapy,Thyroid Cancer,2007-02-22,,2006-09-30,202.0,,,,Observational,Completed,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital,Drug,Switzerland,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00439478
332,NCT00446329,hyperparathyroidism,,Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis,Secondary Hyperparathyroidism,2007-03-09,,,15.0,,Single Group Assignment,,Interventional,Terminated,Phase 4,Papageorgiou General Hospital,Papageorgiou General Hospital,Papageorgiou General Hospital,Drug,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00446329
335,NCT00451880,"thyroid cancer, papillary",A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors,Study of XL281 in Adults With Solid Tumors,Cancer|Colorectal Cancer|Melanoma|Non-small-cell Lung Cancer|Papillary Thyroid Cancer,2007-03-23,2011-10-31,2011-10-31,180.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Exelixis,Exelixis,Premiere Oncology of Arizona|H. Lee Moffitt Cancer Center & Research Institute|Barbara Ann Karmanos Cancer Institute|Memorial Sloan Kettering Cancer Center|Sarah Cannon Research Institute|Mary Crowley Cancer Research Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00451880
338,NCT00452049,hyperparathyroidism,"Observational Study to Evaluate the Effect of Parathyroidectomy on Renal Function, Endothelial Function and Blood Pressure","The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure",Hyperparathyroidism|Hypertension,2007-03-23,,,20.0,Cohort,,Prospective,Observational,Unknown status,,Universitaire Ziekenhuizen Leuven,Universitaire Ziekenhuizen Leuven,University Hopsital Leuven,Procedure,Belgium,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00452049
339,NCT00454077,thyroid neoplasms,Recombinant Human TSH (rhTSH)-Aided Radioiodine (131) Therapy for Thyroid Remnant Ablation in Differentiated Thyroid Cancer Patients: a Comparison Between 1850 MBq and 3700 MBq Activities,rhTSH-Thyroid Ablation With 1850 MBq of 131I,Thyroid Cancer,2007-03-28,,2006-09-30,72.0,Natural History,,Prospective,Observational,Completed,,University of Siena,University of Siena,"Section of Endcrinology, University of Siena",Procedure,Italy,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00454077
340,NCT00454220,goiter,"Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction With Radioiodine for the Treatment of Multinodular Goiter.","Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter",Multinodular Goiter,2007-03-28,2011-07-31,2011-07-31,96.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Sanofi,"Genzyme, a Sanofi Company",,Other|Drug|Drug,Brazil|Canada|Denmark|France|Germany|Italy|Netherlands|United States,35.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00454220
342,NCT00454350,hyperparathyroidism,"A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis",A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis,Secondary Hyperparathyroidism,2007-03-28,,2007-07-31,12.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company",,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00454350
344,NCT00459459,thyroid neoplasms,,Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma,Thyroid Neoplasms,2007-04-11,,2006-12-31,100.0,Defined Population,,Retrospective,Observational,Completed,,National Taiwan University Hospital,National Taiwan University Hospital,"Shyang-Rong, Shih",Procedure,Taiwan,10.0,90.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00459459
345,NCT00459498,thyroid neoplasms,Significant Intracellular NIS Protein Associated With Low Levels of NIS Messenger RNA in Malignant Thyroid Tumors,Expression of NIS Protein and mRNA in Thyroid Tumors,Tumors,2007-04-10,,2006-10-31,30.0,,,Other,Observational,Completed,,University of Sao Paulo,Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo,,,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00459498
346,NCT00463021,hyperparathyroidism,"A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol (Doxercalciferol Capsules) When Converting From Zemplar (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis.",A Phase 4 Study to Determine Dosing of Hectorol Capsules When Converting From Zemplar Injection,Secondary Hyperparathyroidism,2007-04-18,,2007-12-31,36.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company",,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00463021
349,NCT00467506,thyroid neoplasms,Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma,Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma,Thyroid Neoplasms,2007-04-27,2011-01-31,2011-01-31,,,Factorial Assignment,,Interventional,Completed,Phase 2,Nantes University Hospital,Nantes University Hospital,Centre Franois Baclesse|CHU de Grenoble|hpital du Cluzeau|CHU|Hpital de la timone|CHU|CHU|Centre Ren Huguenin|Centre Ren Gauducheau|Centre Paul Strauss|Centre Claudius Rgaud,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00467506
351,NCT00469599,hyperparathyroidism,Treatment of Secondary Hyperparathyroidism in the Uremic Patient. A Study Comparing Alfacalcidol and Paricalcitol,Treatment of Secondary Hyperparathyroidism in the Uremic Patient,Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Deficiency,2007-05-03,2010-09-30,2010-10-31,86.0,,Crossover Assignment,,Interventional,Terminated,Not Applicable,Zealand University Hospital,Zealand University Hospital,Aalborg University Hospital|rhus University Hospital Skejby|Hospital of Southwest Denmark Esbjerg|Holbk County Hospital|Holstebro County Hospital|Odense University Hospital|Roskilde County Hospital|Viborg County Hospital,Drug|Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00469599
353,NCT00470496,"adenocarcinoma, follicular","A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer",Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer,Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage I Follicular Thyroid Cancer|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage II Follicular Thyroid Cancer|Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Papillary Thyroid Cancer|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Papillary Thyroid Cancer|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity,2007-05-03,2011-10-28,2018-08-30,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Roswell Park Cancer Institute,National Cancer Institute (NCI)|Roswell Park Cancer Institute,Roswell Park Cancer Institute,Drug|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00470496
355,NCT00470496,"thyroid cancer, papillary","A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer",Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer,Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage I Follicular Thyroid Cancer|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage II Follicular Thyroid Cancer|Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Papillary Thyroid Cancer|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Papillary Thyroid Cancer|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity,2007-05-03,2011-10-28,2018-08-30,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Roswell Park Cancer Institute,National Cancer Institute (NCI)|Roswell Park Cancer Institute,Roswell Park Cancer Institute,Drug|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00470496
356,NCT00471458,hyperthyroidism,Follow-up Study of Hyperthyroid Patients Treated With RAI in 1965-2002: Morbidity in Long-Term Follow-up,Follow-up Study of the RAI-Treated Hyperthyroid Patients,Atrial Fibrillation|Cardiovascular Diseases|Hyperthyroidism,2007-05-09,,2003-12-31,5222.0,Defined Population,,Retrospective,Observational,Completed,,Tampere University,Tampere University,"Tampere University Hospital, Department of Internal Medicine",,Finland,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00471458
357,NCT00473265,hypoparathyroidism,Bone Properties in Hypoparathyroidism: Effects of PTH,Bone Properties in Hypoparathyroidism: Effects of PTH,Hypoparathyroidism,2007-05-14,2011-01-31,2014-06-30,68.0,,Single Group Assignment,,Interventional,Completed,Phase 2/Phase 3,Columbia University,John P. Bilezikian|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00473265
359,NCT00480428,thyroid nodule,Study to Improve Thyroid Doses From Fallout Exposure in Kazakhstan,Radiation Exposure and Thyroid Disease in Kazakhstan,Other Thyroid Disease|Thyroid Cancer|Thyroid Nodules,2007-05-30,,2017-08-17,117.0,,,Retrospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Semipalatinsk State Medical Academy,,Kazakhstan,65.0,90.0,[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00480428
360,NCT00480428,thyroid neoplasms,Study to Improve Thyroid Doses From Fallout Exposure in Kazakhstan,Radiation Exposure and Thyroid Disease in Kazakhstan,Other Thyroid Disease|Thyroid Cancer|Thyroid Nodules,2007-05-30,,2017-08-17,117.0,,,Retrospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Semipalatinsk State Medical Academy,,Kazakhstan,65.0,90.0,[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00480428
361,NCT00488644,hypothyroidism,Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors,Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors,Brain Tumor|Hypothyroidism,2007-06-19,2010-03-31,2010-03-31,12.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,UT MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00488644
363,NCT00493103,congenital hypothyroidism,Congenital Hypothyroidism Due to Thyroglobulin Mutations in an Inbred Brazilian Family: A Novel Compound Heterozygous Constellation and Intronic Mutation Related to Fetal Goiter.,TG Gene Mutations and Congenital Hypothyroidism,Congenital Hypothyroidism,2007-06-25,,2007-06-30,,,,Other,Observational,Completed,,University of Sao Paulo,Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00493103
365,NCT00497484,pseudohypoparathyroidism,Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia),Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia),"Growth Hormone Deficiency, Dwarfism|Pseudohypoparathyroidism",2007-07-05,,,,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,University of Milan,Eli Lilly and Company|University of Milan,"Endocrine Unit, Dpt. of Medical Sciences, Fondazione Policlinico IRCCS",Drug,Italy,1.0,18.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00497484
367,NCT00497575,congenital hypothyroidism,,Diagnosis and Follow-up of Patients With Subclinical Hypothyroidism,Congenital Hypothyroidism|Follow-Up|L-Thyroxine,2007-07-05,,2006-09-30,,Defined Population,,Prospective,Observational,Completed,,Zhejiang University,Zhejiang University,,,,0.0,5.0,[0-17],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00497575
368,NCT00498238,hypothyroidism,The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients,The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidism,2007-07-06,,2005-09-30,34.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Assaf-Harofeh Medical Center,Assaf-Harofeh Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00498238
370,NCT00501215,hyperparathyroidism,Pilot Study on the Effect of Parathyroidectomy on Sleep,Effect of Parathyroidectomy on Sleep,Hyperparathyroidism,2007-07-12,2017-07-09,2017-07-09,15.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Procedure|Behavioral|Procedure|Behavioral,United States,21.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00501215
371,NCT00505011,graves disease,"Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.",Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves' Disease,Graves' Disease,2007-07-18,,2007-02-28,1998.0,Case-Control,,Other,Observational,Completed,,"University of Campinas, Brazil","Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Campinas, Brazil",,,,2.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00505011
372,NCT00505011,hyperthyroidism,"Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.",Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves' Disease,Graves' Disease,2007-07-18,,2007-02-28,1998.0,Case-Control,,Other,Observational,Completed,,"University of Campinas, Brazil","Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Campinas, Brazil",,,,2.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00505011
373,NCT00505011,goiter,"Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.",Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves' Disease,Graves' Disease,2007-07-18,,2007-02-28,1998.0,Case-Control,,Other,Observational,Completed,,"University of Campinas, Brazil","Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Campinas, Brazil",,,,2.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00505011
375,NCT00505479,congenital hypothyroidism,,Iodine Status in Pregnant Women and Their Newborns: is Congenital Hypothyroidism Related to Iodine Deficiency in Pregnancy?,Congenital Hypothyroidism|Iodine Deficiency|Pregnancy,2007-07-20,,2010-05-31,,,,Prospective,Observational,Unknown status,,Zhejiang University,Zhejiang University,Children's Hospital Zhejiang University School of Medicine,,China,20.0,40.0,[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00505479
376,NCT00507429,"thyroid carcinoma, anaplastic",A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT],Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2007-07-25,2011-10-31,2011-11-30,80.0,,Parallel Assignment,,Interventional,Terminated,Phase 2/Phase 3,Mateon Therapeutics,Mateon Therapeutics,"USC/Norris Comprehensive Cancer Center|University of Colorado Cancer Center|Yale University, School of Medicine|Winship Cancer Institute, Emory University|Sidney Kimmel Comprehensive Cancer Care Center at John Hopkins|University of Minnesota Otolaryngology Department|Ireland Cancer Center/Division od Hematology|Oregon Health and Science University|University of Texas M.D. Anderson Cancer Center|West Virginia University|Belarus National Medical University|Regional Oncology Dispensary with Inpatient Sector|Specialized Hospital for Active Treatment of Oncology|Universtiy Multiprofile Hospital, ISUI, Clinic of Oncotherapy|University Hospital, Cairo|Mediciti Hospital|All India Institute of Medical Sciences|Apollo Cancer Institute|Kidwai Memorial Hospital|Shirdi Sai Baba Cancer Hospital|Tata Memorial Centre|Ruby Hall Clinic|Christian Medial College|Telaviv Sourasky Medical Center, Head and Neck Service Division of Oncology|Lo Studio E la Cura|INT Napoli Fondazione Pascale|Istituto Oncologico Veneto (IOV) - IRCCS|Azienda Ospedaliero - Universitaria Pisana|Zaklad Medyczny Nuklearnej i Endykrynologii|Klinika Nowotworow Glowy i Szyji|Institutul Oncologic|SC Meditech SRL|Centr of Medical Oncology|Clinical County Hospital Sibiu|Emergency Clinical County Hospital ""Sf. loan cel Nou""|City Clinical Oncology Dispensary|Ukrainian Academy of Medical Science|Regional Clinical Oncology Dispensary|Beatson Oncology Centre, Gartnavel General Hospital|Royal Marsden Hospital and Institute of Cancer Research|Southampton Hospital Oncology Centre",Drug|Drug|Drug,Belarus|Bulgaria|Egypt|India|Israel|Italy|Poland|Romania|Russian Federation|Ukraine|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00507429
378,NCT00507897,thyroid neoplasms,,Hemodynamic Parameters in Euthyroid Patients With Thyroid Nodules,Thyroid Nodules,2007-07-25,,2007-12-31,100.0,,,Prospective,Observational,Terminated,,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,,Russian Federation,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00507897
379,NCT00507897,thyroid nodule,,Hemodynamic Parameters in Euthyroid Patients With Thyroid Nodules,Thyroid Nodules,2007-07-25,,2007-12-31,100.0,,,Prospective,Observational,Terminated,,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,,Russian Federation,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00507897
380,NCT00509483,goiter,Long-Term Follow-up and Outcome of Administering Recombinant Human Thyrotropin as an Adjuvant of Therapy With Radioiodine in the Outpatient Treatment of Multinodular Goitres,Three-Year Follow-up of Radioiodine Therapy for Goitre,Tratment of Multinodular Goitre,2007-07-27,,2006-12-31,40.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Sao Paulo,Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo,,Radiation,,20.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00509483
381,NCT00510640,thyroid neoplasms,"Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer",Thyroid Cancer and Sunitinib,Cancer|Thyroid Carcinoma,2007-08-01,2012-03-31,2012-03-31,71.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"University Hospital, Bordeaux","Pfizer|University Hospital, Bordeaux","Centre Paul Papin - 2 rue Moll|Dpartement Endocrinolo-Diabto-Nutrition - CHU d'Angers - 4 rue de Larray|Service d'Oncologie Mdicale et de Radiothrapie - Hpital Saint Andr - 1 rue Jean Burguet|Fdration Endocrinologie - Groupe Hospitalier Est - Hpital neurologique - CHU Lyon - 59 Boulevard Pinel|Service d'Endocrinologie et maladies mtaboliques, Clinique Marc Linquette - rue du Pr Laguesse|Centre Lon Brard - Dpartement de Mdecine - 28 rue Laennec|Service d'Endocrinologie, CHU Timone, AP-HM - 254 rue St Pierre|Service des Maladies Endocriniennes - Hpital Lapeyronie - 191 avenue du Doyen Gaston Giraud|Centre Paul Lamarque - Va d'Aurelle - CRLC Val d'Aurelle - 208 rue des Apothicaires|Centre Antoine Lacassagne - 33 avenue de Valombrose|Service d'Endocrinologie - Hpital de l'Archet I - Route Saint Antoine de Jinestire|Service de Cancrologie Mdicale - HEGP - 20 rue Leblanc|Service d'Oncologie Mdicale, Institut Claudius Regaud - 20-24 rue du Pont Saint Pierre|Service d'endocrinologie et Maladies Mtaboliques, Groupe Hospitalier Rangueil-Larrey CHU Toulouse - avenue Prof Jean Poulhes|Service d'Endocrinologie - CHU de Nancy, Hpital de Brabois - rue du Morvan",Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00510640
382,NCT00513032,hyperparathyroidism,Effects of Methylene Blue on Propofol Requirement During Anaesthesia Induction and Surgery,Interaction Between Anaesthetics and Methylene Blue,Hyperparathyroidism,2007-08-07,,2007-04-30,22.0,Case-Control,,Prospective,Observational,Completed,,"University Hospital, Geneva","University Hospital, Geneva","Service d'Anesthsiologie, Hpitaux Universitaires de Genve, Rue Micheli-du-Crest",Drug,Switzerland,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00513032
384,NCT00514046,thyroid neoplasms,"Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma",Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer,Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B,2007-08-08,2019-12-10,2020-11-01,17.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,5.0,18.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00514046
386,NCT00519896,"thyroid cancer, papillary",Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation,Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2007-08-21,2015-05-31,2015-09-30,35.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Washington,National Cancer Institute (NCI)|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00519896
387,NCT00519896,"adenocarcinoma, follicular",Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation,Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2007-08-21,2015-05-31,2015-09-30,35.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Washington,National Cancer Institute (NCI)|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00519896
388,NCT00522028,hyperparathyroidism,"Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial","Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial",Primary Hyperparathyroidism,2007-08-28,2016-01-31,2016-01-31,191.0,Cohort,,Prospective,Observational,Completed,,Oslo University Hospital,"Gteborg University|Haukeland University Hospital|Karolinska University Hospital|Oslo University Hospital|Rigshospitalet, Denmark|Rikshospitalet University Hospital|St. Olavs Hospital|Uppsala University Hospital",Oslo University Hospital - Rikshospitalet,,Norway,50.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00522028
391,NCT00524238,hypothyroidism,"Impact of Hypothyroidism on Glucose, Lipid, and Amino Acid Turnover",Metabolic Changes in Hypothyroid Patients,Hypothyroidism,2007-08-31,2006-08-31,2006-08-31,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,Aarhus University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00524238
392,NCT00525122,hyperthyroidism,,Treatment of M.Graves With Radioactive Iodine: Follow-up Study,Hyperthyroidism,2007-09-04,,,100.0,Cohort,,Prospective,Observational,Unknown status,,"Medisch Centrum Rijnmond-Zuid, Netherlands","Medisch Centrum Rijnmond-Zuid, Netherlands",MCRZ,,Netherlands,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00525122
393,NCT00525135,thyroid neoplasms,"A Phase II Trial of Valproic Acid (Depakote ER ) in Patients With Advanced Thyroid Cancers of Follicular Origin, Who Are Thyroglobulin Positive/RAI Unresponsive",Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer,Head and Neck Cancer,2007-08-28,2009-03-31,2009-03-31,5.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco",UCSF Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00525135
396,NCT00527085,hyperparathyroidism,"A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism",12-month Study of AMG 073 in Renal Osteodystrophy,Renal Osteodystrophy,2007-09-06,2003-08-31,2003-08-31,45.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00527085
398,NCT00527267,hyperparathyroidism,A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis,Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects,Hyperparathyroidism,2007-09-06,2003-04-30,2003-04-30,320.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00527267
399,NCT00528502,parathyroid diseases,Prevention of Laryngeal Reflexes in Minimal Invasive Parathyroid Surgery by the Use of Topical Lidocaine,Lidocaine Supplement for Minimal Invasive Parathyroid Surgery,Parathyroid Disease,2007-09-11,2008-01-31,2008-01-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 3,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,,Drug|Drug,,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT00528502
401,NCT00528788,hyperparathyroidism,Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease,How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis,"Hyperparathyroidism, Secondary|Kidney Failure, Chronic",2007-09-10,2012-08-31,2012-08-31,24.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Duke University,"Duke University|Genzyme, a Sanofi Company",Duke University Medical Center Dialysis Unit,Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00528788
403,NCT00531713,hypothyroidism,"Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,a Double Blind Randomized Cross-Over Study.",Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,Depression|Quality of Life,2007-09-18,,2007-03-31,59.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,"Dept of endocrinology , Herlev Hospital",Drug,Denmark,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00531713
404,NCT00535561,hypothyroidism,"Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism: A Randomized, Double Blinded Study",Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism,Iron Deficiency Anemia|Subclinical Hypothyroidism,2007-09-25,,2007-09-30,,,Parallel Assignment,,Interventional,Completed,Phase 1,Duzce University,Duzce University,Duzce University School of Medicine,Drug|Drug,Turkey,23.0,73.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00535561
405,NCT00537095,thyroid neoplasms,"A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy",Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer,Thyroid Neoplasms,2007-09-27,2009-12-31,2022-12-31,165.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Other,Belgium|Denmark|France|Norway|Spain|Sweden|Switzerland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00537095
406,NCT00537797,thyroid neoplasms,Limited Neck FDG-PET Imaging for Indeterminate Thyroid Nodules,Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules,Thyroid Neoplasms,2007-09-28,2011-09-30,2014-02-28,84.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Washington University School of Medicine,Washington University School of Medicine,Washington University School of Medicine|St. Louis University School of Medicine|VAMC,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00537797
407,NCT00537797,thyroid nodule,Limited Neck FDG-PET Imaging for Indeterminate Thyroid Nodules,Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules,Thyroid Neoplasms,2007-09-28,2011-09-30,2014-02-28,84.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Washington University School of Medicine,Washington University School of Medicine,Washington University School of Medicine|St. Louis University School of Medicine|VAMC,Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00537797
408,NCT00537979,hyperparathyroidism,"Prospective, Non-randomized, Multicenter Study to Assess the Efficacy and Safety of Oral or Intravenous Paricalcitol Administered Over 6 Months to Patients With Secondary Hyperparathyroidism on Dialysis",Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis,Dialysis|Secondary Hyperparathyroidism,2007-09-28,2010-07-31,2010-07-31,147.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Site Ref # / Investigator 19391|Site Ref # / Investigator 19389|Site Ref # / Investigator 19390|Site Ref # / Investigator 19393|Site Ref # / Investigator 19395|Site Ref # / Investigator 19392|Site Ref # / Investigator 19397|Site Ref # / Investigator 19396|Site Ref # / Investigator 19394|Site Ref # / Investigator 19399|Site Ref # / Investigator 19398|Site Ref # / Investigator 19388,Drug|Drug,Mexico,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00537979
413,NCT00538720,hyperparathyroidism,Pilot Study to Detect and Assess the Effect of Vitamin D Replacement on Gland Size by 4DCT in Patients With Primary Hyperparathyroidism (PHPT),Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT),Hyperparathyroidism,2007-10-02,2018-05-30,2018-05-30,22.0,,Single Group Assignment,,Interventional,Completed,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Drug|Device,United States,21.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00538720
414,NCT00551486,thyroid neoplasms,Diagnostic Value of Pyrosequencing for the BRAFV600E Mutation in Ultrasound-Guided Fine-Needle Aspiration Biopsy Samples of Thyroid Incidentalomas,Pyrosequencing of the BRAFV600E Mutation,Thyroid Neoplasms,2007-10-30,,2006-12-31,101.0,,,Prospective,Observational,Completed,,Chungnam National University,Chungnam National University,Chungnam National University Hospital,Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00551486
415,NCT00552253,thyroid nodule,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Thyroid Nodule,2007-10-30,2008-07-31,2008-07-31,10.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,20.0,90.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00552253
417,NCT00552253,goiter,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Thyroid Nodule,2007-10-30,2008-07-31,2008-07-31,10.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,20.0,90.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00552253
418,NCT00552253,thyroid neoplasms,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Thyroid Nodule,2007-10-30,2008-07-31,2008-07-31,10.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,20.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00552253
421,NCT00552487,hashimoto disease,Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis,Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis,Adrenal Insufficiency|Hashimoto Disease,2007-10-31,,2006-07-31,62.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Wuerzburg,University of Wuerzburg,"University of Wuerzburg, Department of Endocrinology",Drug,Germany,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT00552487
422,NCT00556530,hypoparathyroidism,Genetic Modifiers of 22q11.2 Deletion Syndrome,Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome,22q11.2 Deletion Syndrome|DiGeorge Syndrome,2007-11-08,2022-06-06,2025-07-31,1000.0,Family-Based,,Prospective,Observational,Recruiting,,Albert Einstein College of Medicine,"Albert Einstein College of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",Albert Einstein College of Medicine|Children's Hospital of Philadelphia,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00556530
424,NCT00559949,"thyroid cancer, papillary",Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements,Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,2007-11-16,2016-08-31,2016-08-31,39.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Moffitt Cancer Center|University of Chicago Comprehensive Cancer Center|UNC Lineberger Comprehensive Cancer Center|Fox Chase Cancer Center|Vanderbilt University/Ingram Cancer Center|University Health Network-Princess Margaret Hospital,Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00559949
426,NCT00560300,hyperparathyroidism,Regulation of Bone Formation in Renal Osteodystrophy,Regulation of Bone Formation in Renal Osteodystrophy,Renal Osteodystrophy|Secondary Hyperparathyroidism,2007-11-13,,2006-11-30,61.0,,Factorial Assignment,,Interventional,Completed,Phase 2,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,Drug|Drug|Drug|Drug,,2.0,21.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00560300
429,NCT00565864,hypothyroidism,Neurocognitive and Metabolic Effects of Mild Hypothyroidism,Neurocognitive and Metabolic Effects of Mild Hypothyroidism,Hypothyroidism,2007-11-28,2013-08-31,2013-08-31,173.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Oregon Health and Science University,Oregon Health and Science University,Oregon Health and Science University,Drug,United States,20.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00565864
430,NCT00566488,hypoparathyroidism,"Parathyroid and Thymus Transplantation in DiGeorge Syndrome, #931",Parathyroid and Thymus Transplantation in DiGeorge #931,Complete DiGeorge Syndrome|DiGeorge Syndrome|Hypoparathyroidism,2007-11-30,2007-08-31,2019-12-31,25.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Food and Drug Administration (FDA)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological,United States,0.0,24.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00566488
432,NCT00568438,thyroid neoplasms,Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples,Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample,Breast Cancer|Salivary Gland Neoplasms|Stomach Neoplasms|Thyroid Cancer,2007-12-04,2020-04-30,2020-04-30,300.0,Cohort,,Retrospective,Observational,Unknown status,,Stanford University,Stanford University,Stanford University School of Medicine,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00568438
433,NCT00569920,parathyroid diseases,"Nausea and Pain Prophylaxis During Thyroid Surgery, a Comparison of Low-Dose and High-Dose Dexamethasone to Placebo",Nausea and Pain Prophylaxis During Thyroid Surgery,Parathyroid Diseases|Thyroid Diseases,2007-12-07,2008-12-31,2008-12-31,120.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Sykehuset Telemark,Sykehuset Telemark,"Surgery Unit, Porsgrunn, Acute Care Clinic, Telemark Hospital",Drug|Drug|Drug,Norway,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT00569920
434,NCT00571077,thyroid nodule,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Thyroid Neoplasms|Thyroid Nodules,2007-12-10,,2007-12-31,200.0,,,Prospective,Observational,Completed,,Hadassah Medical Organization,Hadassah Medical Organization|Walter Reed Army Medical Center,Walter Reed Army MEdicla Center|Hadassah-Hebrew University Medical Center,Device,Israel|United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00571077
435,NCT00571077,thyroid neoplasms,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Thyroid Neoplasms|Thyroid Nodules,2007-12-10,,2007-12-31,200.0,,,Prospective,Observational,Completed,,Hadassah Medical Organization,Hadassah Medical Organization|Walter Reed Army Medical Center,Walter Reed Army MEdicla Center|Hadassah-Hebrew University Medical Center,Device,Israel|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00571077
436,NCT00571090,thyroid neoplasms,Evaluation of Thyroid Fine Needle Aspiration Biopsies: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Thyroid Nodule,2007-12-10,2012-07-31,2013-07-31,735.0,Case-Only,,Cross-Sectional,Observational,Completed,,Istanbul Science University,Group Florence Nightingale|Istanbul Science University,Group Florence Nightingale,Procedure,Turkey,15.0,89.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00571090
437,NCT00571090,thyroid nodule,Evaluation of Thyroid Fine Needle Aspiration Biopsies: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Thyroid Nodule,2007-12-10,2012-07-31,2013-07-31,735.0,Case-Only,,Cross-Sectional,Observational,Completed,,Istanbul Science University,Group Florence Nightingale|Istanbul Science University,Group Florence Nightingale,Procedure,Turkey,15.0,89.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00571090
438,NCT00573573,hyperparathyroidism,Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.,Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism,Hyperparathyroidism,2007-12-12,2009-03-31,2009-07-31,2.0,,Single Group Assignment,,Interventional,Unknown status,Phase 1,GAAD Medical Research Institute Inc.,GAAD Medical Research Institute Inc.,The Centre for Incurable Diseases,Radiation,Canada,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00573573
441,NCT00576407,hypoparathyroidism,Phase II Study of Thymus Transplantation in Complete DiGeorge Syndrome #668,Thymus Transplantation in DiGeorge Syndrome #668,Complete Typical DiGeorge Anomaly|DiGeorge Syndrome,2007-12-17,2009-04-30,2017-12-31,26.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00576407
442,NCT00576836,hypoparathyroidism,"Dose Study of Thymus Transplantation in DiGeorge Anomaly, IND 9836, #932.1",Thymus Transplantation Dose in DiGeorge #932,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly|DiGeorge Syndrome,2007-12-17,2010-11-30,2019-12-31,7.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00576836
445,NCT00579527,hypoparathyroidism,"Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950",Phase I/II Thymus Transplantation With Immunosuppression #950,Complete Atypical DiGeorge Anomaly|Complete Atypical DiGeorge Syndrome|Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly,2007-12-20,2011-12-31,2017-12-31,14.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological|Other|Procedure|Drug|Drug|Drug|Drug|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00579527
447,NCT00579709,hypoparathyroidism,"Thymus Transplantation With Immunosuppression, #884",Thymus Transplantation With Immunosuppression,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly|DiGeorge Syndrome,2007-12-20,2006-12-31,2019-12-31,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00579709
448,NCT00580320,parathyroid neoplasms,Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,Carcinoid Tumors|Melanoma|Parathyroid Carcinoma|Small Cell Carcinoma of the Lung|Soft Tissue Sarcoma,2007-12-18,2009-10-31,2013-11-30,17.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Virginia Commonwealth University,Virginia Commonwealth University,Dartmouth Hitchcock Medical Center|Massey Cancer Center/Virginia Commonwealth University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00580320
451,NCT00580788,hyperparathyroidism,Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone-related Protein(1-36): Effects on Bone Formation,One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study,Humoral Hypercalcemia of Malignancy|Hyperparathyroidism|Osteoporosis,2007-12-20,2009-12-31,2009-12-31,14.0,,Single Group Assignment,,Interventional,Completed,Early Phase 1,University of Pittsburgh,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh,University of Pittsburgh Medical Center,Drug,United States,24.0,35.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00580788
452,NCT00581828,hypoparathyroidism,Does Treatment of Hypovitaminosis D Increase Calcium Absorption?,Does Treatment of Hypovitaminosis D Increase Calcium Absorption?,Hypercalcemia|Hypercalciuria|Hypoparathyroidism|Osteopenia|Osteoporosis|Vitamin D Deficiency,2007-12-19,2008-07-31,2008-12-31,19.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University of Wisconsin, Madison","University of Wisconsin, Madison",University of Wisconsin Hospital and Clinics,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00581828
454,NCT00582712,thyroid neoplasms,An Initial Study of Lithium in Patients With Medullary Thyroid Cancer,An Initial Study of Lithium in Patients With Medullary Thyroid Cancer,Medullary Thyroid Cancer,2007-12-19,2009-05-31,2012-04-30,5.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,"University of Wisconsin, Madison","University of Wisconsin, Madison",Uniersity of Wisconsin Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00582712
455,NCT00587158,hyperparathyroidism,Oral Paricalcitol in Kidney Transplant Recipients Receiving a Corticosteroid-free Immunosuppressive Regimen,Oral Paricalcitol in Kidney Transplant Recipients,"Hyperparathyroidism, Secondary|Renal Disease, End Stage|Transplant; Failure, Kidney",2007-12-21,2011-11-30,2011-11-30,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mayo Clinic,Abbott|Mayo Clinic,Mayo Clinic|Mayo Clinic,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00587158
458,NCT00588432,hyperthyroidism,Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE),Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE),Hyperthyroid Myopathy|Immobilization|Myofacial Pain|Stroke,2007-12-26,2009-09-30,2009-09-30,300.0,Case-Control,,Cross-Sectional,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00588432
459,NCT00591032,euthyroid sick syndromes,Development of Rational and Standardized Diagnostics and Staging for a Differentiated Risk Stratification of Non-thyroidal Illness Syndrome,Approach to a Quantitative Follow-up of Non-thyroidal Illness Syndrome,Euthyroid Sick Syndromes|Low T3 Syndrome|Non-thyroidal Illness Syndrome|TACITUS,2007-12-26,2017-11-30,2020-12-31,590.0,Cohort,,Prospective,Observational,Active not recruiting,,Ruhr University of Bochum,Private Sponsor (Chantal C. Guilhemotonia-Urban)|Ruhr University of Bochum|Wissenschaftskommission des Universitaetsklinikums Bergmannsheil,"Department for medical informatics, biometry and epidemiology, Ruhr-University of Bochum|Institute of Clinical Chemistry, Transfusion and Laboratory Medicine, Universittsklinikum Bergmannsheil, Ruhr-Universitt Bochum|Medical Hospital II, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medizinische Klinik I, Universittsklinikum Bergmannsheil, Ruhr-Universitt Bochum|Diabetes-Zentrum, Mathias-Spital|Abteilung fr Laboratoriums- und Transfusionsmedizin, Westpfalz-Klinikum Kaiserslautern",,Germany,0.0,120.0,[0-17]|[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT00591032
460,NCT00595335,graves ophthalmopathy,Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy,Trial of Rituximab for Graves' Ophthalmopathy,Thyroid-associated Ophthalmopathy,2008-01-01,2013-03-31,2013-09-30,25.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Rebecca Bahn,Mayo Clinic,Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00595335
461,NCT00595335,graves disease,Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy,Trial of Rituximab for Graves' Ophthalmopathy,Thyroid-associated Ophthalmopathy,2008-01-01,2013-03-31,2013-09-30,25.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Rebecca Bahn,Mayo Clinic,Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00595335
462,NCT00595335,goiter,Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy,Trial of Rituximab for Graves' Ophthalmopathy,Thyroid-associated Ophthalmopathy,2008-01-01,2013-03-31,2013-09-30,25.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Rebecca Bahn,Mayo Clinic,Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00595335
463,NCT00595335,hyperthyroidism,Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy,Trial of Rituximab for Graves' Ophthalmopathy,Thyroid-associated Ophthalmopathy,2008-01-01,2013-03-31,2013-09-30,25.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Rebecca Bahn,Mayo Clinic,Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00595335
464,NCT00598364,thyroid neoplasms,Molecular Markers in the Diagnostic and Prognostic Evaluation of Thyroid Cancer,Molecular Markers in Thyroid Cancer,Thyroid Cancer,2008-01-10,2010-10-31,2010-10-31,847.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,OHSU Knight Cancer Institute,OHSU Knight Cancer Institute,Oregon Health & Science University,,United States,1.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00598364
467,NCT00601328,hyperparathyroidism,"A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Calcitriol Tablets, 0.25 mg, Under Fasting Conditions",Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions,Hypocalcemia|Secondary Hyperparathyroidism,2008-01-15,2003-08-31,2003-08-31,36.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,West-Ward Pharmaceutical,Roxane Laboratories,"Bio-Kinetic Clinical Applications, Inc.",Drug,United States,18.0,45.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00601328
469,NCT00603941,"thyroid carcinoma, anaplastic","A Phase 1/2 Study of CS7017, an Oral PPAR Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer","A Phase 1/2 Study of CS7017, an Oral PPAR Agonist, in Combination With Paclitaxel",Anaplastic Thyroid Cancer,2008-01-15,2011-12-31,2011-12-31,19.0,,Sequential Assignment,,Interventional,Terminated,Phase 1/Phase 2,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.","Univ of Colorado Cancer Center|Mayo Clinic|Massachusetts General Hospital|Mayo Clinic|Washington University, Siteman Cancer Center|Ohio State Univ|Oregon Health Science Univ|University of Pennsylvania Maloney Hospital|Vanderbilt Ingram Cancer Center|Eastern Virginia Medical School",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00603941
470,NCT00604318,thyroid neoplasms,"Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer?","Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer",Thyroid Cancer,2008-01-17,2012-02-29,2012-02-29,56.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev|Odense University Hospital,"Dept of Oncology, Herlev Hospital",Drug,Denmark,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00604318
472,NCT00615537,"goiter, nodular",Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Nodular Goiter|Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2008-02-03,2011-01-31,2011-01-31,20.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"BioTex, Inc.","BioTex, Inc.|Rhode Island Hospital",Rhode Island Hospital - Department of Diagnostic Imaging Research,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00615537
473,NCT00615537,thyroid nodule,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Nodular Goiter|Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2008-02-03,2011-01-31,2011-01-31,20.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"BioTex, Inc.","BioTex, Inc.|Rhode Island Hospital",Rhode Island Hospital - Department of Diagnostic Imaging Research,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00615537
474,NCT00615537,thyroid neoplasms,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Nodular Goiter|Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2008-02-03,2011-01-31,2011-01-31,20.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"BioTex, Inc.","BioTex, Inc.|Rhode Island Hospital",Rhode Island Hospital - Department of Diagnostic Imaging Research,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00615537
476,NCT00625846,"thyroid carcinoma, anaplastic",A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer,Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer,Recurrent Thyroid Gland Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Thyroid Gland Anaplastic Carcinoma,2008-02-27,2018-12-21,2019-08-13,152.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic in Arizona|University of Colorado Hospital|Mayo Clinic in Florida|University of Iowa/Holden Comprehensive Cancer Center|Johns Hopkins University/Sidney Kimmel Cancer Center|Wayne State University/Karmanos Cancer Institute|Fairview Ridges Hospital|Fairview-Southdale Hospital|Unity Hospital|Minnesota Oncology Hematology PA-Maplewood|Abbott-Northwestern Hospital|Mayo Clinic|Park Nicollet Clinic - Saint Louis Park|United Hospital|Washington University School of Medicine|University of Wisconsin Hospital and Clinics|Sir Charles Gairdner Hospital|Chinese University of Hong Kong-Prince of Wales Hospital|National University Hospital Singapore|National Cancer Centre|Johns Hopkins Singapore|National Taiwan University Hospital,Other|Drug,Australia|China|Singapore|Taiwan|United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00625846
477,NCT00639405,parathyroid neoplasms,Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism,Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas,Parathyroid Diseases|Parathyroid Neoplasm,2008-03-12,2008-08-31,2008-08-31,12.0,Case-Only,,Prospective,Observational,Terminated,,State University of New York - Upstate Medical University,State University of New York - Upstate Medical University,SUNY Upstate Medical University,,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00639405
481,NCT00646282,hyperparathyroidism,Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney,Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients,"Hyperparathyroidism, Secondary",2008-03-25,2010-01-31,2010-01-31,12.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,Emory University,Emory University,Emory University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00646282
482,NCT00647140,thyroid neoplasms,Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer.,Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer,Medullary Carcinoma|Thyroid Carcinoma|Thyroid Neoplasm,2008-03-26,2009-08-31,2010-02-28,29.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Hpital Antoine Beclere,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00647140
483,NCT00651625,thyroid neoplasms,Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures,Reciprocating Medical Devices - a Study of a New Safety Device,Cancer|Osteoarthritis|Rheumatoid Arthritis|Thyroid Nodule|Trauma,2008-03-21,2010-01-31,2010-08-31,437.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of New Mexico,University of New Mexico,University of New Mexico Health Sciences Center,Device|Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00651625
484,NCT00651625,thyroid nodule,Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures,Reciprocating Medical Devices - a Study of a New Safety Device,Cancer|Osteoarthritis|Rheumatoid Arthritis|Thyroid Nodule|Trauma,2008-03-21,2010-01-31,2010-08-31,437.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of New Mexico,University of New Mexico,University of New Mexico Health Sciences Center,Device|Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00651625
485,NCT00654238,"thyroid carcinoma, anaplastic",Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer,Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer,Metastatic Anaplastic Thyroid Cancer|Metastatic Differentiated Thyroid Cancer|Metastatic Medullary Thyroid Cancer|Metastatic Poorly Differentiated Thyroid Cancer,2008-04-01,2010-12-31,2011-03-31,59.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Pennsylvania,University of Pennsylvania,University of Pennsylvania - Abramson Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00654238
487,NCT00664430,hyperparathyroidism,Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects,Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects,Dialysis|Secondary Hyperparathyroidism,2008-04-21,2009-06-30,2009-06-30,13.0,,Single Group Assignment,,Interventional,Terminated,Phase 4,Abbott,Abbott|Statistika Consultoria Ltda,Site Reference ID/Investigator# 7118|Site Reference ID/Investigator# 7114,Drug|Drug,Brazil,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00664430
490,NCT00665795,graves ophthalmopathy,Morphometric Analysis of Orbital Structures in Graves Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.,Morphometric Analysis of Orbital Structures in Graves Orbitopathy,Dysthyroid Orbitopathy,2008-04-22,2013-11-30,2013-11-30,80.0,Cohort,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,General Hospital - University of Sao Paulo - School of Medicine,,Brazil,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00665795
491,NCT00665795,graves disease,Morphometric Analysis of Orbital Structures in Graves Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.,Morphometric Analysis of Orbital Structures in Graves Orbitopathy,Dysthyroid Orbitopathy,2008-04-22,2013-11-30,2013-11-30,80.0,Cohort,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,General Hospital - University of Sao Paulo - School of Medicine,,Brazil,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00665795
492,NCT00665795,goiter,Morphometric Analysis of Orbital Structures in Graves Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.,Morphometric Analysis of Orbital Structures in Graves Orbitopathy,Dysthyroid Orbitopathy,2008-04-22,2013-11-30,2013-11-30,80.0,Cohort,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,General Hospital - University of Sao Paulo - School of Medicine,,Brazil,20.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00665795
493,NCT00665795,hyperthyroidism,Morphometric Analysis of Orbital Structures in Graves Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.,Morphometric Analysis of Orbital Structures in Graves Orbitopathy,Dysthyroid Orbitopathy,2008-04-22,2013-11-30,2013-11-30,80.0,Cohort,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,General Hospital - University of Sao Paulo - School of Medicine,,Brazil,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00665795
495,NCT00667576,hyperparathyroidism,Late Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose),Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis,Chronic Kidney Disease on Hemodialysis|Secondary Hyperparathyroidism,2008-04-24,2009-03-31,2009-03-31,153.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Abbott,"Abbott|Abbott Japan Co.,Ltd",,Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00667576
498,NCT00668811,"thyroid cancer, papillary",Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer,2008-04-25,2015-09-30,2015-12-31,23.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Medstar Health Research Institute,Medstar Health Research Institute|Pfizer,MedStar Washington Hospital Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00668811
499,NCT00668811,"adenocarcinoma, follicular",Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer,2008-04-25,2015-09-30,2015-12-31,23.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Medstar Health Research Institute,Medstar Health Research Institute|Pfizer,MedStar Washington Hospital Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00668811
500,NCT00673010,thyroid neoplasms,Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma,Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma,Thyroid Cancer,2008-05-06,2023-03-31,2023-03-31,20.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,"Gustave Roussy, Cancer Campus, Grand Paris|Memorial Sloan Kettering Cancer Center",Memorial Sloan Kettering Cancer Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00673010
502,NCT00674154,hyperparathyroidism,Effect of Vitamin D Treatment in Primary Hyperparathyroidism,Effect of Vitamin D Treatment in Primary Hyperparathyroidism,Hypercalcemia|Primary Hyperparathyroidism|Vitamin D Deficiency,2008-05-05,2013-08-31,2013-08-31,46.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,University of Aarhus,University of Aarhus,"Osteoporoseklinikken, Aarhus University Hospital, THG",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00674154
504,NCT00677469,graves disease,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Graves Disease,2008-05-12,2008-01-31,2008-01-31,45.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Shiraz University of Medical Sciences,Shiraz University of Medical Sciences,Endocrine and Metabolism Research Center,Drug|Drug|Drug,"Iran, Islamic Republic of",20.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00677469
505,NCT00677469,hyperthyroidism,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Graves Disease,2008-05-12,2008-01-31,2008-01-31,45.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Shiraz University of Medical Sciences,Shiraz University of Medical Sciences,Endocrine and Metabolism Research Center,Drug|Drug|Drug,"Iran, Islamic Republic of",20.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00677469
506,NCT00677469,goiter,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Graves Disease,2008-05-12,2008-01-31,2008-01-31,45.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Shiraz University of Medical Sciences,Shiraz University of Medical Sciences,Endocrine and Metabolism Research Center,Drug|Drug|Drug,"Iran, Islamic Republic of",20.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00677469
507,NCT00687778,thyroid neoplasms,,11C-Acetate PET/CT Non-FDG-Avid Tumors,"Carcinoma, Hepatocellular|Carcinoma, Lobular|GIST|Indolent Lymphoma|Lung Cancer|Neuroendocrine Tumors|Soft Tissue Sarcomas|Teratoma|Thyroid Cancer|Uterine Malignancies",2008-05-28,2009-06-30,2010-06-30,100.0,Cohort,,Prospective,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,"Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center",,Israel,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00687778
508,NCT00691990,goiter,Classic Total Thyroidectomy With or Without Drains,Classic Total Thyroidectomy With or Without Drains,Goiter,2008-06-05,2009-12-31,2011-07-31,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,"3rd Department of Surgery, AHEPA University Hospital",Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00691990
509,NCT00692835,goiter,Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT),Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT),Goiter,2008-06-05,2009-12-31,2012-09-30,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,"3rd Department of Surgery, AHEPA University Hospital",Procedure|Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00692835
510,NCT00693147,goiter,Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T),Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T),Goiter,2008-06-05,2009-12-31,2012-09-30,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,"3rd Department of Surgery, AHEPA University Hospital",Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00693147
511,NCT00697528,graves ophthalmopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Graves' Disease|Graves' Ophthalmopathy,2008-06-11,2008-12-31,2008-12-31,66.0,Case-Control,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,Hospital das Clnicas da Universidade So Paulo,,Brazil,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00697528
512,NCT00697528,goiter,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Graves' Disease|Graves' Ophthalmopathy,2008-06-11,2008-12-31,2008-12-31,66.0,Case-Control,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,Hospital das Clnicas da Universidade So Paulo,,Brazil,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00697528
513,NCT00697528,hyperthyroidism,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Graves' Disease|Graves' Ophthalmopathy,2008-06-11,2008-12-31,2008-12-31,66.0,Case-Control,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,Hospital das Clnicas da Universidade So Paulo,,Brazil,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00697528
514,NCT00697528,graves disease,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Graves' Disease|Graves' Ophthalmopathy,2008-06-11,2008-12-31,2008-12-31,66.0,Case-Control,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,Hospital das Clnicas da Universidade So Paulo,,Brazil,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00697528
515,NCT00701805,hyperparathyroidism,Phase II Study of Paricalcitol Injection Extension Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism,Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD),Hemodialysis|Secondary Hyperparathyroidism,2008-06-17,2009-12-31,2009-12-31,107.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Abbott,"Abbott|Abbott Japan Co.,Ltd",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00701805
518,NCT00704730,thyroid neoplasms,"An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer",Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer,Thyroid Cancer,2008-06-23,2011-10-31,2020-09-30,330.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Exelixis,Exelixis,"University of Alabama at Birmingham, Comprehensive Cancer Center|TGEN Clinical Research Service at Scottsdale Healthcare|University of Arkansas for Medical Sciences|UCLA|Stanford Cancer Center|University of Colorado Cancer Center|Yale University, School of Medicine|Washington Cancer Institute|H. Lee Moffet Cancer Center and Research Institute|University of Chicago|Indiana University Melvin and Bren Simon Cancer Center|University of Iowa|Kansas University Medical Center|Johns Hopkins University|Massachusetts General Hospital|Henry Ford Health System|Mayo Clinic|Capitol Comprehensive Cancer Care Clinic and Research Institute|Washington University School of Medicine|Nebraska Methodist Hospital|Ohio State University, James Cancer Hospital|Oregon Health & Science University|St. Luke's Hospital & Health Network|Hospital of the University of Pennsylvania|Hollings Cancer Center|Vanderbilt University Medical Center|Vermont Cancer Center at Fletcher Allen Health Care|Peninsula Cancer Institute|Multiple site locations|Cliniques Universitaires St. Luc|Universitair Ziekenhuis|Multiple site locations|CHUM - Hopital Saint-Luc|Klinik fuer Nuklearmedizin des Universitaetsklinikums Essen|Gemeinschaftspraxis|Universitaetsklinikum Leipzig|Johannes-Gutenberg Universitaet Mainz|Klinikum der Ludwig-Maximilians-Universitaet Muenchen|Ludwig-Maximilians-Universitaet Muenchen|Universitaetsklinikum Tuebingen|Universitaetsklinikum Wuerzburg|Kidwai Institute of Oncology|Indo-American Cancer Institute and Research Center|SEAROC Cancer Institute, S.K. Soni Hospital|Netaji Subhash Chandra Bose Cancer Hospital Research Institute|Central India Cancer Research Institute|Shatabdi Superspeciality Hospital|All India Institute of Medical Sciences|Deenanath Mangeshkar Hospital & Research Center|Ruby Hall Clinic|Multiple site locations|Multiple site locations|Multiple site locations",Drug|Drug,"Austria|Belgium|Brazil|Canada|Chile|Denmark|France|Germany|Greece|India|Israel|Italy|Korea, Republic of|Netherlands|Peru|Poland|Portugal|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00704730
519,NCT00715572,hypothyroidism,Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone in the Treatment of Primary Hypothyroidism,Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone,Hypothyroidism,2008-07-11,2004-02-29,2004-05-31,36.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,I.M. Sechenov First Moscow State Medical University,I.M. Sechenov First Moscow State Medical University,,Drug|Drug,,18.0,48.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00715572
520,NCT00718770,thyroid neoplasms,Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: A Pilot Clinical Trial and Correlation to Retinoid and PPARy Receptor Expression,A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression,Thyroid Cancer,2008-07-17,2013-01-31,2013-02-28,10.0,,Single Group Assignment,,Interventional,Completed,Early Phase 1,"University of Colorado, Denver","American Cancer Society, Inc.|Eisai Inc.|University of Colorado, Denver",University of Colorado Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00718770
521,NCT00719615,thyroid neoplasms,The Relationship Between Vitamin D and Thyroid Cancer,Assess Vitamin D Levels in Those With & Without Thyroid Cancer,Thyroid Cancer,2008-07-17,2009-03-31,2009-06-30,111.0,Case-Control,,Prospective,Observational,Completed,,University of Nebraska,University of Nebraska,University of Nebraska Medical Center,,United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00719615
522,NCT00729157,"adenocarcinoma, follicular",A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy,Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,2008-08-06,2012-10-31,2012-11-30,41.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center,Radiation|Other|Other|Procedure|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00729157
523,NCT00729157,"thyroid cancer, papillary",A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy,Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,2008-08-06,2012-10-31,2012-11-30,41.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center,Radiation|Other|Other|Procedure|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00729157
526,NCT00730210,hypoparathyroidism,Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life,Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life,Hypoparathyroidism,2008-08-04,2010-08-31,2010-08-31,62.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Aarhus,University of Aarhus,"Osteoporoseklinikken, Aarhus University Hospital",Drug|Drug,Denmark,25.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00730210
528,NCT00732615,hypoparathyroidism,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism",Use of NPSP558 in the Treatment of Hypoparathyroidism,Hypoparathyroidism,2008-08-08,2011-09-28,2011-09-28,124.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Takeda,Shire,"Mayo Clinic-Scottsdale|Advance Medical Research LLC|Diabetes Associates|University of California-San Francisco VA Medical Center|Palm Springs Research Institute|Mayo Clinic Jacksonville|University of Chicago Medical Center|Indiana University School of Medicine|Massachusetts General Hospital|Michigan Bone and Mineral Clinic PC|Mayo Clinic Rochester|Columbia University Medical Center|University Physicians Group|Physicians East|University of Cincinnati Bone Health and Osteoporosis Center|Children's Hospital of Philadelphia|Cetero Research DGD Research Inc.|Hillcrest Family Health Center|The Vancouver Clinic|Chetre Hospitalier Universitaire de Liege|Heritage Medical Research Clinic|Capital District Health Authority, QEII Health Sciences Centre|Oakville Bone Center|Aarhus University Hospital|Odense University Hospital|Hpital Europen Georges Pompidou|Semmelweis University Medical School|University of Pcs, School of Medicine|University of Szeged|University Hospital of Careggi|Royal Liverpool University Hospital",Drug|Drug,Belgium|Canada|Denmark|France|Hungary|Italy|United Kingdom|United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00732615
530,NCT00742716,hyperparathyroidism,"An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis",Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease,Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2008-08-26,2010-02-28,2010-06-30,41.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.","Pines Clinical Research, Inc.|Boise Kidney and Hypertension Institute|Western New England Renal & Transplant Associates (WNERTA)|Southeast Renal Research Institute|U.S. Renal Care|Capital District Heatlth Authority: Centre for Clinical Research|St. Joseph's Health Care London|St. Michael's Hospital|Humber River Regional Hospital|Hpital Charles-Lemoyne|Hpital du Sacr-Coeur de Montral|Hospital de Verdun",Drug,Canada|United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00742716
533,NCT00743782,hypoparathyroidism,Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism,Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism,Hypocalcemia|Hypoparathyroidism,2008-08-28,2014-04-07,2014-04-07,24.0,,Crossover Assignment,,Interventional,Completed,Early Phase 1,National Institutes of Health Clinical Center (CC),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,7.0,70.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00743782
535,NCT00744302,hyperparathyroidism,Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.,Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.,Hypercalcemia|Hyperparathyroidism,2008-08-28,2009-12-31,2009-12-31,180.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Sun Yat-sen University,Sun Yat-sen University,"The 1st Affiliated Hospital, Sun Yet-sen University",Drug,China,14.0,65.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00744302
536,NCT00747760,hypothyroidism,The Prevalence of TSH Receptor Mutation Among the Arab Population of Israel,TSH Receptor Mutations Among a Consanguineous Community,Hypothyroidism,2008-09-04,2006-07-31,2006-12-31,209.0,Cohort,,Prospective,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel|National Institutes of Health (NIH)",Samuell Refetoff|Ha'Emek Medical Center,,Israel|United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00747760
537,NCT00749697,thyroid neoplasms,Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine,Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases,Metastatic Sites Lung Bone Nodal|Thyroid Carcinoma,2008-09-05,2010-01-31,2010-07-31,10.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Other,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00749697
539,NCT00752401,hyperparathyroidism,"VITA-D: Cholecalciferol Substitution in Vitamin D Deficient Kidney Transplant Recipients: A Randomized, Placebo-controlled Study to Evaluate the Posttransplant Outcome",Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients,Kidney Transplantation|Renal Osteodystrophy|Vitamin D Deficiency,2008-09-11,2014-07-31,2014-07-31,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,"Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis",Drug|Drug,Austria,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00752401
541,NCT00754182,thyroid neoplasms,Comparison of Esthetic Results Between Subcuticular Suture and Synthetic Glue in Thyroidectomy Incision: a RCT,Subcuticular Suture Versus Synthetic Glue in Thyroidectomy Incision,Goiter|Parathyroid Pathologies|Thyroid Neoplasms,2008-09-16,2010-05-31,2010-05-31,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero-Universitaria di Modena,Policlinico di Modena,Device|Device,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00754182
544,NCT00754442,hyperparathyroidism,Clinical and Molecular Characterization of Suspected Partial 25-hydroxyvitamin D-1-alpha-hydroxylase Deficiency,Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2008-09-17,2008-08-31,2008-08-31,20.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"University of Maryland, Baltimore","University of Maryland, Baltimore",University of Maryland School of Medicine Division of Endocrinology,Drug,United States,40.0,59.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00754442
546,NCT00768820,hypoparathyroidism,"The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors",The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome,Fragile X Syndrome|Velocardiofacial Syndrome|Williams Syndrome,2008-10-07,2022-12-31,2022-12-31,400.0,,Single Group Assignment,,Interventional,Recruiting,Phase 4,The Chaim Sheba Medical Center,The Chaim Sheba Medical Center,Schneider Children's Mediac Center of Israel,Drug,Israel,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00768820
547,NCT00770016,hypothyroidism,Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism,Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism,Hypothyroidism,2008-10-08,2010-01-31,2011-01-31,0.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,University of Aarhus,"MR Research Center, Skejby Sygehus, Brendstrupgaardsvej 100, 8200 Aarhus N|University of Aarhus","Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus Sygehus,",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00770016
550,NCT00781417,hyperparathyroidism,Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease,Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease,Kidney Disease,2008-10-28,2011-10-31,2011-12-31,48.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Atlanta VA Medical Center,Atlanta VA Medical Center|Emory University,Atlanta VAMC,Dietary Supplement|Other,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00781417
551,NCT00782366,graves disease,Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment,Predictive Genetic Risk Assessment Trial,Atrial Fibrillation|Breast Cancer|Celiac Disease|Colon Cancer|Diabetes Type 2|Graves Disease|Lung Cancer|Myocardial Infarction|Obesity|Osteoarthritis|Prostate Cancer,2008-10-29,2010-01-31,2010-01-31,26.0,Cohort,,Prospective,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,Genetic,United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00782366
552,NCT00782366,goiter,Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment,Predictive Genetic Risk Assessment Trial,Atrial Fibrillation|Breast Cancer|Celiac Disease|Colon Cancer|Diabetes Type 2|Graves Disease|Lung Cancer|Myocardial Infarction|Obesity|Osteoarthritis|Prostate Cancer,2008-10-29,2010-01-31,2010-01-31,26.0,Cohort,,Prospective,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,Genetic,United States,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00782366
553,NCT00782366,hyperthyroidism,Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment,Predictive Genetic Risk Assessment Trial,Atrial Fibrillation|Breast Cancer|Celiac Disease|Colon Cancer|Diabetes Type 2|Graves Disease|Lung Cancer|Myocardial Infarction|Obesity|Osteoarthritis|Prostate Cancer,2008-10-29,2010-01-31,2010-01-31,26.0,Cohort,,Prospective,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,Genetic,United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00782366
554,NCT00784173,hypoparathyroidism,Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome,Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome,Ear Malformations in the Velocardiofacial Syndrome,2008-10-31,2007-03-31,2007-06-30,2.0,Case-Only,,Prospective,Observational,Completed,,Pontificia Universidade Catolica de Sao Paulo,Pontificia Universidade Catolica de Sao Paulo,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00784173
556,NCT00784303,thyroid neoplasms,"Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology","Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology",Thyroid Cancer,2008-10-30,2011-04-11,2019-03-29,117.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Eisai Inc.,Eisai Inc.,,Drug|Drug,Australia|France|Italy|Poland|United Kingdom|United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00784303
557,NCT00786552,thyroid neoplasms,"Phase 2 Trial of Pemetrexed (Alimta) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer",Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer,Thyroid Cancer,2008-11-05,2012-11-30,2013-11-30,47.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,University Hospital Schleswig-Holstein,University Hospital Schleswig-Holstein,"Medical Center II, University of Kiel",Drug,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00786552
558,NCT00792857,hyperparathyroidism,"Single-Dose, Two-Period, Open Label, Dose Determination, Randomized, Cross-Over Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects With Stage 5 CKD and SHPT on Hemodialysis",Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2008-11-14,2009-09-30,2009-10-31,24.0,,Crossover Assignment,,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",Pivotal Reseach Centers|Western New England Renal and Transplant Associates|University of Cincinnati|Northeast Clinical Research|Vanderbilt University|Southwest Houston Research Ltd.,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00792857
562,NCT00793689,hypoparathyroidism,Comparison of the Prognostic Value of Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test in the Evaluation of Parathyroid Function After Total Thyroidectomy,Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test After Total Thyroidectomy,Hypoparathyroidism,2008-11-18,2009-09-30,2009-10-31,127.0,Cohort,,Prospective,Observational,Completed,,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,AHEPA University Hospital,,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00793689
563,NCT00794053,thyroid neoplasms,The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer,The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer,Lymph Node Metastasis|Thyroid Cancer,2008-11-18,2008-12-31,2009-04-30,45.0,,Single Group Assignment,,Interventional,Completed,Phase 3,University of Alexandria,University of Alexandria,Alexandria University Hospitals,Procedure,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00794053
564,NCT00795782,thyroid neoplasms,Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial,Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma,Thyroid Cancer,2008-11-19,2012-06-30,2014-06-30,258.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung Medical Center,Procedure,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00795782
565,NCT00796913,goiter,Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy,Remission Induction and Sustenance in Graves' Disease 2,Graves Disease|Hyperthyroidism,2008-11-21,2015-05-15,2015-05-15,139.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aalborg University Hospital,Aalborg University Hospital,,Other,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00796913
566,NCT00796913,hyperthyroidism,Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy,Remission Induction and Sustenance in Graves' Disease 2,Graves Disease|Hyperthyroidism,2008-11-21,2015-05-15,2015-05-15,139.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aalborg University Hospital,Aalborg University Hospital,,Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00796913
567,NCT00796913,graves disease,Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy,Remission Induction and Sustenance in Graves' Disease 2,Graves Disease|Hyperthyroidism,2008-11-21,2015-05-15,2015-05-15,139.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aalborg University Hospital,Aalborg University Hospital,,Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00796913
568,NCT00800358,hyperparathyroidism,"A Multi Centre, Open Label, Parallel Group, Randomized Controlled Trial to Compare the Safety and Efficacy of Oral Paricalcitol Versus Oral Calcitriol in the Treatment of Secondary Hyperparathyroidism in Dialysis Patients",Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism,Hyperparathyroidism|Kidney Disease,2008-11-30,2009-10-31,2009-12-31,69.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"Penang Hospital, Malaysia","Ministry of Health, Malaysia|Penang Hospital, Malaysia","Hospital Sultanah Bahiyah Haemodialysis Unit KM 6 Jalan Langgar|Hemodialysis Unit, Raja Perempuan Zainab II Hospital|Hemodialysis Unit, Tengku Ampuan Afzan Hospital|Clinical Research Centre, Penang Hospital|Haemodialysis Unit, Seberang Jaya Hospital|Hemodialysis Unit, Taiping Hospital|Nephrology Department, Tengku Ampuan Rahimah Hospital|Hemodialysis Unit, Kuala Lumpur Hospital|Haemodialysis Unit, Serdang Hospital|Hemodialysis Unit, Tuanku Ja'afar Seremban Hospital|Haemodialysis Unit, Melaka Hospital",Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00800358
571,NCT00803712,hyperparathyroidism,Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination With Low Dose Vitamin D for the Treatment of Subjects With Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis,20070360 Incident Dialysis,Chronic Kidney Disease|Secondary Hyperparathyroidism,2008-11-26,2010-12-09,2011-07-05,313.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00803712
574,NCT00804830,"thyroid carcinoma, anaplastic",Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer,Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer,Carcinoma|Metastatic Cancer|Thyroid Cancer|Thyroid Neoplasms,2008-12-08,2012-12-31,2014-12-31,15.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Region Skane,Region Skane,"Jubileumskliniken, Sahlgrenska universitetsjukhuset|Dep of Oncology, Lund University Hospital|Karolinska University Hospital",Drug,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00804830
576,NCT00818896,hypothyroidism,A Model Statewide Trial to Detect and Treat Maternal Hypothyroidism in Pregnancy,Maternal Hypothyroidism in Pregnancy,Hypothyroidism,2009-01-06,2011-08-31,2011-09-30,72.0,Case-Only,,Prospective,Observational,Completed,,Women and Infants Hospital of Rhode Island,Women and Infants Hospital of Rhode Island,Women & Infants Hospital,,United States,17.0,44.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00818896
577,NCT00822289,hyperthyroidism,Effect of Radioactive Iodine on Eradication of Helicobacter Pylori in Patients Treated for Thyroid Diseases,The Effect of Radioactive Iodine Administration for Thyroid Diseases on H.Pylori Eradication,Helicobacter Pylori Infected Patients|Hyperthyroidism|Thyroid Cancer Patients,2009-01-13,,,120.0,Cohort,,Prospective,Observational,Unknown status,,Rabin Medical Center,Rabin Medical Center,,,,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00822289
578,NCT00822289,thyroid neoplasms,Effect of Radioactive Iodine on Eradication of Helicobacter Pylori in Patients Treated for Thyroid Diseases,The Effect of Radioactive Iodine Administration for Thyroid Diseases on H.Pylori Eradication,Helicobacter Pylori Infected Patients|Hyperthyroidism|Thyroid Cancer Patients,2009-01-13,,,120.0,Cohort,,Prospective,Observational,Unknown status,,Rabin Medical Center,Rabin Medical Center,,,,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00822289
581,NCT00823303,hyperparathyroidism,A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism,Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism,2008-12-12,2013-05-31,2013-09-30,110.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Washington University School of Medicine,"Abbott|Feinberg School of Medicine, Northwestern University|Henry Ford Hospital|NorthShore University HealthSystem|Washington University School of Medicine",Northwestern University|Northshore University Health System|Henry Ford Hospital|Washington University,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00823303
582,NCT00824226,hypoparathyroidism,Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients,Magnesium Treatment in Hypoparathyroidism,Hypoparathyroidism,2009-01-15,2011-08-31,2011-08-31,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Tartu,University of Tartu,Tartu University Hospital,Dietary Supplement,Estonia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00824226
585,NCT00828347,hyperparathyroidism,A Study of Maintenance Therapy After Intravenous Maxacalcitol for Secondary Hyperparathyroidism,Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT),Secondary Hyperparathyroidism,2009-01-22,2009-07-31,2009-07-31,35.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Kumamoto University,Kumamoto University,Kumamoto University Hospital,Drug|Drug,Japan,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00828347
587,NCT00849888,hypoparathyroidism,"Phase I Serum-Free Cultured Thymus Transplantation in DiGeorge Anomaly, IND9836",Serum-Free Thymus Transplantation in DiGeorge Anomaly,DiGeorge Anomaly,2009-02-22,2011-02-28,2011-02-28,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 1,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),,Biological|Other,,0.0,2.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00849888
589,NCT00856401,hypoparathyroidism,Phase II Trial of Parathyroid Hormone for the Treatment of Hypoparathyroidism,ADD-ON Study to Existing Hypoparathyroidism Studies,Hypoparathyroidism,2009-03-04,2020-12-31,2021-06-30,62.0,,Single Group Assignment,,Interventional,Unknown status,Phase 3,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University Medical Center,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00856401
591,NCT00858104,thyroid nodule,Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results,Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results,Thyroid Nodule,2009-03-06,2010-03-31,2013-05-31,200.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Elesta S.R.L.,Elesta S.R.L.,Ospedale Regina Apostolorum|Azienda Ospedaliera di Perugia - Osp. S.Maria della Misericordia|Azienda Ospedaliero-Universitaria di Pisa - Presidio di Cisanello|Arcispedale S. Maria Nuova,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00858104
592,NCT00858104,thyroid neoplasms,Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results,Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results,Thyroid Nodule,2009-03-06,2010-03-31,2013-05-31,200.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Elesta S.R.L.,Elesta S.R.L.,Ospedale Regina Apostolorum|Azienda Ospedaliera di Perugia - Osp. S.Maria della Misericordia|Azienda Ospedaliero-Universitaria di Pisa - Presidio di Cisanello|Arcispedale S. Maria Nuova,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00858104
593,NCT00859612,hyperparathyroidism,Renal Osteodystrophy: A Fresh Approach,Renal Osteodystrophy: A Fresh Approach,Renal Osteodystrophy,2009-03-09,2014-02-28,2014-02-28,464.0,Other,,Prospective,Observational,Completed,,University of Kentucky,"Hartmut Malluche, MD",University of Kentucky,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00859612
596,NCT00877630,thyroid neoplasms,Minimal Invasiveness of Endoscopic Thyroidectomy,Minimal Invasiveness of Endoscopic Thyroidectomy,Thyroid Nodule,2009-04-07,2007-05-31,2007-05-31,,Cohort,,Prospective,Observational,Completed,,Second Military Medical University,Second Military Medical University,Minimally Invasive Surgical Center of Changzhang Hospital,,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00877630
597,NCT00877630,thyroid nodule,Minimal Invasiveness of Endoscopic Thyroidectomy,Minimal Invasiveness of Endoscopic Thyroidectomy,Thyroid Nodule,2009-04-07,2007-05-31,2007-05-31,,Cohort,,Prospective,Observational,Completed,,Second Military Medical University,Second Military Medical University,Minimally Invasive Surgical Center of Changzhang Hospital,,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00877630
598,NCT00877981,hyperparathyroidism,Open Compared to Video-Assisted Minimal-Invasive Parathyroid Surgery in Primary Hyperparathyroidism,Open Versus Video-Assisted Minimal-Invasive Parathyroid Surgery,Primary Hyperparathyroidism,2009-04-07,2007-04-30,2007-10-31,143.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Uppsala University,Lund University|University of Aarhus|Uppsala University,"Unit of Breast and Endocrine Surgery, Surgical Department P, Aarhus University Hospital|Department of Surgery, Lund University Hospital|Uppsala University Hospital, Dept of surgery",Procedure,Denmark|Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00877981
601,NCT00880503,thyroid neoplasms,Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute,Collection of Tissue Samples for Study of Multidrug Resistance,Breast Cancer|Breast Carcinoma|Medullary Thyroid Carcinoma,2009-04-10,,2018-02-08,325.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"Childrens Hospital, Pittsburgh",,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00880503
603,NCT00887107,"thyroid cancer, papillary",Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma,Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma,Thyroid Cancer,2009-04-22,,,32.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Leiden University Medical Center,Leiden University Medical Center,Leiden University Medical Center,Drug,Netherlands,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00887107
605,NCT00887666,hyperparathyroidism,"Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure","Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure",Congestive Heart Failure|Hyperparathyroidism|Hypovitaminosis D,2009-04-23,2008-10-31,2008-10-31,48.0,Cohort,,Prospective,Observational,Completed,,State University of New York - Downstate Medical Center,State University of New York - Downstate Medical Center,SUNY Downstate Medical Center,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00887666
606,NCT00888069,hyperparathyroidism,"A Randomized, Open-Label, Single-Dose Pilot Study of Oral and i.v. CTAP101 Evaluating PK and Safety in Stage 3 and 4 CKD Subjects With Vitamin D Insufficiency and SHPT",Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects,Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2009-04-23,2009-11-30,2009-12-31,28.0,,Parallel Assignment,,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",Pivotal Research Centers|Research by Design|Western New England Renal & Transplant Associates|Twin Cities Clinical Research|DCI|MetroHealth Medical Center|Northeast Clinical Research|Southeast Renal Research Institute|Vanderbilt University Medical Center|Southwest Houston Research Ltd|Purity Dialysis Centers / Nephrology Associates|Gunderson Clinic Ltd.,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00888069
610,NCT00891813,hyperparathyroidism,Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose,Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose,"Hemodialysis|Hypercalcemia|Parathyroid Hormone|Renal Insufficiency, Chronic|Secondary Hyperparathyroidism",2009-04-29,2010-09-30,2010-09-30,100.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Site Reference ID/Investigator# 21401|Site Reference ID/Investigator# 23857|Site Reference ID/Investigator# 10941,Drug,Peru,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00891813
613,NCT00896454,parathyroid neoplasms,"A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates",Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium,Breast Cancer|Colon Cancer|Endocrine Cancer|Head and Neck Cancer|Hodgkin's Lymphoma|Hypercalcemia of Malignancy|Kidney Cancer|Lung Cancer|Lymphoma|Metastatic Cancer|Multiple Myeloma|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer|Parathyroid Neoplasms|Renal Cancer|Thyroid Cancer,2009-05-07,2012-09-13,2013-08-21,33.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Canada|France|Italy|Poland|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00896454
614,NCT00902122,thyroid neoplasms,"Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors",rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors,Advanced Malignant Thyroid Tumors,2009-05-12,2012-08-31,2012-08-31,600.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,"Shenzhen SiBiono GeneTech Co.,Ltd","Shenzhen SiBiono GeneTech Co.,Ltd","West China Hospital, Sichuan University",Drug|Procedure|Drug|Radiation,China,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00902122
615,NCT00905866,hyperparathyroidism,Evaluation of Quality of Life in Patients Undergoing Parathyroidectomy,Quality of Life in Patients Undergoing Parathyroidectomy,Hyperparathyroidism|Parathyroidectomy,2009-05-18,2011-07-31,2011-07-31,60.0,Case-Only,,Prospective,Observational,Completed,,Mackay Memorial Hospital,Mackay Memorial Hospital,Mackay Memorial Hospital,Other,Taiwan,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00905866
617,NCT00916955,hypoparathyroidism,Genetic Modifiers for 22q11.2 Syndrome,Genetic Modifiers for 22q11.2 Syndrome,22q11.2 Deletion Syndrome,2008-03-24,2015-02-28,2015-02-28,,Cohort,,Prospective,Observational,Completed,,State University of New York - Upstate Medical University,Albert Einstein College of Medicine|State University of New York - Upstate Medical University,VCFS International Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00916955
620,NCT00917189,hypoparathyroidism,Computer-Based Cognitive Remediation in Adolescents With VCFS,Computerized Cognitive Skills Training for Adolescents With Velocardiofacial Syndrome,Velocardiofacial Syndrome,2009-06-08,2015-04-30,2015-04-30,37.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,State University of New York - Upstate Medical University,National Institute of Mental Health (NIMH)|State University of New York - Upstate Medical University,SUNY Upstate Medical University,Behavioral,United States,12.0,16.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00917189
621,NCT00917241,graves disease,Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone,Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone,Graves' Disease,2009-06-09,2008-12-31,2009-03-31,218.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Nanjing Medical University,Xiao-Ming Mao,,Drug|Drug,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00917241
622,NCT00917241,goiter,Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone,Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone,Graves' Disease,2009-06-09,2008-12-31,2009-03-31,218.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Nanjing Medical University,Xiao-Ming Mao,,Drug|Drug,,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00917241
623,NCT00917241,hyperthyroidism,Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone,Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone,Graves' Disease,2009-06-09,2008-12-31,2009-03-31,218.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Nanjing Medical University,Xiao-Ming Mao,,Drug|Drug,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00917241
624,NCT00921050,hypothyroidism,"Randomized Double Blind Levothyroxine vs Placebo, Mind (NEUROPSI) Improvement in Elderly With Persistent TSH 4-10 mUI/L",Subclinical Hypothyroidism and Mind in the Elderly,Subclinical Hypothyroidism,2009-06-15,2012-03-31,2012-03-31,70.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Universidad Autonoma de Nuevo Leon,Universidad Autonoma de Nuevo Leon,"Endocrinology, Outpatient Hospital Clinic|Community Health Center (Fomerrey 19)",Drug|Drug,Mexico,60.0,95.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00921050
625,NCT00923247,thyroid neoplasms,"A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)","A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)",Medullary Thyroid Carcinoma,2009-06-17,2016-04-01,2016-12-09,22.0,,Parallel Assignment,,Interventional,Terminated,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00923247
626,NCT00926978,thyroid neoplasms,Comparison of I-124 and I-131 Radiopharmacokinetics in Patients Who Have Well-differentiated Thyroid Cancer and Are Prepared With Recombinant Human TSH Injection (rhTSH),Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH),Thyroid Cancer,2009-06-17,2018-10-31,2018-10-31,21.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Medstar Health Research Institute,Medstar Health Research Institute,Washington Hospital Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00926978
629,NCT00928408,hyperparathyroidism,PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice,PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice,"Hyperparathyroidism, Primary",2009-06-25,2011-12-31,2012-02-29,305.0,Other,,Prospective,Observational,Completed,,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00928408
630,NCT00929318,thyroid neoplasms,Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound,Influence of Thyroid Hormones on the Woundhealing Process,Thyroid Carcinoma|Thyroid Neoplasms,2009-06-26,2009-12-31,2010-04-30,26.0,,,,Interventional,Unknown status,Not Applicable,Hannover Medical School,"Genzyme, a Sanofi Company|Hannover Medical School","Medizinische Hoochschule Hannover, Allgemein-, Viszeral-und Transplantationscirurgie OE 6220",Procedure|Procedure,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00929318
633,NCT00936650,hyperparathyroidism,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Dose-Titration Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)",A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT),"Hyperparathyroidism, Primary",2009-06-04,2001-03-31,2001-06-30,78.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00936650
634,NCT00936858,thyroid neoplasms,A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer,RAD001 for Patients With Radioiodine Refractory Thyroid Cancer,Thyroid Cancer,2009-07-09,2020-02-27,2020-02-27,50.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Dana-Farber Cancer Institute,Dana-Farber Cancer Institute|Massachusetts General Hospital|M.D. Anderson Cancer Center|MOUNT SINAI HOSPITAL|Novartis,Massachusetts General Hospital|Dana-Farber Cancer Institute|Mt. Sinai Medical Center|MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00936858
635,NCT00936988,hyperparathyroidism,"A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism","A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism","Hyperparathyroidism, Primary",2009-06-04,2005-06-30,2005-12-31,45.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00936988
638,NCT00941551,goiter,Five-year Follow up of a Randomized Clinical Trial of Unilateral Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively,Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively,Recurrent Goiter,2009-07-16,2003-12-31,2008-12-31,150.0,Case-Control,,Prospective,Observational,Completed,,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Drug|Drug,Poland,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00941551
639,NCT00946296,hyperthyroidism,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Graves Disease|Hyperthyroidism,2009-07-22,2013-04-30,2013-04-30,36.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University of Massachusetts, Worcester","University of Massachusetts, Worcester",UMASS Memorial Health Care,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00946296
640,NCT00946296,goiter,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Graves Disease|Hyperthyroidism,2009-07-22,2013-04-30,2013-04-30,36.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University of Massachusetts, Worcester","University of Massachusetts, Worcester",UMASS Memorial Health Care,Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00946296
641,NCT00946296,graves disease,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Graves Disease|Hyperthyroidism,2009-07-22,2013-04-30,2013-04-30,36.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University of Massachusetts, Worcester","University of Massachusetts, Worcester",UMASS Memorial Health Care,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00946296
642,NCT00946894,goiter,Five-year Follow up of a Randomized Clinical Trial of Total Thyroidectomy Versus Dunhill Operation Versus Bilateral Subtotal Thyroidectomy for Multinodular Non-toxic Goiter.,Outcomes of Different Thyroid Resections for Multinodular Non-toxic Goiter,Goiter,2009-07-23,2003-12-31,2008-12-31,600.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00946894
643,NCT00948337,thyroid neoplasms,"A Randomized Controlled Trial on the Effect of Intervention With Health Educational Material on Knowledge, Attitude, and Behavior in Cancer Survivors",A Study With Health Educational Material on Health Promotion in Cancer Survivors,Breast Cancer|Colon Cancer|Stomach Cancer|Thyroid Cancer,2009-07-28,2009-11-30,2010-12-31,326.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2,"National Cancer Center, Korea","National Cancer Center, Korea",National Cancer Center|Samsung Medical Center,Behavioral,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00948337
644,NCT00954837,thyroid neoplasms,Utility of a Second Ultrasound-guided Fine Needle Aspiration for the Detection of Thyroid Cancer in the Management of Single Thyroid Nodules or Multinodular Goitre.,Assessment of Repeat Fine Needle Aspiration (FNA) to Detect Thyroid Cancer,Thyroid Cancer,2009-07-30,2011-12-31,2012-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,,Procedure,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00954837
645,NCT00958113,goiter,Autoimmune Thyroid Disease Genetic Study,Autoimmune Thyroid Disease Genetic Study,Graves' Disease|Hashimoto's Disease,2009-08-11,2013-02-28,2015-05-31,199.0,Case-Control,,Cross-Sectional,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",University of Colorado Denver,,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00958113
647,NCT00958113,graves disease,Autoimmune Thyroid Disease Genetic Study,Autoimmune Thyroid Disease Genetic Study,Graves' Disease|Hashimoto's Disease,2009-08-11,2013-02-28,2015-05-31,199.0,Case-Control,,Cross-Sectional,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",University of Colorado Denver,,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00958113
649,NCT00958113,"thyroiditis, autoimmune",Autoimmune Thyroid Disease Genetic Study,Autoimmune Thyroid Disease Genetic Study,Graves' Disease|Hashimoto's Disease,2009-08-11,2013-02-28,2015-05-31,199.0,Case-Control,,Cross-Sectional,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",University of Colorado Denver,,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT00958113
650,NCT00958113,hyperthyroidism,Autoimmune Thyroid Disease Genetic Study,Autoimmune Thyroid Disease Genetic Study,Graves' Disease|Hashimoto's Disease,2009-08-11,2013-02-28,2015-05-31,199.0,Case-Control,,Cross-Sectional,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",University of Colorado Denver,,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00958113
652,NCT00958451,hyperparathyroidism,Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial,Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients,Chronic Kidney Disease|Secondary Hyperparathyroidism,2009-08-11,2011-01-31,2011-01-31,80.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Salem Veterans Affairs Medical Center,Abbott|Salem Veterans Affairs Medical Center,VA Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00958451
656,NCT00961701,hyperparathyroidism,Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Primary Hyperparathyroidism,Lipids Profile in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2009-08-18,2010-10-31,2016-10-31,100.0,Case-Only,,Cross-Sectional,Observational,Terminated,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel|University of Palermo|University of Zurich","Endocrine Institute , Haemek Medical Center",,Israel,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00961701
657,NCT00962221,hypothyroidism,Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Subclinical Hypothyroidism,Lipids Profile in Subclinical Hypothyroidism,Subclinical Hypothyroidism,2009-08-18,2011-10-31,2012-10-31,100.0,Case-Only,,Cross-Sectional,Observational,Terminated,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel|University of Palermo|University of Zurich","Endocrine Institute, Haemek Medical Center",Procedure,Israel,18.0,85.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00962221
658,NCT00970359,thyroid neoplasms,Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study,Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244,Thyroid Cancer,2009-09-01,2013-04-30,2013-04-30,24.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Memorial Sloan Kettering Cancer Center,"AstraZeneca|Genzyme, a Sanofi Company|Memorial Sloan Kettering Cancer Center",Memorial Sloan-Kettering Cancer Center,Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00970359
660,NCT00973336,hyperparathyroidism,Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Successful Surgery in Patients Without Osteoporosis?,Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?,Bone Metabolism|Primary Hyperparathyroidism,2009-09-08,2017-09-30,2017-09-30,80.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2,Medical University of Vienna,Medical University of Vienna,Medical University of Vienna,Drug,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00973336
662,NCT00975000,hyperparathyroidism,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism",Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients,Chronic Allograft Nephropathy|Chronic Kidney Disease|Chronic Renal Failure|Disordered Mineral Metabolism|End Stage Renal Disease|Hyperparathyroidism|Hypophosphatemia|Kidney Disease|Kidney Transplantation|Post Renal Transplantation,2009-09-10,2012-09-13,2013-04-16,114.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Austria|Belgium|Canada|France|Germany|Italy|Poland|Spain|Switzerland|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00975000
665,NCT00975221,hyperparathyroidism,A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,"Hypercalcemia|Hyperparathyroidism, Primary",2009-09-10,2012-07-12,2012-12-21,67.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Canada|Hungary|Poland|Portugal|Russian Federation|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00975221
667,NCT00977080,hyperparathyroidism,The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism,Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D,Chronic Kidney Disease|Hemodialysis|Secondary Hyperparathyroidism,2009-09-14,2011-05-31,2011-05-31,272.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Site Reference ID/Investigator# 22781|Site Reference ID/Investigator# 24342|Site Reference ID/Investigator# 21142|Site Reference ID/Investigator# 22762|Site Reference ID/Investigator# 22758|Site Reference ID/Investigator# 21442|Site Reference ID/Investigator# 23688|Site Reference ID/Investigator# 21370|Site Reference ID/Investigator# 25902|Site Reference ID/Investigator# 21146|Site Reference ID/Investigator# 26743|Site Reference ID/Investigator# 22788|Site Reference ID/Investigator# 22722|Site Reference ID/Investigator# 23147|Site Reference ID/Investigator# 22778|Site Reference ID/Investigator# 21369|Site Reference ID/Investigator# 22786|Site Reference ID/Investigator# 21144|Site Reference ID/Investigator# 21443|Site Reference ID/Investigator# 21145|Site Reference ID/Investigator# 22505|Site Reference ID/Investigator# 22759|Site Reference ID/Investigator# 22796|Site Reference ID/Investigator# 22770|Site Reference ID/Investigator# 22772|Site Reference ID/Investigator# 21147|Site Reference ID/Investigator# 22982|Site Reference ID/Investigator# 21143|Site Reference ID/Investigator# 22506|Site Reference ID/Investigator# 22776|Site Reference ID/Investigator# 22311|Site Reference ID/Investigator# 22310|Site Reference ID/Investigator# 21624|Site Reference ID/Investigator# 22363|Site Reference ID/Investigator# 23105|Site Reference ID/Investigator# 23909|Site Reference ID/Investigator# 22462|Site Reference ID/Investigator# 21748|Site Reference ID/Investigator# 33268|Site Reference ID/Investigator# 35903|Site Reference ID/Investigator# 21742|Site Reference ID/Investigator# 21744|Site Reference ID/Investigator# 21368|Site Reference ID/Investigator# 22362|Site Reference ID/Investigator# 38970|Site Reference ID/Investigator# 22322|Site Reference ID/Investigator# 22463|Site Reference ID/Investigator# 22323|Site Reference ID/Investigator# 39262|Site Reference ID/Investigator# 22312|Site Reference ID/Investigator# 21746|Site Reference ID/Investigator# 39180|Site Reference ID/Investigator# 22314|Site Reference ID/Investigator# 21367|Site Reference ID/Investigator# 21745|Site Reference ID/Investigator# 21842|Site Reference ID/Investigator# 22309|Site Reference ID/Investigator# 21843|Site Reference ID/Investigator# 38903|Site Reference ID/Investigator# 38531|Site Reference ID/Investigator# 22464|Site Reference ID/Investigator# 23910|Site Reference ID/Investigator# 24643|Site Reference ID/Investigator# 24642|Site Reference ID/Investigator# 21361|Site Reference ID/Investigator# 21364|Site Reference ID/Investigator# 22366|Site Reference ID/Investigator# 38343|Site Reference ID/Investigator# 21362|Site Reference ID/Investigator# 21363|Site Reference ID/Investigator# 22367|Site Reference ID/Investigator# 38462|Site Reference ID/Investigator# 21365|Site Reference ID/Investigator# 23913|Site Reference ID/Investigator# 23782|Site Reference ID/Investigator# 22364|Site Reference ID/Investigator# 23912|Site Reference ID/Investigator# 21747|Site Reference ID/Investigator# 23102|Site Reference ID/Investigator# 23104|Site Reference ID/Investigator# 23103|Site Reference ID/Investigator# 41982|Site Reference ID/Investigator# 40222,Drug|Drug,Czech Republic|Denmark|Germany|Greece|Italy|Netherlands|Portugal|Russian Federation|Spain|Sweden|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00977080
672,NCT00982722,hyperparathyroidism,Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism,Vitamin D Supplementation After Parathyroid Surgery,Primary Hyperparathyroidism,2009-09-22,2018-05-04,2018-05-04,150.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Karolinska University Hospital,Karolinska University Hospital,Karolinska UH|Karolinska University Hospital,Drug|Drug,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00982722
674,NCT00984191,"thyroid cancer, papillary",99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study,Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid,Papillary Thyroid Cancer,2009-09-24,2011-10-31,2011-11-30,15.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Chulalongkorn University,Chulalongkorn University,King Chulalongkorn Hospital,Radiation,Thailand,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00984191
675,NCT00984282,thyroid neoplasms,A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Nexavar Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,2009-09-24,2012-08-31,2017-08-30,417.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Bayer,Amgen|Bayer,Asan Medical Center,Drug|Drug,"Austria|Belgium|Bulgaria|China|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Saudi Arabia|Spain|Sweden|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00984282
677,NCT00990704,hyperparathyroidism,"Phase II, Open Study, Exploratory Examination of Efficacy and Safety of Paricalcitol Injection and Maxacalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism",Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism,Hemodialysis|Secondary Hyperparathyroidism,2009-10-05,2010-05-31,2010-05-31,47.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Abbott,Abbott,Site Ref # / Investigator 53794|Site Ref # / Investigator 53787|Site Ref # / Investigator 53786|Site Ref # / Investigator 53792|Site Ref # / Investigator 53784|Site Ref # / Investigator 53796|Site Ref # / Investigator 53795|Site Ref # / Investigator 21561|Site Ref # / Investigator 53789|Site Ref # / Investigator 53790|Site Ref # / Investigator 53793|Site Ref # / Investigator 53785|Site Ref # / Investigator 53788|Site Ref # / Investigator 53791,Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00990704
679,NCT00993837,thyroid neoplasms,Comparison of Effectiveness and Safety of Thyroidectomy for Thyroid Carcinoma in Patients Undergo Endoscopic Surgery and Those Receive Conversion,Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma,Thyroid Carcinoma,2009-09-29,2011-12-31,2012-06-30,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Second Military Medical University,Second Military Medical University,Changzheng Hospital,Procedure,China,18.0,45.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00993837
681,NCT00995163,hyperparathyroidism,Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D),Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease,"End Stage Renal Disease|Hyperparathyroidism, Secondary",2009-10-14,2011-01-31,2011-01-31,8020.0,Cohort,,Prospective,Observational,Completed,,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",,,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00995163
683,NCT00999037,hyperparathyroidism,FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease,FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease,Secondary Hyperparathyroidism,2009-10-20,2015-06-30,2015-06-30,18.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"University of California, Los Angeles","Loma Linda University|University of California, Los Angeles",UCLA,Drug|Other,United States,6.0,21.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00999037
686,NCT01003652,goiter,Harmonic Focus Shears Versus Clamp-and-technique for Total Thyroidectomy,Clinical Trial on Harmonic Focus Shears,Multinodular Goiter,2009-10-27,2008-12-31,2008-12-31,68.0,Cohort,,Prospective,Observational,Completed,,Cliniques universitaires Saint-Luc- Universit Catholique de Louvain,Cliniques universitaires Saint-Luc- Universit Catholique de Louvain,Cliniques universitaires Saint-Luc- Universit Catholique de Louvain,Procedure,Belgium,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01003652
687,NCT01005654,parathyroid neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Adrenal Neoplasm|Endocrine Tumors|Neuroblastoma|Parathyroid Neoplasms|Thyroid Neoplasms,2009-10-30,,,1900.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01005654
689,NCT01005654,thyroid neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Adrenal Neoplasm|Endocrine Tumors|Neuroblastoma|Parathyroid Neoplasms|Thyroid Neoplasms,2009-10-30,,,1900.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01005654
690,NCT01012414,hyperparathyroidism,The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D,Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease,Chronic Kidney Disease|Coronary Artery Disease|Hypovitaminosis D|Secondary Hyperparathyroidism,2009-11-11,2011-05-31,2011-05-31,10.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,Thomas Jefferson University,Abbott|Thomas Jefferson University,Thomas Jefferson University,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01012414
693,NCT01013597,thyroid neoplasms,A Phase II Trial of LBH589 in Patients With Metastatic Medullary Thyroid Cancer and Radioactive Iodine Resistant Differentiated Thyroid Cancer,Trial of LBH589 in Metastatic Thyroid Cancer,Thyroid Carcinoma,2009-10-28,2013-08-31,2016-02-29,13.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"University of Wisconsin, Madison","Novartis Pharmaceuticals|University of Wisconsin, Madison",St. Vincent Regional Cancer Center CCOP|University of Wisconsin - Madison|Medical College of Wisconsin,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01013597
696,NCT01025128,hyperparathyroidism,,Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density,Osteomalacia|Secondary Hyperparathyroidism|Vitamin D Deficiency,2009-12-01,2014-07-31,2014-07-31,210.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Clalit Health Services,Clalit Health Services,"Endocrinology Clinic, Clalit Health Services",Drug,Israel,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01025128
697,NCT01025453,thyroid neoplasms,Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer,Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer,Thyroid Cancer,2009-12-02,2018-01-16,2018-01-16,37.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|National Comprehensive Cancer Network|Pfizer,Memorial Sloan-Kettering at Basking Ridge|Memorial Sloan-Kettering Cancer Center @ Suffolk|Memorial Sloan Kettering Cancer Center|Memorial Sloan-Kettering at Mercy Medical Center|Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center,Drug,United States,21.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01025453
699,NCT01039714,hypoparathyroidism,Preoperative Vitamin D Levels as a Prognostic Factor for Postoperative Hypocalcemia and Hypoparathyroidism After Total Thyroidectomy,Vitamin D Levels and Postoperative Hypocalcemia After Total Thyroidectomy,Hypocalcemia|Hypoparathyroidism|Thyroidectomy|Vitamin D Deficiency,2009-09-29,2010-04-30,2010-05-31,200.0,Cohort,,Prospective,Observational,Unknown status,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"AHEPA University Hospital Thessaloniki, Greece",,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01039714
700,NCT01039818,graves disease,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism,Graves Disease,2009-12-24,2011-08-31,2011-08-31,30.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,"Thyroid Unit, Endocrine Division, Hospital de Clnicas de Porto Alegre",Radiation|Radiation,Brazil,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01039818
701,NCT01039818,goiter,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism,Graves Disease,2009-12-24,2011-08-31,2011-08-31,30.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,"Thyroid Unit, Endocrine Division, Hospital de Clnicas de Porto Alegre",Radiation|Radiation,Brazil,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01039818
702,NCT01039818,hyperthyroidism,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism,Graves Disease,2009-12-24,2011-08-31,2011-08-31,30.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,"Thyroid Unit, Endocrine Division, Hospital de Clnicas de Porto Alegre",Radiation|Radiation,Brazil,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01039818
703,NCT01042626,hyperparathyroidism,"Dissimilar PTH, Gastrin, and Ionized Calcium Response to Oral Peptones in Normocalcemic Primary Hyperparathyroidism, Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects",Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects,Hypercalcemia|Hyperparathyroidism,2010-01-04,2005-01-31,2005-01-31,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Eastern Piedmont,University of Eastern Piedmont|University of Milan,L. Sacco Hospital (Vialba),Other,Italy,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01042626
706,NCT01043107,thyroid neoplasms,Study on the Relationship Between The Computer Radiation and The Recrudesce Rate of Thyroid Cancer,Relationship Between Computer and Cancer,Thyroid Cancer,2010-01-05,,,2000.0,Cohort,,Retrospective,Observational,Unknown status,,Guangdong Provincial People's Hospital,Guangdong Provincial People's Hospital,Guangdong General Hospital,,China,10.0,60.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01043107
707,NCT01050465,hypothyroidism,MedlinePlus Health Prescriptions: Developing a Real World Approach for Clinic Use,MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use,Acne Vulgaris|Allergic Rhinitis|Anxiety|Asthma|Back Pain|Bursitis|Chronic Obstructive Pulmonary Disease|Coronary Artery Disease|Cough|Depression|Diabetes Mellitus|Diarrhea|Fibromyalgia|Gastroesophageal Reflux|Headache|HIV Infections|Hyperlipidemia|Hypertension|Hypothyroidism|Influenza|Irritable Bowel Syndrome|Menopause|Migraine Disorders|Obesity|Obstructive Sleep Apnea|Osteoarthritis|Prostatic Hyperplasia|Senile Osteoporosis|Shoulder Pain|Sinusitis|Sleep Initiation and Maintenance Disorders|Smoking Cessation|Tobacco Use Cessation|Urinary Incontinence|Urinary Tract Infection|Vaginitis|Vertigo,2010-01-13,2010-10-31,2010-12-31,907.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Missouri-Columbia,National Library of Medicine (NLM)|University of Missouri-Columbia,,Other,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01050465
708,NCT01056419,hyperthyroidism,,The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy,Graves' Ophthalmopathy,2010-01-25,2010-06-30,2010-08-31,40.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ankara University,Ankara University,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department",Procedure|Drug,Turkey,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01056419
709,NCT01056419,graves disease,,The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy,Graves' Ophthalmopathy,2010-01-25,2010-06-30,2010-08-31,40.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ankara University,Ankara University,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department",Procedure|Drug,Turkey,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01056419
710,NCT01056419,graves ophthalmopathy,,The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy,Graves' Ophthalmopathy,2010-01-25,2010-06-30,2010-08-31,40.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ankara University,Ankara University,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department",Procedure|Drug,Turkey,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01056419
711,NCT01056419,goiter,,The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy,Graves' Ophthalmopathy,2010-01-25,2010-06-30,2010-08-31,40.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ankara University,Ankara University,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department",Procedure|Drug,Turkey,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01056419
713,NCT01057732,hyperparathyroidism,The Effect of Parathyroidectomy on Cardiovascular Risk Factors in Patients With Primary Hyperparathyroidism,Effects of Parathyroidectomy on Cardiovascular Risk Factors in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2010-01-25,2006-06-30,2006-12-31,76.0,Case-Control,,Prospective,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel","Endocrine Institute, Haemek Medical Center",,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01057732
715,NCT01060982,parathyroid neoplasms,"Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU)Treatment Procedure: A Monocentre, Open, Uncontrolled Study",Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure,Primary Parathyroid Adenomas,2010-02-01,2013-01-31,2013-01-31,5.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,Hpital Priv des Peupliers|Cochin Hospital,Device,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01060982
719,NCT01073462,hyperparathyroidism,Postmarketing Observational Study to Evaluate the Effect of Zemplar (Paricalcitol IV) on Cardiac Morbidity in Patients With Chronic Kidney Disease Stage 5 Over 2 Years.,Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years,Cardiac Morbidity|Chronic Kidney Disease Stage V|Secondary Hyperparathyroidism,2010-02-20,2013-06-30,2013-06-30,67.0,Cohort,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Assign Data Management and Biostatistics GmbH",Site Reference ID/Investigator# 27447|Site Reference ID/Investigator# 49182|Site Reference ID/Investigator# 27483|Site Reference ID/Investigator# 52742|Site Reference ID/Investigator# 27487|Site Reference ID/Investigator# 36983|Site Reference ID/Investigator# 27484|Site Reference ID/Investigator# 27485|Site Reference ID/Investigator# 27446|Site Reference ID/Investigator# 53469|Site Reference ID/Investigator# 27482|Site Reference ID/Investigator# 10981,,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01073462
720,NCT01074684,thyroid neoplasms,"Defining Predictive Factors of Clinical, Laboratory and Imaging Criteria Routinely Used in the Diagnosis of Thyroid Cancer: Observational, Prospective Multicentered Study","Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer",Thyroid Cancer,2010-02-23,2021-12-31,2022-12-31,959.0,Cohort,,Prospective,Observational,Active not recruiting,,"National Cancer Institute, Naples","National Cancer Institute, Naples",Universit di Cagliari|Azienda Ospedaliera Unviersitaria Careggi - Firenze|ASL TO/4 Ospedale di Ivrea|Istituto Nazionale dei Tumori|Azienda Ospedaliera Universitaria di Padova|Universit Cattolica del Sacro Cuore di Roma Policlinico Gemelli|Ospedale di Taormina|Universit degli studi di Perugia - Sede di Terni,,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01074684
722,NCT01081665,hyperparathyroidism,"A Two-year, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Haemodialysis, Receiving Zemplar for Prevention and Treatment of Secondary Hyperparathyroidism",Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism,Chronic Kidney Failure|Secondary Hyperparathyroidism,2010-02-27,2011-02-28,2011-02-28,237.0,,,Prospective,Observational,Completed,,Abbott,Abbott,Site Reference ID/Investigator# 32055|Site Reference ID/Investigator# 32050|Site Reference ID/Investigator# 32051|Site Reference ID/Investigator# 32049|Site Reference ID/Investigator# 5283|Site Reference ID/Investigator# 32056|Site Reference ID/Investigator# 32057|Site Reference ID/Investigator# 32058|Site Reference ID/Investigator# 32077|Site Reference ID/Investigator# 32076|Site Reference ID/Investigator# 32059|Site Reference ID/Investigator# 32053|Site Reference ID/Investigator# 32060|Site Reference ID/Investigator# 32061|Site Reference ID/Investigator# 32062|Site Reference ID/Investigator# 32048|Site Reference ID/Investigator# 32054|Site Reference ID/Investigator# 32063|Site Reference ID/Investigator# 32075,,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01081665
726,NCT01083186,hyperparathyroidism,Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience,Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience,Chronic Kidney Failure|Secondary Hyperparathyroidism,2010-02-20,2012-01-31,2012-01-31,500.0,,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 47002|Site Reference ID/Investigator# 43772|Site Reference ID/Investigator# 27492|Site Reference ID/Investigator# 43769|Site Reference ID/Investigator# 38257|Site Reference ID/Investigator# 47003|Site Reference ID/Investigator# 27497|Site Reference ID/Investigator# 47004|Site Reference ID/Investigator# 27489|Site Reference ID/Investigator# 27495|Site Reference ID/Investigator# 43773|Site Reference ID/Investigator# 27498|Site Reference ID/Investigator# 38259|Site Reference ID/Investigator# 22121|Site Reference ID/Investigator# 43771|Site Reference ID/Investigator# 43767|Site Reference ID/Investigator# 27496|Site Reference ID/Investigator# 43768|Site Reference ID/Investigator# 27491|Site Reference ID/Investigator# 27494|Site Reference ID/Investigator# 27493|Site Reference ID/Investigator# 38255|Site Reference ID/Investigator# 43770|Site Reference ID/Investigator# 39839,,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01083186
727,NCT01083550,"thyroid cancer, papillary",Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial),Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer,Thyroid Cancer,2010-02-24,2016-11-30,2016-11-30,74.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"University Health Network, Toronto","Canadian Institutes of Health Research (CIHR)|Ontario Ministry of Health and Long Term Care|University Health Network, Toronto",University Health Network,Other,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01083550
730,NCT01083849,hyperparathyroidism,Long-Term Therapy Outcomes When Treating CKD-patients With Paricalcitol in German Clinical Practice (TOP Study),Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice,Kidney Insufficiency|Secondary Hyperparathyroidism,2010-02-25,2013-12-31,2013-12-31,761.0,Cohort,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 64522|Site Reference ID/Investigator# 53506|Site Reference ID/Investigator# 53524|Site Reference ID/Investigator# 74733|Site Reference ID/Investigator# 64523|Site Reference ID/Investigator# 53525|Site Reference ID/Investigator# 53526|Site Reference ID/Investigator# 69662|Site Reference ID/Investigator# 53508|Site Reference ID/Investigator# 53523|Site Reference ID/Investigator# 53507|Site Reference ID/Investigator# 28352|Site Reference ID/Investigator# 28359|Site Reference ID/Investigator# 28305|Site Reference ID/Investigator# 28306|Site Reference ID/Investigator# 28003|Site Reference ID/Investigator# 81613|Site Reference ID/Investigator# 28017|Site Reference ID/Investigator# 28301|Site Reference ID/Investigator# 28296|Site Reference ID/Investigator# 28021|Site Reference ID/Investigator# 28024|Site Reference ID/Investigator# 28303|Site Reference ID/Investigator# 54050|Site Reference ID/Investigator# 28022|Site Reference ID/Investigator# 30862|Site Reference ID/Investigator# 28007|Site Reference ID/Investigator# 28304|Site Reference ID/Investigator# 28014|Site Reference ID/Investigator# 28023|Site Reference ID/Investigator# 28134|Site Reference ID/Investigator# 28037|Site Reference ID/Investigator# 43903|Site Reference ID/Investigator# 99777|Site Reference ID/Investigator# 28284|Site Reference ID/Investigator# 124118|Site Reference ID/Investigator# 54054|Site Reference ID/Investigator# 48864|Site Reference ID/Investigator# 72343|Site Reference ID/Investigator# 28029|Site Reference ID/Investigator# 28287|Site Reference ID/Investigator# 28276|Site Reference ID/Investigator# 28351|Site Reference ID/Investigator# 28280|Site Reference ID/Investigator# 48865|Site Reference ID/Investigator# 28300|Site Reference ID/Investigator# 28011|Site Reference ID/Investigator# 124119|Site Reference ID/Investigator# 28019|Site Reference ID/Investigator# 28135|Site Reference ID/Investigator# 28286|Site Reference ID/Investigator# 28353|Site Reference ID/Investigator# 28044|Site Reference ID/Investigator# 48863|Site Reference ID/Investigator# 28013|Site Reference ID/Investigator# 28025|Site Reference ID/Investigator# 28290|Site Reference ID/Investigator# 10982|Site Reference ID/Investigator# 28291|Site Reference ID/Investigator# 28036|Site Reference ID/Investigator# 28302|Site Reference ID/Investigator# 54051|Site Reference ID/Investigator# 28278|Site Reference ID/Investigator# 99778|Site Reference ID/Investigator# 99776|Site Reference ID/Investigator# 124120|Site Reference ID/Investigator# 28275|Site Reference ID/Investigator# 43904|Site Reference ID/Investigator# 28277|Site Reference ID/Investigator# 28297|Site Reference ID/Investigator# 28307|Site Reference ID/Investigator# 28295|Site Reference ID/Investigator# 28294|Site Reference ID/Investigator# 48862|Site Reference ID/Investigator# 28042|Site Reference ID/Investigator# 28282|Site Reference ID/Investigator# 28033|Site Reference ID/Investigator# 54052|Site Reference ID/Investigator# 28005|Site Reference ID/Investigator# 28020|Site Reference ID/Investigator# 28293|Site Reference ID/Investigator# 28018|Site Reference ID/Investigator# 28298|Site Reference ID/Investigator# 28292|Site Reference ID/Investigator# 48882|Site Reference ID/Investigator# 28299|Site Reference ID/Investigator# 28279,,Austria|Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01083849
732,NCT01084356,parathyroid neoplasms,Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination,Evaluation of a New CZT System,Parathyroid Adenoma|Thyroid Adenoma,2010-03-09,2011-03-31,,100.0,Cohort,,Prospective,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,"Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center",,Israel,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01084356
733,NCT01084356,thyroid neoplasms,Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination,Evaluation of a New CZT System,Parathyroid Adenoma|Thyroid Adenoma,2010-03-09,2011-03-31,,100.0,Cohort,,Prospective,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,"Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center",,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01084356
736,NCT01087619,hyperparathyroidism,Primary Hyperparathyroidism in Patients Older Than 65 Years: A Prospective Randomized Trial of Surgical Treatment Compared With Follow-up,Surgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up,Primary Hyperparathyroidism,2010-03-15,2023-12-31,2025-12-31,115.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Region Skane,Region Skane,"Skne University Hospital, Department of Surgery, Lund",Procedure,Sweden,66.0,120.0,[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01087619
739,NCT01089335,"thyroid cancer, papillary",Sentinel Node Investigation in Patients With Highly Differentiated Papillary Thyroid Carcinoma and in Patients With Thyroid Neoplasia of Unclear Malignant Potential,Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia,Thyroid Cancer|Thyroid Neoplasms,2010-03-16,2018-12-31,2018-12-31,100.0,Cohort,,Prospective,Observational,Completed,,Region Skane,Region Skane,"Department of Surgery and Department of Imaging, Skne University Hospital",Procedure,Sweden,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01089335
740,NCT01095341,hyperthyroidism,Postoperative Hyperthyroidism After Parathyroidectomy,Postoperative Hyperthyroidism,Hyperthyroidism,2010-03-29,2009-04-30,2009-04-30,57.0,Case-Control,,Prospective,Observational,Completed,,Heidelberg University,Heidelberg University,University Hospital Heidelberg,Other,Germany,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01095341
741,NCT01100619,"adenocarcinoma, follicular",A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors,A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors,Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Renal Cell Carcinoma,2010-03-22,2012-08-31,,40.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Exelixis,Exelixis,City of Hope Comprehensive Cancer Center|Dana Farber Cancer Institute|Montefiore Medical Center|Hospital of the University of Pennsylvania|The University of Texas M.D. Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01100619
743,NCT01100619,"thyroid cancer, papillary",A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors,A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors,Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Renal Cell Carcinoma,2010-03-22,2012-08-31,,40.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Exelixis,Exelixis,City of Hope Comprehensive Cancer Center|Dana Farber Cancer Institute|Montefiore Medical Center|Hospital of the University of Pennsylvania|The University of Texas M.D. Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01100619
744,NCT01100723,hyperparathyroidism,Trial to Optimize Mineral Outcomes in End Stage Renal Disease (ESRD) Patients,Trial to Optimize Mineral Outcomes in Dialysis Patients,Chronic Kidney Disease|Secondary Hyperparathyroidism,2010-04-07,2011-08-31,2011-08-31,92.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University of Colorado, Denver","University of Colorado, Denver","Lynchburg Nephrology Associates, P.L.L.C.",Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01100723
747,NCT01101113,hyperparathyroidism,Phase 4 Study of Cinacalcet Efficacy in Combination With Vitamin D for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients,Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level,Secondary Hyperparathyroidism,2010-04-04,2012-03-31,2012-06-30,66.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Seoul National University Hospital,Jeil-Kirin Pharmaceutical Inc.|Seoul National University Hospital,Seoul National University Hospital|Kyungpook National University|Gil Hospital|Hallym University Sacred Hospital|Seoul National University Bundang Hospital|Eulji University|Samsung Medical Center,Drug|Drug,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01101113
750,NCT01102127,thyroid neoplasms,Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease.,Elastography in Thyroid Nodules,Nodular Goiter|Thyroid Cancer,2010-04-12,2010-09-30,2010-09-30,128.0,Case-Control,,Cross-Sectional,Observational,Completed,,Castilla-Len Health Service,Castilla-Len Health Service,Complejo Asistencial de Len,Device,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01102127
752,NCT01102127,"goiter, nodular",Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease.,Elastography in Thyroid Nodules,Nodular Goiter|Thyroid Cancer,2010-04-12,2010-09-30,2010-09-30,128.0,Case-Control,,Cross-Sectional,Observational,Completed,,Castilla-Len Health Service,Castilla-Len Health Service,Complejo Asistencial de Len,Device,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01102127
753,NCT01102127,thyroid nodule,Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease.,Elastography in Thyroid Nodules,Nodular Goiter|Thyroid Cancer,2010-04-12,2010-09-30,2010-09-30,128.0,Case-Control,,Cross-Sectional,Observational,Completed,,Castilla-Len Health Service,Castilla-Len Health Service,Complejo Asistencial de Len,Device,Spain,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01102127
756,NCT01102205,"thyroiditis, autoimmune",Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease,Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease,Hashimoto Disease,2010-04-09,2010-04-30,2010-10-31,130.0,Cohort,,Prospective,Observational,Completed,,Vakif Gureba Training and Research Hospital,Vakif Gureba Training and Research Hospital,Vakif Gureba Training and Research Hospital,,Turkey,18.0,95.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01102205
758,NCT01103206,hyperparathyroidism,Evaluation of a Parathyroid Hormone Suppression Test With Cinacalcet. Comparison: 1- With the Results of the Intravenous Calcium Suppression Test in Healthy Controls; 2- Between Healthy Controls and Patients With Primary Hyperparathyroidism.,Evaluation of a Cincalcet Suppression Test,Parathyroid Hormone Suppression Test With Cinacalcet,2010-04-12,2013-02-28,2013-02-28,36.0,,Crossover Assignment,,Interventional,Completed,Phase 4,"University Hospital, Rouen","Institut National de la Sant Et de la Recherche Mdicale, France|University Hospital, Rouen",University hospital,Drug|Drug|Drug,France,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01103206
759,NCT01103557,"thyroid cancer, papillary",The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis,Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma,Lymphatic Metastasis|Thyroid Neoplasm,2010-04-12,,,62.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Pusan National University Hospital,Pusan National University Hospital,,Procedure,,20.0,76.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01103557
761,NCT01105923,hypothyroidism,Making Accurate Problem Lists in the EHR,Study of an Intervention to Improve Problem List Accuracy and Use,Asthma|Attention Deficit Disorder With Hyperactivity|Breast Cancer|Congestive Heart Failure|COPD|Coronary Artery Disease|Diabetes|Glaucoma|Hemophilia|Hypertension|Hyperthyroidism|Hypothyroidism|Myasthenia Gravis|Osteopenia|Osteoporosis|Renal Failure|Renal Insufficiency|Sickle Cell Disease|Stroke,2010-04-15,2010-11-30,2017-11-30,140.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Other,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01105923
762,NCT01105923,hyperthyroidism,Making Accurate Problem Lists in the EHR,Study of an Intervention to Improve Problem List Accuracy and Use,Asthma|Attention Deficit Disorder With Hyperactivity|Breast Cancer|Congestive Heart Failure|COPD|Coronary Artery Disease|Diabetes|Glaucoma|Hemophilia|Hypertension|Hyperthyroidism|Hypothyroidism|Myasthenia Gravis|Osteopenia|Osteoporosis|Renal Failure|Renal Insufficiency|Sickle Cell Disease|Stroke,2010-04-15,2010-11-30,2017-11-30,140.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Other,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01105923
763,NCT01106443,thyroid neoplasms,Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial,Central Compartment Neck Dissection With Thyroidectomy,Indeterminate Thyroid Nodules,2010-04-14,2013-07-31,2016-10-31,128.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,University of Alberta,University of Alberta,University of Alberta|Dalhouise University,Procedure|Procedure|Procedure|Procedure,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01106443
764,NCT01106443,thyroid nodule,Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial,Central Compartment Neck Dissection With Thyroidectomy,Indeterminate Thyroid Nodules,2010-04-14,2013-07-31,2016-10-31,128.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,University of Alberta,University of Alberta,University of Alberta|Dalhouise University,Procedure|Procedure|Procedure|Procedure,Canada,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01106443
765,NCT01109420,"thyroid cancer, papillary",Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer,Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer,Non-Medullary Thyroid Cancer,2010-04-22,,,300.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01109420
767,NCT01114503,graves disease,"A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy",A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease,Graves Ophthalmopathy,2010-04-29,2012-08-29,2012-08-29,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug|Drug|Drug|Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01114503
768,NCT01114503,hyperthyroidism,"A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy",A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease,Graves Ophthalmopathy,2010-04-29,2012-08-29,2012-08-29,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug|Drug|Drug|Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01114503
769,NCT01114503,graves ophthalmopathy,"A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy",A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease,Graves Ophthalmopathy,2010-04-29,2012-08-29,2012-08-29,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug|Drug|Drug|Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01114503
770,NCT01114503,goiter,"A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy",A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease,Graves Ophthalmopathy,2010-04-29,2012-08-29,2012-08-29,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug|Drug|Drug|Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01114503
771,NCT01115543,hyperparathyroidism,A Randomized Trial Comparing Pulse Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients,Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism,End Stage Renal Disease|Secondary Hyperparathyroidism,2010-05-01,2009-08-31,2009-08-31,32.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Mahidol University,Mahidol University,Siriraj Medical School,Drug,Thailand,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01115543
774,NCT01118065,thyroid neoplasms,"A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma","Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer",Head and Neck Cancer,2010-05-05,2012-05-31,,42.0,,,,Interventional,Unknown status,Phase 2,National Cancer Institute (NCI),Leiden University Medical Center,Leiden University Medical Center,Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01118065
775,NCT01126060,thyroid neoplasms,Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections,Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain,Thyroid Carcinoma|Thyroidectomy,2010-04-15,2011-01-31,2011-01-31,78.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung Medical Center,Drug|Procedure,"Korea, Republic of",20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01126060
776,NCT01127503,hypoparathyroidism,"A Double-Blind, Placebo-Controlled, Multi-Center, Randomized Trial of the Safety and Efficacy of Metyrosine (Demser) for the Treatment of Psychotic Disorders in Patients With Velo-Cardio-Facial Syndrome",Metyrosine (Demser) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome,Psychosis|Velo-cardio-facial Syndrome,2010-05-19,2010-11-30,2011-09-30,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",VCFS International Center,Drug|Drug,United States,16.0,65.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01127503
780,NCT01129492,hashimoto disease,"Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis: Randomized, Placebo Controlled Clinical Trial",Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis,Autoimmune Thyroiditis,2010-05-14,2009-03-31,2009-03-31,43.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Sao Paulo General Hospital,Conselho Nacional de Desenvolvimento Cientfico e Tecnolgico|Coordenao de Aperfeioamento de Pessoal de Nvel Superior.|Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Device,Brazil,20.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01129492
782,NCT01134315,hyperparathyroidism,"A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice",Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice,End-Stage Renal Disease|Secondary Hyperparathyroidism,2010-05-28,2012-05-31,2012-05-31,61.0,Cohort,,Prospective,Observational,Terminated,,AbbVie,"AbbVie (prior sponsor, Abbott)|North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)",Site Reference ID/Investigator# 37082|Site Reference ID/Investigator# 26762|Site Reference ID/Investigator# 28529|Site Reference ID/Investigator# 26748|Site Reference ID/Investigator# 37582|Site Reference ID/Investigator# 39973|Site Reference ID/Investigator# 26769|Site Reference ID/Investigator# 26768|Site Reference ID/Investigator# 26747|Site Reference ID/Investigator# 26749|Site Reference ID/Investigator# 26751|Site Reference ID/Investigator# 26765|Site Reference ID/Investigator# 28528|Site Reference ID/Investigator# 26763|Site Reference ID/Investigator# 28526|Site Reference ID/Investigator# 26758|Site Reference ID/Investigator# 40382|Site Reference ID/Investigator# 26759,Drug|Drug,United States,0.0,16.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01134315
786,NCT01134549,hyperparathyroidism,"A Double-Blind, Randomized, Placebo-Controlled, Rising Single Intravenous Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers","Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers","Hyperparathyroidism, Secondary",2010-05-28,2010-07-31,2010-07-31,32.0,,Parallel Assignment,,Interventional,Completed,Phase 1,KAI Pharmaceuticals,KAI Pharmaceuticals|Nucleus Network Ltd,,Drug|Drug,Australia,18.0,45.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01134549
789,NCT01134562,hyperparathyroidism,"A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism","Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism","Hyperparathyroidism, Secondary",2010-05-28,2011-04-02,2011-04-02,28.0,,Sequential Assignment,,Interventional,Completed,Phase 1,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug|Drug,Australia|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01134562
790,NCT01137097,thyroid neoplasms,Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study,Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC,Thyroid Neoplasm,2010-06-02,2011-01-31,2011-01-31,278.0,,Single Group Assignment,,Interventional,Completed,Phase 2/Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung Medical Center,Procedure,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01137097
791,NCT01138475,hyperparathyroidism,"A Prospective, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Pilot Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery",Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,2010-06-04,2015-08-31,2015-08-31,49.0,,Parallel Assignment,,Interventional,Completed,Phase 3,William Beaumont Hospitals,"Abbott|Kerstyn C. Zalesin, M.D.",William Beaumont Health Center,Drug|Drug|Drug,United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01138475
794,NCT01141309,thyroid neoplasms,Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer,Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer,Thyroid Cancer,2010-06-09,2022-06-30,2022-06-30,41.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Cancer Center|Memorial Sloan Kettering Cancer Center @ Suffolk|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01141309
796,NCT01143987,hyperparathyroidism,Effect of Cinacalcet Treatment on Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism,Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism,Arterial Stiffness|Hyperparathyroidism,2010-06-10,2013-02-28,2013-02-28,44.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Chinese University of Hong Kong,Chinese University of Hong Kong,"Prince of Wales Hospital, Chinese University of Hong Kong",Drug,Hong Kong,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01143987
798,NCT01145040,hypothyroidism,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation. A Correlation Study,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation,Hyperthyroidism|Hypothyroidism,2010-06-14,2018-07-31,2021-01-31,138.0,Cohort,,Cross-Sectional,Observational,Active not recruiting,,Ruhr University of Bochum,Ruhr University of Bochum,"Klinikum Ludwigsburg-Bietigheim|Institute for diagnostical radiology, interventional radiology and nuclear medicine, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medical Hospital I, Bergmannsheil University Hospitals, Ruhr University of Bochum",,Germany,14.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01145040
799,NCT01145040,hyperthyroidism,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation. A Correlation Study,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation,Hyperthyroidism|Hypothyroidism,2010-06-14,2018-07-31,2021-01-31,138.0,Cohort,,Cross-Sectional,Observational,Active not recruiting,,Ruhr University of Bochum,Ruhr University of Bochum,"Klinikum Ludwigsburg-Bietigheim|Institute for diagnostical radiology, interventional radiology and nuclear medicine, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medical Hospital I, Bergmannsheil University Hospitals, Ruhr University of Bochum",,Germany,14.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01145040
801,NCT01149291,hyperparathyroidism,"A 18 Months, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving sVDRA's for Prevention and Treatment of Secondary Hyperparathyroidism","A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism",End Stage Renal Disease|Secondary Hyperparathyroidism,2010-06-22,2014-12-31,2014-12-31,511.0,Case-Only,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 37822|Site Reference ID/Investigator# 68286|Site Reference ID/Investigator# 40677|Site Reference ID/Investigator# 85153|Site Reference ID/Investigator# 40672|Site Reference ID/Investigator# 40674|Site Reference ID/Investigator# 40678|Site Reference ID/Investigator# 40686|Site Reference ID/Investigator# 61585|Site Reference ID/Investigator# 63764|Site Reference ID/Investigator# 63765|Site Reference ID/Investigator# 63766|Site Reference ID/Investigator# 69973|Site Reference ID/Investigator# 63763|Site Reference ID/Investigator# 48127|Site Reference ID/Investigator# 64444|Site Reference ID/Investigator# 40684|Site Reference ID/Investigator# 48132|Site Reference ID/Investigator# 68283|Site Reference ID/Investigator# 68281|Site Reference ID/Investigator# 68282|Site Reference ID/Investigator# 69974,,Turkey,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01149291
803,NCT01150318,thyroid neoplasms,Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma,Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients,Thyroid Neoplasms,2010-04-29,2010-06-30,2010-06-30,48.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,"Saint Antoine Hospital, Endocrinology Unit",Drug,France,18.0,55.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01150318
804,NCT01153360,euthyroid sick syndromes,Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery,Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery,Non-thyroidal Illness Syndrome,2010-06-29,2011-08-31,2011-09-30,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,75.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01153360
805,NCT01153945,thyroid neoplasms,Association Between Cancer Cells and Normal Vs. Low Levels of Thyroid Hormones in the Serum,Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum,Thyroid Cancer,2010-06-29,2011-07-31,2011-07-31,0.0,,,,Observational,Withdrawn,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01153945
806,NCT01163565,goiter,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,96.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01163565
807,NCT01163565,thyroid nodule,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,96.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01163565
808,NCT01163565,graves disease,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,96.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01163565
809,NCT01163565,thyroid neoplasms,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,96.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01163565
810,NCT01163565,hyperthyroidism,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,96.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01163565
812,NCT01163669,hyperparathyroidism,A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients,A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients,Hyperparathyroidism,2010-07-14,2012-11-30,2012-11-30,15.0,Cohort,,Prospective,Observational,Completed,,The Cleveland Clinic,Amgen|The Cleveland Clinic,Cleveland Clinic,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01163669
813,NCT01164176,thyroid neoplasms,An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer,Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer,Head and Neck Cancer,2010-07-15,2014-10-31,2014-10-31,40.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Yonsei University,Yonsei University,Hallym University Sacred Heart Hospital|Yeungnam University Medical Center|National Cancer Center - Korea|Kosin Medical Center Gospel Hospital|Seoul National University Hospital|Yonsei Cancer Center at Yonsei University Medical Center|Gangnam Severance Hospital,Drug|Other,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01164176
816,NCT01167309,hyperparathyroidism,"LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease","LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients",Secondary Hyperparathyroidism,2010-07-02,2011-10-31,2011-12-31,72.0,,Single Group Assignment,,Interventional,Completed,Phase 1,LEO Pharma,LEO Pharma,CRS Clinical Research Services Kiel GmbH|Centralny Szpital Kliniczny MON,Drug,Germany|Poland,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01167309
817,NCT01171690,hypoparathyroidism,Pilot Study of Teriparatide for Postsurgical Hypoparathyroidism,Teriparatide for Postsurgical Hypoparathyroidism,Hypoparathyroidism Post-surgical,2010-07-27,2013-12-31,2013-12-31,5.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Mayo Clinic,Mayo Clinic,Mayo Clinic,Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01171690
819,NCT01173289,thyroid neoplasms,A Phase II Study of External Beam Radiotherapy for Locoregionally Advanced or Recurrent Differentiated Thyroid Carcinoma,Study of External Beam Radiotherapy to Thyroid Carcinoma,Thyroid Cancer,2010-07-22,2015-08-31,2015-08-31,62.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"National Cancer Center, Korea","National Cancer Center, Korea","National Cancer Center, Korea",Radiation,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01173289
822,NCT01178450,hyperparathyroidism,"A Prospective, Randomized Trial to Compare Subtotal Parathyroidectomy Versus Cinacalcet in the Treatment of Persistent Secondary Hyperparathyroidism Post Renal Transplantation",Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation,Secondary Hyperparathyroidism,2010-04-19,2014-09-30,2014-09-30,30.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Hospital Universitari de Bellvitge,Josep M Cruzado,Hospital Universitari de Bellvitge|Hospital Clinic de Barcelona,Procedure|Drug,Spain,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01178450
824,NCT01181531,hyperparathyroidism,"A Multicenter, Randomized, Open Label Study to Compare the Efficacy of Cinacalcet Versus Traditional Vitamin D Therapy for Management of Secondary Hyperparathyroidism Among Subjects Undergoing Hemodialysis",Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis,"Hyperparathyroidism, Secondary",2010-08-12,2012-07-17,2012-08-14,312.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01181531
826,NCT01182285,thyroid neoplasms,A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin,A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin,Thyroid Neoplasm,2010-08-13,2015-09-28,2016-04-28,13.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01182285
827,NCT01182584,graves disease,Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy,Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease,Graves' Disease,2010-08-12,2011-10-31,2011-12-31,200.0,Cohort,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University,,Taiwan,16.0,60.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01182584
828,NCT01182584,goiter,Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy,Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease,Graves' Disease,2010-08-12,2011-10-31,2011-12-31,200.0,Cohort,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University,,Taiwan,16.0,60.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01182584
829,NCT01182584,hyperthyroidism,Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy,Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease,Graves' Disease,2010-08-12,2011-10-31,2011-12-31,200.0,Cohort,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University,,Taiwan,16.0,60.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01182584
830,NCT01191762,hyperparathyroidism,The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Chronic Kidney Disease|Hyperparathyroidism,2010-08-27,2012-08-31,2013-04-30,30.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Phelps, Kenneth R., M.D.","Genzyme, a Sanofi Company|Kenneth R. Phelps, M.D.",Stratton Veterans Affairs Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01191762
833,NCT01197183,hypothyroidism,Survey for the Initial Treatment of Hypothyroidism in France,"Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in France",Hypothyroidism,2010-08-18,2009-05-31,2009-09-30,1285.0,Cohort,,Prospective,Observational,Completed,,"Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",Merck Lipha Sant Laboratories,,France,35.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01197183
835,NCT01199614,hypoparathyroidism,"HEXT: The Hypoparathyroidism Studies, EXTended: The Effect of PTH on the Skeleton in Hypoparathyroidism",HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism,Hypoparathyroidism,2010-09-09,2020-12-31,2020-12-31,75.0,,Single Group Assignment,,Interventional,Unknown status,Phase 3,Columbia University,John P. Bilezikian|NPS Pharma|Shire,Columbia University Medical Center,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01199614
836,NCT01204359,hypothyroidism,"""5010 Clinical Research Programme""of Sun Yat-sen University",The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions,Exophthalmos|Hypothyroidism,2010-09-15,2016-07-31,2016-12-31,627.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Sun Yat-sen University,Sun Yat-sen University,Sun Yat-sen Memorial Hospital|Ningyi Jiang,Radiation,China,8.0,90.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01204359
837,NCT01208051,"adenocarcinoma, follicular",Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer,Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer,Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Follicular Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Papillary Carcinoma|Unresectable Thyroid Gland Carcinoma,2010-09-22,2020-02-01,2020-02-01,127.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|USC / Norris Comprehensive Cancer Center|University of California Davis Comprehensive Cancer Center P2C|University of California Davis Comprehensive Cancer Center|City of Hope South Pasadena|University of Colorado Hospital|Moffitt Cancer Center|Northwestern University|University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|UC Comprehensive Cancer Center at Silver Cross|Illinois CancerCare-Peoria|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Indiana University/Melvin and Bren Simon Cancer Center|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Wayne State University/Karmanos Cancer Institute|Minnesota Oncology Hematology PA-Minneapolis|Metro Minnesota Community Oncology Research Consortium|Washington University School of Medicine|Mercy Hospital Saint Louis|Rutgers Cancer Institute of New Jersey|UNC Lineberger Comprehensive Cancer Center|Penn State Children's Hospital|Fox Chase Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center|University of Wisconsin Hospital and Clinics|Tom Baker Cancer Centre|London Regional Cancer Program|University Health Network-Princess Margaret Hospital,Drug|Drug|Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01208051
839,NCT01208051,"thyroid cancer, papillary",Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer,Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer,Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Follicular Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Papillary Carcinoma|Unresectable Thyroid Gland Carcinoma,2010-09-22,2020-02-01,2020-02-01,127.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|USC / Norris Comprehensive Cancer Center|University of California Davis Comprehensive Cancer Center P2C|University of California Davis Comprehensive Cancer Center|City of Hope South Pasadena|University of Colorado Hospital|Moffitt Cancer Center|Northwestern University|University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|UC Comprehensive Cancer Center at Silver Cross|Illinois CancerCare-Peoria|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Indiana University/Melvin and Bren Simon Cancer Center|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Wayne State University/Karmanos Cancer Institute|Minnesota Oncology Hematology PA-Minneapolis|Metro Minnesota Community Oncology Research Consortium|Washington University School of Medicine|Mercy Hospital Saint Louis|Rutgers Cancer Institute of New Jersey|UNC Lineberger Comprehensive Cancer Center|Penn State Children's Hospital|Fox Chase Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center|University of Wisconsin Hospital and Clinics|Tom Baker Cancer Centre|London Regional Cancer Program|University Health Network-Princess Margaret Hospital,Drug|Drug|Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01208051
841,NCT01219855,hyperparathyroidism,"A Randomized, Double Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of CTAP101 Capsules in Subjects With Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism",Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,2010-10-11,2011-11-30,2011-11-30,78.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"OPKO Health, Inc.","OPKO Health, Inc.","OPKO Health, Inc",Drug|Drug|Drug|Drug|Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01219855
844,NCT01220050,hyperparathyroidism,"A PROSPECTIVE, PILOT, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF PARICALCITOL IN REDUCING PARATHYROID HORMONE LEVELS AND AMELIORATING MARKERS OF BONE REMODELLING IN RENAL TRANSPLANT RECIPIENTS WITH SECONDARY HYPERPARATHYROIDISM",Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism,Renal Transplant|Secondary Hyperparathyroidism,2010-10-11,2012-07-31,2013-02-28,43.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Mario Negri Institute for Pharmacological Research,Mario Negri Institute for Pharmacological Research,Mario Negri Institute - Clinical Research Center for Rare Diseases,Drug|Drug,Italy,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01220050
847,NCT01221896,hyperparathyroidism,,Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma,Hyperparathyroidism,2010-10-14,2014-01-31,,100.0,Cohort,,Prospective,Observational,Unknown status,,Hadassah Medical Organization,Hadassah Medical Organization,Hadassah Hebrew University Medical Center,Procedure,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01221896
849,NCT01222026,hyperparathyroidism,Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I,Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate,Osteopenia|Osteoporosis|Primary Hyperparathyroidism,2010-10-15,2014-12-31,2014-12-31,63.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Medical University of Vienna,Medical University of Vienna|National Bank of Austria,"Medical University Vienna, General Hospital Vienna (AKH Wien)",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01222026
852,NCT01223638,congenital hypothyroidism,,The Prevalence of Hearing Loss Among Children With Congenital Hypothyroidism,Congenital Hypothyroidism|Hearing Loss,2010-10-03,2012-12-31,2015-06-30,0.0,Case-Control,,Prospective,Observational,Withdrawn,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",Ha'Emek Medical Center,Other,Israel,2.0,30.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01223638
854,NCT01224782,hyperparathyroidism,"Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) Stage 3 or 4 in the Conditions of Routine Clinical Practice. A Multi-country, Multi-center Post Marketing Observational Study in Routine Clinical Use in Eastern European Countries.",Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism,2010-09-27,2013-08-31,2013-08-31,994.0,,,,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 66544|Site Reference ID/Investigator# 47685|Site Reference ID/Investigator# 66546|Site Reference ID/Investigator# 47683|Site Reference ID/Investigator# 66543|Site Reference ID/Investigator# 47684|Site Reference ID/Investigator# 66542|Site Reference ID/Investigator# 66545|Site Reference ID/Investigator# 47687|Site Reference ID/Investigator# 43449|Site Reference ID/Investigator# 46744|Site Reference ID/Investigator# 73353|Site Reference ID/Investigator# 47690|Site Reference ID/Investigator# 46742|Site Reference ID/Investigator# 49542|Site Reference ID/Investigator# 67442|Site Reference ID/Investigator# 67443|Site Reference ID/Investigator# 51003|Site Reference ID/Investigator# 51004|Site Reference ID/Investigator# 43522|Site Reference ID/Investigator# 43523|Site Reference ID/Investigator# 43524|Site Reference ID/Investigator# 45483|Site Reference ID/Investigator# 43453|Site Reference ID/Investigator# 46743|Site Reference ID/Investigator# 51008|Site Reference ID/Investigator# 47842|Site Reference ID/Investigator# 68462|Site Reference ID/Investigator# 51009|Site Reference ID/Investigator# 51005|Site Reference ID/Investigator# 51011|Site Reference ID/Investigator# 48210|Site Reference ID/Investigator# 45487|Site Reference ID/Investigator# 51012|Site Reference ID/Investigator# 51002|Site Reference ID/Investigator# 43448|Site Reference ID/Investigator# 45485|Site Reference ID/Investigator# 42992|Site Reference ID/Investigator# 42879|Site Reference ID/Investigator# 42880|Site Reference ID/Investigator# 42881|Site Reference ID/Investigator# 42882|Site Reference ID/Investigator# 42883|Site Reference ID/Investigator# 42963|Site Reference ID/Investigator# 42970|Site Reference ID/Investigator# 42877|Site Reference ID/Investigator# 42878|Site Reference ID/Investigator# 42973|Site Reference ID/Investigator# 42975|Site Reference ID/Investigator# 42976|Site Reference ID/Investigator# 42981|Site Reference ID/Investigator# 42982|Site Reference ID/Investigator# 42980|Site Reference ID/Investigator# 63623|Site Reference ID/Investigator# 43009|Site Reference ID/Investigator# 43002|Site Reference ID/Investigator# 43003|Site Reference ID/Investigator# 43006|Site Reference ID/Investigator# 42991|Site Reference ID/Investigator# 42988|Site Reference ID/Investigator# 42989|Site Reference ID/Investigator# 42999|Site Reference ID/Investigator# 43000|Site Reference ID/Investigator# 42979|Site Reference ID/Investigator# 42984|Site Reference ID/Investigator# 42985|Site Reference ID/Investigator# 42987|Site Reference ID/Investigator# 42994|Site Reference ID/Investigator# 42995,,Bulgaria|Czech Republic|Romania,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01224782
856,NCT01225016,thyroid neoplasms,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Thyroid Nodules,2010-10-14,2011-12-31,2011-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,University of Alabama at Birmingham,University of Alabama at Birmingham,Universith of Alabama at Birmingham,Drug,United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01225016
857,NCT01225016,thyroid nodule,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Thyroid Nodules,2010-10-14,2011-12-31,2011-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,University of Alabama at Birmingham,University of Alabama at Birmingham,Universith of Alabama at Birmingham,Drug,United States,19.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01225016
859,NCT01226810,hyperparathyroidism,A Novel Approach to Ultrafast Parathyroid SPECT Imaging Using a Solid State CZT SPECT Camera,The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration,Hypercalcemia|Hyperparathyroidism,2010-10-21,,,50.0,Case-Only,,Cross-Sectional,Observational,Unknown status,,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Healthcare Campus,,Israel,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01226810
860,NCT01226914,thyroid neoplasms,"A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL Fibrin Sealant in Thyroidectomy",A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL Fibrin Sealant in Thyroidectomy,Goiter|Thyroid Neoplasm,2010-10-21,2014-07-31,2014-07-31,55.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Medical University of South Carolina,"Ethicon, Inc.|Medical University of South Carolina",,Drug,,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01226914
861,NCT01227499,graves disease,Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease,Differential Diagnosis of STA-PSV in Thyrotoxicosis,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,2010-10-22,2011-11-30,2011-11-30,169.0,Cohort,,Prospective,Observational,Completed,,Huashan Hospital,Fudan University|xiaolong zhao|Zhongda Hospital,Xiaolong Zhao,,China,15.0,85.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01227499
862,NCT01227499,thyroiditis,Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease,Differential Diagnosis of STA-PSV in Thyrotoxicosis,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,2010-10-22,2011-11-30,2011-11-30,169.0,Cohort,,Prospective,Observational,Completed,,Huashan Hospital,Fudan University|xiaolong zhao|Zhongda Hospital,Xiaolong Zhao,,China,15.0,85.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01227499
863,NCT01227499,goiter,Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease,Differential Diagnosis of STA-PSV in Thyrotoxicosis,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,2010-10-22,2011-11-30,2011-11-30,169.0,Cohort,,Prospective,Observational,Completed,,Huashan Hospital,Fudan University|xiaolong zhao|Zhongda Hospital,Xiaolong Zhao,,China,15.0,85.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01227499
865,NCT01227499,hyperthyroidism,Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease,Differential Diagnosis of STA-PSV in Thyrotoxicosis,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,2010-10-22,2011-11-30,2011-11-30,169.0,Cohort,,Prospective,Observational,Completed,,Huashan Hospital,Fudan University|xiaolong zhao|Zhongda Hospital,Xiaolong Zhao,,China,15.0,85.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01227499
867,NCT01228786,hyperparathyroidism,Transcriptional and Translational Regulation of Vitamin D Receptor (VDR) and Calcium Sensing Receptor (CaSR) in Patients With Sporadic Primary Hyperparathyroidism,"Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism",Primary Hyperparathyroidism (PHPT),2010-10-26,2012-12-31,2013-06-30,50.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,Postgraduate Institute of Medical Education and Research,Postgraduate Institute of Medical Education and Research,PGIMER,,India,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01228786
869,NCT01229865,thyroid neoplasms,,Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer,Differential Thyroid Cancer,2010-10-26,2014-10-31,2016-06-30,29.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Vascular Biogenics Ltd. operating as VBL Therapeutics,Vascular Biogenics Ltd. operating as VBL Therapeutics,Mayo Clinic|Massachusetts General Hospital|Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01229865
870,NCT01236547,"thyroid carcinoma, anaplastic","A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer",Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Anaplastic Carcinoma,2010-11-05,2020-03-09,,123.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI)|NRG Oncology,University of Alabama at Birmingham Cancer Center|The Kirklin Clinic at Acton Road|Cancer Center at Saint Joseph's|Saint Joseph's Hospital and Medical Center|Arizona Oncology-Deer Valley Center|Arizona Oncology Services Foundation|Sutter Cancer Centers Radiation Oncology Services-Auburn|Alta Bates Summit Medical Center-Herrick Campus|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Medical Center Sacramento|California Pacific Medical Center-Pacific Campus|UCSF Medical Center-Mount Zion|UCSF Medical Center-Parnassus|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Sutter Solano Medical Center/Cancer Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Moffitt Cancer Center|Emory University Hospital Midtown|Emory University Hospital/Winship Cancer Institute|Radiation Oncology Associates PC|Parkview Hospital Randallia|University of Kansas Cancer Center|The James Graham Brown Cancer Center at University of Louisville|Mary Bird Perkins Cancer Center|Touro Infirmary|Greater Baltimore Medical Center|Sinai Hospital of Baltimore|Boston Medical Center|Henry Ford Cancer Institute-Downriver|Henry Ford Macomb Hospital-Clinton Township|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|West Michigan Cancer Center|Henry Ford Medical Center-Columbus|Henry Ford West Bloomfield Hospital|Fairview Ridges Hospital|Mercy Hospital|Fairview Southdale Hospital|Unity Hospital|Minnesota Oncology Hematology PA-Maplewood|Abbott-Northwestern Hospital|Hennepin County Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Metro Minnesota Community Oncology Research Consortium|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Ridgeview Medical Center|Rice Memorial Hospital|University of Mississippi Medical Center|Billings Clinic Cancer Center|Memorial Sloan Kettering Basking Ridge|New York-Presbyterian/Brooklyn Methodist Hospital|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Sleepy Hollow|Memorial Sloan Kettering Nassau|UNC Lineberger Comprehensive Cancer Center|Summa Health System - Akron Campus|Summa Health System - Barberton Campus|University of Cincinnati Cancer Center-UC Medical Center|Case Western Reserve University|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mercy Cancer Center-Elyria|Summa Health Medina Medical Center|UH Seidman Cancer Center at Lake Health Mentor Campus|UH Seidman Cancer Center at Southwest General Hospital|University Hospitals Parma Medical Center|UH Seidman Cancer Center at Firelands Regional Medical Center|University of Cincinnati Cancer Center-West Chester|University of Oklahoma Health Sciences Center|UPMC-Heritage Valley Health System Beaver|UPMC Cancer Centers - Arnold Palmer Pavilion|Penn State Milton S Hershey Medical Center|UPMC-Johnstown/John P. Murtha Regional Cancer Center|UPMC Cancer Center at UPMC McKeesport|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Cancer Center-Natrona Heights|UPMC Jameson|Thomas Jefferson University Hospital|UPMC-Presbyterian Hospital|UPMC-Saint Margaret|UPMC-Shadyside Hospital|UPMC Jefferson Regional Radiation Oncology|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|UPMC Cancer Center at UPMC Northwest|UPMC Uniontown Hospital Radiation Oncology|UPMC Washington Hospital Radiation Oncology|Prisma Health Cancer Institute - Spartanburg|Prisma Health Cancer Institute - Faris|Prisma Health Cancer Institute - Eastside|Prisma Health Cancer Institute - Greer|Prisma Health Cancer Institute - Seneca|Parkland Memorial Hospital|UT Southwestern/Simmons Cancer Center-Dallas|M D Anderson Cancer Center|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|LDS Hospital|Sentara Cancer Institute at Sentara CarePlex Hospital|Sentara Norfolk General Hospital|Sentara Virginia Beach General Hospital|Green Bay Oncology at Saint Vincent Hospital|Saint Vincent Hospital Cancer Center Green Bay|Green Bay Oncology Limited at Saint Mary's Hospital|Saint Vincent Hospital Cancer Center at Saint Mary's|University of Wisconsin Carbone Cancer Center|Holy Family Memorial Hospital|Bay Area Medical Center|Medical College of Wisconsin,Radiation|Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01236547
872,NCT01240590,"thyroid carcinoma, anaplastic",A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),Anaplastic Thyroid Cancer|Solid Tumor,2010-11-11,2015-08-31,2016-12-31,27.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01240590
874,NCT01254565,hyperparathyroidism,"A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism","Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism",Secondary Hyperparathyroidism,2010-12-03,2011-07-31,2011-08-24,87.0,,Sequential Assignment,,Interventional,Completed,Phase 2,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01254565
877,NCT01263951,thyroid neoplasms,A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone,Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone,Differentiated Thyroid Cancer,2010-11-29,2021-02-01,2022-05-31,35.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Thomas Jefferson University,Bayer|Novartis Pharmaceuticals|Thomas Jefferson University,Hospital of the University of Pennsylvania,Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01263951
878,NCT01265381,thyroid neoplasms,Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study,Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study,Thyroid Cancer,2010-12-22,2020-02-26,2020-02-26,673.0,Case-Control,,Retrospective,Observational,Terminated,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Research Center for Radiation Medicine,,Ukraine,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01265381
881,NCT01265992,hyperparathyroidism,Post Marketing Observational Study to Assess Patient Management Practices and Quality of Life With the Capsules Form of Paricalcitol in the Treatment of SHPT in Stage 3 - 5 Chronic Kidney Disease Patients Not Yet on Dialysis Under Conditions of Usual Clinical Care (CAPITOL),Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis,Chronic Kidney Disease|Secondary Hyperparathyroidism,2010-11-29,2012-11-30,2012-11-30,50.0,,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Pharma Consulting Group AB",Site Reference ID/Investigator# 47723|Site Reference ID/Investigator# 41084|Site Reference ID/Investigator# 45190|Site Reference ID/Investigator# 41085|Site Reference ID/Investigator# 41087|Site Reference ID/Investigator# 45188|Site Reference ID/Investigator# 41088|Site Reference ID/Investigator# 57782|Site Reference ID/Investigator# 41089|Site Reference ID/Investigator# 45191,,Sweden,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01265992
883,NCT01268098,hypoparathyroidism,"A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 g and 50 g for the Treatment of Adults With Hypoparathyroidism",Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY),Hypoparathyroidism,2010-12-28,2011-09-23,2011-11-11,42.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Takeda,Shire,Advance Medical Research LLC|University of Chicago Medical Center|Indiana University School of Medicine|Massachusetts General Hospital|Michigan Bone & Mineral Clinic PC|Mayo Clinic Rochester|Columbia University Medical Center|University Physicians Group|Physician East PA|University of Cincinnati Bone Health and Osteoporosis Center|Cetero Research DGD Research Inc.|The Vancouver Clinic,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01268098
884,NCT01269749,goiter,Radioactive Iodide Therapy for Pediatric Graves' Disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Graves' Disease,2010-10-29,2016-06-30,2016-06-30,19.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Florida,Baylor College of Medicine|University of Florida,University of Florida|Texas Childrens Hospital,Radiation|Drug,United States,0.0,18.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01269749
885,NCT01269749,hyperthyroidism,Radioactive Iodide Therapy for Pediatric Graves' Disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Graves' Disease,2010-10-29,2016-06-30,2016-06-30,19.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Florida,Baylor College of Medicine|University of Florida,University of Florida|Texas Childrens Hospital,Radiation|Drug,United States,0.0,18.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01269749
886,NCT01269749,graves disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Graves' Disease,2010-10-29,2016-06-30,2016-06-30,19.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Florida,Baylor College of Medicine|University of Florida,University of Florida|Texas Childrens Hospital,Radiation|Drug,United States,0.0,18.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01269749
887,NCT01270321,thyroid neoplasms,A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer,Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer,Thyroid Cancer,2011-01-04,2019-02-28,2019-02-28,42.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Emory University,Emory University|Novartis,Emory University Hospital Midtown|Emory University Winship Cancer Institute|University of Pittsburgh Cancer Institute,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01270321
890,NCT01270425,thyroid neoplasms,Sonographic Characterization of the Thyroid Gland in Patients With Systemic Sclerosis With and Without Hashimoto Thyroiditis,Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis,Hashimoto Thyroiditis|Systemic Sclerosis|Thyroid Nodules,2011-01-04,2011-12-31,2012-11-30,60.0,Cohort,,Prospective,Observational,Completed,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01270425
891,NCT01270425,hashimoto disease,Sonographic Characterization of the Thyroid Gland in Patients With Systemic Sclerosis With and Without Hashimoto Thyroiditis,Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis,Hashimoto Thyroiditis|Systemic Sclerosis|Thyroid Nodules,2011-01-04,2011-12-31,2012-11-30,60.0,Cohort,,Prospective,Observational,Completed,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01270425
892,NCT01270425,thyroid nodule,Sonographic Characterization of the Thyroid Gland in Patients With Systemic Sclerosis With and Without Hashimoto Thyroiditis,Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis,Hashimoto Thyroiditis|Systemic Sclerosis|Thyroid Nodules,2011-01-04,2011-12-31,2012-11-30,60.0,Cohort,,Prospective,Observational,Completed,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01270425
893,NCT01272414,graves disease,,Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction,Graves Ophthalmopathy,2011-01-06,2012-01-31,2012-02-29,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,University of Toronto,Allergan|University of Toronto,Mount Sinai Hospital,Drug|Drug,Canada,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01272414
894,NCT01272414,hyperthyroidism,,Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction,Graves Ophthalmopathy,2011-01-06,2012-01-31,2012-02-29,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,University of Toronto,Allergan|University of Toronto,Mount Sinai Hospital,Drug|Drug,Canada,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01272414
895,NCT01272414,goiter,,Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction,Graves Ophthalmopathy,2011-01-06,2012-01-31,2012-02-29,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,University of Toronto,Allergan|University of Toronto,Mount Sinai Hospital,Drug|Drug,Canada,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01272414
896,NCT01272414,graves ophthalmopathy,,Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction,Graves Ophthalmopathy,2011-01-06,2012-01-31,2012-02-29,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,University of Toronto,Allergan|University of Toronto,Mount Sinai Hospital,Drug|Drug,Canada,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01272414
897,NCT01273597,hyperparathyroidism,Post-marketing Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Paricalcitol i.v. in the Treatment of Chronic Kidney Disease (CKD) 5 Stage Patients With (Severe) Secondary Hyperparathyroidism in Hungary,Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands,"Kidney Failure, Chronic",2010-11-22,2011-11-30,2011-11-30,60.0,Cohort,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Planimeter Ltd",Site Reference ID/Investigator# 46593|Site Reference ID/Investigator# 46585|Site Reference ID/Investigator# 46594|Site Reference ID/Investigator# 47722|Site Reference ID/Investigator# 46592|Site Reference ID/Investigator# 58644|Site Reference ID/Investigator# 46595|Site Reference ID/Investigator# 46588|Site Reference ID/Investigator# 46597|Site Reference ID/Investigator# 46590|Site Reference ID/Investigator# 46591,,Hungary,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01273597
899,NCT01273714,goiter,Subtotal Versus Total Thyroidectomy for Benign Thyroid Disease - a Prospective Case-control Surgical Outcome Study.,Subtotal Versus Total Thyroidectomy for Benign Goiter,Goiter,2011-01-07,2004-12-31,2009-12-31,8006.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian Univerity, Medical College, 3rd Department of general Surgery",Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01273714
902,NCT01277510,hyperparathyroidism,"A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis",Pediatric Chronic Kidney Disease Safety and Efficacy,"Chronic Kidney Disease|Hyperparathyroidism|Hyperparathyroidism, Secondary|Kidney Disease|Secondary Hyperparathyroidism",2011-01-13,2014-04-30,,43.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug|Drug,Australia|Belgium|Germany|Hungary|Mexico|Poland|Russian Federation|Slovakia|Spain|United States,6.0,17.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01277510
903,NCT01280214,graves ophthalmopathy,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,30.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01280214
904,NCT01280214,goiter,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,30.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01280214
905,NCT01280214,graves disease,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,30.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01280214
906,NCT01280214,hyperthyroidism,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,30.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01280214
907,NCT01280292,hypothyroidism,"Central Hypothyroidism,a New Laboratory Approach for Hormone Measurement","Central Hypothyroidism, a Novel Laboratory Measurement",Central Hypothyroidism,2011-01-19,2013-02-28,2013-07-31,50.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Sheba Medical Center,Sheba Medical Center,,Drug,,18.0,90.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01280292
908,NCT01286753,"thyroid cancer, papillary","An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine",A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation,Neoplasms,2011-01-28,2014-11-30,2015-05-31,51.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,,Drug,France|Italy|Netherlands|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01286753
911,NCT01290029,hyperparathyroidism,"An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis",Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Secondary Hyperparathyroidism",2011-01-20,2015-09-23,2015-09-23,14.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Germany|United Kingdom|United States,0.0,2190.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01290029
913,NCT01291498,parathyroid neoplasms,High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma,High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma,Parathyroid Adenomas,2011-02-07,2013-06-30,2013-06-30,1.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Oxford University Hospitals NHS Trust,Oxford University Hospitals NHS Trust|Theraclion,John Radcliffe Hospital,Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01291498
915,NCT01292044,thyroid neoplasms,The Role of Elastography in the Diagnosis of Thyroid Nodules,The Role of Elastography in the Diagnosis of Thyroid Nodules,Thyroid Neoplasms|Thyroid Nodule,2011-02-08,2014-08-31,2014-08-31,188.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01292044
916,NCT01292044,thyroid nodule,The Role of Elastography in the Diagnosis of Thyroid Nodules,The Role of Elastography in the Diagnosis of Thyroid Nodules,Thyroid Neoplasms|Thyroid Nodule,2011-02-08,2014-08-31,2014-08-31,188.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Other,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01292044
917,NCT01295333,hyperthyroidism,"Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyrodism on Quality of Life, Efficiency and Tolerance","Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyrodism on Quality of Life, Efficiency and Tolerance",Graves Disease (Basedow's Disease),2011-01-27,2014-11-30,2014-12-31,200.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux de Marseille,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01295333
918,NCT01295333,graves disease,"Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyrodism on Quality of Life, Efficiency and Tolerance","Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyrodism on Quality of Life, Efficiency and Tolerance",Graves Disease (Basedow's Disease),2011-01-27,2014-11-30,2014-12-31,200.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux de Marseille,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01295333
919,NCT01295333,goiter,"Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyrodism on Quality of Life, Efficiency and Tolerance","Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyrodism on Quality of Life, Efficiency and Tolerance",Graves Disease (Basedow's Disease),2011-01-27,2014-11-30,2014-12-31,200.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux de Marseille,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01295333
920,NCT01297309,hypoparathyroidism,"A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)","A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)",Hypoparathyroidism,2011-02-11,2018-06-08,2018-06-08,51.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Takeda,Shire,Advance Medical Research LLC|Mayo Clinic Jacksonville|University of Chicago Medical Center|Indiana University School of Medicine|Massachusetts General Hospital|Michigan Bone & Mineral Clinic PC|Mayo Clinic Rochester|Columbia University Medical Center|University Physicians Group|Physician East PA|University of Cincinnati Bone Health and Osteoporosis Center|Children's Hospital of Philadelphia|Cetero Research DGD Research Inc.|The Vancouver Clinic,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01297309
922,NCT01297699,graves disease,"Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.",Tocilizumab Treatment in Graves Ophthalmopathy (Graves Orbitopathy or Thyroid Eye Disease),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,2011-02-16,2015-10-31,2015-12-31,32.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital Clinico Universitario de Santiago,Fundacin Ramn Domnguez|Hospital Clinico Universitario de Santiago,Hospital Clnico de Santiago|Hospital Santa Creu i Sant Pau|Hospital Clnico San Carlos|Hospital Universitario Ramn y Cajal|Centro Oftalmolgico Moreiras|Hospital Universitario Virgen del Roco|Hospital Universitario Virgen Macarena|Hospital Universitario La Fe|Hospital Clnico Universitario Lozano Blesa,Drug|Drug,Spain,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01297699
923,NCT01297699,goiter,"Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.",Tocilizumab Treatment in Graves Ophthalmopathy (Graves Orbitopathy or Thyroid Eye Disease),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,2011-02-16,2015-10-31,2015-12-31,32.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital Clinico Universitario de Santiago,Fundacin Ramn Domnguez|Hospital Clinico Universitario de Santiago,Hospital Clnico de Santiago|Hospital Santa Creu i Sant Pau|Hospital Clnico San Carlos|Hospital Universitario Ramn y Cajal|Centro Oftalmolgico Moreiras|Hospital Universitario Virgen del Roco|Hospital Universitario Virgen Macarena|Hospital Universitario La Fe|Hospital Clnico Universitario Lozano Blesa,Drug|Drug,Spain,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01297699
924,NCT01297699,hyperthyroidism,"Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.",Tocilizumab Treatment in Graves Ophthalmopathy (Graves Orbitopathy or Thyroid Eye Disease),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,2011-02-16,2015-10-31,2015-12-31,32.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital Clinico Universitario de Santiago,Fundacin Ramn Domnguez|Hospital Clinico Universitario de Santiago,Hospital Clnico de Santiago|Hospital Santa Creu i Sant Pau|Hospital Clnico San Carlos|Hospital Universitario Ramn y Cajal|Centro Oftalmolgico Moreiras|Hospital Universitario Virgen del Roco|Hospital Universitario Virgen Macarena|Hospital Universitario La Fe|Hospital Clnico Universitario Lozano Blesa,Drug|Drug,Spain,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01297699
925,NCT01297699,graves ophthalmopathy,"Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.",Tocilizumab Treatment in Graves Ophthalmopathy (Graves Orbitopathy or Thyroid Eye Disease),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,2011-02-16,2015-10-31,2015-12-31,32.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital Clinico Universitario de Santiago,Fundacin Ramn Domnguez|Hospital Clinico Universitario de Santiago,Hospital Clnico de Santiago|Hospital Santa Creu i Sant Pau|Hospital Clnico San Carlos|Hospital Universitario Ramn y Cajal|Centro Oftalmolgico Moreiras|Hospital Universitario Virgen del Roco|Hospital Universitario Virgen Macarena|Hospital Universitario La Fe|Hospital Clnico Universitario Lozano Blesa,Drug|Drug,Spain,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01297699
926,NCT01298323,thyroid neoplasms,"A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib",Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment,Locally Advanced or Metastatic Medullary Thyroid Cancer|Medullary Thyroid Cancer,2011-02-16,2013-04-30,2022-12-31,205.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Sanofi,"Genzyme, a Sanofi Company",Investigational Site Number 301|Investigational Site Number 401|Investigational Site Number 501|Investigational Site Number 701|Investigational Site Number 702|Investigational Site Number 901|Investigational Site Number 1001|Investigational Site Number 1002|Investigational Site Number 1003|Investigational Site Number 1301|Investigational Site Number 1302|Investigational Site Number 1901|Investigational Site Number 2001|Investigational Site Number 2201|Investigational Site Number 2602|Investigational Site Number 2603|Investigational Site Number 2601|Investigational Site Number 3001|Investigational Site Number 3501|Investigational Site Number 3502|Investigational Site Number 4001|Investigational Site Number 4104|Investigational Site Number 4101|Investigational Site Number 4102|Investigational Site Number 6001|Investigational Site Number 5702|Investigational Site Number 5703|Investigational Site Number 6201|Investigational Site Number 6204|Investigational Site Number 6202|Investigational Site Number 6203|Investigational Site Number 7201|Investigational Site Number 2802|Investigational Site Number 2801,Behavioral|Drug,"Australia|Austria|Belgium|Brazil|Bulgaria|Canada|China|Czechia|Denmark|Finland|Germany|Greece|India|Israel|Italy|Korea, Republic of|Poland|Russian Federation|Sweden|United Kingdom",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01298323
927,NCT01306656,hyperparathyroidism,Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism,Vitamin D Repletion in Primary Hyperparathyroidism,Primary Hyperparathyroidism|Vitamin D Deficiency,2011-02-10,2017-02-28,2017-02-28,9.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University Medical Center,Drug|Other|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01306656
930,NCT01306916,hyperthyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Hyperthyroidism,2011-01-12,2010-12-31,2012-07-31,30.0,Cohort,,Prospective,Observational,Completed,,Walter Reed Army Medical Center,Walter Reed Army Medical Center,Walter Reed Army Medical Center,,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01306916
932,NCT01306916,hyperparathyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Hyperthyroidism,2011-01-12,2010-12-31,2012-07-31,30.0,Cohort,,Prospective,Observational,Completed,,Walter Reed Army Medical Center,Walter Reed Army Medical Center,Walter Reed Army Medical Center,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01306916
933,NCT01307761,thyroid neoplasms,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,Thyroid Cancer,2011-02-21,2012-12-31,2013-08-31,500.0,,,Retrospective,Observational,Unknown status,,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,,Taiwan,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01307761
934,NCT01307761,thyroid nodule,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,Thyroid Cancer,2011-02-21,2012-12-31,2013-08-31,500.0,,,Retrospective,Observational,Unknown status,,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,,Taiwan,18.0,90.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01307761
935,NCT01308320,thyroid neoplasms,Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia,Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia,Thyroid Neoplasm,2011-03-03,2010-07-31,2010-07-31,42.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,59.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01308320
937,NCT01311089,"thyroid cancer, papillary",A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction,A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy,Papillary Thyroid Carcinoma,2011-03-08,2011-09-30,2011-09-30,169.0,,,Prospective,Observational,Completed,,Yonsei University,Yonsei University,Severance Hospital,,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01311089
938,NCT01320813,thyroid nodule,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,5.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01320813
939,NCT01320813,graves disease,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,5.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01320813
940,NCT01320813,hyperthyroidism,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,5.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01320813
941,NCT01320813,thyroiditis,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,5.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01320813
942,NCT01320813,goiter,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,5.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01320813
943,NCT01320813,thyroid neoplasms,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,5.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01320813
944,NCT01321554,thyroid neoplasms,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)",Thyroid Cancer,2011-03-10,2013-11-15,2019-03-19,392.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Eisai Inc.,Eisai Inc.,Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 4|Facility 5|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Eisai Trial Site 1|Eisai Trial Site 2|Eisai Trial Site 1|Eisai Trial Site 1|Eisai Trial Site 1|Eisai Trial Site 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 2|Facility 3|Facility 4|Facility 5|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 1|Facility 2|Facility 1|Facility 1,Drug|Drug|Drug,"Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Czechia|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Thailand|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01321554
945,NCT01322165,hypoparathyroidism,National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions,National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions,"Bicuspid Aortic Valve With Coarctation|Bicuspid Aortic Valve With Family History|Bicuspid Aortic Valve Without Known Family History|Ehlers-Danlos Syndrome|Familial Thoracic Aortic Aneurysm and Dissections|FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation|Loeys-Dietz Syndrome|Marfan Syndrome|Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo|Other Congenital Heart Disease|Shprintzen-Goldberg Syndrome|Turner Syndrome",2011-03-22,2015-09-30,2016-09-30,3706.0,Cohort,,Prospective,Observational,Completed,,"National Heart, Lung, and Blood Institute (NHLBI)","National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",Queens Medical Center|Johns Hopkins University|The New York Presbyterian Hospital-Weill Cornell Medical Center|Oregon Health & Science University|University of Pennsylvania School of Medicine|Baylor College of Medicine|University of Texas Medical School at Houston,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01322165
947,NCT01325857,thyroid neoplasms,Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach,Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach,Thyroid Cancer,2011-03-28,2012-02-29,2012-02-29,97.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,Severance Hospital,Procedure|Procedure|Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01325857
948,NCT01329666,hyperparathyroidism,Early Effect of Vitamin D in Primary Hyperparathyroidism,Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D,Hypercalcemia|Osteopenia|Osteoporosis|Primary Hyperparathyroidism|Vitamin D Deficiency,2011-04-04,2015-01-31,2015-01-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University Medical Center,Dietary Supplement|Dietary Supplement,United States,45.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01329666
952,NCT01333267,hyperparathyroidism,Comparison of Skeletal and Mineral Metabolism Responses in Healthy African-Americans and Caucasians Using a Continuous Seven-Day Parathyroid Hormone (PTH) or Parathyroid Hormone-related Protein (PTHrP) Infusion,One Week Comparison Study of PTH and PTHrP Infusions,"Bone Diseases, Endocrine|Hypercalcemia of Malignancy|Hyperparathyroidism|Osteoporosis",2011-04-08,2017-07-31,2017-07-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 1,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh Medical Center,Drug|Drug|Drug,United States,24.0,35.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01333267
953,NCT01335802,hypothyroidism,Relation Between Thyroid Hormone Stimulated Mitochondrial Function and Spontaneous Abortion and Complications of Pregnancy in Subclinical Hypothyroidism,Relation Between Subclinical Hypothyroidism and Outcome of Pregnancy,"Abortion, Spontaneous|Pregnancy Complications|Subclinical Hypothyroidism",2011-04-11,2015-09-30,2016-12-31,113.0,Case-Control,,Prospective,Observational,Completed,,Naestved Hospital,Naestved Hospital|University of Copenhagen,Naestved Hospital,Genetic,Denmark,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01335802
954,NCT01335828,thyroid neoplasms,"""ShearWave"" Elastography Interest in the Management of Thyroid Nodules",Elastography Interest in the Management of Thyroid Nodules,Thyroid Nodules,2010-11-10,2012-10-31,2012-11-30,125.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"University Hospital, Grenoble",AdministrateurCIC,Clinical Investigation Center - Technological Innovation - Inserm 803 - University Hospital France,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01335828
955,NCT01335828,thyroid nodule,"""ShearWave"" Elastography Interest in the Management of Thyroid Nodules",Elastography Interest in the Management of Thyroid Nodules,Thyroid Nodules,2010-11-10,2012-10-31,2012-11-30,125.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"University Hospital, Grenoble",AdministrateurCIC,Clinical Investigation Center - Technological Innovation - Inserm 803 - University Hospital France,Device,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01335828
956,NCT01338597,thyroid neoplasms,Clinical Benefits of Reduced Subcutaneous Dissection in Endoscopic Thyroidectomy,Impact of Dissection Area on the Clinical Outcome of Endoscopic Thyroidectomy,Thyroid Tumor,2011-04-11,2011-12-31,2012-06-30,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Second Military Medical University,Second Military Medical University,"Department of General Surgery, Changzheng Hospital",Procedure,China,18.0,50.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01338597
958,NCT01341782,hyperparathyroidism,Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism,Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism,Hemodialysis|Secondary Hyperparathyroidism,2011-04-25,2012-04-30,2012-04-30,255.0,,Parallel Assignment,,Interventional,Completed,Phase 3,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 53485|Site Reference ID/Investigator# 51571|Site Reference ID/Investigator# 52963|Site Reference ID/Investigator# 52966|Site Reference ID/Investigator# 51578|Site Reference ID/Investigator# 52965|Site Reference ID/Investigator# 53782|Site Reference ID/Investigator# 57483|Site Reference ID/Investigator# 57487|Site Reference ID/Investigator# 53484|Site Reference ID/Investigator# 54385|Site Reference ID/Investigator# 51581|Site Reference ID/Investigator# 59164|Site Reference ID/Investigator# 51574|Site Reference ID/Investigator# 51575|Site Reference ID/Investigator# 52751|Site Reference ID/Investigator# 62025|Site Reference ID/Investigator# 54384|Site Reference ID/Investigator# 52745|Site Reference ID/Investigator# 51569|Site Reference ID/Investigator# 52964|Site Reference ID/Investigator# 53483|Site Reference ID/Investigator# 51582|Site Reference ID/Investigator# 54388|Site Reference ID/Investigator# 51576|Site Reference ID/Investigator# 51577|Site Reference ID/Investigator# 51580|Site Reference ID/Investigator# 52747|Site Reference ID/Investigator# 52748|Site Reference ID/Investigator# 52750|Site Reference ID/Investigator# 51570|Site Reference ID/Investigator# 54387|Site Reference ID/Investigator# 52746|Site Reference ID/Investigator# 51579|Site Reference ID/Investigator# 62024|Site Reference ID/Investigator# 51572|Site Reference ID/Investigator# 52752|Site Reference ID/Investigator# 53482|Site Reference ID/Investigator# 59162|Site Reference ID/Investigator# 59966|Site Reference ID/Investigator# 53783|Site Reference ID/Investigator# 54383|Site Reference ID/Investigator# 52749|Site Reference ID/Investigator# 52962|Site Reference ID/Investigator# 59163,Drug|Drug|Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01341782
960,NCT01341886,thyroid neoplasms,,Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer,Malignant Neoplasm of Thyroid Stage I|Malignant Neoplasm of Thyroid Stage II,2011-04-18,2011-04-30,2011-04-30,51.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug,"Iran, Islamic Republic of",0.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01341886
961,NCT01349634,congenital hypothyroidism,A Study to Measure the Effect of Switching the Salt Supply From Non-iodized to Iodized on Cognitive Development in Ethiopia,The Effects of Iodized Salt on Cognitive Development in Ethiopia,Cretinism|Goiter|Iodine Deficiency,2011-04-20,2014-05-31,2014-05-31,5704.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,McGill University,Ethiopian Health and Nutrition Research Institute|McGill University|Micronutrient Initiative,McGill University,Other,Canada,5.0,61.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01349634
962,NCT01349634,goiter,A Study to Measure the Effect of Switching the Salt Supply From Non-iodized to Iodized on Cognitive Development in Ethiopia,The Effects of Iodized Salt on Cognitive Development in Ethiopia,Cretinism|Goiter|Iodine Deficiency,2011-04-20,2014-05-31,2014-05-31,5704.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,McGill University,Ethiopian Health and Nutrition Research Institute|McGill University|Micronutrient Initiative,McGill University,Other,Canada,5.0,61.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01349634
964,NCT01354639,"thyroid cancer, papillary",Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy,Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy,Papillary Thyroid Carcinoma,2011-05-13,2011-10-31,2011-10-31,150.0,Case-Only,,Prospective,Observational,Completed,,Yonsei University,Yonsei University,Severance Hospital,,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01354639
966,NCT01358136,goiter,ThyrOp: Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter - Focus on Weight Gain and Mitochondrial Dysfunction,ThyrOp: A Study of Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter,Goiter|Hypothyroidism|Weight Gain,2011-05-18,2012-08-31,2013-12-31,30.0,Cohort,,Prospective,Observational,Unknown status,,Naestved Hospital,"Denmark:Department of Otorhinolaryngology Slagelse Hospital, Hospital South|Naestved Hospital|Region Zealand","Slagelse Hospital, Hospital South",,Denmark,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01358136
967,NCT01358136,hypothyroidism,ThyrOp: Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter - Focus on Weight Gain and Mitochondrial Dysfunction,ThyrOp: A Study of Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter,Goiter|Hypothyroidism|Weight Gain,2011-05-18,2012-08-31,2013-12-31,30.0,Cohort,,Prospective,Observational,Unknown status,,Naestved Hospital,"Denmark:Department of Otorhinolaryngology Slagelse Hospital, Hospital South|Naestved Hospital|Region Zealand","Slagelse Hospital, Hospital South",,Denmark,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01358136
969,NCT01368042,hyperparathyroidism,Quality of Life in Greek Hemodialysis Patients Receiving Zemplar i.v (QualitiZe),Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous,Chronic Kidney Disease|Secondary Hyperparathyroidism,2011-06-06,2013-06-30,2013-06-30,265.0,,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 56803|Site Reference ID/Investigator# 53424|Site Reference ID/Investigator# 53425|Site Reference ID/Investigator# 56805|Site Reference ID/Investigator# 56802|Site Reference ID/Investigator# 66291|Site Reference ID/Investigator# 56809|Site Reference ID/Investigator# 50442|Site Reference ID/Investigator# 77554|Site Reference ID/Investigator# 77553|Site Reference ID/Investigator# 53422,,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01368042
971,NCT01369953,hyperparathyroidism,Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants,Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants,Coffin - Sins Syndrome|Coronary Artery Disease|Dubouitz Syndrome|Familial Isolated Hyperparathyroidism|Proteus Syndrome,2011-06-08,,2014-01-31,30.0,,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Human Genome Research Institute (NHGRI),"National Human Genome Research Institute (NHGRI), 9000 Rockville Pike",,United States,18.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01369953
973,NCT01373736,thyroid neoplasms,,123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors,Carcinoid Tumors|Medullary Thyroid Carcinoma|Neuroblastoma|Paraganglioma|Pheochromocytoma,2011-06-13,,,,,,,Interventional,Unknown status,Phase 3,Vancouver Coastal Health,Vancouver Coastal Health,Vancouver Coastal Health,Drug,Canada,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01373736
974,NCT01374659,thyroid neoplasms,Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for Localizing Recurrence in Patients With Differentiated Thyroid Carcinoma Who Have Elevated Serum Thyroglobulin Levels But Are Tumor-negative on Conventional Imaging Studies,Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma,Recurrence|Thyroid Cancer,2011-06-15,2011-06-30,2012-08-31,50.0,,,Prospective,Observational,Unknown status,,Korean Association of Endocrine Surgeons,Korean Association of Endocrine Surgeons,Jandee Lee,,"Korea, Republic of",15.0,85.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01374659
975,NCT01376648,hyperthyroidism,Study on the Relationship Between the Thyroid Hormones and the Activity of Brown Adipose Tissue in Human,Thyroid Hormones Effect on Brown Adipose Tissue,Hyperthyroidism,2011-06-17,2012-05-31,2012-05-31,20.0,,,Prospective,Observational,Unknown status,,Huashan Hospital,Huashan Hospital,Huashan Hospital,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01376648
976,NCT01379170,hypothyroidism,"Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus",Thyroid Study Type 2 Diabetes Mellitus (T2DM),Diabetes|Hypothyroidism,2011-06-21,2014-12-31,2014-12-31,17.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,Maastricht University Medical Center,Maastricht University Medical Center,Maastricht University Medical Centre,Drug,Netherlands,40.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01379170
977,NCT01379196,graves disease,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Graves Ophthalmopathy,2011-05-11,2014-11-30,2014-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1/Phase 2,Rabin Medical Center,Rabin Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01379196
978,NCT01379196,graves ophthalmopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Graves Ophthalmopathy,2011-05-11,2014-11-30,2014-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1/Phase 2,Rabin Medical Center,Rabin Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01379196
979,NCT01379196,hyperthyroidism,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Graves Ophthalmopathy,2011-05-11,2014-11-30,2014-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1/Phase 2,Rabin Medical Center,Rabin Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01379196
980,NCT01379196,goiter,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Graves Ophthalmopathy,2011-05-11,2014-11-30,2014-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1/Phase 2,Rabin Medical Center,Rabin Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01379196
983,NCT01382212,hyperparathyroidism,"A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis",A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis,End-Stage Renal Disease|Secondary Hyperparathyroidism,2011-06-24,2015-04-30,2015-04-30,13.0,,Single Group Assignment,,Interventional,Completed,Phase 3,AbbVie,"AbbVie (prior sponsor, Abbott)",,Drug,,10.0,16.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01382212
984,NCT01382966,hyperparathyroidism,"The Association of Serum Sclerostin Levels,Echocardiographic Parameters, Arteriovenous Fistula Thrombosis and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients","Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients",Chronic Kidney Disease|Left Ventricular Hypertrophy|Renal Osteodystrophy,2011-06-21,2011-09-30,2011-10-31,400.0,,,Cross-Sectional,Observational,Unknown status,,RFM Renal Treatment Services,RFM Renal Treatment Services,Rfm Renal Tedavi Merkezi,,Turkey,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01382966
987,NCT01384786,goiter,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,Hyperthyreosis and Goiter|Thyroid Cancer,2011-06-28,,2005-07-31,4474.0,Cohort,,Retrospective,Observational,Completed,,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,herlev Hospital,,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01384786
988,NCT01384786,hyperthyroidism,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,Hyperthyreosis and Goiter|Thyroid Cancer,2011-06-28,,2005-07-31,4474.0,Cohort,,Retrospective,Observational,Completed,,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,herlev Hospital,,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01384786
989,NCT01384786,thyroid neoplasms,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,Hyperthyreosis and Goiter|Thyroid Cancer,2011-06-28,,2005-07-31,4474.0,Cohort,,Retrospective,Observational,Completed,,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,herlev Hospital,,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01384786
990,NCT01392222,thyroid neoplasms,Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others,Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others,Papillary Microcarcinoma|Thyroid Cancer,2011-06-29,2017-06-30,2017-06-30,21.0,Family-Based,,Prospective,Observational,Completed,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Behavioral|Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01392222
991,NCT01395134,goiter,Randomized Controlled Trial of Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.,Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.,"Goiter,|Thyroid,",2011-07-13,2010-06-30,2010-12-31,210.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Device,Poland,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01395134
992,NCT01396733,thyroid neoplasms,Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake,Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer,Cancer|Thyroid,2011-07-18,2012-12-31,2013-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,Asan Medical Center,Asan Medical Center,Asan Medical Center,Drug,"Korea, Republic of",20.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01396733
993,NCT01398085,thyroid neoplasms,Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients,IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients,Thyroid Cancer,2011-07-06,2023-03-31,2031-03-31,504.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2/Phase 3,"University College, London","Cancer Research UK|University College, London",University Hospitals Birmingham NHS Foundation Trust|Brighton and Sussex University Hospitals NHS Trust|University Hospital Bristol NHS Foundation Trust|Cambridge University Hospitals NHS Foundation Trust|East Kent Hospitals University NHS Foundation Trust|Mid Essex Hospitals Services NHS Trust|Gloucestershire Hospitals NHS Trust|Royal Derby hospital NHS foundation trust|NHS Lothian|Royal Devon and Exeter NHS Trust|Glasgow and Clyde NHS Trust|The Royal Surrey County Hospital NHS Foundation Trust|Ipswich Hospital NHS Trust|Leeds Teaching Hospitals NHS Trust|University Hospitals of Leicester NHS Trust|Royal Marsden NHS Foundation Trust|Imperial College Healthcare NHS Trust|Barts Health NHS Trust|Guys and St Thomas' NHS Foundation Trust|University College London Hospitals NHS Foundation Trust|Maidstone and Tunbridge Wells NHS Trust|The Christie NHS Foundation Trust|South Tees Hospitals NHS Trust|Velindre NHS Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust|Norfolk and Norwich University Hospitals NHS Trust|Nottingham University Hospitals NHS Trust|Portsmouth Hospitals NHS Trust|Sheffield Teaching Hospitals NHS Foundation Trust|Southend University Hospitals NHS Trust|East and North Herts|Royal Wolverhampton NHS Trust,Radiation,United Kingdom,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01398085
995,NCT01398774,pseudopseudohypoparathyroidism,Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study,Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1A,2011-07-19,2015-09-30,2017-11-20,519.0,Cohort,,Cross-Sectional,Observational,Terminated,,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,,United States,5.0,45.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01398774
996,NCT01401478,hyperparathyroidism,"Prospective, Open-label, Multicenter Effectiveness and Safety Observational Study of Zemplar in Patients With Stage 5 Chronic Kidney Disease and Hyperparathyroidism on Hemodialysis in the Russian Federation",Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation,Secondary Hyperparathyroidism,2011-07-22,2013-01-31,2013-01-31,86.0,,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Almedis",Site Reference ID/Investigator# 57348|Site Reference ID/Investigator# 57347|Site Reference ID/Investigator# 58347|Site Reference ID/Investigator# 67404|Site Reference ID/Investigator# 57344|Site Reference ID/Investigator# 57346|Site Reference ID/Investigator# 58356|Site Reference ID/Investigator# 58348|Site Reference ID/Investigator# 57342|Site Reference ID/Investigator# 57364|Site Reference ID/Investigator# 69687|Site Reference ID/Investigator# 57363|Site Reference ID/Investigator# 69688,,Russian Federation,18.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01401478
999,NCT01403324,thyroid neoplasms,Comparison of Dosimetry Following Preparation With Either rhTSH or After Withdrawal of Thyroid Hormone Suppression Therapy in Patients With Metastatic or Locally Advanced Differentiated Thyroid Cancer,Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer,Metastases|Thyroid Cancer,2011-07-26,2016-06-30,2016-06-30,4.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01403324
1000,NCT01408368,goiter,Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease.,Subtotal Versus Total Thyroidectomy for Graves' Disease,Goiter|Thyroid,2011-08-02,2009-12-31,2010-12-31,200.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01408368
1001,NCT01408368,hyperthyroidism,Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease.,Subtotal Versus Total Thyroidectomy for Graves' Disease,Goiter|Thyroid,2011-08-02,2009-12-31,2010-12-31,200.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01408368
1002,NCT01408368,graves disease,Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease.,Subtotal Versus Total Thyroidectomy for Graves' Disease,Goiter|Thyroid,2011-08-02,2009-12-31,2010-12-31,200.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01408368
1005,NCT01409798,hyperparathyroidism,The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry,The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry,Primary Hyperparathyroidism,2011-08-02,2014-12-31,2015-11-30,175.0,Case-Only,,Prospective,Observational,Completed,,University of Nebraska,University of Nebraska,University of Iowa|Kansas University Medical Center|University of Minnesota|University Of Missiouri|University of Nebraska Medical Center|Sanford School of Medicine,,United States,19.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01409798
1006,NCT01412762,thyroid neoplasms,Measuring Patient Expectations for Thyroid Surgery: Development of a Patient-Reported Outcomes Instrument,Measuring Patient Expectations for Thyroid Surgery,Thyroid Cancer,2011-08-03,2024-07-31,2024-07-31,138.0,Case-Only,,Prospective,Observational,Active not recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Behavioral|Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01412762
1007,NCT01413113,"adenocarcinoma, follicular","A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake",Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2011-07-20,2013-11-30,2015-10-31,6.0,,Single Group Assignment,,Interventional,Completed,Phase 1,University of Washington,GlaxoSmithKline|National Cancer Institute (NCI)|National Comprehensive Cancer Network|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01413113
1008,NCT01413113,"thyroid cancer, papillary","A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake",Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2011-07-20,2013-11-30,2015-10-31,6.0,,Single Group Assignment,,Interventional,Completed,Phase 1,University of Washington,GlaxoSmithKline|National Cancer Institute (NCI)|National Comprehensive Cancer Network|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01413113
1010,NCT01414114,hyperparathyroidism,"A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder",Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder,Secondary Hyperparathyroidism,2011-08-09,2012-05-21,2012-05-21,37.0,,Single Group Assignment,,Interventional,Completed,Phase 2,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01414114
1013,NCT01417442,"thyroid cancer, papillary",Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma,BRAF V600E Mutations In Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2011-07-06,2012-07-31,2012-07-31,150.0,,Single Group Assignment,,Interventional,Unknown status,Early Phase 1,Bezmialem Vakif University,Bezmialem Vakif University,Yeliz Emine Ersoy,Genetic,Turkey,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01417442
1016,NCT01421407,hyperparathyroidism,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Uncontrolled Secondary Hyperparathyroidism in Chronic Haemodialysis Patients,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism,End Stage Renal Disease|Parathyroid Hyperplasia|Secondary Hyperparathyroidism,2011-08-19,2014-01-31,2014-01-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Not Applicable,Theraclion,Theraclion,"Ospedale generale regionale ""Miulli""|Ospedale Maggiore Policlinico Mangiagalli e Regina Elena|Hospital Universitario Marqus de Valdecilla",Device,Italy|Spain,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01421407
1018,NCT01424878,thyroid neoplasms,Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients,Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients,Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2,2011-08-26,,2014-02-12,150.0,,,Retrospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Cancer Institute (NCI), 9000 Rockville Pike",,United States,2.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01424878
1021,NCT01426724,hyperparathyroidism,"Effects of Active Form of Vitamin D on Renal Blood Flow, Glomerular Filtration Rate, Proteinuria and Inflammation in Patients With Chronic Kidney Disease and Hyperparathyroidism","Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease",Chronic Kidney Disease|Secondary Hyperparathyroidism,2011-08-29,2013-08-31,2013-08-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,University of Virginia,University of Virginia,University of Virginia,Drug,United States,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01426724
1024,NCT01428167,thyroiditis,Is There Any Association Between Thyroid Cancer and Hashimotos Thyroiditis?,Hashimotos Thyroiditis and Thyroid Cancer,Hashimotos Thyroiditis|Thyroid Cancer,2011-08-10,2012-05-31,2012-05-31,26.0,Case-Control,,Prospective,Observational,Completed,,"The University of Texas Medical Branch, Galveston","The University of Texas Medical Branch, Galveston","University of Texas Medical Branch, Galveston , Endocrine Department",,United States,18.0,80.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01428167
1025,NCT01428167,thyroid neoplasms,Is There Any Association Between Thyroid Cancer and Hashimotos Thyroiditis?,Hashimotos Thyroiditis and Thyroid Cancer,Hashimotos Thyroiditis|Thyroid Cancer,2011-08-10,2012-05-31,2012-05-31,26.0,Case-Control,,Prospective,Observational,Completed,,"The University of Texas Medical Branch, Galveston","The University of Texas Medical Branch, Galveston","University of Texas Medical Branch, Galveston , Endocrine Department",,United States,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01428167
1026,NCT01433809,thyroid neoplasms,Biomarkers in Thyroid Cancer,Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm,"Cancer of the Thyroid|Neoplasms, Thyroid|Thyroid Adenoma|Thyroid Cancer|Thyroid Carcinoma",2011-09-12,2013-05-31,2013-05-31,1.0,Cohort,,Prospective,Observational,Completed,,Mayo Clinic,Norman Eberhardt,Mayo Clinic in Rochester,,United States,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01433809
1028,NCT01436994,thyrotoxicosis,A Randomised Study of Two Anti-thyroid Drug Treatment Regimens in Young People,Antithyroid Drug Treatment of Thyrotoxicosis in Young People,Paediatric Thyrotoxicosis,2011-08-18,2014-12-31,2015-11-30,81.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Newcastle-upon-Tyne Hospitals NHS Trust,Newcastle-upon-Tyne Hospitals NHS Trust,Royal Aberdeen Children's Hospital|Birmingham Children's Hospital|Addebrookes Hospital|Wales College of Medicine|University Hospital|Ninewells Hospital|Royal Hospital for Sick Children|Royal Hospital for Sick Children|Hereford Hospital|Crosshouse Hospital|Alder Hey Children's Hospital|St Bart's Hospital|St George's Hospital|Royal Manchester Children's Hospital|Royal Victoria Infirmary|Norfolk & Norwich University Hospitals|Oxford Radcliffe Hospitals|Sheffield Children's Hospital,Procedure|Procedure|Drug|Drug|Drug,United Kingdom,2.0,16.0,[0-17],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01436994
1029,NCT01437254,thyroid neoplasms,A Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer,To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer,Thyroid Neoplasms,2011-09-19,2012-04-30,2015-01-31,30.0,,Parallel Assignment,,Interventional,Completed,Phase 1,AHS Cancer Control Alberta,"AHS Cancer Control Alberta|Edmonton PET Centre|Natural Resources, Canada",Cross Cancer Institute,Drug|Drug,Canada,18.0,79.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01437254
1030,NCT01438554,thyroid neoplasms,"Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",Cholangiocarcinoma|Soft-tissue Sarcoma|Solid Tumors|Thyroid Cancer,2011-08-23,2016-04-30,2018-08-31,89.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Comprehensive Cancer Network|Novartis|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01438554
1031,NCT01439867,hyperparathyroidism,"An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis",Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism,"Chronic Kidney Disease|Hyperparathyroidism, Secondary",2011-09-22,2016-06-03,2016-06-03,18.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Belgium|Czechia|France|Germany|Hungary|Italy|Mexico|Netherlands|New Zealand|Poland|Russian Federation|Slovakia|United States,0.0,2189.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01439867
1034,NCT01441154,struma ovarii,Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone,Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Malignant Struma Ovarii|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer,2011-09-24,2013-12-12,2013-12-12,16.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Struma ovarii,https://clinicaltrials.gov/ct2/show/NCT01441154
1036,NCT01441154,"thyroid cancer, papillary",Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone,Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Malignant Struma Ovarii|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer,2011-09-24,2013-12-12,2013-12-12,16.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01441154
1037,NCT01441154,"adenocarcinoma, follicular",Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone,Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Malignant Struma Ovarii|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer,2011-09-24,2013-12-12,2013-12-12,16.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01441154
1039,NCT01447368,hyperparathyroidism,Comparison of Medical Therapy (Oral Cinacalcet) Versus Surgical Therapy (Total Parathyroidectomy) on Vascular/Valvular Calcification in Chronic Peritoneal Dialysis Patients With Secondary Hyperparathyroidism - A Pilot Randomized Study,Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients,Kidney Failure|Secondary Hyperparathyroidism|Vascular Diseases,2011-10-04,2017-05-22,2017-05-22,67.0,,Parallel Assignment,,Interventional,Completed,Phase 4,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital and Tung Wah Hospital,Drug|Procedure,Hong Kong,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01447368
1042,NCT01453634,hyperparathyroidism,"A Randomized, Open Label, Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis","Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)",Hemodialysis (HD)|Secondary Hyperparathyroidism (SHPT)|Stage 5 Chronic Kidney Disease (CKD),2011-10-13,2013-07-31,2013-07-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,"OPKO Health, Inc.","OPKO Health, Inc.",,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01453634
1044,NCT01455181,hypoparathyroidism,"A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study","A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary",Hypoparathyroidism,2011-09-15,2012-04-26,2012-04-26,24.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Takeda,Shire,"Semmelweis University Medical School|University of Pcs, School of Medicine|University of Szeged",Drug,Hungary,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01455181
1046,NCT01458600,hyperthyroidism,Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Graves Disease,2011-10-19,2016-02-29,2016-02-29,65.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Region Skane,Mikael Lantz,"Departmenty of Endocrinology, Skane University Hospital|Department of Endocrinology, Karolinska Hospital|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset",Drug|Drug|Drug|Drug|Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01458600
1047,NCT01458600,graves disease,Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Graves Disease,2011-10-19,2016-02-29,2016-02-29,65.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Region Skane,Mikael Lantz,"Departmenty of Endocrinology, Skane University Hospital|Department of Endocrinology, Karolinska Hospital|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset",Drug|Drug|Drug|Drug|Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01458600
1048,NCT01458600,graves ophthalmopathy,Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Graves Disease,2011-10-19,2016-02-29,2016-02-29,65.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Region Skane,Mikael Lantz,"Departmenty of Endocrinology, Skane University Hospital|Department of Endocrinology, Karolinska Hospital|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset",Drug|Drug|Drug|Drug|Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01458600
1049,NCT01458600,goiter,Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Graves Disease,2011-10-19,2016-02-29,2016-02-29,65.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Region Skane,Mikael Lantz,"Departmenty of Endocrinology, Skane University Hospital|Department of Endocrinology, Karolinska Hospital|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset",Drug|Drug|Drug|Drug|Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01458600
1050,NCT01460030,parathyroid neoplasms,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,Hypercalcemia|Parathyroid Carcinoma|Primary Hyperparathyroidism,2011-10-25,2013-02-28,2013-02-28,,,,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01460030
1051,NCT01460030,hyperparathyroidism,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,Hypercalcemia|Parathyroid Carcinoma|Primary Hyperparathyroidism,2011-10-25,2013-02-28,2013-02-28,,,,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01460030
1056,NCT01465867,"thyroiditis, autoimmune",Selenium Supplementation Treatment in Euthyroid Pregnant Women With Autoimmune Thyroid Disease: Effects on Obstetrical Complications,Selenium Supplementation in Pregnancy,Auto-immune Thyroiditis|Infertility|Pregnancy,2011-11-02,2017-06-30,2018-01-31,56.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Roma La Sapienza,University of Roma La Sapienza,"Azienda ospedaliero-universitaria Careggi|Istituto Auxologico Italiano|Ospedale Maggiore Policlinico|University Federico II|University ""Piemonte Orientale, A. Avogadro""|Torvergata University of Rome - Ospedale S. Eugenio|European Hospital|Ospedale S. Giovanni Calibita Fatebenefratelli|Department of Experimental Medicine, ""Sapienza"" University of Rome|Department of Gynecological/Obstetric/Urological Sciences, ""Sapienza"" University of Rome|Dpt of Experimental Medicine",Dietary Supplement|Other|Other|Other,Italy,18.0,38.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01465867
1057,NCT01471288,thyroid neoplasms,Evaluation of the Effect of Carum Carvi on Levels of Plasma Thyroid Hormones and TSH Level in Patients on Thyroid Hormone Therapy and Normal Controls.,Effect of Carum Carvi on Thyroid Hormones and TSH Level,Thyroid Cancer Patients,2011-07-21,2011-12-31,,40.0,,Parallel Assignment,,Interventional,Unknown status,Phase 1/Phase 2,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences|Pharmaceutical Research Center,"Nuclear Medicine Department, Ghaem Hospital",Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01471288
1060,NCT01479088,hyperparathyroidism,"Twelve-month, Multicenter, Intra-subject Controlled (Retrospective-prospective), Open-label, Active-treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Cinacalcet Hydrochloride for the Treatment of Secondary Hyperparathyroidism (SHPT) in Paediatric Subjects With Chronic Kidney Disease (CKD) on Dialysis, Followed by 12-month Study Extension.",Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD),Secondary Hyperparathyroidism,2011-11-22,2013-12-31,2013-12-31,30.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Istituto Giannina Gaslini,ENRICO VERRINA,U.O. Nefrologia e Dialisi- Ospedale Giovanni XXIII|U.O. Nefrologia e Dialisi - Istituto di Ricovero e Cura a Carattere Scientifico Giannina Gaslini|U.O. Nefrologia e Dialisi Pediatrica - Clinica De Marchi|U.O. Nefrologia e Dialisi - Ospedale Santobono|U.O. Nefrologia e Dialisi - Ospedale Bambino Ges,Drug,Italy,2.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01479088
1061,NCT01481402,euthyroid sick syndromes,"Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Heart Function, Body Composition and Metabolic Status",Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF),Heart Failure|Low T3 Syndrome,2011-11-25,2014-02-28,2014-02-28,21.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Herlev Hospital,Jens Faber,"Herlev Hospital, Dept. of Endocrinology",Drug|Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01481402
1064,NCT01484379,hyperparathyroidism,Surgical Approach for Primary Hyperparathyroidism in the Elderly - a Prospective Study,Surgical Approach for Primary Hyperparathyroidism in the Elderly,Multigland Disease in Primary Hyperparathyroidism,2011-12-01,2015-11-30,2015-11-30,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Health Care Campus,Procedure,Israel,65.0,120.0,[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01484379
1065,NCT01486667,hypothyroidism,"Effect of Thyroxin Treatment in Sub Clinical Hypothyroidism Patients, on the Apnea Hypopnea Index Score, Lipid Profiles and Highly Sensitive CRP : A Randomized Double Blind Controlled Trial","Thyroxin Treatment in Sub Clinical Hypothyroidism, on the Apnea Hypopnea Index Score, Lipids and Highly Sensitive CRP",Dyslipidemia,2011-12-03,2013-10-31,,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,King Saud University,King Saud University,University Sleep Disorders Center,Drug|Drug,Saudi Arabia,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01486667
1066,NCT01487057,thyroid neoplasms,"""Evaluation of Lipid Metabolic Status and of Cardiovascular Risk at Patients With Thyroid Carcinoma, Radically Treated and With Chronic Thyroid Hormonal Substitution""",Lipid Metabolic Status in Thyroid Carcinoma,Dyslipidemias|Hormone Replacement|Risk Reduction Behavior|Thyroid Carcinoma,2011-12-05,2012-02-29,2012-05-31,52.0,Cohort,,Prospective,Observational,Completed,,Prof. Dr. I. Chiricuta Institute of Oncology,Iuliu Hatieganu University of Medicine and Pharmacy|Prof. Dr. I. Chiricuta Institute of Oncology,"Institute of Oncology ""Prof.dr.I.Chiricuta""",,Romania,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01487057
1067,NCT01488721,congenital hypothyroidism,"Clinical Evaluation of the xMAP NeoPlex4 Assay for Detection of T4, TSH, 17-OHP and IRT Using the NeoPlex System",Clinical Evaluation of NeoPlex4 Assay and NeoPlex System,"Adrenal Hyperplasia, Congenital|Congenital Hypothyroidism|Cystic Fibrosis",2011-12-06,2012-02-29,2012-04-30,7462.0,Case-Only,,Prospective,Observational,Completed,,Luminex Molecular Diagnostics,Luminex Corporation,New York State Department of Health|Tennessee Department of Health|Unified State Laboratories: Public Health,,United States,0.0,7.0,[0-17],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01488721
1069,NCT01496313,thyroid neoplasms,"An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease",To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer,Thyroid Cancer,2011-12-02,2014-04-30,2022-12-31,81.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 4,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Czechia|India|Israel|Italy|Netherlands|Poland|Russian Federation|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01496313
1070,NCT01498341,hypoparathyroidism,"Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism in Denmark - Epidemiology, Causes, Symptoms and Prognoses",Hypoparathyroidism in Denmark,Hypoparathyroidism,2011-12-20,2012-05-31,2012-05-31,1000.0,,,,Observational,Completed,,University of Aarhus,University of Aarhus,"Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Tage-Hansens Gade",,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01498341
1072,NCT01501110,euthyroid sick syndromes,Evaluation of the Effects of N-acetylcysteine on Thyroid Hormone Levels in the Low T3 Syndrome,Effects of N-acetylcysteine on Low T3 Syndrome,Acute Myocardial Infarction|Euthyroid Sick Syndrome|Ischemic Heart Disease,2011-11-25,2013-07-31,2013-11-30,83.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Federal University of Rio Grande do Sul,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre|Programa de ps-graduao em endocrinologia,Hospital de Clnicas de Porto Alegre|Instituto de Cardiologia,Drug,Brazil,18.0,80.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01501110
1073,NCT01502410,"thyroid cancer, papillary","A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma","Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",Childhood Hepatocellular Carcinoma|Papillary Thyroid Cancer|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Thyroid Cancer|Recurrent Wilms Tumor and Other Childhood Kidney Tumors,2011-12-29,2014-06-30,2014-06-30,20.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|University of Alabama at Birmingham|University of Arkansas for Medical Sciences|Southern California Permanente Medical Group|Miller Children's Hospital|Children's Hospital Los Angeles|Children's Hospital Central California|Childrens Hospital of Orange County|Rady Children's Hospital - San Diego|University of California San Francisco Medical Center-Parnassus|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Alfred I duPont Hospital for Children|Children's National Medical Center|Lee Memorial Health System|Nemours Children's Clinic - Jacksonville|Florida Hospital|Nemours Children's Clinic - Orlando|Nemours Children's Clinic - Pensacola|All Children's Hospital|Saint Joseph Children's Hospital of Tampa|Children's Healthcare of Atlanta - Egleston|University of Hawaii|Saint Luke's Mountain States Tumor Institute|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago|Saint Jude Midwest Affiliate|Southern Illinois University|Riley Hospital for Children|University of Kentucky|Kosair Children's Hospital|Tulane University Health Sciences Center|Sinai Hospital of Baltimore|Mark O Hatfield-Warren Grant Magnuson Clinical Center|Dana-Farber Cancer Institute|Dana-Farber Harvard Cancer Center|Wayne State University/Karmanos Cancer Institute|Bronson Methodist Hospital|University of Minnesota Medical Center-Fairview|Mayo Clinic|University of Mississippi Medical Center|The Childrens Mercy Hospital|Washington University School of Medicine|Children's Hospital and Medical Center of Omaha|Hackensack University Medical Center|Morristown Memorial Hospital|UMDNJ - Robert Wood Johnson University Hospital|Overlook Hospital|University of New Mexico Cancer Center|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|Columbia University Medical Center|Memorial Sloan-Kettering Cancer Center|University of Rochester|State University of New York Upstate Medical University|University of North Carolina|Carolinas Medical Center|Novant Health Presbyterian Medical Center|Wake Forest University Health Sciences|Children's Hospital Medical Center of Akron|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|Nationwide Children's Hospital|Dayton Children's Hospital|University of Oklahoma Health Sciences Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Children's Oncology Group|Children's Hospital of Pittsburgh of UPMC|BI-LO Charities Children's Cancer Center|Greenville Cancer Treatment Center|East Tennessee Childrens Hospital|Vanderbilt-Ingram Cancer Center|Driscoll Children's Hospital|Medical City Dallas Hospital|University of Texas Southwestern Medical Center|Cook Children's Medical Center|Baylor College of Medicine|Childrens Hospital-King's Daughters|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Midwest Children's Cancer Center|Sydney Children's Hospital|Princess Margaret Hospital for Children|British Columbia Children's Hospital|IWK Health Centre|McMaster Children's Hospital at Hamilton Health Sciences|Hospital for Sick Children|The Montreal Children's Hospital of the MUHC|Centre Hospitalier Universitaire Sainte-Justine|Centre Hospitalier Universitaire de Quebec,Drug|Other|Other,Australia|Canada|United States,2.0,30.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01502410
1075,NCT01506947,hyperparathyroidism,"A Prospective, Non-randomised, Single-arm, Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients",A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients,Moderate to Severe Secondary Hyperparathyroidism|Stage 5 Chronic Kidney Diseases,2011-12-28,2016-04-07,2016-04-07,65.0,,Single Group Assignment,,Interventional,Completed,Phase 4,AbbVie,"AbbVie (prior sponsor, Abbott)",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01506947
1079,NCT01510002,"thyroid cancer, papillary",Prophylactic Central Neck Dissection for Papillary Thyroid Cancer,Prophylactic Central Neck Dissection for Papillary Thyroid Cancer,Papillary Thyroid Cancer,2012-01-09,2011-09-30,2011-12-31,640.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian Univerity, Medical College, 3rd Department of General Surgery",Procedure|Procedure,Poland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01510002
1080,NCT01511393,thyroid neoplasms,Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry,An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC),"Diabetes|Diabetes Mellitus, Type 2|Medullary Thyroid Carcinoma|Weight Management",2011-11-30,2035-12-31,2035-12-31,6750.0,Case-Only,,Prospective,Observational [Patient Registry],Enrolling by invitation,,Novo Nordisk A/S,"AstraZeneca|Eli Lilly and Company|Novo Nordisk A/S|United BioSource, LLC","United BioSource, LLC",Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01511393
1081,NCT01512212,thyroid neoplasms,New Thyroid Fine Needle Biopsy Apparatus,New Thyroid Fine Needle Aspiration Biopsy Apparatus,Thyroid Cancer,2012-01-10,2012-06-30,2012-09-30,40.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,SB Istanbul Education and Research Hospital,Bezmialem Vakif University|SB Istanbul Education and Research Hospital,Bezmialem Vakif University,Procedure,Turkey,17.0,85.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01512212
1082,NCT01528904,hypothyroidism,Fetal Thyroid Hormones Concentration In Hyperthyroid or Hypothyroid Pregnant Women,Maternal Autoimmune Thyroid Disease and Fetal Thyroxin,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2012-01-12,2011-03-31,2011-06-30,83.0,Case-Control,,Prospective,Observational,Completed,,University of Belgrade,University of Belgrade,Clinic for Gynecology and Obstetrics,,Serbia,23.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01528904
1083,NCT01528904,hyperthyroidism,Fetal Thyroid Hormones Concentration In Hyperthyroid or Hypothyroid Pregnant Women,Maternal Autoimmune Thyroid Disease and Fetal Thyroxin,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2012-01-12,2011-03-31,2011-06-30,83.0,Case-Control,,Prospective,Observational,Completed,,University of Belgrade,University of Belgrade,Clinic for Gynecology and Obstetrics,,Serbia,23.0,45.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01528904
1085,NCT01530919,hyperparathyroidism,Minimally Invasive Radioguided Parathyroidectomy,Minimally Invasive Radioguided Parathyroidectomy,Primary Hyperparathyroidism,2011-11-30,2009-12-31,2017-04-30,856.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Louisville,Jewish Hospital and St. Mary's Healthcare|Norton Healthcare|University of Louisville,University of Louisville,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01530919
1087,NCT01534169,graves disease,Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients,Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients,Graves' Disease,2012-02-09,2012-03-31,2012-11-30,50.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Nanjing Medical University,Xiao-Ming Mao,Nanjing First Hospital Affiliated to Nanjing Medical University,Drug,China,20.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01534169
1088,NCT01534169,goiter,Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients,Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients,Graves' Disease,2012-02-09,2012-03-31,2012-11-30,50.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Nanjing Medical University,Xiao-Ming Mao,Nanjing First Hospital Affiliated to Nanjing Medical University,Drug,China,20.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01534169
1089,NCT01534169,hyperthyroidism,Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients,Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients,Graves' Disease,2012-02-09,2012-03-31,2012-11-30,50.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Nanjing Medical University,Xiao-Ming Mao,Nanjing First Hospital Affiliated to Nanjing Medical University,Drug,China,20.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01534169
1090,NCT01534897,"thyroid cancer, papillary",Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,Papillary Thyroid Carcinoma,2012-02-10,2014-03-31,2014-03-31,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Massachusetts General Hospital,GlaxoSmithKline|Massachusetts General Hospital,Massachusetts General Hospital,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01534897
1092,NCT01536678,hypothyroidism,"Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers: A Single-dose, Randomized, Open-label, Crossover Study",Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers,Hypothyroidism,2012-02-02,2012-04-30,2012-04-30,26.0,,Crossover Assignment,,Interventional,Completed,Phase 4,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug,India,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01536678
1093,NCT01539486,parathyroid diseases,Relationship of Preoperative PTH and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy,Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy,Parathyroid Disease,2012-02-21,2023-12-31,2023-12-31,200.0,Other,,Retrospective,Observational,Active not recruiting,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01539486
1094,NCT01539499,parathyroid diseases,Complications of Endocrine Surgery: Data From the United Health System Consortium,Complications of Endocrine Surgery: Data From the United HealthSystem Consortium,Endocrine Gland|Parathyroid Disease|Thyroid Disease,2012-02-21,2017-08-31,2017-08-31,1000.0,Case-Only,,Retrospective,Observational,Completed,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01539499
1095,NCT01539655,thyroid neoplasms,"A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects When a Single Oral Dose of Vandetanib 300 mg is Administered Alone and in Combination With Omeprazole or Ranitidine",Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib,Medullary Thyroid Cancer,2012-02-10,2012-09-30,2012-09-30,34.0,,Crossover Assignment,,Interventional,Completed,Phase 1,Sanofi,Sanofi,Research Site,Drug|Drug|Drug,United States,18.0,50.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01539655
1096,NCT01545622,parathyroid diseases,Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease,Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease,Parathyroid Disease,2012-02-21,2016-09-01,2016-09-01,61.0,Other,,Retrospective,Observational,Completed,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01545622
1098,NCT01551498,"thyroiditis, autoimmune","A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Potential Effects of the Dietary Supplement Anatabloc on Antithyroid Autoantibodies and Thyroid Function in Autoimmune Thyroiditis",Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention),"Thyroiditis, Autoimmune",2012-03-05,2013-01-31,2013-02-28,165.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Rock Creek Pharmaceuticals, Inc.","Rock Creek Pharmaceuticals, Inc.","Metabolic Research Institute, Inc.|Florida Medical Clinic, P.A.|Robert J. Becker, M.D., LTD|Associated Endocrinologists, P.C.|New Jersey Physicians, LLC|Texas Diabetes & Endocrinology|North Texas Endocrine Center|Research Institute of Dallas|Texas Diabetes & Endocrinology",Dietary Supplement|Dietary Supplement,United States,18.0,70.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01551498
1099,NCT01552434,thyroid neoplasms,"A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications",Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease,Advanced Malignant Neoplasm|Castleman Disease|Digestive System Carcinoma|Erdheim-Chester Disease|Lip and Oral Cavity Carcinoma|Lymphangioleiomyomatosis|Malignant Endocrine Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Male Reproductive System Neoplasm|Malignant Neoplasm|Malignant Respiratory Tract Neoplasm|Malignant Thoracic Neoplasm|Malignant Urinary System Neoplasm|Mesothelial Neoplasm|Metastatic Malignant Neoplasm|Metastatic Urothelial Carcinoma|Neurofibromatosis Type 2|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Digestive System Carcinoma|Recurrent Female Reproductive System Carcinoma|Recurrent Male Reproductive System Carcinoma|Recurrent Malignant Neoplasm|Recurrent Pharyngeal Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Neoplasm|Soft Tissue Neoplasm|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage III Pharyngeal Cancer|Stage IVA Pharyngeal Cancer|Stage IVB Pharyngeal Cancer|Stage IV Breast Cancer AJCC v6 and v7|Stage IVC Pharyngeal Cancer|Stage IV Pharyngeal Cancer|Thyroid Gland Neoplasm,2012-03-07,2022-03-31,2022-03-31,155.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Biological|Other|Other|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01552434
1100,NCT01558115,hyperparathyroidism,Denosumab in Primary Hyperparathyroidism,Denosumab in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2012-03-16,2014-10-31,2014-10-31,8.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Columbia University,Amgen|John P. Bilezikian|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health (NIH),Columbia University Medical Center,Drug|Other,United States,40.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01558115
1103,NCT01560299,graves disease,,Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients,Graves Disease,2012-03-01,2012-01-31,2012-01-31,150.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01560299
1104,NCT01560299,hyperthyroidism,,Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients,Graves Disease,2012-03-01,2012-01-31,2012-01-31,150.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01560299
1105,NCT01560299,goiter,,Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients,Graves Disease,2012-03-01,2012-01-31,2012-01-31,150.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01560299
1106,NCT01565486,thyroid neoplasms,Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated With the Harmonic ACE Scalpel and LigaSure Precise Instrument During Conventional Thyroidectomy: A Single-blind Prospective Randomized Controlled Trial,Safety and Efficacy Study of Ultrasonic Coagulation Device and Bipolar Energy Sealing System,Thyroid Cancer,2011-09-02,2013-01-31,2017-08-31,304.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Device|Device,"Korea, Republic of",20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01565486
1108,NCT01571843,hyperparathyroidism,Effect of Mechanical Loading on Radius Bone Density and Microarchitecture in Primary Hyperparathyroidism,Radius Loading in Primary Hyperparathyroidism,"Bone Diseases, Metabolic|Bone Loss, Postmenopausal|Osteoporosis, Postmenopausal|Primary Hyperparathyroidism",2012-04-03,2014-10-31,2014-10-31,12.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health (NIH),Columbia University Medical Center,Other|Other,United States,45.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01571843
1110,NCT01573520,hyperparathyroidism,A Randomized Trial Comparing an Integrated Care Approach Using Electronic Cinacalcet Adherence Data Versus Usual Care to Improve Secondary Hyperparathyroidism in Hemodialysis Patients,Treatment Adhesion in Dialysis Patients Treated With Cinacalcet,Chronic Kidney Disease|Hyperparathyroidism,2012-03-23,2011-11-30,2011-11-30,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Centre Hospitalier Universitaire Vaudois,Michel Burnier,Centre Hospitalier Universitaire Vaudois,Other,Switzerland,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01573520
1113,NCT01574287,parathyroid neoplasms,Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC,Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas,Parathyroid Disease,2012-03-31,2019-05-15,2019-05-15,4.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Emory University,"David M. Schuster, MD",Emory University,Drug,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01574287
1114,NCT01574859,hypothyroidism,Central Hypothyroidism and Cardiovascular Risk Factors,Central Hypothyroidism and Cardiovascular Risk,Hypopituitarism,2012-04-07,2012-11-30,2013-03-31,200.0,Cohort,,Retrospective,Observational,Completed,,"Rigshospitalet, Denmark","Rigshospitalet, Denmark",Rigshospitalet,Other,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01574859
1115,NCT01576146,hyperparathyroidism,A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (Also Known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients With Secondary Hyperparathyroidism,Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2012-04-05,2014-05-01,2014-05-01,30.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01576146
1118,NCT01579344,thyroid neoplasms,Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma,Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma,Lacrimal Apparatus Disease,2012-04-15,2014-03-31,,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo,Fabricio Lopes da Fonseca,University of Sao Paulo; Ophthalmology Department,Drug,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01579344
1119,NCT01579539,hyperthyroidism,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,2012-04-13,2017-05-18,2017-05-18,18.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Medical University of Vienna,Medical University of Vienna,"Department of Clinical Pharmacology, Medical University of Vienna",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01579539
1120,NCT01579539,graves disease,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,2012-04-13,2017-05-18,2017-05-18,18.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Medical University of Vienna,Medical University of Vienna,"Department of Clinical Pharmacology, Medical University of Vienna",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01579539
1121,NCT01579539,graves ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,2012-04-13,2017-05-18,2017-05-18,18.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Medical University of Vienna,Medical University of Vienna,"Department of Clinical Pharmacology, Medical University of Vienna",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01579539
1122,NCT01579539,goiter,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,2012-04-13,2017-05-18,2017-05-18,18.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Medical University of Vienna,Medical University of Vienna,"Department of Clinical Pharmacology, Medical University of Vienna",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01579539
1123,NCT01586520,thyroid neoplasms,Diagnosing Thyroid Cancer Using a Blood Test,Diagnosing Thyroid Cancer Using a Blood Test,Differentiated Thyroid Cancer,2012-04-25,2014-10-31,2016-12-31,400.0,Case-Control,,Prospective,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Newcastle-upon-Tyne Hospitals NHS Trust,"Sir Bobby Robson Cancer Researhc Unit|Sir Bobby Robson Cancer Research Unit, Northern Centre for cancer care",,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01586520
1125,NCT01588288,goiter,Diagnosis Interest of Galectin 3 Dosage in Nodular and Multinodular Goiter Pretreatment,Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter,"Goiter, Nodular",2012-04-25,2016-06-30,2016-06-30,193.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"University Hospital, Rouen","University Hospital, Rouen",Centre Henri Becquerel|CHRouen,Procedure,France,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01588288
1127,NCT01598727,hyperparathyroidism,A Phase I Feasibility Study of Intra-operative Near Infra-red Fluorescent Imaging in Thyroid/Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics,Near Infrared Fluorescent Imaging in Thyroid and Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics,Primary Hyperparathyroidism,2012-05-03,2013-01-31,2013-04-30,10.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Sheffield Teaching Hospitals NHS Foundation Trust,"Fluoptics Ltd, Grenoble, France|Sheffield Teaching Hospitals NHS Foundation Trust",Department of General Surgery,Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01598727
1129,NCT01599273,graves disease,,Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections,Thyroid-associated Ophthalmopathy,2012-05-10,2014-08-31,2014-08-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance hospital,Drug,"Korea, Republic of",19.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01599273
1130,NCT01599273,hyperthyroidism,,Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections,Thyroid-associated Ophthalmopathy,2012-05-10,2014-08-31,2014-08-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance hospital,Drug,"Korea, Republic of",19.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01599273
1131,NCT01599273,goiter,,Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections,Thyroid-associated Ophthalmopathy,2012-05-10,2014-08-31,2014-08-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance hospital,Drug,"Korea, Republic of",19.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01599273
1132,NCT01599273,graves ophthalmopathy,,Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections,Thyroid-associated Ophthalmopathy,2012-05-10,2014-08-31,2014-08-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance hospital,Drug,"Korea, Republic of",19.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01599273
1133,NCT01609946,thyroid neoplasms,Evaluation of Realtime-Elastography for Differentiation of Thyroid Nodules: a Multicenter Study,Realtime-Elastography (RTE) and Thyroid Nodules,Thyroid Nodules,2012-05-30,2013-12-31,2014-12-31,602.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Johann Wolfgang Goethe University Hospital,Johannes Vermehren,Caritas-Krankenhaus|Klinikum Bielefeld|Klinikum der J. W. Goethe-Universitt|Brgerhospital|Helfenstein Klinik|Universittsklinikum Leipzig|Klinikum am Steinberg|Endokrinologie und Diabetologie im Zentrum|Universittsklinikum Ulm|Deutsche Klinik fr Diagnostik,Device|Procedure,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01609946
1134,NCT01609946,thyroid nodule,Evaluation of Realtime-Elastography for Differentiation of Thyroid Nodules: a Multicenter Study,Realtime-Elastography (RTE) and Thyroid Nodules,Thyroid Nodules,2012-05-30,2013-12-31,2014-12-31,602.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Johann Wolfgang Goethe University Hospital,Johannes Vermehren,Caritas-Krankenhaus|Klinikum Bielefeld|Klinikum der J. W. Goethe-Universitt|Brgerhospital|Helfenstein Klinik|Universittsklinikum Leipzig|Klinikum am Steinberg|Endokrinologie und Diabetologie im Zentrum|Universittsklinikum Ulm|Deutsche Klinik fr Diagnostik,Device|Procedure,Germany,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01609946
1135,NCT01611896,hyperthyroidism,"GRAves Selenium Supplementation Trial (GRASS) - an Investigator-initiated Randomised, Blinded, Multicentre Clinical Trial of Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism",Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism,Graves' Hyperthyroidism,2012-05-29,2021-08-31,2021-08-31,431.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,"Rigshospitalet, Denmark","Bispebjerg Hospital|Copenhagen Trial Unit, Center for Clinical Intervention Research|Danish Council for Independent Research|Herlev Hospital|Hillerod Hospital, Denmark|Hospital of South West Denmark|Hvidovre University Hospital|Odense University Hospital|Rigshospitalet, Denmark|The Danish Council for Strategic Research","Department of Endocrinology and Gastroenterology, Bispebjerg Hospital|Department of Medical Endocrinology, Rigshospitalet|Department of Endocrinology, Hospital of Southwest Denmark|Department of Medicine, Gentofte Hospital|Department of Internal Medicine O 106, Endocrine Unit, Herlev Hospital|Department of Cardiology and Endocrinology, Endocrine Unit, Hillerd Hospital|Department of Endocrinology, Section 541, Hvidovre Hospital|Department of Endocrinology and Metabolism, Odense University Hospital",Dietary Supplement|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01611896
1136,NCT01616108,goiter,Bupivacaine Injection of Eye Muscles to Treat Strabismus,Bupivacaine Injection of Eye Muscles to Treat Strabismus,"Esotropia|Exotropia|Graves Disease|Ptosis, Eyelid|Strabismus",2012-06-07,2019-09-30,2020-09-30,120.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Smith-Kettlewell Eye Research Institute,Eidactics|Smith-Kettlewell Eye Research Institute|Strabismus Research Foundation|Sutter Health,Strabismus Research Foundation,Drug,United States,8.0,95.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01616108
1137,NCT01616108,graves disease,Bupivacaine Injection of Eye Muscles to Treat Strabismus,Bupivacaine Injection of Eye Muscles to Treat Strabismus,"Esotropia|Exotropia|Graves Disease|Ptosis, Eyelid|Strabismus",2012-06-07,2019-09-30,2020-09-30,120.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Smith-Kettlewell Eye Research Institute,Eidactics|Smith-Kettlewell Eye Research Institute|Strabismus Research Foundation|Sutter Health,Strabismus Research Foundation,Drug,United States,8.0,95.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01616108
1138,NCT01616108,hyperthyroidism,Bupivacaine Injection of Eye Muscles to Treat Strabismus,Bupivacaine Injection of Eye Muscles to Treat Strabismus,"Esotropia|Exotropia|Graves Disease|Ptosis, Eyelid|Strabismus",2012-06-07,2019-09-30,2020-09-30,120.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Smith-Kettlewell Eye Research Institute,Eidactics|Smith-Kettlewell Eye Research Institute|Strabismus Research Foundation|Sutter Health,Strabismus Research Foundation,Drug,United States,8.0,95.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01616108
1139,NCT01616316,thyroid neoplasms,Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study,Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients,Thyroid Cancer,2012-01-18,2012-01-31,2012-02-29,86.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung medical center,Procedure|Procedure,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01616316
1140,NCT01617694,thyroid neoplasms,,Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia,Thyroid Neoplasm,2012-06-05,2011-11-30,2011-11-30,65.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,Severance hospital,Drug|Drug,"Korea, Republic of",20.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01617694
1141,NCT01625520,thyroid neoplasms,"Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression",SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer,Medullary Thyroid Cancer,2012-05-25,2016-03-31,,19.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Federico II University,Federico II University,"Department of Molecular and Clinical Endocrinology and Oncology, ""Federico II"" University of Naples",Drug,Italy,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01625520
1142,NCT01631305,euthyroid sick syndromes,Efficacy and Safety of Levothyroxine in Critical Children With Euthyroid Sick Syndrome in a Pediatric Intensive Care Unit.,Levothyroxine for Children With Euthyroid Sick Syndrome,Euthyroid Sick Syndrome,2012-06-26,2013-12-31,2013-12-31,80.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sinaloa Pediatric Hospital,Sinaloa Pediatric Hospital,Sinaloa Pediatric Hospital,Drug|Other,Mexico,1.0,17.0,[0-17],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01631305
1143,NCT01633853,hyperparathyroidism,"Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease",Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder,Vitamin D Deficiency,2012-06-29,2015-09-30,2015-09-30,204.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Capital Medical University,"Beijing Municipal Science & Technology Commission|Dongliang Zhang, MD",Beijing Friedship Hospital,Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01633853
1146,NCT01638533,thyroid neoplasms,"A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Metastatic Malignant Solid Neoplasm|Neuroendocrine Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Unresectable Solid Neoplasm,2012-07-09,2018-11-29,,36.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1,National Cancer Institute (NCI),Celgene Corporation|National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|University of California Davis Comprehensive Cancer Center|Emory University Hospital/Winship Cancer Institute|University of Chicago Comprehensive Cancer Center|Johns Hopkins University/Sidney Kimmel Cancer Center|National Cancer Institute Developmental Therapeutics Clinic|Wayne State University/Karmanos Cancer Institute|Mayo Clinic in Rochester|Case Western Reserve University|Penn State Milton S Hershey Medical Center|Thomas Jefferson University Hospital|University Health Network-Princess Margaret Hospital,Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01638533
1147,NCT01640184,hyperparathyroidism,Study of the Efficacy and Safety on the Ultrasonic Ablation Treatment for Secondary Hyperthyroidism in Chronic Kidney Disease Patients.,Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients,Disorders of Parathyroid Gland|Hyperparathyroidism,2012-07-09,2014-11-30,2014-11-30,79.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Capital Medical University,"Beijing Municipal Science & Technology Commission|Dongliang Zhang, MD",Beijing Chao-Yang Hospital|Beijing Friendship Hospital,Procedure|Drug|Procedure,China,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01640184
1149,NCT01641679,thyroid neoplasms,Recurrent Differentiated Thyroid Cancer: Towards Personalized Treatment Based on Evaluation of Tumor Characteristics With PET (THYROPET,PET Evaluation of Recurrent Differentiated Thyroid Cancer,Differentiated Thyroid Cancer|Thyroid Neoplasms,2012-07-12,2015-08-31,2016-01-31,100.0,Cohort,,Prospective,Observational,Unknown status,,The Netherlands Cancer Institute,"Amsterdam UMC, location VUmc|The Netherlands Cancer Institute|UMC Utrecht",Rijnstate Hospital|UMC St. Radboud Nijmegen|Bernard Verbeeten Institute|Jeroen Bosch Hospital|Catharina Hospital|Medical Center Alkmaar|St. Lucas Andreas Hospital|VUmc Medical Center|Medical spectrum Twente|Isala Clinics|Meander Medical Center|St. Antonius hospital|Leiden University Medical Center|University Medical Center Groningen|University Medical Center Utrecht,,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01641679
1150,NCT01647503,parathyroid neoplasms,Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease,Differentially Expressed Proteins in Sporadic Parathyroid Tumors,Hypercalcemia|Primary Hyperparathyroidism,2012-07-18,2015-09-30,,50.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,Postgraduate Institute of Medical Education and Research,Postgraduate Institute of Medical Education and Research,PGIMER,,India,15.0,65.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01647503
1153,NCT01647503,hyperparathyroidism,Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease,Differentially Expressed Proteins in Sporadic Parathyroid Tumors,Hypercalcemia|Primary Hyperparathyroidism,2012-07-18,2015-09-30,,50.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,Postgraduate Institute of Medical Education and Research,Postgraduate Institute of Medical Education and Research,PGIMER,,India,15.0,65.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01647503
1154,NCT01647750,hypothyroidism,"Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) SORTED 1 - a Randomised Controlled Trial (Pilot Study), SORTED 2 - Qualitative Interviews, SORTED 3 - Retrospective Cohort",Study of Optimal Replacement of Thyroxine in the Elderly,Hypothyroidism,2012-07-16,2014-08-31,2014-08-31,48.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Newcastle-upon-Tyne Hospitals NHS Trust,"National Institute for Health Research, United Kingdom|Newcastle-upon-Tyne Hospitals NHS Trust",Bensham Hospital|Clinical Research Facility,Drug|Drug,United Kingdom,80.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01647750
1155,NCT01648569,thyroid neoplasms,Proper Extent of Surgery for Papillary Microcarcinoma,Long-term Outcomes of Total Thyroidectomy Versus Less Than Total Thyroidectomy for Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2012-07-18,2012-05-31,2012-07-31,2014.0,Cohort,,Retrospective,Observational,Completed,,Korean Association of Endocrine Surgeons,Korean Association of Endocrine Surgeons,Yonsei University College of Medicidine,,"Korea, Republic of",10.0,60.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01648569
1156,NCT01649206,thyroid nodule,Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study,Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules,Thyroid Nodule,2012-07-16,2011-01-31,2011-06-30,40.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Federico II University,Federico II University,"""Federico II"" University of Naples, Department of Clinical and Molecular Endocrinology and Oncology",Procedure,Italy,18.0,87.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01649206
1157,NCT01649206,thyroid neoplasms,Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study,Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules,Thyroid Nodule,2012-07-16,2011-01-31,2011-06-30,40.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Federico II University,Federico II University,"""Federico II"" University of Naples, Department of Clinical and Molecular Endocrinology and Oncology",Procedure,Italy,18.0,87.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01649206
1158,NCT01651000,hyperparathyroidism,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency",Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",2012-07-23,2014-07-31,2014-07-31,213.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",OPKO Renal,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01651000
1163,NCT01653379,hyperparathyroidism,"A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis",A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2012-07-25,2014-07-31,2014-07-31,42.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Deltanoid Pharmaceuticals,Deltanoid Pharmaceuticals,,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01653379
1164,NCT01655719,thyroid neoplasms,Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene,Pioglitazone in Thyroid Cancers,Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene,2012-07-25,2017-03-31,2017-03-31,1.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Michigan,National Cancer Institute (NCI)|University of Michigan,University of Colorado|University of Michigan|University of Pennsylvania|University of Texas MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01655719
1165,NCT01656070,hyperparathyroidism,Vitamin D Status and T Cell Phenotype in HIV-infected Youth Supplemented With Cholecalciferol: a Randomized Clinical Trial.,Vitamin D Supplementation in HIV-infected Youth,HIV Disease|Hyperparathyroidism|Hypovitaminosis D|Vitamin D Deficiency,2012-07-31,2012-07-31,2012-07-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Milan,University of Milan,Department of Paediatrics - L. Sacco Hospital,Drug|Drug,Italy,0.0,30.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01656070
1167,NCT01658085,goiter,"Harmonic FOCUS Versus Conventional Technique in Total Thyroidectomy for Benign Thyroid Disease. A Randomized, Prospective Study",Budget Impact of Harmonic FOCUS in Thyroidectomy,Multinodular Goiter,2012-07-17,2010-03-31,2012-08-31,56.0,Case-Control,,Prospective,Observational,Unknown status,,Hospital Universitari de Bellvitge,Hospital Universitari de Bellvitge,Hospital UIniversitari de Bellvitge,Device|Device,Spain,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01658085
1168,NCT01659385,"thyroid cancer, papillary","Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls",Leptin Levels in Papillary Thyroid Cancer,"Leptin Levels|Thyroid Cancer, Papillary",2012-08-03,2013-06-30,2013-06-30,18.0,Other,,Cross-Sectional,Observational,Completed,,University of Nebraska,University of Nebraska,University of Nebraska Medical Center,,United States,19.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01659385
1170,NCT01660126,hypothyroidism,Multi-modal Effects of Thyroid Hormone Replacement for Untreated Older Adults With Subclinical Hypothyroidism; a Randomised Placebo-controlled Trial,Thyroid Hormone Replacement for Subclinical Hypothyroidism,Subclinical Hypothyroidism,2012-08-06,2016-11-18,2016-11-18,737.0,,Parallel Assignment,,Interventional,Completed,Phase 4,NHS Greater Glasgow and Clyde,Leiden University Medical Center|NHS Greater Glasgow and Clyde|University College Cork|University of Bern|University of Glasgow,"Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde",Drug|Drug,United Kingdom,65.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01660126
1171,NCT01660984,thyroid neoplasms,Longitudinal Assessment and Natural History Study of Children and Adults With MEN2A or MEN2B With or Without Medullary Thyroid Carcinoma,Natural History Study of Children and Adults With Medullary Thyroid Cancer,Medullary Thyroid Cancer,2012-08-07,,,216.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01660984
1172,NCT01661179,thyroid neoplasms,"A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma",Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma,"Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma",2012-07-17,2013-12-31,2014-07-31,14.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01661179
1173,NCT01665651,hyperparathyroidism,Effect of Kidney Yin/Yang Replenishment on Bone Metabolism in Patients With Renal Osteodystrophy,Kidney Yin/Yang Replenishment on Patients With Renal Osteodystrophy,"Renal Insufficiency, Chronic|Renal Osteodystrophy",2012-08-08,2017-05-31,2017-05-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,Shanghai University of Traditional Chinese Medicine,Bing Shu|Huadong Hospital|Longhua Hospital|The First Affiliated Hospital of Anhui University of Chinese Medicine,The first affiliated hospital of Anhui University of TCM|Huadong hospital affiliated to Fudan University|Longhua Hospital affiliated to Shanghai Uni of TCM,Drug|Drug|Drug|Drug,China,20.0,50.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01665651
1176,NCT01668238,thyroid neoplasms,Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry,Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry,Breast Tumor|Thyroid Tumor,2012-08-07,2012-09-30,2012-09-30,600.0,,,Cross-Sectional,Observational,Unknown status,,Peking University,Peking University|XU Zhi,Peking University Third Hospital,,China,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01668238
1177,NCT01675089,hyperparathyroidism,A Prospective and Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year After Kidney Transplantation,Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation,Renal Osteodystrophy,2012-08-23,2013-07-31,2014-05-31,34.0,,Parallel Assignment,,Interventional,Completed,Phase 4,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Hospital das Clinicas - Faculdade de Medicina da Universidade de So Paulo,Drug,Brazil,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01675089
1180,NCT01690806,thyroid neoplasms,Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.,Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy,Benign Neoplasm of Thyroid Gland|Malignant Neoplasm of Thyroid,2012-09-19,2012-01-31,2012-03-31,328.0,Case-Control,,Prospective,Observational,Completed,,Universit degli Studi dell'Aquila,Universit degli Studi dell'Aquila,ospedale San Salvatore-Reparto di Chirurgia Generale Universitaria,,Italy,0.0,75.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01690806
1181,NCT01691781,hyperparathyroidism,The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study,The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study,Hyperparathyroidism,2012-09-20,2016-08-31,2016-12-31,41.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01691781
1183,NCT01700699,thyroid neoplasms,Impact of BRAFV600E Intratumor Heterogeneity on the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Radioiodine-resistant Thyroid Cancer,Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors,Differentiated Thyroid Cancer,2012-09-22,2013-10-31,2013-10-31,50.0,Cohort,,Retrospective,Observational,Unknown status,,University of Salerno,University of Salerno,"Department of Medicine and Surgery, Univeristy of Salerno",,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01700699
1185,NCT01701349,"thyroid carcinoma, anaplastic","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)",Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2012-10-02,2017-04-30,2017-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 3,Mateon Therapeutics,Mateon Therapeutics,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01701349
1186,NCT01704079,hyperparathyroidism,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency",Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",2012-10-06,2014-08-31,2014-09-30,216.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",OPKO Renal,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01704079
1189,NCT01704586,thyroid neoplasms,Clinical Evaluation of a I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Using PROBE Design,I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer,Differentiated Thyroid Carcinoma,2012-10-04,2021-05-31,2025-11-30,340.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Wuerzburg,"Deutsche Krebshilfe e.V., Bonn (Germany)|University of Wuerzburg","Clinic of Nuclear Medicine, University Clinic Essen|University Clinic Wrzburg",Radiation|Radiation,Germany,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01704586
1190,NCT01707056,hypothyroidism,The Effect of Coffee Consumption on the Intestinal Absorption of Levothyroxine Thyroid Hormone Replacement in Patients With Thyroid Carcinoma,The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma,Hypothyroidism|Thyroid Carcinoma,2012-10-05,2015-06-30,2016-06-30,0.0,,Crossover Assignment,,Interventional,Withdrawn,Not Applicable,Medstar Health Research Institute,Georgetown University|Medstar Health Research Institute,Georgetown University Hospital|Washington Hospital Center|MedStar St. Mary's Hospital,Other|Other|Other|Other,United States,18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01707056
1191,NCT01707056,thyroid neoplasms,The Effect of Coffee Consumption on the Intestinal Absorption of Levothyroxine Thyroid Hormone Replacement in Patients With Thyroid Carcinoma,The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma,Hypothyroidism|Thyroid Carcinoma,2012-10-05,2015-06-30,2016-06-30,0.0,,Crossover Assignment,,Interventional,Withdrawn,Not Applicable,Medstar Health Research Institute,Georgetown University|Medstar Health Research Institute,Georgetown University Hospital|Washington Hospital Center|MedStar St. Mary's Hospital,Other|Other|Other|Other,United States,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01707056
1192,NCT01709292,thyroid neoplasms,Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer,Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer,Thyroid Cancer,2012-07-25,2022-09-30,2023-09-30,24.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,M.D. Anderson Cancer Center,"Genentech, Inc.|M.D. Anderson Cancer Center",University of Texas MD Anderson Cancer Center,Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01709292
1193,NCT01709435,thyroid neoplasms,"A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors",Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors,Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Primary Central Nervous System Neoplasm|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm|Thyroid Gland Medullary Carcinoma,2012-10-16,2018-12-31,2019-12-31,41.0,,Single Group Assignment,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Children's Hospital of Orange County|UCSF Medical Center-Parnassus|UCSF Medical Center-Mission Bay|Children's National Medical Center|Children's Healthcare of Atlanta - Egleston|Lurie Children's Hospital-Chicago|Riley Hospital for Children|National Institutes of Health Clinical Center|C S Mott Children's Hospital|University of Minnesota/Masonic Cancer Center|Washington University School of Medicine|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Cincinnati Children's Hospital Medical Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Childrens Oncology Group|Children's Hospital of Pittsburgh of UPMC|St. Jude Children's Research Hospital|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Seattle Children's Hospital|Children's Hospital of Wisconsin|Hospital for Sick Children,Drug|Other|Other,Canada|United States,2.0,18.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01709435
1194,NCT01723202,"thyroid cancer, papillary",A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,53.0,,Crossover Assignment,,Interventional,Active not recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01723202
1196,NCT01723202,"adenocarcinoma, follicular",A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,53.0,,Crossover Assignment,,Interventional,Active not recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01723202
1198,NCT01725113,hyperparathyroidism,"A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients",Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol,Hypercalcemia|Hyperphosphatemia|Kidney Failure|Secondary Hyperparathyroidism,2012-11-07,2013-12-31,2015-10-31,11.0,,Crossover Assignment,,Interventional,Terminated,Phase 4,Winthrop University Hospital,Winthrop University Hospital,Winthrop University Hospital,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01725113
1200,NCT01727973,hyperthyroidism,"Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,14.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01727973
1201,NCT01727973,graves ophthalmopathy,"Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,14.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01727973
1202,NCT01727973,graves disease,"Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,14.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01727973
1203,NCT01727973,goiter,"Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,14.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01727973
1204,NCT01728623,thyroid neoplasms,A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer,A Study of E7080 in Subjects With Advanced Thyroid Cancer,Thyroid Cancer,2012-09-07,2015-07-09,2015-10-01,51.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Eisai Inc.,"Eisai Co., Ltd.",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01728623
1205,NCT01730638,thyroid neoplasms,Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma.,ImmunoTEP for Patients With Medullary Thyroid Carcinoma.,Medullary Thyroid Carcinoma,2012-11-12,2016-12-31,2016-12-31,25.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Nantes University Hospital,"Gilead Sciences|Institut National de la Sant Et de la Recherche Mdicale, France|Nantes University Hospital","Angers Hospital|Nantes Hospital|Institut de Cancrologie de l'ouest, Ren Gauducheau",Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01730638
1206,NCT01736163,thyroid neoplasms,"A Retrospective, Non-interventional Study of Patients With T4 Tumours Comparing the Thyroid Remnant Ablation Success Following Thyrogen and 131I Administration Versus Thyroid Hormone Withdrawal and 131I Administration",A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours,Thyroid Cancer,2012-11-26,2012-08-31,2012-08-31,144.0,Case-Control,,Retrospective,Observational,Completed,,Sanofi,"Genzyme, a Sanofi Company",Hanover University School of Medicine|Klinikum Grohadern|Policlinico S.Orsola-Malpighi|Instituto Oncologico Veneto|Istituti Fisioterapici Ospitalieri (IFO)|Portuguese Institute of Oncology|Hospital Universitario Reina Sofa|Hospital Universitario Virgen de las Nieves|Hospital Universitario Dr Peset,Drug|Drug|Other,Germany|Italy|Portugal|Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01736163
1207,NCT01736878,thyroid neoplasms,"Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma",Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma,Medullary Thyroid Carcinoma,2012-10-23,2013-04-30,2013-04-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,Eanm Research Ltd,Eanm Research Ltd,"University Hospital Ulm, Clinic for Nuclear Medicine",Drug,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01736878
1208,NCT01738243,graves disease,Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Thyroid Eye Disease,2012-10-06,2021-09-30,2021-09-30,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",Jules Stein Eye Institute|The Jules Stein Eye Institute at UCLA,Drug|Drug,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01738243
1209,NCT01738243,hyperthyroidism,Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Thyroid Eye Disease,2012-10-06,2021-09-30,2021-09-30,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",Jules Stein Eye Institute|The Jules Stein Eye Institute at UCLA,Drug|Drug,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01738243
1210,NCT01738243,goiter,Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Thyroid Eye Disease,2012-10-06,2021-09-30,2021-09-30,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",Jules Stein Eye Institute|The Jules Stein Eye Institute at UCLA,Drug|Drug,United States,21.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01738243
1211,NCT01738243,graves ophthalmopathy,Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Thyroid Eye Disease,2012-10-06,2021-09-30,2021-09-30,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",Jules Stein Eye Institute|The Jules Stein Eye Institute at UCLA,Drug|Drug,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01738243
1212,NCT01739634,thyroid neoplasms,The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer,The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer,Diarrhea|Medullary Thyroid Cancer,2012-11-29,2013-12-31,2013-12-31,10.0,,Single Group Assignment,,Interventional,Unknown status,Phase 1/Phase 2,Salient Pharmaceuticals Incorporated,Salient Pharmaceuticals Incorporated,MD Anderson Cancer Center,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01739634
1213,NCT01739972,hypothyroidism,"Desiccated Thyroid Extract Compared to Levothyroxine in the Treatment of Hypothyroidism: A Randomized, Double-blind, Crossover Study.",Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment,Primary Hypothyroidism.,2012-11-28,2014-05-31,2014-05-31,180.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,Walter Reed National Military Medical Center,Walter Reed National Military Medical Center,"Walter Reed National Military Medical Center, Endocrinology|Walter Reed National Military Medical Center",Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01739972
1216,NCT01741064,hyperparathyroidism,Secondary Hyperparathyroidism Related Vascular and Bone Morbidity After Renal Transplantation - a 6 Year Follow up Retrospective Cohort Study.,Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation,Disorder Related to Renal Transplantation|Secondary Hyperparathyroidism,2012-11-30,2012-10-31,2012-10-31,257.0,Cohort,,Retrospective,Observational,Completed,,Skane University Hospital,Karolinska University Hospital|Skane University Hospital,,,,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01741064
1217,NCT01744743,hypothyroidism,Preconceptional Thyroid Screening and Childhood Nerocognitive Function,Preconceptional Thyroid Screening and Childhood Nerocognitive Function,Hypothyroidism,2012-10-20,2014-12-31,2015-12-31,600.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fudan University,Fudan University|Shanghai Municipal Health Bureau|Shanghai Municipal Science and Technology Commission,"Obstetrics and Gynecology Hospital, Fudan University",Procedure,China,18.0,55.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01744743
1218,NCT01744769,thyroid neoplasms,Effects of Thyroid Hormone Withdrawal on Metabolic and Cardiovascular Parameters During Radioactive Iodine Therapy in Differentiated Thyroid Cancer,Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer,Hypothyroidism,2012-12-05,2013-05-31,2013-05-31,80.0,Case-Only,,Prospective,Observational,Unknown status,,Konkuk University Medical Center,Konkuk University Medical Center,Konkuk University Medical Center,,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01744769
1219,NCT01744769,hypothyroidism,Effects of Thyroid Hormone Withdrawal on Metabolic and Cardiovascular Parameters During Radioactive Iodine Therapy in Differentiated Thyroid Cancer,Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer,Hypothyroidism,2012-12-05,2013-05-31,2013-05-31,80.0,Case-Only,,Prospective,Observational,Unknown status,,Konkuk University Medical Center,Konkuk University Medical Center,Konkuk University Medical Center,,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01744769
1220,NCT01747512,thyroid neoplasms,A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer,An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT),Head and Neck Neoplasms|Thyroid Neoplasms,2012-12-10,2013-05-31,,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Cross Cancer Institute,,Drug|Drug,,18.0,79.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01747512
1221,NCT01750593,thyroid neoplasms,Efficacy of Radiofrequency Ablation in Thyroid Nodules,Radiofrequency Ablation in Thyroid Nodules,Thyroid Nodules,2012-10-07,2014-01-31,2014-06-30,40.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Bezmialem Vakif University medical Faculty|Bezmialem Vakif University|Bezmialem Vakif University,Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01750593
1222,NCT01750593,thyroid nodule,Efficacy of Radiofrequency Ablation in Thyroid Nodules,Radiofrequency Ablation in Thyroid Nodules,Thyroid Nodules,2012-10-07,2014-01-31,2014-06-30,40.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Bezmialem Vakif University medical Faculty|Bezmialem Vakif University|Bezmialem Vakif University,Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01750593
1223,NCT01756534,thyroid nodule,The Effectiveness of an Oxidized Cellulose Patch Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Goiter|Thyroid Diseases|Thyroid Nodule,2012-12-19,2013-03-31,2013-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01756534
1224,NCT01756534,thyroid neoplasms,The Effectiveness of an Oxidized Cellulose Patch Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Goiter|Thyroid Diseases|Thyroid Nodule,2012-12-19,2013-03-31,2013-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01756534
1225,NCT01757470,thyroid neoplasms,Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada,Vandetanib Risk Minimisation Effectiveness,Medullary Thyroid Cancer,2012-12-18,2014-02-28,2014-02-28,12.0,Cohort,,Prospective,Observational,Completed,,Sanofi,"Genzyme, a Sanofi Company",Research Site,,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01757470
1226,NCT01757834,thyroid nodule,Efficacy of Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Thyroid Nodule,2012-12-12,2015-07-31,2015-08-31,175.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,University of Washington,National Cancer Institute (NCI)|University of Washington,University of Washington Medical Center,Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01757834
1227,NCT01757834,thyroid neoplasms,Efficacy of Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Thyroid Nodule,2012-12-12,2015-07-31,2015-08-31,175.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,University of Washington,National Cancer Institute (NCI)|University of Washington,University of Washington Medical Center,Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01757834
1230,NCT01760421,hashimoto disease,The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis,The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis,Hashimoto Thyroiditis,2011-10-20,2012-12-31,2013-08-31,40.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,"Department of Internal Medicine, National Taiwan University Hospital",Drug,Taiwan,20.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01760421
1232,NCT01761149,goiter,"Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial",Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy,Nodular Goiter,2012-12-30,2013-03-31,,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Central South University,Central South University,"Department of Anesthesiology, The Second Xiangya Hospital",Drug,China,18.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01761149
1233,NCT01769157,hypothyroidism,"Single-center, Randomized, Double-Blinded, Comparative Study of the Effectiveness of L-carnitine in Patients'Fatigue Degree Changing With Hypothyroidism Who Take Levothyroxine",Effects of L-carnitine on Hypothyroidism,Hypothyroidism,2013-01-10,2013-06-30,2013-06-30,60.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Korea University Anam Hospital,IlDong Pharmaceutical Co Ltd|Korea University Anam Hospital,Korea University Anam Hospital,Drug|Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01769157
1234,NCT01771523,goiter,Is the Use of Drain for Thyroid Surgery Realistic?,Is the Use of Drain for Thyroid Surgery Realistic?,Goiter,2011-08-03,2013-01-31,2013-01-31,400.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Maltepe University,Maltepe University,"Maltepe University School of Medicine, General Surgery Department",Procedure|Device,Turkey,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01771523
1236,NCT01774279,"thyroid carcinoma, anaplastic",interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT).,interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT),Anaplastic Thyroid Cancer,2013-01-18,2025-02-28,2025-03-31,350.0,Case-Only,,Prospective,Observational [Patient Registry],Recruiting,,Velindre NHS Trust,Velindre NHS Trust,"Beaumont Hospital|St Vincent's Hospital|Galway University Hospital|Addenbrookes Hospital|Velindre Hospital|University Hospitals of Coventry and Warwickshire|Castle Hill Hospital|St James' Institute|Royal Marsden Hospital|Norfolk and Norwich University Hospital NHS Foundation Trust|Nottingham University NHS Trust|Barking, Havering and Redbridge University Hospitals NHS Trust|Weston Park Hospital|Royal Shrewsbury Hospital|New Cross Hospital",Other,Ireland|United Kingdom,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01774279
1237,NCT01776385,parathyroid neoplasms,Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer?,The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma,Benign Tumor of the Thyroid|Mesothelioma|Parathyroid Neoplasms|Pleural Neoplasms|Pneumothorax|Tumor of the Thyroid,2012-03-23,2017-12-31,2018-03-31,9.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nice,Centre Hospitalier Universitaire de Nice,CHU de Nice - LPCE- Hpital de Pasteur - 30 ave de la voie Romaine,Other|Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01776385
1238,NCT01776385,thyroid neoplasms,Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer?,The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma,Benign Tumor of the Thyroid|Mesothelioma|Parathyroid Neoplasms|Pleural Neoplasms|Pneumothorax|Tumor of the Thyroid,2012-03-23,2017-12-31,2018-03-31,9.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nice,Centre Hospitalier Universitaire de Nice,CHU de Nice - LPCE- Hpital de Pasteur - 30 ave de la voie Romaine,Other|Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01776385
1242,NCT01776502,hyperparathyroidism,"A Prospective, Non Randomized, Open, Multicenter Trial to Evaluate Non Specific Symptoms and Quality of Life (SF 36) Before and After Surgery for Mild Primary Hyperparathyroidism",Evaluation of Non Specific Symptoms and Quality of Life Before and After Surgery for Mild Primary Hyperparathyroidism,Primary Hyperparathyroidism,2012-10-24,2010-06-30,2011-06-30,116.0,Cohort,,Prospective,Observational,Completed,,Nantes University Hospital,Nantes University Hospital,Angers University Hospital|Limoges University Hospital|Marseille University Hospital|Nantes University Hospital,,France,0.0,50.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01776502
1243,NCT01778400,thyroid nodule,Single Session Treatment of RFA Versus EA for Predominantly Cystic Thyroid Nodules: A Randomized Controlled Trial,RFA (Radiofrequency Ablation) Versus EA (Ethanol Ablation) for Predominantly Cystic Thyroid Nodules,Thyroid Nodule,2013-01-25,2013-05-31,2014-01-31,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Asan Medical Center,Asan Medical Center,Asan Medical Center,Procedure|Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01778400
1244,NCT01778400,thyroid neoplasms,Single Session Treatment of RFA Versus EA for Predominantly Cystic Thyroid Nodules: A Randomized Controlled Trial,RFA (Radiofrequency Ablation) Versus EA (Ethanol Ablation) for Predominantly Cystic Thyroid Nodules,Thyroid Nodule,2013-01-25,2013-05-31,2014-01-31,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Asan Medical Center,Asan Medical Center,Asan Medical Center,Procedure|Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01778400
1245,NCT01779817,hyperthyroidism,"Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Pregnancy","Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy",Hyperthyroid,2013-01-28,2019-01-31,2019-01-31,252.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,"University Hospital, Angers","University Hospital, Angers",University Hospital of Amiens|University Hospital of Angers|Civil Hospices of Lyon|University Hospital of Kremlin Bicetre|University Hospital of Lille|University Hospital of Marseille|University Hospital of Nantes|Hospital of Saint Antoine|University Hospital of Cochin|University Hospital of Poitiers|University Hospital of Reims|University Hospital of Strasbourg|University Hospital of Toulouse,Behavioral,France,6.0,9.0,[0-17],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01779817
1246,NCT01780584,euthyroid sick syndromes,Oral Triiodothyronine Normalizes T3 Levels After Surgery For Pediatric Congenital Heart Disease,Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?,Low T3 Syndrome,2013-01-28,2010-09-30,2010-10-31,45.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Cardiovascular Center Harapan Kita Hospital Indonesia,National Cardiovascular Center Harapan Kita Hospital Indonesia,Pediatric Cardiac ICU National Cardiovascular Center Harapan Kita Jakarta,Drug|Drug|Drug,Indonesia,0.0,24.0,[0-17]|[18-65],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01780584
1247,NCT01781767,thyroid neoplasms,,Changes in Metabolic Status in Patients With Total Thyroidectomy,Thyroid Cancer,2013-01-27,2014-07-31,2014-07-31,50.0,Case-Control,,Prospective,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Sourasky Medical Center,,Israel,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01781767
1249,NCT01781923,hypoparathyroidism,A Remediation Program for Children at High-Risk of Schizophrenia: 22q11.2 Deletion Syndrome,Cognitive Remediation in 22q11DS,22q11.2 Deletion Syndrome|Velo-Cardio-Facial Syndrome,2013-01-29,2015-06-30,2015-06-30,38.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Duke University,Duke University|Harvard University|National Institute of Mental Health (NIMH)|University of Pittsburgh,Duke University Health Systems,Behavioral|Behavioral,United States,11.0,17.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01781923
1252,NCT01783002,hyperparathyroidism,"Pre-operative Parathyroid Imaging: a Comparison of 11C-Methionine PET, 18F-FDG PET AND SPEC-CT for the Detection of Hyperfunctional Parathyroid Tissues",11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues,Primary Hyperparathyroidism,2013-01-04,2018-03-31,2018-07-31,50.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,University of British Columbia,British Columbia Cancer Agency|University of British Columbia,British Columbia Cancer Agency,Radiation|Radiation|Radiation,Canada,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01783002
1253,NCT01785849,hyperparathyroidism,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis",Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis,"Hyperparathyroidism, Secondary",2013-02-05,2014-05-22,2014-06-12,508.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Poland|Russian Federation|Spain|United Kingdom|United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01785849
1258,NCT01785875,hyperparathyroidism,A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis,Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,"Hyperparathyroidism, Secondary",2013-02-05,2015-07-01,2015-07-01,891.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|United Kingdom|United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01785875
1260,NCT01788046,hyperparathyroidism,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis",Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,"Hyperparathyroidism, Secondary",2013-02-07,2014-04-14,2014-05-09,515.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01788046
1262,NCT01788982,thyroid neoplasms,A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy.,Nintedanib(BIBF1120) in Thyroid Cancer,Differentiated Thyroid Cancer (DTC)|Medullary Thyroid Cancer (MTC),2013-02-08,2019-08-28,2019-08-28,100.0,,Parallel Assignment,,Interventional,Completed,Phase 2,European Organisation for Research and Treatment of Cancer - EORTC,European Organisation for Research and Treatment of Cancer - EORTC,"A.Z. St. Jan|Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet|Cliniques Universitaires Saint-Luc|Universitair Ziekenhuis Antwerpen|Universitair Ziekenhuis Gent|U.Z. Leuven - Campus Gasthuisberg|Odense University Hospital|CHU d'Angers|Institut Bergonie|Centre Regional Francois Baclesse|Centre Georges-Francois-Leclerc|Centre Leon Berard|Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis|Assistance Publique - Hopitaux de Paris - La Piti Salptrire|Centre Jean Godinot|Institut Gustave Roussy|Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern|Universitaetsklinikum Wuerzburg|Fondazione IRCCS Istituto Nazionale dei Tumori|Azienda Ospedaliera Universitaria ""Federico II""|University Medical Center Groningen|Leiden University Medical Centre|Radboud University Medical Center Nijmegen|Maria Sklodowska-Curie Memorial Cancer Centre|Hospital General Vall D'Hebron|Royal Marsden Hospital - Sutton, Surrey|NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital",Drug|Drug,Belgium|Denmark|France|Germany|Italy|Netherlands|Poland|Spain|United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01788982
1263,NCT01789541,hyperthyroidism,Observational Prospective Case-control Study on Prevalence and Impact of Subclinical Hyperthyroidism in Patients Undergoing Atrial Fibrillation Ablation,Is a Low Thyreotropin Level Predictive of Recurrent Arrhythmia After Catheter Ablative Surgery?,Atrial Fibrillation|Subclinical Hyperthyroidism,2013-02-05,2015-10-31,2015-11-30,327.0,Case-Control,,Prospective,Observational,Completed,,Karolinska Institutet,Karolinska Institutet,"Stockholm Arrhythmia Center|Hjrtkliniken, Karolinska Universitetssjukhuset Huddinge",,Sweden,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01789541
1264,NCT01792492,thyroid nodule,The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study,The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2011-07-08,2010-03-31,2015-11-30,50.0,Cohort,,Prospective,Observational,Completed,,Boston Medical Center,Boston Medical Center,Boston Medical Center,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01792492
1265,NCT01792492,thyroid neoplasms,The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study,The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2011-07-08,2010-03-31,2015-11-30,50.0,Cohort,,Prospective,Observational,Completed,,Boston Medical Center,Boston Medical Center,Boston Medical Center,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01792492
1266,NCT01794676,parathyroid diseases,A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers,Genetic Evaluation of Families With Endocrine Cancers,MEN1 Syndrome|Pancreatic Cancer|Parathyroid Disease|Thymic Cancer,2013-02-15,2015-09-30,2015-10-31,9.0,Family-Based,,Prospective,Observational,Completed,,Jersey Shore University Medical Center,Jersey Shore University Medical Center|Rutgers Cancer Institute of New Jersey|Rutgers University,Jersey Shore University Medical Center,Genetic,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01794676
1267,NCT01798966,graves ophthalmopathy,The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Thyroid Eye Disease,2013-02-21,2013-06-30,2013-06-30,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Sensimed AG,"Sensimed AG|University of California, San Diego","Shiley Eye Center, University of California, San Diego",Device,United States,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01798966
1268,NCT01798966,goiter,The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Thyroid Eye Disease,2013-02-21,2013-06-30,2013-06-30,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Sensimed AG,"Sensimed AG|University of California, San Diego","Shiley Eye Center, University of California, San Diego",Device,United States,18.0,90.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01798966
1269,NCT01798966,hyperthyroidism,The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Thyroid Eye Disease,2013-02-21,2013-06-30,2013-06-30,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Sensimed AG,"Sensimed AG|University of California, San Diego","Shiley Eye Center, University of California, San Diego",Device,United States,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01798966
1270,NCT01798966,graves disease,The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Thyroid Eye Disease,2013-02-21,2013-06-30,2013-06-30,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Sensimed AG,"Sensimed AG|University of California, San Diego","Shiley Eye Center, University of California, San Diego",Device,United States,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01798966
1271,NCT01800617,hypothyroidism,Phase II Single Daily-Dose Response Study of a New Liothyronine Sodium (T3) Preparation With Sustained Effects in Hypothyroid Patients,A Study of T3 Therapy in Patients With Hypothyroidism,Hypothyroidism,2013-02-18,2014-07-31,,18.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Ipe, LLC","Ipe, LLC",Georgetown University Hospital,Drug,United States,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01800617
1272,NCT01801033,hypothyroidism,Effects of Pharmacologic Block of Type-1 Deiodinase on Thyroid Hormone Action and on the Circulating Levels of T3 in Hypothyroid Patients,Effects of Thyroid Hormone Enzyme Blocking on Hypothyroidism,Hypothyroidism|Thyroidectomy,2013-02-26,2013-11-29,2013-11-29,0.0,,,Prospective,Observational,Withdrawn,,National Institutes of Health Clinical Center (CC),"National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",,,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01801033
1273,NCT01805856,parathyroid diseases,Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery,Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery,Parathyroid Disease|Thyroid Disease,2013-03-05,2012-05-31,2012-05-31,2164.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Ito Hospital,Ito Hospital,Ito Hospital,Drug|Drug,Japan,10.0,90.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01805856
1274,NCT01809444,graves ophthalmopathy,"The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial",Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy,Thyroid Associated Opthalmopathies,2012-12-02,2016-01-31,2016-01-31,146.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Peking Union Medical College Hospital|Zhongshan Ophthalmic Center|JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong|Shenzhen Eye Hospital|Henan Eye Institue, Henan, China|The second xiangya hospital of central south university",Drug|Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01809444
1275,NCT01809444,hyperthyroidism,"The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial",Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy,Thyroid Associated Opthalmopathies,2012-12-02,2016-01-31,2016-01-31,146.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Peking Union Medical College Hospital|Zhongshan Ophthalmic Center|JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong|Shenzhen Eye Hospital|Henan Eye Institue, Henan, China|The second xiangya hospital of central south university",Drug|Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01809444
1276,NCT01809444,goiter,"The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial",Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy,Thyroid Associated Opthalmopathies,2012-12-02,2016-01-31,2016-01-31,146.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Peking Union Medical College Hospital|Zhongshan Ophthalmic Center|JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong|Shenzhen Eye Hospital|Henan Eye Institue, Henan, China|The second xiangya hospital of central south university",Drug|Drug,China,18.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01809444
1277,NCT01809444,graves disease,"The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial",Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy,Thyroid Associated Opthalmopathies,2012-12-02,2016-01-31,2016-01-31,146.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Peking Union Medical College Hospital|Zhongshan Ophthalmic Center|JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong|Shenzhen Eye Hospital|Henan Eye Institue, Henan, China|The second xiangya hospital of central south university",Drug|Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01809444
1278,NCT01811199,thyroid neoplasms,Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2 and LTC4 Levels,Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2 and LTC4 Levels,Breast Cancer|Thyroid Cancer,2013-03-06,2013-04-30,2013-05-31,100.0,Case-Control,,Prospective,Observational,Unknown status,,Marmara University,Marmara University,Marmara University School of Medicine,,Turkey,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01811199
1279,NCT01811212,"thyroid cancer, papillary",Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy,Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma,2013-03-12,2015-07-13,2017-10-09,25.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),Exelixis|National Cancer Institute (NCI),MedStar Georgetown University Hospital|Mayo Clinic in Florida|University of Chicago Comprehensive Cancer Center|Massachusetts General Hospital Cancer Center|Mayo Clinic|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01811212
1280,NCT01811212,"adenocarcinoma, follicular",Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy,Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma,2013-03-12,2015-07-13,2017-10-09,25.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),Exelixis|National Cancer Institute (NCI),MedStar Georgetown University Hospital|Mayo Clinic in Florida|University of Chicago Comprehensive Cancer Center|Massachusetts General Hospital Cancer Center|Mayo Clinic|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01811212
1282,NCT01812395,goiter,Is Superior Laryngeal Nerve Really Safe During Thyroidectomy Using Ultrasonic Dissector.,Thyroidectomy Using Ultrasonic Dissector: Is Superior Laryngeal Nerve Really Safe ?,Goiter,2013-03-08,2014-03-31,2014-04-30,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,S.B. Konya Education and Research Hospital,S.B. Konya Education and Research Hospital,Konya Education and Research Hospital,Device|Procedure,Turkey,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01812395
1283,NCT01813136,thyroid neoplasms,"A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma",Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma,Thyroid Carcinoma,2013-03-11,2019-01-31,2019-01-31,168.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Centre Leon Berard,Centre Leon Berard|GlaxoSmithKline,CHU Angers|CHU Bordeaux|Institut Bergoni|Centre Franois Baclesse|CHRU Lille Hpital Claude Huriez|Centre Leon Berard|Hpital de la Timone APHM|Centre Antoine Lacassagne|Hpital Saint-Louis APHP|Hpital de la Piti Salptrire APHP|Institut Jean Godinot|Institut Claudius Rgaud|Institut Gustave Roussy,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01813136
1285,NCT01815021,hypoparathyroidism,"A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism.",A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients,Hypoparathyroidism,2013-03-07,2014-06-30,2014-06-30,10.0,,Crossover Assignment,,Interventional,Completed,Phase 1/Phase 2,Amorphical Ltd.,Amorphical Ltd.,Rambam Health Care Campus,Dietary Supplement|Dietary Supplement,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01815021
1286,NCT01821781,hypoparathyroidism,A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime,Immune Disorder HSCT Protocol,Autoimmune Lymphoproliferative Syndrome|Chediak-Higashi Syndrome|Chronic Granulomatous Disease|Common Variable Immune Deficiency|DiGeorge Syndrome|Hemophagocytic Lymphohistiocytosis|Hyper-IgM|Immune Deficiency Disorders|Immune Dysregulatory Disorders|IPEX|Severe Combined Immunodeficiency|Wiskott-Aldrich Syndrome|X-linked Agammaglobulinemia|X-linked Lymphoproliferative Syndrome,2013-03-19,2024-03-31,2024-03-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Washington University School of Medicine,Washington University School of Medicine,Washington University,Drug,United States,0.0,21.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01821781
1288,NCT01830504,thyroid neoplasms,A Multicenter Phase II Pilot Open Label Study to Evaluate the Efficacy and Safety of BKM120 in the Treatment of Patients With Advanced or Metastatic Differentiated Thyroid Cancers,A Multicenter Phase II Pilot Open Label,Thyroid Cancers,2013-04-04,2013-04-30,2017-01-31,47.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01830504
1289,NCT01831869,hypothyroidism,The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study,Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-04-07,2022-04-30,2022-04-30,400.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01831869
1290,NCT01832753,hypothyroidism,Levothyroxine Treatment and Cardiometabolic Outcomes in Adolescents With Down Syndrome,Treatment Trial of Subclinical Hypothyroidism in Down Syndrome,Down Syndrome|Subclinical Hypothyroidism,2013-04-09,2017-10-18,2017-10-18,12.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Children's National Medical Center|The Children's Hospital of Philadelphia,Drug,United States,8.0,20.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01832753
1291,NCT01833650,thyroid neoplasms,A Randomized Controlled Trial of the Effectiveness of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer,The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer,Thyroid Cancer,2013-04-11,2018-08-31,2018-09-30,120.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Cyprus University of Technology,Bank of Cyprus Oncology Centre|Cyprus University of Technology,Bank of Cyprus Oncology,Dietary Supplement,Cyprus,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01833650
1292,NCT01837433,"thyroiditis, subacute",Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis,Short-term Prednisone to Treat STA Study(SPTSS),Subacute Thyroiditis,2013-04-06,2014-12-31,2014-12-31,40.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Xinqiao Hospital of Chongqing,Xinqiao Hospital of Chongqing,"The Second Affiliated Hospital, Third Military Medical University",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroiditis,De Quervain's thyroiditis,https://clinicaltrials.gov/ct2/show/NCT01837433
1293,NCT01837433,thyroiditis,Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis,Short-term Prednisone to Treat STA Study(SPTSS),Subacute Thyroiditis,2013-04-06,2014-12-31,2014-12-31,40.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Xinqiao Hospital of Chongqing,Xinqiao Hospital of Chongqing,"The Second Affiliated Hospital, Third Military Medical University",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01837433
1294,NCT01837745,thyroid neoplasms,Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?,Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?,Low Risk Differentiated Thyroid Cancer,2013-04-16,2020-03-31,2022-05-12,776.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Institut Gustave Roussy,Drug|Drug|Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01837745
1295,NCT01838031,hypothyroidism,Randomized Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study,Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study,Subclinical Hypothyroidism,2013-04-14,2013-09-30,2013-09-30,1000.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Peking Union Medical College Hospital,Beijing Municipal Science & Technology Commission|Peking Union Medical College Hospital,Peking Union Medical College Hospital,Other,China,18.0,42.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01838031
1296,NCT01838629,thyroid neoplasms,,the Effect of Universal Salt Iodization on Thyroid Diseases,Thyroid Nodule,2013-04-19,2012-06-30,2012-06-30,12438.0,Ecologic or Community,,Cross-Sectional,Observational [Patient Registry],Completed,,Hangzhou Center of Disease Control and Prevention,Weimin Xu,Hangzhou Center of Disease Control and Prevention,,China,6.0,86.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01838629
1297,NCT01838629,thyroid nodule,,the Effect of Universal Salt Iodization on Thyroid Diseases,Thyroid Nodule,2013-04-19,2012-06-30,2012-06-30,12438.0,Ecologic or Community,,Cross-Sectional,Observational [Patient Registry],Completed,,Hangzhou Center of Disease Control and Prevention,Weimin Xu,Hangzhou Center of Disease Control and Prevention,,China,6.0,86.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01838629
1298,NCT01838642,thyroid neoplasms,A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer,Ponatinib for Advanced Medullary Thyroid Cancer,Thyroid Neoplasms,2013-04-20,2015-12-31,2016-01-31,3.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01838642
1299,NCT01840332,thyroid neoplasms,Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer,Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer,Thyroid Cancer,2013-04-22,2014-02-28,2014-02-28,20.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Tartu,University of Tartu,East Tallinn Central Hospital|Tartu University Hospital,Drug,Estonia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01840332
1300,NCT01843062,thyroid neoplasms,"A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer",Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2013-03-14,2018-05-18,2019-03-06,233.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,AstraZeneca,AstraZeneca,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug|Drug,Brazil|Denmark|France|Germany|Italy|Poland|Sweden|United States,18.0,130.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01843062
1301,NCT01848171,hypothyroidism,Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism,Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-05-02,2023-07-31,2023-07-31,700.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,40.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01848171
1302,NCT01853579,hypothyroidism,Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) - Subanalysis on Subclinical Hypothyroidism and Depression,The TRUST Study - Depression Substudy,Depression|Subclinical Hypothyroidism,2013-05-06,2018-04-05,2018-04-05,426.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University Hospital Inselspital, Berne","Leiden University Medical Center|University Hospital Inselspital, Berne|University of Bern","Leiden University Medical Center|Department of General Internal Medicine|University Clinic for General Internal Medicine, Bern University Hospital",Drug|Drug,Netherlands|Switzerland,65.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01853579
1303,NCT01856920,thyroid neoplasms,A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer,QUILT-3.006 for Recurrent Medullary Thyroid Cancer,Medullary Thyroid Cancer (MTC),2013-05-08,2019-12-31,2020-03-01,35.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2,"NantCell, Inc.","NantCell, Inc.|National Cancer Institute (NCI)",NIH Clinical Center,Biological,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01856920
1304,NCT01862510,hypothyroidism,Detection of Celiac Disease in Patients With Hypothyroidism,Detection of Celiac Disease in Patients With Hypothyroidism,Celiac Disease|Celiac Sprue|Hypothyroidism|Malabsorption,2013-05-20,2014-12-31,2014-12-31,500.0,Cohort,,Prospective,Observational,Completed,,University of Vermont,University of Vermont,Fletcher Allen Health Care,,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01862510
1305,NCT01865838,thyroid neoplasms,A Study Into the Effect of Seprafilm on Post Operative Adhesions After Open Total Thyroidectomy.,A Study Into the Effect of Seprafilm in Open Total Thyroidectomy,Thyroid Carcinoma,2013-05-14,2014-09-30,2014-09-30,19.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,"National Cancer Centre, Singapore","National Cancer Centre, Singapore|Singapore General Hospital",Singapore General Hospital|National Cancer Centre Singapore,Device,Singapore,21.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01865838
1306,NCT01868750,thyroid nodule,"A Phase 2, Placebo-controlled, Randomized Study to Evaluate the Effect of Pre-operative Vitamin D Supplementation on Hypocalcemia Following Total or Near-total Thyroidectomy",Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia,Hypocalcemia|Thyroid Nodules,2013-05-30,2021-07-08,2021-07-08,67.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Virginia,"David Shonka, MD",University of Virginia,Dietary Supplement|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01868750
1307,NCT01868750,thyroid neoplasms,"A Phase 2, Placebo-controlled, Randomized Study to Evaluate the Effect of Pre-operative Vitamin D Supplementation on Hypocalcemia Following Total or Near-total Thyroidectomy",Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia,Hypocalcemia|Thyroid Nodules,2013-05-30,2021-07-08,2021-07-08,67.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Virginia,"David Shonka, MD",University of Virginia,Dietary Supplement|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01868750
1308,NCT01868997,goiter,"A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)",Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,2013-05-02,2016-03-31,2017-02-22,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Jules Stein Eye Institute at UCLA|University of Denver|Emory University Department of Ophthalmology|University of Iowa Hospitals and Clinics, Department of Ophthalmology|Kellogg Eye Center at University of Michigan|Washington University Department of Ophthalmology|University of Nebraska Medical Center Department of Ophthalmology|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|Johannes Gutenberg University Medical Center|Fondazione Ca' Granda Ospedale Policlinico Graves GO Center|University of Pisa, Azienda Ospedaliera|Moorfields Eye Hospital",Drug|Drug,Germany|Italy|United Kingdom|United States,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01868997
1309,NCT01868997,graves disease,"A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)",Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,2013-05-02,2016-03-31,2017-02-22,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Jules Stein Eye Institute at UCLA|University of Denver|Emory University Department of Ophthalmology|University of Iowa Hospitals and Clinics, Department of Ophthalmology|Kellogg Eye Center at University of Michigan|Washington University Department of Ophthalmology|University of Nebraska Medical Center Department of Ophthalmology|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|Johannes Gutenberg University Medical Center|Fondazione Ca' Granda Ospedale Policlinico Graves GO Center|University of Pisa, Azienda Ospedaliera|Moorfields Eye Hospital",Drug|Drug,Germany|Italy|United Kingdom|United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01868997
1310,NCT01868997,graves ophthalmopathy,"A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)",Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,2013-05-02,2016-03-31,2017-02-22,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Jules Stein Eye Institute at UCLA|University of Denver|Emory University Department of Ophthalmology|University of Iowa Hospitals and Clinics, Department of Ophthalmology|Kellogg Eye Center at University of Michigan|Washington University Department of Ophthalmology|University of Nebraska Medical Center Department of Ophthalmology|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|Johannes Gutenberg University Medical Center|Fondazione Ca' Granda Ospedale Policlinico Graves GO Center|University of Pisa, Azienda Ospedaliera|Moorfields Eye Hospital",Drug|Drug,Germany|Italy|United Kingdom|United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01868997
1311,NCT01868997,hyperthyroidism,"A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)",Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,2013-05-02,2016-03-31,2017-02-22,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Jules Stein Eye Institute at UCLA|University of Denver|Emory University Department of Ophthalmology|University of Iowa Hospitals and Clinics, Department of Ophthalmology|Kellogg Eye Center at University of Michigan|Washington University Department of Ophthalmology|University of Nebraska Medical Center Department of Ophthalmology|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|Johannes Gutenberg University Medical Center|Fondazione Ca' Granda Ospedale Policlinico Graves GO Center|University of Pisa, Azienda Ospedaliera|Moorfields Eye Hospital",Drug|Drug,Germany|Italy|United Kingdom|United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01868997
1312,NCT01872429,hyperparathyroidism,,Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients,Hyperparathyroidism,2013-06-05,2013-04-30,2013-04-30,401.0,Cohort,,Retrospective,Observational,Completed,,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01872429
1314,NCT01876784,thyroid neoplasms,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.","Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",Differentiated Thyroid Cancer,2013-06-11,2015-08-30,2022-12-31,243.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Washington University|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Brazil|China|Czechia|Denmark|France|Italy|Japan|Poland|Russian Federation|Spain|Sweden|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01876784
1315,NCT01880203,thyroid nodule,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Indeterminate Cytology|Surgery Indication|Thyroid Node,2013-06-14,2015-09-30,2015-11-30,140.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Centre Francois Baclesse|Fondation avenir|laboratoire Genzyme,Centre Franois BACLESSE|CHU|Hpital Amricain de Paris|Hpital Piti-salptrire,Procedure,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01880203
1316,NCT01880203,thyroid neoplasms,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Indeterminate Cytology|Surgery Indication|Thyroid Node,2013-06-14,2015-09-30,2015-11-30,140.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Centre Francois Baclesse|Fondation avenir|laboratoire Genzyme,Centre Franois BACLESSE|CHU|Hpital Amricain de Paris|Hpital Piti-salptrire,Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01880203
1317,NCT01882816,thyroid neoplasms,A Phase II Study of Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer,Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer,Thyroid Cancer,2013-06-13,2021-11-04,2021-11-04,27.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Rockville Centre,Radiation|Device|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01882816
1320,NCT01884649,"thyroiditis, autoimmune",Fetuin A as a New Marker of Inflammation in Hashimoto Thyroiditis,Fetuin A in Hashimoto Thyroiditis,Hashimoto Thyroiditis,2013-06-17,2012-10-31,2012-10-31,97.0,,,Cross-Sectional,Observational [Patient Registry],Completed,,Istanbul Medeniyet University,Istanbul Medeniyet University,,,,20.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01884649
1321,NCT01885533,graves disease,POST-RADIOIODINE GRAVES' MANAGEMENT,Post-Radioiodine Graves' Management: The PRAGMA-Study,Graves' Disease,2013-02-15,2015-02-28,2015-12-31,803.0,Cohort,,Retrospective,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Cardiff and Vale University Health Board|Newcastle-upon-Tyne Hospitals NHS Trust|Royal Devon and Exeter NHS Foundation Trust,Newcastle upon Tyne Hospitals NHS Foundation Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01885533
1322,NCT01885533,goiter,POST-RADIOIODINE GRAVES' MANAGEMENT,Post-Radioiodine Graves' Management: The PRAGMA-Study,Graves' Disease,2013-02-15,2015-02-28,2015-12-31,803.0,Cohort,,Retrospective,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Cardiff and Vale University Health Board|Newcastle-upon-Tyne Hospitals NHS Trust|Royal Devon and Exeter NHS Foundation Trust,Newcastle upon Tyne Hospitals NHS Foundation Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01885533
1323,NCT01885533,hyperthyroidism,POST-RADIOIODINE GRAVES' MANAGEMENT,Post-Radioiodine Graves' Management: The PRAGMA-Study,Graves' Disease,2013-02-15,2015-02-28,2015-12-31,803.0,Cohort,,Retrospective,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Cardiff and Vale University Health Board|Newcastle-upon-Tyne Hospitals NHS Trust|Royal Devon and Exeter NHS Foundation Trust,Newcastle upon Tyne Hospitals NHS Foundation Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01885533
1324,NCT01889134,hyperparathyroidism,Osteoprotegerin/sRANKL Ratio and Bone Mineral Density in Patients With Primary Hyperparathyroidism Treated With Parathyroidectomy or Alendronate,OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2013-06-21,2012-06-30,2012-10-31,112.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Wroclaw Medical University,"Ministry of Science and Higher Education, Poland|Wroclaw Medical University","Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University",Drug|Procedure,Poland,25.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01889134
1327,NCT01893450,hyperthyroidism,"Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.",Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment,Graves Ophthalmopathy,2013-06-28,2013-06-30,2013-06-30,31.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Drug|Drug|Drug,Mexico,18.0,45.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01893450
1328,NCT01893450,goiter,"Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.",Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment,Graves Ophthalmopathy,2013-06-28,2013-06-30,2013-06-30,31.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Drug|Drug|Drug,Mexico,18.0,45.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01893450
1329,NCT01893450,graves ophthalmopathy,"Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.",Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment,Graves Ophthalmopathy,2013-06-28,2013-06-30,2013-06-30,31.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Drug|Drug|Drug,Mexico,18.0,45.0,[18-65],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01893450
1330,NCT01893450,graves disease,"Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.",Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment,Graves Ophthalmopathy,2013-06-28,2013-06-30,2013-06-30,31.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Drug|Drug|Drug,Mexico,18.0,45.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01893450
1331,NCT01896232,hyperparathyroidism,"A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism",Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,Chronic Kidney Disease|Secondary Hyperparathyroidism,2013-07-08,2014-11-12,2015-01-08,683.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug|Drug|Drug,Austria|Belgium|Canada|Czechia|Denmark|Estonia|France|Germany|Greece|Hungary|Italy|Latvia|Lithuania|New Zealand|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|Turkey|United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01896232
1334,NCT01896479,thyroid neoplasms,"A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients","A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer",Medullary Thyroid Cancer,2013-07-08,2020-07-31,2022-12-31,250.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 4,Exelixis,Exelixis,,Drug|Drug|Drug|Drug,"Australia|Canada|Croatia|France|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01896479
1335,NCT01907997,thyroid neoplasms,,Effects of Systemic Lidocaine on Postoperative Quality of Recovery After Robot-assisted Thyroidectomy,Thyroid Cancer,2013-07-17,2015-03-31,2015-05-31,90.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei universiy college of medicine",Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01907997
1336,NCT01915485,thyroid neoplasms,The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer,Radiolabeled Molecules for Medullary Thyroid Cancer,Medullary Thyroid Cancer,2013-08-01,2016-11-30,2017-02-28,20.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,"Instituto Nacional de Cancer, Brazil","Instituto Nacional de Cancer, Brazil",Instituto Nacional do Cancer do Rio de Janeiro,Radiation,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01915485
1339,NCT01916018,thyroid dysgenesis,Phenotype and Genotype Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. The Use of Genetic Analysis in the Early Care of Children With Thyroid Dysgenesis,Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.,Congenital Hypothyroidism,2013-08-02,2017-03-17,2017-03-17,558.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,"Pediatric endocrinology gynecology and diabetology, Hpital Necker Enfants Malades, Assistance Publique - Hpitaux de Paris , Universit Paris Descartes, INSERM unit U 845",Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01916018
1340,NCT01916304,hypothyroidism,"A Multicentre, Open-label Switch Study to Investigate the Necessity of Dose Adjustment After Switching From L-Thyroxine Christiaens to the New Levothyroxine Sodium Test Formulation in (Near) Total Thyroidectomised Patients.",Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation,Hypothyroidism,2013-08-01,2014-06-30,2014-06-30,101.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Takeda,Takeda,,Drug,Belgium,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01916304
1341,NCT01921452,hypothyroidism,A Single-center Interventional Study to Verify Clinical Utility of the Quantitative and the Qualitative POC TSH Test Kits Compared With the Third Generation TSH Test Kit,Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit,Hypothyroidism,2013-08-09,2014-02-28,2014-02-28,283.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",Research site,Device|Device|Device,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01921452
1343,NCT01922440,hypoparathyroidism,PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism,A Registry for Participants With Chronic Hypoparathyroidism,Hypoparathyroidism,2013-08-01,2034-11-30,2034-11-30,1064.0,Other,,Prospective,Observational [Patient Registry],Recruiting,,Takeda,"Takeda|Takeda Development Center Americas, Inc.","University of Alabama at Birmingham|University of Arizona Medical Center|Children's Hospital Los Angeles|Cedars-Sinai Medical Center|Dr. Joselito Cabaccan|University of Colorado Hospital|Yale University|Hanson Clinical Research Center|Thyroid & Endocrine Center of Florida|East-West Medical Research Institute|Suburban Endocrinology & Diabetes|University of Chicago Medical Center|Northshore University Health System|Loyola University Medical Center|Indiana University Hospital|Tilak Mallik, MD F.A.C.E., LCC|Model Clinical Research|Medstar Union Memorial Hospital|Massachusetts General Hospital|Brigham and Women's Hospital|Harvard Medical School|Boston Medical Center|University of Minnesota|Mayo Clinic - Rochester|University of Missouri|Diabetes & Endocrine Associates, Methodist Physicians Clinic Diabetes and Endocrine Specialists|Palm Research Center, Inc.|Northern Nevada Endocrinology|Rutgers Robert Wood Johnson Medical School|Rutgers-Robert Wood Johnson Medical School|Albany Med Endocrine Specialists|Brokhin Medical PC|Gerald Friedman Diabetes Institute|Columbia University Medical Center|Endocrine Associates of Long Island, P.C.|University Physicians Group Research Division|State University Of New York Upstate Medical University|Mecklenburg Medical Group|Physicians East, PA|Cleveland Clinic|Ohio State University Wexner Medical Center|Ohio Health Research Institute|Endocrinology Associates of Armstrong|The Children's Hospital of Philadelphia|Thomas Jefferson University|Alleghany General Hospital|Hallett Center for Diabetes and Endocrinology|University of South Carolina|Texas Diabetes and Endocrinology, P.A.|Thyroid Endocrinology and Diabetes|Academy of Diabetes Thyroid and Endocrine|Diabetes and Thyroid Center of Fort Worth, PLLC|University of Vermont|University of Wisconsin|Medizinische Universitaetsklinik Graz, Universittsklinik Fr Innere Medizin Graz|AKH Wien, Universitaetsklinik fuer Innere Medizin III|Nova Scotia Health Authority|McMaster University|Aallborg University Hospital|Aarhus Universitetshospital|Nordsjaellands Hospital - Hillerod|Regions Hospitalet Viborg|Diakonie-Klinikum Stuttgart|Medizinische Hochschule Hannover|University Hospital Duesseldorf|University of Leipzig|Universitaetsklinik Aachen|Charite-Universitiitsmedizin Berlin (CCM)|Praxis an der Kaiserreiche|Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden|Endokrinologikum Frankfurt|MVZ endokrinologikum Gttingen|Universitaet Zur Luebeck|Medicover Neuroendokrinologie MVZ|Medicover Neu-Ulm Mvz|Medicover Oldenburg MVZ|Medicover Saarbuecken Mvz|Endokrinologie Zentrum Ulm|Universitaetsklinikum Wuerzburg|General Hospital Of Athens - Korgialenio-Benakio E.E.S.|General Hospital of Athens Georgios Gennimatas|General Hospital of Athens Alexandra|AHEPA University General Hospital of Thessaloniki|Hippokrateion General Hospital of Thessaloniki|Azienda Ospedaliero-Universitaria Careggi|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico|Azienda Ospedaliera San Giovanni Addolorata|Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza - Ospedale Molinette|Haukeland University Hospital|Spesialistsentret Pilestredet Park|Hospital Del Mar|Hospital Universitario San Cecilio|Hospital Universitario 12 de Octubre|Universitetssjukhuset I Linkoping|Universitetssjukhuset I Orebro|Karolinska Universitetssjukhuset Solna|Akademiska Sjukhuset - Uppsala University Hospital|Queen Elizabeth Hospital-Mindelsohn Way|University of Hospitals of Leicester|Norfolk And Norwich University Hospital - Norwich Medical School",Other,Austria|Canada|Denmark|Germany|Greece|Italy|Norway|Spain|Sweden|United Kingdom|United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01922440
1346,NCT01922843,hyperparathyroidism,"A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis",A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis,"Hyperparathyroidism, Secondary|Kidney Failure, Chronic",2013-08-12,2014-05-31,2014-06-30,62.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Deltanoid Pharmaceuticals,Deltanoid Pharmaceuticals,,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01922843
1347,NCT01927406,graves ophthalmopathy,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,2013-08-16,2016-12-31,2016-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,Stanford University,Stanford University,Stanford Hospital and Clinics,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01927406
1348,NCT01927406,graves disease,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,2013-08-16,2016-12-31,2016-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,Stanford University,Stanford University,Stanford Hospital and Clinics,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01927406
1349,NCT01927406,goiter,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,2013-08-16,2016-12-31,2016-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,Stanford University,Stanford University,Stanford Hospital and Clinics,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01927406
1350,NCT01927406,hyperthyroidism,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,2013-08-16,2016-12-31,2016-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,Stanford University,Stanford University,Stanford Hospital and Clinics,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01927406
1352,NCT01927887,"thyroid cancer, papillary",Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study,Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study,Follicular Thyroid Cancer Lymph Node Metastasis|Metastatic Medullary Thyroid Cancer|Papillary Carcinoma of Thyroid Gland,2013-08-20,2015-04-30,2016-04-30,12.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Drug|Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01927887
1353,NCT01927887,"adenocarcinoma, follicular",Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study,Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study,Follicular Thyroid Cancer Lymph Node Metastasis|Metastatic Medullary Thyroid Cancer|Papillary Carcinoma of Thyroid Gland,2013-08-20,2015-04-30,2016-04-30,12.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Drug|Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01927887
1354,NCT01932970,hyperparathyroidism,"A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416",Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide,"Hyperparathyroidism, Secondary",2013-08-28,2014-01-14,2017-02-14,158.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01932970
1359,NCT01935856,hyperparathyroidism,"A Dose Escalation, Single and Multiple Dose, Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis",Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis,Hyperparathyroidism,2013-09-02,2014-03-31,2014-03-31,20.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug,Japan,20.0,74.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01935856
1360,NCT01939977,hyperparathyroidism,Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.,Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.,Secondary Hyperparathyroidism Due to Renal Causes,2013-08-28,2015-09-30,2015-12-31,148.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Fundacin Senefro,AbbVie|Effice Servicios Para la Investigacion S.L.|Fundacin Senefro,Hospital Universitari Germans Trias I Pujol de Badalona|Hospital Universitari de Bellvitge|Hospital Universitario Marqus de Valdecilla|Hospital Del Mar|Fundaci Puigvert-Iuna|Hospital Universitari Vall D'Hebron|Hospital Puerta Del Mar|Hospital Reina Sofa|Complexo Hospitalario Universitario A Coruna|Complejo Hospitalario Universitario de Canarias|Hospital Ramn Y Cajal|Hospital Universitario 12 de Octubre|Complejo Hospitalario Regional de Mlaga|Hospital Virgen Del Roco|Hospital Universitari I Politcnic La Fe|Hospital Universitario Miguel Servet,Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01939977
1363,NCT01945229,hyperthyroidism,Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE),Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE),Atrial Fibrillation|Hyperthyroidism,2013-09-13,2020-08-31,2020-08-31,110.0,Cohort,,Prospective,Observational,Terminated,,Karolinska Institutet,Karolinska Institutet,"Medicine Clinic, Sahlgrenska University Hospital|Endocrinology Clinik, Karolinska University Hospital|Medicine Clinic, Danderyds Hospital",,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01945229
1364,NCT01945762,thyroid neoplasms,"European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer",Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer,"Advanced/Metastatic Medullary Thyroid Cancer (MTC)|Symptomatic, Aggressive, Sporadic, Unresectable, Locally",2013-09-10,2020-06-18,2020-06-18,31.0,Cohort,,Prospective,Observational,Completed,,Sanofi,"Genzyme, a Sanofi Company|Worldwide Clinical Trials",investigational Site Belgium|investigational Site France|investigational Site Germany|investigational Site Italy|investigational Site Luxembourg|investigational Site Netherlands|investigational Site Spain|investigational Site United Kingdom,Drug,Belgium|France|Germany|Italy|Luxembourg|Netherlands|Spain|United Kingdom,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01945762
1365,NCT01947023,thyroid neoplasms,A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer,Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery,Metastatic Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2013-09-16,2022-07-01,2022-07-01,21.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01947023
1366,NCT01950260,hyperthyroidism,Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease,Early Levothyroxine Post Radioactive Iodine,Graves' Disease,2013-09-23,2017-04-30,2017-04-30,61.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Drug|Other,United States,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01950260
1367,NCT01950260,graves disease,Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease,Early Levothyroxine Post Radioactive Iodine,Graves' Disease,2013-09-23,2017-04-30,2017-04-30,61.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Drug|Other,United States,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01950260
1368,NCT01950260,goiter,Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease,Early Levothyroxine Post Radioactive Iodine,Graves' Disease,2013-09-23,2017-04-30,2017-04-30,61.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Drug|Other,United States,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01950260
1369,NCT01954134,thyroid neoplasms,P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?,P53 in Differentiated Thyroid Cancer,Thyroid Neoplasms,2013-09-11,2013-01-31,2013-01-31,199.0,Case-Control,,Prospective,Observational,Completed,,Cumhuriyet University,Cumhuriyet University,"Cumhuriyet University, School of Medicine, Dept. of Nuclear Medicine",,Turkey,16.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01954134
1370,NCT01964144,thyroid neoplasms,,"An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer",Thyroid Cancer,2013-10-09,2014-10-31,2014-10-31,40.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Yonsei University,Yonsei University,"Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine",Drug,"Korea, Republic of",20.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01964144
1371,NCT01964508,thyroid neoplasms,The Use of a microRNA Panel to Identify Thyroid Malignancy in FNA Leftover Cells and the Effect of These microRNAs on Target Genes.,microRNA in Thyroid Cancer,FNA|microRNA|Thyroid Cancer|Thyroid Nodule,2013-10-14,2015-12-30,2015-12-30,77.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Hadassah Medical Organization,Hadassah Medical Organization,Hadassah Medical Organization,Other,Israel,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01964508
1372,NCT01964508,thyroid nodule,The Use of a microRNA Panel to Identify Thyroid Malignancy in FNA Leftover Cells and the Effect of These microRNAs on Target Genes.,microRNA in Thyroid Cancer,FNA|microRNA|Thyroid Cancer|Thyroid Nodule,2013-10-14,2015-12-30,2015-12-30,77.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Hadassah Medical Organization,Hadassah Medical Organization,Hadassah Medical Organization,Other,Israel,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01964508
1373,NCT01969019,goiter,A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy,"A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy",Graves' Ophthalmopathy,2013-10-21,2013-10-31,2013-10-31,70.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ruijin Hospital,Ruijin Hospital,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital",Drug,China,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01969019
1374,NCT01969019,graves ophthalmopathy,A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy,"A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy",Graves' Ophthalmopathy,2013-10-21,2013-10-31,2013-10-31,70.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ruijin Hospital,Ruijin Hospital,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital",Drug,China,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01969019
1375,NCT01969019,graves disease,A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy,"A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy",Graves' Ophthalmopathy,2013-10-21,2013-10-31,2013-10-31,70.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ruijin Hospital,Ruijin Hospital,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital",Drug,China,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01969019
1376,NCT01969019,hyperthyroidism,A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy,"A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy",Graves' Ophthalmopathy,2013-10-21,2013-10-31,2013-10-31,70.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ruijin Hospital,Ruijin Hospital,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital",Drug,China,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01969019
1378,NCT01974284,"thyroid cancer, papillary",Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma,Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma,Papillary Thyroid Cancer,2013-10-25,2017-03-02,2017-06-29,7.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Yale University,Yale University,Endocrine Surgery Smilow Cancer Hospital at Yale-New Haven,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01974284
1379,NCT01985204,hypothyroidism,Assessment of the Improvement of the Cardiovascular Risk Profile in Obese Women After Correction of Iodine Deficiency,Iodine Supplementation in Obesity,Iodine Deficiency|Subclinical Hypothyroidism,2013-10-31,2014-06-30,2014-07-31,162.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Swiss Federal Institute of Technology,Swiss Federal Institute of Technology,"Universite Caddi Ayad, Faculte de Medecine et de Pharmacie|University Cadi Ayyad, Faculte des Sciences",Dietary Supplement|Dietary Supplement,Morocco,20.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01985204
1380,NCT01994200,thyroid neoplasms,Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) For Newly Diagnosed Thyroid Cancer Patients: Randomized Controlled Trial,Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients,Thyroid Cancer,2013-11-19,2016-06-30,2016-06-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 1/Phase 2,Jewish General Hospital,"Genzyme, a Sanofi Company|Jewish General Hospital",Jewish General Hospital,Other|Other,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01994200
1382,NCT01996072,hyperparathyroidism,A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Parathyroidectomy for Primary Hyperparathyroidism.,EC17 for Intraoperative Imaging for Parathyroidectomy,Primary Hyperparathyroidism,2013-11-21,2014-09-30,2014-09-30,10.0,,Single Group Assignment,,Interventional,Completed,Phase 1,University of Pennsylvania,University of Pennsylvania,Hospital of the University of Pennsylvania,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01996072
1384,NCT01997554,hypothyroidism,Validation of a New TSH Test for Early Screening of Hypothyroidism,Validation of a New TSH Test,Euthyroidism|Hypothyroidism|Sub-clinical Hypothyroidism,2013-10-28,2014-08-31,2014-08-31,1654.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre Hospitalier de Chambry|Centre Hospitalier Lyon Sud,Other,France,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01997554
1385,NCT01999790,graves ophthalmopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Graves Ophthalmopathy,2013-11-17,2014-12-31,2015-02-28,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo,University of Sao Paulo,Hospital das Clinicas - FMUSP,Procedure|Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01999790
1386,NCT01999790,hyperthyroidism,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Graves Ophthalmopathy,2013-11-17,2014-12-31,2015-02-28,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo,University of Sao Paulo,Hospital das Clinicas - FMUSP,Procedure|Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01999790
1387,NCT01999790,goiter,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Graves Ophthalmopathy,2013-11-17,2014-12-31,2015-02-28,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo,University of Sao Paulo,Hospital das Clinicas - FMUSP,Procedure|Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01999790
1388,NCT01999790,graves disease,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Graves Ophthalmopathy,2013-11-17,2014-12-31,2015-02-28,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo,University of Sao Paulo,Hospital das Clinicas - FMUSP,Procedure|Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01999790
1389,NCT02005250,hyperthyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Hyperthyroidism|Hypothyroidism,2013-12-03,2016-10-31,2020-01-01,93.0,Cohort,,Prospective,Observational,Completed,,Odense University Hospital,Steen Bonnema,Odense University Hospital,,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02005250
1390,NCT02005250,hypothyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Hyperthyroidism|Hypothyroidism,2013-12-03,2016-10-31,2020-01-01,93.0,Cohort,,Prospective,Observational,Completed,,Odense University Hospital,Steen Bonnema,Odense University Hospital,,Denmark,18.0,85.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02005250
1391,NCT02012231,thyroid neoplasms,"A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",Cholangiocarcinoma|Colorectal Cancer|Hairy Cell Leukemia|Histiocytosis|Melanoma|Non-small Cell Lung Cancer|Thyroid Cancer,2013-12-05,2014-09-30,2015-06-30,5.0,,Single Group Assignment,,Interventional,Terminated,Phase 1,Fore Biotherapeutics,Fore Biotherapeutics,Scottsdale Healthcare|Huntsman Cancer Institute|Evergreen Hematology & Oncology,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02012231
1392,NCT02012686,thyroid neoplasms,The Effect of Transcutaneous Electrical Nerve Stimulation for Reduction of Posterior Neck Pain After Thyroidectomy,The Effect of Transcutaneous Electrical Nerve Stimulation on Posterior Neck Pain After Thyroidectomy,Neck Pain|Thyroid Cancer,2013-12-04,2014-01-31,2014-02-28,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Gangnam Severance Hospital, Anesthesia and Pain Research Institute, Yonsei University College of Medicine",Device,"Korea, Republic of",20.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02012686
1393,NCT02012699,thyroid neoplasms,Integrated Cancer Repository for Cancer Research,Integrated Cancer Repository for Cancer Research,Anal Cancer|Bile Duct Cancer|Bladder Cancer|Breast Cancer|CNS Cancer|CNS Tumor|Colon Cancer|Duodenal Cancer|Endometrial Cancer|Esophageal Cancer|Familial Adenomatous Polyposis|Gallbladder Cancer|Gastric Cancer|GIST|Healthy Control|Hypopharyngeal Cancer|Kidney Cancer|Laryngeal Cancer|Leukemia|Lip Cancer|Liver Cancer|Lung Cancer|Lynch Syndrome|Melanoma|Mesothelioma|Multiple Myeloma|Nasal Cavity Cancer|Nasopharyngeal Cancer|Neuroendocrine Tumors|Oral Cavity Cancer|Oropharyngeal Cancer|Ovarian Cancer|Pancreatic Cancer|Paranasal Sinus Cancer|Penile Cancer|Peritoneal Surface Malignancies|Plasma Cell Dyscrasia|Prostate Cancer|Rectal Cancer|Salivary Gland Cancer|Sarcoma|Skin Cancer|Small Intestine Cancer|Testicular Cancer|Thymus Cancer|Thyroid Cancer|Unknown Primary Tumor|Ureter Cancer|Urethral Cancer|Vaginal Cancer,2013-12-02,2099-12-31,2099-12-31,999999.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,University of Nebraska,University of Nebraska,"Penrose Cancer Center|Porter Adventist Hospital|Mercy Regional Medical Center|St. Anthony Hospital|Littleton Cancer Center|Longmont Cancer Center|Avista Cancer Center|Parker Adventist Hospital|St. Mary Corwin Medical Center|St. Anthony North Cancer Center|Florida Hospital Memorial Medical Center|Florida Hospital DeLand|Florida Hospital FISH|Florida Hospital Flagler|Rush-Copley Cancer Care Center|Trinity Medical Center|Rush-Copley Healthcare Center|Parkview Research Center|Community Health Network|Community Cancer Center South|Community Cancer Center North|Community Howard Regional Hospital|Methodist Jennie Edmundson Hospital|Genesis Medical Center|Abben Cancer Center|Covenant Medical Center, Inc|Saint Luke's Cancer Instititue - South|Tulane University|Breast Care Specialists of Maine|Northwest Hospital|William E Kahlert Regional Cancer Center|Holyoke Medical Center|University of Michigan Health System|Riverwood Healthcare Center|Essentia Health-St. Joseph's Medical Center|Essentia Health - Duluth Clinic|St. Luke's Hospital of Duluth|Lake Region Healthcare|Avera Cancer Institute- Marshall|Mercy Hospital - Joplin|Saint Luke's Cancer Institute - East|Saint Luke's Cancer Institute|Saint Luke's Cancer Institute - Kansas City North|Saint Luke's Cancer Institute - Liberty|Heartland Regional Medical Center dba Mosaic Life Care|Bozeman Health Deaconess Hospital|Logan Health|Providence St. Patrick Hospital Montana Cancer Center|Mary Lanning Healthcare/Morrison Cancer Center|Faith Regional Health Services, Carson Cancer Center|Great Plains Regional Medical Center|Avera St. Anthony's Hospital|Methodist Estabrook Cancer Center|Nebraska Methodist Health System|University of Nebraska Medical Center|Regional West Health Services|C.R. Wood Cancer Center, Glens Falls Hospital|Faxton St. Luke's Healthcare/Mohawk Valley|Cape Fear Valley Health System|Essentia Health|Trinity Hospital Cancer Care Center|Aultman Alliance Community Hospital|Aultman Hospital|University of Pittsburgh|Avera Medical Group Oncology and Hematology Aberdeen|Avera Cancer Institute|Avera Cancer Institute|Sanford Health|Avera Cancer Center Yankton|Avera Sacred Heart Hospital|Yankton Medical Clinic|Rutland Regional Medical Center|Mary Washington Hospital|Ascension St. Elizabeth Hospital|Wheaton Franciscan Healthcare - Elmbrook Memorial Hospital|Wheaton Franciscan Healthcare - Reiman Cancer Care|Columbia St. Mary's|Columbia St. Mary's|Ascension Mercy Hospital|Wheaton Franciscan Healthcare - All Saints|Wheaton Franciscan Healthcare - Wauwatosa Cancer Care",,United States,19.0,110.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02012699
1396,NCT02013479,"thyroiditis, autoimmune",The Chronic Autoimmune Thyroiditis Quality Of Life Selenium Trial,Selenium Supplementation in Autoimmune Thyroiditis,Autoimmune Thyroiditis,2013-12-03,2022-08-31,2022-12-31,415.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Odense University Hospital,"Bispebjerg Hospital|Hospital of South West Denmark|Pharma Nord|Region of Southern Denmark|Rigshospitalet, Denmark|Steen Bonnema|The Danish Medical Research Council|University of Southern Denmark","Clinic of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet|Department of Endocrinology and Gastroenterology, Bispebjerg Hospital|Department of Internal Medicine, Hospital of South West Denmark|Department of Endorcrinology and Metabolism, Odense University Hospital",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02013479
1397,NCT02017080,hypothyroidism,Efficacy Of Non Invasive Diagnostic Procedures In Evaluating The Influence Of Maternal Autoimmune Thyroid Gland Disease On Fetus,Fetal Thyroid Ultrasound And Fetal Thyroid Hormones,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2013-12-15,2019-12-31,2020-01-31,300.0,Case-Control,,Prospective,Observational,Unknown status,,University of Belgrade,University of Belgrade,"Clinic for Gynecology and Obstetrics , Clinical Center of Serbia",,Serbia,20.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02017080
1398,NCT02017080,hyperthyroidism,Efficacy Of Non Invasive Diagnostic Procedures In Evaluating The Influence Of Maternal Autoimmune Thyroid Gland Disease On Fetus,Fetal Thyroid Ultrasound And Fetal Thyroid Hormones,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2013-12-15,2019-12-31,2020-01-31,300.0,Case-Control,,Prospective,Observational,Unknown status,,University of Belgrade,University of Belgrade,"Clinic for Gynecology and Obstetrics , Clinical Center of Serbia",,Serbia,20.0,45.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02017080
1399,NCT02018276,thyroid neoplasms,,Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery,Thyroid Cancer,2013-12-16,2014-10-31,2014-10-31,135.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain MedicineSeverance Hospital, Yonsei University Health System",Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02018276
1400,NCT02024906,hypothyroidism,Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants,Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants,Cardiovascular Disease|Subclinical Hypothyroid,2013-12-27,2015-09-30,2015-09-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Not Applicable,University of Kansas Medical Center,"Jill Hamilton-Reeves, PhD RD LD|Soy Nutrition Institute",University of Kansas Medical Center,Dietary Supplement|Dietary Supplement,United States,25.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02024906
1401,NCT02041260,thyroid neoplasms,A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,Differentiated Thyroid Cancer (DTC)|Poorly Differentiated Thyroid Cancer,2014-01-17,2022-05-31,2022-05-31,43.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Thomas Jefferson University,Thomas Jefferson University,Abramson Cancer Center of the University of Pennsylvania,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02041260
1404,NCT02054572,hyperparathyroidism,"An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis",Pharmacokinetics and Excretion of [C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis,Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis,2014-02-03,2014-04-15,2014-08-15,6.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Amgen,Amgen,DaVita Clinical Research Center,Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02054572
1405,NCT02055989,thyroid neoplasms,"A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx","A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx","Locally Advanced Larynx, Hypopharyngeal Squamous Cell Cancers|Locally Advanced Thyroid Cancers",2014-02-04,2011-12-31,,105.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Royal Marsden Hospital,Radiation|Radiation,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02055989
1407,NCT02056730,hyperparathyroidism,The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients,The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid,"Hyperparathyroidism, Secondary",2014-01-28,2015-02-28,2015-02-28,60.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Chulalongkorn University,Chulalongkorn University,Chulalongkorn Memorial Hospital,Drug,Thailand,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02056730
1409,NCT02059655,hyperthyroidism,Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial,Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study),Graves' Ophthalmopathy,2014-02-07,2016-03-31,2016-03-31,31.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Cardiff University,Cardiff University|National Institute for Social Care and Health Research,University Hospital of Wales,Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02059655
1410,NCT02059655,graves disease,Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial,Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study),Graves' Ophthalmopathy,2014-02-07,2016-03-31,2016-03-31,31.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Cardiff University,Cardiff University|National Institute for Social Care and Health Research,University Hospital of Wales,Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02059655
1411,NCT02059655,goiter,Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial,Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study),Graves' Ophthalmopathy,2014-02-07,2016-03-31,2016-03-31,31.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Cardiff University,Cardiff University|National Institute for Social Care and Health Research,University Hospital of Wales,Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02059655
1412,NCT02059655,graves ophthalmopathy,Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial,Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study),Graves' Ophthalmopathy,2014-02-07,2016-03-31,2016-03-31,31.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Cardiff University,Cardiff University|National Institute for Social Care and Health Research,University Hospital of Wales,Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02059655
1413,NCT02061111,hypothyroidism,NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease,NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease,Alteration of Mitochondrial Membrane|Autoimmune Thyroid Disease|Subclinical Hypothyroidism,2014-01-22,2017-12-31,2022-11-30,77.0,Cohort,,Prospective,Observational,Active not recruiting,,Naestved Hospital,Naestved Hospital|Region Zealand|University of Southern Denmark,Gynaecologic-Obstetrics Department Naestved Hospital,,Denmark,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02061111
1414,NCT02062632,thyroid neoplasms,"A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy",Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy,Esophageal Carcinoma|Hypopharyngeal Carcinoma|Laryngeal Carcinoma|Lymphoma|Mesothelioma|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Neoplasm in the Pleura|Metastatic Malignant Neoplasm in the Spinal Cord|Non-Small Cell Lung Carcinoma|Sarcoma|Small Cell Lung Carcinoma|Thymic Carcinoma|Thymoma|Thyroid Gland Carcinoma,2014-02-12,2015-05-29,2017-11-06,5.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Mayo Clinic,Mayo Clinic|National Cancer Institute (NCI),Mayo Clinic|University of Nebraska Medical Center|Green Bay Oncology Limited at Saint Mary's Hospital,Drug|Other|Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02062632
1415,NCT02070211,hypoparathyroidism,"Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome Genetically at High Risk for Psychosis: A Randomised, Double Blind, Placebo-controlled Treatment Trial.",Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.,22q11 Deletion Syndrome,2014-02-17,2016-06-30,2016-06-30,80.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Bambino Ges Hospital and Research Institute,Bambino Ges Hospital and Research Institute|National Alliance for Research on Schizophrenia and Depression|Orygen,Bambino Ges Hospital and Research Institute,Dietary Supplement|Other|Dietary Supplement,Holy See (Vatican City State),12.0,26.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02070211
1417,NCT02084732,thyroid neoplasms,Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,Thyroid Cancer,2014-03-07,2019-11-01,2019-11-01,35.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Instituto Nacional de Cancerologia, Columbia","Instituto Nacional de Cancerologia, Columbia",Instituto Nacional de Cancerologa,Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02084732
1418,NCT02088645,thyroid neoplasms,177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.,177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.,"Neuroendocrine Tumor GEP Grade 1-3|Neuroendocrine Tumor of the Lung Grade 1 and 2|Neuroendocrine Tumor of the Thymus Grade 1 and 2|Thyroid Cancer, Medullary",2014-02-19,2021-12-31,2022-03-31,24.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,"University Hospital, Basel, Switzerland","Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland|Krebsforschung Schweiz, Bern, Switzerland|University Hospital, Basel, Switzerland|University Hospital Freiburg|University Hospital, Zrich","University Hospital Basel, Clinic for radiology and nuclear medicine",Drug,Switzerland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02088645
1419,NCT02089542,hyperparathyroidism,Development of a Clinical Protocol to Use Intra-operative Near Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery,Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery,Bilateral Neck Exploration for Primary Hyperparathyroidism|Total Thyroidectomy,2014-03-13,2016-06-30,2016-10-31,41.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Sheffield Teaching Hospitals NHS Foundation Trust,Sheffield Teaching Hospitals NHS Foundation Trust,Department of General Surgery,Other,United Kingdom,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02089542
1422,NCT02090907,hypothyroidism,Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism,Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidism,2014-03-12,2014-02-28,2014-02-28,50.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Isfahan University of Medical Sciences,Isfahan University of Medical Sciences,Khorshid endocrinology clinic,Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02090907
1423,NCT02094079,hypothyroidism,Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women,Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women With Hypothyroidism,Hypothyroidism,2014-03-18,2015-03-31,2015-03-31,80.0,Cohort,,Retrospective,Observational,Completed,,Herlev Hospital,Birte Nygaard,"Endocrine Unit O, Herlev Hospital, University of Copenhagen",Other,Denmark,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02094079
1426,NCT02102204,hyperparathyroidism,A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis,Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis,"Hyperparathyroidism, Secondary",2014-03-03,2016-11-04,2017-06-26,902.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Latvia|Lithuania|Netherlands|New Zealand|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|Turkey|United States,18.0,110.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02102204
1427,NCT02107794,goiter,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Graves' Disease|Hyperthyroidism|Thyroid Disease,2014-03-24,2015-04-30,2015-04-30,93.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Other,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02107794
1428,NCT02107794,hyperthyroidism,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Graves' Disease|Hyperthyroidism|Thyroid Disease,2014-03-24,2015-04-30,2015-04-30,93.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Other,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02107794
1429,NCT02107794,graves disease,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Graves' Disease|Hyperthyroidism|Thyroid Disease,2014-03-24,2015-04-30,2015-04-30,93.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Other,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02107794
1430,NCT02109250,thyroid neoplasms,CAPRELSA REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa) in Current Clinical Practice,CAPRELSA REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa) in Current Clinical Practice,Metastatic Medullary Thyroid Cancer,2014-03-27,2015-06-30,2015-06-30,10.0,Case-Only,,Other,Observational [Patient Registry],Completed,,Sanofi,"Genzyme, a Sanofi Company",Clinique du Sud Luxembourg|AZ Klina|Institut Jules Bordet|UZ Brussel|UCL St-Luc|UZ Gent|AZ Delta|CH de Wallonie,Drug,Belgium,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02109250
1431,NCT02112370,thyroid neoplasms,Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy,Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy,Goiter|Thyroid Neoplasm,2014-04-07,2016-05-31,2016-06-30,148.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Seoul National University Hospital,Seoul National University Bundang Hospital|Seoul National University Hospital,Seoul National University Bundang Hospital|Seoul National University Hospital,Drug|Other,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02112370
1432,NCT02112643,graves ophthalmopathy,Selenium - ITEDS: A North American Study,Selenium in Mild Thyroid Eye Disease in North America,Thyroid Associated Ophthalmopathies,2014-04-08,2016-11-16,2016-11-16,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 3,Columbia University,Columbia University|International Thyroid Eye Disease Society,,Drug|Dietary Supplement,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02112643
1433,NCT02112643,hyperthyroidism,Selenium - ITEDS: A North American Study,Selenium in Mild Thyroid Eye Disease in North America,Thyroid Associated Ophthalmopathies,2014-04-08,2016-11-16,2016-11-16,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 3,Columbia University,Columbia University|International Thyroid Eye Disease Society,,Drug|Dietary Supplement,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02112643
1434,NCT02112643,goiter,Selenium - ITEDS: A North American Study,Selenium in Mild Thyroid Eye Disease in North America,Thyroid Associated Ophthalmopathies,2014-04-08,2016-11-16,2016-11-16,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 3,Columbia University,Columbia University|International Thyroid Eye Disease Society,,Drug|Dietary Supplement,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02112643
1435,NCT02112643,graves disease,Selenium - ITEDS: A North American Study,Selenium in Mild Thyroid Eye Disease in North America,Thyroid Associated Ophthalmopathies,2014-04-08,2016-11-16,2016-11-16,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 3,Columbia University,Columbia University|International Thyroid Eye Disease Society,,Drug|Dietary Supplement,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02112643
1436,NCT02114619,hyperthyroidism,The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease,Comparative Study of Different I-131 Doses in Graves' Disease,Graves' Disease,2014-04-12,2014-12-31,2016-12-31,450.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,"Nuclear Medicine Research Center, Ghaem Hospital",Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02114619
1437,NCT02114619,graves disease,The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease,Comparative Study of Different I-131 Doses in Graves' Disease,Graves' Disease,2014-04-12,2014-12-31,2016-12-31,450.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,"Nuclear Medicine Research Center, Ghaem Hospital",Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02114619
1438,NCT02114619,goiter,The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease,Comparative Study of Different I-131 Doses in Graves' Disease,Graves' Disease,2014-04-12,2014-12-31,2016-12-31,450.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,"Nuclear Medicine Research Center, Ghaem Hospital",Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02114619
1439,NCT02114658,thyroid neoplasms,"A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma",Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients,Thyroid Carcinoma,2014-04-08,2015-02-23,2016-08-02,18.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Bayer,Bayer,,Drug,Japan,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02114658
1442,NCT02126683,"thyroiditis, autoimmune",The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis,The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis,Hashimoto's Thyroiditis,2014-04-28,2016-02-29,2016-09-30,60.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,35.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02126683
1443,NCT02133040,hyperthyroidism,Identification and Regulation of Brown Adipose Tissue (BAT) in Humans. Implications for Energy Expenditure in Humans and in the Treatment of Obesity and Related Metabolic Diseases,Effects of Hyperthyroidism on Amount and Activity of Brown Adipose Tissue,Hyperthyroidism,2014-05-05,2018-05-10,2020-05-10,10.0,Case-Only,,Prospective,Observational,Unknown status,,Aarhus University Hospital,Aarhus University Hospital|Novo Nordisk A/S,Aarhus University Hospital,,Denmark,50.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02133040
1445,NCT02133404,hyperparathyroidism,"Phase II Study of ASP7991 -A Double-blind, Cinacalcet Hydrochloride-controlled, Dose-ascending Study in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis -",A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis,Secondary Hyperparathyroidism,2014-04-29,2014-11-10,2014-11-10,62.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Astellas Pharma Inc,Astellas Pharma Inc,,Drug|Drug|Drug,Japan,20.0,79.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02133404
1447,NCT02138214,"thyroid cancer, papillary",Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer,Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer,Stage III Papillary Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage I Papillary Thyroid Cancer,2014-05-12,2019-10-30,2020-10-26,117.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Wisconsin, Madison",University of Wisconsin,Procedure|Procedure|Other,United States,21.0,73.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02138214
1449,NCT02138838,hyperparathyroidism,"A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis",Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis,"Chronic Kidney Disease, Secondary Hyperparathyroidism",2014-04-01,2016-06-23,2016-06-23,55.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Dietary Supplement,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Lithuania|New Zealand|Poland|Portugal|Russian Federation|Slovakia|Spain|Ukraine|United States,6.0,17.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02138838
1452,NCT02140476,"thyroid cancer, papillary",Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial,Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy,Papillary Thyroid Cancer|Thyroid Goiter,2014-05-09,2015-05-31,2015-07-31,160.0,,Factorial Assignment,,Interventional,Unknown status,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Ethicon Endo-Surgery|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|University of Sao Paulo,"Hospital Das Clinicas, Universidad de Sao Paulo|Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn",Device|Procedure,Brazil|Mexico,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02140476
1454,NCT02140476,goiter,Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial,Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy,Papillary Thyroid Cancer|Thyroid Goiter,2014-05-09,2015-05-31,2015-07-31,160.0,,Factorial Assignment,,Interventional,Unknown status,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Ethicon Endo-Surgery|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|University of Sao Paulo,"Hospital Das Clinicas, Universidad de Sao Paulo|Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn",Device|Procedure,Brazil|Mexico,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02140476
1455,NCT02143271,hyperparathyroidism,A Single-dose Phase 1 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis,Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis,Secondary Hyperparathyroidism,2014-05-14,2014-12-31,2014-12-31,13.0,,Single Group Assignment,,Interventional,Completed,Phase 1,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",Kyowa Hakko Kirin,Drug,Japan,20.0,74.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02143271
1458,NCT02143726,thyroid neoplasms,Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer,"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer",Refractory Hurthle Cell Thyroid Cancer,2014-05-19,2021-01-28,2024-08-06,35.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Alliance for Clinical Trials in Oncology,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Novartis,Mayo Clinic in Florida|Northwestern University|Siouxland Regional Cancer Center|University of Michigan Comprehensive Cancer Center|Mayo Clinic|Nebraska Methodist Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Sleepy Hollow|Memorial Sloan Kettering Nassau|Southeastern Medical Oncology Center-Clinton|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Ohio State University Comprehensive Cancer Center|Fox Chase Cancer Center|Mercy Health System,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02143726
1459,NCT02145143,thyroid neoplasms,"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study","Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",Thyroid Carcinoma,2014-05-20,2023-05-31,2023-05-31,12.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,Memorial Sloan Kettering Cancer Center,"Genentech, Inc.|Memorial Sloan Kettering Cancer Center",Memorial Sloan Kettering Cancer Center,Drug|Device|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02145143
1460,NCT02147782,hyperparathyroidism,Continuous Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency in Different Stages,Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency,Chronic Renal Insufficiency|Renal Osteodystrophy,2014-05-13,2022-12-31,2022-12-31,300.0,Case-Control,,Prospective,Observational [Patient Registry],Recruiting,,Shanghai University of Traditional Chinese Medicine,Anhui Provincial Hospital|Huadong Hospital|Longhua Hospital|Shanghai University of Traditional Chinese Medicine,Anhui Province Hospital of TCM|Jiangsu Province Hospital of TCM|Longhua hospital affiliated to Shanghai University of TCM|Huadong Hospital Affiliated to Fudan University,,China,20.0,50.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02147782
1463,NCT02150772,thyroid neoplasms,Shear Wave Elastography in the Diagnosis and Risk-stratification of Thyroid Nodules - a Prospective Study,The Diagnostic Value of Shear Wave Elastography,Thyroid Nodule,2014-04-14,2016-03-31,2016-03-31,308.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,"re-Nse-Halsafdeling H, Aarhus University Hospital",Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02150772
1464,NCT02150772,thyroid nodule,Shear Wave Elastography in the Diagnosis and Risk-stratification of Thyroid Nodules - a Prospective Study,The Diagnostic Value of Shear Wave Elastography,Thyroid Nodule,2014-04-14,2016-03-31,2016-03-31,308.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,"re-Nse-Halsafdeling H, Aarhus University Hospital",Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02150772
1465,NCT02152137,"thyroid carcinoma, anaplastic","A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer",Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2014-05-29,2019-02-27,,19.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Alliance for Clinical Trials in Oncology,"Alliance for Clinical Trials in Oncology|Daiichi Sankyo, Inc.|National Cancer Institute (NCI)",Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Mayo Clinic Hospital|Mayo Clinic in Arizona|Providence Saint Joseph Medical Center/Disney Family Cancer Center|University of Colorado Hospital|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Regional Hematology and Oncology PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Nanticoke Memorial Hospital|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Hawaii Oncology Inc-Pali Momi|Pali Momi Medical Center|The Cancer Center of Hawaii-Pali Momi|Hawaii Cancer Care Inc-POB II|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Oncology Inc-Kuakini|Kuakini Medical Center|The Cancer Center of Hawaii-Liliha|Kapiolani Medical Center for Women and Children|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Mountain States Tumor Institute|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Medical Center|Walter Knox Memorial Hospital|Saint Luke's Mountain States Tumor Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Mountain States Tumor Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Mountain States Tumor Institute - Nampa|Kootenai Cancer Center|Kootenai Cancer Clinic|Saint Luke's Mountain States Tumor Institute-Twin Falls|Northwestern University|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Menorah Medical Center|Saint Luke's South Hospital|Cancer Center of Kansas - Parsons|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Cancer Center of Kansas - Wellington|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Cancer Center of Kansas - Wichita|Via Christi Regional Medical Center|Cancer Center of Kansas - Winfield|Mercy Medical Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Beaumont Hospital-Dearborn|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Lymphoma Clinic of Michigan|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Saint Mary's of Michigan|Oncology Hematology Associates of Saginaw Valley PC|Bhadresh Nayak MD PC-Sterling Heights|Saint Joseph Health System-Tawas City|Advanced Breast Care Center PLLC|Bhadresh Nayak MD PC-Warren|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Sanford Joe Lueken Cancer Center|Fairview Ridges Hospital|Mercy Hospital|Fairview-Southdale Hospital|Unity Hospital|Fairview Maple Grove Medical Center|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|New Ulm Medical Center|North Memorial Medical Health Center|Mayo Clinic|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Saint Francis Regional Medical Center|Lakeview Hospital|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|Central Care Cancer Center - Bolivar|Centerpoint Medical Center LLC|Freeman Health System|Saint Luke's Hospital of Kansas City|Heartland Hematology and Oncology Associates Incorporated|Research Medical Center|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|Delbert Day Cancer Institute at PCRMC|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital Saint Louis|Mercy Hospital Springfield|CoxHealth South Hospital|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Sanford Bismarck Medical Center|Roger Maris Cancer Center|Sanford Broadway Medical Center|University of Cincinnati/Barrett Cancer Center|Ohio State University Comprehensive Cancer Center|University Pointe|University of Oklahoma Health Sciences Center|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Oncology and Hematology Care Southeast|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Geisinger Medical Center|Pocono Medical Center|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|Geisinger Cancer Services-Pottsville|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|Geisinger Medical Group|Geisinger Wyoming Valley/Henry Cancer Center|Greenville Health System Cancer Institute-Easley|Greenville Health System Cancer Institute-Andrews|Greenville Health System Cancer Institute-Butternut|Greenville Health System Cancer Institute-Faris|Greenville Memorial Hospital|Greenville Health System Cancer Institute-Eastside|Greenville Health System Cancer Institute-Greer|Greenville Health System Cancer Institute-Seneca|Greenville Health System Cancer Institute-Spartanburg|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Providence Regional Cancer System-Centralia|Swedish Medical Center-Edmonds|Providence Regional Cancer Partnership|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|PeaceHealth Saint John Medical Center|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Rockwood Clinic Cancer Treatment Center-Valley|Rockwood Cancer Treatment Center-DHEC-Downtown|Evergreen Hematology and Oncology PS|Rockwood North Cancer Treatment Center|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Froedtert and the Medical College of Wisconsin|Cancer Center of Western Wisconsin|Billings Clinic-Cody|Welch Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02152137
1468,NCT02152228,hypoparathyroidism,A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism,A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism,Hypoparathyroidism,2014-04-22,2015-06-30,2015-07-31,20.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Entera Bio Ltd.,Entera Bio Ltd.,Lin Medical Center,Drug,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02152228
1469,NCT02152995,"adenocarcinoma, follicular","A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,34.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02152995
1470,NCT02152995,"thyroid cancer, papillary","A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,34.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02152995
1472,NCT02155049,hyperthyroidism,Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.,Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues,Thyroid Associated Ophthalmopathies,2014-05-21,2017-05-31,2017-05-31,10.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Rabin Medical Center,Rabin Medical Center,"Ophthalmology clinics, Rabin Medical Center",Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02155049
1473,NCT02155049,goiter,Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.,Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues,Thyroid Associated Ophthalmopathies,2014-05-21,2017-05-31,2017-05-31,10.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Rabin Medical Center,Rabin Medical Center,"Ophthalmology clinics, Rabin Medical Center",Drug,Israel,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02155049
1474,NCT02155049,graves disease,Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.,Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues,Thyroid Associated Ophthalmopathies,2014-05-21,2017-05-31,2017-05-31,10.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Rabin Medical Center,Rabin Medical Center,"Ophthalmology clinics, Rabin Medical Center",Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02155049
1475,NCT02155049,graves ophthalmopathy,Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.,Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues,Thyroid Associated Ophthalmopathies,2014-05-21,2017-05-31,2017-05-31,10.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Rabin Medical Center,Rabin Medical Center,"Ophthalmology clinics, Rabin Medical Center",Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02155049
1476,NCT02156362,thyroid neoplasms,Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis),Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis),Thyroid Cancer,2012-05-29,2023-05-31,2023-05-31,643.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon-Centre de Mdecine Nuclaire Groupement Hospitalier Est 59 boulevard Pinel,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02156362
1477,NCT02169687,thyroid neoplasms,"Pilot, Monocentric, Non-comparative Study of the Effectiveness and Safety of High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules",High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules,Autonomous Hyperfunctioning Thyroid Nodules,2014-05-05,2007-10-31,2007-10-31,2.0,,Single Group Assignment,,Interventional,Terminated,Early Phase 1,Theraclion,Groupe Hospitalier Pitie-Salpetriere|Hpital Saint Louis Paris|Theraclion,Hpital Piti Salpetrire,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02169687
1478,NCT02169687,thyroid nodule,"Pilot, Monocentric, Non-comparative Study of the Effectiveness and Safety of High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules",High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules,Autonomous Hyperfunctioning Thyroid Nodules,2014-05-05,2007-10-31,2007-10-31,2.0,,Single Group Assignment,,Interventional,Terminated,Early Phase 1,Theraclion,Groupe Hospitalier Pitie-Salpetriere|Hpital Saint Louis Paris|Theraclion,Hpital Piti Salpetrire,Device,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02169687
1480,NCT02178345,"thyroid cancer, papillary",Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer,Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer,Papillary Thyroid Cancer,2014-06-25,2021-12-03,2021-12-03,123.0,Cohort,,Prospective,Observational,Completed,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02178345
1481,NCT02185560,thyroid neoplasms,Drug Use Investigation of Sorafenib/ NEXAVAR for Unresectable Differentiated Thyroid Carcinoma (DTC),"Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib",Thyroid Carcinoma,2014-07-04,2020-02-27,2024-06-30,453.0,Cohort,,Other,Observational,Active not recruiting,,Bayer,Bayer,,Drug,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02185560
1482,NCT02186405,hypothyroidism,Effects of Levothyroxine Treatment on Hemodynamic and Isotopic Renal Functions in Subclinical Hypothyroidism,Effects of Levothyroxine Treatment on Hemodynamic and Renal Functions in Subclinical Hypothyroidism,Subclinical hypothyrodism,2014-07-08,2016-10-31,2017-06-30,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 4,Centre Hospitalier Universitaire de Nice,Centre Hospitalier Universitaire de Nice,Nephrology Department,Drug,France,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02186405
1484,NCT02190214,goiter,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,2498.0,Ecologic or Community,,Cross-Sectional,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02190214
1486,NCT02190214,graves disease,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,2498.0,Ecologic or Community,,Cross-Sectional,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02190214
1487,NCT02190214,hashimoto disease,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,2498.0,Ecologic or Community,,Cross-Sectional,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02190214
1488,NCT02190214,hypothyroidism,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,2498.0,Ecologic or Community,,Cross-Sectional,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02190214
1489,NCT02190214,hyperthyroidism,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,2498.0,Ecologic or Community,,Cross-Sectional,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02190214
1490,NCT02194920,graves disease,Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,2014-07-03,2014-10-31,2014-11-30,20.0,Cohort,,Prospective,Observational,Completed,,University of Roma La Sapienza,University of Roma La Sapienza,"General Surgery Unit, ICOT Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02194920
1491,NCT02194920,goiter,Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,2014-07-03,2014-10-31,2014-11-30,20.0,Cohort,,Prospective,Observational,Completed,,University of Roma La Sapienza,University of Roma La Sapienza,"General Surgery Unit, ICOT Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02194920
1492,NCT02194920,hyperthyroidism,Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,2014-07-03,2014-10-31,2014-11-30,20.0,Cohort,,Prospective,Observational,Completed,,University of Roma La Sapienza,University of Roma La Sapienza,"General Surgery Unit, ICOT Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02194920
1493,NCT02194920,thyroid neoplasms,Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,2014-07-03,2014-10-31,2014-11-30,20.0,Cohort,,Prospective,Observational,Completed,,University of Roma La Sapienza,University of Roma La Sapienza,"General Surgery Unit, ICOT Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02194920
1494,NCT02203682,goiter,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,100.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02203682
1495,NCT02203682,graves disease,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,100.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02203682
1496,NCT02203682,graves ophthalmopathy,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,100.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02203682
1497,NCT02203682,hyperthyroidism,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,100.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02203682
1499,NCT02205801,hyperparathyroidism,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,36.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02205801
1500,NCT02205801,graves disease,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,36.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02205801
1501,NCT02205801,thyroid neoplasms,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,36.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02205801
1502,NCT02205801,thyroid nodule,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,36.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02205801
1503,NCT02205801,hyperthyroidism,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,36.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02205801
1504,NCT02205801,goiter,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,36.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02205801
1506,NCT02208544,thyroid neoplasms,Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study,FDG-PET/CT in Evaluation of Cytological Indeterminate Thyroid Nodules to Prevent Unnecessary Surgery (EfFECTS),Thyroid Neoplasms|Thyroid Nodule,2014-07-22,2020-01-01,2022-02-15,132.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Radboudumc|MUMC|AMC|VUmc|MeanderMC|LUMC|ErasmusMC|Onze Lieve Vrouwe Gasthuis|Rijnstate|Reinier de Graaf Ziekenhuis|UMCG|St. Antonius|HagaZiekenhuis|UMCU|Isala Klinieken,Procedure|Device|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02208544
1507,NCT02208544,thyroid nodule,Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study,FDG-PET/CT in Evaluation of Cytological Indeterminate Thyroid Nodules to Prevent Unnecessary Surgery (EfFECTS),Thyroid Neoplasms|Thyroid Nodule,2014-07-22,2020-01-01,2022-02-15,132.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Radboudumc|MUMC|AMC|VUmc|MeanderMC|LUMC|ErasmusMC|Onze Lieve Vrouwe Gasthuis|Rijnstate|Reinier de Graaf Ziekenhuis|UMCG|St. Antonius|HagaZiekenhuis|UMCU|Isala Klinieken,Procedure|Device|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02208544
1508,NCT02210741,graves disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,200.0,Case-Only,,Prospective,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02210741
1509,NCT02210741,hyperthyroidism,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,200.0,Case-Only,,Prospective,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02210741
1510,NCT02210741,goiter,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,200.0,Case-Only,,Prospective,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02210741
1512,NCT02216656,hyperparathyroidism,"A Randomized, Double-blind, Parallel-group, Dose-finding Study of KHK7580 for Secondary Hyperparathyroidism Patients Receiving Hemodialysis",Phase 2 Study of KHK7580,Secondary Hyperparathyroidism,2014-08-11,2015-02-28,2015-02-28,201.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug|Drug|Drug|Drug|Drug,Japan,20.0,74.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02216656
1514,NCT02223052,thyroid neoplasms,"A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects",Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies,Acute Myeloid Leukemia|Breast Cancer|Genitourinary|Glioblastoma Multiforme|Hematological Neoplasms|Hodgkin's Lymphoma|Leukemia|Lymphoma|Melanoma|Metastatic Breast Cancer|Multiple Myeloma|Myelodysplastic Syndromes|Neoplasms|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer|Osteosarcoma|Renal Cell Carcinoma|Sarcoma|Small Cell Lung Cancer|Thyroid Cancer,2014-08-20,2018-06-11,2018-12-18,89.0,,Parallel Assignment,,Interventional,Completed,Phase 1,Celgene,Celgene,Scottsdale Healthcare Research Institute|Mayo Clinic - Arizona|University of Arizona Cancer Center|University of Iowa|Henry Ford Health System|Cancer Institute of New Jersey|Cleveland Clinic Foundation|Greenville Hospital System|Vanderbilt- Ingram Cancer Center|The Methodist Hospital Research Institute l,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02223052
1515,NCT02225509,thyroid nodule,Clinical Validation of the Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule With Indeterminate Cytological Analysis,Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology,Thyroid Cancer|Thyroid Nodule,2014-08-19,2016-12-31,,1000.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Diaxonhit,Diaxonhit,,Procedure,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02225509
1516,NCT02225509,thyroid neoplasms,Clinical Validation of the Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule With Indeterminate Cytological Analysis,Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology,Thyroid Cancer|Thyroid Nodule,2014-08-19,2016-12-31,,1000.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Diaxonhit,Diaxonhit,,Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02225509
1517,NCT02227264,hyperparathyroidism,Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?,Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?,Primary Hyperparathyroidism,2014-08-17,2021-12-31,2021-12-31,123.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Karolinska University Hospital,Karolinska Institutet|Karolinska University Hospital,Karolinska University Hospital,Drug|Procedure,Sweden,40.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02227264
1522,NCT02240563,"thyroiditis, autoimmune",Long-term Follow-up After Treatment of Chronic Autoimmune Thyroiditis With Low Level Laser,Low Level Laser Therapy for Autoimmune Thyroiditis,Autoimmune Thyroiditis,2014-06-23,2016-03-31,2016-03-31,43.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo General Hospital,"University of Sao Paulo General Hospital, Radiology Institute|University of Sao Paulo General Hospital",Procedure|Procedure,Brazil,20.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02240563
1523,NCT02244463,"thyroid carcinoma, anaplastic",A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Thyroid Cancer,2014-09-17,2022-12-31,2023-12-31,46.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Dana-Farber Cancer Institute,"Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.",Hoag Memorial Hospital Presbyterian|Dana-Farber Cancer Institute|University of Michigan Medical School,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02244463
1525,NCT02246504,thyroid neoplasms,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Non-malignant Thyroid Nodule,2014-09-16,2017-03-07,2017-03-07,20.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,"Clinic of thyroid and metabolite bone disease of the Acad. of Ivan Penchev UDHATE - 2, Zdrave street",Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02246504
1526,NCT02246504,thyroid nodule,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Non-malignant Thyroid Nodule,2014-09-16,2017-03-07,2017-03-07,20.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,"Clinic of thyroid and metabolite bone disease of the Acad. of Ivan Penchev UDHATE - 2, Zdrave street",Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02246504
1527,NCT02258347,thyroid nodule,Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,HIFU in Patients With Non-malignant Thyroid Nodules,Non-malignant Thyroid Nodules,2014-09-26,2015-10-13,2015-10-13,4.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,Istituto in tecnologie avanzate e modelli assistenziali in oncologia,Device,Italy,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02258347
1528,NCT02258347,thyroid neoplasms,Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,HIFU in Patients With Non-malignant Thyroid Nodules,Non-malignant Thyroid Nodules,2014-09-26,2015-10-13,2015-10-13,4.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,Istituto in tecnologie avanzate e modelli assistenziali in oncologia,Device,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02258347
1529,NCT02268734,thyroid neoplasms,Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer (sMTC) Patients and Possible Correlation With Vandetanib Therapy,Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib,Metastatic Sporadic Medullary Thyroid Cancer,2014-09-04,2017-12-31,2018-12-31,36.0,Case-Only,,Retrospective,Observational,Completed,,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02268734
1530,NCT02273570,hyperparathyroidism,"Single-center, Open-label, Randomized Study of Anemia Management Improvement in End Stage Renal Disease (ESRD) Patients With Secondary Hyperparathyroidism",Optimal Anemia Treatment in End Stage Renal Disease (ERSD),"Hyperparathyroidism, Secondary",2014-06-27,2016-12-31,2017-03-31,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Azienda Ospedaliera Sant'Anna,Amgen|Azienda Ospedaliera Sant'Anna,Azienda Ospedaliera Sant'Anna,Drug|Drug,Italy,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02273570
1534,NCT02274623,hyperparathyroidism,"Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid",Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid,"Bone Neoplasms|Breast Cancer|Hyperparathyroidism, Secondary|Hypocalcemia|Prostate Cancer",2014-10-22,2017-02-27,2017-03-17,33.0,,Single Group Assignment,,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO Health, Inc.","Coast Hematology-Oncology Associates|Mount Sinai Medical Center, Comprehensive Cancer Center|Research by Design LLC|Roswell Park Cancer Institute|University of Cincinnati Cancer Institute|Inova Dwight and Martha Schar Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02274623
1536,NCT02278198,thyroid neoplasms,Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123,Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123,Differentiated Thyroid Cancer,2014-10-27,2019-09-20,2019-09-20,5.0,,Single Group Assignment,,Interventional,Completed,Phase 1,"University of Colorado, Denver","University of Colorado, Denver",Fawn N White,Drug,United States,21.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02278198
1537,NCT02280330,hypothyroidism,Iodine Intake & Status of Preschoolers Given Micronutrient Powder for 6 Months,Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months,Hypothyroidism|Iodine Deficiency|Iodine Deficiency Disorder,2014-10-27,2015-03-31,2015-03-31,396.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Nutrition Center of the Philippines,Nutrition Center of the Philippines,La Trinidad Benguet Day Care Centers,Dietary Supplement|Other,Philippines,4.0,6.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02280330
1538,NCT02282813,hyperparathyroidism,"A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)",Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",2014-10-31,2015-05-31,2015-05-31,298.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"OPKO Health, Inc.","OPKO Health, Inc.",,Drug|Drug|Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02282813
1541,NCT02289144,"thyroid carcinoma, anaplastic",Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer,"Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer|Metastatic Anaplastic Thyroid Cancer",2014-10-06,2019-01-31,2019-01-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 2,University of Texas Southwestern Medical Center,Novartis|University of Texas Southwestern Medical Center,UT Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02289144
1543,NCT02290704,graves ophthalmopathy,Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People,Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People,Graves' Ophthalmopathy,2014-11-03,2017-11-30,2017-11-30,200.0,Other,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02290704
1544,NCT02290704,goiter,Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People,Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People,Graves' Ophthalmopathy,2014-11-03,2017-11-30,2017-11-30,200.0,Other,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,,China,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02290704
1545,NCT02290704,hyperthyroidism,Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People,Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People,Graves' Ophthalmopathy,2014-11-03,2017-11-30,2017-11-30,200.0,Other,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02290704
1546,NCT02290704,graves disease,Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People,Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People,Graves' Ophthalmopathy,2014-11-03,2017-11-30,2017-11-30,200.0,Other,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02290704
1547,NCT02301520,hypothyroidism,"Vitamin D Deficiency, Iodine Deficiency and Lead Levels in Haitian Infants and Children.","Vitamin D, Iodine, and Lead Levels in Haitian Infants and Children.",Hypothyroidism|Iodine Deficiency|Lead Intoxication|Rickets|Vitamin D Deficiency,2014-11-23,2015-06-30,2015-06-30,299.0,Ecologic or Community,,Cross-Sectional,Observational,Completed,,Boston Children's Hospital,"Boston Children's Hospital|Fondation Haitienne de Diabete et de Maladies Cardiovasculaires (FHADIMAC)|Kay Mackenson Clinic, Inc.",Kay Mackenson Clinic|FHADIMAC,,Haiti,9.0,6.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02301520
1549,NCT02302768,thyroiditis,Effect of Supplementation of Two Doses of L-selenomethionine (Semet; 80 and 160 mcg) Versus Placebo in Patients With Chronic Autoimmune Thyroiditis (AIT) With Normal Thyroid Function.,Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT,Thyroiditis Autoimmune,2014-11-20,2014-01-31,2015-01-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2,University of Siena,IBSA Institut Biochimique SA|University of Siena,,Dietary Supplement|Other,,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02302768
1550,NCT02303444,thyroid neoplasms,RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors,An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors,Thyroid Neoplasms,2014-11-25,2020-06-10,2020-07-24,667.0,Cohort,,Prospective,Observational,Completed,,Bayer,Bayer,,Drug|Drug,Algeria|Argentina|Brazil|Egypt|France|Germany|Greece|India|Japan|Lebanon|Mexico|Netherlands|Philippines|Russian Federation|Saudi Arabia|Spain|Taiwan|Turkey|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02303444
1551,NCT02304757,thyroid neoplasms,Prospective Trial of 99Tc-MDP and Fosamax in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis Treated With Supraphysiological Doses of Thyroid Hormone,99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis,Differentiated Thyroid Cancer|Osteoporosis,2014-11-24,2019-12-30,2019-12-30,142.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Nuclear Medicine Xinhua Hospital,Drug|Drug,China,45.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02304757
1553,NCT02307175,congenital hypothyroidism,A Phase I Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron (CYCLOTEC) in Patients With Thyroid Scan Indication,A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication,Autoimmune Thyroid Disease|Congenital Hypothyroidism,2014-09-24,2016-08-31,2016-10-31,30.0,Case-Control,,Prospective,Observational,Completed,,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Centre hospitalier universitaire de Sherbrooke,,Canada,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02307175
1554,NCT02316691,goiter,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,Thyroid Eye Disease,2014-12-08,2019-11-30,2019-11-30,2.0,Cohort,,Prospective,Observational,Terminated,,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh,,United States,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02316691
1555,NCT02316691,hyperthyroidism,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,Thyroid Eye Disease,2014-12-08,2019-11-30,2019-11-30,2.0,Cohort,,Prospective,Observational,Terminated,,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh,,United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02316691
1556,NCT02316691,graves ophthalmopathy,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,Thyroid Eye Disease,2014-12-08,2019-11-30,2019-11-30,2.0,Cohort,,Prospective,Observational,Terminated,,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh,,United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02316691
1557,NCT02316691,graves disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,Thyroid Eye Disease,2014-12-08,2019-11-30,2019-11-30,2.0,Cohort,,Prospective,Observational,Terminated,,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh,,United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02316691
1558,NCT02316743,hypothyroidism,Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism,Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism,Sub-clinical Hypothyroidism|Systolic Heart Failure,2013-05-10,2015-06-30,2015-07-31,40.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,Universit de Sherbrooke,Universit de Sherbrooke,Centre Hospitalier Universitaire de Sherbrooke,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02316743
1559,NCT02317926,hypothyroidism,,Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism,Hypothyroidism,2014-12-08,2018-05-31,,81.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,Walter Reed National Military Medical Center,Walter Reed National Military Medical Center,Walter Reed National Military Medical Center,Drug|Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02317926
1562,NCT02318160,"thyroiditis, autoimmune",Oxidative Status in Children and Adolescents With Autoimmune Thyroiditis: A Tertiary Center Study From Upper Egypt,Oxidative Status in Children With Autoimmune Thyroiditis,Autoimmune Thyroiditis,2014-12-11,2014-03-31,2014-03-31,64.0,Case-Control,,Prospective,Observational [Patient Registry],Completed,,Assiut University,Assiut University,,Other,,6.0,18.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02318160
1565,NCT02319538,thyroiditis,Surgical Treatment of Hashimotos Disease. Effect on Antibodies and Clinical Symptoms.,Hashimoto - a Surgical Disease. Total Thyroidectomy Makes Antibodies Disappear and Ameliorates Symptoms,Hashimoto's Disease,2014-12-15,2017-07-15,2017-07-15,150.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Sykehuset Telemark,Haukeland University Hospital|Helse Stavanger HF|Sykehuset Telemark,"Telemark Hospital Trust, surgical department",Procedure,Norway,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02319538
1567,NCT02323724,"thyroid cancer, papillary",APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.,APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.,Papillary Thyroid Carcinoma,2014-12-18,2015-07-31,2015-07-31,25.0,Case-Only,,Retrospective,Observational,Completed,,Corporacion Parc Tauli,Corporacion Parc Tauli,Corporaci Sanitria Parc Taul,Genetic,Spain,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02323724
1568,NCT02329379,goiter,Therapeutic Role of Levothyroxine on the Patients With Atypia of Undetermined Significance (AUS) Goiter,The Role of Levothyroxine on Goiter With Atypia of Undetermined Significance,Goiter,2014-12-29,2015-12-31,2015-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,"National Defense Medical Center, Taiwan",Sheng-Chiang Su,,Drug,,20.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02329379
1570,NCT02332135,hyperparathyroidism,The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis,The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis,Maintenance Hemodialysis|Secondary Hyperparathyroidism,2015-01-04,2017-03-31,2018-03-31,30.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Beijing Friendship Hospital,Wenhu Liu,Beijing Friedship Hospital,Procedure|Drug,China,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02332135
1573,NCT02338934,hyperparathyroidism,An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients,Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients,Secondary Hyperparathyroidism,2015-01-11,2017-01-31,2017-01-31,30.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,"Penang Hospital, Malaysia","Ministry of Health, Malaysia|Penang Hospital, Malaysia","Clinical Research Centre, Penang Hospital|Penang Hospital",Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02338934
1575,NCT02339142,goiter,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Graves Ophthalmopathy,2015-01-12,2018-12-31,2019-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,University of British Columbia,University of British Columbia,,Radiation|Drug,,35.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02339142
1576,NCT02339142,hyperthyroidism,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Graves Ophthalmopathy,2015-01-12,2018-12-31,2019-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,University of British Columbia,University of British Columbia,,Radiation|Drug,,35.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02339142
1577,NCT02339142,graves disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Graves Ophthalmopathy,2015-01-12,2018-12-31,2019-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,University of British Columbia,University of British Columbia,,Radiation|Drug,,35.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02339142
1578,NCT02339142,graves ophthalmopathy,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Graves Ophthalmopathy,2015-01-12,2018-12-31,2019-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,University of British Columbia,University of British Columbia,,Radiation|Drug,,35.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02339142
1580,NCT02341417,hyperparathyroidism,A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis,Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis,"Secondary Hyperparathyroidism, Chronic Kidney Disease",2014-12-02,2017-03-15,2017-03-15,28.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Poland|Russian Federation|Ukraine|United States,0.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02341417
1582,NCT02347683,thyroid neoplasms,Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy,Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy,Thyroid Cancer,2015-01-21,2016-02-29,2016-02-29,50.0,Cohort,,Prospective,Observational,Completed,,University of Nebraska,University of Nebraska,University of Nebraska Medical Center,,United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02347683
1583,NCT02352766,thyroid neoplasms,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Thyroid Nodule,2015-01-28,2019-02-15,2019-02-15,256.0,Case-Only,,Cross-Sectional,Observational,Completed,,University of Pittsburgh,"Duke University|Johns Hopkins University|Medstar Health Research Institute|Ohio State University|University of Cincinnati|University of Colorado, Denver|University of Pennsylvania|University of Pittsburgh|University of Wisconsin, Madison",University of Pittsburgh,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02352766
1584,NCT02352766,thyroid nodule,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Thyroid Nodule,2015-01-28,2019-02-15,2019-02-15,256.0,Case-Only,,Cross-Sectional,Observational,Completed,,University of Pittsburgh,"Duke University|Johns Hopkins University|Medstar Health Research Institute|Ohio State University|University of Cincinnati|University of Colorado, Denver|University of Pennsylvania|University of Pittsburgh|University of Wisconsin, Madison",University of Pittsburgh,,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02352766
1585,NCT02363647,thyroid neoplasms,Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer,Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer,Colon Cancer|Medullary Thyroid Cancer,2015-02-03,2021-06-30,2021-06-30,10.0,,Single Group Assignment,,Interventional,Suspended,Not Applicable,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02363647
1586,NCT02364102,hypothyroidism,Effect of Restoration of Euthyroidism in Patients With Primary Hypothyroidism on Brown Adipose Tissue Thermogenesis - the ThyroBAT Study,Effect of Hypothyroidism on Brown Adipose Tissue,Hypothyroidism,2015-02-09,2017-08-31,2017-08-31,42.0,Cohort,,Prospective,Observational,Completed,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",,Switzerland,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02364102
1587,NCT02373995,graves disease,Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy,Role of the Microbiome in Graves' Orbitopathy,Graves' Disease,2015-01-29,2015-07-31,2016-12-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 1/Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Cultech Ltd, Port Talbot, UK|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy|School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK|Universitt Duisburg-Essen",Fondazione Ca' Granda Ospedale Maggiore Policlinico,Biological,Italy,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02373995
1588,NCT02373995,graves ophthalmopathy,Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy,Role of the Microbiome in Graves' Orbitopathy,Graves' Disease,2015-01-29,2015-07-31,2016-12-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 1/Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Cultech Ltd, Port Talbot, UK|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy|School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK|Universitt Duisburg-Essen",Fondazione Ca' Granda Ospedale Maggiore Policlinico,Biological,Italy,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02373995
1589,NCT02373995,goiter,Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy,Role of the Microbiome in Graves' Orbitopathy,Graves' Disease,2015-01-29,2015-07-31,2016-12-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 1/Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Cultech Ltd, Port Talbot, UK|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy|School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK|Universitt Duisburg-Essen",Fondazione Ca' Granda Ospedale Maggiore Policlinico,Biological,Italy,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02373995
1590,NCT02373995,hyperthyroidism,Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy,Role of the Microbiome in Graves' Orbitopathy,Graves' Disease,2015-01-29,2015-07-31,2016-12-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 1/Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Cultech Ltd, Port Talbot, UK|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy|School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK|Universitt Duisburg-Essen",Fondazione Ca' Granda Ospedale Maggiore Policlinico,Biological,Italy,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02373995
1592,NCT02374593,congenital hypothyroidism,Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism,Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism,Congenital Hypothyroidism,2015-02-18,2016-05-31,2016-05-31,24.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Indiana University,Erica Eugster,Riley Hospital for Children,Drug|Device,United States,0.0,2.0,[0-17],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02374593
1593,NCT02375451,hyperthyroidism,Effect of Childhood Radioiodine Therapy on Salivary Function,Effect of Childhood Radioiodine Therapy on Salivary Function,Hyperthyroidism|Thyroid Cancer|Xerostomia,2014-10-03,2016-09-30,2016-09-30,70.0,Cohort,,Cross-Sectional,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Boston Children's Hospital,Other,United States,3.0,55.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02375451
1594,NCT02375451,thyroid neoplasms,Effect of Childhood Radioiodine Therapy on Salivary Function,Effect of Childhood Radioiodine Therapy on Salivary Function,Hyperthyroidism|Thyroid Cancer|Xerostomia,2014-10-03,2016-09-30,2016-09-30,70.0,Cohort,,Cross-Sectional,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Boston Children's Hospital,Other,United States,3.0,55.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02375451
1595,NCT02376088,graves disease,Characteristics of Islet -cell Functions in Chinese Patients With Graves' Disease,Characteristics of Islet -cell Functions in Chinese Patients With Graves' Disease,Graves Disease,2015-02-18,2014-06-30,2014-06-30,328.0,Cohort,,Prospective,Observational,Completed,,Qilu Hospital of Shandong University,Weikai Hou,,Drug,,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02376088
1596,NCT02376088,hyperthyroidism,Characteristics of Islet -cell Functions in Chinese Patients With Graves' Disease,Characteristics of Islet -cell Functions in Chinese Patients With Graves' Disease,Graves Disease,2015-02-18,2014-06-30,2014-06-30,328.0,Cohort,,Prospective,Observational,Completed,,Qilu Hospital of Shandong University,Weikai Hou,,Drug,,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02376088
1597,NCT02376088,goiter,Characteristics of Islet -cell Functions in Chinese Patients With Graves' Disease,Characteristics of Islet -cell Functions in Chinese Patients With Graves' Disease,Graves Disease,2015-02-18,2014-06-30,2014-06-30,328.0,Cohort,,Prospective,Observational,Completed,,Qilu Hospital of Shandong University,Weikai Hou,,Drug,,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02376088
1598,NCT02378298,graves ophthalmopathy,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,Rituximab (RTX) Therapy in Patients With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,26.0,,Factorial Assignment,,Interventional,Active not recruiting,Phase 4,Gteborg University,"Gteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mlndal|Department of Rheumatology, Sahlgrenska University Hospital/Mlndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02378298
1599,NCT02378298,goiter,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,Rituximab (RTX) Therapy in Patients With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,26.0,,Factorial Assignment,,Interventional,Active not recruiting,Phase 4,Gteborg University,"Gteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mlndal|Department of Rheumatology, Sahlgrenska University Hospital/Mlndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02378298
1600,NCT02378298,hyperthyroidism,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,Rituximab (RTX) Therapy in Patients With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,26.0,,Factorial Assignment,,Interventional,Active not recruiting,Phase 4,Gteborg University,"Gteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mlndal|Department of Rheumatology, Sahlgrenska University Hospital/Mlndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02378298
1601,NCT02378298,graves disease,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,Rituximab (RTX) Therapy in Patients With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,26.0,,Factorial Assignment,,Interventional,Active not recruiting,Phase 4,Gteborg University,"Gteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mlndal|Department of Rheumatology, Sahlgrenska University Hospital/Mlndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02378298
1602,NCT02381457,hypoparathyroidism,SNP-based Microdeletion and Aneuploidy RegisTry,SNP-based Microdeletion and Aneuploidy RegisTry (SMART),1p36 Deletion Syndrome|22q11 Deletion Syndrome|Angelman Syndrome|Cri-du-Chat Syndrome|DiGeorge Syndrome|Monosomy X|Prader-Willi Syndrome|Sex Chromosome Abnormalities|Trisomy 13|Trisomy 18|Trisomy 21,2015-03-02,2020-06-30,2020-06-30,20960.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,"Natera, Inc.","Children's Hospital of Philadelphia|George Washington University|Montefiore Medical Center|Natera, Inc.|University of California, San Francisco","University of California, San Francisco|Cooper University Hospital|Virtua|St. Peter's University|Complete Women's Healthcare|North Shore University Hospital|Madonna Perinatal|Long Island Jewish Medical Center|New York University|Icahn School of Medicine Mt Sinai|Columbia University|Montefiore Medical Center|Suffolk OB|North Austin Maternal Fetal Medicine|Zeid Women's Health Center|University of Utah|Royal Prince Alfred|Royal College Surgeons in Ireland|Dexeus|Sahlgrenska University Hospital|St. George University Hospital",,Australia|Ireland|Spain|Sweden|United Kingdom|United States,18.0,48.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02381457
1604,NCT02381925,parathyroid neoplasms,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Parathyroid Adenoma,2015-03-03,2016-06-30,2016-12-31,0.0,Cohort,,Prospective,Observational [Patient Registry],Withdrawn,,Duke University,"Duke University|University of Arkansas|University of California, Los Angeles",,,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02381925
1607,NCT02381925,hyperparathyroidism,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Parathyroid Adenoma,2015-03-03,2016-06-30,2016-12-31,0.0,Cohort,,Prospective,Observational [Patient Registry],Withdrawn,,Duke University,"Duke University|University of Arkansas|University of California, Los Angeles",,,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02381925
1608,NCT02383927,thyroid neoplasms,An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations,Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations,HRAS Mutant Tumor|Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor|Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)|Thyroid Cancer,2015-02-20,2020-11-30,2020-11-30,63.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Kura Oncology, Inc.","Kura Oncology, Inc.","University of California, Los Angeles|Wihship Cancer Institute of Emory University|Dana-Farber Cancer Institute|University of Michigan Comprehensive Cancer Center|Mayo Clinic|Memorial Sloan-Kettering Cancer Center|Oklahoma University Health Sciences Center|Fox Chase Cancer Center|The University of Texas MD Anderson Cancer Center|University Hospital Antwerp|Cliniques universitaires Saint-Luc|CHU|Insitut Bergonie|Centre Lon Brard|Centre Antoine Lacassagne|Institute Gustave Roussy (IGR)|University Hospital Wuerazburg|Attikon University Hospital|Instituto Nazionale Tumori|Asan Medical Center|Samsung Medical Center|University Medical Center|Hospital Vall d' Hebron|Hospital Clinic de Barcelona|Hospital del Mar|Hospital Universitario Doce de Octubre|Hospital Universitario La Paz|MD Anderson Cancer Center Madrid|START, Centro Integral Oncologico Clara Campal|Hospital Universitario Virgen de la Victoria|Complejo Hospitalario de Navarro|Hospital Universitario Virgen de la Rocio|Hospital Universitario y Politcnico La Fe|Royal Marsden|University College Hospital",Drug,"Belgium|France|Germany|Greece|Italy|Korea, Republic of|Netherlands|Spain|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02383927
1609,NCT02384668,hyperthyroidism,"The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial.",D-vitamin And Graves' Disease; Morbidity And Relapse Reduction,Graves' Disease,2015-01-09,2021-01-31,2021-01-31,260.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Aarhus,"Aarhus University Hospital|Herning Hospital|Randers Regional Hospital|Regional Hospital Holstebro|Regionshospitalet Horsens|Regionshospitalet Silkeborg|Regionshospitalet Viborg, Skive|University of Aarhus","Department of Endocrinology and Internal Medicine, Aarhus University Hospital|Gentofte Hospital|Department of Internal Medicine, Regionshospitalet Herning|Department of Internal Medicine, Regionshospitalet Holstebro|Department of Internal Medicine, Regionshospitalet Horsens|Department of Internal Medicine, Regionhospitalet Randers|Department of Internal Medicine, Diagnostisk Center, Regionshospitalet Silkeborg|Department of Internal Medicine, Regionshospitalet Viborg",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02384668
1610,NCT02384668,graves disease,"The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial.",D-vitamin And Graves' Disease; Morbidity And Relapse Reduction,Graves' Disease,2015-01-09,2021-01-31,2021-01-31,260.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Aarhus,"Aarhus University Hospital|Herning Hospital|Randers Regional Hospital|Regional Hospital Holstebro|Regionshospitalet Horsens|Regionshospitalet Silkeborg|Regionshospitalet Viborg, Skive|University of Aarhus","Department of Endocrinology and Internal Medicine, Aarhus University Hospital|Gentofte Hospital|Department of Internal Medicine, Regionshospitalet Herning|Department of Internal Medicine, Regionshospitalet Holstebro|Department of Internal Medicine, Regionshospitalet Horsens|Department of Internal Medicine, Regionhospitalet Randers|Department of Internal Medicine, Diagnostisk Center, Regionshospitalet Silkeborg|Department of Internal Medicine, Regionshospitalet Viborg",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02384668
1611,NCT02384668,goiter,"The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial.",D-vitamin And Graves' Disease; Morbidity And Relapse Reduction,Graves' Disease,2015-01-09,2021-01-31,2021-01-31,260.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Aarhus,"Aarhus University Hospital|Herning Hospital|Randers Regional Hospital|Regional Hospital Holstebro|Regionshospitalet Horsens|Regionshospitalet Silkeborg|Regionshospitalet Viborg, Skive|University of Aarhus","Department of Endocrinology and Internal Medicine, Aarhus University Hospital|Gentofte Hospital|Department of Internal Medicine, Regionshospitalet Herning|Department of Internal Medicine, Regionshospitalet Holstebro|Department of Internal Medicine, Regionshospitalet Horsens|Department of Internal Medicine, Regionhospitalet Randers|Department of Internal Medicine, Diagnostisk Center, Regionshospitalet Silkeborg|Department of Internal Medicine, Regionshospitalet Viborg",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02384668
1612,NCT02390739,thyroid neoplasms,Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to Patients With Thyroglobulin Expressing Thyroid Cancer,Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer,Metastatic Thyroid Cancer,2015-03-17,2017-03-22,2017-03-22,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),,Drug|Drug|Drug|Biological,,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02390739
1613,NCT02390934,thyroid neoplasms,Single Arm Phase II Trial Evaluating the Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer,Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer,Thyroid Cancer,2014-10-01,2019-04-02,2019-04-02,13.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Radiation,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02390934
1614,NCT02393183,graves disease,"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED),Thyroid Eye Disease,2015-03-07,2022-06-15,2022-12-15,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Rassoul Akram Hospital,Drug|Dietary Supplement|Other,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02393183
1615,NCT02393183,graves ophthalmopathy,"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED),Thyroid Eye Disease,2015-03-07,2022-06-15,2022-12-15,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Rassoul Akram Hospital,Drug|Dietary Supplement|Other,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02393183
1616,NCT02393183,goiter,"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED),Thyroid Eye Disease,2015-03-07,2022-06-15,2022-12-15,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Rassoul Akram Hospital,Drug|Dietary Supplement|Other,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02393183
1617,NCT02393183,hyperthyroidism,"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED),Thyroid Eye Disease,2015-03-07,2022-06-15,2022-12-15,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Rassoul Akram Hospital,Drug|Dietary Supplement|Other,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02393183
1619,NCT02393690,"thyroid cancer, papillary",Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,60.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02393690
1620,NCT02393690,"adenocarcinoma, follicular",Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,60.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02393690
1621,NCT02397109,goiter,Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies,mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX),Dysthyroid Ophthalmopathies,2015-03-19,2020-09-30,2020-09-30,294.0,Case-Only,,Cross-Sectional,Observational,Completed,,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,,France,18.0,90.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02397109
1622,NCT02397109,hyperthyroidism,Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies,mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX),Dysthyroid Ophthalmopathies,2015-03-19,2020-09-30,2020-09-30,294.0,Case-Only,,Cross-Sectional,Observational,Completed,,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,,France,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02397109
1623,NCT02397109,graves ophthalmopathy,Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies,mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX),Dysthyroid Ophthalmopathies,2015-03-19,2020-09-30,2020-09-30,294.0,Case-Only,,Cross-Sectional,Observational,Completed,,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,,France,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02397109
1624,NCT02397109,graves disease,Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies,mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX),Dysthyroid Ophthalmopathies,2015-03-19,2020-09-30,2020-09-30,294.0,Case-Only,,Cross-Sectional,Observational,Completed,,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,,France,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02397109
1625,NCT02398721,thyroid neoplasms,A Prospective Randomized Study on Health-related Quality of Life of Patients With Incidental Small (<2cm) Asymptomatic Thyroid Nodules and Cost-effectiveness Analysis in Managing Small Incidental Thyroid Nodules,Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules,Thyroid Nodules,2015-03-20,2017-07-31,2018-02-28,314.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Other,Hong Kong,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02398721
1626,NCT02398721,thyroid nodule,A Prospective Randomized Study on Health-related Quality of Life of Patients With Incidental Small (<2cm) Asymptomatic Thyroid Nodules and Cost-effectiveness Analysis in Managing Small Incidental Thyroid Nodules,Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules,Thyroid Nodules,2015-03-20,2017-07-31,2018-02-28,314.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Other,Hong Kong,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02398721
1627,NCT02399475,hypothyroidism,"The Thyroid Axis in Older Individuals With Persistent Subclinical Hypothyroidism: a Mechanistic, Randomized, Double-Blind, Cross-Over Study of Levothyroxine and Liothyronine Administration",Mechanistic Study of Subclinical Hypothyroidism In the Elderly,Subclinical Hypothyroidism,2015-02-03,2019-09-30,2019-09-30,14.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,University of Pennsylvania,National Institute on Aging (NIA)|University of Pennsylvania,University of Pennsylvania,Drug|Drug|Drug,United States,70.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02399475
1628,NCT02404441,"thyroid carcinoma, anaplastic",Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies,Phase I/II Study of PDR001 in Patients With Advanced Malignancies,Anaplastic Thyroid Cancer|Melanoma|Non-small Sell Lung Cancer (NSCLC)|Other Solid Tumors|Triple Negative Breast Cancer,2015-03-20,2020-07-21,2020-07-21,319.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Novartis,Novartis Pharmaceuticals,The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins|Massachusetts General Hospital|Oregon Health and Science University SC-10|Sarah Cannon Research Institute SCRI RC|University of Texas MD Anderson Cancer Center MD Anderson PSC|Huntsman Cancer Institute Univ. of Utah HCI|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Biological,Canada|France|Germany|Hungary|Italy|Lebanon|Netherlands|Norway|Poland|Spain|Taiwan|Thailand|Turkey|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02404441
1631,NCT02408887,"thyroid cancer, papillary",Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer,Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer,Endocrine Malignancy|Low-risk Papillary Thyroid Cancer|Thyroid Cancer,2015-04-03,2019-03-26,2019-05-07,14.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02408887
1632,NCT02410928,thyroid neoplasms,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Thyroid Nodule,2015-02-14,2015-06-30,2015-07-31,75.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Diskapi Teaching and Research Hospital,Diskapi Teaching and Research Hospital,Diskapi Yildirim Beyazit Teaching and Research Hospital,Device|Device|Device,Turkey,19.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02410928
1633,NCT02410928,thyroid nodule,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Thyroid Nodule,2015-02-14,2015-06-30,2015-07-31,75.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Diskapi Teaching and Research Hospital,Diskapi Teaching and Research Hospital,Diskapi Yildirim Beyazit Teaching and Research Hospital,Device|Device|Device,Turkey,19.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02410928
1635,NCT02411461,pseudohypoparathyroidism,Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism,Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism,2015-02-25,2017-01-31,2017-01-31,39.0,Case-Control,,Cross-Sectional,Observational,Completed,,Vanderbilt University Medical Center,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Vanderbilt University Medical Center,Vanderbilt University,,United States,6.0,18.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02411461
1636,NCT02412150,thyroid neoplasms,Effect of Dexmedetomidine Infusion for Postoperative Outcome and Smooth Emergence After Thyroidectomy,Effect of Dexmedetomidine After Thyroidectomy,Thyroid Tumor,2015-03-31,2020-11-21,2020-11-25,139.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Chosun University Hospital,Chosun University Hospital,Chosun University Hospital,Drug|Drug|Procedure|Other|Behavioral|Behavioral|Other|Behavioral|Other|Other|Other|Drug|Drug,"Korea, Republic of",20.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02412150
1637,NCT02417389,hyperparathyroidism,Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism,Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism,"Hyperparathyroidism, Primary|Osteoporosis",2015-04-08,2011-10-31,2012-12-31,22.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Istituto Auxologico Italiano,Istituto Auxologico Italiano,Istituto Auxologico Italiano IRCCS,Drug|Drug,Italy,50.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02417389
1640,NCT02418247,thyroid neoplasms,Phase  Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients,Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer,Thyroid Neoplasms,2015-04-13,2017-12-31,2020-12-31,556.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,"National Cancer Center, Korea","National Cancer Center, Korea","Chungnam National University Hospital|National Cancer Center, Korea|Seoul National University Boramae Medical Center|Seoul National University Hospital|Seoul National University Bundang Hospital",Drug|Drug,"Korea, Republic of",18.0,79.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02418247
1642,NCT02418390,"thyroid cancer, papillary",The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma,The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma,"Thyroid Cancer, Papillary",2015-04-07,2022-02-28,2022-02-28,5750.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Procedure,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02418390
1643,NCT02422368,goiter,"The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease,Thyroid Eye Disease,2015-04-11,2024-06-30,2024-11-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Private Thyroid eye disease clinic|Rassoul Akram Hospital,Drug|Drug,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02422368
1644,NCT02422368,graves ophthalmopathy,"The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease,Thyroid Eye Disease,2015-04-11,2024-06-30,2024-11-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Private Thyroid eye disease clinic|Rassoul Akram Hospital,Drug|Drug,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02422368
1645,NCT02422368,graves disease,"The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease,Thyroid Eye Disease,2015-04-11,2024-06-30,2024-11-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Private Thyroid eye disease clinic|Rassoul Akram Hospital,Drug|Drug,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02422368
1646,NCT02422368,hyperthyroidism,"The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease,Thyroid Eye Disease,2015-04-11,2024-06-30,2024-11-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Private Thyroid eye disease clinic|Rassoul Akram Hospital,Drug|Drug,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02422368
1648,NCT02430584,hypoparathyroidism,Whole Blood Specimen Collection From Pregnant Subjects,Whole Blood Specimen Collection From Pregnant Subjects,DiGeorge Syndrome|Down Syndrome|Edwards Syndrome|Klinefelter Syndrome|Patau Syndrome|Perinatal Infections|Turner Syndrome,2015-04-27,2021-03-31,2021-05-31,5000.0,Family-Based,,Prospective,Observational,Active not recruiting,,"Progenity, Inc.","Progenity, Inc.",Regional Obstetrical Consultants,Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02430584
1649,NCT02430714,thyroid neoplasms,Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T),Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T),Thyroid Neoplasms,2015-04-27,2016-11-06,2016-11-06,629.0,Other,,Prospective,Observational,Completed,,Eisai Inc.,"Eisai Co., Ltd.",,Drug,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02430714
1650,NCT02430857,hypothyroidism,Osteopathy and Latent Hypothyroidism: Effectiveness of Osteopathic Treatment on TSH in Patients With Latent Hypothyroidism,Osteopathy and Latent Hypothyroidism,Latent Hypothyroidism,2015-04-27,2015-10-31,2016-01-31,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,"Diekmann, Emanuel Amier",Emanuel Amier Diekmann,,Other,,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02430857
1651,NCT02432274,thyroid neoplasms,Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,Differentiated Thyroid Cancer (DTC)|Osteosarcoma|Solid Malignant Tumors|Tumors,2015-04-22,2019-07-18,2022-03-31,117.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 1/Phase 2,Eisai Inc.,Eisai Limited|Merck Sharp & Dohme LLC,Texas Children's Hospital|CHU Strasbourg - Hopital Hautepierre|Centre Oscar Lambret Lille|Centre Leon Berard|CHU Nantes - Hopital Mere-Enfant|Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris|Institut Gustave Roussy|CHU de Toulouse - Hopital des Enfants|Universitaetsklinikum Muenster|Kinderklinik des Olga hospitals|Istituto Ortopedico Rizzoli|Fondazione IRCCS Istituto Nazionale dei Tumori|Ospedale Pediatrico Bambino Gesu|Hospital Universitari Vall d'Hebron|Hospital Infantil Universitario Nino Jesus|Hospital Universitario y Politecnico La Fe Hospital La Fe Valencia|Birmingham Children's Hospital|University College London Hospital|Royal Victoria Infirmary,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug,France|Germany|Italy|Spain|United Kingdom|United States,2.0,25.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02432274
1652,NCT02432599,hyperparathyroidism,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Hyperparathyroidism,2015-04-29,2017-02-28,2017-02-28,28.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Centre Francois Baclesse,Centre Francois Baclesse,CHU|Centre Franois Baclesse,Radiation,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02432599
1653,NCT02432599,parathyroid neoplasms,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Hyperparathyroidism,2015-04-29,2017-02-28,2017-02-28,28.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Centre Francois Baclesse,Centre Francois Baclesse,CHU|Centre Franois Baclesse,Radiation,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02432599
1656,NCT02440581,hyperparathyroidism,Renal Osteodystrophy: A Fresh Approach,Renal Osteodystrophy: An Individual Management Approach,"Kidney Failure, Chronic",2015-05-07,2023-06-30,2023-06-30,120.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,University of Kentucky,"Hartmut Malluche, MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Wright State University",University of Kentucky,Drug|Drug|Drug,United States,21.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02440581
1659,NCT02442661,"thyroid cancer, papillary",Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer,Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer,Papillary Thyroid Cancer,2015-04-22,2016-12-31,2017-05-31,103.0,Other,,Prospective,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",Rebecca J Guigli,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02442661
1660,NCT02452073,euthyroid sick syndromes,,An Analysis of the Relative Risk for Low Triiodothyronine Syndrome in Patients With Chronic Radiation Enteritis,The Clinical Incidence of Low Triiodothyronine Syndrome,2015-05-15,2015-01-31,2015-04-30,48.0,Cohort,,Retrospective,Observational,Completed,,"Jinling Hospital, China",Shengxian Fan,,Other,,0.0,120.0,[0-17]|[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT02452073
1661,NCT02456701,thyroid neoplasms,"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in",Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,Thyroid Cancer,2015-05-20,2016-10-13,2016-10-13,7.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Celldex Therapeutics,Celldex Therapeutics|Memorial Sloan Kettering Cancer Center,Memorial Sloan-Kettering Cancer Center,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02456701
1663,NCT02460328,hypoparathyroidism,Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome,Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome,22q11.2 Deletion Syndrome|Immune Defect,2015-04-10,2016-02-29,2016-02-29,43.0,Case-Only,,,Observational,Completed,,Mahidol University,Mahidol University,Siriraj Hospital,,Thailand,0.0,15.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02460328
1664,NCT02462512,thyroid neoplasms,Validation of Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Elastography|Thyroid Nodule,2015-04-20,2016-03-31,2017-08-31,590.0,Cohort,,Prospective,Observational,Unknown status,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St Mary's Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02462512
1665,NCT02462512,thyroid nodule,Validation of Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Elastography|Thyroid Nodule,2015-04-20,2016-03-31,2017-08-31,590.0,Cohort,,Prospective,Observational,Unknown status,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St Mary's Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02462512
1667,NCT02463409,pseudopseudohypoparathyroidism,Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a,Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy),Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1a,2015-05-20,2016-10-31,2016-10-31,6.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Vanderbilt University Medical Center,Massachusetts General Hospital|Vanderbilt University Medical Center,Vanderbilt Unversity,Drug,United States,10.0,21.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02463409
1669,NCT02464072,hyperparathyroidism,Randomized Clinical Trial of Subtotal Parathyroidectomy or Total Parathyroidectomy With Immediate Heterotopic Autograft in Chronic Renal Disease Patients Stage V Under Dialysis,Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis,"Hyperparathyroidism, Secondary",2015-05-18,2021-03-31,2021-03-31,133.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure|Procedure|Procedure,Brazil,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02464072
1671,NCT02465060,thyroid neoplasms,Molecular Analysis for Therapy Choice (MATCH),"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,2015-06-03,2025-12-31,2025-12-31,6452.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|Thomas Hospital|Mobile Infirmary Medical Center|University of South Alabama Mitchell Cancer Institute|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Fairbanks Memorial Hospital|CTCA at Western Regional Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Saint Joseph's Hospital and Medical Center|Mayo Clinic Hospital in Arizona|Mayo Clinic in Arizona|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro|University of Arkansas for Medical Sciences|Kaiser Permanente-Anaheim|Kaiser Permanente-Deer Valley Medical Center|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Sutter Auburn Faith Hospital|Sutter Cancer Centers Radiation Oncology Services-Auburn|AIS Cancer Center at San Joaquin Community Hospital|Kaiser Permanente-Baldwin Park|Kaiser Permanente-Bellflower|Alta Bates Summit Medical Center-Herrick Campus|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|Community Cancer Institute|University Oncology Associates|John Muir Medical Center-Concord Campus|City of Hope Corona|UC Irvine Health Cancer Center-Newport|Sutter Davis Hospital|City of Hope Comprehensive Cancer Center|Epic Care-Dublin|Kaiser Permanente Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Kaiser Permanente-Fontana|Kaiser Permanente-Fremont|Palo Alto Medical Foundation-Fremont|Fresno Cancer Center|Kaiser Permanente-Fresno|Saint Jude Medical Center|Marin Cancer Care Inc|Marin General Hospital|Kaiser Permanente - Harbor City|Kaiser Permanente-Irvine|UC San Diego Moores Cancer Center|Loma Linda University Medical Center|Kaiser Permanente Los Angeles Medical Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|Kaiser Permanente West Los Angeles|Cedars Sinai Medical Center|Contra Costa Regional Medical Center|Fremont - Rideout Cancer Center|Memorial Medical Center|Kaiser Permanente-Modesto|Community Hospital of Monterey Peninsula|Pacific Cancer Care-Monterey|Palo Alto Medical Foundation-Camino Division|Palo Alto Medical Foundation-Gynecologic Oncology|USC Norris Oncology/Hematology-Newport Beach|Sutter Cancer Research Consortium|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Kaiser Permanente Oakland-Broadway|Kaiser Permanente-Oakland|Kaiser Permanente-Ontario|Saint Joseph Hospital - Orange|UC Irvine Health/Chao Family Comprehensive Cancer Center|Desert Regional Medical Center|Palo Alto Medical Foundation Health Care|Stanford Cancer Institute Palo Alto|VA Palo Alto Health Care System|Kaiser Permanente - Panorama City|Keck Medical Center of USC Pasadena|Kaiser Permanente-Rancho Cordova Cancer Center|Eisenhower Medical Center|Kaiser Permanente- Marshall Medical Offices|Kaiser Permanente-Redwood City|Kaiser Permanente-Richmond|Kaiser Permanente-Riverside|Rohnert Park Cancer Center|Kaiser Permanente-Roseville|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Roseville Medical Center|The Permanente Medical Group-Roseville Radiation Oncology|Kaiser Permanente Downtown Commons|Sutter Medical Center Sacramento|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-South Sacramento|South Sacramento Cancer Center|Kaiser Permanente - Sacramento|Saint Helena Hospital|UC San Diego Medical Center - Hillcrest|Kaiser Permanente-San Diego Mission|Kaiser Permanente-San Diego Zion|Rady Children's Hospital - San Diego|Sharp Memorial Hospital|Naval Medical Center -San Diego|California Pacific Medical Center-Pacific Campus|Kaiser Permanente-San Francisco|Kaiser Permanente-Santa Teresa-San Jose|Kaiser Permanente San Leandro|Pacific Central Coast Health Center-San Luis Obispo|Kaiser Permanente-San Marcos|Mills Health Center|Kaiser Permanente-San Rafael|Kaiser San Rafael-Gallinas|Kaiser Permanente Medical Center - Santa Clara|Palo Alto Medical Foundation-Santa Cruz|Mission Hope Medical Oncology - Santa Maria|Kaiser Permanente-Santa Rosa|Sutter Pacific Medical Foundation|Kaiser Permanente Cancer Treatment Center|Kaiser Permanente-South San Francisco|Saint Joseph's Medical Center|Kaiser Permanente-Stockton|Palo Alto Medical Foundation-Sunnyvale|Gene Upshaw Memorial Tahoe Forest Cancer Center|City of Hope Upland|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Kaiser Permanente Medical Center-Vacaville|Kaiser Permanente-Vallejo|Sutter Solano Medical Center/Cancer Center|Kaiser Permanente-Walnut Creek|Epic Care Cyberknife Center|John Muir Medical Center-Walnut Creek|City of Hope West Covina|Presbyterian Intercommunity Hospital|Kaiser Permanente-Woodland Hills|Rocky Mountain Cancer Centers-Aurora|The Medical Center of Aurora|University of Colorado Hospital|Boulder Community Hospital|Boulder Community Foothills Hospital|Rocky Mountain Cancer Centers-Boulder|Rocky Mountain Cancer Centers - Centennial|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|UCHealth Memorial Hospital Central|Memorial Hospital North|Saint Francis Cancer Center|Cancer Center of Colorado at Sloan's Lake|Denver Health Medical Center|Kaiser Permanente-Franklin|National Jewish Health-Main Campus|The Women's Imaging Center|Porter Adventist Hospital|Colorado Blood Cancer Institute|Presbyterian - Saint Lukes Medical Center - Health One|Rocky Mountain Cancer Centers-Midtown|SCL Health Saint Joseph Hospital|Rocky Mountain Cancer Centers-Rose|Rose Medical Center|Mercy Medical Center|Southwest Oncology PC|Mountain Blue Cancer Care Center - Swedish|Rocky Mountain Cancer Centers - Swedish|Swedish Medical Center|Poudre Valley Hospital|Mountain Blue Cancer Care Center|National Jewish Health-Western Hematology Oncology|Saint Mary's Hospital and Regional Medical Center|Grand Valley Oncology|North Colorado Medical Center|Rocky Mountain Cancer Centers-Greenwood Village|Good Samaritan Medical Center|Kaiser Permanente-Rock Creek|Rocky Mountain Cancer Centers-Lakewood|Saint Anthony Hospital|Rocky Mountain Cancer Centers-Littleton|Littleton Adventist Hospital|Kaiser Permanente-Lone Tree|Rocky Mountain Cancer Centers-Sky Ridge|Sky Ridge Medical Center|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|McKee Medical Center|Parker Adventist Hospital|Rocky Mountain Cancer Centers-Parker|Saint Mary Corwin Medical Center|Rocky Mountain Cancer Centers - Pueblo|National Jewish Health-Northern Hematology Oncology|Rocky Mountain Cancer Centers-Thornton|SCL Health Lutheran Medical Center|Smilow Cancer Hospital-Derby Care Center|Smilow Cancer Hospital Care Center-Fairfield|Smilow Cancer Hospital Care Center at Glastonbury|Smilow Cancer Hospital Care Center at Greenwich|Smilow Cancer Hospital Care Center - Guiford|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Yale-New Haven Hospital North Haven Medical Center|Eastern Connecticut Hematology and Oncology Associates|Smilow Cancer Hospital-Orange Care Center|Stamford Hospital/Bennett Cancer Center|Smilow Cancer Hospital-Torrington Care Center|Smilow Cancer Hospital Care Center-Trumbull|Smilow Cancer Hospital-Waterbury Care Center|Smilow Cancer Hospital Care Center - Waterford|Veterans Affairs Connecticut Healthcare System-West Haven Campus|Beebe South Coastal Health Campus|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|TidalHealth Nanticoke / Allen Cancer Center|Christiana Care Health System-Wilmington Hospital|MedStar Georgetown University Hospital|MedStar Washington Hospital Center|Sibley Memorial Hospital|Mount Sinai Comprehensive Cancer Center at Aventura|UM Sylvester Comprehensive Cancer Center at Coral Gables|UM Sylvester Comprehensive Cancer Center at Coral Springs|Broward Health North|UM Sylvester Comprehensive Cancer Center at Deerfield Beach|Holy Cross Hospital|Broward Health Medical Center|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|UM Sylvester Comprehensive Cancer Center at Hollywood|Mayo Clinic in Florida|The Watson Clinic|Mount Sinai Medical Center|University of Miami Miller School of Medicine-Sylvester Cancer Center|Miami Cancer Institute|UM Sylvester Comprehensive Cancer Center at Kendall|Health Central|Orlando Health Cancer Institute|Memorial Hospital West|UM Sylvester Comprehensive Cancer Center at Plantation|Saint Joseph's Hospital/Children's Hospital-Tampa|Moffitt Cancer Center|Indian River Medical Center|University Cancer and Blood Center LLC|Emory University Hospital Midtown|Piedmont Hospital|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|Northside Hospital|Augusta University Medical Center|Northeast Georgia Medical Center Braselton|John B Amos Cancer Center|Northside Hospital-Forsyth|Dekalb Medical Center|Northside Hospital - Duluth|Northeast Georgia Medical Center-Gainesville|The Longstreet Clinic - Gainesville|Northside Hospital - Gwinnett|Central Georgia Gynecologic Oncology|Medical Center of Central Georgia|CTCA at Southeastern Regional Medical Center|Harbin Clinic Medical Oncology and Clinical Research|Low Country Cancer Care|Memorial Health University Medical Center|Summit Cancer Care-Memorial|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler|Summit Cancer Care-Candler|Suburban Hematology Oncology Associates - Snellville|Lewis Hall Singletary Oncology Center|South Georgia Medical Center/Pearlman Cancer Center|Hawaii Cancer Care - Savio|Pali Momi Medical Center|Queen's Cancer Center - Pearlridge|Straub Pearlridge Clinic|The Cancer Center of Hawaii-Pali Momi|The Queen's Medical Center - West Oahu|Hawaii Cancer Care Inc - Waterfront Plaza|Island Urology|Queen's Cancer Cenrer - POB I|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Diagnostic Radiology Services LLC|Kuakini Medical Center|Queen's Cancer Center - Kuakini|The Cancer Center of Hawaii-Liliha|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Straub Medical Center - Kahului Clinic|Castle Medical Center|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Saint Joseph Medical Center|Illinois CancerCare-Bloomington|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Centralia Oncology Clinic|Mount Sinai Hospital Medical Center|Northwestern University|John H Stroger Jr Hospital of Cook County|Rush University Medical Center|University of Illinois|Swedish Covenant Hospital|University of Chicago Comprehensive Cancer Center|Advocate Illinois Masonic Medical Center|AMG Crystal Lake - Oncology|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Northwestern Medicine Cancer Center Kishwaukee|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|AMITA Health Alexian Brothers Medical Center|Elmhurst Memorial Hospital|Illinois CancerCare-Eureka|NorthShore University HealthSystem-Evanston Hospital|Saint Francis Hospital|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Northwestern Medicine Cancer Center Delnor|NorthShore University HealthSystem-Glenbrook Hospital|Ingalls Memorial Hospital|NorthShore University HealthSystem-Highland Park Hospital|Duly Health and Care Joliet|Presence Saint Mary's Hospital|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|AMG Libertyville - Oncology|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Trinity Medical Center|Good Samaritan Regional Health Center|Edward Hospital/Cancer Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Radiation Oncology of Northern Illinois|Illinois CancerCare-Pekin|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center|Illinois CancerCare-Peoria|OSF Saint Francis Radiation Oncology at Peoria Cancer Center|Methodist Medical Center of Illinois|OSF Saint Francis Medical Center|Illinois CancerCare-Peru|Valley Radiation Oncology|Edward Hospital/Cancer Center?Plainfield|Illinois CancerCare-Princeton|Hematology Oncology Associates of Illinois - Skokie|North Shore Medical Center|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Northwestern Medicine Cancer Center Warrenville|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Midwestern Regional Medical Center|Michiana Hematology Oncology PC-Crown Point|Michiana Hematology Oncology PC-Elkhart|Deaconess Clinic Downtown|Indiana University/Melvin and Bren Simon Cancer Center|Sidney and Lois Eskenazi Hospital|Community Cancer Center East|Community Cancer Center South|Community Cancer Center North|Springmill Medical Center|Community Howard Regional Health|IU Health Arnett Cancer Care|Franciscan Saint Anthony Health-Michigan City|Woodland Cancer Care Center|Memorial Regional Cancer Center Day Road|Michiana Hematology Oncology PC-Mishawaka|Baptist Health Floyd|Chancellor Center for Oncology|Michiana Hematology Oncology PC-Plymouth|Reid Health|Memorial Hospital of South Bend|Michiana Hematology Oncology PC-Westville|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Saint Anthony Regional Hospital|Physicians' Clinic of Iowa PC|Mercy Hospital|Oncology Associates at Mercy Medical Center|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Jennie Edmundson Memorial Hospital|Alegent Health Mercy Hospital|Heartland Oncology and Hematology LLP|Greater Regional Medical Center|Iowa Methodist Medical Center|Medical Oncology and Hematology Associates-Des Moines|Broadlawns Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|Iowa Lutheran Hospital|JCHC McCreery Cancer Center|McFarland Clinic PC-Trinity Cancer Center|Trinity Regional Medical Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Ottumwa Regional Health Center|Siouxland Regional Cancer Center|Methodist West Hospital|Mercy Medical Center-West Lakes|Coffeyville Regional Medical Center|Newman Regional Health|University of Kansas Clinical Research Center|Central Care Cancer Center - Garden City|Saint Catherine Hospital|Central Care Cancer Center - Great Bend|Saint Rose Ambulatory and Surgery Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center-West|University of Kansas Cancer Center|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Olathe Health Cancer Center|Menorah Medical Center|University of Kansas Cancer Center-Overland Park|Saint Luke's South Hospital|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|Flaget Memorial Hospital|Baptist Health Corbin|Commonwealth Cancer Center-Corbin|Oncology Hematology Care Inc-Crestview|Saint Elizabeth Medical Center South|Baptist Health Hardin|Saint Elizabeth Fort Thomas|Baptist Health Lexington|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|University of Kentucky/Markey Cancer Center|Saint Joseph London|Jewish Hospital|The James Graham Brown Cancer Center at University of Louisville|Baptist Health Louisville|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Baptist Health Madisonville/Merle Mahr Cancer Center|Baptist Health Paducah|Jewish Hospital Medical Center South|LSU Health Baton Rouge-North Clinic|Baton Rouge General Medical Center|Our Lady of The Lake|Hematology/Oncology Clinic PLLC|Louisiana Hematology Oncology Associates LLC|Mary Bird Perkins Cancer Center|Ochsner Health Center-Summa|Our Lady of the Lake Physicians Group - Medical Oncology|The NeuroMedical Center-Clinic|Medical Center of Baton Rouge|Our Lady of the Lake Medical Oncology|Ochsner High Grove|Mary Bird Perkins Cancer Center - Covington|Northshore Oncology Associates-Covington|Ochsner Hematology Oncology North Shore - Covington (West Region)|Women's Cancer Care-Covington|Ochsner Medical Center West Bank|Mary Bird Perkins Cancer Center - Houma|Oncology Center of The South Incorporated|Terrebonne General Medical Center|Ochsner Medical Center Kenner|West Jefferson Medical Center|East Jefferson General Hospital|Robert Veith MD LLC|Ochsner LSU Health Monroe Medical Center|Louisiana State University Health Science Center|Tulane University Health Sciences Center|University Medical Center New Orleans|Ochsner Medical Center Jefferson|LSU Health Sciences Center at Shreveport|CHRISTUS Highland Medical Center|Harold Alfond Center for Cancer Care|Eastern Maine Medical Center|Waldo County General Hospital|MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford|Lafayette Family Cancer Center-EMMC|Maine Center for Cancer Medicine-Kennebunk|Stephens Memorial Hospital|Penobscot Bay Medical Center|MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford|Maine Center for Cancer Medicine-Scarborough|Maine Medical Center- Scarborough Campus|Maine Medical Partners - South Portland|Maine Center for Cancer Medicine-Topsham|Anne Arundel Medical Center|University of Maryland/Greenebaum Cancer Center|Greater Baltimore Medical Center|Sinai Hospital of Baltimore|MedStar Union Memorial Hospital|MedStar Franklin Square Medical Center/Weinberg Cancer Institute|MedStar Good Samaritan Hospital|Johns Hopkins University/Sidney Kimmel Cancer Center|Walter Reed National Military Medical Center|National Institutes of Health Clinical Center|Western Maryland Regional Medical Center|University of Maryland Shore Medical Center at Easton|Christiana Care - Union Hospital|Frederick Memorial Hospital|FMH James M Stockman Cancer Institute|MedStar Montgomery Medical Center|Northwest Hospital Center|TidalHealth Peninsula Regional|Holy Cross Hospital|William E Kahlert Regional Cancer Center/Sinai Hospital|Beverly Hospital|Tufts Medical Center|Massachusetts General Hospital Cancer Center|Boston Medical Center|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Lahey Hospital and Medical Center|Simonds-Sinon Regional Cancer Center|MetroWest Medical Center-Framingham Union Hospital|Addison Gilbert Hospital|Lowell General Hospital|Lahey Medical Center-Peabody|Mercy Medical Center|Baystate Medical Center|Winchester Hospital|UMass Memorial Medical Center - University Campus|Hickman Cancer Center|Saint Joseph Mercy Hospital|C S Mott Children's Hospital|University of Michigan Comprehensive Cancer Center|Bronson Battle Creek|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Beaumont Hospital - Dearborn|Henry Ford Medical Center-Fairlane|Wayne State University/Karmanos Cancer Institute|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Michigan State University Clinical Center|Green Bay Oncology - Escanaba|Beaumont Hospital - Farmington Hills|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Helen DeVos Children's Hospital at Spectrum Health|Mercy Health Saint Mary's|Spectrum Health at Butterworth Campus|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|William Beaumont Hospital-Grosse Pointe|Allegiance Health|Bronson Methodist Hospital|West Michigan Cancer Center|Borgess Medical Center|Karmanos Cancer Institute at McLaren Greater Lansing|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|Mid-Michigan Medical Center - Midland|Monroe Cancer Center|Toledo Clinic Cancer Centers-Monroe|Mercy Health Mercy Campus|Lakeland Hospital Niles|Cancer and Hematology Centers of Western Michigan - Norton Shores|Ascension Providence Hospitals - Novi|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Spectrum Health Reed City Hospital|Great Lakes Cancer Management Specialists-Rochester Hills|Michigan Cancer Specialists|Oakland Colon Rectal Associates|Beaumont Children's Hospital-Royal Oak|Cancer Care Associates PC|Comprehensive Medical Center PLLC|Hematology Oncology Consultants PC|Oakland Medical Group|William Beaumont Hospital-Royal Oak|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Lakeland Medical Center Saint Joseph|Marie Yeager Cancer Center|Henry Ford Macomb Health Center - Shelby Township|Ascension Providence Hospitals - Southfield|Bhadresh Nayak MD PC-Sterling Heights|Premier Hematology Oncology Care|Mitchell Folbe MD PC|Ascension Saint Joseph Hospital|Munson Medical Center|Michigan Institute of Urology-Town Center|Claudia BR Herke MD PC|William Beaumont Hospital - Troy|Hematology Oncology Consultants PC-Troy|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Henry Ford Wyandotte Hospital|Metro Health Hospital|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Sanford Joe Lueken Cancer Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|University of Minnesota/Masonic Cancer Center|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Sanford Cancer Center Worthington|Fairview Lakes Medical Center|Baptist Memorial Hospital and Cancer Center-Golden Triangle|Baptist Cancer Center-Grenada|Hattiesburg Clinic - Hematology/Oncology Clinic|Forrest General Hospital / Cancer Center|University of Mississippi Medical Center|Baptist Memorial Hospital and Cancer Center-Union County|Baptist Memorial Hospital and Cancer Center-Oxford|Singing River Hospital|Baptist Memorial Hospital and Cancer Center-Desoto|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Saint Luke's Hospital|University of Missouri - Ellis Fischel|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Centerpoint Medical Center LLC|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|Saint Luke's Hospital of Kansas City|The University of Kansas Cancer Center-South|Research Medical Center|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|University of Kansas Cancer Center at North Kansas City Hospital|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Community Hospital of Anaconda|Billings Clinic Cancer Center|Saint Vincent Healthcare|Saint Vincent Frontier Cancer Center|Bozeman Deaconess Hospital|Saint James Community Hospital and Cancer Treatment Center|Benefis Healthcare- Sletten Cancer Institute|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Nebraska Medicine-Bellevue|CHI Health Saint Francis|Heartland Hematology and Oncology|CHI Health Good Samaritan|Nebraska Hematology and Oncology|Nebraska Cancer Research Center|Saint Elizabeth Regional Medical Center|Southeast Nebraska Cancer Center - 68th Street Place|Faith Regional Health Services Carson Cancer Center|Great Plains Health Callahan Cancer Center|Nebraska Cancer Specialists/Oncology Hematology West PC - MECC|Nebraska Methodist Hospital|Oncology Associates PC|Nebraska Medicine-Village Pointe|Alegent Health Immanuel Medical Center|Hematology and Oncology Consultants PC|Alegent Health Bergan Mercy Medical Center|Nebraska Cancer Specialists - Omaha|Alegent Health Lakeside Hospital|Oncology Hematology West PC|Creighton University Medical Center|University of Nebraska Medical Center|Midlands Community Hospital|Regional West Medical Center Cancer Center|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Cancer Therapy and Integrative Medicine|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|Hope Cancer Care of Nevada-Pahrump|Center of Hope at Renown Medical Center|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|New Hampshire Oncology Hematology PA-Concord|Dartmouth Hitchcock Medical Center|Norris Cotton Cancer Center-Manchester|Elliot Hospital|Solinsky Center for Cancer Care|Norris Cotton Cancer Center-Nashua|Ocean Medical Center|AtlantiCare Health Park-Cape May Court House|AtlantiCare Surgery Center|Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus|Hunterdon Medical Center|Hackensack University Medical Center|Bayshore Community Hospital|Monmouth Medical Center Southern Campus|Saint Barnabas Medical Center|Monmouth Medical Center|Southern Ocean County Medical Center|Memorial Sloan Kettering Monmouth|Morristown Medical Center|Inspira Medical Center Mullica Hill|Jersey Shore Medical Center|Rutgers Cancer Institute of New Jersey|Newark Beth Israel Medical Center|Capital Health Medical Center-Hopewell|Riverview Medical Center/Booker Cancer Center|Sidney Kimmel Cancer Center Washington Township|Overlook Hospital|Inspira Medical Center Vineland|Lovelace Medical Center-Downtown|University of New Mexico Cancer Center|Southwest Gynecologic Oncology Associates Inc|New Mexico Oncology Hematology Consultants|Presbyterian Kaseman Hospital|Memorial Medical Center - Las Cruces|Presbyterian Rust Medical Center/Jorgensen Cancer Center|Christus Saint Vincent Regional Cancer Center|South Shore University Hospital|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Children's Hospital at Montefiore|Montefiore Medical Center - Moses Campus|State University of New York Downstate Medical Center|Roswell Park Cancer Institute|Arnot Ogden Medical Center/Falck Cancer Center|Glens Falls Hospital|Memorial Sloan Kettering Westchester|Northwell Health/Center for Advanced Medicine|North Shore University Hospital|Long Island Jewish Medical Center|Lenox Hill Hospital|Mount Sinai Hospital|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Manhattan Eye Ear and Throat Hospital|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|Rochester General Hospital|University of Rochester|Stony Brook University Medical Center|State University of New York Upstate Medical University|SUNY Upstate Medical Center-Community Campus|Dickstein Cancer Treatment Center|Mission Hospital|AdventHealth Infusion Center Asheville|Messino Cancer Centers|Hope Women's Cancer Centers-Asheville|Waverly Hematology Oncology|UNC Lineberger Comprehensive Cancer Center|Novant Health Presbyterian Medical Center|Novant Health Carolina Surgical - Randolph|Oncology Specialists of Charlotte|Southern Oncology Specialists-Charlotte|Southeastern Medical Oncology Center-Clinton|AdventHealth Infusion Center Haywood|Durham VA Medical Center|Duke University Medical Center|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Novant Health Breast Surgery - Greensboro|Hendersonville Hematology and Oncology at Pardee|Margaret R Pardee Memorial Hospital|AdventHealth Hendersonville|Novant Health Cancer Institute - Huntersville|Novant Health Presbyterian Medical Center Huntersville|Southern Oncology Specialists-Huntersville|Onslow Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Novant Health Cancer Institute - Kernersville|Matthews Radiation Oncology Center|Novant Health Cancer Specialists-Matthews|Lake Norman Radiation Oncology Center-Mooresville|Novant Health Cancer Institute - Mooresville|Novant Health Cancer Institute - Mount Airy|FirstHealth of the Carolinas-Moore Regional Hospital|Duke Raleigh Hospital|Novant Health Cancer Institute - Rowan|Rowan Regional Medical Center|Novant Health Cancer Institute - Statesville|Novant Health Cancer Institute - Thomasville|Marion L Shepard Cancer Center at Vidant Beaufort Hospital|AdventHealth Infusion Center Weaverville|Novant Health Cancer Institute - Wilkesboro|Novant Health Forsyth Medical Center|Novant Health Oncology Specialists|Winston-Salem Health Care|Wake Forest University Health Sciences|Sanford Bismarck Medical Center|Essentia Health Cancer Center-South University Clinic|Sanford South University Medical Center|Sanford Broadway Medical Center|Sanford Clinic North-Fargo|Sanford Roger Maris Cancer Center|Essentia Health - Jamestown Clinic|Trinity Cancer Care Center|Aultman Alliance Community Hospital|UHHS-Chagrin Highlands Medical Center|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Cleveland Clinic Mercy Hospital|Mercy Hematology and Oncology Associates Inc|Aultman Health Foundation|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Geauga Hospital|Adena Regional Medical Center|Oncology Hematology Care Inc-Eden Park|Oncology Hematology Care Inc-Mercy West|The Christ Hospital|Good Samaritan Hospital - Cincinnati|Cincinnati Children's Hospital Medical Center|Oncology Hematology Care Inc-Anderson|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|Oncology Hematology Care Inc-Blue Ash|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|Case Western Reserve University|MetroHealth Medical Center|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Delaware Radiation Oncology|Grady Memorial Hospital|Columbus Oncology and Hematology Associates|Dublin Methodist Hospital|Hematology Oncology Center Incorporated|Mercy Cancer Center-Elyria|Oncology Hematology Care Inc-Healthplex|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Toledo Clinic Cancer Centers-Maumee|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center|UH Seidman Cancer Center at Landerbrook Health Center|UH Seidman Cancer Center at Lake Health Mentor Campus|UH Seidman Cancer Center at Southwest General Hospital|Dayton Physicians LLC-Signal Point|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Saint Charles Hospital|University Hospitals Parma Medical Center|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|UH Seidman Cancer Center at Firelands Regional Medical Center|Dayton Physicians LLC-Wilson|Springfield Regional Cancer Center|Springfield Regional Medical Center|Trinity's Tony Teramana Cancer Center|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|Saint Vincent Mercy Medical Center|University of Toledo|Mercy Health - Saint Anne Hospital|Toledo Clinic Cancer Centers-Toledo|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|University Hospitals Sharon Health Center|Saint Joseph Warren Hospital|Saint Ann's Hospital|UH Seidman Cancer Center at Saint John Medical Center|UHHS-Westlake Medical Center|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Integris Southwest Medical Center|Mercy Hospital Oklahoma City|Integris Cancer Institute of Oklahoma|Cancer Treatment Centers of America|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Good Samaritan Hospital|Legacy Mount Hood Medical Center|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Legacy Good Samaritan Hospital and Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Kaiser Permanente Northwest|Oregon Health and Science University|Saint Charles Health System-Redmond|Legacy Meridian Park Hospital|Jefferson Abington Hospital|Lehigh Valley Hospital-Cedar Crest|UPMC Altoona|UPMC-Heritage Valley Health System Beaver|Lehigh Valley Hospital - Muhlenberg|Bryn Mawr Hospital|UPMC Hillman Cancer Center at Butler Health System|UPMC Camp Hill|Carlisle Regional Cancer Center|Christiana Care Health System-Concord Health Center|Chambersburg Hospital|Main Line Health Center-Collegeville|UPMC Hillman Cancer Center - Passavant - Cranberry|Geisinger Medical Center|Doylestown Hospital|Pocono Medical Center|Easton Hospital|Ephrata Cancer Center|Ephrata Community Hospital|UPMC Hillman Cancer Center Erie|UPMC Hamot|Main Line Health Center-Exton|UPMC Cancer Center at UPMC Horizon|Adams Cancer Center|UPMC Cancer Centers - Arnold Palmer Pavilion|Oncology Hematology Associates|Cherry Tree Cancer Center|UPMC Pinnacle Harrisburg|UPMC Pinnacle Cancer Center/Community Osteopathic Campus|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Penn State Milton S Hershey Medical Center|IRMC Cancer Center|UPMC-Johnstown/John P. Murtha Regional Cancer Center|Armstrong Center for Medicine and Health|Lancaster General Ann B Barshinger Cancer Institute|Lancaster General Hospital|Sechler Family Cancer Center|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|UPMC Cancer Center at UPMC McKeesport|Holy Redeemer Hospital and Medical Center|UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion|Riddle Memorial Hospital|Forbes Hospital|UPMC Hillman Cancer Center - Monroeville|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Hillman Cancer Center - Part of Frick Hospital|Arnold Palmer Cancer Center Medical Oncology Norwin|Allegheny Valley Hospital|UPMC Cancer Center-Natrona Heights|UPMC Hillman Cancer Center - New Castle|Suburban Community Hospital and Cancer Center|Paoli Memorial Hospital|Drexel University School of Medicine|Thomas Jefferson University Hospital|Fox Chase Cancer Center|Jefferson Torresdale Hospital|Eastern Regional Medical Center|Nazareth Hospital|Phoenixville Hospital|Allegheny General Hospital|UPMC-Magee Womens Hospital|Oncology Hematology Association|UPMC-Saint Margaret|UPMC-Mercy Hospital|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Geisinger Cancer Services-Pottsville|Penn State Health Saint Joseph Medical Center|Guthrie Medical Group PC-Robert Packer Hospital|Hematology and Oncology Associates of North East Pennsylvania|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|UPMC Cancer Center at UPMC Northwest|Geisinger Medical Group|Mount Nittany Medical Center|UPMC Cancer Center-Uniontown|UPMC Cancer Center-Washington|Chester County Hospital|UPMC West Mifflin-Cancer Center Jefferson|Reading Hospital|Geisinger Wyoming Valley/Henry Cancer Center|UPMC Susquehanna|Divine Providence Hospital|Asplundh Cancer Pavilion|Lankenau Medical Center|WellSpan Health-York Cancer Center|WellSpan Health-York Hospital|UPMC Memorial|Newport Hospital|Rhode Island Hospital|Women and Infants Hospital|Miriam Hospital|Smilow Cancer Hospital Care Center - Westerly|AnMed Health Cancer Center|Beaufort Memorial Hospital|Prisma Health Cancer Institute - Spartanburg|Roper Hospital|Charleston Oncology - Roper|Lowcountry Hematology Oncology PA-North Charleston|Bon Secours Saint Francis Hospital|Charleston Oncology - Saint Francis|Lowcountry Hematology Oncology PA-West Ashley|Medical University of South Carolina|Prisma Health Cancer Institute - Easley|McLeod Regional Medical Center|Gibbs Cancer Center-Gaffney|Tidelands Georgetown Memorial Hospital|Greenville Health System Cancer Institute-Andrews|Saint Francis Hospital|Prisma Health Cancer Institute - Butternut|Prisma Health Cancer Institute - Faris|Prisma Health Greenville Memorial Hospital|Saint Francis Cancer Center|Prisma Health Cancer Institute - Eastside|Self Regional Healthcare|Prisma Health Cancer Institute - Greer|Gibbs Cancer Center-Pelham|South Carolina Cancer Specialists PC|The Radiation Oncology Center-Hilton Head/Bluffton|Lowcountry Hematology Oncology PA-Mount Pleasant|Prisma Health Cancer Institute - Seneca|North Grove Medical Park|Spartanburg Medical Center|Spartanburg Medical Center - Mary Black Campus|MGC Hematology Oncology-Union|Avera Cancer Institute-Aberdeen|Rapid City Regional Hospital|Sanford Cancer Center Oncology Clinic|Avera Cancer Institute|Sanford USD Medical Center - Sioux Falls|Memorial Hospital|Integrity Oncology PLLC-Collierville|Cookeville Regional Medical Center|Vanderbilt-Ingram Cancer Center Cool Springs|Pulmonary Medicine Center of Chattanooga-Hixson|Tennessee Cancer Specialists-Dowell Springs|Thompson Cancer Survival Center|Thompson Cancer Survival Center - West|Thompson Oncology Group-Maryville|Baptist Memorial Hospital and Cancer Center-Memphis|Family Cancer Center-Memphis|Vanderbilt Breast Center at One Hundred Oaks|Meharry Medical College|Vanderbilt University/Ingram Cancer Center|Thompson Oncology Group-Oak Ridge|Memorial GYN Plus|Dell Seton Medical Center at The University of Texas|Saint Joseph Regional Cancer Center|MD Anderson in The Woodlands|Parkland Memorial Hospital|Baylor University Medical Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Houston Methodist Hospital|M D Anderson Cancer Center|Memorial Hermann Texas Medical Center|MD Anderson West Houston|Memorial Hermann Northeast Hospital|MD Anderson League City|Covenant Medical Center-Lakeside|UT Southwestern Clinical Center at Richardson/Plano|Cancer Therapy and Research Center at The UT Health Science Center at San Antonio|Methodist Children's Hospital of South Texas|University Hospital|University of Texas Health Science Center at San Antonio|MD Anderson in Sugar Land|Memorial Hermann The Woodlands Hospital|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Farmington Health Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Riverton Hospital|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|Huntsman Cancer Institute/University of Utah|LDS Hospital|South Jordan Health Center|Central Vermont Medical Center/National Life Cancer Treatment|University of Vermont Medical Center|University of Vermont and State Agricultural College|Norris Cotton Cancer Center-North|Danville Regional Medical Center|Inova Schar Cancer Institute|Inova Fair Oaks Hospital|Inova Fairfax Hospital|Augusta Health Center for Cancer and Blood Disorders|Hematology Oncology Associates of Fredericksburg Inc|Centra Lynchburg Hematology-Oncology Clinic Inc|Sovah Health Martinsville|Bon Secours Memorial Regional Medical Center|Bon Secours Westchester Emergency Center|Bon Secours Saint Francis Medical Center|Children's Hospital of The King's Daughters|Bon Secours Saint Mary's Hospital|Virginia Cancer Institute|Bon Secours Cancer Institute at Reynolds Crossing|VCU Massey Cancer Center at Stony Point|Virginia Commonwealth University/Massey Cancer Center|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|MultiCare Auburn Medical Center|Virginia Mason Bainbridge Island Medical Center|Overlake Medical Center|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Virginia Mason Federal Way Medical Center|Saint Francis Hospital|Tacoma/Valley Radiation Oncology Centers-Gig Harbor|MultiCare Gig Harbor Medical Park|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Northwest Cancer Clinic|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Virginia Mason Lynnwood Medical Center|Skagit Valley Hospital Regional Cancer Care Center|Skagit Valley Hospital|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Peninsula Cancer Center|MultiCare Good Samaritan Hospital|Tacoma/Valley Radiation Oncology Centers-Puyallup|Valley Medical Center|Virginia Mason Medical Center|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Fred Hutchinson Cancer Research Center|Seattle Cancer Care Alliance|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|University of Washington Medical Center - Montlake|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|MultiCare Deaconess Cancer and Blood Specialty Center - Valley|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown|Providence Sacred Heart Medical Center and Children's Hospital|Spokane Valley Cancer Center-Mayfair|Spokane Valley Cancer Center-Mission|Evergreen Hematology and Oncology PS|MultiCare Deaconess Cancer and Blood Specialty Center - North|Tacoma/Valley Radiation Oncology Centers-Jackson Hall|Franciscan Research Center-Northwest Medical Plaza|Mary Bridge Children's Hospital and Health Center|MultiCare Tacoma General Hospital|Northwest Medical Specialties PLLC|Tacoma/Valley Radiation Oncology Centers-Saint Joe's|PeaceHealth Southwest Medical Center|Legacy Cancer Institute Medical Oncology and Day Treatment|Legacy Salmon Creek Hospital|Providence Saint Mary Regional Cancer Center|Wenatchee Valley Hospital and Clinics|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|United Hospital Center|West Virginia University Charleston Division|Edwards Comprehensive Cancer Center|WVUH-Berkely Medical Center|Monongalia Hospital|West Virginia University Healthcare|Camden Clark Medical Center|Wheeling Hospital/Schiffler Cancer Center|Langlade Hospital and Cancer Center|Ascension Saint Elizabeth Hospital|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Ascension Southeast Wisconsin Hospital - Elmbrook Campus|Aurora Cancer Care-Southern Lakes VLCC|Ascension Calumet Hospital|Marshfield Clinic-Chippewa Center|Aurora Saint Luke's South Shore|HSHS Sacred Heart Hospital|Marshfield Clinic Cancer Center at Sacred Heart|Marshfield Medical Center-EC Cancer Center|Aurora Health Center-Fond du Lac|Ascension Saint Francis - Reiman Cancer Center|Ascension Southeast Wisconsin Hospital - Franklin|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Green Bay Oncology at Saint Vincent Hospital|Saint Vincent Hospital Cancer Center Green Bay|Green Bay Oncology Limited at Saint Mary's Hospital|Saint Vincent Hospital Cancer Center at Saint Mary's|Aurora BayCare Medical Center|Mercyhealth Hospital and Cancer Center - Janesville|Aurora Cancer Care-Kenosha South|Gundersen Lutheran Medical Center|Marshfield Clinic - Ladysmith Center|University of Wisconsin Carbone Cancer Center|Holy Family Memorial Hospital|Aurora Bay Area Medical Group-Marinette|Saint Vincent Hospital Cancer Center at Marinette|Marshfield Medical Center-Marshfield|Marshfield Medical Center|Aspirus Medford Hospital|Ascension Columbia Saint Mary's Hospital Ozaukee|Aurora Cancer Care-Milwaukee|Ascension Southeast Wisconsin Hospital - Saint Joseph Campus|Ascension Columbia Saint Mary's Hospital - Milwaukee|Ascension Saint Francis Hospital|Aurora Saint Luke's Medical Center|Medical College of Wisconsin|Aurora Sinai Medical Center|Marshfield Clinic-Minocqua Center|ProHealth D N Greenwald Center|Cancer Center of Western Wisconsin|ProHealth Oconomowoc Memorial Hospital|Saint Vincent Hospital Cancer Center at Oconto Falls|Ascension Mercy Hospital|Vince Lombardi Cancer Clinic - Oshkosh|Ascension All Saints Hospital|Aurora Cancer Care-Racine|Ascension Saint Mary's Hospital|Saint Mary's Hospital|Lakeview Medical Center-Marshfield Clinic|Marshfield Medical Center-Rice Lake|HSHS Saint Nicholas Hospital|Vince Lombardi Cancer Clinic-Sheboygan|Ascension Saint Michael's Hospital|Marshfield Clinic Stevens Point Center|Saint Vincent Hospital Cancer Center at Sturgeon Bay|Green Bay Oncology - Sturgeon Bay|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|Aurora Cancer Care-Waukesha|ProHealth Waukesha Memorial Hospital|UW Cancer Center at ProHealth Care|Aspirus Regional Cancer Center|Marshfield Clinic-Wausau Center|Ascension Medical Group Southeast Wisconsin - Mayfair Road|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center|Diagnostic and Treatment Center|Marshfield Medical Center - Weston|Aspirus Cancer Care - Wisconsin Rapids|Marshfield Clinic - Wisconsin Rapids Center|Cheyenne Regional Medical Center-West|Big Horn Basin Cancer Center|Billings Clinic-Cody|Welch Cancer Center|FHP Health Center-Guam|Cancer Center-Metro Medical Center Bayamon|Doctors Cancer Center|San Juan Community Oncology Group|San Juan City Hospital,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Other|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Other|Drug|Drug|Biological|Drug|Drug|Biological|Drug|Biological|Drug|Drug|Drug|Drug|Biological|Biological|Drug|Drug,Guam|Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02465060
1672,NCT02465424,thyroid neoplasms,Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients,Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients,Medullary Thyroid Cancer,2015-06-01,2017-12-31,2017-12-31,173.0,Case-Only,,Other,Observational,Completed,,Velindre NHS Trust,Velindre NHS Trust,Velindre Hospital|University Hospitals of Coventry and Warwickshire|Western general Hospital|Imperial Hospital|St. Bartholomew's Hospital|Christie Hospital|Weston Park Hospital,Other,United Kingdom,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02465424
1673,NCT02467244,hypothyroidism,"Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism","Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism",Hypothyroidism,2015-06-04,2018-09-30,2018-12-30,120.0,Cohort,,Prospective,Observational,Completed,,"All India Institute of Medical Sciences, Bhubaneswar","All India Institute of Medical Sciences, Bhubaneswar","AIIMS, Bhubaneswar",Drug,India,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02467244
1674,NCT02468921,goiter,The Impact of Surgical Treatment of Benign Non-toxic Goiter on the Voice Function,Goitres Influence on Voice Function - The Impact of Surgery,Goiter,2015-01-19,2018-10-31,2018-10-31,60.0,Cohort,,Prospective,Observational,Unknown status,,University of Southern Denmark,Odense University Hospital|University of Southern Denmark,Odense University Hospital,Procedure,Denmark,20.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02468921
1675,NCT02472080,thyroid neoplasms,Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients,Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study,Thyroid Cancer,2015-05-12,2018-04-01,2019-01-15,21.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Groupe Hospitalier Piti Salpetriere,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02472080
1676,NCT02491502,thyroid nodule,Treatment of Benign Thyroid Nodules With FastScan High Intensity Focused Ultrasound (HIFU),Treatment of Benign Thyroid Nodules With FastScan HIFU,Benign Thyroid Nodules,2015-06-24,2020-04-30,2020-07-31,36.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,University Hospital of Endocrinology USBALE,Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02491502
1677,NCT02491502,thyroid neoplasms,Treatment of Benign Thyroid Nodules With FastScan High Intensity Focused Ultrasound (HIFU),Treatment of Benign Thyroid Nodules With FastScan HIFU,Benign Thyroid Nodules,2015-06-24,2020-04-30,2020-07-31,36.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,University Hospital of Endocrinology USBALE,Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02491502
1679,NCT02491567,goiter,Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases,DNA Methylation and Autoimmune Thyroid Diseases,Graves Disease|Hashimoto Thyroiditis,2014-12-23,2016-09-30,2018-04-30,110.0,Case-Control,,Cross-Sectional,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",,Greece,4.0,18.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02491567
1681,NCT02491567,graves disease,Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases,DNA Methylation and Autoimmune Thyroid Diseases,Graves Disease|Hashimoto Thyroiditis,2014-12-23,2016-09-30,2018-04-30,110.0,Case-Control,,Cross-Sectional,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",,Greece,4.0,18.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02491567
1682,NCT02491567,"thyroiditis, autoimmune",Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases,DNA Methylation and Autoimmune Thyroid Diseases,Graves Disease|Hashimoto Thyroiditis,2014-12-23,2016-09-30,2018-04-30,110.0,Case-Control,,Cross-Sectional,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",,Greece,4.0,18.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02491567
1683,NCT02491567,hyperthyroidism,Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases,DNA Methylation and Autoimmune Thyroid Diseases,Graves Disease|Hashimoto Thyroiditis,2014-12-23,2016-09-30,2018-04-30,110.0,Case-Control,,Cross-Sectional,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",,Greece,4.0,18.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02491567
1684,NCT02499471,hypothyroidism,Brown Adipose Tissue Activity and Thyroid Hormone,Brown Adipose Tissue Activity and Thyroid Hormone,Hyperthyroidism|Hypothyroidism|Obesity,2015-07-06,2012-12-31,2014-07-31,12.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Maastricht University Medical Center,Maastricht University Medical Center,Maastricht UMC,Other,Netherlands,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02499471
1685,NCT02499471,hyperthyroidism,Brown Adipose Tissue Activity and Thyroid Hormone,Brown Adipose Tissue Activity and Thyroid Hormone,Hyperthyroidism|Hypothyroidism|Obesity,2015-07-06,2012-12-31,2014-07-31,12.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Maastricht University Medical Center,Maastricht University Medical Center,Maastricht UMC,Other,Netherlands,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02499471
1686,NCT02500342,hypothyroidism,Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism,Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism,Fatigue|Mental Fatigue|Thyroid Dysfunction,2015-06-18,2018-04-05,2018-04-05,276.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University Hospital Inselspital, Berne","University College Cork|University Hospital Inselspital, Berne|University of Lausanne Hospitals","University College Cork, National University of Ireland|Department of General Internal Medicine|Clinic for General Internal Medicine, Bern University Hospital Bern",Drug|Drug,Ireland|Switzerland,65.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02500342
1687,NCT02512978,hypothyroidism,Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction,Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI),Hypothyroidism|Myocardial Infarction,2015-07-27,2018-12-31,2019-06-30,160.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,"Chinese Academy of Medical Sciences, Fuwai Hospital","Beijing Anzhen Hospital|Beijing Chao Yang Hospital|Beijing Friendship Hospital|Beijing Municipal Science & Technology Commission|Chinese Academy of Medical Sciences, Fuwai Hospital|Peking Union Medical College Hospital|Peking University Third Hospital|The Luhe Teaching Hospital of the Capital Medical University",Fuwai Cardiovascular Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02512978
1688,NCT02514187,hyperthyroidism,A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients,A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients,Hyperthyroidism,2015-07-27,2017-04-30,2017-04-30,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,British Columbia Cancer Agency,"British Columbia Cancer Agency|Canadian Institutes of Health Research (CIHR)|Centre for Probe Development and Commercialization|Lawson Health Research Institute|Natural Resources, Canada|TRIUMF",Vancouver General Hospital - Nuclear Medicine|Hamilton Health Sciences Centre|London Regional Health Sciences Centre,Drug|Drug,Canada,19.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02514187
1689,NCT02515084,thyroid neoplasms,Preliminary Study of the Interest of Diffusion-weighted Magnetic Resonance Imaging in the Early Detection of Differentiated Thyroid Carcinoma Cervical Recurrence. Comparison with18F-FDG PET/CT,Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma,Relapse|Thyroid Cancer,2015-07-24,2015-07-31,2016-07-31,37.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Centre Henri Becquerel,Centre Henri Becquerel,Centre Henri Becquerel,Device|Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02515084
1690,NCT02516774,"thyroid carcinoma, anaplastic","A Phase I Trial Assessing Adalimumab (Humira), a Tumor Necrosis Factor  Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers",A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers,Anaplastic Thyroid Cancers,2015-04-29,2015-12-31,2015-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy Cancer Campus Grand Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02516774
1692,NCT02523209,hyperparathyroidism,Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation - A Monocentric Study,Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation,"Chronic Kidney Diseases|Hyperparathyroidism, Secondary",2015-07-15,2017-04-30,2017-04-30,102.0,Cohort,,Prospective,Observational,Completed,,Centre Hospitalier Universitaire de Saint Etienne,Centre Hospitalier Universitaire de Saint Etienne,Chu Saint-Etienne,Device|Device,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02523209
1695,NCT02524041,hyperparathyroidism,Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism,Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism,Hyperparathyroidism,2015-08-13,2016-04-30,2016-04-30,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Saint Etienne,"Centre Hospitalier Universitaire de Saint Etienne|University Hospital, Geneva",CHU de SAINT-ETIENNE,Device|Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02524041
1700,NCT02525796,hyperparathyroidism,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2015-08-14,2021-10-01,2021-10-02,69.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Drug|Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02525796
1701,NCT02535975,goiter,,The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy,Mild Graves' Ophthalmopathy,2015-08-12,2019-10-31,2019-10-31,80.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Endocrinology, Internal Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02535975
1702,NCT02535975,hyperthyroidism,,The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy,Mild Graves' Ophthalmopathy,2015-08-12,2019-10-31,2019-10-31,80.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Endocrinology, Internal Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02535975
1703,NCT02535975,graves ophthalmopathy,,The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy,Mild Graves' Ophthalmopathy,2015-08-12,2019-10-31,2019-10-31,80.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Endocrinology, Internal Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02535975
1704,NCT02535975,graves disease,,The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy,Mild Graves' Ophthalmopathy,2015-08-12,2019-10-31,2019-10-31,80.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Endocrinology, Internal Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02535975
1706,NCT02536287,hyperparathyroidism,Comparison of Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Without Autotransplantation:A Randomized Clinical Trial,Comparison of Total Parathyroidectomy With and Without Autotransplantation,Secondary Hyperparathyroidism,2015-08-22,2016-12-31,2018-12-31,96.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,The Second Hospital of Anhui Medical University,The Second Hospital of Anhui Medical University,the Second Affiliated Hospital of Anhui Medical University,Procedure|Procedure,China,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02536287
1709,NCT02539498,hyperparathyroidism,Characterization of Bone Architectural Parameters Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Post-menopausal Women Affected With Primary Hyperparathyroidism,Bone Architectural Parameters in Postmenopausal Women Affected With Primary Hyperparathyroidism,Bone Disease|Primary Hyperparathyroidism,2015-04-27,2016-12-31,2016-12-31,82.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Hopital Lariboisiere|Hopital Cochin|Hopital Europeen Georges Pompidou,Device,France,0.0,81.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02539498
1711,NCT02548715,hypothyroidism,Levothyroxine Treatment of Subclinical Hypothyroidism After Non-thyroid Head and Neck Surgery: A Randomized Controlled Trial,Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery,Hypothyroidism|Neoplasms|Postoperative Complications,2015-09-08,2017-07-31,2017-07-31,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,University of Alberta,University of Alberta,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02548715
1714,NCT02549391,hyperparathyroidism,"Phase 3 Study of KHK7580 (A Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)",Phase 3 Study of KHK7580,Secondary Hyperparathyroidism,2015-09-09,2016-11-30,2016-11-30,634.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02549391
1717,NCT02549404,hyperparathyroidism,Phase 3 Study of KHK7580 (A Long-term Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis),Phase 3 Study of KHK7580,Secondary Hyperparathyroidism,2015-09-09,2016-12-06,2016-12-28,137.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02549404
1720,NCT02549417,hyperparathyroidism,Phase 3 Study of KHK7580 (A Clinical Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Peritoneal Dialysis),Phase 3 Study of KHK7580,Secondary Hyperparathyroidism,2015-09-09,2016-12-22,2016-12-22,39.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02549417
1723,NCT02551120,pseudohypoparathyroidism,"Characterization of Patients With Idiopathic Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism",Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism,Autosomal Dominant Hypocalcaemia|Idiopathic Hypoparathyroidism|Pseudohypoparathyroidism,2015-06-17,2017-08-31,2020-08-31,100.0,Cohort,,Prospective,Observational,Unknown status,,University of Aarhus,University of Aarhus,Aarhus University Hospital,,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02551120
1724,NCT02551120,hypoparathyroidism,"Characterization of Patients With Idiopathic Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism",Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism,Autosomal Dominant Hypocalcaemia|Idiopathic Hypoparathyroidism|Pseudohypoparathyroidism,2015-06-17,2017-08-31,2020-08-31,100.0,Cohort,,Prospective,Observational,Unknown status,,University of Aarhus,University of Aarhus,Aarhus University Hospital,,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02551120
1725,NCT02556216,hyperparathyroidism,Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD),Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD),Renal Osteodystrophy,2015-08-06,2019-01-31,2019-07-31,100.0,Cohort,,Cross-Sectional,Observational,Unknown status,,Hannover Medical School,Hannover Medical School|University of Jena,Hannover Medical School,,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02556216
1729,NCT02561533,"thyroid cancer, papillary",Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC,Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2015-09-17,2017-07-31,2017-07-31,53.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,Aarhus University Hospital,Other,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02561533
1730,NCT02567877,hypothyroidism,Is Levothyroxine Alone Adequate Thyroid Hormone Replacement for All Patients?,Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?,Hypothyroidism|Postsurgical Hypothyroidism,2015-10-01,2025-06-30,2025-06-30,190.0,Cohort,,Prospective,Observational,Recruiting,,"University of Colorado, Denver","Charite University, Berlin, Germany|University of Colorado, Denver",University of Colorado Anschutz Medical Campus,Procedure|Drug,United States,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02567877
1732,NCT02568267,"thyroid cancer, papillary","An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","Adult Solid Tumor|Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Salivary Gland Cancers|Sarcomas",2015-10-02,2024-12-31,2025-04-01,700.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Western Regional Medical Center at Cancer Treatment Centers of America|Dignity Health St Joseph's Hospital and Medical Center|Mayo Clinic|City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics|Scripps Clinic|University of California San Diego Moores Cancer Center; Dept of Lung Cancer|University of Southern California Medical Center|Univ Of California Irvine College Of Medicine; 300194620|Southern California Kaiser Permanente|UCSF Mount Zion Medical Ctr|Sarcoma Oncology Center|University of Colorado Cancer Center|Yale University|Georgetown University Medical Center Lombardi Cancer Center|Florida Cancer Specialists - Sarasota|H. Lee Moffitt Cancer Center and Research Inst.|Cleveland Clinic Florida|University Cancer & Blood Center, LLC; Research|Winship Cancer Institute|Southeastern Regional Medical Center, Inc.|University of Hawaii Cancer Center|Northwestern University|Advocate Medical Group - Park Ridge, Luther Lane - Oncology|Midwestern Regional Medical Center|Weinberg Cancer Institution at Franklin Square|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana Farber Cancer Institute|University of Michigan Comprehensive Cancer Center; Clinical Trials Office|Karmanos Cancer Center|Henry Ford Hospital|Regents of the University of Minnesota|Washington University|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley|Dartmouth Hitchcock Medical Center|North Shore Hem Onc Associates|Memorial Sloan Kettering Cancer Center|Levine Cancer Institute|Duke Cancer Institute|Cleveland Clinic|OSU, James Cancer Hospital|Cancer Treatment Centers of America; Tulsa|Providence Portland Medical Center|Oregon Health & Science Univ|Cancer Treatment Centers of America - Eastern Regional Medical Center|Mary Crowley Medical Research Center|University Hospital Medical Oncology Clinic; Harold C. Simmons Comprehensive Cancer Center|University of Texas MD Anderson Cancer Center|Baylor Scott & White Health|University of Utah Hospitals & Clinics|Virginia Cancer Specialists, PC|Virginia Oncology Associates - Hampton|University of Washington Seattle Cancer Care Alliance|Wheaton Franciscan Cancer Care-All Saints|Border Medical Oncology Research Unit|Liverpool Hospital|Newcastle Private Hospital|Flinders Medical Centre|Austin Health|Antwerp University Hospital|Beijing Cancer Hospital|Sichuan Provincial Cancer Hospital|Cancer Center of Guangzhou Medical University|Harbin Medical University Cancer Hospital|Fudan University Shanghai Cancer Center|Shanghai chest hospital|Shenzhen People's Hospital|Tianjin Cancer Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Zhejiang Cancer Hospital|Institut de Cancerologie de l Ouest|Institut Bergonie; Oncologie|Centre Oscar Lambret; Chir Cancerologie General|Centre Leon Berard; Departement Oncologie Medicale|Hpital de la Timone; Oncologie Mdicale Hmatologie & Soins Palliatifs|Hpital Nord - AP-HM Marseille#; Service d'Oncologie Multidisciplinaire|Institut de Recherche en Cancrologie de Montpellier|Hpital Europen Georges Pompidou; Hmatologie Oncologie|Institut Curie; Oncologie Medicale|Institut De Cancerologie De L'ouest - Rene Gauducheau - Biology|Institut Claudius Regaud; Departement Oncologie Medicale|Institut Gustave Roussy; Pathologie Thoracique|Charite Universitaetsmedizin Berlin - Campus Charite Mitte ; Charite Comprehensive Cancer Center|Evang. Lungenklinik Berlin Klinik fr Pneumologie|Universitaetsklinikum Carl Gustav Carus TU Dresden|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie|Universitaetsmedizin Goettingen; Abteilung Haematologie und Onkologie|NCT Uniklinikum Heidelberg; Medizinische Onkologie|Universitaetsklinikum Koeln; Innere Medizin I, Haematologie|Hong Kong Integrated Oncology Centre|Princess Margaret Hospital|The University of Hong Kong|Queen Elizabeth Hospital|The Chinese University of Hong Kong|Seconda Universit degli Studi di Napoli; Servizio Epato-Gastroenterologia|Universit Campus Bio-Medico di Roma; Oncologia Medica|Azienda Ospedaliero Universitaria San Martino; Lung Cancer Unit|Fondazione IRCCS Istituto Nazionale dei Tumori|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck|Fondazione del Piemonte per l'Oncologia - IRCCS;Ematologia|Azienda Ospedaliero-Universitaria S.Luigi Gonzaga; SSD Oncologia Polmonare|A.O Citt della Salute e della Scienza di Torino; Colorectal Cancer Unit (CRCU) - SSCVD|Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia ; S.C. Oncologia Medica|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II|Aichi Cancer Center Hospital; Respiratory Medicine|NHO Shikoku Cancer Center; Dept of Respiratory Medicine|NHO Kyushu Cancer Center|Hyogo Cancer Center, Dept of Respiratory Medicine|National Cancer Center Hospital; Dept of Respiratory Medicine|Miyagi Cancer Center; Respiratory Medicine|Niigata Cancer Center Hospital; Internal Medicine|OSAKA CITY GENERAL HOSPITAL;Medical Oncology|Kindai University Hospital; Medical Oncology|Shizuoka Cancer Center; Respiratory Internal Medicine|Chungbuk National University Hospital|Seoul National University Hospital|Severance Hospital, Yonsei University Health System|Samsung Medical Center|Asan Medical Center.|NKI The Netherlands Cancer Institute|Leids Universitair Medisch Centrum|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii|Centrum Onkologii-Instytut im.M.Sklodowskiej Curie; Dept of Nuclear Med. and Endocrine Oncology|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology & subdiv. of oncology|Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego; Chemotherapy|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego|National University Hospital; Haematology/Oncology|National Cancer Centre|Centro Nacional de Investigaciones Oncolgicas(CNIO); Gastrointestinal Cancer Clinical Research Unit|Vall dHebron Institute of Oncology (VHIO), Barcelona|Hospital Universitario de La Princesa; Servicio de Oncologia|Hospital Universitario Ramon y Cajal; Servicio de Farmacia|Hospital Universitario Clnico San Carlos; Servicio de Oncologia|Hospital Universitario 12 de Octubre; Servicio de Oncologia|Hospital Universitario La Paz; Servicio de Oncologia|Centro Integral Oncologico Clara Campal; Servicio de Oncologa|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia|Hospital Universitario Virgen del Rocio; Servicio de Oncologia|Changhua Christian Hospital|National Cheng Kung University Hospital|Taipei Veterans General Hospital|National Taiwan University Hospital|Taichung Veterans General Hospital|Addenbrookes Hospital|Sarah Cannon Research Institute|Christie Hospital Nhs Trust; Medical Oncology",Drug,"Australia|Belgium|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02568267
1733,NCT02577367,hypothyroidism,The Effect of Holding Tube Feeding When Administering Levothyroxine on the Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding,Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding,Hypothyroidism,2015-09-14,2020-04-08,2020-04-08,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,Maimonides Medical Center,Jocelyne Karam|Maimonides Medical Center,Maimonides Medical Center,Drug,United States,18.0,100.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02577367
1734,NCT02586337,thyroid neoplasms,"A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032)",Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032),Differentiated Thyroid Cancer,2015-10-22,2019-12-31,2019-12-31,113.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Tongren Hospital|Peking Union Medical College Hospital|Chongqing Cancer Hospital|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Harbin medical university affiliated tumor hospital|Henan Province Tumor Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Hunan Province Tumor Hospital|Jiangsu province tumor hospital|Jilin Cancer Hospital|Liaoning Province Tumor Hospital|Cancer Hospital of Fudan University|West China Hospital Of Sichuan University|20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .|The First Affiliated Hospital of Kunming Medical University|Zhejiang Cancer Hospital",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02586337
1735,NCT02586350,thyroid neoplasms,"A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031)",Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031),Medullary Thyroid Carcinoma,2015-10-22,2018-09-30,2018-09-30,91.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Tongren Hospital|Peking Union Medical College Hospital|Chongqing Cancer Hospital|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Harbin medical university affiliated tumor hospital|Henan Province Tumor Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Hunan Province Tumor Hospital|Jiangsu province tumor hospital|Jilin Cancer Hospital|Liaoning Province Tumor Hospital|Cancer Hospital of Fudan University|West China Hospital Of Sichuan University|20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .|The First Affiliated Hospital of Kunming Medical University|Zhejiang Cancer Hospital",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02586350
1737,NCT02591160,hyperparathyroidism,Optimal Hydrochlorothiazide Cessation in Diagnosis of Hyperparathyroidism,Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism,Hyperparathyroidism,2015-10-27,2017-09-13,2017-09-13,2.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Missouri-Columbia,University of Missouri-Columbia,University of Missouri,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02591160
1738,NCT02592356,thyroid neoplasms,Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study,Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer,Differentiated Thyroid Gland Carcinoma|Malignant Adrenal Gland Pheochromocytoma|Malignant Paraganglioma|Thyroid Gland Medullary Carcinoma,2015-10-27,2022-11-30,2022-11-30,23.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Procedure|Procedure|Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02592356
1739,NCT02602717,thyroid neoplasms,,"The Evaluation of the Diagnostic Properties of Intra-operative In-situ Thyroglobin Levels of Cervical Lymph Nodes, in the Discrimination Between Benign and Malignant Lymph Nodes in Thyroid Cancer: a Prospective Multicentre Study.",Thyroid Cancer,2015-10-22,2017-05-17,2018-12-31,110.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,APHM,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02602717
1740,NCT02609685,thyroid neoplasms,Active Surveillance of Papillary Thyroid Microcarcinoma,Active Surveillance of Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2015-11-18,2030-12-31,2030-12-31,216.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Cedars-Sinai Medical Center,Cedars-Sinai Medical Center,Cedars-Sinai Medical Center,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02609685
1741,NCT02614495,thyroid neoplasms,"A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)",Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma,Thyroid Carcinoma,2015-11-24,2018-09-30,2018-09-30,66.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Hutchison Medipharma Limited,Hutchison Medipharma Limited,Peking Union Medical College Hospital|Fudan University Shanghai Cancer Center,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02614495
1742,NCT02620085,graves disease,Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status,Thyroid Disease and Personality Study,Graves' Disease,2015-11-04,2021-07-31,2021-07-31,500.0,Cohort,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shyang-Rong Shih,Procedure,Taiwan,20.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02620085
1743,NCT02620085,goiter,Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status,Thyroid Disease and Personality Study,Graves' Disease,2015-11-04,2021-07-31,2021-07-31,500.0,Cohort,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shyang-Rong Shih,Procedure,Taiwan,20.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02620085
1744,NCT02620085,hyperthyroidism,Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status,Thyroid Disease and Personality Study,Graves' Disease,2015-11-04,2021-07-31,2021-07-31,500.0,Cohort,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shyang-Rong Shih,Procedure,Taiwan,20.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02620085
1745,NCT02628067,thyroid neoplasms,A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158),Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),Advanced Cancer|Advanced Solid Tumors|Anal Cancer|Anal Carcinoma|Bile Duct Cancer|Biliary Cancer|Carcinoid Tumor|Cervical Cancer|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Carcinoma|Endometrial Cancer|Endometrial Carcinoma|Mesothelioma|Neuroendocrine Tumor|Parotid Gland Cancer|Salivary Cancer|Salivary Gland Cancer|Salivary Gland Carcinoma|Small Cell Lung Cancer (SCLC)|Small Cell Lung Carcinoma|Thyroid Cancer|Thyroid Carcinoma|Vulvar Cancer|Vulvar Carcinoma,2015-12-09,2026-06-18,2026-06-18,1595.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,"Call for Information (Investigational Site 0202)|Call for Information (Investigational Site 0017)|Call for Information (Investigational Site 0015)|Call for Information (Investigational Site 0010)|Call for Information (Investigational Site 0209)|Call for Information (Investigational Site 0008)|Call for Information (Investigational Site 0004)|Merck Sharp & Dohme|MSD Brasil|Merck Canada|Merck Sharp & Dohme (China) Ltd.|MDS Colombia SAS|Merck Sharp & Dohme|MSD France|MSD Sharp & Dohme GmbH|Merck Sharp & Dohme Co. Ltd.|MSD Italia S.r.l.|MSD Korea LTD|Merck Sharp & Dohme BV|MSD Norge A/S|Merck Sharp & Dohme (I.A.) Corporation|Merck Sharp & Dohme IDEA, Inc.|MSD (Pty) LTD South Africa|Merck Sharp and Dohme de Espana S.A.|Merck Sharp & Dohme (I.A.) Corp.",Biological|Biological,"Australia|Brazil|Canada|China|Colombia|Denmark|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Philippines|Russian Federation|South Africa|Spain|Taiwan|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02628067
1746,NCT02638077,thyroid neoplasms,"A Multi-center, Prospective Study to Observe the Initial Management of Patients With Differentiated Thyroid Cancer in the Real World in China (DTCC Study)",Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China,Differentiated Thyroid Cancer,2015-12-18,2017-04-30,2017-04-30,2000.0,Cohort,,Prospective,Observational,Unknown status,,Huazhong University of Science and Technology,Chinese PLA General Hospital|First Hospital of China Medical University|Gansu Cancer Hospital|Huazhong University of Science and Technology|Jilin University|Sir Run Run Shaw Hospital|The First Affiliated Hospital of Kunming Medical College|Tongji Hospital|West China Hospital,"Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02638077
1749,NCT02644707,"thyroiditis, autoimmune",L-selenomethionine Supplementation in Children and Adolescents With Autoimmune Thyroiditis: a Randomized Blind Placebo-controlled Clinical Trial,Selenium Supplementation in Youths With Autoimmune Thyroiditis,Autoimmune Thyroiditis,2015-12-29,2016-10-31,2018-08-31,100.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",Dietary Supplement|Other,Greece,4.0,18.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02644707
1751,NCT02645786,thyroid neoplasms,Cardiac Effects of Thyrotropin Over-Suppression With Levothyroxine in Young Women With Differentiated Thyroid Cancer,Thyrotropin Over-suppression and Heart,Heart Diseases|Malignant Neoplasm of Thyroid|Thyrotoxicosis on Thyroxine Therapy,2015-12-20,2013-11-30,2014-04-30,31.0,Case-Control,,Prospective,Observational,Completed,,Chuncheon Sacred Heart Hospital,Chuncheon Sacred Heart Hospital,,,,32.0,51.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02645786
1752,NCT02645786,thyrotoxicosis,Cardiac Effects of Thyrotropin Over-Suppression With Levothyroxine in Young Women With Differentiated Thyroid Cancer,Thyrotropin Over-suppression and Heart,Heart Diseases|Malignant Neoplasm of Thyroid|Thyrotoxicosis on Thyroxine Therapy,2015-12-20,2013-11-30,2014-04-30,31.0,Case-Control,,Prospective,Observational,Completed,,Chuncheon Sacred Heart Hospital,Chuncheon Sacred Heart Hospital,,,,32.0,51.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02645786
1753,NCT02648399,"thyroid cancer, papillary",,Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma,Thyroid Papillary Carcinoma,2015-12-13,2016-12-31,2016-12-31,300.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Procedure|Procedure,China,15.0,60.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02648399
1755,NCT02651818,goiter,The Impact of Surgical Treatment of Benign Non-toxic Goiter on Quality of Life,Changes in Quality of Life Following Surgical Treatment of Benign Non-toxic Goiter,Goiter,2016-01-06,2017-10-24,2017-10-24,104.0,Cohort,,Prospective,Observational,Completed,,University of Southern Denmark,University of Southern Denmark,Odense University Hospital,Procedure,Denmark,20.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02651818
1756,NCT02652884,hypoparathyroidism,Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy,Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy,Transient Hypoparathyroidism,2016-01-05,2016-12-31,2017-12-31,110.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Hospital Italiano de Buenos Aires,Hospital Italiano de Buenos Aires,Hospital Italiano de Buenos Aires,Drug|Drug,Argentina,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02652884
1758,NCT02657369,"thyroid carcinoma, anaplastic","An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)",A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC),"Thyroid Carcinoma, Anaplastic",2016-01-13,2018-09-26,2018-09-26,34.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Eisai Inc.,Eisai Inc.,,Drug,Australia|France|Italy|United Kingdom|United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02657369
1760,NCT02657551,thyroid neoplasms,A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,Thyroid Cancer,2015-11-09,2022-12-31,2023-12-31,33.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Dana-Farber Cancer Institute,Bayer|Dana-Farber Cancer Institute,Yale Cancer Center|Dana-Farber Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02657551
1761,NCT02658513,thyroid neoplasms,Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer,Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer,Cancer of the Thyroid|Cancer of Thyroid|Thyroid Cancer|Thyroid Carcinoma,2015-12-24,2019-03-31,2019-03-31,35.0,Cohort,,Prospective,Observational,Completed,,Royal Surrey County Hospital NHS Foundation Trust,Royal Surrey County Hospital NHS Foundation Trust,Royal Surrey County Hospital NHS Foundation Trust,Other|Other,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02658513
1762,NCT02658552,thyroid neoplasms,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,Benign Thyroid Nodules,2016-01-06,2016-02-29,2016-07-31,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02658552
1763,NCT02658552,thyroid nodule,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,Benign Thyroid Nodules,2016-01-06,2016-02-29,2016-07-31,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02658552
1764,NCT02665325,thyroid neoplasms,Cognitive Functions and Mood During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma,Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma,Cognitive Impairment,2016-01-17,2017-12-31,2018-12-31,100.0,Cohort,,Prospective,Observational,Unknown status,,The Affiliated Hospital of Inner Mongolia Medical University,National Natural Science Foundation of China|The Affiliated Hospital of Inner Mongolia Medical University,Shan Jin,Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02665325
1765,NCT02681328,thyroid nodule,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Thyroid,2016-02-10,2023-12-01,2024-12-01,300.0,Cohort,,Prospective,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center at UCLA,Other|Other|Other|Other,United States,18.0,100.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02681328
1766,NCT02681328,thyroid neoplasms,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Thyroid,2016-02-10,2023-12-01,2024-12-01,300.0,Cohort,,Prospective,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center at UCLA,Other|Other|Other|Other,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02681328
1767,NCT02685514,hyperthyroidism,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,Rrelapsed Graves' Disease,2016-02-14,2016-04-30,2016-04-30,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02685514
1768,NCT02685514,goiter,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,Rrelapsed Graves' Disease,2016-02-14,2016-04-30,2016-04-30,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02685514
1769,NCT02685514,graves disease,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,Rrelapsed Graves' Disease,2016-02-14,2016-04-30,2016-04-30,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02685514
1771,NCT02688608,"thyroid carcinoma, anaplastic",Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer,Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,Anaplastic Thyroid Cancer,2016-01-20,2020-10-31,2021-10-31,6.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Stanford University,Merck Sharp & Dohme LLC|Saad A Khan,UT Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02688608
1772,NCT02689609,hypothyroidism,Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma,Post-radiation Hypothyroidism After IMRT for Nasopharyngeal Carcinoma,Complications|Hypothyroidism,2016-02-15,2013-12-31,2016-12-31,149.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,The University of Hong Kong,City University of Hong Kong|The University of Hong Kong,,Radiation,,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02689609
1773,NCT02693808,goiter,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,Thyroid-Associated Ophthalmopathy,2015-12-04,2018-01-31,2018-05-31,29.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Haukeland University Hospital,Haukeland University Hospital,Department of Ophthalmology Haukeland University Hospital,Procedure|Procedure,Norway,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02693808
1774,NCT02693808,graves disease,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,Thyroid-Associated Ophthalmopathy,2015-12-04,2018-01-31,2018-05-31,29.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Haukeland University Hospital,Haukeland University Hospital,Department of Ophthalmology Haukeland University Hospital,Procedure|Procedure,Norway,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02693808
1775,NCT02693808,graves ophthalmopathy,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,Thyroid-Associated Ophthalmopathy,2015-12-04,2018-01-31,2018-05-31,29.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Haukeland University Hospital,Haukeland University Hospital,Department of Ophthalmology Haukeland University Hospital,Procedure|Procedure,Norway,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02693808
1776,NCT02693808,hyperthyroidism,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,Thyroid-Associated Ophthalmopathy,2015-12-04,2018-01-31,2018-05-31,29.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Haukeland University Hospital,Haukeland University Hospital,Department of Ophthalmology Haukeland University Hospital,Procedure|Procedure,Norway,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02693808
1779,NCT02697578,hyperparathyroidism,Artificial Intelligence: to Analyse CKD-MBD in Hemodialysis and Cardiovascular Risk,Artificial Intelligence: a New Alternative to Analyse CKD-MBD in Hemodialysis,Chronic Kidney Disease Mineral and Bone Disorder,2016-02-23,2018-12-19,2018-12-19,197.0,Cohort,,Prospective,Observational,Completed,,Maimnides Biomedical Research Institute of Crdoba,Maimnides Biomedical Research Institute of Crdoba,Hospital Universitario Reina Sofa,,Spain,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02697578
1780,NCT02702388,thyroid neoplasms,"A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile","A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",Thyroid Cancer,2016-03-03,2019-12-12,2020-09-10,241.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Eisai Inc.,Eisai Inc.|Merck Sharp & Dohme LLC,Facility#1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility#2|Facility#1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #1|Royal Brisbane and Women's Hospital|Facility#2|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #6|Facility #1|Facility #2|Facility #3|Facility #2|Facility #3|Facility #4|Facility #5|Facility #1|Facility #1|Facility #6|Facility #7|Facility #2|Facility #4|Facility #2|Facility #1|Facility #1|Facility#1|Facility #1|Facility #3|Facility #4|Facility #1|Facility #2|Facility #2|Facility #1|Facility #1|Facility #4|Facility #3|Facility #4|Facility #1|Facility #2|Facility #1|Facility #3|Facility #1|Facility #2|Facility #1|Facility #2|Facility #1|Facility #2|Facility #1|Facility #2|Facility #3|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1,Drug|Drug,"Australia|Belgium|Canada|Denmark|France|Germany|Israel|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02702388
1781,NCT02706743,thyroid neoplasms,Effect of Radioiodine Remnant Ablation on Quality of Life in Patients With Differentiated Thyroid Cancer:a Prospective Cohort Study,Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer,Thyroid Neoplasms,2015-05-29,2016-12-31,2016-12-31,300.0,Cohort,,Prospective,Observational,Unknown status,,"Southern Medical University, China","Southern Medical University, China","Zhujiang Hospital,Southern Medical University",,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02706743
1783,NCT02708368,hyperparathyroidism,Investigation to Develop Standard Operating Procedures (SOP) for the Determination of Innovative CKD-MBD(Chronic Kidney Disease - Mineral Bone Disorder)-Serum-(Plasma-)Parameters,SOP's for CKD-MBD-Biomarkers,Chronic Kidney Diseases,2016-02-29,2016-09-30,2016-09-30,32.0,Case-Control,,Prospective,Observational,Unknown status,,RWTH Aachen University,RWTH Aachen University,"Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine at the University Hospital, RWTH Aachen|Clinic for Nephrology and Diabetology, Hospital St. Franziskus (Maria-Hilf-Clinic)",Other,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02708368
1785,NCT02709889,thyroid neoplasms,An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors,Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors,Glioblastoma|High Grade Gastroenteropancreatic Neuroendocrine Carcinoma|Large-Cell Neuroendocrine Carcinoma|Malignant Melanoma|Medullary Thyroid Cancer|Neuroendocrine Prostate Cancer|Other Neuroendocrine Carcinoma|Other Solid Tumors,2016-03-02,2019-08-27,2019-08-27,200.0,,Single Group Assignment,,Interventional,Terminated,Phase 1/Phase 2,AbbVie,AbbVie,"Banner MD Anderson Cancer Ctr /ID# 155424|Mayo Clinic - Scottsdale /ID# 155419|University of California, Los Angeles /ID# 155429|Univ California, San Francisco /ID# 155409|Cedars-Sinai Medical Center - West Hollywood /ID# 155428|Univ of Colorado Cancer Center /ID# 155415|Sarah Cannon Research Institute at HealthONE - Denver /ID# 155420|University of Florida - Archer /ID# 155414|Moffitt Cancer Center /ID# 170220|Emory University Hospital /ID# 155417|University of Kentucky Chandler Medical Center /ID# 155423|Johns Hopkins University /ID# 155412|Massachusetts General Hospital /ID# 155411|Dana-Farber Cancer Institute /ID# 171044|Mayo Clinic - Rochester /ID# 155416|Washington University-School of Medicine /ID# 155425|Rutgers Cancer Institute of NJ /ID# 162010|University of New Mexico /ID# 205054|Roswell Park Comprehensive Cancer Center /ID# 162015|Weill Cornell Medical College /ID# 155418|Duke University Medical Center /ID# 155421|Univ Hosp Cleveland /ID# 155410|Oregon Health and Science University /ID# 162011|Greenville Hospital System /ID# 155427|Mary Crowley Cancer Research /ID# 162014|Texas Oncology - Forth Worth /ID# 162045|University of Texas MD Anderson Cancer Center /ID# 155413|University of Utah /ID# 155426|Virginia Cancer Specialists /ID# 162006|Northwest Cancer Specialists, P.C. /ID# 155431",Drug|Drug,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02709889
1786,NCT02710799,thyroid neoplasms,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,3470.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Ps-Graduao em Epidemiologia da UFRGS|Secretaria Estadual da Sade do Estado do Rio Grande do Sul|TelessadeRS / UFRGS,Secretaria Estadual da Sade,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02710799
1787,NCT02710799,hypothyroidism,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,3470.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Ps-Graduao em Epidemiologia da UFRGS|Secretaria Estadual da Sade do Estado do Rio Grande do Sul|TelessadeRS / UFRGS,Secretaria Estadual da Sade,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02710799
1788,NCT02710799,thyroid nodule,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,3470.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Ps-Graduao em Epidemiologia da UFRGS|Secretaria Estadual da Sade do Estado do Rio Grande do Sul|TelessadeRS / UFRGS,Secretaria Estadual da Sade,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02710799
1789,NCT02710799,hyperthyroidism,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,3470.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Ps-Graduao em Epidemiologia da UFRGS|Secretaria Estadual da Sade do Estado do Rio Grande do Sul|TelessadeRS / UFRGS,Secretaria Estadual da Sade,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02710799
1791,NCT02711059,hyperparathyroidism,"Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation",Insulin Resistance in Primary Hyperparathyroidism,Diabetes|Hypercalcemia|Hyperparathyroidism,2015-10-18,2021-12-31,2022-06-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Not Applicable,Karolinska University Hospital,Karolinska University Hospital,Karolinska University Hospital,Procedure,Sweden,50.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02711059
1793,NCT02713256,graves disease,An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease,A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease,Graves' Disease,2016-03-15,2017-04-24,2017-04-24,15.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug,Germany|United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02713256
1794,NCT02713256,goiter,An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease,A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease,Graves' Disease,2016-03-15,2017-04-24,2017-04-24,15.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug,Germany|United States,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02713256
1795,NCT02713256,hyperthyroidism,An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease,A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease,Graves' Disease,2016-03-15,2017-04-24,2017-04-24,15.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug,Germany|United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02713256
1796,NCT02713269,thyroid neoplasms,A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement,Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord,Malignant Digestive System Neoplasm|Metastatic Head and Neck Carcinoma|Metastatic Kidney Carcinoma|Metastatic Malignant Neoplasm in the Spine|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Melanoma|Prostate Carcinoma Metastatic in the Bone|Sarcoma|Solid Neoplasm|Spinal Cord Compression|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Thyroid Gland Carcinoma,2016-03-15,2022-07-01,2022-07-01,60.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Other|Other|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02713269
1797,NCT02714946,thyroid nodule,Prospective Randomized Comparative Study of the Effectiveness and Safety of Ultrasound-guided Laser and Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules,Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules,Thyroid Nodule,2016-02-19,2019-09-30,2020-01-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Campus Bio-Medico University,Campus Bio-Medico University,Santa Maria Goretti Hospital,Device|Device,Italy,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02714946
1798,NCT02714946,thyroid neoplasms,Prospective Randomized Comparative Study of the Effectiveness and Safety of Ultrasound-guided Laser and Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules,Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules,Thyroid Nodule,2016-02-19,2019-09-30,2020-01-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Campus Bio-Medico University,Campus Bio-Medico University,Santa Maria Goretti Hospital,Device|Device,Italy,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02714946
1799,NCT02721992,hyperthyroidism,A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia,Graves' Orbitopathy and Hypercholesterolemia,Graves' Ophthalmopathy|Hypercholesterolemia,2016-03-17,2017-06-30,2017-06-30,250.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02721992
1800,NCT02721992,graves ophthalmopathy,A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia,Graves' Orbitopathy and Hypercholesterolemia,Graves' Ophthalmopathy|Hypercholesterolemia,2016-03-17,2017-06-30,2017-06-30,250.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02721992
1801,NCT02721992,graves disease,A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia,Graves' Orbitopathy and Hypercholesterolemia,Graves' Ophthalmopathy|Hypercholesterolemia,2016-03-17,2017-06-30,2017-06-30,250.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02721992
1802,NCT02721992,goiter,A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia,Graves' Orbitopathy and Hypercholesterolemia,Graves' Ophthalmopathy|Hypercholesterolemia,2016-03-17,2017-06-30,2017-06-30,250.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02721992
1803,NCT02724176,"thyroid cancer, papillary",Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer,Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer,Thyroid Cancer,2016-03-18,2016-01-31,2016-01-31,140.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Beijing Cancer Hospital,Beijing Cancer Hospital,,Drug,,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02724176
1807,NCT02725879,"thyroiditis, autoimmune","Association of Serum Fibroblast Growth Factor 21 (FGF-21) Levels With Resting Metabolic Rate (RMR), in Children and Adolescents With Hashimoto's Thyroiditis.",FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL),Thyroiditis Hashimoto,2016-01-09,2020-09-30,2020-12-31,60.0,Other,,Prospective,Observational,Unknown status,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"2nd Department of Paediatrics, School of Medicine Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital Thessaloniki, Greece",Other,Greece,5.0,18.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02725879
1808,NCT02726282,thyroid neoplasms,Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences,Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey,Thyroid Cancer,2016-03-29,2017-03-31,2017-03-31,0.0,Other,,Prospective,Observational,Withdrawn,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02726282
1810,NCT02726503,"thyroid carcinoma, anaplastic",Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE),Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2016-03-29,2020-02-25,2020-03-20,39.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",Nagoya University Hospital|Fujita Health University Hospital|IUHW Ichikawa Hospital|National Cancer Center Hospital East|Japanese Red Cross Narita Hospital|Kuma Hospital|Kobe Univbersity Hospital|University of Tsukuba Hospital|Iwate Medical University Hospital|Kitasato University Hospital|Showa University Northern Yokohama Hospital|Kanagawa Cancer Center|Miyaghi Cancer Center|Tohoku University Hospital|Shinsyu University School of Medicine Department of Surgery|Nara Hospital Kinki University Faculty of Medicine|Nara Medical University|Osaka Police Hospital|Osaka City University Graduate School of Medicine and Faculty of Medicine|Nippon Medical School Hospital|The Cancer Institute Hospital of JFCR|Ito Hospital|Tokyo Medical University Hospital,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02726503
1811,NCT02727738,graves disease,Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism,Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole,Graves' Disease,2015-06-30,2015-09-30,2015-12-31,30.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Pisa,University of Pisa,Endocrinology Unit,Dietary Supplement|Drug,Italy,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02727738
1812,NCT02727738,goiter,Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism,Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole,Graves' Disease,2015-06-30,2015-09-30,2015-12-31,30.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Pisa,University of Pisa,Endocrinology Unit,Dietary Supplement|Drug,Italy,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02727738
1813,NCT02727738,hyperthyroidism,Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism,Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole,Graves' Disease,2015-06-30,2015-09-30,2015-12-31,30.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Pisa,University of Pisa,Endocrinology Unit,Dietary Supplement|Drug,Italy,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02727738
1814,NCT02731352,thyroid neoplasms,Study of Apatinib in Patients With Local Advanced/Metastatic Iodine-131131I-Refractory/Resistant Differentiated Thyroid Cancer,Study of Apatinib in Patients With Differentiated Thyroid Cancer,Thyroid Cancer,2016-03-07,2020-02-27,2021-02-28,20.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02731352
1815,NCT02747888,thyroid neoplasms,Hereditary Risk Factors for Thyroid Cancer,Hereditary Risk Factors for Thyroid Cancer,Thyroid Cancer,2016-03-31,2024-03-01,2024-03-01,250.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Dana-Farber Cancer Institute,Dana-Farber Cancer Institute,Dana Farber Cancer Institute,Genetic,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02747888
1817,NCT02747979,hyperparathyroidism,The Effect and Safety of Combination Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients,The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients,Hyperparathyroidism|Insomnia|Ostalgia|Refractory Pruritus,2015-05-21,2010-05-31,2010-05-31,20.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"The 1st Affiliated Hospital, Sun Yet-sen University",Other|Other|Other,China,16.0,75.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02747979
1818,NCT02758158,thyroid nodule,Clinical Evaluation of a Prototype Tri-modal Imaging Instrument for Thyroid Cancer,Tri-modal Imaging Instrument for Thyroid Cancer,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2016-03-09,2017-02-28,2017-02-28,9.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",Princess Margaret Cancer Centre,Device,Canada,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02758158
1819,NCT02758158,thyroid neoplasms,Clinical Evaluation of a Prototype Tri-modal Imaging Instrument for Thyroid Cancer,Tri-modal Imaging Instrument for Thyroid Cancer,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2016-03-09,2017-02-28,2017-02-28,9.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",Princess Margaret Cancer Centre,Device,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02758158
1820,NCT02764554,thyroid neoplasms,Post-Marketing Surveillance of Lenvima in Korean Patients,Post-Marketing Surveillance of Lenvima in Korean Patients,Differentiated Thyroid Carcinoma (DTC),2016-05-04,2021-09-29,2021-09-29,132.0,Other,,Prospective,Observational,Completed,,Eisai Inc.,Eisai Korea Inc.,Eisai Trial Site #18|Eisai Trial Site #30|Eisai Trial Site #14|Eisai Trial Site #27|Eisai Trial Site #34|Eisai Trial Site #21|Eisai Trial Site #24|Eisai Trial Site #15|Eisai Trial Site #16|Eisai Trial Site #17|Eisai Trial Site #20|Eisai Trial Site #22|Eisai Trial Site #37|Eisai Trial Site #36|Eisai Trial Site #4|Eisai Trial Site #13|Eisai Trial Site #25|Eisai Trial Site #26|Eisai Trial Site #32|Eisai Trial Site #19|Eisai Trial Site #1|Eisai Trial Site #23|Eisai Trial Site #29|Eisai Trial Site #31|Eisai Trial Site #33|Eisai Trial Site #35|Eisai Trial Site #38|Eisai Trial Site #39|Eisai Trial Site #8|Eisai Trial Site #9|Eisai Trial Site #12|Eisai Trial Site #6,,"Korea, Republic of",0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02764554
1821,NCT02766283,hypothyroidism,Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure,Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure,Hypothyroidism,2016-05-06,2016-08-30,2016-08-30,843.0,Cohort,,Retrospective,Observational,Completed,,Bayer,Bayer,,Drug,Israel,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02766283
1822,NCT02766660,hyperthyroidism,"Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy","Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy",Thyroid Associated Ophthalmopathy,2016-04-24,2013-01-31,2013-01-31,102.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Neon Hospital,Neon Hospital|Ondokuz Mays University,,Device,,12.0,73.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02766660
1823,NCT02766660,goiter,"Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy","Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy",Thyroid Associated Ophthalmopathy,2016-04-24,2013-01-31,2013-01-31,102.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Neon Hospital,Neon Hospital|Ondokuz Mays University,,Device,,12.0,73.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02766660
1824,NCT02766660,graves disease,"Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy","Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy",Thyroid Associated Ophthalmopathy,2016-04-24,2013-01-31,2013-01-31,102.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Neon Hospital,Neon Hospital|Ondokuz Mays University,,Device,,12.0,73.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02766660
1825,NCT02766660,graves ophthalmopathy,"Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy","Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy",Thyroid Associated Ophthalmopathy,2016-04-24,2013-01-31,2013-01-31,102.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Neon Hospital,Neon Hospital|Ondokuz Mays University,,Device,,12.0,73.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02766660
1827,NCT02767245,thyrotoxicosis,Efficacy of Thiamine Supplement for Improve Cardiovascular Function in Patients With Severe Hyperthyroidism,Thiamine Supplement in Patients With Severe Hyperthyroidism,Thyrotoxicosis,2016-05-09,2016-07-31,2016-07-31,12.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Ramathibodi Hospital,Ramathibodi Hospital,"Faculty of Medicine Ramathibodi Hospital, Mahidol University",Drug,Thailand,15.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02767245
1828,NCT02768753,"thyroid cancer, papillary",Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy,Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy,Thyroidectomy|Thyroid Papillary Carcinoma,2016-05-02,2017-04-30,2017-04-30,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jinan Military General Hospital,Jinan Military General Hospital,"Department of thyroid and breast surgery, General Hospital of Jinan Military Area",Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02768753
1830,NCT02772705,goiter,Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans,Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans,Emission-Computed|Hyperthyroidism|Single-Photon|Tomography,2016-05-09,2016-08-31,2017-01-31,100.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,West China Hospital,"Air Force Military Medical University, China|Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|Tianjin Medical University General Hospital|West China Hospital|Zhejiang Cancer Hospital",Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|The People's Hospital of Inner Mongolia Autonomous Region|Fourth Military Medical Universit|West China Hospital|Tianjin Medical University General Hospital|Zhejiang Cancer Hospital,,China,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02772705
1831,NCT02772705,graves disease,Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans,Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans,Emission-Computed|Hyperthyroidism|Single-Photon|Tomography,2016-05-09,2016-08-31,2017-01-31,100.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,West China Hospital,"Air Force Military Medical University, China|Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|Tianjin Medical University General Hospital|West China Hospital|Zhejiang Cancer Hospital",Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|The People's Hospital of Inner Mongolia Autonomous Region|Fourth Military Medical Universit|West China Hospital|Tianjin Medical University General Hospital|Zhejiang Cancer Hospital,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02772705
1832,NCT02772705,hyperthyroidism,Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans,Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans,Emission-Computed|Hyperthyroidism|Single-Photon|Tomography,2016-05-09,2016-08-31,2017-01-31,100.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,West China Hospital,"Air Force Military Medical University, China|Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|Tianjin Medical University General Hospital|West China Hospital|Zhejiang Cancer Hospital",Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|The People's Hospital of Inner Mongolia Autonomous Region|Fourth Military Medical Universit|West China Hospital|Tianjin Medical University General Hospital|Zhejiang Cancer Hospital,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02772705
1833,NCT02773667,thyroid neoplasms,Relationship Between Estimated Glomerular Filtration Rate and Biological Half-life of 131I. Prospective Analysis in Patients With Differentiated Thyroid Carcinoma.,Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine,Thyroid Carcinoma,2016-05-11,2022-07-31,2022-07-31,110.0,Case-Only,,Prospective,Observational,Recruiting,,Jena University Hospital,Jena University Hospital,University Hospital Jena,,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02773667
1834,NCT02778412,thyroid neoplasms,Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Thyroid Cancer in Patients Undergoing Diagnostic Fine Needle Aspirations of the Thyroid,ctDNA in Patients With Thyroid Nodules,Thyroid Adenoma|Thyroid Cancer|Thyroiditis|Thyroid Nodules,2016-05-16,2017-08-31,2017-08-31,66.0,Cohort,,Prospective,Observational,Terminated,,Pathway Genomics,Pathway Genomics,Thyroid & Endocrine Center of Florida,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02778412
1835,NCT02778412,thyroid nodule,Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Thyroid Cancer in Patients Undergoing Diagnostic Fine Needle Aspirations of the Thyroid,ctDNA in Patients With Thyroid Nodules,Thyroid Adenoma|Thyroid Cancer|Thyroiditis|Thyroid Nodules,2016-05-16,2017-08-31,2017-08-31,66.0,Cohort,,Prospective,Observational,Terminated,,Pathway Genomics,Pathway Genomics,Thyroid & Endocrine Center of Florida,,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02778412
1836,NCT02778412,thyroiditis,Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Thyroid Cancer in Patients Undergoing Diagnostic Fine Needle Aspirations of the Thyroid,ctDNA in Patients With Thyroid Nodules,Thyroid Adenoma|Thyroid Cancer|Thyroiditis|Thyroid Nodules,2016-05-16,2017-08-31,2017-08-31,66.0,Cohort,,Prospective,Observational,Terminated,,Pathway Genomics,Pathway Genomics,Thyroid & Endocrine Center of Florida,,United States,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02778412
1837,NCT02781844,hypoparathyroidism,"An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism",Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism,Hypoparathyroidism,2016-04-19,2019-03-08,2019-03-08,34.0,,Crossover Assignment,,Interventional,Completed,Phase 1,Takeda,Shire,"Providence Clinical Research|Indiana University|University Of Kentucky School of Medicine|Crescent City Clinical Research Center, LLC|Massachusetts General Hospital|Mayo Clinic - PPDS|Columbia University Medical Center|Ohio State University Wexner Medical Center|Thomas Jefferson University|New Orleans Center for Clinical Research (NOCCR) - Knoxville|CHU de Quebec-Universite Laval|Aarhus Universitetshospital|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont|Semmelweis Egyetem|Pcsi Tudomnyegyetem",Drug|Drug|Drug,Canada|Denmark|Hungary|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02781844
1839,NCT02784223,thyroid neoplasms,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Thyroid Gland,2016-05-24,2019-03-28,2019-03-28,107.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Cancerople Nord Ouest|Centre Francois Baclesse,Centre Franois Baclesse,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02784223
1840,NCT02784223,thyroid nodule,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Thyroid Gland,2016-05-24,2019-03-28,2019-03-28,107.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Cancerople Nord Ouest|Centre Francois Baclesse,Centre Franois Baclesse,Device,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02784223
1841,NCT02787486,hypoparathyroidism,"A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women",Expanded Noninvasive Genomic Medical Assessment: The Enigma Study,Aneuploidy|Chromosome Deletion|DiGeorge Syndrome|Down Syndrome|Edwards Syndrome|Klinefelter Syndrome|Patau Syndrome|Turner Syndrome,2016-05-26,2018-09-30,2018-09-30,760.0,Family-Based,,Prospective,Observational,Completed,,"Progenity, Inc.","Progenity, Inc.","Valley Perinatal|Heinen Obstectrics & Gynecology|Newlife Wellness OBGYN|Lakeshore Women's Specialists|Cincinnati Obgyn|James D. Kasten, M.D., Inc.|Regional Obstetrical Consultants|Texas Maternal-Fetal Medicine",Other,United States,18.0,54.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02787486
1843,NCT02798965,goiter,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Graves Disease,2016-06-09,2014-05-31,2014-05-31,52.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens,Biological,France,18.0,99.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02798965
1844,NCT02798965,hyperthyroidism,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Graves Disease,2016-06-09,2014-05-31,2014-05-31,52.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens,Biological,France,18.0,99.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02798965
1845,NCT02798965,graves disease,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Graves Disease,2016-06-09,2014-05-31,2014-05-31,52.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens,Biological,France,18.0,99.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02798965
1846,NCT02812888,hyperthyroidism,Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism,Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism,Hyperthyroidism,2016-06-20,2017-03-31,2017-06-30,240.0,Case-Control,,Cross-Sectional,Observational [Patient Registry],Unknown status,,The First People's Hospital of Xuzhou,Hu Hao,"The First People's Hospital of Xuzhou,",Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02812888
1848,NCT02814032,"thyroid cancer, papillary",Differences Protein Expression in Papillary Thyroid Carcinoma,Proteomics of Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2016-06-23,2016-12-31,2017-06-30,32.0,Cohort,,Prospective,Observational,Unknown status,,The Affiliated Hospital of Inner Mongolia Medical University,The Affiliated Hospital of Inner Mongolia Medical University,Shan Jin,,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02814032
1849,NCT02824016,hypothyroidism,A Prospective Multicentric Evaluation of the Rate of Incidence of Hypothyroidism After Supraclavicular Irradiation for Breast Cancer,Evaluation of Hypothyroidism Incidence After Breast Cancer Supraclavicular Irradiation,Irradiation; Adverse Effect|Irradiation Hypothyroidism,2014-08-25,2015-07-31,2020-07-31,500.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Institut Jean-Godinot,Institut Jean-Godinot,Institut Jean Godinot|Centre Paul Strauss|Institut de Cancerologie de Lorraine,Biological|Radiation,France,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02824016
1850,NCT02824718,hypoparathyroidism,A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism,Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism,Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment,2016-07-01,2020-05-28,2020-05-28,16.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Assistance Publique - Hpitaux de Paris,"Assistance Publique - Hpitaux de Paris|Ministry of Health, France",AP-HP Hopital Europeen Georges Pompidou,Drug|Drug|Drug|Drug,France,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02824718
1852,NCT02826746,thyroid neoplasms,,Effect of Intravenous Magnesium on Postoperative Sore Throat After Thyroidectomy,Thyroid Neoplasms,2016-07-06,2019-03-31,2019-03-31,20.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Ajou University School of Medicine,Ajou University School of Medicine,"Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine",Drug|Drug,"Korea, Republic of",20.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02826746
1854,NCT02830789,hyperparathyroidism,Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass in Order to Treat Secondary Hyperparathyroidism: A Clinical Randomized Trial,Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass,"Hyperparathyroidism, Secondary|Roux-en-Y Gastric Bypass",2016-07-06,2017-05-31,2017-05-31,38.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,"Department of Enodocrinology and Internal Medicine, Aarhus University Hospital",Dietary Supplement|Dietary Supplement|Dietary Supplement|Procedure,Denmark,20.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02830789
1856,NCT02831179,thyroid neoplasms,A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors,"Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",Functional Pancreatic Neuroendocrine Tumor|Malignant Somatostatinoma|Merkel Cell Carcinoma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Carcinoid Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Neuroendocrine Neoplasm|Non-Functional Pancreatic Neuroendocrine Tumor|Pancreatic Glucagonoma|Pancreatic Insulinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Merkel Cell Carcinoma|Somatostatin-Producing Neuroendocrine Tumor|Stage III Adrenal Cortex Carcinoma|Stage IIIA Merkel Cell Carcinoma|Stage IIIB Merkel Cell Carcinoma|Stage III Thyroid Gland Medullary Carcinoma|Stage IV Adrenal Cortex Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma|Stage IVB Thyroid Gland Medullary Carcinoma|Stage IVC Thyroid Gland Medullary Carcinoma|Stage IV Merkel Cell Carcinoma|Thymic Carcinoid Tumor|VIP-Producing Neuroendocrine Tumor|Well Differentiated Adrenal Cortex Carcinoma|Zollinger Ellison Syndrome,2016-07-10,2019-02-28,2020-02-29,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,,Drug|Drug|Drug|Other|Other,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02831179
1857,NCT02833857,hyperparathyroidism,"An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis",A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis,"Chronic Kidney Disease, Secondary Hyperparathyroidism",2016-06-09,2018-10-31,2018-10-31,11.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Belgium|Germany|Lithuania|Poland|United Kingdom|United States,2.0,17.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02833857
1860,NCT02834013,thyroid neoplasms,DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors,Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,"Acinar Cell Carcinoma|Adenoid Cystic Carcinoma|Adrenal Cortex Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Angiosarcoma|Apocrine Neoplasm|Appendix Mucinous Adenocarcinoma|Bartholin Gland Transitional Cell Carcinoma|Basal Cell Carcinoma|Bladder Adenocarcinoma|Breast Metaplastic Carcinoma|Cervical Adenocarcinoma|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Desmoid Fibromatosis|Endometrial Transitional Cell Carcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Extramammary Paget Disease|Fallopian Tube Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fibromyxoid Tumor|Gallbladder Carcinoma|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Gastric Undifferentiated Carcinoma|Gastrointestinal Stromal Tumor|Gestational Trophoblastic Tumor|Giant Cell Carcinoma|Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Carcinoid Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Solid Neoplasm|Malignant Testicular Sex Cord-Stromal Tumor|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Pituitary Neuroendocrine Tumor|Minimally Invasive Lung Adenocarcinoma|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Ovarian Transitional Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|PEComa|Peritoneal Mesothelioma|Placental Choriocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Rare Disorder|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Squamous Cell Carcinoma of the Penis|Teratoma With Somatic-Type Malignancy|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Carcinoma",2016-07-13,2023-10-31,2023-10-31,818.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|University of South Alabama Mitchell Cancer Institute|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Fairbanks Memorial Hospital|CTCA at Western Regional Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Highlands Oncology Group PA - Fayetteville|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro|University of Arkansas for Medical Sciences|Highlands Oncology Group|Highlands Oncology Group - Springdale|Kaiser Permanente-Anaheim|Kaiser Permanente-Deer Valley Medical Center|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Sutter Auburn Faith Hospital|Sutter Cancer Centers Radiation Oncology Services-Auburn|AIS Cancer Center at San Joaquin Community Hospital|Kaiser Permanente-Baldwin Park|Kaiser Permanente-Bellflower|Alta Bates Summit Medical Center-Herrick Campus|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|UC Irvine Health Cancer Center-Newport|Sutter Davis Hospital|City of Hope Comprehensive Cancer Center|Epic Care-Dublin|Kaiser Permanente Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Kaiser Permanente-Fontana|Kaiser Permanente-Fremont|Palo Alto Medical Foundation-Fremont|Kaiser Permanente-Fresno|Kaiser Permanente - Harbor City|Keck Medicine of USC Huntington Beach|Kaiser Permanente-Irvine|UC San Diego Moores Cancer Center|Loma Linda University Medical Center|Kaiser Permanente Los Angeles Medical Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|Kaiser Permanente West Los Angeles|Cedars Sinai Medical Center|Contra Costa Regional Medical Center|Fremont - Rideout Cancer Center|Mercy UC Davis Cancer Center|Memorial Medical Center|Kaiser Permanente-Modesto|Palo Alto Medical Foundation-Camino Division|Palo Alto Medical Foundation-Gynecologic Oncology|Providence Queen of The Valley|USC Norris Oncology/Hematology-Newport Beach|Sutter Cancer Research Consortium|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Kaiser Permanente-Oakland|Kaiser Permanente-Ontario|Saint Joseph Hospital - Orange|UC Irvine Health/Chao Family Comprehensive Cancer Center|Desert Regional Medical Center|Palo Alto Medical Foundation Health Care|Kaiser Permanente - Panorama City|Keck Medical Center of USC Pasadena|Eisenhower Medical Center|Kaiser Permanente- Marshall Medical Offices|Kaiser Permanente-Redwood City|Kaiser Permanente-Richmond|Kaiser Permanente-Riverside|Kaiser Permanente-Roseville|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Roseville Medical Center|Kaiser Permanente Downtown Commons|Sutter Medical Center Sacramento|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-South Sacramento|Kaiser Permanente - Sacramento|Kaiser Permanente-San Diego Mission|Kaiser Permanente-San Diego Zion|Sharp Memorial Hospital|California Pacific Medical Center-Pacific Campus|Kaiser Permanente-San Francisco|Kaiser Permanente-Santa Teresa-San Jose|Kaiser Permanente San Leandro|Pacific Central Coast Health Center-San Luis Obispo|Kaiser Permanente-San Marcos|Mills Health Center|Kaiser Permanente-San Rafael|Kaiser San Rafael-Gallinas|Kaiser Permanente Medical Center - Santa Clara|Palo Alto Medical Foundation-Santa Cruz|Mission Hope Medical Oncology - Santa Maria|Kaiser Permanente-Santa Rosa|Providence Medical Foundation - Santa Rosa|Sutter Pacific Medical Foundation|Providence Santa Rosa Memorial Hospital|Kaiser Permanente-South San Francisco|Kaiser Permanente-Stockton|Palo Alto Medical Foundation-Sunnyvale|Gene Upshaw Memorial Tahoe Forest Cancer Center|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Kaiser Permanente Medical Center-Vacaville|Kaiser Permanente-Vallejo|Sutter Solano Medical Center/Cancer Center|Kaiser Permanente-Walnut Creek|Epic Care Cyberknife Center|Kaiser Permanente-Woodland Hills|Rocky Mountain Cancer Centers-Aurora|The Medical Center of Aurora|University of Colorado Hospital|Boulder Community Hospital|Boulder Community Foothills Hospital|Rocky Mountain Cancer Centers-Boulder|Rocky Mountain Cancer Centers - Centennial|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|UCHealth Memorial Hospital Central|Memorial Hospital North|Saint Francis Cancer Center|Cancer Center of Colorado at Sloan's Lake|Denver Health Medical Center|Kaiser Permanente-Franklin|National Jewish Health-Main Campus|The Women's Imaging Center|Porter Adventist Hospital|Colorado Blood Cancer Institute|Presbyterian - Saint Lukes Medical Center - Health One|Rocky Mountain Cancer Centers-Midtown|SCL Health Saint Joseph Hospital|Rocky Mountain Cancer Centers-Rose|Rose Medical Center|Mercy Medical Center|Southwest Oncology PC|Mountain Blue Cancer Care Center - Swedish|Rocky Mountain Cancer Centers - Swedish|Swedish Medical Center|The Melanoma and Skin Cancer Institute|Poudre Valley Hospital|Valley View Hospital Cancer Center|Mountain Blue Cancer Care Center|National Jewish Health-Western Hematology Oncology|Saint Mary's Hospital and Regional Medical Center|Grand Valley Oncology|North Colorado Medical Center|Rocky Mountain Cancer Centers-Greenwood Village|Good Samaritan Medical Center|Kaiser Permanente-Rock Creek|Rocky Mountain Cancer Centers-Lakewood|Saint Anthony Hospital|Rocky Mountain Cancer Centers-Littleton|Littleton Adventist Hospital|Kaiser Permanente-Lone Tree|Rocky Mountain Cancer Centers-Sky Ridge|Sky Ridge Medical Center|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|McKee Medical Center|Parker Adventist Hospital|Rocky Mountain Cancer Centers-Parker|Saint Mary Corwin Medical Center|Rocky Mountain Cancer Centers - Pueblo|National Jewish Health-Northern Hematology Oncology|Rocky Mountain Cancer Centers-Thornton|SCL Health Lutheran Medical Center|Smilow Cancer Hospital-Derby Care Center|Smilow Cancer Hospital Care Center-Fairfield|Smilow Cancer Hospital Care Center - Guiford|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Yale-New Haven Hospital North Haven Medical Center|Stamford Hospital/Bennett Cancer Center|Smilow Cancer Hospital Care Center-Trumbull|Smilow Cancer Hospital-Waterbury Care Center|Veterans Affairs Connecticut Healthcare System-West Haven Campus|Beebe South Coastal Health Campus|Beebe Medical Center|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|TidalHealth Nanticoke / Allen Cancer Center|Christiana Care Health System-Wilmington Hospital|MedStar Georgetown University Hospital|Sibley Memorial Hospital|AdventHealth Altamonte|Mount Sinai Comprehensive Cancer Center at Aventura|Holy Cross Hospital|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|AdventHealth Kissimmee|Mount Sinai Medical Center|AdventHealth Medical Group Urology at Orlando|AdventHealth Orlando|Orlando Health Cancer Institute|AdventHealth East Orlando|Memorial Hospital West|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|AdventHealth Winter Park|Emory University Hospital Midtown|Piedmont Hospital|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|John B Amos Cancer Center|Atlanta VA Medical Center|Piedmont Fayette Hospital|Harbin Clinic Medical Oncology and Clinical Research|Low Country Cancer Care|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler|Summit Cancer Care-Candler|South Georgia Medical Center/Pearlman Cancer Center|Hawaii Cancer Care - Savio|Pali Momi Medical Center|Queen's Cancer Center - Pearlridge|Straub Pearlridge Clinic|The Cancer Center of Hawaii-Pali Momi|The Queen's Medical Center - West Oahu|Hawaii Cancer Care Inc - Waterfront Plaza|Island Urology|Queen's Cancer Cenrer - POB I|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Diagnostic Radiology Services LLC|Kuakini Medical Center|Queen's Cancer Center - Kuakini|The Cancer Center of Hawaii-Liliha|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Straub Medical Center - Kahului Clinic|Castle Medical Center|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Saint Joseph Medical Center|Illinois CancerCare-Bloomington|Loyola Center for Health at Burr Ridge|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Centralia Oncology Clinic|Mount Sinai Hospital Medical Center|Northwestern University|John H Stroger Jr Hospital of Cook County|Rush University Medical Center|University of Chicago Comprehensive Cancer Center|Advocate Illinois Masonic Medical Center|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Northwestern Medicine Cancer Center Kishwaukee|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|Illinois CancerCare-Eureka|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Northwestern Medicine Cancer Center Delnor|Ingalls Memorial Hospital|Loyola Medicine Homer Glen|Presence Saint Mary's Hospital|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Good Samaritan Regional Health Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Illinois CancerCare-Pekin|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center|Illinois CancerCare-Peoria|OSF Saint Francis Radiation Oncology at Peoria Cancer Center|Methodist Medical Center of Illinois|OSF Saint Francis Medical Center|Illinois CancerCare-Peru|Valley Radiation Oncology|Illinois CancerCare-Princeton|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Northwestern Medicine Cancer Center Warrenville|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Midwestern Regional Medical Center|IU Health West Hospital|IU Health North Hospital|Deaconess Clinic Downtown|Parkview Regional Medical Center|Indiana University/Melvin and Bren Simon Cancer Center|Sidney and Lois Eskenazi Hospital|Springmill Medical Center|Memorial Regional Cancer Center Day Road|Chancellor Center for Oncology|Reid Health|Memorial Hospital of South Bend|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Saint Anthony Regional Hospital|Mercy Hospital|Oncology Associates at Mercy Medical Center|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Alegent Health Mercy Hospital|Greater Regional Medical Center|Iowa Methodist Medical Center|Medical Oncology and Hematology Associates-Des Moines|Broadlawns Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|Iowa Lutheran Hospital|McFarland Clinic PC-Trinity Cancer Center|Trinity Regional Medical Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Methodist West Hospital|Mercy Medical Center-West Lakes|Cancer Center of Kansas - Chanute|Coffeyville Regional Medical Center|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|University of Kansas Clinical Research Center|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Saint Catherine Hospital|Central Care Cancer Center - Great Bend|HaysMed University of Kansas Health System|Cancer Center of Kansas-Independence|University of Kansas Cancer Center-West|University of Kansas Cancer Center|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|University of Kansas Hospital-Indian Creek Campus|Cancer Center of Kansas - Parsons|Ascension Via Christi - Pittsburg|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|Cancer Center of Kansas - Wellington|University of Kansas Hospital-Westwood Cancer Center|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Ascension Via Christi Hospitals Wichita|Cancer Center of Kansas - Wichita|Wesley Medical Center|Cancer Center of Kansas - Winfield|Flaget Memorial Hospital|Commonwealth Cancer Center-Corbin|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|Saint Joseph London|Jewish Hospital|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Jewish Hospital Medical Center South|Baton Rouge General Medical Center|Hematology/Oncology Clinic PLLC|Ochsner Health Center-Summa|Medical Center of Baton Rouge|Ochsner High Grove|Ochsner Medical Center Kenner|East Jefferson General Hospital|LSU Healthcare Network / Metairie Multi-Specialty Clinic|Louisiana State University Health Science Center|Tulane University Health Sciences Center|University Medical Center New Orleans|Ochsner Medical Center Jefferson|Eastern Maine Medical Center|Lafayette Family Cancer Center-EMMC|Greater Baltimore Medical Center|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Western Maryland Regional Medical Center|Frederick Memorial Hospital|FMH James M Stockman Cancer Institute|Lahey Hospital and Medical Center|Lahey Medical Center-Peabody|Mercy Medical Center|Baystate Medical Center|Hickman Cancer Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|Bronson Battle Creek|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|University of Michigan - Brighton Center for Specialty Care|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Beaumont Hospital - Dearborn|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Green Bay Oncology - Escanaba|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Helen DeVos Children's Hospital at Spectrum Health|Mercy Health Saint Mary's|Spectrum Health at Butterworth Campus|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Bronson Methodist Hospital|West Michigan Cancer Center|Ascension Borgess Cancer Center|Borgess Medical Center|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Green Bay Oncology-Manistique|Saint Mary's Oncology/Hematology Associates of Marlette|Monroe Cancer Center|Toledo Clinic Cancer Centers-Monroe|Mercy Health Mercy Campus|Lakeland Hospital Niles|Cancer and Hematology Centers of Western Michigan - Norton Shores|Ascension Providence Hospitals - Novi|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Spectrum Health Reed City Hospital|Great Lakes Cancer Management Specialists-Rochester Hills|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Lakeland Medical Center Saint Joseph|Marie Yeager Cancer Center|Henry Ford Macomb Health Center - Shelby Township|Ascension Providence Hospitals - Southfield|Bhadresh Nayak MD PC-Sterling Heights|Ascension Saint Joseph Hospital|Munson Medical Center|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Henry Ford Wyandotte Hospital|Metro Health Hospital|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Sanford Joe Lueken Cancer Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Sanford Thief River Falls Medical Center|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Sanford Cancer Center Worthington|Fairview Lakes Medical Center|Baptist Memorial Hospital and Cancer Center-Golden Triangle|Baptist Cancer Center-Grenada|Gulfport Memorial Hospital|Hattiesburg Clinic - Hematology/Oncology Clinic|Forrest General Hospital / Cancer Center|University of Mississippi Medical Center|Baptist Memorial Hospital and Cancer Center-Union County|Baptist Memorial Hospital and Cancer Center-Oxford|Baptist Memorial Hospital and Cancer Center-Desoto|Saint Louis Cancer and Breast Institute-Ballwin|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Saint Luke's Hospital|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|Kansas City Veterans Affairs Medical Center|The University of Kansas Cancer Center-South|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Mercy Hospital Washington|Community Hospital of Anaconda|Billings Clinic Cancer Center|Saint Vincent Healthcare|Saint Vincent Frontier Cancer Center|Bozeman Deaconess Hospital|Saint James Community Hospital and Cancer Treatment Center|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Community Medical Hospital|CHI Health Saint Francis|Heartland Hematology and Oncology|CHI Health Good Samaritan|Saint Elizabeth Regional Medical Center|Nebraska Cancer Specialists/Oncology Hematology West PC - MECC|Nebraska Methodist Hospital|Oncology Associates PC|Alegent Health Immanuel Medical Center|Hematology and Oncology Consultants PC|Alegent Health Bergan Mercy Medical Center|Alegent Health Lakeside Hospital|Creighton University Medical Center|Midlands Community Hospital|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Hope Cancer Care of Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Cancer Therapy and Integrative Medicine|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|University Cancer Center|Hope Cancer Care of Nevada-Pahrump|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|Dartmouth Hitchcock Medical Center|Norris Cotton Cancer Center-Manchester|Norris Cotton Cancer Center-Nashua|Morristown Medical Center|Chilton Medical Center|Overlook Hospital|Inspira Medical Center Vineland|Lovelace Medical Center-Saint Joseph Square|University of New Mexico Cancer Center|Southwest Gynecologic Oncology Associates Inc|New Mexico Oncology Hematology Consultants|Presbyterian Kaseman Hospital|Memorial Medical Center - Las Cruces|Presbyterian Rust Medical Center/Jorgensen Cancer Center|Christus Saint Vincent Regional Cancer Center|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|Arnot Ogden Medical Center/Falck Cancer Center|Glens Falls Hospital|Laura and Isaac Perlmutter Cancer Center at NYU Langone|University of Rochester|Stony Brook University Medical Center|AdventHealth Infusion Center Asheville|Southeastern Medical Oncology Center-Clinton|AdventHealth Infusion Center Haywood|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Margaret R Pardee Memorial Hospital|AdventHealth Hendersonville|Onslow Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Vidant Oncology-Kenansville|Vidant Oncology-Kinston|Vidant Oncology-Richlands|AdventHealth Infusion Center Weaverville|Sanford Bismarck Medical Center|Essentia Health Cancer Center-South University Clinic|Sanford South University Medical Center|Sanford Broadway Medical Center|Sanford Roger Maris Cancer Center|Essentia Health - Jamestown Clinic|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Cleveland Clinic Mercy Hospital|Mercy Hematology and Oncology Associates Inc|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Adena Regional Medical Center|Good Samaritan Hospital - Cincinnati|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|MetroHealth Medical Center|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Delaware Radiation Oncology|Grady Memorial Hospital|Columbus Oncology and Hematology Associates|Dublin Methodist Hospital|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|OhioHealth Mansfield Hospital|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Toledo Clinic Cancer Centers-Maumee|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center|Dayton Physicians LLC-Signal Point|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|North Coast Cancer Care|Dayton Physicians LLC-Wilson|Springfield Regional Cancer Center|Springfield Regional Medical Center|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|Saint Vincent Mercy Medical Center|Mercy Health - Saint Anne Hospital|Toledo Clinic Cancer Centers-Toledo|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|South Pointe Hospital|Saint Joseph Warren Hospital|Saint Ann's Hospital|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Mercy Hospital Oklahoma City|Cancer Treatment Centers of America|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Legacy Mount Hood Medical Center|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Legacy Good Samaritan Hospital and Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Kaiser Permanente Northwest|Oregon Health and Science University|Saint Charles Health System-Redmond|Legacy Meridian Park Hospital|Lehigh Valley Hospital-Cedar Crest|UPMC-Heritage Valley Health System Beaver|Lehigh Valley Hospital - Muhlenberg|Christiana Care Health System-Concord Health Center|UPMC Hillman Cancer Center - Passavant - Cranberry|Doylestown Hospital|Pocono Medical Center|Saint Vincent Hospital|UPMC Cancer Centers - Arnold Palmer Pavilion|Lehigh Valley Hospital-Hazleton|Jefferson Hospital|UPMC-Johnstown/John P. Murtha Regional Cancer Center|UPMC Cancer Center at UPMC McKeesport|Forbes Hospital|UPMC Hillman Cancer Center - Monroeville|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Hillman Cancer Center - Part of Frick Hospital|Arnold Palmer Cancer Center Medical Oncology Norwin|Thomas Jefferson University Hospital|Eastern Regional Medical Center|Temple University Hospital|Allegheny General Hospital|UPMC-Magee Womens Hospital|UPMC-Presbyterian Hospital|UPMC-Saint Margaret|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Shadyside Hospital|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Pottstown Hospital|UPMC Cancer Center at UPMC Northwest|UPMC Uniontown Hospital Radiation Oncology|UPMC Cancer Center-Washington|UPMC Washington Hospital Radiation Oncology|UPMC West Mifflin-Cancer Center Jefferson|Wexford Health and Wellness Pavilion|Prisma Health Cancer Institute - Spartanburg|Medical University of South Carolina|Prisma Health Cancer Institute - Laurens|Prisma Health Cancer Institute - Easley|Gibbs Cancer Center-Gaffney|Tidelands Georgetown Memorial Hospital|Saint Francis Hospital|Prisma Health Cancer Institute - Butternut|Prisma Health Cancer Institute - Faris|Prisma Health Greenville Memorial Hospital|Saint Francis Cancer Center|Prisma Health Cancer Institute - Eastside|Prisma Health Cancer Institute - Greer|Gibbs Cancer Center-Pelham|Prisma Health Cancer Institute - Seneca|North Grove Medical Park|Spartanburg Medical Center|Spartanburg Medical Center - Mary Black Campus|MGC Hematology Oncology-Union|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Memorial Hospital|Baptist Memorial Hospital and Cancer Center-Collierville|Vanderbilt-Ingram Cancer Center Cool Springs|Pulmonary Medicine Center of Chattanooga-Hixson|Baptist Memorial Hospital and Cancer Center-Memphis|Vanderbilt Breast Center at One Hundred Oaks|Meharry Medical College|Vanderbilt University/Ingram Cancer Center|Memorial GYN Plus|Saint Joseph Regional Cancer Center|Parkland Memorial Hospital|Baylor University Medical Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|Lyndon Baines Johnson General Hospital|M D Anderson Cancer Center|UT Southwestern Clinical Center at Richardson/Plano|University Hospital|University of Texas Health Science Center at San Antonio|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Farmington Health Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Riverton Hospital|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|Huntsman Cancer Institute/University of Utah|LDS Hospital|South Jordan Health Center|Central Vermont Medical Center/National Life Cancer Treatment|University of Vermont Medical Center|University of Vermont and State Agricultural College|Norris Cotton Cancer Center-North|Virginia Commonwealth University/Massey Cancer Center|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|MultiCare Auburn Medical Center|Virginia Mason Bainbridge Island Medical Center|Overlake Medical Center|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Virginia Mason Federal Way Medical Center|Saint Francis Hospital|Tacoma/Valley Radiation Oncology Centers-Gig Harbor|MultiCare Gig Harbor Medical Park|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Northwest Cancer Clinic|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Virginia Mason Lynnwood Medical Center|Skagit Valley Hospital Regional Cancer Care Center|Skagit Valley Hospital|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Peninsula Cancer Center|MultiCare Good Samaritan Hospital|Tacoma/Valley Radiation Oncology Centers-Puyallup|Valley Medical Center|Virginia Mason Medical Center|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Fred Hutchinson Cancer Research Center|Seattle Cancer Care Alliance|Kaiser Permanente Washington|Swedish Medical Center-First Hill|University of Washington Medical Center - Montlake|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|MultiCare Deaconess Cancer and Blood Specialty Center - Valley|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown|Spokane Valley Cancer Center-Mayfair|Spokane Valley Cancer Center-Mission|MultiCare Deaconess Cancer and Blood Specialty Center - North|Tacoma/Valley Radiation Oncology Centers-Jackson Hall|Franciscan Research Center-Northwest Medical Plaza|Mary Bridge Children's Hospital and Health Center|MultiCare Tacoma General Hospital|Northwest Medical Specialties PLLC|Tacoma/Valley Radiation Oncology Centers-Saint Joe's|PeaceHealth Southwest Medical Center|Legacy Cancer Institute Medical Oncology and Day Treatment|Legacy Salmon Creek Hospital|Providence Saint Mary Regional Cancer Center|Wenatchee Valley Hospital and Clinics|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Edwards Comprehensive Cancer Center|Ascension Saint Elizabeth Hospital|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Ascension Southeast Wisconsin Hospital - Elmbrook Campus|Ascension Calumet Hospital|Marshfield Clinic-Chippewa Center|Marshfield Clinic Cancer Center at Sacred Heart|Marshfield Medical Center-EC Cancer Center|Ascension Saint Francis - Reiman Cancer Center|Ascension Southeast Wisconsin Hospital - Franklin|Saint Vincent Hospital Cancer Center Green Bay|Saint Vincent Hospital Cancer Center at Saint Mary's|Gundersen Lutheran Medical Center|Marshfield Clinic - Ladysmith Center|Holy Family Memorial Hospital|Saint Vincent Hospital Cancer Center at Marinette|Marshfield Medical Center-Marshfield|Ascension Columbia Saint Mary's Hospital Ozaukee|Ascension Southeast Wisconsin Hospital - Saint Joseph Campus|Ascension Columbia Saint Mary's Hospital - Milwaukee|Ascension Saint Francis Hospital|Marshfield Clinic-Minocqua Center|Cancer Center of Western Wisconsin|Saint Vincent Hospital Cancer Center at Oconto Falls|Ascension Mercy Hospital|Ascension All Saints Hospital|Ascension Saint Mary's Hospital|Marshfield Medical Center-Rice Lake|HSHS Saint Nicholas Hospital|Ascension Saint Michael's Hospital|Marshfield Clinic Stevens Point Center|Saint Vincent Hospital Cancer Center at Sturgeon Bay|Marshfield Clinic-Wausau Center|Ascension Medical Group Southeast Wisconsin - Mayfair Road|Marshfield Medical Center - Weston|Marshfield Clinic - Wisconsin Rapids Center|Cheyenne Regional Medical Center-West|Billings Clinic-Cody|Welch Cancer Center|FHP Health Center-Guam,Procedure|Biological|Biological,Guam|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02834013
1861,NCT02838927,hypoparathyroidism,Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France,Survey on Epidemiology of Hypoparathyroidism in France,Hypoparathyroidism,2016-07-09,2030-09-30,2031-09-30,1000.0,Cohort,,Prospective,Observational,Recruiting,,European Georges Pompidou Hospital,European Georges Pompidou Hospital|Oscar - Filire Sant Maladies Rares,"Felix Guyon Hospital|Hpital Priv de Provence|Amiens University Hospital|Clinic Auch Area|Henri Mondor Hospital|Jean Minjoz Hospital|Avicenne Hospital, AP-HP|Jean Verdier Hospital, AP-HP|University Hospital|Bourgoin Jallieu Hospital|La Cavale Blanche Hospital|Cte de Nacre Hospital|Henri Mondor Hospital, APHP|Dax-Cte d'Argent Hospital|University Hospital|Grenoble Alpes Hospital|CHD Vende|Kremlin-Bictre Hospital, APHP|Le Mans Hospital|Libourne Hospital|Claude Huriez Hospital|Edouard Herriot Hospital, HCL|La Conception Hospital, AP-HM|Clinic Metz Area|Mercy Hospital|Arnaud de Villeneuve Hospital|Clinic area|Brabois Hospital|University Hospital|University Hospital|Georges Renon Hospital|Caremeau Hospital|European Georges Pompidou Hospital, APHP|Clinic Paris Area|Cochin Hospital, APHP|Lariboisire Hospital, APHP|Necker Hospital, AP-HP|Piti-Salptrire Hospital, APHP|Tenon Hospital, APHP|Clinic Poitiers Area|Laennec Hospital|Reims University Hospital|Clinic Rennes Area|Charles Nicolle Hospital|Clinic Area|Clinique du Landy|Hautepierre Hospital|Sainte Anne Hospital, HIA|Larrey Hospital|Guy Chatiliez Hospital|Bretonneau Hospital|Valenciennes Hospital|CHIV - Lucie et Raymond Aubrac",Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02838927
1863,NCT02839655,thyroid neoplasms,Prospective Study Assessing Thyroidectomy Using Robot,Prospective Study Assessing Thyroidectomy Using Robot,Patients With Thyroid Cancer,2016-07-12,2018-05-15,2022-08-31,17.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02839655
1864,NCT02843542,hyperthyroidism,Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study,Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI),Primary Hyperthyroidism,2016-07-14,2018-08-31,2018-12-31,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Assuta Medical Center,Assuta Medical Center,Assuta Medical Center,Device|Device,Israel,18.0,50.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02843542
1866,NCT02843542,parathyroid neoplasms,Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study,Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI),Primary Hyperthyroidism,2016-07-14,2018-08-31,2018-12-31,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Assuta Medical Center,Assuta Medical Center,Assuta Medical Center,Device|Device,Israel,18.0,50.0,[18-65],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02843542
1867,NCT02845336,hyperthyroidism,An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease,Celecoxib for Thyroid Eye Disease,Thyroid Eye Disease,2016-07-20,2019-06-30,2019-06-30,7.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Johns Hopkins University,Johns Hopkins University,"Wilmer Eye Institute, Johns Hopkins University",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02845336
1868,NCT02845336,graves ophthalmopathy,An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease,Celecoxib for Thyroid Eye Disease,Thyroid Eye Disease,2016-07-20,2019-06-30,2019-06-30,7.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Johns Hopkins University,Johns Hopkins University,"Wilmer Eye Institute, Johns Hopkins University",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02845336
1869,NCT02845336,goiter,An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease,Celecoxib for Thyroid Eye Disease,Thyroid Eye Disease,2016-07-20,2019-06-30,2019-06-30,7.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Johns Hopkins University,Johns Hopkins University,"Wilmer Eye Institute, Johns Hopkins University",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02845336
1870,NCT02845336,graves disease,An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease,Celecoxib for Thyroid Eye Disease,Thyroid Eye Disease,2016-07-20,2019-06-30,2019-06-30,7.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Johns Hopkins University,Johns Hopkins University,"Wilmer Eye Institute, Johns Hopkins University",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02845336
1871,NCT02854345,hyperparathyroidism,Preliminary Study Concerning the Validity of Parathyroid Exploration on a Discovery NM 530c CZT Camera,Preliminary Study Concerning the Validity of Parathyroid Exploration on a CZT Camera,Primary Hyperparathyroidism,2016-07-29,2019-03-31,2019-09-30,90.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Centre Hospitalier Universitaire de Besancon,Centre Hospitalier Universitaire de Besancon,CHU Besancon,Device,France,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02854345
1874,NCT02856347,thyroid neoplasms,Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET ( Positron Emission Tomography) F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin,Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin,Medullary Thyroid Cancer,2016-07-27,2020-12-20,2020-12-20,24.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Institut Claudius Regaud,Institut Claudius Regaud,CHU Haut-Lvque|CHU Limoges|CHU Timone|ICM Montpellier|Institut Claudius Regaud,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02856347
1877,NCT02859896,hyperparathyroidism,"An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis",Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis,Secondary Hyperparathyroidism-Chronic Kidney Disease,2016-08-04,2025-11-12,2025-11-12,84.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Sanofi,Sanofi,Investigational Site Number :8400022|Investigational Site Number :8400023|Investigational Site Number :8400033|Investigational Site Number :8400005|Investigational Site Number :8400029|Investigational Site Number :8400006|Investigational Site Number :8400008|Investigational Site Number :8400020|Investigational Site Number :8400036|Investigational Site Number :8400014|Investigational Site Number :8400015|Investigational Site Number :8400010|Investigational Site Number :8400016|Investigational Site Number :8400017|Investigational Site Number :8400007|Investigational Site Number :8400021|Investigational Site Number :8400034|Investigational Site Number :8400025|Investigational Site Number :8400004|Investigational Site Number :8400035|Investigational Site Number :8400028|Investigational Site Number :8400027|Investigational Site Number :8400024|Investigational Site Number :8400013|Investigational Site Number :8400019|Investigational Site Number :8400026|Investigational Site Number :8400009|Investigational Site Number :8400001|Investigational Site Number :1520004|Investigational Site Number :1520003,Drug|Drug,Chile|United States,5.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02859896
1878,NCT02862470,"thyroid carcinoma, anaplastic",Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Thyroid Cancer,2016-07-27,2018-10-31,2020-08-24,22.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,National Taiwan University Hospital,National Taiwan University Hospital,,,,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02862470
1880,NCT02862470,"adenocarcinoma, follicular",Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Thyroid Cancer,2016-07-27,2018-10-31,2020-08-24,22.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,National Taiwan University Hospital,National Taiwan University Hospital,,,,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02862470
1881,NCT02867592,thyroid neoplasms,"Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",Adrenal Cortex Carcinoma|Alveolar Soft Part Sarcoma|Central Nervous System Neoplasm|Childhood Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of Soft Tissue|Ewing Sarcoma|Hepatoblastoma|Hepatocellular Carcinoma|Osteosarcoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Alveolar Soft Part Sarcoma|Recurrent Clear Cell Sarcoma of Soft Tissue|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Hepatocellular Carcinoma|Recurrent Kidney Wilms Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Recurrent Primary Malignant Central Nervous System Neoplasm|Recurrent Renal Cell Carcinoma|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Medullary Carcinoma|Refractory Clear Cell Sarcoma of Soft Tissue|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Hepatocellular Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Primary Malignant Central Nervous System Neoplasm|Refractory Renal Cell Carcinoma|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Thyroid Gland Medullary Carcinoma|Renal Cell Carcinoma|Rhabdomyosarcoma|Solid Neoplasm|Thyroid Gland Medullary Carcinoma|Wilms Tumor,2016-08-15,2021-06-30,2022-07-01,109.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Providence Alaska Medical Center|Arkansas Children's Hospital|Kaiser Permanente-Anaheim|Kaiser Permanente-Bellflower|Kaiser Permanente Downey Medical Center|Kaiser Permanente-Fontana|Loma Linda University Medical Center|Children's Hospital Los Angeles|Kaiser Permanente Los Angeles Medical Center|Valley Children's Hospital|UCSF Benioff Children's Hospital Oakland|Kaiser Permanente-Oakland|Children's Hospital of Orange County|Lucile Packard Children's Hospital Stanford University|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-San Diego Mission|Rady Children's Hospital - San Diego|UCSF Medical Center-Mission Bay|Children's Hospital Colorado|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Yale University|Alfred I duPont Hospital for Children|Kaiser Permanente-Capitol Hill Medical Center|MedStar Georgetown University Hospital|Children's National Medical Center|Golisano Children's Hospital of Southwest Florida|University of Florida Health Science Center - Gainesville|Nemours Children's Clinic-Jacksonville|University of Miami Miller School of Medicine-Sylvester Cancer Center|Nicklaus Children's Hospital|AdventHealth Orlando|Arnold Palmer Hospital for Children|Nemours Children's Hospital|Nemours Children's Clinic - Pensacola|Johns Hopkins All Children's Hospital|Children's Healthcare of Atlanta - Egleston|Straub Clinic and Hospital|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Saint Luke's Cancer Institute - Boise|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago Comprehensive Cancer Center|Carle on Vermilion|Carle Physician Group-Effingham|Carle Physician Group-Mattoon/Charleston|Saint Jude Midwest Affiliate|Carle Cancer Center|The Carle Foundation Hospital|Riley Hospital for Children|Saint Vincent Hospital and Health Care Center|Blank Children's Hospital|Iowa Methodist Medical Center|Iowa Lutheran Hospital|University of Iowa/Holden Comprehensive Cancer Center|University of Kentucky/Markey Cancer Center|Norton Children's Hospital|Children's Hospital New Orleans|Eastern Maine Medical Center|Lafayette Family Cancer Center-EMMC|Sinai Hospital of Baltimore|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute|C S Mott Children's Hospital|Wayne State University/Karmanos Cancer Institute|Ascension Saint John Hospital|Huron Medical Center PC|Beaumont Children's Hospital-Royal Oak|Children's Hospitals and Clinics of Minnesota - Minneapolis|University of Minnesota/Masonic Cancer Center|Mayo Clinic in Rochester|University of Mississippi Medical Center|Siteman Cancer Center at West County Hospital|Children's Mercy Hospitals and Clinics|Cardinal Glennon Children's Medical Center|Barnes-Jewish Hospital|Washington University School of Medicine|Siteman Cancer Center-South County|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Children's Hospital and Medical Center of Omaha|University of Nebraska Medical Center|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Sunrise Hospital and Medical Center|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Summerlin Hospital Medical Center|Hope Cancer Care of Nevada-Pahrump|Radiation Oncology Associates|Dartmouth Hitchcock Medical Center|Hackensack University Medical Center|Morristown Medical Center|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital|Roswell Park Cancer Institute|NYU Winthrop Hospital|The Steven and Alexandra Cohen Children's Medical Center of New York|Laura and Isaac Perlmutter Cancer Center at NYU Langone|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|State University of New York Upstate Medical University|UNC Lineberger Comprehensive Cancer Center|Carolinas Medical Center/Levine Cancer Institute|Southeastern Medical Oncology Center-Clinton|Duke University Medical Center|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|East Carolina University|Southeastern Medical Oncology Center-Jacksonville|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|MetroHealth Medical Center|Cleveland Clinic Foundation|Nationwide Children's Hospital|Dayton Children's Hospital|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|University of Oklahoma Health Sciences Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Children's Hospital of Pittsburgh of UPMC|Medical University of South Carolina|Saint Francis Hospital|BI-LO Charities Children's Cancer Center|Saint Francis Cancer Center|East Tennessee Childrens Hospital|Saint Jude Children's Research Hospital|The Children's Hospital at TriStar Centennial|Medical City Dallas Hospital|UT Southwestern/Simmons Cancer Center-Dallas|El Paso Children's Hospital|Texas Tech University Health Sciences Center-El Paso|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Children's Hospital of San Antonio|University of Vermont and State Agricultural College|University of Virginia Cancer Center|Children's Hospital of The King's Daughters|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Gundersen Lutheran Medical Center|University of Wisconsin Carbone Cancer Center|Children's Hospital of Wisconsin,Drug|Drug|Other,United States,2.0,30.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02867592
1882,NCT02869620,thyroid neoplasms,Institut Paoli Calmettes Thyroid Cancer Database,Institut Paoli Calmettes Thyroid Cancer Database,Thyroid Neoplasms,2016-08-11,2030-01-31,2030-12-31,3000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Institut Paoli-Calmettes,Institut Paoli-Calmettes,Institut Paoli-Calmettes,Other,France,18.0,95.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02869620
1883,NCT02870569,thyroid neoplasms,"A Multicenter, Randomized, Open-Label,Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer",Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2016-08-12,2018-07-02,2018-12-31,48.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02870569
1884,NCT02878044,thyroid nodule,Shared Decision Making in Patients With Thyroid Nodules,Shared Decision Making in Patients With Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2016-08-16,2019-05-23,2019-05-23,21.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic Jacksonville|Mayo Clinic in Rochester,Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02878044
1885,NCT02878044,thyroid neoplasms,Shared Decision Making in Patients With Thyroid Nodules,Shared Decision Making in Patients With Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2016-08-16,2019-05-23,2019-05-23,21.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic Jacksonville|Mayo Clinic in Rochester,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02878044
1887,NCT02886949,thyrotoxicosis,"The Relationship of Vascular Cell Adhesion Molecule 1, C-reactive Protein, Brain-derived Neurotrophic Factor, Orexin and Depressive Symptoms in the Subjects With Thyroid Disease",The Association Between Autoimmune or Inflammation and Thyroid Disease,THYROTOXICOSIS,2015-09-02,2020-12-31,2024-12-31,500.0,Cohort,,Prospective,Observational,Recruiting,,Taichung Veterans General Hospital,Taichung Veterans General Hospital,"Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital",,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02886949
1889,NCT02890472,hypoparathyroidism,Research of Thymix Dysgenesis in Prenatal Examination of Deletion 22q11 Syndrome,Prenatal Examination of Deletion 22q11 Syndrome : Thymic Dysgenesis THYMI Study,22q11 Deletion Syndrome Di George Syndrome,2016-08-26,2020-07-01,2020-12-31,13.0,Cohort,,Prospective,Observational,Completed,,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHUNimes,,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02890472
1890,NCT02891668,hypothyroidism,"Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition","Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition",Hypothyroidism,2016-05-17,2018-05-20,2018-05-20,42.0,Case-Control,,Prospective,Observational,Completed,,Herlev Hospital,Herlev Hospital,"Department of internal Medicine, Herlev Hospital",Drug,Denmark,20.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02891668
1891,NCT02895061,hyperparathyroidism,Effectiveness Between Daily Versus Pulse Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: A Randomized Controlled Trial and Multicenter Study,Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.,"Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis",2016-09-04,2015-10-31,2016-01-31,502.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Phramongkutklao College of Medicine and Hospital,Phramongkutklao College of Medicine and Hospital,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02895061
1895,NCT02895906,hypoparathyroidism,"A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)",Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions,22q11.2 Deletion Syndrome,2016-08-29,2017-04-13,2017-04-20,2.0,,Single Group Assignment,,Interventional,Completed,Phase 1,"Avalo Therapeutics, Inc.","Aevi Genomic Medicine, LLC, a Cerecor company",Children's Hospital of Philadelphia,Drug,United States,12.0,17.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02895906
1896,NCT02901873,parathyroid diseases,Phase 1 Study of Electrical Impedance Spectroscopy in Thyroid and Parathyroid Surgery,EIS in Thyroid and Parathyroid Surgery,Parathyroid Diseases|Thyroidectomy,2016-09-12,2017-06-27,2017-06-27,56.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Sheffield Teaching Hospitals NHS Foundation Trust,Sheffield Teaching Hospitals NHS Foundation Trust,Royal Hallamshire Hospital,Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT02901873
1897,NCT02904330,hyperthyroidism,"K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease",K1-70 - A Study in Subjects With Graves' Disease,Graves' Disease,2016-08-18,2021-04-30,2021-04-30,18.0,,Single Group Assignment,,Interventional,Completed,Phase 1,AV7 Limited,AV7 Limited,Royal Liverpool University Hospital Clinical Research Unit|Medicines Evaluation Unit,Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02904330
1898,NCT02904330,goiter,"K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease",K1-70 - A Study in Subjects With Graves' Disease,Graves' Disease,2016-08-18,2021-04-30,2021-04-30,18.0,,Single Group Assignment,,Interventional,Completed,Phase 1,AV7 Limited,AV7 Limited,Royal Liverpool University Hospital Clinical Research Unit|Medicines Evaluation Unit,Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02904330
1899,NCT02904330,graves disease,"K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease",K1-70 - A Study in Subjects With Graves' Disease,Graves' Disease,2016-08-18,2021-04-30,2021-04-30,18.0,,Single Group Assignment,,Interventional,Completed,Phase 1,AV7 Limited,AV7 Limited,Royal Liverpool University Hospital Clinical Research Unit|Medicines Evaluation Unit,Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02904330
1900,NCT02910466,hypoparathyroidism,"A Phase 4, Open-Label, Single-Center Clinical Study of Extended Use of rhPTH(1-84) in Hypoparathyroidism",A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism,Chronic Hypoparathyroidism|Hypoparathyroidism,2016-09-20,2019-12-20,2019-12-20,39.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Takeda,Shire,Columbia University Medical Center,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02910466
1902,NCT02911155,thyroid neoplasms,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,Brain Cancer|Breast Cancer|Circulatory Disease|Thyroid Cancer,2016-09-21,2020-05-01,2020-05-01,229.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"University of Minnesota, School of Public Health Environmental Health Sciences",,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02911155
1903,NCT02915172,thyroid neoplasms,A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies,Lenvatinib and Capecitabine in Patients With Advanced Malignancies,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,2016-09-23,2022-12-31,,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1,M.D. Anderson Cancer Center,Eisai Inc.|M.D. Anderson Cancer Center,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02915172
1904,NCT02917863,hypothyroidism,Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism,Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism,Hypothyroidism,2016-09-07,2018-05-31,2019-05-31,70.0,,Crossover Assignment,,Interventional,Unknown status,Phase 4,Meyer Children's Hospital,Meyer Children's Hospital,Meyer Children's Hospital,Drug|Drug,Italy,3.0,18.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02917863
1905,NCT02924532,hypoparathyroidism,Diagnostic Value of Immediate Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy: A Retrospective Observational Study,Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy,Hypoparathyroidism,2016-09-13,2013-12-31,,300.0,Cohort,,Retrospective,Observational,Completed,,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,,Biological,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02924532
1907,NCT02938702,thyroid neoplasms,,Active Surveillance on Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid Cancer,2016-02-17,2025-03-31,2030-03-31,1211.0,Cohort,,Prospective,Observational,Active not recruiting,,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02938702
1908,NCT02946918,hypothyroidism,Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients,Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy,Postsurgical Hypothyroidism|Thyroid Cancer,2016-10-21,2019-11-04,2019-11-04,14.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,University of Texas Southwestern Medical Center,Akrimax Pharmaceuticals|University of Texas Southwestern Medical Center,University of Texas Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02946918
1909,NCT02946918,thyroid neoplasms,Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients,Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy,Postsurgical Hypothyroidism|Thyroid Cancer,2016-10-21,2019-11-04,2019-11-04,14.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,University of Texas Southwestern Medical Center,Akrimax Pharmaceuticals|University of Texas Southwestern Medical Center,University of Texas Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02946918
1910,NCT02947035,thyroid neoplasms,Molecular Testing to Direct Extent of Initial Thyroid Surgery,Molecular Testing to Direct Extent of Initial Thyroid Surgery,Thyroid Cancer,2016-10-20,2023-02-01,2023-02-28,90.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh|Medical College of Wisconsin,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02947035
1911,NCT02947399,thyroid neoplasms,Comparison of I-124 and I-131 Radiopharmacokinetics In Patient With Well Differentiated Thyroid Cancer After Thyroid Hormone Withdrawal,Comparison of I-124 and I-131 Radiopharmacokinetics in DTC Patients With Thyroid Hormone Withdrawal,Thyroid Cancer,2016-10-25,2018-10-31,2018-10-31,16.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Medstar Health Research Institute,Medstar Health Research Institute,Washington Hospital Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02947399
1913,NCT02952612,"thyroid cancer, papillary",Active Surveillance of Papillary Thyroid Microcarcinoma (PTMC) in Catholic Medical Center,Active Surveillance of Papillary Thyroid Microcarcinoma,"Thyroid Cancer, Papillary",2016-10-31,2017-10-31,2021-10-31,300.0,Case-Only,,Prospective,Observational,Unknown status,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St Mary's Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02952612
1914,NCT02953288,thyroid nodule,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Thyroid Cancer,2016-11-01,2017-06-30,2018-12-31,3000.0,Case-Crossover,,Cross-Sectional,Observational,Unknown status,,Shanghai 10th People's Hospital,Shanghai 10th People's Hospital,"Department of Endocrinology, Shanghai Tenth People's Hospital",,China,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02953288
1915,NCT02953288,thyroid neoplasms,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Thyroid Cancer,2016-11-01,2017-06-30,2018-12-31,3000.0,Case-Crossover,,Cross-Sectional,Observational,Unknown status,,Shanghai 10th People's Hospital,Shanghai 10th People's Hospital,"Department of Endocrinology, Shanghai Tenth People's Hospital",,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02953288
1916,NCT02959827,hypothyroidism,Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States,Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States,Hypothyroidism,2016-10-11,2017-06-15,2017-06-15,2320.0,Cohort,,Retrospective,Observational,Completed,,Bayer,Bayer,Oakland,Drug,United States,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02959827
1917,NCT02966093,thyroid neoplasms,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China",A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China,Differentiated Thyroid Cancer (DTC),2016-11-15,2019-07-31,2021-12-29,151.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Eisai Inc.,"Eisai Co., Ltd.",1002 Eisai Trial Site|1006 Eisai Trial Site|1020 Eisai Trial Site|1026 Eisai Trial Site|1025 Eisai Trial Site|1012 Eisai Trial Site|1003 Eisai Trial Site|1027 Eisai Trial Site|1018 Eisai Trial Site|1023 Eisai Trial Site|1016 Eisai Trial Site|1021 Eisai Trial Site|1008 Eisai Trial Site|1014 Eisai Trial Site|1022 Eisai Trial Site|1015 Eisai Trial Site|1004 Eisai Trial Site|1017 Eisai Trial Site|1019 Eisai Trial Site|1011 Eisai Trial Site|1007 Eisai Trial Site|1001 Eisai Trial Site|1010 Eisai Trial Site|1005 Eisai Trial Site,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02966093
1918,NCT02973802,hyperthyroidism,"Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection",ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy,Graves Disease,2016-11-14,2018-02-14,2018-02-14,12.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Apitope International NV,"Apitope International NV|European Commission|Quintiles, Inc.",Queen Elizabeth Hospital|University Hospital of Wales|Royal Devon and Exeter Hospital|St James's University Hospital|Hammersmith Hospital|Kings College Hospital|The Christie|Royal Victoria Infirmary,Biological,United Kingdom,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02973802
1919,NCT02973802,goiter,"Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection",ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy,Graves Disease,2016-11-14,2018-02-14,2018-02-14,12.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Apitope International NV,"Apitope International NV|European Commission|Quintiles, Inc.",Queen Elizabeth Hospital|University Hospital of Wales|Royal Devon and Exeter Hospital|St James's University Hospital|Hammersmith Hospital|Kings College Hospital|The Christie|Royal Victoria Infirmary,Biological,United Kingdom,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02973802
1920,NCT02973802,graves disease,"Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection",ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy,Graves Disease,2016-11-14,2018-02-14,2018-02-14,12.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Apitope International NV,"Apitope International NV|European Commission|Quintiles, Inc.",Queen Elizabeth Hospital|University Hospital of Wales|Royal Devon and Exeter Hospital|St James's University Hospital|Hammersmith Hospital|Kings College Hospital|The Christie|Royal Victoria Infirmary,Biological,United Kingdom,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02973802
1921,NCT02973997,"thyroid cancer, papillary","Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC),Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,60.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02973997
1922,NCT02973997,"adenocarcinoma, follicular","Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC),Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,60.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02973997
1924,NCT02986607,hyperparathyroidism,Corticosteroid Rhythms in Hypoparathyroid Patients,Corticosteroid Rhythms in Hypoparathyroid Patients,Hyperparathyroidism|Hypoparathyroidism,2016-12-05,2018-01-31,2018-06-30,30.0,,Single Group Assignment,,Interventional,Unknown status,Early Phase 1,University of Bergen,Haukeland University Hospital|University of Bergen,Haukeland University Hospital,Drug,Norway,18.0,60.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02986607
1926,NCT02986607,hypoparathyroidism,Corticosteroid Rhythms in Hypoparathyroid Patients,Corticosteroid Rhythms in Hypoparathyroid Patients,Hyperparathyroidism|Hypoparathyroidism,2016-12-05,2018-01-31,2018-06-30,30.0,,Single Group Assignment,,Interventional,Unknown status,Early Phase 1,University of Bergen,Haukeland University Hospital|University of Bergen,Haukeland University Hospital,Drug,Norway,18.0,60.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02986607
1927,NCT02988817,thyroid neoplasms,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax-AXL-ADC) in Patients With Solid Tumors",Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors,Cervical Cancer|Endometrial Cancer|Melanoma|Non Small Cell Lung Cancer|Ovarian Cancer|Sarcoma|Thyroid Cancer,2016-12-01,2021-11-12,2021-11-12,306.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Genmab,Genmab,"Mayo Clinic Scottsdale|University of Colorado Cancer Center|Yale University, Smilow Cancer Center at Yale New Haven Hospital|Mayo Clinic Jacksonville|Moffitt Cancer Center|Emory University School of Medicine, Winship Cancer Institute|University of Iowa|Dana-Farber Cancer Institute|University of Michigan Comprehensive Cancer Center|Mayo Clinic Rochester|Washington University|Roswell Park Comprehensive Cancer Center|NYU Medical Center|Herbert Irving Comprehensive Cancer Center|Duke Cancer Institute|Fox Chase Cancer Center|Mary Crowley Cancer Reearch Center|MD Anderson|Huntsman Cancer Institute|University of Wisconsin Carbone Cancer Center|Universitair Ziekenhuizen Leuven|Institut Roi Albert II - Cliniques Universitaires Saint Luc|Universitair Ziekenhuis Brussel - Oncologisch Centrum|Medische oncologie, Oncologisch Centrum - AZ Groeninge|U.Z. Leuven Gasthuisberg, Department of General Medical Oncology|CHU de Lige, Medical Oncology et. Domaine Universitaire du Sart Tilman|Rigshospitalet, Copenhagen University Hospital|The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital|Leiden University Medical Centre|Erasmus MC, Medical Oncology|UMC Utrecht Cancer Center|Hospital Unversitario Vall D'hebron|Oncologia Mdica/ Medical Oncology Department Institut Catal d'Oncologia (ICO)|University Hospital of Girona|Hospital Universitario 12 Octubre|Hospital Virgen de la Victoria|University Hospital Lozano Blesa, Aragn Health Research Institute (IIS Aragn)|Universtity College London Hospitals|The Royal Marsden NHS Foundation Trust|The Christie NHS Foundation Trust Clinical Trials Unit|Sir Bobby Robson Clinical Trials Unit at the Northern Centre for Cancer Care, Freeman Hospital",Biological,Belgium|Denmark|Netherlands|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02988817
1928,NCT02989103,hyperthyroidism,Hyperthyroid Follow-Up Study,Hyperthyroid Follow-Up Study,All-Cause Mortality|Circulatory and Other Disease Mortality|Thyroid and Other Cancer Mortality,2016-12-06,2020-09-01,2020-10-28,35593.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"Social and Scientific Systems, Inc.",,United States,18.0,105.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02989103
1929,NCT02989428,hyperparathyroidism,Cardiovascular Health in Patients With Primary Hyperparathyroidism: Effect of Parathyroidectomy on Cardiovascular Health: A Randomized Controlled Trial,Effect of Parathyroidectomy on Cardiovascular Health,Primary Hyperparathyroidism,2016-12-02,2018-09-01,2018-09-01,69.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,Aarhus University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02989428
1932,NCT02993302,hyperthyroidism,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Graves Disease,2016-12-07,2015-03-31,2015-03-31,25.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Dr Cipto Mangunkusumo General Hospital,Dr Cipto Mangunkusumo General Hospital|Indonesia University,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02993302
1933,NCT02993302,graves disease,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Graves Disease,2016-12-07,2015-03-31,2015-03-31,25.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Dr Cipto Mangunkusumo General Hospital,Dr Cipto Mangunkusumo General Hospital|Indonesia University,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02993302
1934,NCT02993302,goiter,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Graves Disease,2016-12-07,2015-03-31,2015-03-31,25.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Dr Cipto Mangunkusumo General Hospital,Dr Cipto Mangunkusumo General Hospital|Indonesia University,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02993302
1935,NCT02993562,hypothyroidism,Levothyroxine Substitution Therapy in Hypothyroid Patients - Impact on Appetite and Food Intake,"Hypothyroidism, Metabolism and Food Intake",Hypothyroidism,2016-10-20,2018-08-30,2018-08-30,18.0,Case-Control,,Prospective,Observational,Completed,,Herlev Hospital,"Center for Diabetes Research, Herlev and Gentofte Hospital.|Herlev Hospital","Center for Diabetes Research, Herlev and Gentofte Hospitals",Drug,Denmark,20.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02993562
1936,NCT03002623,"thyroid carcinoma, anaplastic",A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer,CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,Differentiated Thyroid Cancer|Poorly Differentiated and Undifferentiated Thyroid Cancer|Thyroid Neoplasms,2016-12-22,2018-02-12,2018-02-12,7.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),National Institutes of Health Clinical Center,Drug,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03002623
1940,NCT03004209,hashimoto disease,Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients,Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients,Autoimmune Encephalitis,2016-12-21,2018-02-06,2018-02-06,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 4,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Drug,"Korea, Republic of",18.0,85.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03004209
1941,NCT03006289,thyroid neoplasms,Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer,Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer,Thyroid Cancer,2016-12-26,2017-10-31,2017-11-30,3000.0,,,,Observational,Unknown status,,Qianfoshan Hospital,Lin Liao,,,,8.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03006289
1942,NCT03009279,thyroid neoplasms,Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Metabolic Syndrome|Thyroid Nodule,2016-12-26,2017-11-30,2017-12-31,10000.0,,,,Observational,Unknown status,,Qianfoshan Hospital,Lin Liao,,,,15.0,90.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03009279
1943,NCT03009279,thyroid nodule,Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Metabolic Syndrome|Thyroid Nodule,2016-12-26,2017-11-30,2017-12-31,10000.0,,,,Observational,Unknown status,,Qianfoshan Hospital,Lin Liao,,,,15.0,90.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03009279
1944,NCT03009357,graves disease,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis",Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis,Graves Disease|Thyroiditis|Thyrotoxicosis,2016-12-29,2017-06-30,2017-08-31,40.0,Cohort,,Prospective,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03009357
1945,NCT03009357,thyroiditis,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis",Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis,Graves Disease|Thyroiditis|Thyrotoxicosis,2016-12-29,2017-06-30,2017-08-31,40.0,Cohort,,Prospective,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,,"Korea, Republic of",20.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03009357
1947,NCT03009357,goiter,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis",Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis,Graves Disease|Thyroiditis|Thyrotoxicosis,2016-12-29,2017-06-30,2017-08-31,40.0,Cohort,,Prospective,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,,"Korea, Republic of",20.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03009357
1948,NCT03009357,hyperthyroidism,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis",Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis,Graves Disease|Thyroiditis|Thyrotoxicosis,2016-12-29,2017-06-30,2017-08-31,40.0,Cohort,,Prospective,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03009357
1949,NCT03011736,hyperparathyroidism,"Single-Arm, Non-inferiority Study of Omission of Intraoperative Intact Parathyroid Hormone (PTH) During Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism",Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism,Parathyroid Gland Adenoma|Primary Hyperparathyroidism,2017-01-04,2018-07-12,2018-12-24,6.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Roswell Park Cancer Institute,Roswell Park Cancer Institute,Roswell Park Cancer Institute,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03011736
1952,NCT03012620,thyroid neoplasms,Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types,Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types,"Carcinoma, Neuroendocrine|Central Nervous System Neoplasm|Neoplasms, Germ Cell and Embryonal|NK/T-cell Lymphoma|Ovarian Neoplasm|Sarcoma|Thyroid Neoplasm",2017-01-02,2023-01-31,2023-12-31,334.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,UNICANCER,"Ligue contre le cancer, France|Merck Sharp & Dohme LLC|National Cancer Institute, France|UNICANCER",Gustave Roussy Cancer Campus,Drug,France,15.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03012620
1953,NCT03013257,goiter,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",HIFU vs RAI in the Relapsed Graves' Disease,Graves Disease,2017-01-04,2020-04-30,2020-06-30,240.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03013257
1954,NCT03013257,graves disease,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",HIFU vs RAI in the Relapsed Graves' Disease,Graves Disease,2017-01-04,2020-04-30,2020-06-30,240.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03013257
1955,NCT03013257,hyperthyroidism,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",HIFU vs RAI in the Relapsed Graves' Disease,Graves Disease,2017-01-04,2020-04-30,2020-06-30,240.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03013257
1956,NCT03023748,hyperparathyroidism,Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs,Intravenous Paricalcitol in Chronic Hemodialysis Patients,Endstage Renal Disease|Secondary Hyperparathyroidism,2017-01-07,2017-12-31,2018-01-31,30.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,The University of Hong Kong,AbbVie|The University of Hong Kong,Queen Mary Hospital and Tung Wah Hospital,Drug,Hong Kong,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03023748
1959,NCT03024151,thyroid neoplasms,"The Effects of T4 Mono Replacement Versus T4/T3 Combination Replacement on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients; Prospective, Randomized, Double Blind, T4 Comparative Clinical Study",The Effects of T4 Versus T4/T3 on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients,Anxiety|Depression|Distress|Fatigue|Thyroid Cancer,2017-01-10,2017-11-30,2017-11-30,150.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Inje University,Dongnam Institute of Radiological & Medical Sciences|Inje University,Dong sik Bae|Dongsik Bae,Drug|Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03024151
1960,NCT03027349,hyperparathyroidism,,"Serum Calcium to Phosphorous Ratio (Ca/P) as a Simple, Inexpensive Screening Tool in the Diagnosis of Primary Hyperparathyroidism",Hyperparathyroidism,2017-01-18,2017-02-28,2017-02-28,180.0,Case-Control,,Retrospective,Observational,Completed,,Azienda USL Modena,Azienda USL Modena,Azienda USL of Modena,Other,Italy,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03027349
1962,NCT03027557,parathyroid neoplasms,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Parathyroid Adenoma|Parathyroid Hyperplasia|Primary Hyperparathyroidism,2017-01-16,2019-04-01,2019-09-12,46.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Aalborg University Hospital,Aalborg University|Peter Vestergaard,Aalborg University Hospital,Drug|Drug|Other|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03027557
1965,NCT03027557,hyperparathyroidism,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Parathyroid Adenoma|Parathyroid Hyperplasia|Primary Hyperparathyroidism,2017-01-16,2019-04-01,2019-09-12,46.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Aalborg University Hospital,Aalborg University|Peter Vestergaard,Aalborg University Hospital,Drug|Drug|Other|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03027557
1967,NCT03029429,pseudopseudohypoparathyroidism,Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism,Theophylline Treatment for Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism,2017-01-18,2023-07-01,2023-11-01,34.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Vanderbilt University Medical Center,Harvard University|Vanderbilt University Medical Center,Ashley Shoemaker,Drug|Drug,United States,13.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03029429
1968,NCT03031639,thyroid neoplasms,Khon Kaen University's Thyroidectomy Registry,Khon Kaen University's Thyroidectomy Registry,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2017-01-20,2021-01-12,2021-01-12,98.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Khon Kaen University,Khon Kaen University,"Department of Otolaryngology, Khonkaen University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03031639
1969,NCT03031639,thyroid nodule,Khon Kaen University's Thyroidectomy Registry,Khon Kaen University's Thyroidectomy Registry,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2017-01-20,2021-01-12,2021-01-12,98.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Khon Kaen University,Khon Kaen University,"Department of Otolaryngology, Khonkaen University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03031639
1970,NCT03032198,thyroid nodule,"""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""","""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""",Feasibility Study for Thyroid Indication,2017-01-20,2018-06-17,2019-04-19,37.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Seno Medical Instruments Inc.,Seno Medical Instruments Inc.,Invision Sally Jobe|UT Health Science Center,Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03032198
1971,NCT03032198,thyroid neoplasms,"""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""","""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""",Feasibility Study for Thyroid Indication,2017-01-20,2018-06-17,2019-04-19,37.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Seno Medical Instruments Inc.,Seno Medical Instruments Inc.,Invision Sally Jobe|UT Health Science Center,Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03032198
1972,NCT03034707,parathyroid diseases,Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing,Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing,Parathyroid Diseases|Thoracic Diseases,2017-01-17,2016-10-31,2018-12-31,12.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Minnesota,Boston Medical Center|Children's Mercy Hospital Kansas City|Johns Hopkins University|University of Minnesota,,Dietary Supplement,,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03034707
1973,NCT03036956,hypothyroidism,The Prevalence of Sub Clinical Hypothyroidism During Early Pregnancy in Pakistan,The Prevalence of Sub Clinical Hypothyroidism During Early Pregnancy in Pakistan,Subclinical Hypothyroidism,2017-01-26,2018-01-31,2018-01-31,500.0,Cohort,,Prospective,Observational,Completed,,Abbott,Abbott|Dimension Research,Isra University hospital|Pakistam Insititute of Medical science|Atia Hospital Hospital|Boluvard Hospital|MediCell Hospital|Services Hospital|Sir Ganga Ram hospital|Welcare Medical Centre|Lady Reading hospital,,Pakistan,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03036956
1975,NCT03037385,"thyroid cancer, papillary","A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors","Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","Adenocarcinoma|Adenocarcinoma, Papillary|Bronchial Neoplasms|Carcinoma|Carcinoma, Bronchogenic|Carcinoma, Neuroendocrine|Carcinoma, Non-Small-Cell Lung|Colonic Diseases|Colonic Neoplasms|Colorectal Neoplasms|Digestive System Disease|Digestive System Neoplasm|Endocrine Gland Neoplasm|Endocrine System Diseases|Gastrointestinal Disease|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Disease|Intestinal Neoplasms|Lung Diseases|Lung Neoplasm|Medullary Thyroid Cancer|Neoplasms|Neoplasms by Histologic Type|Neoplasms by Site|Neoplasms, Germ Cell and Embryonal|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Neuroectodermal Tumors|Neuroendocrine Tumors|Respiratory Tract Disease|Respiratory Tract Neoplasms|RET-altered Colon Cancer|RET-altered Non Small Cell Lung Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Solid Tumors|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Diseases|Thyroid Neoplasm",2017-01-20,2023-12-31,2024-02-29,589.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 1/Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Mayo Clinic|UC Irvine Medical Center|University of Colorado Cancer Center|Georgetown University Medical Center|Mayo Clinic|University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center|Maryland Oncology Hematology, PA - Columbia|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University School of Medicine, Siteman Cancer Center|Albany Medical Center|Jack D. Weiler Hospital|Cornell University|Oregon Health and Science University|University of Pennsylvania Hospital|UPMC CancerCenter|Texas Oncology - Austin|Texas Oncology - Baylor Charles A. Sammons Cancer Center|University of Texas MD Anderson Cancer Center|University of Washington, Seattle Cancer Care Alliance|Antwerp University Hospital|Beijing Cancer Hospital|West China Hospital, Sichuan University|Sichuan Cancer Hospital & Institute|Chongqing Cancer Hospital|Fujian Provincial Cancer Hospital|First Affiliated Hospital of Gannan Medical University|Sun Yat-sen University Cancer Center|Guangdong Provincial People's Hospital|Nanfang Hospital of Southern Medical University|Zhejiang Provincial People's Hospital|Zhejiang Cancer Hospital|Anhui Provincial Cancer Hospital|Jinan Central Hospital|Gansu Provincial Cancer Hospital|Fudan University Shanghai Cancer Center|Liaoning Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Henan Cancer Hospital|Institut Bergoni|CHRU de Lille - Hpital Claude Hurier Servide d'Endocrinologie et Diabtologie|Centre Leon Berard|Centre Antoine Lacassagne|Hospital Tenon|Institut Curie|CHU de Rennes - Hpital Pontchaillou|Insitut Claudius Regaud|Gustave Roussy|HELIOS Klinikum Emil von Behring|Universittsklinikum Essen|Thoraxklinik Heidelberg|Klinikum der Universitat Munchen|Pius-Hospital Oldenberg|The Chinese University of Hong Kong|Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative|Grande Ospedale Metropolitano Niguarda|Ospedale Santa Maria delle Croci|Istituto Nazionale Tumori Regina Elena|Seoul National University Hospital|Severance Hospital|Asan Medical Center|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis|University Medical Center Groningen|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Clinic Barcelona|Hospital Duran I Reynals|Hospital Universitario Ramon y Cajal|Hospital Universitario 12 de Octubre Servicio de Oncologia Medica|National Taiwan University Hospital|Taipei Veterans General Hospital|NHS Grampian - Aberdeen Royal Infirmary|Sarah Cannon Research Institute|Guy's Hospital St. Thomas NHS Foundation Trust|NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust|The Christie NHS Foundation Trust",Drug,"Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03037385
1976,NCT03039439,parathyroid neoplasms,Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents,Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors,Parathyroid Gland Adenoma|Parathyroid Gland Atypical Adenoma|Parathyroid Gland Carcinoma|Primary Hyperparathyroidism,2017-01-30,2020-11-30,2020-11-30,310.0,Case-Only,,Retrospective,Observational,Unknown status,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03039439
1979,NCT03039439,hyperparathyroidism,Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents,Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors,Parathyroid Gland Adenoma|Parathyroid Gland Atypical Adenoma|Parathyroid Gland Carcinoma|Primary Hyperparathyroidism,2017-01-30,2020-11-30,2020-11-30,310.0,Case-Only,,Retrospective,Observational,Unknown status,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03039439
1981,NCT03044600,hyperparathyroidism,Gene Expression in Hyperparathyroidism: Identifying Molecular Differences in MEN1 Patients Versus Young MEN1 Negative Patients,Gene Expression in Hyperparathyroidism,Hyperparathyroidism|Parathyroid Disease,2017-02-03,2017-10-18,2017-10-18,22.0,Cohort,,Prospective,Observational,Terminated,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03044600
1982,NCT03046524,parathyroid neoplasms,Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior,Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior,Parathyroid Carcinoma|Parathyroid Neoplasm,2017-02-02,2017-10-16,2017-10-16,100.0,Cohort,,Retrospective,Observational,Completed,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03046524
1986,NCT03048708,thyroiditis,Changes in Thyroid Function Tests and Texture Following Bariatric Surgery Induced Weight Loss,Thyroid in Bariatric Surgery,Autoimmune Thyroiditis|Insulin Resistance|Obesity|Thyroid,2017-02-07,2013-12-31,2016-08-31,10.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University Hospitals Coventry and Warwickshire NHS Trust,University Hospitals Coventry and Warwickshire NHS Trust,,Procedure,,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03048708
1987,NCT03048877,thyroid neoplasms,"A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer",Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2017-02-03,2020-03-25,2022-07-31,118.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Nanjing PLA 81 Hospital|Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03048877
1988,NCT03051126,parathyroid diseases,Establishment of a Parathyroid Tissue Bank,Establishment of a Parathyroid Tissue Bank,Parathyroid Disease,2017-02-02,2025-07-01,2025-07-01,10000.0,Cohort,,Prospective,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03051126
1989,NCT03052075,hyperparathyroidism,Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Primary Hyperparathyroidism,2017-02-10,2020-09-30,2020-09-30,250.0,Cohort,,Retrospective,Observational,Unknown status,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03052075
1992,NCT03053115,hypothyroidism,"Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients: Effects on Peripheral Tissues. A Prospective, Randomized, Controlled, Double-blind Study",Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients,Hypothyroidism,2016-11-25,2021-12-31,2021-12-31,160.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2/Phase 3,Azienda USL Modena,Azienda USL Modena,AziendaUSLModena,Drug|Drug|Drug,Italy,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03053115
1993,NCT03053999,hyperparathyroidism,Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET),Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET),Hyperparathyroidism|Multiple Endocrine Neoplasia|Pancreatic Neuroendocrine Tumors,2017-02-13,2022-10-31,2023-10-31,53.0,Case-Control,,Retrospective,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03053999
1995,NCT03057925,thyroid nodule,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Thyroid Nodule,2017-02-12,2017-12-31,2018-12-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,First Affiliated Hospital of Wenzhou Medical University,First Affiliated Hospital of Wenzhou Medical University|Wenjun Wu,The First Affiliated Hospital of Wenzhou Medical University,Device,China,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03057925
1996,NCT03057925,thyroid neoplasms,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Thyroid Nodule,2017-02-12,2017-12-31,2018-12-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,First Affiliated Hospital of Wenzhou Medical University,First Affiliated Hospital of Wenzhou Medical University|Wenjun Wu,The First Affiliated Hospital of Wenzhou Medical University,Device,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03057925
1997,NCT03061318,thyroid neoplasms,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-02-17,2017-08-30,2017-08-30,3100.0,Cohort,,Prospective,Observational,Completed,,Pontificia Universidad Catolica de Chile,Hernn Gonzlez,Centro de Diagnstico Plaza Italia|Clnica Alemana de Santiago|Hospital Clnico de la Pontificia Universidad Catlica de Chile|Clnica San Carlos de Apoquindo|Clnica Santa Mara|Fundacin Arturo Lpez Prez|Hospital del Salvador|Hospital San Juan de Dios|Hospital Clnico de la Universidad de Chile,,Chile,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03061318
1998,NCT03061318,thyroid nodule,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-02-17,2017-08-30,2017-08-30,3100.0,Cohort,,Prospective,Observational,Completed,,Pontificia Universidad Catolica de Chile,Hernn Gonzlez,Centro de Diagnstico Plaza Italia|Clnica Alemana de Santiago|Hospital Clnico de la Pontificia Universidad Catlica de Chile|Clnica San Carlos de Apoquindo|Clnica Santa Mara|Fundacin Arturo Lpez Prez|Hospital del Salvador|Hospital San Juan de Dios|Hospital Clnico de la Universidad de Chile,,Chile,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03061318
2000,NCT03063190,hyperparathyroidism,Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome,Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease,"Adynamic Bone Disease|Hyperparathyroidism, Secondary|Renal Disease Bone|Renal Disease, End Stage|Restless Leg Disorder|Vitamin D Deficiency",2017-02-21,2022-03-31,2023-03-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Hospital das Clinicas,Drug|Drug,Brazil,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03063190
2002,NCT03064542,hyperthyroidism,"The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure","The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure",Hyperthyroidism,2017-02-09,2024-10-24,2024-10-24,30.0,Cohort,,Other,Observational [Patient Registry],Active not recruiting,,"Clinical Nutrition Research Centre, Singapore","Agency for Science, Technology and Research|Clinical Nutrition Research Centre, Singapore","Tan Tock Seng Hospital, Endocrinology Clinic",Drug,Singapore,21.0,50.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03064542
2003,NCT03065218,thyroid neoplasms,"Evaluation of 99mTc Sestamibi Scans In Patients Who Have Differentiated Thyroid Cancer, Elevated Serum Thyroglobulin Levels, and Negative Diagnostic Imaging Studies",99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients,Thyroid Cancer,2016-10-27,2021-02-15,2021-02-15,4.0,,Single Group Assignment,,Interventional,Terminated,Phase 4,Medstar Health Research Institute,Medstar Health Research Institute,Washington Hospital Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03065218
2004,NCT03066076,goiter,Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up,Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,2017-01-27,2019-02-01,2019-06-01,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,Department of Surgery and Department of Ophthalmology Medical University Vienna,Drug|Procedure,Austria,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03066076
2005,NCT03066076,hyperthyroidism,Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up,Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,2017-01-27,2019-02-01,2019-06-01,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,Department of Surgery and Department of Ophthalmology Medical University Vienna,Drug|Procedure,Austria,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03066076
2006,NCT03066076,graves ophthalmopathy,Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up,Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,2017-01-27,2019-02-01,2019-06-01,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,Department of Surgery and Department of Ophthalmology Medical University Vienna,Drug|Procedure,Austria,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03066076
2007,NCT03066076,graves disease,Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up,Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,2017-01-27,2019-02-01,2019-06-01,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,Department of Surgery and Department of Ophthalmology Medical University Vienna,Drug|Procedure,Austria,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03066076
2008,NCT03072160,thyroid neoplasms,Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,Medullary Thyroid Cancer (MTC),2017-03-03,2019-11-22,2019-11-22,17.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),National Institutes of Health Clinical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03072160
2010,NCT03072654,goiter,Thyroidectomy Improves Tracheal Anatomy and Airflow in Patients With Nodular Goiter: A Prospective Cohort Study,Tracheal Anatomy After Thyroidectomy,"Goiter, Nodular",2017-03-02,2017-03-01,2017-03-02,72.0,Cohort,,Prospective,Observational,Completed,,University of Southern Denmark,University of Southern Denmark,,Procedure,,20.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03072654
2012,NCT03082742,hyperparathyroidism,The Effect of Thiazide and Loop Diuretic on Mineral and Bone Disorder in Chronic Kidney Disease Patients,The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients,Chronic Kidney Disease|Secondary Hyperparathyroidism,2017-02-27,2018-06-30,2018-06-30,52.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Hospital das Clinicas,Drug|Drug,Brazil,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03082742
2014,NCT03085056,"thyroid carcinoma, anaplastic",A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2017-03-15,2023-09-30,2023-09-30,13.0,,Single Group Assignment,,Interventional,Active not recruiting,Early Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|Novartis,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited Protocol Activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau (Limited Protocol Activities),Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03085056
2016,NCT03085615,euthyroid sick syndromes,Feeding the Critically Ill During Phases of Altered Redox Status (FEDOX): a Prospective Randomized Trial,Feeding the Critically Ill During Phases of Altered Redox Status,Acute Respiratory Distress Syndrome|Euthyroid Sick Syndromes|Oxidative Stress|Systemic Inflammatory Response Syndrome,2017-03-15,2018-06-04,2018-10-13,35.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Illinois at Chicago,American Society for Parenteral and Enteral Nutrition|Rush University Medical Center|University of Illinois at Chicago,Rush University Medical Center,Other,United States,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT03085615
2019,NCT03091140,hyperparathyroidism,Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.,Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.,"Hyperparathyroidism, Primary|Parathyroidectomy",2017-03-03,2018-12-31,2018-12-31,200.0,Cohort,,Prospective,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"AHEPA University General Hospital, Aristotle University of Thessaloniki",,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03091140
2020,NCT03093909,thyroid neoplasms,Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases,Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases,Malignant Neoplasm of Bone and Articular Cartilage|Malignant Neoplasm of Male Genital Organs|Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract|Melanoma and Other Malignant Neoplasms of Skin,2017-03-21,2021-11-30,2022-11-30,44.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,Gateway for Cancer Research|James B. and Lois R. Archer Charitable Foundation|M.D. Anderson Cancer Center,The University of Texas MD Anderson Cancer Center,Drug,United States,12.0,50.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03093909
2021,NCT03094416,hypothyroidism,An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors,Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors,Hypothyroidism;Postablative,2017-03-17,2020-06-15,2020-06-15,66.0,,Single Group Assignment,,Interventional,Completed,Phase 4,IBSA Institut Biochimique SA,IBSA Institut Biochimique SA,"California Head and Neck Specialists|Coastal Metabolic Research Centre|Washington Hospital Center|MedStar Union Memorial Hospital|NYC Health + Hospitals/ Queens|Diabetes & Endocrinology Consultants, PC|Carolina Ear Nose and Throat Clinic|Virginia Commonwealth University|Stonesifer Endocrine Care & Clinical Research Inc., PS",Drug|Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03094416
2022,NCT03095963,hypothyroidism,Effects of Probiotics Assumption on Serum Thyroid Hormone and TSH Levels in Hypothyroid Patients on Levothyroxine Treatment,Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients,Hypothyroidism,2017-03-15,2016-10-25,2016-10-25,80.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Azienda USL Modena,Azienda USL Modena,,Other|Drug,,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03095963
2023,NCT03096613,hypothyroidism,"Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial",Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF),Heart Failure|Subclinical Hypothyroidism,2017-03-25,2019-02-28,2019-02-28,124.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,"Chinese Academy of Medical Sciences, Fuwai Hospital","Chinese Academy of Medical Sciences, Fuwai Hospital|Henan Provincial People's Hospital|The First Hospital of Hebei Medical University|The Luhe Teaching Hospital of the Capital Medical University|Tianjin Medical University Second Hospital","Chinese Academy of Medical Sciences, Fuwai Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03096613
2024,NCT03098225,graves disease,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy,Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,120.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03098225
2025,NCT03098225,graves ophthalmopathy,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy,Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,120.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03098225
2026,NCT03098225,hyperthyroidism,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy,Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,120.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03098225
2027,NCT03098225,goiter,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy,Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,120.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03098225
2028,NCT03099356,thyroid neoplasms,"An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",Metastatic Thyroid Cancer,2017-03-28,2022-05-12,2023-05-12,19.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,University of Michigan Rogel Cancer Center,University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03099356
2029,NCT03102099,thyroid neoplasms,Application Value of Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Thyroid Nodules,2017-03-10,2018-06-30,2019-06-30,400.0,Case-Control,,Prospective,Observational,Unknown status,,Peking University Third Hospital,Peking University Third Hospital,Peking University Third Hospital,Procedure|Procedure,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03102099
2030,NCT03102099,thyroid nodule,Application Value of Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Thyroid Nodules,2017-03-10,2018-06-30,2019-06-30,400.0,Case-Control,,Prospective,Observational,Unknown status,,Peking University Third Hospital,Peking University Third Hospital,Peking University Third Hospital,Procedure|Procedure,China,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03102099
2031,NCT03102177,hypothyroidism,Hypothyroidism Treatment in Aging and Thyroid Cancer,"Effect of Age, Weight and Sex on Levothyroxine Pharmacokinetics",Hypothyroidism Primary,2017-03-27,2013-11-30,2016-07-26,41.0,,Single Group Assignment,,Interventional,Completed,Early Phase 1,Georgetown University,Georgetown University,,Drug,,21.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03102177
2032,NCT03103607,graves ophthalmopathy,Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term,Disappearance of Graves' Orbitopathy,Thyroid Eye Disease,2017-03-27,2014-12-31,2016-02-28,99.0,Cohort,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Diagnostic Test|Diagnostic Test,,18.0,100.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03103607
2033,NCT03103607,hyperthyroidism,Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term,Disappearance of Graves' Orbitopathy,Thyroid Eye Disease,2017-03-27,2014-12-31,2016-02-28,99.0,Cohort,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Diagnostic Test|Diagnostic Test,,18.0,100.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03103607
2034,NCT03103607,goiter,Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term,Disappearance of Graves' Orbitopathy,Thyroid Eye Disease,2017-03-27,2014-12-31,2016-02-28,99.0,Cohort,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Diagnostic Test|Diagnostic Test,,18.0,100.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03103607
2035,NCT03103607,graves disease,Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term,Disappearance of Graves' Orbitopathy,Thyroid Eye Disease,2017-03-27,2014-12-31,2016-02-28,99.0,Cohort,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Diagnostic Test|Diagnostic Test,,18.0,100.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03103607
2038,NCT03103776,"thyroiditis, autoimmune",Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis.,Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis.,"Polyoma Virus Infection|Thyroiditis, Autoimmune",2017-03-31,2018-10-31,2018-10-31,49.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03103776
2039,NCT03105648,thyroid neoplasms,Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm,Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm,Computerized Cytomorphometry,2017-04-04,2026-04-20,2026-04-20,3000.0,Case-Control,,Retrospective,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Other,Taiwan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03105648
2040,NCT03106337,thyroid neoplasms,A Multivariate Analysis of Factors Predictive of Carcinoma in Follicular Neoplasms of the Thyroid Gland,Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid,Follicular Neoplasm|Thyroid Nodule,2014-04-25,2012-04-30,2012-04-30,35.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03106337
2041,NCT03106337,thyroid nodule,A Multivariate Analysis of Factors Predictive of Carcinoma in Follicular Neoplasms of the Thyroid Gland,Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid,Follicular Neoplasm|Thyroid Nodule,2014-04-25,2012-04-30,2012-04-30,35.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03106337
2042,NCT03106935,hypothyroidism,Effect of Levothyroxine Treatment on Pregnancy Outcome in RPL Women With Subclinical Hypothyroidism,Recurrent Pregnancy Loss and Thyroid Disease,Recurrent Pregnancy Loss,2017-02-27,2017-12-31,2018-06-30,300.0,,Parallel Assignment,,Interventional,Unknown status,Early Phase 1,Second Affiliated Hospital of Soochow University,Second Affiliated Hospital of Soochow University,Second Affiliated Hospital of Soochow University,Drug,China,18.0,39.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03106935
2043,NCT03107078,graves disease,"Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial","Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial",Thyroid Associated Ophthalmopathy,2017-03-08,2019-10-01,2021-10-01,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,The Third Affiliated Hospital of Southern Medical University,Huadu District People's Hospital of Guangzhou|Jie Shen|The Fifth Affiliated Hospital of Southern Medical University|Zhujiang Hospital,the Third Affiliated Hospital of Southern Medical University,Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03107078
2044,NCT03107078,hyperthyroidism,"Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial","Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial",Thyroid Associated Ophthalmopathy,2017-03-08,2019-10-01,2021-10-01,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,The Third Affiliated Hospital of Southern Medical University,Huadu District People's Hospital of Guangzhou|Jie Shen|The Fifth Affiliated Hospital of Southern Medical University|Zhujiang Hospital,the Third Affiliated Hospital of Southern Medical University,Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03107078
2045,NCT03107078,goiter,"Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial","Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial",Thyroid Associated Ophthalmopathy,2017-03-08,2019-10-01,2021-10-01,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,The Third Affiliated Hospital of Southern Medical University,Huadu District People's Hospital of Guangzhou|Jie Shen|The Fifth Affiliated Hospital of Southern Medical University|Zhujiang Hospital,the Third Affiliated Hospital of Southern Medical University,Drug,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03107078
2046,NCT03107078,graves ophthalmopathy,"Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial","Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial",Thyroid Associated Ophthalmopathy,2017-03-08,2019-10-01,2021-10-01,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,The Third Affiliated Hospital of Southern Medical University,Huadu District People's Hospital of Guangzhou|Jie Shen|The Fifth Affiliated Hospital of Southern Medical University|Zhujiang Hospital,the Third Affiliated Hospital of Southern Medical University,Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03107078
2047,NCT03108222,hyperparathyroidism,Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease,Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease,Chronic Kidney Disease Mineral and Bone Disorder,2017-04-05,2019-08-30,2019-12-31,20.0,Other,,Prospective,Observational,Unknown status,,Purdue University,Purdue University,Purdue University Nutrition Science Department,Other,United States,30.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03108222
2050,NCT03109847,thyroid neoplasms,Pilot Study of Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Well-Differentiated Thyroid Cancers,Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer,Thyroid,2017-03-06,2022-01-31,2022-01-31,13.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Drug|Other|Other,United States,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03109847
2051,NCT03110835,graves disease,Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy,Low-dose Radioiodine Ablation in Graves' Disease,Thyroid Diseases,2017-03-14,2017-03-28,2017-03-28,12.0,Case-Control,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Radiation,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03110835
2052,NCT03110835,goiter,Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy,Low-dose Radioiodine Ablation in Graves' Disease,Thyroid Diseases,2017-03-14,2017-03-28,2017-03-28,12.0,Case-Control,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Radiation,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03110835
2053,NCT03110835,hyperthyroidism,Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy,Low-dose Radioiodine Ablation in Graves' Disease,Thyroid Diseases,2017-03-14,2017-03-28,2017-03-28,12.0,Case-Control,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Radiation,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03110835
2054,NCT03110848,graves disease,"A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study",Effects of Atorvastatin in Graves' Orbitopathy (GO),Hypercholesterolemia|Thyroid Associated Ophthalmopathy,2017-03-23,2021-04-30,2021-04-30,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03110848
2055,NCT03110848,hyperthyroidism,"A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study",Effects of Atorvastatin in Graves' Orbitopathy (GO),Hypercholesterolemia|Thyroid Associated Ophthalmopathy,2017-03-23,2021-04-30,2021-04-30,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03110848
2056,NCT03110848,goiter,"A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study",Effects of Atorvastatin in Graves' Orbitopathy (GO),Hypercholesterolemia|Thyroid Associated Ophthalmopathy,2017-03-23,2021-04-30,2021-04-30,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03110848
2057,NCT03110848,graves ophthalmopathy,"A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study",Effects of Atorvastatin in Graves' Orbitopathy (GO),Hypercholesterolemia|Thyroid Associated Ophthalmopathy,2017-03-23,2021-04-30,2021-04-30,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03110848
2060,NCT03114267,thyroiditis,Involvement of Viral Infections in the Pathogenesis of Chronic Lymphocytic Thyroiditis,Involvement of Viral Infections in the Pathogenesis of Chronic Lymphocytic Thyroiditis,Autoimmune Diseases|Chronic Lymphocytic Thyroiditis,2017-04-11,2015-01-06,2015-01-06,64.0,Cohort,,Retrospective,Observational,Completed,,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03114267
2061,NCT03115515,hypothyroidism,"Randomized, Prospective Trial Comparing the Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy",Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy,Pregnancy Related|Thyroid,2017-04-07,2018-02-28,2018-02-28,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Medstar Health Research Institute,Medstar Health Research Institute,Medstar Washington Hospital Center,Drug,United States,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03115515
2062,NCT03120221,hypothyroidism,Iodine Status in Pregnant Women in Israel,Iodine Status in Pregnant Women in Israel,Iodine-Deficiency; Hypothyroidism,2017-04-01,2018-12-31,2018-12-31,160.0,Case-Only,,Prospective,Observational,Unknown status,,Clalit Health Services,Clalit Health Services,Women Health Service|Women Health Center,Diagnostic Test,Israel,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03120221
2063,NCT03122496,"thyroid carcinoma, anaplastic",A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer,Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer,Metastatic Anaplastic Thyroid Cancer,2017-04-18,2023-04-30,2023-04-30,13.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,AstraZeneca|Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge|Memoral Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memoral Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering @ Rockville|Memorial Sloan Kettering Nassau,Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03122496
2065,NCT03122847,graves disease,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves Ophthalmopathy,Glucocorticoids and Bone in Graves' Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,30.0,Cohort,,Prospective,Observational,Active not recruiting,,Aarhus University Hospital,Odense University Hospital|Torben Harslf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03122847
2066,NCT03122847,hyperthyroidism,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves Ophthalmopathy,Glucocorticoids and Bone in Graves' Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,30.0,Cohort,,Prospective,Observational,Active not recruiting,,Aarhus University Hospital,Odense University Hospital|Torben Harslf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03122847
2067,NCT03122847,goiter,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves Ophthalmopathy,Glucocorticoids and Bone in Graves' Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,30.0,Cohort,,Prospective,Observational,Active not recruiting,,Aarhus University Hospital,Odense University Hospital|Torben Harslf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03122847
2068,NCT03122847,graves ophthalmopathy,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves Ophthalmopathy,Glucocorticoids and Bone in Graves' Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,30.0,Cohort,,Prospective,Observational,Active not recruiting,,Aarhus University Hospital,Odense University Hospital|Torben Harslf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03122847
2069,NCT03123406,hyperparathyroidism,"A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT)","Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT","Hyperparathyroidism; Secondary, Renal",2017-03-29,2019-04-20,2019-09-06,750.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"Kyowa Hakko Kirin China Pharmaceutical Co., LTD.","Kyowa Hakko Kirin China Pharmaceutical Co., LTD.",Nanjing Jinling Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03123406
2072,NCT03127098,thyroid neoplasms,"Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",Breast Cancer|Colon Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Thyroid Cancer,2017-04-20,2017-12-07,2017-12-07,3.0,,Sequential Assignment,,Interventional,Completed,Phase 1/Phase 2,"NantCell, Inc.","NantCell, Inc.",Medical Oncology Associates,Biological|Biological,United States,21.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03127098
2073,NCT03128255,thyroid nodule,"I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics",Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.,Thyroid Diseases|Thyroid Goitre|Thyroid Nodule,2017-04-20,2017-07-31,2018-04-30,70.0,Case-Control,,Prospective,Observational,Unknown status,,Jena University Hospital,GE Healthcare|Jena University Hospital,University Hospital Jena,Other,Germany,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03128255
2074,NCT03128255,goiter,"I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics",Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.,Thyroid Diseases|Thyroid Goitre|Thyroid Nodule,2017-04-20,2017-07-31,2018-04-30,70.0,Case-Control,,Prospective,Observational,Unknown status,,Jena University Hospital,GE Healthcare|Jena University Hospital,University Hospital Jena,Other,Germany,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03128255
2075,NCT03128255,thyroid neoplasms,"I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics",Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.,Thyroid Diseases|Thyroid Goitre|Thyroid Nodule,2017-04-20,2017-07-31,2018-04-30,70.0,Case-Control,,Prospective,Observational,Unknown status,,Jena University Hospital,GE Healthcare|Jena University Hospital,University Hospital Jena,Other,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03128255
2076,NCT03131206,thyroid neoplasms,A Phase 1/2 Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,ALK-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Thyroid Cancer,2017-04-19,2018-11-08,2019-04-08,5.0,,Parallel Assignment,,Interventional,Terminated,Phase 1/Phase 2,Dana-Farber Cancer Institute,"Dana-Farber Cancer Institute|Genentech, Inc.","University of California, Irvine|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana Farber Cancer Institute",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03131206
2077,NCT03131726,goiter,Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malm",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03131726
2078,NCT03131726,graves disease,Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malm",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03131726
2079,NCT03131726,graves ophthalmopathy,Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malm",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03131726
2080,NCT03131726,hyperthyroidism,Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malm",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03131726
2081,NCT03134976,hypothyroidism,Wound Complications in Head and Neck Surgery,Wound Complications in Head and Neck Surgery,Head and Neck Cancer|Hypothyroidism; Surgery|Laryngeal Cancer|Laryngeal Fistula|Wound Heal,2017-04-20,2020-04-01,2020-05-01,51.0,Cohort,,Prospective,Observational,Completed,,University of Michigan,University of Michigan,University of Michigan,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03134976
2082,NCT03137316,hyperparathyroidism,Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy,Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy,Diabetic Nephropathies|Secondary Hyperparathyroidism,2017-04-28,2017-02-28,2017-03-01,437.0,Cohort,,Retrospective,Observational,Completed,,Benha University,Benha University|New Jeddah Clinic Hospital,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03137316
2085,NCT03139747,thyroid neoplasms,UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,Thyroid Cancer,2017-05-02,2022-05-30,2022-05-30,5.0,,Single Group Assignment,,Interventional,Suspended,Phase 2,Thomas Jefferson University,Thomas Jefferson University,Abramson Cancer Center of the University of Pennsylvania,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03139747
2086,NCT03150108,hypoparathyroidism,"A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects",Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects,Hypoparathyroidism,2017-05-01,2017-06-26,2017-06-26,24.0,,Crossover Assignment,,Interventional,Completed,Phase 1,Takeda,Shire,Glendale Adventist Medical Center,Drug|Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03150108
2088,NCT03157128,thyroid neoplasms,"A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)","A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)",Any Solid Tumor|Colon Cancer|Medullary Thyroid Cancer|Non-Small Cell Lung Cancer,2017-05-09,2022-11-21,2023-11-21,989.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","Mayo Clinic of Scottsdale|City of Hope National Medical Center|University of California - San Diego|UCLA Medical Center|Hoag Memorial Hospital Presbyterian|Irvine Medical Center|UCSF Medical Center at Mission Bay|Kaiser Permanente|Kaiser Permanente Medical Center|Sarah Cannon Research Institute at HealthOne|Yale Cancer Center|Johns Hopkins University|Mayo Clinic in Florida|Memorial Hospital Pembroke|Emory University|University of Chicago Medicine-Comprehensive Cancer Center|Ochsner Clinic Foundation|University of Maryland Medical Center|Massachusetts General Hospital|Dana-Farber Cancer Institute|University of Michigan|START Midwest|Mayo Clinic|Washington University Medical School|Comprehensive Cancer Centers of Nevada|Roswell Park Cancer Institute|NYU Langone|Memorial Sloan Kettering Cancer Center|University of North Carolina|Cleveland Clinic Foundation|Ohio State University Hospital|Oregon Health and Science University|University of Pennsylvania Hospital|Thomas Jefferson University|Sarah Cannon Research Institute SCRI|Vanderbilt University Medical Center|University of Texas Southwestern Medical Center at Dallas|University of Texas MD Anderson Cancer Center|Huntsman Cancer Institute|Virginia Cancer Specialists, PC|University of Wisconsin-Madison Hospital and Health Clinic|Royal North Shore Hospital|Peter MacCallum Cancer Centre|BC Cancer Vancouver|Rigshospitalet|Hpital Europen Georges Pompidou|Institut Bergoni - Centre Rgional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest|Centre Leon Berard|APHM Hpital de la Timone|Institut du Cancer de Montpellier - Val d'aurelle|Gustave Roussy|Universittsklinikum Wrzburg A. . R.|Universittsklinikum Kln|Prince of Wales Hospital|Sheba Medical Center|Shaare Zedek Medical Center|Soroka Medical Center - Pediatric Outpatient Clinic|Hadassah Medical Center|Istituto Nazionale dei Tumori|Nagoya University Hospital|National Cancer Center Hospital East|Hokkaido University Hospital|Hyogo Cancer Center|Kanazawa University Hospital|Kindai University Hospital|Shizuoka Cancer Center|National Cancer Center Hospital|Japanese Foundation for Cancer Research|Tottori University Hospital|National Hospital Organization Kyushu Cancer Center|Okayama University Hospital|Osaka City General Hospital|National Cancer Center|Seoul National University Bundang Hospital|Asan Medical Center|Samsung Medical Center|Severance Hospital, Yonsei University Health System|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Universitario Fundacin Jimnez Daz|Hospital Madrid Norte Sanchinarro|Kantonsspital Luzern|Taichung Veterans General Hospital|National Taiwan University Hospital|Royal Marsden Hospital",Drug,"Australia|Canada|Denmark|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Singapore|Spain|Switzerland|Taiwan|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03157128
2089,NCT03157466,euthyroid sick syndromes,Diaphragmatic Efficiency After Thyroid Hormone Replacement Therapy in Ventilated Patients With the Nonthyroidal Illness Syndrome: a Physiological Study,Respiratory Muscle Function After Thyroid Hormone Replacement Therapy in Nonthyroidal Illness Syndrome,Respiratory Failure|Thyroid Diseases,2017-05-12,2018-05-01,2018-05-01,15.0,Cohort,,Prospective,Observational,Completed,,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Fondazione Policlinico Universitario Agostino Gemelli,,Italy,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT03157466
2090,NCT03158961,thyroid nodule,A Prospective Evaluation of the Feasibility and Safety of the Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) as a Treatment for Benign Thyroid Nodules,The Feasibility and Safety of the TOETVA for Benign Thyroid Nodules,Thyroid Diseases,2017-05-15,2019-05-31,2019-07-31,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Procedure,Hong Kong,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03158961
2091,NCT03158961,thyroid neoplasms,A Prospective Evaluation of the Feasibility and Safety of the Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) as a Treatment for Benign Thyroid Nodules,The Feasibility and Safety of the TOETVA for Benign Thyroid Nodules,Thyroid Diseases,2017-05-15,2019-05-31,2019-07-31,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Procedure,Hong Kong,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03158961
2092,NCT03160274,thyroid neoplasms,"Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions",Associated Conditions|Bone Cancer|Inherited Cancer Syndrome|Kidney Neoplasms|Other Cancer|Paraganglioma|Pheochromocytoma|Thyroid Neoplasms,2017-05-05,2030-12-31,2030-12-31,2000.0,Cohort,,Other,Observational [Patient Registry],Recruiting,,The University of Texas Health Science Center at San Antonio,National Institute of General Medical Sciences (NIGMS)|The University of Texas Health Science Center at San Antonio,University of Texas Health Science Center,Genetic,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03160274
2093,NCT03160482,thyroid neoplasms,Evaluation of PACE4 Isoforms as Biomarkers in Thyroid Cancer,PACE4 in Thyroid Cancer,Thyroid Nodule,2017-05-16,2018-01-15,2018-01-15,39.0,Cohort,,Cross-Sectional,Observational,Completed,,Universit de Sherbrooke,Robert Day,CIUSSS de l'Estrie - CHUS,Diagnostic Test,Canada,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03160482
2094,NCT03160482,thyroid nodule,Evaluation of PACE4 Isoforms as Biomarkers in Thyroid Cancer,PACE4 in Thyroid Cancer,Thyroid Nodule,2017-05-16,2018-01-15,2018-01-15,39.0,Cohort,,Cross-Sectional,Observational,Completed,,Universit de Sherbrooke,Robert Day,CIUSSS de l'Estrie - CHUS,Diagnostic Test,Canada,18.0,100.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03160482
2095,NCT03162627,thyroid neoplasms,"Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance",Selumetinib and Olaparib in Solid Tumors,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands,2017-05-18,2026-08-30,2026-08-30,90.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,AstraZeneca|M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03162627
2096,NCT03167385,thyroid neoplasms,The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial.,Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma,Differentiated Thyroid Carcinoma,2017-05-24,2019-01-31,2020-12-31,20.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Tianjin Medical University Cancer Institute and Hospital,Tianjin Medical University Cancer Institute and Hospital,Tianjin Medical University Cancer Institute and Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03167385
2097,NCT03170804,thyroid neoplasms,Registry for Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Thymic Carcinoma|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2017-05-25,2018-01-01,2020-01-01,200.0,Cohort,,Prospective,Observational [Patient Registry],Unknown status,,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03170804
2098,NCT03170804,thyroid nodule,Registry for Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Thymic Carcinoma|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2017-05-25,2018-01-01,2020-01-01,200.0,Cohort,,Prospective,Observational [Patient Registry],Unknown status,,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03170804
2099,NCT03170960,thyroid neoplasms,A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,Castration-resistant Prostate Cancer|Colorectal Cancer|Differentiated Thyroid Cancer|Endometrial Cancer|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Head and Neck Cancer|Hepatocellular Carcinoma|Lower Esophageal Cancer|Non-Small Cell Lung Cancer|Ovarian Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer|Urothelial Carcinoma,2017-05-23,2022-12-31,2022-12-31,1732.0,,Sequential Assignment,,Interventional,Active not recruiting,Phase 1/Phase 2,Exelixis,Exelixis,Exelixis Clinical Site #53|Exelixis Clinical Site #18|Exelixis Clinical Site #1|Exelixis Clinical Site #20|Exelixis Clinical Site #46|Exelixis Clinical Site #51|Exelixis Clinical Site #62|Exelixis Clinical Site #21|Exelixis Clinical Site #34|Exelixis Clinical Site #50|Exelixis Clinical Site #42|Exelixis Clinical Site #48|Exelixis Clinical Site #16|Exelixis Clinical Site #76|Exelixis Clinical Site #60|Exelixis Clinical Site #79|Exelixis Clinical Site #32|Exelixis Clinical Site #23|Exelixis Clinical Site #57|Exelixis Clinical Site #24|Exelixis Clinical Site #10|Exelixis Clinical Site #3|Exelixis Clinical Site #17|Exelixis Clinical Site #65|Exelixis Clinical Site #43|Exelixis Clinical Site #35|Exelixis Clinical Site #59|Exelixis Clinical Site #61|Exelixis Clinical Site #38|Exelixis Clinical Site #27|Exelixis Clinical Site #31|Exelixis Clinical Site #37|Exelixis Clinical Site #40|Exelixis Clinical Site #11|Exelixis Clinical Site #67|Exelixis Clinical Site #49|Exelixis Clinical Site #64|Exelixis Clinical Site #71|Exelixis Clinical Site #6|Exelixis Clinical Site #102|Exelixis Clinical Site #45|Exelixis Clinical Site #41|Exelixis Clinical Site #15|Exelixis Clinical Site #55|Exelixis Clinical Site #66|Exelixis Clinical Site #95|Exelixis Clinical Site #13|Exelixis Clinical Site #26|Exelixis Clinical Site #114|Exelixis Clinical Site #29|Exelixis Clinical Site #39|Exelixis Clinical Site #44|Exelixis Clinical Site #33|Exelixis Clinical Site #63|Exelixis Clinical Site #2|Exelixis Clinical Site #30|Exelixis Clinical Site #14|Exelixis Clinical Site #98|Exelixis Clinical Site #101|Exelixis Clinical Site #115|Exelixis Clinical Site #112|Exelixis Clinical Site #123|Exelixis Clinical Site #99|Exelixis Clinical Site #52|Exelixis Clinical Site #54|Exelixis Clinical Site #88|Exelixis Clinical Site #8|Exelixis Clinical Site #92|Exelixis Clinical Site #93|Exelixis Clinical Site #87|Exelixis Clinical Site #69|Exelixis Clinical Site #97|Exelixis Clinical Site #89|Exelixis Clinical Site #109|Exelixis Clinical Site #104|Exelixis Clinical Site #80|Exelixis Clinical Site #78|Exelixis Clinical Site #7|Exelixis Clinical Site #68|Exelixis Clinical Site #72|Exelixis Clinical Site #82|Exelixis Clinical Site #119|Exelixis Clinical Site #107|Exelixis Clinical Site #105|Exelixis Clinical Site #56|Exelixis Clinical Site #36|Exelixis Clinical Site #84|Exelixis Clinical Site #47|Exelixis Clinical Site #108|Exelixis Clinical Site #103|Exelixis Clinical Site #25|Exelixis Clinical Site #4|Exelixis Clinical Site #85|Exelixis Clinical Site #121|Exelixis Clinical Site #110|Exelixis Clinical Site #12|Exelixis Clinical Site #74|Exelixis Clinical Site #91|Exelixis Clinical Site #94|Exelixis Clinical Site #70|Exelixis Clinical Site #113|Exelixis Clinical Site #116|Exelixis Clinical Site #96|Exelixis Clinical Site #90|Exelixis Clinical Site #117|Exelixis Clinical Site #75|Exelixis Clinical Site #58|Exelixis Clinical Site #83|Exelixis Clinical Site #86|Exelixis Clinical Site #28|Exelixis Clinical Site #9|Exelixis Clinical Site #73|Exelixis Clinical Site #118|Exelixis Clinical Site #77|Exelixis Clinical Site #106|Exelixis Clinical Site #111|Exelixis Clinical Site #22|Exelixis Clinical Site #5|Exelixis Clinical Site #81|Exelixis Clinical Site #100|Exelixis Clinical Site #122|Exelixis Clinical Site #120|Exelixis Clinical Site #124|Exelixis Clinical Site #19,Drug|Drug|Drug|Drug,Australia|Belgium|France|Germany|Italy|Netherlands|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03170960
2100,NCT03174925,thyroid nodule,Elastography in Thyroid Nodule Evaluation,Ultrasound Elastography in Imaging Patients With Thyroid Nodules,Malignant Thyroid Gland Neoplasm|Thyroid Gland Nodule,2017-05-18,2018-02-13,2019-02-13,55.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Stanford University,Stanford University,"Stanford University, School of Medicine",Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03174925
2101,NCT03174925,thyroid neoplasms,Elastography in Thyroid Nodule Evaluation,Ultrasound Elastography in Imaging Patients With Thyroid Nodules,Malignant Thyroid Gland Neoplasm|Thyroid Gland Nodule,2017-05-18,2018-02-13,2019-02-13,55.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Stanford University,Stanford University,"Stanford University, School of Medicine",Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03174925
2102,NCT03176485,thyroid neoplasms,"Pilot Study to Evaluate the Signaling Pathway Modulation Demonstrated by Raf, MEK, and Kinase Inhibitors In Human Skin With or Without Solar Simulated Light","Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors",Colon Cancer|Differentiated Thyroid Cancer|HCC|Hepatocellular Carcinoma|Melanoma|Metastatic Cancer|Metastatic Colon Cancer|Metastatic Melanoma|Renal Cell Carcinoma,2017-06-01,2018-11-01,2018-11-01,45.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Arizona,University of Arizona,University of Arizona Cancer Center,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03176485
2103,NCT03178253,hypothyroidism,Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy,Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy,Hypothyroidism in Diabetes,2017-06-03,2017-06-30,2018-06-30,100.0,Case-Control,,Prospective,Observational,Unknown status,,Assiut University,Assiut University,Maria Hamdy,,Egypt,40.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03178253
2104,NCT03180892,hypothyroidism,Non-immune Related Hypothyroidism in Iodine Sufficient Area,Non-immune Related Hypothyroidism in Iodine Sufficient Area,Hypothyroidism,2017-06-02,2016-12-31,2016-12-31,6564.0,Cohort,,Other,Observational [Patient Registry],Completed,,Samsung Medical Center,Samsung Medical Center,,Other,,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03180892
2105,NCT03181100,"thyroid carcinoma, anaplastic",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,2017-06-06,2023-07-27,2023-07-27,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological|Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03181100
2108,NCT03182699,hyperparathyroidism,Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial,Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients,Chronic Kidney Disease Requiring Chronic Dialysis|Left Ventricular Hypertrophy|Secondary Hyperparathyroidism,2017-05-31,2019-12-20,2019-12-20,62.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Medical University of Vienna,Amgen|Rainer Oberbauer,Medical University of Vienna|Wiener Dialysezentrum,Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03182699
2110,NCT03183752,thyroid neoplasms,The Role of Insulin Resistance and the Effect of Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance|Thyroid Nodule,2017-06-08,2018-10-17,2019-04-17,28.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hospital Universitrio Clementino Fraga Filho,Hospital Universitrio Clementino Fraga Filho,Patricia Santos,Drug|Drug,Brazil,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03183752
2111,NCT03183752,thyroid nodule,The Role of Insulin Resistance and the Effect of Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance|Thyroid Nodule,2017-06-08,2018-10-17,2019-04-17,28.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hospital Universitrio Clementino Fraga Filho,Hospital Universitrio Clementino Fraga Filho,Patricia Santos,Drug|Drug,Brazil,18.0,80.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03183752
2112,NCT03191643,thyroid neoplasms,18F-FDG PET-guided External Beam Radiotherapy in Iodine-refractory Differentiated Thyroid Cancer,PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2017-06-15,2016-01-31,2016-01-31,16.0,Cohort,,Retrospective,Observational,Completed,,IRCCS Azienda Ospedaliero-Universitaria di Bologna,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03191643
2113,NCT03194087,hyperparathyroidism,the Study on Difference Prognostic for Low Parathyroid Hormone Levels and Severe Secondary Hyperparathyroidism in Hemodialysis Patients,the Study on Prognostic for Hemodialysis Patients,Secondary Hyperparathyroidism,2017-05-31,2019-01-01,2019-01-01,827.0,Cohort,,Prospective,Observational,Unknown status,,Beijing Friendship Hospital,Beijing Friendship Hospital,Beijing Friendship hospital,,China,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03194087
2116,NCT03195296,goiter,T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features,T and B Cells in Graves' Orbitopathy,Graves Ophthalmopathy,2017-06-19,2017-05-31,2017-05-31,20.0,Case-Only,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Other,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03195296
2117,NCT03195296,graves ophthalmopathy,T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features,T and B Cells in Graves' Orbitopathy,Graves Ophthalmopathy,2017-06-19,2017-05-31,2017-05-31,20.0,Case-Only,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Other,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03195296
2118,NCT03195296,graves disease,T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features,T and B Cells in Graves' Orbitopathy,Graves Ophthalmopathy,2017-06-19,2017-05-31,2017-05-31,20.0,Case-Only,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Other,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03195296
2119,NCT03195296,hyperthyroidism,T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features,T and B Cells in Graves' Orbitopathy,Graves Ophthalmopathy,2017-06-19,2017-05-31,2017-05-31,20.0,Case-Only,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Other,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03195296
2120,NCT03196518,thyroid neoplasms,PET Imaging of Thyroid Tissue Expressing Sodium-iodine Symporter Using the New Tracer 18F-tetrafluoroborate (18F-TFB),Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer,Thyroid Cancer,2017-06-21,2023-06-30,2023-06-30,5.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03196518
2121,NCT03199677,thyroid neoplasms,"An Exploratory Single-center, Open-label , Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer",A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer,Refractory Cancer,2017-06-16,2018-06-30,2018-06-30,40.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Chinese Academy of Medical Sciences,Chinese Academy of Medical Sciences,"Cancer Hospital, Chinese Academy of Medical Sciences",Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03199677
2122,NCT03202160,goiter,Cases of Goiter in Children Attending Assiut University Children Hospital,Causes of Goiter in Children Attending Assiut University Children Hospital,Goiter,2017-06-27,2019-04-15,2019-09-15,50.0,Case-Only,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,,,,0.0,18.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03202160
2124,NCT03203668,hyperparathyroidism,Diagnostic Value of 18F-fluorocholine PET/CT Imaging in Localization of Hyperfunctioning Parathyroid Tissue in Hyperparathyroidism,18F-fluorocholine PET/CT Imaging in Hyperparathyroidism,Hyperparathyroidism,2017-04-17,2020-12-31,2020-12-31,1000.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,University Medical Centre Ljubljana,Institute of Oncology Ljubljana|University Medical Centre Ljubljana,"Department for nuclear medicine, University medical centre Ljubljana",Radiation,Slovenia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03203668
2126,NCT03211117,"thyroid carcinoma, anaplastic",Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer,"Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,2017-07-06,2018-02-12,2019-03-28,3.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Mayo Clinic,Mayo Clinic|National Cancer Institute (NCI),Mayo Clinic,Drug|Drug|Radiation|Other|Biological|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03211117
2127,NCT03215095,thyroid neoplasms,"Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers",RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers,Thyroid Cancer,2017-07-11,2023-07-31,2023-07-31,11.0,,Single Group Assignment,,Interventional,Active not recruiting,Early Phase 1,Memorial Sloan Kettering Cancer Center,AstraZeneca|MedImmune LLC|Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge|Memoral Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03215095
2130,NCT03226171,hyperparathyroidism,Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism,Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2017-07-20,2018-09-11,2018-09-11,58.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Sanwa Kagaku Kenkyusho Co., Ltd.","Sanwa Kagaku Kenkyusho Co., Ltd.",Investigational site (there may be other sites in this country),Drug,Japan,20.0,79.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03226171
2131,NCT03239769,thyroid neoplasms,"A Study to Evaluate and Compare the Surgical Outcomes, Aesthetic Effects and Incision Length of Different Access Procedures in Patients With DTC",Compare the Aesthetic Effect of Different Thyroidectomies,Differentiated Thyroid Carcinoma (DTC),2017-08-01,2015-06-01,2015-06-01,120.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Beijing Cancer Hospital,Beijing Cancer Hospital,,Procedure,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03239769
2132,NCT03244956,thyroid neoplasms,Efficacy of a Selective MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors Associated With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer With RAS or BRAFV600E Mutation,Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer,Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation,2017-08-07,2021-11-18,2022-12-31,40.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Drug|Drug|Radiation|Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03244956
2133,NCT03246659,thyroid neoplasms,Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma,Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC,Medullary Thyroid Carcinoma,2017-07-28,2018-11-30,2018-11-30,16.0,,Sequential Assignment,,Interventional,Completed,Phase 1,"Azienda Ospedaliero, Universitaria Pisana","Erasmus Medical Center|INRASTES, NCSR Demokritos, Athens, Greece|Jagiellonian University|Medical University Innsbruck|NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland|Paola Anna Erba|University Hospital Freiburg|University Medical Centre Ljubljana","Department of Nuclear Medicine, Innsbruck Medical University|Department of Nuclear Medicine, University Hospital Freiburg|Erasmus University Rotterdam|Department of Endocrinology, Jagiellonian University Medical College|Department of Nuclear Medicine, University Medical Centre Ljubljana",Drug|Drug,Austria|Germany|Netherlands|Poland|Slovenia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03246659
2134,NCT03246958,thyroid neoplasms,"A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer",Nivolumab Plus Ipilimumab in Thyroid Cancer,Thyroid Cancer,2017-08-08,2022-12-31,2025-03-31,53.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Dana-Farber Cancer Institute,Bristol-Myers Squibb|Dana-Farber Cancer Institute,Dana Farber Cancer Institute,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03246958
2136,NCT03249012,hypoparathyroidism,Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism,Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism,Hypoparathyroidism Postprocedural|Quality of Life,2017-08-09,2022-09-01,2022-09-01,120.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,CHU de Quebec-Universite Laval,CHU de Quebec-Universite Laval,CHU de Quebec,Other|Other,Canada,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03249012
2137,NCT03257566,hypothyroidism,Risk Factors of Incidence of Hypothyroidism in Patients With Type 1 Diabetes,Hypothyroidism in Patients With Type 1 Diabetes,Hypothyroidism,2017-08-15,2019-07-31,2019-09-30,300.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,,,,8.0,15.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03257566
2138,NCT03257930,thyroid neoplasms,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Thyroid Nodule,2017-08-17,2018-07-11,2019-01-01,1.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Assiut University,hassan harby mohamed,Assiut University,Drug,Egypt,15.0,60.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03257930
2139,NCT03257930,thyroid nodule,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Thyroid Nodule,2017-08-17,2018-07-11,2019-01-01,1.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Assiut University,hassan harby mohamed,Assiut University,Drug,Egypt,15.0,60.0,[0-17]|[18-65],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03257930
2140,NCT03268785,hypoparathyroidism,Intra-operative Rapid Identification of Lymph Node and Parathyroid by Fine Needle Puncture for Thyroid Carcinoma,Intra-operative Rapid Identification of Lymph Node and Parathyroid,Hypocalcemia|Hypoparathyroidism Postprocedural|Parathyroid; Absent|Thyroid Cancer,2017-08-28,2018-08-01,2020-08-01,200.0,,Sequential Assignment,,Interventional,Unknown status,Not Applicable,Xijing Hospital,Xijing Hospital,Xijing hospital|Xijing Hospital,Diagnostic Test,China,18.0,60.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03268785
2142,NCT03268785,thyroid neoplasms,Intra-operative Rapid Identification of Lymph Node and Parathyroid by Fine Needle Puncture for Thyroid Carcinoma,Intra-operative Rapid Identification of Lymph Node and Parathyroid,Hypocalcemia|Hypoparathyroidism Postprocedural|Parathyroid; Absent|Thyroid Cancer,2017-08-28,2018-08-01,2020-08-01,200.0,,Sequential Assignment,,Interventional,Unknown status,Not Applicable,Xijing Hospital,Xijing Hospital,Xijing hospital|Xijing Hospital,Diagnostic Test,China,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03268785
2143,NCT03271892,"thyroid cancer, papillary",Deciding on Active Surveillance as an Alternative Option to Surgery in the Primary Management of Low Risk Papillary Thyroid Cancer,Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer,Thyroid Cancer Stage I,2017-08-28,2026-05-11,2026-12-31,200.0,Cohort,,Prospective,Observational,Recruiting,,"University Health Network, Toronto","Canadian Cancer Society (CCS)|Ontario Ministry of Health and Long Term Care|University Health Network, Toronto",University Health Network|University Health Network,,Canada,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03271892
2145,NCT03274258,thyroid neoplasms,Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,Kidney Medullary Carcinoma|Loss of INI 1 Protein Expression|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,2017-09-05,2022-07-31,2023-07-31,10.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03274258
2146,NCT03278964,graves disease,"Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy",Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy,Graves Ophthalmopathy,2017-09-04,2019-01-31,2019-01-31,42.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03278964
2147,NCT03278964,graves ophthalmopathy,"Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy",Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy,Graves Ophthalmopathy,2017-09-04,2019-01-31,2019-01-31,42.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03278964
2148,NCT03278964,goiter,"Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy",Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy,Graves Ophthalmopathy,2017-09-04,2019-01-31,2019-01-31,42.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03278964
2149,NCT03278964,hyperthyroidism,"Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy",Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy,Graves Ophthalmopathy,2017-09-04,2019-01-31,2019-01-31,42.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03278964
2151,NCT03280264,parathyroid neoplasms,An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy,Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism,Parathyroid Carcinoma|Primary Hyperparathyroidism,2017-09-07,2019-04-09,2019-04-09,18.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",Osaka City University Hospital,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03280264
2153,NCT03280264,hyperparathyroidism,An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy,Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism,Parathyroid Carcinoma|Primary Hyperparathyroidism,2017-09-07,2019-04-09,2019-04-09,18.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",Osaka City University Hospital,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03280264
2155,NCT03283098,hyperparathyroidism,"A Phase 1, Multiple Dose, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pharmacokinetics, Safety and Tolerability of AMG 416 Administered Intravenously to Chinese Subjects With Chronic Kidney Disease on Hemodialysis","A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416",Secondary Hyperparathyroidism,2017-08-31,2019-02-04,2019-02-04,33.0,,Parallel Assignment,,Interventional,Completed,Phase 1,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03283098
2157,NCT03284060,hypoparathyroidism,Social Cognition Training and Cognitive Remediation : a New Tool for 22q11.2 Deletion Syndrome,Social Cognition Training and Cognitive Remediation,22q11.2 Deletion Syndrome,2017-09-13,2018-03-09,2019-05-21,3.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Hpital le Vinatier,Hpital le Vinatier,Hopital Vinatier,Behavioral,France,5.0,13.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03284060
2159,NCT03285230,thyroid neoplasms,The French E3N Prospective Cohort Study (Etude Epidmiologique auprs de Femmes de la Mutuelle Gnrale de l'Education Nationale),The French E3N Prospective Cohort Study,Asthma|Breast Cancer|Cardiovascular Diseases|Colo-rectal Cancer|Crohn Disease|Depression|Diabetes|Endometrial Cancer|Endometriosis|Hypertension|Inflammatory Bowel Diseases|Melanoma|Parkinson Disease|Thyroid Cancer,2017-07-27,1991-11-15,2025-12-15,100000.0,Cohort,,Prospective,Observational,Active not recruiting,,"Institut National de la Sant Et de la Recherche Mdicale, France","Gustave Roussy, Cancer Campus, Grand Paris|Institut National de la Sant Et de la Recherche Mdicale, France|Ligue contre le cancer, France|Universit Paris-Sud",,,,40.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03285230
2162,NCT03285854,hyperparathyroidism,Assessing Calcium Balance in Children With Chronic Kidney Disease to Optimise Treatment Strategies,Calcium Balance Studies in Children With CKD and on Dialysis,Chronic Kidney Disease Mineral and Bone Disorder,2017-09-12,2021-12-30,2022-12-30,120.0,Case-Control,,Prospective,Observational,Active not recruiting,,Great Ormond Street Hospital for Children NHS Foundation Trust,"Athens General Children's Hospital ""Pan. & Aglaia Kyriakou""|Cukurova University|Great Ormond Street Hospital for Children NHS Foundation Trust|University of Kiel",Great Ormond Street Hospital for Children NHS Foundation Trust,Diagnostic Test,United Kingdom,0.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03285854
2165,NCT03289403,"thyroiditis, autoimmune",The Role of Immunomodulatory Treatment in Success of ICSI in Patients Who Have Infertility With Autoimmune Thyroiditis,The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis,Autoimmune Thyroiditis|Infertility,2017-09-17,2019-09-15,2019-10-20,100.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Aljazeera Hospital,Aljazeera Hospital,Aljazeera (Al Gazeera) hospital,Drug|Drug,Egypt,18.0,35.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03289403
2166,NCT03294005,thyroid neoplasms,Clinical Prediction Thyroid Cancer With Thyroid Ultrasonography,Clinical Prediction Thyroid Cancer With Thyroid Ultrasonography,Thyroid Cancer,2017-09-22,2020-06-30,2020-06-30,1949.0,Other,,Retrospective,Observational,Completed,,China Medical University Hospital,China Medical University Hospital,China Medical University Hospital,Diagnostic Test,Taiwan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03294005
2167,NCT03295955,thyroid neoplasms,Comparing Efficacy of Postoperative Antibiotic Use in Transoral Thyroidectomy: a Prospective Randomized Controlled Trial Study,Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy,Surgical Wound Infection|Thyroid Nodule,2017-09-20,2018-09-03,2018-12-03,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Jin Wook Yi,Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03295955
2168,NCT03295955,thyroid nodule,Comparing Efficacy of Postoperative Antibiotic Use in Transoral Thyroidectomy: a Prospective Randomized Controlled Trial Study,Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy,Surgical Wound Infection|Thyroid Nodule,2017-09-20,2018-09-03,2018-12-03,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Jin Wook Yi,Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03295955
2169,NCT03298867,goiter,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",Graves' Orbitopathy|Thyroid Eye Disease,2017-09-27,2019-02-13,2020-11-30,83.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|The Lennar Foundation Medical|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee Health Science Center|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|University of Pisa, Department of Clinical and Experimental Medicine|University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit",Biological|Other,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03298867
2170,NCT03298867,graves ophthalmopathy,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",Graves' Orbitopathy|Thyroid Eye Disease,2017-09-27,2019-02-13,2020-11-30,83.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|The Lennar Foundation Medical|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee Health Science Center|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|University of Pisa, Department of Clinical and Experimental Medicine|University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit",Biological|Other,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03298867
2171,NCT03298867,graves disease,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",Graves' Orbitopathy|Thyroid Eye Disease,2017-09-27,2019-02-13,2020-11-30,83.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|The Lennar Foundation Medical|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee Health Science Center|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|University of Pisa, Department of Clinical and Experimental Medicine|University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit",Biological|Other,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03298867
2172,NCT03298867,hyperthyroidism,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",Graves' Orbitopathy|Thyroid Eye Disease,2017-09-27,2019-02-13,2020-11-30,83.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|The Lennar Foundation Medical|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee Health Science Center|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|University of Pisa, Department of Clinical and Experimental Medicine|University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit",Biological|Other,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03298867
2174,NCT03299244,hyperparathyroidism,"A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism",Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism,2017-09-15,2020-04-08,2020-04-08,637.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,"China|Hong Kong|India|Korea, Republic of|Malaysia|Taiwan",18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03299244
2176,NCT03300284,"thyroid cancer, papillary",Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer,Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer,Thyroid Cancer,2017-09-28,2022-08-31,2022-08-31,186.0,Cohort,,Prospective,Observational,Active not recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Hartford Healthcare (Data Collection)|Memoral Sloan Kettering Monmouth (Consent and Follow up)|MAIMONIDES MEDICAL CENTER (Data collection only)|NYU Langone Health|Memorial Sloan Kettering Cancer Center|Lehigh Valley Health Network,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03300284
2178,NCT03300765,thyroid neoplasms,Intensity Modulated Radiation Therapy Combined With Apatinib for Inoperable or Iodine Refractory Thyroid Cancer: A Phase II Single-arm Study,Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer,Thyroid Cancer,2017-09-26,2019-07-01,2020-05-01,20.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Fudan University,"Xiayun He, MD",Fudan University Shanghai Cancer Center,Drug|Radiation,China,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03300765
2179,NCT03303053,hyperthyroidism,"A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism",Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism,Graves Disease|Hyperthyroidism,2017-09-13,2018-03-01,2018-03-01,135.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,"Clinical Research Centre, Malaysia","Clinical Research Centre, Malaysia|Ministry of Health, Malaysia",Hospital Queen Elizabeth 2|Hospital Ampang|Hospital Putrajaya,Drug|Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03303053
2180,NCT03303053,goiter,"A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism",Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism,Graves Disease|Hyperthyroidism,2017-09-13,2018-03-01,2018-03-01,135.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,"Clinical Research Centre, Malaysia","Clinical Research Centre, Malaysia|Ministry of Health, Malaysia",Hospital Queen Elizabeth 2|Hospital Ampang|Hospital Putrajaya,Drug|Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03303053
2181,NCT03303053,graves disease,"A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism",Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism,Graves Disease|Hyperthyroidism,2017-09-13,2018-03-01,2018-03-01,135.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,"Clinical Research Centre, Malaysia","Clinical Research Centre, Malaysia|Ministry of Health, Malaysia",Hospital Queen Elizabeth 2|Hospital Ampang|Hospital Putrajaya,Drug|Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03303053
2182,NCT03307694,thyroid neoplasms,Multi-Angle Compound Shear Wave Elasticity Imaging for the Characterization of Thyroid Nodules,Thyroid Ultrasound Elasticity (TrUE) Imaging,"Cancer, Thyroid",2017-10-03,2018-07-13,2018-07-13,31.0,Other,,Prospective,Observational,Completed,,Emory University,Emory University,Emory Univeristy Hospital Midtown,Diagnostic Test|Diagnostic Test|Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03307694
2183,NCT03307694,thyroid nodule,Multi-Angle Compound Shear Wave Elasticity Imaging for the Characterization of Thyroid Nodules,Thyroid Ultrasound Elasticity (TrUE) Imaging,"Cancer, Thyroid",2017-10-03,2018-07-13,2018-07-13,31.0,Other,,Prospective,Observational,Completed,,Emory University,Emory University,Emory Univeristy Hospital Midtown,Diagnostic Test|Diagnostic Test|Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03307694
2184,NCT03309384,hypoparathyroidism,Intraoperative Monitoring (Parathormone Values and Continuous Neuromonitoring) to Predict Postoperative Complications After Total Thyroidectomy,Intraoperative Monitoring to Predict Postoperative Complications After Thyroidectomy,Endocrine Procedural Complications|Laryngeal Injury|Parathyroid; Deficiency|Thyroid,2017-09-06,2026-03-20,2026-03-20,1000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHU Nancy,,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03309384
2186,NCT03309631,thyroid neoplasms,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-10-01,2018-03-30,2018-06-30,1500.0,Cohort,,Prospective,Observational,Unknown status,,Pontificia Universidad Catolica de Chile,Geneprodx|Pontificia Universidad Catolica de Chile,Avantt Research|Stanford University|Lee Moffit Cancer Center|Tulane University|Universidad de Cincinnati|University of Texas MD Anderson Cancer Center,Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03309631
2187,NCT03309631,thyroid nodule,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-10-01,2018-03-30,2018-06-30,1500.0,Cohort,,Prospective,Observational,Unknown status,,Pontificia Universidad Catolica de Chile,Geneprodx|Pontificia Universidad Catolica de Chile,Avantt Research|Stanford University|Lee Moffit Cancer Center|Tulane University|Universidad de Cincinnati|University of Texas MD Anderson Cancer Center,Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03309631
2188,NCT03324022,hyperthyroidism,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Graves Ophthalmopathy,2017-10-16,2017-12-25,2020-12-25,80.0,Case-Control,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,"National Taiwan University Hospital Taipei, Taiwan",,Taiwan,20.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03324022
2189,NCT03324022,graves ophthalmopathy,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Graves Ophthalmopathy,2017-10-16,2017-12-25,2020-12-25,80.0,Case-Control,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,"National Taiwan University Hospital Taipei, Taiwan",,Taiwan,20.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03324022
2190,NCT03324022,graves disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Graves Ophthalmopathy,2017-10-16,2017-12-25,2020-12-25,80.0,Case-Control,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,"National Taiwan University Hospital Taipei, Taiwan",,Taiwan,20.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03324022
2191,NCT03324022,goiter,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Graves Ophthalmopathy,2017-10-16,2017-12-25,2020-12-25,80.0,Case-Control,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,"National Taiwan University Hospital Taipei, Taiwan",,Taiwan,20.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03324022
2192,NCT03324334,graves disease,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Ulcerative Colitis,2017-10-24,2018-10-01,2019-02-28,95.0,Case-Control,,Retrospective,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test|Diagnostic Test,,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03324334
2193,NCT03324334,hyperthyroidism,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Ulcerative Colitis,2017-10-24,2018-10-01,2019-02-28,95.0,Case-Control,,Retrospective,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test|Diagnostic Test,,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03324334
2194,NCT03324334,goiter,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Ulcerative Colitis,2017-10-24,2018-10-01,2019-02-28,95.0,Case-Control,,Retrospective,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test|Diagnostic Test,,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03324334
2195,NCT03324880,hypoparathyroidism,"A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]",A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE),Hypoparathyroidism,2017-10-10,2022-05-23,2022-05-23,150.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Takeda,Shire,"University of Chicago|Michigan Bone and Mineral Clinic|Mayo Clinic - PPDS|Physicians East PA|Ohio State University Wexner Medical Center|Children's Hospital of Philadelphia|UZ Gent|UZ Leuven|Nova Scotia Health Authority (Capital District Health Authority)|Bone Research and Education Centre|CHU de Quebec-Universite Laval|Eastern Health - Health Sciences Center- General Hospital|Aarhus Universitetshospital|Odense Universitetshospital|CHU Angers|Hopital Jean Minjoz|CHU Bictre|CHRU Lille|Universittsklinikum Carl Gustav Carus an der TU Dresden|Fondazione IRCCS C Granda Ospedale Maggiore Policlinico|Universita di Firenze, Dipartimento di Chirurgia e Medicina Traslazionale (DCMT)|Universit Campus Bio Medico Di Roma|VU Medisch Centrum|Leids Universitair Medisch Centrum|Erasmus MC|Haukeland Universitetssykehus|Oslo Universitetssykehus HF Rikshospitalet|Oslo Universitetssykehus Aker|Centro Hospitalar E Universitrio de Coimbra EPE|Unidade Local de Sade de Matosinhos SA|Centro Hospitalar de So Joo, E.P.E.|C.H. Regional Reina Sofia - PPDS|Hospital Universitario Quironsalud Madrid|Hospital Universitario Fundacion Jimenez Diaz|Hospital Universitario 12 de Octubre|Karolinska Universitetssjukhuset Solna|Sahlgrenska Universitetssjukhuset|Skanes Universitetssjukhus Lund|Ninewells Hospital - PPDS|Norfolk and Norwich University Hospital|Queen Elizabeth Hospital|Leicester Royal Infirmary|Manchester Royal Infirmary - PPDS",Biological|Biological,Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|Norway|Portugal|Spain|Sweden|United Kingdom|United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03324880
2199,NCT03324893,hyperparathyroidism,18F-Fluorocholine PET/MRI for the Localization of Parathyroid Adenomas,FCH PET/MRI Parathyroid Localization,"18F-fluorocholine|Hyperparathyroidism, Primary|Positron-Emission Tomography",2017-10-17,2021-06-30,2021-06-30,47.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",UHN,Diagnostic Test,Canada,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03324893
2200,NCT03327636,thyroid neoplasms,A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC),A Trial Comparing USG-HIFU vs AS in Management of Low-risk PTMC,Papillary Thyroid Microcarcinoma,2017-10-25,2024-08-31,2024-12-31,103.0,,Parallel Assignment,,Interventional,Suspended,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,19.0,74.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03327636
2201,NCT03331172,thyroid neoplasms,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Reapplication in Benign Thyroid Nodules That Had Less-than Adequate Shrinkage Following Single-session HIFU Treatment.,HIFU Reapplication in Benign Nodules,Thyroid Nodule,2017-10-27,2018-06-30,2018-08-30,28.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03331172
2202,NCT03331172,thyroid nodule,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Reapplication in Benign Thyroid Nodules That Had Less-than Adequate Shrinkage Following Single-session HIFU Treatment.,HIFU Reapplication in Benign Nodules,Thyroid Nodule,2017-10-27,2018-06-30,2018-08-30,28.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,19.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03331172
2203,NCT03342001,hypothyroidism,Assessing Quality of Life Changes Using Calcitonin in Patients With Hypothyroidism on Biochemical Replacement With Levothyroxine,Hypothyroidism Treated With Calcitonin,Hypothyroidism,2017-11-09,2019-06-30,2019-08-14,11.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University of Maryland, Baltimore","University of Maryland, Baltimore",University of Maryland Center for Diabetes and Endocrinology,Drug,United States,18.0,88.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03342001
2204,NCT03359668,"thyroid cancer, papillary",CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer,CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer,Papillary Thyroid Cancer,2017-11-16,2017-04-20,2017-04-20,47.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",,Diagnostic Test,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03359668
2206,NCT03360890,thyroid neoplasms,Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study.,Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors,Salivary Gland Cancer|Thyroid Cancer,2017-11-20,2022-09-30,2022-09-30,46.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,University of Chicago,University of Chicago,University of Chicago Comprehensive Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03360890
2207,NCT03363347,"thyroid cancer, papillary",Association Between BRAF V600E and Redifferentiation Therapy in Patients With Radioiodine-refractory Papillary Thyroid Cancer,BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer,Thyroid Cancer,2017-11-20,2014-12-31,2014-12-31,25.0,Case-Control,,Retrospective,Observational,Completed,,Heidelberg University,Heidelberg University,,Drug,,24.0,69.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03363347
2210,NCT03364738,hypoparathyroidism,An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects With Hypoparathyroidism,Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism,Hypoparathyroidism,2017-11-20,2020-04-14,2020-04-14,22.0,,Single Group Assignment,,Interventional,Terminated,Phase 3,Takeda,Shire,"University of Kentucky Medical Center|Crescent City Clinical Research Center, LLC|Northern Nevada Endocrinology - Lisa Abbott MD|Ohio State University|Thomas Jefferson University, Jefferson Rheumatology Associates|Bone Research and Education Centre|CHU de Quebec-Universite Laval|Aarhus Universitetshospital|Semmelweis Egyetem|Pecsi Tudomanyegyetem, I. sz. Belgyogyaszati Klinika",Biological,Canada|Denmark|Hungary|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03364738
2211,NCT03375359,hypoparathyroidism,"First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome - ReFaPo02","First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome",Pregnancy,2017-12-12,2022-08-31,2022-08-31,1000.0,Case-Only,,Prospective,Observational,Recruiting,,University Hospital Tuebingen,University Hospital Tuebingen,"University Hospital Tuebingen, Department of Women's Health",Diagnostic Test,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03375359
2213,NCT03375931,thyroid neoplasms,The Effects of Preoperative Prayer on Postoperative Quality of Recovery in Patients Undergoing Thyroidectomy,The Effects of Preoperative Prayer on Postoperative Quality of Recovery in Patients Undergoing Thyroidectomy,Thyroid Cancer,2017-12-05,2020-05-31,2020-05-31,36.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine",Behavioral|Behavioral,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03375931
2214,NCT03377829,thyroid neoplasms,A Multicenter Prospective Controlled Trial of Laser Ablation Versus Surgery for the Treatment of Papillary Thyroid Microcarcinoma,A Multicenter Trial of PLA vs. Surgery for Treating PTMC,Thyroid Cancer|Treatment Related Cancer,2017-11-26,2021-08-31,2022-12-31,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Ruijin Hospital,WeiWei Zhan,"Ultrasound Department, Chinese PLA General Hospital|Ultrasound Department of the Third Hospital Affiliated to Zhongshan University|Ultrasound Department, the Second Affiliated Hospital of Harbin Medical Univercity|Ultrasound Department, the Xiangya Third Hospital of Zhongnan University|Ultrasound Department, the First Affliction Hospital of Nanjing Medical University|Ultrasound Department, the First Affiliated Hospital of Soochow University|Ultrasound Department, First people's Hospital Affiliated to Medical School of Shanghai Jiaotong University|Ultrasound Department, Ruijin Hospital Affiliated to Medical School of Shanghai Jiaotong University|The department of ultrasound ,second affiliated hospital of xi'an jiaotong university|Department of Ultrasonography, Zhejiang Cancer Hospital|Department of Ultrasound Medicine, the First Hospital Affiliated to Medical School of Zhejiang University|Department of Endocrinology, Regina Apostolorum Hospital|Diagnostic Imaging, Regina Apostolorum Hospital",Procedure|Procedure,China|Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03377829
2215,NCT03379181,hyperthyroidism,Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy,Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy,Hyperthyroidism,2017-12-07,2020-02-12,2020-02-12,19.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Drug,Switzerland,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03379181
2217,NCT03382158,"goiter, nodular","International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions",International PPB/DICER1 Registry,Ciliary Body Medulloepithelioma|Cystic Nephroma|DICER1 Syndrome|Embryonal Rhabdomyosarcoma|Nasal Chondromesenchymal Hamartoma|Neuroblastoma|Nodular Hyperplasia of Thyroid|Pineoblastoma|Pituitary Cancer|Pleuropulmonary Blastoma|Renal Sarcoma|Sertoli-Leydig Cell Tumor|Wilms Tumor,2017-10-11,2023-12-06,2026-12-06,3400.0,Cohort,,Other,Observational,Recruiting,,Children's Hospitals and Clinics of Minnesota,"Beijing Children's Hospital|Children's Hospitals and Clinics of Minnesota|Children's National Research Institute|Dana-Farber Cancer Institute|Emory University|ResourcePath, LLC|University of Cambridge|Washington University School of Medicine",Children's Minnesota,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03382158
2218,NCT03387943,thyroid neoplasms,"A Prospective, Multicenter, Open Label Phase  Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma",PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma,Poorly Differentiated Thyroid Carcinoma,2017-12-11,2018-12-31,2019-12-31,30.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Zhejiang Cancer Hospital,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03387943
2219,NCT03392402,thyroid neoplasms,Prospective Validation of the Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Thyroid Cancer|Thyroid Neoplasm|Thyroid Nodule,2018-01-02,2020-03-31,2020-12-31,599.0,Cohort,,Prospective,Observational,Completed,,Maria Sklodowska-Curie National Research Institute of Oncology,Maria Sklodowska-Curie National Research Institute of Oncology,"Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology",,Poland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03392402
2220,NCT03392402,thyroid nodule,Prospective Validation of the Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Thyroid Cancer|Thyroid Neoplasm|Thyroid Nodule,2018-01-02,2020-03-31,2020-12-31,599.0,Cohort,,Prospective,Observational,Completed,,Maria Sklodowska-Curie National Research Institute of Oncology,Maria Sklodowska-Curie National Research Institute of Oncology,"Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology",,Poland,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03392402
2221,NCT03393728,hyperthyroidism,Short Term Effects of Propanolol on Heart Rate Variability of Hyperthyroidism,Heart Rate Variability and Hyperthyroidism: Evaluation of the Short-term Effects of Propanolol,Hyperthyroidism,2017-12-21,2008-12-30,2009-09-30,10.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Yaounde Central Hospital,Yaounde Central Hospital,,Drug,,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03393728
2222,NCT03395925,thyroid neoplasms,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Thyroid Nodule,2017-12-17,2021-10-30,2022-01-30,40.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,Olympus Surgical Technologies Europe,Olympus Surgical Technologies Europe,Johann-Wolfgang Goethe University,Device,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03395925
2223,NCT03395925,thyroid nodule,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Thyroid Nodule,2017-12-17,2021-10-30,2022-01-30,40.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,Olympus Surgical Technologies Europe,Olympus Surgical Technologies Europe,Johann-Wolfgang Goethe University,Device,Germany,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03395925
2224,NCT03397238,thyroid neoplasms,Myeloid Cell Reprogramming in the Context of Radioiodine Therapy in Patients With Non-Medullary Thyroid Carcinoma,Myeloid Cell Reprogramming in Thyroid Carcinoma,Thyroid Cancer,2017-12-18,2019-11-26,2021-01-05,41.0,Case-Control,,Prospective,Observational,Completed,,Radboud University Medical Center,Radboud University Medical Center,Radboudumc,,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03397238
2225,NCT03411187,"thyroid cancer, papillary",Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy,Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy,Endoscopy|Papillary Thyroid Carcinoma|Thyroid Cancer|Thyroidectomy,2018-01-19,2018-06-30,2018-12-30,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Wen-xin ZHAO,Device|Device,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03411187
2227,NCT03416686,thyroid neoplasms,Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy,Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy,Differentiated Thyroid Cancer,2017-12-07,2021-02-28,2021-02-28,18.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Hpital Saint Louis,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03416686
2228,NCT03420963,thyroid neoplasms,Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults,"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors",Recurrent Cutaneous Melanoma|Recurrent Lip and Oral Cavity Carcinoma|Recurrent Malignant Endocrine Neoplasm|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Male Reproductive System Neoplasm|Recurrent Malignant Mesothelioma|Recurrent Malignant Neoplasm of Multiple Primary Sites|Recurrent Malignant Oral Neoplasm|Recurrent Malignant Pharyngeal Neoplasm|Recurrent Malignant Skin Neoplasm|Recurrent Malignant Soft Tissue Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Malignant Thyroid Gland Neoplasm|Recurrent Malignant Urinary System Neoplasm|Refractory Cutaneous Melanoma|Refractory Malignant Bone Neoplasm|Refractory Malignant Endocrine Neoplasm|Refractory Malignant Female Reproductive System Neoplasm|Refractory Malignant Male Reproductive System Neoplasm|Refractory Malignant Mesothelioma|Refractory Malignant Neoplasm of Multiple Primary Sites|Refractory Malignant Oral Neoplasm|Refractory Malignant Pharyngeal Neoplasm|Refractory Malignant Skin Neoplasm|Refractory Malignant Soft Tissue Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Malignant Thyroid Gland Neoplasm|Refractory Malignant Urinary System Neoplasm,2018-01-29,2022-12-01,2022-12-01,38.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Drug|Drug,United States,12.0,40.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03420963
2230,NCT03425747,hypoparathyroidism,CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM,Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism,Chronic Hypoparathyroidism,2018-01-27,2020-04-01,2020-04-01,26.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Campus Bio-Medico University,Campus Bio-Medico University,Campus Bio-Medico University,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03425747
2231,NCT03432299,thyroid neoplasms,Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy,Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid Cancer,2018-01-22,2023-07-31,2023-12-31,100.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Procedure,"Korea, Republic of",19.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03432299
2233,NCT03434067,hyperparathyroidism,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,Hyperthyroidism|Immunochromatographic|PTH|Thyroidectomy,2018-01-27,2018-06-30,2018-12-30,90.0,Cohort,,Prospective,Observational [Patient Registry],Unknown status,,Fujian Medical University,"Bo Wang,MD",Wen-xin ZHAO,,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03434067
2234,NCT03434067,hyperthyroidism,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,Hyperthyroidism|Immunochromatographic|PTH|Thyroidectomy,2018-01-27,2018-06-30,2018-12-30,90.0,Cohort,,Prospective,Observational [Patient Registry],Unknown status,,Fujian Medical University,"Bo Wang,MD",Wen-xin ZHAO,,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03434067
2235,NCT03435952,thyroid neoplasms,A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors,Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,2018-02-09,2024-10-01,2024-10-01,18.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,"BioMed Valley Discoveries, Inc|M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC",University of Texas MD Anderson Cancer Center,Drug|Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03435952
2237,NCT03437174,hypoparathyroidism,Burden of Illness and Disease Associated Emergencies in Chronic Hypoparathyroidism,Burden of Illness in Hypoparathyroidism,Hypoparathyroidism,2018-02-10,2017-12-01,2018-01-01,205.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Wuerzburg,"Charite University, Berlin, Germany|Endocrine Practice, Oldenburg, Germany|Ludwig-Maximilians - University of Munich|Praxis Endokrinologie in Charlottenburg, Berlin|University Medical Center Rostock|University of Wuerzburg","Endokrinologie in Charlottenburg|Charite Berlin|Ludwig-Maximilians-Universitt|University Hospital Rostock|Dept. of Endocrinology and Diabetology, Dept. of Medicine I, University Hospital Wuerzburg",,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03437174
2239,NCT03440697,hypoparathyroidism,Pathogenetic Basis of Aortopathy and Aortic Valve Disease,Pathogenetic Basis of Aortopathy and Aortic Valve Disease,Aortic Valve Disease|Aortopathies|Arterial Tortuosity Syndrome|Ascending Aortic Aneurysm|Ascending Aortic Disease|Autosomal Recessive Cutis Laxa|Congenital Contractural Arachnodactyly|Descending Aortic Aneurysm|Descending Aortic Disease|Ehlers-Danlos Syndrome|Loeys-Dietz Syndrome|Marfan Syndrome|PHACE Syndrome|Shprintzen-Goldberg Syndrome|Thoracic Aortic Aneurysm|Thoracic Aortic Disease|Thoracic Aortic Dissection|Thoracic Aortic Rupture|Turner Syndrome,2017-10-06,2025-12-31,2028-12-31,3000.0,Cohort,,Prospective,Observational,Recruiting,,Indiana University,Indiana University,IU School of Medicine,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03440697
2240,NCT03444246,hyperthyroidism,"A Parallel, Double-blind, Randomized Controlled Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt",A Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt,Hyperthyroidism,2018-02-06,2019-03-01,2019-06-01,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Xijing Hospital,Xijing Hospital,"Xijing Hospital, Fourth Military Medical university",Dietary Supplement|Dietary Supplement,China,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03444246
2243,NCT03447093,thyroiditis,The Oral Microbiota in Autoimmune Thyroiditis is Distinctive And Predictive,The Oral Microbiota is Associated With Autoimmune Thyroiditis,Microbiota,2018-02-08,2019-12-31,2021-12-31,120.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03447093
2244,NCT03449108,"thyroid carcinoma, anaplastic",Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types,"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,2018-02-22,2023-06-30,2024-06-30,95.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,"Iovance Biotherapeutics, Inc.|M.D. Anderson Cancer Center|National Cancer Institute (NCI)",M D Anderson Cancer Center,Biological|Biological|Biological|Drug|Drug|Biological|Biological|Other|Other,United States,16.0,70.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03449108
2246,NCT03454464,thyroid neoplasms,"To Evaluate the Practicable, Thoroughness and Clinical Value of Bilateral Central Compartment Dissection While Preserve Contrary Thyroid Glands",Evaluation of Central Compartment Dissection Without Thyroidectomy,Central Compartment Neck Dissction|Thyroid Cancer|Thyroidectomy,2018-02-07,2018-12-31,2018-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Wen-xin ZHAO,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03454464
2247,NCT03454477,"thyroid cancer, papillary","From the Endoscope to the Robot, the Initial Experience of Robotic Thyroidectomy is Summarized","Comparison Between Robotic, Endoscopic and Traditional Open Surgery in Thyroidectomy",Endoscopy|Papillary Thyroid Carcinoma|Robotics|Thyroidectomy,2018-02-07,2018-10-01,2018-10-01,90.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Wen-xin ZHAO,Procedure|Procedure|Device,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03454477
2249,NCT03461211,goiter,"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease",Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,2018-03-05,2020-06-08,2021-02-17,51.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science|Hamilton Eye Institute at University of Tennessee Health|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca Granda Ospedale Maggiore|University of Pisa, Department of Clinical and Experimental Medicine|Azienda Ospedaliero Universitaria Pisana",Biological,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03461211
2250,NCT03461211,graves ophthalmopathy,"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease",Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,2018-03-05,2020-06-08,2021-02-17,51.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science|Hamilton Eye Institute at University of Tennessee Health|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca Granda Ospedale Maggiore|University of Pisa, Department of Clinical and Experimental Medicine|Azienda Ospedaliero Universitaria Pisana",Biological,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03461211
2251,NCT03461211,hyperthyroidism,"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease",Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,2018-03-05,2020-06-08,2021-02-17,51.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science|Hamilton Eye Institute at University of Tennessee Health|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca Granda Ospedale Maggiore|University of Pisa, Department of Clinical and Experimental Medicine|Azienda Ospedaliero Universitaria Pisana",Biological,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03461211
2252,NCT03461211,graves disease,"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease",Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,2018-03-05,2020-06-08,2021-02-17,51.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science|Hamilton Eye Institute at University of Tennessee Health|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca Granda Ospedale Maggiore|University of Pisa, Department of Clinical and Experimental Medicine|Azienda Ospedaliero Universitaria Pisana",Biological,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03461211
2253,NCT03463889,thyroid neoplasms,Gallium-68 Prostate Specific Membrane Antigen (68Ga-PSMA) PET for Imaging of Thyroid Cancer: A Feasibility Study,Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer,Thyroid Gland Carcinoma,2018-02-09,2020-09-30,2020-10-31,12.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,"University of California, San Francisco","University of California, San Francisco","University of California, San Francisco",Drug|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03463889
2256,NCT03464149,hyperparathyroidism,Intact Versus Biointact Assays for Longitudinal Assessment of Parathyroid Hormone - The Longitudinal PTH Study,The Longitudinal PTH-Study,CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder|Kidney Replacement|Secondary Hyperparathyroidism,2018-02-12,2018-12-05,2019-08-07,132.0,Cohort,,Prospective,Observational,Completed,,Medical University of Vienna,Medical University of Vienna,"Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria",Diagnostic Test,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03464149
2257,NCT03465176,hypothyroidism,The Effect of Aroma on Fatigue Scores Among Women With Hypothyroidism,The Effect of Aroma on Fatigue Scores Among Women With Hypothyroidism,Fatigue|Hypothyroidism,2018-03-08,2018-03-30,2018-05-31,42.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Franklin Health Research,Franklin Health Research,Franklin Institute of Wellness,Other|Other,United States,18.0,55.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03465176
2259,NCT03469011,"thyroid cancer, papillary",A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients,A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.,Papillary Thyroid Cancer,2018-03-12,2021-12-31,2021-12-31,18.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Alberta Cancer Foundation,Cross Cancer Institute,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03469011
2260,NCT03469310,goiter,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,126.0,,Parallel Assignment,,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03469310
2261,NCT03469310,thyroid neoplasms,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,126.0,,Parallel Assignment,,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03469310
2262,NCT03469310,thyroid nodule,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,126.0,,Parallel Assignment,,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03469310
2263,NCT03469310,parathyroid neoplasms,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,126.0,,Parallel Assignment,,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03469310
2265,NCT03469544,thyroid neoplasms,Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer,Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer,Thyroid Cancer,2018-03-10,2019-12-29,2020-03-29,90.0,Case-Control,,Retrospective,Observational,Unknown status,,Assiut University,Assiut University,,Other,,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03469544
2266,NCT03470259,"thyroid cancer, papillary",Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and,Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging,Lymph Node Metastases|Papillary Thyroid Cancer,2018-02-21,2019-12-31,2019-12-31,19.0,,Parallel Assignment,,Interventional,Completed,Phase 1,University Medical Center Groningen,Erasmus Medical Center|University Medical Center Groningen,University Medical Center Groningen|Erasmus Medical Center,Drug|Device|Device,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03470259
2268,NCT03475953,thyroid neoplasms,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,"Biliary Tract Cancer|Colorectal Cancer Not MSI-H or MMR-deficient|Gastro-enteropancreatic Neuroendocrine Tumor|GIST|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Oesophageal or Gastric Carcinoma|Soft-tissue Sarcoma|Solid Tumor, Adult|Thyroid Cancer",2018-02-20,2020-12-31,2022-12-31,482.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Institut Bergoni,"Bayer|Institut Bergoni|Merck KGaA, Darmstadt, Germany",Institut Bergoni|Centre Hospitalier Rgional Universitaire - CHU Morvan|Centre Lon Brard|Institut de Cancrologie de Montpellier|Institut Curie|IUCT Oncople - Institut Claudius Regaud|Institut Gustave Roussy,Drug|Drug|Drug|Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03475953
2269,NCT03479801,thyroid neoplasms,"Comparative Study of Surgical Results in Endoscopic Thyroidectomy Via Oral Approach, Via Breast Approach and Conventional Open Thyroidectomy","Comparative Study in Oral, Breast Approach and Open Thyroidectomy",Thyroid Neoplasms,2018-03-15,2018-12-31,2018-12-31,150.0,Case-Control,,Prospective,Observational,Unknown status,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",SAHZhejiangU,Procedure,China,15.0,55.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03479801
2270,NCT03483337,thyroid neoplasms,Quantitative Imaging Tools to Derive DW-MRI Oncological Biomarkers,New MRI Biomarkers in Head and Neck Cancers,Head and Neck Cancer|Thyroid Cancer,2018-03-19,2024-03-31,2024-03-31,200.0,Cohort,,Prospective,Observational,Recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03483337
2271,NCT03484416,thyroid neoplasms,Routine Low-dose Calcium and Vitamin D Supplementation for Preventing Symptomatic Postthyroidectomy Hypocalcemia,Routine Calcium for Preventing Hypocalcemia,Thyroid Neoplasm,2018-03-25,2017-05-30,2017-05-30,138.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Ewha Womans University Mokdong Hospital,Ewha Womans University Mokdong Hospital,Ewha Womans University Medical Center,Drug,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03484416
2272,NCT03484884,thyroid neoplasms,A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer,A Study of Optical Imaging With Light From Radiotracers in Cancer Patients,Thyroid Cancer,2018-03-20,2023-03-31,2023-03-31,128.0,Cohort,,Prospective,Observational,Recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan - Kettering Cancer Center,Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03484884
2273,NCT03488134,thyroid neoplasms,"A Prospective Study of Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3","Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3",Thyroid Cancer,2018-03-28,2022-01-31,2023-07-31,74.0,Cohort,,Prospective,Observational [Patient Registry],Active not recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03488134
2274,NCT03496363,hypothyroidism,Evaluation of Thyroid Function in Children With Congenital Heart Disease,Hypothyroidism With Congenital Heart Disease (CHD),CHD|Hypothyroidism,2018-03-10,2019-05-01,2020-05-01,50.0,Case-Control,,Prospective,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test,,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03496363
2275,NCT03498183,thyroid neoplasms,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (15 mm) Classified Bethesda III or IV on Cytology,Malignancy of Thyroid Nodules,2018-03-29,2021-07-01,2021-07-01,321.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2/Phase 3,Nantes University Hospital,Nantes University Hospital,Centre Hospitalier et Universitaire (chu)|CHU|CHU|CHU|Hospices Civils|CHU|Assistance publique des Hpitaux de Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03498183
2276,NCT03498183,thyroid nodule,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (15 mm) Classified Bethesda III or IV on Cytology,Malignancy of Thyroid Nodules,2018-03-29,2021-07-01,2021-07-01,321.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2/Phase 3,Nantes University Hospital,Nantes University Hospital,Centre Hospitalier et Universitaire (chu)|CHU|CHU|CHU|Hospices Civils|CHU|Assistance publique des Hpitaux de Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03498183
2278,NCT03498417,hyperthyroidism,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,135.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03498417
2279,NCT03498417,graves ophthalmopathy,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,135.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03498417
2280,NCT03498417,graves disease,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,135.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03498417
2282,NCT03498417,goiter,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,135.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03498417
2283,NCT03498417,hashimoto disease,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,135.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03498417
2284,NCT03500666,thyroid neoplasms,A Comparative Study of Robot Assisted BABA Approach and Chest Breast Approach for Lateral Neck Dissection,Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection,Endoscopic Surgery|Robot Surgery|Thyroid Carcinoma,2018-04-02,2018-12-31,2018-12-31,10.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital|Wen-xin ZHAO,Device|Device,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03500666
2285,NCT03506048,"thyroid cancer, papillary",A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer,Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer,Differentiated Thyroid Gland Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma,2018-04-13,2021-06-24,2021-06-24,3.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Emory University,Eisai Inc.|Emory University,Emory University Hospital/Winship Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03506048
2286,NCT03506048,"adenocarcinoma, follicular",A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer,Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer,Differentiated Thyroid Gland Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma,2018-04-13,2021-06-24,2021-06-24,3.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Emory University,Eisai Inc.|Emory University,Emory University Hospital/Winship Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03506048
2288,NCT03510143,thyroid neoplasms,"Effect of Polyglycolic Acid Mesh (Neoveil) for Reducing Drain Amount and Chyle Leakage After Thyroid Cancer Surgery: A Prospective, Randomized Controlled Study",Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery,Thoracic Duct Leak|Thyroid Cancer|Thyroid Gland Carcinoma,2018-03-20,2020-05-01,2020-12-31,330.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Green Cross Corporation|Seoul National University Hospital,Jin Wook Yi,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03510143
2289,NCT03514251,hypoparathyroidism,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Complication of Surgical Procedure|Hypoparathyroidism|Marker; Structural|Parathyroid Function Low Adverse Event|Thyroid Cancer,2018-04-20,2018-09-30,2018-09-30,400.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Fujian Medical University Union Hospital,Procedure,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03514251
2290,NCT03514251,thyroid neoplasms,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Complication of Surgical Procedure|Hypoparathyroidism|Marker; Structural|Parathyroid Function Low Adverse Event|Thyroid Cancer,2018-04-20,2018-09-30,2018-09-30,400.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Fujian Medical University Union Hospital,Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03514251
2292,NCT03515863,graves disease,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Natural History and Risk Factors of TAO,Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,400.0,Case-Control,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03515863
2293,NCT03515863,graves ophthalmopathy,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Natural History and Risk Factors of TAO,Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,400.0,Case-Control,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03515863
2294,NCT03515863,goiter,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Natural History and Risk Factors of TAO,Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,400.0,Case-Control,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03515863
2295,NCT03515863,hyperthyroidism,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Natural History and Risk Factors of TAO,Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,400.0,Case-Control,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03515863
2297,NCT03516747,parathyroid neoplasms,Ultrasound Guided Fine Needle Aspiration of Parathyroid Gland as a Pre Operative Localization Tool to Identify Pathological Parathyroid,Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland,Hypercalcemia|Parathyroid Adenoma,2018-04-03,2020-04-09,2020-08-09,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",Haemek Medical Center,Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Israel,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03516747
2298,NCT03516773,hypoparathyroidism,An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA in Patients With Hypoparathyroidism,Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism,Hypoparathyroidism,2018-04-23,2018-12-05,2019-02-24,20.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Entera Bio Ltd.,Entera Bio Ltd.,Clinical Research Center Hadassah Ein Kerem Medical Center,Drug|Drug,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03516773
2300,NCT03517267,thyroid nodule,Validation of the New Thyroid Imaging Reporting and Data System (TIRADS) From 2017 Risk Assessment of Thyroid Nodules in Comparison to the American Thyroid Association (ATA) Guidelines From 2015,Thyroid Imaging Reporting and Data System (TIRADS ) Versus Thyroid Association (ATA) Guidelines,Thyroid Nodule,2018-03-28,2019-06-30,2019-06-30,1000.0,Case-Only,,Prospective,Observational [Patient Registry],Unknown status,,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Medical Center,Diagnostic Test,Israel,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03517267
2301,NCT03517267,thyroid neoplasms,Validation of the New Thyroid Imaging Reporting and Data System (TIRADS) From 2017 Risk Assessment of Thyroid Nodules in Comparison to the American Thyroid Association (ATA) Guidelines From 2015,Thyroid Imaging Reporting and Data System (TIRADS ) Versus Thyroid Association (ATA) Guidelines,Thyroid Nodule,2018-03-28,2019-06-30,2019-06-30,1000.0,Case-Only,,Prospective,Observational [Patient Registry],Unknown status,,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Medical Center,Diagnostic Test,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03517267
2302,NCT03517579,thyroid neoplasms,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Personalized Treatment in Thyroid Disorders,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,10.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03517579
2303,NCT03517579,hyperthyroidism,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Personalized Treatment in Thyroid Disorders,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,10.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03517579
2304,NCT03517579,goiter,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Personalized Treatment in Thyroid Disorders,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,10.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03517579
2305,NCT03517579,graves disease,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Personalized Treatment in Thyroid Disorders,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,10.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03517579
2306,NCT03530033,thyroid neoplasms,"Lidocaine Reduces Muscle Tremor Caused by Electric Energy Devices, Which is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring During Endoscopic Thyroid Lateral Neck Dissection",Lidocaine Reduces Muscle Tremor is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring,Accessory Nerve Injuries|EMG: Repetitive Nerve Stimulation Abnormality|Neck Cancer|Recurrent Laryngeal Nerve Injuries|Thyroid Cancer,2018-05-08,2018-10-31,2018-10-31,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Fujian Medical University Union Hospital,Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03530033
2309,NCT03530462,"thyroiditis, autoimmune",The Usage of Neuropsychological Tests and Multi-mode Magnetic Resonance Imaging in Patients With Autoimmune Encephalitis for Cognitive Neural Mechanism,To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI,Autoimmune Encephalitis|Cognitive Impairment,2018-03-18,2018-02-28,2018-02-28,22.0,Case-Control,,Retrospective,Observational,Completed,,First Affiliated Hospital of Zhejiang University,First Affiliated Hospital of Zhejiang University,"The First Affiliated Hospital, Zhejiang University",Drug|Drug|Drug|Drug,China,16.0,60.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03530462
2310,NCT03535090,graves disease,High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII,Coagulation After Intravenous Methylprednisolone Administration,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,2018-04-29,2014-12-31,2014-12-31,26.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Piotr Miskiewicz,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03535090
2311,NCT03535090,graves ophthalmopathy,High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII,Coagulation After Intravenous Methylprednisolone Administration,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,2018-04-29,2014-12-31,2014-12-31,26.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Piotr Miskiewicz,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03535090
2312,NCT03535090,goiter,High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII,Coagulation After Intravenous Methylprednisolone Administration,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,2018-04-29,2014-12-31,2014-12-31,26.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Piotr Miskiewicz,,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03535090
2313,NCT03535090,hyperthyroidism,High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII,Coagulation After Intravenous Methylprednisolone Administration,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,2018-04-29,2014-12-31,2014-12-31,26.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Piotr Miskiewicz,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03535090
2314,NCT03535974,thyroid nodule,Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules,Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules,Benign Thyroid Nodule,2018-05-02,2018-12-20,2018-12-21,38.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Fundatia Bio-Forum,Fundatia Bio-Forum,Fundatia Bio-Forum,Dietary Supplement|Dietary Supplement,Romania,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03535974
2315,NCT03535974,thyroid neoplasms,Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules,Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules,Benign Thyroid Nodule,2018-05-02,2018-12-20,2018-12-21,38.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Fundatia Bio-Forum,Fundatia Bio-Forum,Fundatia Bio-Forum,Dietary Supplement|Dietary Supplement,Romania,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03535974
2319,NCT03543891,thyroid neoplasms,Correlation Study of Thyroid Cancer and Intestinal Microbiota,Intestinal Microbiota and Thyroid Cancer,Microbiota,2018-05-21,2018-02-28,2018-04-30,100.0,Case-Control,,Cross-Sectional,Observational,Completed,,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Other,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03543891
2320,NCT03547648,thyroid nodule,Comparison of the Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding Points in Thyroidectomies,Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding in Thryroidectomies,Thyroid Neoplasms|Thyroid Nodule,2018-05-23,2018-11-16,2018-11-16,132.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Istanbul University,Istanbul University,Turkey,Procedure,Turkey,18.0,60.0,[18-65],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03547648
2321,NCT03547648,thyroid neoplasms,Comparison of the Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding Points in Thyroidectomies,Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding in Thryroidectomies,Thyroid Neoplasms|Thyroid Nodule,2018-05-23,2018-11-16,2018-11-16,132.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Istanbul University,Istanbul University,Turkey,Procedure,Turkey,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03547648
2322,NCT03555487,parathyroid diseases,Clinical Value of 18F -Fluorocholine (18F-FCH) PET in Localizing Parathyroid Lesions: Comparison With 99mTc-sestamibi (MIBI) Scan.,Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions: Comparison With MIBI Scan.,Parathyroid Diseases,2018-05-20,2018-06-30,2018-10-01,103.0,,Single Group Assignment,,Interventional,Completed,Phase 3,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan Univeristy Hospital,Drug,Taiwan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03555487
2324,NCT03565536,"thyroid carcinoma, anaplastic",Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer,Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer,"Thyroid Cancer, Anaplastic",2018-05-26,2019-04-30,2019-10-30,10.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Drug|Procedure|Radiation,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03565536
2325,NCT03566537,thyroid neoplasms,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Benign Thyroid Nodule|Quality of Life,2018-06-11,2020-06-11,2021-01-11,73.0,Case-Control,,Prospective,Observational [Patient Registry],Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,Ahepa Hospital,Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03566537
2326,NCT03566537,thyroid nodule,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Benign Thyroid Nodule|Quality of Life,2018-06-11,2020-06-11,2021-01-11,73.0,Case-Control,,Prospective,Observational [Patient Registry],Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,Ahepa Hospital,Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03566537
2327,NCT03569787,hypothyroidism,A Retrospective Cohort Study of Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire (UHCW),Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire,Hyperprolactinemia|Subclinical hypothyrodism|Subfertility,2018-04-30,2017-12-01,2017-12-01,107.0,Cohort,,Retrospective,Observational,Completed,,University Hospitals Coventry and Warwickshire NHS Trust,University Hospitals Coventry and Warwickshire NHS Trust,Megan Crowe,Diagnostic Test,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03569787
2328,NCT03570021,thyroid neoplasms,ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer,ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer,Thyroid Cancer,2018-06-15,2026-06-30,2026-06-30,1000.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Procedure|Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03570021
2329,NCT03573960,thyroid neoplasms,"Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer",A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,2018-06-19,2022-12-31,2022-12-31,50.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 4,Eisai Inc.,Eisai Pharmaceuticals India Pvt. Ltd,"All India Institute of Medical Sciences|Indraprastha Apollo Hospital|Shetty's Hospital|Deenanath Mangeshkar Hospital|All India Institute of Medical Sciences|S. P. Medical College & A. G. Hospitals|Tata Memorial Hospital|BL Kapoor Hospital, New Delhi|Indrayani Hospital, Alandi|City Cancer Centre",Drug,India,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03573960
2330,NCT03574051,hypothyroidism,Distinct Shifts in the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism,the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism,Microbiota,2018-06-19,2020-05-01,2022-05-01,30.0,,Single Group Assignment,,Interventional,Unknown status,Early Phase 1,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Drug,China,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03574051
2331,NCT03577951,thyroid neoplasms,Comparing the Two Ways of Creating a High Position and Low Position Operating Space in Endoscopic Thyroid Surgery,Comparing the Establishment of Operation Space Between High Position and Low Position in Endoscopic Thyroid Surgery,Endoscopy|Thyroid Cancer,2018-06-24,2018-08-31,2018-10-31,48.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03577951
2333,NCT03588884,hyperparathyroidism,"An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency","Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency",CKD Stage 3|CKD Stage 4|Secondary Hyperparathyroidism Due to Renal Causes|Vitamin D Deficiency,2018-06-28,2020-04-24,2020-04-24,69.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"OPKO Health, Inc.","OPKO Health, Inc.","National Institute of Clinical Research, Inc.|Research by Design, LLC|Spaulding Clinical Research",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03588884
2335,NCT03590080,graves ophthalmopathy,Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy,Impact of Intravenous Methylprednisolone Treatment on Blood Pressure,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,2018-06-30,2015-12-30,2015-12-30,32.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03590080
2336,NCT03590080,hyperthyroidism,Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy,Impact of Intravenous Methylprednisolone Treatment on Blood Pressure,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,2018-06-30,2015-12-30,2015-12-30,32.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03590080
2337,NCT03590080,graves disease,Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy,Impact of Intravenous Methylprednisolone Treatment on Blood Pressure,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,2018-06-30,2015-12-30,2015-12-30,32.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03590080
2338,NCT03590080,goiter,Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy,Impact of Intravenous Methylprednisolone Treatment on Blood Pressure,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,2018-06-30,2015-12-30,2015-12-30,32.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03590080
2340,NCT03602261,hyperparathyroidism,"A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.","Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI",Chronic Kidney Diseases|Secondary Hyperparathyroidism Due to Renal Causes|Stage 5 Chronic Kidney Disease|Vitamin D Deficiency,2018-07-13,2023-03-31,2023-03-31,256.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,"OPKO Health, Inc.","OPKO Health, Inc.","AKDHC Medical Research Services|AKDHC Medical Research Services|AKDHC Medical Research Services|AKDHC Medical Research Services|WCCT Global, Inc.|Hacienda Dialysis Center|California Institute of Renal Research CKD/Dialysis & Transplant Division|Long Beach Quest Dialysis Center|Ontario Dialysis Center|North America Research Institute, Inc.|Laurel Canyon Dialysis, LLC|University of Colorado Denver Anschutz Medical Campus|Research by Design, LLC|Northshore University Health|Renal and Transplant Associates of New England|Southwest MS Nephrology|Southwest Houston Research LTD|Kidney & Hypertension Specialists",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03602261
2342,NCT03602495,thyroid neoplasms,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Donafenib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer",A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2018-07-18,2021-02-28,2021-07-15,204.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03602495
2344,NCT03605472,hyperparathyroidism,Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism,Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2018-07-20,2019-10-05,2020-03-05,100.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,CHU de Reims,CHU de Reims,Damien JOLLY,Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03605472
2346,NCT03606824,hypothyroidism,Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in Patients With Atherosclerotic Cardiovascular Diseases (ThyroHeart-Lipid Study),Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study),ASCVD|Dyslipidemia|Statin|Subclinical hypothyrodism,2018-07-11,2020-02-28,2020-05-31,248.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,China National Center for Cardiovascular Diseases,"Beijing Chao Yang Hospital|Beijing Friendship Hospital|Chinese Academy of Medical Sciences, Fuwai Hospital|Peking University Third Hospital|Shaochun.Li|Xuanwu Hospital, Beijing","Fuwai Hospital, China National Center for Cardiovascular Diseases",Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03606824
2347,NCT03612908,hyperthyroidism,TSHX1 Splice Variant Expression and D2 Thr92Ala Polymorphism Analysis in Pregnant Women With Thyroid Diseases,TSHX1 and D2 THR92ALA in Pregnancy,Hyperthyroidism|Hypothyroidism|Pregnancy Related,2018-07-20,2017-12-15,2018-06-30,96.0,Case-Control,,Prospective,Observational,Completed,,Materno-Perinatal Hospital of the State of Mexico,Ciprs Grupo Mdico CGM SC|Materno-Perinatal Hospital of the State of Mexico|Universidad Autonoma del Estado de Mexico,"Materno-Perinatal Hospital ""Mnica Pretelini""",,Mexico,18.0,44.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03612908
2348,NCT03612908,hypothyroidism,TSHX1 Splice Variant Expression and D2 Thr92Ala Polymorphism Analysis in Pregnant Women With Thyroid Diseases,TSHX1 and D2 THR92ALA in Pregnancy,Hyperthyroidism|Hypothyroidism|Pregnancy Related,2018-07-20,2017-12-15,2018-06-30,96.0,Case-Control,,Prospective,Observational,Completed,,Materno-Perinatal Hospital of the State of Mexico,Ciprs Grupo Mdico CGM SC|Materno-Perinatal Hospital of the State of Mexico|Universidad Autonoma del Estado de Mexico,"Materno-Perinatal Hospital ""Mnica Pretelini""",,Mexico,18.0,44.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03612908
2349,NCT03614988,hypothyroidism,Comparative Evaluation of Evening Versus Morning Levothyroxine Administration in Treatment of Hypothyroidism in Elderly,Evaluation of Evening Versus Morning Levothyroxine Intake in Elderly,Aging|Interaction Drug Food|Primary Hypothyroidism,2018-07-30,2019-11-30,2020-03-31,208.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre,Other|Other,Brazil,60.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03614988
2350,NCT03615456,goiter,Sutureless Thyroidectomy Versus Conventional Thyroidectomy: Prospective Randomized Clinical Trial,Sutureless Versus Conventional Thyroidectomy,Goiter,2018-07-30,2018-02-28,2018-05-12,42.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mansoura University,Mansoura University,Mansoura university hospital,Procedure|Procedure,Egypt,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03615456
2352,NCT03623516,"thyroid cancer, papillary",Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014,Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014,Papillary Thyroid Cancer,2018-07-19,2014-12-01,2014-12-01,2008.0,Cohort,,Retrospective,Observational,Completed,,CHU de Reims,CHU de Reims,Damien JOLLY,,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03623516
2353,NCT03624751,thyroid neoplasms,Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment,Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment,Thyroid Cancer,2018-05-24,2028-06-30,2030-06-30,300.0,Cohort,,Prospective,Observational,Recruiting,,Taichung Veterans General Hospital,Taichung Veterans General Hospital,Division of Endocrinology and Metabolism in Taichung Veterans General Hospital,Radiation,Taiwan,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03624751
2355,NCT03626246,hyperparathyroidism,Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease,Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease,Chronic Kidney Disease|Chronic Kidney Disease Mineral and Bone Disorder|End Stage Kidney Disease|Renal Osteodystrophy|Secondary Hyperparathyroidism,2018-08-08,2020-02-28,2020-02-28,50.0,Cohort,,Cross-Sectional,Observational,Completed,,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia/CUMC,Other,United States,40.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03626246
2357,NCT03626948,hyperparathyroidism,SK-1403 Long-term Treatment Study - Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis -,SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis,Secondary Hyperparathyroidism,2018-08-08,2020-02-04,2020-02-05,157.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Sanwa Kagaku Kenkyusho Co., Ltd.","Sanwa Kagaku Kenkyusho Co., Ltd.",Investigational site (there may be other sites in this country),Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03626948
2360,NCT03627611,hypothyroidism,"A Randomized Crossover Study, Examining Differential Effects of Levothyroxine and Liothyronine",Identification of Non-responders to Levothyroxine Therapy,Biomarkers|Endocrine System Diseases|Hypothyroidism,2018-05-25,2020-06-22,2020-06-22,69.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Oslo University Hospital,Hormonlaboratoriet|Oslo University Hospital|Spesialistsenteret Pilestredet Park,Oslo University Hospital,Drug|Drug,Norway,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03627611
2361,NCT03630120,"thyroid cancer, papillary",Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer,"Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Medullary",2018-08-10,2019-11-14,2019-12-05,6.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03630120
2362,NCT03630120,"adenocarcinoma, follicular",Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer,"Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Medullary",2018-08-10,2019-11-14,2019-12-05,6.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03630120
2364,NCT03631771,hypothyroidism,"A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.",Pediatric Risk of Hypothyroidism With Iodinated Contrast Media,Hypothyroidism,2018-08-13,2024-08-31,2025-02-28,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 4,GE Healthcare,Bayer|GE Healthcare|Guerbet/Liebel-Flarsheim,,Drug|Drug|Drug|Drug,,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03631771
2366,NCT03633708,hyperparathyroidism,"Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease|Secondary Hyperparathyroidism,2018-08-14,2023-01-31,2023-01-31,56.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Amgen,Amgen,Childrens Hospital of Los Angeles|Childrens Hospital Colorado|Childrens Mercy Hospital|Mount Sinai Kidney Center - B1 Renal Treatment|Cincinnati Childrens Hospital Medical Center|Cleveland Clinic|The Childrens Hospital at Oklahoma University Medical Center|Childrens Hospital of Philadelphia|Childrens Medical Center Dallas|Primary Childrens Hospital Outpatient Services|Hospital Italiano|Fresenius Escobar|Centro Infantil Del Rinon|Fortis Flt Lt Rajan Dhall Hospital|All India Institute of Medical Sciences|Sir Ganga Ram Hospital|Manipal Hospital|KLES Dr Prabhakar Kore Hospital and Medical Research Centre|NRS Medical College and Hospital|Seoul National University Hospital|Pusan National University Yangsan Hospital|Hospital Raja Perempuan Zainab II|Hospital TuanKu Jaafar|Hospital Wanita Dan Kanak-Kanak Kuala Lumpur|SBHI Pediatrics city clinical hospital of Saint Vladimir|Municipal Children Hospital 1|State Budgetary Healthcare Institution Samara Regional Clinical Hospital na V D Seredavin|National University Hospital|Kaohsiung Veterans General Hospital|National Cheng Kung University Hospital|National Taiwan University Hospital|Linkou Chang Gung Memorial Hospital|Hacettepe Universitesi Tip Fakultesi Ihsan Dogramaci Cocuk Hastanesi|Baskent Universitesi Ankara Hastanesi|Gazi Universitesi Tip Fakultesi|Istanbul Universitesi Cerrahpasa Tip Fakultesi|Ege Universitesi Tip Fakultesi|Erciyes Universitesi Tip Fakultesi Mustafa Eraslan ve Fevzi Mercan Cocuk Hastanesi|National Childrens Specializated Hospital OKHMATDIT,Drug,"Argentina|India|Korea, Republic of|Malaysia|Russian Federation|Singapore|Taiwan|Turkey|Ukraine|United States",0.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03633708
2368,NCT03636945,thyroid neoplasms,Evaluation of the Clinical Performance of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma: Multicenter Prospective Study,Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma,Medullary Thyroid Carcinoma,2018-08-16,2021-03-31,2021-09-30,62.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Des Hopitaux de Marseille,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03636945
2370,NCT03639662,"adenocarcinoma, follicular",Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer Compared With Usual Initial Management: Multicenter Randomized Prospective Study,Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer,Follicular Thyroid Cancer,2018-08-17,2022-03-31,2022-11-30,232.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Des Hopitaux de Marseille,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03639662
2371,NCT03640247,parathyroid diseases,Are Narcotic Pain Medications Necessary Following Thyroidectomy and Parathyroidectomy,Pain Medications Following Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Disease,2018-07-24,2019-12-01,2019-12-01,126.0,,Parallel Assignment,,Interventional,Completed,Phase 1,MetroHealth Medical Center,MetroHealth Medical Center,MetroHealth Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03640247
2372,NCT03641638,postpartum thyroiditis,Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregancy,Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregnancy,Postpartum Thyroiditis,2018-07-08,2020-10-31,2020-12-31,400.0,Case-Control,,Prospective,Observational,Unknown status,,China National Nuclear Corporation 416 Hospital,China National Nuclear Corporation 416 Hospital,China National Nuclear corporation 416 Hospital,,China,18.0,35.0,[18-65],Thyroiditis,Other thyroiditis,https://clinicaltrials.gov/ct2/show/NCT03641638
2374,NCT03641638,thyroiditis,Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregancy,Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregnancy,Postpartum Thyroiditis,2018-07-08,2020-10-31,2020-12-31,400.0,Case-Control,,Prospective,Observational,Unknown status,,China National Nuclear Corporation 416 Hospital,China National Nuclear Corporation 416 Hospital,China National Nuclear corporation 416 Hospital,,China,18.0,35.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03641638
2375,NCT03643055,thyroid neoplasms,Diagnostic Value of 18F-Fluorocholine PET/CT for the Detection of Medullary Thyroid Cancer,18F-Fluorocholine PET/CT in Medullary Thyroid Cancer,Medullary Thyroid Cancer,2018-08-20,2021-03-03,2024-09-03,80.0,Case-Only,,Prospective,Observational,Active not recruiting,,University Medical Centre Ljubljana,Institute of Oncology Ljubljana|University Medical Centre Ljubljana,"Department for nuclear medicine, University medical centre Ljubljana",Diagnostic Test,Slovenia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03643055
2377,NCT03643081,hyperparathyroidism,"Evaluation of the Interest of the Medical Device Called ""Fluobeam"" in the Localization, Visualization of the Parathyroid Glands for Patients With Mild Primary Hyperparathyroidism. A Randomized Controled Prospective Open -Labeled Monocentric Study.","Evaluation of the Interest of the Medical Device Called ""Fluobeam"" in the Localization, Visualization of the Parathyroid Glands for Patients With Mild Primary Hyperparathyroidism",Mild Primary Hyperparathyroidism,2018-08-21,2024-06-30,2024-06-30,132.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Nantes University Hospital,Nantes University Hospital,CHU de Nantes,Device,France,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03643081
2379,NCT03646383,thyroid nodule,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules by Percutaneous Radiological Approach,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules,Benign Thyroid Nodules,2018-03-25,2021-12-31,2021-12-31,40.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,"University Hospital, Toulouse","University Hospital, Toulouse","CHU Toulouse, Hpital Larrey",Procedure,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03646383
2380,NCT03646383,thyroid neoplasms,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules by Percutaneous Radiological Approach,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules,Benign Thyroid Nodules,2018-03-25,2021-12-31,2021-12-31,40.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,"University Hospital, Toulouse","University Hospital, Toulouse","CHU Toulouse, Hpital Larrey",Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03646383
2381,NCT03647358,thyroid neoplasms,Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma,Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma,Metastatic Thyroid Carcinoma|Thyroid Carcinoma,2018-08-22,2022-08-31,2022-08-31,100.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|Weill Cornell Medical Center,Device|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03647358
2382,NCT03647657,thyroid neoplasms,177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B),177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer,"Thyroid Cancer, Medullary",2018-08-20,2021-12-14,2021-12-14,8.0,,Crossover Assignment,,Interventional,Completed,Early Phase 1,"University Hospital, Basel, Switzerland","Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland|Krebsforschung Schweiz, Bern, Switzerland|University Hospital, Basel, Switzerland|University Hospital Freiburg|University Hospital, Zrich","University Hospital Basel, Clinic for radiology and nuclear medicine",Drug|Drug,Switzerland,18.0,64.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03647657
2383,NCT03657654,thyroid neoplasms,Voice Outcomes Following Thyroidectomy Compared to Surgeries That Do Not Involve Risk to the Laryngeal Nerves,Voice Outcomes Following Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2018-08-29,2023-12-15,2023-12-15,45.0,Cohort,,Prospective,Observational,Recruiting,,University of Virginia,University of Virginia,University of Virginia,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03657654
2384,NCT03657654,thyroid nodule,Voice Outcomes Following Thyroidectomy Compared to Surgeries That Do Not Involve Risk to the Laryngeal Nerves,Voice Outcomes Following Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2018-08-29,2023-12-15,2023-12-15,45.0,Cohort,,Prospective,Observational,Recruiting,,University of Virginia,University of Virginia,University of Virginia,Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03657654
2387,NCT03660800,hyperparathyroidism,"An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101 (Calcifediol) Extended-release Capsules in Japanese and Non-Japanese Healthy Subjects",Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects,Secondary Hyperparathyroidism|Vitamin D Insufficiency,2018-08-23,2018-10-24,2019-01-22,67.0,,Parallel Assignment,,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO Health, Inc.","WCCT Global, Inc.",Drug,United States,18.0,55.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03660800
2388,NCT03667157,graves ophthalmopathy,Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy,Liver Function After Intravenous Methylprednisolone Administration,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",2018-09-08,2016-10-30,2016-10-30,68.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Medical University of Warsaw,Medical University of Warsaw,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03667157
2389,NCT03667157,hyperthyroidism,Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy,Liver Function After Intravenous Methylprednisolone Administration,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",2018-09-08,2016-10-30,2016-10-30,68.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Medical University of Warsaw,Medical University of Warsaw,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03667157
2390,NCT03667157,goiter,Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy,Liver Function After Intravenous Methylprednisolone Administration,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",2018-09-08,2016-10-30,2016-10-30,68.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Medical University of Warsaw,Medical University of Warsaw,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03667157
2391,NCT03667157,graves disease,Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy,Liver Function After Intravenous Methylprednisolone Administration,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",2018-09-08,2016-10-30,2016-10-30,68.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Medical University of Warsaw,Medical University of Warsaw,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03667157
2392,NCT03669432,thyroid neoplasms,Phase II Randomized Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers.,To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.,Radiation Toxicity|Thyroid Cancer Stage IV,2018-05-04,2026-07-31,2026-07-31,72.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Tata Memorial Hospital,Department of Atomic Energy|Tata Memorial Hospital,Gouri Pantvaidya,Radiation|Procedure,India,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03669432
2393,NCT03676348,thyroid neoplasms,"Health Related Quality of Life in Thyroid Cancer Patients, and in Patients With Thyroid Nodules Suspicious of Cancer",HRQOL in Thyroid Cancer and Thyroid Tumours,Quality of Life|Thyroid Cancer|Thyroid Nodule,2018-09-17,2023-04-30,2028-04-30,200.0,Cohort,,Prospective,Observational,Recruiting,,Oslo University Hospital,Oslo University Hospital,"ENT department, Oslo University Hospital",,Norway,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03676348
2394,NCT03676348,thyroid nodule,"Health Related Quality of Life in Thyroid Cancer Patients, and in Patients With Thyroid Nodules Suspicious of Cancer",HRQOL in Thyroid Cancer and Thyroid Tumours,Quality of Life|Thyroid Cancer|Thyroid Nodule,2018-09-17,2023-04-30,2028-04-30,200.0,Cohort,,Prospective,Observational,Recruiting,,Oslo University Hospital,Oslo University Hospital,"ENT department, Oslo University Hospital",,Norway,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03676348
2395,NCT03676647,thyroid nodule,Retrospective-Prospective Collection of Thyroid Specimens After FNA,Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules,Thyroid Gland Nodule,2018-09-17,2023-12-31,2023-12-31,600.0,Cohort,,Other,Observational,Recruiting,,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Other,United States,19.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03676647
2396,NCT03676647,thyroid neoplasms,Retrospective-Prospective Collection of Thyroid Specimens After FNA,Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules,Thyroid Gland Nodule,2018-09-17,2023-12-31,2023-12-31,600.0,Cohort,,Other,Observational,Recruiting,,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Other,United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03676647
2397,NCT03680222,thyroid neoplasms,Effect of Reversed Tracking Method of Stimulating Cricothyroid Muscles on the Identification and Protection of EBSLN in Thyroid Surgery,Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery,Recurrent Laryngeal Nerve Injuries|Thyroid Cancer,2018-09-09,2019-09-30,2020-09-30,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Procedure,China,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03680222
2398,NCT03690388,thyroid neoplasms,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy,Differentiated Thyroid Cancer,2018-09-26,2020-08-19,2022-12-31,258.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Exelixis,Exelixis,Exelixis Clinical Site #2|Exelixis Clinical Site #98|Exelixis Clinical Site #69|Exelixis Clinical Site #10|Exelixis Clinical Site #3|Exelixis Clinical Site #9|Exelixis Clinical Site #21|Exelixis Clinical Site #4|Exelixis Clinical Site #94|Exelixis Clinical Site #93|Exelixis Clinical Site #6|Exelixis Clinical Site #164|Exelixis Clinical Site #54|Exelixis Clinical Site #153|Exelixis Clinical Site #80|Exelixis Clinical Site #78|Exelixis Clinical Site #22|Exelixis Clinical Site #63|Exelixis Clinical Site #42|Exelixis Clinical Site #11|Exelixis Clinical Site #118|Exelixis Clinical Site #76|Exelixis Clinical Site #19|Exelixis Clinical Site #7|Exelixis Clinical Site #5|Exelixis Clinical Site #1|Exelixis Clinical Site #75|Exelixis Clinical Site #134|Exelixis Clinical Site #68|Exelixis Clinical Site #8|Exelixis Clinical Site #113|Exelixis Clinical Site #96|Exelixis Clinical Site #97|Exelixis Clinical Site #129|Exelixis Clinical Site #17|Exelixis Clinical Site #25|Exelixis Clinical Site #86|Exelixis Clinical Site #24|Exelixis Clinical Site #12|Exelixis Clinical Site #62|Exelixis Clinical Site #119|Exelixis Clinical Site #90|Exelixis Clinical Site #31|Exelixis Clinical Site #26|Exelixis Clinical Site #74|Exelixis Clinical Site #100|Exelixis Clinical Site #27|Exelixis Clinical Site #35|Exelixis Clinical Site #39|Exelixis Clinical Site #140|Exelixis Clinical Site #38|Exelixis Clinical Site #40|Exelixis Clinical Site #116|Exelixis Clinical Site #92|Exelixis Clinical Site #47|Exelixis Clinical Site #20|Exelixis Clinical Site #18|Exelixis Clinical Site #107|Exelixis Clinical Site #83|Exelixis Clinical Site #145|Exelixis Clinical Site #137|Exelixis Clinical Site #138|Exelixis Clinical Site #105|Exelixis Clinical Site #104|Exelixis Clinical Site #32|Exelixis Clinical Site #44|Exelixis Clinical Site #67|Exelixis Clinical Site #45|Exelixis Clinical Site #72|Exelixis Clinical Site #102|Exelixis Clinical Site #91|Exelixis Clinical Site #82|Exelixis Clinical Site #152|Exelixis Clinical Site #95|Exelixis Clinical Site #121|Exelixis Clinical Site #156|Exelixis Clinical Site #125|Exelixis Clinical Site #163|Exelixis Clinical Site #124|Exelixis Clinical Site #151|Exelixis Clinical Site #155|Exelixis Clinical Site #131|Exelixis Clinical Site #154|Exelixis Clinical Site #160|Exelixis Clinical Site #159|Exelixis Clinical Site #139|Exelixis Clinical Site #28|Exelixis Clinical Site #46|Exelixis Clinical Site #37|Exelixis Clinical Site #43|Exelixis Clinical Site #41|Exelixis Clinical Site #58|Exelixis Clinical Site #109|Exelixis Clinical Site #135|Exelixis Clinical Site #132|Exelixis Clinical Site #144|Exelixis Clinical Site #143|Exelixis Clinical Site #29|Exelixis Clinical Site #120|Exelixis Clinical Site #103|Exelixis Clinical Site #110|Exelixis Clinical Site #115|Exelixis Clinical Site #108|Exelixis Clinical Site #56|Exelixis Clinical Site #123|Exelixis Clinical Site #87|Exelixis Clinical Site #127|Exelixis Clinical Site #111|Exelixis Clinical Site #70|Exelixis Clinical Site #79|Exelixis Clinical Site #36|Exelixis Clinical Site #34|Exelixis Clinical Site #158|Exelixis Clinical Site #133|Exelixis Clinical Site #147|Exelixis Clinical Site #148|Exelixis Clinical Site #161|Exelixis Clinical Site #128|Exelixis Clinical Site #117|Exelixis Clinical Site #15|Exelixis Clinical Site #61|Exelixis Clinical Site #59|Exelixis Clinical Site #149|Exelixis Clinical Site #150|Exelixis Clinical Site #142|Exelixis Clinical Site #146|Exelixis Clinical Site #48|Exelixis Clinical Site #55|Exelixis Clinical Site #157|Exelixis Clinical Site #49|Exelixis Clinical Site #53|Exelixis Clinical Site #84|Exelixis Clinical Site #85|Exelixis Clinical Site #106|Exelixis Clinical Site #89|Exelixis Clinical Site #52|Exelixis Clinical Site #66|Exelixis Clinical Site #14|Exelixis Clinical Site #99|Exelixis Clinical Site #114|Exelixis Clinical Site #30|Exelixis Clinical Site #13|Exelixis Clinical Site #16|Exelixis Clinical Site #33|Exelixis Clinical Site #73|Exelixis Clinical Site #23|Exelixis Clinical Site #81|Exelixis Clinical Site #136|Exelixis Clinical Site #112|Exelixis Clinical Site #77|Exelixis Clinical Site #101|Exelixis Clinical Site #126|Exelixis Clinical Site #122|Exelixis Clinical Site #141|Exelixis Clinical Site #130|Exelixis Clinical Site #88|Exelixis Clinical Site #71|Exelixis Clinical Site #162|Exelixis Clinical Site #51|Exelixis Clinical Site #64|Exelixis Clinical Site #50|Exelixis Clinical Site #60|Exelixis Clinical Site #65|Exelixis Clinical Site #57,Drug|Drug,"Argentina|Australia|Austria|Belgium|Brazil|Canada|Croatia|Czechia|France|Germany|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|United Kingdom|United States",16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03690388
2399,NCT03699098,hypothyroidism,The Incidence and Risk Factors of Radiotherapy Induced Hypothyroidism in Head and Neck Cancer,The Incidence and Risk Factors of Radiotherapy Induced Hypothyroidism in Head and Neck Cancer With Long Term Follow up,Head and Neck Cancer,2018-10-02,2018-06-01,2018-06-05,101.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Cairo University,Cairo University,"Department of clinical oncology and nuclear medicine, Cairo university",Diagnostic Test,Egypt,18.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03699098
2400,NCT03700762,thyroid neoplasms,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Thyroid Nodule,2018-07-07,2019-10-01,2020-10-01,300.0,Case-Only,,Prospective,Observational,Unknown status,,First People's Hospital of Hangzhou,First People's Hospital of Hangzhou,The first people's hospital of Hangzhou,Diagnostic Test,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03700762
2401,NCT03700762,thyroid nodule,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Thyroid Nodule,2018-07-07,2019-10-01,2020-10-01,300.0,Case-Only,,Prospective,Observational,Unknown status,,First People's Hospital of Hangzhou,First People's Hospital of Hangzhou,The first people's hospital of Hangzhou,Diagnostic Test,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03700762
2402,NCT03708627,graves disease,The Role of Bimatoprost in Graves' Periorbitopathy,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,2018-10-13,2024-07-01,2024-07-01,3.0,,Parallel Assignment,,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03708627
2403,NCT03708627,graves ophthalmopathy,The Role of Bimatoprost in Graves' Periorbitopathy,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,2018-10-13,2024-07-01,2024-07-01,3.0,,Parallel Assignment,,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03708627
2404,NCT03708627,hyperthyroidism,The Role of Bimatoprost in Graves' Periorbitopathy,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,2018-10-13,2024-07-01,2024-07-01,3.0,,Parallel Assignment,,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03708627
2405,NCT03708627,goiter,The Role of Bimatoprost in Graves' Periorbitopathy,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,2018-10-13,2024-07-01,2024-07-01,3.0,,Parallel Assignment,,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03708627
2406,NCT03712683,hypothyroidism,Prevalence of Subclinical Hypothyroidism in Women With Unexplained Infertility and the Effect of Thyroxin on Pregnancy Rate,Thyroxin in Subclinical Hypothyroidism,Pregnancy Loss|Sub Clinical Hypothyroidism,2018-10-17,2017-07-01,2017-07-01,168.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hawler Medical University,Hawler Medical University,,Drug,,18.0,42.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03712683
2409,NCT03713671,hyperparathyroidism,The Effect of Quadriceps Femoris Muscle Fatigue Protocol on Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Primary Hyperparathyroidism,2018-10-18,2022-01-10,2022-01-30,40.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Recep Tayyip Erdogan University Training and Research Hospital,Ankara Education and Research Hospital|Hacettepe University|Recep Tayyip Erdogan University Training and Research Hospital,Ankara Education and Research Hospital,Diagnostic Test,Turkey,45.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03713671
2410,NCT03716128,hyperparathyroidism,Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function Can 18F-PET Replace Bone Histomorphometry,Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function,Renal Osteodystrophy,2018-09-26,2020-10-31,2020-10-31,40.0,Other,,Cross-Sectional,Observational,Unknown status,,Herlev Hospital,Ditte Hansen|Universiteit Antwerpen|University of Copenhagen,Herlev Hospital,Diagnostic Test,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03716128
2414,NCT03718403,pseudopseudohypoparathyroidism,Effect of Theophylline in Pseudohypoparathyroidism,Effect of Theophylline in Pseudohypoparathyroidism,Php1C|PHP Ia|PHP IB,2017-09-08,2030-04-10,2032-04-10,40.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 4,Massachusetts General Hospital,Massachusetts General Hospital,,Drug,,5.0,21.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03718403
2416,NCT03720210,hyperthyroidism,Pilot Study for Treatment of Amiodarone-Induced Thyroiditis With Radiofrequency Ablation,Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis,Amiodarone-Induced Thyrotoxicosis,2018-10-17,2020-12-07,2020-12-07,1.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Device,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03720210
2418,NCT03724188,hyperparathyroidism,Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients,Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients,Hyperparathyroidism Tertiary,2018-10-24,2022-12-30,2022-12-30,40.0,Case-Only,,Prospective,Observational,Recruiting,,Mansoura General Hospital,Mansoura General Hospital,Faculty of medicine - Mansoura university,Procedure,Egypt,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03724188
2419,NCT03728959,hypoparathyroidism,Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism (KS-4-HypoPT).,Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.,Hypoparathyroidism,2018-10-31,2019-04-12,2019-04-12,7.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,University of Copenhagen,Hvidovre University Hospital|University of Copenhagen,Hvidovre University Hospital,Other|Other|Other|Other,Denmark,18.0,76.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03728959
2423,NCT03732157,hyperparathyroidism,"Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients, for Treatment of Primary Hyperparathyroidism",Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients,Primary Hyperparathyroidism,2018-09-18,2019-07-31,2019-07-31,140.0,Cohort,,Prospective,Observational,Unknown status,,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,,Procedure|Procedure,,19.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03732157
2424,NCT03732495,thyroid neoplasms,"A Prospective, Multicentre Phase II Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)",Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas,Thyroid Cancer Metastatic,2018-10-31,2022-12-15,2023-01-15,35.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Centre Leon Berard,Centre Leon Berard,CHU Angers|CHRU Besanon|CHU Bordeaux - Hpital Saint-Andr|Institut Bergonie|Hospices Civils de Lyon - Groupement Hospitalier Est|Centre Geogres Franois Leclerc|Centre Lon Brard|Centre Antoine Lacassagne|APHP Saint Louis|APHP La Piti Salptrire|Institut Jean Godinot|Institut du Cancer Strasbourg (ICANS)|Institut Universitaire du Cancer de Toulouse - Oncopole|Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03732495
2425,NCT03747029,hyperparathyroidism,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Hyperparathyroidism|Hypoparathyroidism|Parathyroid Diseases|Phosphorus and Calcium Disorders,2018-11-16,2018-12-31,2018-12-31,1038.0,Case-Control,,Retrospective,Observational,Completed,,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero - Universitaria di Modena,Other,Italy,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03747029
2426,NCT03747029,hypoparathyroidism,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Hyperparathyroidism|Hypoparathyroidism|Parathyroid Diseases|Phosphorus and Calcium Disorders,2018-11-16,2018-12-31,2018-12-31,1038.0,Case-Control,,Retrospective,Observational,Completed,,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero - Universitaria di Modena,Other,Italy,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03747029
2428,NCT03753919,"thyroid cancer, papillary","A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial","Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial",Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,2018-11-20,2022-07-31,2022-12-31,46.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|MFAR,Instituto Cataln de Oncologa de Hospitalet|Hospital Provincial de Castelln|Hospital Clnic Barcelona|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Clnico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario HM Sanchinarro|Hospital Universitario La Paz|Hospital Universitario Ramn y Cajal|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Clnica Universidad de Navarra|Instituto Valenciano de Oncologa|Complejo Hospitalario Universitario de Vigo (CHUVI),Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03753919
2429,NCT03753919,"adenocarcinoma, follicular","A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial","Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial",Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,2018-11-20,2022-07-31,2022-12-31,46.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|MFAR,Instituto Cataln de Oncologa de Hospitalet|Hospital Provincial de Castelln|Hospital Clnic Barcelona|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Clnico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario HM Sanchinarro|Hospital Universitario La Paz|Hospital Universitario Ramn y Cajal|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Clnica Universidad de Navarra|Instituto Valenciano de Oncologa|Complejo Hospitalario Universitario de Vigo (CHUVI),Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03753919
2431,NCT03754621,hypothyroidism,What is the Rational Upper Limit for TSH and T4 During First and Second Trimester Pregnancy in West Black Sea Region of Turkey,Upper Limit for TSH of First and Second Trimester Pregnancy in Turkey,Hypothyroidism|Pregnancy Early|Thyroid|Thyroid Dysfunction,2018-11-23,2019-07-02,2019-07-15,400.0,Case-Control,,Prospective,Observational,Unknown status,,Bartin State Hospital,Bartin State Hospital,Bartin State Hospital,Diagnostic Test,Turkey,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03754621
2432,NCT03757637,thyroid neoplasms,"Yeur-Hur Lai, PhD, RN, School of Nursing, College of Medicine, National Taiwan University",Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients,Differentiated Thyroid Cancer,2018-11-27,2022-12-31,2022-12-31,380.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,"Department of Surgery, National Taiwan University Hospital, No.7, Chung-Shan South Road, Taipei, TAIWAN, R.O.C.",Other|Other,Taiwan,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03757637
2434,NCT03761290,pseudohypoparathyroidism,Glucose Homeostasis and Beta Cell Function in Pseudohypoparathyroidism,Glucose Homeostasis in Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism|Pseudohypoparathyroidism Type Ia,2018-11-29,2021-04-30,2021-04-30,14.0,Case-Control,,Cross-Sectional,Observational,Terminated,,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Vanderbilt University Medical Center,,United States,6.0,50.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03761290
2435,NCT03764007,parathyroid neoplasms,18F-Fluorocholine for the Detection of Parathyroid Adenomas,18F-Fluorocholine for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2018-11-30,2021-05-31,2021-05-31,98.0,,Single Group Assignment,,Interventional,Completed,Phase 2/Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03764007
2437,NCT03764007,hyperparathyroidism,18F-Fluorocholine for the Detection of Parathyroid Adenomas,18F-Fluorocholine for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2018-11-30,2021-05-31,2021-05-31,98.0,,Single Group Assignment,,Interventional,Completed,Phase 2/Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03764007
2439,NCT03765333,thyroid neoplasms,"Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic",GETNE Registration of Thyroid Cancer,Thyroid Cancer,2018-11-20,2021-09-30,2021-11-30,20.0,Ecologic or Community,,Cross-Sectional,Observational,Recruiting,,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos,Hospital Universitari Vall d'Hebron,,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03765333
2440,NCT03772496,thyroid nodule,"A Multicenter, Double-blind, Prospective Cohort Study of Diagnostic Significance of Circulating Tumor Cells in Patients With Thyroid Nodules",Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells),Diagnoses Disease|Thyroid Nodule,2018-11-23,2019-12-20,2020-02-20,200.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Beijing Chao Yang Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|China-Japan Friendship Hospital|Chinese PLA General Hospital","Cancer Hospital, Chinese Academy of Medical Science",Diagnostic Test|Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03772496
2441,NCT03772496,thyroid neoplasms,"A Multicenter, Double-blind, Prospective Cohort Study of Diagnostic Significance of Circulating Tumor Cells in Patients With Thyroid Nodules",Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells),Diagnoses Disease|Thyroid Nodule,2018-11-23,2019-12-20,2020-02-20,200.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Beijing Chao Yang Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|China-Japan Friendship Hospital|Chinese PLA General Hospital","Cancer Hospital, Chinese Academy of Medical Science",Diagnostic Test|Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03772496
2442,NCT03773120,"adenocarcinoma, follicular",Effectiveness of Intraoperative Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroid Surgery,Effectiveness of Intraoperative Neuromonitoring of External Branch of Superior Laryngeal Nerve During Thyroid Surgery,"Carcinoma, Papillary, Follicular",2018-04-12,2019-07-23,2019-07-23,5.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Device,"Korea, Republic of",18.0,79.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03773120
2444,NCT03774771,hyperparathyroidism,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-week Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Clinical Effects of an Oral Calcimimetic Agent (AMG 073) in Primary Hyperparathyroidism","Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism",Primary Hyperparathyroidism,2018-12-11,1999-12-13,1999-12-13,48.0,,Sequential Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03774771
2446,NCT03774862,thyroid neoplasms,Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study,Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study,Colorectal Medullary Carcinoma,2018-09-05,2017-12-31,2018-08-01,13.0,Cohort,,Retrospective,Observational,Completed,,"V.K.V. American Hospital, Istanbul","V.K.V. American Hospital, Istanbul",,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03774862
2449,NCT03776058,hyperparathyroidism,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Clinical Effects of Twice-daily Doses of an Oral Calcimimetic Agent (AMG 073) in Subjects With Primary Hyperparathyroidism (HPT)","Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)",Primary Hyperparathyroidism,2018-12-13,2000-12-26,2000-12-26,10.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03776058
2450,NCT03779906,hypothyroidism,"A Prospective, Multicenter Observational Study to Evaluate Thyroid Function of Pediatric Subjects From Birth to 3 Years Exposed to ISOVUE (Iopamidol Injection)",Thyroid Function of Pediatric Subjects Following Isovue Administration,Hypothyroidism,2018-12-17,2024-12-01,2025-01-31,1560.0,,Single Group Assignment,,Interventional,Recruiting,Phase 4,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",Children's Hospital and Medical Center,Drug,United States,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03779906
2451,NCT03787121,thyroid neoplasms,Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers : Involvement of Overtreatment,Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers,Thyroid Cancer,2018-12-24,2020-12-31,2020-12-31,361.0,Cohort,,Retrospective,Observational,Completed,,"University Hospital, Toulouse","University Hospital, Toulouse",University HospitalToulouse,Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03787121
2452,NCT03794375,thyroid neoplasms,Impact of Primary Care Transfer for Thyroid Cancer Patients,Primary Care Transfer for Thyroid Cancer Patients,Differentiated Thyroid Cancer,2018-12-28,2022-12-31,2024-12-31,472.0,,Parallel Assignment,,Interventional,Enrolling by invitation,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre,Hospital de Clnicas de Porto Alegre,Other|Other,Brazil,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03794375
2454,NCT03801980,hyperparathyroidism,Phase 3 Study of SK-1403 ; Double-blinded Parallel Group in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis,Phase 3 Study of SK-1403,Secondary Hyperparathyroidism,2019-01-08,2019-12-17,2019-12-21,153.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Sanwa Kagaku Kenkyusho Co., Ltd.","Sanwa Kagaku Kenkyusho Co., Ltd.",Investigational site (there may be other sites in this country),Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03801980
2456,NCT03808779,thyroid neoplasms,"A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC)",A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.,Papillary Thyroid Microcarcinoma,2019-01-13,2024-02-01,2024-02-01,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University","General Surgery Department, Tianjin Medical University General Hospital|Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University|Interventional Oncology Centre, State Institution ""Grigoriev Intstitute for Medical Radiology NAMS of Ukraine""",Procedure|Procedure,China|Ukraine,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03808779
2458,NCT03813173,"thyroid cancer, papillary",Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma: a Prospective Study,Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma,Lymph Node Metastases,2019-01-16,2040-12-31,2040-12-31,6000.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Zhejiang University,Zhejiang University,,Procedure,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03813173
2460,NCT03813706,"thyroid cancer, papillary",Prospective Study for the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma,the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma,Lymph Node Metastases,2019-01-16,2040-12-31,2040-12-31,4000.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Zhejiang University,Zhejiang University,,Procedure,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03813706
2463,NCT03822507,hyperparathyroidism,"A Phase 3, Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis",Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia,Secondary Hyperparathyroidism,2019-01-29,2021-09-23,2021-09-23,404.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Hakko Kirin China Pharmaceutical Co., LTD.|Kyowa Kirin Co., Ltd.|Kyowa Kirin Korea Co., Ltd.",Research site_29|Research site_34|Research site_25|Research site_22|Research site_23|Research site_30|Research site_28|Research site_32|Research site_33|Research site_24|Research site_26|Research site_27|Research site_31|Research site_11|Research site_21|Research site_13|Research site_15|Research site_12|Research site_18|Research site_14|Research site_17|Research site_19|Research site_20|Research site_16|Research site_2|Research site_3|Research site_5|Research site_9|Research site_4|Research site_7|Research site_10|Research site_1|Research site_6|Research site_8,Drug|Drug,"China|Hong Kong|Korea, Republic of|Taiwan",18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03822507
2464,NCT03823859,hypothyroidism,Metabolomics of Thyroid Hormones,Metabolomics of Thyroid Hormones,Central Hypothyroidism|Hyperthyroidism|Hypothyroidism,2019-01-28,2021-07-28,2021-12-31,332.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,"University Hospital, Basel, Switzerland","ETH Zurich|University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Diagnostic Test|Diagnostic Test|Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03823859
2465,NCT03823859,hyperthyroidism,Metabolomics of Thyroid Hormones,Metabolomics of Thyroid Hormones,Central Hypothyroidism|Hyperthyroidism|Hypothyroidism,2019-01-28,2021-07-28,2021-12-31,332.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,"University Hospital, Basel, Switzerland","ETH Zurich|University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Diagnostic Test|Diagnostic Test|Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03823859
2466,NCT03826680,thyroid neoplasms,"The Relationship of Modified Cormack Lehane Scores Between Preoperative Awake Flexible Fiberoptic Laryngoscopy and Intraoperative Direct Laryngoscopy in Thyroidectomies, a Prospective, Clinical Study",Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia,Thyroid Adenoma|Thyroid Cancer|Thyroid Nodule,2019-01-29,2020-06-30,2020-07-31,200.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,Istanbul University,Istanbul University,"Istanbul University- Cerrahpasa Department of Anesthesiology, general surgery, ENT surgery",Procedure|Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03826680
2467,NCT03826680,thyroid nodule,"The Relationship of Modified Cormack Lehane Scores Between Preoperative Awake Flexible Fiberoptic Laryngoscopy and Intraoperative Direct Laryngoscopy in Thyroidectomies, a Prospective, Clinical Study",Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia,Thyroid Adenoma|Thyroid Cancer|Thyroid Nodule,2019-01-29,2020-06-30,2020-07-31,200.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,Istanbul University,Istanbul University,"Istanbul University- Cerrahpasa Department of Anesthesiology, general surgery, ENT surgery",Procedure|Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03826680
2468,NCT03830242,"thyroid cancer, papillary","Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer",Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.,Lymph Node Metastases|Positron-Emission Tomography|Thyroid Cancer,2018-12-17,2022-12-31,2022-12-31,50.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University",Diagnostic Test|Diagnostic Test,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03830242
2470,NCT03831620,hyperparathyroidism,The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism,The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2019-01-25,2022-07-31,2022-07-31,90.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,"University Hospital Inselspital, Berne","University Hospital Inselspital, Berne","Department of visceral surgery and transplant surgery, Berne University Hospital",,Switzerland,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03831620
2475,NCT03835728,thyroiditis,Exploratory Study of Efficacy of Ocrelizumab in Autoimmune Encephalitis,Efficacy of Ocrelizumab in Autoimmune Encephalitis,Autoimmune Encephalitis,2019-02-05,2020-10-02,2020-10-02,3.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,University of Texas Southwestern Medical Center,"Genentech, Inc.|University of Texas Southwestern Medical Center",UT Southwestern Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03835728
2477,NCT03836300,hypoparathyroidism,Piloting an Early Intervention Program for Infants With Rare Neurogenetic Disorders,Parent-Infant Inter(X)Action Intervention (PIXI),Angelman Syndrome|Chromosome 22q11.2 Deletion Syndrome|Down Syndrome|Duchenne Muscular Dystrophy|Dup15Q Syndrome|Fragile X Syndrome|Klinefelter Syndrome|Phelan-McDermid Syndrome|Prader-Willi Syndrome|Rett Syndrome|Smith Magenis Syndrome|Tuberous Sclerosis|Turner Syndrome|Williams Syndrome,2019-02-07,2022-12-01,2022-12-31,120.0,,Single Group Assignment,,Interventional,Enrolling by invitation,Not Applicable,RTI International,"RTI International|University of North Carolina, Chapel Hill",RTI International,Behavioral,United States,0.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03836300
2478,NCT03838692,thyroid neoplasms,A Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer (MTC),Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer,Medullary Thyroid Cancer,2019-02-11,2021-06-14,2021-06-14,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 2,Columbia University,"Antonio Fojo|Millennium Pharmaceuticals, Inc.",,Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03838692
2479,NCT03841617,thyroid neoplasms,The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer,The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer,Thyroid Cancer,2019-02-13,2024-02-01,2029-02-01,30.0,,Crossover Assignment,,Interventional,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,Drug|Radiation|Radiation|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03841617
2480,NCT03845647,thyroid neoplasms,"Significance of Single Center, Open and Prospective Evaluation of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.",Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.,Differentiated Thyroid Carcinoma|Lymph Node Dissection|Lymph Node Metastases,2019-02-17,2020-12-28,2020-12-28,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,"Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University",Procedure,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03845647
2481,NCT03866382,thyroid neoplasms,"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)",Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors,"Bladder Adenocarcinoma|Bladder Clear Cell Adenocarcinoma|Bladder Mixed Adenocarcinoma|Bladder Neuroendocrine Carcinoma|Bladder Small Cell Neuroendocrine Carcinoma|Bladder Squamous Cell Carcinoma|Bladder Urachal Adenocarcinoma|Chromophobe Renal Cell Carcinoma|Collecting Duct Carcinoma|Infiltrating Bladder Lymphoepithelioma-Like Carcinoma|Infiltrating Bladder Urothelial Carcinoma|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Infiltrating Bladder Urothelial Carcinoma With Giant Cells|Kidney Medullary Carcinoma|Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Carcinoma|Metastatic Bladder Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Small Cell Neuroendocrine Carcinoma|Metastatic Bladder Squamous Cell Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Metastatic Kidney Medullary Carcinoma|Metastatic Malignant Genitourinary System Neoplasm|Metastatic Penile Carcinoma|Metastatic Prostate Small Cell Neuroendocrine Carcinoma|Metastatic Sarcomatoid Renal Cell Carcinoma|Metastatic Urethral Carcinoma|Papillary Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IVA Bladder Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Testicular Leydig Cell Tumor|Testicular Sertoli Cell Tumor|Urethral Clear Cell Adenocarcinoma",2019-03-06,2023-02-28,2023-02-28,224.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Mayo Clinic Hospital in Arizona|Mayo Clinic in Arizona|University of Arizona Cancer Center-Orange Grove Campus|Banner University Medical Center - Tucson|University of Arizona Cancer Center-North Campus|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Community Cancer Institute|University Oncology Associates|Epic Care-Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Marin Cancer Care Inc|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|UCLA / Jonsson Comprehensive Cancer Center|Contra Costa Regional Medical Center|USC Norris Oncology/Hematology-Newport Beach|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Pacific Central Coast Health Center-San Luis Obispo|Mission Hope Medical Oncology - Santa Maria|Epic Care Cyberknife Center|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|Porter Adventist Hospital|Mercy Medical Center|Southwest Oncology PC|Saint Anthony Hospital|Littleton Adventist Hospital|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|Parker Adventist Hospital|Saint Mary Corwin Medical Center|MedStar Georgetown University Hospital|Mount Sinai Comprehensive Cancer Center at Aventura|Holy Cross Hospital|Mayo Clinic in Florida|Mount Sinai Medical Center|Orlando Health Cancer Institute|Emory University Hospital Midtown|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|Emory Johns Creek Hospital|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Illinois CancerCare-Bloomington|Loyola Center for Health at Burr Ridge|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Northwestern University|Rush University Medical Center|University of Illinois|University of Chicago Comprehensive Cancer Center|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|Illinois CancerCare-Eureka|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Loyola Medicine Homer Glen|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Good Samaritan Regional Health Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Illinois CancerCare-Pekin|Illinois CancerCare-Peoria|Methodist Medical Center of Illinois|Illinois CancerCare-Peru|Valley Radiation Oncology|Illinois CancerCare-Princeton|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Reid Health|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Alegent Health Mercy Hospital|Greater Regional Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|McFarland Clinic PC-Trinity Cancer Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Mercy Medical Center-West Lakes|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|University of Kansas Clinical Research Center|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|HaysMed University of Kansas Health System|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Olathe Health Cancer Center|Cancer Center of Kansas - Parsons|Ascension Via Christi - Pittsburg|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|Cancer Center of Kansas - Wellington|University of Kansas Hospital-Westwood Cancer Center|Cancer Center of Kansas-Wichita Medical Arts Tower|Ascension Via Christi Hospitals Wichita|Cancer Center of Kansas - Wichita|Cancer Center of Kansas - Winfield|Flaget Memorial Hospital|Commonwealth Cancer Center-Corbin|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|University of Kentucky/Markey Cancer Center|Saint Joseph London|Jewish Hospital|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Jewish Hospital Medical Center South|Hematology/Oncology Clinic PLLC|Ochsner High Grove|Ochsner Medical Center Kenner|East Jefferson General Hospital|LSU Healthcare Network / Metairie Multi-Specialty Clinic|Louisiana State University Health Science Center|Tulane University Health Sciences Center|Ochsner Medical Center Jefferson|Greater Baltimore Medical Center|National Institutes of Health Clinical Center|Lahey Hospital and Medical Center|Lahey Medical Center-Peabody|Mercy Medical Center|Winchester Hospital|Saint Joseph Mercy Hospital|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Henry Ford Macomb Health Center - Shelby Township|Bhadresh Nayak MD PC-Sterling Heights|Ascension Saint Joseph Hospital|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|University of Mississippi Medical Center|Saint Louis Cancer and Breast Institute-Ballwin|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|University of Kansas Cancer Center - Lee's Summit|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Mercy Hospital Washington|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Nebraska Medicine-Bellevue|CHI Health Saint Francis|CHI Health Good Samaritan|Saint Elizabeth Regional Medical Center|Nebraska Methodist Hospital|Nebraska Medicine-Village Pointe|Alegent Health Immanuel Medical Center|Alegent Health Bergan Mercy Medical Center|Alegent Health Lakeside Hospital|Creighton University Medical Center|University of Nebraska Medical Center|Midlands Community Hospital|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Hope Cancer Care of Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|University Cancer Center|Hope Cancer Care of Nevada-Pahrump|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|New York-Presbyterian/Brooklyn Methodist Hospital|Maimonides Medical Center|Roswell Park Cancer Institute|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Northwell Health/Center for Advanced Medicine|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|University of Rochester|State University of New York Upstate Medical University|Memorial Sloan Kettering Nassau|UNC Lineberger Comprehensive Cancer Center|Margaret R Pardee Memorial Hospital|Essentia Health Cancer Center-South University Clinic|Essentia Health - Jamestown Clinic|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Adena Regional Medical Center|University of Cincinnati Cancer Center-UC Medical Center|Good Samaritan Hospital - Cincinnati|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Grady Memorial Hospital|Dublin Methodist Hospital|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Central Ohio Breast and Endocrine Surgery|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|OhioHealth Mansfield Hospital|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|Springfield Regional Cancer Center|Springfield Regional Medical Center|Saint Vincent Mercy Medical Center|Mercy Health - Saint Anne Hospital|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|Saint Joseph Warren Hospital|University of Cincinnati Cancer Center-West Chester|Saint Ann's Hospital|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Mercy Hospital Oklahoma City|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Oregon Health and Science University|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Pocono Medical Center|UPMC Hillman Cancer Center Erie|Saint Vincent Hospital|UPMC Cancer Centers - Arnold Palmer Pavilion|Lehigh Valley Hospital-Hazleton|Jefferson Hospital|Forbes Hospital|UPMC Cancer Center - Monroeville|UPMC Hillman Cancer Center - Monroeville|Arnold Palmer Cancer Center Medical Oncology Norwin|Allegheny Valley Hospital|Allegheny General Hospital|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Shadyside Hospital|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Wexford Health and Wellness Pavilion|Medical University of South Carolina|Vanderbilt-Ingram Cancer Center Cool Springs|University of Tennessee - Knoxville|Vanderbilt Breast Center at One Hundred Oaks|Vanderbilt University/Ingram Cancer Center|Saint Joseph Regional Cancer Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|UT Southwestern Clinical Center at Richardson/Plano|Providence Regional Cancer System-Aberdeen|Overlake Medical Center|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Saint Francis Hospital|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Harrison HealthPartners Hematology and Oncology-Poulsbo|Valley Medical Center|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Franciscan Research Center-Northwest Medical Plaza|Northwest Medical Specialties PLLC|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Aurora Cancer Care-Southern Lakes VLCC|Aurora Saint Luke's South Shore|Marshfield Medical Center-EC Cancer Center|Mayo Clinic Health System-Eau Claire Clinic|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Aurora BayCare Medical Center|Aurora Cancer Care-Kenosha South|Aurora Bay Area Medical Group-Marinette|Marshfield Medical Center-Marshfield|Aurora Cancer Care-Milwaukee|Aurora Saint Luke's Medical Center|Aurora Sinai Medical Center|Marshfield Clinic-Minocqua Center|ProHealth D N Greenwald Center|Cancer Center of Western Wisconsin|ProHealth Oconomowoc Memorial Hospital|Vince Lombardi Cancer Clinic - Oshkosh|Aurora Cancer Care-Racine|Marshfield Medical Center-Rice Lake|Vince Lombardi Cancer Clinic-Sheboygan|Marshfield Clinic Stevens Point Center|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|ProHealth Waukesha Memorial Hospital|UW Cancer Center at ProHealth Care|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center|Marshfield Medical Center - Weston|Billings Clinic-Cody|Welch Cancer Center|Pan American Center for Oncology Trials LLC,Drug|Biological|Biological,Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03866382
2482,NCT03871387,thyroid neoplasms,The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change; Prospective Randomized Control Trial,The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change,Thyroid Neoplasms,2019-02-26,2020-02-24,2020-02-24,88.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03871387
2485,NCT03872284,thyroiditis,Study of Neuro-ophthalmology Disorders in Autoimmune Encephalitis (NODE),Neuro-ophthalmology and Autoimmune Encephalitis (NODE),Autoimmune Encephalitis,2019-03-11,2027-01-24,2027-01-24,70.0,Cohort,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Other,France,18.0,70.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03872284
2486,NCT03878953,hypoparathyroidism,"A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism",A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism,Chronic Hypoparathyroidism,2019-03-15,2023-05-31,2023-05-31,12.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 3,Takeda,Shire,Fujita Health University Hospital|University of Occupational and Environmental Health Japan|Osaka City University Hospital|Shimane University Hospital|Tokushima University Hospital|University of Tokyo Hospital|The Cancer Institute Hospital of JFCR|Toranomon Hospital|Keio University Hospital|Tokyo Women's Medical University Hospital,Drug,Japan,20.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03878953
2488,NCT03880578,hypothyroidism,Influence of Radioiodine Treatment on Thyroid Function and Quality of Life of Patients,Quality of Life After Interventional Thyroid Treatment,Quality of Life|Thyroid; Deficiency,2019-03-14,2022-03-15,2022-03-15,102.0,Cohort,,Prospective,Observational,Completed,,Klinikum Ldenscheid,Klinikum Ldenscheid,Department of Nuclear Medicine Klinikum Luedenscheid,Drug,Germany,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03880578
2489,NCT03884140,thyroid nodule,Clinical Diagnostic Evaluation of Thyroid Nodules,Clinical Diagnostic Approach for Cases of Thyroid Nodules,Thyroid Nodule,2019-03-19,2022-06-01,2022-09-01,1.0,Case-Crossover,,Cross-Sectional,Observational [Patient Registry],Not yet recruiting,,Assiut University,Assiut University,,,,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03884140
2490,NCT03884140,thyroid neoplasms,Clinical Diagnostic Evaluation of Thyroid Nodules,Clinical Diagnostic Approach for Cases of Thyroid Nodules,Thyroid Nodule,2019-03-19,2022-06-01,2022-09-01,1.0,Case-Crossover,,Cross-Sectional,Observational [Patient Registry],Not yet recruiting,,Assiut University,Assiut University,,,,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03884140
2491,NCT03887611,thyroid neoplasms,A Multi-center Study of Differential Diagnosis Thyroid Nodules by Ultrasound Artificial Intelligence and Ultrasound Elastography,Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Thyroid Nodules,Thyroid Nodule,2019-03-21,2020-01-18,2020-03-18,2000.0,Case-Only,,Prospective,Observational,Unknown status,,Tongji Hospital,"Affiliated Hospital of Jiangsu University|Anqing People's Hospital|Enshi State Central Hospital|Huai'an First People's Hospital|Huainan People's Hospital|Huangshi Central Hospital, China|Jiangxia District First People's Hospital|Lianyungang Third People's Hospital|Macheng People's Hospital|Taizhou Hospital|The Central Hospital of Lishui City|The First People's Hospital of Yichang|The Second Hospital of Anhui Medical University|The Second People's Hospital of Yichang|Wenzhou Central Hospital|WISCO General Hospital|Wuhan Hospital of Traditional Chinese and Western Medicine|Xiangyang Central Hospital|Xiangyang First People's Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Xin-Wu Cui|Xuzhou First People's Hospital",Xin-Wu Cui,Device,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03887611
2492,NCT03887611,thyroid nodule,A Multi-center Study of Differential Diagnosis Thyroid Nodules by Ultrasound Artificial Intelligence and Ultrasound Elastography,Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Thyroid Nodules,Thyroid Nodule,2019-03-21,2020-01-18,2020-03-18,2000.0,Case-Only,,Prospective,Observational,Unknown status,,Tongji Hospital,"Affiliated Hospital of Jiangsu University|Anqing People's Hospital|Enshi State Central Hospital|Huai'an First People's Hospital|Huainan People's Hospital|Huangshi Central Hospital, China|Jiangxia District First People's Hospital|Lianyungang Third People's Hospital|Macheng People's Hospital|Taizhou Hospital|The Central Hospital of Lishui City|The First People's Hospital of Yichang|The Second Hospital of Anhui Medical University|The Second People's Hospital of Yichang|Wenzhou Central Hospital|WISCO General Hospital|Wuhan Hospital of Traditional Chinese and Western Medicine|Xiangyang Central Hospital|Xiangyang First People's Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Xin-Wu Cui|Xuzhou First People's Hospital",Xin-Wu Cui,Device,China,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03887611
2493,NCT03889431,goiter,Community Salt Testing and Relation of Iodine Intake to Visual Information Processing of Ethiopian Infants,Community Salt Testing and Relation of Iodine Intake to Visual Information Processing of Ethiopian Infants,Infant Development|Iodine Deficiency Goiter,2019-03-20,2013-01-30,2013-08-10,106.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Oklahoma State University,Oklahoma State University,Hawassa University,Dietary Supplement|Other,Ethiopia,18.0,45.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03889431
2495,NCT03889769,"thyroid cancer, papillary",Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma,Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma,Lymph Node Metastases|Papillary Thyroid Cancer,2019-03-23,2019-04-01,2019-09-30,50.0,Case-Only,,Prospective,Observational,Unknown status,,University of Cagliari,University of Cagliari,Policlinico di Monserrato,Diagnostic Test,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03889769
2496,NCT03891043,goiter,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy to Reduce Its,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy,Thyroid Orbitopathy,2019-03-15,2016-04-30,2016-04-30,33.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Instituto de Oftalmologa Fundacin Conde de Valenciana,Instituto de Oftalmologa Fundacin Conde de Valenciana,,Dietary Supplement|Other,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03891043
2497,NCT03891043,hyperthyroidism,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy to Reduce Its,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy,Thyroid Orbitopathy,2019-03-15,2016-04-30,2016-04-30,33.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Instituto de Oftalmologa Fundacin Conde de Valenciana,Instituto de Oftalmologa Fundacin Conde de Valenciana,,Dietary Supplement|Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03891043
2498,NCT03891043,graves disease,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy to Reduce Its,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy,Thyroid Orbitopathy,2019-03-15,2016-04-30,2016-04-30,33.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Instituto de Oftalmologa Fundacin Conde de Valenciana,Instituto de Oftalmologa Fundacin Conde de Valenciana,,Dietary Supplement|Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03891043
2499,NCT03891043,graves ophthalmopathy,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy to Reduce Its,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy,Thyroid Orbitopathy,2019-03-15,2016-04-30,2016-04-30,33.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Instituto de Oftalmologa Fundacin Conde de Valenciana,Instituto de Oftalmologa Fundacin Conde de Valenciana,,Dietary Supplement|Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03891043
2500,NCT03892993,thyroid neoplasms,"Designing a Decision Aid to Help People With Medullary Thyroid Cancer Make Decisions With Their Doctors About Whether to Start or Stop New Drugs, Enroll in Clinical Trials, or Continue With Active Surveillance","Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers",Thyroid Gland Medullary Carcinoma,2019-02-21,2023-04-19,2024-04-19,120.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03892993
2501,NCT03896958,"thyroid carcinoma, anaplastic",The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology),The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology),"Adenocarcinoma Lung|Adrenal Cancer|Breast Cancer|Bronchoalveolar Cell Lung Cancer|Cancer, Advanced|Cancer, All Types|Cancer, Anal|Cancer, Anaplastic Thyroid|Cancer, Bile Duct|Cancer, Bladder|Cancer Cords Vocal|Cancer Differentiated Poorly|Cancer, Metastatic|Cancer of Brain and Nervous System|Cancer of Cervix|Cancer of Colon|Cancer of Esophagus|Cancer of Head and Neck|Cancer of Kidney|Cancer of Larynx|Cancer of Liver|Cancer of Lung|Cancer of Neck|Cancer of Pancreas|Cancer of Prostate|Cancer of Rectum|Cancer of Stomach|Cancer of Vulva, Disseminated|Cancer, Other|Cancers Cell Neuroendocrine|Cancer Skin|Cancer Unknown Primary|Cholangiocarcinoma|GIST|Glioblastoma Multiforme|Hepatocellular Carcinoma|Melanoma|Oligodendroglioma|Renal Cell Carcinoma|Sarcoma|Small-cell Lung Cancer|Squamous Cell Carcinoma|Testicular Cancer|Transitional Cell Carcinoma|Uterine Cancer",2019-03-26,2024-03-12,2024-03-12,1000.0,Case-Only,,Prospective,Observational,Recruiting,,SpeciCare,Georgia Institute of Technology|Netnoids|Northeast Georgia Hospital System|Predictive Oncology|SpeciCare|University of Washington,Specicare,,United States,1.0,99.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03896958
2502,NCT03898622,hypothyroidism,"Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without Renal Replacement Therapy: Randomized, Double-blind Clinical Trial at Guadalajara Civil Hospital.",Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without TRR.,Chronic Kidney Diseases|Subclinical Hypothyroidism,2018-08-28,2019-01-31,2019-03-01,32.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital Civil de Guadalajara,Hospital Civil de Guadalajara,"Kidney health clinic, Civil Hospital of Guadalajara",Drug,Mexico,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03898622
2504,NCT03899792,"thyroid cancer, papillary",A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors,A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors,Infantile Fibrosarcoma|Infantile Myofibromatosis|Medullary Thyroid Cancer|Papillary Thyroid Cancer|Soft Tissue Sarcoma,2019-02-06,2023-03-26,2024-03-26,100.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Childrens Hospital of Los Angeles|Lucile Packard Children's Hospital|The Children's Hospital for Cancer and Blood Disorders|Nemours Children's Health|Dana-Farber Cancer Institute|University of Minnesota Hospital|Memorial Sloan Kettering Cancer Center|Cincinnati Children's Hospital Medical Center|Children's Hospital of Philadelphia|St. Jude Children's Research Hospital|University of Texas Southwestern Medical Center at Dallas|Texas Childrens Hospital|Seattle Children's Hospital Research Foundation|The Children's Hospital at Westmead|Royal Children's Hospital|The Hospital for Sick Children|Rigshospitalet|Gustave Roussy|Universittsklinikum Heidelberg|Fondazione IRCCS Istituto Nazionale dei Tumori|Hokkaido University Hospital|National Cancer Center Hospital|Hiroshima University Hospital|Kyoto University Hospital|Seoul National University Hospital|Hospital Universitari Vall d'Hebron|University College Hospital - London,Drug,"Australia|Canada|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Spain|United Kingdom|United States",6.0,21.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03899792
2505,NCT03905369,thyroid neoplasms,Focus on Values to Stimulate Shared Decisions in Patients With Thyroid Cancer: A Multifaceted COMmunication BOoster (COMBO),Focus on Values to Stimulate Shared Decisions,Thyroid Cancer,2019-03-21,2022-09-01,2023-03-01,128.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Rijnstate hospital|CWZ|Radboudumc|MUMC|Catharina hospital|AUMC|AVL|Haga|LUMC|UMCG|UMC Utrecht,Other|Other,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03905369
2506,NCT03910049,hypoparathyroidism,Does Indocyanine Imaging Scoring Predicts Postoperative PTH Levels at 24 Hours After Total Thyroidectomy,Does Indocyanine Imaging Scoring Predicts Postoperative Parathormone Levels at 24 Hours After Total Thyroidectomy,Parathyroid; Deficiency|Thyroid,2019-02-19,2019-04-26,2019-04-26,60.0,Cohort,,Prospective,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Endocrine Surgery, Interbalkan Medical Center, Thessaloniki, Greece|1st Propedeutic Department of Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki",Drug,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03910049
2508,NCT03914300,"thyroid cancer, papillary",Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy,"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma,2019-04-11,2023-01-15,2023-01-15,24.0,,Single Group Assignment,,Interventional,Suspended,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|USC Norris Oncology/Hematology-Newport Beach|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|University of Kansas Clinical Research Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|University of Kentucky/Markey Cancer Center|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Truman Medical Centers|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|University of Kansas Cancer Center at North Kansas City Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau|Ohio State University Comprehensive Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|University of Utah Sugarhouse Health Center|Huntsman Cancer Institute/University of Utah,Drug|Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03914300
2509,NCT03914300,"adenocarcinoma, follicular",Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy,"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma,2019-04-11,2023-01-15,2023-01-15,24.0,,Single Group Assignment,,Interventional,Suspended,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|USC Norris Oncology/Hematology-Newport Beach|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|University of Kansas Clinical Research Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|University of Kentucky/Markey Cancer Center|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Truman Medical Centers|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|University of Kansas Cancer Center at North Kansas City Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau|Ohio State University Comprehensive Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|University of Utah Sugarhouse Health Center|Huntsman Cancer Institute/University of Utah,Drug|Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03914300
2511,NCT03922321,hyperthyroidism,"A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy",Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,2019-04-17,2020-02-29,2020-05-21,7.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"UBC/VGH Eye Care Center|Toronto Retina Institute|University of Ottwa Eye Institute|CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont",Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03922321
2512,NCT03922321,graves ophthalmopathy,"A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy",Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,2019-04-17,2020-02-29,2020-05-21,7.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"UBC/VGH Eye Care Center|Toronto Retina Institute|University of Ottwa Eye Institute|CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont",Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03922321
2513,NCT03922321,goiter,"A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy",Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,2019-04-17,2020-02-29,2020-05-21,7.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"UBC/VGH Eye Care Center|Toronto Retina Institute|University of Ottwa Eye Institute|CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont",Drug,Canada,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03922321
2514,NCT03922321,graves disease,"A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy",Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,2019-04-17,2020-02-29,2020-05-21,7.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"UBC/VGH Eye Care Center|Toronto Retina Institute|University of Ottwa Eye Institute|CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont",Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03922321
2515,NCT03924804,thyroid nodule,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Cholecystolithiasis and Thyroid Nodule,2019-04-18,2022-05-12,2022-05-12,90.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"China Medical University, China","China Medical University, China",the First Hospital of China Medical University,Drug|Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03924804
2516,NCT03924804,thyroid neoplasms,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Cholecystolithiasis and Thyroid Nodule,2019-04-18,2022-05-12,2022-05-12,90.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"China Medical University, China","China Medical University, China",the First Hospital of China Medical University,Drug|Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03924804
2517,NCT03926585,hypothyroidism,Longtime Effect of Combination Treatment With L-thyroxine (L-T4) and Liothyronine (L-T3) in Patients With Persistent Hypothyroid Symptoms - Relation to Polymorphisms (SNP) in the DIO2 and the MCT10 Gene,Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment,Hypothyroidism,2019-04-15,2022-04-30,2022-04-30,82.0,Cohort,,Cross-Sectional,Observational,Recruiting,,Herlev Hospital,Birte Nygaard,Herlev Hospital,,Denmark,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03926585
2518,NCT03931109,hyperparathyroidism,Circulating microRNA Signatures in Primary Hyperparathyroidism,Circulating miRNA in Primary Hyperparathyroidism,"Osteoporosis, Postmenopausal|Primary Hyperparathyroidism",2019-04-15,2022-04-30,2022-04-30,100.0,Cohort,,Prospective,Observational [Patient Registry],Active not recruiting,,University of Pennsylvania,University of Pennsylvania,Perelman Center for Advanced Medicine/ Hospital of the University of Pennsylvania,,United States,50.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03931109
2521,NCT03935984,hyperparathyroidism,Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan With Calcitonin Pre-treatment for Primary Hyperparathyroidism,Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity,Hypercalcemia|Primary Hyperparathyroidism,2019-04-30,2021-04-01,2021-10-01,37.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,ProMedica Health System,ProMedica Health System|University of Toledo Health Science Campus,ProMedica Toledo Hospital,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03935984
2524,NCT03937349,hyperparathyroidism,Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients: a Prospective Cohort Study,Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients,Chronic Kidney Disease Mineral and Bone Disorder|Dialysis|Secondary Hyperparathyroidism|Vascular Calcification,2019-05-01,2023-12-31,2023-12-31,60.0,Cohort,,Prospective,Observational,Recruiting,,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia","Saint-Petersburg State University, Clinic of advanced medical technologies n.a. N.I.Pirogov",,Russian Federation,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03937349
2527,NCT03938545,graves ophthalmopathy,"ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy","ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",Graves' Ophthalmopathy (GO),2019-05-01,2021-02-02,2021-04-15,65.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"Multispecialty Aesthetic Clinical Research Organziation (MACRO)|Doheny Eye Center UCLA|University of Miami Miller School of Medicine Bascom Palmer Eye Institute|University of Iowa Hospitals & Clinics - Eye Clinic|University of Michigan - Kellogg Eye Center|Mayo Clinic|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center|University of Rochester Medical Center|Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill|Eye Wellness Center|Eyelid Center of Utah|West Virginia University Eye Institute|University of British Columbia|Toronto Retina Institute|University of Ottawa Eye Institute|Ophthalmology University Center- Hpital Maisonneuve-Rosemont|Universitat Duisburg-Essen|Orbitazentrum Frankfurt|Universittsmedizin Mainz|ARNAS Garibaldi, Presidio di Nesima|Fondazione IRCCS C Granda-Ospedale Maggiore Policlinico|Unit Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana|Hospital Universitari de Bellvitge|Centro de Oftalmologia Barraquer|University Hospital Ramon y Cajal",Drug|Other,Canada|Germany|Italy|Spain|United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03938545
2528,NCT03938545,hyperthyroidism,"ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy","ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",Graves' Ophthalmopathy (GO),2019-05-01,2021-02-02,2021-04-15,65.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"Multispecialty Aesthetic Clinical Research Organziation (MACRO)|Doheny Eye Center UCLA|University of Miami Miller School of Medicine Bascom Palmer Eye Institute|University of Iowa Hospitals & Clinics - Eye Clinic|University of Michigan - Kellogg Eye Center|Mayo Clinic|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center|University of Rochester Medical Center|Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill|Eye Wellness Center|Eyelid Center of Utah|West Virginia University Eye Institute|University of British Columbia|Toronto Retina Institute|University of Ottawa Eye Institute|Ophthalmology University Center- Hpital Maisonneuve-Rosemont|Universitat Duisburg-Essen|Orbitazentrum Frankfurt|Universittsmedizin Mainz|ARNAS Garibaldi, Presidio di Nesima|Fondazione IRCCS C Granda-Ospedale Maggiore Policlinico|Unit Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana|Hospital Universitari de Bellvitge|Centro de Oftalmologia Barraquer|University Hospital Ramon y Cajal",Drug|Other,Canada|Germany|Italy|Spain|United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03938545
2529,NCT03938545,goiter,"ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy","ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",Graves' Ophthalmopathy (GO),2019-05-01,2021-02-02,2021-04-15,65.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"Multispecialty Aesthetic Clinical Research Organziation (MACRO)|Doheny Eye Center UCLA|University of Miami Miller School of Medicine Bascom Palmer Eye Institute|University of Iowa Hospitals & Clinics - Eye Clinic|University of Michigan - Kellogg Eye Center|Mayo Clinic|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center|University of Rochester Medical Center|Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill|Eye Wellness Center|Eyelid Center of Utah|West Virginia University Eye Institute|University of British Columbia|Toronto Retina Institute|University of Ottawa Eye Institute|Ophthalmology University Center- Hpital Maisonneuve-Rosemont|Universitat Duisburg-Essen|Orbitazentrum Frankfurt|Universittsmedizin Mainz|ARNAS Garibaldi, Presidio di Nesima|Fondazione IRCCS C Granda-Ospedale Maggiore Policlinico|Unit Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana|Hospital Universitari de Bellvitge|Centro de Oftalmologia Barraquer|University Hospital Ramon y Cajal",Drug|Other,Canada|Germany|Italy|Spain|United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03938545
2530,NCT03938545,graves disease,"ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy","ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",Graves' Ophthalmopathy (GO),2019-05-01,2021-02-02,2021-04-15,65.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"Multispecialty Aesthetic Clinical Research Organziation (MACRO)|Doheny Eye Center UCLA|University of Miami Miller School of Medicine Bascom Palmer Eye Institute|University of Iowa Hospitals & Clinics - Eye Clinic|University of Michigan - Kellogg Eye Center|Mayo Clinic|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center|University of Rochester Medical Center|Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill|Eye Wellness Center|Eyelid Center of Utah|West Virginia University Eye Institute|University of British Columbia|Toronto Retina Institute|University of Ottawa Eye Institute|Ophthalmology University Center- Hpital Maisonneuve-Rosemont|Universitat Duisburg-Essen|Orbitazentrum Frankfurt|Universittsmedizin Mainz|ARNAS Garibaldi, Presidio di Nesima|Fondazione IRCCS C Granda-Ospedale Maggiore Policlinico|Unit Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana|Hospital Universitari de Bellvitge|Centro de Oftalmologia Barraquer|University Hospital Ramon y Cajal",Drug|Other,Canada|Germany|Italy|Spain|United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03938545
2533,NCT03941184,goiter,Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjgren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",2019-04-01,2020-11-10,2020-11-10,114.0,Case-Control,,Retrospective,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,110.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03941184
2534,NCT03941184,hyperthyroidism,Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjgren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",2019-04-01,2020-11-10,2020-11-10,114.0,Case-Control,,Retrospective,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,110.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03941184
2535,NCT03941184,"thyroiditis, autoimmune",Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjgren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",2019-04-01,2020-11-10,2020-11-10,114.0,Case-Control,,Retrospective,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,110.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03941184
2536,NCT03941184,graves disease,Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjgren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",2019-04-01,2020-11-10,2020-11-10,114.0,Case-Control,,Retrospective,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,110.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03941184
2537,NCT03942380,thyroid neoplasms,Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer,Cell-free Tumor DNA in Head and Neck Cancer Patients,Head and Neck Cancer|Head and Neck Neoplasms|Head and Neck Squamous Cell Carcinoma|Hypopharynx Cancer|Hypopharynx Carcinoma|Hypopharynx Neoplasm|Larynx Cancer|Larynx Carcinoma|Larynx Neoplasm|Nasopharyngeal Cancer|Nasopharyngeal Carcinoma|Nasopharynx Neoplasm|Oral Cancer|Oral Cavity Cancer|Oral Neoplasm|Oropharynx Cancer|Oropharynx Carcinoma|Oropharynx Neoplasm|Salivary Gland Cancer|Salivary Gland Carcinoma|Salivary Gland Neoplasms|Sinonasal Cancer|Sinonasal Carcinoma|Sinonasal Neoplasm|Thyroid Cancer|Thyroid Carcinoma|Thyroid Neoplasms,2019-04-15,2025-02-01,2025-02-01,500.0,,Sequential Assignment,,Interventional,Recruiting,Not Applicable,"Rigshospitalet, Denmark","Christian von Buchwald|Copenhagen University Hospital, Denmark|Department of Otorhinolaryngology, Head and Neck Surgery and Audiology","University Hospital of Copenhagen, Rigshospitalet",Diagnostic Test,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03942380
2538,NCT03948191,goiter,"A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.",99Tc-MDP for Thyroid-Associated Ophthalmopathy,Thyroid-Associated Ophthalmopathy,2019-05-10,2018-12-30,2019-03-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Dalian University,Dalian University,Affiliated Zhongshan Hospital of Dalian University,Drug|Drug,China,18.0,76.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03948191
2539,NCT03948191,graves disease,"A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.",99Tc-MDP for Thyroid-Associated Ophthalmopathy,Thyroid-Associated Ophthalmopathy,2019-05-10,2018-12-30,2019-03-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Dalian University,Dalian University,Affiliated Zhongshan Hospital of Dalian University,Drug|Drug,China,18.0,76.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03948191
2540,NCT03948191,graves ophthalmopathy,"A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.",99Tc-MDP for Thyroid-Associated Ophthalmopathy,Thyroid-Associated Ophthalmopathy,2019-05-10,2018-12-30,2019-03-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Dalian University,Dalian University,Affiliated Zhongshan Hospital of Dalian University,Drug|Drug,China,18.0,76.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03948191
2541,NCT03948191,hyperthyroidism,"A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.",99Tc-MDP for Thyroid-Associated Ophthalmopathy,Thyroid-Associated Ophthalmopathy,2019-05-10,2018-12-30,2019-03-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Dalian University,Dalian University,Affiliated Zhongshan Hospital of Dalian University,Drug|Drug,China,18.0,76.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03948191
2542,NCT03951532,hyperthyroidism,Morbidity and Mortality Associated With the Care Journey in Children and Adolescents With Hyperthyroidism,Morbidity and Mortality Associated With the Care Journey in Children and Adolescents With Hyperthyroidism,Hyperthyroidism,2019-03-12,2020-12-31,2020-12-31,1650.0,Cohort,,Retrospective,Observational,Completed,,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Hpital Robert Debr,,France,6.0,17.0,[0-17],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03951532
2545,NCT03957616,hashimoto disease,Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018,Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2019-05-17,2019-05-30,2019-07-31,600.0,Cohort,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de rfrence des syndromes neurologiques paranoplasiques et encphalites auto-immunes,,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03957616
2548,NCT03960437,hyperparathyroidism,The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease,The Effect of Etelcalcetide on CKD-MBD,"Chronic Kidney Disease Mineral and Bone Disorder|Hyperparathyroidism; Secondary, Renal|Renal Osteodystrophy|Vascular Calcification",2019-05-21,2021-12-31,2021-12-31,35.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Columbia University,"Thomas Nickolas, MD MS",Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03960437
2551,NCT03960554,hyperparathyroidism,"The Effects of 12-months of Denosumab on Bone Density, Quality and Strength in Prevalent Kidney Transplant Recipients",The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients,Kidney Transplant; Complications|Osteoporosis|Renal Osteodystrophy,2019-05-21,2021-12-02,2021-12-02,15.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Columbia University,"Thomas Nickolas, MD MS","Northwestern University, Feinburg School of Medicine|NorthShore University HealthSystem|Columbia University Medical Center",Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03960554
2554,NCT03968510,hyperparathyroidism,The Effect of Parathyroidectomy on Swallowing Related Quality of Life in Primary Hyperparathyroidism,Swalqol in Primary Hyperparathyroidism,Hyperparathyroidism,2019-03-20,2020-07-01,2020-11-01,150.0,Case-Crossover,,Prospective,Observational [Patient Registry],Completed,,Uak University,Uak University,Uak University,Procedure,Turkey,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03968510
2555,NCT03969108,graves disease,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Graves Disease|Thyroid Cancer|Thyroid Goiter,2019-05-24,2019-11-12,2019-11-13,10.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University Health Network, Toronto","University Health Network, Toronto",University Health Network,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03969108
2556,NCT03969108,goiter,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Graves Disease|Thyroid Cancer|Thyroid Goiter,2019-05-24,2019-11-12,2019-11-13,10.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University Health Network, Toronto","University Health Network, Toronto",University Health Network,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03969108
2557,NCT03969108,hyperthyroidism,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Graves Disease|Thyroid Cancer|Thyroid Goiter,2019-05-24,2019-11-12,2019-11-13,10.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University Health Network, Toronto","University Health Network, Toronto",University Health Network,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03969108
2558,NCT03969108,thyroid neoplasms,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Graves Disease|Thyroid Cancer|Thyroid Goiter,2019-05-24,2019-11-12,2019-11-13,10.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University Health Network, Toronto","University Health Network, Toronto",University Health Network,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03969108
2560,NCT03969329,hyperparathyroidism,"Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents  2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis,Secondary Hyperparathyroidism,2019-05-29,2026-08-02,2026-08-02,20.0,,Single Group Assignment,,Interventional,Recruiting,Phase 3,Amgen,Amgen,"Universitair Ziekenhuis Gent|Fakultni nemocnice v Motole|Hospices Civils de Lyon Hopital Femme Mere Enfant|Hpital Armand Trousseau|Kindernierenzentrum Bonn|Universittsklinikum Hamburg-Eppendorf|Medizinische Hochschule Hannover|Zentrum fr Kinder und Jugendmedizin des Universittsklinikums Heidelberg|Universittsklinikum Kln|General Children Hospital Panagioti and Aglaias Kyriakou|Ippokrateio General Hospital of Thessaloniki|Semmelweis Egyetem|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar|Azienda Ospedaliera Universitaria Meyer|Childrens Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos|Uniwersytecki Szpital Dzieciecy w Krakowie|Centro Hospitalar Universitario do Porto - Hospital de Santo Antonio|Hospital Universitari Vall d Hebron|Royal Hospital for Sick Children|Great Ormond Street Hospital for Children",Drug,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Lithuania|Poland|Portugal|Spain|United Kingdom,2.0,17.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03969329
2562,NCT03973450,hyperparathyroidism,"Epidemiology of Pituitary Tumours: Prevalence of Associated Endocrine and Non-endocrine Tumours and Potential Implications in the Management and Follow-up of Patients""",Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia,Endocrine Neoplasia|Familial Tumor Syndrome|Hyperparathyroidism|Pituitary Tumor|Solid Tumor,2019-05-25,2021-11-30,2022-02-28,400.0,Cohort,,Retrospective,Observational,Recruiting,,Neuromed IRCCS,Neuromed IRCCS,Neuromed,Other,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03973450
2564,NCT03975231,"thyroid carcinoma, anaplastic",A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer,"Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",BRAF NP_004324.2:p.V600E|BRAF V600K Mutation Present|Thyroid Gland Anaplastic Carcinoma,2019-06-03,2025-04-30,2025-04-30,6.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center|Ohio State University Comprehensive Cancer Center,Drug|Radiation|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03975231
2566,NCT03977207,hypothyroidism,A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients,A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients,Hemodialysis|Hypothyroidism|Thyroid; Functional Disturbance,2019-05-28,2024-06-30,2024-06-30,336.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of California, Irvine","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Irvine",University of California Irvine,Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03977207
2567,NCT03978351,thyroid neoplasms,The Role of Midkine in Diagnosis of Thyroid Cancer,The Role of Midkine in Diagnosis of Thyroid Cancer,Thyroid Cancer,2018-11-24,2020-11-30,2020-12-31,85.0,Case-Control,,Retrospective,Observational,Unknown status,,Assiut University,Assiut University,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03978351
2568,NCT03980132,goiter,"Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.",Preoperative Preparation With Lugol Solution in Patients With Graves-Basedow Disease.,"Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,270.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa,Jess Mara Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clnico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clnico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Maran|Hospital Universitario Ramn y Cajal|Hospital Universitario Fundacin Jimnez Daz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Roco|Hospital Clnico Universitario|Hospital Clnico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03980132
2569,NCT03980132,graves disease,"Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.",Preoperative Preparation With Lugol Solution in Patients With Graves-Basedow Disease.,"Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,270.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa,Jess Mara Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clnico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clnico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Maran|Hospital Universitario Ramn y Cajal|Hospital Universitario Fundacin Jimnez Daz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Roco|Hospital Clnico Universitario|Hospital Clnico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03980132
2570,NCT03980132,hyperthyroidism,"Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.",Preoperative Preparation With Lugol Solution in Patients With Graves-Basedow Disease.,"Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,270.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa,Jess Mara Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clnico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clnico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Maran|Hospital Universitario Ramn y Cajal|Hospital Universitario Fundacin Jimnez Daz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Roco|Hospital Clnico Universitario|Hospital Clnico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03980132
2571,NCT03986437,thyroid neoplasms,A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.,A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.,Differentiated Thyroid Cancer,2019-06-11,2021-05-21,2021-05-21,29.0,Cohort,,Prospective,Observational,Completed,,Institut Claudius Regaud,Institut Claudius Regaud,IUCT-O,,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03986437
2572,NCT03986593,thyroid neoplasms,Cone-beam Computed Tomography Guided Percutaneous Cryoablation of Bone Metastases From Endocrine Tumors,Cryoablation of Bone Metastases From Endocrine Tumors,Adrenal Neoplasm|Bone Metastases|Neoplasm Metastasis|Neuroendocrine Tumors|Pheochromocytoma|Thyroid Neoplasm,2019-05-22,2022-06-15,2023-06-15,30.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Instituto do Cancer do Estado de So Paulo,Instituto do Cancer do Estado de So Paulo|University of Sao Paulo General Hospital,Instituto do Cancer do Estado de So Paulo,Device,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03986593
2573,NCT03988517,hypothyroidism,A Prospective Study Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan,Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan,Hypothyroidism,2019-06-11,2018-01-08,2018-01-08,106.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hamad Medical Corporation,Hamad Medical Corporation,Hamad General Hospital,Other,Qatar,18.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03988517
2577,NCT04000880,thyroid neoplasms,Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health,Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health,Breast Cancer|Colorectal Cancer|Endometrial Cancer|Kidney Cancer|Multiple Myeloma|Non-Hodgkin Lymphoma|Ovary Cancer|Prostate Cancer|Thyroid Cancer,2019-06-21,2024-08-31,2024-08-31,652.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Alabama at Birmingham,National Cancer Institute (NCI)|University of Alabama at Birmingham|University of Tennessee Health Science Center,University of Alabama at Birmingham|University of Tennessee Health Science Center,Behavioral|Other|Other|Other,United States,50.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04000880
2578,NCT04009291,hypoparathyroidism,"PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism","A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism",Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,2019-06-20,2020-03-06,2023-03-31,40.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Ascendis Pharma A/S,Ascendis Pharma A/S,Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site,Combination Product|Combination Product,Canada|Denmark|Germany|Italy|Norway|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04009291
2580,NCT04009863,goiter,"A Randomized, Open-label, Parallel-group Study to Determine the Efficacy of Sequential High-intensity Focused Ultrasound (HIFU) Ablation Versus Fixed-dose Radioiodine-131 Therapy in Moderate-sized Non-toxic Multinodular Goiter",HIFU Ablation vs Fixed-dose RAI-131 Therapy in Moderate-sized Non-toxic MNG,High Intensity Focused Ultrasound|Non Toxic Multinodular Goiter|RAI,2019-06-26,2022-02-20,2022-04-30,156.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device|Radiation,Hong Kong,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04009863
2582,NCT04012476,hypoparathyroidism,Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy,Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy,Hypocalcemia|Hypoparathyroidism Postprocedural|Total Thyroidectomy,2019-06-28,2020-03-31,2020-10-31,40.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,Hospital Son Espases,Hospital Son Espases|Universitat de les Illes Balears,Hospital Universitari Son Espases,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04012476
2583,NCT04013100,parathyroid neoplasms,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Primary Hyperparathyroidism,2019-07-05,2029-12-31,2029-12-31,800.0,Cohort,,Prospective,Observational [Patient Registry],Not yet recruiting,,IHU Strasbourg,IHU Strasbourg,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04013100
2586,NCT04013100,hyperparathyroidism,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Primary Hyperparathyroidism,2019-07-05,2029-12-31,2029-12-31,800.0,Cohort,,Prospective,Observational [Patient Registry],Not yet recruiting,,IHU Strasbourg,IHU Strasbourg,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04013100
2589,NCT04013139,hyperparathyroidism,Evaluation of the Relationship Between Cardiopulmonary Exercise Testing (CPET ) Abnormalities and Ca-P Status in CKD Stage3-5,Relationship Between Cardiopulmonary Exercise Testing and Ca-P in Chronic Kidney Disease (CKD),Ckd-Mbd,2019-06-23,2021-08-01,2021-10-01,200.0,Cohort,,Prospective,Observational,Completed,,Shahid Beheshti University of Medical Sciences,Shahid Beheshti University of Medical Sciences,Nooshin Dalili,Diagnostic Test,"Iran, Islamic Republic of",18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04013139
2591,NCT04019379,hyperparathyroidism,Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease,Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease,Chronic Kidney Disease Mineral and Bone Disorder|Chronic Kidney Diseases|Phosphorus and Calcium Disorders,2019-07-09,2020-10-28,2022-12-01,3.0,,Crossover Assignment,,Interventional,Active not recruiting,Not Applicable,University of Minnesota,Indiana University|University of Minnesota,Indiana CTSI CRC,Other|Other,United States,30.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04019379
2593,NCT04025034,graves ophthalmopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression With Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy,"Exophthalmos|Orbitopathy, Graves|Surgery",2019-07-15,2017-12-31,2019-01-01,35.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospital Universitario 12 de Octubre,Hospital del Ro Hortega|Hospital Universitario 12 de Octubre|The Queen Elizabeth Hospital,,Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04025034
2594,NCT04025034,graves disease,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression With Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy,"Exophthalmos|Orbitopathy, Graves|Surgery",2019-07-15,2017-12-31,2019-01-01,35.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospital Universitario 12 de Octubre,Hospital del Ro Hortega|Hospital Universitario 12 de Octubre|The Queen Elizabeth Hospital,,Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04025034
2595,NCT04025034,goiter,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression With Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy,"Exophthalmos|Orbitopathy, Graves|Surgery",2019-07-15,2017-12-31,2019-01-01,35.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospital Universitario 12 de Octubre,Hospital del Ro Hortega|Hospital Universitario 12 de Octubre|The Queen Elizabeth Hospital,,Procedure,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04025034
2596,NCT04025034,hyperthyroidism,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression With Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy,"Exophthalmos|Orbitopathy, Graves|Surgery",2019-07-15,2017-12-31,2019-01-01,35.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospital Universitario 12 de Octubre,Hospital del Ro Hortega|Hospital Universitario 12 de Octubre|The Queen Elizabeth Hospital,,Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04025034
2598,NCT04028479,parathyroid neoplasms,The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT),The Registry of Oncology Outcomes Associated With Testing and Treatment,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adenocarcinoma|Adenocystic Carcinoma|Adrenal Cancer|Anal Cancer|Appendix Cancer|Astrocytoma|Bile Duct Cancer|Bladder Cancer|Bone Cancer|Brain Stem Neoplasms|Brain Tumor|Breast Cancer|Cancer, Advanced|Cancer of Colon|Cancer of Pancreas|Carcinoid Tumor|Cervical Cancer|Cholangiocarcinoma|Chondrosarcoma|Chronic Myeloid Leukemia|CNS Cancer|Colon Cancer|Colorectal Cancer|Esophageal Cancer|Esophagus Cancer|Fallopian Tube Cancer|Gestational Trophoblastic Tumor|Glioblastoma|Head and Neck Neoplasms|Hepatic Cancer|Kidney Cancer|Larynx Cancer|Liposarcoma|Liver Cancer|Lung Cancer|Melanoma|Mesothelioma|Multiple Endocrine Neoplasia|Multiple Myeloma|Nasopharyngeal Carcinoma|Neuroendocrine Tumors|Non Hodgkin Lymphoma|Osteosarcoma|Ovarian Cancer|Pancreatic Cancer|Parathyroid Neoplasms|Parotid Tumor|Penile Cancer|Pharynx Cancer|Pheochromocytoma|Prostate Cancer|Pulmonary Carcinoma|Rectal Cancer|Renal Cell Carcinoma|Salivary Gland Cancer|Sarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Skin Cancer|Small Bowel Cancer|Small Cell Carcinoma|Stomach Cancer|Synovial Sarcoma|Testicular Cancer|Testis Cancer|Thymus Cancer|Thyroid Cancer|Tongue Cancer|Unknown Primary Tumors|Ureter Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia",2019-07-17,2029-10-01,2031-10-01,100000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Taproot Health,Taproot Health,Teton Cancer Institute,Diagnostic Test|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04028479
2599,NCT04031339,thyroid neoplasms,"Multicenter, Prospective, Observational Study of Clinical Outcomes of Thyroid Cancer",Study of Clinical Outcomes of Thyroid Cancer,Thyroid Neoplasms,2019-06-25,2025-01-31,2025-01-31,15000.0,Cohort,,Prospective,Observational,Recruiting,,University of Roma La Sapienza,Catholic University of the Sacred Heart|Italian Thyroid Cancer Observatory (ITCO) Foundation|University of Roma La Sapienza,"Ospedali Riuniti di Ancona|Universit degli Studi di Bari|Azienda Unit Sanitaria di Bologna - Ospedale Maggiore|University of Bologna, S. Orsola Malpighi Hospital|ASST Valle Olona - Ospedale di Busto Arsizio|University of Florence|Ente Ospedaliero Ospedali Galliera|Sapienza University of Rome, Santa Maria Goretti Hospital|Tinchi Pisticci Hospital|University of Milan, Fondazione IRCCS, National Cancer Institute of Milan|University of Modena and Reggio Emilia|University of Naples Federico II|University of Parma|Bio-Medical Campus University|Sapienza University of Rome, Sant'Andrea Hospital|Sapienza University of Rome|University of Siena|University of Turin, Gradenigo Hospital|University of Turin, Molinette Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04031339
2600,NCT04031638,thyroid neoplasms,Prospective and Retrospective Thyroid Cancer Database,Thyroid Cancer Database,Patients With a Thyroid Tumor Who Received Radioactive Iodine Treatment,2019-07-01,2025-01-01,2025-01-01,2300.0,Cohort,,Prospective,Observational,Recruiting,,Centre Georges Francois Leclerc,Centre Georges Francois Leclerc,"Methodology, Biostatistics and Data Management",Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04031638
2601,NCT04040673,thyroid neoplasms,Evaluation of the Role of Vibrational Spectroscopy in the Diagnosis of Premalignant and Malignant Disease of the Thyroid RAFTER (RAman For Thyroid cancER),RAman For Thyroid cancER,Thyroid Cancer|Thyroid Diseases,2019-07-29,2022-10-01,2022-10-01,40.0,Case-Only,,Retrospective,Observational,Not yet recruiting,,Gloucestershire Hospitals NHS Foundation Trust,Gloucestershire Hospitals NHS Foundation Trust,Biophotonics Research Unit,Procedure|Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04040673
2602,NCT04040946,parathyroid neoplasms,Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,F18-choline|Hyperparathyroidism|Parathyroid Adenoma,2019-07-29,2022-05-05,2023-03-31,58.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|Fondation de l'Avenir,CHU Brest|Centre Franois Baclesse|Centre Eugne Marquis|CHU,Diagnostic Test|Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04040946
2605,NCT04040946,hyperparathyroidism,Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,F18-choline|Hyperparathyroidism|Parathyroid Adenoma,2019-07-29,2022-05-05,2023-03-31,58.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|Fondation de l'Avenir,CHU Brest|Centre Franois Baclesse|Centre Eugne Marquis|CHU,Diagnostic Test|Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04040946
2606,NCT04046354,thyroid neoplasms,Clinical Trial of Microwave Ablation System,Microwave vs. Radiofrequency Ablation for Benign Thyroid Nodules: A Multicenter Randomized Controlled Trial Study,Ablation|Benign Thyroid Nodules,2019-08-05,2020-11-19,2021-12-31,149.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Device|Device,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04046354
2607,NCT04046354,thyroid nodule,Clinical Trial of Microwave Ablation System,Microwave vs. Radiofrequency Ablation for Benign Thyroid Nodules: A Multicenter Randomized Controlled Trial Study,Ablation|Benign Thyroid Nodules,2019-08-05,2020-11-19,2021-12-31,149.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Device|Device,China,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04046354
2608,NCT04051099,hyperparathyroidism,Bilateral Superficial Cervical Plexus Block Combined With Intravenous Sedation Versus General Anesthesia in Selected Patients for Thyroid/Parathyroid Surgery ; a Prospective Randomized Control Trial,Bilateral Superficial Cervical Plexus Block in Thyroid/Parathyroid Surgery,Benign Tumor of Thyroid|Hyperparathyroidism,2018-03-27,2021-09-30,2021-12-15,52.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure|Drug|Procedure|Procedure,Thailand,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04051099
2610,NCT04053114,struma ovarii,MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii,MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii,Ovarian Cancer,2019-07-04,2019-12-31,2020-05-31,20.0,Other,,Retrospective,Observational,Unknown status,,Institut Bergoni,Institut Bergoni,Institut Bergoni,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Struma ovarii,https://clinicaltrials.gov/ct2/show/NCT04053114
2612,NCT04053647,hypoparathyroidism,Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy,Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy (Qol-Hypopara),Hypoparathyroidism|Quality of Life,2019-05-22,2020-06-24,2020-06-24,143.0,Case-Control,,Prospective,Observational,Completed,,Nantes University Hospital,"Central Hospital, Nancy, France|Centre Hospitalier le Mans|Nantes University Hospital|Piti-Salptrire Hospital|University Hospital, Angers|University Hospital, Limoges",CHU Angers|Centre Hospitalier Le Mans|CHU Limoges|CHU Nancy|CHU Nantes|AP-HP La Piti Salptrire,Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04053647
2615,NCT04059380,hypoparathyroidism,Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism: The EMPATHY Study,Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism (EMPATHY),Hypoparathyroidism|Hypoparathyroidism Due to Impaired Parathormone Secretion|Hypoparathyroidism Postprocedural,2019-08-14,2020-06-30,2020-07-31,40.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,University of Roma La Sapienza,University of Roma La Sapienza,"Department of Experimental Medicine, ""Sapienza"" University of Rome",,Italy,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04059380
2616,NCT04061980,thyroid neoplasms,Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer,Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer,BRAF NP_004324.2:p.V600M|BRAF V600E Mutation Present|Metastatic Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8,2019-08-18,2022-07-30,2024-08-01,40.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Providence Health & Services,Providence Health & Services,Providence Portland Medical Center,Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04061980
2618,NCT04064827,hyperparathyroidism,"A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis","A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)",Chronic Kidney Disease (CKD)|Secondary Hyperparathyroidism (SHPT),2019-08-20,2024-03-09,2026-10-30,16.0,,Single Group Assignment,,Interventional,Recruiting,Phase 3,AbbVie,AbbVie,"Arkansas Children's Hospital /ID# 225417|University of California, Los Angeles /ID# 140668|Children's National Medical Center /ID# 225991|Holtz Childrens Hospital, University of Miami /ID# 225636|Nicklaus Children's Hospital /ID# 210517|Emory Midtown Infectious Disease Clinic /ID# 140665|Boston Children's Hospital /ID# 162863|Levine Children's Specialty Center- Charlotte /ID# 216057|Children's Hospital of Philadelphia - Main /ID# 213802|University of Texas Southwestern Medical Center /ID# 210495|University of Utah /ID# 140669|Seattle Children's Hospital /ID# 162861|School of Medicine University of Puerto Rico-Medical Science Campus /ID# 140663",Drug,Puerto Rico|United States,0.0,9.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04064827
2620,NCT04072731,thyroid neoplasms,SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer,SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer,Thyroid Cancer,2018-01-16,2017-07-30,2018-01-01,140.0,Cohort,,Retrospective,Observational,Completed,,People's Hospital of Zhengzhou University,People's Hospital of Zhengzhou University,the Affiliated Cancer Hospital of Xiangya Medical School,Other,China,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04072731
2623,NCT04075851,hashimoto disease,The Prevalence of Serum Thyroid Hormone Autoantibodies in Autoimmune Thyroid Diseases,The Prevalence of Serum Thyroid Hormone Autoantibodies in Autoimmune Thyroid Diseases,Autoimmune Thyroid Disease,2019-08-29,2022-08-01,2022-08-01,600.0,Cohort,,Cross-Sectional,Observational,Recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Province Hospital,,China,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04075851
2625,NCT04076514,"thyroid cancer, papillary",The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma,The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma,Papillary Thyroid Cancer,2019-08-28,2020-09-30,2020-11-01,20.0,Case-Only,,Prospective,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Kamel,Procedure,Egypt,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04076514
2626,NCT04080505,hyperthyroidism,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04080505
2627,NCT04080505,goiter,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04080505
2628,NCT04080505,graves disease,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04080505
2629,NCT04085419,hyperparathyroidism,Management of Osteoporosis in Patients With Primary Hyperparathyroidism,Osteoporosis in Primary Hyperparathyroidism,Osteoporosis|Primary Hyperparathyroidism,2019-09-02,2022-05-31,2022-05-31,40.0,,Parallel Assignment,,Interventional,Enrolling by invitation,Phase 4,University Medical Centre Ljubljana,University Medical Centre Ljubljana,Endocrinology Department,Drug|Drug,Slovenia,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04085419
2633,NCT04085913,parathyroid neoplasms,Intraoperative Injection of Exparel Effect on Postoperative Opioid Use in Thyroid and Parathyroid Surgery,Exparel Injection Effect on Postoperative Opioid Usage,Parathyroid Adenoma|Thyroid,2019-06-21,2023-07-31,2023-07-31,100.0,,Crossover Assignment,,Interventional,Enrolling by invitation,Early Phase 1,University of Missouri-Columbia,University of Missouri-Columbia,University of Missouri,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04085913
2634,NCT04096612,hyperthyroidism,The Therapeutic Effect of Dysthyroid Optic Neuropathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,Thyroid Eye Disease,2018-12-27,2018-12-31,2019-12-31,20.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Opthalmic Center,Procedure,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04096612
2635,NCT04096612,graves ophthalmopathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,Thyroid Eye Disease,2018-12-27,2018-12-31,2019-12-31,20.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Opthalmic Center,Procedure,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04096612
2636,NCT04096612,graves disease,The Therapeutic Effect of Dysthyroid Optic Neuropathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,Thyroid Eye Disease,2018-12-27,2018-12-31,2019-12-31,20.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Opthalmic Center,Procedure,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04096612
2637,NCT04096612,goiter,The Therapeutic Effect of Dysthyroid Optic Neuropathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,Thyroid Eye Disease,2018-12-27,2018-12-31,2019-12-31,20.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Opthalmic Center,Procedure,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04096612
2638,NCT04098991,hypothyroidism,Improving White Matter Integrity With Thyroid Hormone,Improving White Matter Integrity With Thyroid Hormone,Hypothyroidism,2018-02-27,2019-11-08,2019-11-08,5.0,Cohort,,Prospective,Observational,Completed,,University of Illinois at Chicago,National Institute of Neurological Disorders and Stroke (NINDS)|University of Illinois at Chicago,University of Illinois at Chicago,Drug,United States,21.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04098991
2639,NCT04104529,thyroid neoplasms,Establishment of a Monocentric and Prospective Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department,Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department,Neuroendocrine Tumors|Prostate Cancer|Thyroid Cancer,2019-09-24,2024-10-31,2024-10-31,350.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Institut du Cancer de Montpellier - Val d'Aurelle,Institut du Cancer de Montpellier - Val d'Aurelle,Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04104529
2642,NCT04106596,"thyroiditis, autoimmune",Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis,HLA Analysis in Autoimmune Encephalitis and Related Disorders,Autoimmune Cerebellar Ataxia|Autoimmune Encephalitis|Imbic Encephalitis|Stiff-person Syndrome,2019-09-25,2020-02-01,2020-10-01,160.0,Case-Control,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de rfrence des syndromes neurologiques paranoplasiques et encphalites auto-immunes,,France,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04106596
2643,NCT04106843,thyroid neoplasms,"A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma","Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers",Locally Advanced Adrenal Gland Pheochromocytoma|Locally Advanced Paraganglioma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Paraganglioma|Metastatic Parathyroid Gland Carcinoma|Pituitary Gland Carcinoma|Somatostatin Receptor Positive|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Unresectable Adrenal Gland Pheochromocytoma|Unresectable Paraganglioma,2019-09-25,2020-09-03,2020-09-03,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04106843
2644,NCT04124705,hypothyroidism,"A Multicenter, Randomized, Double-blind, Dose-conversion Study to Evaluate the Safety and Efficacy of Hormone Replacement Therapy With Armour Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants Who Are Euthyroid on T4 Replacement Therapy",A Study of Armour Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants,Euthyroid|Hypothyroidism|Thyroid Disease|Thyroid Gland|Thyroid Hormones,2019-10-10,2021-06-22,2021-06-22,284.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Allergan,Allergan,"Central Research Associates /ID# 237950|Atria Clinical Research /ID# 237986|NorCal Medical Research Inc /ID# 235210|Diabetes-Lipid Management & Research Center /ID# 235716|Center for Excellence in Diabetes and Endocrinology /ID# 238120|Care Access Research /ID# 238026|San Fernando Valley Health Institute /ID# 238258|Creekside Endocrine Associates PC /ID# 235866|The Center for Diabetes and Endocrine Care /ID# 235853|Metabolic Research Inst /ID# 236809|Atlanta Diabetes Associates /ID# 235032|Columbus Regional Research Ins /ID# 237199|Physicians Research Associates, LLC /ID# 238088|Kentucky Diabetes Endocrinology Center /ID# 235714|L-MARC Research Center /ID# 236701|Mountain Diabetes and Endocrine Center /ID# 235202|Physician's East Endocrinology /ID# 235204|OnSite Clinical Solutions, LLC - Hickory /ID# 238023|Texas Diabetes and Endocrinology - Central Austin /ID# 237137|Texas Diabetes and Endocrinology - South Austin /ID# 238071|North TX Endocrine Center /ID# 237652|Research Institute Dallas /ID# 237655|Academy of Diabetes Thyroid and Endocrine /ID# 235870|Texas Diabetes & Endocrinology /ID# 235860|Diabetes & Glandular Disease Clinic P.A. /ID# 235894|Rainier Clinical Research Center LLC /ID# 235211|MultiCare Institute for Research & Innovation /ID# 236022|Multicare Institute for Research and Innovation /ID# 236977",Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04124705
2645,NCT04126941,hypoparathyroidism,Bi-daily Injection of Subcutaneous Teriparatide in Children With Hypoparathyroidism: Single-center Experience,Monocentric Study on the Use of Teriparatide in Children With hypoparathyrodism,Hypoparathyroidism,2019-10-11,2020-06-30,2020-12-31,9.0,Cohort,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Service de Nphrologie, Rhumatologie et Dermatologie Pdiatriques - Hpital Femme Mre Enfant",Other,France,2.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04126941
2647,NCT04126954,hyperparathyroidism,Multicentric Retrospective Study on the Use of Cinacalcet in an Off-label Phosphocalcic Context,Study on the Use of Cinacalcet in Phosphocalcic Context.,"Hyperparathyroidism, Primary|Hyperparathyroidism, Secondary",2019-10-11,2021-01-31,2023-12-31,25.0,Cohort,,Retrospective,Observational,Not yet recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Endocrinologie Diabte et Maladies Mtaboliques - Hpital Gabriel Montpied|Service de Nphrologie Pdiatrique -Hpital Jeanne de Flandre|Service d'Endocrinologie Pdiatrique - Hpital de la mre et de l'Enfant|Pole Femme Mre Enfant - Pdiatrie spcialise - Centre Hospitalier Universitaire|Service de Nphrologie pdiatrique - Clinique Mdicale Pdiatrique|Service d'endocrinologie et Diabtologie Pdiatrique-Hpital Robert Debr|Service de Diabtologie et endocrinologie pdiatriques - Centre Hospitalier Universitaire|Ple Nphrologie-Urologie-Diabtologie-Endocrinologie|Service d'Endocrinologie, Maladies Osseuses, Gyncologie, Gntique|Unit Endocrinologie, Nutrition, Diabtologie -Hpital Bretonneau",Other,France,0.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04126954
2651,NCT04128631,thyroid neoplasms,Role of of F-18-fluoro-deoxy-glucose (FDG) PET/CT in Thyroid Cancer Patients With Negative I-131whole Body Scan and Elevated Thyroglobulin Level or Positive Anti Thyroglobulin Antibodies,Thyroid Cancer and (FDG)PET/CT Scan,Thyroid Cancer,2019-09-26,2020-09-01,2020-12-01,35.0,Other,,Prospective,Observational [Patient Registry],Unknown status,,Assiut University,Assiut University,,,,10.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04128631
2652,NCT04129281,thyroid neoplasms,Prospective Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma,Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma,Papillary Microcarcinoma of the Thyroid,2019-10-15,2022-01-23,2023-02-23,40.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"National Cancer Institute, Naples","National Cancer Institute, Naples",Istitute Nazionale Tumori - Fondazione G. Pascale,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04129281
2653,NCT04129411,"thyroid cancer, papillary",Pilot Study for the Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation,Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation,Papillary Thyroid Cancer|Papillary Thyroid Microcarcinoma,2019-10-04,2022-03-31,2022-03-31,5.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Device,United States,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04129411
2655,NCT04133870,thyroid neoplasms,Exploratory Study of the Molecular Profile of Thyroid Cancer,Identification of Molecular Biomarkers for Thyroid Cancer,Thyroid Cancer,2017-01-26,2018-04-30,2020-07-30,52.0,Cohort,,Prospective,Observational,Unknown status,,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04133870
2656,NCT04135573,goiter,Mechanism of NK Cell Disfunction in Graves' Disease,The Relationship Between NK Cell and Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,200.0,Case-Control,,Prospective,Observational [Patient Registry],Active not recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04135573
2657,NCT04135573,graves disease,Mechanism of NK Cell Disfunction in Graves' Disease,The Relationship Between NK Cell and Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,200.0,Case-Control,,Prospective,Observational [Patient Registry],Active not recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04135573
2658,NCT04135573,hyperthyroidism,Mechanism of NK Cell Disfunction in Graves' Disease,The Relationship Between NK Cell and Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,200.0,Case-Control,,Prospective,Observational [Patient Registry],Active not recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04135573
2659,NCT04136912,thyroid neoplasms,High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging,3-D Super Resolution Ultrasound Microvascular Imaging,Breast Cancer|Thyroid Cancer,2019-10-21,2023-12-31,2023-12-31,35.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI)|UNC Lineberger Comprehensive Cancer Center,Univeristy of North Carolina Chapel Hill,Drug|Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04136912
2660,NCT04137185,thyroid neoplasms,"Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients","Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients",Differentiated Thyroid Cancer,2019-09-20,2022-12-30,2022-12-30,64.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04137185
2661,NCT04139096,thyroid neoplasms,Genetic Susceptibility to Radiation Induced Thyroid Cancer,Genetic Susceptibility to Radiation Induced Thyroid Cancer,Genetic Susceptibility|Radiation Exposure|Thyroid Neoplasms,2019-10-09,2020-04-30,2020-04-30,60.0,Case-Control,,Retrospective,Observational,Unknown status,,"Institut National de la Sant Et de la Recherche Mdicale, France","Institut National de la Sant Et de la Recherche Mdicale, France",Gustae Roussy,,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04139096
2662,NCT04141306,thyroid neoplasms,"Radioiodine-avid Bone Metastases From Differentiated Thyroid Cancer Without Structural Abnormality, a Singular Entity With Heterogeneous Outcomes.",Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality,Bone Metastases|Thyroid Cancer,2019-10-22,2019-12-31,2019-12-31,30.0,Cohort,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,,Other|Other|Other|Other|Other|Other,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04141306
2664,NCT04141540,hypoparathyroidism,"Translational 22q11.2:""Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With Variable Phenotypic 22q11.2 Microdeletional Syndrom""",Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With Variable Phenotypic 22q11,Di George Syndrome,2019-10-24,2020-11-30,2020-12-30,2.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hpital le Vinatier,Hpital le Vinatier,Hopital Vinatier,Genetic,France,18.0,45.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04141540
2665,NCT04146259,hypoparathyroidism,Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism,Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism,Hypoparathyroidism Postprocedural,2019-10-29,2018-12-31,2019-08-01,109.0,Cohort,,Prospective,Observational,Completed,,University of Athens,University of Athens,Symeon Tournis,Drug,Greece,19.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04146259
2667,NCT04160637,parathyroid diseases,Early Postoperative Serum Parathyroid Hormone Levels as a Predictor of Hypocalcaemia After Total Thyroidectomy: A Prospective Non-Randomized Study,Is There Benefit From Early Postoperative PTH Monitoring?,Hormone Disturbance|Hypocalcemia|Parathyroid Dysfunction|Postoperative Complications|Thyroid,2019-11-09,2019-12-01,2019-12-31,120.0,Cohort,,Prospective,Observational,Unknown status,,"University Hospital ""Sestre Milosrdnice""","University Hospital ""Sestre Milosrdnice""",University Hospital Center Sestre milosrdnice,Diagnostic Test,Croatia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04160637
2668,NCT04161391,thyroid neoplasms,"A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations","Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations",Advanced Solid Tumor|Medullary Thyroid Cancer|Metastatic Solid Tumor|Non Small Cell Lung Cancer|RET Gene Mutation,2019-11-11,2025-12-31,2026-11-30,462.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"Turning Point Therapeutics, Inc.","Turning Point Therapeutics, Inc.","UCI Health - Chao Family Comprehensive Cancer Center|UC San Diego Moores Cancer Center|University of Colorado, Denver|Sarah Cannon Research Institute at HealthONE|Georgetown University Medical Center|Moffitt Cancer Center|Winship Cancer Institute, Emory University|University of Chicago Medical Center|Massachusetts General Hospital|Karmanos Cancer Institute|Memorial Sloan Kettering Cancer Center|Fox Chase Cancer Center|MD Anderson Cancer Center|Virginia Cancer Specialists|The University of Washington, Seattle Cancer Care Alliance|Severance Hospital, Yonsei University Health System",Drug,"Korea, Republic of|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04161391
2669,NCT04171622,"thyroid carcinoma, anaplastic",Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,25.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04171622
2673,NCT04175522,hashimoto disease,"A Phase 2a, Prospective, Open-label, Single-arm, Single Center, Proof of Concept Study to Evaluate the Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis",Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:,Autoimmune Encephalitis,2019-11-21,2020-06-11,2020-06-11,23.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Green Cross Corporation,Green Cross Corporation,Seoul National University Hospital,Drug,"Korea, Republic of",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04175522
2674,NCT04178928,hypothyroidism,Can Levothyroxine Treatment Reduce the Development of Cardio-metabolic Disorder in Subclinical Hypothyroidism?,Can Levothyroxine Treatment Reduce the Development of Cardio-metabolic Disorder in Subclinical Hypothyroidism?,Subclinical hypothyrodism,2019-11-25,2021-01-31,2021-02-28,40.0,,Parallel Assignment,,Interventional,Unknown status,Phase 1/Phase 2,Ain Shams University,Ain Shams University,,Drug,,5.0,15.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04178928
2675,NCT04180007,thyroid neoplasms,Evaluating the Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen,Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers,Apatinib|Metastasis|Thyroid,2019-11-24,2020-04-10,2020-05-30,10.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,"Nanjing First Hospital, Nanjing Medical University","Nanjing First Hospital, Nanjing Medical University",Nanjing First Hospital,Drug,China,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04180007
2676,NCT04193332,hypoparathyroidism,Near Infrared (NIR) Autofluorescence Image-guided Thyroid Surgery Can Prevent Post-thyroidectomy Hypoparathyroidism,Near Infrared (NIR) Autofluorescence Image-guided Thyroid Surgery,Hypocalcemia|Hypoparathyroidism Postprocedural|Surgery--Complications,2019-12-06,2023-10-01,2023-12-01,214.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"Rigshospitalet, Denmark","Cluster for molecular imaging, Denmark|Dept of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Denmark|Rigshospitalet, Denmark","Rigshospitalet|Dept of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Denmark",Device,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04193332
2678,NCT04197960,"thyroid cancer, papillary",A Prospective Multicenter Study to Compare the Therapeutic Outcomes of Microwave Ablation With Surgical Resection for Micropapillary Thyroid Carcinoma,Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2019-12-04,2020-09-30,2022-12-31,820.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Procedure|Procedure,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04197960
2680,NCT04209179,hypoparathyroidism,"A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients With Hypoparathyroidism","A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism",Hypoparathyroidism,2019-11-28,2020-12-28,2021-05-25,5.0,,Sequential Assignment,,Interventional,Terminated,Phase 1,Chugai Pharmaceutical,Chugai Pharmaceutical,"The Lundquist Institute|University of Chicago|Indiana University School of Medicine|University of Kentucky|Massachusetts General Hospital|Mayo Clinic|Ohio State University Wexner Medical Center|Thomas Jefferson University|Endocrinologie et nphrologie Centre de recherche du CHU de Qubec|McMaster University Bone Research & Education Centre|Semmelweis Egyetem, ltalnos Orvostudomnyi Kar, Belgygyszati s Onkolgiai Klinika",Drug|Drug,Canada|Hungary|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04209179
2682,NCT04211337,thyroid neoplasms,"A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Nave, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)",A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer,Medullary Thyroid Cancer,2019-12-24,2024-05-20,2026-11-13,400.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","University of Alabama at Birmingham|Mayo Clinic Hospital|City of Hope National Medical Center|UCLA Medical Center|University of California, Davis - Health Systems|UCSF Medical Center at Mission Bay|Los Angeles Biomedical Research Institute at Harbor - UCLA Medical|Mayo Clinic in Florida|Emory University|University of Chi Med Center|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University Medical School|Memorial Sloan Kettering Cancer Center|University of Cincinnati Cancer Institute|Ohio State University Medical Center|University of Pennsylvania Hospital|Thomas Jefferson University|University of Texas MD Anderson Cancer Center|University of Wisconsin-Madison Hospital and Health Clinic|Chris O'Brien Lifehouse|Royal North Shore Hospital|Peter MacCallum Cancer Centre|The Alfred Hospital|Sir Charles Gairdner Hospital|Universitair Ziekenhuis Antwerpen|Centre Hospitalier Universitaire Sart Tilman|Oncocentro BH|Hospital de Cancer de Londrina|Hospital de Clinicas de Porto Alegre|Instituto de Educao, Pesquisa e Gesto em Sade|Fundao Pio XII - Hospital de Cncer de Barretos|Clinica Onco Star|Hospital PUC-CAMPINAS|Hospital das Clinicas da FMRP|INCA Hospital do Cncer III|Oncoclinicas Rio de Janeiro S.A.|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology|Icesp - Instituto Do Cncer Do Estado de So Paulo|Centro Paulista de Oncologia|London Health Science Centre - Victoria Hospital|Princess Margaret Hospital|Anhui Provincial Hospital|Beijing Tongren Hospital affiliated to Capital Medical Unive|The First Affiliated Hospital of Fujian Medical University|Gansu Province Cancer Hospital|Sun Yat-sen University Cancer Center|Harbin Medical University Cancer Hospital|Henan Cancer Hospital|Hunan Cancer Hospital|Jilin Cancer Hospital|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School|Jinan Central Hospital|Fudan University Shanghai Cancer Center|West China Hospital of Sichuan University|First Affiliated Hospital of Kunming Medical University|Zhejiang Provincial People's Hospital|Sir Run Run Shaw Hospital|Zhejiang Cancer Hospital|Chongqing Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Fakultni nemocnice Brno|Fakultni nemocnice Olomouc|Fakultni Nemocnice v Motole|Assistance Publique Hpitaux de Marseille - Hpital Nord|Centre Georges Franois Leclerc|Centre Hospitalier Universitaire d'Angers|Centre Jean Perrin - Centre Rgional de Lutte contre le Cancer d'Auvergne|Centre Leon Berard|Institut Bergoni - Centre Rgional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest|Centre Franois Baclesse|Hpital C. HURIEZ|Hopital Pitie Salpetriere -Unit Thyrode-Tumeurs Endocrines|Institut de cancrologie Strasbourg Europe|Institut Claudius Regaud|Gustave Roussy|Klinikum der Universitt Mnchen Grohadern|Universittsklinikum Wrzburg A. . R.|Medizinische Hochschule Hanover|Universittsmedizin Johannes Gutenberg Universitt Mainz|Charit Campus Mitte|Universitaetsklinikum Essen|Studiengesellschaft Hmato-Onkologie Hamburg - Prof Laack & Partner|Otto-von-Guericke-Universitt|Alexandra General Hospital of Athens|University General Hospital of Heraklion|European Interbalkan Medical Center|Regional Cancer Centre|HCG Manavata Cancer Centre|Ruby Hall Clinic and Grant Medical Foundation|Deenanath Mangeshkar Hospital & Research Centre|Apollo Gleneagles Hospitals Kolkata|Postgraduate Institute of Medical Education & Research|Hadassah Medical Center|Rabin Medical Center|Sheba Medical Center|Istituto Nazionale dei Tumori|Ospedale San Luca, IRCCS Istituto Auxologico|Polic.Umberto I -Univ. La Sapienza|A.O.U. Senese Policlinico Santa Maria alle Scotte|Istituto Oncologico Veneto IRCCS|Ospedale Garibaldi-Nesima|Azienda Ospedaliera Universitaria Federico II|Azienda Ospedlaliero-Univeristaria Pisana, Stabilimento Ospedaliero di Cisanello|I.F.O. Istituto Nazionale Tumori Regina Elena|Azienda Ospedaliero-Universitaria S.Giovanni Battista|Aichi Cancer Center Hospital|National Cancer Center Hospital East|Hokkaido University Hospital|Kobe University Hospital|Yokohama City University Hospital|Osaka University Hospital|Japanese Foundation for Cancer Research|National Hospital Organization Kyushu Medical Center|National Cancer Center|Seoul National University Bundang Hospital|Chonnam National University Hwasun Hospital|Seoul National University Hospital|Severance Hospital, Yonsei University Health System|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek|University Medical Center Groningen|Leids Universitair Medisch Centrum|Maastricht UMC+|Erasmus Medisch Centrum|Narodowy Instytut Onkologii im. Marii Skodowskiej-Curie|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej|National medical research center of radiology Obninsk|Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (policlinic, hospital)|LLC Evimed|Blokhin Cancer Research Center|National Medical Research Center of Endocrinology of Ministry of Health Dept|Saint-Petersburg City Clinical Oncology Dispensary|Hospital Universitario Virgen de la Victoria|Hospital Universitari Vall d'Hebron|Hospital Universitari de Girona Dr. Josep Trueta|Hospital Universitario Ramn y Cajal|Clinica Universidad de Navarra|Clinica Universitaria De Navarra|Institut Catala d'Oncologia|Hospital General Universitario Gregorio Maraon|Hospital Clinico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital Universitario Miguel Servet|China Medical University Hospital|National Cheng-Kung Uni. Hosp.|National Taiwan University Hospital|Gartnavel General Hospital|University College Hospital - London|Royal Marsden NHS Trust|Velindre Cancer Centre|Weston Park Hospital|Royal Marsden Hospital",Drug|Drug|Drug,"Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Taiwan|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04211337
2683,NCT04216732,thyroid neoplasms,Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management,Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management,Advanced Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,2019-11-14,2023-09-01,2023-09-01,2030.0,Cohort,,Prospective,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),University of California San Francisco|M D Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04216732
2684,NCT04224792,thyroid neoplasms,Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors,Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors,Thyroid Cancer,2020-01-08,2024-09-30,2024-12-30,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04224792
2685,NCT04233398,thyroid nodule,"A Multi-center, Randomized, Controlled Trial of High Intensity Focused Ultrasound (HIFU) Treatment of Benign Thyroid Nodules",HIFU Treatment of Benign Thyroid Nodules,Thyroid Nodule (Benign),2020-01-15,2023-11-30,2023-11-30,240.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Theraclion,Theraclion,,Device,,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04233398
2686,NCT04233398,thyroid neoplasms,"A Multi-center, Randomized, Controlled Trial of High Intensity Focused Ultrasound (HIFU) Treatment of Benign Thyroid Nodules",HIFU Treatment of Benign Thyroid Nodules,Thyroid Nodule (Benign),2020-01-15,2023-11-30,2023-11-30,240.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Theraclion,Theraclion,,Device,,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04233398
2687,NCT04236232,hypothyroidism,The Impact of Subclinical Hypothyroidism on the Cardiovascular System,The Impact of Subclinical Hypothyroidism on Cardiovascular System,Hypothyroidism,2019-09-24,2021-05-01,2021-06-01,100.0,Other,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test,,18.0,55.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04236232
2689,NCT04238624,"thyroid carcinoma, anaplastic","A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib",Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|BRAF Gene Mutation|BRAF Mutation-Related Tumors|Thyroid Cancer,2020-01-21,2022-06-20,2022-06-20,15.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited Protocol Activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau (Limited Protocol Activities),Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04238624
2690,NCT04239521,goiter,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,51955.0,Cohort,,Retrospective,Observational,Active not recruiting,,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04239521
2691,NCT04239521,hyperthyroidism,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,51955.0,Cohort,,Retrospective,Observational,Active not recruiting,,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04239521
2694,NCT04239521,thyroiditis,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,51955.0,Cohort,,Retrospective,Observational,Active not recruiting,,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04239521
2695,NCT04239521,graves disease,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,51955.0,Cohort,,Retrospective,Observational,Active not recruiting,,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04239521
2697,NCT04240821,pseudopseudohypoparathyroidism,Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism,Theophylline for Treatment of Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism|Pseudohypoparathyroidism Type 1a,2020-01-21,2025-06-30,2025-06-30,34.0,,Single Group Assignment,,Interventional,Enrolling by invitation,Phase 2,Vanderbilt University Medical Center,Ashley Shoemaker,Vanderbilt University Medical Center,Drug,United States,2.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04240821
2698,NCT04248114,thyroid neoplasms,The Natural Neck Crease as an Anatomic Landmark for Thyroid Surgery Incision,Skin-crease Thyroidectomy,Thyroid Nodule,2020-01-28,2018-08-31,2018-08-31,118.0,Case-Only,,Retrospective,Observational,Completed,,Western Galilee Hospital-Nahariya,Western Galilee Hospital-Nahariya,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04248114
2699,NCT04248114,thyroid nodule,The Natural Neck Crease as an Anatomic Landmark for Thyroid Surgery Incision,Skin-crease Thyroidectomy,Thyroid Nodule,2020-01-28,2018-08-31,2018-08-31,118.0,Case-Only,,Retrospective,Observational,Completed,,Western Galilee Hospital-Nahariya,Western Galilee Hospital-Nahariya,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04248114
2700,NCT04248166,thyroid nodule,Diagnosis of Thyroid Cancer Using Photoacoustic Imaging,Thyroid Cancer and Photoacoustic Imaging,Thyroid Cancer|Thyroid Nodule,2020-01-28,2020-06-30,2020-12-31,100.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Seoul St. Mary's Hospital,Pohang University of Science and Technology|Seoul St. Mary's Hospital,Seoul St. Mary's hospital,Device,"Korea, Republic of",19.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04248166
2701,NCT04248166,thyroid neoplasms,Diagnosis of Thyroid Cancer Using Photoacoustic Imaging,Thyroid Cancer and Photoacoustic Imaging,Thyroid Cancer|Thyroid Nodule,2020-01-28,2020-06-30,2020-12-31,100.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Seoul St. Mary's Hospital,Pohang University of Science and Technology|Seoul St. Mary's Hospital,Seoul St. Mary's hospital,Device,"Korea, Republic of",19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04248166
2702,NCT04252001,thyroid dysgenesis,Growing up With the Young Endocrine Support System (YESS!): Innovative E-technology to Improve Transition From Paediatric to Adult Care,Growing up With the Young Endocrine Support System (YESS!),Addison's Disease|Androgen Insensitivity Syndrome|Combined Pituitary Hormone Deficiency|Congenital Adrenal Hyperplasia|Growth Hormone Deficiency|Hypogonadotropic Hypogonadism|Klinefelter Syndrome|Thyroid Dysgenesis|Turner Syndrome,2020-01-21,2022-12-01,2023-12-01,160.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Erasmus Medical Center,dr. Laura C. G. de Graaff-Herder,Ghent University Hospital|Erasmus Medical Center|Hospital Infantil Universitario Nio Jess|Queen Elizabeth University Hospital|Royal Hospital for Children|The Royal London Hospital (Barts Health NHS Trust)|University College London Hospital (UCL Institute of Child Health),Device|Device|Other,Belgium|Netherlands|Spain|United Kingdom,15.0,20.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04252001
2703,NCT04267965,hyperparathyroidism,"Changes of Pulmonary Function, Voice and Swallowing Symptoms After Total Parathyroidectomy for Secondary Hyperparathyroidism in the Presence of Intact Recurrent Laryngeal Nerve","Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy",Secondary Hyperparathyroidism Due to Renal Causes,2020-01-22,2019-07-31,2019-07-31,48.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Fong-Fu Chou,Procedure,Taiwan,20.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04267965
2706,NCT04268407,thyroid neoplasms,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,Thyroid Nodule,2020-02-07,2021-07-31,2021-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,,Drug,,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04268407
2707,NCT04268407,thyroid nodule,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,Thyroid Nodule,2020-02-07,2021-07-31,2021-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,,Drug,,20.0,80.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04268407
2708,NCT04270110,hypothyroidism,Assessment of Bone Mineral Density in Patients With Subclinical Hypothyroidism,Assessment of Bone Mineral Density in Patients With Subclinical Hypothyroidism,Subclinical hypothyrodism,2020-01-16,2020-12-01,2021-12-31,100.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,Assiut university Hospital,,Egypt,0.0,55.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04270110
2709,NCT04274829,thyroid neoplasms,Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid,Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid,Lymph Node Metastases|Thyroid Cancer,2020-02-15,2018-01-31,2020-02-29,300.0,Case-Control,,Retrospective,Observational,Completed,,University of Cagliari,University of Cagliari,AOU Cagliari,Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04274829
2710,NCT04280081,thyroid neoplasms,"A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation",Medullary Thyroid Cancer|Solid Tumor,2020-02-20,2021-03-25,2025-11-20,75.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","Nanfang Affiliated Hospital South Medical University|The First Affiated Hospital Of Guangzhou Medical Collage|Hunan Cancer Hospital|Jilin Province Tumor Hospital|Jinan Central Hospital|Shanghai Chest Hospital|Zhejiang Cancer Hospital|First Affiliated Hosp of College of Med, Zhejiang University|Zhejiang Provincial People's Hospital|Beijing Cancer Hospital|Fudan University Shanghai Cancer Center|Shanghai East Hospital|Tianjin Medical University Cancer Institute & Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04280081
2711,NCT04281875,hypoparathyroidism,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Postoperative Hypoparathyroidism|Thyroid Cancer|Thyroid Neoplasms,2020-02-19,2023-03-31,2023-09-30,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04281875
2713,NCT04281875,thyroid neoplasms,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Postoperative Hypoparathyroidism|Thyroid Cancer|Thyroid Neoplasms,2020-02-19,2023-03-31,2023-09-30,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04281875
2714,NCT04284774,thyroid neoplasms,NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations,"Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial",Malignant Solid Neoplasm|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Ectomesenchymoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Kidney Wilms Tumor|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Medulloblastoma|Recurrent Melanoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdoid Tumor of the Kidney|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Carcinoma|Recurrent WHO Grade 2 Glioma|Refractory Adrenal Gland Pheochromocytoma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Medulloblastoma|Refractory Melanoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdoid Tumor of the Kidney|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Thyroid Gland Carcinoma|Refractory WHO Grade 2 Glioma,2020-02-25,2027-09-30,2027-09-30,49.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Providence Alaska Medical Center|Banner Children's at Desert|Phoenix Childrens Hospital|Banner University Medical Center - Tucson|Arkansas Children's Hospital|Kaiser Permanente Downey Medical Center|City of Hope Comprehensive Cancer Center|Loma Linda University Medical Center|Miller Children's and Women's Hospital Long Beach|Children's Hospital Los Angeles|Cedars Sinai Medical Center|Mattel Children's Hospital UCLA|Valley Children's Hospital|UCSF Benioff Children's Hospital Oakland|Kaiser Permanente-Oakland|Children's Hospital of Orange County|Lucile Packard Children's Hospital Stanford University|University of California Davis Comprehensive Cancer Center|Rady Children's Hospital - San Diego|Naval Medical Center -San Diego|UCSF Medical Center-Mission Bay|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Children's Hospital Colorado|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Yale University|Alfred I duPont Hospital for Children|MedStar Georgetown University Hospital|Children's National Medical Center|Broward Health Medical Center|Golisano Children's Hospital of Southwest Florida|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|Nemours Children's Clinic-Jacksonville|University of Miami Miller School of Medicine-Sylvester Cancer Center|Nicklaus Children's Hospital|Miami Cancer Institute|AdventHealth Orlando|Arnold Palmer Hospital for Children|Nemours Children's Hospital|Sacred Heart Hospital|Johns Hopkins All Children's Hospital|Tampa General Hospital|Saint Joseph's Hospital/Children's Hospital-Tampa|Saint Mary's Hospital|Children's Healthcare of Atlanta - Egleston|Memorial Health University Medical Center|Kapiolani Medical Center for Women and Children|Saint Luke's Cancer Institute - Boise|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago Comprehensive Cancer Center|Loyola University Medical Center|Saint Jude Midwest Affiliate|Southern Illinois University School of Medicine|Riley Hospital for Children|Saint Vincent Hospital and Health Care Center|Blank Children's Hospital|University of Iowa/Holden Comprehensive Cancer Center|University of Kentucky/Markey Cancer Center|Norton Children's Hospital|Children's Hospital New Orleans|Ochsner Medical Center Jefferson|Eastern Maine Medical Center|Maine Children's Cancer Program|University of Maryland/Greenebaum Cancer Center|Sinai Hospital of Baltimore|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute|UMass Memorial Medical Center - University Campus|C S Mott Children's Hospital|Wayne State University/Karmanos Cancer Institute|Helen DeVos Children's Hospital at Spectrum Health|Bronson Methodist Hospital|Beaumont Children's Hospital-Royal Oak|Children's Hospitals and Clinics of Minnesota - Minneapolis|University of Minnesota/Masonic Cancer Center|Mayo Clinic in Rochester|University of Mississippi Medical Center|Children's Mercy Hospitals and Clinics|Cardinal Glennon Children's Medical Center|Washington University School of Medicine|Mercy Hospital Saint Louis|Children's Hospital and Medical Center of Omaha|University of Nebraska Medical Center|University Medical Center of Southern Nevada|Sunrise Hospital and Medical Center|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Summerlin Hospital Medical Center|Renown Regional Medical Center|Dartmouth Hitchcock Medical Center|Hackensack University Medical Center|Morristown Medical Center|Saint Peter's University Hospital|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital|Albany Medical Center|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|NYU Winthrop Hospital|The Steven and Alexandra Cohen Children's Medical Center of New York|Laura and Isaac Perlmutter Cancer Center at NYU Langone|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|University of Rochester|Stony Brook University Medical Center|State University of New York Upstate Medical University|New York Medical College|Mission Hospital|UNC Lineberger Comprehensive Cancer Center|Carolinas Medical Center/Levine Cancer Institute|Novant Health Presbyterian Medical Center|Duke University Medical Center|East Carolina University|Wake Forest University Health Sciences|Sanford Broadway Medical Center|Children's Hospital Medical Center of Akron|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|Cleveland Clinic Foundation|Nationwide Children's Hospital|Dayton Children's Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|University of Oklahoma Health Sciences Center|Legacy Emanuel Children's Hospital|Oregon Health and Science University|Lehigh Valley Hospital-Cedar Crest|Geisinger Medical Center|Children's Hospital of Philadelphia|Saint Christopher's Hospital for Children|Children's Hospital of Pittsburgh of UPMC|Rhode Island Hospital|Prisma Health Richland Hospital|BI-LO Charities Children's Cancer Center|Sanford USD Medical Center - Sioux Falls|T C Thompson Children's Hospital|East Tennessee Childrens Hospital|Saint Jude Children's Research Hospital|The Children's Hospital at TriStar Centennial|Vanderbilt University/Ingram Cancer Center|Dell Children's Medical Center of Central Texas|Driscoll Children's Hospital|Medical City Dallas Hospital|UT Southwestern/Simmons Cancer Center-Dallas|El Paso Children's Hospital|Cook Children's Medical Center|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|M D Anderson Cancer Center|Covenant Children's Hospital|UMC Cancer Center / UMC Health System|Children's Hospital of San Antonio|Methodist Children's Hospital of South Texas|University of Texas Health Science Center at San Antonio|Scott and White Memorial Hospital|Primary Children's Hospital|University of Vermont and State Agricultural College|Children's Hospital of The King's Daughters|Naval Medical Center - Portsmouth|Virginia Commonwealth University/Massey Cancer Center|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Mary Bridge Children's Hospital and Health Center|Madigan Army Medical Center|West Virginia University Healthcare|University of Wisconsin Carbone Cancer Center|Marshfield Medical Center-Marshfield|Children's Hospital of Wisconsin|University Pediatric Hospital,Drug,Puerto Rico|United States,12.0,21.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04284774
2715,NCT04285476,thyroid neoplasms,Study of the Predictive Value of a Signature of 10 microRNA in Thyroid Cytologies of Undetermined Type,Predictive Value of 10 microRNA in Thyroid Cytologies of Undetermined Type,Thyroid Cancer,2020-02-24,2022-07-31,2023-03-31,70.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Institut du Cancer de Montpellier - Val d'Aurelle,Institut du Cancer de Montpellier - Val d'Aurelle,CHU de Toulouse|Institut rgional du Cancer de Montpellier,Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04285476
2716,NCT04288115,hypothyroidism,"Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism: a Pilot Randomized, Double-blinded, Placebo-controlled Study",Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidism,2020-02-14,2022-05-31,2022-12-31,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,VA Office of Research and Development,Central Arkansas Veterans Healthcare System|VA Office of Research and Development,"Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR",Drug|Other,United States,18.0,89.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04288115
2717,NCT04288531,hypothyroidism,"Observational Study on the Impact of Iodine Supplementation on Maternal and Child's Thyroid Hormone Homeostasis and on the Child's Psychomotor Development, in the Portuguese Minho Region (IodineMinho)","Iodine Impact on Thyroid Function and Psychomotor Development, Observational Study in the Portuguese Minho Region",Hypothyroidism in Pregnancy|Iodine Deficiency|Nutrient Deficiency|Pregnancy Related|Psychomotor Impairment|Thyroid,2020-02-25,2024-01-10,2025-01-10,304.0,Cohort,,Prospective,Observational,Recruiting,,University of Minho,"Administrao Regional de Sade do Norte, Portugal|Clinical Academic Center (2CA-Braga)|Hospital de Braga|Instituto Nacional de Sade Dr Ricardo Jorge, Portugal|University of Minho",Usf Maxisaude|Usf Braga Norte|Usf Rues|Usf S. Loureno|Usf Gualtar|Usf + Carand|Usf Manuel Rocha Peixoto|Usf Bracara Augusta|Usf Do Minho|Usf S. Joo de Braga,Dietary Supplement,Portugal,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04288531
2718,NCT04290663,thyroid neoplasms,Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy,Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up,Intermediate Risk|Thyroid Cancer,2020-02-20,2026-02-28,2028-02-29,476.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|French cancer Institute INCa,Centre Francois Baclesse,Drug|Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04290663
2719,NCT04298684,thyroid neoplasms,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes,"Diabetes Mellitus, Type 2|Thyroid Nodule (Benign)",2020-02-05,2022-02-01,2024-07-01,90.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Centre Hospitalier Universitaire de Pointe-a-Pitre,Centre Hospitalier Universitaire de Pointe-a-Pitre,CHU Bordeaux|CHU Limoges|University Hospital Center of Guadeloupe|CHU de la Runion,Drug|Drug,France|Guadeloupe|Runion,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04298684
2720,NCT04298684,thyroid nodule,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes,"Diabetes Mellitus, Type 2|Thyroid Nodule (Benign)",2020-02-05,2022-02-01,2024-07-01,90.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Centre Hospitalier Universitaire de Pointe-a-Pitre,Centre Hospitalier Universitaire de Pointe-a-Pitre,CHU Bordeaux|CHU Limoges|University Hospital Center of Guadeloupe|CHU de la Runion,Drug|Drug,France|Guadeloupe|Runion,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04298684
2721,NCT04299425,parathyroid neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Hyperplasia|Parathyroid Neoplasms|Primary Hyperparathyroidism,2020-03-04,2023-03-31,2023-09-30,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04299425
2722,NCT04299425,hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Hyperplasia|Parathyroid Neoplasms|Primary Hyperparathyroidism,2020-03-04,2023-03-31,2023-09-30,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04299425
2725,NCT04304573,parathyroid diseases,Is Correcting Total Serum Calcium Levels for Serum Albumin Necessary in Assessing Symptomatic Hypocalcemia After Total Thyroidectomy: a Prospective Cohort Study,Is Correcting Total Serum Calcium Levels Important After Thyroidectomy,Calcium Disorder|Hormone Disturbance|Hypocalcemia|Parathyroid Dysfunction|Postoperative Complications|Thyroid,2020-03-09,2020-08-09,2020-09-09,100.0,Cohort,,Prospective,Observational,Unknown status,,"University Hospital ""Sestre Milosrdnice""","University Hospital ""Sestre Milosrdnice""",University Hospital Center Sestre milosrdnice,Diagnostic Test,Croatia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04304573
2726,NCT04304794,goiter,Prevention of Iodinated Contrast Media Induced Hyperthyroidism in Patients With Euthyroid Goiter,Iodinated Contrast Media Induced Hyperthyroidism,Contrast Media Adverse Reaction|Hyperthyroidism; Goiter|Hyperthyroidism/Thyrotoxicosis|Iodine Induced Thyrotoxicosis|Thyrotoxicosis of Other Specified Origin,2020-03-03,2020-02-20,2020-02-20,36.0,Cohort,,Retrospective,Observational,Completed,,Medical University of Warsaw,"Institute of Cardiology, Warsaw, Poland|Medical University of Warsaw",,Procedure|Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04304794
2728,NCT04304794,thyrotoxicosis,Prevention of Iodinated Contrast Media Induced Hyperthyroidism in Patients With Euthyroid Goiter,Iodinated Contrast Media Induced Hyperthyroidism,Contrast Media Adverse Reaction|Hyperthyroidism; Goiter|Hyperthyroidism/Thyrotoxicosis|Iodine Induced Thyrotoxicosis|Thyrotoxicosis of Other Specified Origin,2020-03-03,2020-02-20,2020-02-20,36.0,Cohort,,Retrospective,Observational,Completed,,Medical University of Warsaw,"Institute of Cardiology, Warsaw, Poland|Medical University of Warsaw",,Procedure|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04304794
2730,NCT04305561,hyperparathyroidism,Comparison of CEUS With Conventional Ultrasound (US) to Dual-tracer 99mTcO4-/99mTc-MIBI Subtraction Scintigraphy With SPECT/CT for Localizing Pathological Parathyroid Glands in Patients With Primary Hyperparathyroidism,Preoperative Localization Strategies in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2020-01-24,2021-12-31,2021-12-31,172.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Odense University Hospital,Odense University Hospital,Odense University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04305561
2732,NCT04309136,thyroid neoplasms,The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: a Single-arm Phase II Clinical Trial,Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer,Thyroid Cancer,2020-03-12,2021-02-01,2022-06-01,13.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug|Procedure|Procedure,China,14.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04309136
2733,NCT04311606,graves disease,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Anti-VEGF Therapy for Acute Thyroid Eye Disease,Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,24.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04311606
2734,NCT04311606,goiter,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Anti-VEGF Therapy for Acute Thyroid Eye Disease,Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,24.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04311606
2735,NCT04311606,hyperthyroidism,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Anti-VEGF Therapy for Acute Thyroid Eye Disease,Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,24.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04311606
2736,NCT04311606,graves ophthalmopathy,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Anti-VEGF Therapy for Acute Thyroid Eye Disease,Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,24.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04311606
2737,NCT04312087,thyroid neoplasms,Lateral Neck Lymph Node Mapping in Papillary Thyroid Carcinoma,Lateral Neck Lymph Node Mapping in Thyroid Cancer,Thyroid Cancer,2020-03-14,2021-08-01,2022-12-31,250.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Procedure|Procedure|Procedure,China,14.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04312087
2738,NCT04312646,thyroid neoplasms,Added Value of Ultrasound Elasatography in Characterization of Thyroid Nodules,Elastography in Thyroid Nodules,Thyroid Nodule,2020-03-16,2021-04-01,2022-04-01,50.0,Case-Only,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,,Device,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04312646
2739,NCT04312646,thyroid nodule,Added Value of Ultrasound Elasatography in Characterization of Thyroid Nodules,Elastography in Thyroid Nodules,Thyroid Nodule,2020-03-16,2021-04-01,2022-04-01,50.0,Case-Only,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,,Device,,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04312646
2740,NCT04316845,hyperparathyroidism,18F-Fluorocholine PET/CT in the Pre-operative Localization of Hyperfunctional Parathyroid Gland in Primary and Secondary Hyperparathyroidism,18F-fluorocholine PET/CT for Hyperparathyroidism,Hyperparathyroidism,2020-03-17,2019-11-06,2019-12-31,38.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Buddhist Tzu Chi General Hospital,Buddhist Tzu Chi General Hospital,Hualien Tzu Chi Hospital,Diagnostic Test,Taiwan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04316845
2742,NCT04320901,thyroid neoplasms,Comparative Analysis Between Harmonic Versus LigaSure in Transoral Endoscopic Thyroidectomy: A Randomized Controlled Trial,Energy Device Study in Transoral Endoscopic Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2020-03-20,2022-12-31,2023-02-28,40.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device|Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04320901
2743,NCT04320901,thyroid nodule,Comparative Analysis Between Harmonic Versus LigaSure in Transoral Endoscopic Thyroidectomy: A Randomized Controlled Trial,Energy Device Study in Transoral Endoscopic Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2020-03-20,2022-12-31,2023-02-28,40.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device|Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04320901
2744,NCT04321954,thyroid neoplasms,A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer,Lenvatinib in Locally Advanced Invasive Thyroid Cancer,Advanced Cancer|Differentiated Thyroid Cancer,2020-03-24,2023-09-30,2024-03-31,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Eisai Inc.|Massachusetts Eye and Ear Infirmary,Massachusetts General Hospital Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04321954
2745,NCT04327999,thyroid neoplasms,Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System of Patients Following Radioiodine Therapy for Thyroid Carcinoma,Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System,Radioactive Iodine Level|Thyroid Carcinoma,2020-03-04,2023-07-31,2024-07-31,15.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Vanderbilt-Ingram Cancer Center,Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04327999
2746,NCT04329455,thyroid neoplasms,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Safety and Cosmetic Issues in Endoscopic Thyroidectomy,2020-03-30,2022-04-01,2023-04-01,30.0,Cohort,,Prospective,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Gamal,Procedure,Egypt,18.0,55.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04329455
2747,NCT04329455,thyroid nodule,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Safety and Cosmetic Issues in Endoscopic Thyroidectomy,2020-03-30,2022-04-01,2023-04-01,30.0,Cohort,,Prospective,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Gamal,Procedure,Egypt,18.0,55.0,[18-65],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04329455
2748,NCT04332770,hypothyroidism,Clinical Application of Continuous Monitoring Data for Biosignals by Commercially Available Wearable Devices in the Patients With Hypothyroidism,Biosignals by Wearable Devices in Hypothyroidism,Hypothyroidism,2019-12-13,2020-10-15,2020-10-15,45.0,Cohort,,Prospective,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Other,"Korea, Republic of",20.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04332770
2749,NCT04333342,goiter,Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Heart Rate Monitoring by Wearable Devices in Graves' Disease,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,180.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04333342
2750,NCT04333342,hyperthyroidism,Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Heart Rate Monitoring by Wearable Devices in Graves' Disease,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,180.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04333342
2751,NCT04333342,graves disease,Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Heart Rate Monitoring by Wearable Devices in Graves' Disease,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,180.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04333342
2753,NCT04336696,"thyroid cancer, papillary","Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?","Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?",Papillary Thyroid Carcinoma,2020-04-01,2020-04-03,2020-05-03,199.0,,Sequential Assignment,,Interventional,Unknown status,Not Applicable,Zagazig University,Bassem Mohamed Sieda,Zagazig University Hospitals,Procedure,Egypt,42.0,55.0,[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04336696
2756,NCT04339127,hashimoto disease,Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature,Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis,Anti NMDA Receptor Encephalitis|Autoimmune Encephalitis|Herpetic Encephalitis,2020-04-06,2020-06-01,2020-10-01,12.0,Cohort,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospice Civils de Lyon,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04339127
2759,NCT04339205,"thyroiditis, autoimmune",Diffusion Imaging in Acute Auto-immune Encephalitis : a Cohort of 80 Patients,Diffusion Imaging in Acute Auto-immune Encephalitis,Auto-immune Encephalitis,2020-04-06,2020-03-01,2020-07-01,80.0,Cohort,,Retrospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04339205
2760,NCT04339478,thyroid neoplasms,Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection,Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection,Thyroid Cancer|Thyroidectomy With Central Lymph Node Dissection,2020-04-06,2022-03-30,2022-08-30,180.0,Cohort,,Prospective,Observational,Recruiting,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki|The Hashemite University|Umraniye Education and Research Hospital,"1st Propedeutic Department of Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki|Department of Surgery, Faculty of Medicine, Hashemite University|Umraniye Education and Research Hospital",,Greece|Jordan|Turkey,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04339478
2762,NCT04344886,parathyroid neoplasms,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery,Parathyroid Adenoma|Parathyroid Diseases|Primary Hyperparathyroidism|Thyroid Disease,2020-04-09,2020-11-30,2020-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University Hospital Ostrava,University Hospital Ostrava,University Hospital Ostrava,Procedure|Procedure|Procedure|Procedure,Czechia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04344886
2763,NCT04344886,hyperparathyroidism,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery,Parathyroid Adenoma|Parathyroid Diseases|Primary Hyperparathyroidism|Thyroid Disease,2020-04-09,2020-11-30,2020-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University Hospital Ostrava,University Hospital Ostrava,University Hospital Ostrava,Procedure|Procedure|Procedure|Procedure,Czechia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04344886
2765,NCT04346901,hyperthyroidism,Comparative Study of mMASI Before and After Hyperthyroid Therapy in Hyperthyroid Subjects With Melasma,Comparative Study of mMASI Before and After Hyperthyroid Therapy in Hyperthyroid Subjects With Melasma,Hyperthyroidism|Melasma,2020-04-10,2020-01-27,2020-02-15,23.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Indonesia University,"Dr.dr.Irma Bernadette, SpKK (K)",dr. Cipto Mangunkusumo Hospital,Drug,Indonesia,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04346901
2767,NCT04354324,"thyroid cancer, papillary",Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma Patients Without Metastasis: a Double-blind Randomized Clinical Trial,Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma,Papillary Thyroid Cancer,2020-03-01,2024-06-30,2024-06-30,254.0,,Crossover Assignment,,Interventional,Not yet recruiting,Not Applicable,Zhujiang Hospital,Zhujiang Hospital,,Drug,,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04354324
2768,NCT04354896,hypothyroidism,The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism - a Substudy of TRUST and IEMO Trials,The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism,Sarcopenia|Subclinical Hypothyroidism,2020-04-08,2018-05-04,2018-05-04,322.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University Hospital Inselspital, Berne","Leiden University Medical Center|University Hospital Inselspital, Berne|University of Lausanne Hospitals","Department of Gerontology and Geriatrics, Leiden University Medical Center|Department of Public Health and Primary Care, Leiden University Medical Center|Institute for Evidence-Based Medicine in Old Age|Department of General Internal Medicine|Clinic for General Internal Medicine, Bern University Hospital Bern",Drug|Drug,Netherlands|Switzerland,65.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04354896
2769,NCT04359979,goiter,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Tamsulosin for Thyroid Lid Retraction,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,50.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04359979
2770,NCT04359979,hyperthyroidism,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Tamsulosin for Thyroid Lid Retraction,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,50.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04359979
2771,NCT04359979,graves ophthalmopathy,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Tamsulosin for Thyroid Lid Retraction,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,50.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04359979
2772,NCT04359979,graves disease,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Tamsulosin for Thyroid Lid Retraction,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,50.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04359979
2773,NCT04372225,hypoparathyroidism,Predicting Risk Factors of Postoperative Hypocalcemia After Total Thyroidectomy: is Safe Discharge Without Supplementation Possible?,Predicting Risk Factors of Postoperative Hypocalcemia After Total Thyroidectomy,Hypoparathyroidism,2020-04-25,2020-04-25,2020-04-25,477.0,Cohort,,Prospective,Observational,Completed,,Aix Marseille Universit,Aix Marseille Universit,Conception Hospital,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04372225
2776,NCT04373226,hypoparathyroidism,Study of Arithmetic Abilities of Children With 22q11.2 Deletion Syndrome Aged From 4 to 11 Years Old,Arithmetic Abilities in Children With 22q11.2DS,22q11.2 Deletion Syndrome,2020-04-30,2023-07-20,2023-10-20,120.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Hpital le Vinatier,Hpital le Vinatier,Hopital Vinatier,Behavioral,France,4.0,11.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04373226
2777,NCT04376203,thyroid neoplasms,What is the Relation of Microbiome to Papillary Thyroid Microcarcinoma Development?,Microbiome and Papillary Thyroid Microcarcinoma,Microbiome|Papillary Thyroid Microcarcinoma,2020-05-02,2022-05-30,2023-05-30,40.0,Case-Control,,Prospective,Observational,Not yet recruiting,,University of Ioannina,University of Ioannina,,Procedure,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04376203
2778,NCT04383795,graves disease,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Change of Gut Microbiome in the Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,40.0,Case-Only,,Prospective,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04383795
2779,NCT04383795,hyperthyroidism,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Change of Gut Microbiome in the Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,40.0,Case-Only,,Prospective,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04383795
2780,NCT04383795,goiter,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Change of Gut Microbiome in the Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,40.0,Case-Only,,Prospective,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04383795
2781,NCT04391244,thyroid neoplasms,Investigating National Solutions for Personalised Iodine-131 Radiation Exposure - Measuring Absorbed Dose to Tumour and Organs at Risk Following Routine Iodine Ablation Therapy,Investigating National Solutions for Personalised Iodine-131 Radiation Exposure,Differentiated Thyroid Cancer,2020-05-12,2022-07-31,2022-07-31,50.0,Cohort,,Prospective,Observational,Recruiting,,Royal Marsden NHS Foundation Trust,European Commission|Royal Marsden NHS Foundation Trust,The Royal Marsden NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04391244
2782,NCT04391439,graves ophthalmopathy,Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy,Heart Rhythm After Intravenous Methylprednisolone Administration,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,2020-05-05,2020-02-20,2020-02-20,40.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04391439
2783,NCT04391439,hyperthyroidism,Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy,Heart Rhythm After Intravenous Methylprednisolone Administration,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,2020-05-05,2020-02-20,2020-02-20,40.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04391439
2784,NCT04391439,goiter,Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy,Heart Rhythm After Intravenous Methylprednisolone Administration,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,2020-05-05,2020-02-20,2020-02-20,40.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04391439
2785,NCT04391439,graves disease,Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy,Heart Rhythm After Intravenous Methylprednisolone Administration,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,2020-05-05,2020-02-20,2020-02-20,40.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04391439
2786,NCT04396158,thyroid neoplasms,Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer,Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer,Ovarian Insufficiency|Radiation Exposure,2020-05-16,2021-06-15,2021-12-15,38.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Assiut University,Assiut University,,Radiation,,15.0,45.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04396158
2787,NCT04396912,hypoparathyroidism,"Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines",Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort,"Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,100.0,Cohort,,Prospective,Observational,Unknown status,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04396912
2788,NCT04396912,"thyroid cancer, papillary","Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines",Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort,"Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,100.0,Cohort,,Prospective,Observational,Unknown status,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04396912
2789,NCT04396912,thyroid nodule,"Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines",Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort,"Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,100.0,Cohort,,Prospective,Observational,Unknown status,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04396912
2792,NCT04400474,"thyroid carcinoma, anaplastic",Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study,Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study,Adenocarcinoma|Anaplastic Thyroid Cancer|Neuroendocrine Tumor|Paraganglioma|Pheochromocytoma,2020-05-12,2023-03-31,2024-03-31,144.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|Ipsen|Roche Pharma AG,Hospital Germans Trias i Pujol - ICO Badalona|Hospital Duran i Reynals - ICO L'Hospitalet|Hospital General Universitario Elche|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Universitario Ramn y Cajal|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Hospital Universitario Central de Asturias|Hospital Universitario Marqus de Valdecilla|Hospital Universitario Virgen del Roco|Hospital Universitario de Canarias|Hospital Universitario Miguel Servet,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04400474
2793,NCT04410601,goiter,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,500.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04410601
2794,NCT04410601,thyroid nodule,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,500.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04410601
2795,NCT04410601,thyroid neoplasms,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,500.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04410601
2796,NCT04410601,thyroiditis,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,500.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04410601
2797,NCT04411290,"thyroid cancer, papillary","Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial","Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","Aspiration|Multifocal Dysplasia|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Carcinoma|Thyroid Diseases|Thyroid Goiter|Thyroid Neoplasms|Thyroid Nodule|Thyroid Papillary Carcinoma",2020-05-15,2021-06-01,2021-06-01,200.0,Cohort,,Prospective,Observational,Unknown status,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences Universit",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04411290
2798,NCT04411290,goiter,"Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial","Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","Aspiration|Multifocal Dysplasia|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Carcinoma|Thyroid Diseases|Thyroid Goiter|Thyroid Neoplasms|Thyroid Nodule|Thyroid Papillary Carcinoma",2020-05-15,2021-06-01,2021-06-01,200.0,Cohort,,Prospective,Observational,Unknown status,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences Universit",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04411290
2799,NCT04411290,thyroid nodule,"Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial","Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","Aspiration|Multifocal Dysplasia|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Carcinoma|Thyroid Diseases|Thyroid Goiter|Thyroid Neoplasms|Thyroid Nodule|Thyroid Papillary Carcinoma",2020-05-15,2021-06-01,2021-06-01,200.0,Cohort,,Prospective,Observational,Unknown status,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences Universit",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04411290
2801,NCT04412694,hypoparathyroidism,The Impact of Preoperative Oral Dexamethasone Supplementation on the Biochemical Parameters and Results of Surgical Treatment in Patients With Nontoxic Multinodular Goiter Undergoing Total Thyroidectomy.,The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients.,Hypocalcemia|Hypoparathyroidism Postprocedural|Postoperative Complications|Postoperative Nausea|Postoperative Pain|Vitamin D Deficiency|Voice Hoarseness,2020-05-23,2022-09-30,2022-12-31,100.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Medical University of Lodz,Medical University of Lodz,"Department of General and Oncological Surgery, Medical University of Lodz",Drug|Drug|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Procedure|Other|Other|Other|Other|Other|Other|Other|Other,Poland,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04412694
2803,NCT04420689,thyroid neoplasms,Phase 1/2 Trial of ALM-488 in Patients Undergoing Head & Neck Surgery,A Study of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery,Head and Neck Neoplasms|Imaging|Nerve Injury|Parotid Neoplasm|Surgery|Thyroid Neoplasms,2020-06-03,2021-06-25,2022-02-15,41.0,,Sequential Assignment,,Interventional,Completed,Phase 1/Phase 2,"Alume Biosciences, Inc.","Alume Biosciences, Inc.",University of California San Diego|Stanford University|Harvard-Mass Eye & Ear,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04420689
2804,NCT04420754,"thyroid carcinoma, anaplastic",A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer,Study of AIC100 in Relapsed/Refractory Thyroid Cancer,Anaplastic Thyroid Cancer|Relapsed/Refractory Poorly Differentiated Thyroid Cancer,2020-06-03,2023-07-31,2024-07-31,24.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1,"AffyImmune Therapeutics, Inc.","AffyImmune Therapeutics, Inc.",Weill Cornell Medical College,Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04420754
2807,NCT04424485,"thyroid cancer, papillary",Near-infrared (NIR) Fluorescence Imaging With Indocyanine Green (ICG) for Identification of Sentinel Lymph Nodes and Parathyroid Glands During Total Thyroidectomy: Prospective Randomized Clinical Trial,Near-infrared Fluorescence With Indocyanine Green for Identification of Sentinels and Parathyroids During Thyroidectomy,"Lymph Node Metastases|Sentinel Lymph Node|Thyroid Cancer|Thyroid Carcinoma, Papillary|Thyroid Metastases|Thyroid Neoplasms",2020-06-02,2021-06-01,2021-06-01,100.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Department of General Surgery",Procedure|Procedure|Diagnostic Test|Diagnostic Test,Turkey,17.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04424485
2808,NCT04425512,thyroid neoplasms,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Differentiation of Thyroid Malignancy and Nodular Goiter,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy,Delta Neutrophyl Index|Immature Granulocyte Count|Neutrophyl to Lymphocyte Ratio|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2020-04-23,2019-11-01,2019-11-01,333.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Kahramanmaras Sutcu Imam University,Kahramanmaras Sutcu Imam University,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04425512
2809,NCT04425512,thyroid nodule,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Differentiation of Thyroid Malignancy and Nodular Goiter,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy,Delta Neutrophyl Index|Immature Granulocyte Count|Neutrophyl to Lymphocyte Ratio|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2020-04-23,2019-11-01,2019-11-01,333.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Kahramanmaras Sutcu Imam University,Kahramanmaras Sutcu Imam University,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04425512
2810,NCT04433936,hyperthyroidism,Corneal Tomographic Analysis Among Patients With Thyroid Gland Dysfunction.,Corneal Tomographic Parameters in TGD,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,2020-06-13,2018-06-01,2018-06-01,100.0,Case-Control,,Prospective,Observational,Completed,,Mansoura University,Ameera Gamal Abdelhameed,Mansoura University,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04433936
2811,NCT04433936,graves disease,Corneal Tomographic Analysis Among Patients With Thyroid Gland Dysfunction.,Corneal Tomographic Parameters in TGD,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,2020-06-13,2018-06-01,2018-06-01,100.0,Case-Control,,Prospective,Observational,Completed,,Mansoura University,Ameera Gamal Abdelhameed,Mansoura University,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04433936
2812,NCT04433936,graves ophthalmopathy,Corneal Tomographic Analysis Among Patients With Thyroid Gland Dysfunction.,Corneal Tomographic Parameters in TGD,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,2020-06-13,2018-06-01,2018-06-01,100.0,Case-Control,,Prospective,Observational,Completed,,Mansoura University,Ameera Gamal Abdelhameed,Mansoura University,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04433936
2813,NCT04433936,goiter,Corneal Tomographic Analysis Among Patients With Thyroid Gland Dysfunction.,Corneal Tomographic Parameters in TGD,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,2020-06-13,2018-06-01,2018-06-01,100.0,Case-Control,,Prospective,Observational,Completed,,Mansoura University,Ameera Gamal Abdelhameed,Mansoura University,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04433936
2814,NCT04447183,thyroid neoplasms,A Phase II Study of the Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.,The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.,Differentiated Thyroid Cancer,2020-06-23,2022-02-28,2022-10-31,120.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Other,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04447183
2815,NCT04450472,euthyroid sick syndromes,Nonthyroidal Illness Syndrome in Patients With Short Bowel Syndrome,Nonthyroidal Illness Syndrome in SBS,Nonthyroidal Illness Syndrome|Short Bowel Syndrome,2020-06-25,2018-12-31,2018-12-31,51.0,Cohort,,Retrospective,Observational,Completed,,"Jinling Hospital, China","Jinling Hospital, China",,,,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT04450472
2816,NCT04458233,thyroid neoplasms,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,Thyroid Nodule,2020-06-30,2021-06-01,2021-07-01,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Ziv Hospital,Ziv Hospital,Ziv Medical Center,Procedure,Israel,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04458233
2817,NCT04458233,thyroid nodule,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,Thyroid Nodule,2020-06-30,2021-06-01,2021-07-01,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Ziv Hospital,Ziv Hospital,Ziv Medical Center,Procedure,Israel,18.0,85.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04458233
2818,NCT04459273,thyroid neoplasms,PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation,Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers,Bladder Carcinoma|Cervical Carcinoma|Cholangiocarcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Hepatocellular Carcinoma|Malignant Adrenal Gland Neoplasm|Malignant Brain Neoplasm|Malignant Pleural Neoplasm|Malignant Skin Neoplasm|Malignant Solid Neoplasm|Malignant Testicular Neoplasm|Malignant Thymus Neoplasm|Neuroendocrine Neoplasm|Thyroid Gland Carcinoma|Urothelial Carcinoma,2020-07-01,2023-07-01,2024-07-01,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04459273
2819,NCT04462471,"thyroid cancer, papillary",A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers,Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers,"BRAF V600E Mutation Positive|Thyroid Cancer|Thyroid Cancer, Follicular|Thyroid Cancer (Follicular Cell)|Thyroid Cancer, Papillary|Thyroid Carcinoma",2020-07-02,2023-12-31,2024-12-31,32.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan-Kettering Cancer Center (All protocol activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Diagnostic Test|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04462471
2821,NCT04463316,hypoparathyroidism,GROWing Up With Rare GENEtic Syndromes .When Children With Complex Genetic Syndromes Reach Adult Age,GROWing Up With Rare GENEtic Syndromes,"17p- Deletiesyndrome|1q25-32 Deletie|22q11 Deletion Syndrome|46, XY DSD|Albright Hereditaire Osteodystrofie|Allan-Herndon-Dudley Syndrome|Bardet Biedl Syndrome|CHARGE Syndrome|Congenital Adrenal Hyperplasia|Congenital Hypopituitarism|Cornelia de Lange Syndrome|Disorders of Sex Development|Jacobsen Syndrome / 11 q Syndrome|Kallmann Syndrome|Klinefelter (XXY-)Syndrome|Myrhe Syndrome|Neurofibromatosis|Noonan Syndrome|Ohdo Syndrome|POLR3A Mutatie|Prader-Willi Syndrome|PWS-like Syndrome|Rare Bone Disorders|Rett Syndrome|Saethre-Chotzen Syndrome|Silver Russel Syndrome|Tuberous Sclerosis|Turner Syndrome|VCF Syndrome|Williams-Beuren Syndrome|XXXX Syndrome (Tetra-X Syndrome)|XXXXY Syndrome|XXYY Syndrome",2020-07-02,2030-01-01,2030-01-01,600.0,Cohort,,Retrospective,Observational,Recruiting,,Erasmus Medical Center,dr. Laura C. G. de Graaff-Herder,Erasmus Medical Center,Diagnostic Test,Netherlands,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04463316
2823,NCT04463719,thyroid neoplasms,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-06,2022-06-30,2025-06-30,90.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral|Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04463719
2824,NCT04463719,thyroid nodule,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-06,2022-06-30,2025-06-30,90.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral|Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04463719
2825,NCT04467021,thyroid neoplasms,Cancer Therapy Risk-Reduction With Intensive Systolic BP Management (CARISMA) - a Phase II Study,"Cancer and Blood Pressure Management, CARISMA Study",Cardiovascular Disorder|Chronic Kidney Disease|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,2020-07-07,2023-02-01,2023-02-01,60.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Eastern Cooperative Oncology Group,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI),Siteman Cancer Center at West County Hospital|Washington University School of Medicine|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Montefiore Medical Center - Moses Campus|University of Pennsylvania/Abramson Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|UT Southwestern/Simmons Cancer Center-Dallas|Aurora Cancer Care-Southern Lakes VLCC|Aurora Saint Luke's South Shore|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Aurora BayCare Medical Center|Aurora Cancer Care-Kenosha South|Aurora Bay Area Medical Group-Marinette|Aurora Cancer Care-Milwaukee|Aurora Saint Luke's Medical Center|Aurora Sinai Medical Center|Vince Lombardi Cancer Clinic - Oshkosh|Aurora Cancer Care-Racine|Vince Lombardi Cancer Clinic-Sheboygan|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center,Other|Other|Other|Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04467021
2826,NCT04472026,thyroid neoplasms,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM1: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-10,2022-06-30,2025-06-30,90.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04472026
2827,NCT04472026,thyroid nodule,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM1: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-10,2022-06-30,2025-06-30,90.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04472026
2830,NCT04472988,thyroiditis,The Effects of Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults: a Randomized Controlled Trial,Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults,Hashimoto,2020-07-07,2020-12-05,2021-03-23,91.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Bucharest,University of Bucharest,University of Bucharest,Behavioral|Other|Drug,Romania,18.0,55.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04472988
2831,NCT04477798,thyroid nodule,Protein Classifier for Thyroid Indeterminate Nodules a Multi-center Prospective Clinical Study,Protein Classifier for Thyroid Indeterminate Nodules,Thyroid Nodule,2020-07-10,2021-07-01,2021-12-31,320.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Zhejiang University,Luo Dingcun,Hangzhou First People's Hospital Affiliated to Zhejiang University Medical College,Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04477798
2832,NCT04477798,thyroid neoplasms,Protein Classifier for Thyroid Indeterminate Nodules a Multi-center Prospective Clinical Study,Protein Classifier for Thyroid Indeterminate Nodules,Thyroid Nodule,2020-07-10,2021-07-01,2021-12-31,320.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Zhejiang University,Luo Dingcun,Hangzhou First People's Hospital Affiliated to Zhejiang University Medical College,Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04477798
2833,NCT04481893,thyroid neoplasms,Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy,Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy,Thyroid Cancer|Thyroidectomy,2020-07-07,2024-04-30,2024-04-30,72.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Centre Francois Baclesse,Centre Francois Baclesse,Centre Franois Baclesse|CHU CAEN|Clinique Mathilde,Behavioral,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04481893
2834,NCT04482907,thyroiditis,Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients,Effect of Dill in Thyroiditis and Nodular Goiter Patients,Thyroid Nodule,2020-07-16,2019-12-16,2020-04-05,68.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Sabahattin Destek,Dietary Supplement,Turkey,18.0,76.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04482907
2835,NCT04482907,thyroid neoplasms,Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients,Effect of Dill in Thyroiditis and Nodular Goiter Patients,Thyroid Nodule,2020-07-16,2019-12-16,2020-04-05,68.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Sabahattin Destek,Dietary Supplement,Turkey,18.0,76.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04482907
2837,NCT04482907,goiter,Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients,Effect of Dill in Thyroiditis and Nodular Goiter Patients,Thyroid Nodule,2020-07-16,2019-12-16,2020-04-05,68.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Sabahattin Destek,Dietary Supplement,Turkey,18.0,76.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04482907
2838,NCT04482907,thyroid nodule,Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients,Effect of Dill in Thyroiditis and Nodular Goiter Patients,Thyroid Nodule,2020-07-16,2019-12-16,2020-04-05,68.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Sabahattin Destek,Dietary Supplement,Turkey,18.0,76.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04482907
2840,NCT04484116,hyperparathyroidism,USEFULNESS OF IOPTH AS A PREDICTOR FOR SUCCESSFUL PARATHYROIDECTOMY IN SECONDARY HYPERPARATHYROIDISM: A COHORT STUDY,IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2020-07-20,2019-11-30,2019-11-30,30.0,Cohort,,Prospective,Observational,Completed,,Hospital General Ajusco Medio,Hospital General Ajusco Medio,Hospital General Ajusco Medio,Diagnostic Test,Mexico,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04484116
2843,NCT04485975,thyrotoxicosis,Preoperative Therapeutic Plasma Exchange and Surgical Treatment in Thyrotoxicosis Patients: a Single-centre Retrospective Cohort Study,Therapeutic Plasma Exchange in Thyrotoxicosis,Thyrotoxicosis,2020-06-30,2019-02-01,2020-04-01,27.0,Cohort,,Retrospective,Observational,Completed,,Baskent University,Baskent University,,Device,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04485975
2844,NCT04488406,graves disease,Genetics and Epigenetics of Graves' Orbitopathy,Genetics and Epigenetics of Graves' Orbitopathy,Graves Ophthalmopathy,2020-07-17,2020-03-31,2020-03-31,12.0,Case-Control,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04488406
2845,NCT04488406,graves ophthalmopathy,Genetics and Epigenetics of Graves' Orbitopathy,Genetics and Epigenetics of Graves' Orbitopathy,Graves Ophthalmopathy,2020-07-17,2020-03-31,2020-03-31,12.0,Case-Control,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04488406
2846,NCT04488406,goiter,Genetics and Epigenetics of Graves' Orbitopathy,Genetics and Epigenetics of Graves' Orbitopathy,Graves Ophthalmopathy,2020-07-17,2020-03-31,2020-03-31,12.0,Case-Control,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04488406
2847,NCT04488406,hyperthyroidism,Genetics and Epigenetics of Graves' Orbitopathy,Genetics and Epigenetics of Graves' Orbitopathy,Graves Ophthalmopathy,2020-07-17,2020-03-31,2020-03-31,12.0,Case-Control,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04488406
2848,NCT04488640,thyroid neoplasms,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With Thyroid Imaging Reporting and Data System Score and Surgical Pathology,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With TIRADS Score and Surgical Pathology,Thyroid Nodule,2020-07-15,2020-01-01,2020-05-01,4.0,Cohort,,Retrospective,Observational,Completed,,Bezmialem Vakif University,Bezmialem Vakif University,,Procedure,,24.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04488640
2849,NCT04488640,thyroid nodule,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With Thyroid Imaging Reporting and Data System Score and Surgical Pathology,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With TIRADS Score and Surgical Pathology,Thyroid Nodule,2020-07-15,2020-01-01,2020-05-01,4.0,Cohort,,Retrospective,Observational,Completed,,Bezmialem Vakif University,Bezmialem Vakif University,,Procedure,,24.0,85.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04488640
2850,NCT04495985,thyroid neoplasms,Breast Uptake on Radioiodine Scan and Serum Prolactin in Thyroid Cancer Patients Prepared by Thyroid Hormone Withdrawal or Recombinant Human Thyrotropin: A Prospective Study,CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer,Thyroid Cancer,2020-06-10,2023-06-30,2023-08-31,130.0,Cohort,,Prospective,Observational,Enrolling by invitation,,The Cleveland Clinic,The Cleveland Clinic,Cleveland Clinic,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04495985
2851,NCT04500925,"thyroid cancer, papillary",The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience,The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience,Papillary Thyroid Cancer|Well Differentiated Thyroid Carcinoma,2020-07-31,2018-01-01,2020-01-01,301.0,Cohort,,Retrospective,Observational,Completed,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,,Procedure,,38.0,61.0,[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04500925
2853,NCT04509011,hypoparathyroidism,Randomized Controlled Trial of Fluobeam LX Compared With Clinical Assessment of Parathyroid Glands to Counteract Postoperatively Failing Parathyroid Function With Low Blood Calcium After Thyroid Surgery,Autofluorescence vs Clinical Assessment of Parathyroid Glands During Thyroid Surgery,Hypoparathyroidism Postprocedural,2020-08-04,2022-12-31,2023-07-31,400.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Region Skane,"Haukeland University Hospital|Hospital Rudolfstiftung|Jagiellonian University|Region Skane|Sahlgrenska University Hospital, Sweden","Rudolfstiftung|Haukeland University Hospital|Jagiellonian University Medical College|Sahlgrenska University Hospital|Skne University Hospital, Department of Surgery, Lund",Device,Austria|Norway|Poland|Sweden,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04509011
2855,NCT04514484,thyroid neoplasms,Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection,Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV,Advanced Differentiated Thyroid Gland Carcinoma|Advanced Head and Neck Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Kaposi Sarcoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Prostate Carcinoma|Advanced Renal Cell Carcinoma|Advanced Thyroid Gland Medullary Carcinoma|Advanced Urothelial Carcinoma|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|HIV Infection|Metastatic Differentiated Thyroid Gland Carcinoma|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Kaposi Sarcoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Kaposi Sarcoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Medullary Carcinoma|Recurrent Triple-Negative Breast Carcinoma|Recurrent Urothelial Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Triple-Negative Breast Carcinoma,2020-08-14,2025-11-02,2025-11-02,18.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Northwestern University|Montefiore Medical Center-Einstein Campus|University of Pittsburgh Cancer Institute (UPCI),Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04514484
2856,NCT04521348,thyroid neoplasms,A Phase II Study to Explore the Safety and Efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined With Anti-Programmed Death-1(PD-1) Antibody in the Treatment of Advanced Thyroid Cancer,Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer,Thyroid Cancer,2019-10-25,2022-06-30,2023-06-30,115.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04521348
2857,NCT04522570,thyroid neoplasms,Ultrasound Guided Percutaneous Thermal Ablation of Cervical Metastases From Thyroid Carcinoma,Thermal Ablation of Cervical Metastases From Thyroid Carcinoma,Lymph Node Metastases|Medullary Thyroid Cancer|Thyroid Neoplasia|Well-Differentiated Thyroid Cancer,2020-08-10,2022-12-31,2023-12-31,120.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Instituto do Cancer do Estado de So Paulo,Instituto do Cancer do Estado de So Paulo,Instituto do Cancer do Estado de So Paulo,Device|Device|Device,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04522570
2859,NCT04522622,hyperparathyroidism,Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease,Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease,Adynamic Bone Disease|Cardiac Disease|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,2020-08-13,2024-02-01,2025-02-01,66.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Herlev Hospital,"Ditte Hansen|Odense University Hospital|Rigshospitalet, Denmark|Steno Diabetes Center Copenhagen|Universiteit Antwerpen","Steno Diabetes Center Copenhagen|Herlev and Gentofte Hospital, Herlev Hospital|Odense University Hospital",Drug|Diagnostic Test|Procedure|Diagnostic Test|Other|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04522622
2862,NCT04523974,hyperparathyroidism,Preemptive Surgical Intervention and Precise Efficacy Evaluation for Hyperparathyroidism Secondary to Chronic Kidney Disease,Preemptive and Precise Intervention for CKD-SHPT,"Hyperparathyroidism; Secondary, Renal",2020-08-17,2022-09-30,2022-12-31,50.0,Cohort,,Prospective,Observational,Not yet recruiting,,Shanghai Zhongshan Hospital,Shanghai Zhongshan Hospital,,Procedure,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04523974
2864,NCT04524884,thyroid neoplasms,The Efficacy and Safety of Anti-PD-1 Antibody Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study,Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study,Thyroid Cancer,2020-08-20,2022-04-30,2022-09-30,10.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,Fudan University,Fudan University,"270 Dongan Road, Fudan University Shanghai Cancer Center",Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04524884
2865,NCT04528225,hypothyroidism,Hypothyroidism After Postoperative Radiation Therapy in Patients With Breast Cancera Prospective Clinical Study,A Prospective Study of Hypothyroidism After Radiotherapy for Breast Cancer,Breast Neoplasms|Hypothyroidism|Radiation Toxicity,2020-08-22,2020-02-24,2020-02-24,729.0,Cohort,,Prospective,Observational,Completed,,Chinese Academy of Medical Sciences,Chinese Academy of Medical Sciences,"Cancer Hospital, Chinese Academy of Medical Sciences",,China,18.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04528225
2866,NCT04544111,"thyroid cancer, papillary",Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2023-09-02,2023-09-02,30.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04544111
2868,NCT04544111,"adenocarcinoma, follicular",Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2023-09-02,2023-09-02,30.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT04544111
2869,NCT04548284,hyperthyroidism,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,142.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04548284
2870,NCT04548284,goiter,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,142.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04548284
2871,NCT04548284,graves disease,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,142.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04548284
2872,NCT04548284,graves ophthalmopathy,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,142.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04548284
2874,NCT04551170,pseudopseudohypoparathyroidism,Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism,Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism|Pseudohypoparathyroidism Type 1a,2020-09-09,2025-06-30,2025-06-30,34.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Drug|Drug,United States,2.0,12.0,[0-17],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04551170
2875,NCT04552769,"thyroid carcinoma, anaplastic",Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Anaplastic Thyroid Cancer|Thyroid Cancer|Undifferentiated Thyroid Cancer,2020-09-11,2022-09-30,2023-09-30,17.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Stanford University,Stanford University,Stanford University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04552769
2877,NCT04554680,thyroid neoplasms,Phase II Clinical Trial in Radioactive Iodine-Refractory Advanced Thyroid Carcinoma Evaluating BRAF & MEK Blockade Therapy for Re-differentiation- Applying a Novel Time-Dependent Concept,Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy,Thyroid Cancer,2020-08-29,2021-12-31,2022-04-30,5.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"National University Hospital, Singapore","National University Hospital, Singapore|Singapore General Hospital",National University Hospital,Drug,Singapore,21.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04554680
2878,NCT04560127,thyroid neoplasms,"A Single-arm, Non-randomized, Single-center Study to Evaluate Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer",Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer,Radioactive Iodine-refractory Differentiated Thyroid Cancer,2020-09-17,2022-12-31,2023-06-30,10.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04560127
2879,NCT04560426,thyroid neoplasms,Protective Effect of Intraoperative Parathyroid Gland Auxiliary Recognition System in Thyroid Malignant Tumor Operation,Protective Effect of Intraoperative Parathyroid Gland Auxiliary Recognition System in Thyroid Malignant Tumor Operation,Intraoperative Monitoring|Parathyroid|Thyroid Cancer,2020-08-29,2021-10-31,2022-10-31,200.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Device,China,20.0,50.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04560426
2880,NCT04563780,thyroid neoplasms,The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer,The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2020-09-21,2021-12-31,2021-12-31,113.0,Other,,Retrospective,Observational,Recruiting,,Assiut University,Assiut University,Aya Khaled Mahmoud,Device,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04563780
2881,NCT04564924,hyperparathyroidism,To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease Compared to Healthy Volunteers With MRI,To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease With MRI,Chronic Kidney Disease-Mineral and Bone Disorder,2020-09-14,2021-09-30,2022-01-30,200.0,Cohort,,Prospective,Observational,Recruiting,,Tongji Hospital,Tongji Hospital,Tongji Hospital,Radiation,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04564924
2884,NCT04569513,parathyroid diseases,The Analysis of Thyroidectomy and Parathyroidectomy,The Analysis of Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Diseases,2020-05-11,2024-06-30,2024-12-31,12000.0,Cohort,,Retrospective,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,Ting-Chun Kuo,Biological,Taiwan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04569513
2886,NCT04569604,hypoparathyroidism,Impaired Quality of Life and Cognitive Function in Patients With Hypoparathyroidism Might be Explained by Disturbed Capillary Flow Patterns in the Brain,QoL and Cognitive Function in Patients With Hypoparathyroidism,Hypoparathyroidism|Pseudo Hypoparathyroidism,2019-09-02,2020-10-01,2021-12-01,64.0,Case-Control,,Cross-Sectional,Observational,Completed,,University of Aarhus,University of Aarhus,"Clinic for Osteoporosis, Aarhus University Hospital",Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Denmark,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04569604
2888,NCT04569604,pseudohypoparathyroidism,Impaired Quality of Life and Cognitive Function in Patients With Hypoparathyroidism Might be Explained by Disturbed Capillary Flow Patterns in the Brain,QoL and Cognitive Function in Patients With Hypoparathyroidism,Hypoparathyroidism|Pseudo Hypoparathyroidism,2019-09-02,2020-10-01,2021-12-01,64.0,Case-Control,,Cross-Sectional,Observational,Completed,,University of Aarhus,University of Aarhus,"Clinic for Osteoporosis, Aarhus University Hospital",Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Denmark,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04569604
2889,NCT04570033,parathyroid neoplasms,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,Hyperparathyroidism|Parathyroid Adenoma,2020-09-21,2020-01-01,2020-01-01,65.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"Military Institute of Medicine, Poland","Medical University of Warsaw|Military Institute of Medicine, Poland",,Diagnostic Test,,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04570033
2891,NCT04570033,hyperparathyroidism,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,Hyperparathyroidism|Parathyroid Adenoma,2020-09-21,2020-01-01,2020-01-01,65.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"Military Institute of Medicine, Poland","Medical University of Warsaw|Military Institute of Medicine, Poland",,Diagnostic Test,,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04570033
2892,NCT04574258,thyroid neoplasms,Contrast-enhanced Ultrasound in Thyroid Tumor by Sonozoid,Prospective Multicenter Study on Clinical Application of Sonozoid in Thyroid Tumor,Ultrasound,2020-09-18,2021-05-01,2021-08-01,371.0,Other,,Prospective,Observational,Completed,,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04574258
2893,NCT04574817,"thyroid carcinoma, anaplastic","A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With Anaplastic Thyroid Cancer",Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC),Anaplastic Thyroid Cancer,2020-09-29,2022-05-30,2023-05-30,66.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,Taizhou Hanzhong biomedical co. LTD,Taizhou Hanzhong biomedical co. LTD,"Cancer Hospital, Chinese Academy of Medical Sciences",Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04574817
2895,NCT04574947,parathyroid neoplasms,Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study),Lidocaine And Neuromonitoring in Thyroid Surgery,Anesthesia|Parathyroid Neoplasms|Thyroid Neoplasm,2020-09-24,2021-11-15,2021-12-01,231.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",St. Petersburg State University Hospital,Drug|Drug|Procedure|Procedure,Russian Federation,45.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04574947
2897,NCT04574947,thyroid neoplasms,Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study),Lidocaine And Neuromonitoring in Thyroid Surgery,Anesthesia|Parathyroid Neoplasms|Thyroid Neoplasm,2020-09-24,2021-11-15,2021-12-01,231.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",St. Petersburg State University Hospital,Drug|Drug|Procedure|Procedure,Russian Federation,45.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04574947
2898,NCT04577664,hyperthyroidism,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Total Versus Subtotal Thyroidectomy in Graves' Disease At AUH,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,60.0,,Single Group Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04577664
2899,NCT04577664,goiter,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Total Versus Subtotal Thyroidectomy in Graves' Disease At AUH,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,60.0,,Single Group Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04577664
2900,NCT04577664,graves disease,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Total Versus Subtotal Thyroidectomy in Graves' Disease At AUH,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,60.0,,Single Group Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04577664
2901,NCT04579757,"thyroid carcinoma, anaplastic",An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors,Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors,Anaplastic Thyroid Cancer|Colorectal Cancer|Gastric Cancer|Metastatic Solid Tumor|Neuroendocrine Tumors|Small Cell Lung Cancer|Soft Tissue Sarcoma,2020-09-02,2024-04-30,2024-06-30,135.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Hutchison Medipharma Limited,BeiGene|Hutchison Medipharma Limited,"Arizona Oncology Associated, PC-HOPE|City of Hope|Rocky Mountain Cancer Centers Midtown|Johns Hopkins University - Sibley Memorial Hospital|Emory University - Winship Cancer Institute|Holden Comprehensive Cancer Center, University of Iowa|Memorial Sloan Kettering Cancer Center|University Hospitals Cleveland Medical Center|University of Pennsylvania, Perelman Center for Advanced Medicine|Prisma Health - Upstate (ITOR)|Sarah Cannon|Vanderbilt University Medical Center|Mary Crowley Cancer Research|Texas Oncology - Baylor Charles A. Sammons Cancer Center|Texas Oncology, P.A.|The University of Texas MD Anderson Cancer Center|Texas Oncology, P.A.|Virginia Cancer Specialists, PC",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04579757
2902,NCT04580199,thyroid nodule,"Surgical (Total or Hemithyroidectomy)Versus Non Surgical (Ethanol Ablation ,RF Ablation ,Laser Ablation) Management of Thyroid Nodule",Surgical Versus Non Surgical Management of Thyroid Nodule,Thyroid Nodule,2020-10-02,2021-12-01,2022-12-01,100.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Mahmoud Fahd,,Procedure,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04580199
2903,NCT04580199,thyroid neoplasms,"Surgical (Total or Hemithyroidectomy)Versus Non Surgical (Ethanol Ablation ,RF Ablation ,Laser Ablation) Management of Thyroid Nodule",Surgical Versus Non Surgical Management of Thyroid Nodule,Thyroid Nodule,2020-10-02,2021-12-01,2022-12-01,100.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Mahmoud Fahd,,Procedure,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04580199
2904,NCT04583735,graves disease,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",A Study Evaluating TEPEZZA Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,57.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Ophthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Neuro-Eye Clinical Trials|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04583735
2905,NCT04583735,hyperthyroidism,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",A Study Evaluating TEPEZZA Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,57.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Ophthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Neuro-Eye Clinical Trials|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04583735
2906,NCT04583735,graves ophthalmopathy,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",A Study Evaluating TEPEZZA Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,57.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Ophthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Neuro-Eye Clinical Trials|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04583735
2907,NCT04583735,goiter,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",A Study Evaluating TEPEZZA Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,57.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Ophthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Neuro-Eye Clinical Trials|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04583735
2908,NCT04589624,thyroid neoplasms,Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer,An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy,Thyroid Gland Carcinoma,2020-09-20,2022-12-31,2022-12-31,12.0,,Parallel Assignment,,Interventional,Recruiting,Early Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04589624
2909,NCT04589884,parathyroid diseases,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Digestive Cancer|Digestive Perfusion|Liver Cancer|Liver Metastases|Parathyroid Diseases|Thyroid Diseases,2020-10-09,2024-09-22,2024-10-22,600.0,Cohort,,Prospective,Observational,Recruiting,,IHU Strasbourg,ARC Foundation for Cancer Research|IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04589884
2910,NCT04594720,"thyroid cancer, papillary",Using Circulating Biomarkers to Identify Thyroid Cancer From the Patients With Thyroid Nodules,Circulating Biomarkers to Identify Thyroid Cancer,"Benign Thyroid Tumor|Thyroid Cancer|Thyroid Cancer, Papillary",2020-10-16,2019-10-31,2020-09-30,100.0,Case-Control,,Retrospective,Observational,Completed,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Kaohsiung Chang Gung Memorial Hospital,Other|Other,Taiwan,20.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04594720
2912,NCT04598815,graves ophthalmopathy,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus for Graves' Orbitopathy (GO),Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,54.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04598815
2913,NCT04598815,hyperthyroidism,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus for Graves' Orbitopathy (GO),Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,54.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04598815
2914,NCT04598815,goiter,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus for Graves' Orbitopathy (GO),Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,54.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04598815
2915,NCT04598815,graves disease,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus for Graves' Orbitopathy (GO),Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,54.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04598815
2918,NCT04600349,hashimoto disease,The Influence of Identity Oriented Psychotrauma Therapy on Hashimoto Disease Activity: a Randomized Controlled Trial,Identity Oriented Psychotrauma Therapy on Hashimoto in Adults,Autoimmune Thyroiditis,2020-10-19,2020-12-30,2021-03-01,70.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Bucharest,University of Bucharest,University of Bucharest,Behavioral|Drug,Romania,18.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04600349
2919,NCT04601298,"thyroid cancer, papillary",The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category IIIAUS/FLUSby Thyroid Fine-Needle AspirationFNACould be Assisted by Tumor Size for Precision Treatment,The Risk Stratification of Papillary Thyroid Cancer With AUS/FLUS by FNA,Atypia of Undetermined Significance|FLUS|Thyroid Cancer,2020-09-29,2020-09-30,2020-09-30,290.0,Case-Crossover,,Cross-Sectional,Observational,Completed,,Shanghai 10th People's Hospital,Shanghai 10th People's Hospital,Shanghai 10Th People'S Hospital,Other,China,18.0,77.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04601298
2922,NCT04604808,hypoparathyroidism,Observational Prospective Study on the Effects of Hypoparathyroidism on Post-thyroidectomy Health-related Quality of Life (QoL-hPTP),Study on the Effects of Hypoparathyroidism on Post-thyroidectomy Health-related Quality of Life (QoL-hPTP),Hypoparathyroidism Postprocedural,2020-09-29,2021-03-31,2021-11-30,40.0,Cohort,,Prospective,Observational,Completed,,Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa,Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa,Hospital Universitario de La princesa,,Spain,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04604808
2924,NCT04608253,hyperparathyroidism,A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT for Detection of Hyperfunctioning Parathyroid Glands After Prior Negative or Discordant Imaging in Primary Hyperparathyroidism,A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT in Primary Hyperparathyroidism,Primary Hyperparathyroidism|Primary Hyperparathyroidism Due to Adenoma,2020-10-27,2019-12-31,2020-08-01,36.0,Cohort,,Retrospective,Observational,Completed,,University Medical Center Groningen,University Medical Center Groningen,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04608253
2926,NCT04610723,goiter,Immunological Follow-up of Patients With Basedow's Orbitopathy : SIPO,Immunological Follow-up of Patients With Basedow's Orbitopathy,Graves Orbitopathy,2020-10-26,2021-11-01,2021-11-30,15.0,Cohort,,Prospective,Observational,Completed,,"University Hospital, Montpellier","University Hospital, Montpellier",Uhmontpellier,,France,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04610723
2927,NCT04610723,graves ophthalmopathy,Immunological Follow-up of Patients With Basedow's Orbitopathy : SIPO,Immunological Follow-up of Patients With Basedow's Orbitopathy,Graves Orbitopathy,2020-10-26,2021-11-01,2021-11-30,15.0,Cohort,,Prospective,Observational,Completed,,"University Hospital, Montpellier","University Hospital, Montpellier",Uhmontpellier,,France,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04610723
2928,NCT04610723,graves disease,Immunological Follow-up of Patients With Basedow's Orbitopathy : SIPO,Immunological Follow-up of Patients With Basedow's Orbitopathy,Graves Orbitopathy,2020-10-26,2021-11-01,2021-11-30,15.0,Cohort,,Prospective,Observational,Completed,,"University Hospital, Montpellier","University Hospital, Montpellier",Uhmontpellier,,France,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04610723
2929,NCT04610723,hyperthyroidism,Immunological Follow-up of Patients With Basedow's Orbitopathy : SIPO,Immunological Follow-up of Patients With Basedow's Orbitopathy,Graves Orbitopathy,2020-10-26,2021-11-01,2021-11-30,15.0,Cohort,,Prospective,Observational,Completed,,"University Hospital, Montpellier","University Hospital, Montpellier",Uhmontpellier,,France,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04610723
2930,NCT04612894,thyroid neoplasms,The Efficacy and Safety of Anti-PD-1 Antibody Camrelizumab Combined With Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study,Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer,Thyroid Cancer,2020-10-30,2022-12-01,2023-12-31,31.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug|Procedure|Procedure,China,14.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04612894
2933,NCT04613323,hashimoto disease,Management of Thyroid Function in Hashimoto's Thyroiditis During Pregnancy: Real-word Experience in a Secondary Endocrine Centre in Italy,Management of Thyroid Function in Hashimoto's Thyroiditis During Pregnancy,Hashimoto Disease|Pregnancy Related|Thyroid Dysfunction,2020-07-14,2022-07-01,2022-09-01,100.0,Case-Only,,Retrospective,Observational,Not yet recruiting,,Centro Diagnostico Priamar,Centro Diagnostico Priamar,,,,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04613323
2934,NCT04614389,thyroid nodule,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography in Conjunction With ACR TI-RADS for the Evaluation of Thyroid Nodules,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography,Thyroid Nodule,2019-09-25,2021-04-30,2021-07-01,200.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Southern California,Siemens Medical Solutions USA - CSG|University of Southern California,USC Department of Radiology,Other|Other|Device,United States,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04614389
2935,NCT04614389,thyroid neoplasms,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography in Conjunction With ACR TI-RADS for the Evaluation of Thyroid Nodules,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography,Thyroid Nodule,2019-09-25,2021-04-30,2021-07-01,200.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Southern California,Siemens Medical Solutions USA - CSG|University of Southern California,USC Department of Radiology,Other|Other|Device,United States,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04614389
2936,NCT04619316,thyroid neoplasms,Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: A Single Center Pilot Study,Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition,Metastatic Thyroid Cancer,2020-11-01,2024-12-31,2024-12-31,20.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,"University Hospital, Essen","University Hospital, Essen",Manuel M. Weber,Drug|Drug,Germany,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04619316
2937,NCT04623801,thyroid neoplasms,Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma,Laser Ablation of Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid|Thyroid Cancer,2020-11-06,2022-10-31,2022-10-31,10.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04623801
2939,NCT04624477,"thyroid cancer, papillary",Active Surveillance or Surgery for Primary Management of Very Low Risk Papillary Thyroid Cancer: How Often Are the Long-term Disease Management Goals Achieved?,Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer,Papillary Microcarcinoma of the Thyroid|Papillary Thyroid Cancer|Papillary Thyroid Carcinoma,2020-10-27,2025-03-31,2030-03-31,450.0,Cohort,,Prospective,Observational,Recruiting,,"University Health Network, Toronto","Canadian Cancer Society (CCS)|Canadian Institutes of Health Research (CIHR)|Centre hospitalier de l'Universit de Montral (CHUM)|CHU de Quebec-Universite Laval|Dalhousie University|Lawson Health Research Institute|McMaster University|Ottawa Hospital Research Institute|University Health Network, Toronto|University of British Columbia|University of Calgary",Nova Scotia Health|Lawson Health Research Institute|Ottawa Hospital Research Institute|University Health Network|CHU de Qubec - Universit Laval,,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04624477
2940,NCT04632524,goiter,Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection: A Randomized Controlled Trial,Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection,Haemodynamic Stability,2020-08-30,2021-12-20,2022-01-30,60.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Fayoum University Hospital,Fayoum University Hospital,Atef,Drug,Egypt,20.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04632524
2941,NCT04637360,hyperparathyroidism,To Study the Bone Turnover Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Calcium Sensing Receptor Agonist Cinacalcet Treatment,Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment,"Hyperparathyroidism; Secondary, Renal",2020-11-06,2018-12-31,2020-06-30,40.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Min-Sheng General Hospital,En Chu Kong Hospital|Min-Sheng General Hospital|National Taiwan University|Taichung Tzu Chi Hospital|Taipei Medical University|Taipei Medical University Shuang Ho Hospital,Min sheng general hospital,Drug|Drug,Taiwan,20.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04637360
2944,NCT04639388,hypoparathyroidism,Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old,Understanding of Psychotic Disorders in Children With 22q11.2DS,22q11.2 Deletion Syndrome,2020-10-01,2024-10-31,2025-01-31,80.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Hpital le Vinatier,Hpital le Vinatier,Hopital Vinatier,Behavioral,France,4.0,13.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04639388
2947,NCT04639960,hypoparathyroidism,Effects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome,Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome,22q11.2 Deletion Syndrome,2020-11-03,2021-05-01,2021-05-01,16.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,"University of Geneva, Switzerland","University of Geneva, Switzerland",Developmental imaging and psychopathology lab,Drug|Drug,Switzerland,11.0,25.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04639960
2948,NCT04644315,"thyroid cancer, papillary","A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors,"Brain Neoplasms|Bronchial Neoplasms|Carcinoma, Bronchogenic|Central Nervous System|Cholangiocarcinoma|Colonic Diseases|Colorectal Neoplasms|Digestive System Diseases|Digestive System Neoplasms|Gastrointestinal Diseases|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Diseases|Intestinal Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neoplasms|Neoplasms by Site|Neuroendocrine Tumors|Ovarian Neoplasms|Pancreatic Neoplasms|Respiratory Tract Diseases|Respiratory Tract Neoplasms|Salivary Gland Neoplasms|Sarcoma|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Neoplasms",2020-11-20,2025-08-01,2025-12-01,50.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Science 37, Inc|Science 37-Basem; Dept 004- Basem|Science 37-Beg; Dept 001 Dr. M. Beg|Science 37-Ben; Dept 003-Ben|Science 37-Cannon; Dept 002-Cannon|Science 37-Kurzrock; Dept 005-Kurzrock|Science 37-Thomas; Dept 006-Thomas|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04644315
2950,NCT04647006,thyroid neoplasms,"Comparison of Transoral Endoscopic Thyroidectomy Vestibular Approach and Open Conventional Thyroidectomy for Inflammatory Responses, Pain and Patient Satisfaction: A Prospective Study",Comparison of TOETVA and Conventional Thyroidectomy,Surgery|Thyroid|Thyroid Nodule,2020-10-06,2020-01-28,2020-03-30,40.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Basaksehir Cam & Sakura ehir Hospital,MUnlu|Sisli Hamidiye Etfal Training and Research Hospital,Sisli Etfal Research Hospiatl,Procedure,Turkey,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04647006
2951,NCT04647006,thyroid nodule,"Comparison of Transoral Endoscopic Thyroidectomy Vestibular Approach and Open Conventional Thyroidectomy for Inflammatory Responses, Pain and Patient Satisfaction: A Prospective Study",Comparison of TOETVA and Conventional Thyroidectomy,Surgery|Thyroid|Thyroid Nodule,2020-10-06,2020-01-28,2020-03-30,40.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Basaksehir Cam & Sakura ehir Hospital,MUnlu|Sisli Hamidiye Etfal Training and Research Hospital,Sisli Etfal Research Hospiatl,Procedure,Turkey,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04647006
2952,NCT04647500,hypoparathyroidism,Effects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome,Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome,22q11.2 Deletion Syndrome,2020-11-03,2022-09-30,2022-09-30,30.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of Geneva, Switzerland","University of Geneva, Switzerland",Developmental imaging and psychopathology lab,Drug,Switzerland,8.0,25.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04647500
2954,NCT04648722,hypothyroidism,Higher Post-operative Levothyroxine Substitution Dose Needed in Right Compared to Left Lobe Hemithyroidectomy - a Retrospective Cohort Study,Higher Levothyroxine Requirements After Right-side Hemithyroidectomy,Hemithyroidectomy|Hypothyroidism,2020-11-22,2020-06-12,2020-06-12,459.0,Cohort,,Retrospective,Observational,Completed,,Medical University of Vienna,Medical University of Vienna,Medical University of Vienna,Procedure,Austria,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04648722
2955,NCT04662190,hyperthyroidism,Eficcia i Seguretat de la descompressi orbitria en Orbitopatia distirodal Utilitzant Models Individualitzats d'impressi 3D Per la planificaci i simulaci de la Cirurgia.,Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,12.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitria de Manresa,Althaia Xarxa Assistencial Universitria de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04662190
2956,NCT04662190,goiter,Eficcia i Seguretat de la descompressi orbitria en Orbitopatia distirodal Utilitzant Models Individualitzats d'impressi 3D Per la planificaci i simulaci de la Cirurgia.,Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,12.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitria de Manresa,Althaia Xarxa Assistencial Universitria de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04662190
2957,NCT04662190,graves disease,Eficcia i Seguretat de la descompressi orbitria en Orbitopatia distirodal Utilitzant Models Individualitzats d'impressi 3D Per la planificaci i simulaci de la Cirurgia.,Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,12.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitria de Manresa,Althaia Xarxa Assistencial Universitria de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04662190
2958,NCT04662190,graves ophthalmopathy,Eficcia i Seguretat de la descompressi orbitria en Orbitopatia distirodal Utilitzant Models Individualitzats d'impressi 3D Per la planificaci i simulaci de la Cirurgia.,Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,12.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitria de Manresa,Althaia Xarxa Assistencial Universitria de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04662190
2959,NCT04663451,hyperthyroidism,"An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI For Hyperthyroidism, And it's Prognostic Factors.",An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.,Nodule Solitary Thyroid|Radioactive Iodine-Induced Hypothyroidism|Toxic Multinodular Goiter,2020-11-26,2020-11-24,2021-05-31,150.0,Cohort,,Retrospective,Observational,Active not recruiting,,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Radiation,Belgium,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04663451
2960,NCT04663451,hypothyroidism,"An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI For Hyperthyroidism, And it's Prognostic Factors.",An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.,Nodule Solitary Thyroid|Radioactive Iodine-Induced Hypothyroidism|Toxic Multinodular Goiter,2020-11-26,2020-11-24,2021-05-31,150.0,Cohort,,Retrospective,Observational,Active not recruiting,,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Radiation,Belgium,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04663451
2962,NCT04664413,"thyroid cancer, papillary",Correlations Between Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma,Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma,Papillary Thyroid Cancer,2020-12-05,2021-04-30,2021-05-30,300.0,Case-Only,,Retrospective,Observational,Not yet recruiting,,University of Salerno,University of Salerno,"Department of Medicine and Surgery, Univeristy of Salerno",,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04664413
2963,NCT04666103,thyroid neoplasms,Preserving Function Integrity of Neck Anatomy in Thyroid Surgery: A Randomized Clinical Trial,Function Integrity of Neck Anatomy in Thyroid Surgery,Ablation; Retina|Thyroid Carcinoma|Thyroid Nodule (Benign),2020-12-07,2021-12-31,2026-12-12,1264.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Wuhan University,Wuhan University,Zhongnan Hospital of Wuhan University,Procedure,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04666103
2964,NCT04666103,thyroid nodule,Preserving Function Integrity of Neck Anatomy in Thyroid Surgery: A Randomized Clinical Trial,Function Integrity of Neck Anatomy in Thyroid Surgery,Ablation; Retina|Thyroid Carcinoma|Thyroid Nodule (Benign),2020-12-07,2021-12-31,2026-12-12,1264.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Wuhan University,Wuhan University,Zhongnan Hospital of Wuhan University,Procedure,China,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04666103
2965,NCT04671719,hypoparathyroidism,Autotaxin in Patients With GNAS/PTH Abnormalities,Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,2020-12-11,2024-03-10,2024-03-10,110.0,Case-Control,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Centre de comptence des maladies rares de l'insulino-scrtion et de l'insulino-sensibilit|Centre de rfrence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hpital Edouard Herriot, Lyon|Centre de Rfrence des Maladies Rares du Mtabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabte de l'Enfant Hpital Bictre Paris Saclay",Biological,France,10.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04671719
2967,NCT04671719,hyperparathyroidism,Autotaxin in Patients With GNAS/PTH Abnormalities,Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,2020-12-11,2024-03-10,2024-03-10,110.0,Case-Control,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Centre de comptence des maladies rares de l'insulino-scrtion et de l'insulino-sensibilit|Centre de rfrence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hpital Edouard Herriot, Lyon|Centre de Rfrence des Maladies Rares du Mtabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabte de l'Enfant Hpital Bictre Paris Saclay",Biological,France,10.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04671719
2968,NCT04671719,pseudohypoparathyroidism,Autotaxin in Patients With GNAS/PTH Abnormalities,Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,2020-12-11,2024-03-10,2024-03-10,110.0,Case-Control,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Centre de comptence des maladies rares de l'insulino-scrtion et de l'insulino-sensibilit|Centre de rfrence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hpital Edouard Herriot, Lyon|Centre de Rfrence des Maladies Rares du Mtabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabte de l'Enfant Hpital Bictre Paris Saclay",Biological,France,10.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04671719
2970,NCT04675710,"thyroid carcinoma, anaplastic",Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer,"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2020-12-05,2024-06-30,2024-06-30,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Drug|Radiation|Biological|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04675710
2972,NCT04680650,thyroid neoplasms,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Thyroid Nodule,2020-12-11,2021-03-31,2021-03-31,66.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Cancer Center of Guangzhou Medical University,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04680650
2973,NCT04680650,thyroid nodule,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Thyroid Nodule,2020-12-11,2021-03-31,2021-03-31,66.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Cancer Center of Guangzhou Medical University,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04680650
2975,NCT04682340,graves disease,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,80.0,Case-Control,,Prospective,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04682340
2976,NCT04682340,goiter,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,80.0,Case-Control,,Prospective,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04682340
2977,NCT04682340,hypothyroidism,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,80.0,Case-Control,,Prospective,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04682340
2979,NCT04682340,hyperthyroidism,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,80.0,Case-Control,,Prospective,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04682340
2980,NCT04682340,hashimoto disease,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,80.0,Case-Control,,Prospective,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04682340
2981,NCT04683575,thyroid neoplasms,Distribution of Selenium in Patients With Differentiated Thyroid Carcinoma and Effect of Selenium Supplement on Prognosis of Patients With Differentiated Thyroid Carcinoma.,Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma,Metastasis|Recurrence|Selenium Deficiency|Thyroid Cancer TNM Staging,2020-11-26,2025-12-31,2025-12-31,5000.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Qianfoshan Hospital,Qianfoshan Hospital,The First affiliated hospital of Shandong First Medical University,Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04683575
2982,NCT04686006,graves disease,"Effectiveness of Classical Potassium Iodide Therapy for the Treatment of Untreated Patients With Graves' Hyperthyroidism, Avoiding Thionamide Drugs With Serious Side Effects of Agranulocytosis, Liver Injury, Vasculitis, Embryopathy or Frequent Side Effects of Skin Eruption",Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects,Graves Disease,2020-12-22,2005-07-01,,504.0,Case-Only,,Retrospective,Observational,Completed,,Kyushu University,Kyushu University,,Drug,,15.0,90.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04686006
2983,NCT04686006,hyperthyroidism,"Effectiveness of Classical Potassium Iodide Therapy for the Treatment of Untreated Patients With Graves' Hyperthyroidism, Avoiding Thionamide Drugs With Serious Side Effects of Agranulocytosis, Liver Injury, Vasculitis, Embryopathy or Frequent Side Effects of Skin Eruption",Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects,Graves Disease,2020-12-22,2005-07-01,,504.0,Case-Only,,Retrospective,Observational,Completed,,Kyushu University,Kyushu University,,Drug,,15.0,90.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04686006
2984,NCT04686006,goiter,"Effectiveness of Classical Potassium Iodide Therapy for the Treatment of Untreated Patients With Graves' Hyperthyroidism, Avoiding Thionamide Drugs With Serious Side Effects of Agranulocytosis, Liver Injury, Vasculitis, Embryopathy or Frequent Side Effects of Skin Eruption",Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects,Graves Disease,2020-12-22,2005-07-01,,504.0,Case-Only,,Retrospective,Observational,Completed,,Kyushu University,Kyushu University,,Drug,,15.0,90.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04686006
2986,NCT04690842,hypoparathyroidism,Implementation of PTH Measurement Intra / Post Thyroidectomy to Improve Post Surgical Safety in Pediatric Patients,Improving Safety in Pediatric Thyroidectomy by PTH Measurements,Hypoparathyroidism Postprocedural,2020-12-28,2020-04-30,2020-04-30,66.0,Cohort,,Prospective,Observational,Completed,,Hospital de Nios R. Gutierrez de Buenos Aires,Hospital de Nios R. Gutierrez de Buenos Aires,,Diagnostic Test,,2.0,19.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04690842
2987,NCT04693377,thyroid neoplasms,Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases,"Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial",Castration-Resistant Prostate Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Sarcoma|Metastatic Thyroid Gland Carcinoma|Metastatic Urothelial Carcinoma|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,2020-10-13,2023-04-01,2023-04-01,40.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Other|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04693377
2990,NCT04693936,"thyroiditis, autoimmune",Study of Metabolic Pathways for the Identification of Biomarkers in Hashimoto's Thyroiditis and Psoriasis,Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis,Hashimoto Disease|Psoriasis,2020-12-23,2023-01-31,2024-01-31,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Crete,University of Crete,"Metabolomic Medicine, Private Health Clinics",Combination Product,Greece,18.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04693936
2992,NCT04701203,hypoparathyroidism,"PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism","A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism",Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,2021-01-06,2022-01-12,2025-01-31,82.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Ascendis Pharma A/S,Ascendis Pharma Bone Diseases A/S,Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site,Combination Product|Combination Product,Canada|Denmark|Germany|Hungary|Italy|Norway|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04701203
2993,NCT04704349,parathyroid diseases,Latest Imaging SPECT System Evaluation Phase 1,Latest Imaging SPECT System Evaluation Phase 1,Dementia|Heart Diseases|Kidney Diseases|Neoplasms|Parathyroid Diseases|Parkinsonian Disorders|Pulmonary Embolism|Rheumatic Disease|Thyroid Diseases,2021-01-06,2021-01-27,2021-01-27,68.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Rgional d'Orlans,Centre Hospitalier Rgional d'Orlans,CHR d'Orleans,Radiation,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04704349
2994,NCT04704414,graves disease,Exophthalmometry With 3D Face Scanners,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,180.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04704414
2995,NCT04704414,graves ophthalmopathy,Exophthalmometry With 3D Face Scanners,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,180.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04704414
2996,NCT04704414,hyperthyroidism,Exophthalmometry With 3D Face Scanners,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,180.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04704414
2997,NCT04704414,goiter,Exophthalmometry With 3D Face Scanners,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,180.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04704414
2998,NCT04706962,thyroid neoplasms,"A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors",TH1902 in Patients With Advanced Solid Tumors,Cutaneous Melanoma|Endometrial Cancer|Epithelial Ovarian Cancer|Hormone Receptor-positive Breast Cancer|Prostate Cancer|Small-cell Lung Cancer|Solid Tumor|Thyroid Cancer|TNBC - Triple-Negative Breast Cancer,2021-01-07,2023-03-31,2023-03-31,70.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Theratechnologies,PPD|Theratechnologies,Cedars-Sinai|Karmanos Cancer Institute|START Midwest|Gettysburg Cancer Center|Mary Crowley Cancer Research|University of Texas MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04706962
3001,NCT04708626,"thyroiditis, autoimmune",Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden,Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2021-01-11,2022-08-31,2022-09-30,110.0,Cohort,,Retrospective,Observational,Active not recruiting,,Uppsala University,Uppsala University,Uppsala University,Other|Other,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04708626
3003,NCT04712760,congenital hypothyroidism,Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.,Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.,Congenital Hypothyroidism,2021-01-11,2021-03-01,2021-04-01,60.0,Case-Control,,Retrospective,Observational,Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHRU Nancy,,France,0.0,42.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04712760
3004,NCT04714918,hyperparathyroidism,Chinese Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Prevalence Survey,Chinese CKD-MBD Prevalence Survey (CRISS-MBD),Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,2021-01-14,2021-11-28,2021-11-28,9863.0,Case-Only,,Cross-Sectional,Observational,Recruiting,,Peking Union Medical College Hospital,Limeng Chen,"Peking Union Medical College Hospital|The First Affiliated Hospital, Chongqing Medical University|Fujian Provincial Hospital|The Seventh Affiliated Hospital, Sun Yat-sen University|Xiangya Hospital of Central South University|The First Hospital of China Medical University|People's Hospital of Ningxia Hui Autonomous Region|People's Hospital of Xinjiang Uygur Autonomous Region|The Second Affiliated Hospital Zhejiang University School of Medicine",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04714918
3007,NCT04730726,thyroid nodule,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,Thyroid Nodule,2021-01-26,2021-12-01,2022-04-01,50.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University Medical Center Groningen,University Medical Center Groningen,University Medical Center Groningen,Device,Netherlands,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04730726
3008,NCT04730726,thyroid neoplasms,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,Thyroid Nodule,2021-01-26,2021-12-01,2022-04-01,50.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University Medical Center Groningen,University Medical Center Groningen,University Medical Center Groningen,Device,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04730726
3009,NCT04731467,"thyroid cancer, papillary","A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors",A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors,Colorectal Adenocarcinoma|Melanoma|Non Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Solid Tumor,2021-01-24,2024-02-29,2024-03-31,80.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Purple Biotech Ltd.,Bristol-Myers Squibb|Famewave Ltd.,HonorHealth Research Institute|Yale University|Barbara Ann Karmanos Cancer Institute|The University of Texas M.D. Anderson Cancer Center|Rambam Health Care Campus|Sheba Medical Center,Drug|Drug|Drug|Drug,Israel|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04731467
3011,NCT04731740,"thyroid carcinoma, anaplastic",Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer,Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage,2021-01-26,2023-12-28,2023-12-28,36.0,,Parallel Assignment,,Interventional,Suspended,Phase 2,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies,Drug|Biological|Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04731740
3013,NCT04734457,congenital hypothyroidism,Final Height in Patients With Congenital Hypothyroidism Diagnosed by Neonatal Screening,Final Height in Patients With CH Diagnosed by the Screening,Congenital Hypothyroidism,2021-01-11,2022-03-01,2022-04-01,60.0,Cohort,,Retrospective,Observational,Not yet recruiting,,Ain Shams University,Ain Shams University,Ain Shams University,Drug,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04734457
3015,NCT04737330,graves disease,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,70.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04737330
3016,NCT04737330,goiter,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,70.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04737330
3017,NCT04737330,hyperthyroidism,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,70.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04737330
3018,NCT04737330,graves ophthalmopathy,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,70.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04737330
3020,NCT04739566,"thyroid carcinoma, anaplastic",Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO),Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer,Thyroid Gland Anaplastic Carcinoma,2021-01-29,2024-01-22,2026-01-22,18.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies,Drug|Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04739566
3021,NCT04740502,hyperparathyroidism,Surgical Approach and Outcomes in Patients With Primary Hyperparathyroidism and Unclear Preoperative Localisation Studies,Surgical Outcomes in Patients With Primary Hyperparathyroidism and Unclear Preoperative Localisation Studies,Primary Hyperparathyroidism,2021-02-01,2019-12-31,2020-12-31,242.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Cagliari,University of Cagliari,Policlinico di Monserrato|Policlinico di Monserrato,Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04740502
3024,NCT04742608,thyroid neoplasms,Isolation and Characterization of Extracellular Vesicles in Patients With Thyroid Nodules and Thyroid Cancer,Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer,Thyroid Gland Carcinoma|Thyroid Gland Nodule,2021-02-03,2023-02-01,2024-02-01,250.0,Cohort,,Prospective,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04742608
3025,NCT04742608,thyroid nodule,Isolation and Characterization of Extracellular Vesicles in Patients With Thyroid Nodules and Thyroid Cancer,Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer,Thyroid Gland Carcinoma|Thyroid Gland Nodule,2021-02-03,2023-02-01,2024-02-01,250.0,Cohort,,Prospective,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04742608
3026,NCT04742959,thyroid neoplasms,"A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors",Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,Advanced Solid Tumor|Bladder Cancer|Cholangiocarcinoma|Gallbladder Cancer|Gastric Cancer|HER2-negative Breast Cancer|Prostate Cancer|Sarcoma|Small-cell Lung Cancer|Thyroid Cancer|Triple Negative Breast Cancer,2021-02-02,2022-04-01,2022-12-01,105.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"TransThera Sciences (Nanjing), Inc.","TransThera Sciences (Nanjing), Inc.",City of Hope|The University of Chicago|Rutgers Cancer Institute|MD Anderson Cancer Center,Drug|Combination Product,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04742959
3027,NCT04745793,parathyroid diseases,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Parathyroid Diseases|Thyroid Diseases,2021-02-04,2024-02-04,2024-03-04,200.0,Cohort,,Prospective,Observational,Recruiting,,IHU Strasbourg,IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04745793
3028,NCT04747275,hypothyroidism,Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients,Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients,Hypothyroidism|Trisomy 21,2021-02-03,2022-05-31,2022-07-31,22.0,,Crossover Assignment,,Interventional,Recruiting,Phase 4,Children's Mercy Hospital Kansas City,Children's Mercy Hospital Kansas City,Children's Mercy Hospital,Drug|Drug,United States,2.0,4.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04747275
3031,NCT04750460,hypoparathyroidism,"The Effect of Teriparatide on the Early Postoperative Hypocalcemia After Parathyroidectomy in Dialysis Patients: a Pilot, Randomized Trial",Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis|Hypocalcemia|Hypoparathyroidism|Secondary Hyperparathyroidism,2021-02-02,2021-07-31,2021-07-31,20.0,,Parallel Assignment,,Interventional,Enrolling by invitation,Phase 3,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University Hospital,Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04750460
3032,NCT04750460,hyperparathyroidism,"The Effect of Teriparatide on the Early Postoperative Hypocalcemia After Parathyroidectomy in Dialysis Patients: a Pilot, Randomized Trial",Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis|Hypocalcemia|Hypoparathyroidism|Secondary Hyperparathyroidism,2021-02-02,2021-07-31,2021-07-31,20.0,,Parallel Assignment,,Interventional,Enrolling by invitation,Phase 3,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University Hospital,Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04750460
3035,NCT04752202,"thyroiditis, autoimmune",The Influence of Reducing Diets on Changes in Thyroid Parameters in Women Suffering From Obesity and Hashimoto's Disease,The Influence of Reducing Diets on Changes in Thyroid Parameters in Obese Women With Hashimoto's Disease,Hashimoto Disease|Obesity,2021-02-02,2019-04-19,2019-10-31,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Medical University of Bialystok,Medical University of Bialystok,Department of Dietetic and Clinical Nutrition; Medical University of Bialystok,Behavioral|Behavioral,Poland,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04752202
3038,NCT04754607,thyroiditis,"Effects of Low-Level Laser Therapy on Oxidative Stress Levels, Fatigue and Quality of Life in Patients With Hashimoto Thyroiditis",Effects of Low-Level Laser Therapy on Oxidative Stress Levels...,Autoimmune Diseases|Autoimmune Thyroiditis|Hashimoto Thyroiditis|Thyroid Diseases|Thyroiditis,2021-02-12,2022-04-15,2022-06-30,44.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Istanbul Medipol University Hospital,Istanbul Medipol University Hospital,Sumeyye TUNC,Other,Turkey,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04754607
3039,NCT04759053,thyroid neoplasms,"Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules, A Prospective Study",Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules,Thyroid Diseases|Thyroid Gland; Node|Thyroid Nodule,2021-02-09,2018-01-01,2018-02-01,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Kafrelsheikh University,Alexandria University|Kafrelsheikh University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04759053
3040,NCT04759053,thyroid nodule,"Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules, A Prospective Study",Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules,Thyroid Diseases|Thyroid Gland; Node|Thyroid Nodule,2021-02-09,2018-01-01,2018-02-01,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Kafrelsheikh University,Alexandria University|Kafrelsheikh University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04759053
3041,NCT04759911,"thyroid carcinoma, anaplastic",Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04759911
3043,NCT04759911,"thyroid cancer, papillary",Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04759911
3044,NCT04760171,thyroid neoplasms,An ex Vivo Study to Purify Amyloid Fibrils and Solve Their 3D Structures Using Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis,Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis,Alzheimer Disease|Amyloid|Dementia|Medullary Thyroid Cancer,2021-02-10,2023-02-28,2026-02-28,10.0,Cohort,,Prospective,Observational,Not yet recruiting,,The Leeds Teaching Hospitals NHS Trust,The Leeds Teaching Hospitals NHS Trust|University of Leeds,,,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04760171
3045,NCT04760288,thyroid neoplasms,"A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.",A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).,Thyroid Cancer,2021-02-17,2026-04-15,2028-04-15,198.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,Hoffmann-La Roche,Hoffmann-La Roche,"The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente|Instituto de Investigaciones Metabolicas (Idim)|Centro Mdico Privado CEMAIC|Instituto Medico de la Fundacion Estudios Clinicos|Sanatorio Britanico de Rosario|Centro de Investigacin Clnica - Clnica Viedma|Macquarie University Hospital|Royal North Shore Hospital|Ashford Cancer Center Research|The Alfred Hospital;Clinical Trial Pharmacy|Medizinische Universitt Graz; Klinische Abteilung fr Allgemeine HNO|CETUS Hospital Dia Oncologia|Hospital de Clinicas de Porto Alegre (HCPA) - PPDS|Irmandade Da Santa Casa de Misericordia de Porto Alegre|Fundao Pio XII Hospital de Cncer de Barretos|Instituto Do Cncer Do Estado de So Paulo Octvio Frias de Oliveira|Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncology|Complex Oncology Center Plovdiv; Department of Medical Oncology and Oncology Diseases in Pneumology|University Multiprofile Hospital For Active Treatment ""Sveti Ivan Rilski"" EAD; clinical hematology|Tom Baker Cancer Centre; Dept of Pathology|Cross Cancer Institute; Clinical Trials|McGill University Health Center; Glen-Cedars Cancer Centre, Oncology Pharmacy|Centre Hospitalier Universitaire de Sherbrooke; Pharmacie de Chimiotherapie|Clinical Hospital Centre Osijek; Hematology|Clinical Hospital Sestre Milosrdnice|Klinicki bolnicki centar Zagreb|Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed|Htel Dieu -Angers; Pharmacie / Secteur Essais Cliniques|EDOG - Institut Bergonie - PPDS|Centre Hospitalier Universitaire Lyon; Institut Hmatologique et d'Oncologie Pdiatrique|CHU Nantes|Centre Antoine Lacassagne Centre Rgional de Lutte Contre Le Cancer|Hopital Cochin|Institut Curie; Pharmacie|Hpital Saint-Louis|ICANS|Institut Universitaire de Cancer de Toulouse Oncopole; IUCT- Oncopole|Attikon University General Hospital|University of Athens Medical School - Regional General Hospital Alexandra|Kianous Stavros|Semmelweis Egyetem, II. Belgygyszati Klinika|Debreceni Egyetem Klinikai Kozpont|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont|Panchshil Hospital|Unity Hospital-Surat|Tata Memorial Hospital; Dept of Medical Oncology|HCG NCHRI Cancer Center|Deenanath Mangeshkar Hospital & Research Centre|Sparsh Hospitals & Critical Care (P) Ltd.|Dayanand Medical College and Hospital|Hadassah Medical Center|C.H. Regional Reina Sofia - PPDS|National Cancer Center|Seoul National University Hospital|Samsung Medical Center - PPDS|VU Medisch Centrum|Saint Louis University Hospital of Sacred Heart|St. Luke's Medical Center - Quezon City|Centrum Onkologii-Instytut Im. Marii Skodowskiej Curie; I Klinika Radioterapii i Chemioterapii|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Krakowie - Apteka/Pharmacy; Pharmacy|Instituto Portugus de Oncologia de Lisboa Francisco Gentil, E.P.E.|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe|Institutul National de Endocrinologie ""C. I. Parhon""; Sectorul 1 BUCURETI|Prof Dr I Chiricuta Institute of Oncology; Oncology Department|Onco Clinic Consult SA|CHUS - H. Clinico U. de Santiago|Clinica Universidad Navarra; Servicio de Farmacia|Hospital Universitario Vall d'Hebron|Hospital Clinic de Barcelona|MD Anderson Cancer Center Madrid - Espaa; Servicio de Farmacia|Hospital Universitario Ramon y Cajal|Hospital Universitario HM Sanchinarro - CIOCC; Farmacia - Ensayos Clnicos|Hospital Regional Universitario de Malaga|Hospital Universitario Virgen del Rocio|Phramongkutklao Hospital|Siriraj Hospital, Mahidol Uni ; Division of Rheumatology, Dept. of Medicine|Chulalongkorn University Hospital; Hematology|SI Institute for general and urgent surgery n.a. V.T.Zaitseva of NAMS of Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital # 4"" of Dnipro City Council - PPDS|Ukr. Scientific Practical Center of Endocrine Surgery,Transplantation of Endocrine organs&Tissues|Clinic Verum Expert LLC|Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima|St Bartholomew's Hospital|Guys Hospital; Guys Cancer Center|The Christie NHS Foundation Trust|The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton",Drug|Drug|Drug,"Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Croatia|Denmark|France|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Netherlands|Philippines|Poland|Portugal|Romania|Spain|Thailand|Ukraine|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04760288
3046,NCT04763122,thyroid neoplasms,Decline in Radioiodine Use But Not Total Thyroidectomy in Thyroid Cancer Patients Treated in United Arab Emirates- A Retrospective Study,Thyroid Cancer in United Arab Emirates,Cancer|Thyroid,2021-02-09,2018-12-31,2020-12-31,762.0,Case-Control,,Retrospective,Observational,Completed,,Tawam Hospital,Tawam Hospital,,Other,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04763122
3047,NCT04767763,hypothyroidism,Association of Continuous Veno-venous Hemodiafiltration With Citrate Anticoagulation to Thyroid Function in Critically Ill Patients,Thyroid Function in Critically Ill Patients With Acute Kidney Injury,Secondary Hypothyroidism,2021-02-17,2020-02-01,2020-02-01,32.0,Case-Control,,Prospective,Observational,Completed,,Medical University of Gdansk,Medical University of Gdansk,Medical University of Gdansk - Departament of Anesthesiology and Intensive Care,Diagnostic Test,Poland,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04767763
3048,NCT04776993,graves disease,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy,Graves' Orbitopathy,2021-02-25,2023-01-30,2025-01-30,52.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04776993
3049,NCT04776993,graves ophthalmopathy,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy,Graves' Orbitopathy,2021-02-25,2023-01-30,2025-01-30,52.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04776993
3050,NCT04776993,goiter,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy,Graves' Orbitopathy,2021-02-25,2023-01-30,2025-01-30,52.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04776993
3051,NCT04776993,hyperthyroidism,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy,Graves' Orbitopathy,2021-02-25,2023-01-30,2025-01-30,52.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04776993
3054,NCT04778865,thyroiditis,Effect of Vitamin D Supplementation on Autoimmunity and Thyroid Function in Subjects With Hashimoto's Thyroiditis and Vitamin D Deficiency: Clinical Pilot Trial.,Effect of Treatment for Vitamin D Deficiency on Thyroid Function and Autoimmunity in Hashimoto's Thyroiditis.,Hashimoto Disease|Treatment Levothyroxine|Vitamin D Deficiency,2021-02-24,2021-12-31,2021-12-31,50.0,,Crossover Assignment,,Interventional,Recruiting,Not Applicable,Universidad de Valparaiso,Universidad de Valparaiso,Escuela de Nutricin. Facultad de Farmacia. Universidad de Valparaso.,Dietary Supplement|Dietary Supplement,Chile,18.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04778865
3055,NCT04782856,goiter,Energy Metabolism in Thyroidectomized Patients,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2023-05-31,2023-05-31,30.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04782856
3056,NCT04782856,thyroid neoplasms,Energy Metabolism in Thyroidectomized Patients,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2023-05-31,2023-05-31,30.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04782856
3057,NCT04782856,hypothyroidism,Energy Metabolism in Thyroidectomized Patients,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2023-05-31,2023-05-31,30.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04782856
3058,NCT04784208,hypothyroidism,A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY),A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY),Healthy|Hypothyroidism,2021-02-25,2022-06-30,2022-06-30,232.0,Other,,Prospective,Observational,Recruiting,,Abbott,Abbott,"Dr.Prasanna Kumar|Dr. MV Rama Mohan, MD, DM",Diagnostic Test,India,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04784208
3060,NCT04785443,hypoparathyroidism,Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Thyroid Diseases,2021-02-25,2024-06-30,2025-03-31,242.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,"University Hospital, Brest","University Hospital, Brest",CHRU de Brest,Drug|Procedure,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04785443
3061,NCT04787328,thyroid neoplasms,"A Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)",A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC),Medullary Thyroid Carcinoma,2021-02-24,2023-03-31,2025-03-31,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","Beijing Tongren Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Henan Province Tumor Hospital|Jiangsu province tumor hospital|Cancer Hospital of Fudan University|Sichuan Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Tianjin People's Hospital|The First Affiliated Hospital of Kunming Medical University|Zhejiang Provincial People's Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04787328
3063,NCT04789993,graves disease,Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France,Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,2021-02-20,2021-03-31,2021-04-30,250.0,Cohort,,Retrospective,Observational,Enrolling by invitation,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",Hpital d'Enfants de Brabois,Other,France,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04789993
3065,NCT04789993,goiter,Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France,Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,2021-02-20,2021-03-31,2021-04-30,250.0,Cohort,,Retrospective,Observational,Enrolling by invitation,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",Hpital d'Enfants de Brabois,Other,France,6.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04789993
3066,NCT04789993,hyperthyroidism,Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France,Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,2021-02-20,2021-03-31,2021-04-30,250.0,Cohort,,Retrospective,Observational,Enrolling by invitation,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",Hpital d'Enfants de Brabois,Other,France,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04789993
3067,NCT04789993,thyroiditis,Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France,Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,2021-02-20,2021-03-31,2021-04-30,250.0,Cohort,,Retrospective,Observational,Enrolling by invitation,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",Hpital d'Enfants de Brabois,Other,France,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04789993
3068,NCT04795947,hypothyroidism,Correlation Between Thyroid Function and Quality of Life in Well-controlled Hypothyroidism Patients,Correlation Between Thyroid Function and Quality of Life in Hypothyroidism,Hypothyroidism,2021-03-10,2021-11-01,2021-11-01,98.0,Other,,Cross-Sectional,Observational,Active not recruiting,,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,BeijingCYH,Behavioral,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04795947
3069,NCT04798092,hyperparathyroidism,Impact of Parathyroidectomy on Renal Function in Patients With Primary Hyperparathyroidism,Impact of Parathyroidectomy on Renal Function,Primary Hyperparathyroidism,2021-01-29,2022-01-31,2022-01-31,500.0,Cohort,,Retrospective,Observational,Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHRU Nancy,Procedure,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04798092
3072,NCT04802876,thyroid neoplasms,Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff,Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors,Anal Carcinoma|Bladder Carcinoma|Carcinoma of Unknown Primary|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Adenocarcinoma|Esophageal Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|HER2-positive Breast Cancer|Hormone Receptor Positive / HER2-negative Breast Cancer|Kidney Clear Cell Carcinoma|Lung Adenocarcinoma|Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation|Lung Squamous Cell Carcinoma|Melanoma|Mesothelioma|MSI-H Colorectal Cancer|Other Histology|Ovarian Serous Cystadenocarcinoma|Pancreatic Adenocarcinoma|Prostate Adenocarcinoma|Sarcoma|Small Cell Lung Cancer|Squamous Esophageal Carcinoma|Stomach Adenocarcinoma|Thyroid Carcinoma|Triple Negative Breast Cancer|Uterine Carcinosarcoma|Uterine Endometrial Carcinoma|Uveal Melanoma,2021-03-14,2023-12-31,2024-12-11,141.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,SOLTI Breast Cancer Research Group,Novartis|SOLTI Breast Cancer Research Group,Ico Badalona|Hospital Universitari Sant Joan de Reus|IOB - H. Quironsalud Barcelona|Hospital Vall Hebron|Hospital Clinic Barcelona|Complejo Asistencial Universitario de Len|Fundacin Jimnez Daz|Hospital Universitario 12 de Octubre|Instituto Valenciano de Oncologa (IVO)|Hospital Clnico Universitario de Valencia,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04802876
3074,NCT04806269,hypothyroidism,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Symptom Survey by Wearable Device in the Patients With Thyroid Dysfunction",Biosignals by Wearables in Thyroid Dysfunction,Hypothyroidism|Thyrotoxicosis,2021-01-26,2022-05-30,2022-12-31,120.0,Case-Control,,Prospective,Observational,Recruiting,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Device,"Korea, Republic of",18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04806269
3075,NCT04806269,thyrotoxicosis,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Symptom Survey by Wearable Device in the Patients With Thyroid Dysfunction",Biosignals by Wearables in Thyroid Dysfunction,Hypothyroidism|Thyrotoxicosis,2021-01-26,2022-05-30,2022-12-31,120.0,Case-Control,,Prospective,Observational,Recruiting,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Device,"Korea, Republic of",18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04806269
3076,NCT04806672,euthyroid sick syndromes,Euthyroid Sick Syndrome (ESS).. Can it Influence Morbidity and Mortality in Moderate to Severe Traumatic Brain Injury Patients or Correlate With Glial Fibrillary Acidic Protein (GFAP) Level.,Euthyroid Sick Syndrome (ESS) Effect on Traumatic Brain Injury Patients and Its Relation With GFAP Level,Euthyroid Sick Syndromes in Traumatic Brain Injury Patient and GFAP Level,2021-03-14,2021-12-31,2022-04-30,50.0,Cohort,,Prospective,Observational,Not yet recruiting,,Minia University,Minia University,,,,18.0,60.0,[18-65],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT04806672
3077,NCT04809454,hyperthyroidism,Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt: A Cross Sectional Study,Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt,Thyroid Dysfunction,2021-03-16,2022-03-31,2022-03-31,100.0,Other,,Cross-Sectional,Observational,Not yet recruiting,,"Services Institute of Medical Sciences, Pakistan","Services Institute of Medical Sciences, Pakistan",Mehwish Iftikhar,,Pakistan,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04809454
3078,NCT04821336,thyroid neoplasms,"Cholesterol Metabolites (Dendrogenin A or DDA, 6-oxo-cholestane-3,5-diol or OCDO,...) Quantification in Malignant Versus Normal Human Thyroid Tissue Refractory to Iodine",Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance,Thyroid Cancer,2021-03-25,2022-06-30,2022-06-30,30.0,Other,,Retrospective,Observational,Not yet recruiting,,Institut Claudius Regaud,Cancer Research Center of Toulouse|Institut Claudius Regaud,Institut Claudius regaud IUCT Oncopole,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04821336
3081,NCT04823728,hashimoto disease,Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis: Part II,HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2021-03-26,2024-12-31,2025-12-31,700.0,Case-Control,,Retrospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hpital Neurologique,Genetic,France,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04823728
3082,NCT04825964,hyperthyroidism,Comparison of Exercise Capacity and Physical Activity Levels in Patients With Hyperthyroid and Healthy Controls,"Exercise Capacity, Physical Activity Levels in Patients With Hyperthyroid",Hyperthyroidism,2021-03-20,2021-11-30,2021-12-31,30.0,Case-Control,,Prospective,Observational,Completed,,Gazi University,Gazi University,"Gazi University Facutly of Health Sciences Department of Physiotheraphy and Rehabilitation, Cardiopulmonary Rehabilitation Unit",,Turkey,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04825964
3083,NCT04831957,hypothyroidism,Hypothyroidism After the TAVI Procedure in Elderly Patients,Hypothyroidism After the TAVI Procedure in Elderly Patients,Hypothyroidism|TAVI,2021-03-19,2023-12-31,2023-12-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,UZ brussel,Diagnostic Test,Belgium,70.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04831957
3084,NCT04842994,thyroid neoplasms,"Phase III, Assessor Blinded, Randomised Controlled Trial of Use of Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery(ACTION)",Trial on Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery.,Malignant Neoplasm of Thyroid Gland,2020-10-06,2024-08-31,2024-08-31,448.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Tata Memorial Hospital,Tata Memorial Hospital,Tata Memorial Hospital,Device,India,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04842994
3085,NCT04844164,hyperparathyroidism,"Prospective Non-randomised Controlled Study of Vitamin D Metabolism in Patients With Endocrine Disorders (Acromegaly, Cushing's Disease, Primary Hyperparathyroidism, Diabetes Mellitus Type 1) Treated With Cholecalciferol Bolus Dose",Vitamin D Metabolism in Patients With Endocrine Disorders,"Acromegaly|Diabetes Mellitus, Type 1|Pituitary ACTH Hypersecretion|Primary Hyperparathyroidism",2021-04-09,2021-05-15,2021-06-01,240.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1,"Endocrinology Research Centre, Moscow","Endocrinology Research Centre, Moscow|Russian Science Foundation","Endocrinology Research Centre, Moscow",Drug,Russian Federation,18.0,60.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04844164
3088,NCT04846010,hypothyroidism,Treating Sequalae Caused by Post-acute Sequelae of SARS (Severe Acute Respiratory Syndrome)-CoV-2 Infection,"Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2","Anxiety Disorders|Depression|Depression, Anxiety|Depression, Bipolar|Gastro Esophageal Reflux|GERD|Glomerulonephritis|Hepatitis|Insomnia|Post Infection Glomerulonephritis|Post-Infectious Arthritis|Post-Infectious Disorder (Disorder)|Post-Infectious Hypothyroidism|Post Infectious Osteoarthritis|Post-Infectious Parkinsonism|Post-Infectious Peripheral Neuralgia|Post-Infectious Polyneuritis|Sequelae of; Infection",2021-03-31,2022-05-01,2022-10-01,2000.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC","All Natural Medicine Clinic, LLC","All Natural Medicine Clinic, LLC",Combination Product|Combination Product|Combination Product|Combination Product|Combination Product|Combination Product|Combination Product,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04846010
3089,NCT04853680,thyroid nodule,A Prospective Randomized Controlled Study of Whether Anti-adhesion Barrier Can Prevent Voice Quality After Thyroidectomy.,Effect of Anti-adhesion Barrier on the Voice Quality After Thyroidectomy.,Thyroid Cancer|Thyroid Nodule|Voice Disorders,2021-04-11,2023-06-30,2023-07-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04853680
3090,NCT04853680,thyroid neoplasms,A Prospective Randomized Controlled Study of Whether Anti-adhesion Barrier Can Prevent Voice Quality After Thyroidectomy.,Effect of Anti-adhesion Barrier on the Voice Quality After Thyroidectomy.,Thyroid Cancer|Thyroid Nodule|Voice Disorders,2021-04-11,2023-06-30,2023-07-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04853680
3092,NCT04856488,graves disease,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,182.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04856488
3093,NCT04856488,goiter,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,182.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04856488
3094,NCT04856488,hyperthyroidism,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,182.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04856488
3095,NCT04857086,thyroid neoplasms,A Multi-center Study to Observe Five-year Outcomes of the Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China (The Second Stage of DTCC),The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China,Differentiated Thyroid Cancer,2021-04-20,2022-07-30,2023-03-28,1400.0,Cohort,,Retrospective,Observational,Recruiting,,Huazhong University of Science and Technology,"China-Japan Union Hospital, Jilin University|Chinese PLA General Hospital|First Hospital of China Medical University|Gansu Cancer Hospital|Huazhong University of Science and Technology|Sir Run Run Shaw Hospital|The First Affiliated Hospital of Kunming Medical College|Tongji Hospital|West China Hospital|Wuhan Union Hospital, China","Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04857086
3096,NCT04858867,thyroid neoplasms,Reinducing Radioiodine-sensitivity in Radioiodine-refractory Differentiated Thyroid Cancer Using Lenvatinib (RESET),Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET),Differentiated Thyroid Cancer,2021-04-09,2024-01-01,2024-06-01,12.0,,Sequential Assignment,,Interventional,Recruiting,Not Applicable,Leiden University Medical Center,Leiden University Medical Center,Leiden University Medical Center,Radiation|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04858867
3097,NCT04860622,hypothyroidism,Normal Range of TSH and FT4 in Pregnancy,Normal Range of TSH and FT4 in Pregnancy,Dysfunction|Hypothyroidism|Iodine Deficiency|Pregnancy Related|Thyroid,2021-04-22,2021-08-15,2021-09-01,528.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital,Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital,Sehit Prof Dr Ilhan Varank Sancaktepe Training and Research Hospital,Diagnostic Test,Turkey,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04860622
3098,NCT04868045,thyroid neoplasms,Evaluation of The Development of Central Resistance to Thyroid Hormone After Prolonged Exposure to Excess Thyroid Hormone in Thyroid Cancer Patients,Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer,Thyroid Cancer,2021-04-28,2023-04-30,2023-04-30,16.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04868045
3102,NCT04876287,thyroid neoplasms,Salivary dysfuncTion After Radioiodine Treatment,Salivary dysfuncTion After Radioiodine Treatment,Thyroid Cancer,2021-04-26,2021-04-26,2021-04-26,138.0,Cohort,,Prospective,Observational,Completed,,Institut de Radioprotection et de Surete Nucleaire,Institut de Radioprotection et de Surete Nucleaire,Piti-Salptrire hospital,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04876287
3103,NCT04876534,hyperthyroidism,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Tocilizumab in Active Moderate-severe Graves' Orbitopathy,Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,64.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04876534
3104,NCT04876534,graves disease,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Tocilizumab in Active Moderate-severe Graves' Orbitopathy,Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,64.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04876534
3105,NCT04876534,graves ophthalmopathy,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Tocilizumab in Active Moderate-severe Graves' Orbitopathy,Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,64.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04876534
3106,NCT04876534,goiter,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Tocilizumab in Active Moderate-severe Graves' Orbitopathy,Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,64.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04876534
3107,NCT04877613,thyroid neoplasms,Phase I Trial of GFR4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer,GFR4 CAR T Cells in MTC Patients,Metastatic Medullary Thyroid Cancer,2021-05-03,2039-06-01,2039-06-01,18.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1,University of Pennsylvania,University of Pennsylvania,University of Pennsylvania,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04877613
3108,NCT04877665,hypothyroidism,Establishing Reference Intervals for Thyroid Stimulating Hormone in Children Under the Age of Two Years,Establishing RIs for TSH in Children Under the Age of Two Years,Hypothyroidism,2021-05-05,2019-03-30,2019-03-30,131.0,Other,,Prospective,Observational [Patient Registry],Completed,,"Aga Khan University Hospital, Pakistan","Aga Khan University Hospital, Pakistan",The Aga Khan University,,Pakistan,1.0,24.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04877665
3109,NCT04878614,hypothyroidism,Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding,Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding,Hypothyroidism,2021-05-04,2022-04-30,2023-04-30,34.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",UCLA Center for Human Nutrition,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04878614
3111,NCT04879173,thyrotoxicosis,The Clinical Value of Microvascular Ultrasonography in Real-time Differential Diagnosis of Thyrotoxic Patients Between Hyperthyroidism and Thyroiditis,Clinical Value of Microvascular Ultrasonography in Real-time Differential Diagnosis of Thyrotoxic Patients,Hyperthyroidism/Thyrotoxicosis,2021-05-04,2021-10-31,2022-10-31,50.0,Case-Only,,Prospective,Observational,Recruiting,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St. Mary hospital,Device,"Korea, Republic of",0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04879173
3112,NCT04879355,thyroid neoplasms,The Use of Spinal Needles for Ultrasound-guided Fine Needle Aspiration From Thyroid Nodules - a Protocol for a Multicentre Randomised Controlled Trial,Spinal Needles in Ultrasound-guided Fine Needle Aspirations From Thyroid Nodules,Thyroid Nodule,2021-03-07,2022-11-01,2023-12-01,350.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Zealand University Hospital,"Herlev Hospital|Preben Home|Rigshospitalet, Denmark",,Device|Device,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04879355
3113,NCT04879355,thyroid nodule,The Use of Spinal Needles for Ultrasound-guided Fine Needle Aspiration From Thyroid Nodules - a Protocol for a Multicentre Randomised Controlled Trial,Spinal Needles in Ultrasound-guided Fine Needle Aspirations From Thyroid Nodules,Thyroid Nodule,2021-03-07,2022-11-01,2023-12-01,350.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Zealand University Hospital,"Herlev Hospital|Preben Home|Rigshospitalet, Denmark",,Device|Device,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04879355
3114,NCT04880798,thyroid neoplasms,Effect of Thyrotropin Level on Iodine Uptake: a Prospective 124I PET/CT Study in Metastatic Differentiated Thyroid Cancer,Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2021-05-06,2022-12-31,2022-12-31,10.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Peking Union Medical College Hospital,Beijing Cancer Hospital|Peking Union Medical College Hospital,Peking Union Medical College Hospital|Beijing Cancer Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04880798
3115,NCT04883294,thyroid neoplasms,Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer,Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer,Thyroid Neoplasm,2021-05-11,2024-01-01,2025-01-01,1500.0,Cohort,,Prospective,Observational,Not yet recruiting,,Maastricht University Medical Center,Maastricht University Medical Center,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04883294
3116,NCT04892303,thyroid neoplasms,Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer,Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer,Recurrent Thyroid Cancer,2021-05-03,2025-03-31,2025-08-31,48.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,The Johns Hopkins SKCCC,Combination Product,United States,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04892303
3118,NCT04895631,parathyroid neoplasms,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2021-05-13,2026-06-30,2027-06-30,140.0,,Single Group Assignment,,Interventional,Recruiting,Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04895631
3119,NCT04895631,hyperparathyroidism,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2021-05-13,2026-06-30,2027-06-30,140.0,,Single Group Assignment,,Interventional,Recruiting,Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04895631
3121,NCT04904159,thyroid neoplasms,A New Scoring System in the Diagnosis of Thyroid Gland Pathologies,Scoring System for Thyroid Gland Pathologies,Thyroid Cancer|Thyroid Nodule,2021-05-17,2023-01-01,2023-05-01,300.0,Cohort,,Prospective,Observational [Patient Registry],Enrolling by invitation,,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Kartal Dr Lutfi Kirdar Tranining and Research Hospital,Procedure|Procedure,Turkey,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04904159
3122,NCT04904159,thyroid nodule,A New Scoring System in the Diagnosis of Thyroid Gland Pathologies,Scoring System for Thyroid Gland Pathologies,Thyroid Cancer|Thyroid Nodule,2021-05-17,2023-01-01,2023-05-01,300.0,Cohort,,Prospective,Observational [Patient Registry],Enrolling by invitation,,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Kartal Dr Lutfi Kirdar Tranining and Research Hospital,Procedure|Procedure,Turkey,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04904159
3123,NCT04905641,parathyroid neoplasms,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy Under Moderate Sedation; Retrospective Study,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy,Parathyroid Adenoma|Thyroid Nodule,2021-05-26,2017-05-25,2017-07-31,19.0,Case-Only,,Retrospective,Observational,Completed,,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04905641
3124,NCT04905641,thyroid neoplasms,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy Under Moderate Sedation; Retrospective Study,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy,Parathyroid Adenoma|Thyroid Nodule,2021-05-26,2017-05-25,2017-07-31,19.0,Case-Only,,Retrospective,Observational,Completed,,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04905641
3126,NCT04905641,thyroid nodule,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy Under Moderate Sedation; Retrospective Study,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy,Parathyroid Adenoma|Thyroid Nodule,2021-05-26,2017-05-25,2017-07-31,19.0,Case-Only,,Retrospective,Observational,Completed,,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04905641
3127,NCT04916262,thyroid neoplasms,Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer,Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer,Differentiated Thyroid Carcinoma|TCM Syndrome Type,2021-05-24,2021-12-01,2022-01-01,160.0,Cohort,,Prospective,Observational,Not yet recruiting,,Qianfoshan Hospital,Qianfoshan Hospital,,,,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04916262
3128,NCT04919694,goiter,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04919694
3129,NCT04919694,graves disease,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04919694
3130,NCT04919694,graves ophthalmopathy,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04919694
3131,NCT04919694,hyperthyroidism,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04919694
3132,NCT04922801,thyroid neoplasms,OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE),Optimising Molecular Radionuclide Therapy,Hyperthyroidism|Neuroendocrine Tumors|Thyroid Cancer|Thyroid Carcinoma,2021-05-17,2022-04-20,2022-06-30,60.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,King's College London,Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas Hospitals Foundation Trust,Diagnostic Test|Diagnostic Test|Diagnostic Test|Device|Diagnostic Test,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04922801
3133,NCT04922801,hyperthyroidism,OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE),Optimising Molecular Radionuclide Therapy,Hyperthyroidism|Neuroendocrine Tumors|Thyroid Cancer|Thyroid Carcinoma,2021-05-17,2022-04-20,2022-06-30,60.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,King's College London,Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas Hospitals Foundation Trust,Diagnostic Test|Diagnostic Test|Diagnostic Test|Device|Diagnostic Test,United Kingdom,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04922801
3136,NCT04922892,hyperparathyroidism,Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism,Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism,Secondary Hyperparathyroidism;Parathyroidectomy,2021-06-07,2023-05-31,2028-05-31,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,The Second Hospital of Nanjing Medical University,The Second Hospital of Nanjing Medical University,NanjingMU,Procedure,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04922892
3137,NCT04927416,thyroid neoplasms,The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer,The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer,Metastic Thyroid Cancer,2021-06-15,2030-11-30,2030-11-30,54.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04927416
3138,NCT04927468,graves ophthalmopathy,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04927468
3139,NCT04927468,hyperthyroidism,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04927468
3140,NCT04927468,goiter,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04927468
3141,NCT04927468,graves disease,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04927468
3142,NCT04931576,thyroid neoplasms,The Feasibility of no Drainage During Transoral Endoscopic Thyroidectomy Via the Vestibular Approach in Treatment of Papillary Thyroid Carcinoma,No Drainage During Transoral Endoscopic Thyroidectomy Vestibular Approach(TOETVA),Drainage|Thyroid Cancer,2021-06-14,2023-06-01,2023-10-01,600.0,,Crossover Assignment,,Interventional,Not yet recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",,Procedure,,18.0,55.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04931576
3143,NCT04932135,hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,40.0,Cohort,,Prospective,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04932135
3144,NCT04932135,graves disease,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,40.0,Cohort,,Prospective,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04932135
3145,NCT04932135,goiter,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,40.0,Cohort,,Prospective,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04932135
3146,NCT04936854,hyperthyroidism,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04936854
3147,NCT04936854,graves ophthalmopathy,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04936854
3148,NCT04936854,graves disease,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04936854
3149,NCT04936854,goiter,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04936854
3150,NCT04940052,thyroid neoplasms,"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)","Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer",Differentiated Thyroid Cancer,2021-06-22,2024-02-19,2026-10-30,150.0,,Crossover Assignment,,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug|Drug|Drug,"China|India|Korea, Republic of|Malaysia|Taiwan|Turkey",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04940052
3153,NCT04942769,"thyroiditis, autoimmune",Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis,Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis,Selenium,2021-06-24,2021-07-30,2021-10-30,30.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,"Beijing Chao-Yang Hospital, Capital Medical University",Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04942769
3154,NCT04946123,hyperthyroidism,Association of Methimazole With L-carnitine and Selenium in Patients With Hyperthyroidism,Hyperthyroidism: Methimazole Plus L-carnitine and Selenium,Hyperthyroidism,2021-06-15,2022-06-30,2022-07-31,60.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Lo.Li.Pharma s.r.l,Lo.Li.Pharma s.r.l,Azienda Ospedaliero-Universitaria Citt della scienza e degli studi di Torino,Dietary Supplement,Italy,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04946123
3156,NCT04948437,"thyroid cancer, papillary",Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Well-differentiated Thyroid Cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer,Follicular Thyroid Cancer|Papillary Thyroid Cancer|Thyroid Cancer,2021-06-24,2024-10-31,2026-10-31,103.0,Cohort,,Prospective,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,"Chih-Yuan Wang, M.D",,Taiwan,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04948437
3157,NCT04948437,"adenocarcinoma, follicular",Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Well-differentiated Thyroid Cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer,Follicular Thyroid Cancer|Papillary Thyroid Cancer|Thyroid Cancer,2021-06-24,2024-10-31,2026-10-31,103.0,Cohort,,Prospective,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,"Chih-Yuan Wang, M.D",,Taiwan,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT04948437
3159,NCT04948671,hyperparathyroidism,Primary Hyperparathyroidism and Gut Microbiota Unravelling an Unexpected Relationship: the HYPOGEUM Study,Primary Hyperparathyroidism and Gut Microbiota,"Hyperparathyroidism, Primary",2021-06-28,2023-02-28,2024-02-28,90.0,Case-Control,,Prospective,Observational,Recruiting,,Centre Hospitalier Universitaire Vaudois,Centre Hospitalier Universitaire Vaudois|The Novartis Foundation,Patrizia D'amelio,Other,Switzerland,30.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04948671
3162,NCT04952012,"thyroiditis, autoimmune",The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,"Thyroiditis, Autoimmune",2021-06-20,2021-11-30,2022-11-30,4000.0,Case-Control,,Retrospective,Observational,Recruiting,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Changxing People's Hospital|First People's Hospital of Yuhang|Second Affiliated Hospital, School of Medicine, Zhejiang University|Taizhou Women and Children's Hospital Affiliated to Wenzhou Medical University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Drug,China,18.0,45.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04952012
3163,NCT04952493,thyroid neoplasms,"The Efficacy and Safety of Anlotinib Hydrochloride or Penpulimab In Combination With RAI in Patients With Local Advanced or Metastatic Differentiated Thyroid Cancer: A Randomized, Open-label, Exploratory Clinical Trial",Anlotinib or Penpulimab in Combination With RAI for DTC,Thyroid Cancer,2021-06-27,2023-07-20,2024-07-20,42.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Peking Union Medical College Hospital",Peking Union Medical College Hospital,Drug|Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04952493
3164,NCT04953195,hypothyroidism,Effect of Thyroid Replacement Therapy on Thyroid Structure in Patients With Subclinical Hypothyroidism,Thyroid Replacement Therapy in Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidisms,2021-06-25,2021-09-15,2021-10-30,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 4,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,"Beijing Chao-Yang Hospital, Capital Medical University",Drug,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04953195
3165,NCT04964284,thyroid neoplasms,"A Randomized, Open-label, Multi-center, Controlled Phase  Study to Evaluate the Safety and Efficacy of Recombinant Human Thryoid Stimulating HormonerhTSH for Adjuvant Radioiodine Ablation Therapy in Postoperative Patients With Differentiated Thyroid Cancer",Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2021-07-06,2022-09-30,2022-12-31,328.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Biological|Radiation,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04964284
3166,NCT04969926,parathyroid neoplasms,Natural History Study of Parathyroid Disorders,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,3000.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04969926
3169,NCT04969926,hyperparathyroidism,Natural History Study of Parathyroid Disorders,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,3000.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04969926
3171,NCT04969926,pseudohypoparathyroidism,Natural History Study of Parathyroid Disorders,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,3000.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04969926
3172,NCT04970134,thyroid neoplasms,Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY Project,Spanish Study for Molecular Characterization of Thyroid Carcinoma,Differentiated Thyroid Carcinoma|Medullary Thyroid Carcinoma,2021-07-16,2023-03-31,2024-03-31,150.0,Other,,Retrospective,Observational,Recruiting,,Grupo Espaol de Tratamiento de Tumores de Cabeza y Cuello,Grupo Espaol de Tratamiento de Tumores de Cabeza y Cuello,Hospital Universitario Durn i Reinals|Fundaci Althaia|Consorci Corporaci Sanitria Parc Taul de Sabadell|Hospital Universitario Vall d'Hebron|Hospital Clnic de Barcelona|Institut Catal d'Oncologia Girona - ICO Girona|Hospital Universitario Ramn y Cajal|Hospital Universitario La Paz|Hospital universitario Marqus de Valdecilla|Hospital General Universitario de Valencia|Hospital Universitario y Politcnico La Fe|Hospital Universitario Miguel Servet,Other|Other|Other,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04970134
3173,NCT04971473,thyroid neoplasms,"An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal",Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal,Differentiated Thyroid Cancer,2021-07-07,2023-06-30,2023-07-31,201.0,,Single Group Assignment,,Interventional,Recruiting,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Biological,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04971473
3174,NCT04976816,graves disease,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,64.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04976816
3175,NCT04976816,goiter,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,64.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04976816
3176,NCT04976816,graves ophthalmopathy,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,64.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04976816
3177,NCT04976816,hyperthyroidism,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,64.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04976816
3178,NCT04988802,hypothyroidism,The Effect of Dietary Supplements for Pregnant Women on Levothyroxine Absorption,The Effect of Dietary Supplements for Pregnant Women on Levothyroxine Absorption,Hypothyroidism Primary,2021-07-25,2022-07-30,2022-09-30,37.0,,Crossover Assignment,,Interventional,Recruiting,Not Applicable,University Hospital Dubrava,University Hospital Dubrava,Dubrava University Hospital,Dietary Supplement|Other,Croatia,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04988802
3179,NCT04994080,hyperparathyroidism,"A Multi-center, Randomized, Double-blind, Parallel Grouping, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Paricalcitol Soft Capsules in the Treatment of Secondary Hyperparathyroidism in Subjects With Stage 3 and Stage 4 Chronic Kidney Disease",A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2021-07-21,2023-03-31,2023-03-31,84.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,"Chengdu Suncadia Medicine Co., Ltd.","Chengdu Suncadia Medicine Co., Ltd.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04994080
3183,NCT04998968,hypoparathyroidism,Quality of Life in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy in a Swedish Population Based Cohort,Quality in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy,Permanent Hypoparathyroidism,2021-08-09,2021-12-31,2022-05-31,1700.0,Cohort,,Prospective,Observational,Enrolling by invitation,,Uppsala University,Uppsala University,Uppsala University Hospital,,Sweden,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04998968
3184,NCT05002998,graves disease,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",TEPEZZA (Teprotumumab-trbw) Post-Marketing Requirement Study,Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,300.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute|Mayo Clinic|Washington University in St. Louis|University of Nebraska Medical Center|Casey Eye Institute - OHSU|Hospital La Arruzafa|Hospital Universitario Ramon Y Cajal|Hospital Universitario Virgen Macarena,Drug|Drug,Spain|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05002998
3185,NCT05002998,graves ophthalmopathy,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",TEPEZZA (Teprotumumab-trbw) Post-Marketing Requirement Study,Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,300.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute|Mayo Clinic|Washington University in St. Louis|University of Nebraska Medical Center|Casey Eye Institute - OHSU|Hospital La Arruzafa|Hospital Universitario Ramon Y Cajal|Hospital Universitario Virgen Macarena,Drug|Drug,Spain|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05002998
3186,NCT05002998,hyperthyroidism,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",TEPEZZA (Teprotumumab-trbw) Post-Marketing Requirement Study,Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,300.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute|Mayo Clinic|Washington University in St. Louis|University of Nebraska Medical Center|Casey Eye Institute - OHSU|Hospital La Arruzafa|Hospital Universitario Ramon Y Cajal|Hospital Universitario Virgen Macarena,Drug|Drug,Spain|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05002998
3187,NCT05002998,goiter,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",TEPEZZA (Teprotumumab-trbw) Post-Marketing Requirement Study,Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,300.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute|Mayo Clinic|Washington University in St. Louis|University of Nebraska Medical Center|Casey Eye Institute - OHSU|Hospital La Arruzafa|Hospital Universitario Ramon Y Cajal|Hospital Universitario Virgen Macarena,Drug|Drug,Spain|United States,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05002998
3188,NCT05003856,thyroid nodule,Radiofrequency Ablation Use in Thyroid Nodule,Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule,Benign Thyroid Gland Neoplasm|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|Thyroid Gland Nodule|Thyroid Gland Papillary Carcinoma,2021-08-05,2025-06-30,2025-06-30,100.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 4,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05003856
3189,NCT05003856,"thyroid cancer, papillary",Radiofrequency Ablation Use in Thyroid Nodule,Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule,Benign Thyroid Gland Neoplasm|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|Thyroid Gland Nodule|Thyroid Gland Papillary Carcinoma,2021-08-05,2025-06-30,2025-06-30,100.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 4,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05003856
3191,NCT05007093,thyroid neoplasms,An Exploratory Study on Efficacy of Anlotinib Hydrochloride in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer,Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib,DTC - Differentiated Thyroid Cancer,2021-08-09,2023-12-07,2023-12-07,10.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,Yansong Lin,Peking Union Medical College Hospital,Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05007093
3192,NCT05012033,goiter,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,120.0,Case-Only,,Cross-Sectional,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05012033
3193,NCT05012033,graves disease,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,120.0,Case-Only,,Cross-Sectional,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05012033
3194,NCT05012033,graves ophthalmopathy,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,120.0,Case-Only,,Cross-Sectional,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05012033
3195,NCT05012033,hyperthyroidism,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,120.0,Case-Only,,Cross-Sectional,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05012033
3196,NCT05014698,thyroid neoplasms,IDEntification of New Predisposition Genes in Differentiated THYroid Cancer,IDEntification of New Predisposition Genes in Differentiated THYroid Cancer,"Differentiated Thyroid Cancer|Thyroid Cancer, Nonmedullary",2021-08-05,2025-02-28,2025-02-28,95.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Nantes University Hospital,Nantes University Hospital,Vende Hospital|Nantes University Hospital,Genetic,France,8.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05014698
3197,NCT05015127,graves disease,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease,Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,36.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05015127
3198,NCT05015127,hyperthyroidism,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease,Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,36.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05015127
3199,NCT05015127,graves ophthalmopathy,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease,Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,36.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05015127
3200,NCT05015127,goiter,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease,Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,36.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05015127
3201,NCT05015725,hypothyroidism,"A Single Center Cross-sectional Study to Evaluate the Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients","The Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients",Hypothyroidism,2021-06-30,2022-07-05,2022-07-05,350.0,Case-Only,,Cross-Sectional,Observational,Recruiting,,Semmelweis University,Semmelweis University,Semmelweis University - Departement Medicine and Oncology,Diagnostic Test,Hungary,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05015725
3204,NCT05017142,"thyroiditis, autoimmune",Swiss Pediatric Inflammatory Bain Disease Cohort Study,Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD),"Acute Disseminated Encephalomyelitis|Anti-AMPAR-1/2 Associated Autoimmune Encephalitis|Anti-CASPR-2 Associated Autoimmune Encephalitis|Anti-GABAR-1/2 Associated Autoimmune Encephalitis|Anti-GAD65 Associated Autoimmune Encephalitis|Anti-Lgi-1 Associated Autoimmune Encephalitis|Anti-NMDAR Encephalitis|CNS Lupus|CNS Sarcoidosis|CNS Vasculitis|Hashimoto Encephalitis|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis|Optic Neuritis|Rasmussen Encephalitis|Transverse Myelitis",2021-08-04,2071-01-01,2071-01-01,500.0,Cohort,,Other,Observational [Patient Registry],Recruiting,,University of Bern,"Novartis|Roche Pharma (Switzerland) Ltd|Schweizerische Multiple Sklerose Gesellschaft|University Hospital Inselspital, Berne|University of Bern","Kantonsspital Aarau|Kantonsspital Graubnden|Children's Hospital of Eastern Switzerland|Pediatric Institute of Southern Switzerland, Ospedale San Giovanni|University Children's Hospital Lausanne (CHUV)|Kinderspital Winterthur|University Children's Hospital Basel, UKBB|University Children's Hospital, Inselspital Bern|Institute of Social and Preventive Medicine, University of Bern|University Hospitals of Geneva (HUG)|Luzerner Kantonsspital|University Children's Hospital Zurich",,Switzerland,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05017142
3205,NCT05019118,hypothyroidism,"Dietary Intervention With nicla Dairy Products, Naturally Enriched With Selenium and Omega-3 Fatty Acids, May Improve Thyroid-stimulating Hormone (TSH) Levels in Women With Subclinical Hypothyroidism",Dietary Intervention With nicla Dairy Products (DANTIAN),Subclinical Hypothyroidism,2021-08-13,2021-12-30,2022-05-30,90.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Cooperativas Lacteas Unidas,Cooperativas Lacteas Unidas|Galician South Health Research Institute,Nursing University School of Ourense,Other|Other|Other|Other|Other|Other,Spain,40.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05019118
3207,NCT05022641,hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Neoplasms|Primary Hyperparathyroidism,2021-08-22,2023-08-31,2023-08-31,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05022641
3208,NCT05022641,parathyroid neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Neoplasms|Primary Hyperparathyroidism,2021-08-22,2023-08-31,2023-08-31,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05022641
3210,NCT05022667,hypoparathyroidism,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,2021-08-22,2023-08-31,2023-08-31,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05022667
3211,NCT05022667,thyroid neoplasms,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,2021-08-22,2023-08-31,2023-08-31,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05022667
3214,NCT05024929,"thyroid cancer, papillary",Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Papillary Thyroid Cancer,Targeted Therapy to Increase RAI Uptake in Metastatic PTC,Papillary Thyroid Cancer|Pediatric Cancer,2021-08-23,2031-02-01,2033-02-01,32.0,Cohort,,Prospective,Observational,Recruiting,,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Procedure,United States,0.0,21.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05024929
3215,NCT05025046,thyroid nodule,"Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules",NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2021-08-25,2022-06-30,2022-06-30,400.0,Cohort,,Prospective,Observational,Recruiting,,Rigen Biotech,"Guangdong Provincial People's Hospital|RenJi Hospital|Rigen Biotech|Shenzhen People's Hospital|The First People's Hospital of Changzhou|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Provincial People's Hospital|Zhongshan People's Hospital, Guangdong, China",Zhongshan City People's Hospital|The First Peple's Hospital of Changzhou|Guangdong Provincial People's Hospital|Zhejiang Provincial People's Hospital|Shanghai Jiaotong University School of Medicine|Shenzhen People's Hospital|Tianjin Medical University Center Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05025046
3216,NCT05025046,thyroid neoplasms,"Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules",NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2021-08-25,2022-06-30,2022-06-30,400.0,Cohort,,Prospective,Observational,Recruiting,,Rigen Biotech,"Guangdong Provincial People's Hospital|RenJi Hospital|Rigen Biotech|Shenzhen People's Hospital|The First People's Hospital of Changzhou|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Provincial People's Hospital|Zhongshan People's Hospital, Guangdong, China",Zhongshan City People's Hospital|The First Peple's Hospital of Changzhou|Guangdong Provincial People's Hospital|Zhejiang Provincial People's Hospital|Shanghai Jiaotong University School of Medicine|Shenzhen People's Hospital|Tianjin Medical University Center Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05025046
3217,NCT05033496,hypothyroidism,The Yield of Postnatal Thyroid Function Test in Term Newborn Infants in the Well Baby Nursery in Addition to the National Screening Test Program,The Yield of Postnatal Thyroid Function Test in the Well Baby Nursery,Hypothyroidism,2021-08-25,2020-12-31,2021-10-03,40601.0,Case-Only,,Retrospective,Observational,Completed,,Hillel Yaffe Medical Center,Hillel Yaffe Medical Center,Hillel Yaffe medical center,Diagnostic Test,Israel,0.0,30.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05033496
3218,NCT05043233,graves disease,The Observation Study of Graves' Disease Cohort,Observation in the Treatment of Graves' Disease,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,1000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05043233
3219,NCT05043233,goiter,The Observation Study of Graves' Disease Cohort,Observation in the Treatment of Graves' Disease,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,1000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05043233
3220,NCT05043233,hyperthyroidism,The Observation Study of Graves' Disease Cohort,Observation in the Treatment of Graves' Disease,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,1000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05043233
3221,NCT05043584,hypoparathyroidism,Prevention of Postoperative Hypoparathyroidism Following Thyroid Surgery by Using Intraoperative Autofluorescence,"Near-infrared Autofluorescence (NIRAF) in Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Centers",Autofluorescence|Hypocalcemia|Hypoparathyroidism|Thyroidectomy,2021-09-05,2023-09-30,2024-03-31,78.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Regional Hospital West Jutland,Hospital of South West Jutland|Regional Hospital West Jutland,"Department of Otorhinolaryngology, Hospital South West Jutland|Department of Otorhinolaryngology, Regional Hospital West Jutland",Device,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05043584
3223,NCT05049551,hyperthyroidism,Quantitative Analysis of 99mTc-Pertechnetate Thyroid Uptake With a Large Field CZT Gamma Camera: Feasibility and Comparison Between SPECT/CT and Planar Acquisitions,Thyroid Uptake Quantification on a New Generation of Gamma Camera,Hyperthyroidism,2021-09-09,2020-06-22,2020-09-07,23.0,Other,,Retrospective,Observational,Completed,,Centre Hospitalier Princesse Grace,Centre Hospitalier Princesse Grace,Centre Hospitalier Princesse Grace,,Monaco,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05049551
3224,NCT05049603,graves ophthalmopathy,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study,Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,102.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,Universit degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05049603
3225,NCT05049603,hyperthyroidism,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study,Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,102.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,Universit degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05049603
3226,NCT05049603,goiter,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study,Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,102.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,Universit degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05049603
3227,NCT05049603,graves disease,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study,Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,102.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,Universit degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05049603
3229,NCT05052359,"adenocarcinoma, follicular",Aberrant Helix Pomatia Agglutinin Binding Glycan Expression Changes With the Phenotype of Follicular Thyroid Tumours,Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours,Follicular Thyroid Cancer,2021-09-02,2021-08-01,2021-09-01,37.0,Cohort,,Retrospective,Observational,Completed,,"National University Health System, Singapore","National University Health System, Singapore",National University Hospital,Diagnostic Test,Singapore,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT05052359
3230,NCT05054634,thyroid neoplasms,Psycho-oncological Intervention Through Counselling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine: A Non-randomized Controlled Study,Psycho-oncological Intervention Through Counselling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine,Thyroid Cancer,2021-09-03,2014-09-30,2015-03-31,75.0,Cohort,,Prospective,Observational,Completed,,Quironsalud,Quironsalud,Hospital Quironsalud Torrevieja,Behavioral,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05054634
3231,NCT05059470,thyroid neoplasms,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,Thyroid,2021-09-15,2023-10-01,2023-10-01,35.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05059470
3232,NCT05068687,thyroid neoplasms,"Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Malignancies of the Head and Neck, a Pilot Study",Peroperative Assessment of Malignancies of the Head and Neck Using High-resolution 18F-FDG-PET/CT,Head and Neck Neoplasms|Skin Neoplasm|Thyroid Neoplasm,2021-09-24,2022-09-30,2022-09-30,40.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,"University Hospital, Ghent","University Hospital, Ghent|XEOS Medical",Ghent University Hospital,Diagnostic Test,Belgium,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05068687
3233,NCT05070091,thyroiditis,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,180.0,Other,,Prospective,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05070091
3234,NCT05070091,"thyroiditis, subacute",The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,180.0,Other,,Prospective,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],Thyroiditis,De Quervain's thyroiditis,https://clinicaltrials.gov/ct2/show/NCT05070091
3235,NCT05070091,hyperthyroidism,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,180.0,Other,,Prospective,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05070091
3236,NCT05070091,hypothyroidism,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,180.0,Other,,Prospective,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05070091
3239,NCT05077865,hashimoto disease,"A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MYMD1 Capsules in Healthy Male and Female Adult Subjects","Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects",Hashimoto Disease,2021-10-01,2021-08-10,2021-08-10,32.0,,Parallel Assignment,,Interventional,Completed,Phase 1,"MyMD Pharmaceuticals, Inc.","MyMD Pharmaceuticals, Inc.","Clinical Research of West Florida, Inc",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05077865
3240,NCT05078853,thyroid neoplasms,Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma- A Multi-Center Validation Study,Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma,Differentiated Thyroid Cancer|Lymph Node Metastases,2021-09-27,2022-12-31,2022-12-31,250.0,Other,,Cross-Sectional,Observational,Recruiting,,Soroka University Medical Center,Soroka University Medical Center,Barzilai Medical Center|Soroka University Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05078853
3241,NCT05088187,thyroid nodule,Longitudinal Evaluation of Objective Cognitive Function and Quality of Life in Patients Undergoing Surgery for Malignant and Benign Thyroid Nodules,Cognition and QoL After Thyroid Surgery,"Cognitive Decline|Survivorship|Symptoms, Cognitive|Thyroid Cancer|Thyroid Nodule",2021-10-11,2023-11-01,2026-11-01,320.0,Cohort,,Prospective,Observational,Not yet recruiting,,Karolinska University Hospital,Karolinska University Hospital|The Netherlands Cancer Institute,,,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05088187
3242,NCT05088187,thyroid neoplasms,Longitudinal Evaluation of Objective Cognitive Function and Quality of Life in Patients Undergoing Surgery for Malignant and Benign Thyroid Nodules,Cognition and QoL After Thyroid Surgery,"Cognitive Decline|Survivorship|Symptoms, Cognitive|Thyroid Cancer|Thyroid Nodule",2021-10-11,2023-11-01,2026-11-01,320.0,Cohort,,Prospective,Observational,Not yet recruiting,,Karolinska University Hospital,Karolinska University Hospital|The Netherlands Cancer Institute,,,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05088187
3243,NCT05096195,hyperparathyroidism,"Denosumab for the Prevention of Fragility Fractures in Hemodialysis: a Pilot Study for an Innovative, Randomized-controlled Trial, Embedded in Routine Care",PREventing FracturEs in Renal Disease - 1,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis; Complications|Fragility Fracture|Kidney Diseases,2021-09-21,2023-12-31,2023-12-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,"Western University, Canada","Academic Medical Organization of Southwestern Ontario|ICES|The Kidney Foundation of Canada|Western University|Western University, Canada",,Drug|Other|Diagnostic Test,,40.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05096195
3246,NCT05098600,goiter,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,1000.0,Cohort,,Retrospective,Observational,Active not recruiting,,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05098600
3247,NCT05098600,hyperthyroidism,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,1000.0,Cohort,,Retrospective,Observational,Active not recruiting,,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05098600
3248,NCT05098600,hypothyroidism,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,1000.0,Cohort,,Retrospective,Observational,Active not recruiting,,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05098600
3249,NCT05098600,graves disease,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,1000.0,Cohort,,Retrospective,Observational,Active not recruiting,,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05098600
3251,NCT05102292,"thyroid carcinoma, anaplastic","An Open Label, Multicenter Phase Ib/II Clinical Study to Evaluate Efficacy , Safety and PK of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation",The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation,Anaplastic Thyroid Cancer|ATC,2021-10-20,2023-05-30,2024-12-30,25.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Shanghai Henlius Biotech,Shanghai Henlius Biotech,Fudan University Affiliated Oncology Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT05102292
3252,NCT05103956,goiter,"Regular Treatment Versus Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Immediate Postoperative of the Thyroidectomy, Unicentric Study, Non-inferiority, Open and Randomized (Tiropatch Study)",Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Postoperative of the Thyroidectomy.,Goiter,2021-10-07,2022-04-01,2022-04-01,108.0,Case-Control,,Prospective,Observational,Recruiting,,Fundacin Pblica Andaluza para la gestin de la Investigacin en Sevilla,Fundacin Pblica Andaluza para la gestin de la Investigacin en Sevilla,Hospital Universitario Virgen del Roco,,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05103956
3253,NCT05108298,thyroid neoplasms,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,"Bone Cancer, NOS|Breast Cancer, NOS|Cervical Cancer, NOS|CNS Primary Tumor, NOS|Colorectal Cancer, NOS|Leukemia, NOS|Lymphoma, NOS|Melanoma|Miscellaneous Neoplasm, NOS|Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS|Testicular Nonseminomatous Germ Cell Tumor, NOS|Thyroid Cancer, NOS",2021-10-05,2023-03-31,2024-10-31,400.0,Cohort,,Prospective,Observational,Recruiting,,Eastern Cooperative Oncology Group,Eastern Cooperative Oncology Group,Wake Forest School of Medicine,Other,United States,18.0,39.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05108298
3254,NCT05110040,graves ophthalmopathy,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Multi-model Image of Immunosuppressive Agents in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,12.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05110040
3255,NCT05110040,graves disease,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Multi-model Image of Immunosuppressive Agents in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,12.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05110040
3256,NCT05110040,goiter,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Multi-model Image of Immunosuppressive Agents in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,12.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05110040
3257,NCT05110040,hyperthyroidism,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Multi-model Image of Immunosuppressive Agents in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,12.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05110040
3258,NCT05112211,hyperthyroidism,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Multi-model Image of Doxycycline in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05112211
3259,NCT05112211,graves ophthalmopathy,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Multi-model Image of Doxycycline in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05112211
3260,NCT05112211,graves disease,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Multi-model Image of Doxycycline in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05112211
3261,NCT05112211,goiter,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Multi-model Image of Doxycycline in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05112211
3263,NCT05114980,hypoparathyroidism,Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism,Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism,Hypoparathyroidism,2021-10-29,2024-01-31,2025-01-31,5.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Alabama at Birmingham,University of Alabama at Birmingham,University of Alabama at Birmingham,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05114980
3265,NCT05117853,hypoparathyroidism,The Use of Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Total Thyroidectomy: A Randomized Clinical Trial,Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Thyroidectomy,Hypoparathyroidism Postprocedural|Thyroid Disease,2021-10-21,2024-10-31,2025-05-31,300.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Drug|Procedure,Belgium,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05117853
3266,NCT05118542,graves disease,"Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness",Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis,Atherosclerosis of Artery|Graves Disease|Hyperthyroidism|Pathophysiology,2021-10-06,2020-06-01,2020-08-01,36.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Indonesia University,Indonesia University,University of Indonesia,Drug|Drug,Indonesia,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05118542
3267,NCT05118542,hyperthyroidism,"Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness",Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis,Atherosclerosis of Artery|Graves Disease|Hyperthyroidism|Pathophysiology,2021-10-06,2020-06-01,2020-08-01,36.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Indonesia University,Indonesia University,University of Indonesia,Drug|Drug,Indonesia,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05118542
3268,NCT05118542,goiter,"Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness",Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis,Atherosclerosis of Artery|Graves Disease|Hyperthyroidism|Pathophysiology,2021-10-06,2020-06-01,2020-08-01,36.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Indonesia University,Indonesia University,University of Indonesia,Drug|Drug,Indonesia,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05118542
3269,NCT05119296,"thyroid carcinoma, anaplastic",Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Thyroid Cancer,2021-10-29,2024-11-30,2026-11-30,20.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Stanford University,Merck Sharp & Dohme LLC|Stanford University,Stanford University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT05119296
3271,NCT05124938,thyroid neoplasms,Assessment of CA19-9 in Patients' With Thyroid Malignancies,Assessment of CA 19-9 in Patients' With Thyroid Malignancies,Thyroid Cancer,2021-10-26,2022-06-01,2022-12-01,120.0,Case-Control,,Retrospective,Observational,Not yet recruiting,,Sohag University,Sohag University,Sohag faculty of medicine,Diagnostic Test,Egypt,1.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05124938
3272,NCT05126147,graves ophthalmopathy,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,104.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05126147
3273,NCT05126147,goiter,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,104.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05126147
3274,NCT05126147,graves disease,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,104.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05126147
3275,NCT05126147,hyperthyroidism,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,104.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05126147
3276,NCT05126706,thyroid neoplasms,Validating Efficacy for Digital Lifestyle Management for Weight Loss Control After Thyroidectomy in Thyroid Cancer Patients,Digital Lifestyle Management for Weight Loss Control After Thyroidectomy in Thyroid Cancer Patients,"Weight Change, Body",2021-09-26,2024-08-30,2024-08-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Behavioral,"Korea, Republic of",19.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05126706
3278,NCT05130476,hypoparathyroidism,Intraoperative Near-infrared Imaging Techniques for Identifying and Preserving Viable Parathyroid Glands During Total and Completion Thyroidectomy: a Matched Cohort Study,Near-infrared Imaging Techniques for Identifying and Preserving Viable Parathyroid Glands During Thyroidectomy,Hypoparathyroidism Postprocedural,2021-11-08,2023-09-30,2025-03-31,139.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Odense University Hospital,Odense University Hospital,Odense University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05130476
3279,NCT05132205,"thyroid cancer, papillary",Radiofrequency Ablation of Papillary Thyroid Microcarcinoma,Radiofrequency Ablation of Papillary Thyroid Microcarcinoma,Papillary Thyroid Cancer,2021-11-10,2024-09-28,2024-09-28,10.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Procedure,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05132205
3281,NCT05132478,thyroid nodule,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer: a Randomized Hypothetical Choice Experiment,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer,Benign Thyroid Nodule|Thyroid Cancer|Thyroid Nodule,2021-11-12,2023-11-30,2023-11-30,118.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Michigan|University of Wisconsin, Madison",University of Wisconsin Carbone Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05132478
3282,NCT05132478,thyroid neoplasms,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer: a Randomized Hypothetical Choice Experiment,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer,Benign Thyroid Nodule|Thyroid Cancer|Thyroid Nodule,2021-11-12,2023-11-30,2023-11-30,118.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Michigan|University of Wisconsin, Madison",University of Wisconsin Carbone Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05132478
3283,NCT05142904,thyroid nodule,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,232.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05142904
3284,NCT05142904,thyroid neoplasms,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,232.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05142904
3285,NCT05142904,hyperthyroidism,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,232.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05142904
3286,NCT05143918,hypothyroidism,Assessment of Quality of Life Among Hypothyroid Patients in Assiut University Hospitals,Quality of Life Among Egyptian Hypothyroid Patients,Hypothyroidism,2021-11-23,2022-12-30,2023-12-30,176.0,Case-Control,,Cross-Sectional,Observational,Not yet recruiting,,Assiut University,Assiut University,,Other,,18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05143918
3287,NCT05149898,hypoparathyroidism,"Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome",Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome,22Q Deletion Syndrome,2021-10-05,2022-11-30,2022-12-31,20.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1/Phase 2,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",Greenwood Genetic Center|Lady Cilento Children's Hospital - South Brisbane|Genetics Clinics Australia,Drug,Australia|United States,4.0,17.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05149898
3289,NCT05152927,hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",2021-11-29,2025-01-31,2025-01-31,110.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco|Vanderbilt University Medical Center","University of California, San Francisco",Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05152927
3290,NCT05152927,parathyroid neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",2021-11-29,2025-01-31,2025-01-31,110.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco|Vanderbilt University Medical Center","University of California, San Francisco",Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05152927
3293,NCT05172921,thyroid neoplasms,The Role of Environmental Factors in Thyroid Cancer,Environmental Factors and Thyroid Cancer,Thyroid Cancer,2021-12-23,2030-01-31,2030-01-31,500.0,Case-Control,,Prospective,Observational [Patient Registry],Recruiting,,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05172921
3294,NCT05175404,thyroid neoplasms,Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers,Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers,Thyroid Cancer,2021-12-14,2022-12-31,2022-12-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"University Hospital, Ghent","University Hospital, Ghent",University hospital Ghent,Diagnostic Test,Belgium,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05175404
3295,NCT05176639,graves ophthalmopathy,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)","A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,76.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05176639
3296,NCT05176639,hyperthyroidism,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)","A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,76.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05176639
3297,NCT05176639,goiter,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)","A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,76.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05176639
3298,NCT05176639,graves disease,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)","A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,76.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05176639
3301,NCT05177939,"thyroiditis, autoimmune",Phase III Study to Evaluate the Efficacy and Safety of NPB-01 in Patients With Autoimmune Encephalitis Refractory to Steroid Pulse Therapy,Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis,Autoimmune Encephalitis,2021-12-03,2024-05-31,2024-10-31,40.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,"Nihon Pharmaceutical Co., Ltd","Nihon Pharmaceutical Co., Ltd",,Drug|Drug,,15.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05177939
3302,NCT05178186,thyroid neoplasms,Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer: an International Multicenter Study,Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer,Thyroid Carcinoma,2021-12-30,2022-02-15,2022-03-30,1000.0,,Single Group Assignment,,Interventional,Enrolling by invitation,Not Applicable,University of Cagliari,University of Cagliari,AOU Cagliari,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05178186
3303,NCT05180214,goiter,The Effect of Adding Ketorolac to Bupivacaine in Superficial Cervical Plexus Block in Thyroid Surgery.,Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it.,Thyroid Goiter|Thyroid Nodule,2021-12-17,2021-08-19,2021-09-15,46.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Sohag University,Sohag University,Sohag University Faculty of Medicine,Drug|Drug,Egypt,20.0,50.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05180214
3304,NCT05180214,thyroid nodule,The Effect of Adding Ketorolac to Bupivacaine in Superficial Cervical Plexus Block in Thyroid Surgery.,Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it.,Thyroid Goiter|Thyroid Nodule,2021-12-17,2021-08-19,2021-09-15,46.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Sohag University,Sohag University,Sohag University Faculty of Medicine,Drug|Drug,Egypt,20.0,50.0,[18-65],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05180214
3305,NCT05180214,thyroid neoplasms,The Effect of Adding Ketorolac to Bupivacaine in Superficial Cervical Plexus Block in Thyroid Surgery.,Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it.,Thyroid Goiter|Thyroid Nodule,2021-12-17,2021-08-19,2021-09-15,46.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Sohag University,Sohag University,Sohag University Faculty of Medicine,Drug|Drug,Egypt,20.0,50.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05180214
3306,NCT05182931,thyroid neoplasms,"A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)","A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)",Thyroid Cancer,2021-11-23,2024-12-30,2025-12-30,80.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,Olivia Newton-John Cancer Research Institute,"Austin Health|Eastern Health|Monash Health|Olivia Newton-John Cancer Research Institute|Peter MacCallum Cancer Centre, Australia|Royal Brisbane and Women's Hospital|Royal North Shore Hospital|Sir Charles Gairdner Hospital|The Alfred",Royal North Shore Hospital|Royal Brisbane and Women's Hospital|Eastern Health|Monash Health|Austin Health|Alfred Hospital|Sir Charles Gairdner Hospital|Peter MacCallum Cancer Centre,Drug|Drug,Australia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05182931
3308,NCT05186883,hypoparathyroidism,Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells,Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells,Postoperative Hypoparathyroidism,2021-12-01,2023-12-31,2023-12-31,20.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 1/Phase 2,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,Belarusian State Medical University|Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,,Biological|Other,,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05186883
3309,NCT05189314,thyroid nodule,Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules,RFA of Benign Thyroid Nodules: Clinical Outcomes and Quality of Life Study,Thyroid Nodules,2021-12-28,2023-08-30,2024-08-30,100.0,Cohort,,Prospective,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05189314
3310,NCT05189314,thyroid neoplasms,Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules,RFA of Benign Thyroid Nodules: Clinical Outcomes and Quality of Life Study,Thyroid Nodules,2021-12-28,2023-08-30,2024-08-30,100.0,Cohort,,Prospective,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05189314
3311,NCT05189808,thyroid nodule,Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules,Radiofrequency Ablation for BIII Thyroid Nodules,Indeterminate Bethesda III Thyroid Nodules,2021-12-28,2023-08-31,2024-08-31,50.0,Cohort,,Prospective,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05189808
3312,NCT05189808,thyroid neoplasms,Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules,Radiofrequency Ablation for BIII Thyroid Nodules,Indeterminate Bethesda III Thyroid Nodules,2021-12-28,2023-08-31,2024-08-31,50.0,Cohort,,Prospective,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05189808
3313,NCT05189821,thyroid neoplasms,RFA Treatment for Papillary Thyroid Microcarcinoma Cohort,RFA Treatment for Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2021-12-28,2025-11-30,2026-11-30,50.0,Cohort,,Prospective,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05189821
3315,NCT05191927,"thyroid cancer, papillary",A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma Suitable for Primary Hospitals,A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma,Thyroid Papillary Carcinoma,2021-11-17,2021-01-01,2021-08-01,1200.0,Cohort,,Retrospective,Observational,Completed,,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|The First Affiliated Hospital of Zhengzhou University,Sun Yat-sen Memorial Hospital of Sun Yat-Sen University,Other,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05191927
3319,NCT05199103,graves ophthalmopathy,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy,Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05199103
3320,NCT05199103,goiter,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy,Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05199103
3321,NCT05199103,graves disease,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy,Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05199103
3322,NCT05199103,hyperthyroidism,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy,Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05199103
3323,NCT05214274,hypoparathyroidism,The Status of Diagnosis and Treatment of Chronic Hypoparathyroidism in Chinese Adults: a Multicenter Registry Study,Multicenter Registry Study of Chronic Hypoparathyroidism in Chinese Adults,Chronic Hypoparathyroidism,2021-12-24,2022-12-31,2022-12-31,500.0,Other,,Cross-Sectional,Observational,Recruiting,,Peking University,"Central South University|First Affiliated Hospital of Xinjiang Medical University|First Affiliated Hospital, Sun Yat-Sen University|First Hospital of China Medical University|Peking Union Medical College Hospital|Peking University|Shanghai 6th People's Hospital|West China Hospital","Peking Union Medical College Hospital|The First Hospital of China Medical University|The First Affiliated Hospital , Sun Yat-sen University|The Second Xiangya Hospital of Central South University|Shanghai Sixth People's Hospital|West China Hospital of Sichuan University|The First Affiliated Hospital of Xinjiang Medical University",Other,China,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05214274
3325,NCT05216718,thyroid nodule,Prospective Randomized Controlled Study on Mini-flap Bilateral Axillo-breast Approach Robotic Thyroidectomy : Effect on Postoperative Pain and Sensation,Mini-flap BABA (Bilateral Axillo-breast Approach) Robotic Thyroidectomy is Safe,Thyroid Nodule,2021-12-30,2022-12-31,2023-12-01,80.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Inje University,Inje University,Dong sik Bae,Procedure|Procedure,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05216718
3326,NCT05216718,thyroid neoplasms,Prospective Randomized Controlled Study on Mini-flap Bilateral Axillo-breast Approach Robotic Thyroidectomy : Effect on Postoperative Pain and Sensation,Mini-flap BABA (Bilateral Axillo-breast Approach) Robotic Thyroidectomy is Safe,Thyroid Nodule,2021-12-30,2022-12-31,2023-12-01,80.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Inje University,Inje University,Dong sik Bae,Procedure|Procedure,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05216718
3327,NCT05218395,thyroid neoplasms,Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer,Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer,Organic Pollutant|Thyroid Cancer|Type 2 Diabetes,2022-01-20,2024-12-29,2025-12-30,900.0,Case-Control,,Prospective,Observational,Recruiting,,Qianfoshan Hospital,Chinese Academy of Sciences|Qianfoshan Hospital,Xiaoling Guan,,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05218395
3329,NCT05221008,hyperparathyroidism,"Study on Tolerability, Pharmacokinetics and Pharmacodynamics of SHR6508 in Chinese Patients With Secondary Hyperparathyroidism of Chronic Kidney Disease Treated by Maintenance Hemodialysis",A Trial of SHR6508 in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2022-01-07,2022-09-01,2022-09-30,55.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 1,"Shanghai Hengrui Pharmaceutical Co., Ltd.","Shanghai Hengrui Pharmaceutical Co., Ltd.",,Drug|Drug|Drug|Drug,,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05221008
3333,NCT05225883,thyroiditis,GEnome-wide Association Study in N-methyl-D-Aspartate Receptor and Other autoiMmune Encephalitis.,GWAS in NMDAR Encephalitis,Autoimmune Encephalitis,2022-01-25,2023-12-31,2025-12-31,2000.0,Case-Control,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de rfrence des syndromes neurologiques paranoplasiques et encphalites auto-immunes,Genetic,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05225883
3334,NCT05228184,congenital hypothyroidism,A Randomized Comparative Study Between Liquid (Tirosint-SOL) and Tablet Formulations of Levothyroxine in Neonates and Infants With Congenital Hypothyroidism,Use of Tirosint-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH),Congenital Hypothyroidism,2021-12-21,2023-06-15,2023-06-15,126.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,IBSA Institut Biochimique SA,Cromsource|IBSA Institut Biochimique SA,CHOC Children's Hospital|Ann & Robert H. Lurie Children's Hospital of Chicago|Children's Mercy Hospital and Clinics|Icahn School of Medicine at Mount Sinai|Cook Children's Health Care Systems,Drug|Drug,United States,0.0,9.0,[0-17],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05228184
3336,NCT05229341,thyroid neoplasms,Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules,Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules,Thyroid Gland Carcinoma,2022-02-04,2026-10-22,2026-10-22,1450.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Procedure|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05229341
3337,NCT05229341,thyroid nodule,Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules,Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules,Thyroid Gland Carcinoma,2022-02-04,2026-10-22,2026-10-22,1450.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Procedure|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05229341
3339,NCT05239221,hypoparathyroidism,"A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism",AZP-3601 SAD and MAD Study in Healthy Subjects and Subjects With Hypoparathyroidism,Chronic Hypoparathyroidism,2022-01-07,2022-12-31,2023-01-31,130.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 1,Amolyt Pharma,Amolyt Pharma,Amolyt Pharma Investigational Site Hungary|PRA-EDS,Drug|Drug,Hungary|Netherlands,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05239221
3340,NCT05240911,hypothyroidism,Compare a New Method to the Traditional One to Estimate Levothyroxine Dose for Patients Needing Replacement Therapy After Total or Completion Thyroidectomy,Individual Dosing of Levothyroxine After Thyroidectomy,Hypothyroidism|Surgery|Thyroid Neoplasms,2022-02-06,2023-02-10,2023-06-10,202.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Second Affiliated Hospital Zhejiang University School of Medicine,Drug,China,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05240911
3341,NCT05240911,thyroid neoplasms,Compare a New Method to the Traditional One to Estimate Levothyroxine Dose for Patients Needing Replacement Therapy After Total or Completion Thyroidectomy,Individual Dosing of Levothyroxine After Thyroidectomy,Hypothyroidism|Surgery|Thyroid Neoplasms,2022-02-06,2023-02-10,2023-06-10,202.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Second Affiliated Hospital Zhejiang University School of Medicine,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05240911
3342,NCT05241626,hyperthyroidism,Anterior Segment Optical Coherence Tomography Study of the Tear Film and Cornea in Thyroid Eye Diseases.,AS-OCT of the Cornea in Thyroid Diseases,Thyroid Eye Disease,2022-02-04,2022-10-29,2022-10-29,70.0,Case-Control,,Prospective,Observational,Enrolling by invitation,,Minia University,Minia University,Minia Faculty of medicine|Minia University hospital,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05241626
3343,NCT05241626,graves ophthalmopathy,Anterior Segment Optical Coherence Tomography Study of the Tear Film and Cornea in Thyroid Eye Diseases.,AS-OCT of the Cornea in Thyroid Diseases,Thyroid Eye Disease,2022-02-04,2022-10-29,2022-10-29,70.0,Case-Control,,Prospective,Observational,Enrolling by invitation,,Minia University,Minia University,Minia Faculty of medicine|Minia University hospital,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05241626
3344,NCT05241626,graves disease,Anterior Segment Optical Coherence Tomography Study of the Tear Film and Cornea in Thyroid Eye Diseases.,AS-OCT of the Cornea in Thyroid Diseases,Thyroid Eye Disease,2022-02-04,2022-10-29,2022-10-29,70.0,Case-Control,,Prospective,Observational,Enrolling by invitation,,Minia University,Minia University,Minia Faculty of medicine|Minia University hospital,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05241626
3345,NCT05241626,goiter,Anterior Segment Optical Coherence Tomography Study of the Tear Film and Cornea in Thyroid Eye Diseases.,AS-OCT of the Cornea in Thyroid Diseases,Thyroid Eye Disease,2022-02-04,2022-10-29,2022-10-29,70.0,Case-Control,,Prospective,Observational,Enrolling by invitation,,Minia University,Minia University,Minia Faculty of medicine|Minia University hospital,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05241626
3346,NCT05241834,thyroid neoplasms,"A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors",A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment,"Carcinoma, Non-Small-Cell Lung|Thyroid Neoplasms",2022-02-08,2026-04-30,2026-04-30,140.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Cleveland Clinic Foundation|Sarah Cannon Cancer Center,Drug,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05241834
3347,NCT05242055,hyperparathyroidism,"A Prospective, Cohort, and Observational Study of the Effect of Integrated Diagnosis and Treatment of Chronic Kidney Disease (CKD) on Clinical Outcomes in Real World Clinical Practice",Integrated Diagnosis and Treatment of CKD on Outcomes,Anemia|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases|Hyperglycemia|Hyperlipidemias|Hypertension|Malnutrition,2022-01-29,2026-12-31,2026-12-31,1000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Capital Medical University,Capital Medical University,Nephrology Department of Beijing Jishuitan Hospital,Other,China,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05242055
3350,NCT05243979,parathyroid diseases,"The Relation Between Thyroid , Parathyroid Hormones and Estimated Glomerular Filtration Rate in Chronic Kidney Disease Patients in Assiut","The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut",CKD|Parathyroid Diseases|Thyroid,2022-02-08,2023-03-01,2023-04-01,80.0,Other,,Prospective,Observational,Not yet recruiting,,Assiut University,Assiut University,,Radiation,,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05243979
3351,NCT05247476,"thyroid cancer, papillary",Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused,Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.,"Hypothyroidism|Thyroid Cancer, Papillary",2022-02-09,2022-03-31,2022-09-30,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Zhongshan Hospital Xiamen University,Zhongshan Hospital Xiamen University,Yan Ling,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05247476
3352,NCT05247476,hypothyroidism,Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused,Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.,"Hypothyroidism|Thyroid Cancer, Papillary",2022-02-09,2022-03-31,2022-09-30,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Zhongshan Hospital Xiamen University,Zhongshan Hospital Xiamen University,Yan Ling,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05247476
3354,NCT05252884,hyperthyroidism,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,180.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05252884
3355,NCT05252884,thyroid neoplasms,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,180.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05252884
3356,NCT05252884,thyroiditis,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,180.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05252884
3357,NCT05260255,hyperparathyroidism,The Effect of Vitamin D Supplementation on Disease Activity of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial in Rajavithi Hospital,Effect of Vitamin D Supplement on Disease Activity in SLE,Hyperparathyroidism|Hypocalcemia|Systemic Lupus Erythematosus (Disorder)|Vitamin D Deficiency,2021-05-12,2022-05-01,2022-12-01,100.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Rajavithi Hospital,Rajavithi Hospital,Rajavithi Hospital,Drug|Drug,Thailand,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05260255
3360,NCT05263141,"thyroid cancer, papillary","Single-center, Prospective, Non-Randomized Control Clinical Trial of Retro-Auricular Single-Site Endoscopic Versus Open Surgery in Patients With Early Stage Papillary Thyroid Carcinoma",Retro-Auricular Single-Site Endoscopic to Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2022-02-20,2023-06-30,2023-06-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Sun Yat-Sen University Cancer Center,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05263141
3361,NCT05264857,thyroid nodule,Decision Aid for Management of Thyroid Nodules and Early Thyroid Cancer,Decision Aid and Thyroid Nodules Management,Thyroid Nodule,2022-02-17,2026-09-30,2026-09-30,134.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Stony Brook University,Stony Brook University,Stony Brook University Cancer Center,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05264857
3362,NCT05264857,thyroid neoplasms,Decision Aid for Management of Thyroid Nodules and Early Thyroid Cancer,Decision Aid and Thyroid Nodules Management,Thyroid Nodule,2022-02-17,2026-09-30,2026-09-30,134.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Stony Brook University,Stony Brook University,Stony Brook University Cancer Center,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05264857
3363,NCT05265819,thyroid neoplasms,Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy,Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy,Thyroid Cancer,2022-02-23,2022-12-05,2022-12-05,80.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Cairo University,Nabil Mahmoud Ismail Abdel-Aal,,Device|Dietary Supplement|Drug,,18.0,45.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05265819
3364,NCT05270798,euthyroid sick syndromes,Triiodothyronine Hormone Replacement Therapy in Patients With Septic Shock With Euthyroid Sick Syndrome,Thyroid Hormone Replacement in Patients With Septic Shock,Euthyroid Sick Syndromes|Septic Shock,2022-02-26,2023-03-15,2023-03-15,108.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,Cantonal Hospital Zenica,Cantonal Hospital Zenica,,Drug,,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT05270798
3365,NCT05275374,thyroid neoplasms,A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE),XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation,BRAF V600 Mutation|Cancer|Colorectal Cancer|Melanoma|Nonsmall Cell Lung Cancer|Thyroid Cancer,2022-02-20,2024-12-31,2026-12-31,221.0,,Sequential Assignment,,Interventional,Not yet recruiting,Phase 1/Phase 2,"Xynomic Pharmaceuticals, Inc.","Xynomic Pharmaceuticals, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05275374
3366,NCT05275946,thyroid neoplasms,"Phase I Investigator-initiated Clinical Trial in Patients With Differentiated Thyroid Cancer (Papillary Cancer, Follicular Cancer) by the Targeted Alpha Therapy Drug TAH-1005 ([211At] NaAt) (Alpha-T1 Study)",Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer,Thyroid Cancer,2022-01-22,2023-09-30,2024-03-31,11.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Osaka University,Osaka University,Osaka University Hospital,Drug,Japan,0.0,18.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05275946
3367,NCT05276063,graves disease,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,75.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05276063
3368,NCT05276063,hyperthyroidism,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,75.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05276063
3369,NCT05276063,graves ophthalmopathy,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,75.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05276063
3370,NCT05276063,goiter,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,75.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05276063
3371,NCT05276856,hypothyroidism,Rate of Recovery of Secondary Hypothyroidism in Patients With Pituitary Disorders.,Recovery Rate in Secondary Hypothyroidism,Secondary Hypothyroidism,2022-02-28,2022-11-01,2022-12-15,90.0,Cohort,,Prospective,Observational,Not yet recruiting,,Nova Scotia Health Authority,Nova Scotia Health Authority,,Drug,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05276856
3372,NCT05278364,thyroid neoplasms,"A Phase I, Open-Label, Single-arm , Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of SY-5007 in Patients With RET-altered Advanced Solid Tumor.","A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SY-5007 in Patients With Advanced Solid Tumors",Medullary Thyroid Cancer|Non-Small Cell Lung Cancer|Solid Tumor,2022-03-08,2023-03-01,2023-06-01,80.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Shouyao Holdings (Beijing) Co. LTD,Shouyao Holdings (Beijing) Co. LTD,Shanghai Pulmonary Hospital|Tianjin People's Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05278364
3373,NCT05280379,thyroid neoplasms,Trained Immunity of Myeloid Cells and Their Progenitors in Patients With Non-medullary Thyroid Carcinoma and Colon Carcinoma,Trained Immunity in Thyroid Carcinoma and Colon Carcinoma,"Colon Carcinoma|Thyroid Cancer, Nonmedullary",2022-02-24,2024-04-07,2025-04-07,60.0,Other,,Cross-Sectional,Observational,Not yet recruiting,,Radboud University Medical Center,Radboud University Medical Center,,Other,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05280379
3376,NCT05280600,hashimoto disease,Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis,Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis,Anti-N-Methyl-D-Aspartate Receptor Encephalitis|Autoimmune Encephalitis,2022-02-10,2024-02-28,2026-02-28,75.0,Cohort,,Prospective,Observational,Not yet recruiting,,King's College London,Action Medical Research|Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas' NHS Foundation Trust,Other,United Kingdom,8.0,24.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05280600
3377,NCT05286801,thyroid neoplasms,A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors,Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors,Atypical Teratoid/Rhabdoid Tumor|Epithelioid Sarcoma|Kidney Medullary Carcinoma|Malignant Solid Neoplasm|Poorly Differentiated Chordoma|Recurrent Atypical Teratoid/Rhabdoid Tumor|Recurrent Chordoma|Recurrent Epithelioid Sarcoma|Recurrent Kidney Medullary Carcinoma|Recurrent Rhabdoid Tumor|Refractory Atypical Teratoid/Rhabdoid Tumor|Refractory Chordoma|Refractory Epithelioid Sarcoma|Refractory Kidney Medullary Carcinoma|Refractory Rhabdoid Tumor|Rhabdoid Tumor,2022-03-15,2025-07-31,2025-07-31,78.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),,Biological|Biological,,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05286801
3379,NCT05290493,hypoparathyroidism,"A Randomized, Placebo-Controlled Crossover Trial to Assess the Safety and Efficacy of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome",NB-001 in Children and Adolescents With 22q11 Deletion Syndrome,22q11 Deletion Syndrome,2022-01-26,2022-12-31,2023-01-30,34.0,,Crossover Assignment,,Interventional,Recruiting,Phase 2,"Nobias Therapeutics, Inc.","Nobias Therapeutics, Inc.",Children's Hospital of Philadelphia (CHOP)|Seattle Children's Hospital|The Hospital for Sick Children (SickKids),Drug|Other,Canada|United States,6.0,17.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05290493
3380,NCT05294393,parathyroid diseases,Evaluation of Ropivacaine and Ropivacaine Plus Magnesium Sulphate Infiltration for Postoperative Analgesia in Patients Undergoing Thyroidectomy,Ropivacaine Plus Magnesium Sulphate Infiltration,"Anesthesia, Local|Parathyroid Diseases|Postoperative Pain|Thyroid Diseases",2022-03-01,2024-01-21,2024-01-21,64.0,,Parallel Assignment,,Interventional,Enrolling by invitation,Phase 4,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,Aristotle University,Drug|Drug|Drug,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05294393
3381,NCT05299437,thyroid neoplasms,Personalized Therapy of Metastatic Thyroid Cancer: Biological Characterization and Optimization With 124I PET Dosimetry,Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry,Metastatic Differentiated Thyroid Cancer,2022-03-07,2024-03-30,2024-09-30,50.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Associazione Italiana per la Ricerca sul Cancro|Carlo Chiesa,"Nuclear Medicine, Ospedale Sacro Cuore - Don Calabria|Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori",Drug,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05299437
3382,NCT05299632,hyperparathyroidism,Pre-operative Localization of Parathyroid Adenomas Using F-18 PSMA PET/CT: A Pilot Study,F-18 PSMA for Localization of Parathyroid Adenoma,Hyperparathyroidism,2022-03-09,2023-03-31,2023-12-31,10.0,Other,,Prospective,Observational,Recruiting,,Emory University,Emory University,Emory Saint Joseph's Hospital|Emory University Hospital (EUH)|Emory Johns Creek Hospital,Diagnostic Test|Diagnostic Test,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05299632
3384,NCT05299632,parathyroid neoplasms,Pre-operative Localization of Parathyroid Adenomas Using F-18 PSMA PET/CT: A Pilot Study,F-18 PSMA for Localization of Parathyroid Adenoma,Hyperparathyroidism,2022-03-09,2023-03-31,2023-12-31,10.0,Other,,Prospective,Observational,Recruiting,,Emory University,Emory University,Emory Saint Joseph's Hospital|Emory University Hospital (EUH)|Emory Johns Creek Hospital,Diagnostic Test|Diagnostic Test,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05299632
3385,NCT05314790,hypothyroidism,"Management of Patients With Diagnosis of Hypothyroidism, as Hospitalized and as Outpatients, in Internal Medicine Units: Observational Study Before & After Educational Programme","Management of Patients With Diagnosis of Hypothyroidism, as Hospitalized and as Outpatients, in Internal Medicine Units: Observational Study Before & After Educational Programme",Hypothyroidism,2022-01-20,2018-01-01,2019-01-01,1200.0,Cohort,,Retrospective,Observational,Completed,,"Fadoi Foundation, Italy","Fadoi Foundation, Italy","ULSS1 Belluno San Martino|Ospedale Versilia|Ospedale di Canicatt|Ospedale di Castiglione del Lago, Medicina del Trasimeno|Garibaldi Nesima|Ospedale G.B. Morgagni - P.L. Pierantoni|Ospedale G.P. Delogu|Ospedale Gubbio-Gualdo Tadino|Ospedale ""F. Veneziale""|ASL Latina|Ospedale S. Andrea|Ospedale S. Croce di Moncalieri - ASL TO5|Ospedale Del Mare|Ospedale Fatebenefratelli|Ospedale Maggiore di Novara|Ospedale Civico di Partinico|Ospedale ""Bianchi-Melacrino-Morelli""|Casa Sollievo della Sofferenza|AOU di Sassari|Ospedale San Paolo",Other,Italy,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05314790
3386,NCT05316922,hypothyroidism,Protection From Iatrogenic Hypothyroidism Patients With MBL and Pediatric Patients With HL and Non-HL Needing Radiotherapy on Thyroid Site,TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients,Hypothyroidism; Irradiation,2021-09-14,2029-09-30,2029-09-30,68.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Fondazione IRCCS Istituto Nazionale dei Tumori,Drug,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05316922
3387,NCT05323669,thyroid neoplasms,Study of Molecular-genetic Profile of Thyroid Nodules,Molecular Profile of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2022-04-05,2023-12-29,2024-12-31,400.0,Cohort,,Retrospective,Observational,Not yet recruiting,,Belarusian State Medical University,Belarusian State Medical University|Minsk City Clinical Oncologic Centre|The Institute of Genetics and Cytology National Academy of Sciences of Belarus,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05323669
3388,NCT05323669,thyroid nodule,Study of Molecular-genetic Profile of Thyroid Nodules,Molecular Profile of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2022-04-05,2023-12-29,2024-12-31,400.0,Cohort,,Retrospective,Observational,Not yet recruiting,,Belarusian State Medical University,Belarusian State Medical University|Minsk City Clinical Oncologic Centre|The Institute of Genetics and Cytology National Academy of Sciences of Belarus,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05323669
3390,NCT05328076,thyroid neoplasms,Analysis of Parathyroid Vascularization During Total Thyroidectomy Using Quantitative Real-time Indocyanine Green Angiography,Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography,Hypoparathyroidism|Thyroid|Thyroid Cancer|Vascularization,2022-04-07,2023-04-30,2023-05-31,66.0,Cohort,,Prospective,Observational,Recruiting,,IRCCS San Raffaele,IRCCS San Raffaele,San Raffaele Hospital,Drug|Device,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05328076
3391,NCT05328076,hypoparathyroidism,Analysis of Parathyroid Vascularization During Total Thyroidectomy Using Quantitative Real-time Indocyanine Green Angiography,Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography,Hypoparathyroidism|Thyroid|Thyroid Cancer|Vascularization,2022-04-07,2023-04-30,2023-05-31,66.0,Cohort,,Prospective,Observational,Recruiting,,IRCCS San Raffaele,IRCCS San Raffaele,San Raffaele Hospital,Drug|Device,Italy,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05328076
3393,NCT05329935,hypoparathyroidism,Congenital Athymia Patient Registry of RETHYMIC,Congenital Athymia Patient Registry,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|Congenital Athymia,2022-03-24,2026-04-30,2026-04-30,75.0,Cohort,,Other,Observational,Recruiting,,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH,Duke University School of Medicine,Biological,United States,0.0,21.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05329935
3394,NCT05334069,thyroid neoplasms,Blinded Reference Set for Multicancer Early Detection Blood Tests,Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Ann Arbor Stage III Lymphoma|Ann Arbor Stage II Lymphoma|Ann Arbor Stage I Lymphoma|Ann Arbor Stage IV Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Gastroesophageal Junction Adenocarcinoma|Head and Neck Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Invasive Breast Carcinoma|Kidney Carcinoma|Malignant Hepatobiliary Neoplasm|Malignant Solid Neoplasm|Melanoma|Muscle-Invasive Bladder Carcinoma|RISS Stage III Plasma Cell Myeloma|RISS Stage II Plasma Cell Myeloma|RISS Stage I Plasma Cell Myeloma|Sarcoma|Stage I Bladder Cancer AJCC v6 and v7|Stage I Breast Cancer AJCC v7|Stage I Colorectal Cancer AJCC v6 and v7|Stage I Esophageal Cancer AJCC V7|Stage I Gastric Cancer AJCC V7|Stage II Bladder Cancer AJCC v6 and v7|Stage II Breast Cancer AJCC v6 and v7|Stage II Colorectal Cancer AJCC v7|Stage II Esophageal Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage III Bladder Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Esophageal Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Uterine Corpus Cancer AJCC v7|Stage II Lung Cancer AJCC v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage II Prostate Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7|Stage I Lung Cancer AJCC v7|Stage I Ovarian Cancer AJCC v6 and v7|Stage I Pancreatic Cancer AJCC v6 and v7|Stage I Prostate Cancer AJCC v7|Stage I Uterine Corpus Cancer AJCC v7|Stage IV Bladder Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Thyroid Gland Carcinoma,2022-04-12,2025-01-31,2025-02-28,2000.0,Case-Control,,Prospective,Observational,Not yet recruiting,,Alliance for Clinical Trials in Oncology,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),,Other|Procedure,,40.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05334069
3395,NCT05334771,hypothyroidism,Early Detection of Endolymphatic Hydrops in Hypothyroid Patients,Early Detection of Endolymphatic Hydrops in Hypothyroid Patients,Hypothyroidism,2022-03-11,2024-03-31,2025-04-30,50.0,Cohort,,Prospective,Observational,Not yet recruiting,,Assiut University,Assiut University,,Device,,25.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05334771
3396,NCT05345119,goiter,"An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus in Graves' Orbitopathy,Graves Ophthalmopathy,2022-04-19,2021-06-15,2021-06-15,30.0,Cohort,,Retrospective,Observational,Completed,,University of Pisa,University of Pisa,Endocrinologia II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05345119
3397,NCT05345119,hyperthyroidism,"An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus in Graves' Orbitopathy,Graves Ophthalmopathy,2022-04-19,2021-06-15,2021-06-15,30.0,Cohort,,Retrospective,Observational,Completed,,University of Pisa,University of Pisa,Endocrinologia II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05345119
3398,NCT05345119,graves ophthalmopathy,"An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus in Graves' Orbitopathy,Graves Ophthalmopathy,2022-04-19,2021-06-15,2021-06-15,30.0,Cohort,,Retrospective,Observational,Completed,,University of Pisa,University of Pisa,Endocrinologia II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05345119
3399,NCT05345119,graves disease,"An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus in Graves' Orbitopathy,Graves Ophthalmopathy,2022-04-19,2021-06-15,2021-06-15,30.0,Cohort,,Retrospective,Observational,Completed,,University of Pisa,University of Pisa,Endocrinologia II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05345119
3400,NCT05346419,hyperparathyroidism,Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients,Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients,Hyperparathyroidism|Hypovitaminosis D|Postmenopausal Osteoporosis,2022-04-15,2022-02-03,2022-02-26,33.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospital Regional 1o de Octubre,"Hospital Regional 1o de Octubre|National Polytechnic Institute, Mexico|Universidad Nacional Autonoma de Mexico",Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE,Drug|Drug,Mexico,40.0,78.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05346419
3403,NCT05347082,hyperparathyroidism,Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women,Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment,"Hyperparathyroidism, Primary|Hyperparathyroidism, Secondary|Hypovitaminosis D|Postmenopausal Osteoporosis|Postmenopause",2022-04-17,2021-12-29,2022-02-20,47.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospital Regional 1o de Octubre,"Hospital Regional 1o de Octubre|National Polytechnic Institute, Mexico|Universidad Nacional Autonoma de Mexico",Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE,Drug,Mexico,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05347082
3406,NCT05355701,thyroid neoplasms,"A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS",A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors.,Colorectal Cancer|Glioma|Melanoma|Non-Small-Cell Lung Cancer|Thyroid Cancer,2022-04-26,2026-02-23,2027-08-27,174.0,,Sequential Assignment,,Interventional,Not yet recruiting,Phase 1,Pfizer,Pfizer,,Drug|Drug|Biological,,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05355701
3408,NCT05371262,congenital hypothyroidism,"Evaluation of Long-term Benefit-risk Profile of Levothyroxine Treatment in Children With Congenital Hypothyroidism: Influence of Initial Levothyroxine Dose on Neurodevelopmental, Growth, Cardiovascular and Skeletal Outcomes",Influence of Initial Levothyroxine Dose on Neurodevelopmental and Growth Outcomes in Congenital Hypothyroidism,Congenital Hypothyroidism,2022-05-04,2018-05-31,2018-05-31,72.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Federico II University,Federico II University,,Drug,,0.0,29.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05371262
3409,NCT05377736,thyroid nodule,Thyroid Nodule Gene Sequencing in a Danish Population - A Pilot Study,Thyroid Nodule Gene Sequencing in a Danish Population,Thyroid Cancer|Thyroid Nodule (Diagnosis),2022-03-15,2022-12-31,2027-01-18,30.0,,Single Group Assignment,,Interventional,Enrolling by invitation,Not Applicable,University of Aarhus,Aarhus University Hospital|Odense University Hospital|University of Aarhus,Aarhus Universityhospital,Genetic,Denmark,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05377736
3410,NCT05377736,thyroid neoplasms,Thyroid Nodule Gene Sequencing in a Danish Population - A Pilot Study,Thyroid Nodule Gene Sequencing in a Danish Population,Thyroid Cancer|Thyroid Nodule (Diagnosis),2022-03-15,2022-12-31,2027-01-18,30.0,,Single Group Assignment,,Interventional,Enrolling by invitation,Not Applicable,University of Aarhus,Aarhus University Hospital|Odense University Hospital|University of Aarhus,Aarhus Universityhospital,Genetic,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05377736
3411,NCT05382988,hyperparathyroidism,Effect of Sodium Zirconium Cyclosilicate on Hyperkalemia After Parathyroidectomy in Secondary Hyperparathyroidism Patients With Maintenance Hemodialysis,Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy,"Hyperkalemia|Hyperparathyroidism, Secondary|Sodium Zirconium Cyclosilicate",2022-05-09,2021-12-31,2021-12-31,62.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Guangdong Provincial People's Hospital,Guangdong Provincial People's Hospital,,Drug,,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05382988
3414,NCT05385029,hyperthyroidism,Thyroid Function Tests in Infants of COVID-19 Positive Pregnant Mothers,Fetal and Neonatal Thyroid in Pregnancies With Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS- COV2 ) COVID-19,Hyperthyroidism|Hypothyroidism|Thyroid Dysfunction,2022-05-10,2021-09-30,2021-09-30,95.0,Case-Control,,Prospective,Observational [Patient Registry],Completed,,Security Forces Hospital,OMER B ABDELBASIT,Security Forces Hospital,Drug,Saudi Arabia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05385029
3415,NCT05385029,hypothyroidism,Thyroid Function Tests in Infants of COVID-19 Positive Pregnant Mothers,Fetal and Neonatal Thyroid in Pregnancies With Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS- COV2 ) COVID-19,Hyperthyroidism|Hypothyroidism|Thyroid Dysfunction,2022-05-10,2021-09-30,2021-09-30,95.0,Case-Control,,Prospective,Observational [Patient Registry],Completed,,Security Forces Hospital,OMER B ABDELBASIT,Security Forces Hospital,Drug,Saudi Arabia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05385029
48,NCT02378233,thyroid diseases,A Double-blinded Randomised Study of Iodine Supplementation to Lactating Women in an Iodine-sufficient Area in Sweden and Evaluation of Maternal and Neonatal Iodine Levels and Thyroid Function,Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant,Lactation|Thyroid Gland; Node,2015-01-19,2017-12-31,2023-12-31,221.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Gteborg University,"Gteborg University|Sahlgrenska University Hospital, Sweden",Health Care center,Dietary Supplement|Dietary Supplement,Sweden,18.0,40.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02378233
61,NCT02742597,thyroid diseases,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Multimorbidity|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,2016-03-21,2019-04-07,2022-03-30,175.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Lawson Health Research Institute,"Canadian Institutes of Health Research (CIHR)|Lawson Health Research Institute|Michael Garron Hospital|Mount Sinai Hospital, Canada|Providence Healthcare|Sunnybrook Health Sciences Centre|Toronto Central Community Care Access Centre|Unity Health Toronto|Universit de Sherbrooke|University Health Network, Toronto|Western University, Canada|Women's College Hospital",Western University|Mount Sinai Hospital|Providence Healthcare|St. Michael's Hospital|Sunnybrook Health Sciences Centre|Toronto Central Community Care Access Centre|Toronto East General Hospital|University Hospital Network|Women's College Hospital,Behavioral,Canada,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02742597
64,NCT02789800,thyroid diseases,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,2016-03-16,2022-04-01,2022-04-02,1956.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Universit de Sherbrooke,"Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean|Canadian Institutes of Health Research (CIHR)|Universit de Sherbrooke|Western University, Canada",Universit de Sherbrooke|CIUSSS du Sageunay-Lac-Saint-Jean,Behavioral,Canada,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02789800
68,NCT02868476,thyroid diseases,Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases,Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases,Thyroid Diseases,2016-08-05,2017-05-26,2024-07-30,532.0,Cohort,,Prospective,Observational [Patient Registry],Active not recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,,,,20.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02868476
73,NCT02966405,thyroid diseases,The Establish of Trimester-specific Reference Ranges for Thyroid Tests in Pregnant Women and the Influence of Thyroid Disorders on Pregnancy and Its Outcomes.,The Establish of Specific Reference Ranges for Thyroid Tests in Pregnant Women,Diseases Pregnancy Thyroid,2016-10-24,2020-12-31,2020-12-31,1000.0,Case-Only,,Prospective,Observational [Patient Registry],Recruiting,,Peking University International Hospital,Xiaomei Zhang,Peking University International Hospital|Peking University International Hospital,,China,19.0,45.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02966405
89,NCT03149354,thyroid diseases,Prevalence of Thyroid Function Abnormalities in HIV-infected Patients: State of Play in 2012,Prevalence of Thyroid Function Abnormalities in HIV-infected Patients,HIV Infections|Thyroid,2017-05-04,2022-12-19,2022-12-19,104.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03149354
95,NCT03191188,thyroid diseases,A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients,A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients,"Kidney Diseases, Chronic|Thyroid Disease",2017-06-13,2021-07-31,2021-07-31,96.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of California, Irvine","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Irvine",University Dialysis Center of Orange,Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03191188
105,NCT03369405,thyroid diseases,Thyroid Insufficiency as a Modifying Factor for Chronic Periodontitis,Thyroid Disease and Chronic Periodontitis,Chronic Periodontitis|Thyroid Diseases,2017-11-28,2022-08-01,2022-08-01,2000.0,Other,,Retrospective,Observational,Active not recruiting,,University at Buffalo,University at Buffalo,"School of Dental Medicine, University at Buffalo",Other,United States,35.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03369405
109,NCT03414021,thyroid diseases,Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies,Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor,Bone Diseases|Brain Diseases|Heart Diseases|Kidney Diseases|Thyroid Diseases,2018-01-23,2023-01-30,2023-01-30,250.0,Cohort,,Prospective,Observational,Recruiting,,Lille Catholic University,Lille Catholic University,Humanitep|Hopital Priv Le Bois,Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03414021
151,NCT03922087,thyroid diseases,Huizhou Mother-infant Cohort,No-worry Baby Project,"Allergic Disorder|Anemia in Pregnancy|Asthma|Complications, Pregnancy|Depression|Gestational Diabetes Mellitus in Pregnancy|Gestational Hypertension|Immune System Diseases|Neurodevelopmental Disorders|Obesity|Obstetric Labor Complications|Reproductive Disorder|Thyroid Disease Pregnancy",2019-04-13,2022-04-01,2025-12-31,10000.0,Case-Control,,Prospective,Observational,Recruiting,,Sun Yat-sen University,Huizhou No.1 Maternal and Child Care Service Cencer|Sun Yat-sen University,School of Public Health of Sun Yat-sen University (North Campus),Other,China,18.0,49.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03922087
153,NCT03932487,thyroid diseases,"The Relationship Between Urine Iodine, Urine Bisphenol A and Autoimmune Thyroid Disease in Reproductive Women","The Relationship Between Urine Iodine, Urine Bisphenol A and Autoimmune Thyroid Disease in Reproductive Women",The Effect of Iodine and BPA on AITD in Reproduction Women,2019-04-24,2022-10-01,2022-10-01,142.0,Other,,Cross-Sectional,Observational,Recruiting,,Peking University International Hospital,Xiaomei Zhang,Peking University international hospital,Other,China,20.0,45.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03932487
161,NCT04019509,thyroid diseases,The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology,The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology,Fertility Disorders|Thyroid Dysfunction,2019-07-10,2022-01-01,2022-09-01,900.0,,Factorial Assignment,,Interventional,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,UZ Brussel,Diagnostic Test|Other,Belgium,18.0,36.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04019509
180,NCT04208503,thyroid diseases,Ultrasound and Functional Thyroid Evaluation in Preterm Infants Born Between 24 and 32 Weeks of Gestation,Ultrasound and Functional Thyroid Evaluation,Gland; Functional Disturbance|Thyroid,2019-12-13,2021-12-30,2021-12-31,200.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,"Princess Anna Mazowiecka Hospital, Warsaw, Poland","Princess Anna Mazowiecka Hospital, Warsaw, Poland",Department of Neonatology and Neonatal Intensive Care Warsaw Medical University|Department of Neonatology and Neonatal Intensive Care Warsaw Medical University,Diagnostic Test,Poland,0.0,12.0,[0-17],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04208503
188,NCT04279184,thyroid diseases,Urinary Incontinence and Endocrine Factors.,Urinary Incontinence and Endocrine Factors. A Part of Lolland-Falster Health Study (LOFUS).,Diabetes|Thyroid Diseases|Urinary Incontinence,2020-01-16,2020-02-29,2021-02-28,6000.0,Cohort,,Cross-Sectional,Observational,Recruiting,,Nykbing Falster County Hospital,Nykbing Falster County Hospital|Region Zealand|University of Southern Denmark|Zealand University Hospital,Randi Jepsen,,Denmark,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04279184
202,NCT04323007,thyroid diseases,Thyroid Dysfunction in Patients With Nephrotic Syndrome,Thyroid Dysfunction in Patients With Nephrotic Syndrome,Thyroid Dysfunction,2020-01-12,2021-10-01,2022-10-01,100.0,,Single Group Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University|Merna Makram,,Diagnostic Test,,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04323007
208,NCT04351945,thyroid diseases,A Study of Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors,Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors,Cortisol Deficiency|Diabetes Insipidus|Endocrine System Diseases|End-stage Heart Failure|End Stage Lung Disease|Thyroid Diseases,2020-04-15,2022-05-15,2022-07-01,100.0,Cohort,,Prospective,Observational,Active not recruiting,,Semmelweis University Heart and Vascular Center,Semmelweis University|Semmelweis University Heart and Vascular Center,Heart and Vascular Center,Procedure,Hungary,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04351945
213,NCT04388956,thyroid diseases,Diagnosis of Thyroid Tumors by Multiple Ultrasonic Factors.,Thyroid Disease Diagnosis by Mutiple Ultrasonic Factors.,Diagnoses Disease|Nodule|Thyroid,2020-05-12,2022-12-31,2022-12-31,300.0,Case-Only,,Prospective,Observational [Patient Registry],Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,0.0,120.0,[0-17]|[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04388956
217,NCT04427904,thyroid diseases,Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery: A Randomized Controlled Trial,Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery,"Anesthesia, Local|Postoperative Pain|Thyroid Diseases",2020-05-26,2023-12-31,2024-12-31,210.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,St. Joseph's Healthcare Hamilton,St. Joseph's Healthcare Hamilton,St. Joeseph's Healthcare Hamilton,Drug|Drug,Canada,18.0,100.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04427904
224,NCT04471597,thyroid diseases,Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia In Patients Undergoing Elective Thyroidectomy. A Randomized Controlled Study,Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia,Thyroid Diseases,2020-07-12,2022-04-01,2022-05-01,48.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Zagazig University,Zagazig University,"Faculty of medicine, zagazig university",Drug|Drug,Egypt,21.0,60.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04471597
232,NCT04542278,thyroid diseases,Randomized Controlled Trial of Preoperative Steroids in Autoimmune Thyroid Disease,Preoperative Steroids in Autoimmune Thyroid Disease,Thyroid Diseases,2020-09-01,2022-10-31,2022-10-31,30.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 4,"University of Wisconsin, Madison","University of Wisconsin, Madison",University of Wisconsin Hospital and Clinics,Drug,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04542278
241,NCT04571736,thyroid diseases,Interest of Improving Preoperative Medical Information by Video Support and Personalized and Secure Web Platform: Pilot Study in Thyroid Surgery (AMEDOP),Pilot Study for Thyroid Surgery by Preoperative Video Support and Personalized and Secure Web Platform,Thyroid,2020-07-27,2022-11-30,2022-11-30,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University Hospital, Montpellier","EDOP|University Hospital, Montpellier",CHU Gui de Chauliac,Other,France,18.0,75.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04571736
247,NCT04585126,thyroid diseases,Effect of Ultrasound-guided Intermediate Cervical Block on Recurrent Laryngeal Nerve Monitoring During Thyroid Surgery : a Randomised Non-inferiority Study,Effect of Cervical Block on Recurrent Laryngeal Nerve Monitoring During Thyroid Surgery,Thyroid Surgery,2020-10-02,2021-11-30,2021-11-30,120.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University Hospital, Caen","Centre Francois Baclesse|University Hospital, Caen",Caen University Hospital,Drug,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04585126
254,NCT04615988,thyroid diseases,Correlation of Serum Vitamin D Level With the Development of Endocrine Autoimmune Complications During Treatment With Immune Checkpoint Inhibitors,Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors,Cancer|PD-1|Thyroid,2020-10-29,2022-12-31,2024-06-30,153.0,Cohort,,Prospective,Observational,Recruiting,,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Mount Sinai Hospital /Tisch Cancer Cancer/Ruttenberg Treatment Center,,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04615988
260,NCT04658524,thyroid diseases,Evaluation of Thyroid Function in Patients With Chronic Kidney Disease,Evaluation of Thyroid Function in Patients With Chronic Kidney Disease,Chronic Kidney Disease|Thyroid Dysfunction,2020-11-20,2019-11-30,2025-12-30,44.0,Cohort,,Cross-Sectional,Observational,Active not recruiting,,Rio de Janeiro State University,Rio de Janeiro State University,Ana Beatriz Winter Tavares,Diagnostic Test,Brazil,18.0,100.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04658524
268,NCT04684953,thyroid diseases,Implantation of Thyroid Gland After Total Thyroidectomy in Quadriceps Femoris Muscle,Thyroid Autotransplantation in Quadriceps Femoris Muscle,Thyroid,2020-12-22,2022-10-31,2022-12-31,40.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Drug,,15.0,40.0,[0-17]|[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04684953
274,NCT04708704,thyroid diseases,Investigation of Photodegraded Edible Food Dyes in Drinking Water on Thyroid Function,Photodegraded Edible Food Dyes,Thyroid; Functional Disturbance,2020-12-21,2023-12-31,2024-12-31,10.0,,Sequential Assignment,,Interventional,Not yet recruiting,Not Applicable,Yale University,Yale University,Yale University,Dietary Supplement|Dietary Supplement|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04708704
295,NCT04794257,thyroid diseases,Clinical Validation of NerveTrend vs. Conventional i-IONM Mode of NIM Vital in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.,NerveTrend vs. i-IONM in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.,Recurrent Laryngeal Nerve Injuries|Surgery|Thyroid Diseases,2021-03-07,2022-12-31,2023-03-31,264.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Jagiellonian University,Marcin Barczynski,"Department of Endocrine Surgery, Jagiellonian University College of Medicine",Device,Poland,18.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04794257
304,NCT04842942,thyroid diseases,The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach,The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach,Surgery|Thyroid Diseases,2021-02-19,2021-12-31,2022-07-31,15.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,"University Health Network, Toronto","University Health Network, Toronto",Univeristy Health Network,Procedure,Canada,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04842942
306,NCT04845867,thyroid diseases,Thyroid HEmorrhage DetectOr Study,Thyroid HEmorrhage DetectOr Study,Thyroid,2021-04-13,2022-06-30,2022-08-31,1470.0,Cohort,,Prospective,Observational [Patient Registry],Not yet recruiting,,ISAR-M GmbH,CRI-The Clinical Research Institute GmbH|ISAR-M GmbH,,Device,,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04845867
329,NCT04936698,thyroid diseases,The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan,The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan,Thyroid Disease Pregnancy,2021-06-17,2022-03-31,2022-03-31,2000.0,Cohort,,Prospective,Observational,Recruiting,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Chang Gung Memorial hospital,Drug|Drug,Taiwan,18.0,50.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04936698
333,NCT04943146,thyroid diseases,An Assessment of Aspirin Plus Prednisone Treatment for Euthyroid Women With Thyroid Autoimmunity Undergoing In Vitro Fertilization,An Assessment of Aspirin Plus Prednisone Treatment for Euthyroid Women With Thyroid Autoimmunity,Thyroid Diseases,2021-06-21,2021-06-30,2022-03-31,402.0,Case-Only,,Retrospective,Observational,Recruiting,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Ningbo Women and Children's Hospital|People's Hospital of Jinhua|Second Affiliated Hospital, School of Medicine, Zhejiang University",People's Hospital of Jinhua|Ningbo Women and Children's Hospital,Drug,China,18.0,40.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04943146
344,NCT04991493,thyroid diseases,Effect of Tramadol on Postoperative Sore Throat in Thyroid Surgery Under General Anesthesia With Endotracheal Intubation: A Randomized Controlled Trial,Effect of Tramadol on Postoperative Sore Throat After General Anesthesia,Intubation Intratracheal|Post-operative Sore Throat|Thyroid Surgery,2021-07-27,2023-07-31,2023-12-31,168.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Affiliated Cancer Hospital of Shantou University Medical College,Affiliated Cancer Hospital of Shantou University Medical College,Affiliated Cancer Hospital of Shantou University Medical College Medical,Drug|Other,China,18.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04991493
352,NCT05016518,thyroid diseases,Comparison of Quality of Recovery (QoR)-15 Scores According to the Use of Anesthetics During Total Intravenous Anesthesia in Female Patients Undergoing Thyroid Surgery,Comparison of Quality of Recovery (QoR)-15 Scores Between Propofol and Remimazolam Anesthesia,Patients Undergoing Thyroid Surgery for Neoplasm,2021-08-10,2022-06-30,2022-07-04,140.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Gangnam Severance Hospital,Gangnam Severance Hospital,Gangnam Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05016518
358,NCT05036525,thyroid diseases,"Evaluation of the Efficacy and Safety of a High Molecular Weight Native Hyaluronic Acid Gel (HANBIO BarriGel) in Adhesion Prevention After Open Thyroidectomy: a Prospective, Randomized Controlled, Single Blind Study.",Evaluation of the Efficacy and Safety of a Hyaluronic Acid Gel in Adhesion Prevention After Open Thyroidectomy.,Adhesion|Thyroid Diseases,2021-09-02,2023-06-30,2023-06-30,100.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,HAN Biomedical Inc,HAN Biomedical Inc,,Device,,20.0,70.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05036525
367,NCT05103774,thyroid diseases,Thyroid Functions in Children With Congenital Heart Diseases,Thyroid Functions in Children With Congenital Heart Diseases,Value of Thyroid Functions in Children With Congenital Heart Diseases,2021-10-18,2022-11-01,2022-11-15,100.0,Other,,Retrospective,Observational,Not yet recruiting,,Sohag University,Sohag University,Hospital of Sohag University,Diagnostic Test,Egypt,1.0,12.0,[0-17],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05103774
375,NCT05126108,thyroid diseases,Evaluation of the Decurarisation Kinetics of Rocuronium in Cervical Surgery,Decurarisation Kinetics of Rocuronium in Cervical Surgery,Equiring General Anesthesia With Intubation With a Nerve Integrity Monitor (NIM) Tube|Non-morbidly Obese Patients (BMI<35)|Thyroid and Parathyroid Surgery,2021-11-08,2022-05-31,2022-05-31,50.0,Cohort,,Prospective,Observational,Not yet recruiting,,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Surgical anesthesia service - Cochin Hospital,Procedure|Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05126108
382,NCT05151120,thyroid diseases,Harmonization of Thyroid-stimulating Hormone Immunoassays Reagents - Blood Collection From Patients With Thyroid Disorders,Harmonization of Thyroid-stimulating Hormone Immunoassays Reagents,"Thyroid Disorders|Thyroid Stimulating; Hormone, C",2021-10-21,2023-11-05,2023-11-05,100.0,Other,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Service D'endocrinologie - Hpital Louis Pradel - Hospices Civils de Lyon|Service de Mdecine Nuclaire - Hpital Louis Pradel - Hospices Civils de Lyon,Biological,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05151120
402,NCT05251194,thyroid diseases,The Effect of McGrath Video Laryngoscope on the Glottic View at Thyroid Surgery Position in Tracheal Intubation,The Effect of McGrath Video Laryngoscope on the Glottic View at Thyroid Surgery Position,Thyroid Surgery,2022-02-11,2022-06-30,2022-08-31,39.0,,Single Group Assignment,,Interventional,Not yet recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital|SMG-SNU Boramae Medical Center,Seoul Metropolitan Government Seoul National University Boramae Medical Center,Device,"Korea, Republic of",19.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05251194
418,NCT05323539,thyroid diseases,Comparison of Thyroid Volumes by Ultrasonography in Patients With and Without Endometrioma,Comparison of Thyroid Volumes in Patients With and Without Endometrioma,Endometrioma|Thyroid,2022-04-05,2022-05-31,2022-05-31,60.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Adana City Training and Research Hospital,Adana City Training and Research Hospital,Adana City Education and Research Hospital,Other,Turkey,18.0,45.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05323539
0,NCT00001159,Grave's Disease|Hyperthyroidism|Hypothyroidism,Evaluation of Patients With Thyroid Function Disorders,Evaluation of Patients With Thyroid Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,2500.0,Case-Only,,Retrospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00001159
4,NCT00001160,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,Studies on Thyroid Nodules and Thyroid Cancer,Studies on Tumors of the Thyroid,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,1999-11-03,,,2500.0,Case-Only,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00001160
7,NCT00001242,Hypocalcemia|Osteomalacia|Pseudohypoparathyroidism|Pseudopseudohpoparathyroidism|Rickets,Studies of States With Resistance to Vitamin D and Parathyroid Hormone,Studies of States With Resistance to Vitamin D and Parathyroid Hormone,Hypocalcemia|Osteomalacia|Pseudohypoparathyroidism|Pseudopseudohpoparathyroidism|Rickets,1999-11-03,,,3000.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,2.0,100.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00001242
9,NCT00001277,Hypercalcemia|Hyperparathyroidism|MEN1|Multiple Endocrine Neoplasia|Parathyroid Neoplasm,Studies of Hyperparathyroidism and Related Disorders,Studies of Elevated Parathyroid Activity,Hypercalcemia|Hyperparathyroidism|MEN1|Multiple Endocrine Neoplasia|Parathyroid Neoplasm,1999-11-03,2020-03-11,2020-12-23,1553.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,2.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00001277
12,NCT00001304,Hypoparathyroidism,Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34,Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34,Hypoparathyroidism,1999-11-03,2014-03-31,2014-04-30,27.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,17.0,69.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00001304
14,NCT00001394,Parathyroid Neoplasms,Use of Hypocalcemic Intraarterial Infusion Into the Thyroid/Parathyroid Bed to Localize Occult Parathyroid Adenomas,Using X-Ray Dye to Locate Hidden Parathyroid Tumors,Parathyroid Neoplasms,1999-11-03,,2005-07-31,150.0,,,,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00001394
16,NCT00001730,Hypothyroidism|Thyroid Neoplasms,A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal,Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,Hypothyroidism|Thyroid Neoplasms,1999-11-03,,2000-04-30,20.0,,,,Interventional,Completed,Phase 4,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00001730
18,NCT00004048,Head and Neck Cancer,Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin,Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer,Head and Neck Cancer,1999-12-10,2002-05-31,2002-05-31,30.0,,,,Interventional,Completed,Phase 1/Phase 2,Garden State Cancer Center at the Center for Molecular Medicine and Immunology,Garden State Cancer Center at the Center for Molecular Medicine and Immunology,Garden State Cancer Center|St. Joseph's Hospital and Medical Center,Biological|Drug|Procedure|Procedure|Radiation|Radiation,United States,16.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00004048
19,NCT00004074,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00004074
25,NCT00004089,Head and Neck Cancer,A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer,Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer,Head and Neck Cancer,1999-12-10,2002-04-30,2002-04-30,,,,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"Robert H. Lurie Comprehensive Cancer Center, Northwestern University|University of Illinois at Chicago|University of Chicago Cancer Research Center",Biological|Drug|Drug|Drug|Procedure|Radiation,United States,15.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00004089
26,NCT00004340,End Stage Renal Disease|Renal Osteodystrophy,,Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis,End Stage Renal Disease|Renal Osteodystrophy,1999-10-18,,,109.0,,,,Interventional,Completed,Phase 2,National Center for Research Resources (NCRR),"National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Los Angeles",University of California Los Angeles School of Medicine,Drug|Drug,United States,1.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00004340
29,NCT00004351,Angelman Syndrome|Chromosome Abnormalities|DiGeorge Syndrome|Prader-Willi Syndrome|Shprintzen Syndrome|Smith-Magenis Syndrome|Williams Syndrome,,Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes,Angelman Syndrome|Chromosome Abnormalities|DiGeorge Syndrome|Prader-Willi Syndrome|Shprintzen Syndrome|Smith-Magenis Syndrome|Williams Syndrome,1999-10-18,,,20.0,,,,Observational,Completed,,Office of Rare Diseases (ORD),Baylor College of Medicine|National Institute of Neurological Disorders and Stroke (NINDS),Baylor College of Medicine,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00004351
31,NCT00004361,"Conotruncal Cardiac Defects|Heart Defects, Congenital|Hypoparathyroidism|Pulmonary Atresia|Pulmonary Valve Stenosis|Tetralogy of Fallot",,Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects,"Conotruncal Cardiac Defects|Heart Defects, Congenital|Hypoparathyroidism|Pulmonary Atresia|Pulmonary Valve Stenosis|Tetralogy of Fallot",1999-10-18,,,150.0,,,,Observational,Completed,,Office of Rare Diseases (ORD),Ann & Robert H Lurie Children's Hospital of Chicago|National Center for Research Resources (NCRR),,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00004361
33,NCT00004660,Graves' Disease,Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Graves' Disease,2000-02-24,1998-01-31,1998-01-31,42.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic,Radiation|Radiation,United States,30.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00004660
37,NCT00004661,Pseudohypoparathyroidism,,Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism,Pseudohypoparathyroidism,2000-02-24,,,20.0,,,,Observational,Completed,,Office of Rare Diseases (ORD),"National Center for Research Resources (NCRR)|University of California, Los Angeles",,,,12.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00004661
39,NCT00004843,Hyperparathyroidism,A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic,A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic Primary Hyperparathyroidism,Hyperparathyroidism,2000-02-24,1999-03-30,1999-03-30,53.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Henry Ford Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,Procedure|Other,,50.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00004843
41,NCT00005102,"Abnormalities, Multiple|Chromosome Abnormalities|Conotruncal Cardiac Defects|DiGeorge Syndrome|Shprintzen Syndrome",Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome,Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome,"Abnormalities, Multiple|Chromosome Abnormalities|Conotruncal Cardiac Defects|DiGeorge Syndrome|Shprintzen Syndrome",2000-04-06,,,11.0,Natural History,,,Observational,Unknown status,,National Center for Research Resources (NCRR),Children's Hospital of Philadelphia|National Center for Research Resources (NCRR),Children's Hospital of Philadelphia,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00005102
43,NCT00005184,Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Heart Diseases|Hypertension|Hypothyroidism|Obesity,,Immunogenetic Factors of Coronary Heart Disease,Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Heart Diseases|Hypertension|Hypothyroidism|Obesity,2000-05-25,,1989-11-30,,,,,Observational,Completed,,"National Heart, Lung, and Blood Institute (NHLBI)","National Heart, Lung, and Blood Institute (NHLBI)",,,,0.0,100.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00005184
44,NCT00006329,Hyperparathyroidism,,Comparison of Two Methods of Parathyroidectomy for Primary Hyperparathyroidism,Hyperparathyroidism,2000-10-04,,,,,,,Interventional,Completed,Phase 2/Phase 3,National Center for Research Resources (NCRR),National Center for Research Resources (NCRR),"Univ. of Michigan Hosp, Dept. of Surgery",Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00006329
46,NCT00037193,Secondary Hyperparathyroidism,Acute Regulation of Parathyroid Hormone by Dietary Phosphate,Acute Regulation of Parathyroid Hormone by Dietary Phosphate,Secondary Hyperparathyroidism,2002-05-16,,,,Defined Population,,Prospective,Observational,Completed,,National Center for Research Resources (NCRR),National Center for Research Resources (NCRR),Washington University Medical School,,United States,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00037193
49,NCT00037518,Hyperparathyroidism|Parathyroid Neoplasms,An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.,A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer,Hyperparathyroidism|Parathyroid Neoplasms,2002-05-17,,,46.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00037518
53,NCT00037635,End Stage Renal Disease|Secondary Hyperparathyroidism,A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis,A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients,End Stage Renal Disease|Secondary Hyperparathyroidism,2002-05-17,2003-03-31,2003-03-31,400.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00037635
56,NCT00042432,Chronic Renal Insufficiency|Secondary Hyperparathyroidism,A Study of an Investigational Medication for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients,Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients,Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2002-07-29,2003-03-31,2003-08-31,54.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00042432
59,NCT00042653,End Stage Renal Disease|Secondary Hyperparathyroidism,"A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis)",A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis,End Stage Renal Disease|Secondary Hyperparathyroidism,2002-08-02,2003-07-31,2003-07-31,380.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00042653
62,NCT00053547,End Stage Renal Disease|Secondary Hyperparathyroidism,Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis,Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis,End Stage Renal Disease|Secondary Hyperparathyroidism,2003-01-30,,,28.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Stanford University Medical Center|Miami Children's Hospital|The Children's Hospital of Buffalo|Texas Children's Hospital|University of Texas at Houston|Medical College of Wisconsin,Drug,United States,2.0,20.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00053547
65,NCT00060242,Head and Neck Cancer,Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid,Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer,Head and Neck Cancer,2003-05-06,2007-02-28,2008-01-31,26.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Case Comprehensive Cancer Center,Case Comprehensive Cancer Center|National Cancer Institute (NCI),"Josephine Ford Cancer Center at Henry Ford Hospital|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center|Hillman Cancer Center at University of Pittsburgh Cancer Institute",Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00060242
66,NCT00061906,Head and Neck Cancer,Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma,Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer,Head and Neck Cancer,2003-06-05,2006-06-30,2006-06-30,25.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Ohio State University Comprehensive Cancer Center,Ohio State University Comprehensive Cancer Center,Ohio State University Comrehensive Cancer Center|University of Texas - MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00061906
67,NCT00068497,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,"Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,40.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00068497
73,NCT00073710,Chronic Kidney Disease|Secondary Hyperparathyroidism,"A Phase IV, Single-Center, Active-Controlled Cross-Over Pilot Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium",Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium,Chronic Kidney Disease|Secondary Hyperparathyroidism,2003-12-03,,,30.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Creighton University,Drug|Procedure|Drug,United States,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00073710
76,NCT00077103,Head and Neck Cancer,Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation],Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer,Head and Neck Cancer,2004-02-10,2007-02-28,2007-12-31,4.0,,Single Group Assignment,,Interventional,Terminated,Phase 1/Phase 2,Case Comprehensive Cancer Center,Case Comprehensive Cancer Center|National Cancer Institute (NCI),"Josephine Ford Cancer Center at Henry Ford Hospital|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center|Hillman Cancer Center at University of Pittsburgh Cancer Institute",Biological|Biological|Drug|Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00077103
78,NCT00080574,Thyroid Cancer,The Effects of Thyroid Hormone on Cytochrome P450 and P-Glycoprotein Activity in Thyroid Cancer Patients,The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients,Thyroid Cancer,2004-04-07,,2005-11-30,20.0,,,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00080574
79,NCT00085293,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine,Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2004-06-10,2014-01-31,2014-05-31,12.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Colorado at Denver|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center,Drug|Radiation|Biological|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00085293
82,NCT00094055,Thyroid Neoplasms,Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131 I Treatment,Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer,Thyroid Neoplasms,2004-10-08,2009-01-31,2009-01-31,60.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Pfizer,Pfizer,Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00094055
83,NCT00094237,Cardiovascular Diseases|Cerebrovascular Accident|Heart Diseases|Hypothyroidism|Myocardial Infarction,Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke,Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke,Cardiovascular Diseases|Cerebrovascular Accident|Heart Diseases|Hypothyroidism|Myocardial Infarction,2004-10-15,2007-07-31,2007-07-31,3200.0,Cohort,,Prospective,Observational,Completed,,"University of North Carolina, Chapel Hill","National Heart, Lung, and Blood Institute (NHLBI)|University of North Carolina, Chapel Hill",,,,50.0,79.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00094237
84,NCT00094484,Chronic Kidney Disease|Kidney Disease,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis",Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis,Chronic Kidney Disease|Kidney Disease,2004-10-19,,,400.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00094484
87,NCT00095693,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-11-05,2005-08-31,2011-12-31,25.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug|Other|Other|Radiation|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00095693
91,NCT00095836,Head and Neck Cancer,A Phase II Study of ZD 1839 (IRESSA) in Patients With Advanced Thyroid Cancer,Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy,Head and Neck Cancer,2004-11-09,2011-03-31,2011-03-31,27.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Massachusetts General Hospital,AstraZeneca|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Massachusetts General Hospital|National Cancer Institute (NCI),Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00095836
92,NCT00098345,Thyroid Cancer,"An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.",Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer,Thyroid Cancer,2004-12-07,2008-02-29,2017-04-19,40.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,France|United States,18.0,130.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00098345
93,NCT00098813,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,"A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma",Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-12-08,2009-08-31,2009-08-31,20.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center at Suffolk,Drug|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00098813
96,NCT00098852,Head and Neck Cancer,A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer,Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer,Head and Neck Cancer,2004-12-08,2010-06-30,,25.0,,,,Interventional,Unknown status,Phase 2,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Helen Diller Family Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00098852
97,NCT00100828,Head and Neck Cancer,Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer,Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer,Head and Neck Cancer,2005-01-06,2008-11-30,2008-11-30,6.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|University of Michigan Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00100828
98,NCT00103155,Head and Neck Cancer,Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study,Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer,Head and Neck Cancer,2005-02-07,,,,,,,Interventional,Unknown status,Phase 1,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Comprehensive Cancer Center,Procedure|Procedure,United States,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00103155
99,NCT00104871,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma,Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2005-03-03,2010-05-31,2014-04-30,24.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"University of Colorado at Denver Health Sciences Center|Lombardi Comprehensive Cancer Center at Georgetown University|Emory University|Massachusetts General Hospital Cancer Center|Dana-Farber Harvard Cancer Center|Cleveland Clinic Foundation|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00104871
102,NCT00105274,22q11.2 Syndrome|DiGeorge Syndrome|Velocardiofacial Syndrome,Intermediate Phenotype and Genetic Mechanisms for Psychosis and Cognitive Disturbance in 22q11.2-Hemideletion Syndrome,Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study,22q11.2 Syndrome|DiGeorge Syndrome|Velocardiofacial Syndrome,2005-03-10,,2010-02-02,,,,,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Mental Health (NIMH),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00105274
104,NCT00108394,Osteopenia|Renal Osteodystrophy,Osteopenia and Renal Osteodystrophy: Evaluation and Management,Osteopenia and Renal Osteodystrophy: Evaluation and Management,Osteopenia|Renal Osteodystrophy,2005-04-14,,2007-09-30,,,Parallel Assignment,,Interventional,Completed,Phase 4,VA Office of Research and Development,US Department of Veterans Affairs,VA Puget Sound Health Care System,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00108394
107,NCT00110929,End Stage Renal Disease,A Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens Are Used in Subjects With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD),Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD),End Stage Renal Disease,2005-05-16,,,850.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00110929
110,NCT00111735,Hypothyroidism,"What is the Optimal Serum TSH Concentration During Thyroxine Treatment for Primary Hypothyroidism? Effects of Fine Titration of Thyroxine Dosage on Wellbeing, Quality of Life and Cognitive Function",Thyroxine Titration Study,Hypothyroidism,2005-05-24,,2005-03-31,55.0,,Crossover Assignment,,Interventional,Unknown status,Phase 4,Sir Charles Gairdner Hospital,Sir Charles Gairdner Hospital,Sir Charles Gairdner Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00111735
111,NCT00115739,Thyroid Cancer,Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer,Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma,Thyroid Cancer,2005-06-23,2008-05-31,2010-08-31,11.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,University of Michigan Rogel Cancer Center,University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00115739
112,NCT00115895,Thyroid Neoplasms,Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq,The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy,Thyroid Neoplasms,2005-06-26,2004-10-31,2020-09-30,160.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,University of Helsinki,Helsinki University Central Hospital|University of Helsinki,"Helsinki University Central Hospital, Department of Oncology",Drug,Finland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00115895
113,NCT00117052,End Stage Renal Disease|Secondary Hyperparathyroidism,SENSOR: Study to InvestigatE Cinacalcet TreatmeNt in Haemodialysis Patients With SecOndary HyperparathyRoidism,SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism,End Stage Renal Disease|Secondary Hyperparathyroidism,2005-06-30,2005-11-30,2006-02-28,673.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00117052
116,NCT00118248,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma,Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-07-08,2009-08-31,2012-04-30,41.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00118248
119,NCT00121628,Thyroid Cancer,"A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer","A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer",Thyroid Cancer,2005-07-12,2006-11-30,2010-10-31,184.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00121628
120,NCT00123461,Chronic Renal Insufficiency|Renal Failure|Secondary Hyperparathyroidism,"A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT).","Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism",Chronic Renal Insufficiency|Renal Failure|Secondary Hyperparathyroidism,2005-07-21,2007-10-31,2007-10-31,70.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company","AKDHC Medical Research Services|UCLA Diabetes Reseach Center|Apex Research of Riverside|George Washington University Hospital|Discovery Medical Research Group|Nephrology Associates|Georgia Kidney Associates, Inc.|Michigan Kidney Consultants, P.C.|Twin Cities Clinical Research|Montefiore Medical Center|University of Rochester Medical Center|Wake Nephrology Associates, PA|Wake Forest University School of Medicine|Altru Health System Research Center|DaVita Lewiston Dialysis Center|Temple University|Virginia Commonwealth University|Instituto Renal del Este|Jose Cangiano, MD",Drug,Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00123461
123,NCT00123760,Brain Neoplasms|Colorectal Neoplasms|Lung Neoplasms|Lymphoma|Thyroid Neoplasms,"A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer",Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer,Brain Neoplasms|Colorectal Neoplasms|Lung Neoplasms|Lymphoma|Thyroid Neoplasms,2005-07-22,2008-12-31,2008-12-31,10838.0,,Single Group Assignment,,Interventional,Completed,Phase 2/Phase 3,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Cross Cancer Institute,Cross Cancer Institute,Procedure,Canada,15.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00123760
124,NCT00124527,Thyroid Cancer,Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer,Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer,Thyroid Cancer,2005-07-26,2006-08-31,2006-08-31,35.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Eisai Inc.,Eisai Inc.,,Drug,Argentina|France|Peru|Russian Federation|Ukraine|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00124527
125,NCT00126568,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2005-08-02,2011-09-30,2011-09-30,20.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Case Western Reserve University,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00126568
127,NCT00132431,Chronic Kidney Disease|Kidney Disease|Secondary Hyperparathyroidism,Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism,START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism,Chronic Kidney Disease|Kidney Disease|Secondary Hyperparathyroidism,2005-08-19,,2005-07-31,300.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00132431
130,NCT00134043,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma,Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-08-22,2009-03-31,2009-03-31,19.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00134043
133,NCT00135304,Secondary Hyperparathyroidism,ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone,ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2005-08-24,2006-10-31,2006-12-31,170.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00135304
136,NCT00144079,Thyroid Neoplasms,Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma,Multicenter Study Differentiated Thyroid Carcinoma,Thyroid Neoplasms,2005-09-01,,2010-01-31,500.0,,Parallel Assignment,,Interventional,Completed,Phase 3,University Hospital Muenster,"Deutsche Krebshilfe e.V., Bonn (Germany)|University Hospital Muenster","Department of Nuclear Medicine|Department of Nuclear Medicine, Wien University Hospital|Department of Nuclear Medicine, University Halle-Wittenberg|Department of Nuclear medicine, Saarland University|Department of Nuclear Medicine, Cologne University|Department of Nuclear Medicine, Mnster University Hospital|Department of Nuclear Medicine, Katharinen-Hospital|Department of Nuclear Medicine, Helios-Klinikum Wuppertal|Department of Nuclear Medicine, Wrzburg University|Department of Nuclear Medicine, Zrich University Hospital",Procedure,Austria|Germany|Switzerland,18.0,69.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00144079
137,NCT00145366,Benign Nontoxic and Toxic Goiter|Graves' Disease,"Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.","rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter",Benign Nontoxic and Toxic Goiter|Graves' Disease,2005-09-02,,2005-07-31,110.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00145366
140,NCT00147433,Child Development Disorders|Pregnancy|Subclinical Hypothyroidism,Are IQs Low in Offspring of Euthyroid Women With Low T4?,The Effect of Thyroid Hormone Levels in Pregnant Women on the Intelligence Quotient (IQ) of Their Children,Child Development Disorders|Pregnancy|Subclinical Hypothyroidism,2005-09-02,,2008-11-30,5000.0,Case-Control,,Other,Observational,Unknown status,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Foundation for Blood Research,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00147433
141,NCT00148213,Thyroid Neoplasms,Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma,Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma,Thyroid Neoplasms,2005-09-06,,2005-06-30,100.0,,,Other,Observational,Completed,,University Hospital Muenster,"Nichols Institute Diagnostika GmbH, Bad Vilbel, Germany|University Hospital Muenster","Department of Nuclear Medicine, Mnster University Hospital",,Germany,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00148213
142,NCT00150111,Graves Disease|Thyroid Associated Ophthalmopathy,B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease,Rituximab in the Treatment of Graves' Disease,Graves Disease|Thyroid Associated Ophthalmopathy,2005-09-06,,2006-10-31,20.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital|Department of Hematology, Odense University Hospital",Drug|Drug|Biological,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00150111
146,NCT00150124,Graves' Disease|Toxic Nodular Goitre,The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism,Block-replacement Therapy During Radioiodine Therapy,Graves' Disease|Toxic Nodular Goitre,2005-09-06,2008-12-31,2009-03-31,100.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Odense University Hospital,Steen Bonnema,"Department of Endocrinology, Odense University Hospital",Drug|Drug,Denmark,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00150124
150,NCT00150137,Graves Disease|Toxic Nodular Goitre,The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism,Antithyroid Drugs During Radioiodine Therapy,Graves Disease|Toxic Nodular Goitre,2005-09-06,,2004-12-31,80.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00150137
154,NCT00150150,Benign Solitary Solid|Cystic Thyroid Nodules,Ultrasound Guided Interstitial Laser Photocoagulation on Benign Thyroid Nodules,Laser Therapy of Benign Thyroid Nodules,Benign Solitary Solid|Cystic Thyroid Nodules,2005-09-06,,2006-03-31,70.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Procedure,Denmark,20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00150150
156,NCT00151723,Hyperthyroidism,"Subclinical Hyperthyroidism ""To Treat or Not to Treat?"" A Dutch Multicenter Trial",Does Radioiodine Treatment Prevent Atrial Fibrillation and Bone Loss in Endogenous Subclinical Hyperthyroidism?,Hyperthyroidism,2005-09-08,,,200.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Radboud University Medical Center,Radboud University Medical Center,Academical Medical Centre Amsterdam|Martini Ziekenhuis Groningen|University Hospital Groningen|Radboud University Medical Centre Nijmegen|Maxima Medisch Centrum,Procedure,Netherlands,40.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00151723
157,NCT00161109,Chromosome 22q11.2 Deletion Syndrome,Genetics and Psychopathology in the 22q11 Deletion Syndrome,Genetics and Psychopathology in the 22q11 Deletion Syndrome,Chromosome 22q11.2 Deletion Syndrome,2005-09-08,,2012-10-31,175.0,Defined Population,,Prospective,Observational,Unknown status,,UMC Utrecht,Children's Hospital of Philadelphia|Netherlands Brain Foundation|UMC Utrecht,"Children's Hospital of Philadelphia, Dpt of Genetics and Dpt of Child and Adolescent Psychiatry|UMC Utrecht, Dpt of Child and Adolescent Psychiatry",,Netherlands|United States,8.0,20.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00161109
159,NCT00169806,Cystinuria|Hypercalciuria|Hyperparathyroidism|Nephrocalcinosis|Renal Calculi,Randall's Plaques: Pathogenesis and Relationship to Nephrolithiasis,Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis,Cystinuria|Hypercalciuria|Hyperparathyroidism|Nephrocalcinosis|Renal Calculi,2005-09-12,2025-12-31,2025-12-31,600.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Indiana Kidney Stone Institute,Indiana Kidney Stone Institute|Indiana University School of Medicine|University of Chicago,IU Health Methodist Hospital,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00169806
161,NCT00174057,Graves' Ophthalmopathy,,"The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy",Graves' Ophthalmopathy,2005-09-13,,2006-07-31,50.0,Case-Control,,Other,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shu Lang Liao,,Taiwan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00174057
165,NCT00175149,Chronic Kidney Disease|Left Ventricular Hypertrophy|Secondary Hyperparathyroidism,"The Efficacy of 1,25 Dihydroxycholecalciferol on the Cardiovascular System in Patients With Renal Dysfunction",Active Vitamin D Effect on Left Ventricular Hypertrophy,Chronic Kidney Disease|Left Ventricular Hypertrophy|Secondary Hyperparathyroidism,2005-09-11,2008-12-31,2008-12-31,24.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,University of Aarhus,Per Ivarsen,"Department of Renal Medicne C, Skejby Hospital",Drug,Denmark,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00175149
168,NCT00176748,Thyroid Cancer,Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment,Treatment for Patients With Metastatic Thyroid Cancer,Thyroid Cancer,2005-09-09,2006-08-31,2009-06-30,3.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Michigan Rogel Cancer Center,Pfizer|University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00176748
169,NCT00181168,Thyroid Cancer,Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-differentiated Epithelial Thyroid Cancer,Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer,Thyroid Cancer,2005-09-12,2003-09-30,2003-09-30,63.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Johns Hopkins University,"Genzyme, a Sanofi Company|Gustave Roussy, Cancer Campus, Grand Paris|Johns Hopkins University|M.D. Anderson Cancer Center",Johns Hopkins Division of Endocrinology & Metabolism|M.D. Anderson Cancer Center|Institute Gustave Roussy,Drug,France|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00181168
170,NCT00189501,Nephrology,"A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)","A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)",Nephrology,2005-09-12,,,1000.0,,,Prospective,Observational,Completed,,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00189501
173,NCT00196729,Thyroid Neoplasms,"A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State",Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration,Thyroid Neoplasms,2005-09-13,,2003-09-30,63.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Sanofi,"Genzyme, a Sanofi Company",,Drug,,20.0,68.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00196729
174,NCT00205348,Hypothyroidism,Swallowing Function Before and After Surgery for Thyroid Goiter,Swallowing Function Before and After Surgery for Thyroid Goiter,Hypothyroidism,2005-09-13,2009-01-31,2009-01-31,146.0,Case-Only,,Prospective,Observational,Completed,,"University of Wisconsin, Madison","University of Wisconsin, Madison",,,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00205348
175,NCT00206375,Hypothyroidism,Concomitant Use of Growth Hormone and GnRH Agonist in Adolescent Patients With Acquired Hypothyroidism,Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism,Hypothyroidism,2005-09-13,2011-09-30,2011-11-30,16.0,,Single Group Assignment,,Interventional,Terminated,Phase 4,Baylor College of Medicine,Baylor College of Medicine|Eli Lilly and Company|TAP Pharmaceutical Products Inc.,Baylor college of Medicine,Drug|Drug,United States,8.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT00206375
176,NCT00209235,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1A,Natural History Study of Albright Hereditary Osteodystrophy: Includes Substudies on Effects of Growth Hormone in Patients With Pseudohypoparathyroidism Type 1a and Cognitive & Behavioral Studies in Albright Hereditary Osteodystrophy,"Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments",Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1A,2005-09-13,2026-10-31,2027-12-31,600.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Connecticut Children's Medical Center,"Connecticut Children's Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Johns Hopkins University|UConn Health",Connecticut Children's Medical Center,Behavioral,United States,2.0,89.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00209235
178,NCT00211939,"Arteriosclerosis|Calcinosis|Hyperparathyroidism, Secondary",CARE-2 (Calcium Acetate (PhosLo)/Sevelamer(Renagel) Evaluation Study 2),CARE-2 (Calcium Acetate [PhosLo]/Sevelamer[Renagel] Evaluation Study 2) for Heart Calcification in Dialysis Patients,"Arteriosclerosis|Calcinosis|Hyperparathyroidism, Secondary",2005-09-13,2006-12-31,2007-03-31,203.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Nabi Biopharmaceuticals,Nabi Biopharmaceuticals,University of Texas Health Sciences Center,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00211939
181,NCT00213720,Atrial Fibrillation|Subclinical Hyperthyroidism,Place de l'Iode RadioActif Dans l'HyperThyrodiE Sub-clinique (PIRHATES)/ Evaluation of the Interest of Subclinical Hyperthyroidism Treatment,Treatment of Subclinical Hyperthyroidism,Atrial Fibrillation|Subclinical Hyperthyroidism,2005-09-13,2019-11-30,2020-01-31,145.0,Cohort,,Prospective,Observational,Terminated,,"University Hospital, Strasbourg, France","University Hospital, Strasbourg, France",Patrick Roger|Philippe Thiblot|Jean-Marcel Brun|Jean-Louis Wemeau|Marie-Pierre Teissier|Jacques Orgiazzi|Bernard Conte-Delvox|CH de Montbrison|Jacques Bringer|Marc Klein|Michel Rodier|Laurence Leenhardt|Richard Marechaud|Brigitte Delemer|Claire Schvartz|Jean-Marc Kuhn|Bruno Estour|Centre Paul Strauss|Hopitaux Universitaires de Strasbourg|Philippe Caron|Pierre Lecomte,,France,50.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00213720
182,NCT00215605,Cancer|Lymphoma|Thyroid Carcinoma,A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies,Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies,Cancer|Lymphoma|Thyroid Carcinoma,2005-09-20,2011-04-30,2012-07-31,85.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Exelixis,Exelixis,University of Chicago|Johns Hopkins University|Memorial Sloan Kettering Cancer Center|Fox Chase Cancer Center|Univ. of Texas MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00215605
183,NCT00223158,Thyroid Cancer,L-T3 Preparation for I131 Whole Body Scintigraphy: A Randomized Controlled Trial,Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer,Thyroid Cancer,2005-09-19,2005-05-31,2005-05-31,70.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Universit de Sherbrooke,Patrice Perron|Theramed co.,Centre Hospitalier Universitaire de Sherbrooke,Drug,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00223158
184,NCT00230802,Hypothyroidism|Pregnancy,Thyroid Hormone Dose Adjustments During Pregnancy in Women With Primary Hypothyroidism.,Thyroid Hormone Dose Adjustment in Pregnancy,Hypothyroidism|Pregnancy,2005-09-29,2010-07-31,2010-07-31,48.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital|Harvard Medical School (HMS and HSDM),Brigham and Women's Hospital,Drug|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00230802
185,NCT00251316,Differentiated Thyroid Carcinoma|Thyroid Cancer,The Effects of Lithium Carbonate on Low Dose Radioiodine Ablation in Early Thyroid Cancer Treatment,Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer,Differentiated Thyroid Carcinoma|Thyroid Cancer,2005-11-09,2011-12-31,2011-12-31,34.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00251316
186,NCT00257920,"Chronic Kidney Disease, Stage 5|Secondary Hyperparathyroidism","A Phase 4, Single-Center, Open-Label, Randomized, Active-Controlled, Cross-over Pilot Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar Injection and Hectorol Injection, on Intestinal Absorption of Calcium in CKD Stage 5 Subjects on Hemodialysis",A Study of Zemplar Injection and Hectorol Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease,"Chronic Kidney Disease, Stage 5|Secondary Hyperparathyroidism",2005-11-22,2008-01-31,,41.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,,Drug|Drug,United States,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00257920
189,NCT00261950,Secondary Hyperparathyroidism,Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease,Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease,Secondary Hyperparathyroidism,2005-12-02,2011-05-31,2011-05-31,110.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,"Belgium|Czech Republic|Hungary|Italy|Macedonia, The Former Yugoslav Republic of|Poland|Portugal|Spain|Switzerland|Turkey|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00261950
192,NCT00271427,Autoimmune Thyroiditis|Hashimotos Thyroiditis,Selenium Treatment in Autoimmune Thyroiditis: Long Term Follow-Up With Variable Doses,Selenium Treatment in Autoimmune Thyroiditis (AIT),Autoimmune Thyroiditis|Hashimotos Thyroiditis,2005-12-30,,2005-08-31,100.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Ege University,Ege University,"Dep. of Nuc. Med., Ege University Faculty of Medicine.",Drug,Turkey,15.0,70.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00271427
195,NCT00275171,Nodular Goiter,"The Effect of 0.1 mg Recombinant Human Thyrotropin (rhTSH) on Thyroid Radioiodine-uptake and the Degree of Goiter Reduction Following 131I-therapy, in Patients With Benign Non-toxic Nodular Goiter. A Randomized, Double-blind, Placebo-controlled Trial.","rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter",Nodular Goiter,2006-01-09,2009-04-30,2009-09-30,90.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Odense University Hospital,Steen Bonnema,Odense University Hospital,Drug|Drug|Other,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00275171
197,NCT00277589,"Goiter, Nodular","TSH-adapted Therapy in a Large Randomized, Observer-blind, Placebo-controlled, Prospective Treatment Study of Patients With Nodular Goiter",LISA-study : Levothyroxin in Nodular Goiter,"Goiter, Nodular",2006-01-13,2008-12-31,2008-12-31,1024.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sanofi,Sanofi,Sanofi-Aventis Administrative Office,Drug|Drug|Drug|Drug,Germany,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00277589
199,NCT00278005,Congenital Heart Defects|DiGeorge Syndrome,Incidence of Infection in the Patient With DiGeorge Syndrome Following Surgery for Congenital Heart Disease,Infection in DiGeorge Following CHD Surgery,Congenital Heart Defects|DiGeorge Syndrome,2006-01-13,2008-03-31,2008-03-31,400.0,,,Retrospective,Observational,Terminated,,Children's Healthcare of Atlanta,Children's Healthcare of Atlanta,Children's Healthcare of Atlanta,,United States,0.0,15.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT00278005
201,NCT00279721,Thyroid Neoplasms,Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.,Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.,Thyroid Neoplasms,2006-01-18,2010-06-30,2010-06-30,40.0,,Single Group Assignment,,Interventional,Completed,Phase 2,AHS Cancer Control Alberta,Alberta Health Services,,Procedure,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00279721
202,NCT00280852,Anaplastic Thyroid Cancer,A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer,Review of Multimodality Management of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2006-01-20,2006-06-30,2006-06-30,5.0,,,Retrospective,Observational,Completed,,AHS Cancer Control Alberta,Alberta Health Services,Tom Baker Cancer Centre,,Canada,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00280852
204,NCT00285467,Renal Osteodystrophy,Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in CKD,Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease,Renal Osteodystrophy,2006-01-31,2009-12-31,2009-12-31,55.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Indiana University,Indiana University School of Medicine,Indiana University School of Medicine,Drug|Drug,United States,18.0,82.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00285467
207,NCT00287144,Hypothyroidism,Observations of Leng Term Effects From Post Partum Thyroiditis.,Post Partum Thyroiditis 2: Long Term Observations,Hypothyroidism,2006-02-02,2015-12-31,2016-12-31,0.0,Cohort,,Retrospective,Observational,Withdrawn,,Sykehuset Telemark,Sykehuset Telemark,Sykehuset Telemark HF,,Norway,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00287144
211,NCT00287287,Thyroid Neoplasms,Phase II Trial of REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas,REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas,Thyroid Neoplasms,2006-02-03,2010-07-06,2010-07-06,25.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Kentucky,Celgene Corporation|Kenneth Ain,University of Kentucky Markey Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00287287
213,NCT00288522,Thyroid-Associated Ophthalmopathy,"A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.",Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment,Thyroid-Associated Ophthalmopathy,2006-02-07,2007-04-30,2007-04-30,5.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Ipsen,Ipsen,Hospital General d'Alacant,Drug,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00288522
217,NCT00288873,Obesity|Secondary Hyperparathyroidism|Vitamin D Deficiency,Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity,Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity,Obesity|Secondary Hyperparathyroidism|Vitamin D Deficiency,2006-02-06,2007-07-31,2007-07-31,60.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Weill Medical College of Cornell University,Weill Medical College of Cornell University,Weill Cornell Medical College,Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00288873
220,NCT00295763,Differentiated Thyroid Cancer,Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method.,"A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.",Differentiated Thyroid Cancer,2006-02-22,2006-07-31,2006-09-30,61.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Sanofi,"Genzyme, a Sanofi Company",University of Colorado Health Sciences Centre|Johns Hopkins University|Ohio State University|MD Anderson Cancer Centre|LHRI Research Services|Centre Rene Huguenin|Institut Gustave Roussy|University of Wurzburg|University of Pisa,Drug,Canada|France|Germany|Italy|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00295763
221,NCT00297297,Thyroid Nodules,"Preoperative Selection of Solitary Solid Cold Thyroid Nodules - A Prospective Study on the Value of Sonography, Cytology, Immunostaining and Molecular Profiling",Improved Preoperative Selection of Cold Thyroid Nodules,Thyroid Nodules,2006-02-27,,2011-03-31,100.0,Case-Only,,Prospective,Observational,Unknown status,,Herlev Hospital,Herlev Hospital,"Outpatient clinic of The Department of Endocrinology, Herlev University Hospital",Other,Denmark,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00297297
223,NCT00307840,Secondary Hyperparathyroidism,Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism,Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2006-03-27,,2005-07-31,,,Parallel Assignment,,Interventional,Completed,Phase 4,Papageorgiou General Hospital,Papageorgiou General Hospital,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00307840
226,NCT00316823,Head and Neck Cancer,Gene Expression Analysis in Thyroid Nodule FNA Samples,Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules,Head and Neck Cancer,2006-04-19,2009-12-31,,400.0,,,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Helen Diller Family Comprehensive Cancer Center,Genetic|Genetic|Genetic|Other|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00316823
228,NCT00322322,Complication of Hemodialysis|Hyperthyroidism Treated or Under Control,Early Administration of L-carnitine in Hemodialysis Patients: Double Blind Randomized Trial Versus Placebo,Early Administration of L-carnitine in Hemodialysis Patients,Complication of Hemodialysis|Hyperthyroidism Treated or Under Control,2006-05-03,2010-06-30,2010-06-30,110.0,,Factorial Assignment,,Interventional,Completed,Phase 3,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,"Assistance Publique Hopitaux de Paris|HOPITAL LA PITIE SALPETRIERE, service de Nphrologie",Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00322322
229,NCT00325104,Familial Primary Hyperparathyroidism|Hypercalcemia,Cinacalcet Actions in Familial Primary Hyperparathyroidism,Cinacalcet to Treat Familial Primary Hyperparathyroidism,Familial Primary Hyperparathyroidism|Hypercalcemia,2006-05-11,,2007-03-31,25.0,,,,Interventional,Completed,Phase 3,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00325104
232,NCT00335062,Graves' Disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,Graves' Disease,2006-06-06,2010-02-28,2010-02-28,19.0,Cohort,,Prospective,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Childrens' Hospital Boston,,United States,2.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00335062
235,NCT00336102,Breast Cancer|Fatigue|Hypothyroidism,Thyroid Function & Breast Cancer: A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed With Breast Cancer and the Magnitude of Change in Thyroid Function Post-Chemotherapy,Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers,Breast Cancer|Fatigue|Hypothyroidism,2006-06-08,2015-06-30,2015-06-30,541.0,Case-Control,,Prospective,Observational,Completed,,University of South Florida,National Cancer Institute (NCI)|University of South Florida,"CCOP - Western Regional, Arizona|North Colorado Medical Center|McKee Medical Center|Cancer Centers of Central Florida, PA|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida|Northeast Georgia Cancer Care, LLC - Medical Oncology|Medical College of Georgia Cancer Center|MBCCOP - Medical College of Georgia Cancer Center|Saint Anthony's Hospital at Saint Anthony's Health Center|Good Samaritan Regional Health Center|MBCCOP - LSU Health Sciences Center|Feist-Weiller Cancer Center at Louisiana State University Health Sciences|CCOP - Beaumont|William Beaumont Hospital - Royal Oak Campus|William Beaumont Hospital - Troy Campus|MeritCare Bemidji|Southeast Cancer Center|Saint Francis Medical Center|David C. Pratt Cancer Center at St. John's Mercy|St. John's Regional Health Center|CCOP - Cancer Research for the Ozarks|Hulston Cancer Center at Cox Medical Center South|CCOP - St. Louis-Cape Girardeau|Newark Beth Israel Medical Center|MBCCOP - Our Lady of Mercy Comprehensive Cancer Center|Our Lady of Mercy Medical Center Comprehensive Cancer Center|Mission Hospitals - Memorial Campus|Rutherford Internal Medicine Associates, PA|CCOP - Southeast Cancer Control Consortium|Southeastern Medical Oncology Center - Goldsboro|Moses Cone Regional Cancer Center at Wesley Long Community Hospital|Pardee Memorial Hospital|Iredell Memorial Hospital|Southeastern Medical Oncology Center - Wilson|Forsyth Regional Cancer Center at Forsyth Medical Center|CCOP - MeritCare Hospital|Roger Maris Cancer Center at MeritCare Hospital|AnMed Cancer Center|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center|CCOP - Scott and White Hospital|Scott and White Cancer Institute",Other|Procedure|Procedure,United States,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00336102
236,NCT00339716,Non-Cancer Thyroid Disease|Non Thyroid Cancer|Thyroid Cancer,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident,Non-Cancer Thyroid Disease|Non Thyroid Cancer|Thyroid Cancer,2006-06-19,2020-03-11,2020-03-11,19456.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Republican Resear ch Center for Radiation Medicine and Human Ecology|Ministry of Health Republic of Belarus,,Belarus,30.0,51.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00339716
237,NCT00341094,Non-Cancer Thyroid Disease|Non Thyroid Cancer|Thyroid Cancer,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Diseases in Ukraine Following the Chernobyl Accident,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Ukraine Following the Chernobyl Accident,Non-Cancer Thyroid Disease|Non Thyroid Cancer|Thyroid Cancer,2006-06-19,2020-10-08,2020-10-08,23143.0,Cohort,,Retrospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"Research Institute of Endocrinology and Metabolism, Kiev, Ukraine",,Ukraine,18.0,48.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00341094
238,NCT00341185,Thyroid Cancer,Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing,Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing,Thyroid Cancer,2006-06-19,,2016-11-18,2997.0,Cohort,,Retrospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Semipalatinsk State Medical Academy,,Kazakhstan,63.0,71.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00341185
239,NCT00342407,Breast Cancer|Melanoma|Non-Melanoma Skin Cancer|Thyroid Cancer,The Incidence of Breast and Other Cancers Among Female Flight Attendants,The Incidence of Breast and Other Cancers Among Female Flight Attendants,Breast Cancer|Melanoma|Non-Melanoma Skin Cancer|Thyroid Cancer,2006-06-19,2005-12-31,2020-04-09,6093.0,Case-Only,,Other,Observational,Completed,,National Institutes of Health Clinical Center (CC),Centers for Disease Control and Prevention|National Cancer Institute (NCI)|National Institute for Occupational Safety and Health (NIOSH/CDC),National Institute for Occupational Safety and Health (NIOSH),,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00342407
240,NCT00342446,"Breast Cancer|Colorectal Cancer, Melanoma|Endometrial Cancer|Ovarian Cancer|Thyroid Cancer",Follow-Up Study of Women Evaluated and Treated for Infertility,A Follow-up Study of Women Evaluated and Treated for Infertility,"Breast Cancer|Colorectal Cancer, Melanoma|Endometrial Cancer|Ovarian Cancer|Thyroid Cancer",2006-06-19,,,12193.0,Cohort,,Prospective,Observational,Active not recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Columbia University,,United States,44.0,88.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00342446
241,NCT00342641,Hepatitis C Virus,Associations of Hematologic Malignancies and Thyroid Cancer With HCV Infection Among US Military Veterans,Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers,Hepatitis C Virus,2006-06-19,,2011-12-13,815000.0,,,,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Houston Veterans AFfairs Medical Center,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00342641
242,NCT00345839,Chronic Kidney Disease|Secondary Hyperparathyroidism,EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events,E.V.O.L.V.E. Trial: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events,Chronic Kidney Disease|Secondary Hyperparathyroidism,2006-06-27,2012-04-10,2012-04-10,3883.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00345839
245,NCT00348413,Graves Ophthalmopathy,"Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.",Thyroid Treatment Trial,Graves Ophthalmopathy,2006-07-03,2008-07-31,2008-07-31,80.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Singapore National Eye Centre,International Stem Cell Forum|Singapore National Eye Centre,Singapore National Centre,Drug,Singapore,21.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00348413
249,NCT00352170,Osteoporosis|Secondary Hyperparathyroidism,Calcium and Vitamin D Malnutrition in Elderly Women,Calcium and Vitamin D Malnutrition in Elderly Women,Osteoporosis|Secondary Hyperparathyroidism,2006-07-12,2005-07-31,2005-07-31,1180.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Creighton University,Creighton University|GlaxoSmithKline,,Dietary Supplement|Dietary Supplement|Dietary Supplement,,55.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00352170
252,NCT00354523,Solid Tumor|Thyroid Cancer,A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma,Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma,Solid Tumor|Thyroid Cancer,2006-07-18,2006-11-30,2013-08-31,21.0,,Single Group Assignment,,Interventional,Terminated,Phase 1/Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|Novartis Pharmaceuticals,UT MD Anderson Cancer Center,Drug|Drug|Drug,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00354523
253,NCT00356512,Hypoparathyroidism,Physiologic Regulation of FGF-23,Physiologic Regulation of FGF-23,Hypoparathyroidism,2006-07-25,2009-09-02,,20.0,,,,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Dental and Craniofacial Research (NIDCR),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00356512
255,NCT00358956,Thyroid Cancer,"A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer",A Study To Assess ZD6474 (ZACTIMA) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer,Thyroid Cancer,2006-07-28,2008-01-31,2014-05-31,19.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Australia|Canada|Italy|Netherlands|Romania|Spain|Switzerland|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00358956
256,NCT00359385,Hyperparathyroidism,The Effects of Alendronate After Cure of Primary Hyperparathyroidism,The Effects of Alendronate After Cure of Primary Hyperparathyroidism,Hyperparathyroidism,2006-08-01,2009-09-30,2009-09-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,Columbia University,Columbia University|Merck Sharp & Dohme LLC,CUMC,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00359385
259,NCT00360074,Hyperlipidemias|Hypopituitarism|Secondary Hypothyroidism,"A Randomised, Controlled, Crossover Study: Treatment With Thyroxin Compared to Thyroxin + Triiodothyronin in Patients With Secondary Hypothyroidism",Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation,Hyperlipidemias|Hypopituitarism|Secondary Hypothyroidism,2006-08-02,,2007-04-30,25.0,,Crossover Assignment,,Interventional,Completed,Phase 4,University Hospital Freiburg,University Hospital Freiburg,"University Hospital Freiburg, Department of Medicine",Drug,Germany,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00360074
260,NCT00364234,Renal Osteodystrophy,Low Magnitute Mechanical Stimuli Effects on Bone Structure in ESRD,Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD,Renal Osteodystrophy,2006-08-14,2007-09-30,2007-09-30,30.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Childen's Hospital of Philadelphia,Device,United States,21.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00364234
263,NCT00373711,Thyroid Cancer,"Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection","Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA",Thyroid Cancer,2006-09-06,,,100.0,Cohort,,Prospective,Observational,Withdrawn,,Stanford University,Stanford University,,Drug|Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00373711
264,NCT00374595,Cardiovascular Disease|Chronic Kidney Disease|Diabetes|Hyperparathyroidism|Vitamin D Deficiency,Vascular Risk After Kidney Transplantation,Vascular Risk After Kidney Transplantation,Cardiovascular Disease|Chronic Kidney Disease|Diabetes|Hyperparathyroidism|Vitamin D Deficiency,2006-09-08,2019-03-29,2019-04-30,342.0,Other,,Prospective,Observational,Unknown status,,University of Nebraska,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Nebraska,University of Nebraska Medical Center,,United States,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00374595
266,NCT00374712,Chronic Kidney Disease|End Stage Renal Disease|Hyperphosphatemia|Renal Osteodystrophy,Study of Klotho Gene Polymorphisms in the Regulation of Serum Phosphate Levels in Hemodialysis Patients,Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia,Chronic Kidney Disease|End Stage Renal Disease|Hyperphosphatemia|Renal Osteodystrophy,2005-09-12,,2007-11-30,40.0,,,Prospective,Observational,Terminated,,Assistance Publique - Hpitaux de Paris,"Assistance Publique - Hpitaux de Paris|Institut National de la Sant Et de la Recherche Mdicale, France",Clinique de l'Orangerie - Service de Nphrologie et Dialyse,,France,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00374712
269,NCT00377312,"Bone Diseases, Endocrine|Hyperparathyroidism|Osteoporosis",Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone(1-34): Effects on Bone Formation,7 Day Continuous Parathyroid Hormone IV Infusion,"Bone Diseases, Endocrine|Hyperparathyroidism|Osteoporosis",2006-09-14,2007-12-31,2007-12-31,11.0,,Single Group Assignment,,Interventional,Completed,Early Phase 1,University of Pittsburgh,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh,University of Pittsburgh Medical Center,Drug,United States,24.0,35.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00377312
271,NCT00379899,Calcification|Cardiovascular Disease|Chronic Kidney Disease|Chronic Renal Failure|Coronary Artery Calcification|End Stage Renal Disease|Hyperparathyroidism|Kidney Disease|Nephrology|Secondary Hyperparathyroidism|Vascular Calcification,A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis,ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis,Calcification|Cardiovascular Disease|Chronic Kidney Disease|Chronic Renal Failure|Coronary Artery Calcification|End Stage Renal Disease|Hyperparathyroidism|Kidney Disease|Nephrology|Secondary Hyperparathyroidism|Vascular Calcification,2006-09-21,2009-05-31,2009-11-30,360.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00379899
274,NCT00381641,Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,"Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers",Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery,Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2006-09-26,2016-12-31,,63.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|Duly Health and Care Joliet|Loyola University Medical Center|Illinois CancerCare-Peoria|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Northern Indiana Cancer Research Consortium|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Oncology Care Associates PLLC|Mercy Hospital Saint Louis|M D Anderson Cancer Center|Medical College of Wisconsin,Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00381641
277,NCT00385983,Goiter|Thyroid Neoplasm|Thyroid Nodule,Total Thyroidectomy With Harmonic Scalpel Versus Standard Surgery. Open Multicentric Randomized Controlled Trial,Total Thyroidectomy With Harmonic Scalpel,Goiter|Thyroid Neoplasm|Thyroid Nodule,2006-10-10,,,280.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Brazilian Society of Head and Neck Surgery,Brazilian Society of Head and Neck Surgery|Johnson & Johnson,Hospital Araujo Jorge|Hospital Erasto Gaertner|Instituto Nacional de Cancer INCA|Hospital do Cancer de Natal|Hospital do Cancer AC Camargo|Hospital Heliopolis|Hospital Sao Paulo-UNIFESP|Instituto Arnaldo Vieira de Carvalho|Santa Casa de Misericordia,Device,Brazil,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00385983
279,NCT00388297,Hypothyroxinemia|Pregnancy|Subclinical Hypothyroidism,A Randomized Trial of Thyroxine Therapy for Subclinical Hypothyroidism or Hypothyroxinemia Diagnosed During Pregnancy,Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy,Hypothyroxinemia|Pregnancy|Subclinical Hypothyroidism,2006-10-12,2015-08-31,2015-10-31,1203.0,,Single Group Assignment,,Interventional,Completed,Phase 3,The George Washington University Biostatistics Center,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Neurological Disorders and Stroke (NINDS)|The George Washington University Biostatistics Center,University of Alabama - Birmingham|Northwestern University|Wayne State University|Columbia University|University of North Carolina - Chapel Hill|Case Western University|Ohio State University|Oregon Health & Sciences University|University of Pittsburgh Magee Womens Hospital|Brown University|University of Texas - Southwest|University of Texas Medical Branch - Galveston|University of Texas-Houston|University of Utah Medical Center,Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00388297
280,NCT00389441,Thyroid Neoplasms,A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer,Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer,Thyroid Neoplasms,2006-10-16,2012-09-30,2012-09-30,52.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Pfizer,Pfizer,Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site,Drug,Canada|China|Czech Republic|India|Italy|Poland|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00389441
281,NCT00390325,Hereditary Thyroid Gland Medullary Carcinoma|Locally Advanced Thyroid Gland Medullary Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Recurrent Thyroid Gland Medullary Carcinoma|Sporadic Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7,Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer",Hereditary Thyroid Gland Medullary Carcinoma|Locally Advanced Thyroid Gland Medullary Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Recurrent Thyroid Gland Medullary Carcinoma|Sporadic Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7,2006-10-18,2017-01-30,,21.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Washington University School of Medicine|Duke University Medical Center|Ohio State University Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00390325
282,NCT00395538,DiGeorge Syndrome|Hypoparathyroidism,Effects of PTH Replacement on Bone in Hypoparathyroidism,Effects of PTH Replacement on Bone in Hypoparathyroidism,DiGeorge Syndrome|Hypoparathyroidism,2006-11-02,2017-09-30,2017-10-04,46.0,,Single Group Assignment,,Interventional,Terminated,Phase 3,National Institutes of Health Clinical Center (CC),National Institute of Dental and Craniofacial Research (NIDCR),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00395538
284,NCT00395902,Hyperparathyroidism|Kidney Tansplant|Secondary Hyperparathyroidism,A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients,Post Transplant Study,Hyperparathyroidism|Kidney Tansplant|Secondary Hyperparathyroidism,2006-11-02,,,50.0,,,Retrospective,Observational,Completed,,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00395902
287,NCT00397475,"Hyperparathyroidism, Secondary|RENAL INSUFFICIENCY, CHRONIC",Evaluation of Colecalciferol Substitution in Dialysis Patients,Evaluation of Colecalciferol Substitution in Dialysis Patients,"Hyperparathyroidism, Secondary|RENAL INSUFFICIENCY, CHRONIC",2006-11-07,,2007-03-31,50.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"University Hospital, Saarland","University Hospital, Saarland","University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension",Drug,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00397475
290,NCT00400465,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,116.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00400465
295,NCT00403390,Congenital Hypothyroidism|Hypothyroidism,Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism,Generic vs. Name-Brand Levothyroxine,Congenital Hypothyroidism|Hypothyroidism,2006-11-21,2009-12-31,2010-03-31,34.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Boston Children's Hospital,Boston Children's Hospital,Children's Hospital Boston,Drug|Drug,United States,3.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00403390
297,NCT00403598,Osteitis Deformans|Osteoporosis|Parathyroid Diseases,,Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders,Osteitis Deformans|Osteoporosis|Parathyroid Diseases,2006-11-23,,,,,,Other,Observational,Unknown status,,Sheba Medical Center,Ben-Gurion University of the Negev|Sheba Medical Center,"Sheba Medical Center, Tel Hashomer",,Israel,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00403598
298,NCT00405405,Head and Neck Cancer|Melanoma|Parotid Gland Cancer|Stage IV Head and Neck Cancer|Thyroid Gland Cancer,A Phase I Study of the Combination of Chemoradiotherapy With Biologic Therapy for Advanced Head and Neck Cancer,Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer,Head and Neck Cancer|Melanoma|Parotid Gland Cancer|Stage IV Head and Neck Cancer|Thyroid Gland Cancer,2006-11-29,2010-06-30,2010-06-30,13.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Thomas Jefferson University,"Genentech, Inc.|Sidney Kimmel Cancer Center at Thomas Jefferson University",Thomas Jefferson University,Drug|Drug|Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00405405
299,NCT00410761,Thyroid Cancer,"An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer",An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer,Thyroid Cancer,2006-12-06,2009-07-31,2022-12-31,437.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Sanofi,"Genzyme, a Sanofi Company",Investigational Site Number 3|Investigational Site Number 8|Investigational Site Number 9|Investigational Site Number 11|Investigational Site Number 15|Investigational Site Number 18|Investigational Site Number 17|Investigational Site Number 2|Investigational Site Number 7|Investigational Site Number 14|Investigational Site Number 10|Investigational Site Number 6|Investigational Site Number 22|Investigational Site Number 19|Investigational Site Number 13|Investigational Site Number 21|Investigational Site Number 1001|Investigational Site Number 1901|Investigational Site Number 1101|Investigational Site Number 1102|Investigational Site Number 2301|Investigational Site Number 2302|Investigational Site Number 1203|Investigational Site Number 1202|Investigational Site Number 1201|Investigational Site Number 1204|Investigational Site Number 1205|Investigational Site Number 3601|Investigational Site Number 2701|Investigational Site Number 2802|Investigational Site Number 2803|Investigational Site Number 2801|Investigational Site Number 2002|Investigational Site Number 2001|Investigational Site Number 2005|Investigational Site Number 1601|Investigational Site Number 1401|Investigational Site Number 1402|Investigational Site Number 2506|Investigational Site Number 2502|Investigational Site Number 2503|Investigational Site Number 2501|Investigational Site Number 2505|Investigational Site Number 2504|Investigational Site Number 1501|Investigational Site Number 2403|Investigational Site Number 2402|Investigational Site Number 2404|Investigational Site Number 2902|Investigational Site Number 2901|Investigational Site Number 1701|Investigational Site Number 1702|Investigational Site Number 1703|Investigational Site Number 2602|Investigational Site Number 2601|Investigational Site Number 1801|Investigational Site Number 3301|Investigational Site Number 3402|Investigational Site Number 3401|Investigational Site Number 3003|Investigational Site Number 3001|Investigational Site Number 3002|Investigational Site Number 3102|Investigational Site Number 3101|Investigational Site Number 2101|Investigational Site Number 2102,Drug,"Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|France|Germany|Hungary|India|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00410761
300,NCT00415233,Head and Neck Cancer,"Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO]",High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer,Head and Neck Cancer,2006-12-20,2011-06-30,2025-07-31,438.0,,Factorial Assignment,,Interventional,Active not recruiting,Phase 3,"University College, London","University College, London",Sussex Cancer Centre at Royal Sussex County Hospital|Addenbrooke's Hospital|Kent and Canterbury Hospital|Castle Hill Hospital|Derbyshire Royal Infirmary|Royal Devon and Exeter Hospital|Gloucestershire Royal Hospital|St. Luke's Cancer Centre at Royal Surrey County Hospital|Ipswich Hospital|Leeds Cancer Centre at St. James's University Hospital|Leicester Royal Infirmary|Guy's Hospital|Royal Marsden - London|Maidstone Hospital|Christie Hospital|James Cook University Hospital|Newcastle Upon Tyne Hospitals NHS Trust|Northampton General Hospital|Mount Vernon Cancer Centre at Mount Vernon Hospital|Norfolk and Norwich University Hospital|Dorset Cancer Centre|Cancer Research Centre at Weston Park Hospital|University Hospital of North Staffordshire|Velindre Cancer Center at Velindre Hospital|Glan Clwyd Hospital,Biological|Radiation,United Kingdom,16.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00415233
301,NCT00415584,Hypercalcemia|Secondary Hyperparathyroidism,"Cinacalcet for Treatment of Persistent Secondary Hyperparathyroidism in Renal Transplant Recipients: Effect on Renal Function, Serum Calcium and Bone Histomorphometry",Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients,Hypercalcemia|Secondary Hyperparathyroidism,2006-12-21,2009-11-30,2009-11-30,18.0,,Single Group Assignment,,Interventional,Terminated,Phase 1/Phase 2,Montefiore Medical Center,Montefiore Medical Center,Montefiore Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00415584
304,NCT00416949,Head and Neck Cancer,Dose-Response in Radionuclide Therapy of Thyroid Cancer,Iodine I 131 in Treating Patients With Thyroid Cancer,Head and Neck Cancer,2006-12-27,2009-10-31,2009-10-31,9.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Device,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00416949
305,NCT00417612,"Hyperparathyroidism|Hypophosphatemia, Familial",The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH),Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets,"Hyperparathyroidism|Hypophosphatemia, Familial",2006-12-28,2012-08-31,2012-08-31,33.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Yale University,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yale University,Yale University School of Medicine,Drug|Other,United States,9.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00417612
307,NCT00418600,Secondary Hyperparathyroidism,"A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol Capsules When Converting From Hectorol Injection for the Treatment of SHPT in Stage 5 CKD Subjects on Hemodialysis","A Phase 4, Conversion Study of Hectorol Injection to Hectorol Capsules in Stage 5 CKD Patients on Dialysis",Secondary Hyperparathyroidism,2007-01-03,2007-06-30,2007-08-31,36.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company",,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00418600
310,NCT00424151,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,2007-01-17,2009-03-31,2009-03-31,12.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,"Silkiss, Rona Z., M.D., FACS","Coleman, Morton M.D.|Lauer, Simeon, M.D.|Reier, Alice M.D.|Silkiss, Rona Z., M.D., FACS","Rona Z. Silkiss, MD, FACS|Simeon A. Lauer, MD",Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00424151
314,NCT00430547,Graves' Ophthalmopathy,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Graves' Ophthalmopathy,2007-02-01,,2006-01-31,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Barwon Health,"Barwon Health|National Health and Medical Research Council, Australia|University of Melbourne",Barwon Health - The Geelong Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00430547
318,NCT00431496,Anemia|Secondary Hyperparathyroidism,A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management,A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD),Anemia|Secondary Hyperparathyroidism,2007-02-01,2009-06-30,2009-10-31,71.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00431496
321,NCT00432146,Graves Disease,Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease,Effect of Lugol's Solution in the Patients With Graves' Disease,Graves Disease,2007-02-05,,2006-09-30,36.0,,,Prospective,Observational,Completed,,Istanbul University,Istanbul University,,Drug,,14.0,61.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00432146
324,NCT00432939,Primary Hyperparathyroidism,Primary Hyperparathyroidism: Non-classical Manifestations,Primary Hyperparathyroidism: Non-classical Manifestations,Primary Hyperparathyroidism,2007-02-06,2009-11-30,2012-12-31,58.0,Cohort,,Prospective,Observational,Completed,,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Metabolic Bone Diseases Unit,,United States,50.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00432939
327,NCT00435851,Thyroid Cancer,Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl,Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients,Thyroid Cancer,2007-02-15,,,950.0,,Factorial Assignment,,Interventional,Unknown status,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France",Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00435851
328,NCT00437931,Hyperthyroidism|Subclinical Hypothyroidism|Thyroid Dysfunction,,Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction,Hyperthyroidism|Subclinical Hypothyroidism|Thyroid Dysfunction,2007-02-19,2008-02-29,2008-02-29,60.0,Case-Control,,Prospective,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel","Haemek Medical Center, Department of Radiology",,Israel,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00437931
330,NCT00439127,Differentiated Thyroid Carcinoma,Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma?,OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation,Differentiated Thyroid Carcinoma,2007-02-22,,2007-01-31,28.0,Defined Population,,Other,Observational,Completed,,Oncology Institute of Southern Switzerland,Oncology Institute of Southern Switzerland,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00439127
331,NCT00439478,Thyroid Cancer,The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer,Dental Safety Profile of High-Dose Radioiodine Therapy,Thyroid Cancer,2007-02-22,,2006-09-30,202.0,,,,Observational,Completed,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital,Drug,Switzerland,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00439478
332,NCT00446329,Secondary Hyperparathyroidism,,Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis,Secondary Hyperparathyroidism,2007-03-09,,,15.0,,Single Group Assignment,,Interventional,Terminated,Phase 4,Papageorgiou General Hospital,Papageorgiou General Hospital,Papageorgiou General Hospital,Drug,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00446329
335,NCT00451880,Cancer|Colorectal Cancer|Melanoma|Non-small-cell Lung Cancer|Papillary Thyroid Cancer,A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors,Study of XL281 in Adults With Solid Tumors,Cancer|Colorectal Cancer|Melanoma|Non-small-cell Lung Cancer|Papillary Thyroid Cancer,2007-03-23,2011-10-31,2011-10-31,180.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Exelixis,Exelixis,Premiere Oncology of Arizona|H. Lee Moffitt Cancer Center & Research Institute|Barbara Ann Karmanos Cancer Institute|Memorial Sloan Kettering Cancer Center|Sarah Cannon Research Institute|Mary Crowley Cancer Research Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00451880
337,NCT00452049,Hyperparathyroidism|Hypertension,"Observational Study to Evaluate the Effect of Parathyroidectomy on Renal Function, Endothelial Function and Blood Pressure","The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure",Hyperparathyroidism|Hypertension,2007-03-23,,,20.0,Cohort,,Prospective,Observational,Unknown status,,Universitaire Ziekenhuizen Leuven,Universitaire Ziekenhuizen Leuven,University Hopsital Leuven,Procedure,Belgium,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00452049
339,NCT00454077,Thyroid Cancer,Recombinant Human TSH (rhTSH)-Aided Radioiodine (131) Therapy for Thyroid Remnant Ablation in Differentiated Thyroid Cancer Patients: a Comparison Between 1850 MBq and 3700 MBq Activities,rhTSH-Thyroid Ablation With 1850 MBq of 131I,Thyroid Cancer,2007-03-28,,2006-09-30,72.0,Natural History,,Prospective,Observational,Completed,,University of Siena,University of Siena,"Section of Endcrinology, University of Siena",Procedure,Italy,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00454077
340,NCT00454220,Multinodular Goiter,"Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction With Radioiodine for the Treatment of Multinodular Goiter.","Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter",Multinodular Goiter,2007-03-28,2011-07-31,2011-07-31,96.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Sanofi,"Genzyme, a Sanofi Company",,Other|Drug|Drug,Brazil|Canada|Denmark|France|Germany|Italy|Netherlands|United States,35.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00454220
341,NCT00454350,Secondary Hyperparathyroidism,"A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis",A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis,Secondary Hyperparathyroidism,2007-03-28,,2007-07-31,12.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company",,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00454350
344,NCT00459459,Thyroid Neoplasms,,Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma,Thyroid Neoplasms,2007-04-11,,2006-12-31,100.0,Defined Population,,Retrospective,Observational,Completed,,National Taiwan University Hospital,National Taiwan University Hospital,"Shyang-Rong, Shih",Procedure,Taiwan,10.0,90.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00459459
345,NCT00459498,Tumors,Significant Intracellular NIS Protein Associated With Low Levels of NIS Messenger RNA in Malignant Thyroid Tumors,Expression of NIS Protein and mRNA in Thyroid Tumors,Tumors,2007-04-10,,2006-10-31,30.0,,,Other,Observational,Completed,,University of Sao Paulo,Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo,,,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00459498
346,NCT00463021,Secondary Hyperparathyroidism,"A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol (Doxercalciferol Capsules) When Converting From Zemplar (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis.",A Phase 4 Study to Determine Dosing of Hectorol Capsules When Converting From Zemplar Injection,Secondary Hyperparathyroidism,2007-04-18,,2007-12-31,36.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company",,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00463021
349,NCT00467506,Thyroid Neoplasms,Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma,Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma,Thyroid Neoplasms,2007-04-27,2011-01-31,2011-01-31,,,Factorial Assignment,,Interventional,Completed,Phase 2,Nantes University Hospital,Nantes University Hospital,Centre Franois Baclesse|CHU de Grenoble|hpital du Cluzeau|CHU|Hpital de la timone|CHU|CHU|Centre Ren Huguenin|Centre Ren Gauducheau|Centre Paul Strauss|Centre Claudius Rgaud,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00467506
350,NCT00469599,Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Deficiency,Treatment of Secondary Hyperparathyroidism in the Uremic Patient. A Study Comparing Alfacalcidol and Paricalcitol,Treatment of Secondary Hyperparathyroidism in the Uremic Patient,Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Deficiency,2007-05-03,2010-09-30,2010-10-31,86.0,,Crossover Assignment,,Interventional,Terminated,Not Applicable,Zealand University Hospital,Zealand University Hospital,Aalborg University Hospital|rhus University Hospital Skejby|Hospital of Southwest Denmark Esbjerg|Holbk County Hospital|Holstebro County Hospital|Odense University Hospital|Roskilde County Hospital|Viborg County Hospital,Drug|Drug,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00469599
353,NCT00470496,Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage I Follicular Thyroid Cancer|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage II Follicular Thyroid Cancer|Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Papillary Thyroid Cancer|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Papillary Thyroid Cancer|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity,"A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer",Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer,Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage I Follicular Thyroid Cancer|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage II Follicular Thyroid Cancer|Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Papillary Thyroid Cancer|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Papillary Thyroid Cancer|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity,2007-05-03,2011-10-28,2018-08-30,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Roswell Park Cancer Institute,National Cancer Institute (NCI)|Roswell Park Cancer Institute,Roswell Park Cancer Institute,Drug|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00470496
356,NCT00471458,Atrial Fibrillation|Cardiovascular Diseases|Hyperthyroidism,Follow-up Study of Hyperthyroid Patients Treated With RAI in 1965-2002: Morbidity in Long-Term Follow-up,Follow-up Study of the RAI-Treated Hyperthyroid Patients,Atrial Fibrillation|Cardiovascular Diseases|Hyperthyroidism,2007-05-09,,2003-12-31,5222.0,Defined Population,,Retrospective,Observational,Completed,,Tampere University,Tampere University,"Tampere University Hospital, Department of Internal Medicine",,Finland,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00471458
357,NCT00473265,Hypoparathyroidism,Bone Properties in Hypoparathyroidism: Effects of PTH,Bone Properties in Hypoparathyroidism: Effects of PTH,Hypoparathyroidism,2007-05-14,2011-01-31,2014-06-30,68.0,,Single Group Assignment,,Interventional,Completed,Phase 2/Phase 3,Columbia University,John P. Bilezikian|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00473265
359,NCT00480428,Other Thyroid Disease|Thyroid Cancer|Thyroid Nodules,Study to Improve Thyroid Doses From Fallout Exposure in Kazakhstan,Radiation Exposure and Thyroid Disease in Kazakhstan,Other Thyroid Disease|Thyroid Cancer|Thyroid Nodules,2007-05-30,,2017-08-17,117.0,,,Retrospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Semipalatinsk State Medical Academy,,Kazakhstan,65.0,90.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00480428
361,NCT00488644,Brain Tumor|Hypothyroidism,Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors,Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors,Brain Tumor|Hypothyroidism,2007-06-19,2010-03-31,2010-03-31,12.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,UT MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00488644
362,NCT00493103,Congenital Hypothyroidism,Congenital Hypothyroidism Due to Thyroglobulin Mutations in an Inbred Brazilian Family: A Novel Compound Heterozygous Constellation and Intronic Mutation Related to Fetal Goiter.,TG Gene Mutations and Congenital Hypothyroidism,Congenital Hypothyroidism,2007-06-25,,2007-06-30,,,,Other,Observational,Completed,,University of Sao Paulo,Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00493103
364,NCT00497484,"Growth Hormone Deficiency, Dwarfism|Pseudohypoparathyroidism",Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia),Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia),"Growth Hormone Deficiency, Dwarfism|Pseudohypoparathyroidism",2007-07-05,,,,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,University of Milan,Eli Lilly and Company|University of Milan,"Endocrine Unit, Dpt. of Medical Sciences, Fondazione Policlinico IRCCS",Drug,Italy,1.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00497484
366,NCT00497575,Congenital Hypothyroidism|Follow-Up|L-Thyroxine,,Diagnosis and Follow-up of Patients With Subclinical Hypothyroidism,Congenital Hypothyroidism|Follow-Up|L-Thyroxine,2007-07-05,,2006-09-30,,Defined Population,,Prospective,Observational,Completed,,Zhejiang University,Zhejiang University,,,,0.0,5.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT00497575
368,NCT00498238,Subclinical Hypothyroidism,The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients,The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidism,2007-07-06,,2005-09-30,34.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Assaf-Harofeh Medical Center,Assaf-Harofeh Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00498238
369,NCT00501215,Hyperparathyroidism,Pilot Study on the Effect of Parathyroidectomy on Sleep,Effect of Parathyroidectomy on Sleep,Hyperparathyroidism,2007-07-12,2017-07-09,2017-07-09,15.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Procedure|Behavioral|Procedure|Behavioral,United States,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00501215
371,NCT00505011,Graves' Disease,"Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.",Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves' Disease,Graves' Disease,2007-07-18,,2007-02-28,1998.0,Case-Control,,Other,Observational,Completed,,"University of Campinas, Brazil","Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Campinas, Brazil",,,,2.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00505011
374,NCT00505479,Congenital Hypothyroidism|Iodine Deficiency|Pregnancy,,Iodine Status in Pregnant Women and Their Newborns: is Congenital Hypothyroidism Related to Iodine Deficiency in Pregnancy?,Congenital Hypothyroidism|Iodine Deficiency|Pregnancy,2007-07-20,,2010-05-31,,,,Prospective,Observational,Unknown status,,Zhejiang University,Zhejiang University,Children's Hospital Zhejiang University School of Medicine,,China,20.0,40.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00505479
376,NCT00507429,Anaplastic Thyroid Cancer,A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT],Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2007-07-25,2011-10-31,2011-11-30,80.0,,Parallel Assignment,,Interventional,Terminated,Phase 2/Phase 3,Mateon Therapeutics,Mateon Therapeutics,"USC/Norris Comprehensive Cancer Center|University of Colorado Cancer Center|Yale University, School of Medicine|Winship Cancer Institute, Emory University|Sidney Kimmel Comprehensive Cancer Care Center at John Hopkins|University of Minnesota Otolaryngology Department|Ireland Cancer Center/Division od Hematology|Oregon Health and Science University|University of Texas M.D. Anderson Cancer Center|West Virginia University|Belarus National Medical University|Regional Oncology Dispensary with Inpatient Sector|Specialized Hospital for Active Treatment of Oncology|Universtiy Multiprofile Hospital, ISUI, Clinic of Oncotherapy|University Hospital, Cairo|Mediciti Hospital|All India Institute of Medical Sciences|Apollo Cancer Institute|Kidwai Memorial Hospital|Shirdi Sai Baba Cancer Hospital|Tata Memorial Centre|Ruby Hall Clinic|Christian Medial College|Telaviv Sourasky Medical Center, Head and Neck Service Division of Oncology|Lo Studio E la Cura|INT Napoli Fondazione Pascale|Istituto Oncologico Veneto (IOV) - IRCCS|Azienda Ospedaliero - Universitaria Pisana|Zaklad Medyczny Nuklearnej i Endykrynologii|Klinika Nowotworow Glowy i Szyji|Institutul Oncologic|SC Meditech SRL|Centr of Medical Oncology|Clinical County Hospital Sibiu|Emergency Clinical County Hospital ""Sf. loan cel Nou""|City Clinical Oncology Dispensary|Ukrainian Academy of Medical Science|Regional Clinical Oncology Dispensary|Beatson Oncology Centre, Gartnavel General Hospital|Royal Marsden Hospital and Institute of Cancer Research|Southampton Hospital Oncology Centre",Drug|Drug|Drug,Belarus|Bulgaria|Egypt|India|Israel|Italy|Poland|Romania|Russian Federation|Ukraine|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00507429
378,NCT00507897,Thyroid Nodules,,Hemodynamic Parameters in Euthyroid Patients With Thyroid Nodules,Thyroid Nodules,2007-07-25,,2007-12-31,100.0,,,Prospective,Observational,Terminated,,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,,Russian Federation,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00507897
380,NCT00509483,Tratment of Multinodular Goitre,Long-Term Follow-up and Outcome of Administering Recombinant Human Thyrotropin as an Adjuvant of Therapy With Radioiodine in the Outpatient Treatment of Multinodular Goitres,Three-Year Follow-up of Radioiodine Therapy for Goitre,Tratment of Multinodular Goitre,2007-07-27,,2006-12-31,40.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Sao Paulo,Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo,,Radiation,,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00509483
381,NCT00510640,Cancer|Thyroid Carcinoma,"Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer",Thyroid Cancer and Sunitinib,Cancer|Thyroid Carcinoma,2007-08-01,2012-03-31,2012-03-31,71.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"University Hospital, Bordeaux","Pfizer|University Hospital, Bordeaux","Centre Paul Papin - 2 rue Moll|Dpartement Endocrinolo-Diabto-Nutrition - CHU d'Angers - 4 rue de Larray|Service d'Oncologie Mdicale et de Radiothrapie - Hpital Saint Andr - 1 rue Jean Burguet|Fdration Endocrinologie - Groupe Hospitalier Est - Hpital neurologique - CHU Lyon - 59 Boulevard Pinel|Service d'Endocrinologie et maladies mtaboliques, Clinique Marc Linquette - rue du Pr Laguesse|Centre Lon Brard - Dpartement de Mdecine - 28 rue Laennec|Service d'Endocrinologie, CHU Timone, AP-HM - 254 rue St Pierre|Service des Maladies Endocriniennes - Hpital Lapeyronie - 191 avenue du Doyen Gaston Giraud|Centre Paul Lamarque - Va d'Aurelle - CRLC Val d'Aurelle - 208 rue des Apothicaires|Centre Antoine Lacassagne - 33 avenue de Valombrose|Service d'Endocrinologie - Hpital de l'Archet I - Route Saint Antoine de Jinestire|Service de Cancrologie Mdicale - HEGP - 20 rue Leblanc|Service d'Oncologie Mdicale, Institut Claudius Regaud - 20-24 rue du Pont Saint Pierre|Service d'endocrinologie et Maladies Mtaboliques, Groupe Hospitalier Rangueil-Larrey CHU Toulouse - avenue Prof Jean Poulhes|Service d'Endocrinologie - CHU de Nancy, Hpital de Brabois - rue du Morvan",Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00510640
382,NCT00513032,Hyperparathyroidism,Effects of Methylene Blue on Propofol Requirement During Anaesthesia Induction and Surgery,Interaction Between Anaesthetics and Methylene Blue,Hyperparathyroidism,2007-08-07,,2007-04-30,22.0,Case-Control,,Prospective,Observational,Completed,,"University Hospital, Geneva","University Hospital, Geneva","Service d'Anesthsiologie, Hpitaux Universitaires de Genve, Rue Micheli-du-Crest",Drug,Switzerland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00513032
384,NCT00514046,Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B,"Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma",Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer,Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B,2007-08-08,2019-12-10,2020-11-01,17.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,5.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00514046
385,NCT00519896,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation,Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2007-08-21,2015-05-31,2015-09-30,35.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Washington,National Cancer Institute (NCI)|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00519896
388,NCT00522028,Primary Hyperparathyroidism,"Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial","Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial",Primary Hyperparathyroidism,2007-08-28,2016-01-31,2016-01-31,191.0,Cohort,,Prospective,Observational,Completed,,Oslo University Hospital,"Gteborg University|Haukeland University Hospital|Karolinska University Hospital|Oslo University Hospital|Rigshospitalet, Denmark|Rikshospitalet University Hospital|St. Olavs Hospital|Uppsala University Hospital",Oslo University Hospital - Rikshospitalet,,Norway,50.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00522028
391,NCT00524238,Hypothyroidism,"Impact of Hypothyroidism on Glucose, Lipid, and Amino Acid Turnover",Metabolic Changes in Hypothyroid Patients,Hypothyroidism,2007-08-31,2006-08-31,2006-08-31,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,Aarhus University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00524238
392,NCT00525122,Hyperthyroidism,,Treatment of M.Graves With Radioactive Iodine: Follow-up Study,Hyperthyroidism,2007-09-04,,,100.0,Cohort,,Prospective,Observational,Unknown status,,"Medisch Centrum Rijnmond-Zuid, Netherlands","Medisch Centrum Rijnmond-Zuid, Netherlands",MCRZ,,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00525122
393,NCT00525135,Head and Neck Cancer,"A Phase II Trial of Valproic Acid (Depakote ER ) in Patients With Advanced Thyroid Cancers of Follicular Origin, Who Are Thyroglobulin Positive/RAI Unresponsive",Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer,Head and Neck Cancer,2007-08-28,2009-03-31,2009-03-31,5.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco",UCSF Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00525135
394,NCT00527085,Renal Osteodystrophy,"A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism",12-month Study of AMG 073 in Renal Osteodystrophy,Renal Osteodystrophy,2007-09-06,2003-08-31,2003-08-31,45.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00527085
397,NCT00527267,Hyperparathyroidism,A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis,Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects,Hyperparathyroidism,2007-09-06,2003-04-30,2003-04-30,320.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00527267
399,NCT00528502,Parathyroid Disease,Prevention of Laryngeal Reflexes in Minimal Invasive Parathyroid Surgery by the Use of Topical Lidocaine,Lidocaine Supplement for Minimal Invasive Parathyroid Surgery,Parathyroid Disease,2007-09-11,2008-01-31,2008-01-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 3,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,,Drug|Drug,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00528502
400,NCT00528788,"Hyperparathyroidism, Secondary|Kidney Failure, Chronic",Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease,How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis,"Hyperparathyroidism, Secondary|Kidney Failure, Chronic",2007-09-10,2012-08-31,2012-08-31,24.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Duke University,"Duke University|Genzyme, a Sanofi Company",Duke University Medical Center Dialysis Unit,Drug,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00528788
403,NCT00531713,Depression|Quality of Life,"Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,a Double Blind Randomized Cross-Over Study.",Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,Depression|Quality of Life,2007-09-18,,2007-03-31,59.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,"Dept of endocrinology , Herlev Hospital",Drug,Denmark,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00531713
404,NCT00535561,Iron Deficiency Anemia|Subclinical Hypothyroidism,"Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism: A Randomized, Double Blinded Study",Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism,Iron Deficiency Anemia|Subclinical Hypothyroidism,2007-09-25,,2007-09-30,,,Parallel Assignment,,Interventional,Completed,Phase 1,Duzce University,Duzce University,Duzce University School of Medicine,Drug|Drug,Turkey,23.0,73.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00535561
405,NCT00537095,Thyroid Neoplasms,"A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy",Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer,Thyroid Neoplasms,2007-09-27,2009-12-31,2022-12-31,165.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Other,Belgium|Denmark|France|Norway|Spain|Sweden|Switzerland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00537095
406,NCT00537797,Thyroid Neoplasms,Limited Neck FDG-PET Imaging for Indeterminate Thyroid Nodules,Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules,Thyroid Neoplasms,2007-09-28,2011-09-30,2014-02-28,84.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Washington University School of Medicine,Washington University School of Medicine,Washington University School of Medicine|St. Louis University School of Medicine|VAMC,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00537797
408,NCT00537979,Dialysis|Secondary Hyperparathyroidism,"Prospective, Non-randomized, Multicenter Study to Assess the Efficacy and Safety of Oral or Intravenous Paricalcitol Administered Over 6 Months to Patients With Secondary Hyperparathyroidism on Dialysis",Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis,Dialysis|Secondary Hyperparathyroidism,2007-09-28,2010-07-31,2010-07-31,147.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Site Ref # / Investigator 19391|Site Ref # / Investigator 19389|Site Ref # / Investigator 19390|Site Ref # / Investigator 19393|Site Ref # / Investigator 19395|Site Ref # / Investigator 19392|Site Ref # / Investigator 19397|Site Ref # / Investigator 19396|Site Ref # / Investigator 19394|Site Ref # / Investigator 19399|Site Ref # / Investigator 19398|Site Ref # / Investigator 19388,Drug|Drug,Mexico,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00537979
411,NCT00538720,Hyperparathyroidism,Pilot Study to Detect and Assess the Effect of Vitamin D Replacement on Gland Size by 4DCT in Patients With Primary Hyperparathyroidism (PHPT),Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT),Hyperparathyroidism,2007-10-02,2018-05-30,2018-05-30,22.0,,Single Group Assignment,,Interventional,Completed,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Drug|Device,United States,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00538720
414,NCT00551486,Thyroid Neoplasms,Diagnostic Value of Pyrosequencing for the BRAFV600E Mutation in Ultrasound-Guided Fine-Needle Aspiration Biopsy Samples of Thyroid Incidentalomas,Pyrosequencing of the BRAFV600E Mutation,Thyroid Neoplasms,2007-10-30,,2006-12-31,101.0,,,Prospective,Observational,Completed,,Chungnam National University,Chungnam National University,Chungnam National University Hospital,Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00551486
415,NCT00552253,Thyroid Nodule,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Thyroid Nodule,2007-10-30,2008-07-31,2008-07-31,10.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,20.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00552253
419,NCT00552487,Adrenal Insufficiency|Hashimoto Disease,Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis,Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis,Adrenal Insufficiency|Hashimoto Disease,2007-10-31,,2006-07-31,62.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Wuerzburg,University of Wuerzburg,"University of Wuerzburg, Department of Endocrinology",Drug,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00552487
422,NCT00556530,22q11.2 Deletion Syndrome|DiGeorge Syndrome,Genetic Modifiers of 22q11.2 Deletion Syndrome,Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome,22q11.2 Deletion Syndrome|DiGeorge Syndrome,2007-11-08,2022-06-06,2025-07-31,1000.0,Family-Based,,Prospective,Observational,Recruiting,,Albert Einstein College of Medicine,"Albert Einstein College of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",Albert Einstein College of Medicine|Children's Hospital of Philadelphia,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00556530
424,NCT00559949,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements,Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,2007-11-16,2016-08-31,2016-08-31,39.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Moffitt Cancer Center|University of Chicago Comprehensive Cancer Center|UNC Lineberger Comprehensive Cancer Center|Fox Chase Cancer Center|Vanderbilt University/Ingram Cancer Center|University Health Network-Princess Margaret Hospital,Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00559949
426,NCT00560300,Renal Osteodystrophy|Secondary Hyperparathyroidism,Regulation of Bone Formation in Renal Osteodystrophy,Regulation of Bone Formation in Renal Osteodystrophy,Renal Osteodystrophy|Secondary Hyperparathyroidism,2007-11-13,,2006-11-30,61.0,,Factorial Assignment,,Interventional,Completed,Phase 2,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,Drug|Drug|Drug|Drug,,2.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00560300
429,NCT00565864,Hypothyroidism,Neurocognitive and Metabolic Effects of Mild Hypothyroidism,Neurocognitive and Metabolic Effects of Mild Hypothyroidism,Hypothyroidism,2007-11-28,2013-08-31,2013-08-31,173.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Oregon Health and Science University,Oregon Health and Science University,Oregon Health and Science University,Drug,United States,20.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00565864
430,NCT00566488,Complete DiGeorge Syndrome|DiGeorge Syndrome|Hypoparathyroidism,"Parathyroid and Thymus Transplantation in DiGeorge Syndrome, #931",Parathyroid and Thymus Transplantation in DiGeorge #931,Complete DiGeorge Syndrome|DiGeorge Syndrome|Hypoparathyroidism,2007-11-30,2007-08-31,2019-12-31,25.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Food and Drug Administration (FDA)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological,United States,0.0,24.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00566488
432,NCT00568438,Breast Cancer|Salivary Gland Neoplasms|Stomach Neoplasms|Thyroid Cancer,Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples,Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample,Breast Cancer|Salivary Gland Neoplasms|Stomach Neoplasms|Thyroid Cancer,2007-12-04,2020-04-30,2020-04-30,300.0,Cohort,,Retrospective,Observational,Unknown status,,Stanford University,Stanford University,Stanford University School of Medicine,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00568438
433,NCT00569920,Parathyroid Diseases|Thyroid Diseases,"Nausea and Pain Prophylaxis During Thyroid Surgery, a Comparison of Low-Dose and High-Dose Dexamethasone to Placebo",Nausea and Pain Prophylaxis During Thyroid Surgery,Parathyroid Diseases|Thyroid Diseases,2007-12-07,2008-12-31,2008-12-31,120.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Sykehuset Telemark,Sykehuset Telemark,"Surgery Unit, Porsgrunn, Acute Care Clinic, Telemark Hospital",Drug|Drug|Drug,Norway,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00569920
434,NCT00571077,Thyroid Neoplasms|Thyroid Nodules,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Thyroid Neoplasms|Thyroid Nodules,2007-12-10,,2007-12-31,200.0,,,Prospective,Observational,Completed,,Hadassah Medical Organization,Hadassah Medical Organization|Walter Reed Army Medical Center,Walter Reed Army MEdicla Center|Hadassah-Hebrew University Medical Center,Device,Israel|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00571077
436,NCT00571090,Thyroid Nodule,Evaluation of Thyroid Fine Needle Aspiration Biopsies: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Thyroid Nodule,2007-12-10,2012-07-31,2013-07-31,735.0,Case-Only,,Cross-Sectional,Observational,Completed,,Istanbul Science University,Group Florence Nightingale|Istanbul Science University,Group Florence Nightingale,Procedure,Turkey,15.0,89.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00571090
438,NCT00573573,Hyperparathyroidism,Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.,Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism,Hyperparathyroidism,2007-12-12,2009-03-31,2009-07-31,2.0,,Single Group Assignment,,Interventional,Unknown status,Phase 1,GAAD Medical Research Institute Inc.,GAAD Medical Research Institute Inc.,The Centre for Incurable Diseases,Radiation,Canada,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00573573
440,NCT00576407,Complete Typical DiGeorge Anomaly|DiGeorge Syndrome,Phase II Study of Thymus Transplantation in Complete DiGeorge Syndrome #668,Thymus Transplantation in DiGeorge Syndrome #668,Complete Typical DiGeorge Anomaly|DiGeorge Syndrome,2007-12-17,2009-04-30,2017-12-31,26.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00576407
442,NCT00576836,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly|DiGeorge Syndrome,"Dose Study of Thymus Transplantation in DiGeorge Anomaly, IND 9836, #932.1",Thymus Transplantation Dose in DiGeorge #932,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly|DiGeorge Syndrome,2007-12-17,2010-11-30,2019-12-31,7.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00576836
444,NCT00579527,Complete Atypical DiGeorge Anomaly|Complete Atypical DiGeorge Syndrome|Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly,"Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950",Phase I/II Thymus Transplantation With Immunosuppression #950,Complete Atypical DiGeorge Anomaly|Complete Atypical DiGeorge Syndrome|Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly,2007-12-20,2011-12-31,2017-12-31,14.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological|Other|Procedure|Drug|Drug|Drug|Drug|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00579527
446,NCT00579709,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly|DiGeorge Syndrome,"Thymus Transplantation With Immunosuppression, #884",Thymus Transplantation With Immunosuppression,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly|DiGeorge Syndrome,2007-12-20,2006-12-31,2019-12-31,15.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00579709
448,NCT00580320,Carcinoid Tumors|Melanoma|Parathyroid Carcinoma|Small Cell Carcinoma of the Lung|Soft Tissue Sarcoma,Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,Carcinoid Tumors|Melanoma|Parathyroid Carcinoma|Small Cell Carcinoma of the Lung|Soft Tissue Sarcoma,2007-12-18,2009-10-31,2013-11-30,17.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Virginia Commonwealth University,Virginia Commonwealth University,Dartmouth Hitchcock Medical Center|Massey Cancer Center/Virginia Commonwealth University,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00580320
450,NCT00580788,Humoral Hypercalcemia of Malignancy|Hyperparathyroidism|Osteoporosis,Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone-related Protein(1-36): Effects on Bone Formation,One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study,Humoral Hypercalcemia of Malignancy|Hyperparathyroidism|Osteoporosis,2007-12-20,2009-12-31,2009-12-31,14.0,,Single Group Assignment,,Interventional,Completed,Early Phase 1,University of Pittsburgh,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh,University of Pittsburgh Medical Center,Drug,United States,24.0,35.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00580788
452,NCT00581828,Hypercalcemia|Hypercalciuria|Hypoparathyroidism|Osteopenia|Osteoporosis|Vitamin D Deficiency,Does Treatment of Hypovitaminosis D Increase Calcium Absorption?,Does Treatment of Hypovitaminosis D Increase Calcium Absorption?,Hypercalcemia|Hypercalciuria|Hypoparathyroidism|Osteopenia|Osteoporosis|Vitamin D Deficiency,2007-12-19,2008-07-31,2008-12-31,19.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University of Wisconsin, Madison","University of Wisconsin, Madison",University of Wisconsin Hospital and Clinics,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00581828
454,NCT00582712,Medullary Thyroid Cancer,An Initial Study of Lithium in Patients With Medullary Thyroid Cancer,An Initial Study of Lithium in Patients With Medullary Thyroid Cancer,Medullary Thyroid Cancer,2007-12-19,2009-05-31,2012-04-30,5.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,"University of Wisconsin, Madison","University of Wisconsin, Madison",Uniersity of Wisconsin Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00582712
455,NCT00587158,"Hyperparathyroidism, Secondary|Renal Disease, End Stage|Transplant; Failure, Kidney",Oral Paricalcitol in Kidney Transplant Recipients Receiving a Corticosteroid-free Immunosuppressive Regimen,Oral Paricalcitol in Kidney Transplant Recipients,"Hyperparathyroidism, Secondary|Renal Disease, End Stage|Transplant; Failure, Kidney",2007-12-21,2011-11-30,2011-11-30,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mayo Clinic,Abbott|Mayo Clinic,Mayo Clinic|Mayo Clinic,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00587158
458,NCT00588432,Hyperthyroid Myopathy|Immobilization|Myofacial Pain|Stroke,Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE),Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE),Hyperthyroid Myopathy|Immobilization|Myofacial Pain|Stroke,2007-12-26,2009-09-30,2009-09-30,300.0,Case-Control,,Cross-Sectional,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00588432
459,NCT00591032,Euthyroid Sick Syndromes|Low T3 Syndrome|Non-thyroidal Illness Syndrome|TACITUS,Development of Rational and Standardized Diagnostics and Staging for a Differentiated Risk Stratification of Non-thyroidal Illness Syndrome,Approach to a Quantitative Follow-up of Non-thyroidal Illness Syndrome,Euthyroid Sick Syndromes|Low T3 Syndrome|Non-thyroidal Illness Syndrome|TACITUS,2007-12-26,2017-11-30,2020-12-31,590.0,Cohort,,Prospective,Observational,Active not recruiting,,Ruhr University of Bochum,Private Sponsor (Chantal C. Guilhemotonia-Urban)|Ruhr University of Bochum|Wissenschaftskommission des Universitaetsklinikums Bergmannsheil,"Department for medical informatics, biometry and epidemiology, Ruhr-University of Bochum|Institute of Clinical Chemistry, Transfusion and Laboratory Medicine, Universittsklinikum Bergmannsheil, Ruhr-Universitt Bochum|Medical Hospital II, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medizinische Klinik I, Universittsklinikum Bergmannsheil, Ruhr-Universitt Bochum|Diabetes-Zentrum, Mathias-Spital|Abteilung fr Laboratoriums- und Transfusionsmedizin, Westpfalz-Klinikum Kaiserslautern",,Germany,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00591032
460,NCT00595335,Thyroid-associated Ophthalmopathy,Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy,Trial of Rituximab for Graves' Ophthalmopathy,Thyroid-associated Ophthalmopathy,2008-01-01,2013-03-31,2013-09-30,25.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Rebecca Bahn,Mayo Clinic,Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00595335
464,NCT00598364,Thyroid Cancer,Molecular Markers in the Diagnostic and Prognostic Evaluation of Thyroid Cancer,Molecular Markers in Thyroid Cancer,Thyroid Cancer,2008-01-10,2010-10-31,2010-10-31,847.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,OHSU Knight Cancer Institute,OHSU Knight Cancer Institute,Oregon Health & Science University,,United States,1.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00598364
465,NCT00601328,Hypocalcemia|Secondary Hyperparathyroidism,"A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Calcitriol Tablets, 0.25 mg, Under Fasting Conditions",Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions,Hypocalcemia|Secondary Hyperparathyroidism,2008-01-15,2003-08-31,2003-08-31,36.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,West-Ward Pharmaceutical,Roxane Laboratories,"Bio-Kinetic Clinical Applications, Inc.",Drug,United States,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00601328
468,NCT00603941,Anaplastic Thyroid Cancer,"A Phase 1/2 Study of CS7017, an Oral PPAR Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer","A Phase 1/2 Study of CS7017, an Oral PPAR Agonist, in Combination With Paclitaxel",Anaplastic Thyroid Cancer,2008-01-15,2011-12-31,2011-12-31,19.0,,Sequential Assignment,,Interventional,Terminated,Phase 1/Phase 2,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.","Univ of Colorado Cancer Center|Mayo Clinic|Massachusetts General Hospital|Mayo Clinic|Washington University, Siteman Cancer Center|Ohio State Univ|Oregon Health Science Univ|University of Pennsylvania Maloney Hospital|Vanderbilt Ingram Cancer Center|Eastern Virginia Medical School",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00603941
470,NCT00604318,Thyroid Cancer,"Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer?","Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer",Thyroid Cancer,2008-01-17,2012-02-29,2012-02-29,56.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev|Odense University Hospital,"Dept of Oncology, Herlev Hospital",Drug,Denmark,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00604318
471,NCT00615537,Nodular Goiter|Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Nodular Goiter|Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2008-02-03,2011-01-31,2011-01-31,20.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"BioTex, Inc.","BioTex, Inc.|Rhode Island Hospital",Rhode Island Hospital - Department of Diagnostic Imaging Research,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00615537
475,NCT00625846,Recurrent Thyroid Gland Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Thyroid Gland Anaplastic Carcinoma,A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer,Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer,Recurrent Thyroid Gland Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Thyroid Gland Anaplastic Carcinoma,2008-02-27,2018-12-21,2019-08-13,152.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic in Arizona|University of Colorado Hospital|Mayo Clinic in Florida|University of Iowa/Holden Comprehensive Cancer Center|Johns Hopkins University/Sidney Kimmel Cancer Center|Wayne State University/Karmanos Cancer Institute|Fairview Ridges Hospital|Fairview-Southdale Hospital|Unity Hospital|Minnesota Oncology Hematology PA-Maplewood|Abbott-Northwestern Hospital|Mayo Clinic|Park Nicollet Clinic - Saint Louis Park|United Hospital|Washington University School of Medicine|University of Wisconsin Hospital and Clinics|Sir Charles Gairdner Hospital|Chinese University of Hong Kong-Prince of Wales Hospital|National University Hospital Singapore|National Cancer Centre|Johns Hopkins Singapore|National Taiwan University Hospital,Other|Drug,Australia|China|Singapore|Taiwan|United States,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00625846
477,NCT00639405,Parathyroid Diseases|Parathyroid Neoplasm,Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism,Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas,Parathyroid Diseases|Parathyroid Neoplasm,2008-03-12,2008-08-31,2008-08-31,12.0,Case-Only,,Prospective,Observational,Terminated,,State University of New York - Upstate Medical University,State University of New York - Upstate Medical University,SUNY Upstate Medical University,,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00639405
479,NCT00646282,"Hyperparathyroidism, Secondary",Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney,Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients,"Hyperparathyroidism, Secondary",2008-03-25,2010-01-31,2010-01-31,12.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,Emory University,Emory University,Emory University,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00646282
482,NCT00647140,Medullary Carcinoma|Thyroid Carcinoma|Thyroid Neoplasm,Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer.,Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer,Medullary Carcinoma|Thyroid Carcinoma|Thyroid Neoplasm,2008-03-26,2009-08-31,2010-02-28,29.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Hpital Antoine Beclere,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00647140
483,NCT00651625,Cancer|Osteoarthritis|Rheumatoid Arthritis|Thyroid Nodule|Trauma,Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures,Reciprocating Medical Devices - a Study of a New Safety Device,Cancer|Osteoarthritis|Rheumatoid Arthritis|Thyroid Nodule|Trauma,2008-03-21,2010-01-31,2010-08-31,437.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of New Mexico,University of New Mexico,University of New Mexico Health Sciences Center,Device|Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00651625
485,NCT00654238,Metastatic Anaplastic Thyroid Cancer|Metastatic Differentiated Thyroid Cancer|Metastatic Medullary Thyroid Cancer|Metastatic Poorly Differentiated Thyroid Cancer,Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer,Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer,Metastatic Anaplastic Thyroid Cancer|Metastatic Differentiated Thyroid Cancer|Metastatic Medullary Thyroid Cancer|Metastatic Poorly Differentiated Thyroid Cancer,2008-04-01,2010-12-31,2011-03-31,59.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Pennsylvania,University of Pennsylvania,University of Pennsylvania - Abramson Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00654238
487,NCT00664430,Dialysis|Secondary Hyperparathyroidism,Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects,Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects,Dialysis|Secondary Hyperparathyroidism,2008-04-21,2009-06-30,2009-06-30,13.0,,Single Group Assignment,,Interventional,Terminated,Phase 4,Abbott,Abbott|Statistika Consultoria Ltda,Site Reference ID/Investigator# 7118|Site Reference ID/Investigator# 7114,Drug|Drug,Brazil,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00664430
490,NCT00665795,Dysthyroid Orbitopathy,Morphometric Analysis of Orbital Structures in Graves Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.,Morphometric Analysis of Orbital Structures in Graves Orbitopathy,Dysthyroid Orbitopathy,2008-04-22,2013-11-30,2013-11-30,80.0,Cohort,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,General Hospital - University of Sao Paulo - School of Medicine,,Brazil,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00665795
494,NCT00667576,Chronic Kidney Disease on Hemodialysis|Secondary Hyperparathyroidism,Late Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose),Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis,Chronic Kidney Disease on Hemodialysis|Secondary Hyperparathyroidism,2008-04-24,2009-03-31,2009-03-31,153.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Abbott,"Abbott|Abbott Japan Co.,Ltd",,Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00667576
497,NCT00668811,Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer,2008-04-25,2015-09-30,2015-12-31,23.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Medstar Health Research Institute,Medstar Health Research Institute|Pfizer,MedStar Washington Hospital Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00668811
500,NCT00673010,Thyroid Cancer,Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma,Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma,Thyroid Cancer,2008-05-06,2023-03-31,2023-03-31,20.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,"Gustave Roussy, Cancer Campus, Grand Paris|Memorial Sloan Kettering Cancer Center",Memorial Sloan Kettering Cancer Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00673010
501,NCT00674154,Hypercalcemia|Primary Hyperparathyroidism|Vitamin D Deficiency,Effect of Vitamin D Treatment in Primary Hyperparathyroidism,Effect of Vitamin D Treatment in Primary Hyperparathyroidism,Hypercalcemia|Primary Hyperparathyroidism|Vitamin D Deficiency,2008-05-05,2013-08-31,2013-08-31,46.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,University of Aarhus,University of Aarhus,"Osteoporoseklinikken, Aarhus University Hospital, THG",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00674154
504,NCT00677469,Graves Disease,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Graves Disease,2008-05-12,2008-01-31,2008-01-31,45.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Shiraz University of Medical Sciences,Shiraz University of Medical Sciences,Endocrine and Metabolism Research Center,Drug|Drug|Drug,"Iran, Islamic Republic of",20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00677469
507,NCT00687778,"Carcinoma, Hepatocellular|Carcinoma, Lobular|GIST|Indolent Lymphoma|Lung Cancer|Neuroendocrine Tumors|Soft Tissue Sarcomas|Teratoma|Thyroid Cancer|Uterine Malignancies",,11C-Acetate PET/CT Non-FDG-Avid Tumors,"Carcinoma, Hepatocellular|Carcinoma, Lobular|GIST|Indolent Lymphoma|Lung Cancer|Neuroendocrine Tumors|Soft Tissue Sarcomas|Teratoma|Thyroid Cancer|Uterine Malignancies",2008-05-28,2009-06-30,2010-06-30,100.0,Cohort,,Prospective,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,"Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center",,Israel,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00687778
508,NCT00691990,Goiter,Classic Total Thyroidectomy With or Without Drains,Classic Total Thyroidectomy With or Without Drains,Goiter,2008-06-05,2009-12-31,2011-07-31,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,"3rd Department of Surgery, AHEPA University Hospital",Procedure,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00691990
509,NCT00692835,Goiter,Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT),Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT),Goiter,2008-06-05,2009-12-31,2012-09-30,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,"3rd Department of Surgery, AHEPA University Hospital",Procedure|Procedure,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00692835
510,NCT00693147,Goiter,Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T),Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T),Goiter,2008-06-05,2009-12-31,2012-09-30,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,"3rd Department of Surgery, AHEPA University Hospital",Procedure,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00693147
511,NCT00697528,Graves' Disease|Graves' Ophthalmopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Graves' Disease|Graves' Ophthalmopathy,2008-06-11,2008-12-31,2008-12-31,66.0,Case-Control,,Prospective,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,Hospital das Clnicas da Universidade So Paulo,,Brazil,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00697528
515,NCT00701805,Hemodialysis|Secondary Hyperparathyroidism,Phase II Study of Paricalcitol Injection Extension Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism,Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD),Hemodialysis|Secondary Hyperparathyroidism,2008-06-17,2009-12-31,2009-12-31,107.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Abbott,"Abbott|Abbott Japan Co.,Ltd",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00701805
518,NCT00704730,Thyroid Cancer,"An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer",Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer,Thyroid Cancer,2008-06-23,2011-10-31,2020-09-30,330.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Exelixis,Exelixis,"University of Alabama at Birmingham, Comprehensive Cancer Center|TGEN Clinical Research Service at Scottsdale Healthcare|University of Arkansas for Medical Sciences|UCLA|Stanford Cancer Center|University of Colorado Cancer Center|Yale University, School of Medicine|Washington Cancer Institute|H. Lee Moffet Cancer Center and Research Institute|University of Chicago|Indiana University Melvin and Bren Simon Cancer Center|University of Iowa|Kansas University Medical Center|Johns Hopkins University|Massachusetts General Hospital|Henry Ford Health System|Mayo Clinic|Capitol Comprehensive Cancer Care Clinic and Research Institute|Washington University School of Medicine|Nebraska Methodist Hospital|Ohio State University, James Cancer Hospital|Oregon Health & Science University|St. Luke's Hospital & Health Network|Hospital of the University of Pennsylvania|Hollings Cancer Center|Vanderbilt University Medical Center|Vermont Cancer Center at Fletcher Allen Health Care|Peninsula Cancer Institute|Multiple site locations|Cliniques Universitaires St. Luc|Universitair Ziekenhuis|Multiple site locations|CHUM - Hopital Saint-Luc|Klinik fuer Nuklearmedizin des Universitaetsklinikums Essen|Gemeinschaftspraxis|Universitaetsklinikum Leipzig|Johannes-Gutenberg Universitaet Mainz|Klinikum der Ludwig-Maximilians-Universitaet Muenchen|Ludwig-Maximilians-Universitaet Muenchen|Universitaetsklinikum Tuebingen|Universitaetsklinikum Wuerzburg|Kidwai Institute of Oncology|Indo-American Cancer Institute and Research Center|SEAROC Cancer Institute, S.K. Soni Hospital|Netaji Subhash Chandra Bose Cancer Hospital Research Institute|Central India Cancer Research Institute|Shatabdi Superspeciality Hospital|All India Institute of Medical Sciences|Deenanath Mangeshkar Hospital & Research Center|Ruby Hall Clinic|Multiple site locations|Multiple site locations|Multiple site locations",Drug|Drug,"Austria|Belgium|Brazil|Canada|Chile|Denmark|France|Germany|Greece|India|Israel|Italy|Korea, Republic of|Netherlands|Peru|Poland|Portugal|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00704730
519,NCT00715572,Hypothyroidism,Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone in the Treatment of Primary Hypothyroidism,Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone,Hypothyroidism,2008-07-11,2004-02-29,2004-05-31,36.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,I.M. Sechenov First Moscow State Medical University,I.M. Sechenov First Moscow State Medical University,,Drug|Drug,,18.0,48.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00715572
520,NCT00718770,Thyroid Cancer,Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: A Pilot Clinical Trial and Correlation to Retinoid and PPARy Receptor Expression,A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression,Thyroid Cancer,2008-07-17,2013-01-31,2013-02-28,10.0,,Single Group Assignment,,Interventional,Completed,Early Phase 1,"University of Colorado, Denver","American Cancer Society, Inc.|Eisai Inc.|University of Colorado, Denver",University of Colorado Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00718770
521,NCT00719615,Thyroid Cancer,The Relationship Between Vitamin D and Thyroid Cancer,Assess Vitamin D Levels in Those With & Without Thyroid Cancer,Thyroid Cancer,2008-07-17,2009-03-31,2009-06-30,111.0,Case-Control,,Prospective,Observational,Completed,,University of Nebraska,University of Nebraska,University of Nebraska Medical Center,,United States,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00719615
522,NCT00729157,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy,Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,2008-08-06,2012-10-31,2012-11-30,41.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center,Radiation|Other|Other|Procedure|Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00729157
525,NCT00730210,Hypoparathyroidism,Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life,Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life,Hypoparathyroidism,2008-08-04,2010-08-31,2010-08-31,62.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Aarhus,University of Aarhus,"Osteoporoseklinikken, Aarhus University Hospital",Drug|Drug,Denmark,25.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00730210
527,NCT00732615,Hypoparathyroidism,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism",Use of NPSP558 in the Treatment of Hypoparathyroidism,Hypoparathyroidism,2008-08-08,2011-09-28,2011-09-28,124.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Takeda,Shire,"Mayo Clinic-Scottsdale|Advance Medical Research LLC|Diabetes Associates|University of California-San Francisco VA Medical Center|Palm Springs Research Institute|Mayo Clinic Jacksonville|University of Chicago Medical Center|Indiana University School of Medicine|Massachusetts General Hospital|Michigan Bone and Mineral Clinic PC|Mayo Clinic Rochester|Columbia University Medical Center|University Physicians Group|Physicians East|University of Cincinnati Bone Health and Osteoporosis Center|Children's Hospital of Philadelphia|Cetero Research DGD Research Inc.|Hillcrest Family Health Center|The Vancouver Clinic|Chetre Hospitalier Universitaire de Liege|Heritage Medical Research Clinic|Capital District Health Authority, QEII Health Sciences Centre|Oakville Bone Center|Aarhus University Hospital|Odense University Hospital|Hpital Europen Georges Pompidou|Semmelweis University Medical School|University of Pcs, School of Medicine|University of Szeged|University Hospital of Careggi|Royal Liverpool University Hospital",Drug|Drug,Belgium|Canada|Denmark|France|Hungary|Italy|United Kingdom|United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00732615
529,NCT00742716,Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,"An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis",Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease,Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2008-08-26,2010-02-28,2010-06-30,41.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.","Pines Clinical Research, Inc.|Boise Kidney and Hypertension Institute|Western New England Renal & Transplant Associates (WNERTA)|Southeast Renal Research Institute|U.S. Renal Care|Capital District Heatlth Authority: Centre for Clinical Research|St. Joseph's Health Care London|St. Michael's Hospital|Humber River Regional Hospital|Hpital Charles-Lemoyne|Hpital du Sacr-Coeur de Montral|Hospital de Verdun",Drug,Canada|United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00742716
532,NCT00743782,Hypocalcemia|Hypoparathyroidism,Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism,Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism,Hypocalcemia|Hypoparathyroidism,2008-08-28,2014-04-07,2014-04-07,24.0,,Crossover Assignment,,Interventional,Completed,Early Phase 1,National Institutes of Health Clinical Center (CC),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,7.0,70.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00743782
534,NCT00744302,Hypercalcemia|Hyperparathyroidism,Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.,Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.,Hypercalcemia|Hyperparathyroidism,2008-08-28,2009-12-31,2009-12-31,180.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Sun Yat-sen University,Sun Yat-sen University,"The 1st Affiliated Hospital, Sun Yet-sen University",Drug,China,14.0,65.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00744302
536,NCT00747760,Hypothyroidism,The Prevalence of TSH Receptor Mutation Among the Arab Population of Israel,TSH Receptor Mutations Among a Consanguineous Community,Hypothyroidism,2008-09-04,2006-07-31,2006-12-31,209.0,Cohort,,Prospective,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel|National Institutes of Health (NIH)",Samuell Refetoff|Ha'Emek Medical Center,,Israel|United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00747760
537,NCT00749697,Metastatic Sites Lung Bone Nodal|Thyroid Carcinoma,Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine,Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases,Metastatic Sites Lung Bone Nodal|Thyroid Carcinoma,2008-09-05,2010-01-31,2010-07-31,10.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Other,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00749697
538,NCT00752401,Kidney Transplantation|Renal Osteodystrophy|Vitamin D Deficiency,"VITA-D: Cholecalciferol Substitution in Vitamin D Deficient Kidney Transplant Recipients: A Randomized, Placebo-controlled Study to Evaluate the Posttransplant Outcome",Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients,Kidney Transplantation|Renal Osteodystrophy|Vitamin D Deficiency,2008-09-11,2014-07-31,2014-07-31,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,"Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis",Drug|Drug,Austria,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00752401
541,NCT00754182,Goiter|Parathyroid Pathologies|Thyroid Neoplasms,Comparison of Esthetic Results Between Subcuticular Suture and Synthetic Glue in Thyroidectomy Incision: a RCT,Subcuticular Suture Versus Synthetic Glue in Thyroidectomy Incision,Goiter|Parathyroid Pathologies|Thyroid Neoplasms,2008-09-16,2010-05-31,2010-05-31,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero-Universitaria di Modena,Policlinico di Modena,Device|Device,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00754182
542,NCT00754442,Secondary Hyperparathyroidism,Clinical and Molecular Characterization of Suspected Partial 25-hydroxyvitamin D-1-alpha-hydroxylase Deficiency,Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2008-09-17,2008-08-31,2008-08-31,20.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"University of Maryland, Baltimore","University of Maryland, Baltimore",University of Maryland School of Medicine Division of Endocrinology,Drug,United States,40.0,59.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00754442
545,NCT00768820,Fragile X Syndrome|Velocardiofacial Syndrome|Williams Syndrome,"The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors",The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome,Fragile X Syndrome|Velocardiofacial Syndrome|Williams Syndrome,2008-10-07,2022-12-31,2022-12-31,400.0,,Single Group Assignment,,Interventional,Recruiting,Phase 4,The Chaim Sheba Medical Center,The Chaim Sheba Medical Center,Schneider Children's Mediac Center of Israel,Drug,Israel,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00768820
547,NCT00770016,Hypothyroidism,Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism,Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism,Hypothyroidism,2008-10-08,2010-01-31,2011-01-31,0.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,University of Aarhus,"MR Research Center, Skejby Sygehus, Brendstrupgaardsvej 100, 8200 Aarhus N|University of Aarhus","Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus Sygehus,",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00770016
548,NCT00781417,Kidney Disease,Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease,Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease,Kidney Disease,2008-10-28,2011-10-31,2011-12-31,48.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Atlanta VA Medical Center,Atlanta VA Medical Center|Emory University,Atlanta VAMC,Dietary Supplement|Other,United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00781417
551,NCT00782366,Atrial Fibrillation|Breast Cancer|Celiac Disease|Colon Cancer|Diabetes Type 2|Graves Disease|Lung Cancer|Myocardial Infarction|Obesity|Osteoarthritis|Prostate Cancer,Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment,Predictive Genetic Risk Assessment Trial,Atrial Fibrillation|Breast Cancer|Celiac Disease|Colon Cancer|Diabetes Type 2|Graves Disease|Lung Cancer|Myocardial Infarction|Obesity|Osteoarthritis|Prostate Cancer,2008-10-29,2010-01-31,2010-01-31,26.0,Cohort,,Prospective,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,Genetic,United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00782366
554,NCT00784173,Ear Malformations in the Velocardiofacial Syndrome,Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome,Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome,Ear Malformations in the Velocardiofacial Syndrome,2008-10-31,2007-03-31,2007-06-30,2.0,Case-Only,,Prospective,Observational,Completed,,Pontificia Universidade Catolica de Sao Paulo,Pontificia Universidade Catolica de Sao Paulo,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00784173
556,NCT00784303,Thyroid Cancer,"Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology","Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology",Thyroid Cancer,2008-10-30,2011-04-11,2019-03-29,117.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Eisai Inc.,Eisai Inc.,,Drug|Drug,Australia|France|Italy|Poland|United Kingdom|United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00784303
557,NCT00786552,Thyroid Cancer,"Phase 2 Trial of Pemetrexed (Alimta) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer",Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer,Thyroid Cancer,2008-11-05,2012-11-30,2013-11-30,47.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,University Hospital Schleswig-Holstein,University Hospital Schleswig-Holstein,"Medical Center II, University of Kiel",Drug,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00786552
558,NCT00792857,Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,"Single-Dose, Two-Period, Open Label, Dose Determination, Randomized, Cross-Over Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects With Stage 5 CKD and SHPT on Hemodialysis",Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2008-11-14,2009-09-30,2009-10-31,24.0,,Crossover Assignment,,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",Pivotal Reseach Centers|Western New England Renal and Transplant Associates|University of Cincinnati|Northeast Clinical Research|Vanderbilt University|Southwest Houston Research Ltd.,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00792857
561,NCT00793689,Hypoparathyroidism,Comparison of the Prognostic Value of Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test in the Evaluation of Parathyroid Function After Total Thyroidectomy,Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test After Total Thyroidectomy,Hypoparathyroidism,2008-11-18,2009-09-30,2009-10-31,127.0,Cohort,,Prospective,Observational,Completed,,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,AHEPA University Hospital,,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00793689
563,NCT00794053,Lymph Node Metastasis|Thyroid Cancer,The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer,The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer,Lymph Node Metastasis|Thyroid Cancer,2008-11-18,2008-12-31,2009-04-30,45.0,,Single Group Assignment,,Interventional,Completed,Phase 3,University of Alexandria,University of Alexandria,Alexandria University Hospitals,Procedure,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00794053
564,NCT00795782,Thyroid Cancer,Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial,Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma,Thyroid Cancer,2008-11-19,2012-06-30,2014-06-30,258.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung Medical Center,Procedure,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00795782
565,NCT00796913,Graves Disease|Hyperthyroidism,Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy,Remission Induction and Sustenance in Graves' Disease 2,Graves Disease|Hyperthyroidism,2008-11-21,2015-05-15,2015-05-15,139.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Aalborg University Hospital,Aalborg University Hospital,,Other,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00796913
568,NCT00800358,Hyperparathyroidism|Kidney Disease,"A Multi Centre, Open Label, Parallel Group, Randomized Controlled Trial to Compare the Safety and Efficacy of Oral Paricalcitol Versus Oral Calcitriol in the Treatment of Secondary Hyperparathyroidism in Dialysis Patients",Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism,Hyperparathyroidism|Kidney Disease,2008-11-30,2009-10-31,2009-12-31,69.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"Penang Hospital, Malaysia","Ministry of Health, Malaysia|Penang Hospital, Malaysia","Hospital Sultanah Bahiyah Haemodialysis Unit KM 6 Jalan Langgar|Hemodialysis Unit, Raja Perempuan Zainab II Hospital|Hemodialysis Unit, Tengku Ampuan Afzan Hospital|Clinical Research Centre, Penang Hospital|Haemodialysis Unit, Seberang Jaya Hospital|Hemodialysis Unit, Taiping Hospital|Nephrology Department, Tengku Ampuan Rahimah Hospital|Hemodialysis Unit, Kuala Lumpur Hospital|Haemodialysis Unit, Serdang Hospital|Hemodialysis Unit, Tuanku Ja'afar Seremban Hospital|Haemodialysis Unit, Melaka Hospital",Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00800358
571,NCT00803712,Chronic Kidney Disease|Secondary Hyperparathyroidism,Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination With Low Dose Vitamin D for the Treatment of Subjects With Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis,20070360 Incident Dialysis,Chronic Kidney Disease|Secondary Hyperparathyroidism,2008-11-26,2010-12-09,2011-07-05,313.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00803712
574,NCT00804830,Carcinoma|Metastatic Cancer|Thyroid Cancer|Thyroid Neoplasms,Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer,Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer,Carcinoma|Metastatic Cancer|Thyroid Cancer|Thyroid Neoplasms,2008-12-08,2012-12-31,2014-12-31,15.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Region Skane,Region Skane,"Jubileumskliniken, Sahlgrenska universitetsjukhuset|Dep of Oncology, Lund University Hospital|Karolinska University Hospital",Drug,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00804830
576,NCT00818896,Hypothyroidism,A Model Statewide Trial to Detect and Treat Maternal Hypothyroidism in Pregnancy,Maternal Hypothyroidism in Pregnancy,Hypothyroidism,2009-01-06,2011-08-31,2011-09-30,72.0,Case-Only,,Prospective,Observational,Completed,,Women and Infants Hospital of Rhode Island,Women and Infants Hospital of Rhode Island,Women & Infants Hospital,,United States,17.0,44.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00818896
577,NCT00822289,Helicobacter Pylori Infected Patients|Hyperthyroidism|Thyroid Cancer Patients,Effect of Radioactive Iodine on Eradication of Helicobacter Pylori in Patients Treated for Thyroid Diseases,The Effect of Radioactive Iodine Administration for Thyroid Diseases on H.Pylori Eradication,Helicobacter Pylori Infected Patients|Hyperthyroidism|Thyroid Cancer Patients,2009-01-13,,,120.0,Cohort,,Prospective,Observational,Unknown status,,Rabin Medical Center,Rabin Medical Center,,,,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00822289
579,NCT00823303,Chronic Kidney Disease|Secondary Hyperparathyroidism,A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism,Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism,2008-12-12,2013-05-31,2013-09-30,110.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Washington University School of Medicine,"Abbott|Feinberg School of Medicine, Northwestern University|Henry Ford Hospital|NorthShore University HealthSystem|Washington University School of Medicine",Northwestern University|Northshore University Health System|Henry Ford Hospital|Washington University,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00823303
582,NCT00824226,Hypoparathyroidism,Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients,Magnesium Treatment in Hypoparathyroidism,Hypoparathyroidism,2009-01-15,2011-08-31,2011-08-31,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Tartu,University of Tartu,Tartu University Hospital,Dietary Supplement,Estonia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00824226
584,NCT00828347,Secondary Hyperparathyroidism,A Study of Maintenance Therapy After Intravenous Maxacalcitol for Secondary Hyperparathyroidism,Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT),Secondary Hyperparathyroidism,2009-01-22,2009-07-31,2009-07-31,35.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Kumamoto University,Kumamoto University,Kumamoto University Hospital,Drug|Drug,Japan,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00828347
587,NCT00849888,DiGeorge Anomaly,"Phase I Serum-Free Cultured Thymus Transplantation in DiGeorge Anomaly, IND9836",Serum-Free Thymus Transplantation in DiGeorge Anomaly,DiGeorge Anomaly,2009-02-22,2011-02-28,2011-02-28,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 1,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),,Biological|Other,,0.0,2.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT00849888
589,NCT00856401,Hypoparathyroidism,Phase II Trial of Parathyroid Hormone for the Treatment of Hypoparathyroidism,ADD-ON Study to Existing Hypoparathyroidism Studies,Hypoparathyroidism,2009-03-04,2020-12-31,2021-06-30,62.0,,Single Group Assignment,,Interventional,Unknown status,Phase 3,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University Medical Center,Drug,United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00856401
591,NCT00858104,Thyroid Nodule,Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results,Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results,Thyroid Nodule,2009-03-06,2010-03-31,2013-05-31,200.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Elesta S.R.L.,Elesta S.R.L.,Ospedale Regina Apostolorum|Azienda Ospedaliera di Perugia - Osp. S.Maria della Misericordia|Azienda Ospedaliero-Universitaria di Pisa - Presidio di Cisanello|Arcispedale S. Maria Nuova,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00858104
593,NCT00859612,Renal Osteodystrophy,Renal Osteodystrophy: A Fresh Approach,Renal Osteodystrophy: A Fresh Approach,Renal Osteodystrophy,2009-03-09,2014-02-28,2014-02-28,464.0,Other,,Prospective,Observational,Completed,,University of Kentucky,"Hartmut Malluche, MD",University of Kentucky,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00859612
596,NCT00877630,Thyroid Nodule,Minimal Invasiveness of Endoscopic Thyroidectomy,Minimal Invasiveness of Endoscopic Thyroidectomy,Thyroid Nodule,2009-04-07,2007-05-31,2007-05-31,,Cohort,,Prospective,Observational,Completed,,Second Military Medical University,Second Military Medical University,Minimally Invasive Surgical Center of Changzhang Hospital,,China,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00877630
598,NCT00877981,Primary Hyperparathyroidism,Open Compared to Video-Assisted Minimal-Invasive Parathyroid Surgery in Primary Hyperparathyroidism,Open Versus Video-Assisted Minimal-Invasive Parathyroid Surgery,Primary Hyperparathyroidism,2009-04-07,2007-04-30,2007-10-31,143.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Uppsala University,Lund University|University of Aarhus|Uppsala University,"Unit of Breast and Endocrine Surgery, Surgical Department P, Aarhus University Hospital|Department of Surgery, Lund University Hospital|Uppsala University Hospital, Dept of surgery",Procedure,Denmark|Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00877981
601,NCT00880503,Breast Cancer|Breast Carcinoma|Medullary Thyroid Carcinoma,Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute,Collection of Tissue Samples for Study of Multidrug Resistance,Breast Cancer|Breast Carcinoma|Medullary Thyroid Carcinoma,2009-04-10,,2018-02-08,325.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"Childrens Hospital, Pittsburgh",,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00880503
602,NCT00887107,Thyroid Cancer,Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma,Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma,Thyroid Cancer,2009-04-22,,,32.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Leiden University Medical Center,Leiden University Medical Center,Leiden University Medical Center,Drug,Netherlands,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00887107
604,NCT00887666,Congestive Heart Failure|Hyperparathyroidism|Hypovitaminosis D,"Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure","Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure",Congestive Heart Failure|Hyperparathyroidism|Hypovitaminosis D,2009-04-23,2008-10-31,2008-10-31,48.0,Cohort,,Prospective,Observational,Completed,,State University of New York - Downstate Medical Center,State University of New York - Downstate Medical Center,SUNY Downstate Medical Center,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00887666
606,NCT00888069,Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,"A Randomized, Open-Label, Single-Dose Pilot Study of Oral and i.v. CTAP101 Evaluating PK and Safety in Stage 3 and 4 CKD Subjects With Vitamin D Insufficiency and SHPT",Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects,Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2009-04-23,2009-11-30,2009-12-31,28.0,,Parallel Assignment,,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",Pivotal Research Centers|Research by Design|Western New England Renal & Transplant Associates|Twin Cities Clinical Research|DCI|MetroHealth Medical Center|Northeast Clinical Research|Southeast Renal Research Institute|Vanderbilt University Medical Center|Southwest Houston Research Ltd|Purity Dialysis Centers / Nephrology Associates|Gunderson Clinic Ltd.,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00888069
609,NCT00891813,"Hemodialysis|Hypercalcemia|Parathyroid Hormone|Renal Insufficiency, Chronic|Secondary Hyperparathyroidism",Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose,Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose,"Hemodialysis|Hypercalcemia|Parathyroid Hormone|Renal Insufficiency, Chronic|Secondary Hyperparathyroidism",2009-04-29,2010-09-30,2010-09-30,100.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Site Reference ID/Investigator# 21401|Site Reference ID/Investigator# 23857|Site Reference ID/Investigator# 10941,Drug,Peru,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00891813
612,NCT00896454,Breast Cancer|Colon Cancer|Endocrine Cancer|Head and Neck Cancer|Hodgkin's Lymphoma|Hypercalcemia of Malignancy|Kidney Cancer|Lung Cancer|Lymphoma|Metastatic Cancer|Multiple Myeloma|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer|Parathyroid Neoplasms|Renal Cancer|Thyroid Cancer,"A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates",Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium,Breast Cancer|Colon Cancer|Endocrine Cancer|Head and Neck Cancer|Hodgkin's Lymphoma|Hypercalcemia of Malignancy|Kidney Cancer|Lung Cancer|Lymphoma|Metastatic Cancer|Multiple Myeloma|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer|Parathyroid Neoplasms|Renal Cancer|Thyroid Cancer,2009-05-07,2012-09-13,2013-08-21,33.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Canada|France|Italy|Poland|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00896454
614,NCT00902122,Advanced Malignant Thyroid Tumors,"Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors",rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors,Advanced Malignant Thyroid Tumors,2009-05-12,2012-08-31,2012-08-31,600.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,"Shenzhen SiBiono GeneTech Co.,Ltd","Shenzhen SiBiono GeneTech Co.,Ltd","West China Hospital, Sichuan University",Drug|Procedure|Drug|Radiation,China,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00902122
615,NCT00905866,Hyperparathyroidism|Parathyroidectomy,Evaluation of Quality of Life in Patients Undergoing Parathyroidectomy,Quality of Life in Patients Undergoing Parathyroidectomy,Hyperparathyroidism|Parathyroidectomy,2009-05-18,2011-07-31,2011-07-31,60.0,Case-Only,,Prospective,Observational,Completed,,Mackay Memorial Hospital,Mackay Memorial Hospital,Mackay Memorial Hospital,Other,Taiwan,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00905866
617,NCT00916955,22q11.2 Deletion Syndrome,Genetic Modifiers for 22q11.2 Syndrome,Genetic Modifiers for 22q11.2 Syndrome,22q11.2 Deletion Syndrome,2008-03-24,2015-02-28,2015-02-28,,Cohort,,Prospective,Observational,Completed,,State University of New York - Upstate Medical University,Albert Einstein College of Medicine|State University of New York - Upstate Medical University,VCFS International Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00916955
619,NCT00917189,Velocardiofacial Syndrome,Computer-Based Cognitive Remediation in Adolescents With VCFS,Computerized Cognitive Skills Training for Adolescents With Velocardiofacial Syndrome,Velocardiofacial Syndrome,2009-06-08,2015-04-30,2015-04-30,37.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,State University of New York - Upstate Medical University,National Institute of Mental Health (NIMH)|State University of New York - Upstate Medical University,SUNY Upstate Medical University,Behavioral,United States,12.0,16.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT00917189
621,NCT00917241,Graves' Disease,Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone,Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone,Graves' Disease,2009-06-09,2008-12-31,2009-03-31,218.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Nanjing Medical University,Xiao-Ming Mao,,Drug|Drug,,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00917241
624,NCT00921050,Subclinical Hypothyroidism,"Randomized Double Blind Levothyroxine vs Placebo, Mind (NEUROPSI) Improvement in Elderly With Persistent TSH 4-10 mUI/L",Subclinical Hypothyroidism and Mind in the Elderly,Subclinical Hypothyroidism,2009-06-15,2012-03-31,2012-03-31,70.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Universidad Autonoma de Nuevo Leon,Universidad Autonoma de Nuevo Leon,"Endocrinology, Outpatient Hospital Clinic|Community Health Center (Fomerrey 19)",Drug|Drug,Mexico,60.0,95.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00921050
625,NCT00923247,Medullary Thyroid Carcinoma,"A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)","A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)",Medullary Thyroid Carcinoma,2009-06-17,2016-04-01,2016-12-09,22.0,,Parallel Assignment,,Interventional,Terminated,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00923247
626,NCT00926978,Thyroid Cancer,Comparison of I-124 and I-131 Radiopharmacokinetics in Patients Who Have Well-differentiated Thyroid Cancer and Are Prepared With Recombinant Human TSH Injection (rhTSH),Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH),Thyroid Cancer,2009-06-17,2018-10-31,2018-10-31,21.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Medstar Health Research Institute,Medstar Health Research Institute,Washington Hospital Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00926978
627,NCT00928408,"Hyperparathyroidism, Primary",PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice,PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice,"Hyperparathyroidism, Primary",2009-06-25,2011-12-31,2012-02-29,305.0,Other,,Prospective,Observational,Completed,,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00928408
630,NCT00929318,Thyroid Carcinoma|Thyroid Neoplasms,Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound,Influence of Thyroid Hormones on the Woundhealing Process,Thyroid Carcinoma|Thyroid Neoplasms,2009-06-26,2009-12-31,2010-04-30,26.0,,,,Interventional,Unknown status,Not Applicable,Hannover Medical School,"Genzyme, a Sanofi Company|Hannover Medical School","Medizinische Hoochschule Hannover, Allgemein-, Viszeral-und Transplantationscirurgie OE 6220",Procedure|Procedure,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00929318
631,NCT00936650,"Hyperparathyroidism, Primary","A Double-Blind, Randomized, Placebo-Controlled, Multicenter Dose-Titration Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)",A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT),"Hyperparathyroidism, Primary",2009-06-04,2001-03-31,2001-06-30,78.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00936650
634,NCT00936858,Thyroid Cancer,A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer,RAD001 for Patients With Radioiodine Refractory Thyroid Cancer,Thyroid Cancer,2009-07-09,2020-02-27,2020-02-27,50.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Dana-Farber Cancer Institute,Dana-Farber Cancer Institute|Massachusetts General Hospital|M.D. Anderson Cancer Center|MOUNT SINAI HOSPITAL|Novartis,Massachusetts General Hospital|Dana-Farber Cancer Institute|Mt. Sinai Medical Center|MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00936858
635,NCT00936988,"Hyperparathyroidism, Primary","A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism","A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism","Hyperparathyroidism, Primary",2009-06-04,2005-06-30,2005-12-31,45.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00936988
638,NCT00941551,Recurrent Goiter,Five-year Follow up of a Randomized Clinical Trial of Unilateral Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively,Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively,Recurrent Goiter,2009-07-16,2003-12-31,2008-12-31,150.0,Case-Control,,Prospective,Observational,Completed,,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Drug|Drug,Poland,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00941551
639,NCT00946296,Graves Disease|Hyperthyroidism,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Graves Disease|Hyperthyroidism,2009-07-22,2013-04-30,2013-04-30,36.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University of Massachusetts, Worcester","University of Massachusetts, Worcester",UMASS Memorial Health Care,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00946296
642,NCT00946894,Goiter,Five-year Follow up of a Randomized Clinical Trial of Total Thyroidectomy Versus Dunhill Operation Versus Bilateral Subtotal Thyroidectomy for Multinodular Non-toxic Goiter.,Outcomes of Different Thyroid Resections for Multinodular Non-toxic Goiter,Goiter,2009-07-23,2003-12-31,2008-12-31,600.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00946894
643,NCT00948337,Breast Cancer|Colon Cancer|Stomach Cancer|Thyroid Cancer,"A Randomized Controlled Trial on the Effect of Intervention With Health Educational Material on Knowledge, Attitude, and Behavior in Cancer Survivors",A Study With Health Educational Material on Health Promotion in Cancer Survivors,Breast Cancer|Colon Cancer|Stomach Cancer|Thyroid Cancer,2009-07-28,2009-11-30,2010-12-31,326.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2,"National Cancer Center, Korea","National Cancer Center, Korea",National Cancer Center|Samsung Medical Center,Behavioral,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00948337
644,NCT00954837,Thyroid Cancer,Utility of a Second Ultrasound-guided Fine Needle Aspiration for the Detection of Thyroid Cancer in the Management of Single Thyroid Nodules or Multinodular Goitre.,Assessment of Repeat Fine Needle Aspiration (FNA) to Detect Thyroid Cancer,Thyroid Cancer,2009-07-30,2011-12-31,2012-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,,Procedure,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00954837
645,NCT00958113,Graves' Disease|Hashimoto's Disease,Autoimmune Thyroid Disease Genetic Study,Autoimmune Thyroid Disease Genetic Study,Graves' Disease|Hashimoto's Disease,2009-08-11,2013-02-28,2015-05-31,199.0,Case-Control,,Cross-Sectional,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",University of Colorado Denver,,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00958113
651,NCT00958451,Chronic Kidney Disease|Secondary Hyperparathyroidism,Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial,Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients,Chronic Kidney Disease|Secondary Hyperparathyroidism,2009-08-11,2011-01-31,2011-01-31,80.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Salem Veterans Affairs Medical Center,Abbott|Salem Veterans Affairs Medical Center,VA Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00958451
654,NCT00961701,Primary Hyperparathyroidism,Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Primary Hyperparathyroidism,Lipids Profile in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2009-08-18,2010-10-31,2016-10-31,100.0,Case-Only,,Cross-Sectional,Observational,Terminated,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel|University of Palermo|University of Zurich","Endocrine Institute , Haemek Medical Center",,Israel,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00961701
657,NCT00962221,Subclinical Hypothyroidism,Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Subclinical Hypothyroidism,Lipids Profile in Subclinical Hypothyroidism,Subclinical Hypothyroidism,2009-08-18,2011-10-31,2012-10-31,100.0,Case-Only,,Cross-Sectional,Observational,Terminated,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel|University of Palermo|University of Zurich","Endocrine Institute, Haemek Medical Center",Procedure,Israel,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00962221
658,NCT00970359,Thyroid Cancer,Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study,Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244,Thyroid Cancer,2009-09-01,2013-04-30,2013-04-30,24.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Memorial Sloan Kettering Cancer Center,"AstraZeneca|Genzyme, a Sanofi Company|Memorial Sloan Kettering Cancer Center",Memorial Sloan-Kettering Cancer Center,Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00970359
659,NCT00973336,Bone Metabolism|Primary Hyperparathyroidism,Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Successful Surgery in Patients Without Osteoporosis?,Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?,Bone Metabolism|Primary Hyperparathyroidism,2009-09-08,2017-09-30,2017-09-30,80.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2,Medical University of Vienna,Medical University of Vienna,Medical University of Vienna,Drug,Austria,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00973336
662,NCT00975000,Chronic Allograft Nephropathy|Chronic Kidney Disease|Chronic Renal Failure|Disordered Mineral Metabolism|End Stage Renal Disease|Hyperparathyroidism|Hypophosphatemia|Kidney Disease|Kidney Transplantation|Post Renal Transplantation,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism",Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients,Chronic Allograft Nephropathy|Chronic Kidney Disease|Chronic Renal Failure|Disordered Mineral Metabolism|End Stage Renal Disease|Hyperparathyroidism|Hypophosphatemia|Kidney Disease|Kidney Transplantation|Post Renal Transplantation,2009-09-10,2012-09-13,2013-04-16,114.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Austria|Belgium|Canada|France|Germany|Italy|Poland|Spain|Switzerland|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00975000
664,NCT00975221,"Hypercalcemia|Hyperparathyroidism, Primary",A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,"Hypercalcemia|Hyperparathyroidism, Primary",2009-09-10,2012-07-12,2012-12-21,67.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Canada|Hungary|Poland|Portugal|Russian Federation|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00975221
667,NCT00977080,Chronic Kidney Disease|Hemodialysis|Secondary Hyperparathyroidism,The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism,Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D,Chronic Kidney Disease|Hemodialysis|Secondary Hyperparathyroidism,2009-09-14,2011-05-31,2011-05-31,272.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Abbott,Abbott,Site Reference ID/Investigator# 22781|Site Reference ID/Investigator# 24342|Site Reference ID/Investigator# 21142|Site Reference ID/Investigator# 22762|Site Reference ID/Investigator# 22758|Site Reference ID/Investigator# 21442|Site Reference ID/Investigator# 23688|Site Reference ID/Investigator# 21370|Site Reference ID/Investigator# 25902|Site Reference ID/Investigator# 21146|Site Reference ID/Investigator# 26743|Site Reference ID/Investigator# 22788|Site Reference ID/Investigator# 22722|Site Reference ID/Investigator# 23147|Site Reference ID/Investigator# 22778|Site Reference ID/Investigator# 21369|Site Reference ID/Investigator# 22786|Site Reference ID/Investigator# 21144|Site Reference ID/Investigator# 21443|Site Reference ID/Investigator# 21145|Site Reference ID/Investigator# 22505|Site Reference ID/Investigator# 22759|Site Reference ID/Investigator# 22796|Site Reference ID/Investigator# 22770|Site Reference ID/Investigator# 22772|Site Reference ID/Investigator# 21147|Site Reference ID/Investigator# 22982|Site Reference ID/Investigator# 21143|Site Reference ID/Investigator# 22506|Site Reference ID/Investigator# 22776|Site Reference ID/Investigator# 22311|Site Reference ID/Investigator# 22310|Site Reference ID/Investigator# 21624|Site Reference ID/Investigator# 22363|Site Reference ID/Investigator# 23105|Site Reference ID/Investigator# 23909|Site Reference ID/Investigator# 22462|Site Reference ID/Investigator# 21748|Site Reference ID/Investigator# 33268|Site Reference ID/Investigator# 35903|Site Reference ID/Investigator# 21742|Site Reference ID/Investigator# 21744|Site Reference ID/Investigator# 21368|Site Reference ID/Investigator# 22362|Site Reference ID/Investigator# 38970|Site Reference ID/Investigator# 22322|Site Reference ID/Investigator# 22463|Site Reference ID/Investigator# 22323|Site Reference ID/Investigator# 39262|Site Reference ID/Investigator# 22312|Site Reference ID/Investigator# 21746|Site Reference ID/Investigator# 39180|Site Reference ID/Investigator# 22314|Site Reference ID/Investigator# 21367|Site Reference ID/Investigator# 21745|Site Reference ID/Investigator# 21842|Site Reference ID/Investigator# 22309|Site Reference ID/Investigator# 21843|Site Reference ID/Investigator# 38903|Site Reference ID/Investigator# 38531|Site Reference ID/Investigator# 22464|Site Reference ID/Investigator# 23910|Site Reference ID/Investigator# 24643|Site Reference ID/Investigator# 24642|Site Reference ID/Investigator# 21361|Site Reference ID/Investigator# 21364|Site Reference ID/Investigator# 22366|Site Reference ID/Investigator# 38343|Site Reference ID/Investigator# 21362|Site Reference ID/Investigator# 21363|Site Reference ID/Investigator# 22367|Site Reference ID/Investigator# 38462|Site Reference ID/Investigator# 21365|Site Reference ID/Investigator# 23913|Site Reference ID/Investigator# 23782|Site Reference ID/Investigator# 22364|Site Reference ID/Investigator# 23912|Site Reference ID/Investigator# 21747|Site Reference ID/Investigator# 23102|Site Reference ID/Investigator# 23104|Site Reference ID/Investigator# 23103|Site Reference ID/Investigator# 41982|Site Reference ID/Investigator# 40222,Drug|Drug,Czech Republic|Denmark|Germany|Greece|Italy|Netherlands|Portugal|Russian Federation|Spain|Sweden|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00977080
670,NCT00982722,Primary Hyperparathyroidism,Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism,Vitamin D Supplementation After Parathyroid Surgery,Primary Hyperparathyroidism,2009-09-22,2018-05-04,2018-05-04,150.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Karolinska University Hospital,Karolinska University Hospital,Karolinska UH|Karolinska University Hospital,Drug|Drug,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00982722
673,NCT00984191,Papillary Thyroid Cancer,99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study,Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid,Papillary Thyroid Cancer,2009-09-24,2011-10-31,2011-11-30,15.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Chulalongkorn University,Chulalongkorn University,King Chulalongkorn Hospital,Radiation,Thailand,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00984191
675,NCT00984282,Thyroid Neoplasms,A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Nexavar Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,2009-09-24,2012-08-31,2017-08-30,417.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Bayer,Amgen|Bayer,Asan Medical Center,Drug|Drug,"Austria|Belgium|Bulgaria|China|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Saudi Arabia|Spain|Sweden|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00984282
676,NCT00990704,Hemodialysis|Secondary Hyperparathyroidism,"Phase II, Open Study, Exploratory Examination of Efficacy and Safety of Paricalcitol Injection and Maxacalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism",Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism,Hemodialysis|Secondary Hyperparathyroidism,2009-10-05,2010-05-31,2010-05-31,47.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Abbott,Abbott,Site Ref # / Investigator 53794|Site Ref # / Investigator 53787|Site Ref # / Investigator 53786|Site Ref # / Investigator 53792|Site Ref # / Investigator 53784|Site Ref # / Investigator 53796|Site Ref # / Investigator 53795|Site Ref # / Investigator 21561|Site Ref # / Investigator 53789|Site Ref # / Investigator 53790|Site Ref # / Investigator 53793|Site Ref # / Investigator 53785|Site Ref # / Investigator 53788|Site Ref # / Investigator 53791,Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00990704
679,NCT00993837,Thyroid Carcinoma,Comparison of Effectiveness and Safety of Thyroidectomy for Thyroid Carcinoma in Patients Undergo Endoscopic Surgery and Those Receive Conversion,Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma,Thyroid Carcinoma,2009-09-29,2011-12-31,2012-06-30,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Second Military Medical University,Second Military Medical University,Changzheng Hospital,Procedure,China,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00993837
680,NCT00995163,"End Stage Renal Disease|Hyperparathyroidism, Secondary",Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D),Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease,"End Stage Renal Disease|Hyperparathyroidism, Secondary",2009-10-14,2011-01-31,2011-01-31,8020.0,Cohort,,Prospective,Observational,Completed,,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",,,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT00995163
683,NCT00999037,Secondary Hyperparathyroidism,FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease,FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease,Secondary Hyperparathyroidism,2009-10-20,2015-06-30,2015-06-30,18.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"University of California, Los Angeles","Loma Linda University|University of California, Los Angeles",UCLA,Drug|Other,United States,6.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT00999037
686,NCT01003652,Multinodular Goiter,Harmonic Focus Shears Versus Clamp-and-technique for Total Thyroidectomy,Clinical Trial on Harmonic Focus Shears,Multinodular Goiter,2009-10-27,2008-12-31,2008-12-31,68.0,Cohort,,Prospective,Observational,Completed,,Cliniques universitaires Saint-Luc- Universit Catholique de Louvain,Cliniques universitaires Saint-Luc- Universit Catholique de Louvain,Cliniques universitaires Saint-Luc- Universit Catholique de Louvain,Procedure,Belgium,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01003652
687,NCT01005654,Adrenal Neoplasm|Endocrine Tumors|Neuroblastoma|Parathyroid Neoplasms|Thyroid Neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Adrenal Neoplasm|Endocrine Tumors|Neuroblastoma|Parathyroid Neoplasms|Thyroid Neoplasms,2009-10-30,,,1900.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01005654
690,NCT01012414,Chronic Kidney Disease|Coronary Artery Disease|Hypovitaminosis D|Secondary Hyperparathyroidism,The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D,Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease,Chronic Kidney Disease|Coronary Artery Disease|Hypovitaminosis D|Secondary Hyperparathyroidism,2009-11-11,2011-05-31,2011-05-31,10.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,Thomas Jefferson University,Abbott|Thomas Jefferson University,Thomas Jefferson University,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01012414
693,NCT01013597,Thyroid Carcinoma,A Phase II Trial of LBH589 in Patients With Metastatic Medullary Thyroid Cancer and Radioactive Iodine Resistant Differentiated Thyroid Cancer,Trial of LBH589 in Metastatic Thyroid Cancer,Thyroid Carcinoma,2009-10-28,2013-08-31,2016-02-29,13.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"University of Wisconsin, Madison","Novartis Pharmaceuticals|University of Wisconsin, Madison",St. Vincent Regional Cancer Center CCOP|University of Wisconsin - Madison|Medical College of Wisconsin,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01013597
694,NCT01025128,Osteomalacia|Secondary Hyperparathyroidism|Vitamin D Deficiency,,Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density,Osteomalacia|Secondary Hyperparathyroidism|Vitamin D Deficiency,2009-12-01,2014-07-31,2014-07-31,210.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Clalit Health Services,Clalit Health Services,"Endocrinology Clinic, Clalit Health Services",Drug,Israel,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01025128
697,NCT01025453,Thyroid Cancer,Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer,Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer,Thyroid Cancer,2009-12-02,2018-01-16,2018-01-16,37.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|National Comprehensive Cancer Network|Pfizer,Memorial Sloan-Kettering at Basking Ridge|Memorial Sloan-Kettering Cancer Center @ Suffolk|Memorial Sloan Kettering Cancer Center|Memorial Sloan-Kettering at Mercy Medical Center|Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center,Drug,United States,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01025453
698,NCT01039714,Hypocalcemia|Hypoparathyroidism|Thyroidectomy|Vitamin D Deficiency,Preoperative Vitamin D Levels as a Prognostic Factor for Postoperative Hypocalcemia and Hypoparathyroidism After Total Thyroidectomy,Vitamin D Levels and Postoperative Hypocalcemia After Total Thyroidectomy,Hypocalcemia|Hypoparathyroidism|Thyroidectomy|Vitamin D Deficiency,2009-09-29,2010-04-30,2010-05-31,200.0,Cohort,,Prospective,Observational,Unknown status,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"AHEPA University Hospital Thessaloniki, Greece",,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01039714
700,NCT01039818,Graves Disease,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism,Graves Disease,2009-12-24,2011-08-31,2011-08-31,30.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,"Thyroid Unit, Endocrine Division, Hospital de Clnicas de Porto Alegre",Radiation|Radiation,Brazil,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01039818
703,NCT01042626,Hypercalcemia|Hyperparathyroidism,"Dissimilar PTH, Gastrin, and Ionized Calcium Response to Oral Peptones in Normocalcemic Primary Hyperparathyroidism, Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects",Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects,Hypercalcemia|Hyperparathyroidism,2010-01-04,2005-01-31,2005-01-31,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Eastern Piedmont,University of Eastern Piedmont|University of Milan,L. Sacco Hospital (Vialba),Other,Italy,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01042626
706,NCT01043107,Thyroid Cancer,Study on the Relationship Between The Computer Radiation and The Recrudesce Rate of Thyroid Cancer,Relationship Between Computer and Cancer,Thyroid Cancer,2010-01-05,,,2000.0,Cohort,,Retrospective,Observational,Unknown status,,Guangdong Provincial People's Hospital,Guangdong Provincial People's Hospital,Guangdong General Hospital,,China,10.0,60.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01043107
707,NCT01050465,Acne Vulgaris|Allergic Rhinitis|Anxiety|Asthma|Back Pain|Bursitis|Chronic Obstructive Pulmonary Disease|Coronary Artery Disease|Cough|Depression|Diabetes Mellitus|Diarrhea|Fibromyalgia|Gastroesophageal Reflux|Headache|HIV Infections|Hyperlipidemia|Hypertension|Hypothyroidism|Influenza|Irritable Bowel Syndrome|Menopause|Migraine Disorders|Obesity|Obstructive Sleep Apnea|Osteoarthritis|Prostatic Hyperplasia|Senile Osteoporosis|Shoulder Pain|Sinusitis|Sleep Initiation and Maintenance Disorders|Smoking Cessation|Tobacco Use Cessation|Urinary Incontinence|Urinary Tract Infection|Vaginitis|Vertigo,MedlinePlus Health Prescriptions: Developing a Real World Approach for Clinic Use,MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use,Acne Vulgaris|Allergic Rhinitis|Anxiety|Asthma|Back Pain|Bursitis|Chronic Obstructive Pulmonary Disease|Coronary Artery Disease|Cough|Depression|Diabetes Mellitus|Diarrhea|Fibromyalgia|Gastroesophageal Reflux|Headache|HIV Infections|Hyperlipidemia|Hypertension|Hypothyroidism|Influenza|Irritable Bowel Syndrome|Menopause|Migraine Disorders|Obesity|Obstructive Sleep Apnea|Osteoarthritis|Prostatic Hyperplasia|Senile Osteoporosis|Shoulder Pain|Sinusitis|Sleep Initiation and Maintenance Disorders|Smoking Cessation|Tobacco Use Cessation|Urinary Incontinence|Urinary Tract Infection|Vaginitis|Vertigo,2010-01-13,2010-10-31,2010-12-31,907.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Missouri-Columbia,National Library of Medicine (NLM)|University of Missouri-Columbia,,Other,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01050465
708,NCT01056419,Graves' Ophthalmopathy,,The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy,Graves' Ophthalmopathy,2010-01-25,2010-06-30,2010-08-31,40.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ankara University,Ankara University,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department",Procedure|Drug,Turkey,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01056419
712,NCT01057732,Primary Hyperparathyroidism,The Effect of Parathyroidectomy on Cardiovascular Risk Factors in Patients With Primary Hyperparathyroidism,Effects of Parathyroidectomy on Cardiovascular Risk Factors in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2010-01-25,2006-06-30,2006-12-31,76.0,Case-Control,,Prospective,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel","Endocrine Institute, Haemek Medical Center",,Israel,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01057732
715,NCT01060982,Primary Parathyroid Adenomas,"Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU)Treatment Procedure: A Monocentre, Open, Uncontrolled Study",Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure,Primary Parathyroid Adenomas,2010-02-01,2013-01-31,2013-01-31,5.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,Hpital Priv des Peupliers|Cochin Hospital,Device,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01060982
717,NCT01073462,Cardiac Morbidity|Chronic Kidney Disease Stage V|Secondary Hyperparathyroidism,Postmarketing Observational Study to Evaluate the Effect of Zemplar (Paricalcitol IV) on Cardiac Morbidity in Patients With Chronic Kidney Disease Stage 5 Over 2 Years.,Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years,Cardiac Morbidity|Chronic Kidney Disease Stage V|Secondary Hyperparathyroidism,2010-02-20,2013-06-30,2013-06-30,67.0,Cohort,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Assign Data Management and Biostatistics GmbH",Site Reference ID/Investigator# 27447|Site Reference ID/Investigator# 49182|Site Reference ID/Investigator# 27483|Site Reference ID/Investigator# 52742|Site Reference ID/Investigator# 27487|Site Reference ID/Investigator# 36983|Site Reference ID/Investigator# 27484|Site Reference ID/Investigator# 27485|Site Reference ID/Investigator# 27446|Site Reference ID/Investigator# 53469|Site Reference ID/Investigator# 27482|Site Reference ID/Investigator# 10981,,Austria,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01073462
720,NCT01074684,Thyroid Cancer,"Defining Predictive Factors of Clinical, Laboratory and Imaging Criteria Routinely Used in the Diagnosis of Thyroid Cancer: Observational, Prospective Multicentered Study","Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer",Thyroid Cancer,2010-02-23,2021-12-31,2022-12-31,959.0,Cohort,,Prospective,Observational,Active not recruiting,,"National Cancer Institute, Naples","National Cancer Institute, Naples",Universit di Cagliari|Azienda Ospedaliera Unviersitaria Careggi - Firenze|ASL TO/4 Ospedale di Ivrea|Istituto Nazionale dei Tumori|Azienda Ospedaliera Universitaria di Padova|Universit Cattolica del Sacro Cuore di Roma Policlinico Gemelli|Ospedale di Taormina|Universit degli studi di Perugia - Sede di Terni,,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01074684
721,NCT01081665,Chronic Kidney Failure|Secondary Hyperparathyroidism,"A Two-year, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Haemodialysis, Receiving Zemplar for Prevention and Treatment of Secondary Hyperparathyroidism",Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism,Chronic Kidney Failure|Secondary Hyperparathyroidism,2010-02-27,2011-02-28,2011-02-28,237.0,,,Prospective,Observational,Completed,,Abbott,Abbott,Site Reference ID/Investigator# 32055|Site Reference ID/Investigator# 32050|Site Reference ID/Investigator# 32051|Site Reference ID/Investigator# 32049|Site Reference ID/Investigator# 5283|Site Reference ID/Investigator# 32056|Site Reference ID/Investigator# 32057|Site Reference ID/Investigator# 32058|Site Reference ID/Investigator# 32077|Site Reference ID/Investigator# 32076|Site Reference ID/Investigator# 32059|Site Reference ID/Investigator# 32053|Site Reference ID/Investigator# 32060|Site Reference ID/Investigator# 32061|Site Reference ID/Investigator# 32062|Site Reference ID/Investigator# 32048|Site Reference ID/Investigator# 32054|Site Reference ID/Investigator# 32063|Site Reference ID/Investigator# 32075,,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01081665
724,NCT01083186,Chronic Kidney Failure|Secondary Hyperparathyroidism,Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience,Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience,Chronic Kidney Failure|Secondary Hyperparathyroidism,2010-02-20,2012-01-31,2012-01-31,500.0,,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 47002|Site Reference ID/Investigator# 43772|Site Reference ID/Investigator# 27492|Site Reference ID/Investigator# 43769|Site Reference ID/Investigator# 38257|Site Reference ID/Investigator# 47003|Site Reference ID/Investigator# 27497|Site Reference ID/Investigator# 47004|Site Reference ID/Investigator# 27489|Site Reference ID/Investigator# 27495|Site Reference ID/Investigator# 43773|Site Reference ID/Investigator# 27498|Site Reference ID/Investigator# 38259|Site Reference ID/Investigator# 22121|Site Reference ID/Investigator# 43771|Site Reference ID/Investigator# 43767|Site Reference ID/Investigator# 27496|Site Reference ID/Investigator# 43768|Site Reference ID/Investigator# 27491|Site Reference ID/Investigator# 27494|Site Reference ID/Investigator# 27493|Site Reference ID/Investigator# 38255|Site Reference ID/Investigator# 43770|Site Reference ID/Investigator# 39839,,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01083186
727,NCT01083550,Thyroid Cancer,Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial),Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer,Thyroid Cancer,2010-02-24,2016-11-30,2016-11-30,74.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"University Health Network, Toronto","Canadian Institutes of Health Research (CIHR)|Ontario Ministry of Health and Long Term Care|University Health Network, Toronto",University Health Network,Other,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01083550
729,NCT01083849,Kidney Insufficiency|Secondary Hyperparathyroidism,Long-Term Therapy Outcomes When Treating CKD-patients With Paricalcitol in German Clinical Practice (TOP Study),Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice,Kidney Insufficiency|Secondary Hyperparathyroidism,2010-02-25,2013-12-31,2013-12-31,761.0,Cohort,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 64522|Site Reference ID/Investigator# 53506|Site Reference ID/Investigator# 53524|Site Reference ID/Investigator# 74733|Site Reference ID/Investigator# 64523|Site Reference ID/Investigator# 53525|Site Reference ID/Investigator# 53526|Site Reference ID/Investigator# 69662|Site Reference ID/Investigator# 53508|Site Reference ID/Investigator# 53523|Site Reference ID/Investigator# 53507|Site Reference ID/Investigator# 28352|Site Reference ID/Investigator# 28359|Site Reference ID/Investigator# 28305|Site Reference ID/Investigator# 28306|Site Reference ID/Investigator# 28003|Site Reference ID/Investigator# 81613|Site Reference ID/Investigator# 28017|Site Reference ID/Investigator# 28301|Site Reference ID/Investigator# 28296|Site Reference ID/Investigator# 28021|Site Reference ID/Investigator# 28024|Site Reference ID/Investigator# 28303|Site Reference ID/Investigator# 54050|Site Reference ID/Investigator# 28022|Site Reference ID/Investigator# 30862|Site Reference ID/Investigator# 28007|Site Reference ID/Investigator# 28304|Site Reference ID/Investigator# 28014|Site Reference ID/Investigator# 28023|Site Reference ID/Investigator# 28134|Site Reference ID/Investigator# 28037|Site Reference ID/Investigator# 43903|Site Reference ID/Investigator# 99777|Site Reference ID/Investigator# 28284|Site Reference ID/Investigator# 124118|Site Reference ID/Investigator# 54054|Site Reference ID/Investigator# 48864|Site Reference ID/Investigator# 72343|Site Reference ID/Investigator# 28029|Site Reference ID/Investigator# 28287|Site Reference ID/Investigator# 28276|Site Reference ID/Investigator# 28351|Site Reference ID/Investigator# 28280|Site Reference ID/Investigator# 48865|Site Reference ID/Investigator# 28300|Site Reference ID/Investigator# 28011|Site Reference ID/Investigator# 124119|Site Reference ID/Investigator# 28019|Site Reference ID/Investigator# 28135|Site Reference ID/Investigator# 28286|Site Reference ID/Investigator# 28353|Site Reference ID/Investigator# 28044|Site Reference ID/Investigator# 48863|Site Reference ID/Investigator# 28013|Site Reference ID/Investigator# 28025|Site Reference ID/Investigator# 28290|Site Reference ID/Investigator# 10982|Site Reference ID/Investigator# 28291|Site Reference ID/Investigator# 28036|Site Reference ID/Investigator# 28302|Site Reference ID/Investigator# 54051|Site Reference ID/Investigator# 28278|Site Reference ID/Investigator# 99778|Site Reference ID/Investigator# 99776|Site Reference ID/Investigator# 124120|Site Reference ID/Investigator# 28275|Site Reference ID/Investigator# 43904|Site Reference ID/Investigator# 28277|Site Reference ID/Investigator# 28297|Site Reference ID/Investigator# 28307|Site Reference ID/Investigator# 28295|Site Reference ID/Investigator# 28294|Site Reference ID/Investigator# 48862|Site Reference ID/Investigator# 28042|Site Reference ID/Investigator# 28282|Site Reference ID/Investigator# 28033|Site Reference ID/Investigator# 54052|Site Reference ID/Investigator# 28005|Site Reference ID/Investigator# 28020|Site Reference ID/Investigator# 28293|Site Reference ID/Investigator# 28018|Site Reference ID/Investigator# 28298|Site Reference ID/Investigator# 28292|Site Reference ID/Investigator# 48882|Site Reference ID/Investigator# 28299|Site Reference ID/Investigator# 28279,,Austria|Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01083849
732,NCT01084356,Parathyroid Adenoma|Thyroid Adenoma,Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination,Evaluation of a New CZT System,Parathyroid Adenoma|Thyroid Adenoma,2010-03-09,2011-03-31,,100.0,Cohort,,Prospective,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,"Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center",,Israel,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01084356
735,NCT01087619,Primary Hyperparathyroidism,Primary Hyperparathyroidism in Patients Older Than 65 Years: A Prospective Randomized Trial of Surgical Treatment Compared With Follow-up,Surgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up,Primary Hyperparathyroidism,2010-03-15,2023-12-31,2025-12-31,115.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Region Skane,Region Skane,"Skne University Hospital, Department of Surgery, Lund",Procedure,Sweden,66.0,120.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01087619
738,NCT01089335,Thyroid Cancer|Thyroid Neoplasms,Sentinel Node Investigation in Patients With Highly Differentiated Papillary Thyroid Carcinoma and in Patients With Thyroid Neoplasia of Unclear Malignant Potential,Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia,Thyroid Cancer|Thyroid Neoplasms,2010-03-16,2018-12-31,2018-12-31,100.0,Cohort,,Prospective,Observational,Completed,,Region Skane,Region Skane,"Department of Surgery and Department of Imaging, Skne University Hospital",Procedure,Sweden,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01089335
740,NCT01095341,Hyperthyroidism,Postoperative Hyperthyroidism After Parathyroidectomy,Postoperative Hyperthyroidism,Hyperthyroidism,2010-03-29,2009-04-30,2009-04-30,57.0,Case-Control,,Prospective,Observational,Completed,,Heidelberg University,Heidelberg University,University Hospital Heidelberg,Other,Germany,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01095341
741,NCT01100619,Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Renal Cell Carcinoma,A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors,A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors,Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Renal Cell Carcinoma,2010-03-22,2012-08-31,,40.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Exelixis,Exelixis,City of Hope Comprehensive Cancer Center|Dana Farber Cancer Institute|Montefiore Medical Center|Hospital of the University of Pennsylvania|The University of Texas M.D. Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01100619
744,NCT01100723,Chronic Kidney Disease|Secondary Hyperparathyroidism,Trial to Optimize Mineral Outcomes in End Stage Renal Disease (ESRD) Patients,Trial to Optimize Mineral Outcomes in Dialysis Patients,Chronic Kidney Disease|Secondary Hyperparathyroidism,2010-04-07,2011-08-31,2011-08-31,92.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University of Colorado, Denver","University of Colorado, Denver","Lynchburg Nephrology Associates, P.L.L.C.",Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01100723
747,NCT01101113,Secondary Hyperparathyroidism,Phase 4 Study of Cinacalcet Efficacy in Combination With Vitamin D for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients,Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level,Secondary Hyperparathyroidism,2010-04-04,2012-03-31,2012-06-30,66.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Seoul National University Hospital,Jeil-Kirin Pharmaceutical Inc.|Seoul National University Hospital,Seoul National University Hospital|Kyungpook National University|Gil Hospital|Hallym University Sacred Hospital|Seoul National University Bundang Hospital|Eulji University|Samsung Medical Center,Drug|Drug,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01101113
750,NCT01102127,Nodular Goiter|Thyroid Cancer,Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease.,Elastography in Thyroid Nodules,Nodular Goiter|Thyroid Cancer,2010-04-12,2010-09-30,2010-09-30,128.0,Case-Control,,Cross-Sectional,Observational,Completed,,Castilla-Len Health Service,Castilla-Len Health Service,Complejo Asistencial de Len,Device,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01102127
754,NCT01102205,Hashimoto Disease,Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease,Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease,Hashimoto Disease,2010-04-09,2010-04-30,2010-10-31,130.0,Cohort,,Prospective,Observational,Completed,,Vakif Gureba Training and Research Hospital,Vakif Gureba Training and Research Hospital,Vakif Gureba Training and Research Hospital,,Turkey,18.0,95.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01102205
757,NCT01103206,Parathyroid Hormone Suppression Test With Cinacalcet,Evaluation of a Parathyroid Hormone Suppression Test With Cinacalcet. Comparison: 1- With the Results of the Intravenous Calcium Suppression Test in Healthy Controls; 2- Between Healthy Controls and Patients With Primary Hyperparathyroidism.,Evaluation of a Cincalcet Suppression Test,Parathyroid Hormone Suppression Test With Cinacalcet,2010-04-12,2013-02-28,2013-02-28,36.0,,Crossover Assignment,,Interventional,Completed,Phase 4,"University Hospital, Rouen","Institut National de la Sant Et de la Recherche Mdicale, France|University Hospital, Rouen",University hospital,Drug|Drug|Drug,France,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01103206
759,NCT01103557,Lymphatic Metastasis|Thyroid Neoplasm,The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis,Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma,Lymphatic Metastasis|Thyroid Neoplasm,2010-04-12,,,62.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Pusan National University Hospital,Pusan National University Hospital,,Procedure,,20.0,76.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01103557
761,NCT01105923,Asthma|Attention Deficit Disorder With Hyperactivity|Breast Cancer|Congestive Heart Failure|COPD|Coronary Artery Disease|Diabetes|Glaucoma|Hemophilia|Hypertension|Hyperthyroidism|Hypothyroidism|Myasthenia Gravis|Osteopenia|Osteoporosis|Renal Failure|Renal Insufficiency|Sickle Cell Disease|Stroke,Making Accurate Problem Lists in the EHR,Study of an Intervention to Improve Problem List Accuracy and Use,Asthma|Attention Deficit Disorder With Hyperactivity|Breast Cancer|Congestive Heart Failure|COPD|Coronary Artery Disease|Diabetes|Glaucoma|Hemophilia|Hypertension|Hyperthyroidism|Hypothyroidism|Myasthenia Gravis|Osteopenia|Osteoporosis|Renal Failure|Renal Insufficiency|Sickle Cell Disease|Stroke,2010-04-15,2010-11-30,2017-11-30,140.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01105923
763,NCT01106443,Indeterminate Thyroid Nodules,Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial,Central Compartment Neck Dissection With Thyroidectomy,Indeterminate Thyroid Nodules,2010-04-14,2013-07-31,2016-10-31,128.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,University of Alberta,University of Alberta,University of Alberta|Dalhouise University,Procedure|Procedure|Procedure|Procedure,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01106443
765,NCT01109420,Non-Medullary Thyroid Cancer,Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer,Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer,Non-Medullary Thyroid Cancer,2010-04-22,,,300.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01109420
767,NCT01114503,Graves Ophthalmopathy,"A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy",A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease,Graves Ophthalmopathy,2010-04-29,2012-08-29,2012-08-29,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug|Drug|Drug|Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01114503
771,NCT01115543,End Stage Renal Disease|Secondary Hyperparathyroidism,A Randomized Trial Comparing Pulse Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients,Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism,End Stage Renal Disease|Secondary Hyperparathyroidism,2010-05-01,2009-08-31,2009-08-31,32.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Mahidol University,Mahidol University,Siriraj Medical School,Drug,Thailand,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01115543
774,NCT01118065,Head and Neck Cancer,"A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma","Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer",Head and Neck Cancer,2010-05-05,2012-05-31,,42.0,,,,Interventional,Unknown status,Phase 2,National Cancer Institute (NCI),Leiden University Medical Center,Leiden University Medical Center,Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01118065
775,NCT01126060,Thyroid Carcinoma|Thyroidectomy,Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections,Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain,Thyroid Carcinoma|Thyroidectomy,2010-04-15,2011-01-31,2011-01-31,78.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung Medical Center,Drug|Procedure,"Korea, Republic of",20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01126060
776,NCT01127503,Psychosis|Velo-cardio-facial Syndrome,"A Double-Blind, Placebo-Controlled, Multi-Center, Randomized Trial of the Safety and Efficacy of Metyrosine (Demser) for the Treatment of Psychotic Disorders in Patients With Velo-Cardio-Facial Syndrome",Metyrosine (Demser) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome,Psychosis|Velo-cardio-facial Syndrome,2010-05-19,2010-11-30,2011-09-30,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",VCFS International Center,Drug|Drug,United States,16.0,65.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01127503
778,NCT01129492,Autoimmune Thyroiditis,"Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis: Randomized, Placebo Controlled Clinical Trial",Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis,Autoimmune Thyroiditis,2010-05-14,2009-03-31,2009-03-31,43.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Sao Paulo General Hospital,Conselho Nacional de Desenvolvimento Cientfico e Tecnolgico|Coordenao de Aperfeioamento de Pessoal de Nvel Superior.|Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Device,Brazil,20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01129492
781,NCT01134315,End-Stage Renal Disease|Secondary Hyperparathyroidism,"A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice",Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice,End-Stage Renal Disease|Secondary Hyperparathyroidism,2010-05-28,2012-05-31,2012-05-31,61.0,Cohort,,Prospective,Observational,Terminated,,AbbVie,"AbbVie (prior sponsor, Abbott)|North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)",Site Reference ID/Investigator# 37082|Site Reference ID/Investigator# 26762|Site Reference ID/Investigator# 28529|Site Reference ID/Investigator# 26748|Site Reference ID/Investigator# 37582|Site Reference ID/Investigator# 39973|Site Reference ID/Investigator# 26769|Site Reference ID/Investigator# 26768|Site Reference ID/Investigator# 26747|Site Reference ID/Investigator# 26749|Site Reference ID/Investigator# 26751|Site Reference ID/Investigator# 26765|Site Reference ID/Investigator# 28528|Site Reference ID/Investigator# 26763|Site Reference ID/Investigator# 28526|Site Reference ID/Investigator# 26758|Site Reference ID/Investigator# 40382|Site Reference ID/Investigator# 26759,Drug|Drug,United States,0.0,16.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01134315
784,NCT01134549,"Hyperparathyroidism, Secondary","A Double-Blind, Randomized, Placebo-Controlled, Rising Single Intravenous Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers","Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers","Hyperparathyroidism, Secondary",2010-05-28,2010-07-31,2010-07-31,32.0,,Parallel Assignment,,Interventional,Completed,Phase 1,KAI Pharmaceuticals,KAI Pharmaceuticals|Nucleus Network Ltd,,Drug|Drug,Australia,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01134549
787,NCT01134562,"Hyperparathyroidism, Secondary","A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism","Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism","Hyperparathyroidism, Secondary",2010-05-28,2011-04-02,2011-04-02,28.0,,Sequential Assignment,,Interventional,Completed,Phase 1,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug|Drug,Australia|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01134562
790,NCT01137097,Thyroid Neoplasm,Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study,Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC,Thyroid Neoplasm,2010-06-02,2011-01-31,2011-01-31,278.0,,Single Group Assignment,,Interventional,Completed,Phase 2/Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung Medical Center,Procedure,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01137097
791,NCT01138475,Gastric Bypass|Parathyroid Hormone,"A Prospective, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Pilot Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery",Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,2010-06-04,2015-08-31,2015-08-31,49.0,,Parallel Assignment,,Interventional,Completed,Phase 3,William Beaumont Hospitals,"Abbott|Kerstyn C. Zalesin, M.D.",William Beaumont Health Center,Drug|Drug|Drug,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01138475
794,NCT01141309,Thyroid Cancer,Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer,Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer,Thyroid Cancer,2010-06-09,2022-06-30,2022-06-30,41.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Cancer Center|Memorial Sloan Kettering Cancer Center @ Suffolk|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01141309
795,NCT01143987,Arterial Stiffness|Hyperparathyroidism,Effect of Cinacalcet Treatment on Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism,Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism,Arterial Stiffness|Hyperparathyroidism,2010-06-10,2013-02-28,2013-02-28,44.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Chinese University of Hong Kong,Chinese University of Hong Kong,"Prince of Wales Hospital, Chinese University of Hong Kong",Drug,Hong Kong,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01143987
798,NCT01145040,Hyperthyroidism|Hypothyroidism,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation. A Correlation Study,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation,Hyperthyroidism|Hypothyroidism,2010-06-14,2018-07-31,2021-01-31,138.0,Cohort,,Cross-Sectional,Observational,Active not recruiting,,Ruhr University of Bochum,Ruhr University of Bochum,"Klinikum Ludwigsburg-Bietigheim|Institute for diagnostical radiology, interventional radiology and nuclear medicine, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medical Hospital I, Bergmannsheil University Hospitals, Ruhr University of Bochum",,Germany,14.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01145040
800,NCT01149291,End Stage Renal Disease|Secondary Hyperparathyroidism,"A 18 Months, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving sVDRA's for Prevention and Treatment of Secondary Hyperparathyroidism","A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism",End Stage Renal Disease|Secondary Hyperparathyroidism,2010-06-22,2014-12-31,2014-12-31,511.0,Case-Only,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 37822|Site Reference ID/Investigator# 68286|Site Reference ID/Investigator# 40677|Site Reference ID/Investigator# 85153|Site Reference ID/Investigator# 40672|Site Reference ID/Investigator# 40674|Site Reference ID/Investigator# 40678|Site Reference ID/Investigator# 40686|Site Reference ID/Investigator# 61585|Site Reference ID/Investigator# 63764|Site Reference ID/Investigator# 63765|Site Reference ID/Investigator# 63766|Site Reference ID/Investigator# 69973|Site Reference ID/Investigator# 63763|Site Reference ID/Investigator# 48127|Site Reference ID/Investigator# 64444|Site Reference ID/Investigator# 40684|Site Reference ID/Investigator# 48132|Site Reference ID/Investigator# 68283|Site Reference ID/Investigator# 68281|Site Reference ID/Investigator# 68282|Site Reference ID/Investigator# 69974,,Turkey,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01149291
803,NCT01150318,Thyroid Neoplasms,Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma,Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients,Thyroid Neoplasms,2010-04-29,2010-06-30,2010-06-30,48.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,"Saint Antoine Hospital, Endocrinology Unit",Drug,France,18.0,55.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01150318
804,NCT01153360,Non-thyroidal Illness Syndrome,Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery,Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery,Non-thyroidal Illness Syndrome,2010-06-29,2011-08-31,2011-09-30,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01153360
805,NCT01153945,Thyroid Cancer,Association Between Cancer Cells and Normal Vs. Low Levels of Thyroid Hormones in the Serum,Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum,Thyroid Cancer,2010-06-29,2011-07-31,2011-07-31,0.0,,,,Observational,Withdrawn,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01153945
806,NCT01163565,Grave's Disease|Multinodular Goitre|Thyroid Nodule,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,96.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01163565
811,NCT01163669,Hyperparathyroidism,A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients,A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients,Hyperparathyroidism,2010-07-14,2012-11-30,2012-11-30,15.0,Cohort,,Prospective,Observational,Completed,,The Cleveland Clinic,Amgen|The Cleveland Clinic,Cleveland Clinic,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01163669
813,NCT01164176,Head and Neck Cancer,An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer,Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer,Head and Neck Cancer,2010-07-15,2014-10-31,2014-10-31,40.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Yonsei University,Yonsei University,Hallym University Sacred Heart Hospital|Yeungnam University Medical Center|National Cancer Center - Korea|Kosin Medical Center Gospel Hospital|Seoul National University Hospital|Yonsei Cancer Center at Yonsei University Medical Center|Gangnam Severance Hospital,Drug|Other,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01164176
814,NCT01167309,Secondary Hyperparathyroidism,"LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease","LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients",Secondary Hyperparathyroidism,2010-07-02,2011-10-31,2011-12-31,72.0,,Single Group Assignment,,Interventional,Completed,Phase 1,LEO Pharma,LEO Pharma,CRS Clinical Research Services Kiel GmbH|Centralny Szpital Kliniczny MON,Drug,Germany|Poland,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01167309
817,NCT01171690,Hypoparathyroidism Post-surgical,Pilot Study of Teriparatide for Postsurgical Hypoparathyroidism,Teriparatide for Postsurgical Hypoparathyroidism,Hypoparathyroidism Post-surgical,2010-07-27,2013-12-31,2013-12-31,5.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Mayo Clinic,Mayo Clinic,Mayo Clinic,Drug,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01171690
819,NCT01173289,Thyroid Cancer,A Phase II Study of External Beam Radiotherapy for Locoregionally Advanced or Recurrent Differentiated Thyroid Carcinoma,Study of External Beam Radiotherapy to Thyroid Carcinoma,Thyroid Cancer,2010-07-22,2015-08-31,2015-08-31,62.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"National Cancer Center, Korea","National Cancer Center, Korea","National Cancer Center, Korea",Radiation,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01173289
820,NCT01178450,Secondary Hyperparathyroidism,"A Prospective, Randomized Trial to Compare Subtotal Parathyroidectomy Versus Cinacalcet in the Treatment of Persistent Secondary Hyperparathyroidism Post Renal Transplantation",Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation,Secondary Hyperparathyroidism,2010-04-19,2014-09-30,2014-09-30,30.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Hospital Universitari de Bellvitge,Josep M Cruzado,Hospital Universitari de Bellvitge|Hospital Clinic de Barcelona,Procedure|Drug,Spain,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01178450
823,NCT01181531,"Hyperparathyroidism, Secondary","A Multicenter, Randomized, Open Label Study to Compare the Efficacy of Cinacalcet Versus Traditional Vitamin D Therapy for Management of Secondary Hyperparathyroidism Among Subjects Undergoing Hemodialysis",Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis,"Hyperparathyroidism, Secondary",2010-08-12,2012-07-17,2012-08-14,312.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01181531
826,NCT01182285,Thyroid Neoplasm,A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin,A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin,Thyroid Neoplasm,2010-08-13,2015-09-28,2016-04-28,13.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01182285
827,NCT01182584,Graves' Disease,Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy,Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease,Graves' Disease,2010-08-12,2011-10-31,2011-12-31,200.0,Cohort,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University,,Taiwan,16.0,60.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01182584
830,NCT01191762,Chronic Kidney Disease|Hyperparathyroidism,The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Chronic Kidney Disease|Hyperparathyroidism,2010-08-27,2012-08-31,2013-04-30,30.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Phelps, Kenneth R., M.D.","Genzyme, a Sanofi Company|Kenneth R. Phelps, M.D.",Stratton Veterans Affairs Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01191762
833,NCT01197183,Hypothyroidism,Survey for the Initial Treatment of Hypothyroidism in France,"Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in France",Hypothyroidism,2010-08-18,2009-05-31,2009-09-30,1285.0,Cohort,,Prospective,Observational,Completed,,"Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",Merck Lipha Sant Laboratories,,France,35.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01197183
834,NCT01199614,Hypoparathyroidism,"HEXT: The Hypoparathyroidism Studies, EXTended: The Effect of PTH on the Skeleton in Hypoparathyroidism",HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism,Hypoparathyroidism,2010-09-09,2020-12-31,2020-12-31,75.0,,Single Group Assignment,,Interventional,Unknown status,Phase 3,Columbia University,John P. Bilezikian|NPS Pharma|Shire,Columbia University Medical Center,Drug,United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01199614
836,NCT01204359,Exophthalmos|Hypothyroidism,"""5010 Clinical Research Programme""of Sun Yat-sen University",The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions,Exophthalmos|Hypothyroidism,2010-09-15,2016-07-31,2016-12-31,627.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Sun Yat-sen University,Sun Yat-sen University,Sun Yat-sen Memorial Hospital|Ningyi Jiang,Radiation,China,8.0,90.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01204359
837,NCT01208051,Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Follicular Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Papillary Carcinoma|Unresectable Thyroid Gland Carcinoma,Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer,Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer,Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Follicular Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Papillary Carcinoma|Unresectable Thyroid Gland Carcinoma,2010-09-22,2020-02-01,2020-02-01,127.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|USC / Norris Comprehensive Cancer Center|University of California Davis Comprehensive Cancer Center P2C|University of California Davis Comprehensive Cancer Center|City of Hope South Pasadena|University of Colorado Hospital|Moffitt Cancer Center|Northwestern University|University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|UC Comprehensive Cancer Center at Silver Cross|Illinois CancerCare-Peoria|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Indiana University/Melvin and Bren Simon Cancer Center|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Wayne State University/Karmanos Cancer Institute|Minnesota Oncology Hematology PA-Minneapolis|Metro Minnesota Community Oncology Research Consortium|Washington University School of Medicine|Mercy Hospital Saint Louis|Rutgers Cancer Institute of New Jersey|UNC Lineberger Comprehensive Cancer Center|Penn State Children's Hospital|Fox Chase Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center|University of Wisconsin Hospital and Clinics|Tom Baker Cancer Centre|London Regional Cancer Program|University Health Network-Princess Margaret Hospital,Drug|Drug|Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01208051
840,NCT01219855,Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,"A Randomized, Double Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of CTAP101 Capsules in Subjects With Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism",Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,2010-10-11,2011-11-30,2011-11-30,78.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"OPKO Health, Inc.","OPKO Health, Inc.","OPKO Health, Inc",Drug|Drug|Drug|Drug|Drug,United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01219855
843,NCT01220050,Renal Transplant|Secondary Hyperparathyroidism,"A PROSPECTIVE, PILOT, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF PARICALCITOL IN REDUCING PARATHYROID HORMONE LEVELS AND AMELIORATING MARKERS OF BONE REMODELLING IN RENAL TRANSPLANT RECIPIENTS WITH SECONDARY HYPERPARATHYROIDISM",Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism,Renal Transplant|Secondary Hyperparathyroidism,2010-10-11,2012-07-31,2013-02-28,43.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Mario Negri Institute for Pharmacological Research,Mario Negri Institute for Pharmacological Research,Mario Negri Institute - Clinical Research Center for Rare Diseases,Drug|Drug,Italy,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01220050
846,NCT01221896,Hyperparathyroidism,,Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma,Hyperparathyroidism,2010-10-14,2014-01-31,,100.0,Cohort,,Prospective,Observational,Unknown status,,Hadassah Medical Organization,Hadassah Medical Organization,Hadassah Hebrew University Medical Center,Procedure,Israel,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01221896
848,NCT01222026,Osteopenia|Osteoporosis|Primary Hyperparathyroidism,Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I,Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate,Osteopenia|Osteoporosis|Primary Hyperparathyroidism,2010-10-15,2014-12-31,2014-12-31,63.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Medical University of Vienna,Medical University of Vienna|National Bank of Austria,"Medical University Vienna, General Hospital Vienna (AKH Wien)",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01222026
851,NCT01223638,Congenital Hypothyroidism|Hearing Loss,,The Prevalence of Hearing Loss Among Children With Congenital Hypothyroidism,Congenital Hypothyroidism|Hearing Loss,2010-10-03,2012-12-31,2015-06-30,0.0,Case-Control,,Prospective,Observational,Withdrawn,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",Ha'Emek Medical Center,Other,Israel,2.0,30.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01223638
853,NCT01224782,Chronic Kidney Disease|Secondary Hyperparathyroidism,"Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) Stage 3 or 4 in the Conditions of Routine Clinical Practice. A Multi-country, Multi-center Post Marketing Observational Study in Routine Clinical Use in Eastern European Countries.",Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism,2010-09-27,2013-08-31,2013-08-31,994.0,,,,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 66544|Site Reference ID/Investigator# 47685|Site Reference ID/Investigator# 66546|Site Reference ID/Investigator# 47683|Site Reference ID/Investigator# 66543|Site Reference ID/Investigator# 47684|Site Reference ID/Investigator# 66542|Site Reference ID/Investigator# 66545|Site Reference ID/Investigator# 47687|Site Reference ID/Investigator# 43449|Site Reference ID/Investigator# 46744|Site Reference ID/Investigator# 73353|Site Reference ID/Investigator# 47690|Site Reference ID/Investigator# 46742|Site Reference ID/Investigator# 49542|Site Reference ID/Investigator# 67442|Site Reference ID/Investigator# 67443|Site Reference ID/Investigator# 51003|Site Reference ID/Investigator# 51004|Site Reference ID/Investigator# 43522|Site Reference ID/Investigator# 43523|Site Reference ID/Investigator# 43524|Site Reference ID/Investigator# 45483|Site Reference ID/Investigator# 43453|Site Reference ID/Investigator# 46743|Site Reference ID/Investigator# 51008|Site Reference ID/Investigator# 47842|Site Reference ID/Investigator# 68462|Site Reference ID/Investigator# 51009|Site Reference ID/Investigator# 51005|Site Reference ID/Investigator# 51011|Site Reference ID/Investigator# 48210|Site Reference ID/Investigator# 45487|Site Reference ID/Investigator# 51012|Site Reference ID/Investigator# 51002|Site Reference ID/Investigator# 43448|Site Reference ID/Investigator# 45485|Site Reference ID/Investigator# 42992|Site Reference ID/Investigator# 42879|Site Reference ID/Investigator# 42880|Site Reference ID/Investigator# 42881|Site Reference ID/Investigator# 42882|Site Reference ID/Investigator# 42883|Site Reference ID/Investigator# 42963|Site Reference ID/Investigator# 42970|Site Reference ID/Investigator# 42877|Site Reference ID/Investigator# 42878|Site Reference ID/Investigator# 42973|Site Reference ID/Investigator# 42975|Site Reference ID/Investigator# 42976|Site Reference ID/Investigator# 42981|Site Reference ID/Investigator# 42982|Site Reference ID/Investigator# 42980|Site Reference ID/Investigator# 63623|Site Reference ID/Investigator# 43009|Site Reference ID/Investigator# 43002|Site Reference ID/Investigator# 43003|Site Reference ID/Investigator# 43006|Site Reference ID/Investigator# 42991|Site Reference ID/Investigator# 42988|Site Reference ID/Investigator# 42989|Site Reference ID/Investigator# 42999|Site Reference ID/Investigator# 43000|Site Reference ID/Investigator# 42979|Site Reference ID/Investigator# 42984|Site Reference ID/Investigator# 42985|Site Reference ID/Investigator# 42987|Site Reference ID/Investigator# 42994|Site Reference ID/Investigator# 42995,,Bulgaria|Czech Republic|Romania,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01224782
856,NCT01225016,Thyroid Nodules,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Thyroid Nodules,2010-10-14,2011-12-31,2011-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,University of Alabama at Birmingham,University of Alabama at Birmingham,Universith of Alabama at Birmingham,Drug,United States,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01225016
858,NCT01226810,Hypercalcemia|Hyperparathyroidism,A Novel Approach to Ultrafast Parathyroid SPECT Imaging Using a Solid State CZT SPECT Camera,The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration,Hypercalcemia|Hyperparathyroidism,2010-10-21,,,50.0,Case-Only,,Cross-Sectional,Observational,Unknown status,,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Healthcare Campus,,Israel,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01226810
860,NCT01226914,Goiter|Thyroid Neoplasm,"A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL Fibrin Sealant in Thyroidectomy",A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL Fibrin Sealant in Thyroidectomy,Goiter|Thyroid Neoplasm,2010-10-21,2014-07-31,2014-07-31,55.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Medical University of South Carolina,"Ethicon, Inc.|Medical University of South Carolina",,Drug,,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01226914
861,NCT01227499,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease,Differential Diagnosis of STA-PSV in Thyrotoxicosis,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,2010-10-22,2011-11-30,2011-11-30,169.0,Cohort,,Prospective,Observational,Completed,,Huashan Hospital,Fudan University|xiaolong zhao|Zhongda Hospital,Xiaolong Zhao,,China,15.0,85.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01227499
866,NCT01228786,Primary Hyperparathyroidism (PHPT),Transcriptional and Translational Regulation of Vitamin D Receptor (VDR) and Calcium Sensing Receptor (CaSR) in Patients With Sporadic Primary Hyperparathyroidism,"Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism",Primary Hyperparathyroidism (PHPT),2010-10-26,2012-12-31,2013-06-30,50.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,Postgraduate Institute of Medical Education and Research,Postgraduate Institute of Medical Education and Research,PGIMER,,India,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01228786
869,NCT01229865,Differential Thyroid Cancer,,Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer,Differential Thyroid Cancer,2010-10-26,2014-10-31,2016-06-30,29.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Vascular Biogenics Ltd. operating as VBL Therapeutics,Vascular Biogenics Ltd. operating as VBL Therapeutics,Mayo Clinic|Massachusetts General Hospital|Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01229865
870,NCT01236547,Thyroid Gland Anaplastic Carcinoma,"A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer",Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Anaplastic Carcinoma,2010-11-05,2020-03-09,,123.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI)|NRG Oncology,University of Alabama at Birmingham Cancer Center|The Kirklin Clinic at Acton Road|Cancer Center at Saint Joseph's|Saint Joseph's Hospital and Medical Center|Arizona Oncology-Deer Valley Center|Arizona Oncology Services Foundation|Sutter Cancer Centers Radiation Oncology Services-Auburn|Alta Bates Summit Medical Center-Herrick Campus|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Medical Center Sacramento|California Pacific Medical Center-Pacific Campus|UCSF Medical Center-Mount Zion|UCSF Medical Center-Parnassus|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Sutter Solano Medical Center/Cancer Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Moffitt Cancer Center|Emory University Hospital Midtown|Emory University Hospital/Winship Cancer Institute|Radiation Oncology Associates PC|Parkview Hospital Randallia|University of Kansas Cancer Center|The James Graham Brown Cancer Center at University of Louisville|Mary Bird Perkins Cancer Center|Touro Infirmary|Greater Baltimore Medical Center|Sinai Hospital of Baltimore|Boston Medical Center|Henry Ford Cancer Institute-Downriver|Henry Ford Macomb Hospital-Clinton Township|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|West Michigan Cancer Center|Henry Ford Medical Center-Columbus|Henry Ford West Bloomfield Hospital|Fairview Ridges Hospital|Mercy Hospital|Fairview Southdale Hospital|Unity Hospital|Minnesota Oncology Hematology PA-Maplewood|Abbott-Northwestern Hospital|Hennepin County Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Metro Minnesota Community Oncology Research Consortium|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Ridgeview Medical Center|Rice Memorial Hospital|University of Mississippi Medical Center|Billings Clinic Cancer Center|Memorial Sloan Kettering Basking Ridge|New York-Presbyterian/Brooklyn Methodist Hospital|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Sleepy Hollow|Memorial Sloan Kettering Nassau|UNC Lineberger Comprehensive Cancer Center|Summa Health System - Akron Campus|Summa Health System - Barberton Campus|University of Cincinnati Cancer Center-UC Medical Center|Case Western Reserve University|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mercy Cancer Center-Elyria|Summa Health Medina Medical Center|UH Seidman Cancer Center at Lake Health Mentor Campus|UH Seidman Cancer Center at Southwest General Hospital|University Hospitals Parma Medical Center|UH Seidman Cancer Center at Firelands Regional Medical Center|University of Cincinnati Cancer Center-West Chester|University of Oklahoma Health Sciences Center|UPMC-Heritage Valley Health System Beaver|UPMC Cancer Centers - Arnold Palmer Pavilion|Penn State Milton S Hershey Medical Center|UPMC-Johnstown/John P. Murtha Regional Cancer Center|UPMC Cancer Center at UPMC McKeesport|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Cancer Center-Natrona Heights|UPMC Jameson|Thomas Jefferson University Hospital|UPMC-Presbyterian Hospital|UPMC-Saint Margaret|UPMC-Shadyside Hospital|UPMC Jefferson Regional Radiation Oncology|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|UPMC Cancer Center at UPMC Northwest|UPMC Uniontown Hospital Radiation Oncology|UPMC Washington Hospital Radiation Oncology|Prisma Health Cancer Institute - Spartanburg|Prisma Health Cancer Institute - Faris|Prisma Health Cancer Institute - Eastside|Prisma Health Cancer Institute - Greer|Prisma Health Cancer Institute - Seneca|Parkland Memorial Hospital|UT Southwestern/Simmons Cancer Center-Dallas|M D Anderson Cancer Center|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|LDS Hospital|Sentara Cancer Institute at Sentara CarePlex Hospital|Sentara Norfolk General Hospital|Sentara Virginia Beach General Hospital|Green Bay Oncology at Saint Vincent Hospital|Saint Vincent Hospital Cancer Center Green Bay|Green Bay Oncology Limited at Saint Mary's Hospital|Saint Vincent Hospital Cancer Center at Saint Mary's|University of Wisconsin Carbone Cancer Center|Holy Family Memorial Hospital|Bay Area Medical Center|Medical College of Wisconsin,Radiation|Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01236547
872,NCT01240590,Anaplastic Thyroid Cancer|Solid Tumor,A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),Anaplastic Thyroid Cancer|Solid Tumor,2010-11-11,2015-08-31,2016-12-31,27.0,,Parallel Assignment,,Interventional,Completed,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01240590
874,NCT01254565,Secondary Hyperparathyroidism,"A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism","Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism",Secondary Hyperparathyroidism,2010-12-03,2011-07-31,2011-08-24,87.0,,Sequential Assignment,,Interventional,Completed,Phase 2,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01254565
877,NCT01263951,Differentiated Thyroid Cancer,A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone,Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone,Differentiated Thyroid Cancer,2010-11-29,2021-02-01,2022-05-31,35.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Thomas Jefferson University,Bayer|Novartis Pharmaceuticals|Thomas Jefferson University,Hospital of the University of Pennsylvania,Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01263951
878,NCT01265381,Thyroid Cancer,Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study,Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study,Thyroid Cancer,2010-12-22,2020-02-26,2020-02-26,673.0,Case-Control,,Retrospective,Observational,Terminated,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Research Center for Radiation Medicine,,Ukraine,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01265381
879,NCT01265992,Chronic Kidney Disease|Secondary Hyperparathyroidism,Post Marketing Observational Study to Assess Patient Management Practices and Quality of Life With the Capsules Form of Paricalcitol in the Treatment of SHPT in Stage 3 - 5 Chronic Kidney Disease Patients Not Yet on Dialysis Under Conditions of Usual Clinical Care (CAPITOL),Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis,Chronic Kidney Disease|Secondary Hyperparathyroidism,2010-11-29,2012-11-30,2012-11-30,50.0,,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Pharma Consulting Group AB",Site Reference ID/Investigator# 47723|Site Reference ID/Investigator# 41084|Site Reference ID/Investigator# 45190|Site Reference ID/Investigator# 41085|Site Reference ID/Investigator# 41087|Site Reference ID/Investigator# 45188|Site Reference ID/Investigator# 41088|Site Reference ID/Investigator# 57782|Site Reference ID/Investigator# 41089|Site Reference ID/Investigator# 45191,,Sweden,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01265992
882,NCT01268098,Hypoparathyroidism,"A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 g and 50 g for the Treatment of Adults With Hypoparathyroidism",Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY),Hypoparathyroidism,2010-12-28,2011-09-23,2011-11-11,42.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Takeda,Shire,Advance Medical Research LLC|University of Chicago Medical Center|Indiana University School of Medicine|Massachusetts General Hospital|Michigan Bone & Mineral Clinic PC|Mayo Clinic Rochester|Columbia University Medical Center|University Physicians Group|Physician East PA|University of Cincinnati Bone Health and Osteoporosis Center|Cetero Research DGD Research Inc.|The Vancouver Clinic,Drug,United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01268098
884,NCT01269749,Graves' Disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Graves' Disease,2010-10-29,2016-06-30,2016-06-30,19.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Florida,Baylor College of Medicine|University of Florida,University of Florida|Texas Childrens Hospital,Radiation|Drug,United States,0.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01269749
887,NCT01270321,Thyroid Cancer,A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer,Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer,Thyroid Cancer,2011-01-04,2019-02-28,2019-02-28,42.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Emory University,Emory University|Novartis,Emory University Hospital Midtown|Emory University Winship Cancer Institute|University of Pittsburgh Cancer Institute,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01270321
888,NCT01270425,Hashimoto Thyroiditis|Systemic Sclerosis|Thyroid Nodules,Sonographic Characterization of the Thyroid Gland in Patients With Systemic Sclerosis With and Without Hashimoto Thyroiditis,Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis,Hashimoto Thyroiditis|Systemic Sclerosis|Thyroid Nodules,2011-01-04,2011-12-31,2012-11-30,60.0,Cohort,,Prospective,Observational,Completed,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01270425
893,NCT01272414,Graves Ophthalmopathy,,Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction,Graves Ophthalmopathy,2011-01-06,2012-01-31,2012-02-29,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,University of Toronto,Allergan|University of Toronto,Mount Sinai Hospital,Drug|Drug,Canada,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01272414
897,NCT01273597,"Kidney Failure, Chronic",Post-marketing Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Paricalcitol i.v. in the Treatment of Chronic Kidney Disease (CKD) 5 Stage Patients With (Severe) Secondary Hyperparathyroidism in Hungary,Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands,"Kidney Failure, Chronic",2010-11-22,2011-11-30,2011-11-30,60.0,Cohort,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Planimeter Ltd",Site Reference ID/Investigator# 46593|Site Reference ID/Investigator# 46585|Site Reference ID/Investigator# 46594|Site Reference ID/Investigator# 47722|Site Reference ID/Investigator# 46592|Site Reference ID/Investigator# 58644|Site Reference ID/Investigator# 46595|Site Reference ID/Investigator# 46588|Site Reference ID/Investigator# 46597|Site Reference ID/Investigator# 46590|Site Reference ID/Investigator# 46591,,Hungary,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01273597
899,NCT01273714,Goiter,Subtotal Versus Total Thyroidectomy for Benign Thyroid Disease - a Prospective Case-control Surgical Outcome Study.,Subtotal Versus Total Thyroidectomy for Benign Goiter,Goiter,2011-01-07,2004-12-31,2009-12-31,8006.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian Univerity, Medical College, 3rd Department of general Surgery",Procedure,Poland,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01273714
900,NCT01277510,"Chronic Kidney Disease|Hyperparathyroidism|Hyperparathyroidism, Secondary|Kidney Disease|Secondary Hyperparathyroidism","A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis",Pediatric Chronic Kidney Disease Safety and Efficacy,"Chronic Kidney Disease|Hyperparathyroidism|Hyperparathyroidism, Secondary|Kidney Disease|Secondary Hyperparathyroidism",2011-01-13,2014-04-30,,43.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug|Drug,Australia|Belgium|Germany|Hungary|Mexico|Poland|Russian Federation|Slovakia|Spain|United States,6.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01277510
903,NCT01280214,Thyroid Disease,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,30.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01280214
907,NCT01280292,Central Hypothyroidism,"Central Hypothyroidism,a New Laboratory Approach for Hormone Measurement","Central Hypothyroidism, a Novel Laboratory Measurement",Central Hypothyroidism,2011-01-19,2013-02-28,2013-07-31,50.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Sheba Medical Center,Sheba Medical Center,,Drug,,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01280292
908,NCT01286753,Neoplasms,"An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine",A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation,Neoplasms,2011-01-28,2014-11-30,2015-05-31,51.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,,Drug,France|Italy|Netherlands|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01286753
910,NCT01290029,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Secondary Hyperparathyroidism","An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis",Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Secondary Hyperparathyroidism",2011-01-20,2015-09-23,2015-09-23,14.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Germany|United Kingdom|United States,0.0,2190.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01290029
913,NCT01291498,Parathyroid Adenomas,High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma,High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma,Parathyroid Adenomas,2011-02-07,2013-06-30,2013-06-30,1.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Oxford University Hospitals NHS Trust,Oxford University Hospitals NHS Trust|Theraclion,John Radcliffe Hospital,Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01291498
915,NCT01292044,Thyroid Neoplasms|Thyroid Nodule,The Role of Elastography in the Diagnosis of Thyroid Nodules,The Role of Elastography in the Diagnosis of Thyroid Nodules,Thyroid Neoplasms|Thyroid Nodule,2011-02-08,2014-08-31,2014-08-31,188.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01292044
917,NCT01295333,Graves Disease (Basedow's Disease),"Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyrodism on Quality of Life, Efficiency and Tolerance","Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyrodism on Quality of Life, Efficiency and Tolerance",Graves Disease (Basedow's Disease),2011-01-27,2014-11-30,2014-12-31,200.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux de Marseille,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01295333
920,NCT01297309,Hypoparathyroidism,"A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)","A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)",Hypoparathyroidism,2011-02-11,2018-06-08,2018-06-08,51.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Takeda,Shire,Advance Medical Research LLC|Mayo Clinic Jacksonville|University of Chicago Medical Center|Indiana University School of Medicine|Massachusetts General Hospital|Michigan Bone & Mineral Clinic PC|Mayo Clinic Rochester|Columbia University Medical Center|University Physicians Group|Physician East PA|University of Cincinnati Bone Health and Osteoporosis Center|Children's Hospital of Philadelphia|Cetero Research DGD Research Inc.|The Vancouver Clinic,Drug,United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01297309
922,NCT01297699,Graves Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,"Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.",Tocilizumab Treatment in Graves Ophthalmopathy (Graves Orbitopathy or Thyroid Eye Disease),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,2011-02-16,2015-10-31,2015-12-31,32.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital Clinico Universitario de Santiago,Fundacin Ramn Domnguez|Hospital Clinico Universitario de Santiago,Hospital Clnico de Santiago|Hospital Santa Creu i Sant Pau|Hospital Clnico San Carlos|Hospital Universitario Ramn y Cajal|Centro Oftalmolgico Moreiras|Hospital Universitario Virgen del Roco|Hospital Universitario Virgen Macarena|Hospital Universitario La Fe|Hospital Clnico Universitario Lozano Blesa,Drug|Drug,Spain,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01297699
926,NCT01298323,Locally Advanced or Metastatic Medullary Thyroid Cancer|Medullary Thyroid Cancer,"A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib",Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment,Locally Advanced or Metastatic Medullary Thyroid Cancer|Medullary Thyroid Cancer,2011-02-16,2013-04-30,2022-12-31,205.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Sanofi,"Genzyme, a Sanofi Company",Investigational Site Number 301|Investigational Site Number 401|Investigational Site Number 501|Investigational Site Number 701|Investigational Site Number 702|Investigational Site Number 901|Investigational Site Number 1001|Investigational Site Number 1002|Investigational Site Number 1003|Investigational Site Number 1301|Investigational Site Number 1302|Investigational Site Number 1901|Investigational Site Number 2001|Investigational Site Number 2201|Investigational Site Number 2602|Investigational Site Number 2603|Investigational Site Number 2601|Investigational Site Number 3001|Investigational Site Number 3501|Investigational Site Number 3502|Investigational Site Number 4001|Investigational Site Number 4104|Investigational Site Number 4101|Investigational Site Number 4102|Investigational Site Number 6001|Investigational Site Number 5702|Investigational Site Number 5703|Investigational Site Number 6201|Investigational Site Number 6204|Investigational Site Number 6202|Investigational Site Number 6203|Investigational Site Number 7201|Investigational Site Number 2802|Investigational Site Number 2801,Behavioral|Drug,"Australia|Austria|Belgium|Brazil|Bulgaria|Canada|China|Czechia|Denmark|Finland|Germany|Greece|India|Israel|Italy|Korea, Republic of|Poland|Russian Federation|Sweden|United Kingdom",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01298323
927,NCT01306656,Primary Hyperparathyroidism|Vitamin D Deficiency,Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism,Vitamin D Repletion in Primary Hyperparathyroidism,Primary Hyperparathyroidism|Vitamin D Deficiency,2011-02-10,2017-02-28,2017-02-28,9.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University Medical Center,Drug|Other|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01306656
930,NCT01306916,Hyperthyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Hyperthyroidism,2011-01-12,2010-12-31,2012-07-31,30.0,Cohort,,Prospective,Observational,Completed,,Walter Reed Army Medical Center,Walter Reed Army Medical Center,Walter Reed Army Medical Center,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01306916
933,NCT01307761,Thyroid Cancer,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,Thyroid Cancer,2011-02-21,2012-12-31,2013-08-31,500.0,,,Retrospective,Observational,Unknown status,,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,,Taiwan,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01307761
935,NCT01308320,Thyroid Neoplasm,Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia,Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia,Thyroid Neoplasm,2011-03-03,2010-07-31,2010-07-31,42.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,59.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01308320
936,NCT01311089,Papillary Thyroid Carcinoma,A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction,A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy,Papillary Thyroid Carcinoma,2011-03-08,2011-09-30,2011-09-30,169.0,,,Prospective,Observational,Completed,,Yonsei University,Yonsei University,Severance Hospital,,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01311089
938,NCT01320813,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,5.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHU de Nmes - Hpital Universitaire Carmeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01320813
944,NCT01321554,Thyroid Cancer,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)",Thyroid Cancer,2011-03-10,2013-11-15,2019-03-19,392.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Eisai Inc.,Eisai Inc.,Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 4|Facility 5|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Eisai Trial Site 1|Eisai Trial Site 2|Eisai Trial Site 1|Eisai Trial Site 1|Eisai Trial Site 1|Eisai Trial Site 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 2|Facility 3|Facility 4|Facility 5|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 1|Facility 2|Facility 1|Facility 1,Drug|Drug|Drug,"Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Czechia|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Thailand|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01321554
945,NCT01322165,"Bicuspid Aortic Valve With Coarctation|Bicuspid Aortic Valve With Family History|Bicuspid Aortic Valve Without Known Family History|Ehlers-Danlos Syndrome|Familial Thoracic Aortic Aneurysm and Dissections|FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation|Loeys-Dietz Syndrome|Marfan Syndrome|Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo|Other Congenital Heart Disease|Shprintzen-Goldberg Syndrome|Turner Syndrome",National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions,National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions,"Bicuspid Aortic Valve With Coarctation|Bicuspid Aortic Valve With Family History|Bicuspid Aortic Valve Without Known Family History|Ehlers-Danlos Syndrome|Familial Thoracic Aortic Aneurysm and Dissections|FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation|Loeys-Dietz Syndrome|Marfan Syndrome|Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo|Other Congenital Heart Disease|Shprintzen-Goldberg Syndrome|Turner Syndrome",2011-03-22,2015-09-30,2016-09-30,3706.0,Cohort,,Prospective,Observational,Completed,,"National Heart, Lung, and Blood Institute (NHLBI)","National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",Queens Medical Center|Johns Hopkins University|The New York Presbyterian Hospital-Weill Cornell Medical Center|Oregon Health & Science University|University of Pennsylvania School of Medicine|Baylor College of Medicine|University of Texas Medical School at Houston,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01322165
947,NCT01325857,Thyroid Cancer,Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach,Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach,Thyroid Cancer,2011-03-28,2012-02-29,2012-02-29,97.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,Severance Hospital,Procedure|Procedure|Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01325857
948,NCT01329666,Hypercalcemia|Osteopenia|Osteoporosis|Primary Hyperparathyroidism|Vitamin D Deficiency,Early Effect of Vitamin D in Primary Hyperparathyroidism,Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D,Hypercalcemia|Osteopenia|Osteoporosis|Primary Hyperparathyroidism|Vitamin D Deficiency,2011-04-04,2015-01-31,2015-01-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University Medical Center,Dietary Supplement|Dietary Supplement,United States,45.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01329666
951,NCT01333267,"Bone Diseases, Endocrine|Hypercalcemia of Malignancy|Hyperparathyroidism|Osteoporosis",Comparison of Skeletal and Mineral Metabolism Responses in Healthy African-Americans and Caucasians Using a Continuous Seven-Day Parathyroid Hormone (PTH) or Parathyroid Hormone-related Protein (PTHrP) Infusion,One Week Comparison Study of PTH and PTHrP Infusions,"Bone Diseases, Endocrine|Hypercalcemia of Malignancy|Hyperparathyroidism|Osteoporosis",2011-04-08,2017-07-31,2017-07-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 1,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh Medical Center,Drug|Drug|Drug,United States,24.0,35.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01333267
953,NCT01335802,"Abortion, Spontaneous|Pregnancy Complications|Subclinical Hypothyroidism",Relation Between Thyroid Hormone Stimulated Mitochondrial Function and Spontaneous Abortion and Complications of Pregnancy in Subclinical Hypothyroidism,Relation Between Subclinical Hypothyroidism and Outcome of Pregnancy,"Abortion, Spontaneous|Pregnancy Complications|Subclinical Hypothyroidism",2011-04-11,2015-09-30,2016-12-31,113.0,Case-Control,,Prospective,Observational,Completed,,Naestved Hospital,Naestved Hospital|University of Copenhagen,Naestved Hospital,Genetic,Denmark,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01335802
954,NCT01335828,Thyroid Nodules,"""ShearWave"" Elastography Interest in the Management of Thyroid Nodules",Elastography Interest in the Management of Thyroid Nodules,Thyroid Nodules,2010-11-10,2012-10-31,2012-11-30,125.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"University Hospital, Grenoble",AdministrateurCIC,Clinical Investigation Center - Technological Innovation - Inserm 803 - University Hospital France,Device,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01335828
956,NCT01338597,Thyroid Tumor,Clinical Benefits of Reduced Subcutaneous Dissection in Endoscopic Thyroidectomy,Impact of Dissection Area on the Clinical Outcome of Endoscopic Thyroidectomy,Thyroid Tumor,2011-04-11,2011-12-31,2012-06-30,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Second Military Medical University,Second Military Medical University,"Department of General Surgery, Changzheng Hospital",Procedure,China,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01338597
957,NCT01341782,Hemodialysis|Secondary Hyperparathyroidism,Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism,Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism,Hemodialysis|Secondary Hyperparathyroidism,2011-04-25,2012-04-30,2012-04-30,255.0,,Parallel Assignment,,Interventional,Completed,Phase 3,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 53485|Site Reference ID/Investigator# 51571|Site Reference ID/Investigator# 52963|Site Reference ID/Investigator# 52966|Site Reference ID/Investigator# 51578|Site Reference ID/Investigator# 52965|Site Reference ID/Investigator# 53782|Site Reference ID/Investigator# 57483|Site Reference ID/Investigator# 57487|Site Reference ID/Investigator# 53484|Site Reference ID/Investigator# 54385|Site Reference ID/Investigator# 51581|Site Reference ID/Investigator# 59164|Site Reference ID/Investigator# 51574|Site Reference ID/Investigator# 51575|Site Reference ID/Investigator# 52751|Site Reference ID/Investigator# 62025|Site Reference ID/Investigator# 54384|Site Reference ID/Investigator# 52745|Site Reference ID/Investigator# 51569|Site Reference ID/Investigator# 52964|Site Reference ID/Investigator# 53483|Site Reference ID/Investigator# 51582|Site Reference ID/Investigator# 54388|Site Reference ID/Investigator# 51576|Site Reference ID/Investigator# 51577|Site Reference ID/Investigator# 51580|Site Reference ID/Investigator# 52747|Site Reference ID/Investigator# 52748|Site Reference ID/Investigator# 52750|Site Reference ID/Investigator# 51570|Site Reference ID/Investigator# 54387|Site Reference ID/Investigator# 52746|Site Reference ID/Investigator# 51579|Site Reference ID/Investigator# 62024|Site Reference ID/Investigator# 51572|Site Reference ID/Investigator# 52752|Site Reference ID/Investigator# 53482|Site Reference ID/Investigator# 59162|Site Reference ID/Investigator# 59966|Site Reference ID/Investigator# 53783|Site Reference ID/Investigator# 54383|Site Reference ID/Investigator# 52749|Site Reference ID/Investigator# 52962|Site Reference ID/Investigator# 59163,Drug|Drug|Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01341782
960,NCT01341886,Malignant Neoplasm of Thyroid Stage I|Malignant Neoplasm of Thyroid Stage II,,Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer,Malignant Neoplasm of Thyroid Stage I|Malignant Neoplasm of Thyroid Stage II,2011-04-18,2011-04-30,2011-04-30,51.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug,"Iran, Islamic Republic of",0.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01341886
961,NCT01349634,Cretinism|Goiter|Iodine Deficiency,A Study to Measure the Effect of Switching the Salt Supply From Non-iodized to Iodized on Cognitive Development in Ethiopia,The Effects of Iodized Salt on Cognitive Development in Ethiopia,Cretinism|Goiter|Iodine Deficiency,2011-04-20,2014-05-31,2014-05-31,5704.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,McGill University,Ethiopian Health and Nutrition Research Institute|McGill University|Micronutrient Initiative,McGill University,Other,Canada,5.0,61.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01349634
964,NCT01354639,Papillary Thyroid Carcinoma,Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy,Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy,Papillary Thyroid Carcinoma,2011-05-13,2011-10-31,2011-10-31,150.0,Case-Only,,Prospective,Observational,Completed,,Yonsei University,Yonsei University,Severance Hospital,,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01354639
966,NCT01358136,Goiter|Hypothyroidism|Weight Gain,ThyrOp: Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter - Focus on Weight Gain and Mitochondrial Dysfunction,ThyrOp: A Study of Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter,Goiter|Hypothyroidism|Weight Gain,2011-05-18,2012-08-31,2013-12-31,30.0,Cohort,,Prospective,Observational,Unknown status,,Naestved Hospital,"Denmark:Department of Otorhinolaryngology Slagelse Hospital, Hospital South|Naestved Hospital|Region Zealand","Slagelse Hospital, Hospital South",,Denmark,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01358136
968,NCT01368042,Chronic Kidney Disease|Secondary Hyperparathyroidism,Quality of Life in Greek Hemodialysis Patients Receiving Zemplar i.v (QualitiZe),Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous,Chronic Kidney Disease|Secondary Hyperparathyroidism,2011-06-06,2013-06-30,2013-06-30,265.0,,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 56803|Site Reference ID/Investigator# 53424|Site Reference ID/Investigator# 53425|Site Reference ID/Investigator# 56805|Site Reference ID/Investigator# 56802|Site Reference ID/Investigator# 66291|Site Reference ID/Investigator# 56809|Site Reference ID/Investigator# 50442|Site Reference ID/Investigator# 77554|Site Reference ID/Investigator# 77553|Site Reference ID/Investigator# 53422,,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01368042
971,NCT01369953,Coffin - Sins Syndrome|Coronary Artery Disease|Dubouitz Syndrome|Familial Isolated Hyperparathyroidism|Proteus Syndrome,Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants,Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants,Coffin - Sins Syndrome|Coronary Artery Disease|Dubouitz Syndrome|Familial Isolated Hyperparathyroidism|Proteus Syndrome,2011-06-08,,2014-01-31,30.0,,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Human Genome Research Institute (NHGRI),"National Human Genome Research Institute (NHGRI), 9000 Rockville Pike",,United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01369953
973,NCT01373736,Carcinoid Tumors|Medullary Thyroid Carcinoma|Neuroblastoma|Paraganglioma|Pheochromocytoma,,123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors,Carcinoid Tumors|Medullary Thyroid Carcinoma|Neuroblastoma|Paraganglioma|Pheochromocytoma,2011-06-13,,,,,,,Interventional,Unknown status,Phase 3,Vancouver Coastal Health,Vancouver Coastal Health,Vancouver Coastal Health,Drug,Canada,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01373736
974,NCT01374659,Recurrence|Thyroid Cancer,Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for Localizing Recurrence in Patients With Differentiated Thyroid Carcinoma Who Have Elevated Serum Thyroglobulin Levels But Are Tumor-negative on Conventional Imaging Studies,Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma,Recurrence|Thyroid Cancer,2011-06-15,2011-06-30,2012-08-31,50.0,,,Prospective,Observational,Unknown status,,Korean Association of Endocrine Surgeons,Korean Association of Endocrine Surgeons,Jandee Lee,,"Korea, Republic of",15.0,85.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01374659
975,NCT01376648,Hyperthyroidism,Study on the Relationship Between the Thyroid Hormones and the Activity of Brown Adipose Tissue in Human,Thyroid Hormones Effect on Brown Adipose Tissue,Hyperthyroidism,2011-06-17,2012-05-31,2012-05-31,20.0,,,Prospective,Observational,Unknown status,,Huashan Hospital,Huashan Hospital,Huashan Hospital,,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01376648
976,NCT01379170,Diabetes|Hypothyroidism,"Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus",Thyroid Study Type 2 Diabetes Mellitus (T2DM),Diabetes|Hypothyroidism,2011-06-21,2014-12-31,2014-12-31,17.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,Maastricht University Medical Center,Maastricht University Medical Center,Maastricht University Medical Centre,Drug,Netherlands,40.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01379170
977,NCT01379196,Graves Ophthalmopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Graves Ophthalmopathy,2011-05-11,2014-11-30,2014-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1/Phase 2,Rabin Medical Center,Rabin Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01379196
981,NCT01382212,End-Stage Renal Disease|Secondary Hyperparathyroidism,"A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis",A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis,End-Stage Renal Disease|Secondary Hyperparathyroidism,2011-06-24,2015-04-30,2015-04-30,13.0,,Single Group Assignment,,Interventional,Completed,Phase 3,AbbVie,"AbbVie (prior sponsor, Abbott)",,Drug,,10.0,16.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01382212
984,NCT01382966,Chronic Kidney Disease|Left Ventricular Hypertrophy|Renal Osteodystrophy,"The Association of Serum Sclerostin Levels,Echocardiographic Parameters, Arteriovenous Fistula Thrombosis and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients","Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients",Chronic Kidney Disease|Left Ventricular Hypertrophy|Renal Osteodystrophy,2011-06-21,2011-09-30,2011-10-31,400.0,,,Cross-Sectional,Observational,Unknown status,,RFM Renal Treatment Services,RFM Renal Treatment Services,Rfm Renal Tedavi Merkezi,,Turkey,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01382966
987,NCT01384786,Hyperthyreosis and Goiter|Thyroid Cancer,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,Hyperthyreosis and Goiter|Thyroid Cancer,2011-06-28,,2005-07-31,4474.0,Cohort,,Retrospective,Observational,Completed,,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,herlev Hospital,,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01384786
990,NCT01392222,Papillary Microcarcinoma|Thyroid Cancer,Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others,Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others,Papillary Microcarcinoma|Thyroid Cancer,2011-06-29,2017-06-30,2017-06-30,21.0,Family-Based,,Prospective,Observational,Completed,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Behavioral|Behavioral,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01392222
991,NCT01395134,"Goiter,|Thyroid,",Randomized Controlled Trial of Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.,Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.,"Goiter,|Thyroid,",2011-07-13,2010-06-30,2010-12-31,210.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Device,Poland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01395134
992,NCT01396733,Cancer|Thyroid,Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake,Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer,Cancer|Thyroid,2011-07-18,2012-12-31,2013-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,Asan Medical Center,Asan Medical Center,Asan Medical Center,Drug,"Korea, Republic of",20.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01396733
993,NCT01398085,Thyroid Cancer,Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients,IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients,Thyroid Cancer,2011-07-06,2023-03-31,2031-03-31,504.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2/Phase 3,"University College, London","Cancer Research UK|University College, London",University Hospitals Birmingham NHS Foundation Trust|Brighton and Sussex University Hospitals NHS Trust|University Hospital Bristol NHS Foundation Trust|Cambridge University Hospitals NHS Foundation Trust|East Kent Hospitals University NHS Foundation Trust|Mid Essex Hospitals Services NHS Trust|Gloucestershire Hospitals NHS Trust|Royal Derby hospital NHS foundation trust|NHS Lothian|Royal Devon and Exeter NHS Trust|Glasgow and Clyde NHS Trust|The Royal Surrey County Hospital NHS Foundation Trust|Ipswich Hospital NHS Trust|Leeds Teaching Hospitals NHS Trust|University Hospitals of Leicester NHS Trust|Royal Marsden NHS Foundation Trust|Imperial College Healthcare NHS Trust|Barts Health NHS Trust|Guys and St Thomas' NHS Foundation Trust|University College London Hospitals NHS Foundation Trust|Maidstone and Tunbridge Wells NHS Trust|The Christie NHS Foundation Trust|South Tees Hospitals NHS Trust|Velindre NHS Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust|Norfolk and Norwich University Hospitals NHS Trust|Nottingham University Hospitals NHS Trust|Portsmouth Hospitals NHS Trust|Sheffield Teaching Hospitals NHS Foundation Trust|Southend University Hospitals NHS Trust|East and North Herts|Royal Wolverhampton NHS Trust,Radiation,United Kingdom,16.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01398085
994,NCT01398774,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1A,Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study,Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1A,2011-07-19,2015-09-30,2017-11-20,519.0,Cohort,,Cross-Sectional,Observational,Terminated,,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,,United States,5.0,45.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01398774
996,NCT01401478,Secondary Hyperparathyroidism,"Prospective, Open-label, Multicenter Effectiveness and Safety Observational Study of Zemplar in Patients With Stage 5 Chronic Kidney Disease and Hyperparathyroidism on Hemodialysis in the Russian Federation",Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation,Secondary Hyperparathyroidism,2011-07-22,2013-01-31,2013-01-31,86.0,,,Prospective,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Almedis",Site Reference ID/Investigator# 57348|Site Reference ID/Investigator# 57347|Site Reference ID/Investigator# 58347|Site Reference ID/Investigator# 67404|Site Reference ID/Investigator# 57344|Site Reference ID/Investigator# 57346|Site Reference ID/Investigator# 58356|Site Reference ID/Investigator# 58348|Site Reference ID/Investigator# 57342|Site Reference ID/Investigator# 57364|Site Reference ID/Investigator# 69687|Site Reference ID/Investigator# 57363|Site Reference ID/Investigator# 69688,,Russian Federation,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01401478
999,NCT01403324,Metastases|Thyroid Cancer,Comparison of Dosimetry Following Preparation With Either rhTSH or After Withdrawal of Thyroid Hormone Suppression Therapy in Patients With Metastatic or Locally Advanced Differentiated Thyroid Cancer,Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer,Metastases|Thyroid Cancer,2011-07-26,2016-06-30,2016-06-30,4.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01403324
1000,NCT01408368,Goiter|Thyroid,Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease.,Subtotal Versus Total Thyroidectomy for Graves' Disease,Goiter|Thyroid,2011-08-02,2009-12-31,2010-12-31,200.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01408368
1003,NCT01409798,Primary Hyperparathyroidism,The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry,The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry,Primary Hyperparathyroidism,2011-08-02,2014-12-31,2015-11-30,175.0,Case-Only,,Prospective,Observational,Completed,,University of Nebraska,University of Nebraska,University of Iowa|Kansas University Medical Center|University of Minnesota|University Of Missiouri|University of Nebraska Medical Center|Sanford School of Medicine,,United States,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01409798
1006,NCT01412762,Thyroid Cancer,Measuring Patient Expectations for Thyroid Surgery: Development of a Patient-Reported Outcomes Instrument,Measuring Patient Expectations for Thyroid Surgery,Thyroid Cancer,2011-08-03,2024-07-31,2024-07-31,138.0,Case-Only,,Prospective,Observational,Active not recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Behavioral|Behavioral,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01412762
1007,NCT01413113,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,"A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake",Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2011-07-20,2013-11-30,2015-10-31,6.0,,Single Group Assignment,,Interventional,Completed,Phase 1,University of Washington,GlaxoSmithKline|National Cancer Institute (NCI)|National Comprehensive Cancer Network|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01413113
1010,NCT01414114,Secondary Hyperparathyroidism,"A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder",Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder,Secondary Hyperparathyroidism,2011-08-09,2012-05-21,2012-05-21,37.0,,Single Group Assignment,,Interventional,Completed,Phase 2,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01414114
1013,NCT01417442,Papillary Thyroid Carcinoma,Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma,BRAF V600E Mutations In Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2011-07-06,2012-07-31,2012-07-31,150.0,,Single Group Assignment,,Interventional,Unknown status,Early Phase 1,Bezmialem Vakif University,Bezmialem Vakif University,Yeliz Emine Ersoy,Genetic,Turkey,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01417442
1015,NCT01421407,End Stage Renal Disease|Parathyroid Hyperplasia|Secondary Hyperparathyroidism,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Uncontrolled Secondary Hyperparathyroidism in Chronic Haemodialysis Patients,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism,End Stage Renal Disease|Parathyroid Hyperplasia|Secondary Hyperparathyroidism,2011-08-19,2014-01-31,2014-01-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Not Applicable,Theraclion,Theraclion,"Ospedale generale regionale ""Miulli""|Ospedale Maggiore Policlinico Mangiagalli e Regina Elena|Hospital Universitario Marqus de Valdecilla",Device,Italy|Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01421407
1018,NCT01424878,Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2,Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients,Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients,Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2,2011-08-26,,2014-02-12,150.0,,,Retrospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Cancer Institute (NCI), 9000 Rockville Pike",,United States,2.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01424878
1019,NCT01426724,Chronic Kidney Disease|Secondary Hyperparathyroidism,"Effects of Active Form of Vitamin D on Renal Blood Flow, Glomerular Filtration Rate, Proteinuria and Inflammation in Patients With Chronic Kidney Disease and Hyperparathyroidism","Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease",Chronic Kidney Disease|Secondary Hyperparathyroidism,2011-08-29,2013-08-31,2013-08-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,University of Virginia,University of Virginia,University of Virginia,Drug,United States,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01426724
1022,NCT01428167,Hashimotos Thyroiditis|Thyroid Cancer,Is There Any Association Between Thyroid Cancer and Hashimotos Thyroiditis?,Hashimotos Thyroiditis and Thyroid Cancer,Hashimotos Thyroiditis|Thyroid Cancer,2011-08-10,2012-05-31,2012-05-31,26.0,Case-Control,,Prospective,Observational,Completed,,"The University of Texas Medical Branch, Galveston","The University of Texas Medical Branch, Galveston","University of Texas Medical Branch, Galveston , Endocrine Department",,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01428167
1026,NCT01433809,"Cancer of the Thyroid|Neoplasms, Thyroid|Thyroid Adenoma|Thyroid Cancer|Thyroid Carcinoma",Biomarkers in Thyroid Cancer,Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm,"Cancer of the Thyroid|Neoplasms, Thyroid|Thyroid Adenoma|Thyroid Cancer|Thyroid Carcinoma",2011-09-12,2013-05-31,2013-05-31,1.0,Cohort,,Prospective,Observational,Completed,,Mayo Clinic,Norman Eberhardt,Mayo Clinic in Rochester,,United States,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01433809
1027,NCT01436994,Paediatric Thyrotoxicosis,A Randomised Study of Two Anti-thyroid Drug Treatment Regimens in Young People,Antithyroid Drug Treatment of Thyrotoxicosis in Young People,Paediatric Thyrotoxicosis,2011-08-18,2014-12-31,2015-11-30,81.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Newcastle-upon-Tyne Hospitals NHS Trust,Newcastle-upon-Tyne Hospitals NHS Trust,Royal Aberdeen Children's Hospital|Birmingham Children's Hospital|Addebrookes Hospital|Wales College of Medicine|University Hospital|Ninewells Hospital|Royal Hospital for Sick Children|Royal Hospital for Sick Children|Hereford Hospital|Crosshouse Hospital|Alder Hey Children's Hospital|St Bart's Hospital|St George's Hospital|Royal Manchester Children's Hospital|Royal Victoria Infirmary|Norfolk & Norwich University Hospitals|Oxford Radcliffe Hospitals|Sheffield Children's Hospital,Procedure|Procedure|Drug|Drug|Drug,United Kingdom,2.0,16.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01436994
1029,NCT01437254,Thyroid Neoplasms,A Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer,To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer,Thyroid Neoplasms,2011-09-19,2012-04-30,2015-01-31,30.0,,Parallel Assignment,,Interventional,Completed,Phase 1,AHS Cancer Control Alberta,"AHS Cancer Control Alberta|Edmonton PET Centre|Natural Resources, Canada",Cross Cancer Institute,Drug|Drug,Canada,18.0,79.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01437254
1030,NCT01438554,Cholangiocarcinoma|Soft-tissue Sarcoma|Solid Tumors|Thyroid Cancer,"Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",Cholangiocarcinoma|Soft-tissue Sarcoma|Solid Tumors|Thyroid Cancer,2011-08-23,2016-04-30,2018-08-31,89.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Comprehensive Cancer Network|Novartis|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01438554
1031,NCT01439867,"Chronic Kidney Disease|Hyperparathyroidism, Secondary","An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis",Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism,"Chronic Kidney Disease|Hyperparathyroidism, Secondary",2011-09-22,2016-06-03,2016-06-03,18.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Belgium|Czechia|France|Germany|Hungary|Italy|Mexico|Netherlands|New Zealand|Poland|Russian Federation|Slovakia|United States,0.0,2189.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01439867
1034,NCT01441154,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Malignant Struma Ovarii|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer,Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone,Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Malignant Struma Ovarii|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer,2011-09-24,2013-12-12,2013-12-12,16.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01441154
1038,NCT01447368,Kidney Failure|Secondary Hyperparathyroidism|Vascular Diseases,Comparison of Medical Therapy (Oral Cinacalcet) Versus Surgical Therapy (Total Parathyroidectomy) on Vascular/Valvular Calcification in Chronic Peritoneal Dialysis Patients With Secondary Hyperparathyroidism - A Pilot Randomized Study,Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients,Kidney Failure|Secondary Hyperparathyroidism|Vascular Diseases,2011-10-04,2017-05-22,2017-05-22,67.0,,Parallel Assignment,,Interventional,Completed,Phase 4,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital and Tung Wah Hospital,Drug|Procedure,Hong Kong,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01447368
1041,NCT01453634,Hemodialysis (HD)|Secondary Hyperparathyroidism (SHPT)|Stage 5 Chronic Kidney Disease (CKD),"A Randomized, Open Label, Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis","Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)",Hemodialysis (HD)|Secondary Hyperparathyroidism (SHPT)|Stage 5 Chronic Kidney Disease (CKD),2011-10-13,2013-07-31,2013-07-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,"OPKO Health, Inc.","OPKO Health, Inc.",,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01453634
1044,NCT01455181,Hypoparathyroidism,"A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study","A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary",Hypoparathyroidism,2011-09-15,2012-04-26,2012-04-26,24.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Takeda,Shire,"Semmelweis University Medical School|University of Pcs, School of Medicine|University of Szeged",Drug,Hungary,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01455181
1046,NCT01458600,Graves Disease,Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Adjuvant Treatment of Graves Ophthalmopathy With NSAID (aGO Study),Graves Disease,2011-10-19,2016-02-29,2016-02-29,65.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Region Skane,Mikael Lantz,"Departmenty of Endocrinology, Skane University Hospital|Department of Endocrinology, Karolinska Hospital|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset",Drug|Drug|Drug|Drug|Drug,Sweden,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01458600
1050,NCT01460030,Hypercalcemia|Parathyroid Carcinoma|Primary Hyperparathyroidism,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,Hypercalcemia|Parathyroid Carcinoma|Primary Hyperparathyroidism,2011-10-25,2013-02-28,2013-02-28,,,,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01460030
1054,NCT01465867,Auto-immune Thyroiditis|Infertility|Pregnancy,Selenium Supplementation Treatment in Euthyroid Pregnant Women With Autoimmune Thyroid Disease: Effects on Obstetrical Complications,Selenium Supplementation in Pregnancy,Auto-immune Thyroiditis|Infertility|Pregnancy,2011-11-02,2017-06-30,2018-01-31,56.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Roma La Sapienza,University of Roma La Sapienza,"Azienda ospedaliero-universitaria Careggi|Istituto Auxologico Italiano|Ospedale Maggiore Policlinico|University Federico II|University ""Piemonte Orientale, A. Avogadro""|Torvergata University of Rome - Ospedale S. Eugenio|European Hospital|Ospedale S. Giovanni Calibita Fatebenefratelli|Department of Experimental Medicine, ""Sapienza"" University of Rome|Department of Gynecological/Obstetric/Urological Sciences, ""Sapienza"" University of Rome|Dpt of Experimental Medicine",Dietary Supplement|Other|Other|Other,Italy,18.0,38.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01465867
1057,NCT01471288,Thyroid Cancer Patients,Evaluation of the Effect of Carum Carvi on Levels of Plasma Thyroid Hormones and TSH Level in Patients on Thyroid Hormone Therapy and Normal Controls.,Effect of Carum Carvi on Thyroid Hormones and TSH Level,Thyroid Cancer Patients,2011-07-21,2011-12-31,,40.0,,Parallel Assignment,,Interventional,Unknown status,Phase 1/Phase 2,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences|Pharmaceutical Research Center,"Nuclear Medicine Department, Ghaem Hospital",Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01471288
1058,NCT01479088,Secondary Hyperparathyroidism,"Twelve-month, Multicenter, Intra-subject Controlled (Retrospective-prospective), Open-label, Active-treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Cinacalcet Hydrochloride for the Treatment of Secondary Hyperparathyroidism (SHPT) in Paediatric Subjects With Chronic Kidney Disease (CKD) on Dialysis, Followed by 12-month Study Extension.",Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD),Secondary Hyperparathyroidism,2011-11-22,2013-12-31,2013-12-31,30.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Istituto Giannina Gaslini,ENRICO VERRINA,U.O. Nefrologia e Dialisi- Ospedale Giovanni XXIII|U.O. Nefrologia e Dialisi - Istituto di Ricovero e Cura a Carattere Scientifico Giannina Gaslini|U.O. Nefrologia e Dialisi Pediatrica - Clinica De Marchi|U.O. Nefrologia e Dialisi - Ospedale Santobono|U.O. Nefrologia e Dialisi - Ospedale Bambino Ges,Drug,Italy,2.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01479088
1061,NCT01481402,Heart Failure|Low T3 Syndrome,"Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Heart Function, Body Composition and Metabolic Status",Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF),Heart Failure|Low T3 Syndrome,2011-11-25,2014-02-28,2014-02-28,21.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Herlev Hospital,Jens Faber,"Herlev Hospital, Dept. of Endocrinology",Drug|Drug,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01481402
1062,NCT01484379,Multigland Disease in Primary Hyperparathyroidism,Surgical Approach for Primary Hyperparathyroidism in the Elderly - a Prospective Study,Surgical Approach for Primary Hyperparathyroidism in the Elderly,Multigland Disease in Primary Hyperparathyroidism,2011-12-01,2015-11-30,2015-11-30,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Health Care Campus,Procedure,Israel,65.0,120.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01484379
1065,NCT01486667,Dyslipidemia,"Effect of Thyroxin Treatment in Sub Clinical Hypothyroidism Patients, on the Apnea Hypopnea Index Score, Lipid Profiles and Highly Sensitive CRP : A Randomized Double Blind Controlled Trial","Thyroxin Treatment in Sub Clinical Hypothyroidism, on the Apnea Hypopnea Index Score, Lipids and Highly Sensitive CRP",Dyslipidemia,2011-12-03,2013-10-31,,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,King Saud University,King Saud University,University Sleep Disorders Center,Drug|Drug,Saudi Arabia,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01486667
1066,NCT01487057,Dyslipidemias|Hormone Replacement|Risk Reduction Behavior|Thyroid Carcinoma,"""Evaluation of Lipid Metabolic Status and of Cardiovascular Risk at Patients With Thyroid Carcinoma, Radically Treated and With Chronic Thyroid Hormonal Substitution""",Lipid Metabolic Status in Thyroid Carcinoma,Dyslipidemias|Hormone Replacement|Risk Reduction Behavior|Thyroid Carcinoma,2011-12-05,2012-02-29,2012-05-31,52.0,Cohort,,Prospective,Observational,Completed,,Prof. Dr. I. Chiricuta Institute of Oncology,Iuliu Hatieganu University of Medicine and Pharmacy|Prof. Dr. I. Chiricuta Institute of Oncology,"Institute of Oncology ""Prof.dr.I.Chiricuta""",,Romania,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01487057
1067,NCT01488721,"Adrenal Hyperplasia, Congenital|Congenital Hypothyroidism|Cystic Fibrosis","Clinical Evaluation of the xMAP NeoPlex4 Assay for Detection of T4, TSH, 17-OHP and IRT Using the NeoPlex System",Clinical Evaluation of NeoPlex4 Assay and NeoPlex System,"Adrenal Hyperplasia, Congenital|Congenital Hypothyroidism|Cystic Fibrosis",2011-12-06,2012-02-29,2012-04-30,7462.0,Case-Only,,Prospective,Observational,Completed,,Luminex Molecular Diagnostics,Luminex Corporation,New York State Department of Health|Tennessee Department of Health|Unified State Laboratories: Public Health,,United States,0.0,7.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01488721
1069,NCT01496313,Thyroid Cancer,"An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease",To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer,Thyroid Cancer,2011-12-02,2014-04-30,2022-12-31,81.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 4,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Czechia|India|Israel|Italy|Netherlands|Poland|Russian Federation|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01496313
1070,NCT01498341,Hypoparathyroidism,"Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism in Denmark - Epidemiology, Causes, Symptoms and Prognoses",Hypoparathyroidism in Denmark,Hypoparathyroidism,2011-12-20,2012-05-31,2012-05-31,1000.0,,,,Observational,Completed,,University of Aarhus,University of Aarhus,"Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Tage-Hansens Gade",,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01498341
1072,NCT01501110,Acute Myocardial Infarction|Euthyroid Sick Syndrome|Ischemic Heart Disease,Evaluation of the Effects of N-acetylcysteine on Thyroid Hormone Levels in the Low T3 Syndrome,Effects of N-acetylcysteine on Low T3 Syndrome,Acute Myocardial Infarction|Euthyroid Sick Syndrome|Ischemic Heart Disease,2011-11-25,2013-07-31,2013-11-30,83.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Federal University of Rio Grande do Sul,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre|Programa de ps-graduao em endocrinologia,Hospital de Clnicas de Porto Alegre|Instituto de Cardiologia,Drug,Brazil,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01501110
1073,NCT01502410,Childhood Hepatocellular Carcinoma|Papillary Thyroid Cancer|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Thyroid Cancer|Recurrent Wilms Tumor and Other Childhood Kidney Tumors,"A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma","Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",Childhood Hepatocellular Carcinoma|Papillary Thyroid Cancer|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Thyroid Cancer|Recurrent Wilms Tumor and Other Childhood Kidney Tumors,2011-12-29,2014-06-30,2014-06-30,20.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|University of Alabama at Birmingham|University of Arkansas for Medical Sciences|Southern California Permanente Medical Group|Miller Children's Hospital|Children's Hospital Los Angeles|Children's Hospital Central California|Childrens Hospital of Orange County|Rady Children's Hospital - San Diego|University of California San Francisco Medical Center-Parnassus|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Alfred I duPont Hospital for Children|Children's National Medical Center|Lee Memorial Health System|Nemours Children's Clinic - Jacksonville|Florida Hospital|Nemours Children's Clinic - Orlando|Nemours Children's Clinic - Pensacola|All Children's Hospital|Saint Joseph Children's Hospital of Tampa|Children's Healthcare of Atlanta - Egleston|University of Hawaii|Saint Luke's Mountain States Tumor Institute|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago|Saint Jude Midwest Affiliate|Southern Illinois University|Riley Hospital for Children|University of Kentucky|Kosair Children's Hospital|Tulane University Health Sciences Center|Sinai Hospital of Baltimore|Mark O Hatfield-Warren Grant Magnuson Clinical Center|Dana-Farber Cancer Institute|Dana-Farber Harvard Cancer Center|Wayne State University/Karmanos Cancer Institute|Bronson Methodist Hospital|University of Minnesota Medical Center-Fairview|Mayo Clinic|University of Mississippi Medical Center|The Childrens Mercy Hospital|Washington University School of Medicine|Children's Hospital and Medical Center of Omaha|Hackensack University Medical Center|Morristown Memorial Hospital|UMDNJ - Robert Wood Johnson University Hospital|Overlook Hospital|University of New Mexico Cancer Center|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|Columbia University Medical Center|Memorial Sloan-Kettering Cancer Center|University of Rochester|State University of New York Upstate Medical University|University of North Carolina|Carolinas Medical Center|Novant Health Presbyterian Medical Center|Wake Forest University Health Sciences|Children's Hospital Medical Center of Akron|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|Nationwide Children's Hospital|Dayton Children's Hospital|University of Oklahoma Health Sciences Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Children's Oncology Group|Children's Hospital of Pittsburgh of UPMC|BI-LO Charities Children's Cancer Center|Greenville Cancer Treatment Center|East Tennessee Childrens Hospital|Vanderbilt-Ingram Cancer Center|Driscoll Children's Hospital|Medical City Dallas Hospital|University of Texas Southwestern Medical Center|Cook Children's Medical Center|Baylor College of Medicine|Childrens Hospital-King's Daughters|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Midwest Children's Cancer Center|Sydney Children's Hospital|Princess Margaret Hospital for Children|British Columbia Children's Hospital|IWK Health Centre|McMaster Children's Hospital at Hamilton Health Sciences|Hospital for Sick Children|The Montreal Children's Hospital of the MUHC|Centre Hospitalier Universitaire Sainte-Justine|Centre Hospitalier Universitaire de Quebec,Drug|Other|Other,Australia|Canada|United States,2.0,30.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01502410
1075,NCT01506947,Moderate to Severe Secondary Hyperparathyroidism|Stage 5 Chronic Kidney Diseases,"A Prospective, Non-randomised, Single-arm, Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients",A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients,Moderate to Severe Secondary Hyperparathyroidism|Stage 5 Chronic Kidney Diseases,2011-12-28,2016-04-07,2016-04-07,65.0,,Single Group Assignment,,Interventional,Completed,Phase 4,AbbVie,"AbbVie (prior sponsor, Abbott)",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01506947
1078,NCT01510002,Papillary Thyroid Cancer,Prophylactic Central Neck Dissection for Papillary Thyroid Cancer,Prophylactic Central Neck Dissection for Papillary Thyroid Cancer,Papillary Thyroid Cancer,2012-01-09,2011-09-30,2011-12-31,640.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian Univerity, Medical College, 3rd Department of General Surgery",Procedure|Procedure,Poland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01510002
1080,NCT01511393,"Diabetes|Diabetes Mellitus, Type 2|Medullary Thyroid Carcinoma|Weight Management",Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry,An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC),"Diabetes|Diabetes Mellitus, Type 2|Medullary Thyroid Carcinoma|Weight Management",2011-11-30,2035-12-31,2035-12-31,6750.0,Case-Only,,Prospective,Observational [Patient Registry],Enrolling by invitation,,Novo Nordisk A/S,"AstraZeneca|Eli Lilly and Company|Novo Nordisk A/S|United BioSource, LLC","United BioSource, LLC",Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01511393
1081,NCT01512212,Thyroid Cancer,New Thyroid Fine Needle Biopsy Apparatus,New Thyroid Fine Needle Aspiration Biopsy Apparatus,Thyroid Cancer,2012-01-10,2012-06-30,2012-09-30,40.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,SB Istanbul Education and Research Hospital,Bezmialem Vakif University|SB Istanbul Education and Research Hospital,Bezmialem Vakif University,Procedure,Turkey,17.0,85.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01512212
1082,NCT01528904,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,Fetal Thyroid Hormones Concentration In Hyperthyroid or Hypothyroid Pregnant Women,Maternal Autoimmune Thyroid Disease and Fetal Thyroxin,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2012-01-12,2011-03-31,2011-06-30,83.0,Case-Control,,Prospective,Observational,Completed,,University of Belgrade,University of Belgrade,Clinic for Gynecology and Obstetrics,,Serbia,23.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01528904
1084,NCT01530919,Primary Hyperparathyroidism,Minimally Invasive Radioguided Parathyroidectomy,Minimally Invasive Radioguided Parathyroidectomy,Primary Hyperparathyroidism,2011-11-30,2009-12-31,2017-04-30,856.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Louisville,Jewish Hospital and St. Mary's Healthcare|Norton Healthcare|University of Louisville,University of Louisville,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01530919
1087,NCT01534169,Graves' Disease,Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients,Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients,Graves' Disease,2012-02-09,2012-03-31,2012-11-30,50.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Nanjing Medical University,Xiao-Ming Mao,Nanjing First Hospital Affiliated to Nanjing Medical University,Drug,China,20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01534169
1090,NCT01534897,Papillary Thyroid Carcinoma,Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,Papillary Thyroid Carcinoma,2012-02-10,2014-03-31,2014-03-31,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Massachusetts General Hospital,GlaxoSmithKline|Massachusetts General Hospital,Massachusetts General Hospital,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01534897
1092,NCT01536678,Hypothyroidism,"Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers: A Single-dose, Randomized, Open-label, Crossover Study",Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers,Hypothyroidism,2012-02-02,2012-04-30,2012-04-30,26.0,,Crossover Assignment,,Interventional,Completed,Phase 4,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug,India,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01536678
1093,NCT01539486,Parathyroid Disease,Relationship of Preoperative PTH and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy,Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy,Parathyroid Disease,2012-02-21,2023-12-31,2023-12-31,200.0,Other,,Retrospective,Observational,Active not recruiting,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01539486
1094,NCT01539499,Endocrine Gland|Parathyroid Disease|Thyroid Disease,Complications of Endocrine Surgery: Data From the United Health System Consortium,Complications of Endocrine Surgery: Data From the United HealthSystem Consortium,Endocrine Gland|Parathyroid Disease|Thyroid Disease,2012-02-21,2017-08-31,2017-08-31,1000.0,Case-Only,,Retrospective,Observational,Completed,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01539499
1095,NCT01539655,Medullary Thyroid Cancer,"A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects When a Single Oral Dose of Vandetanib 300 mg is Administered Alone and in Combination With Omeprazole or Ranitidine",Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib,Medullary Thyroid Cancer,2012-02-10,2012-09-30,2012-09-30,34.0,,Crossover Assignment,,Interventional,Completed,Phase 1,Sanofi,Sanofi,Research Site,Drug|Drug|Drug,United States,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01539655
1096,NCT01545622,Parathyroid Disease,Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease,Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease,Parathyroid Disease,2012-02-21,2016-09-01,2016-09-01,61.0,Other,,Retrospective,Observational,Completed,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01545622
1097,NCT01551498,"Thyroiditis, Autoimmune","A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Potential Effects of the Dietary Supplement Anatabloc on Antithyroid Autoantibodies and Thyroid Function in Autoimmune Thyroiditis",Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention),"Thyroiditis, Autoimmune",2012-03-05,2013-01-31,2013-02-28,165.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Rock Creek Pharmaceuticals, Inc.","Rock Creek Pharmaceuticals, Inc.","Metabolic Research Institute, Inc.|Florida Medical Clinic, P.A.|Robert J. Becker, M.D., LTD|Associated Endocrinologists, P.C.|New Jersey Physicians, LLC|Texas Diabetes & Endocrinology|North Texas Endocrine Center|Research Institute of Dallas|Texas Diabetes & Endocrinology",Dietary Supplement|Dietary Supplement,United States,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01551498
1099,NCT01552434,Advanced Malignant Neoplasm|Castleman Disease|Digestive System Carcinoma|Erdheim-Chester Disease|Lip and Oral Cavity Carcinoma|Lymphangioleiomyomatosis|Malignant Endocrine Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Male Reproductive System Neoplasm|Malignant Neoplasm|Malignant Respiratory Tract Neoplasm|Malignant Thoracic Neoplasm|Malignant Urinary System Neoplasm|Mesothelial Neoplasm|Metastatic Malignant Neoplasm|Metastatic Urothelial Carcinoma|Neurofibromatosis Type 2|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Digestive System Carcinoma|Recurrent Female Reproductive System Carcinoma|Recurrent Male Reproductive System Carcinoma|Recurrent Malignant Neoplasm|Recurrent Pharyngeal Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Neoplasm|Soft Tissue Neoplasm|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage III Pharyngeal Cancer|Stage IVA Pharyngeal Cancer|Stage IVB Pharyngeal Cancer|Stage IV Breast Cancer AJCC v6 and v7|Stage IVC Pharyngeal Cancer|Stage IV Pharyngeal Cancer|Thyroid Gland Neoplasm,"A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications",Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease,Advanced Malignant Neoplasm|Castleman Disease|Digestive System Carcinoma|Erdheim-Chester Disease|Lip and Oral Cavity Carcinoma|Lymphangioleiomyomatosis|Malignant Endocrine Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Male Reproductive System Neoplasm|Malignant Neoplasm|Malignant Respiratory Tract Neoplasm|Malignant Thoracic Neoplasm|Malignant Urinary System Neoplasm|Mesothelial Neoplasm|Metastatic Malignant Neoplasm|Metastatic Urothelial Carcinoma|Neurofibromatosis Type 2|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Digestive System Carcinoma|Recurrent Female Reproductive System Carcinoma|Recurrent Male Reproductive System Carcinoma|Recurrent Malignant Neoplasm|Recurrent Pharyngeal Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Neoplasm|Soft Tissue Neoplasm|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage III Pharyngeal Cancer|Stage IVA Pharyngeal Cancer|Stage IVB Pharyngeal Cancer|Stage IV Breast Cancer AJCC v6 and v7|Stage IVC Pharyngeal Cancer|Stage IV Pharyngeal Cancer|Thyroid Gland Neoplasm,2012-03-07,2022-03-31,2022-03-31,155.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Biological|Other|Other|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01552434
1100,NCT01558115,Primary Hyperparathyroidism,Denosumab in Primary Hyperparathyroidism,Denosumab in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2012-03-16,2014-10-31,2014-10-31,8.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Columbia University,Amgen|John P. Bilezikian|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health (NIH),Columbia University Medical Center,Drug|Other,United States,40.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01558115
1103,NCT01560299,Graves Disease,,Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients,Graves Disease,2012-03-01,2012-01-31,2012-01-31,150.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01560299
1106,NCT01565486,Thyroid Cancer,Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated With the Harmonic ACE Scalpel and LigaSure Precise Instrument During Conventional Thyroidectomy: A Single-blind Prospective Randomized Controlled Trial,Safety and Efficacy Study of Ultrasonic Coagulation Device and Bipolar Energy Sealing System,Thyroid Cancer,2011-09-02,2013-01-31,2017-08-31,304.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Device|Device,"Korea, Republic of",20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01565486
1107,NCT01571843,"Bone Diseases, Metabolic|Bone Loss, Postmenopausal|Osteoporosis, Postmenopausal|Primary Hyperparathyroidism",Effect of Mechanical Loading on Radius Bone Density and Microarchitecture in Primary Hyperparathyroidism,Radius Loading in Primary Hyperparathyroidism,"Bone Diseases, Metabolic|Bone Loss, Postmenopausal|Osteoporosis, Postmenopausal|Primary Hyperparathyroidism",2012-04-03,2014-10-31,2014-10-31,12.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health (NIH),Columbia University Medical Center,Other|Other,United States,45.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01571843
1110,NCT01573520,Chronic Kidney Disease|Hyperparathyroidism,A Randomized Trial Comparing an Integrated Care Approach Using Electronic Cinacalcet Adherence Data Versus Usual Care to Improve Secondary Hyperparathyroidism in Hemodialysis Patients,Treatment Adhesion in Dialysis Patients Treated With Cinacalcet,Chronic Kidney Disease|Hyperparathyroidism,2012-03-23,2011-11-30,2011-11-30,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Centre Hospitalier Universitaire Vaudois,Michel Burnier,Centre Hospitalier Universitaire Vaudois,Other,Switzerland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01573520
1112,NCT01574287,Parathyroid Disease,Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC,Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas,Parathyroid Disease,2012-03-31,2019-05-15,2019-05-15,4.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Emory University,"David M. Schuster, MD",Emory University,Drug,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01574287
1114,NCT01574859,Hypopituitarism,Central Hypothyroidism and Cardiovascular Risk Factors,Central Hypothyroidism and Cardiovascular Risk,Hypopituitarism,2012-04-07,2012-11-30,2013-03-31,200.0,Cohort,,Retrospective,Observational,Completed,,"Rigshospitalet, Denmark","Rigshospitalet, Denmark",Rigshospitalet,Other,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01574859
1115,NCT01576146,Secondary Hyperparathyroidism,A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (Also Known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients With Secondary Hyperparathyroidism,Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2012-04-05,2014-05-01,2014-05-01,30.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01576146
1118,NCT01579344,Lacrimal Apparatus Disease,Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma,Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma,Lacrimal Apparatus Disease,2012-04-15,2014-03-31,,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo,Fabricio Lopes da Fonseca,University of Sao Paulo; Ophthalmology Department,Drug,Brazil,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01579344
1119,NCT01579539,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,2012-04-13,2017-05-18,2017-05-18,18.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Medical University of Vienna,Medical University of Vienna,"Department of Clinical Pharmacology, Medical University of Vienna",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01579539
1123,NCT01586520,Differentiated Thyroid Cancer,Diagnosing Thyroid Cancer Using a Blood Test,Diagnosing Thyroid Cancer Using a Blood Test,Differentiated Thyroid Cancer,2012-04-25,2014-10-31,2016-12-31,400.0,Case-Control,,Prospective,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Newcastle-upon-Tyne Hospitals NHS Trust,"Sir Bobby Robson Cancer Researhc Unit|Sir Bobby Robson Cancer Research Unit, Northern Centre for cancer care",,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01586520
1124,NCT01588288,"Goiter, Nodular",Diagnosis Interest of Galectin 3 Dosage in Nodular and Multinodular Goiter Pretreatment,Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter,"Goiter, Nodular",2012-04-25,2016-06-30,2016-06-30,193.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"University Hospital, Rouen","University Hospital, Rouen",Centre Henri Becquerel|CHRouen,Procedure,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01588288
1126,NCT01598727,Primary Hyperparathyroidism,A Phase I Feasibility Study of Intra-operative Near Infra-red Fluorescent Imaging in Thyroid/Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics,Near Infrared Fluorescent Imaging in Thyroid and Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics,Primary Hyperparathyroidism,2012-05-03,2013-01-31,2013-04-30,10.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Sheffield Teaching Hospitals NHS Foundation Trust,"Fluoptics Ltd, Grenoble, France|Sheffield Teaching Hospitals NHS Foundation Trust",Department of General Surgery,Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01598727
1129,NCT01599273,Thyroid-associated Ophthalmopathy,,Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections,Thyroid-associated Ophthalmopathy,2012-05-10,2014-08-31,2014-08-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance hospital,Drug,"Korea, Republic of",19.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01599273
1133,NCT01609946,Thyroid Nodules,Evaluation of Realtime-Elastography for Differentiation of Thyroid Nodules: a Multicenter Study,Realtime-Elastography (RTE) and Thyroid Nodules,Thyroid Nodules,2012-05-30,2013-12-31,2014-12-31,602.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Johann Wolfgang Goethe University Hospital,Johannes Vermehren,Caritas-Krankenhaus|Klinikum Bielefeld|Klinikum der J. W. Goethe-Universitt|Brgerhospital|Helfenstein Klinik|Universittsklinikum Leipzig|Klinikum am Steinberg|Endokrinologie und Diabetologie im Zentrum|Universittsklinikum Ulm|Deutsche Klinik fr Diagnostik,Device|Procedure,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01609946
1135,NCT01611896,Graves' Hyperthyroidism,"GRAves Selenium Supplementation Trial (GRASS) - an Investigator-initiated Randomised, Blinded, Multicentre Clinical Trial of Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism",Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism,Graves' Hyperthyroidism,2012-05-29,2021-08-31,2021-08-31,431.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,"Rigshospitalet, Denmark","Bispebjerg Hospital|Copenhagen Trial Unit, Center for Clinical Intervention Research|Danish Council for Independent Research|Herlev Hospital|Hillerod Hospital, Denmark|Hospital of South West Denmark|Hvidovre University Hospital|Odense University Hospital|Rigshospitalet, Denmark|The Danish Council for Strategic Research","Department of Endocrinology and Gastroenterology, Bispebjerg Hospital|Department of Medical Endocrinology, Rigshospitalet|Department of Endocrinology, Hospital of Southwest Denmark|Department of Medicine, Gentofte Hospital|Department of Internal Medicine O 106, Endocrine Unit, Herlev Hospital|Department of Cardiology and Endocrinology, Endocrine Unit, Hillerd Hospital|Department of Endocrinology, Section 541, Hvidovre Hospital|Department of Endocrinology and Metabolism, Odense University Hospital",Dietary Supplement|Other,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01611896
1136,NCT01616108,"Esotropia|Exotropia|Graves Disease|Ptosis, Eyelid|Strabismus",Bupivacaine Injection of Eye Muscles to Treat Strabismus,Bupivacaine Injection of Eye Muscles to Treat Strabismus,"Esotropia|Exotropia|Graves Disease|Ptosis, Eyelid|Strabismus",2012-06-07,2019-09-30,2020-09-30,120.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Smith-Kettlewell Eye Research Institute,Eidactics|Smith-Kettlewell Eye Research Institute|Strabismus Research Foundation|Sutter Health,Strabismus Research Foundation,Drug,United States,8.0,95.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01616108
1139,NCT01616316,Thyroid Cancer,Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study,Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients,Thyroid Cancer,2012-01-18,2012-01-31,2012-02-29,86.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung medical center,Procedure|Procedure,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01616316
1140,NCT01617694,Thyroid Neoplasm,,Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia,Thyroid Neoplasm,2012-06-05,2011-11-30,2011-11-30,65.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,Severance hospital,Drug|Drug,"Korea, Republic of",20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01617694
1141,NCT01625520,Medullary Thyroid Cancer,"Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression",SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer,Medullary Thyroid Cancer,2012-05-25,2016-03-31,,19.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Federico II University,Federico II University,"Department of Molecular and Clinical Endocrinology and Oncology, ""Federico II"" University of Naples",Drug,Italy,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01625520
1142,NCT01631305,Euthyroid Sick Syndrome,Efficacy and Safety of Levothyroxine in Critical Children With Euthyroid Sick Syndrome in a Pediatric Intensive Care Unit.,Levothyroxine for Children With Euthyroid Sick Syndrome,Euthyroid Sick Syndrome,2012-06-26,2013-12-31,2013-12-31,80.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Sinaloa Pediatric Hospital,Sinaloa Pediatric Hospital,Sinaloa Pediatric Hospital,Drug|Other,Mexico,1.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01631305
1143,NCT01633853,Vitamin D Deficiency,"Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease",Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder,Vitamin D Deficiency,2012-06-29,2015-09-30,2015-09-30,204.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Capital Medical University,"Beijing Municipal Science & Technology Commission|Dongliang Zhang, MD",Beijing Friedship Hospital,Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01633853
1146,NCT01638533,Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Metastatic Malignant Solid Neoplasm|Neuroendocrine Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Unresectable Solid Neoplasm,"A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Metastatic Malignant Solid Neoplasm|Neuroendocrine Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Unresectable Solid Neoplasm,2012-07-09,2018-11-29,,36.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1,National Cancer Institute (NCI),Celgene Corporation|National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|University of California Davis Comprehensive Cancer Center|Emory University Hospital/Winship Cancer Institute|University of Chicago Comprehensive Cancer Center|Johns Hopkins University/Sidney Kimmel Cancer Center|National Cancer Institute Developmental Therapeutics Clinic|Wayne State University/Karmanos Cancer Institute|Mayo Clinic in Rochester|Case Western Reserve University|Penn State Milton S Hershey Medical Center|Thomas Jefferson University Hospital|University Health Network-Princess Margaret Hospital,Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01638533
1147,NCT01640184,Disorders of Parathyroid Gland|Hyperparathyroidism,Study of the Efficacy and Safety on the Ultrasonic Ablation Treatment for Secondary Hyperthyroidism in Chronic Kidney Disease Patients.,Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients,Disorders of Parathyroid Gland|Hyperparathyroidism,2012-07-09,2014-11-30,2014-11-30,79.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Capital Medical University,"Beijing Municipal Science & Technology Commission|Dongliang Zhang, MD",Beijing Chao-Yang Hospital|Beijing Friendship Hospital,Procedure|Drug|Procedure,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01640184
1149,NCT01641679,Differentiated Thyroid Cancer|Thyroid Neoplasms,Recurrent Differentiated Thyroid Cancer: Towards Personalized Treatment Based on Evaluation of Tumor Characteristics With PET (THYROPET,PET Evaluation of Recurrent Differentiated Thyroid Cancer,Differentiated Thyroid Cancer|Thyroid Neoplasms,2012-07-12,2015-08-31,2016-01-31,100.0,Cohort,,Prospective,Observational,Unknown status,,The Netherlands Cancer Institute,"Amsterdam UMC, location VUmc|The Netherlands Cancer Institute|UMC Utrecht",Rijnstate Hospital|UMC St. Radboud Nijmegen|Bernard Verbeeten Institute|Jeroen Bosch Hospital|Catharina Hospital|Medical Center Alkmaar|St. Lucas Andreas Hospital|VUmc Medical Center|Medical spectrum Twente|Isala Clinics|Meander Medical Center|St. Antonius hospital|Leiden University Medical Center|University Medical Center Groningen|University Medical Center Utrecht,,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01641679
1150,NCT01647503,Hypercalcemia|Primary Hyperparathyroidism,Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease,Differentially Expressed Proteins in Sporadic Parathyroid Tumors,Hypercalcemia|Primary Hyperparathyroidism,2012-07-18,2015-09-30,,50.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,Postgraduate Institute of Medical Education and Research,Postgraduate Institute of Medical Education and Research,PGIMER,,India,15.0,65.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01647503
1154,NCT01647750,Hypothyroidism,"Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) SORTED 1 - a Randomised Controlled Trial (Pilot Study), SORTED 2 - Qualitative Interviews, SORTED 3 - Retrospective Cohort",Study of Optimal Replacement of Thyroxine in the Elderly,Hypothyroidism,2012-07-16,2014-08-31,2014-08-31,48.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Newcastle-upon-Tyne Hospitals NHS Trust,"National Institute for Health Research, United Kingdom|Newcastle-upon-Tyne Hospitals NHS Trust",Bensham Hospital|Clinical Research Facility,Drug|Drug,United Kingdom,80.0,120.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01647750
1155,NCT01648569,Papillary Thyroid Microcarcinoma,Proper Extent of Surgery for Papillary Microcarcinoma,Long-term Outcomes of Total Thyroidectomy Versus Less Than Total Thyroidectomy for Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2012-07-18,2012-05-31,2012-07-31,2014.0,Cohort,,Retrospective,Observational,Completed,,Korean Association of Endocrine Surgeons,Korean Association of Endocrine Surgeons,Yonsei University College of Medicidine,,"Korea, Republic of",10.0,60.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01648569
1156,NCT01649206,Thyroid Nodule,Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study,Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules,Thyroid Nodule,2012-07-16,2011-01-31,2011-06-30,40.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Federico II University,Federico II University,"""Federico II"" University of Naples, Department of Clinical and Molecular Endocrinology and Oncology",Procedure,Italy,18.0,87.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01649206
1158,NCT01651000,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency",Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",2012-07-23,2014-07-31,2014-07-31,213.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",OPKO Renal,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01651000
1161,NCT01653379,Secondary Hyperparathyroidism,"A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis",A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2012-07-25,2014-07-31,2014-07-31,42.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Deltanoid Pharmaceuticals,Deltanoid Pharmaceuticals,,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01653379
1164,NCT01655719,Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene,Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene,Pioglitazone in Thyroid Cancers,Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene,2012-07-25,2017-03-31,2017-03-31,1.0,,Single Group Assignment,,Interventional,Completed,Phase 2,University of Michigan,National Cancer Institute (NCI)|University of Michigan,University of Colorado|University of Michigan|University of Pennsylvania|University of Texas MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01655719
1165,NCT01656070,HIV Disease|Hyperparathyroidism|Hypovitaminosis D|Vitamin D Deficiency,Vitamin D Status and T Cell Phenotype in HIV-infected Youth Supplemented With Cholecalciferol: a Randomized Clinical Trial.,Vitamin D Supplementation in HIV-infected Youth,HIV Disease|Hyperparathyroidism|Hypovitaminosis D|Vitamin D Deficiency,2012-07-31,2012-07-31,2012-07-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Milan,University of Milan,Department of Paediatrics - L. Sacco Hospital,Drug|Drug,Italy,0.0,30.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01656070
1167,NCT01658085,Multinodular Goiter,"Harmonic FOCUS Versus Conventional Technique in Total Thyroidectomy for Benign Thyroid Disease. A Randomized, Prospective Study",Budget Impact of Harmonic FOCUS in Thyroidectomy,Multinodular Goiter,2012-07-17,2010-03-31,2012-08-31,56.0,Case-Control,,Prospective,Observational,Unknown status,,Hospital Universitari de Bellvitge,Hospital Universitari de Bellvitge,Hospital UIniversitari de Bellvitge,Device|Device,Spain,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01658085
1168,NCT01659385,"Leptin Levels|Thyroid Cancer, Papillary","Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls",Leptin Levels in Papillary Thyroid Cancer,"Leptin Levels|Thyroid Cancer, Papillary",2012-08-03,2013-06-30,2013-06-30,18.0,Other,,Cross-Sectional,Observational,Completed,,University of Nebraska,University of Nebraska,University of Nebraska Medical Center,,United States,19.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01659385
1170,NCT01660126,Subclinical Hypothyroidism,Multi-modal Effects of Thyroid Hormone Replacement for Untreated Older Adults With Subclinical Hypothyroidism; a Randomised Placebo-controlled Trial,Thyroid Hormone Replacement for Subclinical Hypothyroidism,Subclinical Hypothyroidism,2012-08-06,2016-11-18,2016-11-18,737.0,,Parallel Assignment,,Interventional,Completed,Phase 4,NHS Greater Glasgow and Clyde,Leiden University Medical Center|NHS Greater Glasgow and Clyde|University College Cork|University of Bern|University of Glasgow,"Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde",Drug|Drug,United Kingdom,65.0,120.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01660126
1171,NCT01660984,Medullary Thyroid Cancer,Longitudinal Assessment and Natural History Study of Children and Adults With MEN2A or MEN2B With or Without Medullary Thyroid Carcinoma,Natural History Study of Children and Adults With Medullary Thyroid Cancer,Medullary Thyroid Cancer,2012-08-07,,,216.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01660984
1172,NCT01661179,"Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma","A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma",Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma,"Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma",2012-07-17,2013-12-31,2014-07-31,14.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site,Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01661179
1173,NCT01665651,"Renal Insufficiency, Chronic|Renal Osteodystrophy",Effect of Kidney Yin/Yang Replenishment on Bone Metabolism in Patients With Renal Osteodystrophy,Kidney Yin/Yang Replenishment on Patients With Renal Osteodystrophy,"Renal Insufficiency, Chronic|Renal Osteodystrophy",2012-08-08,2017-05-31,2017-05-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,Shanghai University of Traditional Chinese Medicine,Bing Shu|Huadong Hospital|Longhua Hospital|The First Affiliated Hospital of Anhui University of Chinese Medicine,The first affiliated hospital of Anhui University of TCM|Huadong hospital affiliated to Fudan University|Longhua Hospital affiliated to Shanghai Uni of TCM,Drug|Drug|Drug|Drug,China,20.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01665651
1176,NCT01668238,Breast Tumor|Thyroid Tumor,Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry,Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry,Breast Tumor|Thyroid Tumor,2012-08-07,2012-09-30,2012-09-30,600.0,,,Cross-Sectional,Observational,Unknown status,,Peking University,Peking University|XU Zhi,Peking University Third Hospital,,China,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01668238
1177,NCT01675089,Renal Osteodystrophy,A Prospective and Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year After Kidney Transplantation,Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation,Renal Osteodystrophy,2012-08-23,2013-07-31,2014-05-31,34.0,,Parallel Assignment,,Interventional,Completed,Phase 4,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Hospital das Clinicas - Faculdade de Medicina da Universidade de So Paulo,Drug,Brazil,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01675089
1180,NCT01690806,Benign Neoplasm of Thyroid Gland|Malignant Neoplasm of Thyroid,Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.,Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy,Benign Neoplasm of Thyroid Gland|Malignant Neoplasm of Thyroid,2012-09-19,2012-01-31,2012-03-31,328.0,Case-Control,,Prospective,Observational,Completed,,Universit degli Studi dell'Aquila,Universit degli Studi dell'Aquila,ospedale San Salvatore-Reparto di Chirurgia Generale Universitaria,,Italy,0.0,75.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01690806
1181,NCT01691781,Hyperparathyroidism,The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study,The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study,Hyperparathyroidism,2012-09-20,2016-08-31,2016-12-31,41.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Drug,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01691781
1183,NCT01700699,Differentiated Thyroid Cancer,Impact of BRAFV600E Intratumor Heterogeneity on the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Radioiodine-resistant Thyroid Cancer,Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors,Differentiated Thyroid Cancer,2012-09-22,2013-10-31,2013-10-31,50.0,Cohort,,Retrospective,Observational,Unknown status,,University of Salerno,University of Salerno,"Department of Medicine and Surgery, Univeristy of Salerno",,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01700699
1184,NCT01701349,Anaplastic Thyroid Cancer,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)",Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2012-10-02,2017-04-30,2017-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 3,Mateon Therapeutics,Mateon Therapeutics,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01701349
1186,NCT01704079,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency",Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",2012-10-06,2014-08-31,2014-09-30,216.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",OPKO Renal,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01704079
1189,NCT01704586,Differentiated Thyroid Carcinoma,Clinical Evaluation of a I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Using PROBE Design,I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer,Differentiated Thyroid Carcinoma,2012-10-04,2021-05-31,2025-11-30,340.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Wuerzburg,"Deutsche Krebshilfe e.V., Bonn (Germany)|University of Wuerzburg","Clinic of Nuclear Medicine, University Clinic Essen|University Clinic Wrzburg",Radiation|Radiation,Germany,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01704586
1190,NCT01707056,Hypothyroidism|Thyroid Carcinoma,The Effect of Coffee Consumption on the Intestinal Absorption of Levothyroxine Thyroid Hormone Replacement in Patients With Thyroid Carcinoma,The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma,Hypothyroidism|Thyroid Carcinoma,2012-10-05,2015-06-30,2016-06-30,0.0,,Crossover Assignment,,Interventional,Withdrawn,Not Applicable,Medstar Health Research Institute,Georgetown University|Medstar Health Research Institute,Georgetown University Hospital|Washington Hospital Center|MedStar St. Mary's Hospital,Other|Other|Other|Other,United States,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01707056
1192,NCT01709292,Thyroid Cancer,Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer,Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer,Thyroid Cancer,2012-07-25,2022-09-30,2023-09-30,24.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,M.D. Anderson Cancer Center,"Genentech, Inc.|M.D. Anderson Cancer Center",University of Texas MD Anderson Cancer Center,Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01709292
1193,NCT01709435,Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Primary Central Nervous System Neoplasm|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm|Thyroid Gland Medullary Carcinoma,"A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors",Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors,Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Primary Central Nervous System Neoplasm|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm|Thyroid Gland Medullary Carcinoma,2012-10-16,2018-12-31,2019-12-31,41.0,,Single Group Assignment,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Children's Hospital of Orange County|UCSF Medical Center-Parnassus|UCSF Medical Center-Mission Bay|Children's National Medical Center|Children's Healthcare of Atlanta - Egleston|Lurie Children's Hospital-Chicago|Riley Hospital for Children|National Institutes of Health Clinical Center|C S Mott Children's Hospital|University of Minnesota/Masonic Cancer Center|Washington University School of Medicine|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Cincinnati Children's Hospital Medical Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Childrens Oncology Group|Children's Hospital of Pittsburgh of UPMC|St. Jude Children's Research Hospital|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Seattle Children's Hospital|Children's Hospital of Wisconsin|Hospital for Sick Children,Drug|Other|Other,Canada|United States,2.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01709435
1194,NCT01723202,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,53.0,,Crossover Assignment,,Interventional,Active not recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01723202
1197,NCT01725113,Hypercalcemia|Hyperphosphatemia|Kidney Failure|Secondary Hyperparathyroidism,"A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients",Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol,Hypercalcemia|Hyperphosphatemia|Kidney Failure|Secondary Hyperparathyroidism,2012-11-07,2013-12-31,2015-10-31,11.0,,Crossover Assignment,,Interventional,Terminated,Phase 4,Winthrop University Hospital,Winthrop University Hospital,Winthrop University Hospital,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01725113
1200,NCT01727973,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases","Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,14.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01727973
1204,NCT01728623,Thyroid Cancer,A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer,A Study of E7080 in Subjects With Advanced Thyroid Cancer,Thyroid Cancer,2012-09-07,2015-07-09,2015-10-01,51.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Eisai Inc.,"Eisai Co., Ltd.",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01728623
1205,NCT01730638,Medullary Thyroid Carcinoma,Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma.,ImmunoTEP for Patients With Medullary Thyroid Carcinoma.,Medullary Thyroid Carcinoma,2012-11-12,2016-12-31,2016-12-31,25.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Nantes University Hospital,"Gilead Sciences|Institut National de la Sant Et de la Recherche Mdicale, France|Nantes University Hospital","Angers Hospital|Nantes Hospital|Institut de Cancrologie de l'ouest, Ren Gauducheau",Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01730638
1206,NCT01736163,Thyroid Cancer,"A Retrospective, Non-interventional Study of Patients With T4 Tumours Comparing the Thyroid Remnant Ablation Success Following Thyrogen and 131I Administration Versus Thyroid Hormone Withdrawal and 131I Administration",A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours,Thyroid Cancer,2012-11-26,2012-08-31,2012-08-31,144.0,Case-Control,,Retrospective,Observational,Completed,,Sanofi,"Genzyme, a Sanofi Company",Hanover University School of Medicine|Klinikum Grohadern|Policlinico S.Orsola-Malpighi|Instituto Oncologico Veneto|Istituti Fisioterapici Ospitalieri (IFO)|Portuguese Institute of Oncology|Hospital Universitario Reina Sofa|Hospital Universitario Virgen de las Nieves|Hospital Universitario Dr Peset,Drug|Drug|Other,Germany|Italy|Portugal|Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01736163
1207,NCT01736878,Medullary Thyroid Carcinoma,"Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma",Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma,Medullary Thyroid Carcinoma,2012-10-23,2013-04-30,2013-04-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,Eanm Research Ltd,Eanm Research Ltd,"University Hospital Ulm, Clinic for Nuclear Medicine",Drug,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01736878
1208,NCT01738243,Thyroid Eye Disease,Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Thyroid Eye Disease,2012-10-06,2021-09-30,2021-09-30,2.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",Jules Stein Eye Institute|The Jules Stein Eye Institute at UCLA,Drug|Drug,United States,21.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01738243
1212,NCT01739634,Diarrhea|Medullary Thyroid Cancer,The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer,The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer,Diarrhea|Medullary Thyroid Cancer,2012-11-29,2013-12-31,2013-12-31,10.0,,Single Group Assignment,,Interventional,Unknown status,Phase 1/Phase 2,Salient Pharmaceuticals Incorporated,Salient Pharmaceuticals Incorporated,MD Anderson Cancer Center,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01739634
1213,NCT01739972,Primary Hypothyroidism.,"Desiccated Thyroid Extract Compared to Levothyroxine in the Treatment of Hypothyroidism: A Randomized, Double-blind, Crossover Study.",Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment,Primary Hypothyroidism.,2012-11-28,2014-05-31,2014-05-31,180.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,Walter Reed National Military Medical Center,Walter Reed National Military Medical Center,"Walter Reed National Military Medical Center, Endocrinology|Walter Reed National Military Medical Center",Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01739972
1214,NCT01741064,Disorder Related to Renal Transplantation|Secondary Hyperparathyroidism,Secondary Hyperparathyroidism Related Vascular and Bone Morbidity After Renal Transplantation - a 6 Year Follow up Retrospective Cohort Study.,Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation,Disorder Related to Renal Transplantation|Secondary Hyperparathyroidism,2012-11-30,2012-10-31,2012-10-31,257.0,Cohort,,Retrospective,Observational,Completed,,Skane University Hospital,Karolinska University Hospital|Skane University Hospital,,,,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01741064
1217,NCT01744743,Hypothyroidism,Preconceptional Thyroid Screening and Childhood Nerocognitive Function,Preconceptional Thyroid Screening and Childhood Nerocognitive Function,Hypothyroidism,2012-10-20,2014-12-31,2015-12-31,600.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fudan University,Fudan University|Shanghai Municipal Health Bureau|Shanghai Municipal Science and Technology Commission,"Obstetrics and Gynecology Hospital, Fudan University",Procedure,China,18.0,55.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01744743
1218,NCT01744769,Hypothyroidism,Effects of Thyroid Hormone Withdrawal on Metabolic and Cardiovascular Parameters During Radioactive Iodine Therapy in Differentiated Thyroid Cancer,Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer,Hypothyroidism,2012-12-05,2013-05-31,2013-05-31,80.0,Case-Only,,Prospective,Observational,Unknown status,,Konkuk University Medical Center,Konkuk University Medical Center,Konkuk University Medical Center,,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01744769
1220,NCT01747512,Head and Neck Neoplasms|Thyroid Neoplasms,A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer,An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT),Head and Neck Neoplasms|Thyroid Neoplasms,2012-12-10,2013-05-31,,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Cross Cancer Institute,,Drug|Drug,,18.0,79.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01747512
1221,NCT01750593,Thyroid Nodules,Efficacy of Radiofrequency Ablation in Thyroid Nodules,Radiofrequency Ablation in Thyroid Nodules,Thyroid Nodules,2012-10-07,2014-01-31,2014-06-30,40.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Bezmialem Vakif University medical Faculty|Bezmialem Vakif University|Bezmialem Vakif University,Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01750593
1223,NCT01756534,Goiter|Thyroid Diseases|Thyroid Nodule,The Effectiveness of an Oxidized Cellulose Patch Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Goiter|Thyroid Diseases|Thyroid Nodule,2012-12-19,2013-03-31,2013-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01756534
1225,NCT01757470,Medullary Thyroid Cancer,Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada,Vandetanib Risk Minimisation Effectiveness,Medullary Thyroid Cancer,2012-12-18,2014-02-28,2014-02-28,12.0,Cohort,,Prospective,Observational,Completed,,Sanofi,"Genzyme, a Sanofi Company",Research Site,,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01757470
1226,NCT01757834,Thyroid Nodule,Efficacy of Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Thyroid Nodule,2012-12-12,2015-07-31,2015-08-31,175.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,University of Washington,National Cancer Institute (NCI)|University of Washington,University of Washington Medical Center,Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01757834
1228,NCT01760421,Hashimoto Thyroiditis,The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis,The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis,Hashimoto Thyroiditis,2011-10-20,2012-12-31,2013-08-31,40.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,"Department of Internal Medicine, National Taiwan University Hospital",Drug,Taiwan,20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01760421
1231,NCT01761149,Nodular Goiter,"Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial",Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy,Nodular Goiter,2012-12-30,2013-03-31,,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Central South University,Central South University,"Department of Anesthesiology, The Second Xiangya Hospital",Drug,China,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01761149
1233,NCT01769157,Hypothyroidism,"Single-center, Randomized, Double-Blinded, Comparative Study of the Effectiveness of L-carnitine in Patients'Fatigue Degree Changing With Hypothyroidism Who Take Levothyroxine",Effects of L-carnitine on Hypothyroidism,Hypothyroidism,2013-01-10,2013-06-30,2013-06-30,60.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Korea University Anam Hospital,IlDong Pharmaceutical Co Ltd|Korea University Anam Hospital,Korea University Anam Hospital,Drug|Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01769157
1234,NCT01771523,Goiter,Is the Use of Drain for Thyroid Surgery Realistic?,Is the Use of Drain for Thyroid Surgery Realistic?,Goiter,2011-08-03,2013-01-31,2013-01-31,400.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Maltepe University,Maltepe University,"Maltepe University School of Medicine, General Surgery Department",Procedure|Device,Turkey,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01771523
1235,NCT01774279,Anaplastic Thyroid Cancer,interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT).,interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT),Anaplastic Thyroid Cancer,2013-01-18,2025-02-28,2025-03-31,350.0,Case-Only,,Prospective,Observational [Patient Registry],Recruiting,,Velindre NHS Trust,Velindre NHS Trust,"Beaumont Hospital|St Vincent's Hospital|Galway University Hospital|Addenbrookes Hospital|Velindre Hospital|University Hospitals of Coventry and Warwickshire|Castle Hill Hospital|St James' Institute|Royal Marsden Hospital|Norfolk and Norwich University Hospital NHS Foundation Trust|Nottingham University NHS Trust|Barking, Havering and Redbridge University Hospitals NHS Trust|Weston Park Hospital|Royal Shrewsbury Hospital|New Cross Hospital",Other,Ireland|United Kingdom,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01774279
1237,NCT01776385,Benign Tumor of the Thyroid|Mesothelioma|Parathyroid Neoplasms|Pleural Neoplasms|Pneumothorax|Tumor of the Thyroid,Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer?,The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma,Benign Tumor of the Thyroid|Mesothelioma|Parathyroid Neoplasms|Pleural Neoplasms|Pneumothorax|Tumor of the Thyroid,2012-03-23,2017-12-31,2018-03-31,9.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nice,Centre Hospitalier Universitaire de Nice,CHU de Nice - LPCE- Hpital de Pasteur - 30 ave de la voie Romaine,Other|Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01776385
1240,NCT01776502,Primary Hyperparathyroidism,"A Prospective, Non Randomized, Open, Multicenter Trial to Evaluate Non Specific Symptoms and Quality of Life (SF 36) Before and After Surgery for Mild Primary Hyperparathyroidism",Evaluation of Non Specific Symptoms and Quality of Life Before and After Surgery for Mild Primary Hyperparathyroidism,Primary Hyperparathyroidism,2012-10-24,2010-06-30,2011-06-30,116.0,Cohort,,Prospective,Observational,Completed,,Nantes University Hospital,Nantes University Hospital,Angers University Hospital|Limoges University Hospital|Marseille University Hospital|Nantes University Hospital,,France,0.0,50.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01776502
1243,NCT01778400,Thyroid Nodule,Single Session Treatment of RFA Versus EA for Predominantly Cystic Thyroid Nodules: A Randomized Controlled Trial,RFA (Radiofrequency Ablation) Versus EA (Ethanol Ablation) for Predominantly Cystic Thyroid Nodules,Thyroid Nodule,2013-01-25,2013-05-31,2014-01-31,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Asan Medical Center,Asan Medical Center,Asan Medical Center,Procedure|Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01778400
1245,NCT01779817,Hyperthyroid,"Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Pregnancy","Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy",Hyperthyroid,2013-01-28,2019-01-31,2019-01-31,252.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,"University Hospital, Angers","University Hospital, Angers",University Hospital of Amiens|University Hospital of Angers|Civil Hospices of Lyon|University Hospital of Kremlin Bicetre|University Hospital of Lille|University Hospital of Marseille|University Hospital of Nantes|Hospital of Saint Antoine|University Hospital of Cochin|University Hospital of Poitiers|University Hospital of Reims|University Hospital of Strasbourg|University Hospital of Toulouse,Behavioral,France,6.0,9.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01779817
1246,NCT01780584,Low T3 Syndrome,Oral Triiodothyronine Normalizes T3 Levels After Surgery For Pediatric Congenital Heart Disease,Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?,Low T3 Syndrome,2013-01-28,2010-09-30,2010-10-31,45.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Cardiovascular Center Harapan Kita Hospital Indonesia,National Cardiovascular Center Harapan Kita Hospital Indonesia,Pediatric Cardiac ICU National Cardiovascular Center Harapan Kita Jakarta,Drug|Drug|Drug,Indonesia,0.0,24.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01780584
1247,NCT01781767,Thyroid Cancer,,Changes in Metabolic Status in Patients With Total Thyroidectomy,Thyroid Cancer,2013-01-27,2014-07-31,2014-07-31,50.0,Case-Control,,Prospective,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Sourasky Medical Center,,Israel,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01781767
1248,NCT01781923,22q11.2 Deletion Syndrome|Velo-Cardio-Facial Syndrome,A Remediation Program for Children at High-Risk of Schizophrenia: 22q11.2 Deletion Syndrome,Cognitive Remediation in 22q11DS,22q11.2 Deletion Syndrome|Velo-Cardio-Facial Syndrome,2013-01-29,2015-06-30,2015-06-30,38.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Duke University,Duke University|Harvard University|National Institute of Mental Health (NIMH)|University of Pittsburgh,Duke University Health Systems,Behavioral|Behavioral,United States,11.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT01781923
1250,NCT01783002,Primary Hyperparathyroidism,"Pre-operative Parathyroid Imaging: a Comparison of 11C-Methionine PET, 18F-FDG PET AND SPEC-CT for the Detection of Hyperfunctional Parathyroid Tissues",11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues,Primary Hyperparathyroidism,2013-01-04,2018-03-31,2018-07-31,50.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,University of British Columbia,British Columbia Cancer Agency|University of British Columbia,British Columbia Cancer Agency,Radiation|Radiation|Radiation,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01783002
1253,NCT01785849,"Hyperparathyroidism, Secondary","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis",Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis,"Hyperparathyroidism, Secondary",2013-02-05,2014-05-22,2014-06-12,508.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Poland|Russian Federation|Spain|United Kingdom|United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01785849
1256,NCT01785875,"Hyperparathyroidism, Secondary",A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis,Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,"Hyperparathyroidism, Secondary",2013-02-05,2015-07-01,2015-07-01,891.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|United Kingdom|United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01785875
1259,NCT01788046,"Hyperparathyroidism, Secondary","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis",Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,"Hyperparathyroidism, Secondary",2013-02-07,2014-04-14,2014-05-09,515.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01788046
1262,NCT01788982,Differentiated Thyroid Cancer (DTC)|Medullary Thyroid Cancer (MTC),A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy.,Nintedanib(BIBF1120) in Thyroid Cancer,Differentiated Thyroid Cancer (DTC)|Medullary Thyroid Cancer (MTC),2013-02-08,2019-08-28,2019-08-28,100.0,,Parallel Assignment,,Interventional,Completed,Phase 2,European Organisation for Research and Treatment of Cancer - EORTC,European Organisation for Research and Treatment of Cancer - EORTC,"A.Z. St. Jan|Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet|Cliniques Universitaires Saint-Luc|Universitair Ziekenhuis Antwerpen|Universitair Ziekenhuis Gent|U.Z. Leuven - Campus Gasthuisberg|Odense University Hospital|CHU d'Angers|Institut Bergonie|Centre Regional Francois Baclesse|Centre Georges-Francois-Leclerc|Centre Leon Berard|Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis|Assistance Publique - Hopitaux de Paris - La Piti Salptrire|Centre Jean Godinot|Institut Gustave Roussy|Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern|Universitaetsklinikum Wuerzburg|Fondazione IRCCS Istituto Nazionale dei Tumori|Azienda Ospedaliera Universitaria ""Federico II""|University Medical Center Groningen|Leiden University Medical Centre|Radboud University Medical Center Nijmegen|Maria Sklodowska-Curie Memorial Cancer Centre|Hospital General Vall D'Hebron|Royal Marsden Hospital - Sutton, Surrey|NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital",Drug|Drug,Belgium|Denmark|France|Germany|Italy|Netherlands|Poland|Spain|United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01788982
1263,NCT01789541,Atrial Fibrillation|Subclinical Hyperthyroidism,Observational Prospective Case-control Study on Prevalence and Impact of Subclinical Hyperthyroidism in Patients Undergoing Atrial Fibrillation Ablation,Is a Low Thyreotropin Level Predictive of Recurrent Arrhythmia After Catheter Ablative Surgery?,Atrial Fibrillation|Subclinical Hyperthyroidism,2013-02-05,2015-10-31,2015-11-30,327.0,Case-Control,,Prospective,Observational,Completed,,Karolinska Institutet,Karolinska Institutet,"Stockholm Arrhythmia Center|Hjrtkliniken, Karolinska Universitetssjukhuset Huddinge",,Sweden,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01789541
1264,NCT01792492,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study,The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2011-07-08,2010-03-31,2015-11-30,50.0,Cohort,,Prospective,Observational,Completed,,Boston Medical Center,Boston Medical Center,Boston Medical Center,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01792492
1266,NCT01794676,MEN1 Syndrome|Pancreatic Cancer|Parathyroid Disease|Thymic Cancer,A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers,Genetic Evaluation of Families With Endocrine Cancers,MEN1 Syndrome|Pancreatic Cancer|Parathyroid Disease|Thymic Cancer,2013-02-15,2015-09-30,2015-10-31,9.0,Family-Based,,Prospective,Observational,Completed,,Jersey Shore University Medical Center,Jersey Shore University Medical Center|Rutgers Cancer Institute of New Jersey|Rutgers University,Jersey Shore University Medical Center,Genetic,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01794676
1267,NCT01798966,Thyroid Eye Disease,The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Thyroid Eye Disease,2013-02-21,2013-06-30,2013-06-30,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Sensimed AG,"Sensimed AG|University of California, San Diego","Shiley Eye Center, University of California, San Diego",Device,United States,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01798966
1271,NCT01800617,Hypothyroidism,Phase II Single Daily-Dose Response Study of a New Liothyronine Sodium (T3) Preparation With Sustained Effects in Hypothyroid Patients,A Study of T3 Therapy in Patients With Hypothyroidism,Hypothyroidism,2013-02-18,2014-07-31,,18.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Ipe, LLC","Ipe, LLC",Georgetown University Hospital,Drug,United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01800617
1272,NCT01801033,Hypothyroidism|Thyroidectomy,Effects of Pharmacologic Block of Type-1 Deiodinase on Thyroid Hormone Action and on the Circulating Levels of T3 in Hypothyroid Patients,Effects of Thyroid Hormone Enzyme Blocking on Hypothyroidism,Hypothyroidism|Thyroidectomy,2013-02-26,2013-11-29,2013-11-29,0.0,,,Prospective,Observational,Withdrawn,,National Institutes of Health Clinical Center (CC),"National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",,,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01801033
1273,NCT01805856,Parathyroid Disease|Thyroid Disease,Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery,Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery,Parathyroid Disease|Thyroid Disease,2013-03-05,2012-05-31,2012-05-31,2164.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Ito Hospital,Ito Hospital,Ito Hospital,Drug|Drug,Japan,10.0,90.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01805856
1274,NCT01809444,Thyroid Associated Opthalmopathies,"The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial",Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy,Thyroid Associated Opthalmopathies,2012-12-02,2016-01-31,2016-01-31,146.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Peking Union Medical College Hospital|Zhongshan Ophthalmic Center|JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong|Shenzhen Eye Hospital|Henan Eye Institue, Henan, China|The second xiangya hospital of central south university",Drug|Drug,China,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01809444
1278,NCT01811199,Breast Cancer|Thyroid Cancer,Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2 and LTC4 Levels,Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2 and LTC4 Levels,Breast Cancer|Thyroid Cancer,2013-03-06,2013-04-30,2013-05-31,100.0,Case-Control,,Prospective,Observational,Unknown status,,Marmara University,Marmara University,Marmara University School of Medicine,,Turkey,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01811199
1279,NCT01811212,Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma,Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy,Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma,2013-03-12,2015-07-13,2017-10-09,25.0,,Single Group Assignment,,Interventional,Completed,Phase 2,National Cancer Institute (NCI),Exelixis|National Cancer Institute (NCI),MedStar Georgetown University Hospital|Mayo Clinic in Florida|University of Chicago Comprehensive Cancer Center|Massachusetts General Hospital Cancer Center|Mayo Clinic|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01811212
1282,NCT01812395,Goiter,Is Superior Laryngeal Nerve Really Safe During Thyroidectomy Using Ultrasonic Dissector.,Thyroidectomy Using Ultrasonic Dissector: Is Superior Laryngeal Nerve Really Safe ?,Goiter,2013-03-08,2014-03-31,2014-04-30,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,S.B. Konya Education and Research Hospital,S.B. Konya Education and Research Hospital,Konya Education and Research Hospital,Device|Procedure,Turkey,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01812395
1283,NCT01813136,Thyroid Carcinoma,"A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma",Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma,Thyroid Carcinoma,2013-03-11,2019-01-31,2019-01-31,168.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Centre Leon Berard,Centre Leon Berard|GlaxoSmithKline,CHU Angers|CHU Bordeaux|Institut Bergoni|Centre Franois Baclesse|CHRU Lille Hpital Claude Huriez|Centre Leon Berard|Hpital de la Timone APHM|Centre Antoine Lacassagne|Hpital Saint-Louis APHP|Hpital de la Piti Salptrire APHP|Institut Jean Godinot|Institut Claudius Rgaud|Institut Gustave Roussy,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01813136
1284,NCT01815021,Hypoparathyroidism,"A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism.",A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients,Hypoparathyroidism,2013-03-07,2014-06-30,2014-06-30,10.0,,Crossover Assignment,,Interventional,Completed,Phase 1/Phase 2,Amorphical Ltd.,Amorphical Ltd.,Rambam Health Care Campus,Dietary Supplement|Dietary Supplement,Israel,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01815021
1286,NCT01821781,Autoimmune Lymphoproliferative Syndrome|Chediak-Higashi Syndrome|Chronic Granulomatous Disease|Common Variable Immune Deficiency|DiGeorge Syndrome|Hemophagocytic Lymphohistiocytosis|Hyper-IgM|Immune Deficiency Disorders|Immune Dysregulatory Disorders|IPEX|Severe Combined Immunodeficiency|Wiskott-Aldrich Syndrome|X-linked Agammaglobulinemia|X-linked Lymphoproliferative Syndrome,A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime,Immune Disorder HSCT Protocol,Autoimmune Lymphoproliferative Syndrome|Chediak-Higashi Syndrome|Chronic Granulomatous Disease|Common Variable Immune Deficiency|DiGeorge Syndrome|Hemophagocytic Lymphohistiocytosis|Hyper-IgM|Immune Deficiency Disorders|Immune Dysregulatory Disorders|IPEX|Severe Combined Immunodeficiency|Wiskott-Aldrich Syndrome|X-linked Agammaglobulinemia|X-linked Lymphoproliferative Syndrome,2013-03-19,2024-03-31,2024-03-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Washington University School of Medicine,Washington University School of Medicine,Washington University,Drug,United States,0.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01821781
1288,NCT01830504,Thyroid Cancers,A Multicenter Phase II Pilot Open Label Study to Evaluate the Efficacy and Safety of BKM120 in the Treatment of Patients With Advanced or Metastatic Differentiated Thyroid Cancers,A Multicenter Phase II Pilot Open Label,Thyroid Cancers,2013-04-04,2013-04-30,2017-01-31,47.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01830504
1289,NCT01831869,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study,Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-04-07,2022-04-30,2022-04-30,400.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01831869
1290,NCT01832753,Down Syndrome|Subclinical Hypothyroidism,Levothyroxine Treatment and Cardiometabolic Outcomes in Adolescents With Down Syndrome,Treatment Trial of Subclinical Hypothyroidism in Down Syndrome,Down Syndrome|Subclinical Hypothyroidism,2013-04-09,2017-10-18,2017-10-18,12.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Children's National Medical Center|The Children's Hospital of Philadelphia,Drug,United States,8.0,20.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01832753
1291,NCT01833650,Thyroid Cancer,A Randomized Controlled Trial of the Effectiveness of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer,The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer,Thyroid Cancer,2013-04-11,2018-08-31,2018-09-30,120.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Cyprus University of Technology,Bank of Cyprus Oncology Centre|Cyprus University of Technology,Bank of Cyprus Oncology,Dietary Supplement,Cyprus,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01833650
1292,NCT01837433,Subacute Thyroiditis,Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis,Short-term Prednisone to Treat STA Study(SPTSS),Subacute Thyroiditis,2013-04-06,2014-12-31,2014-12-31,40.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Xinqiao Hospital of Chongqing,Xinqiao Hospital of Chongqing,"The Second Affiliated Hospital, Third Military Medical University",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01837433
1294,NCT01837745,Low Risk Differentiated Thyroid Cancer,Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?,Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?,Low Risk Differentiated Thyroid Cancer,2013-04-16,2020-03-31,2022-05-12,776.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Institut Gustave Roussy,Drug|Drug|Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01837745
1295,NCT01838031,Subclinical Hypothyroidism,Randomized Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study,Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study,Subclinical Hypothyroidism,2013-04-14,2013-09-30,2013-09-30,1000.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Peking Union Medical College Hospital,Beijing Municipal Science & Technology Commission|Peking Union Medical College Hospital,Peking Union Medical College Hospital,Other,China,18.0,42.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01838031
1296,NCT01838629,Thyroid Nodule,,the Effect of Universal Salt Iodization on Thyroid Diseases,Thyroid Nodule,2013-04-19,2012-06-30,2012-06-30,12438.0,Ecologic or Community,,Cross-Sectional,Observational [Patient Registry],Completed,,Hangzhou Center of Disease Control and Prevention,Weimin Xu,Hangzhou Center of Disease Control and Prevention,,China,6.0,86.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01838629
1298,NCT01838642,Thyroid Neoplasms,A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer,Ponatinib for Advanced Medullary Thyroid Cancer,Thyroid Neoplasms,2013-04-20,2015-12-31,2016-01-31,3.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01838642
1299,NCT01840332,Thyroid Cancer,Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer,Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer,Thyroid Cancer,2013-04-22,2014-02-28,2014-02-28,20.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Tartu,University of Tartu,East Tallinn Central Hospital|Tartu University Hospital,Drug,Estonia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01840332
1300,NCT01843062,Differentiated Thyroid Cancer,"A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer",Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2013-03-14,2018-05-18,2019-03-06,233.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,AstraZeneca,AstraZeneca,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug|Drug,Brazil|Denmark|France|Germany|Italy|Poland|Sweden|United States,18.0,130.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01843062
1301,NCT01848171,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism,Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-05-02,2023-07-31,2023-07-31,700.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,40.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01848171
1302,NCT01853579,Depression|Subclinical Hypothyroidism,Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) - Subanalysis on Subclinical Hypothyroidism and Depression,The TRUST Study - Depression Substudy,Depression|Subclinical Hypothyroidism,2013-05-06,2018-04-05,2018-04-05,426.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University Hospital Inselspital, Berne","Leiden University Medical Center|University Hospital Inselspital, Berne|University of Bern","Leiden University Medical Center|Department of General Internal Medicine|University Clinic for General Internal Medicine, Bern University Hospital",Drug|Drug,Netherlands|Switzerland,65.0,120.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01853579
1303,NCT01856920,Medullary Thyroid Cancer (MTC),A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer,QUILT-3.006 for Recurrent Medullary Thyroid Cancer,Medullary Thyroid Cancer (MTC),2013-05-08,2019-12-31,2020-03-01,35.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2,"NantCell, Inc.","NantCell, Inc.|National Cancer Institute (NCI)",NIH Clinical Center,Biological,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01856920
1304,NCT01862510,Celiac Disease|Celiac Sprue|Hypothyroidism|Malabsorption,Detection of Celiac Disease in Patients With Hypothyroidism,Detection of Celiac Disease in Patients With Hypothyroidism,Celiac Disease|Celiac Sprue|Hypothyroidism|Malabsorption,2013-05-20,2014-12-31,2014-12-31,500.0,Cohort,,Prospective,Observational,Completed,,University of Vermont,University of Vermont,Fletcher Allen Health Care,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01862510
1305,NCT01865838,Thyroid Carcinoma,A Study Into the Effect of Seprafilm on Post Operative Adhesions After Open Total Thyroidectomy.,A Study Into the Effect of Seprafilm in Open Total Thyroidectomy,Thyroid Carcinoma,2013-05-14,2014-09-30,2014-09-30,19.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,"National Cancer Centre, Singapore","National Cancer Centre, Singapore|Singapore General Hospital",Singapore General Hospital|National Cancer Centre Singapore,Device,Singapore,21.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01865838
1306,NCT01868750,Hypocalcemia|Thyroid Nodules,"A Phase 2, Placebo-controlled, Randomized Study to Evaluate the Effect of Pre-operative Vitamin D Supplementation on Hypocalcemia Following Total or Near-total Thyroidectomy",Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia,Hypocalcemia|Thyroid Nodules,2013-05-30,2021-07-08,2021-07-08,67.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Virginia,"David Shonka, MD",University of Virginia,Dietary Supplement|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01868750
1308,NCT01868997,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,"A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)",Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,2013-05-02,2016-03-31,2017-02-22,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Jules Stein Eye Institute at UCLA|University of Denver|Emory University Department of Ophthalmology|University of Iowa Hospitals and Clinics, Department of Ophthalmology|Kellogg Eye Center at University of Michigan|Washington University Department of Ophthalmology|University of Nebraska Medical Center Department of Ophthalmology|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|Johannes Gutenberg University Medical Center|Fondazione Ca' Granda Ospedale Policlinico Graves GO Center|University of Pisa, Azienda Ospedaliera|Moorfields Eye Hospital",Drug|Drug,Germany|Italy|United Kingdom|United States,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01868997
1312,NCT01872429,Hyperparathyroidism,,Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients,Hyperparathyroidism,2013-06-05,2013-04-30,2013-04-30,401.0,Cohort,,Retrospective,Observational,Completed,,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01872429
1314,NCT01876784,Differentiated Thyroid Cancer,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.","Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",Differentiated Thyroid Cancer,2013-06-11,2015-08-30,2022-12-31,243.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Washington University|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Brazil|China|Czechia|Denmark|France|Italy|Japan|Poland|Russian Federation|Spain|Sweden|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01876784
1315,NCT01880203,Indeterminate Cytology|Surgery Indication|Thyroid Node,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Indeterminate Cytology|Surgery Indication|Thyroid Node,2013-06-14,2015-09-30,2015-11-30,140.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Centre Francois Baclesse|Fondation avenir|laboratoire Genzyme,Centre Franois BACLESSE|CHU|Hpital Amricain de Paris|Hpital Piti-salptrire,Procedure,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01880203
1317,NCT01882816,Thyroid Cancer,A Phase II Study of Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer,Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer,Thyroid Cancer,2013-06-13,2021-11-04,2021-11-04,27.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Rockville Centre,Radiation|Device|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01882816
1318,NCT01884649,Hashimoto Thyroiditis,Fetuin A as a New Marker of Inflammation in Hashimoto Thyroiditis,Fetuin A in Hashimoto Thyroiditis,Hashimoto Thyroiditis,2013-06-17,2012-10-31,2012-10-31,97.0,,,Cross-Sectional,Observational [Patient Registry],Completed,,Istanbul Medeniyet University,Istanbul Medeniyet University,,,,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01884649
1321,NCT01885533,Graves' Disease,POST-RADIOIODINE GRAVES' MANAGEMENT,Post-Radioiodine Graves' Management: The PRAGMA-Study,Graves' Disease,2013-02-15,2015-02-28,2015-12-31,803.0,Cohort,,Retrospective,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Cardiff and Vale University Health Board|Newcastle-upon-Tyne Hospitals NHS Trust|Royal Devon and Exeter NHS Foundation Trust,Newcastle upon Tyne Hospitals NHS Foundation Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01885533
1324,NCT01889134,Primary Hyperparathyroidism,Osteoprotegerin/sRANKL Ratio and Bone Mineral Density in Patients With Primary Hyperparathyroidism Treated With Parathyroidectomy or Alendronate,OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2013-06-21,2012-06-30,2012-10-31,112.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Wroclaw Medical University,"Ministry of Science and Higher Education, Poland|Wroclaw Medical University","Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University",Drug|Procedure,Poland,25.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01889134
1327,NCT01893450,Graves Ophthalmopathy,"Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.",Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment,Graves Ophthalmopathy,2013-06-28,2013-06-30,2013-06-30,31.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Drug|Drug|Drug,Mexico,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01893450
1331,NCT01896232,Chronic Kidney Disease|Secondary Hyperparathyroidism,"A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism",Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,Chronic Kidney Disease|Secondary Hyperparathyroidism,2013-07-08,2014-11-12,2015-01-08,683.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug|Drug|Drug,Austria|Belgium|Canada|Czechia|Denmark|Estonia|France|Germany|Greece|Hungary|Italy|Latvia|Lithuania|New Zealand|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|Turkey|United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01896232
1334,NCT01896479,Medullary Thyroid Cancer,"A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients","A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer",Medullary Thyroid Cancer,2013-07-08,2020-07-31,2022-12-31,250.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 4,Exelixis,Exelixis,,Drug|Drug|Drug|Drug,"Australia|Canada|Croatia|France|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01896479
1335,NCT01907997,Thyroid Cancer,,Effects of Systemic Lidocaine on Postoperative Quality of Recovery After Robot-assisted Thyroidectomy,Thyroid Cancer,2013-07-17,2015-03-31,2015-05-31,90.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei universiy college of medicine",Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01907997
1336,NCT01915485,Medullary Thyroid Cancer,The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer,Radiolabeled Molecules for Medullary Thyroid Cancer,Medullary Thyroid Cancer,2013-08-01,2016-11-30,2017-02-28,20.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,"Instituto Nacional de Cancer, Brazil","Instituto Nacional de Cancer, Brazil",Instituto Nacional do Cancer do Rio de Janeiro,Radiation,Brazil,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01915485
1337,NCT01916018,Congenital Hypothyroidism,Phenotype and Genotype Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. The Use of Genetic Analysis in the Early Care of Children With Thyroid Dysgenesis,Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.,Congenital Hypothyroidism,2013-08-02,2017-03-17,2017-03-17,558.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,"Pediatric endocrinology gynecology and diabetology, Hpital Necker Enfants Malades, Assistance Publique - Hpitaux de Paris , Universit Paris Descartes, INSERM unit U 845",Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01916018
1340,NCT01916304,Hypothyroidism,"A Multicentre, Open-label Switch Study to Investigate the Necessity of Dose Adjustment After Switching From L-Thyroxine Christiaens to the New Levothyroxine Sodium Test Formulation in (Near) Total Thyroidectomised Patients.",Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation,Hypothyroidism,2013-08-01,2014-06-30,2014-06-30,101.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Takeda,Takeda,,Drug,Belgium,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01916304
1341,NCT01921452,Hypothyroidism,A Single-center Interventional Study to Verify Clinical Utility of the Quantitative and the Qualitative POC TSH Test Kits Compared With the Third Generation TSH Test Kit,Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit,Hypothyroidism,2013-08-09,2014-02-28,2014-02-28,283.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",Research site,Device|Device|Device,China,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01921452
1342,NCT01922440,Hypoparathyroidism,PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism,A Registry for Participants With Chronic Hypoparathyroidism,Hypoparathyroidism,2013-08-01,2034-11-30,2034-11-30,1064.0,Other,,Prospective,Observational [Patient Registry],Recruiting,,Takeda,"Takeda|Takeda Development Center Americas, Inc.","University of Alabama at Birmingham|University of Arizona Medical Center|Children's Hospital Los Angeles|Cedars-Sinai Medical Center|Dr. Joselito Cabaccan|University of Colorado Hospital|Yale University|Hanson Clinical Research Center|Thyroid & Endocrine Center of Florida|East-West Medical Research Institute|Suburban Endocrinology & Diabetes|University of Chicago Medical Center|Northshore University Health System|Loyola University Medical Center|Indiana University Hospital|Tilak Mallik, MD F.A.C.E., LCC|Model Clinical Research|Medstar Union Memorial Hospital|Massachusetts General Hospital|Brigham and Women's Hospital|Harvard Medical School|Boston Medical Center|University of Minnesota|Mayo Clinic - Rochester|University of Missouri|Diabetes & Endocrine Associates, Methodist Physicians Clinic Diabetes and Endocrine Specialists|Palm Research Center, Inc.|Northern Nevada Endocrinology|Rutgers Robert Wood Johnson Medical School|Rutgers-Robert Wood Johnson Medical School|Albany Med Endocrine Specialists|Brokhin Medical PC|Gerald Friedman Diabetes Institute|Columbia University Medical Center|Endocrine Associates of Long Island, P.C.|University Physicians Group Research Division|State University Of New York Upstate Medical University|Mecklenburg Medical Group|Physicians East, PA|Cleveland Clinic|Ohio State University Wexner Medical Center|Ohio Health Research Institute|Endocrinology Associates of Armstrong|The Children's Hospital of Philadelphia|Thomas Jefferson University|Alleghany General Hospital|Hallett Center for Diabetes and Endocrinology|University of South Carolina|Texas Diabetes and Endocrinology, P.A.|Thyroid Endocrinology and Diabetes|Academy of Diabetes Thyroid and Endocrine|Diabetes and Thyroid Center of Fort Worth, PLLC|University of Vermont|University of Wisconsin|Medizinische Universitaetsklinik Graz, Universittsklinik Fr Innere Medizin Graz|AKH Wien, Universitaetsklinik fuer Innere Medizin III|Nova Scotia Health Authority|McMaster University|Aallborg University Hospital|Aarhus Universitetshospital|Nordsjaellands Hospital - Hillerod|Regions Hospitalet Viborg|Diakonie-Klinikum Stuttgart|Medizinische Hochschule Hannover|University Hospital Duesseldorf|University of Leipzig|Universitaetsklinik Aachen|Charite-Universitiitsmedizin Berlin (CCM)|Praxis an der Kaiserreiche|Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden|Endokrinologikum Frankfurt|MVZ endokrinologikum Gttingen|Universitaet Zur Luebeck|Medicover Neuroendokrinologie MVZ|Medicover Neu-Ulm Mvz|Medicover Oldenburg MVZ|Medicover Saarbuecken Mvz|Endokrinologie Zentrum Ulm|Universitaetsklinikum Wuerzburg|General Hospital Of Athens - Korgialenio-Benakio E.E.S.|General Hospital of Athens Georgios Gennimatas|General Hospital of Athens Alexandra|AHEPA University General Hospital of Thessaloniki|Hippokrateion General Hospital of Thessaloniki|Azienda Ospedaliero-Universitaria Careggi|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico|Azienda Ospedaliera San Giovanni Addolorata|Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza - Ospedale Molinette|Haukeland University Hospital|Spesialistsentret Pilestredet Park|Hospital Del Mar|Hospital Universitario San Cecilio|Hospital Universitario 12 de Octubre|Universitetssjukhuset I Linkoping|Universitetssjukhuset I Orebro|Karolinska Universitetssjukhuset Solna|Akademiska Sjukhuset - Uppsala University Hospital|Queen Elizabeth Hospital-Mindelsohn Way|University of Hospitals of Leicester|Norfolk And Norwich University Hospital - Norwich Medical School",Other,Austria|Canada|Denmark|Germany|Greece|Italy|Norway|Spain|Sweden|United Kingdom|United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01922440
1344,NCT01922843,"Hyperparathyroidism, Secondary|Kidney Failure, Chronic","A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis",A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis,"Hyperparathyroidism, Secondary|Kidney Failure, Chronic",2013-08-12,2014-05-31,2014-06-30,62.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Deltanoid Pharmaceuticals,Deltanoid Pharmaceuticals,,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01922843
1347,NCT01927406,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,2013-08-16,2016-12-31,2016-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,Stanford University,Stanford University,Stanford Hospital and Clinics,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01927406
1351,NCT01927887,Follicular Thyroid Cancer Lymph Node Metastasis|Metastatic Medullary Thyroid Cancer|Papillary Carcinoma of Thyroid Gland,Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study,Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study,Follicular Thyroid Cancer Lymph Node Metastasis|Metastatic Medullary Thyroid Cancer|Papillary Carcinoma of Thyroid Gland,2013-08-20,2015-04-30,2016-04-30,12.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Drug|Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01927887
1354,NCT01932970,"Hyperparathyroidism, Secondary","A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416",Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide,"Hyperparathyroidism, Secondary",2013-08-28,2014-01-14,2017-02-14,158.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01932970
1357,NCT01935856,Hyperparathyroidism,"A Dose Escalation, Single and Multiple Dose, Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis",Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis,Hyperparathyroidism,2013-09-02,2014-03-31,2014-03-31,20.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug,Japan,20.0,74.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01935856
1360,NCT01939977,Secondary Hyperparathyroidism Due to Renal Causes,Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.,Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.,Secondary Hyperparathyroidism Due to Renal Causes,2013-08-28,2015-09-30,2015-12-31,148.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Fundacin Senefro,AbbVie|Effice Servicios Para la Investigacion S.L.|Fundacin Senefro,Hospital Universitari Germans Trias I Pujol de Badalona|Hospital Universitari de Bellvitge|Hospital Universitario Marqus de Valdecilla|Hospital Del Mar|Fundaci Puigvert-Iuna|Hospital Universitari Vall D'Hebron|Hospital Puerta Del Mar|Hospital Reina Sofa|Complexo Hospitalario Universitario A Coruna|Complejo Hospitalario Universitario de Canarias|Hospital Ramn Y Cajal|Hospital Universitario 12 de Octubre|Complejo Hospitalario Regional de Mlaga|Hospital Virgen Del Roco|Hospital Universitari I Politcnic La Fe|Hospital Universitario Miguel Servet,Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01939977
1363,NCT01945229,Atrial Fibrillation|Hyperthyroidism,Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE),Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE),Atrial Fibrillation|Hyperthyroidism,2013-09-13,2020-08-31,2020-08-31,110.0,Cohort,,Prospective,Observational,Terminated,,Karolinska Institutet,Karolinska Institutet,"Medicine Clinic, Sahlgrenska University Hospital|Endocrinology Clinik, Karolinska University Hospital|Medicine Clinic, Danderyds Hospital",,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01945229
1364,NCT01945762,"Advanced/Metastatic Medullary Thyroid Cancer (MTC)|Symptomatic, Aggressive, Sporadic, Unresectable, Locally","European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer",Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer,"Advanced/Metastatic Medullary Thyroid Cancer (MTC)|Symptomatic, Aggressive, Sporadic, Unresectable, Locally",2013-09-10,2020-06-18,2020-06-18,31.0,Cohort,,Prospective,Observational,Completed,,Sanofi,"Genzyme, a Sanofi Company|Worldwide Clinical Trials",investigational Site Belgium|investigational Site France|investigational Site Germany|investigational Site Italy|investigational Site Luxembourg|investigational Site Netherlands|investigational Site Spain|investigational Site United Kingdom,Drug,Belgium|France|Germany|Italy|Luxembourg|Netherlands|Spain|United Kingdom,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01945762
1365,NCT01947023,Metastatic Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer,Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery,Metastatic Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2013-09-16,2022-07-01,2022-07-01,21.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01947023
1366,NCT01950260,Graves' Disease,Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease,Early Levothyroxine Post Radioactive Iodine,Graves' Disease,2013-09-23,2017-04-30,2017-04-30,61.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Drug|Other,United States,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01950260
1369,NCT01954134,Thyroid Neoplasms,P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?,P53 in Differentiated Thyroid Cancer,Thyroid Neoplasms,2013-09-11,2013-01-31,2013-01-31,199.0,Case-Control,,Prospective,Observational,Completed,,Cumhuriyet University,Cumhuriyet University,"Cumhuriyet University, School of Medicine, Dept. of Nuclear Medicine",,Turkey,16.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01954134
1370,NCT01964144,Thyroid Cancer,,"An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer",Thyroid Cancer,2013-10-09,2014-10-31,2014-10-31,40.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Yonsei University,Yonsei University,"Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine",Drug,"Korea, Republic of",20.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01964144
1371,NCT01964508,FNA|microRNA|Thyroid Cancer|Thyroid Nodule,The Use of a microRNA Panel to Identify Thyroid Malignancy in FNA Leftover Cells and the Effect of These microRNAs on Target Genes.,microRNA in Thyroid Cancer,FNA|microRNA|Thyroid Cancer|Thyroid Nodule,2013-10-14,2015-12-30,2015-12-30,77.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Hadassah Medical Organization,Hadassah Medical Organization,Hadassah Medical Organization,Other,Israel,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01964508
1373,NCT01969019,Graves' Ophthalmopathy,A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy,"A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy",Graves' Ophthalmopathy,2013-10-21,2013-10-31,2013-10-31,70.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Ruijin Hospital,Ruijin Hospital,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital",Drug,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01969019
1377,NCT01974284,Papillary Thyroid Cancer,Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma,Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma,Papillary Thyroid Cancer,2013-10-25,2017-03-02,2017-06-29,7.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Yale University,Yale University,Endocrine Surgery Smilow Cancer Hospital at Yale-New Haven,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01974284
1379,NCT01985204,Iodine Deficiency|Subclinical Hypothyroidism,Assessment of the Improvement of the Cardiovascular Risk Profile in Obese Women After Correction of Iodine Deficiency,Iodine Supplementation in Obesity,Iodine Deficiency|Subclinical Hypothyroidism,2013-10-31,2014-06-30,2014-07-31,162.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Swiss Federal Institute of Technology,Swiss Federal Institute of Technology,"Universite Caddi Ayad, Faculte de Medecine et de Pharmacie|University Cadi Ayyad, Faculte des Sciences",Dietary Supplement|Dietary Supplement,Morocco,20.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT01985204
1380,NCT01994200,Thyroid Cancer,Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) For Newly Diagnosed Thyroid Cancer Patients: Randomized Controlled Trial,Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients,Thyroid Cancer,2013-11-19,2016-06-30,2016-06-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 1/Phase 2,Jewish General Hospital,"Genzyme, a Sanofi Company|Jewish General Hospital",Jewish General Hospital,Other|Other,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01994200
1381,NCT01996072,Primary Hyperparathyroidism,A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Parathyroidectomy for Primary Hyperparathyroidism.,EC17 for Intraoperative Imaging for Parathyroidectomy,Primary Hyperparathyroidism,2013-11-21,2014-09-30,2014-09-30,10.0,,Single Group Assignment,,Interventional,Completed,Phase 1,University of Pennsylvania,University of Pennsylvania,Hospital of the University of Pennsylvania,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01996072
1384,NCT01997554,Euthyroidism|Hypothyroidism|Sub-clinical Hypothyroidism,Validation of a New TSH Test for Early Screening of Hypothyroidism,Validation of a New TSH Test,Euthyroidism|Hypothyroidism|Sub-clinical Hypothyroidism,2013-10-28,2014-08-31,2014-08-31,1654.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre Hospitalier de Chambry|Centre Hospitalier Lyon Sud,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01997554
1385,NCT01999790,Graves Ophthalmopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Graves Ophthalmopathy,2013-11-17,2014-12-31,2015-02-28,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo,University of Sao Paulo,Hospital das Clinicas - FMUSP,Procedure|Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT01999790
1389,NCT02005250,Hyperthyroidism|Hypothyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Hyperthyroidism|Hypothyroidism,2013-12-03,2016-10-31,2020-01-01,93.0,Cohort,,Prospective,Observational,Completed,,Odense University Hospital,Steen Bonnema,Odense University Hospital,,Denmark,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02005250
1391,NCT02012231,Cholangiocarcinoma|Colorectal Cancer|Hairy Cell Leukemia|Histiocytosis|Melanoma|Non-small Cell Lung Cancer|Thyroid Cancer,"A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",Cholangiocarcinoma|Colorectal Cancer|Hairy Cell Leukemia|Histiocytosis|Melanoma|Non-small Cell Lung Cancer|Thyroid Cancer,2013-12-05,2014-09-30,2015-06-30,5.0,,Single Group Assignment,,Interventional,Terminated,Phase 1,Fore Biotherapeutics,Fore Biotherapeutics,Scottsdale Healthcare|Huntsman Cancer Institute|Evergreen Hematology & Oncology,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02012231
1392,NCT02012686,Neck Pain|Thyroid Cancer,The Effect of Transcutaneous Electrical Nerve Stimulation for Reduction of Posterior Neck Pain After Thyroidectomy,The Effect of Transcutaneous Electrical Nerve Stimulation on Posterior Neck Pain After Thyroidectomy,Neck Pain|Thyroid Cancer,2013-12-04,2014-01-31,2014-02-28,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Gangnam Severance Hospital, Anesthesia and Pain Research Institute, Yonsei University College of Medicine",Device,"Korea, Republic of",20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02012686
1393,NCT02012699,Anal Cancer|Bile Duct Cancer|Bladder Cancer|Breast Cancer|CNS Cancer|CNS Tumor|Colon Cancer|Duodenal Cancer|Endometrial Cancer|Esophageal Cancer|Familial Adenomatous Polyposis|Gallbladder Cancer|Gastric Cancer|GIST|Healthy Control|Hypopharyngeal Cancer|Kidney Cancer|Laryngeal Cancer|Leukemia|Lip Cancer|Liver Cancer|Lung Cancer|Lynch Syndrome|Melanoma|Mesothelioma|Multiple Myeloma|Nasal Cavity Cancer|Nasopharyngeal Cancer|Neuroendocrine Tumors|Oral Cavity Cancer|Oropharyngeal Cancer|Ovarian Cancer|Pancreatic Cancer|Paranasal Sinus Cancer|Penile Cancer|Peritoneal Surface Malignancies|Plasma Cell Dyscrasia|Prostate Cancer|Rectal Cancer|Salivary Gland Cancer|Sarcoma|Skin Cancer|Small Intestine Cancer|Testicular Cancer|Thymus Cancer|Thyroid Cancer|Unknown Primary Tumor|Ureter Cancer|Urethral Cancer|Vaginal Cancer,Integrated Cancer Repository for Cancer Research,Integrated Cancer Repository for Cancer Research,Anal Cancer|Bile Duct Cancer|Bladder Cancer|Breast Cancer|CNS Cancer|CNS Tumor|Colon Cancer|Duodenal Cancer|Endometrial Cancer|Esophageal Cancer|Familial Adenomatous Polyposis|Gallbladder Cancer|Gastric Cancer|GIST|Healthy Control|Hypopharyngeal Cancer|Kidney Cancer|Laryngeal Cancer|Leukemia|Lip Cancer|Liver Cancer|Lung Cancer|Lynch Syndrome|Melanoma|Mesothelioma|Multiple Myeloma|Nasal Cavity Cancer|Nasopharyngeal Cancer|Neuroendocrine Tumors|Oral Cavity Cancer|Oropharyngeal Cancer|Ovarian Cancer|Pancreatic Cancer|Paranasal Sinus Cancer|Penile Cancer|Peritoneal Surface Malignancies|Plasma Cell Dyscrasia|Prostate Cancer|Rectal Cancer|Salivary Gland Cancer|Sarcoma|Skin Cancer|Small Intestine Cancer|Testicular Cancer|Thymus Cancer|Thyroid Cancer|Unknown Primary Tumor|Ureter Cancer|Urethral Cancer|Vaginal Cancer,2013-12-02,2099-12-31,2099-12-31,999999.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,University of Nebraska,University of Nebraska,"Penrose Cancer Center|Porter Adventist Hospital|Mercy Regional Medical Center|St. Anthony Hospital|Littleton Cancer Center|Longmont Cancer Center|Avista Cancer Center|Parker Adventist Hospital|St. Mary Corwin Medical Center|St. Anthony North Cancer Center|Florida Hospital Memorial Medical Center|Florida Hospital DeLand|Florida Hospital FISH|Florida Hospital Flagler|Rush-Copley Cancer Care Center|Trinity Medical Center|Rush-Copley Healthcare Center|Parkview Research Center|Community Health Network|Community Cancer Center South|Community Cancer Center North|Community Howard Regional Hospital|Methodist Jennie Edmundson Hospital|Genesis Medical Center|Abben Cancer Center|Covenant Medical Center, Inc|Saint Luke's Cancer Instititue - South|Tulane University|Breast Care Specialists of Maine|Northwest Hospital|William E Kahlert Regional Cancer Center|Holyoke Medical Center|University of Michigan Health System|Riverwood Healthcare Center|Essentia Health-St. Joseph's Medical Center|Essentia Health - Duluth Clinic|St. Luke's Hospital of Duluth|Lake Region Healthcare|Avera Cancer Institute- Marshall|Mercy Hospital - Joplin|Saint Luke's Cancer Institute - East|Saint Luke's Cancer Institute|Saint Luke's Cancer Institute - Kansas City North|Saint Luke's Cancer Institute - Liberty|Heartland Regional Medical Center dba Mosaic Life Care|Bozeman Health Deaconess Hospital|Logan Health|Providence St. Patrick Hospital Montana Cancer Center|Mary Lanning Healthcare/Morrison Cancer Center|Faith Regional Health Services, Carson Cancer Center|Great Plains Regional Medical Center|Avera St. Anthony's Hospital|Methodist Estabrook Cancer Center|Nebraska Methodist Health System|University of Nebraska Medical Center|Regional West Health Services|C.R. Wood Cancer Center, Glens Falls Hospital|Faxton St. Luke's Healthcare/Mohawk Valley|Cape Fear Valley Health System|Essentia Health|Trinity Hospital Cancer Care Center|Aultman Alliance Community Hospital|Aultman Hospital|University of Pittsburgh|Avera Medical Group Oncology and Hematology Aberdeen|Avera Cancer Institute|Avera Cancer Institute|Sanford Health|Avera Cancer Center Yankton|Avera Sacred Heart Hospital|Yankton Medical Clinic|Rutland Regional Medical Center|Mary Washington Hospital|Ascension St. Elizabeth Hospital|Wheaton Franciscan Healthcare - Elmbrook Memorial Hospital|Wheaton Franciscan Healthcare - Reiman Cancer Care|Columbia St. Mary's|Columbia St. Mary's|Ascension Mercy Hospital|Wheaton Franciscan Healthcare - All Saints|Wheaton Franciscan Healthcare - Wauwatosa Cancer Care",,United States,19.0,110.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02012699
1394,NCT02013479,Autoimmune Thyroiditis,The Chronic Autoimmune Thyroiditis Quality Of Life Selenium Trial,Selenium Supplementation in Autoimmune Thyroiditis,Autoimmune Thyroiditis,2013-12-03,2022-08-31,2022-12-31,415.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Odense University Hospital,"Bispebjerg Hospital|Hospital of South West Denmark|Pharma Nord|Region of Southern Denmark|Rigshospitalet, Denmark|Steen Bonnema|The Danish Medical Research Council|University of Southern Denmark","Clinic of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet|Department of Endocrinology and Gastroenterology, Bispebjerg Hospital|Department of Internal Medicine, Hospital of South West Denmark|Department of Endorcrinology and Metabolism, Odense University Hospital",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02013479
1397,NCT02017080,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,Efficacy Of Non Invasive Diagnostic Procedures In Evaluating The Influence Of Maternal Autoimmune Thyroid Gland Disease On Fetus,Fetal Thyroid Ultrasound And Fetal Thyroid Hormones,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2013-12-15,2019-12-31,2020-01-31,300.0,Case-Control,,Prospective,Observational,Unknown status,,University of Belgrade,University of Belgrade,"Clinic for Gynecology and Obstetrics , Clinical Center of Serbia",,Serbia,20.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02017080
1399,NCT02018276,Thyroid Cancer,,Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery,Thyroid Cancer,2013-12-16,2014-10-31,2014-10-31,135.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain MedicineSeverance Hospital, Yonsei University Health System",Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02018276
1400,NCT02024906,Cardiovascular Disease|Subclinical Hypothyroid,Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants,Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants,Cardiovascular Disease|Subclinical Hypothyroid,2013-12-27,2015-09-30,2015-09-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Not Applicable,University of Kansas Medical Center,"Jill Hamilton-Reeves, PhD RD LD|Soy Nutrition Institute",University of Kansas Medical Center,Dietary Supplement|Dietary Supplement,United States,25.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02024906
1401,NCT02041260,Differentiated Thyroid Cancer (DTC)|Poorly Differentiated Thyroid Cancer,A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,Differentiated Thyroid Cancer (DTC)|Poorly Differentiated Thyroid Cancer,2014-01-17,2022-05-31,2022-05-31,43.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Thomas Jefferson University,Thomas Jefferson University,Abramson Cancer Center of the University of Pennsylvania,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02041260
1402,NCT02054572,Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis,"An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis",Pharmacokinetics and Excretion of [C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis,Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis,2014-02-03,2014-04-15,2014-08-15,6.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Amgen,Amgen,DaVita Clinical Research Center,Drug,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02054572
1405,NCT02055989,"Locally Advanced Larynx, Hypopharyngeal Squamous Cell Cancers|Locally Advanced Thyroid Cancers","A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx","A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx","Locally Advanced Larynx, Hypopharyngeal Squamous Cell Cancers|Locally Advanced Thyroid Cancers",2014-02-04,2011-12-31,,105.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Royal Marsden Hospital,Radiation|Radiation,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02055989
1406,NCT02056730,"Hyperparathyroidism, Secondary",The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients,The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid,"Hyperparathyroidism, Secondary",2014-01-28,2015-02-28,2015-02-28,60.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Chulalongkorn University,Chulalongkorn University,Chulalongkorn Memorial Hospital,Drug,Thailand,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02056730
1409,NCT02059655,Graves' Ophthalmopathy,Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial,Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study),Graves' Ophthalmopathy,2014-02-07,2016-03-31,2016-03-31,31.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Cardiff University,Cardiff University|National Institute for Social Care and Health Research,University Hospital of Wales,Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02059655
1413,NCT02061111,Alteration of Mitochondrial Membrane|Autoimmune Thyroid Disease|Subclinical Hypothyroidism,NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease,NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease,Alteration of Mitochondrial Membrane|Autoimmune Thyroid Disease|Subclinical Hypothyroidism,2014-01-22,2017-12-31,2022-11-30,77.0,Cohort,,Prospective,Observational,Active not recruiting,,Naestved Hospital,Naestved Hospital|Region Zealand|University of Southern Denmark,Gynaecologic-Obstetrics Department Naestved Hospital,,Denmark,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02061111
1414,NCT02062632,Esophageal Carcinoma|Hypopharyngeal Carcinoma|Laryngeal Carcinoma|Lymphoma|Mesothelioma|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Neoplasm in the Pleura|Metastatic Malignant Neoplasm in the Spinal Cord|Non-Small Cell Lung Carcinoma|Sarcoma|Small Cell Lung Carcinoma|Thymic Carcinoma|Thymoma|Thyroid Gland Carcinoma,"A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy",Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy,Esophageal Carcinoma|Hypopharyngeal Carcinoma|Laryngeal Carcinoma|Lymphoma|Mesothelioma|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Neoplasm in the Pleura|Metastatic Malignant Neoplasm in the Spinal Cord|Non-Small Cell Lung Carcinoma|Sarcoma|Small Cell Lung Carcinoma|Thymic Carcinoma|Thymoma|Thyroid Gland Carcinoma,2014-02-12,2015-05-29,2017-11-06,5.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Mayo Clinic,Mayo Clinic|National Cancer Institute (NCI),Mayo Clinic|University of Nebraska Medical Center|Green Bay Oncology Limited at Saint Mary's Hospital,Drug|Other|Other|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02062632
1415,NCT02070211,22q11 Deletion Syndrome,"Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome Genetically at High Risk for Psychosis: A Randomised, Double Blind, Placebo-controlled Treatment Trial.",Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.,22q11 Deletion Syndrome,2014-02-17,2016-06-30,2016-06-30,80.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,Bambino Ges Hospital and Research Institute,Bambino Ges Hospital and Research Institute|National Alliance for Research on Schizophrenia and Depression|Orygen,Bambino Ges Hospital and Research Institute,Dietary Supplement|Other|Dietary Supplement,Holy See (Vatican City State),12.0,26.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02070211
1417,NCT02084732,Thyroid Cancer,Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,Thyroid Cancer,2014-03-07,2019-11-01,2019-11-01,35.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Instituto Nacional de Cancerologia, Columbia","Instituto Nacional de Cancerologia, Columbia",Instituto Nacional de Cancerologa,Drug,Colombia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02084732
1418,NCT02088645,"Neuroendocrine Tumor GEP Grade 1-3|Neuroendocrine Tumor of the Lung Grade 1 and 2|Neuroendocrine Tumor of the Thymus Grade 1 and 2|Thyroid Cancer, Medullary",177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.,177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.,"Neuroendocrine Tumor GEP Grade 1-3|Neuroendocrine Tumor of the Lung Grade 1 and 2|Neuroendocrine Tumor of the Thymus Grade 1 and 2|Thyroid Cancer, Medullary",2014-02-19,2021-12-31,2022-03-31,24.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,"University Hospital, Basel, Switzerland","Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland|Krebsforschung Schweiz, Bern, Switzerland|University Hospital, Basel, Switzerland|University Hospital Freiburg|University Hospital, Zrich","University Hospital Basel, Clinic for radiology and nuclear medicine",Drug,Switzerland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02088645
1419,NCT02089542,Bilateral Neck Exploration for Primary Hyperparathyroidism|Total Thyroidectomy,Development of a Clinical Protocol to Use Intra-operative Near Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery,Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery,Bilateral Neck Exploration for Primary Hyperparathyroidism|Total Thyroidectomy,2014-03-13,2016-06-30,2016-10-31,41.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Sheffield Teaching Hospitals NHS Foundation Trust,Sheffield Teaching Hospitals NHS Foundation Trust,Department of General Surgery,Other,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02089542
1422,NCT02090907,Subclinical Hypothyroidism,Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism,Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidism,2014-03-12,2014-02-28,2014-02-28,50.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Isfahan University of Medical Sciences,Isfahan University of Medical Sciences,Khorshid endocrinology clinic,Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02090907
1423,NCT02094079,Hypothyroidism,Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women,Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women With Hypothyroidism,Hypothyroidism,2014-03-18,2015-03-31,2015-03-31,80.0,Cohort,,Retrospective,Observational,Completed,,Herlev Hospital,Birte Nygaard,"Endocrine Unit O, Herlev Hospital, University of Copenhagen",Other,Denmark,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02094079
1424,NCT02102204,"Hyperparathyroidism, Secondary",A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis,Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis,"Hyperparathyroidism, Secondary",2014-03-03,2016-11-04,2017-06-26,902.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Latvia|Lithuania|Netherlands|New Zealand|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|Turkey|United States,18.0,110.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02102204
1427,NCT02107794,Graves' Disease|Hyperthyroidism|Thyroid Disease,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Graves' Disease|Hyperthyroidism|Thyroid Disease,2014-03-24,2015-04-30,2015-04-30,93.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02107794
1430,NCT02109250,Metastatic Medullary Thyroid Cancer,CAPRELSA REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa) in Current Clinical Practice,CAPRELSA REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa) in Current Clinical Practice,Metastatic Medullary Thyroid Cancer,2014-03-27,2015-06-30,2015-06-30,10.0,Case-Only,,Other,Observational [Patient Registry],Completed,,Sanofi,"Genzyme, a Sanofi Company",Clinique du Sud Luxembourg|AZ Klina|Institut Jules Bordet|UZ Brussel|UCL St-Luc|UZ Gent|AZ Delta|CH de Wallonie,Drug,Belgium,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02109250
1431,NCT02112370,Goiter|Thyroid Neoplasm,Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy,Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy,Goiter|Thyroid Neoplasm,2014-04-07,2016-05-31,2016-06-30,148.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Seoul National University Hospital,Seoul National University Bundang Hospital|Seoul National University Hospital,Seoul National University Bundang Hospital|Seoul National University Hospital,Drug|Other,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02112370
1432,NCT02112643,Thyroid Associated Ophthalmopathies,Selenium - ITEDS: A North American Study,Selenium in Mild Thyroid Eye Disease in North America,Thyroid Associated Ophthalmopathies,2014-04-08,2016-11-16,2016-11-16,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 3,Columbia University,Columbia University|International Thyroid Eye Disease Society,,Drug|Dietary Supplement,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02112643
1436,NCT02114619,Graves' Disease,The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease,Comparative Study of Different I-131 Doses in Graves' Disease,Graves' Disease,2014-04-12,2014-12-31,2016-12-31,450.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,"Nuclear Medicine Research Center, Ghaem Hospital",Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02114619
1439,NCT02114658,Thyroid Carcinoma,"A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma",Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients,Thyroid Carcinoma,2014-04-08,2015-02-23,2016-08-02,18.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Bayer,Bayer,,Drug,Japan,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02114658
1440,NCT02126683,Hashimoto's Thyroiditis,The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis,The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis,Hashimoto's Thyroiditis,2014-04-28,2016-02-29,2016-09-30,60.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,35.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02126683
1443,NCT02133040,Hyperthyroidism,Identification and Regulation of Brown Adipose Tissue (BAT) in Humans. Implications for Energy Expenditure in Humans and in the Treatment of Obesity and Related Metabolic Diseases,Effects of Hyperthyroidism on Amount and Activity of Brown Adipose Tissue,Hyperthyroidism,2014-05-05,2018-05-10,2020-05-10,10.0,Case-Only,,Prospective,Observational,Unknown status,,Aarhus University Hospital,Aarhus University Hospital|Novo Nordisk A/S,Aarhus University Hospital,,Denmark,50.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02133040
1444,NCT02133404,Secondary Hyperparathyroidism,"Phase II Study of ASP7991 -A Double-blind, Cinacalcet Hydrochloride-controlled, Dose-ascending Study in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis -",A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis,Secondary Hyperparathyroidism,2014-04-29,2014-11-10,2014-11-10,62.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Astellas Pharma Inc,Astellas Pharma Inc,,Drug|Drug|Drug,Japan,20.0,79.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02133404
1447,NCT02138214,Stage III Papillary Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage I Papillary Thyroid Cancer,Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer,Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer,Stage III Papillary Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage I Papillary Thyroid Cancer,2014-05-12,2019-10-30,2020-10-26,117.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Wisconsin, Madison",University of Wisconsin,Procedure|Procedure|Other,United States,21.0,73.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02138214
1449,NCT02138838,"Chronic Kidney Disease, Secondary Hyperparathyroidism","A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis",Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis,"Chronic Kidney Disease, Secondary Hyperparathyroidism",2014-04-01,2016-06-23,2016-06-23,55.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Dietary Supplement,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Lithuania|New Zealand|Poland|Portugal|Russian Federation|Slovakia|Spain|Ukraine|United States,6.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT02138838
1452,NCT02140476,Papillary Thyroid Cancer|Thyroid Goiter,Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial,Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy,Papillary Thyroid Cancer|Thyroid Goiter,2014-05-09,2015-05-31,2015-07-31,160.0,,Factorial Assignment,,Interventional,Unknown status,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Ethicon Endo-Surgery|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|University of Sao Paulo,"Hospital Das Clinicas, Universidad de Sao Paulo|Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn",Device|Procedure,Brazil|Mexico,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02140476
1455,NCT02143271,Secondary Hyperparathyroidism,A Single-dose Phase 1 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis,Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis,Secondary Hyperparathyroidism,2014-05-14,2014-12-31,2014-12-31,13.0,,Single Group Assignment,,Interventional,Completed,Phase 1,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",Kyowa Hakko Kirin,Drug,Japan,20.0,74.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02143271
1458,NCT02143726,Refractory Hurthle Cell Thyroid Cancer,Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer,"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer",Refractory Hurthle Cell Thyroid Cancer,2014-05-19,2021-01-28,2024-08-06,35.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Alliance for Clinical Trials in Oncology,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Novartis,Mayo Clinic in Florida|Northwestern University|Siouxland Regional Cancer Center|University of Michigan Comprehensive Cancer Center|Mayo Clinic|Nebraska Methodist Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Sleepy Hollow|Memorial Sloan Kettering Nassau|Southeastern Medical Oncology Center-Clinton|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Ohio State University Comprehensive Cancer Center|Fox Chase Cancer Center|Mercy Health System,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02143726
1459,NCT02145143,Thyroid Carcinoma,"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study","Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",Thyroid Carcinoma,2014-05-20,2023-05-31,2023-05-31,12.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,Memorial Sloan Kettering Cancer Center,"Genentech, Inc.|Memorial Sloan Kettering Cancer Center",Memorial Sloan Kettering Cancer Center,Drug|Device|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02145143
1460,NCT02147782,Chronic Renal Insufficiency|Renal Osteodystrophy,Continuous Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency in Different Stages,Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency,Chronic Renal Insufficiency|Renal Osteodystrophy,2014-05-13,2022-12-31,2022-12-31,300.0,Case-Control,,Prospective,Observational [Patient Registry],Recruiting,,Shanghai University of Traditional Chinese Medicine,Anhui Provincial Hospital|Huadong Hospital|Longhua Hospital|Shanghai University of Traditional Chinese Medicine,Anhui Province Hospital of TCM|Jiangsu Province Hospital of TCM|Longhua hospital affiliated to Shanghai University of TCM|Huadong Hospital Affiliated to Fudan University,,China,20.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02147782
1463,NCT02150772,Thyroid Nodule,Shear Wave Elastography in the Diagnosis and Risk-stratification of Thyroid Nodules - a Prospective Study,The Diagnostic Value of Shear Wave Elastography,Thyroid Nodule,2014-04-14,2016-03-31,2016-03-31,308.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,"re-Nse-Halsafdeling H, Aarhus University Hospital",Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02150772
1465,NCT02152137,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,"A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer",Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2014-05-29,2019-02-27,,19.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Alliance for Clinical Trials in Oncology,"Alliance for Clinical Trials in Oncology|Daiichi Sankyo, Inc.|National Cancer Institute (NCI)",Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Mayo Clinic Hospital|Mayo Clinic in Arizona|Providence Saint Joseph Medical Center/Disney Family Cancer Center|University of Colorado Hospital|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Regional Hematology and Oncology PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Nanticoke Memorial Hospital|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Hawaii Oncology Inc-Pali Momi|Pali Momi Medical Center|The Cancer Center of Hawaii-Pali Momi|Hawaii Cancer Care Inc-POB II|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Oncology Inc-Kuakini|Kuakini Medical Center|The Cancer Center of Hawaii-Liliha|Kapiolani Medical Center for Women and Children|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Mountain States Tumor Institute|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Medical Center|Walter Knox Memorial Hospital|Saint Luke's Mountain States Tumor Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Mountain States Tumor Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Mountain States Tumor Institute - Nampa|Kootenai Cancer Center|Kootenai Cancer Clinic|Saint Luke's Mountain States Tumor Institute-Twin Falls|Northwestern University|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Menorah Medical Center|Saint Luke's South Hospital|Cancer Center of Kansas - Parsons|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Cancer Center of Kansas - Wellington|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Cancer Center of Kansas - Wichita|Via Christi Regional Medical Center|Cancer Center of Kansas - Winfield|Mercy Medical Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Beaumont Hospital-Dearborn|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Lymphoma Clinic of Michigan|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Saint Mary's of Michigan|Oncology Hematology Associates of Saginaw Valley PC|Bhadresh Nayak MD PC-Sterling Heights|Saint Joseph Health System-Tawas City|Advanced Breast Care Center PLLC|Bhadresh Nayak MD PC-Warren|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Sanford Joe Lueken Cancer Center|Fairview Ridges Hospital|Mercy Hospital|Fairview-Southdale Hospital|Unity Hospital|Fairview Maple Grove Medical Center|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|New Ulm Medical Center|North Memorial Medical Health Center|Mayo Clinic|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Saint Francis Regional Medical Center|Lakeview Hospital|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|Central Care Cancer Center - Bolivar|Centerpoint Medical Center LLC|Freeman Health System|Saint Luke's Hospital of Kansas City|Heartland Hematology and Oncology Associates Incorporated|Research Medical Center|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|Delbert Day Cancer Institute at PCRMC|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital Saint Louis|Mercy Hospital Springfield|CoxHealth South Hospital|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Sanford Bismarck Medical Center|Roger Maris Cancer Center|Sanford Broadway Medical Center|University of Cincinnati/Barrett Cancer Center|Ohio State University Comprehensive Cancer Center|University Pointe|University of Oklahoma Health Sciences Center|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Oncology and Hematology Care Southeast|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Geisinger Medical Center|Pocono Medical Center|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|Geisinger Cancer Services-Pottsville|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|Geisinger Medical Group|Geisinger Wyoming Valley/Henry Cancer Center|Greenville Health System Cancer Institute-Easley|Greenville Health System Cancer Institute-Andrews|Greenville Health System Cancer Institute-Butternut|Greenville Health System Cancer Institute-Faris|Greenville Memorial Hospital|Greenville Health System Cancer Institute-Eastside|Greenville Health System Cancer Institute-Greer|Greenville Health System Cancer Institute-Seneca|Greenville Health System Cancer Institute-Spartanburg|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Providence Regional Cancer System-Centralia|Swedish Medical Center-Edmonds|Providence Regional Cancer Partnership|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|PeaceHealth Saint John Medical Center|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Rockwood Clinic Cancer Treatment Center-Valley|Rockwood Cancer Treatment Center-DHEC-Downtown|Evergreen Hematology and Oncology PS|Rockwood North Cancer Treatment Center|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Froedtert and the Medical College of Wisconsin|Cancer Center of Western Wisconsin|Billings Clinic-Cody|Welch Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02152137
1467,NCT02152228,Hypoparathyroidism,A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism,A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism,Hypoparathyroidism,2014-04-22,2015-06-30,2015-07-31,20.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Entera Bio Ltd.,Entera Bio Ltd.,Lin Medical Center,Drug,Israel,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02152228
1469,NCT02152995,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,"A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,34.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02152995
1472,NCT02155049,Thyroid Associated Ophthalmopathies,Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.,Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues,Thyroid Associated Ophthalmopathies,2014-05-21,2017-05-31,2017-05-31,10.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Rabin Medical Center,Rabin Medical Center,"Ophthalmology clinics, Rabin Medical Center",Drug,Israel,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02155049
1476,NCT02156362,Thyroid Cancer,Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis),Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis),Thyroid Cancer,2012-05-29,2023-05-31,2023-05-31,643.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon-Centre de Mdecine Nuclaire Groupement Hospitalier Est 59 boulevard Pinel,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02156362
1477,NCT02169687,Autonomous Hyperfunctioning Thyroid Nodules,"Pilot, Monocentric, Non-comparative Study of the Effectiveness and Safety of High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules",High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules,Autonomous Hyperfunctioning Thyroid Nodules,2014-05-05,2007-10-31,2007-10-31,2.0,,Single Group Assignment,,Interventional,Terminated,Early Phase 1,Theraclion,Groupe Hospitalier Pitie-Salpetriere|Hpital Saint Louis Paris|Theraclion,Hpital Piti Salpetrire,Device,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02169687
1479,NCT02178345,Papillary Thyroid Cancer,Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer,Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer,Papillary Thyroid Cancer,2014-06-25,2021-12-03,2021-12-03,123.0,Cohort,,Prospective,Observational,Completed,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02178345
1481,NCT02185560,Thyroid Carcinoma,Drug Use Investigation of Sorafenib/ NEXAVAR for Unresectable Differentiated Thyroid Carcinoma (DTC),"Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib",Thyroid Carcinoma,2014-07-04,2020-02-27,2024-06-30,453.0,Cohort,,Other,Observational,Active not recruiting,,Bayer,Bayer,,Drug,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02185560
1482,NCT02186405,Subclinical hypothyrodism,Effects of Levothyroxine Treatment on Hemodynamic and Isotopic Renal Functions in Subclinical Hypothyroidism,Effects of Levothyroxine Treatment on Hemodynamic and Renal Functions in Subclinical Hypothyroidism,Subclinical hypothyrodism,2014-07-08,2016-10-31,2017-06-30,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 4,Centre Hospitalier Universitaire de Nice,Centre Hospitalier Universitaire de Nice,Nephrology Department,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02186405
1483,NCT02190214,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,2498.0,Ecologic or Community,,Cross-Sectional,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02190214
1490,NCT02194920,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,2014-07-03,2014-10-31,2014-11-30,20.0,Cohort,,Prospective,Observational,Completed,,University of Roma La Sapienza,University of Roma La Sapienza,"General Surgery Unit, ICOT Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02194920
1494,NCT02203682,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,100.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02203682
1498,NCT02205801,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,36.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02205801
1506,NCT02208544,Thyroid Neoplasms|Thyroid Nodule,Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study,FDG-PET/CT in Evaluation of Cytological Indeterminate Thyroid Nodules to Prevent Unnecessary Surgery (EfFECTS),Thyroid Neoplasms|Thyroid Nodule,2014-07-22,2020-01-01,2022-02-15,132.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Radboudumc|MUMC|AMC|VUmc|MeanderMC|LUMC|ErasmusMC|Onze Lieve Vrouwe Gasthuis|Rijnstate|Reinier de Graaf Ziekenhuis|UMCG|St. Antonius|HagaZiekenhuis|UMCU|Isala Klinieken,Procedure|Device|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02208544
1508,NCT02210741,Graves Disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,200.0,Case-Only,,Prospective,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02210741
1511,NCT02216656,Secondary Hyperparathyroidism,"A Randomized, Double-blind, Parallel-group, Dose-finding Study of KHK7580 for Secondary Hyperparathyroidism Patients Receiving Hemodialysis",Phase 2 Study of KHK7580,Secondary Hyperparathyroidism,2014-08-11,2015-02-28,2015-02-28,201.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug|Drug|Drug|Drug|Drug,Japan,20.0,74.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02216656
1514,NCT02223052,Acute Myeloid Leukemia|Breast Cancer|Genitourinary|Glioblastoma Multiforme|Hematological Neoplasms|Hodgkin's Lymphoma|Leukemia|Lymphoma|Melanoma|Metastatic Breast Cancer|Multiple Myeloma|Myelodysplastic Syndromes|Neoplasms|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer|Osteosarcoma|Renal Cell Carcinoma|Sarcoma|Small Cell Lung Cancer|Thyroid Cancer,"A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects",Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies,Acute Myeloid Leukemia|Breast Cancer|Genitourinary|Glioblastoma Multiforme|Hematological Neoplasms|Hodgkin's Lymphoma|Leukemia|Lymphoma|Melanoma|Metastatic Breast Cancer|Multiple Myeloma|Myelodysplastic Syndromes|Neoplasms|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer|Osteosarcoma|Renal Cell Carcinoma|Sarcoma|Small Cell Lung Cancer|Thyroid Cancer,2014-08-20,2018-06-11,2018-12-18,89.0,,Parallel Assignment,,Interventional,Completed,Phase 1,Celgene,Celgene,Scottsdale Healthcare Research Institute|Mayo Clinic - Arizona|University of Arizona Cancer Center|University of Iowa|Henry Ford Health System|Cancer Institute of New Jersey|Cleveland Clinic Foundation|Greenville Hospital System|Vanderbilt- Ingram Cancer Center|The Methodist Hospital Research Institute l,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02223052
1515,NCT02225509,Thyroid Cancer|Thyroid Nodule,Clinical Validation of the Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule With Indeterminate Cytological Analysis,Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology,Thyroid Cancer|Thyroid Nodule,2014-08-19,2016-12-31,,1000.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Diaxonhit,Diaxonhit,,Procedure,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02225509
1517,NCT02227264,Primary Hyperparathyroidism,Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?,Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?,Primary Hyperparathyroidism,2014-08-17,2021-12-31,2021-12-31,123.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Karolinska University Hospital,Karolinska Institutet|Karolinska University Hospital,Karolinska University Hospital,Drug|Procedure,Sweden,40.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02227264
1520,NCT02240563,Autoimmune Thyroiditis,Long-term Follow-up After Treatment of Chronic Autoimmune Thyroiditis With Low Level Laser,Low Level Laser Therapy for Autoimmune Thyroiditis,Autoimmune Thyroiditis,2014-06-23,2016-03-31,2016-03-31,43.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,Fundao de Amparo  Pesquisa do Estado de So Paulo|University of Sao Paulo General Hospital,"University of Sao Paulo General Hospital, Radiology Institute|University of Sao Paulo General Hospital",Procedure|Procedure,Brazil,20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02240563
1523,NCT02244463,Anaplastic Thyroid Cancer|Thyroid Cancer,A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Thyroid Cancer,2014-09-17,2022-12-31,2023-12-31,46.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Dana-Farber Cancer Institute,"Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.",Hoag Memorial Hospital Presbyterian|Dana-Farber Cancer Institute|University of Michigan Medical School,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02244463
1525,NCT02246504,Non-malignant Thyroid Nodule,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Non-malignant Thyroid Nodule,2014-09-16,2017-03-07,2017-03-07,20.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,"Clinic of thyroid and metabolite bone disease of the Acad. of Ivan Penchev UDHATE - 2, Zdrave street",Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02246504
1527,NCT02258347,Non-malignant Thyroid Nodules,Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,HIFU in Patients With Non-malignant Thyroid Nodules,Non-malignant Thyroid Nodules,2014-09-26,2015-10-13,2015-10-13,4.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,Istituto in tecnologie avanzate e modelli assistenziali in oncologia,Device,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02258347
1529,NCT02268734,Metastatic Sporadic Medullary Thyroid Cancer,Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer (sMTC) Patients and Possible Correlation With Vandetanib Therapy,Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib,Metastatic Sporadic Medullary Thyroid Cancer,2014-09-04,2017-12-31,2018-12-31,36.0,Case-Only,,Retrospective,Observational,Completed,,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02268734
1530,NCT02273570,"Hyperparathyroidism, Secondary","Single-center, Open-label, Randomized Study of Anemia Management Improvement in End Stage Renal Disease (ESRD) Patients With Secondary Hyperparathyroidism",Optimal Anemia Treatment in End Stage Renal Disease (ERSD),"Hyperparathyroidism, Secondary",2014-06-27,2016-12-31,2017-03-31,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Azienda Ospedaliera Sant'Anna,Amgen|Azienda Ospedaliera Sant'Anna,Azienda Ospedaliera Sant'Anna,Drug|Drug,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02273570
1533,NCT02274623,"Bone Neoplasms|Breast Cancer|Hyperparathyroidism, Secondary|Hypocalcemia|Prostate Cancer","Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid",Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid,"Bone Neoplasms|Breast Cancer|Hyperparathyroidism, Secondary|Hypocalcemia|Prostate Cancer",2014-10-22,2017-02-27,2017-03-17,33.0,,Single Group Assignment,,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO Health, Inc.","Coast Hematology-Oncology Associates|Mount Sinai Medical Center, Comprehensive Cancer Center|Research by Design LLC|Roswell Park Cancer Institute|University of Cincinnati Cancer Institute|Inova Dwight and Martha Schar Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02274623
1536,NCT02278198,Differentiated Thyroid Cancer,Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123,Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123,Differentiated Thyroid Cancer,2014-10-27,2019-09-20,2019-09-20,5.0,,Single Group Assignment,,Interventional,Completed,Phase 1,"University of Colorado, Denver","University of Colorado, Denver",Fawn N White,Drug,United States,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02278198
1537,NCT02280330,Hypothyroidism|Iodine Deficiency|Iodine Deficiency Disorder,Iodine Intake & Status of Preschoolers Given Micronutrient Powder for 6 Months,Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months,Hypothyroidism|Iodine Deficiency|Iodine Deficiency Disorder,2014-10-27,2015-03-31,2015-03-31,396.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Nutrition Center of the Philippines,Nutrition Center of the Philippines,La Trinidad Benguet Day Care Centers,Dietary Supplement|Other,Philippines,4.0,6.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT02280330
1538,NCT02282813,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency","A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)",Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",2014-10-31,2015-05-31,2015-05-31,298.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"OPKO Health, Inc.","OPKO Health, Inc.",,Drug|Drug|Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02282813
1541,NCT02289144,"Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer|Metastatic Anaplastic Thyroid Cancer",Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer,"Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer|Metastatic Anaplastic Thyroid Cancer",2014-10-06,2019-01-31,2019-01-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 2,University of Texas Southwestern Medical Center,Novartis|University of Texas Southwestern Medical Center,UT Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02289144
1543,NCT02290704,Graves' Ophthalmopathy,Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People,Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People,Graves' Ophthalmopathy,2014-11-03,2017-11-30,2017-11-30,200.0,Other,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02290704
1547,NCT02301520,Hypothyroidism|Iodine Deficiency|Lead Intoxication|Rickets|Vitamin D Deficiency,"Vitamin D Deficiency, Iodine Deficiency and Lead Levels in Haitian Infants and Children.","Vitamin D, Iodine, and Lead Levels in Haitian Infants and Children.",Hypothyroidism|Iodine Deficiency|Lead Intoxication|Rickets|Vitamin D Deficiency,2014-11-23,2015-06-30,2015-06-30,299.0,Ecologic or Community,,Cross-Sectional,Observational,Completed,,Boston Children's Hospital,"Boston Children's Hospital|Fondation Haitienne de Diabete et de Maladies Cardiovasculaires (FHADIMAC)|Kay Mackenson Clinic, Inc.",Kay Mackenson Clinic|FHADIMAC,,Haiti,9.0,6.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT02301520
1548,NCT02302768,Thyroiditis Autoimmune,Effect of Supplementation of Two Doses of L-selenomethionine (Semet; 80 and 160 mcg) Versus Placebo in Patients With Chronic Autoimmune Thyroiditis (AIT) With Normal Thyroid Function.,Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT,Thyroiditis Autoimmune,2014-11-20,2014-01-31,2015-01-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2,University of Siena,IBSA Institut Biochimique SA|University of Siena,,Dietary Supplement|Other,,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02302768
1550,NCT02303444,Thyroid Neoplasms,RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors,An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors,Thyroid Neoplasms,2014-11-25,2020-06-10,2020-07-24,667.0,Cohort,,Prospective,Observational,Completed,,Bayer,Bayer,,Drug|Drug,Algeria|Argentina|Brazil|Egypt|France|Germany|Greece|India|Japan|Lebanon|Mexico|Netherlands|Philippines|Russian Federation|Saudi Arabia|Spain|Taiwan|Turkey|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02303444
1551,NCT02304757,Differentiated Thyroid Cancer|Osteoporosis,Prospective Trial of 99Tc-MDP and Fosamax in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis Treated With Supraphysiological Doses of Thyroid Hormone,99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis,Differentiated Thyroid Cancer|Osteoporosis,2014-11-24,2019-12-30,2019-12-30,142.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Nuclear Medicine Xinhua Hospital,Drug|Drug,China,45.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02304757
1552,NCT02307175,Autoimmune Thyroid Disease|Congenital Hypothyroidism,A Phase I Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron (CYCLOTEC) in Patients With Thyroid Scan Indication,A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication,Autoimmune Thyroid Disease|Congenital Hypothyroidism,2014-09-24,2016-08-31,2016-10-31,30.0,Case-Control,,Prospective,Observational,Completed,,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Centre hospitalier universitaire de Sherbrooke,,Canada,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02307175
1554,NCT02316691,Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,Thyroid Eye Disease,2014-12-08,2019-11-30,2019-11-30,2.0,Cohort,,Prospective,Observational,Terminated,,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh,,United States,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02316691
1558,NCT02316743,Sub-clinical Hypothyroidism|Systolic Heart Failure,Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism,Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism,Sub-clinical Hypothyroidism|Systolic Heart Failure,2013-05-10,2015-06-30,2015-07-31,40.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,Universit de Sherbrooke,Universit de Sherbrooke,Centre Hospitalier Universitaire de Sherbrooke,Drug,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02316743
1559,NCT02317926,Hypothyroidism,,Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism,Hypothyroidism,2014-12-08,2018-05-31,,81.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,Walter Reed National Military Medical Center,Walter Reed National Military Medical Center,Walter Reed National Military Medical Center,Drug|Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02317926
1560,NCT02318160,Autoimmune Thyroiditis,Oxidative Status in Children and Adolescents With Autoimmune Thyroiditis: A Tertiary Center Study From Upper Egypt,Oxidative Status in Children With Autoimmune Thyroiditis,Autoimmune Thyroiditis,2014-12-11,2014-03-31,2014-03-31,64.0,Case-Control,,Prospective,Observational [Patient Registry],Completed,,Assiut University,Assiut University,,Other,,6.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02318160
1563,NCT02319538,Hashimoto's Disease,Surgical Treatment of Hashimotos Disease. Effect on Antibodies and Clinical Symptoms.,Hashimoto - a Surgical Disease. Total Thyroidectomy Makes Antibodies Disappear and Ameliorates Symptoms,Hashimoto's Disease,2014-12-15,2017-07-15,2017-07-15,150.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Sykehuset Telemark,Haukeland University Hospital|Helse Stavanger HF|Sykehuset Telemark,"Telemark Hospital Trust, surgical department",Procedure,Norway,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02319538
1566,NCT02323724,Papillary Thyroid Carcinoma,APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.,APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.,Papillary Thyroid Carcinoma,2014-12-18,2015-07-31,2015-07-31,25.0,Case-Only,,Retrospective,Observational,Completed,,Corporacion Parc Tauli,Corporacion Parc Tauli,Corporaci Sanitria Parc Taul,Genetic,Spain,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02323724
1568,NCT02329379,Goiter,Therapeutic Role of Levothyroxine on the Patients With Atypia of Undetermined Significance (AUS) Goiter,The Role of Levothyroxine on Goiter With Atypia of Undetermined Significance,Goiter,2014-12-29,2015-12-31,2015-12-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,"National Defense Medical Center, Taiwan",Sheng-Chiang Su,,Drug,,20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02329379
1569,NCT02332135,Maintenance Hemodialysis|Secondary Hyperparathyroidism,The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis,The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis,Maintenance Hemodialysis|Secondary Hyperparathyroidism,2015-01-04,2017-03-31,2018-03-31,30.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Beijing Friendship Hospital,Wenhu Liu,Beijing Friedship Hospital,Procedure|Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02332135
1572,NCT02338934,Secondary Hyperparathyroidism,An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients,Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients,Secondary Hyperparathyroidism,2015-01-11,2017-01-31,2017-01-31,30.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,"Penang Hospital, Malaysia","Ministry of Health, Malaysia|Penang Hospital, Malaysia","Clinical Research Centre, Penang Hospital|Penang Hospital",Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02338934
1575,NCT02339142,Graves Ophthalmopathy,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Graves Ophthalmopathy,2015-01-12,2018-12-31,2019-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,University of British Columbia,University of British Columbia,,Radiation|Drug,,35.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02339142
1579,NCT02341417,"Secondary Hyperparathyroidism, Chronic Kidney Disease",A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis,Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis,"Secondary Hyperparathyroidism, Chronic Kidney Disease",2014-12-02,2017-03-15,2017-03-15,28.0,,Single Group Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Poland|Russian Federation|Ukraine|United States,0.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02341417
1582,NCT02347683,Thyroid Cancer,Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy,Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy,Thyroid Cancer,2015-01-21,2016-02-29,2016-02-29,50.0,Cohort,,Prospective,Observational,Completed,,University of Nebraska,University of Nebraska,University of Nebraska Medical Center,,United States,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02347683
1583,NCT02352766,Thyroid Nodule,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Thyroid Nodule,2015-01-28,2019-02-15,2019-02-15,256.0,Case-Only,,Cross-Sectional,Observational,Completed,,University of Pittsburgh,"Duke University|Johns Hopkins University|Medstar Health Research Institute|Ohio State University|University of Cincinnati|University of Colorado, Denver|University of Pennsylvania|University of Pittsburgh|University of Wisconsin, Madison",University of Pittsburgh,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02352766
1585,NCT02363647,Colon Cancer|Medullary Thyroid Cancer,Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer,Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer,Colon Cancer|Medullary Thyroid Cancer,2015-02-03,2021-06-30,2021-06-30,10.0,,Single Group Assignment,,Interventional,Suspended,Not Applicable,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02363647
1586,NCT02364102,Hypothyroidism,Effect of Restoration of Euthyroidism in Patients With Primary Hypothyroidism on Brown Adipose Tissue Thermogenesis - the ThyroBAT Study,Effect of Hypothyroidism on Brown Adipose Tissue,Hypothyroidism,2015-02-09,2017-08-31,2017-08-31,42.0,Cohort,,Prospective,Observational,Completed,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",,Switzerland,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02364102
1587,NCT02373995,Graves' Disease,Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy,Role of the Microbiome in Graves' Orbitopathy,Graves' Disease,2015-01-29,2015-07-31,2016-12-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 1/Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Cultech Ltd, Port Talbot, UK|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy|School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK|Universitt Duisburg-Essen",Fondazione Ca' Granda Ospedale Maggiore Policlinico,Biological,Italy,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02373995
1591,NCT02374593,Congenital Hypothyroidism,Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism,Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism,Congenital Hypothyroidism,2015-02-18,2016-05-31,2016-05-31,24.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Indiana University,Erica Eugster,Riley Hospital for Children,Drug|Device,United States,0.0,2.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT02374593
1593,NCT02375451,Hyperthyroidism|Thyroid Cancer|Xerostomia,Effect of Childhood Radioiodine Therapy on Salivary Function,Effect of Childhood Radioiodine Therapy on Salivary Function,Hyperthyroidism|Thyroid Cancer|Xerostomia,2014-10-03,2016-09-30,2016-09-30,70.0,Cohort,,Cross-Sectional,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Boston Children's Hospital,Other,United States,3.0,55.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02375451
1595,NCT02376088,Graves Disease,Characteristics of Islet -cell Functions in Chinese Patients With Graves' Disease,Characteristics of Islet -cell Functions in Chinese Patients With Graves' Disease,Graves Disease,2015-02-18,2014-06-30,2014-06-30,328.0,Cohort,,Prospective,Observational,Completed,,Qilu Hospital of Shandong University,Weikai Hou,,Drug,,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02376088
1598,NCT02378298,"Ophthalmopathy, Thyroid-Associated",Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,Rituximab (RTX) Therapy in Patients With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,26.0,,Factorial Assignment,,Interventional,Active not recruiting,Phase 4,Gteborg University,"Gteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mlndal|Department of Rheumatology, Sahlgrenska University Hospital/Mlndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02378298
1602,NCT02381457,1p36 Deletion Syndrome|22q11 Deletion Syndrome|Angelman Syndrome|Cri-du-Chat Syndrome|DiGeorge Syndrome|Monosomy X|Prader-Willi Syndrome|Sex Chromosome Abnormalities|Trisomy 13|Trisomy 18|Trisomy 21,SNP-based Microdeletion and Aneuploidy RegisTry,SNP-based Microdeletion and Aneuploidy RegisTry (SMART),1p36 Deletion Syndrome|22q11 Deletion Syndrome|Angelman Syndrome|Cri-du-Chat Syndrome|DiGeorge Syndrome|Monosomy X|Prader-Willi Syndrome|Sex Chromosome Abnormalities|Trisomy 13|Trisomy 18|Trisomy 21,2015-03-02,2020-06-30,2020-06-30,20960.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,"Natera, Inc.","Children's Hospital of Philadelphia|George Washington University|Montefiore Medical Center|Natera, Inc.|University of California, San Francisco","University of California, San Francisco|Cooper University Hospital|Virtua|St. Peter's University|Complete Women's Healthcare|North Shore University Hospital|Madonna Perinatal|Long Island Jewish Medical Center|New York University|Icahn School of Medicine Mt Sinai|Columbia University|Montefiore Medical Center|Suffolk OB|North Austin Maternal Fetal Medicine|Zeid Women's Health Center|University of Utah|Royal Prince Alfred|Royal College Surgeons in Ireland|Dexeus|Sahlgrenska University Hospital|St. George University Hospital",,Australia|Ireland|Spain|Sweden|United Kingdom|United States,18.0,48.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02381457
1604,NCT02381925,Parathyroid Adenoma,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Parathyroid Adenoma,2015-03-03,2016-06-30,2016-12-31,0.0,Cohort,,Prospective,Observational [Patient Registry],Withdrawn,,Duke University,"Duke University|University of Arkansas|University of California, Los Angeles",,,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02381925
1608,NCT02383927,HRAS Mutant Tumor|Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor|Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)|Thyroid Cancer,An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations,Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations,HRAS Mutant Tumor|Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor|Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)|Thyroid Cancer,2015-02-20,2020-11-30,2020-11-30,63.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Kura Oncology, Inc.","Kura Oncology, Inc.","University of California, Los Angeles|Wihship Cancer Institute of Emory University|Dana-Farber Cancer Institute|University of Michigan Comprehensive Cancer Center|Mayo Clinic|Memorial Sloan-Kettering Cancer Center|Oklahoma University Health Sciences Center|Fox Chase Cancer Center|The University of Texas MD Anderson Cancer Center|University Hospital Antwerp|Cliniques universitaires Saint-Luc|CHU|Insitut Bergonie|Centre Lon Brard|Centre Antoine Lacassagne|Institute Gustave Roussy (IGR)|University Hospital Wuerazburg|Attikon University Hospital|Instituto Nazionale Tumori|Asan Medical Center|Samsung Medical Center|University Medical Center|Hospital Vall d' Hebron|Hospital Clinic de Barcelona|Hospital del Mar|Hospital Universitario Doce de Octubre|Hospital Universitario La Paz|MD Anderson Cancer Center Madrid|START, Centro Integral Oncologico Clara Campal|Hospital Universitario Virgen de la Victoria|Complejo Hospitalario de Navarro|Hospital Universitario Virgen de la Rocio|Hospital Universitario y Politcnico La Fe|Royal Marsden|University College Hospital",Drug,"Belgium|France|Germany|Greece|Italy|Korea, Republic of|Netherlands|Spain|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02383927
1609,NCT02384668,Graves' Disease,"The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial.",D-vitamin And Graves' Disease; Morbidity And Relapse Reduction,Graves' Disease,2015-01-09,2021-01-31,2021-01-31,260.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Aarhus,"Aarhus University Hospital|Herning Hospital|Randers Regional Hospital|Regional Hospital Holstebro|Regionshospitalet Horsens|Regionshospitalet Silkeborg|Regionshospitalet Viborg, Skive|University of Aarhus","Department of Endocrinology and Internal Medicine, Aarhus University Hospital|Gentofte Hospital|Department of Internal Medicine, Regionshospitalet Herning|Department of Internal Medicine, Regionshospitalet Holstebro|Department of Internal Medicine, Regionshospitalet Horsens|Department of Internal Medicine, Regionhospitalet Randers|Department of Internal Medicine, Diagnostisk Center, Regionshospitalet Silkeborg|Department of Internal Medicine, Regionshospitalet Viborg",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02384668
1612,NCT02390739,Metastatic Thyroid Cancer,Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to Patients With Thyroglobulin Expressing Thyroid Cancer,Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer,Metastatic Thyroid Cancer,2015-03-17,2017-03-22,2017-03-22,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),,Drug|Drug|Drug|Biological,,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02390739
1613,NCT02390934,Thyroid Cancer,Single Arm Phase II Trial Evaluating the Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer,Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer,Thyroid Cancer,2014-10-01,2019-04-02,2019-04-02,13.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Radiation,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02390934
1614,NCT02393183,Thyroid Eye Disease,"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED),Thyroid Eye Disease,2015-03-07,2022-06-15,2022-12-15,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Rassoul Akram Hospital,Drug|Dietary Supplement|Other,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02393183
1618,NCT02393690,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,60.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02393690
1621,NCT02397109,Dysthyroid Ophthalmopathies,Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies,mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX),Dysthyroid Ophthalmopathies,2015-03-19,2020-09-30,2020-09-30,294.0,Case-Only,,Cross-Sectional,Observational,Completed,,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,,France,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02397109
1625,NCT02398721,Thyroid Nodules,A Prospective Randomized Study on Health-related Quality of Life of Patients With Incidental Small (<2cm) Asymptomatic Thyroid Nodules and Cost-effectiveness Analysis in Managing Small Incidental Thyroid Nodules,Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules,Thyroid Nodules,2015-03-20,2017-07-31,2018-02-28,314.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Other,Hong Kong,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02398721
1627,NCT02399475,Subclinical Hypothyroidism,"The Thyroid Axis in Older Individuals With Persistent Subclinical Hypothyroidism: a Mechanistic, Randomized, Double-Blind, Cross-Over Study of Levothyroxine and Liothyronine Administration",Mechanistic Study of Subclinical Hypothyroidism In the Elderly,Subclinical Hypothyroidism,2015-02-03,2019-09-30,2019-09-30,14.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,University of Pennsylvania,National Institute on Aging (NIA)|University of Pennsylvania,University of Pennsylvania,Drug|Drug|Drug,United States,70.0,120.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02399475
1628,NCT02404441,Anaplastic Thyroid Cancer|Melanoma|Non-small Sell Lung Cancer (NSCLC)|Other Solid Tumors|Triple Negative Breast Cancer,Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies,Phase I/II Study of PDR001 in Patients With Advanced Malignancies,Anaplastic Thyroid Cancer|Melanoma|Non-small Sell Lung Cancer (NSCLC)|Other Solid Tumors|Triple Negative Breast Cancer,2015-03-20,2020-07-21,2020-07-21,319.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Novartis,Novartis Pharmaceuticals,The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins|Massachusetts General Hospital|Oregon Health and Science University SC-10|Sarah Cannon Research Institute SCRI RC|University of Texas MD Anderson Cancer Center MD Anderson PSC|Huntsman Cancer Institute Univ. of Utah HCI|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Biological,Canada|France|Germany|Hungary|Italy|Lebanon|Netherlands|Norway|Poland|Spain|Taiwan|Thailand|Turkey|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02404441
1630,NCT02408887,Endocrine Malignancy|Low-risk Papillary Thyroid Cancer|Thyroid Cancer,Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer,Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer,Endocrine Malignancy|Low-risk Papillary Thyroid Cancer|Thyroid Cancer,2015-04-03,2019-03-26,2019-05-07,14.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02408887
1632,NCT02410928,Thyroid Nodule,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Thyroid Nodule,2015-02-14,2015-06-30,2015-07-31,75.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Diskapi Teaching and Research Hospital,Diskapi Teaching and Research Hospital,Diskapi Yildirim Beyazit Teaching and Research Hospital,Device|Device|Device,Turkey,19.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02410928
1634,NCT02411461,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism,Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism,Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism,2015-02-25,2017-01-31,2017-01-31,39.0,Case-Control,,Cross-Sectional,Observational,Completed,,Vanderbilt University Medical Center,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Vanderbilt University Medical Center,Vanderbilt University,,United States,6.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02411461
1636,NCT02412150,Thyroid Tumor,Effect of Dexmedetomidine Infusion for Postoperative Outcome and Smooth Emergence After Thyroidectomy,Effect of Dexmedetomidine After Thyroidectomy,Thyroid Tumor,2015-03-31,2020-11-21,2020-11-25,139.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Chosun University Hospital,Chosun University Hospital,Chosun University Hospital,Drug|Drug|Procedure|Other|Behavioral|Behavioral|Other|Behavioral|Other|Other|Other|Drug|Drug,"Korea, Republic of",20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02412150
1637,NCT02417389,"Hyperparathyroidism, Primary|Osteoporosis",Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism,Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism,"Hyperparathyroidism, Primary|Osteoporosis",2015-04-08,2011-10-31,2012-12-31,22.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Istituto Auxologico Italiano,Istituto Auxologico Italiano,Istituto Auxologico Italiano IRCCS,Drug|Drug,Italy,50.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02417389
1640,NCT02418247,Thyroid Neoplasms,Phase  Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients,Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer,Thyroid Neoplasms,2015-04-13,2017-12-31,2020-12-31,556.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,"National Cancer Center, Korea","National Cancer Center, Korea","Chungnam National University Hospital|National Cancer Center, Korea|Seoul National University Boramae Medical Center|Seoul National University Hospital|Seoul National University Bundang Hospital",Drug|Drug,"Korea, Republic of",18.0,79.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02418247
1641,NCT02418390,"Thyroid Cancer, Papillary",The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma,The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma,"Thyroid Cancer, Papillary",2015-04-07,2022-02-28,2022-02-28,5750.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Procedure,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02418390
1643,NCT02422368,Thyroid Eye Disease,"The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease,Thyroid Eye Disease,2015-04-11,2024-06-30,2024-11-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Private Thyroid eye disease clinic|Rassoul Akram Hospital,Drug|Drug,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02422368
1647,NCT02430584,DiGeorge Syndrome|Down Syndrome|Edwards Syndrome|Klinefelter Syndrome|Patau Syndrome|Perinatal Infections|Turner Syndrome,Whole Blood Specimen Collection From Pregnant Subjects,Whole Blood Specimen Collection From Pregnant Subjects,DiGeorge Syndrome|Down Syndrome|Edwards Syndrome|Klinefelter Syndrome|Patau Syndrome|Perinatal Infections|Turner Syndrome,2015-04-27,2021-03-31,2021-05-31,5000.0,Family-Based,,Prospective,Observational,Active not recruiting,,"Progenity, Inc.","Progenity, Inc.",Regional Obstetrical Consultants,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02430584
1649,NCT02430714,Thyroid Neoplasms,Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T),Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T),Thyroid Neoplasms,2015-04-27,2016-11-06,2016-11-06,629.0,Other,,Prospective,Observational,Completed,,Eisai Inc.,"Eisai Co., Ltd.",,Drug,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02430714
1650,NCT02430857,Latent Hypothyroidism,Osteopathy and Latent Hypothyroidism: Effectiveness of Osteopathic Treatment on TSH in Patients With Latent Hypothyroidism,Osteopathy and Latent Hypothyroidism,Latent Hypothyroidism,2015-04-27,2015-10-31,2016-01-31,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,"Diekmann, Emanuel Amier",Emanuel Amier Diekmann,,Other,,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02430857
1651,NCT02432274,Differentiated Thyroid Cancer (DTC)|Osteosarcoma|Solid Malignant Tumors|Tumors,Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,Differentiated Thyroid Cancer (DTC)|Osteosarcoma|Solid Malignant Tumors|Tumors,2015-04-22,2019-07-18,2022-03-31,117.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 1/Phase 2,Eisai Inc.,Eisai Limited|Merck Sharp & Dohme LLC,Texas Children's Hospital|CHU Strasbourg - Hopital Hautepierre|Centre Oscar Lambret Lille|Centre Leon Berard|CHU Nantes - Hopital Mere-Enfant|Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris|Institut Gustave Roussy|CHU de Toulouse - Hopital des Enfants|Universitaetsklinikum Muenster|Kinderklinik des Olga hospitals|Istituto Ortopedico Rizzoli|Fondazione IRCCS Istituto Nazionale dei Tumori|Ospedale Pediatrico Bambino Gesu|Hospital Universitari Vall d'Hebron|Hospital Infantil Universitario Nino Jesus|Hospital Universitario y Politecnico La Fe Hospital La Fe Valencia|Birmingham Children's Hospital|University College London Hospital|Royal Victoria Infirmary,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug,France|Germany|Italy|Spain|United Kingdom|United States,2.0,25.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02432274
1652,NCT02432599,Hyperparathyroidism,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Hyperparathyroidism,2015-04-29,2017-02-28,2017-02-28,28.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Centre Francois Baclesse,Centre Francois Baclesse,CHU|Centre Franois Baclesse,Radiation,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02432599
1655,NCT02440581,"Kidney Failure, Chronic",Renal Osteodystrophy: A Fresh Approach,Renal Osteodystrophy: An Individual Management Approach,"Kidney Failure, Chronic",2015-05-07,2023-06-30,2023-06-30,120.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,University of Kentucky,"Hartmut Malluche, MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Wright State University",University of Kentucky,Drug|Drug|Drug,United States,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02440581
1658,NCT02442661,Papillary Thyroid Cancer,Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer,Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer,Papillary Thyroid Cancer,2015-04-22,2016-12-31,2017-05-31,103.0,Other,,Prospective,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",Rebecca J Guigli,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02442661
1660,NCT02452073,The Clinical Incidence of Low Triiodothyronine Syndrome,,An Analysis of the Relative Risk for Low Triiodothyronine Syndrome in Patients With Chronic Radiation Enteritis,The Clinical Incidence of Low Triiodothyronine Syndrome,2015-05-15,2015-01-31,2015-04-30,48.0,Cohort,,Retrospective,Observational,Completed,,"Jinling Hospital, China",Shengxian Fan,,Other,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02452073
1661,NCT02456701,Thyroid Cancer,"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in",Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,Thyroid Cancer,2015-05-20,2016-10-13,2016-10-13,7.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Celldex Therapeutics,Celldex Therapeutics|Memorial Sloan Kettering Cancer Center,Memorial Sloan-Kettering Cancer Center,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02456701
1662,NCT02460328,22q11.2 Deletion Syndrome|Immune Defect,Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome,Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome,22q11.2 Deletion Syndrome|Immune Defect,2015-04-10,2016-02-29,2016-02-29,43.0,Case-Only,,,Observational,Completed,,Mahidol University,Mahidol University,Siriraj Hospital,,Thailand,0.0,15.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT02460328
1664,NCT02462512,Elastography|Thyroid Nodule,Validation of Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Elastography|Thyroid Nodule,2015-04-20,2016-03-31,2017-08-31,590.0,Cohort,,Prospective,Observational,Unknown status,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St Mary's Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02462512
1666,NCT02463409,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1a,Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a,Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy),Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1a,2015-05-20,2016-10-31,2016-10-31,6.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Vanderbilt University Medical Center,Massachusetts General Hospital|Vanderbilt University Medical Center,Vanderbilt Unversity,Drug,United States,10.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02463409
1668,NCT02464072,"Hyperparathyroidism, Secondary",Randomized Clinical Trial of Subtotal Parathyroidectomy or Total Parathyroidectomy With Immediate Heterotopic Autograft in Chronic Renal Disease Patients Stage V Under Dialysis,Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis,"Hyperparathyroidism, Secondary",2015-05-18,2021-03-31,2021-03-31,133.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure|Procedure|Procedure,Brazil,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02464072
1671,NCT02465060,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Molecular Analysis for Therapy Choice (MATCH),"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,2015-06-03,2025-12-31,2025-12-31,6452.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|Thomas Hospital|Mobile Infirmary Medical Center|University of South Alabama Mitchell Cancer Institute|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Fairbanks Memorial Hospital|CTCA at Western Regional Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Saint Joseph's Hospital and Medical Center|Mayo Clinic Hospital in Arizona|Mayo Clinic in Arizona|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro|University of Arkansas for Medical Sciences|Kaiser Permanente-Anaheim|Kaiser Permanente-Deer Valley Medical Center|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Sutter Auburn Faith Hospital|Sutter Cancer Centers Radiation Oncology Services-Auburn|AIS Cancer Center at San Joaquin Community Hospital|Kaiser Permanente-Baldwin Park|Kaiser Permanente-Bellflower|Alta Bates Summit Medical Center-Herrick Campus|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|Community Cancer Institute|University Oncology Associates|John Muir Medical Center-Concord Campus|City of Hope Corona|UC Irvine Health Cancer Center-Newport|Sutter Davis Hospital|City of Hope Comprehensive Cancer Center|Epic Care-Dublin|Kaiser Permanente Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Kaiser Permanente-Fontana|Kaiser Permanente-Fremont|Palo Alto Medical Foundation-Fremont|Fresno Cancer Center|Kaiser Permanente-Fresno|Saint Jude Medical Center|Marin Cancer Care Inc|Marin General Hospital|Kaiser Permanente - Harbor City|Kaiser Permanente-Irvine|UC San Diego Moores Cancer Center|Loma Linda University Medical Center|Kaiser Permanente Los Angeles Medical Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|Kaiser Permanente West Los Angeles|Cedars Sinai Medical Center|Contra Costa Regional Medical Center|Fremont - Rideout Cancer Center|Memorial Medical Center|Kaiser Permanente-Modesto|Community Hospital of Monterey Peninsula|Pacific Cancer Care-Monterey|Palo Alto Medical Foundation-Camino Division|Palo Alto Medical Foundation-Gynecologic Oncology|USC Norris Oncology/Hematology-Newport Beach|Sutter Cancer Research Consortium|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Kaiser Permanente Oakland-Broadway|Kaiser Permanente-Oakland|Kaiser Permanente-Ontario|Saint Joseph Hospital - Orange|UC Irvine Health/Chao Family Comprehensive Cancer Center|Desert Regional Medical Center|Palo Alto Medical Foundation Health Care|Stanford Cancer Institute Palo Alto|VA Palo Alto Health Care System|Kaiser Permanente - Panorama City|Keck Medical Center of USC Pasadena|Kaiser Permanente-Rancho Cordova Cancer Center|Eisenhower Medical Center|Kaiser Permanente- Marshall Medical Offices|Kaiser Permanente-Redwood City|Kaiser Permanente-Richmond|Kaiser Permanente-Riverside|Rohnert Park Cancer Center|Kaiser Permanente-Roseville|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Roseville Medical Center|The Permanente Medical Group-Roseville Radiation Oncology|Kaiser Permanente Downtown Commons|Sutter Medical Center Sacramento|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-South Sacramento|South Sacramento Cancer Center|Kaiser Permanente - Sacramento|Saint Helena Hospital|UC San Diego Medical Center - Hillcrest|Kaiser Permanente-San Diego Mission|Kaiser Permanente-San Diego Zion|Rady Children's Hospital - San Diego|Sharp Memorial Hospital|Naval Medical Center -San Diego|California Pacific Medical Center-Pacific Campus|Kaiser Permanente-San Francisco|Kaiser Permanente-Santa Teresa-San Jose|Kaiser Permanente San Leandro|Pacific Central Coast Health Center-San Luis Obispo|Kaiser Permanente-San Marcos|Mills Health Center|Kaiser Permanente-San Rafael|Kaiser San Rafael-Gallinas|Kaiser Permanente Medical Center - Santa Clara|Palo Alto Medical Foundation-Santa Cruz|Mission Hope Medical Oncology - Santa Maria|Kaiser Permanente-Santa Rosa|Sutter Pacific Medical Foundation|Kaiser Permanente Cancer Treatment Center|Kaiser Permanente-South San Francisco|Saint Joseph's Medical Center|Kaiser Permanente-Stockton|Palo Alto Medical Foundation-Sunnyvale|Gene Upshaw Memorial Tahoe Forest Cancer Center|City of Hope Upland|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Kaiser Permanente Medical Center-Vacaville|Kaiser Permanente-Vallejo|Sutter Solano Medical Center/Cancer Center|Kaiser Permanente-Walnut Creek|Epic Care Cyberknife Center|John Muir Medical Center-Walnut Creek|City of Hope West Covina|Presbyterian Intercommunity Hospital|Kaiser Permanente-Woodland Hills|Rocky Mountain Cancer Centers-Aurora|The Medical Center of Aurora|University of Colorado Hospital|Boulder Community Hospital|Boulder Community Foothills Hospital|Rocky Mountain Cancer Centers-Boulder|Rocky Mountain Cancer Centers - Centennial|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|UCHealth Memorial Hospital Central|Memorial Hospital North|Saint Francis Cancer Center|Cancer Center of Colorado at Sloan's Lake|Denver Health Medical Center|Kaiser Permanente-Franklin|National Jewish Health-Main Campus|The Women's Imaging Center|Porter Adventist Hospital|Colorado Blood Cancer Institute|Presbyterian - Saint Lukes Medical Center - Health One|Rocky Mountain Cancer Centers-Midtown|SCL Health Saint Joseph Hospital|Rocky Mountain Cancer Centers-Rose|Rose Medical Center|Mercy Medical Center|Southwest Oncology PC|Mountain Blue Cancer Care Center - Swedish|Rocky Mountain Cancer Centers - Swedish|Swedish Medical Center|Poudre Valley Hospital|Mountain Blue Cancer Care Center|National Jewish Health-Western Hematology Oncology|Saint Mary's Hospital and Regional Medical Center|Grand Valley Oncology|North Colorado Medical Center|Rocky Mountain Cancer Centers-Greenwood Village|Good Samaritan Medical Center|Kaiser Permanente-Rock Creek|Rocky Mountain Cancer Centers-Lakewood|Saint Anthony Hospital|Rocky Mountain Cancer Centers-Littleton|Littleton Adventist Hospital|Kaiser Permanente-Lone Tree|Rocky Mountain Cancer Centers-Sky Ridge|Sky Ridge Medical Center|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|McKee Medical Center|Parker Adventist Hospital|Rocky Mountain Cancer Centers-Parker|Saint Mary Corwin Medical Center|Rocky Mountain Cancer Centers - Pueblo|National Jewish Health-Northern Hematology Oncology|Rocky Mountain Cancer Centers-Thornton|SCL Health Lutheran Medical Center|Smilow Cancer Hospital-Derby Care Center|Smilow Cancer Hospital Care Center-Fairfield|Smilow Cancer Hospital Care Center at Glastonbury|Smilow Cancer Hospital Care Center at Greenwich|Smilow Cancer Hospital Care Center - Guiford|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Yale-New Haven Hospital North Haven Medical Center|Eastern Connecticut Hematology and Oncology Associates|Smilow Cancer Hospital-Orange Care Center|Stamford Hospital/Bennett Cancer Center|Smilow Cancer Hospital-Torrington Care Center|Smilow Cancer Hospital Care Center-Trumbull|Smilow Cancer Hospital-Waterbury Care Center|Smilow Cancer Hospital Care Center - Waterford|Veterans Affairs Connecticut Healthcare System-West Haven Campus|Beebe South Coastal Health Campus|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|TidalHealth Nanticoke / Allen Cancer Center|Christiana Care Health System-Wilmington Hospital|MedStar Georgetown University Hospital|MedStar Washington Hospital Center|Sibley Memorial Hospital|Mount Sinai Comprehensive Cancer Center at Aventura|UM Sylvester Comprehensive Cancer Center at Coral Gables|UM Sylvester Comprehensive Cancer Center at Coral Springs|Broward Health North|UM Sylvester Comprehensive Cancer Center at Deerfield Beach|Holy Cross Hospital|Broward Health Medical Center|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|UM Sylvester Comprehensive Cancer Center at Hollywood|Mayo Clinic in Florida|The Watson Clinic|Mount Sinai Medical Center|University of Miami Miller School of Medicine-Sylvester Cancer Center|Miami Cancer Institute|UM Sylvester Comprehensive Cancer Center at Kendall|Health Central|Orlando Health Cancer Institute|Memorial Hospital West|UM Sylvester Comprehensive Cancer Center at Plantation|Saint Joseph's Hospital/Children's Hospital-Tampa|Moffitt Cancer Center|Indian River Medical Center|University Cancer and Blood Center LLC|Emory University Hospital Midtown|Piedmont Hospital|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|Northside Hospital|Augusta University Medical Center|Northeast Georgia Medical Center Braselton|John B Amos Cancer Center|Northside Hospital-Forsyth|Dekalb Medical Center|Northside Hospital - Duluth|Northeast Georgia Medical Center-Gainesville|The Longstreet Clinic - Gainesville|Northside Hospital - Gwinnett|Central Georgia Gynecologic Oncology|Medical Center of Central Georgia|CTCA at Southeastern Regional Medical Center|Harbin Clinic Medical Oncology and Clinical Research|Low Country Cancer Care|Memorial Health University Medical Center|Summit Cancer Care-Memorial|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler|Summit Cancer Care-Candler|Suburban Hematology Oncology Associates - Snellville|Lewis Hall Singletary Oncology Center|South Georgia Medical Center/Pearlman Cancer Center|Hawaii Cancer Care - Savio|Pali Momi Medical Center|Queen's Cancer Center - Pearlridge|Straub Pearlridge Clinic|The Cancer Center of Hawaii-Pali Momi|The Queen's Medical Center - West Oahu|Hawaii Cancer Care Inc - Waterfront Plaza|Island Urology|Queen's Cancer Cenrer - POB I|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Diagnostic Radiology Services LLC|Kuakini Medical Center|Queen's Cancer Center - Kuakini|The Cancer Center of Hawaii-Liliha|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Straub Medical Center - Kahului Clinic|Castle Medical Center|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Saint Joseph Medical Center|Illinois CancerCare-Bloomington|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Centralia Oncology Clinic|Mount Sinai Hospital Medical Center|Northwestern University|John H Stroger Jr Hospital of Cook County|Rush University Medical Center|University of Illinois|Swedish Covenant Hospital|University of Chicago Comprehensive Cancer Center|Advocate Illinois Masonic Medical Center|AMG Crystal Lake - Oncology|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Northwestern Medicine Cancer Center Kishwaukee|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|AMITA Health Alexian Brothers Medical Center|Elmhurst Memorial Hospital|Illinois CancerCare-Eureka|NorthShore University HealthSystem-Evanston Hospital|Saint Francis Hospital|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Northwestern Medicine Cancer Center Delnor|NorthShore University HealthSystem-Glenbrook Hospital|Ingalls Memorial Hospital|NorthShore University HealthSystem-Highland Park Hospital|Duly Health and Care Joliet|Presence Saint Mary's Hospital|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|AMG Libertyville - Oncology|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Trinity Medical Center|Good Samaritan Regional Health Center|Edward Hospital/Cancer Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Radiation Oncology of Northern Illinois|Illinois CancerCare-Pekin|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center|Illinois CancerCare-Peoria|OSF Saint Francis Radiation Oncology at Peoria Cancer Center|Methodist Medical Center of Illinois|OSF Saint Francis Medical Center|Illinois CancerCare-Peru|Valley Radiation Oncology|Edward Hospital/Cancer Center?Plainfield|Illinois CancerCare-Princeton|Hematology Oncology Associates of Illinois - Skokie|North Shore Medical Center|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Northwestern Medicine Cancer Center Warrenville|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Midwestern Regional Medical Center|Michiana Hematology Oncology PC-Crown Point|Michiana Hematology Oncology PC-Elkhart|Deaconess Clinic Downtown|Indiana University/Melvin and Bren Simon Cancer Center|Sidney and Lois Eskenazi Hospital|Community Cancer Center East|Community Cancer Center South|Community Cancer Center North|Springmill Medical Center|Community Howard Regional Health|IU Health Arnett Cancer Care|Franciscan Saint Anthony Health-Michigan City|Woodland Cancer Care Center|Memorial Regional Cancer Center Day Road|Michiana Hematology Oncology PC-Mishawaka|Baptist Health Floyd|Chancellor Center for Oncology|Michiana Hematology Oncology PC-Plymouth|Reid Health|Memorial Hospital of South Bend|Michiana Hematology Oncology PC-Westville|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Saint Anthony Regional Hospital|Physicians' Clinic of Iowa PC|Mercy Hospital|Oncology Associates at Mercy Medical Center|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Jennie Edmundson Memorial Hospital|Alegent Health Mercy Hospital|Heartland Oncology and Hematology LLP|Greater Regional Medical Center|Iowa Methodist Medical Center|Medical Oncology and Hematology Associates-Des Moines|Broadlawns Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|Iowa Lutheran Hospital|JCHC McCreery Cancer Center|McFarland Clinic PC-Trinity Cancer Center|Trinity Regional Medical Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Ottumwa Regional Health Center|Siouxland Regional Cancer Center|Methodist West Hospital|Mercy Medical Center-West Lakes|Coffeyville Regional Medical Center|Newman Regional Health|University of Kansas Clinical Research Center|Central Care Cancer Center - Garden City|Saint Catherine Hospital|Central Care Cancer Center - Great Bend|Saint Rose Ambulatory and Surgery Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center-West|University of Kansas Cancer Center|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Olathe Health Cancer Center|Menorah Medical Center|University of Kansas Cancer Center-Overland Park|Saint Luke's South Hospital|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|Flaget Memorial Hospital|Baptist Health Corbin|Commonwealth Cancer Center-Corbin|Oncology Hematology Care Inc-Crestview|Saint Elizabeth Medical Center South|Baptist Health Hardin|Saint Elizabeth Fort Thomas|Baptist Health Lexington|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|University of Kentucky/Markey Cancer Center|Saint Joseph London|Jewish Hospital|The James Graham Brown Cancer Center at University of Louisville|Baptist Health Louisville|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Baptist Health Madisonville/Merle Mahr Cancer Center|Baptist Health Paducah|Jewish Hospital Medical Center South|LSU Health Baton Rouge-North Clinic|Baton Rouge General Medical Center|Our Lady of The Lake|Hematology/Oncology Clinic PLLC|Louisiana Hematology Oncology Associates LLC|Mary Bird Perkins Cancer Center|Ochsner Health Center-Summa|Our Lady of the Lake Physicians Group - Medical Oncology|The NeuroMedical Center-Clinic|Medical Center of Baton Rouge|Our Lady of the Lake Medical Oncology|Ochsner High Grove|Mary Bird Perkins Cancer Center - Covington|Northshore Oncology Associates-Covington|Ochsner Hematology Oncology North Shore - Covington (West Region)|Women's Cancer Care-Covington|Ochsner Medical Center West Bank|Mary Bird Perkins Cancer Center - Houma|Oncology Center of The South Incorporated|Terrebonne General Medical Center|Ochsner Medical Center Kenner|West Jefferson Medical Center|East Jefferson General Hospital|Robert Veith MD LLC|Ochsner LSU Health Monroe Medical Center|Louisiana State University Health Science Center|Tulane University Health Sciences Center|University Medical Center New Orleans|Ochsner Medical Center Jefferson|LSU Health Sciences Center at Shreveport|CHRISTUS Highland Medical Center|Harold Alfond Center for Cancer Care|Eastern Maine Medical Center|Waldo County General Hospital|MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford|Lafayette Family Cancer Center-EMMC|Maine Center for Cancer Medicine-Kennebunk|Stephens Memorial Hospital|Penobscot Bay Medical Center|MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford|Maine Center for Cancer Medicine-Scarborough|Maine Medical Center- Scarborough Campus|Maine Medical Partners - South Portland|Maine Center for Cancer Medicine-Topsham|Anne Arundel Medical Center|University of Maryland/Greenebaum Cancer Center|Greater Baltimore Medical Center|Sinai Hospital of Baltimore|MedStar Union Memorial Hospital|MedStar Franklin Square Medical Center/Weinberg Cancer Institute|MedStar Good Samaritan Hospital|Johns Hopkins University/Sidney Kimmel Cancer Center|Walter Reed National Military Medical Center|National Institutes of Health Clinical Center|Western Maryland Regional Medical Center|University of Maryland Shore Medical Center at Easton|Christiana Care - Union Hospital|Frederick Memorial Hospital|FMH James M Stockman Cancer Institute|MedStar Montgomery Medical Center|Northwest Hospital Center|TidalHealth Peninsula Regional|Holy Cross Hospital|William E Kahlert Regional Cancer Center/Sinai Hospital|Beverly Hospital|Tufts Medical Center|Massachusetts General Hospital Cancer Center|Boston Medical Center|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Lahey Hospital and Medical Center|Simonds-Sinon Regional Cancer Center|MetroWest Medical Center-Framingham Union Hospital|Addison Gilbert Hospital|Lowell General Hospital|Lahey Medical Center-Peabody|Mercy Medical Center|Baystate Medical Center|Winchester Hospital|UMass Memorial Medical Center - University Campus|Hickman Cancer Center|Saint Joseph Mercy Hospital|C S Mott Children's Hospital|University of Michigan Comprehensive Cancer Center|Bronson Battle Creek|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Beaumont Hospital - Dearborn|Henry Ford Medical Center-Fairlane|Wayne State University/Karmanos Cancer Institute|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Michigan State University Clinical Center|Green Bay Oncology - Escanaba|Beaumont Hospital - Farmington Hills|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Helen DeVos Children's Hospital at Spectrum Health|Mercy Health Saint Mary's|Spectrum Health at Butterworth Campus|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|William Beaumont Hospital-Grosse Pointe|Allegiance Health|Bronson Methodist Hospital|West Michigan Cancer Center|Borgess Medical Center|Karmanos Cancer Institute at McLaren Greater Lansing|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|Mid-Michigan Medical Center - Midland|Monroe Cancer Center|Toledo Clinic Cancer Centers-Monroe|Mercy Health Mercy Campus|Lakeland Hospital Niles|Cancer and Hematology Centers of Western Michigan - Norton Shores|Ascension Providence Hospitals - Novi|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Spectrum Health Reed City Hospital|Great Lakes Cancer Management Specialists-Rochester Hills|Michigan Cancer Specialists|Oakland Colon Rectal Associates|Beaumont Children's Hospital-Royal Oak|Cancer Care Associates PC|Comprehensive Medical Center PLLC|Hematology Oncology Consultants PC|Oakland Medical Group|William Beaumont Hospital-Royal Oak|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Lakeland Medical Center Saint Joseph|Marie Yeager Cancer Center|Henry Ford Macomb Health Center - Shelby Township|Ascension Providence Hospitals - Southfield|Bhadresh Nayak MD PC-Sterling Heights|Premier Hematology Oncology Care|Mitchell Folbe MD PC|Ascension Saint Joseph Hospital|Munson Medical Center|Michigan Institute of Urology-Town Center|Claudia BR Herke MD PC|William Beaumont Hospital - Troy|Hematology Oncology Consultants PC-Troy|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Henry Ford Wyandotte Hospital|Metro Health Hospital|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Sanford Joe Lueken Cancer Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|University of Minnesota/Masonic Cancer Center|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Sanford Cancer Center Worthington|Fairview Lakes Medical Center|Baptist Memorial Hospital and Cancer Center-Golden Triangle|Baptist Cancer Center-Grenada|Hattiesburg Clinic - Hematology/Oncology Clinic|Forrest General Hospital / Cancer Center|University of Mississippi Medical Center|Baptist Memorial Hospital and Cancer Center-Union County|Baptist Memorial Hospital and Cancer Center-Oxford|Singing River Hospital|Baptist Memorial Hospital and Cancer Center-Desoto|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Saint Luke's Hospital|University of Missouri - Ellis Fischel|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Centerpoint Medical Center LLC|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|Saint Luke's Hospital of Kansas City|The University of Kansas Cancer Center-South|Research Medical Center|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|University of Kansas Cancer Center at North Kansas City Hospital|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Community Hospital of Anaconda|Billings Clinic Cancer Center|Saint Vincent Healthcare|Saint Vincent Frontier Cancer Center|Bozeman Deaconess Hospital|Saint James Community Hospital and Cancer Treatment Center|Benefis Healthcare- Sletten Cancer Institute|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Nebraska Medicine-Bellevue|CHI Health Saint Francis|Heartland Hematology and Oncology|CHI Health Good Samaritan|Nebraska Hematology and Oncology|Nebraska Cancer Research Center|Saint Elizabeth Regional Medical Center|Southeast Nebraska Cancer Center - 68th Street Place|Faith Regional Health Services Carson Cancer Center|Great Plains Health Callahan Cancer Center|Nebraska Cancer Specialists/Oncology Hematology West PC - MECC|Nebraska Methodist Hospital|Oncology Associates PC|Nebraska Medicine-Village Pointe|Alegent Health Immanuel Medical Center|Hematology and Oncology Consultants PC|Alegent Health Bergan Mercy Medical Center|Nebraska Cancer Specialists - Omaha|Alegent Health Lakeside Hospital|Oncology Hematology West PC|Creighton University Medical Center|University of Nebraska Medical Center|Midlands Community Hospital|Regional West Medical Center Cancer Center|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Cancer Therapy and Integrative Medicine|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|Hope Cancer Care of Nevada-Pahrump|Center of Hope at Renown Medical Center|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|New Hampshire Oncology Hematology PA-Concord|Dartmouth Hitchcock Medical Center|Norris Cotton Cancer Center-Manchester|Elliot Hospital|Solinsky Center for Cancer Care|Norris Cotton Cancer Center-Nashua|Ocean Medical Center|AtlantiCare Health Park-Cape May Court House|AtlantiCare Surgery Center|Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus|Hunterdon Medical Center|Hackensack University Medical Center|Bayshore Community Hospital|Monmouth Medical Center Southern Campus|Saint Barnabas Medical Center|Monmouth Medical Center|Southern Ocean County Medical Center|Memorial Sloan Kettering Monmouth|Morristown Medical Center|Inspira Medical Center Mullica Hill|Jersey Shore Medical Center|Rutgers Cancer Institute of New Jersey|Newark Beth Israel Medical Center|Capital Health Medical Center-Hopewell|Riverview Medical Center/Booker Cancer Center|Sidney Kimmel Cancer Center Washington Township|Overlook Hospital|Inspira Medical Center Vineland|Lovelace Medical Center-Downtown|University of New Mexico Cancer Center|Southwest Gynecologic Oncology Associates Inc|New Mexico Oncology Hematology Consultants|Presbyterian Kaseman Hospital|Memorial Medical Center - Las Cruces|Presbyterian Rust Medical Center/Jorgensen Cancer Center|Christus Saint Vincent Regional Cancer Center|South Shore University Hospital|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Children's Hospital at Montefiore|Montefiore Medical Center - Moses Campus|State University of New York Downstate Medical Center|Roswell Park Cancer Institute|Arnot Ogden Medical Center/Falck Cancer Center|Glens Falls Hospital|Memorial Sloan Kettering Westchester|Northwell Health/Center for Advanced Medicine|North Shore University Hospital|Long Island Jewish Medical Center|Lenox Hill Hospital|Mount Sinai Hospital|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Manhattan Eye Ear and Throat Hospital|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|Rochester General Hospital|University of Rochester|Stony Brook University Medical Center|State University of New York Upstate Medical University|SUNY Upstate Medical Center-Community Campus|Dickstein Cancer Treatment Center|Mission Hospital|AdventHealth Infusion Center Asheville|Messino Cancer Centers|Hope Women's Cancer Centers-Asheville|Waverly Hematology Oncology|UNC Lineberger Comprehensive Cancer Center|Novant Health Presbyterian Medical Center|Novant Health Carolina Surgical - Randolph|Oncology Specialists of Charlotte|Southern Oncology Specialists-Charlotte|Southeastern Medical Oncology Center-Clinton|AdventHealth Infusion Center Haywood|Durham VA Medical Center|Duke University Medical Center|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Novant Health Breast Surgery - Greensboro|Hendersonville Hematology and Oncology at Pardee|Margaret R Pardee Memorial Hospital|AdventHealth Hendersonville|Novant Health Cancer Institute - Huntersville|Novant Health Presbyterian Medical Center Huntersville|Southern Oncology Specialists-Huntersville|Onslow Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Novant Health Cancer Institute - Kernersville|Matthews Radiation Oncology Center|Novant Health Cancer Specialists-Matthews|Lake Norman Radiation Oncology Center-Mooresville|Novant Health Cancer Institute - Mooresville|Novant Health Cancer Institute - Mount Airy|FirstHealth of the Carolinas-Moore Regional Hospital|Duke Raleigh Hospital|Novant Health Cancer Institute - Rowan|Rowan Regional Medical Center|Novant Health Cancer Institute - Statesville|Novant Health Cancer Institute - Thomasville|Marion L Shepard Cancer Center at Vidant Beaufort Hospital|AdventHealth Infusion Center Weaverville|Novant Health Cancer Institute - Wilkesboro|Novant Health Forsyth Medical Center|Novant Health Oncology Specialists|Winston-Salem Health Care|Wake Forest University Health Sciences|Sanford Bismarck Medical Center|Essentia Health Cancer Center-South University Clinic|Sanford South University Medical Center|Sanford Broadway Medical Center|Sanford Clinic North-Fargo|Sanford Roger Maris Cancer Center|Essentia Health - Jamestown Clinic|Trinity Cancer Care Center|Aultman Alliance Community Hospital|UHHS-Chagrin Highlands Medical Center|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Cleveland Clinic Mercy Hospital|Mercy Hematology and Oncology Associates Inc|Aultman Health Foundation|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Geauga Hospital|Adena Regional Medical Center|Oncology Hematology Care Inc-Eden Park|Oncology Hematology Care Inc-Mercy West|The Christ Hospital|Good Samaritan Hospital - Cincinnati|Cincinnati Children's Hospital Medical Center|Oncology Hematology Care Inc-Anderson|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|Oncology Hematology Care Inc-Blue Ash|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|Case Western Reserve University|MetroHealth Medical Center|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Delaware Radiation Oncology|Grady Memorial Hospital|Columbus Oncology and Hematology Associates|Dublin Methodist Hospital|Hematology Oncology Center Incorporated|Mercy Cancer Center-Elyria|Oncology Hematology Care Inc-Healthplex|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Toledo Clinic Cancer Centers-Maumee|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center|UH Seidman Cancer Center at Landerbrook Health Center|UH Seidman Cancer Center at Lake Health Mentor Campus|UH Seidman Cancer Center at Southwest General Hospital|Dayton Physicians LLC-Signal Point|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Saint Charles Hospital|University Hospitals Parma Medical Center|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|UH Seidman Cancer Center at Firelands Regional Medical Center|Dayton Physicians LLC-Wilson|Springfield Regional Cancer Center|Springfield Regional Medical Center|Trinity's Tony Teramana Cancer Center|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|Saint Vincent Mercy Medical Center|University of Toledo|Mercy Health - Saint Anne Hospital|Toledo Clinic Cancer Centers-Toledo|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|University Hospitals Sharon Health Center|Saint Joseph Warren Hospital|Saint Ann's Hospital|UH Seidman Cancer Center at Saint John Medical Center|UHHS-Westlake Medical Center|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Integris Southwest Medical Center|Mercy Hospital Oklahoma City|Integris Cancer Institute of Oklahoma|Cancer Treatment Centers of America|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Good Samaritan Hospital|Legacy Mount Hood Medical Center|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Legacy Good Samaritan Hospital and Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Kaiser Permanente Northwest|Oregon Health and Science University|Saint Charles Health System-Redmond|Legacy Meridian Park Hospital|Jefferson Abington Hospital|Lehigh Valley Hospital-Cedar Crest|UPMC Altoona|UPMC-Heritage Valley Health System Beaver|Lehigh Valley Hospital - Muhlenberg|Bryn Mawr Hospital|UPMC Hillman Cancer Center at Butler Health System|UPMC Camp Hill|Carlisle Regional Cancer Center|Christiana Care Health System-Concord Health Center|Chambersburg Hospital|Main Line Health Center-Collegeville|UPMC Hillman Cancer Center - Passavant - Cranberry|Geisinger Medical Center|Doylestown Hospital|Pocono Medical Center|Easton Hospital|Ephrata Cancer Center|Ephrata Community Hospital|UPMC Hillman Cancer Center Erie|UPMC Hamot|Main Line Health Center-Exton|UPMC Cancer Center at UPMC Horizon|Adams Cancer Center|UPMC Cancer Centers - Arnold Palmer Pavilion|Oncology Hematology Associates|Cherry Tree Cancer Center|UPMC Pinnacle Harrisburg|UPMC Pinnacle Cancer Center/Community Osteopathic Campus|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Penn State Milton S Hershey Medical Center|IRMC Cancer Center|UPMC-Johnstown/John P. Murtha Regional Cancer Center|Armstrong Center for Medicine and Health|Lancaster General Ann B Barshinger Cancer Institute|Lancaster General Hospital|Sechler Family Cancer Center|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|UPMC Cancer Center at UPMC McKeesport|Holy Redeemer Hospital and Medical Center|UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion|Riddle Memorial Hospital|Forbes Hospital|UPMC Hillman Cancer Center - Monroeville|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Hillman Cancer Center - Part of Frick Hospital|Arnold Palmer Cancer Center Medical Oncology Norwin|Allegheny Valley Hospital|UPMC Cancer Center-Natrona Heights|UPMC Hillman Cancer Center - New Castle|Suburban Community Hospital and Cancer Center|Paoli Memorial Hospital|Drexel University School of Medicine|Thomas Jefferson University Hospital|Fox Chase Cancer Center|Jefferson Torresdale Hospital|Eastern Regional Medical Center|Nazareth Hospital|Phoenixville Hospital|Allegheny General Hospital|UPMC-Magee Womens Hospital|Oncology Hematology Association|UPMC-Saint Margaret|UPMC-Mercy Hospital|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Geisinger Cancer Services-Pottsville|Penn State Health Saint Joseph Medical Center|Guthrie Medical Group PC-Robert Packer Hospital|Hematology and Oncology Associates of North East Pennsylvania|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|UPMC Cancer Center at UPMC Northwest|Geisinger Medical Group|Mount Nittany Medical Center|UPMC Cancer Center-Uniontown|UPMC Cancer Center-Washington|Chester County Hospital|UPMC West Mifflin-Cancer Center Jefferson|Reading Hospital|Geisinger Wyoming Valley/Henry Cancer Center|UPMC Susquehanna|Divine Providence Hospital|Asplundh Cancer Pavilion|Lankenau Medical Center|WellSpan Health-York Cancer Center|WellSpan Health-York Hospital|UPMC Memorial|Newport Hospital|Rhode Island Hospital|Women and Infants Hospital|Miriam Hospital|Smilow Cancer Hospital Care Center - Westerly|AnMed Health Cancer Center|Beaufort Memorial Hospital|Prisma Health Cancer Institute - Spartanburg|Roper Hospital|Charleston Oncology - Roper|Lowcountry Hematology Oncology PA-North Charleston|Bon Secours Saint Francis Hospital|Charleston Oncology - Saint Francis|Lowcountry Hematology Oncology PA-West Ashley|Medical University of South Carolina|Prisma Health Cancer Institute - Easley|McLeod Regional Medical Center|Gibbs Cancer Center-Gaffney|Tidelands Georgetown Memorial Hospital|Greenville Health System Cancer Institute-Andrews|Saint Francis Hospital|Prisma Health Cancer Institute - Butternut|Prisma Health Cancer Institute - Faris|Prisma Health Greenville Memorial Hospital|Saint Francis Cancer Center|Prisma Health Cancer Institute - Eastside|Self Regional Healthcare|Prisma Health Cancer Institute - Greer|Gibbs Cancer Center-Pelham|South Carolina Cancer Specialists PC|The Radiation Oncology Center-Hilton Head/Bluffton|Lowcountry Hematology Oncology PA-Mount Pleasant|Prisma Health Cancer Institute - Seneca|North Grove Medical Park|Spartanburg Medical Center|Spartanburg Medical Center - Mary Black Campus|MGC Hematology Oncology-Union|Avera Cancer Institute-Aberdeen|Rapid City Regional Hospital|Sanford Cancer Center Oncology Clinic|Avera Cancer Institute|Sanford USD Medical Center - Sioux Falls|Memorial Hospital|Integrity Oncology PLLC-Collierville|Cookeville Regional Medical Center|Vanderbilt-Ingram Cancer Center Cool Springs|Pulmonary Medicine Center of Chattanooga-Hixson|Tennessee Cancer Specialists-Dowell Springs|Thompson Cancer Survival Center|Thompson Cancer Survival Center - West|Thompson Oncology Group-Maryville|Baptist Memorial Hospital and Cancer Center-Memphis|Family Cancer Center-Memphis|Vanderbilt Breast Center at One Hundred Oaks|Meharry Medical College|Vanderbilt University/Ingram Cancer Center|Thompson Oncology Group-Oak Ridge|Memorial GYN Plus|Dell Seton Medical Center at The University of Texas|Saint Joseph Regional Cancer Center|MD Anderson in The Woodlands|Parkland Memorial Hospital|Baylor University Medical Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Houston Methodist Hospital|M D Anderson Cancer Center|Memorial Hermann Texas Medical Center|MD Anderson West Houston|Memorial Hermann Northeast Hospital|MD Anderson League City|Covenant Medical Center-Lakeside|UT Southwestern Clinical Center at Richardson/Plano|Cancer Therapy and Research Center at The UT Health Science Center at San Antonio|Methodist Children's Hospital of South Texas|University Hospital|University of Texas Health Science Center at San Antonio|MD Anderson in Sugar Land|Memorial Hermann The Woodlands Hospital|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Farmington Health Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Riverton Hospital|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|Huntsman Cancer Institute/University of Utah|LDS Hospital|South Jordan Health Center|Central Vermont Medical Center/National Life Cancer Treatment|University of Vermont Medical Center|University of Vermont and State Agricultural College|Norris Cotton Cancer Center-North|Danville Regional Medical Center|Inova Schar Cancer Institute|Inova Fair Oaks Hospital|Inova Fairfax Hospital|Augusta Health Center for Cancer and Blood Disorders|Hematology Oncology Associates of Fredericksburg Inc|Centra Lynchburg Hematology-Oncology Clinic Inc|Sovah Health Martinsville|Bon Secours Memorial Regional Medical Center|Bon Secours Westchester Emergency Center|Bon Secours Saint Francis Medical Center|Children's Hospital of The King's Daughters|Bon Secours Saint Mary's Hospital|Virginia Cancer Institute|Bon Secours Cancer Institute at Reynolds Crossing|VCU Massey Cancer Center at Stony Point|Virginia Commonwealth University/Massey Cancer Center|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|MultiCare Auburn Medical Center|Virginia Mason Bainbridge Island Medical Center|Overlake Medical Center|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Virginia Mason Federal Way Medical Center|Saint Francis Hospital|Tacoma/Valley Radiation Oncology Centers-Gig Harbor|MultiCare Gig Harbor Medical Park|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Northwest Cancer Clinic|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Virginia Mason Lynnwood Medical Center|Skagit Valley Hospital Regional Cancer Care Center|Skagit Valley Hospital|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Peninsula Cancer Center|MultiCare Good Samaritan Hospital|Tacoma/Valley Radiation Oncology Centers-Puyallup|Valley Medical Center|Virginia Mason Medical Center|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Fred Hutchinson Cancer Research Center|Seattle Cancer Care Alliance|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|University of Washington Medical Center - Montlake|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|MultiCare Deaconess Cancer and Blood Specialty Center - Valley|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown|Providence Sacred Heart Medical Center and Children's Hospital|Spokane Valley Cancer Center-Mayfair|Spokane Valley Cancer Center-Mission|Evergreen Hematology and Oncology PS|MultiCare Deaconess Cancer and Blood Specialty Center - North|Tacoma/Valley Radiation Oncology Centers-Jackson Hall|Franciscan Research Center-Northwest Medical Plaza|Mary Bridge Children's Hospital and Health Center|MultiCare Tacoma General Hospital|Northwest Medical Specialties PLLC|Tacoma/Valley Radiation Oncology Centers-Saint Joe's|PeaceHealth Southwest Medical Center|Legacy Cancer Institute Medical Oncology and Day Treatment|Legacy Salmon Creek Hospital|Providence Saint Mary Regional Cancer Center|Wenatchee Valley Hospital and Clinics|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|United Hospital Center|West Virginia University Charleston Division|Edwards Comprehensive Cancer Center|WVUH-Berkely Medical Center|Monongalia Hospital|West Virginia University Healthcare|Camden Clark Medical Center|Wheeling Hospital/Schiffler Cancer Center|Langlade Hospital and Cancer Center|Ascension Saint Elizabeth Hospital|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Ascension Southeast Wisconsin Hospital - Elmbrook Campus|Aurora Cancer Care-Southern Lakes VLCC|Ascension Calumet Hospital|Marshfield Clinic-Chippewa Center|Aurora Saint Luke's South Shore|HSHS Sacred Heart Hospital|Marshfield Clinic Cancer Center at Sacred Heart|Marshfield Medical Center-EC Cancer Center|Aurora Health Center-Fond du Lac|Ascension Saint Francis - Reiman Cancer Center|Ascension Southeast Wisconsin Hospital - Franklin|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Green Bay Oncology at Saint Vincent Hospital|Saint Vincent Hospital Cancer Center Green Bay|Green Bay Oncology Limited at Saint Mary's Hospital|Saint Vincent Hospital Cancer Center at Saint Mary's|Aurora BayCare Medical Center|Mercyhealth Hospital and Cancer Center - Janesville|Aurora Cancer Care-Kenosha South|Gundersen Lutheran Medical Center|Marshfield Clinic - Ladysmith Center|University of Wisconsin Carbone Cancer Center|Holy Family Memorial Hospital|Aurora Bay Area Medical Group-Marinette|Saint Vincent Hospital Cancer Center at Marinette|Marshfield Medical Center-Marshfield|Marshfield Medical Center|Aspirus Medford Hospital|Ascension Columbia Saint Mary's Hospital Ozaukee|Aurora Cancer Care-Milwaukee|Ascension Southeast Wisconsin Hospital - Saint Joseph Campus|Ascension Columbia Saint Mary's Hospital - Milwaukee|Ascension Saint Francis Hospital|Aurora Saint Luke's Medical Center|Medical College of Wisconsin|Aurora Sinai Medical Center|Marshfield Clinic-Minocqua Center|ProHealth D N Greenwald Center|Cancer Center of Western Wisconsin|ProHealth Oconomowoc Memorial Hospital|Saint Vincent Hospital Cancer Center at Oconto Falls|Ascension Mercy Hospital|Vince Lombardi Cancer Clinic - Oshkosh|Ascension All Saints Hospital|Aurora Cancer Care-Racine|Ascension Saint Mary's Hospital|Saint Mary's Hospital|Lakeview Medical Center-Marshfield Clinic|Marshfield Medical Center-Rice Lake|HSHS Saint Nicholas Hospital|Vince Lombardi Cancer Clinic-Sheboygan|Ascension Saint Michael's Hospital|Marshfield Clinic Stevens Point Center|Saint Vincent Hospital Cancer Center at Sturgeon Bay|Green Bay Oncology - Sturgeon Bay|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|Aurora Cancer Care-Waukesha|ProHealth Waukesha Memorial Hospital|UW Cancer Center at ProHealth Care|Aspirus Regional Cancer Center|Marshfield Clinic-Wausau Center|Ascension Medical Group Southeast Wisconsin - Mayfair Road|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center|Diagnostic and Treatment Center|Marshfield Medical Center - Weston|Aspirus Cancer Care - Wisconsin Rapids|Marshfield Clinic - Wisconsin Rapids Center|Cheyenne Regional Medical Center-West|Big Horn Basin Cancer Center|Billings Clinic-Cody|Welch Cancer Center|FHP Health Center-Guam|Cancer Center-Metro Medical Center Bayamon|Doctors Cancer Center|San Juan Community Oncology Group|San Juan City Hospital,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Other|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Other|Drug|Drug|Biological|Drug|Drug|Biological|Drug|Biological|Drug|Drug|Drug|Drug|Biological|Biological|Drug|Drug,Guam|Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02465060
1672,NCT02465424,Medullary Thyroid Cancer,Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients,Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients,Medullary Thyroid Cancer,2015-06-01,2017-12-31,2017-12-31,173.0,Case-Only,,Other,Observational,Completed,,Velindre NHS Trust,Velindre NHS Trust,Velindre Hospital|University Hospitals of Coventry and Warwickshire|Western general Hospital|Imperial Hospital|St. Bartholomew's Hospital|Christie Hospital|Weston Park Hospital,Other,United Kingdom,16.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02465424
1673,NCT02467244,Hypothyroidism,"Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism","Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism",Hypothyroidism,2015-06-04,2018-09-30,2018-12-30,120.0,Cohort,,Prospective,Observational,Completed,,"All India Institute of Medical Sciences, Bhubaneswar","All India Institute of Medical Sciences, Bhubaneswar","AIIMS, Bhubaneswar",Drug,India,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02467244
1674,NCT02468921,Goiter,The Impact of Surgical Treatment of Benign Non-toxic Goiter on the Voice Function,Goitres Influence on Voice Function - The Impact of Surgery,Goiter,2015-01-19,2018-10-31,2018-10-31,60.0,Cohort,,Prospective,Observational,Unknown status,,University of Southern Denmark,Odense University Hospital|University of Southern Denmark,Odense University Hospital,Procedure,Denmark,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02468921
1675,NCT02472080,Thyroid Cancer,Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients,Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study,Thyroid Cancer,2015-05-12,2018-04-01,2019-01-15,21.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Groupe Hospitalier Piti Salpetriere,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02472080
1676,NCT02491502,Benign Thyroid Nodules,Treatment of Benign Thyroid Nodules With FastScan High Intensity Focused Ultrasound (HIFU),Treatment of Benign Thyroid Nodules With FastScan HIFU,Benign Thyroid Nodules,2015-06-24,2020-04-30,2020-07-31,36.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Theraclion,Theraclion,University Hospital of Endocrinology USBALE,Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02491502
1678,NCT02491567,Graves Disease|Hashimoto Thyroiditis,Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases,DNA Methylation and Autoimmune Thyroid Diseases,Graves Disease|Hashimoto Thyroiditis,2014-12-23,2016-09-30,2018-04-30,110.0,Case-Control,,Cross-Sectional,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",,Greece,4.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02491567
1684,NCT02499471,Hyperthyroidism|Hypothyroidism|Obesity,Brown Adipose Tissue Activity and Thyroid Hormone,Brown Adipose Tissue Activity and Thyroid Hormone,Hyperthyroidism|Hypothyroidism|Obesity,2015-07-06,2012-12-31,2014-07-31,12.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Maastricht University Medical Center,Maastricht University Medical Center,Maastricht UMC,Other,Netherlands,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02499471
1686,NCT02500342,Fatigue|Mental Fatigue|Thyroid Dysfunction,Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism,Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism,Fatigue|Mental Fatigue|Thyroid Dysfunction,2015-06-18,2018-04-05,2018-04-05,276.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University Hospital Inselspital, Berne","University College Cork|University Hospital Inselspital, Berne|University of Lausanne Hospitals","University College Cork, National University of Ireland|Department of General Internal Medicine|Clinic for General Internal Medicine, Bern University Hospital Bern",Drug|Drug,Ireland|Switzerland,65.0,120.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02500342
1687,NCT02512978,Hypothyroidism|Myocardial Infarction,Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction,Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI),Hypothyroidism|Myocardial Infarction,2015-07-27,2018-12-31,2019-06-30,160.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,"Chinese Academy of Medical Sciences, Fuwai Hospital","Beijing Anzhen Hospital|Beijing Chao Yang Hospital|Beijing Friendship Hospital|Beijing Municipal Science & Technology Commission|Chinese Academy of Medical Sciences, Fuwai Hospital|Peking Union Medical College Hospital|Peking University Third Hospital|The Luhe Teaching Hospital of the Capital Medical University",Fuwai Cardiovascular Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02512978
1688,NCT02514187,Hyperthyroidism,A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients,A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients,Hyperthyroidism,2015-07-27,2017-04-30,2017-04-30,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,British Columbia Cancer Agency,"British Columbia Cancer Agency|Canadian Institutes of Health Research (CIHR)|Centre for Probe Development and Commercialization|Lawson Health Research Institute|Natural Resources, Canada|TRIUMF",Vancouver General Hospital - Nuclear Medicine|Hamilton Health Sciences Centre|London Regional Health Sciences Centre,Drug|Drug,Canada,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02514187
1689,NCT02515084,Relapse|Thyroid Cancer,Preliminary Study of the Interest of Diffusion-weighted Magnetic Resonance Imaging in the Early Detection of Differentiated Thyroid Carcinoma Cervical Recurrence. Comparison with18F-FDG PET/CT,Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma,Relapse|Thyroid Cancer,2015-07-24,2015-07-31,2016-07-31,37.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Centre Henri Becquerel,Centre Henri Becquerel,Centre Henri Becquerel,Device|Device,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02515084
1690,NCT02516774,Anaplastic Thyroid Cancers,"A Phase I Trial Assessing Adalimumab (Humira), a Tumor Necrosis Factor  Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers",A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers,Anaplastic Thyroid Cancers,2015-04-29,2015-12-31,2015-12-31,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy Cancer Campus Grand Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02516774
1692,NCT02523209,"Chronic Kidney Diseases|Hyperparathyroidism, Secondary",Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation - A Monocentric Study,Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation,"Chronic Kidney Diseases|Hyperparathyroidism, Secondary",2015-07-15,2017-04-30,2017-04-30,102.0,Cohort,,Prospective,Observational,Completed,,Centre Hospitalier Universitaire de Saint Etienne,Centre Hospitalier Universitaire de Saint Etienne,Chu Saint-Etienne,Device|Device,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02523209
1695,NCT02524041,Hyperparathyroidism,Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism,Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism,Hyperparathyroidism,2015-08-13,2016-04-30,2016-04-30,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Saint Etienne,"Centre Hospitalier Universitaire de Saint Etienne|University Hospital, Geneva",CHU de SAINT-ETIENNE,Device|Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02524041
1698,NCT02525796,Primary Hyperparathyroidism,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2015-08-14,2021-10-01,2021-10-02,69.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Drug|Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02525796
1701,NCT02535975,Mild Graves' Ophthalmopathy,,The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy,Mild Graves' Ophthalmopathy,2015-08-12,2019-10-31,2019-10-31,80.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Endocrinology, Internal Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02535975
1705,NCT02536287,Secondary Hyperparathyroidism,Comparison of Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Without Autotransplantation:A Randomized Clinical Trial,Comparison of Total Parathyroidectomy With and Without Autotransplantation,Secondary Hyperparathyroidism,2015-08-22,2016-12-31,2018-12-31,96.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,The Second Hospital of Anhui Medical University,The Second Hospital of Anhui Medical University,the Second Affiliated Hospital of Anhui Medical University,Procedure|Procedure,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02536287
1708,NCT02539498,Bone Disease|Primary Hyperparathyroidism,Characterization of Bone Architectural Parameters Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Post-menopausal Women Affected With Primary Hyperparathyroidism,Bone Architectural Parameters in Postmenopausal Women Affected With Primary Hyperparathyroidism,Bone Disease|Primary Hyperparathyroidism,2015-04-27,2016-12-31,2016-12-31,82.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Hopital Lariboisiere|Hopital Cochin|Hopital Europeen Georges Pompidou,Device,France,0.0,81.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02539498
1711,NCT02548715,Hypothyroidism|Neoplasms|Postoperative Complications,Levothyroxine Treatment of Subclinical Hypothyroidism After Non-thyroid Head and Neck Surgery: A Randomized Controlled Trial,Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery,Hypothyroidism|Neoplasms|Postoperative Complications,2015-09-08,2017-07-31,2017-07-31,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,University of Alberta,University of Alberta,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02548715
1712,NCT02549391,Secondary Hyperparathyroidism,"Phase 3 Study of KHK7580 (A Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)",Phase 3 Study of KHK7580,Secondary Hyperparathyroidism,2015-09-09,2016-11-30,2016-11-30,634.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02549391
1715,NCT02549404,Secondary Hyperparathyroidism,Phase 3 Study of KHK7580 (A Long-term Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis),Phase 3 Study of KHK7580,Secondary Hyperparathyroidism,2015-09-09,2016-12-06,2016-12-28,137.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02549404
1718,NCT02549417,Secondary Hyperparathyroidism,Phase 3 Study of KHK7580 (A Clinical Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Peritoneal Dialysis),Phase 3 Study of KHK7580,Secondary Hyperparathyroidism,2015-09-09,2016-12-22,2016-12-22,39.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02549417
1721,NCT02551120,Autosomal Dominant Hypocalcaemia|Idiopathic Hypoparathyroidism|Pseudohypoparathyroidism,"Characterization of Patients With Idiopathic Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism",Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism,Autosomal Dominant Hypocalcaemia|Idiopathic Hypoparathyroidism|Pseudohypoparathyroidism,2015-06-17,2017-08-31,2020-08-31,100.0,Cohort,,Prospective,Observational,Unknown status,,University of Aarhus,University of Aarhus,Aarhus University Hospital,,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02551120
1725,NCT02556216,Renal Osteodystrophy,Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD),Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD),Renal Osteodystrophy,2015-08-06,2019-01-31,2019-07-31,100.0,Cohort,,Cross-Sectional,Observational,Unknown status,,Hannover Medical School,Hannover Medical School|University of Jena,Hannover Medical School,,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02556216
1728,NCT02561533,Papillary Thyroid Carcinoma,Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC,Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2015-09-17,2017-07-31,2017-07-31,53.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,Aarhus University Hospital,Other,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02561533
1730,NCT02567877,Hypothyroidism|Postsurgical Hypothyroidism,Is Levothyroxine Alone Adequate Thyroid Hormone Replacement for All Patients?,Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?,Hypothyroidism|Postsurgical Hypothyroidism,2015-10-01,2025-06-30,2025-06-30,190.0,Cohort,,Prospective,Observational,Recruiting,,"University of Colorado, Denver","Charite University, Berlin, Germany|University of Colorado, Denver",University of Colorado Anschutz Medical Campus,Procedure|Drug,United States,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02567877
1731,NCT02568267,"Adult Solid Tumor|Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Salivary Gland Cancers|Sarcomas","An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","Adult Solid Tumor|Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Salivary Gland Cancers|Sarcomas",2015-10-02,2024-12-31,2025-04-01,700.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Western Regional Medical Center at Cancer Treatment Centers of America|Dignity Health St Joseph's Hospital and Medical Center|Mayo Clinic|City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics|Scripps Clinic|University of California San Diego Moores Cancer Center; Dept of Lung Cancer|University of Southern California Medical Center|Univ Of California Irvine College Of Medicine; 300194620|Southern California Kaiser Permanente|UCSF Mount Zion Medical Ctr|Sarcoma Oncology Center|University of Colorado Cancer Center|Yale University|Georgetown University Medical Center Lombardi Cancer Center|Florida Cancer Specialists - Sarasota|H. Lee Moffitt Cancer Center and Research Inst.|Cleveland Clinic Florida|University Cancer & Blood Center, LLC; Research|Winship Cancer Institute|Southeastern Regional Medical Center, Inc.|University of Hawaii Cancer Center|Northwestern University|Advocate Medical Group - Park Ridge, Luther Lane - Oncology|Midwestern Regional Medical Center|Weinberg Cancer Institution at Franklin Square|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana Farber Cancer Institute|University of Michigan Comprehensive Cancer Center; Clinical Trials Office|Karmanos Cancer Center|Henry Ford Hospital|Regents of the University of Minnesota|Washington University|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley|Dartmouth Hitchcock Medical Center|North Shore Hem Onc Associates|Memorial Sloan Kettering Cancer Center|Levine Cancer Institute|Duke Cancer Institute|Cleveland Clinic|OSU, James Cancer Hospital|Cancer Treatment Centers of America; Tulsa|Providence Portland Medical Center|Oregon Health & Science Univ|Cancer Treatment Centers of America - Eastern Regional Medical Center|Mary Crowley Medical Research Center|University Hospital Medical Oncology Clinic; Harold C. Simmons Comprehensive Cancer Center|University of Texas MD Anderson Cancer Center|Baylor Scott & White Health|University of Utah Hospitals & Clinics|Virginia Cancer Specialists, PC|Virginia Oncology Associates - Hampton|University of Washington Seattle Cancer Care Alliance|Wheaton Franciscan Cancer Care-All Saints|Border Medical Oncology Research Unit|Liverpool Hospital|Newcastle Private Hospital|Flinders Medical Centre|Austin Health|Antwerp University Hospital|Beijing Cancer Hospital|Sichuan Provincial Cancer Hospital|Cancer Center of Guangzhou Medical University|Harbin Medical University Cancer Hospital|Fudan University Shanghai Cancer Center|Shanghai chest hospital|Shenzhen People's Hospital|Tianjin Cancer Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Zhejiang Cancer Hospital|Institut de Cancerologie de l Ouest|Institut Bergonie; Oncologie|Centre Oscar Lambret; Chir Cancerologie General|Centre Leon Berard; Departement Oncologie Medicale|Hpital de la Timone; Oncologie Mdicale Hmatologie & Soins Palliatifs|Hpital Nord - AP-HM Marseille#; Service d'Oncologie Multidisciplinaire|Institut de Recherche en Cancrologie de Montpellier|Hpital Europen Georges Pompidou; Hmatologie Oncologie|Institut Curie; Oncologie Medicale|Institut De Cancerologie De L'ouest - Rene Gauducheau - Biology|Institut Claudius Regaud; Departement Oncologie Medicale|Institut Gustave Roussy; Pathologie Thoracique|Charite Universitaetsmedizin Berlin - Campus Charite Mitte ; Charite Comprehensive Cancer Center|Evang. Lungenklinik Berlin Klinik fr Pneumologie|Universitaetsklinikum Carl Gustav Carus TU Dresden|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie|Universitaetsmedizin Goettingen; Abteilung Haematologie und Onkologie|NCT Uniklinikum Heidelberg; Medizinische Onkologie|Universitaetsklinikum Koeln; Innere Medizin I, Haematologie|Hong Kong Integrated Oncology Centre|Princess Margaret Hospital|The University of Hong Kong|Queen Elizabeth Hospital|The Chinese University of Hong Kong|Seconda Universit degli Studi di Napoli; Servizio Epato-Gastroenterologia|Universit Campus Bio-Medico di Roma; Oncologia Medica|Azienda Ospedaliero Universitaria San Martino; Lung Cancer Unit|Fondazione IRCCS Istituto Nazionale dei Tumori|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck|Fondazione del Piemonte per l'Oncologia - IRCCS;Ematologia|Azienda Ospedaliero-Universitaria S.Luigi Gonzaga; SSD Oncologia Polmonare|A.O Citt della Salute e della Scienza di Torino; Colorectal Cancer Unit (CRCU) - SSCVD|Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia ; S.C. Oncologia Medica|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II|Aichi Cancer Center Hospital; Respiratory Medicine|NHO Shikoku Cancer Center; Dept of Respiratory Medicine|NHO Kyushu Cancer Center|Hyogo Cancer Center, Dept of Respiratory Medicine|National Cancer Center Hospital; Dept of Respiratory Medicine|Miyagi Cancer Center; Respiratory Medicine|Niigata Cancer Center Hospital; Internal Medicine|OSAKA CITY GENERAL HOSPITAL;Medical Oncology|Kindai University Hospital; Medical Oncology|Shizuoka Cancer Center; Respiratory Internal Medicine|Chungbuk National University Hospital|Seoul National University Hospital|Severance Hospital, Yonsei University Health System|Samsung Medical Center|Asan Medical Center.|NKI The Netherlands Cancer Institute|Leids Universitair Medisch Centrum|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii|Centrum Onkologii-Instytut im.M.Sklodowskiej Curie; Dept of Nuclear Med. and Endocrine Oncology|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology & subdiv. of oncology|Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego; Chemotherapy|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego|National University Hospital; Haematology/Oncology|National Cancer Centre|Centro Nacional de Investigaciones Oncolgicas(CNIO); Gastrointestinal Cancer Clinical Research Unit|Vall dHebron Institute of Oncology (VHIO), Barcelona|Hospital Universitario de La Princesa; Servicio de Oncologia|Hospital Universitario Ramon y Cajal; Servicio de Farmacia|Hospital Universitario Clnico San Carlos; Servicio de Oncologia|Hospital Universitario 12 de Octubre; Servicio de Oncologia|Hospital Universitario La Paz; Servicio de Oncologia|Centro Integral Oncologico Clara Campal; Servicio de Oncologa|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia|Hospital Universitario Virgen del Rocio; Servicio de Oncologia|Changhua Christian Hospital|National Cheng Kung University Hospital|Taipei Veterans General Hospital|National Taiwan University Hospital|Taichung Veterans General Hospital|Addenbrookes Hospital|Sarah Cannon Research Institute|Christie Hospital Nhs Trust; Medical Oncology",Drug,"Australia|Belgium|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02568267
1733,NCT02577367,Hypothyroidism,The Effect of Holding Tube Feeding When Administering Levothyroxine on the Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding,Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding,Hypothyroidism,2015-09-14,2020-04-08,2020-04-08,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,Maimonides Medical Center,Jocelyne Karam|Maimonides Medical Center,Maimonides Medical Center,Drug,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02577367
1734,NCT02586337,Differentiated Thyroid Cancer,"A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032)",Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032),Differentiated Thyroid Cancer,2015-10-22,2019-12-31,2019-12-31,113.0,,Parallel Assignment,,Interventional,Unknown status,Phase 2/Phase 3,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Tongren Hospital|Peking Union Medical College Hospital|Chongqing Cancer Hospital|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Harbin medical university affiliated tumor hospital|Henan Province Tumor Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Hunan Province Tumor Hospital|Jiangsu province tumor hospital|Jilin Cancer Hospital|Liaoning Province Tumor Hospital|Cancer Hospital of Fudan University|West China Hospital Of Sichuan University|20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .|The First Affiliated Hospital of Kunming Medical University|Zhejiang Cancer Hospital",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02586337
1735,NCT02586350,Medullary Thyroid Carcinoma,"A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031)",Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031),Medullary Thyroid Carcinoma,2015-10-22,2018-09-30,2018-09-30,91.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Tongren Hospital|Peking Union Medical College Hospital|Chongqing Cancer Hospital|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Harbin medical university affiliated tumor hospital|Henan Province Tumor Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Hunan Province Tumor Hospital|Jiangsu province tumor hospital|Jilin Cancer Hospital|Liaoning Province Tumor Hospital|Cancer Hospital of Fudan University|West China Hospital Of Sichuan University|20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .|The First Affiliated Hospital of Kunming Medical University|Zhejiang Cancer Hospital",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02586350
1736,NCT02591160,Hyperparathyroidism,Optimal Hydrochlorothiazide Cessation in Diagnosis of Hyperparathyroidism,Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism,Hyperparathyroidism,2015-10-27,2017-09-13,2017-09-13,2.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Missouri-Columbia,University of Missouri-Columbia,University of Missouri,Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02591160
1738,NCT02592356,Differentiated Thyroid Gland Carcinoma|Malignant Adrenal Gland Pheochromocytoma|Malignant Paraganglioma|Thyroid Gland Medullary Carcinoma,Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study,Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer,Differentiated Thyroid Gland Carcinoma|Malignant Adrenal Gland Pheochromocytoma|Malignant Paraganglioma|Thyroid Gland Medullary Carcinoma,2015-10-27,2022-11-30,2022-11-30,23.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Procedure|Procedure|Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02592356
1739,NCT02602717,Thyroid Cancer,,"The Evaluation of the Diagnostic Properties of Intra-operative In-situ Thyroglobin Levels of Cervical Lymph Nodes, in the Discrimination Between Benign and Malignant Lymph Nodes in Thyroid Cancer: a Prospective Multicentre Study.",Thyroid Cancer,2015-10-22,2017-05-17,2018-12-31,110.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,APHM,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02602717
1740,NCT02609685,Papillary Thyroid Microcarcinoma,Active Surveillance of Papillary Thyroid Microcarcinoma,Active Surveillance of Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2015-11-18,2030-12-31,2030-12-31,216.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Cedars-Sinai Medical Center,Cedars-Sinai Medical Center,Cedars-Sinai Medical Center,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02609685
1741,NCT02614495,Thyroid Carcinoma,"A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)",Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma,Thyroid Carcinoma,2015-11-24,2018-09-30,2018-09-30,66.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Hutchison Medipharma Limited,Hutchison Medipharma Limited,Peking Union Medical College Hospital|Fudan University Shanghai Cancer Center,Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02614495
1742,NCT02620085,Graves' Disease,Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status,Thyroid Disease and Personality Study,Graves' Disease,2015-11-04,2021-07-31,2021-07-31,500.0,Cohort,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shyang-Rong Shih,Procedure,Taiwan,20.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02620085
1745,NCT02628067,Advanced Cancer|Advanced Solid Tumors|Anal Cancer|Anal Carcinoma|Bile Duct Cancer|Biliary Cancer|Carcinoid Tumor|Cervical Cancer|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Carcinoma|Endometrial Cancer|Endometrial Carcinoma|Mesothelioma|Neuroendocrine Tumor|Parotid Gland Cancer|Salivary Cancer|Salivary Gland Cancer|Salivary Gland Carcinoma|Small Cell Lung Cancer (SCLC)|Small Cell Lung Carcinoma|Thyroid Cancer|Thyroid Carcinoma|Vulvar Cancer|Vulvar Carcinoma,A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158),Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),Advanced Cancer|Advanced Solid Tumors|Anal Cancer|Anal Carcinoma|Bile Duct Cancer|Biliary Cancer|Carcinoid Tumor|Cervical Cancer|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Carcinoma|Endometrial Cancer|Endometrial Carcinoma|Mesothelioma|Neuroendocrine Tumor|Parotid Gland Cancer|Salivary Cancer|Salivary Gland Cancer|Salivary Gland Carcinoma|Small Cell Lung Cancer (SCLC)|Small Cell Lung Carcinoma|Thyroid Cancer|Thyroid Carcinoma|Vulvar Cancer|Vulvar Carcinoma,2015-12-09,2026-06-18,2026-06-18,1595.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,"Call for Information (Investigational Site 0202)|Call for Information (Investigational Site 0017)|Call for Information (Investigational Site 0015)|Call for Information (Investigational Site 0010)|Call for Information (Investigational Site 0209)|Call for Information (Investigational Site 0008)|Call for Information (Investigational Site 0004)|Merck Sharp & Dohme|MSD Brasil|Merck Canada|Merck Sharp & Dohme (China) Ltd.|MDS Colombia SAS|Merck Sharp & Dohme|MSD France|MSD Sharp & Dohme GmbH|Merck Sharp & Dohme Co. Ltd.|MSD Italia S.r.l.|MSD Korea LTD|Merck Sharp & Dohme BV|MSD Norge A/S|Merck Sharp & Dohme (I.A.) Corporation|Merck Sharp & Dohme IDEA, Inc.|MSD (Pty) LTD South Africa|Merck Sharp and Dohme de Espana S.A.|Merck Sharp & Dohme (I.A.) Corp.",Biological|Biological,"Australia|Brazil|Canada|China|Colombia|Denmark|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Philippines|Russian Federation|South Africa|Spain|Taiwan|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02628067
1746,NCT02638077,Differentiated Thyroid Cancer,"A Multi-center, Prospective Study to Observe the Initial Management of Patients With Differentiated Thyroid Cancer in the Real World in China (DTCC Study)",Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China,Differentiated Thyroid Cancer,2015-12-18,2017-04-30,2017-04-30,2000.0,Cohort,,Prospective,Observational,Unknown status,,Huazhong University of Science and Technology,Chinese PLA General Hospital|First Hospital of China Medical University|Gansu Cancer Hospital|Huazhong University of Science and Technology|Jilin University|Sir Run Run Shaw Hospital|The First Affiliated Hospital of Kunming Medical College|Tongji Hospital|West China Hospital,"Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02638077
1747,NCT02644707,Autoimmune Thyroiditis,L-selenomethionine Supplementation in Children and Adolescents With Autoimmune Thyroiditis: a Randomized Blind Placebo-controlled Clinical Trial,Selenium Supplementation in Youths With Autoimmune Thyroiditis,Autoimmune Thyroiditis,2015-12-29,2016-10-31,2018-08-31,100.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",Dietary Supplement|Other,Greece,4.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02644707
1750,NCT02645786,Heart Diseases|Malignant Neoplasm of Thyroid|Thyrotoxicosis on Thyroxine Therapy,Cardiac Effects of Thyrotropin Over-Suppression With Levothyroxine in Young Women With Differentiated Thyroid Cancer,Thyrotropin Over-suppression and Heart,Heart Diseases|Malignant Neoplasm of Thyroid|Thyrotoxicosis on Thyroxine Therapy,2015-12-20,2013-11-30,2014-04-30,31.0,Case-Control,,Prospective,Observational,Completed,,Chuncheon Sacred Heart Hospital,Chuncheon Sacred Heart Hospital,,,,32.0,51.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02645786
1753,NCT02648399,Thyroid Papillary Carcinoma,,Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma,Thyroid Papillary Carcinoma,2015-12-13,2016-12-31,2016-12-31,300.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Procedure|Procedure,China,15.0,60.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02648399
1755,NCT02651818,Goiter,The Impact of Surgical Treatment of Benign Non-toxic Goiter on Quality of Life,Changes in Quality of Life Following Surgical Treatment of Benign Non-toxic Goiter,Goiter,2016-01-06,2017-10-24,2017-10-24,104.0,Cohort,,Prospective,Observational,Completed,,University of Southern Denmark,University of Southern Denmark,Odense University Hospital,Procedure,Denmark,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02651818
1756,NCT02652884,Transient Hypoparathyroidism,Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy,Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy,Transient Hypoparathyroidism,2016-01-05,2016-12-31,2017-12-31,110.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,Hospital Italiano de Buenos Aires,Hospital Italiano de Buenos Aires,Hospital Italiano de Buenos Aires,Drug|Drug,Argentina,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02652884
1758,NCT02657369,"Thyroid Carcinoma, Anaplastic","An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)",A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC),"Thyroid Carcinoma, Anaplastic",2016-01-13,2018-09-26,2018-09-26,34.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Eisai Inc.,Eisai Inc.,,Drug,Australia|France|Italy|United Kingdom|United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02657369
1760,NCT02657551,Thyroid Cancer,A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,Thyroid Cancer,2015-11-09,2022-12-31,2023-12-31,33.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Dana-Farber Cancer Institute,Bayer|Dana-Farber Cancer Institute,Yale Cancer Center|Dana-Farber Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02657551
1761,NCT02658513,Cancer of the Thyroid|Cancer of Thyroid|Thyroid Cancer|Thyroid Carcinoma,Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer,Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer,Cancer of the Thyroid|Cancer of Thyroid|Thyroid Cancer|Thyroid Carcinoma,2015-12-24,2019-03-31,2019-03-31,35.0,Cohort,,Prospective,Observational,Completed,,Royal Surrey County Hospital NHS Foundation Trust,Royal Surrey County Hospital NHS Foundation Trust,Royal Surrey County Hospital NHS Foundation Trust,Other|Other,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02658513
1762,NCT02658552,Benign Thyroid Nodules,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,Benign Thyroid Nodules,2016-01-06,2016-02-29,2016-07-31,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02658552
1764,NCT02665325,Cognitive Impairment,Cognitive Functions and Mood During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma,Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma,Cognitive Impairment,2016-01-17,2017-12-31,2018-12-31,100.0,Cohort,,Prospective,Observational,Unknown status,,The Affiliated Hospital of Inner Mongolia Medical University,National Natural Science Foundation of China|The Affiliated Hospital of Inner Mongolia Medical University,Shan Jin,Drug,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02665325
1765,NCT02681328,Thyroid,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Thyroid,2016-02-10,2023-12-01,2024-12-01,300.0,Cohort,,Prospective,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center at UCLA,Other|Other|Other|Other,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02681328
1767,NCT02685514,Rrelapsed Graves' Disease,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,Rrelapsed Graves' Disease,2016-02-14,2016-04-30,2016-04-30,22.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02685514
1770,NCT02688608,Anaplastic Thyroid Cancer,Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer,Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,Anaplastic Thyroid Cancer,2016-01-20,2020-10-31,2021-10-31,6.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Stanford University,Merck Sharp & Dohme LLC|Saad A Khan,UT Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02688608
1772,NCT02689609,Complications|Hypothyroidism,Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma,Post-radiation Hypothyroidism After IMRT for Nasopharyngeal Carcinoma,Complications|Hypothyroidism,2016-02-15,2013-12-31,2016-12-31,149.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,The University of Hong Kong,City University of Hong Kong|The University of Hong Kong,,Radiation,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02689609
1773,NCT02693808,Thyroid-Associated Ophthalmopathy,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,Thyroid-Associated Ophthalmopathy,2015-12-04,2018-01-31,2018-05-31,29.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Haukeland University Hospital,Haukeland University Hospital,Department of Ophthalmology Haukeland University Hospital,Procedure|Procedure,Norway,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02693808
1777,NCT02697578,Chronic Kidney Disease Mineral and Bone Disorder,Artificial Intelligence: to Analyse CKD-MBD in Hemodialysis and Cardiovascular Risk,Artificial Intelligence: a New Alternative to Analyse CKD-MBD in Hemodialysis,Chronic Kidney Disease Mineral and Bone Disorder,2016-02-23,2018-12-19,2018-12-19,197.0,Cohort,,Prospective,Observational,Completed,,Maimnides Biomedical Research Institute of Crdoba,Maimnides Biomedical Research Institute of Crdoba,Hospital Universitario Reina Sofa,,Spain,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02697578
1780,NCT02702388,Thyroid Cancer,"A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile","A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",Thyroid Cancer,2016-03-03,2019-12-12,2020-09-10,241.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Eisai Inc.,Eisai Inc.|Merck Sharp & Dohme LLC,Facility#1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility#2|Facility#1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #1|Royal Brisbane and Women's Hospital|Facility#2|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #6|Facility #1|Facility #2|Facility #3|Facility #2|Facility #3|Facility #4|Facility #5|Facility #1|Facility #1|Facility #6|Facility #7|Facility #2|Facility #4|Facility #2|Facility #1|Facility #1|Facility#1|Facility #1|Facility #3|Facility #4|Facility #1|Facility #2|Facility #2|Facility #1|Facility #1|Facility #4|Facility #3|Facility #4|Facility #1|Facility #2|Facility #1|Facility #3|Facility #1|Facility #2|Facility #1|Facility #2|Facility #1|Facility #2|Facility #1|Facility #2|Facility #3|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1,Drug|Drug,"Australia|Belgium|Canada|Denmark|France|Germany|Israel|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02702388
1781,NCT02706743,Thyroid Neoplasms,Effect of Radioiodine Remnant Ablation on Quality of Life in Patients With Differentiated Thyroid Cancer:a Prospective Cohort Study,Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer,Thyroid Neoplasms,2015-05-29,2016-12-31,2016-12-31,300.0,Cohort,,Prospective,Observational,Unknown status,,"Southern Medical University, China","Southern Medical University, China","Zhujiang Hospital,Southern Medical University",,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02706743
1782,NCT02708368,Chronic Kidney Diseases,Investigation to Develop Standard Operating Procedures (SOP) for the Determination of Innovative CKD-MBD(Chronic Kidney Disease - Mineral Bone Disorder)-Serum-(Plasma-)Parameters,SOP's for CKD-MBD-Biomarkers,Chronic Kidney Diseases,2016-02-29,2016-09-30,2016-09-30,32.0,Case-Control,,Prospective,Observational,Unknown status,,RWTH Aachen University,RWTH Aachen University,"Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine at the University Hospital, RWTH Aachen|Clinic for Nephrology and Diabetology, Hospital St. Franziskus (Maria-Hilf-Clinic)",Other,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02708368
1785,NCT02709889,Glioblastoma|High Grade Gastroenteropancreatic Neuroendocrine Carcinoma|Large-Cell Neuroendocrine Carcinoma|Malignant Melanoma|Medullary Thyroid Cancer|Neuroendocrine Prostate Cancer|Other Neuroendocrine Carcinoma|Other Solid Tumors,An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors,Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors,Glioblastoma|High Grade Gastroenteropancreatic Neuroendocrine Carcinoma|Large-Cell Neuroendocrine Carcinoma|Malignant Melanoma|Medullary Thyroid Cancer|Neuroendocrine Prostate Cancer|Other Neuroendocrine Carcinoma|Other Solid Tumors,2016-03-02,2019-08-27,2019-08-27,200.0,,Single Group Assignment,,Interventional,Terminated,Phase 1/Phase 2,AbbVie,AbbVie,"Banner MD Anderson Cancer Ctr /ID# 155424|Mayo Clinic - Scottsdale /ID# 155419|University of California, Los Angeles /ID# 155429|Univ California, San Francisco /ID# 155409|Cedars-Sinai Medical Center - West Hollywood /ID# 155428|Univ of Colorado Cancer Center /ID# 155415|Sarah Cannon Research Institute at HealthONE - Denver /ID# 155420|University of Florida - Archer /ID# 155414|Moffitt Cancer Center /ID# 170220|Emory University Hospital /ID# 155417|University of Kentucky Chandler Medical Center /ID# 155423|Johns Hopkins University /ID# 155412|Massachusetts General Hospital /ID# 155411|Dana-Farber Cancer Institute /ID# 171044|Mayo Clinic - Rochester /ID# 155416|Washington University-School of Medicine /ID# 155425|Rutgers Cancer Institute of NJ /ID# 162010|University of New Mexico /ID# 205054|Roswell Park Comprehensive Cancer Center /ID# 162015|Weill Cornell Medical College /ID# 155418|Duke University Medical Center /ID# 155421|Univ Hosp Cleveland /ID# 155410|Oregon Health and Science University /ID# 162011|Greenville Hospital System /ID# 155427|Mary Crowley Cancer Research /ID# 162014|Texas Oncology - Forth Worth /ID# 162045|University of Texas MD Anderson Cancer Center /ID# 155413|University of Utah /ID# 155426|Virginia Cancer Specialists /ID# 162006|Northwest Cancer Specialists, P.C. /ID# 155431",Drug|Drug,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02709889
1786,NCT02710799,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,3470.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Ps-Graduao em Epidemiologia da UFRGS|Secretaria Estadual da Sade do Estado do Rio Grande do Sul|TelessadeRS / UFRGS,Secretaria Estadual da Sade,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02710799
1790,NCT02711059,Diabetes|Hypercalcemia|Hyperparathyroidism,"Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation",Insulin Resistance in Primary Hyperparathyroidism,Diabetes|Hypercalcemia|Hyperparathyroidism,2015-10-18,2021-12-31,2022-06-30,0.0,,Parallel Assignment,,Interventional,Withdrawn,Not Applicable,Karolinska University Hospital,Karolinska University Hospital,Karolinska University Hospital,Procedure,Sweden,50.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02711059
1793,NCT02713256,Graves' Disease,An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease,A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease,Graves' Disease,2016-03-15,2017-04-24,2017-04-24,15.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug,Germany|United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02713256
1796,NCT02713269,Malignant Digestive System Neoplasm|Metastatic Head and Neck Carcinoma|Metastatic Kidney Carcinoma|Metastatic Malignant Neoplasm in the Spine|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Melanoma|Prostate Carcinoma Metastatic in the Bone|Sarcoma|Solid Neoplasm|Spinal Cord Compression|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Thyroid Gland Carcinoma,A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement,Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord,Malignant Digestive System Neoplasm|Metastatic Head and Neck Carcinoma|Metastatic Kidney Carcinoma|Metastatic Malignant Neoplasm in the Spine|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Melanoma|Prostate Carcinoma Metastatic in the Bone|Sarcoma|Solid Neoplasm|Spinal Cord Compression|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Thyroid Gland Carcinoma,2016-03-15,2022-07-01,2022-07-01,60.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Other|Other|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02713269
1797,NCT02714946,Thyroid Nodule,Prospective Randomized Comparative Study of the Effectiveness and Safety of Ultrasound-guided Laser and Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules,Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules,Thyroid Nodule,2016-02-19,2019-09-30,2020-01-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Campus Bio-Medico University,Campus Bio-Medico University,Santa Maria Goretti Hospital,Device|Device,Italy,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02714946
1799,NCT02721992,Graves' Ophthalmopathy|Hypercholesterolemia,A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia,Graves' Orbitopathy and Hypercholesterolemia,Graves' Ophthalmopathy|Hypercholesterolemia,2016-03-17,2017-06-30,2017-06-30,250.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02721992
1803,NCT02724176,Thyroid Cancer,Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer,Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer,Thyroid Cancer,2016-03-18,2016-01-31,2016-01-31,140.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Beijing Cancer Hospital,Beijing Cancer Hospital,,Drug,,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02724176
1805,NCT02725879,Thyroiditis Hashimoto,"Association of Serum Fibroblast Growth Factor 21 (FGF-21) Levels With Resting Metabolic Rate (RMR), in Children and Adolescents With Hashimoto's Thyroiditis.",FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL),Thyroiditis Hashimoto,2016-01-09,2020-09-30,2020-12-31,60.0,Other,,Prospective,Observational,Unknown status,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"2nd Department of Paediatrics, School of Medicine Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital Thessaloniki, Greece",Other,Greece,5.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02725879
1808,NCT02726282,Thyroid Cancer,Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences,Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey,Thyroid Cancer,2016-03-29,2017-03-31,2017-03-31,0.0,Other,,Prospective,Observational,Withdrawn,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02726282
1809,NCT02726503,Anaplastic Thyroid Cancer,Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE),Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2016-03-29,2020-02-25,2020-03-20,39.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",Nagoya University Hospital|Fujita Health University Hospital|IUHW Ichikawa Hospital|National Cancer Center Hospital East|Japanese Red Cross Narita Hospital|Kuma Hospital|Kobe Univbersity Hospital|University of Tsukuba Hospital|Iwate Medical University Hospital|Kitasato University Hospital|Showa University Northern Yokohama Hospital|Kanagawa Cancer Center|Miyaghi Cancer Center|Tohoku University Hospital|Shinsyu University School of Medicine Department of Surgery|Nara Hospital Kinki University Faculty of Medicine|Nara Medical University|Osaka Police Hospital|Osaka City University Graduate School of Medicine and Faculty of Medicine|Nippon Medical School Hospital|The Cancer Institute Hospital of JFCR|Ito Hospital|Tokyo Medical University Hospital,Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02726503
1811,NCT02727738,Graves' Disease,Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism,Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole,Graves' Disease,2015-06-30,2015-09-30,2015-12-31,30.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Pisa,University of Pisa,Endocrinology Unit,Dietary Supplement|Drug,Italy,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02727738
1814,NCT02731352,Thyroid Cancer,Study of Apatinib in Patients With Local Advanced/Metastatic Iodine-131131I-Refractory/Resistant Differentiated Thyroid Cancer,Study of Apatinib in Patients With Differentiated Thyroid Cancer,Thyroid Cancer,2016-03-07,2020-02-27,2021-02-28,20.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02731352
1815,NCT02747888,Thyroid Cancer,Hereditary Risk Factors for Thyroid Cancer,Hereditary Risk Factors for Thyroid Cancer,Thyroid Cancer,2016-03-31,2024-03-01,2024-03-01,250.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Dana-Farber Cancer Institute,Dana-Farber Cancer Institute,Dana Farber Cancer Institute,Genetic,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02747888
1816,NCT02747979,Hyperparathyroidism|Insomnia|Ostalgia|Refractory Pruritus,The Effect and Safety of Combination Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients,The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients,Hyperparathyroidism|Insomnia|Ostalgia|Refractory Pruritus,2015-05-21,2010-05-31,2010-05-31,20.0,,Parallel Assignment,,Interventional,Completed,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"The 1st Affiliated Hospital, Sun Yet-sen University",Other|Other|Other,China,16.0,75.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02747979
1818,NCT02758158,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,Clinical Evaluation of a Prototype Tri-modal Imaging Instrument for Thyroid Cancer,Tri-modal Imaging Instrument for Thyroid Cancer,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2016-03-09,2017-02-28,2017-02-28,9.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",Princess Margaret Cancer Centre,Device,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02758158
1820,NCT02764554,Differentiated Thyroid Carcinoma (DTC),Post-Marketing Surveillance of Lenvima in Korean Patients,Post-Marketing Surveillance of Lenvima in Korean Patients,Differentiated Thyroid Carcinoma (DTC),2016-05-04,2021-09-29,2021-09-29,132.0,Other,,Prospective,Observational,Completed,,Eisai Inc.,Eisai Korea Inc.,Eisai Trial Site #18|Eisai Trial Site #30|Eisai Trial Site #14|Eisai Trial Site #27|Eisai Trial Site #34|Eisai Trial Site #21|Eisai Trial Site #24|Eisai Trial Site #15|Eisai Trial Site #16|Eisai Trial Site #17|Eisai Trial Site #20|Eisai Trial Site #22|Eisai Trial Site #37|Eisai Trial Site #36|Eisai Trial Site #4|Eisai Trial Site #13|Eisai Trial Site #25|Eisai Trial Site #26|Eisai Trial Site #32|Eisai Trial Site #19|Eisai Trial Site #1|Eisai Trial Site #23|Eisai Trial Site #29|Eisai Trial Site #31|Eisai Trial Site #33|Eisai Trial Site #35|Eisai Trial Site #38|Eisai Trial Site #39|Eisai Trial Site #8|Eisai Trial Site #9|Eisai Trial Site #12|Eisai Trial Site #6,,"Korea, Republic of",0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02764554
1821,NCT02766283,Hypothyroidism,Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure,Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure,Hypothyroidism,2016-05-06,2016-08-30,2016-08-30,843.0,Cohort,,Retrospective,Observational,Completed,,Bayer,Bayer,,Drug,Israel,0.0,3.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT02766283
1822,NCT02766660,Thyroid Associated Ophthalmopathy,"Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy","Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy",Thyroid Associated Ophthalmopathy,2016-04-24,2013-01-31,2013-01-31,102.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Neon Hospital,Neon Hospital|Ondokuz Mays University,,Device,,12.0,73.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02766660
1826,NCT02767245,Thyrotoxicosis,Efficacy of Thiamine Supplement for Improve Cardiovascular Function in Patients With Severe Hyperthyroidism,Thiamine Supplement in Patients With Severe Hyperthyroidism,Thyrotoxicosis,2016-05-09,2016-07-31,2016-07-31,12.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Ramathibodi Hospital,Ramathibodi Hospital,"Faculty of Medicine Ramathibodi Hospital, Mahidol University",Drug,Thailand,15.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02767245
1828,NCT02768753,Thyroidectomy|Thyroid Papillary Carcinoma,Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy,Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy,Thyroidectomy|Thyroid Papillary Carcinoma,2016-05-02,2017-04-30,2017-04-30,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Jinan Military General Hospital,Jinan Military General Hospital,"Department of thyroid and breast surgery, General Hospital of Jinan Military Area",Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02768753
1830,NCT02772705,Emission-Computed|Hyperthyroidism|Single-Photon|Tomography,Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans,Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans,Emission-Computed|Hyperthyroidism|Single-Photon|Tomography,2016-05-09,2016-08-31,2017-01-31,100.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,West China Hospital,"Air Force Military Medical University, China|Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|Tianjin Medical University General Hospital|West China Hospital|Zhejiang Cancer Hospital",Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|The People's Hospital of Inner Mongolia Autonomous Region|Fourth Military Medical Universit|West China Hospital|Tianjin Medical University General Hospital|Zhejiang Cancer Hospital,,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02772705
1833,NCT02773667,Thyroid Carcinoma,Relationship Between Estimated Glomerular Filtration Rate and Biological Half-life of 131I. Prospective Analysis in Patients With Differentiated Thyroid Carcinoma.,Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine,Thyroid Carcinoma,2016-05-11,2022-07-31,2022-07-31,110.0,Case-Only,,Prospective,Observational,Recruiting,,Jena University Hospital,Jena University Hospital,University Hospital Jena,,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02773667
1834,NCT02778412,Thyroid Adenoma|Thyroid Cancer|Thyroiditis|Thyroid Nodules,Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Thyroid Cancer in Patients Undergoing Diagnostic Fine Needle Aspirations of the Thyroid,ctDNA in Patients With Thyroid Nodules,Thyroid Adenoma|Thyroid Cancer|Thyroiditis|Thyroid Nodules,2016-05-16,2017-08-31,2017-08-31,66.0,Cohort,,Prospective,Observational,Terminated,,Pathway Genomics,Pathway Genomics,Thyroid & Endocrine Center of Florida,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02778412
1837,NCT02781844,Hypoparathyroidism,"An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism",Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism,Hypoparathyroidism,2016-04-19,2019-03-08,2019-03-08,34.0,,Crossover Assignment,,Interventional,Completed,Phase 1,Takeda,Shire,"Providence Clinical Research|Indiana University|University Of Kentucky School of Medicine|Crescent City Clinical Research Center, LLC|Massachusetts General Hospital|Mayo Clinic - PPDS|Columbia University Medical Center|Ohio State University Wexner Medical Center|Thomas Jefferson University|New Orleans Center for Clinical Research (NOCCR) - Knoxville|CHU de Quebec-Universite Laval|Aarhus Universitetshospital|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont|Semmelweis Egyetem|Pcsi Tudomnyegyetem",Drug|Drug|Drug,Canada|Denmark|Hungary|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02781844
1839,NCT02784223,Thyroid Gland,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Thyroid Gland,2016-05-24,2019-03-28,2019-03-28,107.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Cancerople Nord Ouest|Centre Francois Baclesse,Centre Franois Baclesse,Device,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02784223
1841,NCT02787486,Aneuploidy|Chromosome Deletion|DiGeorge Syndrome|Down Syndrome|Edwards Syndrome|Klinefelter Syndrome|Patau Syndrome|Turner Syndrome,"A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women",Expanded Noninvasive Genomic Medical Assessment: The Enigma Study,Aneuploidy|Chromosome Deletion|DiGeorge Syndrome|Down Syndrome|Edwards Syndrome|Klinefelter Syndrome|Patau Syndrome|Turner Syndrome,2016-05-26,2018-09-30,2018-09-30,760.0,Family-Based,,Prospective,Observational,Completed,,"Progenity, Inc.","Progenity, Inc.","Valley Perinatal|Heinen Obstectrics & Gynecology|Newlife Wellness OBGYN|Lakeshore Women's Specialists|Cincinnati Obgyn|James D. Kasten, M.D., Inc.|Regional Obstetrical Consultants|Texas Maternal-Fetal Medicine",Other,United States,18.0,54.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02787486
1843,NCT02798965,Graves Disease,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Graves Disease,2016-06-09,2014-05-31,2014-05-31,52.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens,Biological,France,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02798965
1846,NCT02812888,Hyperthyroidism,Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism,Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism,Hyperthyroidism,2016-06-20,2017-03-31,2017-06-30,240.0,Case-Control,,Cross-Sectional,Observational [Patient Registry],Unknown status,,The First People's Hospital of Xuzhou,Hu Hao,"The First People's Hospital of Xuzhou,",Drug,China,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02812888
1847,NCT02814032,Papillary Thyroid Carcinoma,Differences Protein Expression in Papillary Thyroid Carcinoma,Proteomics of Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2016-06-23,2016-12-31,2017-06-30,32.0,Cohort,,Prospective,Observational,Unknown status,,The Affiliated Hospital of Inner Mongolia Medical University,The Affiliated Hospital of Inner Mongolia Medical University,Shan Jin,,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02814032
1849,NCT02824016,Irradiation; Adverse Effect|Irradiation Hypothyroidism,A Prospective Multicentric Evaluation of the Rate of Incidence of Hypothyroidism After Supraclavicular Irradiation for Breast Cancer,Evaluation of Hypothyroidism Incidence After Breast Cancer Supraclavicular Irradiation,Irradiation; Adverse Effect|Irradiation Hypothyroidism,2014-08-25,2015-07-31,2020-07-31,500.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Institut Jean-Godinot,Institut Jean-Godinot,Institut Jean Godinot|Centre Paul Strauss|Institut de Cancerologie de Lorraine,Biological|Radiation,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02824016
1850,NCT02824718,Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment,A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism,Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism,Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment,2016-07-01,2020-05-28,2020-05-28,16.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Assistance Publique - Hpitaux de Paris,"Assistance Publique - Hpitaux de Paris|Ministry of Health, France",AP-HP Hopital Europeen Georges Pompidou,Drug|Drug|Drug|Drug,France,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02824718
1852,NCT02826746,Thyroid Neoplasms,,Effect of Intravenous Magnesium on Postoperative Sore Throat After Thyroidectomy,Thyroid Neoplasms,2016-07-06,2019-03-31,2019-03-31,20.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Ajou University School of Medicine,Ajou University School of Medicine,"Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine",Drug|Drug,"Korea, Republic of",20.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02826746
1853,NCT02830789,"Hyperparathyroidism, Secondary|Roux-en-Y Gastric Bypass",Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass in Order to Treat Secondary Hyperparathyroidism: A Clinical Randomized Trial,Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass,"Hyperparathyroidism, Secondary|Roux-en-Y Gastric Bypass",2016-07-06,2017-05-31,2017-05-31,38.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,"Department of Enodocrinology and Internal Medicine, Aarhus University Hospital",Dietary Supplement|Dietary Supplement|Dietary Supplement|Procedure,Denmark,20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02830789
1856,NCT02831179,Functional Pancreatic Neuroendocrine Tumor|Malignant Somatostatinoma|Merkel Cell Carcinoma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Carcinoid Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Neuroendocrine Neoplasm|Non-Functional Pancreatic Neuroendocrine Tumor|Pancreatic Glucagonoma|Pancreatic Insulinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Merkel Cell Carcinoma|Somatostatin-Producing Neuroendocrine Tumor|Stage III Adrenal Cortex Carcinoma|Stage IIIA Merkel Cell Carcinoma|Stage IIIB Merkel Cell Carcinoma|Stage III Thyroid Gland Medullary Carcinoma|Stage IV Adrenal Cortex Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma|Stage IVB Thyroid Gland Medullary Carcinoma|Stage IVC Thyroid Gland Medullary Carcinoma|Stage IV Merkel Cell Carcinoma|Thymic Carcinoid Tumor|VIP-Producing Neuroendocrine Tumor|Well Differentiated Adrenal Cortex Carcinoma|Zollinger Ellison Syndrome,A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors,"Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",Functional Pancreatic Neuroendocrine Tumor|Malignant Somatostatinoma|Merkel Cell Carcinoma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Carcinoid Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Neuroendocrine Neoplasm|Non-Functional Pancreatic Neuroendocrine Tumor|Pancreatic Glucagonoma|Pancreatic Insulinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Merkel Cell Carcinoma|Somatostatin-Producing Neuroendocrine Tumor|Stage III Adrenal Cortex Carcinoma|Stage IIIA Merkel Cell Carcinoma|Stage IIIB Merkel Cell Carcinoma|Stage III Thyroid Gland Medullary Carcinoma|Stage IV Adrenal Cortex Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma|Stage IVB Thyroid Gland Medullary Carcinoma|Stage IVC Thyroid Gland Medullary Carcinoma|Stage IV Merkel Cell Carcinoma|Thymic Carcinoid Tumor|VIP-Producing Neuroendocrine Tumor|Well Differentiated Adrenal Cortex Carcinoma|Zollinger Ellison Syndrome,2016-07-10,2019-02-28,2020-02-29,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,,Drug|Drug|Drug|Other|Other,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02831179
1857,NCT02833857,"Chronic Kidney Disease, Secondary Hyperparathyroidism","An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis",A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis,"Chronic Kidney Disease, Secondary Hyperparathyroidism",2016-06-09,2018-10-31,2018-10-31,11.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Belgium|Germany|Lithuania|Poland|United Kingdom|United States,2.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT02833857
1860,NCT02834013,"Acinar Cell Carcinoma|Adenoid Cystic Carcinoma|Adrenal Cortex Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Angiosarcoma|Apocrine Neoplasm|Appendix Mucinous Adenocarcinoma|Bartholin Gland Transitional Cell Carcinoma|Basal Cell Carcinoma|Bladder Adenocarcinoma|Breast Metaplastic Carcinoma|Cervical Adenocarcinoma|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Desmoid Fibromatosis|Endometrial Transitional Cell Carcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Extramammary Paget Disease|Fallopian Tube Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fibromyxoid Tumor|Gallbladder Carcinoma|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Gastric Undifferentiated Carcinoma|Gastrointestinal Stromal Tumor|Gestational Trophoblastic Tumor|Giant Cell Carcinoma|Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Carcinoid Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Solid Neoplasm|Malignant Testicular Sex Cord-Stromal Tumor|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Pituitary Neuroendocrine Tumor|Minimally Invasive Lung Adenocarcinoma|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Ovarian Transitional Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|PEComa|Peritoneal Mesothelioma|Placental Choriocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Rare Disorder|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Squamous Cell Carcinoma of the Penis|Teratoma With Somatic-Type Malignancy|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Carcinoma",DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors,Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,"Acinar Cell Carcinoma|Adenoid Cystic Carcinoma|Adrenal Cortex Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Angiosarcoma|Apocrine Neoplasm|Appendix Mucinous Adenocarcinoma|Bartholin Gland Transitional Cell Carcinoma|Basal Cell Carcinoma|Bladder Adenocarcinoma|Breast Metaplastic Carcinoma|Cervical Adenocarcinoma|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Desmoid Fibromatosis|Endometrial Transitional Cell Carcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Extramammary Paget Disease|Fallopian Tube Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fibromyxoid Tumor|Gallbladder Carcinoma|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Gastric Undifferentiated Carcinoma|Gastrointestinal Stromal Tumor|Gestational Trophoblastic Tumor|Giant Cell Carcinoma|Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Carcinoid Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Solid Neoplasm|Malignant Testicular Sex Cord-Stromal Tumor|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Pituitary Neuroendocrine Tumor|Minimally Invasive Lung Adenocarcinoma|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Ovarian Transitional Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|PEComa|Peritoneal Mesothelioma|Placental Choriocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Rare Disorder|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Squamous Cell Carcinoma of the Penis|Teratoma With Somatic-Type Malignancy|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Carcinoma",2016-07-13,2023-10-31,2023-10-31,818.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|University of South Alabama Mitchell Cancer Institute|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Fairbanks Memorial Hospital|CTCA at Western Regional Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Highlands Oncology Group PA - Fayetteville|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro|University of Arkansas for Medical Sciences|Highlands Oncology Group|Highlands Oncology Group - Springdale|Kaiser Permanente-Anaheim|Kaiser Permanente-Deer Valley Medical Center|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Sutter Auburn Faith Hospital|Sutter Cancer Centers Radiation Oncology Services-Auburn|AIS Cancer Center at San Joaquin Community Hospital|Kaiser Permanente-Baldwin Park|Kaiser Permanente-Bellflower|Alta Bates Summit Medical Center-Herrick Campus|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|UC Irvine Health Cancer Center-Newport|Sutter Davis Hospital|City of Hope Comprehensive Cancer Center|Epic Care-Dublin|Kaiser Permanente Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Kaiser Permanente-Fontana|Kaiser Permanente-Fremont|Palo Alto Medical Foundation-Fremont|Kaiser Permanente-Fresno|Kaiser Permanente - Harbor City|Keck Medicine of USC Huntington Beach|Kaiser Permanente-Irvine|UC San Diego Moores Cancer Center|Loma Linda University Medical Center|Kaiser Permanente Los Angeles Medical Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|Kaiser Permanente West Los Angeles|Cedars Sinai Medical Center|Contra Costa Regional Medical Center|Fremont - Rideout Cancer Center|Mercy UC Davis Cancer Center|Memorial Medical Center|Kaiser Permanente-Modesto|Palo Alto Medical Foundation-Camino Division|Palo Alto Medical Foundation-Gynecologic Oncology|Providence Queen of The Valley|USC Norris Oncology/Hematology-Newport Beach|Sutter Cancer Research Consortium|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Kaiser Permanente-Oakland|Kaiser Permanente-Ontario|Saint Joseph Hospital - Orange|UC Irvine Health/Chao Family Comprehensive Cancer Center|Desert Regional Medical Center|Palo Alto Medical Foundation Health Care|Kaiser Permanente - Panorama City|Keck Medical Center of USC Pasadena|Eisenhower Medical Center|Kaiser Permanente- Marshall Medical Offices|Kaiser Permanente-Redwood City|Kaiser Permanente-Richmond|Kaiser Permanente-Riverside|Kaiser Permanente-Roseville|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Roseville Medical Center|Kaiser Permanente Downtown Commons|Sutter Medical Center Sacramento|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-South Sacramento|Kaiser Permanente - Sacramento|Kaiser Permanente-San Diego Mission|Kaiser Permanente-San Diego Zion|Sharp Memorial Hospital|California Pacific Medical Center-Pacific Campus|Kaiser Permanente-San Francisco|Kaiser Permanente-Santa Teresa-San Jose|Kaiser Permanente San Leandro|Pacific Central Coast Health Center-San Luis Obispo|Kaiser Permanente-San Marcos|Mills Health Center|Kaiser Permanente-San Rafael|Kaiser San Rafael-Gallinas|Kaiser Permanente Medical Center - Santa Clara|Palo Alto Medical Foundation-Santa Cruz|Mission Hope Medical Oncology - Santa Maria|Kaiser Permanente-Santa Rosa|Providence Medical Foundation - Santa Rosa|Sutter Pacific Medical Foundation|Providence Santa Rosa Memorial Hospital|Kaiser Permanente-South San Francisco|Kaiser Permanente-Stockton|Palo Alto Medical Foundation-Sunnyvale|Gene Upshaw Memorial Tahoe Forest Cancer Center|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Kaiser Permanente Medical Center-Vacaville|Kaiser Permanente-Vallejo|Sutter Solano Medical Center/Cancer Center|Kaiser Permanente-Walnut Creek|Epic Care Cyberknife Center|Kaiser Permanente-Woodland Hills|Rocky Mountain Cancer Centers-Aurora|The Medical Center of Aurora|University of Colorado Hospital|Boulder Community Hospital|Boulder Community Foothills Hospital|Rocky Mountain Cancer Centers-Boulder|Rocky Mountain Cancer Centers - Centennial|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|UCHealth Memorial Hospital Central|Memorial Hospital North|Saint Francis Cancer Center|Cancer Center of Colorado at Sloan's Lake|Denver Health Medical Center|Kaiser Permanente-Franklin|National Jewish Health-Main Campus|The Women's Imaging Center|Porter Adventist Hospital|Colorado Blood Cancer Institute|Presbyterian - Saint Lukes Medical Center - Health One|Rocky Mountain Cancer Centers-Midtown|SCL Health Saint Joseph Hospital|Rocky Mountain Cancer Centers-Rose|Rose Medical Center|Mercy Medical Center|Southwest Oncology PC|Mountain Blue Cancer Care Center - Swedish|Rocky Mountain Cancer Centers - Swedish|Swedish Medical Center|The Melanoma and Skin Cancer Institute|Poudre Valley Hospital|Valley View Hospital Cancer Center|Mountain Blue Cancer Care Center|National Jewish Health-Western Hematology Oncology|Saint Mary's Hospital and Regional Medical Center|Grand Valley Oncology|North Colorado Medical Center|Rocky Mountain Cancer Centers-Greenwood Village|Good Samaritan Medical Center|Kaiser Permanente-Rock Creek|Rocky Mountain Cancer Centers-Lakewood|Saint Anthony Hospital|Rocky Mountain Cancer Centers-Littleton|Littleton Adventist Hospital|Kaiser Permanente-Lone Tree|Rocky Mountain Cancer Centers-Sky Ridge|Sky Ridge Medical Center|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|McKee Medical Center|Parker Adventist Hospital|Rocky Mountain Cancer Centers-Parker|Saint Mary Corwin Medical Center|Rocky Mountain Cancer Centers - Pueblo|National Jewish Health-Northern Hematology Oncology|Rocky Mountain Cancer Centers-Thornton|SCL Health Lutheran Medical Center|Smilow Cancer Hospital-Derby Care Center|Smilow Cancer Hospital Care Center-Fairfield|Smilow Cancer Hospital Care Center - Guiford|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Yale-New Haven Hospital North Haven Medical Center|Stamford Hospital/Bennett Cancer Center|Smilow Cancer Hospital Care Center-Trumbull|Smilow Cancer Hospital-Waterbury Care Center|Veterans Affairs Connecticut Healthcare System-West Haven Campus|Beebe South Coastal Health Campus|Beebe Medical Center|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|TidalHealth Nanticoke / Allen Cancer Center|Christiana Care Health System-Wilmington Hospital|MedStar Georgetown University Hospital|Sibley Memorial Hospital|AdventHealth Altamonte|Mount Sinai Comprehensive Cancer Center at Aventura|Holy Cross Hospital|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|AdventHealth Kissimmee|Mount Sinai Medical Center|AdventHealth Medical Group Urology at Orlando|AdventHealth Orlando|Orlando Health Cancer Institute|AdventHealth East Orlando|Memorial Hospital West|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|AdventHealth Winter Park|Emory University Hospital Midtown|Piedmont Hospital|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|John B Amos Cancer Center|Atlanta VA Medical Center|Piedmont Fayette Hospital|Harbin Clinic Medical Oncology and Clinical Research|Low Country Cancer Care|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler|Summit Cancer Care-Candler|South Georgia Medical Center/Pearlman Cancer Center|Hawaii Cancer Care - Savio|Pali Momi Medical Center|Queen's Cancer Center - Pearlridge|Straub Pearlridge Clinic|The Cancer Center of Hawaii-Pali Momi|The Queen's Medical Center - West Oahu|Hawaii Cancer Care Inc - Waterfront Plaza|Island Urology|Queen's Cancer Cenrer - POB I|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Diagnostic Radiology Services LLC|Kuakini Medical Center|Queen's Cancer Center - Kuakini|The Cancer Center of Hawaii-Liliha|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Straub Medical Center - Kahului Clinic|Castle Medical Center|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Saint Joseph Medical Center|Illinois CancerCare-Bloomington|Loyola Center for Health at Burr Ridge|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Centralia Oncology Clinic|Mount Sinai Hospital Medical Center|Northwestern University|John H Stroger Jr Hospital of Cook County|Rush University Medical Center|University of Chicago Comprehensive Cancer Center|Advocate Illinois Masonic Medical Center|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Northwestern Medicine Cancer Center Kishwaukee|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|Illinois CancerCare-Eureka|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Northwestern Medicine Cancer Center Delnor|Ingalls Memorial Hospital|Loyola Medicine Homer Glen|Presence Saint Mary's Hospital|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Good Samaritan Regional Health Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Illinois CancerCare-Pekin|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center|Illinois CancerCare-Peoria|OSF Saint Francis Radiation Oncology at Peoria Cancer Center|Methodist Medical Center of Illinois|OSF Saint Francis Medical Center|Illinois CancerCare-Peru|Valley Radiation Oncology|Illinois CancerCare-Princeton|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Northwestern Medicine Cancer Center Warrenville|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Midwestern Regional Medical Center|IU Health West Hospital|IU Health North Hospital|Deaconess Clinic Downtown|Parkview Regional Medical Center|Indiana University/Melvin and Bren Simon Cancer Center|Sidney and Lois Eskenazi Hospital|Springmill Medical Center|Memorial Regional Cancer Center Day Road|Chancellor Center for Oncology|Reid Health|Memorial Hospital of South Bend|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Saint Anthony Regional Hospital|Mercy Hospital|Oncology Associates at Mercy Medical Center|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Alegent Health Mercy Hospital|Greater Regional Medical Center|Iowa Methodist Medical Center|Medical Oncology and Hematology Associates-Des Moines|Broadlawns Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|Iowa Lutheran Hospital|McFarland Clinic PC-Trinity Cancer Center|Trinity Regional Medical Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Methodist West Hospital|Mercy Medical Center-West Lakes|Cancer Center of Kansas - Chanute|Coffeyville Regional Medical Center|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|University of Kansas Clinical Research Center|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Saint Catherine Hospital|Central Care Cancer Center - Great Bend|HaysMed University of Kansas Health System|Cancer Center of Kansas-Independence|University of Kansas Cancer Center-West|University of Kansas Cancer Center|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|University of Kansas Hospital-Indian Creek Campus|Cancer Center of Kansas - Parsons|Ascension Via Christi - Pittsburg|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|Cancer Center of Kansas - Wellington|University of Kansas Hospital-Westwood Cancer Center|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Ascension Via Christi Hospitals Wichita|Cancer Center of Kansas - Wichita|Wesley Medical Center|Cancer Center of Kansas - Winfield|Flaget Memorial Hospital|Commonwealth Cancer Center-Corbin|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|Saint Joseph London|Jewish Hospital|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Jewish Hospital Medical Center South|Baton Rouge General Medical Center|Hematology/Oncology Clinic PLLC|Ochsner Health Center-Summa|Medical Center of Baton Rouge|Ochsner High Grove|Ochsner Medical Center Kenner|East Jefferson General Hospital|LSU Healthcare Network / Metairie Multi-Specialty Clinic|Louisiana State University Health Science Center|Tulane University Health Sciences Center|University Medical Center New Orleans|Ochsner Medical Center Jefferson|Eastern Maine Medical Center|Lafayette Family Cancer Center-EMMC|Greater Baltimore Medical Center|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Western Maryland Regional Medical Center|Frederick Memorial Hospital|FMH James M Stockman Cancer Institute|Lahey Hospital and Medical Center|Lahey Medical Center-Peabody|Mercy Medical Center|Baystate Medical Center|Hickman Cancer Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|Bronson Battle Creek|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|University of Michigan - Brighton Center for Specialty Care|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Beaumont Hospital - Dearborn|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Green Bay Oncology - Escanaba|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Helen DeVos Children's Hospital at Spectrum Health|Mercy Health Saint Mary's|Spectrum Health at Butterworth Campus|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Bronson Methodist Hospital|West Michigan Cancer Center|Ascension Borgess Cancer Center|Borgess Medical Center|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Green Bay Oncology-Manistique|Saint Mary's Oncology/Hematology Associates of Marlette|Monroe Cancer Center|Toledo Clinic Cancer Centers-Monroe|Mercy Health Mercy Campus|Lakeland Hospital Niles|Cancer and Hematology Centers of Western Michigan - Norton Shores|Ascension Providence Hospitals - Novi|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Spectrum Health Reed City Hospital|Great Lakes Cancer Management Specialists-Rochester Hills|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Lakeland Medical Center Saint Joseph|Marie Yeager Cancer Center|Henry Ford Macomb Health Center - Shelby Township|Ascension Providence Hospitals - Southfield|Bhadresh Nayak MD PC-Sterling Heights|Ascension Saint Joseph Hospital|Munson Medical Center|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Henry Ford Wyandotte Hospital|Metro Health Hospital|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Sanford Joe Lueken Cancer Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Sanford Thief River Falls Medical Center|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Sanford Cancer Center Worthington|Fairview Lakes Medical Center|Baptist Memorial Hospital and Cancer Center-Golden Triangle|Baptist Cancer Center-Grenada|Gulfport Memorial Hospital|Hattiesburg Clinic - Hematology/Oncology Clinic|Forrest General Hospital / Cancer Center|University of Mississippi Medical Center|Baptist Memorial Hospital and Cancer Center-Union County|Baptist Memorial Hospital and Cancer Center-Oxford|Baptist Memorial Hospital and Cancer Center-Desoto|Saint Louis Cancer and Breast Institute-Ballwin|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Saint Luke's Hospital|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|Kansas City Veterans Affairs Medical Center|The University of Kansas Cancer Center-South|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Mercy Hospital Washington|Community Hospital of Anaconda|Billings Clinic Cancer Center|Saint Vincent Healthcare|Saint Vincent Frontier Cancer Center|Bozeman Deaconess Hospital|Saint James Community Hospital and Cancer Treatment Center|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Community Medical Hospital|CHI Health Saint Francis|Heartland Hematology and Oncology|CHI Health Good Samaritan|Saint Elizabeth Regional Medical Center|Nebraska Cancer Specialists/Oncology Hematology West PC - MECC|Nebraska Methodist Hospital|Oncology Associates PC|Alegent Health Immanuel Medical Center|Hematology and Oncology Consultants PC|Alegent Health Bergan Mercy Medical Center|Alegent Health Lakeside Hospital|Creighton University Medical Center|Midlands Community Hospital|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Hope Cancer Care of Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Cancer Therapy and Integrative Medicine|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|University Cancer Center|Hope Cancer Care of Nevada-Pahrump|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|Dartmouth Hitchcock Medical Center|Norris Cotton Cancer Center-Manchester|Norris Cotton Cancer Center-Nashua|Morristown Medical Center|Chilton Medical Center|Overlook Hospital|Inspira Medical Center Vineland|Lovelace Medical Center-Saint Joseph Square|University of New Mexico Cancer Center|Southwest Gynecologic Oncology Associates Inc|New Mexico Oncology Hematology Consultants|Presbyterian Kaseman Hospital|Memorial Medical Center - Las Cruces|Presbyterian Rust Medical Center/Jorgensen Cancer Center|Christus Saint Vincent Regional Cancer Center|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|Arnot Ogden Medical Center/Falck Cancer Center|Glens Falls Hospital|Laura and Isaac Perlmutter Cancer Center at NYU Langone|University of Rochester|Stony Brook University Medical Center|AdventHealth Infusion Center Asheville|Southeastern Medical Oncology Center-Clinton|AdventHealth Infusion Center Haywood|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Margaret R Pardee Memorial Hospital|AdventHealth Hendersonville|Onslow Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Vidant Oncology-Kenansville|Vidant Oncology-Kinston|Vidant Oncology-Richlands|AdventHealth Infusion Center Weaverville|Sanford Bismarck Medical Center|Essentia Health Cancer Center-South University Clinic|Sanford South University Medical Center|Sanford Broadway Medical Center|Sanford Roger Maris Cancer Center|Essentia Health - Jamestown Clinic|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Cleveland Clinic Mercy Hospital|Mercy Hematology and Oncology Associates Inc|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Adena Regional Medical Center|Good Samaritan Hospital - Cincinnati|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|MetroHealth Medical Center|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Delaware Radiation Oncology|Grady Memorial Hospital|Columbus Oncology and Hematology Associates|Dublin Methodist Hospital|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|OhioHealth Mansfield Hospital|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Toledo Clinic Cancer Centers-Maumee|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center|Dayton Physicians LLC-Signal Point|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|North Coast Cancer Care|Dayton Physicians LLC-Wilson|Springfield Regional Cancer Center|Springfield Regional Medical Center|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|Saint Vincent Mercy Medical Center|Mercy Health - Saint Anne Hospital|Toledo Clinic Cancer Centers-Toledo|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|South Pointe Hospital|Saint Joseph Warren Hospital|Saint Ann's Hospital|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Mercy Hospital Oklahoma City|Cancer Treatment Centers of America|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Legacy Mount Hood Medical Center|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Legacy Good Samaritan Hospital and Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Kaiser Permanente Northwest|Oregon Health and Science University|Saint Charles Health System-Redmond|Legacy Meridian Park Hospital|Lehigh Valley Hospital-Cedar Crest|UPMC-Heritage Valley Health System Beaver|Lehigh Valley Hospital - Muhlenberg|Christiana Care Health System-Concord Health Center|UPMC Hillman Cancer Center - Passavant - Cranberry|Doylestown Hospital|Pocono Medical Center|Saint Vincent Hospital|UPMC Cancer Centers - Arnold Palmer Pavilion|Lehigh Valley Hospital-Hazleton|Jefferson Hospital|UPMC-Johnstown/John P. Murtha Regional Cancer Center|UPMC Cancer Center at UPMC McKeesport|Forbes Hospital|UPMC Hillman Cancer Center - Monroeville|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Hillman Cancer Center - Part of Frick Hospital|Arnold Palmer Cancer Center Medical Oncology Norwin|Thomas Jefferson University Hospital|Eastern Regional Medical Center|Temple University Hospital|Allegheny General Hospital|UPMC-Magee Womens Hospital|UPMC-Presbyterian Hospital|UPMC-Saint Margaret|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Shadyside Hospital|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Pottstown Hospital|UPMC Cancer Center at UPMC Northwest|UPMC Uniontown Hospital Radiation Oncology|UPMC Cancer Center-Washington|UPMC Washington Hospital Radiation Oncology|UPMC West Mifflin-Cancer Center Jefferson|Wexford Health and Wellness Pavilion|Prisma Health Cancer Institute - Spartanburg|Medical University of South Carolina|Prisma Health Cancer Institute - Laurens|Prisma Health Cancer Institute - Easley|Gibbs Cancer Center-Gaffney|Tidelands Georgetown Memorial Hospital|Saint Francis Hospital|Prisma Health Cancer Institute - Butternut|Prisma Health Cancer Institute - Faris|Prisma Health Greenville Memorial Hospital|Saint Francis Cancer Center|Prisma Health Cancer Institute - Eastside|Prisma Health Cancer Institute - Greer|Gibbs Cancer Center-Pelham|Prisma Health Cancer Institute - Seneca|North Grove Medical Park|Spartanburg Medical Center|Spartanburg Medical Center - Mary Black Campus|MGC Hematology Oncology-Union|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Memorial Hospital|Baptist Memorial Hospital and Cancer Center-Collierville|Vanderbilt-Ingram Cancer Center Cool Springs|Pulmonary Medicine Center of Chattanooga-Hixson|Baptist Memorial Hospital and Cancer Center-Memphis|Vanderbilt Breast Center at One Hundred Oaks|Meharry Medical College|Vanderbilt University/Ingram Cancer Center|Memorial GYN Plus|Saint Joseph Regional Cancer Center|Parkland Memorial Hospital|Baylor University Medical Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|Lyndon Baines Johnson General Hospital|M D Anderson Cancer Center|UT Southwestern Clinical Center at Richardson/Plano|University Hospital|University of Texas Health Science Center at San Antonio|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Farmington Health Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Riverton Hospital|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|Huntsman Cancer Institute/University of Utah|LDS Hospital|South Jordan Health Center|Central Vermont Medical Center/National Life Cancer Treatment|University of Vermont Medical Center|University of Vermont and State Agricultural College|Norris Cotton Cancer Center-North|Virginia Commonwealth University/Massey Cancer Center|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|MultiCare Auburn Medical Center|Virginia Mason Bainbridge Island Medical Center|Overlake Medical Center|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Virginia Mason Federal Way Medical Center|Saint Francis Hospital|Tacoma/Valley Radiation Oncology Centers-Gig Harbor|MultiCare Gig Harbor Medical Park|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Northwest Cancer Clinic|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Virginia Mason Lynnwood Medical Center|Skagit Valley Hospital Regional Cancer Care Center|Skagit Valley Hospital|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Peninsula Cancer Center|MultiCare Good Samaritan Hospital|Tacoma/Valley Radiation Oncology Centers-Puyallup|Valley Medical Center|Virginia Mason Medical Center|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Fred Hutchinson Cancer Research Center|Seattle Cancer Care Alliance|Kaiser Permanente Washington|Swedish Medical Center-First Hill|University of Washington Medical Center - Montlake|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|MultiCare Deaconess Cancer and Blood Specialty Center - Valley|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown|Spokane Valley Cancer Center-Mayfair|Spokane Valley Cancer Center-Mission|MultiCare Deaconess Cancer and Blood Specialty Center - North|Tacoma/Valley Radiation Oncology Centers-Jackson Hall|Franciscan Research Center-Northwest Medical Plaza|Mary Bridge Children's Hospital and Health Center|MultiCare Tacoma General Hospital|Northwest Medical Specialties PLLC|Tacoma/Valley Radiation Oncology Centers-Saint Joe's|PeaceHealth Southwest Medical Center|Legacy Cancer Institute Medical Oncology and Day Treatment|Legacy Salmon Creek Hospital|Providence Saint Mary Regional Cancer Center|Wenatchee Valley Hospital and Clinics|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Edwards Comprehensive Cancer Center|Ascension Saint Elizabeth Hospital|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Ascension Southeast Wisconsin Hospital - Elmbrook Campus|Ascension Calumet Hospital|Marshfield Clinic-Chippewa Center|Marshfield Clinic Cancer Center at Sacred Heart|Marshfield Medical Center-EC Cancer Center|Ascension Saint Francis - Reiman Cancer Center|Ascension Southeast Wisconsin Hospital - Franklin|Saint Vincent Hospital Cancer Center Green Bay|Saint Vincent Hospital Cancer Center at Saint Mary's|Gundersen Lutheran Medical Center|Marshfield Clinic - Ladysmith Center|Holy Family Memorial Hospital|Saint Vincent Hospital Cancer Center at Marinette|Marshfield Medical Center-Marshfield|Ascension Columbia Saint Mary's Hospital Ozaukee|Ascension Southeast Wisconsin Hospital - Saint Joseph Campus|Ascension Columbia Saint Mary's Hospital - Milwaukee|Ascension Saint Francis Hospital|Marshfield Clinic-Minocqua Center|Cancer Center of Western Wisconsin|Saint Vincent Hospital Cancer Center at Oconto Falls|Ascension Mercy Hospital|Ascension All Saints Hospital|Ascension Saint Mary's Hospital|Marshfield Medical Center-Rice Lake|HSHS Saint Nicholas Hospital|Ascension Saint Michael's Hospital|Marshfield Clinic Stevens Point Center|Saint Vincent Hospital Cancer Center at Sturgeon Bay|Marshfield Clinic-Wausau Center|Ascension Medical Group Southeast Wisconsin - Mayfair Road|Marshfield Medical Center - Weston|Marshfield Clinic - Wisconsin Rapids Center|Cheyenne Regional Medical Center-West|Billings Clinic-Cody|Welch Cancer Center|FHP Health Center-Guam,Procedure|Biological|Biological,Guam|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02834013
1861,NCT02838927,Hypoparathyroidism,Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France,Survey on Epidemiology of Hypoparathyroidism in France,Hypoparathyroidism,2016-07-09,2030-09-30,2031-09-30,1000.0,Cohort,,Prospective,Observational,Recruiting,,European Georges Pompidou Hospital,European Georges Pompidou Hospital|Oscar - Filire Sant Maladies Rares,"Felix Guyon Hospital|Hpital Priv de Provence|Amiens University Hospital|Clinic Auch Area|Henri Mondor Hospital|Jean Minjoz Hospital|Avicenne Hospital, AP-HP|Jean Verdier Hospital, AP-HP|University Hospital|Bourgoin Jallieu Hospital|La Cavale Blanche Hospital|Cte de Nacre Hospital|Henri Mondor Hospital, APHP|Dax-Cte d'Argent Hospital|University Hospital|Grenoble Alpes Hospital|CHD Vende|Kremlin-Bictre Hospital, APHP|Le Mans Hospital|Libourne Hospital|Claude Huriez Hospital|Edouard Herriot Hospital, HCL|La Conception Hospital, AP-HM|Clinic Metz Area|Mercy Hospital|Arnaud de Villeneuve Hospital|Clinic area|Brabois Hospital|University Hospital|University Hospital|Georges Renon Hospital|Caremeau Hospital|European Georges Pompidou Hospital, APHP|Clinic Paris Area|Cochin Hospital, APHP|Lariboisire Hospital, APHP|Necker Hospital, AP-HP|Piti-Salptrire Hospital, APHP|Tenon Hospital, APHP|Clinic Poitiers Area|Laennec Hospital|Reims University Hospital|Clinic Rennes Area|Charles Nicolle Hospital|Clinic Area|Clinique du Landy|Hautepierre Hospital|Sainte Anne Hospital, HIA|Larrey Hospital|Guy Chatiliez Hospital|Bretonneau Hospital|Valenciennes Hospital|CHIV - Lucie et Raymond Aubrac",Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02838927
1863,NCT02839655,Patients With Thyroid Cancer,Prospective Study Assessing Thyroidectomy Using Robot,Prospective Study Assessing Thyroidectomy Using Robot,Patients With Thyroid Cancer,2016-07-12,2018-05-15,2022-08-31,17.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Device,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02839655
1864,NCT02843542,Primary Hyperthyroidism,Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study,Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI),Primary Hyperthyroidism,2016-07-14,2018-08-31,2018-12-31,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Assuta Medical Center,Assuta Medical Center,Assuta Medical Center,Device|Device,Israel,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02843542
1867,NCT02845336,Thyroid Eye Disease,An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease,Celecoxib for Thyroid Eye Disease,Thyroid Eye Disease,2016-07-20,2019-06-30,2019-06-30,7.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Johns Hopkins University,Johns Hopkins University,"Wilmer Eye Institute, Johns Hopkins University",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02845336
1871,NCT02854345,Primary Hyperparathyroidism,Preliminary Study Concerning the Validity of Parathyroid Exploration on a Discovery NM 530c CZT Camera,Preliminary Study Concerning the Validity of Parathyroid Exploration on a CZT Camera,Primary Hyperparathyroidism,2016-07-29,2019-03-31,2019-09-30,90.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Centre Hospitalier Universitaire de Besancon,Centre Hospitalier Universitaire de Besancon,CHU Besancon,Device,France,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02854345
1874,NCT02856347,Medullary Thyroid Cancer,Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET ( Positron Emission Tomography) F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin,Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin,Medullary Thyroid Cancer,2016-07-27,2020-12-20,2020-12-20,24.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Institut Claudius Regaud,Institut Claudius Regaud,CHU Haut-Lvque|CHU Limoges|CHU Timone|ICM Montpellier|Institut Claudius Regaud,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02856347
1875,NCT02859896,Secondary Hyperparathyroidism-Chronic Kidney Disease,"An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis",Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis,Secondary Hyperparathyroidism-Chronic Kidney Disease,2016-08-04,2025-11-12,2025-11-12,84.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Sanofi,Sanofi,Investigational Site Number :8400022|Investigational Site Number :8400023|Investigational Site Number :8400033|Investigational Site Number :8400005|Investigational Site Number :8400029|Investigational Site Number :8400006|Investigational Site Number :8400008|Investigational Site Number :8400020|Investigational Site Number :8400036|Investigational Site Number :8400014|Investigational Site Number :8400015|Investigational Site Number :8400010|Investigational Site Number :8400016|Investigational Site Number :8400017|Investigational Site Number :8400007|Investigational Site Number :8400021|Investigational Site Number :8400034|Investigational Site Number :8400025|Investigational Site Number :8400004|Investigational Site Number :8400035|Investigational Site Number :8400028|Investigational Site Number :8400027|Investigational Site Number :8400024|Investigational Site Number :8400013|Investigational Site Number :8400019|Investigational Site Number :8400026|Investigational Site Number :8400009|Investigational Site Number :8400001|Investigational Site Number :1520004|Investigational Site Number :1520003,Drug|Drug,Chile|United States,5.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02859896
1878,NCT02862470,Thyroid Cancer,Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Thyroid Cancer,2016-07-27,2018-10-31,2020-08-24,22.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,National Taiwan University Hospital,National Taiwan University Hospital,,,,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02862470
1881,NCT02867592,Adrenal Cortex Carcinoma|Alveolar Soft Part Sarcoma|Central Nervous System Neoplasm|Childhood Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of Soft Tissue|Ewing Sarcoma|Hepatoblastoma|Hepatocellular Carcinoma|Osteosarcoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Alveolar Soft Part Sarcoma|Recurrent Clear Cell Sarcoma of Soft Tissue|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Hepatocellular Carcinoma|Recurrent Kidney Wilms Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Recurrent Primary Malignant Central Nervous System Neoplasm|Recurrent Renal Cell Carcinoma|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Medullary Carcinoma|Refractory Clear Cell Sarcoma of Soft Tissue|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Hepatocellular Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Primary Malignant Central Nervous System Neoplasm|Refractory Renal Cell Carcinoma|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Thyroid Gland Medullary Carcinoma|Renal Cell Carcinoma|Rhabdomyosarcoma|Solid Neoplasm|Thyroid Gland Medullary Carcinoma|Wilms Tumor,"Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",Adrenal Cortex Carcinoma|Alveolar Soft Part Sarcoma|Central Nervous System Neoplasm|Childhood Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of Soft Tissue|Ewing Sarcoma|Hepatoblastoma|Hepatocellular Carcinoma|Osteosarcoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Alveolar Soft Part Sarcoma|Recurrent Clear Cell Sarcoma of Soft Tissue|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Hepatocellular Carcinoma|Recurrent Kidney Wilms Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Recurrent Primary Malignant Central Nervous System Neoplasm|Recurrent Renal Cell Carcinoma|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Medullary Carcinoma|Refractory Clear Cell Sarcoma of Soft Tissue|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Hepatocellular Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Primary Malignant Central Nervous System Neoplasm|Refractory Renal Cell Carcinoma|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Thyroid Gland Medullary Carcinoma|Renal Cell Carcinoma|Rhabdomyosarcoma|Solid Neoplasm|Thyroid Gland Medullary Carcinoma|Wilms Tumor,2016-08-15,2021-06-30,2022-07-01,109.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Providence Alaska Medical Center|Arkansas Children's Hospital|Kaiser Permanente-Anaheim|Kaiser Permanente-Bellflower|Kaiser Permanente Downey Medical Center|Kaiser Permanente-Fontana|Loma Linda University Medical Center|Children's Hospital Los Angeles|Kaiser Permanente Los Angeles Medical Center|Valley Children's Hospital|UCSF Benioff Children's Hospital Oakland|Kaiser Permanente-Oakland|Children's Hospital of Orange County|Lucile Packard Children's Hospital Stanford University|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-San Diego Mission|Rady Children's Hospital - San Diego|UCSF Medical Center-Mission Bay|Children's Hospital Colorado|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Yale University|Alfred I duPont Hospital for Children|Kaiser Permanente-Capitol Hill Medical Center|MedStar Georgetown University Hospital|Children's National Medical Center|Golisano Children's Hospital of Southwest Florida|University of Florida Health Science Center - Gainesville|Nemours Children's Clinic-Jacksonville|University of Miami Miller School of Medicine-Sylvester Cancer Center|Nicklaus Children's Hospital|AdventHealth Orlando|Arnold Palmer Hospital for Children|Nemours Children's Hospital|Nemours Children's Clinic - Pensacola|Johns Hopkins All Children's Hospital|Children's Healthcare of Atlanta - Egleston|Straub Clinic and Hospital|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Saint Luke's Cancer Institute - Boise|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago Comprehensive Cancer Center|Carle on Vermilion|Carle Physician Group-Effingham|Carle Physician Group-Mattoon/Charleston|Saint Jude Midwest Affiliate|Carle Cancer Center|The Carle Foundation Hospital|Riley Hospital for Children|Saint Vincent Hospital and Health Care Center|Blank Children's Hospital|Iowa Methodist Medical Center|Iowa Lutheran Hospital|University of Iowa/Holden Comprehensive Cancer Center|University of Kentucky/Markey Cancer Center|Norton Children's Hospital|Children's Hospital New Orleans|Eastern Maine Medical Center|Lafayette Family Cancer Center-EMMC|Sinai Hospital of Baltimore|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute|C S Mott Children's Hospital|Wayne State University/Karmanos Cancer Institute|Ascension Saint John Hospital|Huron Medical Center PC|Beaumont Children's Hospital-Royal Oak|Children's Hospitals and Clinics of Minnesota - Minneapolis|University of Minnesota/Masonic Cancer Center|Mayo Clinic in Rochester|University of Mississippi Medical Center|Siteman Cancer Center at West County Hospital|Children's Mercy Hospitals and Clinics|Cardinal Glennon Children's Medical Center|Barnes-Jewish Hospital|Washington University School of Medicine|Siteman Cancer Center-South County|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Children's Hospital and Medical Center of Omaha|University of Nebraska Medical Center|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Sunrise Hospital and Medical Center|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Summerlin Hospital Medical Center|Hope Cancer Care of Nevada-Pahrump|Radiation Oncology Associates|Dartmouth Hitchcock Medical Center|Hackensack University Medical Center|Morristown Medical Center|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital|Roswell Park Cancer Institute|NYU Winthrop Hospital|The Steven and Alexandra Cohen Children's Medical Center of New York|Laura and Isaac Perlmutter Cancer Center at NYU Langone|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|State University of New York Upstate Medical University|UNC Lineberger Comprehensive Cancer Center|Carolinas Medical Center/Levine Cancer Institute|Southeastern Medical Oncology Center-Clinton|Duke University Medical Center|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|East Carolina University|Southeastern Medical Oncology Center-Jacksonville|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|MetroHealth Medical Center|Cleveland Clinic Foundation|Nationwide Children's Hospital|Dayton Children's Hospital|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|University of Oklahoma Health Sciences Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Children's Hospital of Pittsburgh of UPMC|Medical University of South Carolina|Saint Francis Hospital|BI-LO Charities Children's Cancer Center|Saint Francis Cancer Center|East Tennessee Childrens Hospital|Saint Jude Children's Research Hospital|The Children's Hospital at TriStar Centennial|Medical City Dallas Hospital|UT Southwestern/Simmons Cancer Center-Dallas|El Paso Children's Hospital|Texas Tech University Health Sciences Center-El Paso|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Children's Hospital of San Antonio|University of Vermont and State Agricultural College|University of Virginia Cancer Center|Children's Hospital of The King's Daughters|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Gundersen Lutheran Medical Center|University of Wisconsin Carbone Cancer Center|Children's Hospital of Wisconsin,Drug|Drug|Other,United States,2.0,30.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02867592
1882,NCT02869620,Thyroid Neoplasms,Institut Paoli Calmettes Thyroid Cancer Database,Institut Paoli Calmettes Thyroid Cancer Database,Thyroid Neoplasms,2016-08-11,2030-01-31,2030-12-31,3000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Institut Paoli-Calmettes,Institut Paoli-Calmettes,Institut Paoli-Calmettes,Other,France,18.0,95.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02869620
1883,NCT02870569,Differentiated Thyroid Cancer,"A Multicenter, Randomized, Open-Label,Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer",Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2016-08-12,2018-07-02,2018-12-31,48.0,,Parallel Assignment,,Interventional,Completed,Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02870569
1884,NCT02878044,Thyroid Cancer|Thyroid Nodule,Shared Decision Making in Patients With Thyroid Nodules,Shared Decision Making in Patients With Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2016-08-16,2019-05-23,2019-05-23,21.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic Jacksonville|Mayo Clinic in Rochester,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02878044
1886,NCT02886949,THYROTOXICOSIS,"The Relationship of Vascular Cell Adhesion Molecule 1, C-reactive Protein, Brain-derived Neurotrophic Factor, Orexin and Depressive Symptoms in the Subjects With Thyroid Disease",The Association Between Autoimmune or Inflammation and Thyroid Disease,THYROTOXICOSIS,2015-09-02,2020-12-31,2024-12-31,500.0,Cohort,,Prospective,Observational,Recruiting,,Taichung Veterans General Hospital,Taichung Veterans General Hospital,"Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital",,Taiwan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02886949
1888,NCT02890472,22q11 Deletion Syndrome Di George Syndrome,Research of Thymix Dysgenesis in Prenatal Examination of Deletion 22q11 Syndrome,Prenatal Examination of Deletion 22q11 Syndrome : Thymic Dysgenesis THYMI Study,22q11 Deletion Syndrome Di George Syndrome,2016-08-26,2020-07-01,2020-12-31,13.0,Cohort,,Prospective,Observational,Completed,,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,CHUNimes,,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02890472
1890,NCT02891668,Hypothyroidism,"Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition","Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition",Hypothyroidism,2016-05-17,2018-05-20,2018-05-20,42.0,Case-Control,,Prospective,Observational,Completed,,Herlev Hospital,Herlev Hospital,"Department of internal Medicine, Herlev Hospital",Drug,Denmark,20.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02891668
1891,NCT02895061,"Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis",Effectiveness Between Daily Versus Pulse Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: A Randomized Controlled Trial and Multicenter Study,Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.,"Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis",2016-09-04,2015-10-31,2016-01-31,502.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Phramongkutklao College of Medicine and Hospital,Phramongkutklao College of Medicine and Hospital,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02895061
1894,NCT02895906,22q11.2 Deletion Syndrome,"A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)",Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions,22q11.2 Deletion Syndrome,2016-08-29,2017-04-13,2017-04-20,2.0,,Single Group Assignment,,Interventional,Completed,Phase 1,"Avalo Therapeutics, Inc.","Aevi Genomic Medicine, LLC, a Cerecor company",Children's Hospital of Philadelphia,Drug,United States,12.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT02895906
1896,NCT02901873,Parathyroid Diseases|Thyroidectomy,Phase 1 Study of Electrical Impedance Spectroscopy in Thyroid and Parathyroid Surgery,EIS in Thyroid and Parathyroid Surgery,Parathyroid Diseases|Thyroidectomy,2016-09-12,2017-06-27,2017-06-27,56.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Sheffield Teaching Hospitals NHS Foundation Trust,Sheffield Teaching Hospitals NHS Foundation Trust,Royal Hallamshire Hospital,Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02901873
1897,NCT02904330,Graves' Disease,"K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease",K1-70 - A Study in Subjects With Graves' Disease,Graves' Disease,2016-08-18,2021-04-30,2021-04-30,18.0,,Single Group Assignment,,Interventional,Completed,Phase 1,AV7 Limited,AV7 Limited,Royal Liverpool University Hospital Clinical Research Unit|Medicines Evaluation Unit,Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02904330
1900,NCT02910466,Chronic Hypoparathyroidism|Hypoparathyroidism,"A Phase 4, Open-Label, Single-Center Clinical Study of Extended Use of rhPTH(1-84) in Hypoparathyroidism",A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism,Chronic Hypoparathyroidism|Hypoparathyroidism,2016-09-20,2019-12-20,2019-12-20,39.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Takeda,Shire,Columbia University Medical Center,Drug,United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02910466
1902,NCT02911155,Brain Cancer|Breast Cancer|Circulatory Disease|Thyroid Cancer,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,Brain Cancer|Breast Cancer|Circulatory Disease|Thyroid Cancer,2016-09-21,2020-05-01,2020-05-01,229.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"University of Minnesota, School of Public Health Environmental Health Sciences",,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02911155
1903,NCT02915172,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies,Lenvatinib and Capecitabine in Patients With Advanced Malignancies,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,2016-09-23,2022-12-31,,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 1,M.D. Anderson Cancer Center,Eisai Inc.|M.D. Anderson Cancer Center,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02915172
1904,NCT02917863,Hypothyroidism,Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism,Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism,Hypothyroidism,2016-09-07,2018-05-31,2019-05-31,70.0,,Crossover Assignment,,Interventional,Unknown status,Phase 4,Meyer Children's Hospital,Meyer Children's Hospital,Meyer Children's Hospital,Drug|Drug,Italy,3.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02917863
1905,NCT02924532,Hypoparathyroidism,Diagnostic Value of Immediate Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy: A Retrospective Observational Study,Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy,Hypoparathyroidism,2016-09-13,2013-12-31,,300.0,Cohort,,Retrospective,Observational,Completed,,Centre Hospitalier Universitaire de Nmes,Centre Hospitalier Universitaire de Nmes,,Biological,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02924532
1907,NCT02938702,Papillary Thyroid Microcarcinoma|Thyroid Cancer,,Active Surveillance on Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid Cancer,2016-02-17,2025-03-31,2030-03-31,1211.0,Cohort,,Prospective,Observational,Active not recruiting,,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02938702
1908,NCT02946918,Postsurgical Hypothyroidism|Thyroid Cancer,Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients,Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy,Postsurgical Hypothyroidism|Thyroid Cancer,2016-10-21,2019-11-04,2019-11-04,14.0,,Parallel Assignment,,Interventional,Terminated,Phase 4,University of Texas Southwestern Medical Center,Akrimax Pharmaceuticals|University of Texas Southwestern Medical Center,University of Texas Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02946918
1910,NCT02947035,Thyroid Cancer,Molecular Testing to Direct Extent of Initial Thyroid Surgery,Molecular Testing to Direct Extent of Initial Thyroid Surgery,Thyroid Cancer,2016-10-20,2023-02-01,2023-02-28,90.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh|Medical College of Wisconsin,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02947035
1911,NCT02947399,Thyroid Cancer,Comparison of I-124 and I-131 Radiopharmacokinetics In Patient With Well Differentiated Thyroid Cancer After Thyroid Hormone Withdrawal,Comparison of I-124 and I-131 Radiopharmacokinetics in DTC Patients With Thyroid Hormone Withdrawal,Thyroid Cancer,2016-10-25,2018-10-31,2018-10-31,16.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Medstar Health Research Institute,Medstar Health Research Institute,Washington Hospital Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02947399
1912,NCT02952612,"Thyroid Cancer, Papillary",Active Surveillance of Papillary Thyroid Microcarcinoma (PTMC) in Catholic Medical Center,Active Surveillance of Papillary Thyroid Microcarcinoma,"Thyroid Cancer, Papillary",2016-10-31,2017-10-31,2021-10-31,300.0,Case-Only,,Prospective,Observational,Unknown status,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St Mary's Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02952612
1914,NCT02953288,Thyroid Cancer,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Thyroid Cancer,2016-11-01,2017-06-30,2018-12-31,3000.0,Case-Crossover,,Cross-Sectional,Observational,Unknown status,,Shanghai 10th People's Hospital,Shanghai 10th People's Hospital,"Department of Endocrinology, Shanghai Tenth People's Hospital",,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02953288
1916,NCT02959827,Hypothyroidism,Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States,Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States,Hypothyroidism,2016-10-11,2017-06-15,2017-06-15,2320.0,Cohort,,Retrospective,Observational,Completed,,Bayer,Bayer,Oakland,Drug,United States,0.0,3.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT02959827
1917,NCT02966093,Differentiated Thyroid Cancer (DTC),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China",A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China,Differentiated Thyroid Cancer (DTC),2016-11-15,2019-07-31,2021-12-29,151.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Eisai Inc.,"Eisai Co., Ltd.",1002 Eisai Trial Site|1006 Eisai Trial Site|1020 Eisai Trial Site|1026 Eisai Trial Site|1025 Eisai Trial Site|1012 Eisai Trial Site|1003 Eisai Trial Site|1027 Eisai Trial Site|1018 Eisai Trial Site|1023 Eisai Trial Site|1016 Eisai Trial Site|1021 Eisai Trial Site|1008 Eisai Trial Site|1014 Eisai Trial Site|1022 Eisai Trial Site|1015 Eisai Trial Site|1004 Eisai Trial Site|1017 Eisai Trial Site|1019 Eisai Trial Site|1011 Eisai Trial Site|1007 Eisai Trial Site|1001 Eisai Trial Site|1010 Eisai Trial Site|1005 Eisai Trial Site,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02966093
1918,NCT02973802,Graves Disease,"Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection",ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy,Graves Disease,2016-11-14,2018-02-14,2018-02-14,12.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Apitope International NV,"Apitope International NV|European Commission|Quintiles, Inc.",Queen Elizabeth Hospital|University Hospital of Wales|Royal Devon and Exeter Hospital|St James's University Hospital|Hammersmith Hospital|Kings College Hospital|The Christie|Royal Victoria Infirmary,Biological,United Kingdom,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02973802
1921,NCT02973997,Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,"Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC),Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,60.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02973997
1924,NCT02986607,Hyperparathyroidism|Hypoparathyroidism,Corticosteroid Rhythms in Hypoparathyroid Patients,Corticosteroid Rhythms in Hypoparathyroid Patients,Hyperparathyroidism|Hypoparathyroidism,2016-12-05,2018-01-31,2018-06-30,30.0,,Single Group Assignment,,Interventional,Unknown status,Early Phase 1,University of Bergen,Haukeland University Hospital|University of Bergen,Haukeland University Hospital,Drug,Norway,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02986607
1927,NCT02988817,Cervical Cancer|Endometrial Cancer|Melanoma|Non Small Cell Lung Cancer|Ovarian Cancer|Sarcoma|Thyroid Cancer,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax-AXL-ADC) in Patients With Solid Tumors",Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors,Cervical Cancer|Endometrial Cancer|Melanoma|Non Small Cell Lung Cancer|Ovarian Cancer|Sarcoma|Thyroid Cancer,2016-12-01,2021-11-12,2021-11-12,306.0,,Single Group Assignment,,Interventional,Completed,Phase 1/Phase 2,Genmab,Genmab,"Mayo Clinic Scottsdale|University of Colorado Cancer Center|Yale University, Smilow Cancer Center at Yale New Haven Hospital|Mayo Clinic Jacksonville|Moffitt Cancer Center|Emory University School of Medicine, Winship Cancer Institute|University of Iowa|Dana-Farber Cancer Institute|University of Michigan Comprehensive Cancer Center|Mayo Clinic Rochester|Washington University|Roswell Park Comprehensive Cancer Center|NYU Medical Center|Herbert Irving Comprehensive Cancer Center|Duke Cancer Institute|Fox Chase Cancer Center|Mary Crowley Cancer Reearch Center|MD Anderson|Huntsman Cancer Institute|University of Wisconsin Carbone Cancer Center|Universitair Ziekenhuizen Leuven|Institut Roi Albert II - Cliniques Universitaires Saint Luc|Universitair Ziekenhuis Brussel - Oncologisch Centrum|Medische oncologie, Oncologisch Centrum - AZ Groeninge|U.Z. Leuven Gasthuisberg, Department of General Medical Oncology|CHU de Lige, Medical Oncology et. Domaine Universitaire du Sart Tilman|Rigshospitalet, Copenhagen University Hospital|The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital|Leiden University Medical Centre|Erasmus MC, Medical Oncology|UMC Utrecht Cancer Center|Hospital Unversitario Vall D'hebron|Oncologia Mdica/ Medical Oncology Department Institut Catal d'Oncologia (ICO)|University Hospital of Girona|Hospital Universitario 12 Octubre|Hospital Virgen de la Victoria|University Hospital Lozano Blesa, Aragn Health Research Institute (IIS Aragn)|Universtity College London Hospitals|The Royal Marsden NHS Foundation Trust|The Christie NHS Foundation Trust Clinical Trials Unit|Sir Bobby Robson Clinical Trials Unit at the Northern Centre for Cancer Care, Freeman Hospital",Biological,Belgium|Denmark|Netherlands|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02988817
1928,NCT02989103,All-Cause Mortality|Circulatory and Other Disease Mortality|Thyroid and Other Cancer Mortality,Hyperthyroid Follow-Up Study,Hyperthyroid Follow-Up Study,All-Cause Mortality|Circulatory and Other Disease Mortality|Thyroid and Other Cancer Mortality,2016-12-06,2020-09-01,2020-10-28,35593.0,Cohort,,Prospective,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"Social and Scientific Systems, Inc.",,United States,18.0,105.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02989103
1929,NCT02989428,Primary Hyperparathyroidism,Cardiovascular Health in Patients With Primary Hyperparathyroidism: Effect of Parathyroidectomy on Cardiovascular Health: A Randomized Controlled Trial,Effect of Parathyroidectomy on Cardiovascular Health,Primary Hyperparathyroidism,2016-12-02,2018-09-01,2018-09-01,69.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,Aarhus University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02989428
1932,NCT02993302,Graves Disease,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Graves Disease,2016-12-07,2015-03-31,2015-03-31,25.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Dr Cipto Mangunkusumo General Hospital,Dr Cipto Mangunkusumo General Hospital|Indonesia University,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02993302
1935,NCT02993562,Hypothyroidism,Levothyroxine Substitution Therapy in Hypothyroid Patients - Impact on Appetite and Food Intake,"Hypothyroidism, Metabolism and Food Intake",Hypothyroidism,2016-10-20,2018-08-30,2018-08-30,18.0,Case-Control,,Prospective,Observational,Completed,,Herlev Hospital,"Center for Diabetes Research, Herlev and Gentofte Hospital.|Herlev Hospital","Center for Diabetes Research, Herlev and Gentofte Hospitals",Drug,Denmark,20.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02993562
1936,NCT03002623,Differentiated Thyroid Cancer|Poorly Differentiated and Undifferentiated Thyroid Cancer|Thyroid Neoplasms,A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer,CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,Differentiated Thyroid Cancer|Poorly Differentiated and Undifferentiated Thyroid Cancer|Thyroid Neoplasms,2016-12-22,2018-02-12,2018-02-12,7.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),National Institutes of Health Clinical Center,Drug,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03002623
1938,NCT03004209,Autoimmune Encephalitis,Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients,Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients,Autoimmune Encephalitis,2016-12-21,2018-02-06,2018-02-06,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 4,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Drug,"Korea, Republic of",18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03004209
1941,NCT03006289,Thyroid Cancer,Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer,Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer,Thyroid Cancer,2016-12-26,2017-10-31,2017-11-30,3000.0,,,,Observational,Unknown status,,Qianfoshan Hospital,Lin Liao,,,,8.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03006289
1942,NCT03009279,Metabolic Syndrome|Thyroid Nodule,Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Metabolic Syndrome|Thyroid Nodule,2016-12-26,2017-11-30,2017-12-31,10000.0,,,,Observational,Unknown status,,Qianfoshan Hospital,Lin Liao,,,,15.0,90.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03009279
1944,NCT03009357,Graves Disease|Thyroiditis|Thyrotoxicosis,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis",Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis,Graves Disease|Thyroiditis|Thyrotoxicosis,2016-12-29,2017-06-30,2017-08-31,40.0,Cohort,,Prospective,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,,"Korea, Republic of",20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03009357
1949,NCT03011736,Parathyroid Gland Adenoma|Primary Hyperparathyroidism,"Single-Arm, Non-inferiority Study of Omission of Intraoperative Intact Parathyroid Hormone (PTH) During Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism",Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism,Parathyroid Gland Adenoma|Primary Hyperparathyroidism,2017-01-04,2018-07-12,2018-12-24,6.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Roswell Park Cancer Institute,Roswell Park Cancer Institute,Roswell Park Cancer Institute,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03011736
1952,NCT03012620,"Carcinoma, Neuroendocrine|Central Nervous System Neoplasm|Neoplasms, Germ Cell and Embryonal|NK/T-cell Lymphoma|Ovarian Neoplasm|Sarcoma|Thyroid Neoplasm",Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types,Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types,"Carcinoma, Neuroendocrine|Central Nervous System Neoplasm|Neoplasms, Germ Cell and Embryonal|NK/T-cell Lymphoma|Ovarian Neoplasm|Sarcoma|Thyroid Neoplasm",2017-01-02,2023-01-31,2023-12-31,334.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,UNICANCER,"Ligue contre le cancer, France|Merck Sharp & Dohme LLC|National Cancer Institute, France|UNICANCER",Gustave Roussy Cancer Campus,Drug,France,15.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03012620
1953,NCT03013257,Graves Disease,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",HIFU vs RAI in the Relapsed Graves' Disease,Graves Disease,2017-01-04,2020-04-30,2020-06-30,240.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03013257
1956,NCT03023748,Endstage Renal Disease|Secondary Hyperparathyroidism,Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs,Intravenous Paricalcitol in Chronic Hemodialysis Patients,Endstage Renal Disease|Secondary Hyperparathyroidism,2017-01-07,2017-12-31,2018-01-31,30.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,The University of Hong Kong,AbbVie|The University of Hong Kong,Queen Mary Hospital and Tung Wah Hospital,Drug,Hong Kong,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03023748
1959,NCT03024151,Anxiety|Depression|Distress|Fatigue|Thyroid Cancer,"The Effects of T4 Mono Replacement Versus T4/T3 Combination Replacement on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients; Prospective, Randomized, Double Blind, T4 Comparative Clinical Study",The Effects of T4 Versus T4/T3 on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients,Anxiety|Depression|Distress|Fatigue|Thyroid Cancer,2017-01-10,2017-11-30,2017-11-30,150.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Inje University,Dongnam Institute of Radiological & Medical Sciences|Inje University,Dong sik Bae|Dongsik Bae,Drug|Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03024151
1960,NCT03027349,Hyperparathyroidism,,"Serum Calcium to Phosphorous Ratio (Ca/P) as a Simple, Inexpensive Screening Tool in the Diagnosis of Primary Hyperparathyroidism",Hyperparathyroidism,2017-01-18,2017-02-28,2017-02-28,180.0,Case-Control,,Retrospective,Observational,Completed,,Azienda USL Modena,Azienda USL Modena,Azienda USL of Modena,Other,Italy,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03027349
1962,NCT03027557,Parathyroid Adenoma|Parathyroid Hyperplasia|Primary Hyperparathyroidism,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Parathyroid Adenoma|Parathyroid Hyperplasia|Primary Hyperparathyroidism,2017-01-16,2019-04-01,2019-09-12,46.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Aalborg University Hospital,Aalborg University|Peter Vestergaard,Aalborg University Hospital,Drug|Drug|Other|Other,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03027557
1966,NCT03029429,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism,Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism,Theophylline Treatment for Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism,2017-01-18,2023-07-01,2023-11-01,34.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Vanderbilt University Medical Center,Harvard University|Vanderbilt University Medical Center,Ashley Shoemaker,Drug|Drug,United States,13.0,99.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03029429
1968,NCT03031639,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,Khon Kaen University's Thyroidectomy Registry,Khon Kaen University's Thyroidectomy Registry,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2017-01-20,2021-01-12,2021-01-12,98.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Khon Kaen University,Khon Kaen University,"Department of Otolaryngology, Khonkaen University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03031639
1970,NCT03032198,Feasibility Study for Thyroid Indication,"""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""","""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""",Feasibility Study for Thyroid Indication,2017-01-20,2018-06-17,2019-04-19,37.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Seno Medical Instruments Inc.,Seno Medical Instruments Inc.,Invision Sally Jobe|UT Health Science Center,Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03032198
1972,NCT03034707,Parathyroid Diseases|Thoracic Diseases,Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing,Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing,Parathyroid Diseases|Thoracic Diseases,2017-01-17,2016-10-31,2018-12-31,12.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,University of Minnesota,Boston Medical Center|Children's Mercy Hospital Kansas City|Johns Hopkins University|University of Minnesota,,Dietary Supplement,,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03034707
1973,NCT03036956,Subclinical Hypothyroidism,The Prevalence of Sub Clinical Hypothyroidism During Early Pregnancy in Pakistan,The Prevalence of Sub Clinical Hypothyroidism During Early Pregnancy in Pakistan,Subclinical Hypothyroidism,2017-01-26,2018-01-31,2018-01-31,500.0,Cohort,,Prospective,Observational,Completed,,Abbott,Abbott|Dimension Research,Isra University hospital|Pakistam Insititute of Medical science|Atia Hospital Hospital|Boluvard Hospital|MediCell Hospital|Services Hospital|Sir Ganga Ram hospital|Welcare Medical Centre|Lady Reading hospital,,Pakistan,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03036956
1974,NCT03037385,"Adenocarcinoma|Adenocarcinoma, Papillary|Bronchial Neoplasms|Carcinoma|Carcinoma, Bronchogenic|Carcinoma, Neuroendocrine|Carcinoma, Non-Small-Cell Lung|Colonic Diseases|Colonic Neoplasms|Colorectal Neoplasms|Digestive System Disease|Digestive System Neoplasm|Endocrine Gland Neoplasm|Endocrine System Diseases|Gastrointestinal Disease|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Disease|Intestinal Neoplasms|Lung Diseases|Lung Neoplasm|Medullary Thyroid Cancer|Neoplasms|Neoplasms by Histologic Type|Neoplasms by Site|Neoplasms, Germ Cell and Embryonal|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Neuroectodermal Tumors|Neuroendocrine Tumors|Respiratory Tract Disease|Respiratory Tract Neoplasms|RET-altered Colon Cancer|RET-altered Non Small Cell Lung Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Solid Tumors|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Diseases|Thyroid Neoplasm","A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors","Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","Adenocarcinoma|Adenocarcinoma, Papillary|Bronchial Neoplasms|Carcinoma|Carcinoma, Bronchogenic|Carcinoma, Neuroendocrine|Carcinoma, Non-Small-Cell Lung|Colonic Diseases|Colonic Neoplasms|Colorectal Neoplasms|Digestive System Disease|Digestive System Neoplasm|Endocrine Gland Neoplasm|Endocrine System Diseases|Gastrointestinal Disease|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Disease|Intestinal Neoplasms|Lung Diseases|Lung Neoplasm|Medullary Thyroid Cancer|Neoplasms|Neoplasms by Histologic Type|Neoplasms by Site|Neoplasms, Germ Cell and Embryonal|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Neuroectodermal Tumors|Neuroendocrine Tumors|Respiratory Tract Disease|Respiratory Tract Neoplasms|RET-altered Colon Cancer|RET-altered Non Small Cell Lung Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Solid Tumors|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Diseases|Thyroid Neoplasm",2017-01-20,2023-12-31,2024-02-29,589.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 1/Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Mayo Clinic|UC Irvine Medical Center|University of Colorado Cancer Center|Georgetown University Medical Center|Mayo Clinic|University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center|Maryland Oncology Hematology, PA - Columbia|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University School of Medicine, Siteman Cancer Center|Albany Medical Center|Jack D. Weiler Hospital|Cornell University|Oregon Health and Science University|University of Pennsylvania Hospital|UPMC CancerCenter|Texas Oncology - Austin|Texas Oncology - Baylor Charles A. Sammons Cancer Center|University of Texas MD Anderson Cancer Center|University of Washington, Seattle Cancer Care Alliance|Antwerp University Hospital|Beijing Cancer Hospital|West China Hospital, Sichuan University|Sichuan Cancer Hospital & Institute|Chongqing Cancer Hospital|Fujian Provincial Cancer Hospital|First Affiliated Hospital of Gannan Medical University|Sun Yat-sen University Cancer Center|Guangdong Provincial People's Hospital|Nanfang Hospital of Southern Medical University|Zhejiang Provincial People's Hospital|Zhejiang Cancer Hospital|Anhui Provincial Cancer Hospital|Jinan Central Hospital|Gansu Provincial Cancer Hospital|Fudan University Shanghai Cancer Center|Liaoning Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Henan Cancer Hospital|Institut Bergoni|CHRU de Lille - Hpital Claude Hurier Servide d'Endocrinologie et Diabtologie|Centre Leon Berard|Centre Antoine Lacassagne|Hospital Tenon|Institut Curie|CHU de Rennes - Hpital Pontchaillou|Insitut Claudius Regaud|Gustave Roussy|HELIOS Klinikum Emil von Behring|Universittsklinikum Essen|Thoraxklinik Heidelberg|Klinikum der Universitat Munchen|Pius-Hospital Oldenberg|The Chinese University of Hong Kong|Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative|Grande Ospedale Metropolitano Niguarda|Ospedale Santa Maria delle Croci|Istituto Nazionale Tumori Regina Elena|Seoul National University Hospital|Severance Hospital|Asan Medical Center|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis|University Medical Center Groningen|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Clinic Barcelona|Hospital Duran I Reynals|Hospital Universitario Ramon y Cajal|Hospital Universitario 12 de Octubre Servicio de Oncologia Medica|National Taiwan University Hospital|Taipei Veterans General Hospital|NHS Grampian - Aberdeen Royal Infirmary|Sarah Cannon Research Institute|Guy's Hospital St. Thomas NHS Foundation Trust|NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust|The Christie NHS Foundation Trust",Drug,"Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03037385
1976,NCT03039439,Parathyroid Gland Adenoma|Parathyroid Gland Atypical Adenoma|Parathyroid Gland Carcinoma|Primary Hyperparathyroidism,Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents,Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors,Parathyroid Gland Adenoma|Parathyroid Gland Atypical Adenoma|Parathyroid Gland Carcinoma|Primary Hyperparathyroidism,2017-01-30,2020-11-30,2020-11-30,310.0,Case-Only,,Retrospective,Observational,Unknown status,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03039439
1980,NCT03044600,Hyperparathyroidism|Parathyroid Disease,Gene Expression in Hyperparathyroidism: Identifying Molecular Differences in MEN1 Patients Versus Young MEN1 Negative Patients,Gene Expression in Hyperparathyroidism,Hyperparathyroidism|Parathyroid Disease,2017-02-03,2017-10-18,2017-10-18,22.0,Cohort,,Prospective,Observational,Terminated,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03044600
1982,NCT03046524,Parathyroid Carcinoma|Parathyroid Neoplasm,Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior,Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior,Parathyroid Carcinoma|Parathyroid Neoplasm,2017-02-02,2017-10-16,2017-10-16,100.0,Cohort,,Retrospective,Observational,Completed,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03046524
1984,NCT03048708,Autoimmune Thyroiditis|Insulin Resistance|Obesity|Thyroid,Changes in Thyroid Function Tests and Texture Following Bariatric Surgery Induced Weight Loss,Thyroid in Bariatric Surgery,Autoimmune Thyroiditis|Insulin Resistance|Obesity|Thyroid,2017-02-07,2013-12-31,2016-08-31,10.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University Hospitals Coventry and Warwickshire NHS Trust,University Hospitals Coventry and Warwickshire NHS Trust,,Procedure,,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03048708
1987,NCT03048877,Differentiated Thyroid Cancer,"A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer",Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2017-02-03,2020-03-25,2022-07-31,118.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Nanjing PLA 81 Hospital|Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03048877
1988,NCT03051126,Parathyroid Disease,Establishment of a Parathyroid Tissue Bank,Establishment of a Parathyroid Tissue Bank,Parathyroid Disease,2017-02-02,2025-07-01,2025-07-01,10000.0,Cohort,,Prospective,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03051126
1989,NCT03052075,Primary Hyperparathyroidism,Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Primary Hyperparathyroidism,2017-02-10,2020-09-30,2020-09-30,250.0,Cohort,,Retrospective,Observational,Unknown status,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03052075
1992,NCT03053115,Hypothyroidism,"Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients: Effects on Peripheral Tissues. A Prospective, Randomized, Controlled, Double-blind Study",Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients,Hypothyroidism,2016-11-25,2021-12-31,2021-12-31,160.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2/Phase 3,Azienda USL Modena,Azienda USL Modena,AziendaUSLModena,Drug|Drug|Drug,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03053115
1993,NCT03053999,Hyperparathyroidism|Multiple Endocrine Neoplasia|Pancreatic Neuroendocrine Tumors,Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET),Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET),Hyperparathyroidism|Multiple Endocrine Neoplasia|Pancreatic Neuroendocrine Tumors,2017-02-13,2022-10-31,2023-10-31,53.0,Case-Control,,Retrospective,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03053999
1995,NCT03057925,Thyroid Nodule,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Thyroid Nodule,2017-02-12,2017-12-31,2018-12-31,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,First Affiliated Hospital of Wenzhou Medical University,First Affiliated Hospital of Wenzhou Medical University|Wenjun Wu,The First Affiliated Hospital of Wenzhou Medical University,Device,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03057925
1997,NCT03061318,Indeterminate Thyroid Cytology,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-02-17,2017-08-30,2017-08-30,3100.0,Cohort,,Prospective,Observational,Completed,,Pontificia Universidad Catolica de Chile,Hernn Gonzlez,Centro de Diagnstico Plaza Italia|Clnica Alemana de Santiago|Hospital Clnico de la Pontificia Universidad Catlica de Chile|Clnica San Carlos de Apoquindo|Clnica Santa Mara|Fundacin Arturo Lpez Prez|Hospital del Salvador|Hospital San Juan de Dios|Hospital Clnico de la Universidad de Chile,,Chile,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03061318
1999,NCT03063190,"Adynamic Bone Disease|Hyperparathyroidism, Secondary|Renal Disease Bone|Renal Disease, End Stage|Restless Leg Disorder|Vitamin D Deficiency",Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome,Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease,"Adynamic Bone Disease|Hyperparathyroidism, Secondary|Renal Disease Bone|Renal Disease, End Stage|Restless Leg Disorder|Vitamin D Deficiency",2017-02-21,2022-03-31,2023-03-31,0.0,,Parallel Assignment,,Interventional,Withdrawn,Phase 4,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Hospital das Clinicas,Drug|Drug,Brazil,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03063190
2002,NCT03064542,Hyperthyroidism,"The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure","The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure",Hyperthyroidism,2017-02-09,2024-10-24,2024-10-24,30.0,Cohort,,Other,Observational [Patient Registry],Active not recruiting,,"Clinical Nutrition Research Centre, Singapore","Agency for Science, Technology and Research|Clinical Nutrition Research Centre, Singapore","Tan Tock Seng Hospital, Endocrinology Clinic",Drug,Singapore,21.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03064542
2003,NCT03065218,Thyroid Cancer,"Evaluation of 99mTc Sestamibi Scans In Patients Who Have Differentiated Thyroid Cancer, Elevated Serum Thyroglobulin Levels, and Negative Diagnostic Imaging Studies",99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients,Thyroid Cancer,2016-10-27,2021-02-15,2021-02-15,4.0,,Single Group Assignment,,Interventional,Terminated,Phase 4,Medstar Health Research Institute,Medstar Health Research Institute,Washington Hospital Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03065218
2004,NCT03066076,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up,Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,2017-01-27,2019-02-01,2019-06-01,60.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,Department of Surgery and Department of Ophthalmology Medical University Vienna,Drug|Procedure,Austria,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03066076
2008,NCT03072160,Medullary Thyroid Cancer (MTC),Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,Medullary Thyroid Cancer (MTC),2017-03-03,2019-11-22,2019-11-22,17.0,,Parallel Assignment,,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),National Institutes of Health Clinical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03072160
2009,NCT03072654,"Goiter, Nodular",Thyroidectomy Improves Tracheal Anatomy and Airflow in Patients With Nodular Goiter: A Prospective Cohort Study,Tracheal Anatomy After Thyroidectomy,"Goiter, Nodular",2017-03-02,2017-03-01,2017-03-02,72.0,Cohort,,Prospective,Observational,Completed,,University of Southern Denmark,University of Southern Denmark,,Procedure,,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03072654
2011,NCT03082742,Chronic Kidney Disease|Secondary Hyperparathyroidism,The Effect of Thiazide and Loop Diuretic on Mineral and Bone Disorder in Chronic Kidney Disease Patients,The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients,Chronic Kidney Disease|Secondary Hyperparathyroidism,2017-02-27,2018-06-30,2018-06-30,52.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Hospital das Clinicas,Drug|Drug,Brazil,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03082742
2014,NCT03085056,Anaplastic Thyroid Cancer,A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2017-03-15,2023-09-30,2023-09-30,13.0,,Single Group Assignment,,Interventional,Active not recruiting,Early Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|Novartis,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited Protocol Activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau (Limited Protocol Activities),Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03085056
2016,NCT03085615,Acute Respiratory Distress Syndrome|Euthyroid Sick Syndromes|Oxidative Stress|Systemic Inflammatory Response Syndrome,Feeding the Critically Ill During Phases of Altered Redox Status (FEDOX): a Prospective Randomized Trial,Feeding the Critically Ill During Phases of Altered Redox Status,Acute Respiratory Distress Syndrome|Euthyroid Sick Syndromes|Oxidative Stress|Systemic Inflammatory Response Syndrome,2017-03-15,2018-06-04,2018-10-13,35.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Illinois at Chicago,American Society for Parenteral and Enteral Nutrition|Rush University Medical Center|University of Illinois at Chicago,Rush University Medical Center,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03085615
2017,NCT03091140,"Hyperparathyroidism, Primary|Parathyroidectomy",Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.,Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.,"Hyperparathyroidism, Primary|Parathyroidectomy",2017-03-03,2018-12-31,2018-12-31,200.0,Cohort,,Prospective,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"AHEPA University General Hospital, Aristotle University of Thessaloniki",,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03091140
2020,NCT03093909,Malignant Neoplasm of Bone and Articular Cartilage|Malignant Neoplasm of Male Genital Organs|Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract|Melanoma and Other Malignant Neoplasms of Skin,Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases,Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases,Malignant Neoplasm of Bone and Articular Cartilage|Malignant Neoplasm of Male Genital Organs|Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract|Melanoma and Other Malignant Neoplasms of Skin,2017-03-21,2021-11-30,2022-11-30,44.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,Gateway for Cancer Research|James B. and Lois R. Archer Charitable Foundation|M.D. Anderson Cancer Center,The University of Texas MD Anderson Cancer Center,Drug,United States,12.0,50.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03093909
2021,NCT03094416,Hypothyroidism;Postablative,An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors,Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors,Hypothyroidism;Postablative,2017-03-17,2020-06-15,2020-06-15,66.0,,Single Group Assignment,,Interventional,Completed,Phase 4,IBSA Institut Biochimique SA,IBSA Institut Biochimique SA,"California Head and Neck Specialists|Coastal Metabolic Research Centre|Washington Hospital Center|MedStar Union Memorial Hospital|NYC Health + Hospitals/ Queens|Diabetes & Endocrinology Consultants, PC|Carolina Ear Nose and Throat Clinic|Virginia Commonwealth University|Stonesifer Endocrine Care & Clinical Research Inc., PS",Drug|Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03094416
2022,NCT03095963,Hypothyroidism,Effects of Probiotics Assumption on Serum Thyroid Hormone and TSH Levels in Hypothyroid Patients on Levothyroxine Treatment,Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients,Hypothyroidism,2017-03-15,2016-10-25,2016-10-25,80.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Azienda USL Modena,Azienda USL Modena,,Other|Drug,,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03095963
2023,NCT03096613,Heart Failure|Subclinical Hypothyroidism,"Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial",Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF),Heart Failure|Subclinical Hypothyroidism,2017-03-25,2019-02-28,2019-02-28,124.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,"Chinese Academy of Medical Sciences, Fuwai Hospital","Chinese Academy of Medical Sciences, Fuwai Hospital|Henan Provincial People's Hospital|The First Hospital of Hebei Medical University|The Luhe Teaching Hospital of the Capital Medical University|Tianjin Medical University Second Hospital","Chinese Academy of Medical Sciences, Fuwai Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03096613
2024,NCT03098225,Thyroid Associated Ophthalmopathy,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy,Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,120.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03098225
2028,NCT03099356,Metastatic Thyroid Cancer,"An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",Metastatic Thyroid Cancer,2017-03-28,2022-05-12,2023-05-12,19.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,University of Michigan Rogel Cancer Center,University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03099356
2029,NCT03102099,Thyroid Nodules,Application Value of Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Thyroid Nodules,2017-03-10,2018-06-30,2019-06-30,400.0,Case-Control,,Prospective,Observational,Unknown status,,Peking University Third Hospital,Peking University Third Hospital,Peking University Third Hospital,Procedure|Procedure,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03102099
2031,NCT03102177,Hypothyroidism Primary,Hypothyroidism Treatment in Aging and Thyroid Cancer,"Effect of Age, Weight and Sex on Levothyroxine Pharmacokinetics",Hypothyroidism Primary,2017-03-27,2013-11-30,2016-07-26,41.0,,Single Group Assignment,,Interventional,Completed,Early Phase 1,Georgetown University,Georgetown University,,Drug,,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03102177
2032,NCT03103607,Thyroid Eye Disease,Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term,Disappearance of Graves' Orbitopathy,Thyroid Eye Disease,2017-03-27,2014-12-31,2016-02-28,99.0,Cohort,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Diagnostic Test|Diagnostic Test,,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03103607
2036,NCT03103776,"Polyoma Virus Infection|Thyroiditis, Autoimmune",Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis.,Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis.,"Polyoma Virus Infection|Thyroiditis, Autoimmune",2017-03-31,2018-10-31,2018-10-31,49.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03103776
2039,NCT03105648,Computerized Cytomorphometry,Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm,Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm,Computerized Cytomorphometry,2017-04-04,2026-04-20,2026-04-20,3000.0,Case-Control,,Retrospective,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Other,Taiwan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03105648
2040,NCT03106337,Follicular Neoplasm|Thyroid Nodule,A Multivariate Analysis of Factors Predictive of Carcinoma in Follicular Neoplasms of the Thyroid Gland,Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid,Follicular Neoplasm|Thyroid Nodule,2014-04-25,2012-04-30,2012-04-30,35.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03106337
2042,NCT03106935,Recurrent Pregnancy Loss,Effect of Levothyroxine Treatment on Pregnancy Outcome in RPL Women With Subclinical Hypothyroidism,Recurrent Pregnancy Loss and Thyroid Disease,Recurrent Pregnancy Loss,2017-02-27,2017-12-31,2018-06-30,300.0,,Parallel Assignment,,Interventional,Unknown status,Early Phase 1,Second Affiliated Hospital of Soochow University,Second Affiliated Hospital of Soochow University,Second Affiliated Hospital of Soochow University,Drug,China,18.0,39.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03106935
2043,NCT03107078,Thyroid Associated Ophthalmopathy,"Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial","Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial",Thyroid Associated Ophthalmopathy,2017-03-08,2019-10-01,2021-10-01,200.0,,Parallel Assignment,,Interventional,Unknown status,Phase 4,The Third Affiliated Hospital of Southern Medical University,Huadu District People's Hospital of Guangzhou|Jie Shen|The Fifth Affiliated Hospital of Southern Medical University|Zhujiang Hospital,the Third Affiliated Hospital of Southern Medical University,Drug,China,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03107078
2047,NCT03108222,Chronic Kidney Disease Mineral and Bone Disorder,Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease,Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease,Chronic Kidney Disease Mineral and Bone Disorder,2017-04-05,2019-08-30,2019-12-31,20.0,Other,,Prospective,Observational,Unknown status,,Purdue University,Purdue University,Purdue University Nutrition Science Department,Other,United States,30.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03108222
2050,NCT03109847,Thyroid,Pilot Study of Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Well-Differentiated Thyroid Cancers,Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer,Thyroid,2017-03-06,2022-01-31,2022-01-31,13.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Drug|Other|Other,United States,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03109847
2051,NCT03110835,Thyroid Diseases,Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy,Low-dose Radioiodine Ablation in Graves' Disease,Thyroid Diseases,2017-03-14,2017-03-28,2017-03-28,12.0,Case-Control,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Radiation,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03110835
2054,NCT03110848,Hypercholesterolemia|Thyroid Associated Ophthalmopathy,"A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study",Effects of Atorvastatin in Graves' Orbitopathy (GO),Hypercholesterolemia|Thyroid Associated Ophthalmopathy,2017-03-23,2021-04-30,2021-04-30,88.0,,Parallel Assignment,,Interventional,Completed,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03110848
2058,NCT03114267,Autoimmune Diseases|Chronic Lymphocytic Thyroiditis,Involvement of Viral Infections in the Pathogenesis of Chronic Lymphocytic Thyroiditis,Involvement of Viral Infections in the Pathogenesis of Chronic Lymphocytic Thyroiditis,Autoimmune Diseases|Chronic Lymphocytic Thyroiditis,2017-04-11,2015-01-06,2015-01-06,64.0,Cohort,,Retrospective,Observational,Completed,,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03114267
2061,NCT03115515,Pregnancy Related|Thyroid,"Randomized, Prospective Trial Comparing the Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy",Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy,Pregnancy Related|Thyroid,2017-04-07,2018-02-28,2018-02-28,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Medstar Health Research Institute,Medstar Health Research Institute,Medstar Washington Hospital Center,Drug,United States,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03115515
2062,NCT03120221,Iodine-Deficiency; Hypothyroidism,Iodine Status in Pregnant Women in Israel,Iodine Status in Pregnant Women in Israel,Iodine-Deficiency; Hypothyroidism,2017-04-01,2018-12-31,2018-12-31,160.0,Case-Only,,Prospective,Observational,Unknown status,,Clalit Health Services,Clalit Health Services,Women Health Service|Women Health Center,Diagnostic Test,Israel,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03120221
2063,NCT03122496,Metastatic Anaplastic Thyroid Cancer,A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer,Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer,Metastatic Anaplastic Thyroid Cancer,2017-04-18,2023-04-30,2023-04-30,13.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,AstraZeneca|Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge|Memoral Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memoral Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering @ Rockville|Memorial Sloan Kettering Nassau,Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03122496
2065,NCT03122847,Graves Ophthalmopathy,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves Ophthalmopathy,Glucocorticoids and Bone in Graves' Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,30.0,Cohort,,Prospective,Observational,Active not recruiting,,Aarhus University Hospital,Odense University Hospital|Torben Harslf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03122847
2069,NCT03123406,"Hyperparathyroidism; Secondary, Renal","A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT)","Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT","Hyperparathyroidism; Secondary, Renal",2017-03-29,2019-04-20,2019-09-06,750.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"Kyowa Hakko Kirin China Pharmaceutical Co., LTD.","Kyowa Hakko Kirin China Pharmaceutical Co., LTD.",Nanjing Jinling Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03123406
2072,NCT03127098,Breast Cancer|Colon Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Thyroid Cancer,"Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",Breast Cancer|Colon Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Thyroid Cancer,2017-04-20,2017-12-07,2017-12-07,3.0,,Sequential Assignment,,Interventional,Completed,Phase 1/Phase 2,"NantCell, Inc.","NantCell, Inc.",Medical Oncology Associates,Biological|Biological,United States,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03127098
2073,NCT03128255,Thyroid Diseases|Thyroid Goitre|Thyroid Nodule,"I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics",Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.,Thyroid Diseases|Thyroid Goitre|Thyroid Nodule,2017-04-20,2017-07-31,2018-04-30,70.0,Case-Control,,Prospective,Observational,Unknown status,,Jena University Hospital,GE Healthcare|Jena University Hospital,University Hospital Jena,Other,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03128255
2076,NCT03131206,ALK-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Thyroid Cancer,A Phase 1/2 Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,ALK-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Thyroid Cancer,2017-04-19,2018-11-08,2019-04-08,5.0,,Parallel Assignment,,Interventional,Terminated,Phase 1/Phase 2,Dana-Farber Cancer Institute,"Dana-Farber Cancer Institute|Genentech, Inc.","University of California, Irvine|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana Farber Cancer Institute",Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03131206
2077,NCT03131726,Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Treatment of GravesOphthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malm",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03131726
2081,NCT03134976,Head and Neck Cancer|Hypothyroidism; Surgery|Laryngeal Cancer|Laryngeal Fistula|Wound Heal,Wound Complications in Head and Neck Surgery,Wound Complications in Head and Neck Surgery,Head and Neck Cancer|Hypothyroidism; Surgery|Laryngeal Cancer|Laryngeal Fistula|Wound Heal,2017-04-20,2020-04-01,2020-05-01,51.0,Cohort,,Prospective,Observational,Completed,,University of Michigan,University of Michigan,University of Michigan,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03134976
2082,NCT03137316,Diabetic Nephropathies|Secondary Hyperparathyroidism,Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy,Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy,Diabetic Nephropathies|Secondary Hyperparathyroidism,2017-04-28,2017-02-28,2017-03-01,437.0,Cohort,,Retrospective,Observational,Completed,,Benha University,Benha University|New Jeddah Clinic Hospital,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03137316
2085,NCT03139747,Thyroid Cancer,UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,Thyroid Cancer,2017-05-02,2022-05-30,2022-05-30,5.0,,Single Group Assignment,,Interventional,Suspended,Phase 2,Thomas Jefferson University,Thomas Jefferson University,Abramson Cancer Center of the University of Pennsylvania,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03139747
2086,NCT03150108,Hypoparathyroidism,"A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects",Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects,Hypoparathyroidism,2017-05-01,2017-06-26,2017-06-26,24.0,,Crossover Assignment,,Interventional,Completed,Phase 1,Takeda,Shire,Glendale Adventist Medical Center,Drug|Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03150108
2088,NCT03157128,Any Solid Tumor|Colon Cancer|Medullary Thyroid Cancer|Non-Small Cell Lung Cancer,"A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)","A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)",Any Solid Tumor|Colon Cancer|Medullary Thyroid Cancer|Non-Small Cell Lung Cancer,2017-05-09,2022-11-21,2023-11-21,989.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","Mayo Clinic of Scottsdale|City of Hope National Medical Center|University of California - San Diego|UCLA Medical Center|Hoag Memorial Hospital Presbyterian|Irvine Medical Center|UCSF Medical Center at Mission Bay|Kaiser Permanente|Kaiser Permanente Medical Center|Sarah Cannon Research Institute at HealthOne|Yale Cancer Center|Johns Hopkins University|Mayo Clinic in Florida|Memorial Hospital Pembroke|Emory University|University of Chicago Medicine-Comprehensive Cancer Center|Ochsner Clinic Foundation|University of Maryland Medical Center|Massachusetts General Hospital|Dana-Farber Cancer Institute|University of Michigan|START Midwest|Mayo Clinic|Washington University Medical School|Comprehensive Cancer Centers of Nevada|Roswell Park Cancer Institute|NYU Langone|Memorial Sloan Kettering Cancer Center|University of North Carolina|Cleveland Clinic Foundation|Ohio State University Hospital|Oregon Health and Science University|University of Pennsylvania Hospital|Thomas Jefferson University|Sarah Cannon Research Institute SCRI|Vanderbilt University Medical Center|University of Texas Southwestern Medical Center at Dallas|University of Texas MD Anderson Cancer Center|Huntsman Cancer Institute|Virginia Cancer Specialists, PC|University of Wisconsin-Madison Hospital and Health Clinic|Royal North Shore Hospital|Peter MacCallum Cancer Centre|BC Cancer Vancouver|Rigshospitalet|Hpital Europen Georges Pompidou|Institut Bergoni - Centre Rgional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest|Centre Leon Berard|APHM Hpital de la Timone|Institut du Cancer de Montpellier - Val d'aurelle|Gustave Roussy|Universittsklinikum Wrzburg A. . R.|Universittsklinikum Kln|Prince of Wales Hospital|Sheba Medical Center|Shaare Zedek Medical Center|Soroka Medical Center - Pediatric Outpatient Clinic|Hadassah Medical Center|Istituto Nazionale dei Tumori|Nagoya University Hospital|National Cancer Center Hospital East|Hokkaido University Hospital|Hyogo Cancer Center|Kanazawa University Hospital|Kindai University Hospital|Shizuoka Cancer Center|National Cancer Center Hospital|Japanese Foundation for Cancer Research|Tottori University Hospital|National Hospital Organization Kyushu Cancer Center|Okayama University Hospital|Osaka City General Hospital|National Cancer Center|Seoul National University Bundang Hospital|Asan Medical Center|Samsung Medical Center|Severance Hospital, Yonsei University Health System|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Universitario Fundacin Jimnez Daz|Hospital Madrid Norte Sanchinarro|Kantonsspital Luzern|Taichung Veterans General Hospital|National Taiwan University Hospital|Royal Marsden Hospital",Drug,"Australia|Canada|Denmark|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Singapore|Spain|Switzerland|Taiwan|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03157128
2089,NCT03157466,Respiratory Failure|Thyroid Diseases,Diaphragmatic Efficiency After Thyroid Hormone Replacement Therapy in Ventilated Patients With the Nonthyroidal Illness Syndrome: a Physiological Study,Respiratory Muscle Function After Thyroid Hormone Replacement Therapy in Nonthyroidal Illness Syndrome,Respiratory Failure|Thyroid Diseases,2017-05-12,2018-05-01,2018-05-01,15.0,Cohort,,Prospective,Observational,Completed,,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Fondazione Policlinico Universitario Agostino Gemelli,,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03157466
2090,NCT03158961,Thyroid Diseases,A Prospective Evaluation of the Feasibility and Safety of the Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) as a Treatment for Benign Thyroid Nodules,The Feasibility and Safety of the TOETVA for Benign Thyroid Nodules,Thyroid Diseases,2017-05-15,2019-05-31,2019-07-31,10.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Procedure,Hong Kong,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03158961
2092,NCT03160274,Associated Conditions|Bone Cancer|Inherited Cancer Syndrome|Kidney Neoplasms|Other Cancer|Paraganglioma|Pheochromocytoma|Thyroid Neoplasms,"Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions",Associated Conditions|Bone Cancer|Inherited Cancer Syndrome|Kidney Neoplasms|Other Cancer|Paraganglioma|Pheochromocytoma|Thyroid Neoplasms,2017-05-05,2030-12-31,2030-12-31,2000.0,Cohort,,Other,Observational [Patient Registry],Recruiting,,The University of Texas Health Science Center at San Antonio,National Institute of General Medical Sciences (NIGMS)|The University of Texas Health Science Center at San Antonio,University of Texas Health Science Center,Genetic,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03160274
2093,NCT03160482,Thyroid Nodule,Evaluation of PACE4 Isoforms as Biomarkers in Thyroid Cancer,PACE4 in Thyroid Cancer,Thyroid Nodule,2017-05-16,2018-01-15,2018-01-15,39.0,Cohort,,Cross-Sectional,Observational,Completed,,Universit de Sherbrooke,Robert Day,CIUSSS de l'Estrie - CHUS,Diagnostic Test,Canada,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03160482
2095,NCT03162627,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands,"Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance",Selumetinib and Olaparib in Solid Tumors,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands,2017-05-18,2026-08-30,2026-08-30,90.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,AstraZeneca|M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03162627
2096,NCT03167385,Differentiated Thyroid Carcinoma,The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial.,Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma,Differentiated Thyroid Carcinoma,2017-05-24,2019-01-31,2020-12-31,20.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Tianjin Medical University Cancer Institute and Hospital,Tianjin Medical University Cancer Institute and Hospital,Tianjin Medical University Cancer Institute and Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03167385
2097,NCT03170804,Thymic Carcinoma|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,Registry for Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Thymic Carcinoma|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2017-05-25,2018-01-01,2020-01-01,200.0,Cohort,,Prospective,Observational [Patient Registry],Unknown status,,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03170804
2099,NCT03170960,Castration-resistant Prostate Cancer|Colorectal Cancer|Differentiated Thyroid Cancer|Endometrial Cancer|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Head and Neck Cancer|Hepatocellular Carcinoma|Lower Esophageal Cancer|Non-Small Cell Lung Cancer|Ovarian Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer|Urothelial Carcinoma,A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,Castration-resistant Prostate Cancer|Colorectal Cancer|Differentiated Thyroid Cancer|Endometrial Cancer|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Head and Neck Cancer|Hepatocellular Carcinoma|Lower Esophageal Cancer|Non-Small Cell Lung Cancer|Ovarian Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer|Urothelial Carcinoma,2017-05-23,2022-12-31,2022-12-31,1732.0,,Sequential Assignment,,Interventional,Active not recruiting,Phase 1/Phase 2,Exelixis,Exelixis,Exelixis Clinical Site #53|Exelixis Clinical Site #18|Exelixis Clinical Site #1|Exelixis Clinical Site #20|Exelixis Clinical Site #46|Exelixis Clinical Site #51|Exelixis Clinical Site #62|Exelixis Clinical Site #21|Exelixis Clinical Site #34|Exelixis Clinical Site #50|Exelixis Clinical Site #42|Exelixis Clinical Site #48|Exelixis Clinical Site #16|Exelixis Clinical Site #76|Exelixis Clinical Site #60|Exelixis Clinical Site #79|Exelixis Clinical Site #32|Exelixis Clinical Site #23|Exelixis Clinical Site #57|Exelixis Clinical Site #24|Exelixis Clinical Site #10|Exelixis Clinical Site #3|Exelixis Clinical Site #17|Exelixis Clinical Site #65|Exelixis Clinical Site #43|Exelixis Clinical Site #35|Exelixis Clinical Site #59|Exelixis Clinical Site #61|Exelixis Clinical Site #38|Exelixis Clinical Site #27|Exelixis Clinical Site #31|Exelixis Clinical Site #37|Exelixis Clinical Site #40|Exelixis Clinical Site #11|Exelixis Clinical Site #67|Exelixis Clinical Site #49|Exelixis Clinical Site #64|Exelixis Clinical Site #71|Exelixis Clinical Site #6|Exelixis Clinical Site #102|Exelixis Clinical Site #45|Exelixis Clinical Site #41|Exelixis Clinical Site #15|Exelixis Clinical Site #55|Exelixis Clinical Site #66|Exelixis Clinical Site #95|Exelixis Clinical Site #13|Exelixis Clinical Site #26|Exelixis Clinical Site #114|Exelixis Clinical Site #29|Exelixis Clinical Site #39|Exelixis Clinical Site #44|Exelixis Clinical Site #33|Exelixis Clinical Site #63|Exelixis Clinical Site #2|Exelixis Clinical Site #30|Exelixis Clinical Site #14|Exelixis Clinical Site #98|Exelixis Clinical Site #101|Exelixis Clinical Site #115|Exelixis Clinical Site #112|Exelixis Clinical Site #123|Exelixis Clinical Site #99|Exelixis Clinical Site #52|Exelixis Clinical Site #54|Exelixis Clinical Site #88|Exelixis Clinical Site #8|Exelixis Clinical Site #92|Exelixis Clinical Site #93|Exelixis Clinical Site #87|Exelixis Clinical Site #69|Exelixis Clinical Site #97|Exelixis Clinical Site #89|Exelixis Clinical Site #109|Exelixis Clinical Site #104|Exelixis Clinical Site #80|Exelixis Clinical Site #78|Exelixis Clinical Site #7|Exelixis Clinical Site #68|Exelixis Clinical Site #72|Exelixis Clinical Site #82|Exelixis Clinical Site #119|Exelixis Clinical Site #107|Exelixis Clinical Site #105|Exelixis Clinical Site #56|Exelixis Clinical Site #36|Exelixis Clinical Site #84|Exelixis Clinical Site #47|Exelixis Clinical Site #108|Exelixis Clinical Site #103|Exelixis Clinical Site #25|Exelixis Clinical Site #4|Exelixis Clinical Site #85|Exelixis Clinical Site #121|Exelixis Clinical Site #110|Exelixis Clinical Site #12|Exelixis Clinical Site #74|Exelixis Clinical Site #91|Exelixis Clinical Site #94|Exelixis Clinical Site #70|Exelixis Clinical Site #113|Exelixis Clinical Site #116|Exelixis Clinical Site #96|Exelixis Clinical Site #90|Exelixis Clinical Site #117|Exelixis Clinical Site #75|Exelixis Clinical Site #58|Exelixis Clinical Site #83|Exelixis Clinical Site #86|Exelixis Clinical Site #28|Exelixis Clinical Site #9|Exelixis Clinical Site #73|Exelixis Clinical Site #118|Exelixis Clinical Site #77|Exelixis Clinical Site #106|Exelixis Clinical Site #111|Exelixis Clinical Site #22|Exelixis Clinical Site #5|Exelixis Clinical Site #81|Exelixis Clinical Site #100|Exelixis Clinical Site #122|Exelixis Clinical Site #120|Exelixis Clinical Site #124|Exelixis Clinical Site #19,Drug|Drug|Drug|Drug,Australia|Belgium|France|Germany|Italy|Netherlands|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03170960
2100,NCT03174925,Malignant Thyroid Gland Neoplasm|Thyroid Gland Nodule,Elastography in Thyroid Nodule Evaluation,Ultrasound Elastography in Imaging Patients With Thyroid Nodules,Malignant Thyroid Gland Neoplasm|Thyroid Gland Nodule,2017-05-18,2018-02-13,2019-02-13,55.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Stanford University,Stanford University,"Stanford University, School of Medicine",Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03174925
2102,NCT03176485,Colon Cancer|Differentiated Thyroid Cancer|HCC|Hepatocellular Carcinoma|Melanoma|Metastatic Cancer|Metastatic Colon Cancer|Metastatic Melanoma|Renal Cell Carcinoma,"Pilot Study to Evaluate the Signaling Pathway Modulation Demonstrated by Raf, MEK, and Kinase Inhibitors In Human Skin With or Without Solar Simulated Light","Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors",Colon Cancer|Differentiated Thyroid Cancer|HCC|Hepatocellular Carcinoma|Melanoma|Metastatic Cancer|Metastatic Colon Cancer|Metastatic Melanoma|Renal Cell Carcinoma,2017-06-01,2018-11-01,2018-11-01,45.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Arizona,University of Arizona,University of Arizona Cancer Center,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03176485
2103,NCT03178253,Hypothyroidism in Diabetes,Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy,Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy,Hypothyroidism in Diabetes,2017-06-03,2017-06-30,2018-06-30,100.0,Case-Control,,Prospective,Observational,Unknown status,,Assiut University,Assiut University,Maria Hamdy,,Egypt,40.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03178253
2104,NCT03180892,Hypothyroidism,Non-immune Related Hypothyroidism in Iodine Sufficient Area,Non-immune Related Hypothyroidism in Iodine Sufficient Area,Hypothyroidism,2017-06-02,2016-12-31,2016-12-31,6564.0,Cohort,,Other,Observational [Patient Registry],Completed,,Samsung Medical Center,Samsung Medical Center,,Other,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03180892
2105,NCT03181100,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,2017-06-06,2023-07-27,2023-07-27,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological|Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03181100
2107,NCT03182699,Chronic Kidney Disease Requiring Chronic Dialysis|Left Ventricular Hypertrophy|Secondary Hyperparathyroidism,Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial,Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients,Chronic Kidney Disease Requiring Chronic Dialysis|Left Ventricular Hypertrophy|Secondary Hyperparathyroidism,2017-05-31,2019-12-20,2019-12-20,62.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Medical University of Vienna,Amgen|Rainer Oberbauer,Medical University of Vienna|Wiener Dialysezentrum,Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Austria,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03182699
2110,NCT03183752,Insulin Resistance|Thyroid Nodule,The Role of Insulin Resistance and the Effect of Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance|Thyroid Nodule,2017-06-08,2018-10-17,2019-04-17,28.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hospital Universitrio Clementino Fraga Filho,Hospital Universitrio Clementino Fraga Filho,Patricia Santos,Drug|Drug,Brazil,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03183752
2112,NCT03191643,Differentiated Thyroid Cancer,18F-FDG PET-guided External Beam Radiotherapy in Iodine-refractory Differentiated Thyroid Cancer,PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2017-06-15,2016-01-31,2016-01-31,16.0,Cohort,,Retrospective,Observational,Completed,,IRCCS Azienda Ospedaliero-Universitaria di Bologna,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03191643
2113,NCT03194087,Secondary Hyperparathyroidism,the Study on Difference Prognostic for Low Parathyroid Hormone Levels and Severe Secondary Hyperparathyroidism in Hemodialysis Patients,the Study on Prognostic for Hemodialysis Patients,Secondary Hyperparathyroidism,2017-05-31,2019-01-01,2019-01-01,827.0,Cohort,,Prospective,Observational,Unknown status,,Beijing Friendship Hospital,Beijing Friendship Hospital,Beijing Friendship hospital,,China,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03194087
2116,NCT03195296,Graves Ophthalmopathy,T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features,T and B Cells in Graves' Orbitopathy,Graves Ophthalmopathy,2017-06-19,2017-05-31,2017-05-31,20.0,Case-Only,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,,Other,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03195296
2120,NCT03196518,Thyroid Cancer,PET Imaging of Thyroid Tissue Expressing Sodium-iodine Symporter Using the New Tracer 18F-tetrafluoroborate (18F-TFB),Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer,Thyroid Cancer,2017-06-21,2023-06-30,2023-06-30,5.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03196518
2121,NCT03199677,Refractory Cancer,"An Exploratory Single-center, Open-label , Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer",A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer,Refractory Cancer,2017-06-16,2018-06-30,2018-06-30,40.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Chinese Academy of Medical Sciences,Chinese Academy of Medical Sciences,"Cancer Hospital, Chinese Academy of Medical Sciences",Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03199677
2122,NCT03202160,Goiter,Cases of Goiter in Children Attending Assiut University Children Hospital,Causes of Goiter in Children Attending Assiut University Children Hospital,Goiter,2017-06-27,2019-04-15,2019-09-15,50.0,Case-Only,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,,,,0.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03202160
2123,NCT03203668,Hyperparathyroidism,Diagnostic Value of 18F-fluorocholine PET/CT Imaging in Localization of Hyperfunctioning Parathyroid Tissue in Hyperparathyroidism,18F-fluorocholine PET/CT Imaging in Hyperparathyroidism,Hyperparathyroidism,2017-04-17,2020-12-31,2020-12-31,1000.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,University Medical Centre Ljubljana,Institute of Oncology Ljubljana|University Medical Centre Ljubljana,"Department for nuclear medicine, University medical centre Ljubljana",Radiation,Slovenia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03203668
2125,NCT03211117,Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer,"Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,2017-07-06,2018-02-12,2019-03-28,3.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Mayo Clinic,Mayo Clinic|National Cancer Institute (NCI),Mayo Clinic,Drug|Drug|Radiation|Other|Biological|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03211117
2127,NCT03215095,Thyroid Cancer,"Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers",RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers,Thyroid Cancer,2017-07-11,2023-07-31,2023-07-31,11.0,,Single Group Assignment,,Interventional,Active not recruiting,Early Phase 1,Memorial Sloan Kettering Cancer Center,AstraZeneca|MedImmune LLC|Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge|Memoral Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03215095
2128,NCT03226171,Secondary Hyperparathyroidism,Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism,Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2017-07-20,2018-09-11,2018-09-11,58.0,,Single Group Assignment,,Interventional,Completed,Phase 2,"Sanwa Kagaku Kenkyusho Co., Ltd.","Sanwa Kagaku Kenkyusho Co., Ltd.",Investigational site (there may be other sites in this country),Drug,Japan,20.0,79.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03226171
2131,NCT03239769,Differentiated Thyroid Carcinoma (DTC),"A Study to Evaluate and Compare the Surgical Outcomes, Aesthetic Effects and Incision Length of Different Access Procedures in Patients With DTC",Compare the Aesthetic Effect of Different Thyroidectomies,Differentiated Thyroid Carcinoma (DTC),2017-08-01,2015-06-01,2015-06-01,120.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Beijing Cancer Hospital,Beijing Cancer Hospital,,Procedure,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03239769
2132,NCT03244956,Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation,Efficacy of a Selective MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors Associated With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer With RAS or BRAFV600E Mutation,Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer,Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation,2017-08-07,2021-11-18,2022-12-31,40.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Drug|Drug|Radiation|Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03244956
2133,NCT03246659,Medullary Thyroid Carcinoma,Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma,Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC,Medullary Thyroid Carcinoma,2017-07-28,2018-11-30,2018-11-30,16.0,,Sequential Assignment,,Interventional,Completed,Phase 1,"Azienda Ospedaliero, Universitaria Pisana","Erasmus Medical Center|INRASTES, NCSR Demokritos, Athens, Greece|Jagiellonian University|Medical University Innsbruck|NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland|Paola Anna Erba|University Hospital Freiburg|University Medical Centre Ljubljana","Department of Nuclear Medicine, Innsbruck Medical University|Department of Nuclear Medicine, University Hospital Freiburg|Erasmus University Rotterdam|Department of Endocrinology, Jagiellonian University Medical College|Department of Nuclear Medicine, University Medical Centre Ljubljana",Drug|Drug,Austria|Germany|Netherlands|Poland|Slovenia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03246659
2134,NCT03246958,Thyroid Cancer,"A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer",Nivolumab Plus Ipilimumab in Thyroid Cancer,Thyroid Cancer,2017-08-08,2022-12-31,2025-03-31,53.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Dana-Farber Cancer Institute,Bristol-Myers Squibb|Dana-Farber Cancer Institute,Dana Farber Cancer Institute,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03246958
2135,NCT03249012,Hypoparathyroidism Postprocedural|Quality of Life,Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism,Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism,Hypoparathyroidism Postprocedural|Quality of Life,2017-08-09,2022-09-01,2022-09-01,120.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,CHU de Quebec-Universite Laval,CHU de Quebec-Universite Laval,CHU de Quebec,Other|Other,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03249012
2137,NCT03257566,Hypothyroidism,Risk Factors of Incidence of Hypothyroidism in Patients With Type 1 Diabetes,Hypothyroidism in Patients With Type 1 Diabetes,Hypothyroidism,2017-08-15,2019-07-31,2019-09-30,300.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,,,,8.0,15.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT03257566
2138,NCT03257930,Thyroid Nodule,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Thyroid Nodule,2017-08-17,2018-07-11,2019-01-01,1.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Assiut University,hassan harby mohamed,Assiut University,Drug,Egypt,15.0,60.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03257930
2140,NCT03268785,Hypocalcemia|Hypoparathyroidism Postprocedural|Parathyroid; Absent|Thyroid Cancer,Intra-operative Rapid Identification of Lymph Node and Parathyroid by Fine Needle Puncture for Thyroid Carcinoma,Intra-operative Rapid Identification of Lymph Node and Parathyroid,Hypocalcemia|Hypoparathyroidism Postprocedural|Parathyroid; Absent|Thyroid Cancer,2017-08-28,2018-08-01,2020-08-01,200.0,,Sequential Assignment,,Interventional,Unknown status,Not Applicable,Xijing Hospital,Xijing Hospital,Xijing hospital|Xijing Hospital,Diagnostic Test,China,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03268785
2143,NCT03271892,Thyroid Cancer Stage I,Deciding on Active Surveillance as an Alternative Option to Surgery in the Primary Management of Low Risk Papillary Thyroid Cancer,Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer,Thyroid Cancer Stage I,2017-08-28,2026-05-11,2026-12-31,200.0,Cohort,,Prospective,Observational,Recruiting,,"University Health Network, Toronto","Canadian Cancer Society (CCS)|Ontario Ministry of Health and Long Term Care|University Health Network, Toronto",University Health Network|University Health Network,,Canada,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03271892
2145,NCT03274258,Kidney Medullary Carcinoma|Loss of INI 1 Protein Expression|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,Kidney Medullary Carcinoma|Loss of INI 1 Protein Expression|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,2017-09-05,2022-07-31,2023-07-31,10.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03274258
2146,NCT03278964,Graves Ophthalmopathy,"Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy",Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy,Graves Ophthalmopathy,2017-09-04,2019-01-31,2019-01-31,42.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03278964
2150,NCT03280264,Parathyroid Carcinoma|Primary Hyperparathyroidism,An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy,Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism,Parathyroid Carcinoma|Primary Hyperparathyroidism,2017-09-07,2019-04-09,2019-04-09,18.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",Osaka City University Hospital,Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03280264
2154,NCT03283098,Secondary Hyperparathyroidism,"A Phase 1, Multiple Dose, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pharmacokinetics, Safety and Tolerability of AMG 416 Administered Intravenously to Chinese Subjects With Chronic Kidney Disease on Hemodialysis","A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416",Secondary Hyperparathyroidism,2017-08-31,2019-02-04,2019-02-04,33.0,,Parallel Assignment,,Interventional,Completed,Phase 1,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03283098
2157,NCT03284060,22q11.2 Deletion Syndrome,Social Cognition Training and Cognitive Remediation : a New Tool for 22q11.2 Deletion Syndrome,Social Cognition Training and Cognitive Remediation,22q11.2 Deletion Syndrome,2017-09-13,2018-03-09,2019-05-21,3.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Hpital le Vinatier,Hpital le Vinatier,Hopital Vinatier,Behavioral,France,5.0,13.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT03284060
2159,NCT03285230,Asthma|Breast Cancer|Cardiovascular Diseases|Colo-rectal Cancer|Crohn Disease|Depression|Diabetes|Endometrial Cancer|Endometriosis|Hypertension|Inflammatory Bowel Diseases|Melanoma|Parkinson Disease|Thyroid Cancer,The French E3N Prospective Cohort Study (Etude Epidmiologique auprs de Femmes de la Mutuelle Gnrale de l'Education Nationale),The French E3N Prospective Cohort Study,Asthma|Breast Cancer|Cardiovascular Diseases|Colo-rectal Cancer|Crohn Disease|Depression|Diabetes|Endometrial Cancer|Endometriosis|Hypertension|Inflammatory Bowel Diseases|Melanoma|Parkinson Disease|Thyroid Cancer,2017-07-27,1991-11-15,2025-12-15,100000.0,Cohort,,Prospective,Observational,Active not recruiting,,"Institut National de la Sant Et de la Recherche Mdicale, France","Gustave Roussy, Cancer Campus, Grand Paris|Institut National de la Sant Et de la Recherche Mdicale, France|Ligue contre le cancer, France|Universit Paris-Sud",,,,40.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03285230
2160,NCT03285854,Chronic Kidney Disease Mineral and Bone Disorder,Assessing Calcium Balance in Children With Chronic Kidney Disease to Optimise Treatment Strategies,Calcium Balance Studies in Children With CKD and on Dialysis,Chronic Kidney Disease Mineral and Bone Disorder,2017-09-12,2021-12-30,2022-12-30,120.0,Case-Control,,Prospective,Observational,Active not recruiting,,Great Ormond Street Hospital for Children NHS Foundation Trust,"Athens General Children's Hospital ""Pan. & Aglaia Kyriakou""|Cukurova University|Great Ormond Street Hospital for Children NHS Foundation Trust|University of Kiel",Great Ormond Street Hospital for Children NHS Foundation Trust,Diagnostic Test,United Kingdom,0.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03285854
2163,NCT03289403,Autoimmune Thyroiditis|Infertility,The Role of Immunomodulatory Treatment in Success of ICSI in Patients Who Have Infertility With Autoimmune Thyroiditis,The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis,Autoimmune Thyroiditis|Infertility,2017-09-17,2019-09-15,2019-10-20,100.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Aljazeera Hospital,Aljazeera Hospital,Aljazeera (Al Gazeera) hospital,Drug|Drug,Egypt,18.0,35.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03289403
2166,NCT03294005,Thyroid Cancer,Clinical Prediction Thyroid Cancer With Thyroid Ultrasonography,Clinical Prediction Thyroid Cancer With Thyroid Ultrasonography,Thyroid Cancer,2017-09-22,2020-06-30,2020-06-30,1949.0,Other,,Retrospective,Observational,Completed,,China Medical University Hospital,China Medical University Hospital,China Medical University Hospital,Diagnostic Test,Taiwan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03294005
2167,NCT03295955,Surgical Wound Infection|Thyroid Nodule,Comparing Efficacy of Postoperative Antibiotic Use in Transoral Thyroidectomy: a Prospective Randomized Controlled Trial Study,Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy,Surgical Wound Infection|Thyroid Nodule,2017-09-20,2018-09-03,2018-12-03,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Jin Wook Yi,Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03295955
2169,NCT03298867,Graves' Orbitopathy|Thyroid Eye Disease,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",Graves' Orbitopathy|Thyroid Eye Disease,2017-09-27,2019-02-13,2020-11-30,83.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|The Lennar Foundation Medical|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee Health Science Center|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|University of Pisa, Department of Clinical and Experimental Medicine|University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit",Biological|Other,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03298867
2173,NCT03299244,Chronic Kidney Disease|Secondary Hyperparathyroidism,"A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism",Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism,2017-09-15,2020-04-08,2020-04-08,637.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,"China|Hong Kong|India|Korea, Republic of|Malaysia|Taiwan",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03299244
2176,NCT03300284,Thyroid Cancer,Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer,Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer,Thyroid Cancer,2017-09-28,2022-08-31,2022-08-31,186.0,Cohort,,Prospective,Observational,Active not recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Hartford Healthcare (Data Collection)|Memoral Sloan Kettering Monmouth (Consent and Follow up)|MAIMONIDES MEDICAL CENTER (Data collection only)|NYU Langone Health|Memorial Sloan Kettering Cancer Center|Lehigh Valley Health Network,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03300284
2178,NCT03300765,Thyroid Cancer,Intensity Modulated Radiation Therapy Combined With Apatinib for Inoperable or Iodine Refractory Thyroid Cancer: A Phase II Single-arm Study,Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer,Thyroid Cancer,2017-09-26,2019-07-01,2020-05-01,20.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Fudan University,"Xiayun He, MD",Fudan University Shanghai Cancer Center,Drug|Radiation,China,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03300765
2179,NCT03303053,Graves Disease|Hyperthyroidism,"A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism",Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism,Graves Disease|Hyperthyroidism,2017-09-13,2018-03-01,2018-03-01,135.0,,Parallel Assignment,,Interventional,Unknown status,Phase 3,"Clinical Research Centre, Malaysia","Clinical Research Centre, Malaysia|Ministry of Health, Malaysia",Hospital Queen Elizabeth 2|Hospital Ampang|Hospital Putrajaya,Drug|Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03303053
2182,NCT03307694,"Cancer, Thyroid",Multi-Angle Compound Shear Wave Elasticity Imaging for the Characterization of Thyroid Nodules,Thyroid Ultrasound Elasticity (TrUE) Imaging,"Cancer, Thyroid",2017-10-03,2018-07-13,2018-07-13,31.0,Other,,Prospective,Observational,Completed,,Emory University,Emory University,Emory Univeristy Hospital Midtown,Diagnostic Test|Diagnostic Test|Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03307694
2184,NCT03309384,Endocrine Procedural Complications|Laryngeal Injury|Parathyroid; Deficiency|Thyroid,Intraoperative Monitoring (Parathormone Values and Continuous Neuromonitoring) to Predict Postoperative Complications After Total Thyroidectomy,Intraoperative Monitoring to Predict Postoperative Complications After Thyroidectomy,Endocrine Procedural Complications|Laryngeal Injury|Parathyroid; Deficiency|Thyroid,2017-09-06,2026-03-20,2026-03-20,1000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHU Nancy,,France,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03309384
2186,NCT03309631,Indeterminate Thyroid Cytology,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-10-01,2018-03-30,2018-06-30,1500.0,Cohort,,Prospective,Observational,Unknown status,,Pontificia Universidad Catolica de Chile,Geneprodx|Pontificia Universidad Catolica de Chile,Avantt Research|Stanford University|Lee Moffit Cancer Center|Tulane University|Universidad de Cincinnati|University of Texas MD Anderson Cancer Center,Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03309631
2188,NCT03324022,Graves Ophthalmopathy,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Graves Ophthalmopathy,2017-10-16,2017-12-25,2020-12-25,80.0,Case-Control,,Prospective,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,"National Taiwan University Hospital Taipei, Taiwan",,Taiwan,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03324022
2192,NCT03324334,Ulcerative Colitis,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Ulcerative Colitis,2017-10-24,2018-10-01,2019-02-28,95.0,Case-Control,,Retrospective,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test|Diagnostic Test,,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03324334
2195,NCT03324880,Hypoparathyroidism,"A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]",A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE),Hypoparathyroidism,2017-10-10,2022-05-23,2022-05-23,150.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Takeda,Shire,"University of Chicago|Michigan Bone and Mineral Clinic|Mayo Clinic - PPDS|Physicians East PA|Ohio State University Wexner Medical Center|Children's Hospital of Philadelphia|UZ Gent|UZ Leuven|Nova Scotia Health Authority (Capital District Health Authority)|Bone Research and Education Centre|CHU de Quebec-Universite Laval|Eastern Health - Health Sciences Center- General Hospital|Aarhus Universitetshospital|Odense Universitetshospital|CHU Angers|Hopital Jean Minjoz|CHU Bictre|CHRU Lille|Universittsklinikum Carl Gustav Carus an der TU Dresden|Fondazione IRCCS C Granda Ospedale Maggiore Policlinico|Universita di Firenze, Dipartimento di Chirurgia e Medicina Traslazionale (DCMT)|Universit Campus Bio Medico Di Roma|VU Medisch Centrum|Leids Universitair Medisch Centrum|Erasmus MC|Haukeland Universitetssykehus|Oslo Universitetssykehus HF Rikshospitalet|Oslo Universitetssykehus Aker|Centro Hospitalar E Universitrio de Coimbra EPE|Unidade Local de Sade de Matosinhos SA|Centro Hospitalar de So Joo, E.P.E.|C.H. Regional Reina Sofia - PPDS|Hospital Universitario Quironsalud Madrid|Hospital Universitario Fundacion Jimenez Diaz|Hospital Universitario 12 de Octubre|Karolinska Universitetssjukhuset Solna|Sahlgrenska Universitetssjukhuset|Skanes Universitetssjukhus Lund|Ninewells Hospital - PPDS|Norfolk and Norwich University Hospital|Queen Elizabeth Hospital|Leicester Royal Infirmary|Manchester Royal Infirmary - PPDS",Biological|Biological,Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|Norway|Portugal|Spain|Sweden|United Kingdom|United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03324880
2197,NCT03324893,"18F-fluorocholine|Hyperparathyroidism, Primary|Positron-Emission Tomography",18F-Fluorocholine PET/MRI for the Localization of Parathyroid Adenomas,FCH PET/MRI Parathyroid Localization,"18F-fluorocholine|Hyperparathyroidism, Primary|Positron-Emission Tomography",2017-10-17,2021-06-30,2021-06-30,47.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",UHN,Diagnostic Test,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03324893
2200,NCT03327636,Papillary Thyroid Microcarcinoma,A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC),A Trial Comparing USG-HIFU vs AS in Management of Low-risk PTMC,Papillary Thyroid Microcarcinoma,2017-10-25,2024-08-31,2024-12-31,103.0,,Parallel Assignment,,Interventional,Suspended,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,19.0,74.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03327636
2201,NCT03331172,Thyroid Nodule,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Reapplication in Benign Thyroid Nodules That Had Less-than Adequate Shrinkage Following Single-session HIFU Treatment.,HIFU Reapplication in Benign Nodules,Thyroid Nodule,2017-10-27,2018-06-30,2018-08-30,28.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03331172
2203,NCT03342001,Hypothyroidism,Assessing Quality of Life Changes Using Calcitonin in Patients With Hypothyroidism on Biochemical Replacement With Levothyroxine,Hypothyroidism Treated With Calcitonin,Hypothyroidism,2017-11-09,2019-06-30,2019-08-14,11.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University of Maryland, Baltimore","University of Maryland, Baltimore",University of Maryland Center for Diabetes and Endocrinology,Drug,United States,18.0,88.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03342001
2204,NCT03359668,Papillary Thyroid Cancer,CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer,CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer,Papillary Thyroid Cancer,2017-11-16,2017-04-20,2017-04-20,47.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",,Diagnostic Test,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03359668
2206,NCT03360890,Salivary Gland Cancer|Thyroid Cancer,Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study.,Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors,Salivary Gland Cancer|Thyroid Cancer,2017-11-20,2022-09-30,2022-09-30,46.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,University of Chicago,University of Chicago,University of Chicago Comprehensive Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03360890
2207,NCT03363347,Thyroid Cancer,Association Between BRAF V600E and Redifferentiation Therapy in Patients With Radioiodine-refractory Papillary Thyroid Cancer,BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer,Thyroid Cancer,2017-11-20,2014-12-31,2014-12-31,25.0,Case-Control,,Retrospective,Observational,Completed,,Heidelberg University,Heidelberg University,,Drug,,24.0,69.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03363347
2209,NCT03364738,Hypoparathyroidism,An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects With Hypoparathyroidism,Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism,Hypoparathyroidism,2017-11-20,2020-04-14,2020-04-14,22.0,,Single Group Assignment,,Interventional,Terminated,Phase 3,Takeda,Shire,"University of Kentucky Medical Center|Crescent City Clinical Research Center, LLC|Northern Nevada Endocrinology - Lisa Abbott MD|Ohio State University|Thomas Jefferson University, Jefferson Rheumatology Associates|Bone Research and Education Centre|CHU de Quebec-Universite Laval|Aarhus Universitetshospital|Semmelweis Egyetem|Pecsi Tudomanyegyetem, I. sz. Belgyogyaszati Klinika",Biological,Canada|Denmark|Hungary|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03364738
2211,NCT03375359,Pregnancy,"First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome - ReFaPo02","First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome",Pregnancy,2017-12-12,2022-08-31,2022-08-31,1000.0,Case-Only,,Prospective,Observational,Recruiting,,University Hospital Tuebingen,University Hospital Tuebingen,"University Hospital Tuebingen, Department of Women's Health",Diagnostic Test,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03375359
2213,NCT03375931,Thyroid Cancer,The Effects of Preoperative Prayer on Postoperative Quality of Recovery in Patients Undergoing Thyroidectomy,The Effects of Preoperative Prayer on Postoperative Quality of Recovery in Patients Undergoing Thyroidectomy,Thyroid Cancer,2017-12-05,2020-05-31,2020-05-31,36.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine",Behavioral|Behavioral,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03375931
2214,NCT03377829,Thyroid Cancer|Treatment Related Cancer,A Multicenter Prospective Controlled Trial of Laser Ablation Versus Surgery for the Treatment of Papillary Thyroid Microcarcinoma,A Multicenter Trial of PLA vs. Surgery for Treating PTMC,Thyroid Cancer|Treatment Related Cancer,2017-11-26,2021-08-31,2022-12-31,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Ruijin Hospital,WeiWei Zhan,"Ultrasound Department, Chinese PLA General Hospital|Ultrasound Department of the Third Hospital Affiliated to Zhongshan University|Ultrasound Department, the Second Affiliated Hospital of Harbin Medical Univercity|Ultrasound Department, the Xiangya Third Hospital of Zhongnan University|Ultrasound Department, the First Affliction Hospital of Nanjing Medical University|Ultrasound Department, the First Affiliated Hospital of Soochow University|Ultrasound Department, First people's Hospital Affiliated to Medical School of Shanghai Jiaotong University|Ultrasound Department, Ruijin Hospital Affiliated to Medical School of Shanghai Jiaotong University|The department of ultrasound ,second affiliated hospital of xi'an jiaotong university|Department of Ultrasonography, Zhejiang Cancer Hospital|Department of Ultrasound Medicine, the First Hospital Affiliated to Medical School of Zhejiang University|Department of Endocrinology, Regina Apostolorum Hospital|Diagnostic Imaging, Regina Apostolorum Hospital",Procedure|Procedure,China|Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03377829
2215,NCT03379181,Hyperthyroidism,Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy,Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy,Hyperthyroidism,2017-12-07,2020-02-12,2020-02-12,19.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Drug,Switzerland,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03379181
2216,NCT03382158,Ciliary Body Medulloepithelioma|Cystic Nephroma|DICER1 Syndrome|Embryonal Rhabdomyosarcoma|Nasal Chondromesenchymal Hamartoma|Neuroblastoma|Nodular Hyperplasia of Thyroid|Pineoblastoma|Pituitary Cancer|Pleuropulmonary Blastoma|Renal Sarcoma|Sertoli-Leydig Cell Tumor|Wilms Tumor,"International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions",International PPB/DICER1 Registry,Ciliary Body Medulloepithelioma|Cystic Nephroma|DICER1 Syndrome|Embryonal Rhabdomyosarcoma|Nasal Chondromesenchymal Hamartoma|Neuroblastoma|Nodular Hyperplasia of Thyroid|Pineoblastoma|Pituitary Cancer|Pleuropulmonary Blastoma|Renal Sarcoma|Sertoli-Leydig Cell Tumor|Wilms Tumor,2017-10-11,2023-12-06,2026-12-06,3400.0,Cohort,,Other,Observational,Recruiting,,Children's Hospitals and Clinics of Minnesota,"Beijing Children's Hospital|Children's Hospitals and Clinics of Minnesota|Children's National Research Institute|Dana-Farber Cancer Institute|Emory University|ResourcePath, LLC|University of Cambridge|Washington University School of Medicine",Children's Minnesota,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03382158
2218,NCT03387943,Poorly Differentiated Thyroid Carcinoma,"A Prospective, Multicenter, Open Label Phase  Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma",PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma,Poorly Differentiated Thyroid Carcinoma,2017-12-11,2018-12-31,2019-12-31,30.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Zhejiang Cancer Hospital,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03387943
2219,NCT03392402,Thyroid Cancer|Thyroid Neoplasm|Thyroid Nodule,Prospective Validation of the Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Thyroid Cancer|Thyroid Neoplasm|Thyroid Nodule,2018-01-02,2020-03-31,2020-12-31,599.0,Cohort,,Prospective,Observational,Completed,,Maria Sklodowska-Curie National Research Institute of Oncology,Maria Sklodowska-Curie National Research Institute of Oncology,"Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology",,Poland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03392402
2221,NCT03393728,Hyperthyroidism,Short Term Effects of Propanolol on Heart Rate Variability of Hyperthyroidism,Heart Rate Variability and Hyperthyroidism: Evaluation of the Short-term Effects of Propanolol,Hyperthyroidism,2017-12-21,2008-12-30,2009-09-30,10.0,,Single Group Assignment,,Interventional,Completed,Phase 4,Yaounde Central Hospital,Yaounde Central Hospital,,Drug,,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03393728
2222,NCT03395925,Thyroid Nodule,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Thyroid Nodule,2017-12-17,2021-10-30,2022-01-30,40.0,,Single Group Assignment,,Interventional,Active not recruiting,Not Applicable,Olympus Surgical Technologies Europe,Olympus Surgical Technologies Europe,Johann-Wolfgang Goethe University,Device,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03395925
2224,NCT03397238,Thyroid Cancer,Myeloid Cell Reprogramming in the Context of Radioiodine Therapy in Patients With Non-Medullary Thyroid Carcinoma,Myeloid Cell Reprogramming in Thyroid Carcinoma,Thyroid Cancer,2017-12-18,2019-11-26,2021-01-05,41.0,Case-Control,,Prospective,Observational,Completed,,Radboud University Medical Center,Radboud University Medical Center,Radboudumc,,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03397238
2225,NCT03411187,Endoscopy|Papillary Thyroid Carcinoma|Thyroid Cancer|Thyroidectomy,Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy,Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy,Endoscopy|Papillary Thyroid Carcinoma|Thyroid Cancer|Thyroidectomy,2018-01-19,2018-06-30,2018-12-30,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Wen-xin ZHAO,Device|Device,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03411187
2227,NCT03416686,Differentiated Thyroid Cancer,Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy,Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy,Differentiated Thyroid Cancer,2017-12-07,2021-02-28,2021-02-28,18.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Hpital Saint Louis,Device,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03416686
2228,NCT03420963,Recurrent Cutaneous Melanoma|Recurrent Lip and Oral Cavity Carcinoma|Recurrent Malignant Endocrine Neoplasm|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Male Reproductive System Neoplasm|Recurrent Malignant Mesothelioma|Recurrent Malignant Neoplasm of Multiple Primary Sites|Recurrent Malignant Oral Neoplasm|Recurrent Malignant Pharyngeal Neoplasm|Recurrent Malignant Skin Neoplasm|Recurrent Malignant Soft Tissue Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Malignant Thyroid Gland Neoplasm|Recurrent Malignant Urinary System Neoplasm|Refractory Cutaneous Melanoma|Refractory Malignant Bone Neoplasm|Refractory Malignant Endocrine Neoplasm|Refractory Malignant Female Reproductive System Neoplasm|Refractory Malignant Male Reproductive System Neoplasm|Refractory Malignant Mesothelioma|Refractory Malignant Neoplasm of Multiple Primary Sites|Refractory Malignant Oral Neoplasm|Refractory Malignant Pharyngeal Neoplasm|Refractory Malignant Skin Neoplasm|Refractory Malignant Soft Tissue Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Malignant Thyroid Gland Neoplasm|Refractory Malignant Urinary System Neoplasm,Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults,"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors",Recurrent Cutaneous Melanoma|Recurrent Lip and Oral Cavity Carcinoma|Recurrent Malignant Endocrine Neoplasm|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Male Reproductive System Neoplasm|Recurrent Malignant Mesothelioma|Recurrent Malignant Neoplasm of Multiple Primary Sites|Recurrent Malignant Oral Neoplasm|Recurrent Malignant Pharyngeal Neoplasm|Recurrent Malignant Skin Neoplasm|Recurrent Malignant Soft Tissue Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Malignant Thyroid Gland Neoplasm|Recurrent Malignant Urinary System Neoplasm|Refractory Cutaneous Melanoma|Refractory Malignant Bone Neoplasm|Refractory Malignant Endocrine Neoplasm|Refractory Malignant Female Reproductive System Neoplasm|Refractory Malignant Male Reproductive System Neoplasm|Refractory Malignant Mesothelioma|Refractory Malignant Neoplasm of Multiple Primary Sites|Refractory Malignant Oral Neoplasm|Refractory Malignant Pharyngeal Neoplasm|Refractory Malignant Skin Neoplasm|Refractory Malignant Soft Tissue Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Malignant Thyroid Gland Neoplasm|Refractory Malignant Urinary System Neoplasm,2018-01-29,2022-12-01,2022-12-01,38.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Drug|Drug,United States,12.0,40.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03420963
2229,NCT03425747,Chronic Hypoparathyroidism,CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM,Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism,Chronic Hypoparathyroidism,2018-01-27,2020-04-01,2020-04-01,26.0,,Crossover Assignment,,Interventional,Completed,Phase 4,Campus Bio-Medico University,Campus Bio-Medico University,Campus Bio-Medico University,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03425747
2231,NCT03432299,Papillary Thyroid Microcarcinoma|Thyroid Cancer,Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy,Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid Cancer,2018-01-22,2023-07-31,2023-12-31,100.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Procedure,"Korea, Republic of",19.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03432299
2232,NCT03434067,Hyperthyroidism|Immunochromatographic|PTH|Thyroidectomy,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,Hyperthyroidism|Immunochromatographic|PTH|Thyroidectomy,2018-01-27,2018-06-30,2018-12-30,90.0,Cohort,,Prospective,Observational [Patient Registry],Unknown status,,Fujian Medical University,"Bo Wang,MD",Wen-xin ZHAO,,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03434067
2235,NCT03435952,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors,Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,2018-02-09,2024-10-01,2024-10-01,18.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,"BioMed Valley Discoveries, Inc|M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC",University of Texas MD Anderson Cancer Center,Drug|Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03435952
2236,NCT03437174,Hypoparathyroidism,Burden of Illness and Disease Associated Emergencies in Chronic Hypoparathyroidism,Burden of Illness in Hypoparathyroidism,Hypoparathyroidism,2018-02-10,2017-12-01,2018-01-01,205.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Wuerzburg,"Charite University, Berlin, Germany|Endocrine Practice, Oldenburg, Germany|Ludwig-Maximilians - University of Munich|Praxis Endokrinologie in Charlottenburg, Berlin|University Medical Center Rostock|University of Wuerzburg","Endokrinologie in Charlottenburg|Charite Berlin|Ludwig-Maximilians-Universitt|University Hospital Rostock|Dept. of Endocrinology and Diabetology, Dept. of Medicine I, University Hospital Wuerzburg",,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03437174
2238,NCT03440697,Aortic Valve Disease|Aortopathies|Arterial Tortuosity Syndrome|Ascending Aortic Aneurysm|Ascending Aortic Disease|Autosomal Recessive Cutis Laxa|Congenital Contractural Arachnodactyly|Descending Aortic Aneurysm|Descending Aortic Disease|Ehlers-Danlos Syndrome|Loeys-Dietz Syndrome|Marfan Syndrome|PHACE Syndrome|Shprintzen-Goldberg Syndrome|Thoracic Aortic Aneurysm|Thoracic Aortic Disease|Thoracic Aortic Dissection|Thoracic Aortic Rupture|Turner Syndrome,Pathogenetic Basis of Aortopathy and Aortic Valve Disease,Pathogenetic Basis of Aortopathy and Aortic Valve Disease,Aortic Valve Disease|Aortopathies|Arterial Tortuosity Syndrome|Ascending Aortic Aneurysm|Ascending Aortic Disease|Autosomal Recessive Cutis Laxa|Congenital Contractural Arachnodactyly|Descending Aortic Aneurysm|Descending Aortic Disease|Ehlers-Danlos Syndrome|Loeys-Dietz Syndrome|Marfan Syndrome|PHACE Syndrome|Shprintzen-Goldberg Syndrome|Thoracic Aortic Aneurysm|Thoracic Aortic Disease|Thoracic Aortic Dissection|Thoracic Aortic Rupture|Turner Syndrome,2017-10-06,2025-12-31,2028-12-31,3000.0,Cohort,,Prospective,Observational,Recruiting,,Indiana University,Indiana University,IU School of Medicine,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03440697
2240,NCT03444246,Hyperthyroidism,"A Parallel, Double-blind, Randomized Controlled Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt",A Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt,Hyperthyroidism,2018-02-06,2019-03-01,2019-06-01,60.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Xijing Hospital,Xijing Hospital,"Xijing Hospital, Fourth Military Medical university",Dietary Supplement|Dietary Supplement,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03444246
2241,NCT03447093,Microbiota,The Oral Microbiota in Autoimmune Thyroiditis is Distinctive And Predictive,The Oral Microbiota is Associated With Autoimmune Thyroiditis,Microbiota,2018-02-08,2019-12-31,2021-12-31,120.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03447093
2244,NCT03449108,Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types,"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,2018-02-22,2023-06-30,2024-06-30,95.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,"Iovance Biotherapeutics, Inc.|M.D. Anderson Cancer Center|National Cancer Institute (NCI)",M D Anderson Cancer Center,Biological|Biological|Biological|Drug|Drug|Biological|Biological|Other|Other,United States,16.0,70.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03449108
2246,NCT03454464,Central Compartment Neck Dissction|Thyroid Cancer|Thyroidectomy,"To Evaluate the Practicable, Thoroughness and Clinical Value of Bilateral Central Compartment Dissection While Preserve Contrary Thyroid Glands",Evaluation of Central Compartment Dissection Without Thyroidectomy,Central Compartment Neck Dissction|Thyroid Cancer|Thyroidectomy,2018-02-07,2018-12-31,2018-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Wen-xin ZHAO,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03454464
2247,NCT03454477,Endoscopy|Papillary Thyroid Carcinoma|Robotics|Thyroidectomy,"From the Endoscope to the Robot, the Initial Experience of Robotic Thyroidectomy is Summarized","Comparison Between Robotic, Endoscopic and Traditional Open Surgery in Thyroidectomy",Endoscopy|Papillary Thyroid Carcinoma|Robotics|Thyroidectomy,2018-02-07,2018-10-01,2018-10-01,90.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Wen-xin ZHAO,Procedure|Procedure|Device,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03454477
2249,NCT03461211,Thyroid Eye Disease,"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease",Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,2018-03-05,2020-06-08,2021-02-17,51.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science|Hamilton Eye Institute at University of Tennessee Health|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca Granda Ospedale Maggiore|University of Pisa, Department of Clinical and Experimental Medicine|Azienda Ospedaliero Universitaria Pisana",Biological,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03461211
2253,NCT03463889,Thyroid Gland Carcinoma,Gallium-68 Prostate Specific Membrane Antigen (68Ga-PSMA) PET for Imaging of Thyroid Cancer: A Feasibility Study,Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer,Thyroid Gland Carcinoma,2018-02-09,2020-09-30,2020-10-31,12.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,"University of California, San Francisco","University of California, San Francisco","University of California, San Francisco",Drug|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03463889
2254,NCT03464149,CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder|Kidney Replacement|Secondary Hyperparathyroidism,Intact Versus Biointact Assays for Longitudinal Assessment of Parathyroid Hormone - The Longitudinal PTH Study,The Longitudinal PTH-Study,CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder|Kidney Replacement|Secondary Hyperparathyroidism,2018-02-12,2018-12-05,2019-08-07,132.0,Cohort,,Prospective,Observational,Completed,,Medical University of Vienna,Medical University of Vienna,"Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria",Diagnostic Test,Austria,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03464149
2257,NCT03465176,Fatigue|Hypothyroidism,The Effect of Aroma on Fatigue Scores Among Women With Hypothyroidism,The Effect of Aroma on Fatigue Scores Among Women With Hypothyroidism,Fatigue|Hypothyroidism,2018-03-08,2018-03-30,2018-05-31,42.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Franklin Health Research,Franklin Health Research,Franklin Institute of Wellness,Other|Other,United States,18.0,55.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03465176
2258,NCT03469011,Papillary Thyroid Cancer,A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients,A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.,Papillary Thyroid Cancer,2018-03-12,2021-12-31,2021-12-31,18.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Alberta Cancer Foundation,Cross Cancer Institute,Drug,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03469011
2260,NCT03469310,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,126.0,,Parallel Assignment,,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03469310
2265,NCT03469544,Thyroid Cancer,Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer,Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer,Thyroid Cancer,2018-03-10,2019-12-29,2020-03-29,90.0,Case-Control,,Retrospective,Observational,Unknown status,,Assiut University,Assiut University,,Other,,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03469544
2266,NCT03470259,Lymph Node Metastases|Papillary Thyroid Cancer,Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and,Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging,Lymph Node Metastases|Papillary Thyroid Cancer,2018-02-21,2019-12-31,2019-12-31,19.0,,Parallel Assignment,,Interventional,Completed,Phase 1,University Medical Center Groningen,Erasmus Medical Center|University Medical Center Groningen,University Medical Center Groningen|Erasmus Medical Center,Drug|Device|Device,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03470259
2268,NCT03475953,"Biliary Tract Cancer|Colorectal Cancer Not MSI-H or MMR-deficient|Gastro-enteropancreatic Neuroendocrine Tumor|GIST|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Oesophageal or Gastric Carcinoma|Soft-tissue Sarcoma|Solid Tumor, Adult|Thyroid Cancer",A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,"Biliary Tract Cancer|Colorectal Cancer Not MSI-H or MMR-deficient|Gastro-enteropancreatic Neuroendocrine Tumor|GIST|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Oesophageal or Gastric Carcinoma|Soft-tissue Sarcoma|Solid Tumor, Adult|Thyroid Cancer",2018-02-20,2020-12-31,2022-12-31,482.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Institut Bergoni,"Bayer|Institut Bergoni|Merck KGaA, Darmstadt, Germany",Institut Bergoni|Centre Hospitalier Rgional Universitaire - CHU Morvan|Centre Lon Brard|Institut de Cancrologie de Montpellier|Institut Curie|IUCT Oncople - Institut Claudius Regaud|Institut Gustave Roussy,Drug|Drug|Drug|Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03475953
2269,NCT03479801,Thyroid Neoplasms,"Comparative Study of Surgical Results in Endoscopic Thyroidectomy Via Oral Approach, Via Breast Approach and Conventional Open Thyroidectomy","Comparative Study in Oral, Breast Approach and Open Thyroidectomy",Thyroid Neoplasms,2018-03-15,2018-12-31,2018-12-31,150.0,Case-Control,,Prospective,Observational,Unknown status,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",SAHZhejiangU,Procedure,China,15.0,55.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03479801
2270,NCT03483337,Head and Neck Cancer|Thyroid Cancer,Quantitative Imaging Tools to Derive DW-MRI Oncological Biomarkers,New MRI Biomarkers in Head and Neck Cancers,Head and Neck Cancer|Thyroid Cancer,2018-03-19,2024-03-31,2024-03-31,200.0,Cohort,,Prospective,Observational,Recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03483337
2271,NCT03484416,Thyroid Neoplasm,Routine Low-dose Calcium and Vitamin D Supplementation for Preventing Symptomatic Postthyroidectomy Hypocalcemia,Routine Calcium for Preventing Hypocalcemia,Thyroid Neoplasm,2018-03-25,2017-05-30,2017-05-30,138.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Ewha Womans University Mokdong Hospital,Ewha Womans University Mokdong Hospital,Ewha Womans University Medical Center,Drug,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03484416
2272,NCT03484884,Thyroid Cancer,A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer,A Study of Optical Imaging With Light From Radiotracers in Cancer Patients,Thyroid Cancer,2018-03-20,2023-03-31,2023-03-31,128.0,Cohort,,Prospective,Observational,Recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan - Kettering Cancer Center,Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03484884
2273,NCT03488134,Thyroid Cancer,"A Prospective Study of Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3","Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3",Thyroid Cancer,2018-03-28,2022-01-31,2023-07-31,74.0,Cohort,,Prospective,Observational [Patient Registry],Active not recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03488134
2274,NCT03496363,CHD|Hypothyroidism,Evaluation of Thyroid Function in Children With Congenital Heart Disease,Hypothyroidism With Congenital Heart Disease (CHD),CHD|Hypothyroidism,2018-03-10,2019-05-01,2020-05-01,50.0,Case-Control,,Prospective,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test,,0.0,3.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT03496363
2275,NCT03498183,Malignancy of Thyroid Nodules,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (15 mm) Classified Bethesda III or IV on Cytology,Malignancy of Thyroid Nodules,2018-03-29,2021-07-01,2021-07-01,321.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2/Phase 3,Nantes University Hospital,Nantes University Hospital,Centre Hospitalier et Universitaire (chu)|CHU|CHU|CHU|Hospices Civils|CHU|Assistance publique des Hpitaux de Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03498183
2277,NCT03498417,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,135.0,Cohort,,Cross-Sectional,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03498417
2284,NCT03500666,Endoscopic Surgery|Robot Surgery|Thyroid Carcinoma,A Comparative Study of Robot Assisted BABA Approach and Chest Breast Approach for Lateral Neck Dissection,Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection,Endoscopic Surgery|Robot Surgery|Thyroid Carcinoma,2018-04-02,2018-12-31,2018-12-31,10.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital|Wen-xin ZHAO,Device|Device,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03500666
2285,NCT03506048,Differentiated Thyroid Gland Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma,A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer,Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer,Differentiated Thyroid Gland Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma,2018-04-13,2021-06-24,2021-06-24,3.0,,Single Group Assignment,,Interventional,Terminated,Phase 2,Emory University,Eisai Inc.|Emory University,Emory University Hospital/Winship Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03506048
2288,NCT03510143,Thoracic Duct Leak|Thyroid Cancer|Thyroid Gland Carcinoma,"Effect of Polyglycolic Acid Mesh (Neoveil) for Reducing Drain Amount and Chyle Leakage After Thyroid Cancer Surgery: A Prospective, Randomized Controlled Study",Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery,Thoracic Duct Leak|Thyroid Cancer|Thyroid Gland Carcinoma,2018-03-20,2020-05-01,2020-12-31,330.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Green Cross Corporation|Seoul National University Hospital,Jin Wook Yi,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03510143
2289,NCT03514251,Complication of Surgical Procedure|Hypoparathyroidism|Marker; Structural|Parathyroid Function Low Adverse Event|Thyroid Cancer,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Complication of Surgical Procedure|Hypoparathyroidism|Marker; Structural|Parathyroid Function Low Adverse Event|Thyroid Cancer,2018-04-20,2018-09-30,2018-09-30,400.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Fujian Medical University Union Hospital,Procedure,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03514251
2292,NCT03515863,Thyroid Associated Ophthalmopathy,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Natural History and Risk Factors of TAO,Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,400.0,Case-Control,,Prospective,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03515863
2296,NCT03516747,Hypercalcemia|Parathyroid Adenoma,Ultrasound Guided Fine Needle Aspiration of Parathyroid Gland as a Pre Operative Localization Tool to Identify Pathological Parathyroid,Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland,Hypercalcemia|Parathyroid Adenoma,2018-04-03,2020-04-09,2020-08-09,0.0,,Single Group Assignment,,Interventional,Withdrawn,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",Haemek Medical Center,Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Israel,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03516747
2298,NCT03516773,Hypoparathyroidism,An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA in Patients With Hypoparathyroidism,Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism,Hypoparathyroidism,2018-04-23,2018-12-05,2019-02-24,20.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Entera Bio Ltd.,Entera Bio Ltd.,Clinical Research Center Hadassah Ein Kerem Medical Center,Drug|Drug,Israel,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03516773
2300,NCT03517267,Thyroid Nodule,Validation of the New Thyroid Imaging Reporting and Data System (TIRADS) From 2017 Risk Assessment of Thyroid Nodules in Comparison to the American Thyroid Association (ATA) Guidelines From 2015,Thyroid Imaging Reporting and Data System (TIRADS ) Versus Thyroid Association (ATA) Guidelines,Thyroid Nodule,2018-03-28,2019-06-30,2019-06-30,1000.0,Case-Only,,Prospective,Observational [Patient Registry],Unknown status,,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Medical Center,Diagnostic Test,Israel,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03517267
2302,NCT03517579,Graves Disease|Thyroid Cancer,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Personalized Treatment in Thyroid Disorders,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,10.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03517579
2306,NCT03530033,Accessory Nerve Injuries|EMG: Repetitive Nerve Stimulation Abnormality|Neck Cancer|Recurrent Laryngeal Nerve Injuries|Thyroid Cancer,"Lidocaine Reduces Muscle Tremor Caused by Electric Energy Devices, Which is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring During Endoscopic Thyroid Lateral Neck Dissection",Lidocaine Reduces Muscle Tremor is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring,Accessory Nerve Injuries|EMG: Repetitive Nerve Stimulation Abnormality|Neck Cancer|Recurrent Laryngeal Nerve Injuries|Thyroid Cancer,2018-05-08,2018-10-31,2018-10-31,40.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Fujian Medical University Union Hospital,Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03530033
2307,NCT03530462,Autoimmune Encephalitis|Cognitive Impairment,The Usage of Neuropsychological Tests and Multi-mode Magnetic Resonance Imaging in Patients With Autoimmune Encephalitis for Cognitive Neural Mechanism,To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI,Autoimmune Encephalitis|Cognitive Impairment,2018-03-18,2018-02-28,2018-02-28,22.0,Case-Control,,Retrospective,Observational,Completed,,First Affiliated Hospital of Zhejiang University,First Affiliated Hospital of Zhejiang University,"The First Affiliated Hospital, Zhejiang University",Drug|Drug|Drug|Drug,China,16.0,60.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03530462
2310,NCT03535090,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII,Coagulation After Intravenous Methylprednisolone Administration,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,2018-04-29,2014-12-31,2014-12-31,26.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Piotr Miskiewicz,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03535090
2314,NCT03535974,Benign Thyroid Nodule,Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules,Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules,Benign Thyroid Nodule,2018-05-02,2018-12-20,2018-12-21,38.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,Fundatia Bio-Forum,Fundatia Bio-Forum,Fundatia Bio-Forum,Dietary Supplement|Dietary Supplement,Romania,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03535974
2319,NCT03543891,Microbiota,Correlation Study of Thyroid Cancer and Intestinal Microbiota,Intestinal Microbiota and Thyroid Cancer,Microbiota,2018-05-21,2018-02-28,2018-04-30,100.0,Case-Control,,Cross-Sectional,Observational,Completed,,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Other,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03543891
2320,NCT03547648,Thyroid Neoplasms|Thyroid Nodule,Comparison of the Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding Points in Thyroidectomies,Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding in Thryroidectomies,Thyroid Neoplasms|Thyroid Nodule,2018-05-23,2018-11-16,2018-11-16,132.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Istanbul University,Istanbul University,Turkey,Procedure,Turkey,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03547648
2322,NCT03555487,Parathyroid Diseases,Clinical Value of 18F -Fluorocholine (18F-FCH) PET in Localizing Parathyroid Lesions: Comparison With 99mTc-sestamibi (MIBI) Scan.,Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions: Comparison With MIBI Scan.,Parathyroid Diseases,2018-05-20,2018-06-30,2018-10-01,103.0,,Single Group Assignment,,Interventional,Completed,Phase 3,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan Univeristy Hospital,Drug,Taiwan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03555487
2323,NCT03565536,"Thyroid Cancer, Anaplastic",Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer,Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer,"Thyroid Cancer, Anaplastic",2018-05-26,2019-04-30,2019-10-30,10.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Drug|Procedure|Radiation,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03565536
2325,NCT03566537,Benign Thyroid Nodule|Quality of Life,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Benign Thyroid Nodule|Quality of Life,2018-06-11,2020-06-11,2021-01-11,73.0,Case-Control,,Prospective,Observational [Patient Registry],Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,Ahepa Hospital,Procedure,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03566537
2327,NCT03569787,Hyperprolactinemia|Subclinical hypothyrodism|Subfertility,A Retrospective Cohort Study of Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire (UHCW),Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire,Hyperprolactinemia|Subclinical hypothyrodism|Subfertility,2018-04-30,2017-12-01,2017-12-01,107.0,Cohort,,Retrospective,Observational,Completed,,University Hospitals Coventry and Warwickshire NHS Trust,University Hospitals Coventry and Warwickshire NHS Trust,Megan Crowe,Diagnostic Test,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03569787
2328,NCT03570021,Thyroid Cancer,ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer,ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer,Thyroid Cancer,2018-06-15,2026-06-30,2026-06-30,1000.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Procedure|Procedure,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03570021
2329,NCT03573960,Thyroid Neoplasms,"Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer",A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,2018-06-19,2022-12-31,2022-12-31,50.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 4,Eisai Inc.,Eisai Pharmaceuticals India Pvt. Ltd,"All India Institute of Medical Sciences|Indraprastha Apollo Hospital|Shetty's Hospital|Deenanath Mangeshkar Hospital|All India Institute of Medical Sciences|S. P. Medical College & A. G. Hospitals|Tata Memorial Hospital|BL Kapoor Hospital, New Delhi|Indrayani Hospital, Alandi|City Cancer Centre",Drug,India,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03573960
2330,NCT03574051,Microbiota,Distinct Shifts in the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism,the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism,Microbiota,2018-06-19,2020-05-01,2022-05-01,30.0,,Single Group Assignment,,Interventional,Unknown status,Early Phase 1,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Drug,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03574051
2331,NCT03577951,Endoscopy|Thyroid Cancer,Comparing the Two Ways of Creating a High Position and Low Position Operating Space in Endoscopic Thyroid Surgery,Comparing the Establishment of Operation Space Between High Position and Low Position in Endoscopic Thyroid Surgery,Endoscopy|Thyroid Cancer,2018-06-24,2018-08-31,2018-10-31,48.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03577951
2332,NCT03588884,CKD Stage 3|CKD Stage 4|Secondary Hyperparathyroidism Due to Renal Causes|Vitamin D Deficiency,"An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency","Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency",CKD Stage 3|CKD Stage 4|Secondary Hyperparathyroidism Due to Renal Causes|Vitamin D Deficiency,2018-06-28,2020-04-24,2020-04-24,69.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"OPKO Health, Inc.","OPKO Health, Inc.","National Institute of Clinical Research, Inc.|Research by Design, LLC|Spaulding Clinical Research",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03588884
2335,NCT03590080,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy,Impact of Intravenous Methylprednisolone Treatment on Blood Pressure,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,2018-06-30,2015-12-30,2015-12-30,32.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03590080
2339,NCT03602261,Chronic Kidney Diseases|Secondary Hyperparathyroidism Due to Renal Causes|Stage 5 Chronic Kidney Disease|Vitamin D Deficiency,"A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.","Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI",Chronic Kidney Diseases|Secondary Hyperparathyroidism Due to Renal Causes|Stage 5 Chronic Kidney Disease|Vitamin D Deficiency,2018-07-13,2023-03-31,2023-03-31,256.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,"OPKO Health, Inc.","OPKO Health, Inc.","AKDHC Medical Research Services|AKDHC Medical Research Services|AKDHC Medical Research Services|AKDHC Medical Research Services|WCCT Global, Inc.|Hacienda Dialysis Center|California Institute of Renal Research CKD/Dialysis & Transplant Division|Long Beach Quest Dialysis Center|Ontario Dialysis Center|North America Research Institute, Inc.|Laurel Canyon Dialysis, LLC|University of Colorado Denver Anschutz Medical Campus|Research by Design, LLC|Northshore University Health|Renal and Transplant Associates of New England|Southwest MS Nephrology|Southwest Houston Research LTD|Kidney & Hypertension Specialists",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03602261
2342,NCT03602495,Differentiated Thyroid Cancer,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Donafenib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer",A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2018-07-18,2021-02-28,2021-07-15,204.0,,Parallel Assignment,,Interventional,Terminated,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03602495
2343,NCT03605472,Primary Hyperparathyroidism,Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism,Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2018-07-20,2019-10-05,2020-03-05,100.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,CHU de Reims,CHU de Reims,Damien JOLLY,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03605472
2346,NCT03606824,ASCVD|Dyslipidemia|Statin|Subclinical hypothyrodism,Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in Patients With Atherosclerotic Cardiovascular Diseases (ThyroHeart-Lipid Study),Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study),ASCVD|Dyslipidemia|Statin|Subclinical hypothyrodism,2018-07-11,2020-02-28,2020-05-31,248.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,China National Center for Cardiovascular Diseases,"Beijing Chao Yang Hospital|Beijing Friendship Hospital|Chinese Academy of Medical Sciences, Fuwai Hospital|Peking University Third Hospital|Shaochun.Li|Xuanwu Hospital, Beijing","Fuwai Hospital, China National Center for Cardiovascular Diseases",Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03606824
2347,NCT03612908,Hyperthyroidism|Hypothyroidism|Pregnancy Related,TSHX1 Splice Variant Expression and D2 Thr92Ala Polymorphism Analysis in Pregnant Women With Thyroid Diseases,TSHX1 and D2 THR92ALA in Pregnancy,Hyperthyroidism|Hypothyroidism|Pregnancy Related,2018-07-20,2017-12-15,2018-06-30,96.0,Case-Control,,Prospective,Observational,Completed,,Materno-Perinatal Hospital of the State of Mexico,Ciprs Grupo Mdico CGM SC|Materno-Perinatal Hospital of the State of Mexico|Universidad Autonoma del Estado de Mexico,"Materno-Perinatal Hospital ""Mnica Pretelini""",,Mexico,18.0,44.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03612908
2349,NCT03614988,Aging|Interaction Drug Food|Primary Hypothyroidism,Comparative Evaluation of Evening Versus Morning Levothyroxine Administration in Treatment of Hypothyroidism in Elderly,Evaluation of Evening Versus Morning Levothyroxine Intake in Elderly,Aging|Interaction Drug Food|Primary Hypothyroidism,2018-07-30,2019-11-30,2020-03-31,208.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre,Other|Other,Brazil,60.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03614988
2350,NCT03615456,Goiter,Sutureless Thyroidectomy Versus Conventional Thyroidectomy: Prospective Randomized Clinical Trial,Sutureless Versus Conventional Thyroidectomy,Goiter,2018-07-30,2018-02-28,2018-05-12,42.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Mansoura University,Mansoura University,Mansoura university hospital,Procedure|Procedure,Egypt,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03615456
2351,NCT03623516,Papillary Thyroid Cancer,Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014,Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014,Papillary Thyroid Cancer,2018-07-19,2014-12-01,2014-12-01,2008.0,Cohort,,Retrospective,Observational,Completed,,CHU de Reims,CHU de Reims,Damien JOLLY,,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03623516
2353,NCT03624751,Thyroid Cancer,Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment,Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment,Thyroid Cancer,2018-05-24,2028-06-30,2030-06-30,300.0,Cohort,,Prospective,Observational,Recruiting,,Taichung Veterans General Hospital,Taichung Veterans General Hospital,Division of Endocrinology and Metabolism in Taichung Veterans General Hospital,Radiation,Taiwan,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03624751
2354,NCT03626246,Chronic Kidney Disease|Chronic Kidney Disease Mineral and Bone Disorder|End Stage Kidney Disease|Renal Osteodystrophy|Secondary Hyperparathyroidism,Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease,Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease,Chronic Kidney Disease|Chronic Kidney Disease Mineral and Bone Disorder|End Stage Kidney Disease|Renal Osteodystrophy|Secondary Hyperparathyroidism,2018-08-08,2020-02-28,2020-02-28,50.0,Cohort,,Cross-Sectional,Observational,Completed,,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia/CUMC,Other,United States,40.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03626246
2357,NCT03626948,Secondary Hyperparathyroidism,SK-1403 Long-term Treatment Study - Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis -,SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis,Secondary Hyperparathyroidism,2018-08-08,2020-02-04,2020-02-05,157.0,,Single Group Assignment,,Interventional,Completed,Phase 3,"Sanwa Kagaku Kenkyusho Co., Ltd.","Sanwa Kagaku Kenkyusho Co., Ltd.",Investigational site (there may be other sites in this country),Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03626948
2360,NCT03627611,Biomarkers|Endocrine System Diseases|Hypothyroidism,"A Randomized Crossover Study, Examining Differential Effects of Levothyroxine and Liothyronine",Identification of Non-responders to Levothyroxine Therapy,Biomarkers|Endocrine System Diseases|Hypothyroidism,2018-05-25,2020-06-22,2020-06-22,69.0,,Crossover Assignment,,Interventional,Completed,Phase 2,Oslo University Hospital,Hormonlaboratoriet|Oslo University Hospital|Spesialistsenteret Pilestredet Park,Oslo University Hospital,Drug|Drug,Norway,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03627611
2361,NCT03630120,"Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Medullary",Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer,"Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Medullary",2018-08-10,2019-11-14,2019-12-05,6.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03630120
2364,NCT03631771,Hypothyroidism,"A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.",Pediatric Risk of Hypothyroidism With Iodinated Contrast Media,Hypothyroidism,2018-08-13,2024-08-31,2025-02-28,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 4,GE Healthcare,Bayer|GE Healthcare|Guerbet/Liebel-Flarsheim,,Drug|Drug|Drug|Drug,,0.0,3.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT03631771
2365,NCT03633708,Chronic Kidney Disease|Secondary Hyperparathyroidism,"Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease|Secondary Hyperparathyroidism,2018-08-14,2023-01-31,2023-01-31,56.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Amgen,Amgen,Childrens Hospital of Los Angeles|Childrens Hospital Colorado|Childrens Mercy Hospital|Mount Sinai Kidney Center - B1 Renal Treatment|Cincinnati Childrens Hospital Medical Center|Cleveland Clinic|The Childrens Hospital at Oklahoma University Medical Center|Childrens Hospital of Philadelphia|Childrens Medical Center Dallas|Primary Childrens Hospital Outpatient Services|Hospital Italiano|Fresenius Escobar|Centro Infantil Del Rinon|Fortis Flt Lt Rajan Dhall Hospital|All India Institute of Medical Sciences|Sir Ganga Ram Hospital|Manipal Hospital|KLES Dr Prabhakar Kore Hospital and Medical Research Centre|NRS Medical College and Hospital|Seoul National University Hospital|Pusan National University Yangsan Hospital|Hospital Raja Perempuan Zainab II|Hospital TuanKu Jaafar|Hospital Wanita Dan Kanak-Kanak Kuala Lumpur|SBHI Pediatrics city clinical hospital of Saint Vladimir|Municipal Children Hospital 1|State Budgetary Healthcare Institution Samara Regional Clinical Hospital na V D Seredavin|National University Hospital|Kaohsiung Veterans General Hospital|National Cheng Kung University Hospital|National Taiwan University Hospital|Linkou Chang Gung Memorial Hospital|Hacettepe Universitesi Tip Fakultesi Ihsan Dogramaci Cocuk Hastanesi|Baskent Universitesi Ankara Hastanesi|Gazi Universitesi Tip Fakultesi|Istanbul Universitesi Cerrahpasa Tip Fakultesi|Ege Universitesi Tip Fakultesi|Erciyes Universitesi Tip Fakultesi Mustafa Eraslan ve Fevzi Mercan Cocuk Hastanesi|National Childrens Specializated Hospital OKHMATDIT,Drug,"Argentina|India|Korea, Republic of|Malaysia|Russian Federation|Singapore|Taiwan|Turkey|Ukraine|United States",0.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03633708
2368,NCT03636945,Medullary Thyroid Carcinoma,Evaluation of the Clinical Performance of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma: Multicenter Prospective Study,Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma,Medullary Thyroid Carcinoma,2018-08-16,2021-03-31,2021-09-30,62.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Des Hopitaux de Marseille,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03636945
2369,NCT03639662,Follicular Thyroid Cancer,Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer Compared With Usual Initial Management: Multicenter Randomized Prospective Study,Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer,Follicular Thyroid Cancer,2018-08-17,2022-03-31,2022-11-30,232.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Des Hopitaux de Marseille,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03639662
2371,NCT03640247,Parathyroid Diseases|Thyroid Disease,Are Narcotic Pain Medications Necessary Following Thyroidectomy and Parathyroidectomy,Pain Medications Following Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Disease,2018-07-24,2019-12-01,2019-12-01,126.0,,Parallel Assignment,,Interventional,Completed,Phase 1,MetroHealth Medical Center,MetroHealth Medical Center,MetroHealth Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03640247
2372,NCT03641638,Postpartum Thyroiditis,Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregancy,Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregnancy,Postpartum Thyroiditis,2018-07-08,2020-10-31,2020-12-31,400.0,Case-Control,,Prospective,Observational,Unknown status,,China National Nuclear Corporation 416 Hospital,China National Nuclear Corporation 416 Hospital,China National Nuclear corporation 416 Hospital,,China,18.0,35.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03641638
2375,NCT03643055,Medullary Thyroid Cancer,Diagnostic Value of 18F-Fluorocholine PET/CT for the Detection of Medullary Thyroid Cancer,18F-Fluorocholine PET/CT in Medullary Thyroid Cancer,Medullary Thyroid Cancer,2018-08-20,2021-03-03,2024-09-03,80.0,Case-Only,,Prospective,Observational,Active not recruiting,,University Medical Centre Ljubljana,Institute of Oncology Ljubljana|University Medical Centre Ljubljana,"Department for nuclear medicine, University medical centre Ljubljana",Diagnostic Test,Slovenia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03643055
2376,NCT03643081,Mild Primary Hyperparathyroidism,"Evaluation of the Interest of the Medical Device Called ""Fluobeam"" in the Localization, Visualization of the Parathyroid Glands for Patients With Mild Primary Hyperparathyroidism. A Randomized Controled Prospective Open -Labeled Monocentric Study.","Evaluation of the Interest of the Medical Device Called ""Fluobeam"" in the Localization, Visualization of the Parathyroid Glands for Patients With Mild Primary Hyperparathyroidism",Mild Primary Hyperparathyroidism,2018-08-21,2024-06-30,2024-06-30,132.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Nantes University Hospital,Nantes University Hospital,CHU de Nantes,Device,France,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03643081
2379,NCT03646383,Benign Thyroid Nodules,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules by Percutaneous Radiological Approach,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules,Benign Thyroid Nodules,2018-03-25,2021-12-31,2021-12-31,40.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,"University Hospital, Toulouse","University Hospital, Toulouse","CHU Toulouse, Hpital Larrey",Procedure,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03646383
2381,NCT03647358,Metastatic Thyroid Carcinoma|Thyroid Carcinoma,Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma,Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma,Metastatic Thyroid Carcinoma|Thyroid Carcinoma,2018-08-22,2022-08-31,2022-08-31,100.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|Weill Cornell Medical Center,Device|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03647358
2382,NCT03647657,"Thyroid Cancer, Medullary",177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B),177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer,"Thyroid Cancer, Medullary",2018-08-20,2021-12-14,2021-12-14,8.0,,Crossover Assignment,,Interventional,Completed,Early Phase 1,"University Hospital, Basel, Switzerland","Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland|Krebsforschung Schweiz, Bern, Switzerland|University Hospital, Basel, Switzerland|University Hospital Freiburg|University Hospital, Zrich","University Hospital Basel, Clinic for radiology and nuclear medicine",Drug|Drug,Switzerland,18.0,64.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03647657
2383,NCT03657654,Thyroid Cancer|Thyroid Nodule,Voice Outcomes Following Thyroidectomy Compared to Surgeries That Do Not Involve Risk to the Laryngeal Nerves,Voice Outcomes Following Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2018-08-29,2023-12-15,2023-12-15,45.0,Cohort,,Prospective,Observational,Recruiting,,University of Virginia,University of Virginia,University of Virginia,Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03657654
2385,NCT03660800,Secondary Hyperparathyroidism|Vitamin D Insufficiency,"An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101 (Calcifediol) Extended-release Capsules in Japanese and Non-Japanese Healthy Subjects",Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects,Secondary Hyperparathyroidism|Vitamin D Insufficiency,2018-08-23,2018-10-24,2019-01-22,67.0,,Parallel Assignment,,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO Health, Inc.","WCCT Global, Inc.",Drug,United States,18.0,55.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03660800
2388,NCT03667157,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy,Liver Function After Intravenous Methylprednisolone Administration,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",2018-09-08,2016-10-30,2016-10-30,68.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Medical University of Warsaw,Medical University of Warsaw,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03667157
2392,NCT03669432,Radiation Toxicity|Thyroid Cancer Stage IV,Phase II Randomized Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers.,To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.,Radiation Toxicity|Thyroid Cancer Stage IV,2018-05-04,2026-07-31,2026-07-31,72.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Tata Memorial Hospital,Department of Atomic Energy|Tata Memorial Hospital,Gouri Pantvaidya,Radiation|Procedure,India,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03669432
2393,NCT03676348,Quality of Life|Thyroid Cancer|Thyroid Nodule,"Health Related Quality of Life in Thyroid Cancer Patients, and in Patients With Thyroid Nodules Suspicious of Cancer",HRQOL in Thyroid Cancer and Thyroid Tumours,Quality of Life|Thyroid Cancer|Thyroid Nodule,2018-09-17,2023-04-30,2028-04-30,200.0,Cohort,,Prospective,Observational,Recruiting,,Oslo University Hospital,Oslo University Hospital,"ENT department, Oslo University Hospital",,Norway,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03676348
2395,NCT03676647,Thyroid Gland Nodule,Retrospective-Prospective Collection of Thyroid Specimens After FNA,Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules,Thyroid Gland Nodule,2018-09-17,2023-12-31,2023-12-31,600.0,Cohort,,Other,Observational,Recruiting,,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Other,United States,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03676647
2397,NCT03680222,Recurrent Laryngeal Nerve Injuries|Thyroid Cancer,Effect of Reversed Tracking Method of Stimulating Cricothyroid Muscles on the Identification and Protection of EBSLN in Thyroid Surgery,Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery,Recurrent Laryngeal Nerve Injuries|Thyroid Cancer,2018-09-09,2019-09-30,2020-09-30,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Procedure,China,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03680222
2398,NCT03690388,Differentiated Thyroid Cancer,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy,Differentiated Thyroid Cancer,2018-09-26,2020-08-19,2022-12-31,258.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Exelixis,Exelixis,Exelixis Clinical Site #2|Exelixis Clinical Site #98|Exelixis Clinical Site #69|Exelixis Clinical Site #10|Exelixis Clinical Site #3|Exelixis Clinical Site #9|Exelixis Clinical Site #21|Exelixis Clinical Site #4|Exelixis Clinical Site #94|Exelixis Clinical Site #93|Exelixis Clinical Site #6|Exelixis Clinical Site #164|Exelixis Clinical Site #54|Exelixis Clinical Site #153|Exelixis Clinical Site #80|Exelixis Clinical Site #78|Exelixis Clinical Site #22|Exelixis Clinical Site #63|Exelixis Clinical Site #42|Exelixis Clinical Site #11|Exelixis Clinical Site #118|Exelixis Clinical Site #76|Exelixis Clinical Site #19|Exelixis Clinical Site #7|Exelixis Clinical Site #5|Exelixis Clinical Site #1|Exelixis Clinical Site #75|Exelixis Clinical Site #134|Exelixis Clinical Site #68|Exelixis Clinical Site #8|Exelixis Clinical Site #113|Exelixis Clinical Site #96|Exelixis Clinical Site #97|Exelixis Clinical Site #129|Exelixis Clinical Site #17|Exelixis Clinical Site #25|Exelixis Clinical Site #86|Exelixis Clinical Site #24|Exelixis Clinical Site #12|Exelixis Clinical Site #62|Exelixis Clinical Site #119|Exelixis Clinical Site #90|Exelixis Clinical Site #31|Exelixis Clinical Site #26|Exelixis Clinical Site #74|Exelixis Clinical Site #100|Exelixis Clinical Site #27|Exelixis Clinical Site #35|Exelixis Clinical Site #39|Exelixis Clinical Site #140|Exelixis Clinical Site #38|Exelixis Clinical Site #40|Exelixis Clinical Site #116|Exelixis Clinical Site #92|Exelixis Clinical Site #47|Exelixis Clinical Site #20|Exelixis Clinical Site #18|Exelixis Clinical Site #107|Exelixis Clinical Site #83|Exelixis Clinical Site #145|Exelixis Clinical Site #137|Exelixis Clinical Site #138|Exelixis Clinical Site #105|Exelixis Clinical Site #104|Exelixis Clinical Site #32|Exelixis Clinical Site #44|Exelixis Clinical Site #67|Exelixis Clinical Site #45|Exelixis Clinical Site #72|Exelixis Clinical Site #102|Exelixis Clinical Site #91|Exelixis Clinical Site #82|Exelixis Clinical Site #152|Exelixis Clinical Site #95|Exelixis Clinical Site #121|Exelixis Clinical Site #156|Exelixis Clinical Site #125|Exelixis Clinical Site #163|Exelixis Clinical Site #124|Exelixis Clinical Site #151|Exelixis Clinical Site #155|Exelixis Clinical Site #131|Exelixis Clinical Site #154|Exelixis Clinical Site #160|Exelixis Clinical Site #159|Exelixis Clinical Site #139|Exelixis Clinical Site #28|Exelixis Clinical Site #46|Exelixis Clinical Site #37|Exelixis Clinical Site #43|Exelixis Clinical Site #41|Exelixis Clinical Site #58|Exelixis Clinical Site #109|Exelixis Clinical Site #135|Exelixis Clinical Site #132|Exelixis Clinical Site #144|Exelixis Clinical Site #143|Exelixis Clinical Site #29|Exelixis Clinical Site #120|Exelixis Clinical Site #103|Exelixis Clinical Site #110|Exelixis Clinical Site #115|Exelixis Clinical Site #108|Exelixis Clinical Site #56|Exelixis Clinical Site #123|Exelixis Clinical Site #87|Exelixis Clinical Site #127|Exelixis Clinical Site #111|Exelixis Clinical Site #70|Exelixis Clinical Site #79|Exelixis Clinical Site #36|Exelixis Clinical Site #34|Exelixis Clinical Site #158|Exelixis Clinical Site #133|Exelixis Clinical Site #147|Exelixis Clinical Site #148|Exelixis Clinical Site #161|Exelixis Clinical Site #128|Exelixis Clinical Site #117|Exelixis Clinical Site #15|Exelixis Clinical Site #61|Exelixis Clinical Site #59|Exelixis Clinical Site #149|Exelixis Clinical Site #150|Exelixis Clinical Site #142|Exelixis Clinical Site #146|Exelixis Clinical Site #48|Exelixis Clinical Site #55|Exelixis Clinical Site #157|Exelixis Clinical Site #49|Exelixis Clinical Site #53|Exelixis Clinical Site #84|Exelixis Clinical Site #85|Exelixis Clinical Site #106|Exelixis Clinical Site #89|Exelixis Clinical Site #52|Exelixis Clinical Site #66|Exelixis Clinical Site #14|Exelixis Clinical Site #99|Exelixis Clinical Site #114|Exelixis Clinical Site #30|Exelixis Clinical Site #13|Exelixis Clinical Site #16|Exelixis Clinical Site #33|Exelixis Clinical Site #73|Exelixis Clinical Site #23|Exelixis Clinical Site #81|Exelixis Clinical Site #136|Exelixis Clinical Site #112|Exelixis Clinical Site #77|Exelixis Clinical Site #101|Exelixis Clinical Site #126|Exelixis Clinical Site #122|Exelixis Clinical Site #141|Exelixis Clinical Site #130|Exelixis Clinical Site #88|Exelixis Clinical Site #71|Exelixis Clinical Site #162|Exelixis Clinical Site #51|Exelixis Clinical Site #64|Exelixis Clinical Site #50|Exelixis Clinical Site #60|Exelixis Clinical Site #65|Exelixis Clinical Site #57,Drug|Drug,"Argentina|Australia|Austria|Belgium|Brazil|Canada|Croatia|Czechia|France|Germany|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|United Kingdom|United States",16.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03690388
2399,NCT03699098,Head and Neck Cancer,The Incidence and Risk Factors of Radiotherapy Induced Hypothyroidism in Head and Neck Cancer,The Incidence and Risk Factors of Radiotherapy Induced Hypothyroidism in Head and Neck Cancer With Long Term Follow up,Head and Neck Cancer,2018-10-02,2018-06-01,2018-06-05,101.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Cairo University,Cairo University,"Department of clinical oncology and nuclear medicine, Cairo university",Diagnostic Test,Egypt,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03699098
2400,NCT03700762,Thyroid Nodule,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Thyroid Nodule,2018-07-07,2019-10-01,2020-10-01,300.0,Case-Only,,Prospective,Observational,Unknown status,,First People's Hospital of Hangzhou,First People's Hospital of Hangzhou,The first people's hospital of Hangzhou,Diagnostic Test,China,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03700762
2402,NCT03708627,Graves Ophthalmopathy,The Role of Bimatoprost in Graves' Periorbitopathy,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,2018-10-13,2024-07-01,2024-07-01,3.0,,Parallel Assignment,,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03708627
2406,NCT03712683,Pregnancy Loss|Sub Clinical Hypothyroidism,Prevalence of Subclinical Hypothyroidism in Women With Unexplained Infertility and the Effect of Thyroxin on Pregnancy Rate,Thyroxin in Subclinical Hypothyroidism,Pregnancy Loss|Sub Clinical Hypothyroidism,2018-10-17,2017-07-01,2017-07-01,168.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hawler Medical University,Hawler Medical University,,Drug,,18.0,42.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03712683
2407,NCT03713671,Primary Hyperparathyroidism,The Effect of Quadriceps Femoris Muscle Fatigue Protocol on Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Primary Hyperparathyroidism,2018-10-18,2022-01-10,2022-01-30,40.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Recep Tayyip Erdogan University Training and Research Hospital,Ankara Education and Research Hospital|Hacettepe University|Recep Tayyip Erdogan University Training and Research Hospital,Ankara Education and Research Hospital,Diagnostic Test,Turkey,45.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03713671
2410,NCT03716128,Renal Osteodystrophy,Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function Can 18F-PET Replace Bone Histomorphometry,Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function,Renal Osteodystrophy,2018-09-26,2020-10-31,2020-10-31,40.0,Other,,Cross-Sectional,Observational,Unknown status,,Herlev Hospital,Ditte Hansen|Universiteit Antwerpen|University of Copenhagen,Herlev Hospital,Diagnostic Test,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03716128
2413,NCT03718403,Php1C|PHP Ia|PHP IB,Effect of Theophylline in Pseudohypoparathyroidism,Effect of Theophylline in Pseudohypoparathyroidism,Php1C|PHP Ia|PHP IB,2017-09-08,2030-04-10,2032-04-10,40.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 4,Massachusetts General Hospital,Massachusetts General Hospital,,Drug,,5.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03718403
2415,NCT03720210,Amiodarone-Induced Thyrotoxicosis,Pilot Study for Treatment of Amiodarone-Induced Thyroiditis With Radiofrequency Ablation,Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis,Amiodarone-Induced Thyrotoxicosis,2018-10-17,2020-12-07,2020-12-07,1.0,,Single Group Assignment,,Interventional,Terminated,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03720210
2417,NCT03724188,Hyperparathyroidism Tertiary,Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients,Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients,Hyperparathyroidism Tertiary,2018-10-24,2022-12-30,2022-12-30,40.0,Case-Only,,Prospective,Observational,Recruiting,,Mansoura General Hospital,Mansoura General Hospital,Faculty of medicine - Mansoura university,Procedure,Egypt,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03724188
2419,NCT03728959,Hypoparathyroidism,Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism (KS-4-HypoPT).,Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.,Hypoparathyroidism,2018-10-31,2019-04-12,2019-04-12,7.0,,Crossover Assignment,,Interventional,Completed,Not Applicable,University of Copenhagen,Hvidovre University Hospital|University of Copenhagen,Hvidovre University Hospital,Other|Other|Other|Other,Denmark,18.0,76.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03728959
2421,NCT03732157,Primary Hyperparathyroidism,"Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients, for Treatment of Primary Hyperparathyroidism",Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients,Primary Hyperparathyroidism,2018-09-18,2019-07-31,2019-07-31,140.0,Cohort,,Prospective,Observational,Unknown status,,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,,Procedure|Procedure,,19.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03732157
2424,NCT03732495,Thyroid Cancer Metastatic,"A Prospective, Multicentre Phase II Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)",Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas,Thyroid Cancer Metastatic,2018-10-31,2022-12-15,2023-01-15,35.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Centre Leon Berard,Centre Leon Berard,CHU Angers|CHRU Besanon|CHU Bordeaux - Hpital Saint-Andr|Institut Bergonie|Hospices Civils de Lyon - Groupement Hospitalier Est|Centre Geogres Franois Leclerc|Centre Lon Brard|Centre Antoine Lacassagne|APHP Saint Louis|APHP La Piti Salptrire|Institut Jean Godinot|Institut du Cancer Strasbourg (ICANS)|Institut Universitaire du Cancer de Toulouse - Oncopole|Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03732495
2425,NCT03747029,Hyperparathyroidism|Hypoparathyroidism|Parathyroid Diseases|Phosphorus and Calcium Disorders,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Hyperparathyroidism|Hypoparathyroidism|Parathyroid Diseases|Phosphorus and Calcium Disorders,2018-11-16,2018-12-31,2018-12-31,1038.0,Case-Control,,Retrospective,Observational,Completed,,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero - Universitaria di Modena,Other,Italy,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03747029
2428,NCT03753919,Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,"A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial","Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial",Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,2018-11-20,2022-07-31,2022-12-31,46.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|MFAR,Instituto Cataln de Oncologa de Hospitalet|Hospital Provincial de Castelln|Hospital Clnic Barcelona|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Clnico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario HM Sanchinarro|Hospital Universitario La Paz|Hospital Universitario Ramn y Cajal|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Clnica Universidad de Navarra|Instituto Valenciano de Oncologa|Complejo Hospitalario Universitario de Vigo (CHUVI),Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03753919
2431,NCT03754621,Hypothyroidism|Pregnancy Early|Thyroid|Thyroid Dysfunction,What is the Rational Upper Limit for TSH and T4 During First and Second Trimester Pregnancy in West Black Sea Region of Turkey,Upper Limit for TSH of First and Second Trimester Pregnancy in Turkey,Hypothyroidism|Pregnancy Early|Thyroid|Thyroid Dysfunction,2018-11-23,2019-07-02,2019-07-15,400.0,Case-Control,,Prospective,Observational,Unknown status,,Bartin State Hospital,Bartin State Hospital,Bartin State Hospital,Diagnostic Test,Turkey,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03754621
2432,NCT03757637,Differentiated Thyroid Cancer,"Yeur-Hur Lai, PhD, RN, School of Nursing, College of Medicine, National Taiwan University",Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients,Differentiated Thyroid Cancer,2018-11-27,2022-12-31,2022-12-31,380.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,"Department of Surgery, National Taiwan University Hospital, No.7, Chung-Shan South Road, Taipei, TAIWAN, R.O.C.",Other|Other,Taiwan,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03757637
2433,NCT03761290,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism|Pseudohypoparathyroidism Type Ia,Glucose Homeostasis and Beta Cell Function in Pseudohypoparathyroidism,Glucose Homeostasis in Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism|Pseudohypoparathyroidism Type Ia,2018-11-29,2021-04-30,2021-04-30,14.0,Case-Control,,Cross-Sectional,Observational,Terminated,,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Vanderbilt University Medical Center,,United States,6.0,50.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03761290
2435,NCT03764007,"Hyperparathyroidism, Primary",18F-Fluorocholine for the Detection of Parathyroid Adenomas,18F-Fluorocholine for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2018-11-30,2021-05-31,2021-05-31,98.0,,Single Group Assignment,,Interventional,Completed,Phase 2/Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03764007
2439,NCT03765333,Thyroid Cancer,"Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic",GETNE Registration of Thyroid Cancer,Thyroid Cancer,2018-11-20,2021-09-30,2021-11-30,20.0,Ecologic or Community,,Cross-Sectional,Observational,Recruiting,,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos,Hospital Universitari Vall d'Hebron,,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03765333
2440,NCT03772496,Diagnoses Disease|Thyroid Nodule,"A Multicenter, Double-blind, Prospective Cohort Study of Diagnostic Significance of Circulating Tumor Cells in Patients With Thyroid Nodules",Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells),Diagnoses Disease|Thyroid Nodule,2018-11-23,2019-12-20,2020-02-20,200.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Beijing Chao Yang Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|China-Japan Friendship Hospital|Chinese PLA General Hospital","Cancer Hospital, Chinese Academy of Medical Science",Diagnostic Test|Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03772496
2442,NCT03773120,"Carcinoma, Papillary, Follicular",Effectiveness of Intraoperative Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroid Surgery,Effectiveness of Intraoperative Neuromonitoring of External Branch of Superior Laryngeal Nerve During Thyroid Surgery,"Carcinoma, Papillary, Follicular",2018-04-12,2019-07-23,2019-07-23,5.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Device,"Korea, Republic of",18.0,79.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03773120
2443,NCT03774771,Primary Hyperparathyroidism,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-week Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Clinical Effects of an Oral Calcimimetic Agent (AMG 073) in Primary Hyperparathyroidism","Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism",Primary Hyperparathyroidism,2018-12-11,1999-12-13,1999-12-13,48.0,,Sequential Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03774771
2446,NCT03774862,Colorectal Medullary Carcinoma,Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study,Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study,Colorectal Medullary Carcinoma,2018-09-05,2017-12-31,2018-08-01,13.0,Cohort,,Retrospective,Observational,Completed,,"V.K.V. American Hospital, Istanbul","V.K.V. American Hospital, Istanbul",,,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03774862
2447,NCT03776058,Primary Hyperparathyroidism,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Clinical Effects of Twice-daily Doses of an Oral Calcimimetic Agent (AMG 073) in Subjects With Primary Hyperparathyroidism (HPT)","Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)",Primary Hyperparathyroidism,2018-12-13,2000-12-26,2000-12-26,10.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03776058
2450,NCT03779906,Hypothyroidism,"A Prospective, Multicenter Observational Study to Evaluate Thyroid Function of Pediatric Subjects From Birth to 3 Years Exposed to ISOVUE (Iopamidol Injection)",Thyroid Function of Pediatric Subjects Following Isovue Administration,Hypothyroidism,2018-12-17,2024-12-01,2025-01-31,1560.0,,Single Group Assignment,,Interventional,Recruiting,Phase 4,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",Children's Hospital and Medical Center,Drug,United States,0.0,3.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT03779906
2451,NCT03787121,Thyroid Cancer,Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers : Involvement of Overtreatment,Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers,Thyroid Cancer,2018-12-24,2020-12-31,2020-12-31,361.0,Cohort,,Retrospective,Observational,Completed,,"University Hospital, Toulouse","University Hospital, Toulouse",University HospitalToulouse,Procedure,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03787121
2452,NCT03794375,Differentiated Thyroid Cancer,Impact of Primary Care Transfer for Thyroid Cancer Patients,Primary Care Transfer for Thyroid Cancer Patients,Differentiated Thyroid Cancer,2018-12-28,2022-12-31,2024-12-31,472.0,,Parallel Assignment,,Interventional,Enrolling by invitation,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre,Hospital de Clnicas de Porto Alegre,Other|Other,Brazil,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03794375
2453,NCT03801980,Secondary Hyperparathyroidism,Phase 3 Study of SK-1403 ; Double-blinded Parallel Group in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis,Phase 3 Study of SK-1403,Secondary Hyperparathyroidism,2019-01-08,2019-12-17,2019-12-21,153.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Sanwa Kagaku Kenkyusho Co., Ltd.","Sanwa Kagaku Kenkyusho Co., Ltd.",Investigational site (there may be other sites in this country),Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03801980
2456,NCT03808779,Papillary Thyroid Microcarcinoma,"A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC)",A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.,Papillary Thyroid Microcarcinoma,2019-01-13,2024-02-01,2024-02-01,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University","General Surgery Department, Tianjin Medical University General Hospital|Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University|Interventional Oncology Centre, State Institution ""Grigoriev Intstitute for Medical Radiology NAMS of Ukraine""",Procedure|Procedure,China|Ukraine,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03808779
2457,NCT03813173,Lymph Node Metastases,Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma: a Prospective Study,Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma,Lymph Node Metastases,2019-01-16,2040-12-31,2040-12-31,6000.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Zhejiang University,Zhejiang University,,Procedure,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03813173
2459,NCT03813706,Lymph Node Metastases,Prospective Study for the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma,the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma,Lymph Node Metastases,2019-01-16,2040-12-31,2040-12-31,4000.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Zhejiang University,Zhejiang University,,Procedure,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03813706
2461,NCT03822507,Secondary Hyperparathyroidism,"A Phase 3, Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis",Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia,Secondary Hyperparathyroidism,2019-01-29,2021-09-23,2021-09-23,404.0,,Parallel Assignment,,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Hakko Kirin China Pharmaceutical Co., LTD.|Kyowa Kirin Co., Ltd.|Kyowa Kirin Korea Co., Ltd.",Research site_29|Research site_34|Research site_25|Research site_22|Research site_23|Research site_30|Research site_28|Research site_32|Research site_33|Research site_24|Research site_26|Research site_27|Research site_31|Research site_11|Research site_21|Research site_13|Research site_15|Research site_12|Research site_18|Research site_14|Research site_17|Research site_19|Research site_20|Research site_16|Research site_2|Research site_3|Research site_5|Research site_9|Research site_4|Research site_7|Research site_10|Research site_1|Research site_6|Research site_8,Drug|Drug,"China|Hong Kong|Korea, Republic of|Taiwan",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03822507
2464,NCT03823859,Central Hypothyroidism|Hyperthyroidism|Hypothyroidism,Metabolomics of Thyroid Hormones,Metabolomics of Thyroid Hormones,Central Hypothyroidism|Hyperthyroidism|Hypothyroidism,2019-01-28,2021-07-28,2021-12-31,332.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,"University Hospital, Basel, Switzerland","ETH Zurich|University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Diagnostic Test|Diagnostic Test|Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03823859
2466,NCT03826680,Thyroid Adenoma|Thyroid Cancer|Thyroid Nodule,"The Relationship of Modified Cormack Lehane Scores Between Preoperative Awake Flexible Fiberoptic Laryngoscopy and Intraoperative Direct Laryngoscopy in Thyroidectomies, a Prospective, Clinical Study",Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia,Thyroid Adenoma|Thyroid Cancer|Thyroid Nodule,2019-01-29,2020-06-30,2020-07-31,200.0,,Crossover Assignment,,Interventional,Unknown status,Not Applicable,Istanbul University,Istanbul University,"Istanbul University- Cerrahpasa Department of Anesthesiology, general surgery, ENT surgery",Procedure|Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03826680
2468,NCT03830242,Lymph Node Metastases|Positron-Emission Tomography|Thyroid Cancer,"Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer",Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.,Lymph Node Metastases|Positron-Emission Tomography|Thyroid Cancer,2018-12-17,2022-12-31,2022-12-31,50.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University",Diagnostic Test|Diagnostic Test,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03830242
2470,NCT03831620,Primary Hyperparathyroidism,The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism,The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2019-01-25,2022-07-31,2022-07-31,90.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,"University Hospital Inselspital, Berne","University Hospital Inselspital, Berne","Department of visceral surgery and transplant surgery, Berne University Hospital",,Switzerland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03831620
2473,NCT03835728,Autoimmune Encephalitis,Exploratory Study of Efficacy of Ocrelizumab in Autoimmune Encephalitis,Efficacy of Ocrelizumab in Autoimmune Encephalitis,Autoimmune Encephalitis,2019-02-05,2020-10-02,2020-10-02,3.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,University of Texas Southwestern Medical Center,"Genentech, Inc.|University of Texas Southwestern Medical Center",UT Southwestern Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03835728
2476,NCT03836300,Angelman Syndrome|Chromosome 22q11.2 Deletion Syndrome|Down Syndrome|Duchenne Muscular Dystrophy|Dup15Q Syndrome|Fragile X Syndrome|Klinefelter Syndrome|Phelan-McDermid Syndrome|Prader-Willi Syndrome|Rett Syndrome|Smith Magenis Syndrome|Tuberous Sclerosis|Turner Syndrome|Williams Syndrome,Piloting an Early Intervention Program for Infants With Rare Neurogenetic Disorders,Parent-Infant Inter(X)Action Intervention (PIXI),Angelman Syndrome|Chromosome 22q11.2 Deletion Syndrome|Down Syndrome|Duchenne Muscular Dystrophy|Dup15Q Syndrome|Fragile X Syndrome|Klinefelter Syndrome|Phelan-McDermid Syndrome|Prader-Willi Syndrome|Rett Syndrome|Smith Magenis Syndrome|Tuberous Sclerosis|Turner Syndrome|Williams Syndrome,2019-02-07,2022-12-01,2022-12-31,120.0,,Single Group Assignment,,Interventional,Enrolling by invitation,Not Applicable,RTI International,"RTI International|University of North Carolina, Chapel Hill",RTI International,Behavioral,United States,0.0,99.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03836300
2478,NCT03838692,Medullary Thyroid Cancer,A Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer (MTC),Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer,Medullary Thyroid Cancer,2019-02-11,2021-06-14,2021-06-14,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 2,Columbia University,"Antonio Fojo|Millennium Pharmaceuticals, Inc.",,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03838692
2479,NCT03841617,Thyroid Cancer,The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer,The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer,Thyroid Cancer,2019-02-13,2024-02-01,2029-02-01,30.0,,Crossover Assignment,,Interventional,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,Drug|Radiation|Radiation|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03841617
2480,NCT03845647,Differentiated Thyroid Carcinoma|Lymph Node Dissection|Lymph Node Metastases,"Significance of Single Center, Open and Prospective Evaluation of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.",Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.,Differentiated Thyroid Carcinoma|Lymph Node Dissection|Lymph Node Metastases,2019-02-17,2020-12-28,2020-12-28,50.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,"Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University",Procedure,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03845647
2481,NCT03866382,"Bladder Adenocarcinoma|Bladder Clear Cell Adenocarcinoma|Bladder Mixed Adenocarcinoma|Bladder Neuroendocrine Carcinoma|Bladder Small Cell Neuroendocrine Carcinoma|Bladder Squamous Cell Carcinoma|Bladder Urachal Adenocarcinoma|Chromophobe Renal Cell Carcinoma|Collecting Duct Carcinoma|Infiltrating Bladder Lymphoepithelioma-Like Carcinoma|Infiltrating Bladder Urothelial Carcinoma|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Infiltrating Bladder Urothelial Carcinoma With Giant Cells|Kidney Medullary Carcinoma|Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Carcinoma|Metastatic Bladder Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Small Cell Neuroendocrine Carcinoma|Metastatic Bladder Squamous Cell Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Metastatic Kidney Medullary Carcinoma|Metastatic Malignant Genitourinary System Neoplasm|Metastatic Penile Carcinoma|Metastatic Prostate Small Cell Neuroendocrine Carcinoma|Metastatic Sarcomatoid Renal Cell Carcinoma|Metastatic Urethral Carcinoma|Papillary Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IVA Bladder Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Testicular Leydig Cell Tumor|Testicular Sertoli Cell Tumor|Urethral Clear Cell Adenocarcinoma","A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)",Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors,"Bladder Adenocarcinoma|Bladder Clear Cell Adenocarcinoma|Bladder Mixed Adenocarcinoma|Bladder Neuroendocrine Carcinoma|Bladder Small Cell Neuroendocrine Carcinoma|Bladder Squamous Cell Carcinoma|Bladder Urachal Adenocarcinoma|Chromophobe Renal Cell Carcinoma|Collecting Duct Carcinoma|Infiltrating Bladder Lymphoepithelioma-Like Carcinoma|Infiltrating Bladder Urothelial Carcinoma|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Infiltrating Bladder Urothelial Carcinoma With Giant Cells|Kidney Medullary Carcinoma|Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Carcinoma|Metastatic Bladder Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Small Cell Neuroendocrine Carcinoma|Metastatic Bladder Squamous Cell Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Metastatic Kidney Medullary Carcinoma|Metastatic Malignant Genitourinary System Neoplasm|Metastatic Penile Carcinoma|Metastatic Prostate Small Cell Neuroendocrine Carcinoma|Metastatic Sarcomatoid Renal Cell Carcinoma|Metastatic Urethral Carcinoma|Papillary Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IVA Bladder Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Testicular Leydig Cell Tumor|Testicular Sertoli Cell Tumor|Urethral Clear Cell Adenocarcinoma",2019-03-06,2023-02-28,2023-02-28,224.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Mayo Clinic Hospital in Arizona|Mayo Clinic in Arizona|University of Arizona Cancer Center-Orange Grove Campus|Banner University Medical Center - Tucson|University of Arizona Cancer Center-North Campus|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Community Cancer Institute|University Oncology Associates|Epic Care-Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Marin Cancer Care Inc|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|UCLA / Jonsson Comprehensive Cancer Center|Contra Costa Regional Medical Center|USC Norris Oncology/Hematology-Newport Beach|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Pacific Central Coast Health Center-San Luis Obispo|Mission Hope Medical Oncology - Santa Maria|Epic Care Cyberknife Center|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|Porter Adventist Hospital|Mercy Medical Center|Southwest Oncology PC|Saint Anthony Hospital|Littleton Adventist Hospital|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|Parker Adventist Hospital|Saint Mary Corwin Medical Center|MedStar Georgetown University Hospital|Mount Sinai Comprehensive Cancer Center at Aventura|Holy Cross Hospital|Mayo Clinic in Florida|Mount Sinai Medical Center|Orlando Health Cancer Institute|Emory University Hospital Midtown|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|Emory Johns Creek Hospital|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Illinois CancerCare-Bloomington|Loyola Center for Health at Burr Ridge|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Northwestern University|Rush University Medical Center|University of Illinois|University of Chicago Comprehensive Cancer Center|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|Illinois CancerCare-Eureka|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Loyola Medicine Homer Glen|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Good Samaritan Regional Health Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Illinois CancerCare-Pekin|Illinois CancerCare-Peoria|Methodist Medical Center of Illinois|Illinois CancerCare-Peru|Valley Radiation Oncology|Illinois CancerCare-Princeton|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Reid Health|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Alegent Health Mercy Hospital|Greater Regional Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|McFarland Clinic PC-Trinity Cancer Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Mercy Medical Center-West Lakes|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|University of Kansas Clinical Research Center|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|HaysMed University of Kansas Health System|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Olathe Health Cancer Center|Cancer Center of Kansas - Parsons|Ascension Via Christi - Pittsburg|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|Cancer Center of Kansas - Wellington|University of Kansas Hospital-Westwood Cancer Center|Cancer Center of Kansas-Wichita Medical Arts Tower|Ascension Via Christi Hospitals Wichita|Cancer Center of Kansas - Wichita|Cancer Center of Kansas - Winfield|Flaget Memorial Hospital|Commonwealth Cancer Center-Corbin|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|University of Kentucky/Markey Cancer Center|Saint Joseph London|Jewish Hospital|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Jewish Hospital Medical Center South|Hematology/Oncology Clinic PLLC|Ochsner High Grove|Ochsner Medical Center Kenner|East Jefferson General Hospital|LSU Healthcare Network / Metairie Multi-Specialty Clinic|Louisiana State University Health Science Center|Tulane University Health Sciences Center|Ochsner Medical Center Jefferson|Greater Baltimore Medical Center|National Institutes of Health Clinical Center|Lahey Hospital and Medical Center|Lahey Medical Center-Peabody|Mercy Medical Center|Winchester Hospital|Saint Joseph Mercy Hospital|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Henry Ford Macomb Health Center - Shelby Township|Bhadresh Nayak MD PC-Sterling Heights|Ascension Saint Joseph Hospital|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|University of Mississippi Medical Center|Saint Louis Cancer and Breast Institute-Ballwin|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|University of Kansas Cancer Center - Lee's Summit|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Mercy Hospital Washington|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Nebraska Medicine-Bellevue|CHI Health Saint Francis|CHI Health Good Samaritan|Saint Elizabeth Regional Medical Center|Nebraska Methodist Hospital|Nebraska Medicine-Village Pointe|Alegent Health Immanuel Medical Center|Alegent Health Bergan Mercy Medical Center|Alegent Health Lakeside Hospital|Creighton University Medical Center|University of Nebraska Medical Center|Midlands Community Hospital|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Hope Cancer Care of Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|University Cancer Center|Hope Cancer Care of Nevada-Pahrump|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|New York-Presbyterian/Brooklyn Methodist Hospital|Maimonides Medical Center|Roswell Park Cancer Institute|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Northwell Health/Center for Advanced Medicine|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|University of Rochester|State University of New York Upstate Medical University|Memorial Sloan Kettering Nassau|UNC Lineberger Comprehensive Cancer Center|Margaret R Pardee Memorial Hospital|Essentia Health Cancer Center-South University Clinic|Essentia Health - Jamestown Clinic|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Adena Regional Medical Center|University of Cincinnati Cancer Center-UC Medical Center|Good Samaritan Hospital - Cincinnati|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Grady Memorial Hospital|Dublin Methodist Hospital|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Central Ohio Breast and Endocrine Surgery|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|OhioHealth Mansfield Hospital|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|Springfield Regional Cancer Center|Springfield Regional Medical Center|Saint Vincent Mercy Medical Center|Mercy Health - Saint Anne Hospital|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|Saint Joseph Warren Hospital|University of Cincinnati Cancer Center-West Chester|Saint Ann's Hospital|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Mercy Hospital Oklahoma City|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Oregon Health and Science University|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Pocono Medical Center|UPMC Hillman Cancer Center Erie|Saint Vincent Hospital|UPMC Cancer Centers - Arnold Palmer Pavilion|Lehigh Valley Hospital-Hazleton|Jefferson Hospital|Forbes Hospital|UPMC Cancer Center - Monroeville|UPMC Hillman Cancer Center - Monroeville|Arnold Palmer Cancer Center Medical Oncology Norwin|Allegheny Valley Hospital|Allegheny General Hospital|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Shadyside Hospital|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Wexford Health and Wellness Pavilion|Medical University of South Carolina|Vanderbilt-Ingram Cancer Center Cool Springs|University of Tennessee - Knoxville|Vanderbilt Breast Center at One Hundred Oaks|Vanderbilt University/Ingram Cancer Center|Saint Joseph Regional Cancer Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|UT Southwestern Clinical Center at Richardson/Plano|Providence Regional Cancer System-Aberdeen|Overlake Medical Center|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Saint Francis Hospital|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Harrison HealthPartners Hematology and Oncology-Poulsbo|Valley Medical Center|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Franciscan Research Center-Northwest Medical Plaza|Northwest Medical Specialties PLLC|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Aurora Cancer Care-Southern Lakes VLCC|Aurora Saint Luke's South Shore|Marshfield Medical Center-EC Cancer Center|Mayo Clinic Health System-Eau Claire Clinic|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Aurora BayCare Medical Center|Aurora Cancer Care-Kenosha South|Aurora Bay Area Medical Group-Marinette|Marshfield Medical Center-Marshfield|Aurora Cancer Care-Milwaukee|Aurora Saint Luke's Medical Center|Aurora Sinai Medical Center|Marshfield Clinic-Minocqua Center|ProHealth D N Greenwald Center|Cancer Center of Western Wisconsin|ProHealth Oconomowoc Memorial Hospital|Vince Lombardi Cancer Clinic - Oshkosh|Aurora Cancer Care-Racine|Marshfield Medical Center-Rice Lake|Vince Lombardi Cancer Clinic-Sheboygan|Marshfield Clinic Stevens Point Center|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|ProHealth Waukesha Memorial Hospital|UW Cancer Center at ProHealth Care|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center|Marshfield Medical Center - Weston|Billings Clinic-Cody|Welch Cancer Center|Pan American Center for Oncology Trials LLC,Drug|Biological|Biological,Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03866382
2482,NCT03871387,Thyroid Neoplasms,The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change; Prospective Randomized Control Trial,The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change,Thyroid Neoplasms,2019-02-26,2020-02-24,2020-02-24,88.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03871387
2483,NCT03872284,Autoimmune Encephalitis,Study of Neuro-ophthalmology Disorders in Autoimmune Encephalitis (NODE),Neuro-ophthalmology and Autoimmune Encephalitis (NODE),Autoimmune Encephalitis,2019-03-11,2027-01-24,2027-01-24,70.0,Cohort,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Other,France,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03872284
2486,NCT03878953,Chronic Hypoparathyroidism,"A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism",A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism,Chronic Hypoparathyroidism,2019-03-15,2023-05-31,2023-05-31,12.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 3,Takeda,Shire,Fujita Health University Hospital|University of Occupational and Environmental Health Japan|Osaka City University Hospital|Shimane University Hospital|Tokushima University Hospital|University of Tokyo Hospital|The Cancer Institute Hospital of JFCR|Toranomon Hospital|Keio University Hospital|Tokyo Women's Medical University Hospital,Drug,Japan,20.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03878953
2488,NCT03880578,Quality of Life|Thyroid; Deficiency,Influence of Radioiodine Treatment on Thyroid Function and Quality of Life of Patients,Quality of Life After Interventional Thyroid Treatment,Quality of Life|Thyroid; Deficiency,2019-03-14,2022-03-15,2022-03-15,102.0,Cohort,,Prospective,Observational,Completed,,Klinikum Ldenscheid,Klinikum Ldenscheid,Department of Nuclear Medicine Klinikum Luedenscheid,Drug,Germany,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03880578
2489,NCT03884140,Thyroid Nodule,Clinical Diagnostic Evaluation of Thyroid Nodules,Clinical Diagnostic Approach for Cases of Thyroid Nodules,Thyroid Nodule,2019-03-19,2022-06-01,2022-09-01,1.0,Case-Crossover,,Cross-Sectional,Observational [Patient Registry],Not yet recruiting,,Assiut University,Assiut University,,,,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03884140
2491,NCT03887611,Thyroid Nodule,A Multi-center Study of Differential Diagnosis Thyroid Nodules by Ultrasound Artificial Intelligence and Ultrasound Elastography,Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Thyroid Nodules,Thyroid Nodule,2019-03-21,2020-01-18,2020-03-18,2000.0,Case-Only,,Prospective,Observational,Unknown status,,Tongji Hospital,"Affiliated Hospital of Jiangsu University|Anqing People's Hospital|Enshi State Central Hospital|Huai'an First People's Hospital|Huainan People's Hospital|Huangshi Central Hospital, China|Jiangxia District First People's Hospital|Lianyungang Third People's Hospital|Macheng People's Hospital|Taizhou Hospital|The Central Hospital of Lishui City|The First People's Hospital of Yichang|The Second Hospital of Anhui Medical University|The Second People's Hospital of Yichang|Wenzhou Central Hospital|WISCO General Hospital|Wuhan Hospital of Traditional Chinese and Western Medicine|Xiangyang Central Hospital|Xiangyang First People's Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Xin-Wu Cui|Xuzhou First People's Hospital",Xin-Wu Cui,Device,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03887611
2493,NCT03889431,Infant Development|Iodine Deficiency Goiter,Community Salt Testing and Relation of Iodine Intake to Visual Information Processing of Ethiopian Infants,Community Salt Testing and Relation of Iodine Intake to Visual Information Processing of Ethiopian Infants,Infant Development|Iodine Deficiency Goiter,2019-03-20,2013-01-30,2013-08-10,106.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Oklahoma State University,Oklahoma State University,Hawassa University,Dietary Supplement|Other,Ethiopia,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03889431
2494,NCT03889769,Lymph Node Metastases|Papillary Thyroid Cancer,Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma,Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma,Lymph Node Metastases|Papillary Thyroid Cancer,2019-03-23,2019-04-01,2019-09-30,50.0,Case-Only,,Prospective,Observational,Unknown status,,University of Cagliari,University of Cagliari,Policlinico di Monserrato,Diagnostic Test,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03889769
2496,NCT03891043,Thyroid Orbitopathy,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy to Reduce Its,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy,Thyroid Orbitopathy,2019-03-15,2016-04-30,2016-04-30,33.0,,Factorial Assignment,,Interventional,Completed,Not Applicable,Instituto de Oftalmologa Fundacin Conde de Valenciana,Instituto de Oftalmologa Fundacin Conde de Valenciana,,Dietary Supplement|Other,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03891043
2500,NCT03892993,Thyroid Gland Medullary Carcinoma,"Designing a Decision Aid to Help People With Medullary Thyroid Cancer Make Decisions With Their Doctors About Whether to Start or Stop New Drugs, Enroll in Clinical Trials, or Continue With Active Surveillance","Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers",Thyroid Gland Medullary Carcinoma,2019-02-21,2023-04-19,2024-04-19,120.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03892993
2501,NCT03896958,"Adenocarcinoma Lung|Adrenal Cancer|Breast Cancer|Bronchoalveolar Cell Lung Cancer|Cancer, Advanced|Cancer, All Types|Cancer, Anal|Cancer, Anaplastic Thyroid|Cancer, Bile Duct|Cancer, Bladder|Cancer Cords Vocal|Cancer Differentiated Poorly|Cancer, Metastatic|Cancer of Brain and Nervous System|Cancer of Cervix|Cancer of Colon|Cancer of Esophagus|Cancer of Head and Neck|Cancer of Kidney|Cancer of Larynx|Cancer of Liver|Cancer of Lung|Cancer of Neck|Cancer of Pancreas|Cancer of Prostate|Cancer of Rectum|Cancer of Stomach|Cancer of Vulva, Disseminated|Cancer, Other|Cancers Cell Neuroendocrine|Cancer Skin|Cancer Unknown Primary|Cholangiocarcinoma|GIST|Glioblastoma Multiforme|Hepatocellular Carcinoma|Melanoma|Oligodendroglioma|Renal Cell Carcinoma|Sarcoma|Small-cell Lung Cancer|Squamous Cell Carcinoma|Testicular Cancer|Transitional Cell Carcinoma|Uterine Cancer",The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology),The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology),"Adenocarcinoma Lung|Adrenal Cancer|Breast Cancer|Bronchoalveolar Cell Lung Cancer|Cancer, Advanced|Cancer, All Types|Cancer, Anal|Cancer, Anaplastic Thyroid|Cancer, Bile Duct|Cancer, Bladder|Cancer Cords Vocal|Cancer Differentiated Poorly|Cancer, Metastatic|Cancer of Brain and Nervous System|Cancer of Cervix|Cancer of Colon|Cancer of Esophagus|Cancer of Head and Neck|Cancer of Kidney|Cancer of Larynx|Cancer of Liver|Cancer of Lung|Cancer of Neck|Cancer of Pancreas|Cancer of Prostate|Cancer of Rectum|Cancer of Stomach|Cancer of Vulva, Disseminated|Cancer, Other|Cancers Cell Neuroendocrine|Cancer Skin|Cancer Unknown Primary|Cholangiocarcinoma|GIST|Glioblastoma Multiforme|Hepatocellular Carcinoma|Melanoma|Oligodendroglioma|Renal Cell Carcinoma|Sarcoma|Small-cell Lung Cancer|Squamous Cell Carcinoma|Testicular Cancer|Transitional Cell Carcinoma|Uterine Cancer",2019-03-26,2024-03-12,2024-03-12,1000.0,Case-Only,,Prospective,Observational,Recruiting,,SpeciCare,Georgia Institute of Technology|Netnoids|Northeast Georgia Hospital System|Predictive Oncology|SpeciCare|University of Washington,Specicare,,United States,1.0,99.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03896958
2502,NCT03898622,Chronic Kidney Diseases|Subclinical Hypothyroidism,"Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without Renal Replacement Therapy: Randomized, Double-blind Clinical Trial at Guadalajara Civil Hospital.",Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without TRR.,Chronic Kidney Diseases|Subclinical Hypothyroidism,2018-08-28,2019-01-31,2019-03-01,32.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Hospital Civil de Guadalajara,Hospital Civil de Guadalajara,"Kidney health clinic, Civil Hospital of Guadalajara",Drug,Mexico,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03898622
2503,NCT03899792,Infantile Fibrosarcoma|Infantile Myofibromatosis|Medullary Thyroid Cancer|Papillary Thyroid Cancer|Soft Tissue Sarcoma,A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors,A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors,Infantile Fibrosarcoma|Infantile Myofibromatosis|Medullary Thyroid Cancer|Papillary Thyroid Cancer|Soft Tissue Sarcoma,2019-02-06,2023-03-26,2024-03-26,100.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Childrens Hospital of Los Angeles|Lucile Packard Children's Hospital|The Children's Hospital for Cancer and Blood Disorders|Nemours Children's Health|Dana-Farber Cancer Institute|University of Minnesota Hospital|Memorial Sloan Kettering Cancer Center|Cincinnati Children's Hospital Medical Center|Children's Hospital of Philadelphia|St. Jude Children's Research Hospital|University of Texas Southwestern Medical Center at Dallas|Texas Childrens Hospital|Seattle Children's Hospital Research Foundation|The Children's Hospital at Westmead|Royal Children's Hospital|The Hospital for Sick Children|Rigshospitalet|Gustave Roussy|Universittsklinikum Heidelberg|Fondazione IRCCS Istituto Nazionale dei Tumori|Hokkaido University Hospital|National Cancer Center Hospital|Hiroshima University Hospital|Kyoto University Hospital|Seoul National University Hospital|Hospital Universitari Vall d'Hebron|University College Hospital - London,Drug,"Australia|Canada|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Spain|United Kingdom|United States",6.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03899792
2505,NCT03905369,Thyroid Cancer,Focus on Values to Stimulate Shared Decisions in Patients With Thyroid Cancer: A Multifaceted COMmunication BOoster (COMBO),Focus on Values to Stimulate Shared Decisions,Thyroid Cancer,2019-03-21,2022-09-01,2023-03-01,128.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Rijnstate hospital|CWZ|Radboudumc|MUMC|Catharina hospital|AUMC|AVL|Haga|LUMC|UMCG|UMC Utrecht,Other|Other,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03905369
2506,NCT03910049,Parathyroid; Deficiency|Thyroid,Does Indocyanine Imaging Scoring Predicts Postoperative PTH Levels at 24 Hours After Total Thyroidectomy,Does Indocyanine Imaging Scoring Predicts Postoperative Parathormone Levels at 24 Hours After Total Thyroidectomy,Parathyroid; Deficiency|Thyroid,2019-02-19,2019-04-26,2019-04-26,60.0,Cohort,,Prospective,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Endocrine Surgery, Interbalkan Medical Center, Thessaloniki, Greece|1st Propedeutic Department of Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki",Drug,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03910049
2508,NCT03914300,Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma,Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy,"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma,2019-04-11,2023-01-15,2023-01-15,24.0,,Single Group Assignment,,Interventional,Suspended,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|USC Norris Oncology/Hematology-Newport Beach|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|University of Kansas Clinical Research Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|University of Kentucky/Markey Cancer Center|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Truman Medical Centers|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|University of Kansas Cancer Center at North Kansas City Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau|Ohio State University Comprehensive Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|University of Utah Sugarhouse Health Center|Huntsman Cancer Institute/University of Utah,Drug|Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03914300
2511,NCT03922321,Graves' Ophthalmopathy,"A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy",Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,2019-04-17,2020-02-29,2020-05-21,7.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"UBC/VGH Eye Care Center|Toronto Retina Institute|University of Ottwa Eye Institute|CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont",Drug,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03922321
2515,NCT03924804,Cholecystolithiasis and Thyroid Nodule,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Cholecystolithiasis and Thyroid Nodule,2019-04-18,2022-05-12,2022-05-12,90.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,"China Medical University, China","China Medical University, China",the First Hospital of China Medical University,Drug|Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03924804
2517,NCT03926585,Hypothyroidism,Longtime Effect of Combination Treatment With L-thyroxine (L-T4) and Liothyronine (L-T3) in Patients With Persistent Hypothyroid Symptoms - Relation to Polymorphisms (SNP) in the DIO2 and the MCT10 Gene,Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment,Hypothyroidism,2019-04-15,2022-04-30,2022-04-30,82.0,Cohort,,Cross-Sectional,Observational,Recruiting,,Herlev Hospital,Birte Nygaard,Herlev Hospital,,Denmark,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03926585
2518,NCT03931109,"Osteoporosis, Postmenopausal|Primary Hyperparathyroidism",Circulating microRNA Signatures in Primary Hyperparathyroidism,Circulating miRNA in Primary Hyperparathyroidism,"Osteoporosis, Postmenopausal|Primary Hyperparathyroidism",2019-04-15,2022-04-30,2022-04-30,100.0,Cohort,,Prospective,Observational [Patient Registry],Active not recruiting,,University of Pennsylvania,University of Pennsylvania,Perelman Center for Advanced Medicine/ Hospital of the University of Pennsylvania,,United States,50.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03931109
2521,NCT03935984,Hypercalcemia|Primary Hyperparathyroidism,Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan With Calcitonin Pre-treatment for Primary Hyperparathyroidism,Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity,Hypercalcemia|Primary Hyperparathyroidism,2019-04-30,2021-04-01,2021-10-01,37.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,ProMedica Health System,ProMedica Health System|University of Toledo Health Science Campus,ProMedica Toledo Hospital,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03935984
2524,NCT03937349,Chronic Kidney Disease Mineral and Bone Disorder|Dialysis|Secondary Hyperparathyroidism|Vascular Calcification,Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients: a Prospective Cohort Study,Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients,Chronic Kidney Disease Mineral and Bone Disorder|Dialysis|Secondary Hyperparathyroidism|Vascular Calcification,2019-05-01,2023-12-31,2023-12-31,60.0,Cohort,,Prospective,Observational,Recruiting,,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia","Saint-Petersburg State University, Clinic of advanced medical technologies n.a. N.I.Pirogov",,Russian Federation,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03937349
2527,NCT03938545,Graves' Ophthalmopathy (GO),"ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy","ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",Graves' Ophthalmopathy (GO),2019-05-01,2021-02-02,2021-04-15,65.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"Multispecialty Aesthetic Clinical Research Organziation (MACRO)|Doheny Eye Center UCLA|University of Miami Miller School of Medicine Bascom Palmer Eye Institute|University of Iowa Hospitals & Clinics - Eye Clinic|University of Michigan - Kellogg Eye Center|Mayo Clinic|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center|University of Rochester Medical Center|Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill|Eye Wellness Center|Eyelid Center of Utah|West Virginia University Eye Institute|University of British Columbia|Toronto Retina Institute|University of Ottawa Eye Institute|Ophthalmology University Center- Hpital Maisonneuve-Rosemont|Universitat Duisburg-Essen|Orbitazentrum Frankfurt|Universittsmedizin Mainz|ARNAS Garibaldi, Presidio di Nesima|Fondazione IRCCS C Granda-Ospedale Maggiore Policlinico|Unit Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana|Hospital Universitari de Bellvitge|Centro de Oftalmologia Barraquer|University Hospital Ramon y Cajal",Drug|Other,Canada|Germany|Italy|Spain|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03938545
2531,NCT03941184,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjgren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjgren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",2019-04-01,2020-11-10,2020-11-10,114.0,Case-Control,,Retrospective,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,110.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03941184
2537,NCT03942380,Head and Neck Cancer|Head and Neck Neoplasms|Head and Neck Squamous Cell Carcinoma|Hypopharynx Cancer|Hypopharynx Carcinoma|Hypopharynx Neoplasm|Larynx Cancer|Larynx Carcinoma|Larynx Neoplasm|Nasopharyngeal Cancer|Nasopharyngeal Carcinoma|Nasopharynx Neoplasm|Oral Cancer|Oral Cavity Cancer|Oral Neoplasm|Oropharynx Cancer|Oropharynx Carcinoma|Oropharynx Neoplasm|Salivary Gland Cancer|Salivary Gland Carcinoma|Salivary Gland Neoplasms|Sinonasal Cancer|Sinonasal Carcinoma|Sinonasal Neoplasm|Thyroid Cancer|Thyroid Carcinoma|Thyroid Neoplasms,Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer,Cell-free Tumor DNA in Head and Neck Cancer Patients,Head and Neck Cancer|Head and Neck Neoplasms|Head and Neck Squamous Cell Carcinoma|Hypopharynx Cancer|Hypopharynx Carcinoma|Hypopharynx Neoplasm|Larynx Cancer|Larynx Carcinoma|Larynx Neoplasm|Nasopharyngeal Cancer|Nasopharyngeal Carcinoma|Nasopharynx Neoplasm|Oral Cancer|Oral Cavity Cancer|Oral Neoplasm|Oropharynx Cancer|Oropharynx Carcinoma|Oropharynx Neoplasm|Salivary Gland Cancer|Salivary Gland Carcinoma|Salivary Gland Neoplasms|Sinonasal Cancer|Sinonasal Carcinoma|Sinonasal Neoplasm|Thyroid Cancer|Thyroid Carcinoma|Thyroid Neoplasms,2019-04-15,2025-02-01,2025-02-01,500.0,,Sequential Assignment,,Interventional,Recruiting,Not Applicable,"Rigshospitalet, Denmark","Christian von Buchwald|Copenhagen University Hospital, Denmark|Department of Otorhinolaryngology, Head and Neck Surgery and Audiology","University Hospital of Copenhagen, Rigshospitalet",Diagnostic Test,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03942380
2538,NCT03948191,Thyroid-Associated Ophthalmopathy,"A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.",99Tc-MDP for Thyroid-Associated Ophthalmopathy,Thyroid-Associated Ophthalmopathy,2019-05-10,2018-12-30,2019-03-31,50.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Dalian University,Dalian University,Affiliated Zhongshan Hospital of Dalian University,Drug|Drug,China,18.0,76.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03948191
2542,NCT03951532,Hyperthyroidism,Morbidity and Mortality Associated With the Care Journey in Children and Adolescents With Hyperthyroidism,Morbidity and Mortality Associated With the Care Journey in Children and Adolescents With Hyperthyroidism,Hyperthyroidism,2019-03-12,2020-12-31,2020-12-31,1650.0,Cohort,,Retrospective,Observational,Completed,,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Hpital Robert Debr,,France,6.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT03951532
2543,NCT03957616,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018,Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2019-05-17,2019-05-30,2019-07-31,600.0,Cohort,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de rfrence des syndromes neurologiques paranoplasiques et encphalites auto-immunes,,France,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03957616
2546,NCT03960437,"Chronic Kidney Disease Mineral and Bone Disorder|Hyperparathyroidism; Secondary, Renal|Renal Osteodystrophy|Vascular Calcification",The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease,The Effect of Etelcalcetide on CKD-MBD,"Chronic Kidney Disease Mineral and Bone Disorder|Hyperparathyroidism; Secondary, Renal|Renal Osteodystrophy|Vascular Calcification",2019-05-21,2021-12-31,2021-12-31,35.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Columbia University,"Thomas Nickolas, MD MS",Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03960437
2549,NCT03960554,Kidney Transplant; Complications|Osteoporosis|Renal Osteodystrophy,"The Effects of 12-months of Denosumab on Bone Density, Quality and Strength in Prevalent Kidney Transplant Recipients",The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients,Kidney Transplant; Complications|Osteoporosis|Renal Osteodystrophy,2019-05-21,2021-12-02,2021-12-02,15.0,,Parallel Assignment,,Interventional,Terminated,Phase 2,Columbia University,"Thomas Nickolas, MD MS","Northwestern University, Feinburg School of Medicine|NorthShore University HealthSystem|Columbia University Medical Center",Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03960554
2552,NCT03968510,Hyperparathyroidism,The Effect of Parathyroidectomy on Swallowing Related Quality of Life in Primary Hyperparathyroidism,Swalqol in Primary Hyperparathyroidism,Hyperparathyroidism,2019-03-20,2020-07-01,2020-11-01,150.0,Case-Crossover,,Prospective,Observational [Patient Registry],Completed,,Uak University,Uak University,Uak University,Procedure,Turkey,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03968510
2555,NCT03969108,Graves Disease|Thyroid Cancer|Thyroid Goiter,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Graves Disease|Thyroid Cancer|Thyroid Goiter,2019-05-24,2019-11-12,2019-11-13,10.0,,Single Group Assignment,,Interventional,Completed,Phase 4,"University Health Network, Toronto","University Health Network, Toronto",University Health Network,Drug,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03969108
2559,NCT03969329,Secondary Hyperparathyroidism,"Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents  2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis,Secondary Hyperparathyroidism,2019-05-29,2026-08-02,2026-08-02,20.0,,Single Group Assignment,,Interventional,Recruiting,Phase 3,Amgen,Amgen,"Universitair Ziekenhuis Gent|Fakultni nemocnice v Motole|Hospices Civils de Lyon Hopital Femme Mere Enfant|Hpital Armand Trousseau|Kindernierenzentrum Bonn|Universittsklinikum Hamburg-Eppendorf|Medizinische Hochschule Hannover|Zentrum fr Kinder und Jugendmedizin des Universittsklinikums Heidelberg|Universittsklinikum Kln|General Children Hospital Panagioti and Aglaias Kyriakou|Ippokrateio General Hospital of Thessaloniki|Semmelweis Egyetem|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar|Azienda Ospedaliera Universitaria Meyer|Childrens Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos|Uniwersytecki Szpital Dzieciecy w Krakowie|Centro Hospitalar Universitario do Porto - Hospital de Santo Antonio|Hospital Universitari Vall d Hebron|Royal Hospital for Sick Children|Great Ormond Street Hospital for Children",Drug,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Lithuania|Poland|Portugal|Spain|United Kingdom,2.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT03969329
2562,NCT03973450,Endocrine Neoplasia|Familial Tumor Syndrome|Hyperparathyroidism|Pituitary Tumor|Solid Tumor,"Epidemiology of Pituitary Tumours: Prevalence of Associated Endocrine and Non-endocrine Tumours and Potential Implications in the Management and Follow-up of Patients""",Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia,Endocrine Neoplasia|Familial Tumor Syndrome|Hyperparathyroidism|Pituitary Tumor|Solid Tumor,2019-05-25,2021-11-30,2022-02-28,400.0,Cohort,,Retrospective,Observational,Recruiting,,Neuromed IRCCS,Neuromed IRCCS,Neuromed,Other,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03973450
2564,NCT03975231,BRAF NP_004324.2:p.V600E|BRAF V600K Mutation Present|Thyroid Gland Anaplastic Carcinoma,A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer,"Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",BRAF NP_004324.2:p.V600E|BRAF V600K Mutation Present|Thyroid Gland Anaplastic Carcinoma,2019-06-03,2025-04-30,2025-04-30,6.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center|Ohio State University Comprehensive Cancer Center,Drug|Radiation|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03975231
2566,NCT03977207,Hemodialysis|Hypothyroidism|Thyroid; Functional Disturbance,A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients,A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients,Hemodialysis|Hypothyroidism|Thyroid; Functional Disturbance,2019-05-28,2024-06-30,2024-06-30,336.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of California, Irvine","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Irvine",University of California Irvine,Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03977207
2567,NCT03978351,Thyroid Cancer,The Role of Midkine in Diagnosis of Thyroid Cancer,The Role of Midkine in Diagnosis of Thyroid Cancer,Thyroid Cancer,2018-11-24,2020-11-30,2020-12-31,85.0,Case-Control,,Retrospective,Observational,Unknown status,,Assiut University,Assiut University,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03978351
2568,NCT03980132,"Hyperthyroidism, Autoimmune","Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.",Preoperative Preparation With Lugol Solution in Patients With Graves-Basedow Disease.,"Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,270.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa,Jess Mara Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clnico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clnico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Maran|Hospital Universitario Ramn y Cajal|Hospital Universitario Fundacin Jimnez Daz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Roco|Hospital Clnico Universitario|Hospital Clnico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03980132
2571,NCT03986437,Differentiated Thyroid Cancer,A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.,A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.,Differentiated Thyroid Cancer,2019-06-11,2021-05-21,2021-05-21,29.0,Cohort,,Prospective,Observational,Completed,,Institut Claudius Regaud,Institut Claudius Regaud,IUCT-O,,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03986437
2572,NCT03986593,Adrenal Neoplasm|Bone Metastases|Neoplasm Metastasis|Neuroendocrine Tumors|Pheochromocytoma|Thyroid Neoplasm,Cone-beam Computed Tomography Guided Percutaneous Cryoablation of Bone Metastases From Endocrine Tumors,Cryoablation of Bone Metastases From Endocrine Tumors,Adrenal Neoplasm|Bone Metastases|Neoplasm Metastasis|Neuroendocrine Tumors|Pheochromocytoma|Thyroid Neoplasm,2019-05-22,2022-06-15,2023-06-15,30.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Instituto do Cancer do Estado de So Paulo,Instituto do Cancer do Estado de So Paulo|University of Sao Paulo General Hospital,Instituto do Cancer do Estado de So Paulo,Device,Brazil,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03986593
2573,NCT03988517,Hypothyroidism,A Prospective Study Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan,Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan,Hypothyroidism,2019-06-11,2018-01-08,2018-01-08,106.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hamad Medical Corporation,Hamad Medical Corporation,Hamad General Hospital,Other,Qatar,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03988517
2577,NCT04000880,Breast Cancer|Colorectal Cancer|Endometrial Cancer|Kidney Cancer|Multiple Myeloma|Non-Hodgkin Lymphoma|Ovary Cancer|Prostate Cancer|Thyroid Cancer,Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health,Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health,Breast Cancer|Colorectal Cancer|Endometrial Cancer|Kidney Cancer|Multiple Myeloma|Non-Hodgkin Lymphoma|Ovary Cancer|Prostate Cancer|Thyroid Cancer,2019-06-21,2024-08-31,2024-08-31,652.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Alabama at Birmingham,National Cancer Institute (NCI)|University of Alabama at Birmingham|University of Tennessee Health Science Center,University of Alabama at Birmingham|University of Tennessee Health Science Center,Behavioral|Other|Other|Other,United States,50.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04000880
2578,NCT04009291,Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,"PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism","A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism",Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,2019-06-20,2020-03-06,2023-03-31,40.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 2,Ascendis Pharma A/S,Ascendis Pharma A/S,Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site,Combination Product|Combination Product,Canada|Denmark|Germany|Italy|Norway|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04009291
2580,NCT04009863,High Intensity Focused Ultrasound|Non Toxic Multinodular Goiter|RAI,"A Randomized, Open-label, Parallel-group Study to Determine the Efficacy of Sequential High-intensity Focused Ultrasound (HIFU) Ablation Versus Fixed-dose Radioiodine-131 Therapy in Moderate-sized Non-toxic Multinodular Goiter",HIFU Ablation vs Fixed-dose RAI-131 Therapy in Moderate-sized Non-toxic MNG,High Intensity Focused Ultrasound|Non Toxic Multinodular Goiter|RAI,2019-06-26,2022-02-20,2022-04-30,156.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device|Radiation,Hong Kong,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04009863
2581,NCT04012476,Hypocalcemia|Hypoparathyroidism Postprocedural|Total Thyroidectomy,Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy,Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy,Hypocalcemia|Hypoparathyroidism Postprocedural|Total Thyroidectomy,2019-06-28,2020-03-31,2020-10-31,40.0,,Single Group Assignment,,Interventional,Unknown status,Phase 4,Hospital Son Espases,Hospital Son Espases|Universitat de les Illes Balears,Hospital Universitari Son Espases,Drug,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04012476
2583,NCT04013100,Primary Hyperparathyroidism,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Primary Hyperparathyroidism,2019-07-05,2029-12-31,2029-12-31,800.0,Cohort,,Prospective,Observational [Patient Registry],Not yet recruiting,,IHU Strasbourg,IHU Strasbourg,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04013100
2587,NCT04013139,Ckd-Mbd,Evaluation of the Relationship Between Cardiopulmonary Exercise Testing (CPET ) Abnormalities and Ca-P Status in CKD Stage3-5,Relationship Between Cardiopulmonary Exercise Testing and Ca-P in Chronic Kidney Disease (CKD),Ckd-Mbd,2019-06-23,2021-08-01,2021-10-01,200.0,Cohort,,Prospective,Observational,Completed,,Shahid Beheshti University of Medical Sciences,Shahid Beheshti University of Medical Sciences,Nooshin Dalili,Diagnostic Test,"Iran, Islamic Republic of",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04013139
2590,NCT04019379,Chronic Kidney Disease Mineral and Bone Disorder|Chronic Kidney Diseases|Phosphorus and Calcium Disorders,Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease,Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease,Chronic Kidney Disease Mineral and Bone Disorder|Chronic Kidney Diseases|Phosphorus and Calcium Disorders,2019-07-09,2020-10-28,2022-12-01,3.0,,Crossover Assignment,,Interventional,Active not recruiting,Not Applicable,University of Minnesota,Indiana University|University of Minnesota,Indiana CTSI CRC,Other|Other,United States,30.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04019379
2593,NCT04025034,"Exophthalmos|Orbitopathy, Graves|Surgery",Deep Lateral Wall Partial Rim-Sparing Orbital Decompression With Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy,"Exophthalmos|Orbitopathy, Graves|Surgery",2019-07-15,2017-12-31,2019-01-01,35.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospital Universitario 12 de Octubre,Hospital del Ro Hortega|Hospital Universitario 12 de Octubre|The Queen Elizabeth Hospital,,Procedure,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04025034
2597,NCT04028479,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adenocarcinoma|Adenocystic Carcinoma|Adrenal Cancer|Anal Cancer|Appendix Cancer|Astrocytoma|Bile Duct Cancer|Bladder Cancer|Bone Cancer|Brain Stem Neoplasms|Brain Tumor|Breast Cancer|Cancer, Advanced|Cancer of Colon|Cancer of Pancreas|Carcinoid Tumor|Cervical Cancer|Cholangiocarcinoma|Chondrosarcoma|Chronic Myeloid Leukemia|CNS Cancer|Colon Cancer|Colorectal Cancer|Esophageal Cancer|Esophagus Cancer|Fallopian Tube Cancer|Gestational Trophoblastic Tumor|Glioblastoma|Head and Neck Neoplasms|Hepatic Cancer|Kidney Cancer|Larynx Cancer|Liposarcoma|Liver Cancer|Lung Cancer|Melanoma|Mesothelioma|Multiple Endocrine Neoplasia|Multiple Myeloma|Nasopharyngeal Carcinoma|Neuroendocrine Tumors|Non Hodgkin Lymphoma|Osteosarcoma|Ovarian Cancer|Pancreatic Cancer|Parathyroid Neoplasms|Parotid Tumor|Penile Cancer|Pharynx Cancer|Pheochromocytoma|Prostate Cancer|Pulmonary Carcinoma|Rectal Cancer|Renal Cell Carcinoma|Salivary Gland Cancer|Sarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Skin Cancer|Small Bowel Cancer|Small Cell Carcinoma|Stomach Cancer|Synovial Sarcoma|Testicular Cancer|Testis Cancer|Thymus Cancer|Thyroid Cancer|Tongue Cancer|Unknown Primary Tumors|Ureter Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia",The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT),The Registry of Oncology Outcomes Associated With Testing and Treatment,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adenocarcinoma|Adenocystic Carcinoma|Adrenal Cancer|Anal Cancer|Appendix Cancer|Astrocytoma|Bile Duct Cancer|Bladder Cancer|Bone Cancer|Brain Stem Neoplasms|Brain Tumor|Breast Cancer|Cancer, Advanced|Cancer of Colon|Cancer of Pancreas|Carcinoid Tumor|Cervical Cancer|Cholangiocarcinoma|Chondrosarcoma|Chronic Myeloid Leukemia|CNS Cancer|Colon Cancer|Colorectal Cancer|Esophageal Cancer|Esophagus Cancer|Fallopian Tube Cancer|Gestational Trophoblastic Tumor|Glioblastoma|Head and Neck Neoplasms|Hepatic Cancer|Kidney Cancer|Larynx Cancer|Liposarcoma|Liver Cancer|Lung Cancer|Melanoma|Mesothelioma|Multiple Endocrine Neoplasia|Multiple Myeloma|Nasopharyngeal Carcinoma|Neuroendocrine Tumors|Non Hodgkin Lymphoma|Osteosarcoma|Ovarian Cancer|Pancreatic Cancer|Parathyroid Neoplasms|Parotid Tumor|Penile Cancer|Pharynx Cancer|Pheochromocytoma|Prostate Cancer|Pulmonary Carcinoma|Rectal Cancer|Renal Cell Carcinoma|Salivary Gland Cancer|Sarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Skin Cancer|Small Bowel Cancer|Small Cell Carcinoma|Stomach Cancer|Synovial Sarcoma|Testicular Cancer|Testis Cancer|Thymus Cancer|Thyroid Cancer|Tongue Cancer|Unknown Primary Tumors|Ureter Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia",2019-07-17,2029-10-01,2031-10-01,100000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Taproot Health,Taproot Health,Teton Cancer Institute,Diagnostic Test|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04028479
2599,NCT04031339,Thyroid Neoplasms,"Multicenter, Prospective, Observational Study of Clinical Outcomes of Thyroid Cancer",Study of Clinical Outcomes of Thyroid Cancer,Thyroid Neoplasms,2019-06-25,2025-01-31,2025-01-31,15000.0,Cohort,,Prospective,Observational,Recruiting,,University of Roma La Sapienza,Catholic University of the Sacred Heart|Italian Thyroid Cancer Observatory (ITCO) Foundation|University of Roma La Sapienza,"Ospedali Riuniti di Ancona|Universit degli Studi di Bari|Azienda Unit Sanitaria di Bologna - Ospedale Maggiore|University of Bologna, S. Orsola Malpighi Hospital|ASST Valle Olona - Ospedale di Busto Arsizio|University of Florence|Ente Ospedaliero Ospedali Galliera|Sapienza University of Rome, Santa Maria Goretti Hospital|Tinchi Pisticci Hospital|University of Milan, Fondazione IRCCS, National Cancer Institute of Milan|University of Modena and Reggio Emilia|University of Naples Federico II|University of Parma|Bio-Medical Campus University|Sapienza University of Rome, Sant'Andrea Hospital|Sapienza University of Rome|University of Siena|University of Turin, Gradenigo Hospital|University of Turin, Molinette Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04031339
2600,NCT04031638,Patients With a Thyroid Tumor Who Received Radioactive Iodine Treatment,Prospective and Retrospective Thyroid Cancer Database,Thyroid Cancer Database,Patients With a Thyroid Tumor Who Received Radioactive Iodine Treatment,2019-07-01,2025-01-01,2025-01-01,2300.0,Cohort,,Prospective,Observational,Recruiting,,Centre Georges Francois Leclerc,Centre Georges Francois Leclerc,"Methodology, Biostatistics and Data Management",Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04031638
2601,NCT04040673,Thyroid Cancer|Thyroid Diseases,Evaluation of the Role of Vibrational Spectroscopy in the Diagnosis of Premalignant and Malignant Disease of the Thyroid RAFTER (RAman For Thyroid cancER),RAman For Thyroid cancER,Thyroid Cancer|Thyroid Diseases,2019-07-29,2022-10-01,2022-10-01,40.0,Case-Only,,Retrospective,Observational,Not yet recruiting,,Gloucestershire Hospitals NHS Foundation Trust,Gloucestershire Hospitals NHS Foundation Trust,Biophotonics Research Unit,Procedure|Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04040673
2602,NCT04040946,F18-choline|Hyperparathyroidism|Parathyroid Adenoma,Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,F18-choline|Hyperparathyroidism|Parathyroid Adenoma,2019-07-29,2022-05-05,2023-03-31,58.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|Fondation de l'Avenir,CHU Brest|Centre Franois Baclesse|Centre Eugne Marquis|CHU,Diagnostic Test|Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04040946
2606,NCT04046354,Ablation|Benign Thyroid Nodules,Clinical Trial of Microwave Ablation System,Microwave vs. Radiofrequency Ablation for Benign Thyroid Nodules: A Multicenter Randomized Controlled Trial Study,Ablation|Benign Thyroid Nodules,2019-08-05,2020-11-19,2021-12-31,149.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Device|Device,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04046354
2608,NCT04051099,Benign Tumor of Thyroid|Hyperparathyroidism,Bilateral Superficial Cervical Plexus Block Combined With Intravenous Sedation Versus General Anesthesia in Selected Patients for Thyroid/Parathyroid Surgery ; a Prospective Randomized Control Trial,Bilateral Superficial Cervical Plexus Block in Thyroid/Parathyroid Surgery,Benign Tumor of Thyroid|Hyperparathyroidism,2018-03-27,2021-09-30,2021-12-15,52.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure|Drug|Procedure|Procedure,Thailand,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04051099
2610,NCT04053114,Ovarian Cancer,MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii,MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii,Ovarian Cancer,2019-07-04,2019-12-31,2020-05-31,20.0,Other,,Retrospective,Observational,Unknown status,,Institut Bergoni,Institut Bergoni,Institut Bergoni,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04053114
2612,NCT04053647,Hypoparathyroidism|Quality of Life,Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy,Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy (Qol-Hypopara),Hypoparathyroidism|Quality of Life,2019-05-22,2020-06-24,2020-06-24,143.0,Case-Control,,Prospective,Observational,Completed,,Nantes University Hospital,"Central Hospital, Nancy, France|Centre Hospitalier le Mans|Nantes University Hospital|Piti-Salptrire Hospital|University Hospital, Angers|University Hospital, Limoges",CHU Angers|Centre Hospitalier Le Mans|CHU Limoges|CHU Nancy|CHU Nantes|AP-HP La Piti Salptrire,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04053647
2614,NCT04059380,Hypoparathyroidism|Hypoparathyroidism Due to Impaired Parathormone Secretion|Hypoparathyroidism Postprocedural,Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism: The EMPATHY Study,Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism (EMPATHY),Hypoparathyroidism|Hypoparathyroidism Due to Impaired Parathormone Secretion|Hypoparathyroidism Postprocedural,2019-08-14,2020-06-30,2020-07-31,40.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,University of Roma La Sapienza,University of Roma La Sapienza,"Department of Experimental Medicine, ""Sapienza"" University of Rome",,Italy,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04059380
2616,NCT04061980,BRAF NP_004324.2:p.V600M|BRAF V600E Mutation Present|Metastatic Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8,Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer,Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer,BRAF NP_004324.2:p.V600M|BRAF V600E Mutation Present|Metastatic Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8,2019-08-18,2022-07-30,2024-08-01,40.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Providence Health & Services,Providence Health & Services,Providence Portland Medical Center,Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04061980
2617,NCT04064827,Chronic Kidney Disease (CKD)|Secondary Hyperparathyroidism (SHPT),"A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis","A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)",Chronic Kidney Disease (CKD)|Secondary Hyperparathyroidism (SHPT),2019-08-20,2024-03-09,2026-10-30,16.0,,Single Group Assignment,,Interventional,Recruiting,Phase 3,AbbVie,AbbVie,"Arkansas Children's Hospital /ID# 225417|University of California, Los Angeles /ID# 140668|Children's National Medical Center /ID# 225991|Holtz Childrens Hospital, University of Miami /ID# 225636|Nicklaus Children's Hospital /ID# 210517|Emory Midtown Infectious Disease Clinic /ID# 140665|Boston Children's Hospital /ID# 162863|Levine Children's Specialty Center- Charlotte /ID# 216057|Children's Hospital of Philadelphia - Main /ID# 213802|University of Texas Southwestern Medical Center /ID# 210495|University of Utah /ID# 140669|Seattle Children's Hospital /ID# 162861|School of Medicine University of Puerto Rico-Medical Science Campus /ID# 140663",Drug,Puerto Rico|United States,0.0,9.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT04064827
2620,NCT04072731,Thyroid Cancer,SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer,SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer,Thyroid Cancer,2018-01-16,2017-07-30,2018-01-01,140.0,Cohort,,Retrospective,Observational,Completed,,People's Hospital of Zhengzhou University,People's Hospital of Zhengzhou University,the Affiliated Cancer Hospital of Xiangya Medical School,Other,China,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04072731
2621,NCT04075851,Autoimmune Thyroid Disease,The Prevalence of Serum Thyroid Hormone Autoantibodies in Autoimmune Thyroid Diseases,The Prevalence of Serum Thyroid Hormone Autoantibodies in Autoimmune Thyroid Diseases,Autoimmune Thyroid Disease,2019-08-29,2022-08-01,2022-08-01,600.0,Cohort,,Cross-Sectional,Observational,Recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Province Hospital,,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04075851
2624,NCT04076514,Papillary Thyroid Cancer,The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma,The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma,Papillary Thyroid Cancer,2019-08-28,2020-09-30,2020-11-01,20.0,Case-Only,,Prospective,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Kamel,Procedure,Egypt,16.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04076514
2626,NCT04080505,Graves Disease,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04080505
2629,NCT04085419,Osteoporosis|Primary Hyperparathyroidism,Management of Osteoporosis in Patients With Primary Hyperparathyroidism,Osteoporosis in Primary Hyperparathyroidism,Osteoporosis|Primary Hyperparathyroidism,2019-09-02,2022-05-31,2022-05-31,40.0,,Parallel Assignment,,Interventional,Enrolling by invitation,Phase 4,University Medical Centre Ljubljana,University Medical Centre Ljubljana,Endocrinology Department,Drug|Drug,Slovenia,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04085419
2632,NCT04085913,Parathyroid Adenoma|Thyroid,Intraoperative Injection of Exparel Effect on Postoperative Opioid Use in Thyroid and Parathyroid Surgery,Exparel Injection Effect on Postoperative Opioid Usage,Parathyroid Adenoma|Thyroid,2019-06-21,2023-07-31,2023-07-31,100.0,,Crossover Assignment,,Interventional,Enrolling by invitation,Early Phase 1,University of Missouri-Columbia,University of Missouri-Columbia,University of Missouri,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04085913
2634,NCT04096612,Thyroid Eye Disease,The Therapeutic Effect of Dysthyroid Optic Neuropathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,Thyroid Eye Disease,2018-12-27,2018-12-31,2019-12-31,20.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Opthalmic Center,Procedure,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04096612
2638,NCT04098991,Hypothyroidism,Improving White Matter Integrity With Thyroid Hormone,Improving White Matter Integrity With Thyroid Hormone,Hypothyroidism,2018-02-27,2019-11-08,2019-11-08,5.0,Cohort,,Prospective,Observational,Completed,,University of Illinois at Chicago,National Institute of Neurological Disorders and Stroke (NINDS)|University of Illinois at Chicago,University of Illinois at Chicago,Drug,United States,21.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04098991
2639,NCT04104529,Neuroendocrine Tumors|Prostate Cancer|Thyroid Cancer,Establishment of a Monocentric and Prospective Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department,Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department,Neuroendocrine Tumors|Prostate Cancer|Thyroid Cancer,2019-09-24,2024-10-31,2024-10-31,350.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Institut du Cancer de Montpellier - Val d'Aurelle,Institut du Cancer de Montpellier - Val d'Aurelle,Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04104529
2640,NCT04106596,Autoimmune Cerebellar Ataxia|Autoimmune Encephalitis|Imbic Encephalitis|Stiff-person Syndrome,Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis,HLA Analysis in Autoimmune Encephalitis and Related Disorders,Autoimmune Cerebellar Ataxia|Autoimmune Encephalitis|Imbic Encephalitis|Stiff-person Syndrome,2019-09-25,2020-02-01,2020-10-01,160.0,Case-Control,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de rfrence des syndromes neurologiques paranoplasiques et encphalites auto-immunes,,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04106596
2643,NCT04106843,Locally Advanced Adrenal Gland Pheochromocytoma|Locally Advanced Paraganglioma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Paraganglioma|Metastatic Parathyroid Gland Carcinoma|Pituitary Gland Carcinoma|Somatostatin Receptor Positive|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Unresectable Adrenal Gland Pheochromocytoma|Unresectable Paraganglioma,"A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma","Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers",Locally Advanced Adrenal Gland Pheochromocytoma|Locally Advanced Paraganglioma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Paraganglioma|Metastatic Parathyroid Gland Carcinoma|Pituitary Gland Carcinoma|Somatostatin Receptor Positive|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Unresectable Adrenal Gland Pheochromocytoma|Unresectable Paraganglioma,2019-09-25,2020-09-03,2020-09-03,0.0,,Single Group Assignment,,Interventional,Withdrawn,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04106843
2644,NCT04124705,Euthyroid|Hypothyroidism|Thyroid Disease|Thyroid Gland|Thyroid Hormones,"A Multicenter, Randomized, Double-blind, Dose-conversion Study to Evaluate the Safety and Efficacy of Hormone Replacement Therapy With Armour Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants Who Are Euthyroid on T4 Replacement Therapy",A Study of Armour Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants,Euthyroid|Hypothyroidism|Thyroid Disease|Thyroid Gland|Thyroid Hormones,2019-10-10,2021-06-22,2021-06-22,284.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Allergan,Allergan,"Central Research Associates /ID# 237950|Atria Clinical Research /ID# 237986|NorCal Medical Research Inc /ID# 235210|Diabetes-Lipid Management & Research Center /ID# 235716|Center for Excellence in Diabetes and Endocrinology /ID# 238120|Care Access Research /ID# 238026|San Fernando Valley Health Institute /ID# 238258|Creekside Endocrine Associates PC /ID# 235866|The Center for Diabetes and Endocrine Care /ID# 235853|Metabolic Research Inst /ID# 236809|Atlanta Diabetes Associates /ID# 235032|Columbus Regional Research Ins /ID# 237199|Physicians Research Associates, LLC /ID# 238088|Kentucky Diabetes Endocrinology Center /ID# 235714|L-MARC Research Center /ID# 236701|Mountain Diabetes and Endocrine Center /ID# 235202|Physician's East Endocrinology /ID# 235204|OnSite Clinical Solutions, LLC - Hickory /ID# 238023|Texas Diabetes and Endocrinology - Central Austin /ID# 237137|Texas Diabetes and Endocrinology - South Austin /ID# 238071|North TX Endocrine Center /ID# 237652|Research Institute Dallas /ID# 237655|Academy of Diabetes Thyroid and Endocrine /ID# 235870|Texas Diabetes & Endocrinology /ID# 235860|Diabetes & Glandular Disease Clinic P.A. /ID# 235894|Rainier Clinical Research Center LLC /ID# 235211|MultiCare Institute for Research & Innovation /ID# 236022|Multicare Institute for Research and Innovation /ID# 236977",Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04124705
2645,NCT04126941,Hypoparathyroidism,Bi-daily Injection of Subcutaneous Teriparatide in Children With Hypoparathyroidism: Single-center Experience,Monocentric Study on the Use of Teriparatide in Children With hypoparathyrodism,Hypoparathyroidism,2019-10-11,2020-06-30,2020-12-31,9.0,Cohort,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Service de Nphrologie, Rhumatologie et Dermatologie Pdiatriques - Hpital Femme Mre Enfant",Other,France,2.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04126941
2647,NCT04126954,"Hyperparathyroidism, Primary|Hyperparathyroidism, Secondary",Multicentric Retrospective Study on the Use of Cinacalcet in an Off-label Phosphocalcic Context,Study on the Use of Cinacalcet in Phosphocalcic Context.,"Hyperparathyroidism, Primary|Hyperparathyroidism, Secondary",2019-10-11,2021-01-31,2023-12-31,25.0,Cohort,,Retrospective,Observational,Not yet recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Endocrinologie Diabte et Maladies Mtaboliques - Hpital Gabriel Montpied|Service de Nphrologie Pdiatrique -Hpital Jeanne de Flandre|Service d'Endocrinologie Pdiatrique - Hpital de la mre et de l'Enfant|Pole Femme Mre Enfant - Pdiatrie spcialise - Centre Hospitalier Universitaire|Service de Nphrologie pdiatrique - Clinique Mdicale Pdiatrique|Service d'endocrinologie et Diabtologie Pdiatrique-Hpital Robert Debr|Service de Diabtologie et endocrinologie pdiatriques - Centre Hospitalier Universitaire|Ple Nphrologie-Urologie-Diabtologie-Endocrinologie|Service d'Endocrinologie, Maladies Osseuses, Gyncologie, Gntique|Unit Endocrinologie, Nutrition, Diabtologie -Hpital Bretonneau",Other,France,0.0,99.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04126954
2651,NCT04128631,Thyroid Cancer,Role of of F-18-fluoro-deoxy-glucose (FDG) PET/CT in Thyroid Cancer Patients With Negative I-131whole Body Scan and Elevated Thyroglobulin Level or Positive Anti Thyroglobulin Antibodies,Thyroid Cancer and (FDG)PET/CT Scan,Thyroid Cancer,2019-09-26,2020-09-01,2020-12-01,35.0,Other,,Prospective,Observational [Patient Registry],Unknown status,,Assiut University,Assiut University,,,,10.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04128631
2652,NCT04129281,Papillary Microcarcinoma of the Thyroid,Prospective Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma,Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma,Papillary Microcarcinoma of the Thyroid,2019-10-15,2022-01-23,2023-02-23,40.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"National Cancer Institute, Naples","National Cancer Institute, Naples",Istitute Nazionale Tumori - Fondazione G. Pascale,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04129281
2653,NCT04129411,Papillary Thyroid Cancer|Papillary Thyroid Microcarcinoma,Pilot Study for the Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation,Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation,Papillary Thyroid Cancer|Papillary Thyroid Microcarcinoma,2019-10-04,2022-03-31,2022-03-31,5.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Device,United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04129411
2655,NCT04133870,Thyroid Cancer,Exploratory Study of the Molecular Profile of Thyroid Cancer,Identification of Molecular Biomarkers for Thyroid Cancer,Thyroid Cancer,2017-01-26,2018-04-30,2020-07-30,52.0,Cohort,,Prospective,Observational,Unknown status,,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04133870
2656,NCT04135573,Graves Disease,Mechanism of NK Cell Disfunction in Graves' Disease,The Relationship Between NK Cell and Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,200.0,Case-Control,,Prospective,Observational [Patient Registry],Active not recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04135573
2659,NCT04136912,Breast Cancer|Thyroid Cancer,High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging,3-D Super Resolution Ultrasound Microvascular Imaging,Breast Cancer|Thyroid Cancer,2019-10-21,2023-12-31,2023-12-31,35.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI)|UNC Lineberger Comprehensive Cancer Center,Univeristy of North Carolina Chapel Hill,Drug|Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04136912
2660,NCT04137185,Differentiated Thyroid Cancer,"Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients","Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients",Differentiated Thyroid Cancer,2019-09-20,2022-12-30,2022-12-30,64.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04137185
2661,NCT04139096,Genetic Susceptibility|Radiation Exposure|Thyroid Neoplasms,Genetic Susceptibility to Radiation Induced Thyroid Cancer,Genetic Susceptibility to Radiation Induced Thyroid Cancer,Genetic Susceptibility|Radiation Exposure|Thyroid Neoplasms,2019-10-09,2020-04-30,2020-04-30,60.0,Case-Control,,Retrospective,Observational,Unknown status,,"Institut National de la Sant Et de la Recherche Mdicale, France","Institut National de la Sant Et de la Recherche Mdicale, France",Gustae Roussy,,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04139096
2662,NCT04141306,Bone Metastases|Thyroid Cancer,"Radioiodine-avid Bone Metastases From Differentiated Thyroid Cancer Without Structural Abnormality, a Singular Entity With Heterogeneous Outcomes.",Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality,Bone Metastases|Thyroid Cancer,2019-10-22,2019-12-31,2019-12-31,30.0,Cohort,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,,Other|Other|Other|Other|Other|Other,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04141306
2663,NCT04141540,Di George Syndrome,"Translational 22q11.2:""Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With Variable Phenotypic 22q11.2 Microdeletional Syndrom""",Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With Variable Phenotypic 22q11,Di George Syndrome,2019-10-24,2020-11-30,2020-12-30,2.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Hpital le Vinatier,Hpital le Vinatier,Hopital Vinatier,Genetic,France,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04141540
2665,NCT04146259,Hypoparathyroidism Postprocedural,Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism,Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism,Hypoparathyroidism Postprocedural,2019-10-29,2018-12-31,2019-08-01,109.0,Cohort,,Prospective,Observational,Completed,,University of Athens,University of Athens,Symeon Tournis,Drug,Greece,19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04146259
2667,NCT04160637,Hormone Disturbance|Hypocalcemia|Parathyroid Dysfunction|Postoperative Complications|Thyroid,Early Postoperative Serum Parathyroid Hormone Levels as a Predictor of Hypocalcaemia After Total Thyroidectomy: A Prospective Non-Randomized Study,Is There Benefit From Early Postoperative PTH Monitoring?,Hormone Disturbance|Hypocalcemia|Parathyroid Dysfunction|Postoperative Complications|Thyroid,2019-11-09,2019-12-01,2019-12-31,120.0,Cohort,,Prospective,Observational,Unknown status,,"University Hospital ""Sestre Milosrdnice""","University Hospital ""Sestre Milosrdnice""",University Hospital Center Sestre milosrdnice,Diagnostic Test,Croatia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04160637
2668,NCT04161391,Advanced Solid Tumor|Medullary Thyroid Cancer|Metastatic Solid Tumor|Non Small Cell Lung Cancer|RET Gene Mutation,"A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations","Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations",Advanced Solid Tumor|Medullary Thyroid Cancer|Metastatic Solid Tumor|Non Small Cell Lung Cancer|RET Gene Mutation,2019-11-11,2025-12-31,2026-11-30,462.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"Turning Point Therapeutics, Inc.","Turning Point Therapeutics, Inc.","UCI Health - Chao Family Comprehensive Cancer Center|UC San Diego Moores Cancer Center|University of Colorado, Denver|Sarah Cannon Research Institute at HealthONE|Georgetown University Medical Center|Moffitt Cancer Center|Winship Cancer Institute, Emory University|University of Chicago Medical Center|Massachusetts General Hospital|Karmanos Cancer Institute|Memorial Sloan Kettering Cancer Center|Fox Chase Cancer Center|MD Anderson Cancer Center|Virginia Cancer Specialists|The University of Washington, Seattle Cancer Care Alliance|Severance Hospital, Yonsei University Health System",Drug,"Korea, Republic of|United States",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04161391
2669,NCT04171622,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,25.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04171622
2671,NCT04175522,Autoimmune Encephalitis,"A Phase 2a, Prospective, Open-label, Single-arm, Single Center, Proof of Concept Study to Evaluate the Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis",Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:,Autoimmune Encephalitis,2019-11-21,2020-06-11,2020-06-11,23.0,,Single Group Assignment,,Interventional,Completed,Phase 2,Green Cross Corporation,Green Cross Corporation,Seoul National University Hospital,Drug,"Korea, Republic of",12.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04175522
2674,NCT04178928,Subclinical hypothyrodism,Can Levothyroxine Treatment Reduce the Development of Cardio-metabolic Disorder in Subclinical Hypothyroidism?,Can Levothyroxine Treatment Reduce the Development of Cardio-metabolic Disorder in Subclinical Hypothyroidism?,Subclinical hypothyrodism,2019-11-25,2021-01-31,2021-02-28,40.0,,Parallel Assignment,,Interventional,Unknown status,Phase 1/Phase 2,Ain Shams University,Ain Shams University,,Drug,,5.0,15.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT04178928
2675,NCT04180007,Apatinib|Metastasis|Thyroid,Evaluating the Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen,Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers,Apatinib|Metastasis|Thyroid,2019-11-24,2020-04-10,2020-05-30,10.0,,Single Group Assignment,,Interventional,Unknown status,Phase 2,"Nanjing First Hospital, Nanjing Medical University","Nanjing First Hospital, Nanjing Medical University",Nanjing First Hospital,Drug,China,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04180007
2676,NCT04193332,Hypocalcemia|Hypoparathyroidism Postprocedural|Surgery--Complications,Near Infrared (NIR) Autofluorescence Image-guided Thyroid Surgery Can Prevent Post-thyroidectomy Hypoparathyroidism,Near Infrared (NIR) Autofluorescence Image-guided Thyroid Surgery,Hypocalcemia|Hypoparathyroidism Postprocedural|Surgery--Complications,2019-12-06,2023-10-01,2023-12-01,214.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"Rigshospitalet, Denmark","Cluster for molecular imaging, Denmark|Dept of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Denmark|Rigshospitalet, Denmark","Rigshospitalet|Dept of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Denmark",Device,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04193332
2678,NCT04197960,Papillary Thyroid Carcinoma,A Prospective Multicenter Study to Compare the Therapeutic Outcomes of Microwave Ablation With Surgical Resection for Micropapillary Thyroid Carcinoma,Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2019-12-04,2020-09-30,2022-12-31,820.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Procedure|Procedure,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04197960
2680,NCT04209179,Hypoparathyroidism,"A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients With Hypoparathyroidism","A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism",Hypoparathyroidism,2019-11-28,2020-12-28,2021-05-25,5.0,,Sequential Assignment,,Interventional,Terminated,Phase 1,Chugai Pharmaceutical,Chugai Pharmaceutical,"The Lundquist Institute|University of Chicago|Indiana University School of Medicine|University of Kentucky|Massachusetts General Hospital|Mayo Clinic|Ohio State University Wexner Medical Center|Thomas Jefferson University|Endocrinologie et nphrologie Centre de recherche du CHU de Qubec|McMaster University Bone Research & Education Centre|Semmelweis Egyetem, ltalnos Orvostudomnyi Kar, Belgygyszati s Onkolgiai Klinika",Drug|Drug,Canada|Hungary|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04209179
2682,NCT04211337,Medullary Thyroid Cancer,"A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Nave, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)",A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer,Medullary Thyroid Cancer,2019-12-24,2024-05-20,2026-11-13,400.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","University of Alabama at Birmingham|Mayo Clinic Hospital|City of Hope National Medical Center|UCLA Medical Center|University of California, Davis - Health Systems|UCSF Medical Center at Mission Bay|Los Angeles Biomedical Research Institute at Harbor - UCLA Medical|Mayo Clinic in Florida|Emory University|University of Chi Med Center|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University Medical School|Memorial Sloan Kettering Cancer Center|University of Cincinnati Cancer Institute|Ohio State University Medical Center|University of Pennsylvania Hospital|Thomas Jefferson University|University of Texas MD Anderson Cancer Center|University of Wisconsin-Madison Hospital and Health Clinic|Chris O'Brien Lifehouse|Royal North Shore Hospital|Peter MacCallum Cancer Centre|The Alfred Hospital|Sir Charles Gairdner Hospital|Universitair Ziekenhuis Antwerpen|Centre Hospitalier Universitaire Sart Tilman|Oncocentro BH|Hospital de Cancer de Londrina|Hospital de Clinicas de Porto Alegre|Instituto de Educao, Pesquisa e Gesto em Sade|Fundao Pio XII - Hospital de Cncer de Barretos|Clinica Onco Star|Hospital PUC-CAMPINAS|Hospital das Clinicas da FMRP|INCA Hospital do Cncer III|Oncoclinicas Rio de Janeiro S.A.|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology|Icesp - Instituto Do Cncer Do Estado de So Paulo|Centro Paulista de Oncologia|London Health Science Centre - Victoria Hospital|Princess Margaret Hospital|Anhui Provincial Hospital|Beijing Tongren Hospital affiliated to Capital Medical Unive|The First Affiliated Hospital of Fujian Medical University|Gansu Province Cancer Hospital|Sun Yat-sen University Cancer Center|Harbin Medical University Cancer Hospital|Henan Cancer Hospital|Hunan Cancer Hospital|Jilin Cancer Hospital|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School|Jinan Central Hospital|Fudan University Shanghai Cancer Center|West China Hospital of Sichuan University|First Affiliated Hospital of Kunming Medical University|Zhejiang Provincial People's Hospital|Sir Run Run Shaw Hospital|Zhejiang Cancer Hospital|Chongqing Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Fakultni nemocnice Brno|Fakultni nemocnice Olomouc|Fakultni Nemocnice v Motole|Assistance Publique Hpitaux de Marseille - Hpital Nord|Centre Georges Franois Leclerc|Centre Hospitalier Universitaire d'Angers|Centre Jean Perrin - Centre Rgional de Lutte contre le Cancer d'Auvergne|Centre Leon Berard|Institut Bergoni - Centre Rgional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest|Centre Franois Baclesse|Hpital C. HURIEZ|Hopital Pitie Salpetriere -Unit Thyrode-Tumeurs Endocrines|Institut de cancrologie Strasbourg Europe|Institut Claudius Regaud|Gustave Roussy|Klinikum der Universitt Mnchen Grohadern|Universittsklinikum Wrzburg A. . R.|Medizinische Hochschule Hanover|Universittsmedizin Johannes Gutenberg Universitt Mainz|Charit Campus Mitte|Universitaetsklinikum Essen|Studiengesellschaft Hmato-Onkologie Hamburg - Prof Laack & Partner|Otto-von-Guericke-Universitt|Alexandra General Hospital of Athens|University General Hospital of Heraklion|European Interbalkan Medical Center|Regional Cancer Centre|HCG Manavata Cancer Centre|Ruby Hall Clinic and Grant Medical Foundation|Deenanath Mangeshkar Hospital & Research Centre|Apollo Gleneagles Hospitals Kolkata|Postgraduate Institute of Medical Education & Research|Hadassah Medical Center|Rabin Medical Center|Sheba Medical Center|Istituto Nazionale dei Tumori|Ospedale San Luca, IRCCS Istituto Auxologico|Polic.Umberto I -Univ. La Sapienza|A.O.U. Senese Policlinico Santa Maria alle Scotte|Istituto Oncologico Veneto IRCCS|Ospedale Garibaldi-Nesima|Azienda Ospedaliera Universitaria Federico II|Azienda Ospedlaliero-Univeristaria Pisana, Stabilimento Ospedaliero di Cisanello|I.F.O. Istituto Nazionale Tumori Regina Elena|Azienda Ospedaliero-Universitaria S.Giovanni Battista|Aichi Cancer Center Hospital|National Cancer Center Hospital East|Hokkaido University Hospital|Kobe University Hospital|Yokohama City University Hospital|Osaka University Hospital|Japanese Foundation for Cancer Research|National Hospital Organization Kyushu Medical Center|National Cancer Center|Seoul National University Bundang Hospital|Chonnam National University Hwasun Hospital|Seoul National University Hospital|Severance Hospital, Yonsei University Health System|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek|University Medical Center Groningen|Leids Universitair Medisch Centrum|Maastricht UMC+|Erasmus Medisch Centrum|Narodowy Instytut Onkologii im. Marii Skodowskiej-Curie|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej|National medical research center of radiology Obninsk|Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (policlinic, hospital)|LLC Evimed|Blokhin Cancer Research Center|National Medical Research Center of Endocrinology of Ministry of Health Dept|Saint-Petersburg City Clinical Oncology Dispensary|Hospital Universitario Virgen de la Victoria|Hospital Universitari Vall d'Hebron|Hospital Universitari de Girona Dr. Josep Trueta|Hospital Universitario Ramn y Cajal|Clinica Universidad de Navarra|Clinica Universitaria De Navarra|Institut Catala d'Oncologia|Hospital General Universitario Gregorio Maraon|Hospital Clinico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital Universitario Miguel Servet|China Medical University Hospital|National Cheng-Kung Uni. Hosp.|National Taiwan University Hospital|Gartnavel General Hospital|University College Hospital - London|Royal Marsden NHS Trust|Velindre Cancer Centre|Weston Park Hospital|Royal Marsden Hospital",Drug|Drug|Drug,"Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Taiwan|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04211337
2683,NCT04216732,Advanced Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management,Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management,Advanced Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,2019-11-14,2023-09-01,2023-09-01,2030.0,Cohort,,Prospective,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),University of California San Francisco|M D Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04216732
2684,NCT04224792,Thyroid Cancer,Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors,Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors,Thyroid Cancer,2020-01-08,2024-09-30,2024-12-30,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04224792
2685,NCT04233398,Thyroid Nodule (Benign),"A Multi-center, Randomized, Controlled Trial of High Intensity Focused Ultrasound (HIFU) Treatment of Benign Thyroid Nodules",HIFU Treatment of Benign Thyroid Nodules,Thyroid Nodule (Benign),2020-01-15,2023-11-30,2023-11-30,240.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Theraclion,Theraclion,,Device,,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04233398
2687,NCT04236232,Hypothyroidism,The Impact of Subclinical Hypothyroidism on the Cardiovascular System,The Impact of Subclinical Hypothyroidism on Cardiovascular System,Hypothyroidism,2019-09-24,2021-05-01,2021-06-01,100.0,Other,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test,,18.0,55.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04236232
2688,NCT04238624,Anaplastic Thyroid Cancer|BRAF Gene Mutation|BRAF Mutation-Related Tumors|Thyroid Cancer,"A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib",Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|BRAF Gene Mutation|BRAF Mutation-Related Tumors|Thyroid Cancer,2020-01-21,2022-06-20,2022-06-20,15.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited Protocol Activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau (Limited Protocol Activities),Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04238624
2690,NCT04239521,Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,51955.0,Cohort,,Retrospective,Observational,Active not recruiting,,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04239521
2696,NCT04240821,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism|Pseudohypoparathyroidism Type 1a,Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism,Theophylline for Treatment of Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism|Pseudohypoparathyroidism Type 1a,2020-01-21,2025-06-30,2025-06-30,34.0,,Single Group Assignment,,Interventional,Enrolling by invitation,Phase 2,Vanderbilt University Medical Center,Ashley Shoemaker,Vanderbilt University Medical Center,Drug,United States,2.0,99.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04240821
2698,NCT04248114,Thyroid Nodule,The Natural Neck Crease as an Anatomic Landmark for Thyroid Surgery Incision,Skin-crease Thyroidectomy,Thyroid Nodule,2020-01-28,2018-08-31,2018-08-31,118.0,Case-Only,,Retrospective,Observational,Completed,,Western Galilee Hospital-Nahariya,Western Galilee Hospital-Nahariya,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04248114
2700,NCT04248166,Thyroid Cancer|Thyroid Nodule,Diagnosis of Thyroid Cancer Using Photoacoustic Imaging,Thyroid Cancer and Photoacoustic Imaging,Thyroid Cancer|Thyroid Nodule,2020-01-28,2020-06-30,2020-12-31,100.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Seoul St. Mary's Hospital,Pohang University of Science and Technology|Seoul St. Mary's Hospital,Seoul St. Mary's hospital,Device,"Korea, Republic of",19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04248166
2702,NCT04252001,Addison's Disease|Androgen Insensitivity Syndrome|Combined Pituitary Hormone Deficiency|Congenital Adrenal Hyperplasia|Growth Hormone Deficiency|Hypogonadotropic Hypogonadism|Klinefelter Syndrome|Thyroid Dysgenesis|Turner Syndrome,Growing up With the Young Endocrine Support System (YESS!): Innovative E-technology to Improve Transition From Paediatric to Adult Care,Growing up With the Young Endocrine Support System (YESS!),Addison's Disease|Androgen Insensitivity Syndrome|Combined Pituitary Hormone Deficiency|Congenital Adrenal Hyperplasia|Growth Hormone Deficiency|Hypogonadotropic Hypogonadism|Klinefelter Syndrome|Thyroid Dysgenesis|Turner Syndrome,2020-01-21,2022-12-01,2023-12-01,160.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Erasmus Medical Center,dr. Laura C. G. de Graaff-Herder,Ghent University Hospital|Erasmus Medical Center|Hospital Infantil Universitario Nio Jess|Queen Elizabeth University Hospital|Royal Hospital for Children|The Royal London Hospital (Barts Health NHS Trust)|University College London Hospital (UCL Institute of Child Health),Device|Device|Other,Belgium|Netherlands|Spain|United Kingdom,15.0,20.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04252001
2703,NCT04267965,Secondary Hyperparathyroidism Due to Renal Causes,"Changes of Pulmonary Function, Voice and Swallowing Symptoms After Total Parathyroidectomy for Secondary Hyperparathyroidism in the Presence of Intact Recurrent Laryngeal Nerve","Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy",Secondary Hyperparathyroidism Due to Renal Causes,2020-01-22,2019-07-31,2019-07-31,48.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Fong-Fu Chou,Procedure,Taiwan,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04267965
2706,NCT04268407,Thyroid Nodule,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,Thyroid Nodule,2020-02-07,2021-07-31,2021-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,,Drug,,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04268407
2708,NCT04270110,Subclinical hypothyrodism,Assessment of Bone Mineral Density in Patients With Subclinical Hypothyroidism,Assessment of Bone Mineral Density in Patients With Subclinical Hypothyroidism,Subclinical hypothyrodism,2020-01-16,2020-12-01,2021-12-31,100.0,Case-Control,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,Assiut university Hospital,,Egypt,0.0,55.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04270110
2709,NCT04274829,Lymph Node Metastases|Thyroid Cancer,Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid,Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid,Lymph Node Metastases|Thyroid Cancer,2020-02-15,2018-01-31,2020-02-29,300.0,Case-Control,,Retrospective,Observational,Completed,,University of Cagliari,University of Cagliari,AOU Cagliari,Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04274829
2710,NCT04280081,Medullary Thyroid Cancer|Solid Tumor,"A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation",Medullary Thyroid Cancer|Solid Tumor,2020-02-20,2021-03-25,2025-11-20,75.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","Nanfang Affiliated Hospital South Medical University|The First Affiated Hospital Of Guangzhou Medical Collage|Hunan Cancer Hospital|Jilin Province Tumor Hospital|Jinan Central Hospital|Shanghai Chest Hospital|Zhejiang Cancer Hospital|First Affiliated Hosp of College of Med, Zhejiang University|Zhejiang Provincial People's Hospital|Beijing Cancer Hospital|Fudan University Shanghai Cancer Center|Shanghai East Hospital|Tianjin Medical University Cancer Institute & Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04280081
2711,NCT04281875,Postoperative Hypoparathyroidism|Thyroid Cancer|Thyroid Neoplasms,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Postoperative Hypoparathyroidism|Thyroid Cancer|Thyroid Neoplasms,2020-02-19,2023-03-31,2023-09-30,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04281875
2714,NCT04284774,Malignant Solid Neoplasm|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Ectomesenchymoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Kidney Wilms Tumor|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Medulloblastoma|Recurrent Melanoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdoid Tumor of the Kidney|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Carcinoma|Recurrent WHO Grade 2 Glioma|Refractory Adrenal Gland Pheochromocytoma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Medulloblastoma|Refractory Melanoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdoid Tumor of the Kidney|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Thyroid Gland Carcinoma|Refractory WHO Grade 2 Glioma,NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations,"Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial",Malignant Solid Neoplasm|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Ectomesenchymoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Kidney Wilms Tumor|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Medulloblastoma|Recurrent Melanoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdoid Tumor of the Kidney|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Carcinoma|Recurrent WHO Grade 2 Glioma|Refractory Adrenal Gland Pheochromocytoma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Medulloblastoma|Refractory Melanoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdoid Tumor of the Kidney|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Thyroid Gland Carcinoma|Refractory WHO Grade 2 Glioma,2020-02-25,2027-09-30,2027-09-30,49.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Providence Alaska Medical Center|Banner Children's at Desert|Phoenix Childrens Hospital|Banner University Medical Center - Tucson|Arkansas Children's Hospital|Kaiser Permanente Downey Medical Center|City of Hope Comprehensive Cancer Center|Loma Linda University Medical Center|Miller Children's and Women's Hospital Long Beach|Children's Hospital Los Angeles|Cedars Sinai Medical Center|Mattel Children's Hospital UCLA|Valley Children's Hospital|UCSF Benioff Children's Hospital Oakland|Kaiser Permanente-Oakland|Children's Hospital of Orange County|Lucile Packard Children's Hospital Stanford University|University of California Davis Comprehensive Cancer Center|Rady Children's Hospital - San Diego|Naval Medical Center -San Diego|UCSF Medical Center-Mission Bay|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Children's Hospital Colorado|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Yale University|Alfred I duPont Hospital for Children|MedStar Georgetown University Hospital|Children's National Medical Center|Broward Health Medical Center|Golisano Children's Hospital of Southwest Florida|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|Nemours Children's Clinic-Jacksonville|University of Miami Miller School of Medicine-Sylvester Cancer Center|Nicklaus Children's Hospital|Miami Cancer Institute|AdventHealth Orlando|Arnold Palmer Hospital for Children|Nemours Children's Hospital|Sacred Heart Hospital|Johns Hopkins All Children's Hospital|Tampa General Hospital|Saint Joseph's Hospital/Children's Hospital-Tampa|Saint Mary's Hospital|Children's Healthcare of Atlanta - Egleston|Memorial Health University Medical Center|Kapiolani Medical Center for Women and Children|Saint Luke's Cancer Institute - Boise|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago Comprehensive Cancer Center|Loyola University Medical Center|Saint Jude Midwest Affiliate|Southern Illinois University School of Medicine|Riley Hospital for Children|Saint Vincent Hospital and Health Care Center|Blank Children's Hospital|University of Iowa/Holden Comprehensive Cancer Center|University of Kentucky/Markey Cancer Center|Norton Children's Hospital|Children's Hospital New Orleans|Ochsner Medical Center Jefferson|Eastern Maine Medical Center|Maine Children's Cancer Program|University of Maryland/Greenebaum Cancer Center|Sinai Hospital of Baltimore|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute|UMass Memorial Medical Center - University Campus|C S Mott Children's Hospital|Wayne State University/Karmanos Cancer Institute|Helen DeVos Children's Hospital at Spectrum Health|Bronson Methodist Hospital|Beaumont Children's Hospital-Royal Oak|Children's Hospitals and Clinics of Minnesota - Minneapolis|University of Minnesota/Masonic Cancer Center|Mayo Clinic in Rochester|University of Mississippi Medical Center|Children's Mercy Hospitals and Clinics|Cardinal Glennon Children's Medical Center|Washington University School of Medicine|Mercy Hospital Saint Louis|Children's Hospital and Medical Center of Omaha|University of Nebraska Medical Center|University Medical Center of Southern Nevada|Sunrise Hospital and Medical Center|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Summerlin Hospital Medical Center|Renown Regional Medical Center|Dartmouth Hitchcock Medical Center|Hackensack University Medical Center|Morristown Medical Center|Saint Peter's University Hospital|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital|Albany Medical Center|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|NYU Winthrop Hospital|The Steven and Alexandra Cohen Children's Medical Center of New York|Laura and Isaac Perlmutter Cancer Center at NYU Langone|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|University of Rochester|Stony Brook University Medical Center|State University of New York Upstate Medical University|New York Medical College|Mission Hospital|UNC Lineberger Comprehensive Cancer Center|Carolinas Medical Center/Levine Cancer Institute|Novant Health Presbyterian Medical Center|Duke University Medical Center|East Carolina University|Wake Forest University Health Sciences|Sanford Broadway Medical Center|Children's Hospital Medical Center of Akron|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|Cleveland Clinic Foundation|Nationwide Children's Hospital|Dayton Children's Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|University of Oklahoma Health Sciences Center|Legacy Emanuel Children's Hospital|Oregon Health and Science University|Lehigh Valley Hospital-Cedar Crest|Geisinger Medical Center|Children's Hospital of Philadelphia|Saint Christopher's Hospital for Children|Children's Hospital of Pittsburgh of UPMC|Rhode Island Hospital|Prisma Health Richland Hospital|BI-LO Charities Children's Cancer Center|Sanford USD Medical Center - Sioux Falls|T C Thompson Children's Hospital|East Tennessee Childrens Hospital|Saint Jude Children's Research Hospital|The Children's Hospital at TriStar Centennial|Vanderbilt University/Ingram Cancer Center|Dell Children's Medical Center of Central Texas|Driscoll Children's Hospital|Medical City Dallas Hospital|UT Southwestern/Simmons Cancer Center-Dallas|El Paso Children's Hospital|Cook Children's Medical Center|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|M D Anderson Cancer Center|Covenant Children's Hospital|UMC Cancer Center / UMC Health System|Children's Hospital of San Antonio|Methodist Children's Hospital of South Texas|University of Texas Health Science Center at San Antonio|Scott and White Memorial Hospital|Primary Children's Hospital|University of Vermont and State Agricultural College|Children's Hospital of The King's Daughters|Naval Medical Center - Portsmouth|Virginia Commonwealth University/Massey Cancer Center|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Mary Bridge Children's Hospital and Health Center|Madigan Army Medical Center|West Virginia University Healthcare|University of Wisconsin Carbone Cancer Center|Marshfield Medical Center-Marshfield|Children's Hospital of Wisconsin|University Pediatric Hospital,Drug,Puerto Rico|United States,12.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04284774
2715,NCT04285476,Thyroid Cancer,Study of the Predictive Value of a Signature of 10 microRNA in Thyroid Cytologies of Undetermined Type,Predictive Value of 10 microRNA in Thyroid Cytologies of Undetermined Type,Thyroid Cancer,2020-02-24,2022-07-31,2023-03-31,70.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Institut du Cancer de Montpellier - Val d'Aurelle,Institut du Cancer de Montpellier - Val d'Aurelle,CHU de Toulouse|Institut rgional du Cancer de Montpellier,Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04285476
2716,NCT04288115,Subclinical Hypothyroidism,"Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism: a Pilot Randomized, Double-blinded, Placebo-controlled Study",Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidism,2020-02-14,2022-05-31,2022-12-31,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,VA Office of Research and Development,Central Arkansas Veterans Healthcare System|VA Office of Research and Development,"Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR",Drug|Other,United States,18.0,89.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04288115
2717,NCT04288531,Hypothyroidism in Pregnancy|Iodine Deficiency|Nutrient Deficiency|Pregnancy Related|Psychomotor Impairment|Thyroid,"Observational Study on the Impact of Iodine Supplementation on Maternal and Child's Thyroid Hormone Homeostasis and on the Child's Psychomotor Development, in the Portuguese Minho Region (IodineMinho)","Iodine Impact on Thyroid Function and Psychomotor Development, Observational Study in the Portuguese Minho Region",Hypothyroidism in Pregnancy|Iodine Deficiency|Nutrient Deficiency|Pregnancy Related|Psychomotor Impairment|Thyroid,2020-02-25,2024-01-10,2025-01-10,304.0,Cohort,,Prospective,Observational,Recruiting,,University of Minho,"Administrao Regional de Sade do Norte, Portugal|Clinical Academic Center (2CA-Braga)|Hospital de Braga|Instituto Nacional de Sade Dr Ricardo Jorge, Portugal|University of Minho",Usf Maxisaude|Usf Braga Norte|Usf Rues|Usf S. Loureno|Usf Gualtar|Usf + Carand|Usf Manuel Rocha Peixoto|Usf Bracara Augusta|Usf Do Minho|Usf S. Joo de Braga,Dietary Supplement,Portugal,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04288531
2718,NCT04290663,Intermediate Risk|Thyroid Cancer,Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy,Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up,Intermediate Risk|Thyroid Cancer,2020-02-20,2026-02-28,2028-02-29,476.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|French cancer Institute INCa,Centre Francois Baclesse,Drug|Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04290663
2719,NCT04298684,"Diabetes Mellitus, Type 2|Thyroid Nodule (Benign)",Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes,"Diabetes Mellitus, Type 2|Thyroid Nodule (Benign)",2020-02-05,2022-02-01,2024-07-01,90.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Centre Hospitalier Universitaire de Pointe-a-Pitre,Centre Hospitalier Universitaire de Pointe-a-Pitre,CHU Bordeaux|CHU Limoges|University Hospital Center of Guadeloupe|CHU de la Runion,Drug|Drug,France|Guadeloupe|Runion,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04298684
2721,NCT04299425,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Hyperplasia|Parathyroid Neoplasms|Primary Hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Hyperplasia|Parathyroid Neoplasms|Primary Hyperparathyroidism,2020-03-04,2023-03-31,2023-09-30,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04299425
2725,NCT04304573,Calcium Disorder|Hormone Disturbance|Hypocalcemia|Parathyroid Dysfunction|Postoperative Complications|Thyroid,Is Correcting Total Serum Calcium Levels for Serum Albumin Necessary in Assessing Symptomatic Hypocalcemia After Total Thyroidectomy: a Prospective Cohort Study,Is Correcting Total Serum Calcium Levels Important After Thyroidectomy,Calcium Disorder|Hormone Disturbance|Hypocalcemia|Parathyroid Dysfunction|Postoperative Complications|Thyroid,2020-03-09,2020-08-09,2020-09-09,100.0,Cohort,,Prospective,Observational,Unknown status,,"University Hospital ""Sestre Milosrdnice""","University Hospital ""Sestre Milosrdnice""",University Hospital Center Sestre milosrdnice,Diagnostic Test,Croatia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04304573
2726,NCT04304794,Contrast Media Adverse Reaction|Hyperthyroidism; Goiter|Hyperthyroidism/Thyrotoxicosis|Iodine Induced Thyrotoxicosis|Thyrotoxicosis of Other Specified Origin,Prevention of Iodinated Contrast Media Induced Hyperthyroidism in Patients With Euthyroid Goiter,Iodinated Contrast Media Induced Hyperthyroidism,Contrast Media Adverse Reaction|Hyperthyroidism; Goiter|Hyperthyroidism/Thyrotoxicosis|Iodine Induced Thyrotoxicosis|Thyrotoxicosis of Other Specified Origin,2020-03-03,2020-02-20,2020-02-20,36.0,Cohort,,Retrospective,Observational,Completed,,Medical University of Warsaw,"Institute of Cardiology, Warsaw, Poland|Medical University of Warsaw",,Procedure|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04304794
2729,NCT04305561,Primary Hyperparathyroidism,Comparison of CEUS With Conventional Ultrasound (US) to Dual-tracer 99mTcO4-/99mTc-MIBI Subtraction Scintigraphy With SPECT/CT for Localizing Pathological Parathyroid Glands in Patients With Primary Hyperparathyroidism,Preoperative Localization Strategies in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2020-01-24,2021-12-31,2021-12-31,172.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Odense University Hospital,Odense University Hospital,Odense University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04305561
2732,NCT04309136,Thyroid Cancer,The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: a Single-arm Phase II Clinical Trial,Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer,Thyroid Cancer,2020-03-12,2021-02-01,2022-06-01,13.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug|Procedure|Procedure,China,14.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04309136
2733,NCT04311606,Thyroid Eye Disease,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Anti-VEGF Therapy for Acute Thyroid Eye Disease,Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,24.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04311606
2737,NCT04312087,Thyroid Cancer,Lateral Neck Lymph Node Mapping in Papillary Thyroid Carcinoma,Lateral Neck Lymph Node Mapping in Thyroid Cancer,Thyroid Cancer,2020-03-14,2021-08-01,2022-12-31,250.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Procedure|Procedure|Procedure,China,14.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04312087
2738,NCT04312646,Thyroid Nodule,Added Value of Ultrasound Elasatography in Characterization of Thyroid Nodules,Elastography in Thyroid Nodules,Thyroid Nodule,2020-03-16,2021-04-01,2022-04-01,50.0,Case-Only,,Cross-Sectional,Observational,Unknown status,,Assiut University,Assiut University,,Device,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04312646
2740,NCT04316845,Hyperparathyroidism,18F-Fluorocholine PET/CT in the Pre-operative Localization of Hyperfunctional Parathyroid Gland in Primary and Secondary Hyperparathyroidism,18F-fluorocholine PET/CT for Hyperparathyroidism,Hyperparathyroidism,2020-03-17,2019-11-06,2019-12-31,38.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Buddhist Tzu Chi General Hospital,Buddhist Tzu Chi General Hospital,Hualien Tzu Chi Hospital,Diagnostic Test,Taiwan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04316845
2742,NCT04320901,Thyroid Cancer|Thyroid Nodule,Comparative Analysis Between Harmonic Versus LigaSure in Transoral Endoscopic Thyroidectomy: A Randomized Controlled Trial,Energy Device Study in Transoral Endoscopic Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2020-03-20,2022-12-31,2023-02-28,40.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device|Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04320901
2744,NCT04321954,Advanced Cancer|Differentiated Thyroid Cancer,A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer,Lenvatinib in Locally Advanced Invasive Thyroid Cancer,Advanced Cancer|Differentiated Thyroid Cancer,2020-03-24,2023-09-30,2024-03-31,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Eisai Inc.|Massachusetts Eye and Ear Infirmary,Massachusetts General Hospital Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04321954
2745,NCT04327999,Radioactive Iodine Level|Thyroid Carcinoma,Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System of Patients Following Radioiodine Therapy for Thyroid Carcinoma,Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System,Radioactive Iodine Level|Thyroid Carcinoma,2020-03-04,2023-07-31,2024-07-31,15.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Vanderbilt-Ingram Cancer Center,Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04327999
2746,NCT04329455,Safety and Cosmetic Issues in Endoscopic Thyroidectomy,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Safety and Cosmetic Issues in Endoscopic Thyroidectomy,2020-03-30,2022-04-01,2023-04-01,30.0,Cohort,,Prospective,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Gamal,Procedure,Egypt,18.0,55.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04329455
2748,NCT04332770,Hypothyroidism,Clinical Application of Continuous Monitoring Data for Biosignals by Commercially Available Wearable Devices in the Patients With Hypothyroidism,Biosignals by Wearable Devices in Hypothyroidism,Hypothyroidism,2019-12-13,2020-10-15,2020-10-15,45.0,Cohort,,Prospective,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Other,"Korea, Republic of",20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04332770
2749,NCT04333342,Graves' Disease in Remission (Disorder),Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Heart Rate Monitoring by Wearable Devices in Graves' Disease,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,180.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04333342
2752,NCT04336696,Papillary Thyroid Carcinoma,"Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?","Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?",Papillary Thyroid Carcinoma,2020-04-01,2020-04-03,2020-05-03,199.0,,Sequential Assignment,,Interventional,Unknown status,Not Applicable,Zagazig University,Bassem Mohamed Sieda,Zagazig University Hospitals,Procedure,Egypt,42.0,55.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04336696
2754,NCT04339127,Anti NMDA Receptor Encephalitis|Autoimmune Encephalitis|Herpetic Encephalitis,Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature,Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis,Anti NMDA Receptor Encephalitis|Autoimmune Encephalitis|Herpetic Encephalitis,2020-04-06,2020-06-01,2020-10-01,12.0,Cohort,,Retrospective,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospice Civils de Lyon,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04339127
2757,NCT04339205,Auto-immune Encephalitis,Diffusion Imaging in Acute Auto-immune Encephalitis : a Cohort of 80 Patients,Diffusion Imaging in Acute Auto-immune Encephalitis,Auto-immune Encephalitis,2020-04-06,2020-03-01,2020-07-01,80.0,Cohort,,Retrospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04339205
2760,NCT04339478,Thyroid Cancer|Thyroidectomy With Central Lymph Node Dissection,Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection,Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection,Thyroid Cancer|Thyroidectomy With Central Lymph Node Dissection,2020-04-06,2022-03-30,2022-08-30,180.0,Cohort,,Prospective,Observational,Recruiting,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki|The Hashemite University|Umraniye Education and Research Hospital,"1st Propedeutic Department of Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki|Department of Surgery, Faculty of Medicine, Hashemite University|Umraniye Education and Research Hospital",,Greece|Jordan|Turkey,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04339478
2761,NCT04344886,Parathyroid Adenoma|Parathyroid Diseases|Primary Hyperparathyroidism|Thyroid Disease,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery,Parathyroid Adenoma|Parathyroid Diseases|Primary Hyperparathyroidism|Thyroid Disease,2020-04-09,2020-11-30,2020-12-31,100.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,University Hospital Ostrava,University Hospital Ostrava,University Hospital Ostrava,Procedure|Procedure|Procedure|Procedure,Czechia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04344886
2765,NCT04346901,Hyperthyroidism|Melasma,Comparative Study of mMASI Before and After Hyperthyroid Therapy in Hyperthyroid Subjects With Melasma,Comparative Study of mMASI Before and After Hyperthyroid Therapy in Hyperthyroid Subjects With Melasma,Hyperthyroidism|Melasma,2020-04-10,2020-01-27,2020-02-15,23.0,,Single Group Assignment,,Interventional,Completed,Phase 1,Indonesia University,"Dr.dr.Irma Bernadette, SpKK (K)",dr. Cipto Mangunkusumo Hospital,Drug,Indonesia,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04346901
2766,NCT04354324,Papillary Thyroid Cancer,Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma Patients Without Metastasis: a Double-blind Randomized Clinical Trial,Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma,Papillary Thyroid Cancer,2020-03-01,2024-06-30,2024-06-30,254.0,,Crossover Assignment,,Interventional,Not yet recruiting,Not Applicable,Zhujiang Hospital,Zhujiang Hospital,,Drug,,16.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04354324
2768,NCT04354896,Sarcopenia|Subclinical Hypothyroidism,The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism - a Substudy of TRUST and IEMO Trials,The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism,Sarcopenia|Subclinical Hypothyroidism,2020-04-08,2018-05-04,2018-05-04,322.0,,Parallel Assignment,,Interventional,Completed,Phase 4,"University Hospital Inselspital, Berne","Leiden University Medical Center|University Hospital Inselspital, Berne|University of Lausanne Hospitals","Department of Gerontology and Geriatrics, Leiden University Medical Center|Department of Public Health and Primary Care, Leiden University Medical Center|Institute for Evidence-Based Medicine in Old Age|Department of General Internal Medicine|Clinic for General Internal Medicine, Bern University Hospital Bern",Drug|Drug,Netherlands|Switzerland,65.0,120.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04354896
2769,NCT04359979,Eyelid Diseases|Thyroid Eye Disease,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Tamsulosin for Thyroid Lid Retraction,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,50.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04359979
2773,NCT04372225,Hypoparathyroidism,Predicting Risk Factors of Postoperative Hypocalcemia After Total Thyroidectomy: is Safe Discharge Without Supplementation Possible?,Predicting Risk Factors of Postoperative Hypocalcemia After Total Thyroidectomy,Hypoparathyroidism,2020-04-25,2020-04-25,2020-04-25,477.0,Cohort,,Prospective,Observational,Completed,,Aix Marseille Universit,Aix Marseille Universit,Conception Hospital,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04372225
2775,NCT04373226,22q11.2 Deletion Syndrome,Study of Arithmetic Abilities of Children With 22q11.2 Deletion Syndrome Aged From 4 to 11 Years Old,Arithmetic Abilities in Children With 22q11.2DS,22q11.2 Deletion Syndrome,2020-04-30,2023-07-20,2023-10-20,120.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Hpital le Vinatier,Hpital le Vinatier,Hopital Vinatier,Behavioral,France,4.0,11.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT04373226
2777,NCT04376203,Microbiome|Papillary Thyroid Microcarcinoma,What is the Relation of Microbiome to Papillary Thyroid Microcarcinoma Development?,Microbiome and Papillary Thyroid Microcarcinoma,Microbiome|Papillary Thyroid Microcarcinoma,2020-05-02,2022-05-30,2023-05-30,40.0,Case-Control,,Prospective,Observational,Not yet recruiting,,University of Ioannina,University of Ioannina,,Procedure,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04376203
2778,NCT04383795,Graves' Disease,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Change of Gut Microbiome in the Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,40.0,Case-Only,,Prospective,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04383795
2781,NCT04391244,Differentiated Thyroid Cancer,Investigating National Solutions for Personalised Iodine-131 Radiation Exposure - Measuring Absorbed Dose to Tumour and Organs at Risk Following Routine Iodine Ablation Therapy,Investigating National Solutions for Personalised Iodine-131 Radiation Exposure,Differentiated Thyroid Cancer,2020-05-12,2022-07-31,2022-07-31,50.0,Cohort,,Prospective,Observational,Recruiting,,Royal Marsden NHS Foundation Trust,European Commission|Royal Marsden NHS Foundation Trust,The Royal Marsden NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04391244
2782,NCT04391439,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy,Heart Rhythm After Intravenous Methylprednisolone Administration,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,2020-05-05,2020-02-20,2020-02-20,40.0,Cohort,,Prospective,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04391439
2786,NCT04396158,Ovarian Insufficiency|Radiation Exposure,Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer,Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer,Ovarian Insufficiency|Radiation Exposure,2020-05-16,2021-06-15,2021-12-15,38.0,,Single Group Assignment,,Interventional,Unknown status,Not Applicable,Assiut University,Assiut University,,Radiation,,15.0,45.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04396158
2787,NCT04396912,"Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis","Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines",Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort,"Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,100.0,Cohort,,Prospective,Observational,Unknown status,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04396912
2792,NCT04400474,Adenocarcinoma|Anaplastic Thyroid Cancer|Neuroendocrine Tumor|Paraganglioma|Pheochromocytoma,Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study,Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study,Adenocarcinoma|Anaplastic Thyroid Cancer|Neuroendocrine Tumor|Paraganglioma|Pheochromocytoma,2020-05-12,2023-03-31,2024-03-31,144.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|Ipsen|Roche Pharma AG,Hospital Germans Trias i Pujol - ICO Badalona|Hospital Duran i Reynals - ICO L'Hospitalet|Hospital General Universitario Elche|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Universitario Ramn y Cajal|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Hospital Universitario Central de Asturias|Hospital Universitario Marqus de Valdecilla|Hospital Universitario Virgen del Roco|Hospital Universitario de Canarias|Hospital Universitario Miguel Servet,Drug,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04400474
2793,NCT04410601,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,500.0,,Parallel Assignment,,Interventional,Unknown status,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04410601
2797,NCT04411290,"Aspiration|Multifocal Dysplasia|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Carcinoma|Thyroid Diseases|Thyroid Goiter|Thyroid Neoplasms|Thyroid Nodule|Thyroid Papillary Carcinoma","Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial","Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","Aspiration|Multifocal Dysplasia|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Carcinoma|Thyroid Diseases|Thyroid Goiter|Thyroid Neoplasms|Thyroid Nodule|Thyroid Papillary Carcinoma",2020-05-15,2021-06-01,2021-06-01,200.0,Cohort,,Prospective,Observational,Unknown status,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences Universit",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04411290
2801,NCT04412694,Hypocalcemia|Hypoparathyroidism Postprocedural|Postoperative Complications|Postoperative Nausea|Postoperative Pain|Vitamin D Deficiency|Voice Hoarseness,The Impact of Preoperative Oral Dexamethasone Supplementation on the Biochemical Parameters and Results of Surgical Treatment in Patients With Nontoxic Multinodular Goiter Undergoing Total Thyroidectomy.,The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients.,Hypocalcemia|Hypoparathyroidism Postprocedural|Postoperative Complications|Postoperative Nausea|Postoperative Pain|Vitamin D Deficiency|Voice Hoarseness,2020-05-23,2022-09-30,2022-12-31,100.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Medical University of Lodz,Medical University of Lodz,"Department of General and Oncological Surgery, Medical University of Lodz",Drug|Drug|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Procedure|Other|Other|Other|Other|Other|Other|Other|Other,Poland,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04412694
2803,NCT04420689,Head and Neck Neoplasms|Imaging|Nerve Injury|Parotid Neoplasm|Surgery|Thyroid Neoplasms,Phase 1/2 Trial of ALM-488 in Patients Undergoing Head & Neck Surgery,A Study of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery,Head and Neck Neoplasms|Imaging|Nerve Injury|Parotid Neoplasm|Surgery|Thyroid Neoplasms,2020-06-03,2021-06-25,2022-02-15,41.0,,Sequential Assignment,,Interventional,Completed,Phase 1/Phase 2,"Alume Biosciences, Inc.","Alume Biosciences, Inc.",University of California San Diego|Stanford University|Harvard-Mass Eye & Ear,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04420689
2804,NCT04420754,Anaplastic Thyroid Cancer|Relapsed/Refractory Poorly Differentiated Thyroid Cancer,A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer,Study of AIC100 in Relapsed/Refractory Thyroid Cancer,Anaplastic Thyroid Cancer|Relapsed/Refractory Poorly Differentiated Thyroid Cancer,2020-06-03,2023-07-31,2024-07-31,24.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1,"AffyImmune Therapeutics, Inc.","AffyImmune Therapeutics, Inc.",Weill Cornell Medical College,Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04420754
2806,NCT04424485,"Lymph Node Metastases|Sentinel Lymph Node|Thyroid Cancer|Thyroid Carcinoma, Papillary|Thyroid Metastases|Thyroid Neoplasms",Near-infrared (NIR) Fluorescence Imaging With Indocyanine Green (ICG) for Identification of Sentinel Lymph Nodes and Parathyroid Glands During Total Thyroidectomy: Prospective Randomized Clinical Trial,Near-infrared Fluorescence With Indocyanine Green for Identification of Sentinels and Parathyroids During Thyroidectomy,"Lymph Node Metastases|Sentinel Lymph Node|Thyroid Cancer|Thyroid Carcinoma, Papillary|Thyroid Metastases|Thyroid Neoplasms",2020-06-02,2021-06-01,2021-06-01,100.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Department of General Surgery",Procedure|Procedure|Diagnostic Test|Diagnostic Test,Turkey,17.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04424485
2808,NCT04425512,Delta Neutrophyl Index|Immature Granulocyte Count|Neutrophyl to Lymphocyte Ratio|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Differentiation of Thyroid Malignancy and Nodular Goiter,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy,Delta Neutrophyl Index|Immature Granulocyte Count|Neutrophyl to Lymphocyte Ratio|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2020-04-23,2019-11-01,2019-11-01,333.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Kahramanmaras Sutcu Imam University,Kahramanmaras Sutcu Imam University,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04425512
2810,NCT04433936,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,Corneal Tomographic Analysis Among Patients With Thyroid Gland Dysfunction.,Corneal Tomographic Parameters in TGD,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,2020-06-13,2018-06-01,2018-06-01,100.0,Case-Control,,Prospective,Observational,Completed,,Mansoura University,Ameera Gamal Abdelhameed,Mansoura University,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04433936
2814,NCT04447183,Differentiated Thyroid Cancer,A Phase II Study of the Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.,The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.,Differentiated Thyroid Cancer,2020-06-23,2022-02-28,2022-10-31,120.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Other,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04447183
2815,NCT04450472,Nonthyroidal Illness Syndrome|Short Bowel Syndrome,Nonthyroidal Illness Syndrome in Patients With Short Bowel Syndrome,Nonthyroidal Illness Syndrome in SBS,Nonthyroidal Illness Syndrome|Short Bowel Syndrome,2020-06-25,2018-12-31,2018-12-31,51.0,Cohort,,Retrospective,Observational,Completed,,"Jinling Hospital, China","Jinling Hospital, China",,,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04450472
2816,NCT04458233,Thyroid Nodule,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,Thyroid Nodule,2020-06-30,2021-06-01,2021-07-01,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Ziv Hospital,Ziv Hospital,Ziv Medical Center,Procedure,Israel,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04458233
2818,NCT04459273,Bladder Carcinoma|Cervical Carcinoma|Cholangiocarcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Hepatocellular Carcinoma|Malignant Adrenal Gland Neoplasm|Malignant Brain Neoplasm|Malignant Pleural Neoplasm|Malignant Skin Neoplasm|Malignant Solid Neoplasm|Malignant Testicular Neoplasm|Malignant Thymus Neoplasm|Neuroendocrine Neoplasm|Thyroid Gland Carcinoma|Urothelial Carcinoma,PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation,Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers,Bladder Carcinoma|Cervical Carcinoma|Cholangiocarcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Hepatocellular Carcinoma|Malignant Adrenal Gland Neoplasm|Malignant Brain Neoplasm|Malignant Pleural Neoplasm|Malignant Skin Neoplasm|Malignant Solid Neoplasm|Malignant Testicular Neoplasm|Malignant Thymus Neoplasm|Neuroendocrine Neoplasm|Thyroid Gland Carcinoma|Urothelial Carcinoma,2020-07-01,2023-07-01,2024-07-01,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04459273
2819,NCT04462471,"BRAF V600E Mutation Positive|Thyroid Cancer|Thyroid Cancer, Follicular|Thyroid Cancer (Follicular Cell)|Thyroid Cancer, Papillary|Thyroid Carcinoma",A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers,Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers,"BRAF V600E Mutation Positive|Thyroid Cancer|Thyroid Cancer, Follicular|Thyroid Cancer (Follicular Cell)|Thyroid Cancer, Papillary|Thyroid Carcinoma",2020-07-02,2023-12-31,2024-12-31,32.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan-Kettering Cancer Center (All protocol activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Diagnostic Test|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04462471
2821,NCT04463316,"17p- Deletiesyndrome|1q25-32 Deletie|22q11 Deletion Syndrome|46, XY DSD|Albright Hereditaire Osteodystrofie|Allan-Herndon-Dudley Syndrome|Bardet Biedl Syndrome|CHARGE Syndrome|Congenital Adrenal Hyperplasia|Congenital Hypopituitarism|Cornelia de Lange Syndrome|Disorders of Sex Development|Jacobsen Syndrome / 11 q Syndrome|Kallmann Syndrome|Klinefelter (XXY-)Syndrome|Myrhe Syndrome|Neurofibromatosis|Noonan Syndrome|Ohdo Syndrome|POLR3A Mutatie|Prader-Willi Syndrome|PWS-like Syndrome|Rare Bone Disorders|Rett Syndrome|Saethre-Chotzen Syndrome|Silver Russel Syndrome|Tuberous Sclerosis|Turner Syndrome|VCF Syndrome|Williams-Beuren Syndrome|XXXX Syndrome (Tetra-X Syndrome)|XXXXY Syndrome|XXYY Syndrome",GROWing Up With Rare GENEtic Syndromes .When Children With Complex Genetic Syndromes Reach Adult Age,GROWing Up With Rare GENEtic Syndromes,"17p- Deletiesyndrome|1q25-32 Deletie|22q11 Deletion Syndrome|46, XY DSD|Albright Hereditaire Osteodystrofie|Allan-Herndon-Dudley Syndrome|Bardet Biedl Syndrome|CHARGE Syndrome|Congenital Adrenal Hyperplasia|Congenital Hypopituitarism|Cornelia de Lange Syndrome|Disorders of Sex Development|Jacobsen Syndrome / 11 q Syndrome|Kallmann Syndrome|Klinefelter (XXY-)Syndrome|Myrhe Syndrome|Neurofibromatosis|Noonan Syndrome|Ohdo Syndrome|POLR3A Mutatie|Prader-Willi Syndrome|PWS-like Syndrome|Rare Bone Disorders|Rett Syndrome|Saethre-Chotzen Syndrome|Silver Russel Syndrome|Tuberous Sclerosis|Turner Syndrome|VCF Syndrome|Williams-Beuren Syndrome|XXXX Syndrome (Tetra-X Syndrome)|XXXXY Syndrome|XXYY Syndrome",2020-07-02,2030-01-01,2030-01-01,600.0,Cohort,,Retrospective,Observational,Recruiting,,Erasmus Medical Center,dr. Laura C. G. de Graaff-Herder,Erasmus Medical Center,Diagnostic Test,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04463316
2823,NCT04463719,Thyroid Cancer|Thyroid Nodules,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-06,2022-06-30,2025-06-30,90.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral|Behavioral,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04463719
2825,NCT04467021,Cardiovascular Disorder|Chronic Kidney Disease|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,Cancer Therapy Risk-Reduction With Intensive Systolic BP Management (CARISMA) - a Phase II Study,"Cancer and Blood Pressure Management, CARISMA Study",Cardiovascular Disorder|Chronic Kidney Disease|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,2020-07-07,2023-02-01,2023-02-01,60.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Eastern Cooperative Oncology Group,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI),Siteman Cancer Center at West County Hospital|Washington University School of Medicine|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Montefiore Medical Center - Moses Campus|University of Pennsylvania/Abramson Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|UT Southwestern/Simmons Cancer Center-Dallas|Aurora Cancer Care-Southern Lakes VLCC|Aurora Saint Luke's South Shore|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Aurora BayCare Medical Center|Aurora Cancer Care-Kenosha South|Aurora Bay Area Medical Group-Marinette|Aurora Cancer Care-Milwaukee|Aurora Saint Luke's Medical Center|Aurora Sinai Medical Center|Vince Lombardi Cancer Clinic - Oshkosh|Aurora Cancer Care-Racine|Vince Lombardi Cancer Clinic-Sheboygan|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center,Other|Other|Other|Other|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04467021
2826,NCT04472026,Thyroid Cancer|Thyroid Nodules,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM1: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-10,2022-06-30,2025-06-30,90.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04472026
2828,NCT04472988,Hashimoto,The Effects of Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults: a Randomized Controlled Trial,Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults,Hashimoto,2020-07-07,2020-12-05,2021-03-23,91.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Bucharest,University of Bucharest,University of Bucharest,Behavioral|Other|Drug,Romania,18.0,55.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04472988
2831,NCT04477798,Thyroid Nodule,Protein Classifier for Thyroid Indeterminate Nodules a Multi-center Prospective Clinical Study,Protein Classifier for Thyroid Indeterminate Nodules,Thyroid Nodule,2020-07-10,2021-07-01,2021-12-31,320.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Zhejiang University,Luo Dingcun,Hangzhou First People's Hospital Affiliated to Zhejiang University Medical College,Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04477798
2833,NCT04481893,Thyroid Cancer|Thyroidectomy,Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy,Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy,Thyroid Cancer|Thyroidectomy,2020-07-07,2024-04-30,2024-04-30,72.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Centre Francois Baclesse,Centre Francois Baclesse,Centre Franois Baclesse|CHU CAEN|Clinique Mathilde,Behavioral,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04481893
2834,NCT04482907,Thyroid Nodule,Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients,Effect of Dill in Thyroiditis and Nodular Goiter Patients,Thyroid Nodule,2020-07-16,2019-12-16,2020-04-05,68.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Sabahattin Destek,Dietary Supplement,Turkey,18.0,76.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04482907
2839,NCT04484116,Secondary Hyperparathyroidism,USEFULNESS OF IOPTH AS A PREDICTOR FOR SUCCESSFUL PARATHYROIDECTOMY IN SECONDARY HYPERPARATHYROIDISM: A COHORT STUDY,IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2020-07-20,2019-11-30,2019-11-30,30.0,Cohort,,Prospective,Observational,Completed,,Hospital General Ajusco Medio,Hospital General Ajusco Medio,Hospital General Ajusco Medio,Diagnostic Test,Mexico,18.0,90.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04484116
2842,NCT04485975,Thyrotoxicosis,Preoperative Therapeutic Plasma Exchange and Surgical Treatment in Thyrotoxicosis Patients: a Single-centre Retrospective Cohort Study,Therapeutic Plasma Exchange in Thyrotoxicosis,Thyrotoxicosis,2020-06-30,2019-02-01,2020-04-01,27.0,Cohort,,Retrospective,Observational,Completed,,Baskent University,Baskent University,,Device,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04485975
2844,NCT04488406,Graves Ophthalmopathy,Genetics and Epigenetics of Graves' Orbitopathy,Genetics and Epigenetics of Graves' Orbitopathy,Graves Ophthalmopathy,2020-07-17,2020-03-31,2020-03-31,12.0,Case-Control,,Prospective,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04488406
2848,NCT04488640,Thyroid Nodule,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With Thyroid Imaging Reporting and Data System Score and Surgical Pathology,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With TIRADS Score and Surgical Pathology,Thyroid Nodule,2020-07-15,2020-01-01,2020-05-01,4.0,Cohort,,Retrospective,Observational,Completed,,Bezmialem Vakif University,Bezmialem Vakif University,,Procedure,,24.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04488640
2850,NCT04495985,Thyroid Cancer,Breast Uptake on Radioiodine Scan and Serum Prolactin in Thyroid Cancer Patients Prepared by Thyroid Hormone Withdrawal or Recombinant Human Thyrotropin: A Prospective Study,CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer,Thyroid Cancer,2020-06-10,2023-06-30,2023-08-31,130.0,Cohort,,Prospective,Observational,Enrolling by invitation,,The Cleveland Clinic,The Cleveland Clinic,Cleveland Clinic,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04495985
2851,NCT04500925,Papillary Thyroid Cancer|Well Differentiated Thyroid Carcinoma,The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience,The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience,Papillary Thyroid Cancer|Well Differentiated Thyroid Carcinoma,2020-07-31,2018-01-01,2020-01-01,301.0,Cohort,,Retrospective,Observational,Completed,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,,Procedure,,38.0,61.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04500925
2853,NCT04509011,Hypoparathyroidism Postprocedural,Randomized Controlled Trial of Fluobeam LX Compared With Clinical Assessment of Parathyroid Glands to Counteract Postoperatively Failing Parathyroid Function With Low Blood Calcium After Thyroid Surgery,Autofluorescence vs Clinical Assessment of Parathyroid Glands During Thyroid Surgery,Hypoparathyroidism Postprocedural,2020-08-04,2022-12-31,2023-07-31,400.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Region Skane,"Haukeland University Hospital|Hospital Rudolfstiftung|Jagiellonian University|Region Skane|Sahlgrenska University Hospital, Sweden","Rudolfstiftung|Haukeland University Hospital|Jagiellonian University Medical College|Sahlgrenska University Hospital|Skne University Hospital, Department of Surgery, Lund",Device,Austria|Norway|Poland|Sweden,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04509011
2855,NCT04514484,Advanced Differentiated Thyroid Gland Carcinoma|Advanced Head and Neck Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Kaposi Sarcoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Prostate Carcinoma|Advanced Renal Cell Carcinoma|Advanced Thyroid Gland Medullary Carcinoma|Advanced Urothelial Carcinoma|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|HIV Infection|Metastatic Differentiated Thyroid Gland Carcinoma|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Kaposi Sarcoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Kaposi Sarcoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Medullary Carcinoma|Recurrent Triple-Negative Breast Carcinoma|Recurrent Urothelial Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Triple-Negative Breast Carcinoma,Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection,Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV,Advanced Differentiated Thyroid Gland Carcinoma|Advanced Head and Neck Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Kaposi Sarcoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Prostate Carcinoma|Advanced Renal Cell Carcinoma|Advanced Thyroid Gland Medullary Carcinoma|Advanced Urothelial Carcinoma|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|HIV Infection|Metastatic Differentiated Thyroid Gland Carcinoma|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Kaposi Sarcoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Kaposi Sarcoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Medullary Carcinoma|Recurrent Triple-Negative Breast Carcinoma|Recurrent Urothelial Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Triple-Negative Breast Carcinoma,2020-08-14,2025-11-02,2025-11-02,18.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Northwestern University|Montefiore Medical Center-Einstein Campus|University of Pittsburgh Cancer Institute (UPCI),Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04514484
2856,NCT04521348,Thyroid Cancer,A Phase II Study to Explore the Safety and Efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined With Anti-Programmed Death-1(PD-1) Antibody in the Treatment of Advanced Thyroid Cancer,Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer,Thyroid Cancer,2019-10-25,2022-06-30,2023-06-30,115.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04521348
2857,NCT04522570,Lymph Node Metastases|Medullary Thyroid Cancer|Thyroid Neoplasia|Well-Differentiated Thyroid Cancer,Ultrasound Guided Percutaneous Thermal Ablation of Cervical Metastases From Thyroid Carcinoma,Thermal Ablation of Cervical Metastases From Thyroid Carcinoma,Lymph Node Metastases|Medullary Thyroid Cancer|Thyroid Neoplasia|Well-Differentiated Thyroid Cancer,2020-08-10,2022-12-31,2023-12-31,120.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Instituto do Cancer do Estado de So Paulo,Instituto do Cancer do Estado de So Paulo,Instituto do Cancer do Estado de So Paulo,Device|Device|Device,Brazil,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04522570
2858,NCT04522622,Adynamic Bone Disease|Cardiac Disease|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease,Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease,Adynamic Bone Disease|Cardiac Disease|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,2020-08-13,2024-02-01,2025-02-01,66.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Herlev Hospital,"Ditte Hansen|Odense University Hospital|Rigshospitalet, Denmark|Steno Diabetes Center Copenhagen|Universiteit Antwerpen","Steno Diabetes Center Copenhagen|Herlev and Gentofte Hospital, Herlev Hospital|Odense University Hospital",Drug|Diagnostic Test|Procedure|Diagnostic Test|Other|Other,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04522622
2861,NCT04523974,"Hyperparathyroidism; Secondary, Renal",Preemptive Surgical Intervention and Precise Efficacy Evaluation for Hyperparathyroidism Secondary to Chronic Kidney Disease,Preemptive and Precise Intervention for CKD-SHPT,"Hyperparathyroidism; Secondary, Renal",2020-08-17,2022-09-30,2022-12-31,50.0,Cohort,,Prospective,Observational,Not yet recruiting,,Shanghai Zhongshan Hospital,Shanghai Zhongshan Hospital,,Procedure,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04523974
2864,NCT04524884,Thyroid Cancer,The Efficacy and Safety of Anti-PD-1 Antibody Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study,Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study,Thyroid Cancer,2020-08-20,2022-04-30,2022-09-30,10.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,Fudan University,Fudan University,"270 Dongan Road, Fudan University Shanghai Cancer Center",Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04524884
2865,NCT04528225,Breast Neoplasms|Hypothyroidism|Radiation Toxicity,Hypothyroidism After Postoperative Radiation Therapy in Patients With Breast Cancera Prospective Clinical Study,A Prospective Study of Hypothyroidism After Radiotherapy for Breast Cancer,Breast Neoplasms|Hypothyroidism|Radiation Toxicity,2020-08-22,2020-02-24,2020-02-24,729.0,Cohort,,Prospective,Observational,Completed,,Chinese Academy of Medical Sciences,Chinese Academy of Medical Sciences,"Cancer Hospital, Chinese Academy of Medical Sciences",,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04528225
2866,NCT04544111,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2023-09-02,2023-09-02,30.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04544111
2869,NCT04548284,Thyroid Associated Ophthalmopathy,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,142.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04548284
2873,NCT04551170,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism|Pseudohypoparathyroidism Type 1a,Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism,Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism|Pseudohypoparathyroidism Type 1a,2020-09-09,2025-06-30,2025-06-30,34.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Drug|Drug,United States,2.0,12.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT04551170
2875,NCT04552769,Anaplastic Thyroid Cancer|Thyroid Cancer|Undifferentiated Thyroid Cancer,Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Anaplastic Thyroid Cancer|Thyroid Cancer|Undifferentiated Thyroid Cancer,2020-09-11,2022-09-30,2023-09-30,17.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Stanford University,Stanford University,Stanford University,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04552769
2877,NCT04554680,Thyroid Cancer,Phase II Clinical Trial in Radioactive Iodine-Refractory Advanced Thyroid Carcinoma Evaluating BRAF & MEK Blockade Therapy for Re-differentiation- Applying a Novel Time-Dependent Concept,Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy,Thyroid Cancer,2020-08-29,2021-12-31,2022-04-30,5.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"National University Hospital, Singapore","National University Hospital, Singapore|Singapore General Hospital",National University Hospital,Drug,Singapore,21.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04554680
2878,NCT04560127,Radioactive Iodine-refractory Differentiated Thyroid Cancer,"A Single-arm, Non-randomized, Single-center Study to Evaluate Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer",Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer,Radioactive Iodine-refractory Differentiated Thyroid Cancer,2020-09-17,2022-12-31,2023-06-30,10.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04560127
2879,NCT04560426,Intraoperative Monitoring|Parathyroid|Thyroid Cancer,Protective Effect of Intraoperative Parathyroid Gland Auxiliary Recognition System in Thyroid Malignant Tumor Operation,Protective Effect of Intraoperative Parathyroid Gland Auxiliary Recognition System in Thyroid Malignant Tumor Operation,Intraoperative Monitoring|Parathyroid|Thyroid Cancer,2020-08-29,2021-10-31,2022-10-31,200.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Device,China,20.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04560426
2880,NCT04563780,Differentiated Thyroid Cancer,The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer,The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2020-09-21,2021-12-31,2021-12-31,113.0,Other,,Retrospective,Observational,Recruiting,,Assiut University,Assiut University,Aya Khaled Mahmoud,Device,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04563780
2881,NCT04564924,Chronic Kidney Disease-Mineral and Bone Disorder,To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease Compared to Healthy Volunteers With MRI,To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease With MRI,Chronic Kidney Disease-Mineral and Bone Disorder,2020-09-14,2021-09-30,2022-01-30,200.0,Cohort,,Prospective,Observational,Recruiting,,Tongji Hospital,Tongji Hospital,Tongji Hospital,Radiation,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04564924
2884,NCT04569513,Parathyroid Diseases|Thyroid Diseases,The Analysis of Thyroidectomy and Parathyroidectomy,The Analysis of Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Diseases,2020-05-11,2024-06-30,2024-12-31,12000.0,Cohort,,Retrospective,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,Ting-Chun Kuo,Biological,Taiwan,20.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04569513
2885,NCT04569604,Hypoparathyroidism|Pseudo Hypoparathyroidism,Impaired Quality of Life and Cognitive Function in Patients With Hypoparathyroidism Might be Explained by Disturbed Capillary Flow Patterns in the Brain,QoL and Cognitive Function in Patients With Hypoparathyroidism,Hypoparathyroidism|Pseudo Hypoparathyroidism,2019-09-02,2020-10-01,2021-12-01,64.0,Case-Control,,Cross-Sectional,Observational,Completed,,University of Aarhus,University of Aarhus,"Clinic for Osteoporosis, Aarhus University Hospital",Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Denmark,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04569604
2889,NCT04570033,Hyperparathyroidism|Parathyroid Adenoma,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,Hyperparathyroidism|Parathyroid Adenoma,2020-09-21,2020-01-01,2020-01-01,65.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,"Military Institute of Medicine, Poland","Medical University of Warsaw|Military Institute of Medicine, Poland",,Diagnostic Test,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04570033
2892,NCT04574258,Ultrasound,Contrast-enhanced Ultrasound in Thyroid Tumor by Sonozoid,Prospective Multicenter Study on Clinical Application of Sonozoid in Thyroid Tumor,Ultrasound,2020-09-18,2021-05-01,2021-08-01,371.0,Other,,Prospective,Observational,Completed,,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04574258
2893,NCT04574817,Anaplastic Thyroid Cancer,"A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With Anaplastic Thyroid Cancer",Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC),Anaplastic Thyroid Cancer,2020-09-29,2022-05-30,2023-05-30,66.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,Taizhou Hanzhong biomedical co. LTD,Taizhou Hanzhong biomedical co. LTD,"Cancer Hospital, Chinese Academy of Medical Sciences",Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04574817
2895,NCT04574947,Anesthesia|Parathyroid Neoplasms|Thyroid Neoplasm,Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study),Lidocaine And Neuromonitoring in Thyroid Surgery,Anesthesia|Parathyroid Neoplasms|Thyroid Neoplasm,2020-09-24,2021-11-15,2021-12-01,231.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",St. Petersburg State University Hospital,Drug|Drug|Procedure|Procedure,Russian Federation,45.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04574947
2898,NCT04577664,Thyroid Goiter,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Total Versus Subtotal Thyroidectomy in Graves' Disease At AUH,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,60.0,,Single Group Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04577664
2901,NCT04579757,Anaplastic Thyroid Cancer|Colorectal Cancer|Gastric Cancer|Metastatic Solid Tumor|Neuroendocrine Tumors|Small Cell Lung Cancer|Soft Tissue Sarcoma,An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors,Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors,Anaplastic Thyroid Cancer|Colorectal Cancer|Gastric Cancer|Metastatic Solid Tumor|Neuroendocrine Tumors|Small Cell Lung Cancer|Soft Tissue Sarcoma,2020-09-02,2024-04-30,2024-06-30,135.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Hutchison Medipharma Limited,BeiGene|Hutchison Medipharma Limited,"Arizona Oncology Associated, PC-HOPE|City of Hope|Rocky Mountain Cancer Centers Midtown|Johns Hopkins University - Sibley Memorial Hospital|Emory University - Winship Cancer Institute|Holden Comprehensive Cancer Center, University of Iowa|Memorial Sloan Kettering Cancer Center|University Hospitals Cleveland Medical Center|University of Pennsylvania, Perelman Center for Advanced Medicine|Prisma Health - Upstate (ITOR)|Sarah Cannon|Vanderbilt University Medical Center|Mary Crowley Cancer Research|Texas Oncology - Baylor Charles A. Sammons Cancer Center|Texas Oncology, P.A.|The University of Texas MD Anderson Cancer Center|Texas Oncology, P.A.|Virginia Cancer Specialists, PC",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04579757
2902,NCT04580199,Thyroid Nodule,"Surgical (Total or Hemithyroidectomy)Versus Non Surgical (Ethanol Ablation ,RF Ablation ,Laser Ablation) Management of Thyroid Nodule",Surgical Versus Non Surgical Management of Thyroid Nodule,Thyroid Nodule,2020-10-02,2021-12-01,2022-12-01,100.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Mahmoud Fahd,,Procedure,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04580199
2904,NCT04583735,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",A Study Evaluating TEPEZZA Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,57.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Ophthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Neuro-Eye Clinical Trials|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04583735
2908,NCT04589624,Thyroid Gland Carcinoma,Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer,An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy,Thyroid Gland Carcinoma,2020-09-20,2022-12-31,2022-12-31,12.0,,Parallel Assignment,,Interventional,Recruiting,Early Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04589624
2909,NCT04589884,Digestive Cancer|Digestive Perfusion|Liver Cancer|Liver Metastases|Parathyroid Diseases|Thyroid Diseases,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Digestive Cancer|Digestive Perfusion|Liver Cancer|Liver Metastases|Parathyroid Diseases|Thyroid Diseases,2020-10-09,2024-09-22,2024-10-22,600.0,Cohort,,Prospective,Observational,Recruiting,,IHU Strasbourg,ARC Foundation for Cancer Research|IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04589884
2910,NCT04594720,"Benign Thyroid Tumor|Thyroid Cancer|Thyroid Cancer, Papillary",Using Circulating Biomarkers to Identify Thyroid Cancer From the Patients With Thyroid Nodules,Circulating Biomarkers to Identify Thyroid Cancer,"Benign Thyroid Tumor|Thyroid Cancer|Thyroid Cancer, Papillary",2020-10-16,2019-10-31,2020-09-30,100.0,Case-Control,,Retrospective,Observational,Completed,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Kaohsiung Chang Gung Memorial Hospital,Other|Other,Taiwan,20.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04594720
2912,NCT04598815,Graves Ophthalmopathy,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus for Graves' Orbitopathy (GO),Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,54.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04598815
2916,NCT04600349,Autoimmune Thyroiditis,The Influence of Identity Oriented Psychotrauma Therapy on Hashimoto Disease Activity: a Randomized Controlled Trial,Identity Oriented Psychotrauma Therapy on Hashimoto in Adults,Autoimmune Thyroiditis,2020-10-19,2020-12-30,2021-03-01,70.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Bucharest,University of Bucharest,University of Bucharest,Behavioral|Drug,Romania,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04600349
2919,NCT04601298,Atypia of Undetermined Significance|FLUS|Thyroid Cancer,The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category IIIAUS/FLUSby Thyroid Fine-Needle AspirationFNACould be Assisted by Tumor Size for Precision Treatment,The Risk Stratification of Papillary Thyroid Cancer With AUS/FLUS by FNA,Atypia of Undetermined Significance|FLUS|Thyroid Cancer,2020-09-29,2020-09-30,2020-09-30,290.0,Case-Crossover,,Cross-Sectional,Observational,Completed,,Shanghai 10th People's Hospital,Shanghai 10th People's Hospital,Shanghai 10Th People'S Hospital,Other,China,18.0,77.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04601298
2921,NCT04604808,Hypoparathyroidism Postprocedural,Observational Prospective Study on the Effects of Hypoparathyroidism on Post-thyroidectomy Health-related Quality of Life (QoL-hPTP),Study on the Effects of Hypoparathyroidism on Post-thyroidectomy Health-related Quality of Life (QoL-hPTP),Hypoparathyroidism Postprocedural,2020-09-29,2021-03-31,2021-11-30,40.0,Cohort,,Prospective,Observational,Completed,,Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa,Fundacin de Investigacin Biomdica - Hospital Universitario de La Princesa,Hospital Universitario de La princesa,,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04604808
2923,NCT04608253,Primary Hyperparathyroidism|Primary Hyperparathyroidism Due to Adenoma,A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT for Detection of Hyperfunctioning Parathyroid Glands After Prior Negative or Discordant Imaging in Primary Hyperparathyroidism,A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT in Primary Hyperparathyroidism,Primary Hyperparathyroidism|Primary Hyperparathyroidism Due to Adenoma,2020-10-27,2019-12-31,2020-08-01,36.0,Cohort,,Retrospective,Observational,Completed,,University Medical Center Groningen,University Medical Center Groningen,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04608253
2926,NCT04610723,Graves Orbitopathy,Immunological Follow-up of Patients With Basedow's Orbitopathy : SIPO,Immunological Follow-up of Patients With Basedow's Orbitopathy,Graves Orbitopathy,2020-10-26,2021-11-01,2021-11-30,15.0,Cohort,,Prospective,Observational,Completed,,"University Hospital, Montpellier","University Hospital, Montpellier",Uhmontpellier,,France,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04610723
2930,NCT04612894,Thyroid Cancer,The Efficacy and Safety of Anti-PD-1 Antibody Camrelizumab Combined With Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study,Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer,Thyroid Cancer,2020-10-30,2022-12-01,2023-12-31,31.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug|Procedure|Procedure,China,14.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04612894
2931,NCT04613323,Hashimoto Disease|Pregnancy Related|Thyroid Dysfunction,Management of Thyroid Function in Hashimoto's Thyroiditis During Pregnancy: Real-word Experience in a Secondary Endocrine Centre in Italy,Management of Thyroid Function in Hashimoto's Thyroiditis During Pregnancy,Hashimoto Disease|Pregnancy Related|Thyroid Dysfunction,2020-07-14,2022-07-01,2022-09-01,100.0,Case-Only,,Retrospective,Observational,Not yet recruiting,,Centro Diagnostico Priamar,Centro Diagnostico Priamar,,,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04613323
2934,NCT04614389,Thyroid Nodule,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography in Conjunction With ACR TI-RADS for the Evaluation of Thyroid Nodules,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography,Thyroid Nodule,2019-09-25,2021-04-30,2021-07-01,200.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Southern California,Siemens Medical Solutions USA - CSG|University of Southern California,USC Department of Radiology,Other|Other|Device,United States,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04614389
2936,NCT04619316,Metastatic Thyroid Cancer,Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: A Single Center Pilot Study,Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition,Metastatic Thyroid Cancer,2020-11-01,2024-12-31,2024-12-31,20.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,"University Hospital, Essen","University Hospital, Essen",Manuel M. Weber,Drug|Drug,Germany,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04619316
2937,NCT04623801,Papillary Thyroid Microcarcinoma|Thyroid|Thyroid Cancer,Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma,Laser Ablation of Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid|Thyroid Cancer,2020-11-06,2022-10-31,2022-10-31,10.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04623801
2938,NCT04624477,Papillary Microcarcinoma of the Thyroid|Papillary Thyroid Cancer|Papillary Thyroid Carcinoma,Active Surveillance or Surgery for Primary Management of Very Low Risk Papillary Thyroid Cancer: How Often Are the Long-term Disease Management Goals Achieved?,Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer,Papillary Microcarcinoma of the Thyroid|Papillary Thyroid Cancer|Papillary Thyroid Carcinoma,2020-10-27,2025-03-31,2030-03-31,450.0,Cohort,,Prospective,Observational,Recruiting,,"University Health Network, Toronto","Canadian Cancer Society (CCS)|Canadian Institutes of Health Research (CIHR)|Centre hospitalier de l'Universit de Montral (CHUM)|CHU de Quebec-Universite Laval|Dalhousie University|Lawson Health Research Institute|McMaster University|Ottawa Hospital Research Institute|University Health Network, Toronto|University of British Columbia|University of Calgary",Nova Scotia Health|Lawson Health Research Institute|Ottawa Hospital Research Institute|University Health Network|CHU de Qubec - Universit Laval,,Canada,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04624477
2940,NCT04632524,Haemodynamic Stability,Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection: A Randomized Controlled Trial,Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection,Haemodynamic Stability,2020-08-30,2021-12-20,2022-01-30,60.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Fayoum University Hospital,Fayoum University Hospital,Atef,Drug,Egypt,20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04632524
2941,NCT04637360,"Hyperparathyroidism; Secondary, Renal",To Study the Bone Turnover Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Calcium Sensing Receptor Agonist Cinacalcet Treatment,Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment,"Hyperparathyroidism; Secondary, Renal",2020-11-06,2018-12-31,2020-06-30,40.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Min-Sheng General Hospital,En Chu Kong Hospital|Min-Sheng General Hospital|National Taiwan University|Taichung Tzu Chi Hospital|Taipei Medical University|Taipei Medical University Shuang Ho Hospital,Min sheng general hospital,Drug|Drug,Taiwan,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04637360
2944,NCT04639388,22q11.2 Deletion Syndrome,Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old,Understanding of Psychotic Disorders in Children With 22q11.2DS,22q11.2 Deletion Syndrome,2020-10-01,2024-10-31,2025-01-31,80.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Hpital le Vinatier,Hpital le Vinatier,Hopital Vinatier,Behavioral,France,4.0,13.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT04639388
2946,NCT04639960,22q11.2 Deletion Syndrome,Effects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome,Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome,22q11.2 Deletion Syndrome,2020-11-03,2021-05-01,2021-05-01,16.0,,Parallel Assignment,,Interventional,Terminated,Not Applicable,"University of Geneva, Switzerland","University of Geneva, Switzerland",Developmental imaging and psychopathology lab,Drug|Drug,Switzerland,11.0,25.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04639960
2948,NCT04644315,"Brain Neoplasms|Bronchial Neoplasms|Carcinoma, Bronchogenic|Central Nervous System|Cholangiocarcinoma|Colonic Diseases|Colorectal Neoplasms|Digestive System Diseases|Digestive System Neoplasms|Gastrointestinal Diseases|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Diseases|Intestinal Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neoplasms|Neoplasms by Site|Neuroendocrine Tumors|Ovarian Neoplasms|Pancreatic Neoplasms|Respiratory Tract Diseases|Respiratory Tract Neoplasms|Salivary Gland Neoplasms|Sarcoma|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Neoplasms","A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors,"Brain Neoplasms|Bronchial Neoplasms|Carcinoma, Bronchogenic|Central Nervous System|Cholangiocarcinoma|Colonic Diseases|Colorectal Neoplasms|Digestive System Diseases|Digestive System Neoplasms|Gastrointestinal Diseases|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Diseases|Intestinal Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neoplasms|Neoplasms by Site|Neuroendocrine Tumors|Ovarian Neoplasms|Pancreatic Neoplasms|Respiratory Tract Diseases|Respiratory Tract Neoplasms|Salivary Gland Neoplasms|Sarcoma|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Neoplasms",2020-11-20,2025-08-01,2025-12-01,50.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Science 37, Inc|Science 37-Basem; Dept 004- Basem|Science 37-Beg; Dept 001 Dr. M. Beg|Science 37-Ben; Dept 003-Ben|Science 37-Cannon; Dept 002-Cannon|Science 37-Kurzrock; Dept 005-Kurzrock|Science 37-Thomas; Dept 006-Thomas|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine",Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04644315
2950,NCT04647006,Surgery|Thyroid|Thyroid Nodule,"Comparison of Transoral Endoscopic Thyroidectomy Vestibular Approach and Open Conventional Thyroidectomy for Inflammatory Responses, Pain and Patient Satisfaction: A Prospective Study",Comparison of TOETVA and Conventional Thyroidectomy,Surgery|Thyroid|Thyroid Nodule,2020-10-06,2020-01-28,2020-03-30,40.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Basaksehir Cam & Sakura ehir Hospital,MUnlu|Sisli Hamidiye Etfal Training and Research Hospital,Sisli Etfal Research Hospiatl,Procedure,Turkey,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04647006
2952,NCT04647500,22q11.2 Deletion Syndrome,Effects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome,Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome,22q11.2 Deletion Syndrome,2020-11-03,2022-09-30,2022-09-30,30.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of Geneva, Switzerland","University of Geneva, Switzerland",Developmental imaging and psychopathology lab,Drug,Switzerland,8.0,25.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04647500
2954,NCT04648722,Hemithyroidectomy|Hypothyroidism,Higher Post-operative Levothyroxine Substitution Dose Needed in Right Compared to Left Lobe Hemithyroidectomy - a Retrospective Cohort Study,Higher Levothyroxine Requirements After Right-side Hemithyroidectomy,Hemithyroidectomy|Hypothyroidism,2020-11-22,2020-06-12,2020-06-12,459.0,Cohort,,Retrospective,Observational,Completed,,Medical University of Vienna,Medical University of Vienna,Medical University of Vienna,Procedure,Austria,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04648722
2955,NCT04662190,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",Eficcia i Seguretat de la descompressi orbitria en Orbitopatia distirodal Utilitzant Models Individualitzats d'impressi 3D Per la planificaci i simulaci de la Cirurgia.,Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,12.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitria de Manresa,Althaia Xarxa Assistencial Universitria de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04662190
2959,NCT04663451,Nodule Solitary Thyroid|Radioactive Iodine-Induced Hypothyroidism|Toxic Multinodular Goiter,"An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI For Hyperthyroidism, And it's Prognostic Factors.",An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.,Nodule Solitary Thyroid|Radioactive Iodine-Induced Hypothyroidism|Toxic Multinodular Goiter,2020-11-26,2020-11-24,2021-05-31,150.0,Cohort,,Retrospective,Observational,Active not recruiting,,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Radiation,Belgium,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04663451
2961,NCT04664413,Papillary Thyroid Cancer,Correlations Between Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma,Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma,Papillary Thyroid Cancer,2020-12-05,2021-04-30,2021-05-30,300.0,Case-Only,,Retrospective,Observational,Not yet recruiting,,University of Salerno,University of Salerno,"Department of Medicine and Surgery, Univeristy of Salerno",,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04664413
2963,NCT04666103,Ablation; Retina|Thyroid Carcinoma|Thyroid Nodule (Benign),Preserving Function Integrity of Neck Anatomy in Thyroid Surgery: A Randomized Clinical Trial,Function Integrity of Neck Anatomy in Thyroid Surgery,Ablation; Retina|Thyroid Carcinoma|Thyroid Nodule (Benign),2020-12-07,2021-12-31,2026-12-12,1264.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Wuhan University,Wuhan University,Zhongnan Hospital of Wuhan University,Procedure,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04666103
2965,NCT04671719,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,Autotaxin in Patients With GNAS/PTH Abnormalities,Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,2020-12-11,2024-03-10,2024-03-10,110.0,Case-Control,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Centre de comptence des maladies rares de l'insulino-scrtion et de l'insulino-sensibilit|Centre de rfrence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hpital Edouard Herriot, Lyon|Centre de Rfrence des Maladies Rares du Mtabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabte de l'Enfant Hpital Bictre Paris Saclay",Biological,France,10.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04671719
2970,NCT04675710,Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma,Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer,"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2020-12-05,2024-06-30,2024-06-30,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Drug|Radiation|Biological|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04675710
2972,NCT04680650,Thyroid Nodule,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Thyroid Nodule,2020-12-11,2021-03-31,2021-03-31,66.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Cancer Center of Guangzhou Medical University,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04680650
2974,NCT04682340,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,80.0,Case-Control,,Prospective,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04682340
2981,NCT04683575,Metastasis|Recurrence|Selenium Deficiency|Thyroid Cancer TNM Staging,Distribution of Selenium in Patients With Differentiated Thyroid Carcinoma and Effect of Selenium Supplement on Prognosis of Patients With Differentiated Thyroid Carcinoma.,Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma,Metastasis|Recurrence|Selenium Deficiency|Thyroid Cancer TNM Staging,2020-11-26,2025-12-31,2025-12-31,5000.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Qianfoshan Hospital,Qianfoshan Hospital,The First affiliated hospital of Shandong First Medical University,Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04683575
2982,NCT04686006,Graves Disease,"Effectiveness of Classical Potassium Iodide Therapy for the Treatment of Untreated Patients With Graves' Hyperthyroidism, Avoiding Thionamide Drugs With Serious Side Effects of Agranulocytosis, Liver Injury, Vasculitis, Embryopathy or Frequent Side Effects of Skin Eruption",Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects,Graves Disease,2020-12-22,2005-07-01,,504.0,Case-Only,,Retrospective,Observational,Completed,,Kyushu University,Kyushu University,,Drug,,15.0,90.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04686006
2985,NCT04690842,Hypoparathyroidism Postprocedural,Implementation of PTH Measurement Intra / Post Thyroidectomy to Improve Post Surgical Safety in Pediatric Patients,Improving Safety in Pediatric Thyroidectomy by PTH Measurements,Hypoparathyroidism Postprocedural,2020-12-28,2020-04-30,2020-04-30,66.0,Cohort,,Prospective,Observational,Completed,,Hospital de Nios R. Gutierrez de Buenos Aires,Hospital de Nios R. Gutierrez de Buenos Aires,,Diagnostic Test,,2.0,19.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04690842
2987,NCT04693377,Castration-Resistant Prostate Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Sarcoma|Metastatic Thyroid Gland Carcinoma|Metastatic Urothelial Carcinoma|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases,"Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial",Castration-Resistant Prostate Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Sarcoma|Metastatic Thyroid Gland Carcinoma|Metastatic Urothelial Carcinoma|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,2020-10-13,2023-04-01,2023-04-01,40.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Other|Radiation,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04693377
2988,NCT04693936,Hashimoto Disease|Psoriasis,Study of Metabolic Pathways for the Identification of Biomarkers in Hashimoto's Thyroiditis and Psoriasis,Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis,Hashimoto Disease|Psoriasis,2020-12-23,2023-01-31,2024-01-31,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Crete,University of Crete,"Metabolomic Medicine, Private Health Clinics",Combination Product,Greece,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04693936
2991,NCT04701203,Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,"PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism","A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism",Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,2021-01-06,2022-01-12,2025-01-31,82.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 3,Ascendis Pharma A/S,Ascendis Pharma Bone Diseases A/S,Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site,Combination Product|Combination Product,Canada|Denmark|Germany|Hungary|Italy|Norway|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04701203
2993,NCT04704349,Dementia|Heart Diseases|Kidney Diseases|Neoplasms|Parathyroid Diseases|Parkinsonian Disorders|Pulmonary Embolism|Rheumatic Disease|Thyroid Diseases,Latest Imaging SPECT System Evaluation Phase 1,Latest Imaging SPECT System Evaluation Phase 1,Dementia|Heart Diseases|Kidney Diseases|Neoplasms|Parathyroid Diseases|Parkinsonian Disorders|Pulmonary Embolism|Rheumatic Disease|Thyroid Diseases,2021-01-06,2021-01-27,2021-01-27,68.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Centre Hospitalier Rgional d'Orlans,Centre Hospitalier Rgional d'Orlans,CHR d'Orleans,Radiation,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04704349
2994,NCT04704414,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,Exophthalmometry With 3D Face Scanners,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,180.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04704414
2998,NCT04706962,Cutaneous Melanoma|Endometrial Cancer|Epithelial Ovarian Cancer|Hormone Receptor-positive Breast Cancer|Prostate Cancer|Small-cell Lung Cancer|Solid Tumor|Thyroid Cancer|TNBC - Triple-Negative Breast Cancer,"A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors",TH1902 in Patients With Advanced Solid Tumors,Cutaneous Melanoma|Endometrial Cancer|Epithelial Ovarian Cancer|Hormone Receptor-positive Breast Cancer|Prostate Cancer|Small-cell Lung Cancer|Solid Tumor|Thyroid Cancer|TNBC - Triple-Negative Breast Cancer,2021-01-07,2023-03-31,2023-03-31,70.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Theratechnologies,PPD|Theratechnologies,Cedars-Sinai|Karmanos Cancer Institute|START Midwest|Gettysburg Cancer Center|Mary Crowley Cancer Research|University of Texas MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04706962
2999,NCT04708626,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden,Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2021-01-11,2022-08-31,2022-09-30,110.0,Cohort,,Retrospective,Observational,Active not recruiting,,Uppsala University,Uppsala University,Uppsala University,Other|Other,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04708626
3002,NCT04712760,Congenital Hypothyroidism,Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.,Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.,Congenital Hypothyroidism,2021-01-11,2021-03-01,2021-04-01,60.0,Case-Control,,Retrospective,Observational,Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHRU Nancy,,France,0.0,42.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04712760
3004,NCT04714918,Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,Chinese Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Prevalence Survey,Chinese CKD-MBD Prevalence Survey (CRISS-MBD),Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,2021-01-14,2021-11-28,2021-11-28,9863.0,Case-Only,,Cross-Sectional,Observational,Recruiting,,Peking Union Medical College Hospital,Limeng Chen,"Peking Union Medical College Hospital|The First Affiliated Hospital, Chongqing Medical University|Fujian Provincial Hospital|The Seventh Affiliated Hospital, Sun Yat-sen University|Xiangya Hospital of Central South University|The First Hospital of China Medical University|People's Hospital of Ningxia Hui Autonomous Region|People's Hospital of Xinjiang Uygur Autonomous Region|The Second Affiliated Hospital Zhejiang University School of Medicine",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04714918
3007,NCT04730726,Thyroid Nodule,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,Thyroid Nodule,2021-01-26,2021-12-01,2022-04-01,50.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University Medical Center Groningen,University Medical Center Groningen,University Medical Center Groningen,Device,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04730726
3009,NCT04731467,Colorectal Adenocarcinoma|Melanoma|Non Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Solid Tumor,"A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors",A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors,Colorectal Adenocarcinoma|Melanoma|Non Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Solid Tumor,2021-01-24,2024-02-29,2024-03-31,80.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Purple Biotech Ltd.,Bristol-Myers Squibb|Famewave Ltd.,HonorHealth Research Institute|Yale University|Barbara Ann Karmanos Cancer Institute|The University of Texas M.D. Anderson Cancer Center|Rambam Health Care Campus|Sheba Medical Center,Drug|Drug|Drug|Drug,Israel|United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04731467
3011,NCT04731740,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage,Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer,Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage,2021-01-26,2023-12-28,2023-12-28,36.0,,Parallel Assignment,,Interventional,Suspended,Phase 2,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies,Drug|Biological|Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04731740
3013,NCT04734457,Congenital Hypothyroidism,Final Height in Patients With Congenital Hypothyroidism Diagnosed by Neonatal Screening,Final Height in Patients With CH Diagnosed by the Screening,Congenital Hypothyroidism,2021-01-11,2022-03-01,2022-04-01,60.0,Cohort,,Retrospective,Observational,Not yet recruiting,,Ain Shams University,Ain Shams University,Ain Shams University,Drug,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04734457
3015,NCT04737330,Graves Orbitopathy|Thyroid Eye Disease,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,70.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04737330
3019,NCT04739566,Thyroid Gland Anaplastic Carcinoma,Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO),Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer,Thyroid Gland Anaplastic Carcinoma,2021-01-29,2024-01-22,2026-01-22,18.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies,Drug|Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04739566
3021,NCT04740502,Primary Hyperparathyroidism,Surgical Approach and Outcomes in Patients With Primary Hyperparathyroidism and Unclear Preoperative Localisation Studies,Surgical Outcomes in Patients With Primary Hyperparathyroidism and Unclear Preoperative Localisation Studies,Primary Hyperparathyroidism,2021-02-01,2019-12-31,2020-12-31,242.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,University of Cagliari,University of Cagliari,Policlinico di Monserrato|Policlinico di Monserrato,Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04740502
3024,NCT04742608,Thyroid Gland Carcinoma|Thyroid Gland Nodule,Isolation and Characterization of Extracellular Vesicles in Patients With Thyroid Nodules and Thyroid Cancer,Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer,Thyroid Gland Carcinoma|Thyroid Gland Nodule,2021-02-03,2023-02-01,2024-02-01,250.0,Cohort,,Prospective,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04742608
3026,NCT04742959,Advanced Solid Tumor|Bladder Cancer|Cholangiocarcinoma|Gallbladder Cancer|Gastric Cancer|HER2-negative Breast Cancer|Prostate Cancer|Sarcoma|Small-cell Lung Cancer|Thyroid Cancer|Triple Negative Breast Cancer,"A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors",Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,Advanced Solid Tumor|Bladder Cancer|Cholangiocarcinoma|Gallbladder Cancer|Gastric Cancer|HER2-negative Breast Cancer|Prostate Cancer|Sarcoma|Small-cell Lung Cancer|Thyroid Cancer|Triple Negative Breast Cancer,2021-02-02,2022-04-01,2022-12-01,105.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"TransThera Sciences (Nanjing), Inc.","TransThera Sciences (Nanjing), Inc.",City of Hope|The University of Chicago|Rutgers Cancer Institute|MD Anderson Cancer Center,Drug|Combination Product,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04742959
3027,NCT04745793,Parathyroid Diseases|Thyroid Diseases,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Parathyroid Diseases|Thyroid Diseases,2021-02-04,2024-02-04,2024-03-04,200.0,Cohort,,Prospective,Observational,Recruiting,,IHU Strasbourg,IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04745793
3028,NCT04747275,Hypothyroidism|Trisomy 21,Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients,Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients,Hypothyroidism|Trisomy 21,2021-02-03,2022-05-31,2022-07-31,22.0,,Crossover Assignment,,Interventional,Recruiting,Phase 4,Children's Mercy Hospital Kansas City,Children's Mercy Hospital Kansas City,Children's Mercy Hospital,Drug|Drug,United States,2.0,4.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT04747275
3029,NCT04750460,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis|Hypocalcemia|Hypoparathyroidism|Secondary Hyperparathyroidism,"The Effect of Teriparatide on the Early Postoperative Hypocalcemia After Parathyroidectomy in Dialysis Patients: a Pilot, Randomized Trial",Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis|Hypocalcemia|Hypoparathyroidism|Secondary Hyperparathyroidism,2021-02-02,2021-07-31,2021-07-31,20.0,,Parallel Assignment,,Interventional,Enrolling by invitation,Phase 3,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University Hospital,Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04750460
3033,NCT04752202,Hashimoto Disease|Obesity,The Influence of Reducing Diets on Changes in Thyroid Parameters in Women Suffering From Obesity and Hashimoto's Disease,The Influence of Reducing Diets on Changes in Thyroid Parameters in Obese Women With Hashimoto's Disease,Hashimoto Disease|Obesity,2021-02-02,2019-04-19,2019-10-31,100.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Medical University of Bialystok,Medical University of Bialystok,Department of Dietetic and Clinical Nutrition; Medical University of Bialystok,Behavioral|Behavioral,Poland,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04752202
3036,NCT04754607,Autoimmune Diseases|Autoimmune Thyroiditis|Hashimoto Thyroiditis|Thyroid Diseases|Thyroiditis,"Effects of Low-Level Laser Therapy on Oxidative Stress Levels, Fatigue and Quality of Life in Patients With Hashimoto Thyroiditis",Effects of Low-Level Laser Therapy on Oxidative Stress Levels...,Autoimmune Diseases|Autoimmune Thyroiditis|Hashimoto Thyroiditis|Thyroid Diseases|Thyroiditis,2021-02-12,2022-04-15,2022-06-30,44.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Istanbul Medipol University Hospital,Istanbul Medipol University Hospital,Sumeyye TUNC,Other,Turkey,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04754607
3039,NCT04759053,Thyroid Diseases|Thyroid Gland; Node|Thyroid Nodule,"Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules, A Prospective Study",Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules,Thyroid Diseases|Thyroid Gland; Node|Thyroid Nodule,2021-02-09,2018-01-01,2018-02-01,60.0,,Parallel Assignment,,Interventional,Completed,Not Applicable,Kafrelsheikh University,Alexandria University|Kafrelsheikh University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04759053
3041,NCT04759911,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04759911
3044,NCT04760171,Alzheimer Disease|Amyloid|Dementia|Medullary Thyroid Cancer,An ex Vivo Study to Purify Amyloid Fibrils and Solve Their 3D Structures Using Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis,Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis,Alzheimer Disease|Amyloid|Dementia|Medullary Thyroid Cancer,2021-02-10,2023-02-28,2026-02-28,10.0,Cohort,,Prospective,Observational,Not yet recruiting,,The Leeds Teaching Hospitals NHS Trust,The Leeds Teaching Hospitals NHS Trust|University of Leeds,,,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04760171
3045,NCT04760288,Thyroid Cancer,"A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.",A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).,Thyroid Cancer,2021-02-17,2026-04-15,2028-04-15,198.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,Hoffmann-La Roche,Hoffmann-La Roche,"The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente|Instituto de Investigaciones Metabolicas (Idim)|Centro Mdico Privado CEMAIC|Instituto Medico de la Fundacion Estudios Clinicos|Sanatorio Britanico de Rosario|Centro de Investigacin Clnica - Clnica Viedma|Macquarie University Hospital|Royal North Shore Hospital|Ashford Cancer Center Research|The Alfred Hospital;Clinical Trial Pharmacy|Medizinische Universitt Graz; Klinische Abteilung fr Allgemeine HNO|CETUS Hospital Dia Oncologia|Hospital de Clinicas de Porto Alegre (HCPA) - PPDS|Irmandade Da Santa Casa de Misericordia de Porto Alegre|Fundao Pio XII Hospital de Cncer de Barretos|Instituto Do Cncer Do Estado de So Paulo Octvio Frias de Oliveira|Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncology|Complex Oncology Center Plovdiv; Department of Medical Oncology and Oncology Diseases in Pneumology|University Multiprofile Hospital For Active Treatment ""Sveti Ivan Rilski"" EAD; clinical hematology|Tom Baker Cancer Centre; Dept of Pathology|Cross Cancer Institute; Clinical Trials|McGill University Health Center; Glen-Cedars Cancer Centre, Oncology Pharmacy|Centre Hospitalier Universitaire de Sherbrooke; Pharmacie de Chimiotherapie|Clinical Hospital Centre Osijek; Hematology|Clinical Hospital Sestre Milosrdnice|Klinicki bolnicki centar Zagreb|Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed|Htel Dieu -Angers; Pharmacie / Secteur Essais Cliniques|EDOG - Institut Bergonie - PPDS|Centre Hospitalier Universitaire Lyon; Institut Hmatologique et d'Oncologie Pdiatrique|CHU Nantes|Centre Antoine Lacassagne Centre Rgional de Lutte Contre Le Cancer|Hopital Cochin|Institut Curie; Pharmacie|Hpital Saint-Louis|ICANS|Institut Universitaire de Cancer de Toulouse Oncopole; IUCT- Oncopole|Attikon University General Hospital|University of Athens Medical School - Regional General Hospital Alexandra|Kianous Stavros|Semmelweis Egyetem, II. Belgygyszati Klinika|Debreceni Egyetem Klinikai Kozpont|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont|Panchshil Hospital|Unity Hospital-Surat|Tata Memorial Hospital; Dept of Medical Oncology|HCG NCHRI Cancer Center|Deenanath Mangeshkar Hospital & Research Centre|Sparsh Hospitals & Critical Care (P) Ltd.|Dayanand Medical College and Hospital|Hadassah Medical Center|C.H. Regional Reina Sofia - PPDS|National Cancer Center|Seoul National University Hospital|Samsung Medical Center - PPDS|VU Medisch Centrum|Saint Louis University Hospital of Sacred Heart|St. Luke's Medical Center - Quezon City|Centrum Onkologii-Instytut Im. Marii Skodowskiej Curie; I Klinika Radioterapii i Chemioterapii|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Krakowie - Apteka/Pharmacy; Pharmacy|Instituto Portugus de Oncologia de Lisboa Francisco Gentil, E.P.E.|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe|Institutul National de Endocrinologie ""C. I. Parhon""; Sectorul 1 BUCURETI|Prof Dr I Chiricuta Institute of Oncology; Oncology Department|Onco Clinic Consult SA|CHUS - H. Clinico U. de Santiago|Clinica Universidad Navarra; Servicio de Farmacia|Hospital Universitario Vall d'Hebron|Hospital Clinic de Barcelona|MD Anderson Cancer Center Madrid - Espaa; Servicio de Farmacia|Hospital Universitario Ramon y Cajal|Hospital Universitario HM Sanchinarro - CIOCC; Farmacia - Ensayos Clnicos|Hospital Regional Universitario de Malaga|Hospital Universitario Virgen del Rocio|Phramongkutklao Hospital|Siriraj Hospital, Mahidol Uni ; Division of Rheumatology, Dept. of Medicine|Chulalongkorn University Hospital; Hematology|SI Institute for general and urgent surgery n.a. V.T.Zaitseva of NAMS of Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital # 4"" of Dnipro City Council - PPDS|Ukr. Scientific Practical Center of Endocrine Surgery,Transplantation of Endocrine organs&Tissues|Clinic Verum Expert LLC|Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima|St Bartholomew's Hospital|Guys Hospital; Guys Cancer Center|The Christie NHS Foundation Trust|The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton",Drug|Drug|Drug,"Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Croatia|Denmark|France|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Netherlands|Philippines|Poland|Portugal|Romania|Spain|Thailand|Ukraine|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04760288
3046,NCT04763122,Cancer|Thyroid,Decline in Radioiodine Use But Not Total Thyroidectomy in Thyroid Cancer Patients Treated in United Arab Emirates- A Retrospective Study,Thyroid Cancer in United Arab Emirates,Cancer|Thyroid,2021-02-09,2018-12-31,2020-12-31,762.0,Case-Control,,Retrospective,Observational,Completed,,Tawam Hospital,Tawam Hospital,,Other,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04763122
3047,NCT04767763,Secondary Hypothyroidism,Association of Continuous Veno-venous Hemodiafiltration With Citrate Anticoagulation to Thyroid Function in Critically Ill Patients,Thyroid Function in Critically Ill Patients With Acute Kidney Injury,Secondary Hypothyroidism,2021-02-17,2020-02-01,2020-02-01,32.0,Case-Control,,Prospective,Observational,Completed,,Medical University of Gdansk,Medical University of Gdansk,Medical University of Gdansk - Departament of Anesthesiology and Intensive Care,Diagnostic Test,Poland,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04767763
3048,NCT04776993,Graves' Orbitopathy,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy,Graves' Orbitopathy,2021-02-25,2023-01-30,2025-01-30,52.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04776993
3052,NCT04778865,Hashimoto Disease|Treatment Levothyroxine|Vitamin D Deficiency,Effect of Vitamin D Supplementation on Autoimmunity and Thyroid Function in Subjects With Hashimoto's Thyroiditis and Vitamin D Deficiency: Clinical Pilot Trial.,Effect of Treatment for Vitamin D Deficiency on Thyroid Function and Autoimmunity in Hashimoto's Thyroiditis.,Hashimoto Disease|Treatment Levothyroxine|Vitamin D Deficiency,2021-02-24,2021-12-31,2021-12-31,50.0,,Crossover Assignment,,Interventional,Recruiting,Not Applicable,Universidad de Valparaiso,Universidad de Valparaiso,Escuela de Nutricin. Facultad de Farmacia. Universidad de Valparaso.,Dietary Supplement|Dietary Supplement,Chile,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04778865
3055,NCT04782856,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,Energy Metabolism in Thyroidectomized Patients,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2023-05-31,2023-05-31,30.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04782856
3058,NCT04784208,Healthy|Hypothyroidism,A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY),A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY),Healthy|Hypothyroidism,2021-02-25,2022-06-30,2022-06-30,232.0,Other,,Prospective,Observational,Recruiting,,Abbott,Abbott,"Dr.Prasanna Kumar|Dr. MV Rama Mohan, MD, DM",Diagnostic Test,India,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04784208
3059,NCT04785443,Thyroid Diseases,Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Thyroid Diseases,2021-02-25,2024-06-30,2025-03-31,242.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,"University Hospital, Brest","University Hospital, Brest",CHRU de Brest,Drug|Procedure,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04785443
3061,NCT04787328,Medullary Thyroid Carcinoma,"A Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)",A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC),Medullary Thyroid Carcinoma,2021-02-24,2023-03-31,2025-03-31,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","Beijing Tongren Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Henan Province Tumor Hospital|Jiangsu province tumor hospital|Cancer Hospital of Fudan University|Sichuan Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Tianjin People's Hospital|The First Affiliated Hospital of Kunming Medical University|Zhejiang Provincial People's Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04787328
3062,NCT04789993,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France,Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,2021-02-20,2021-03-31,2021-04-30,250.0,Cohort,,Retrospective,Observational,Enrolling by invitation,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",Hpital d'Enfants de Brabois,Other,France,6.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04789993
3068,NCT04795947,Hypothyroidism,Correlation Between Thyroid Function and Quality of Life in Well-controlled Hypothyroidism Patients,Correlation Between Thyroid Function and Quality of Life in Hypothyroidism,Hypothyroidism,2021-03-10,2021-11-01,2021-11-01,98.0,Other,,Cross-Sectional,Observational,Active not recruiting,,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,BeijingCYH,Behavioral,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04795947
3069,NCT04798092,Primary Hyperparathyroidism,Impact of Parathyroidectomy on Renal Function in Patients With Primary Hyperparathyroidism,Impact of Parathyroidectomy on Renal Function,Primary Hyperparathyroidism,2021-01-29,2022-01-31,2022-01-31,500.0,Cohort,,Retrospective,Observational,Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHRU Nancy,Procedure,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04798092
3072,NCT04802876,Anal Carcinoma|Bladder Carcinoma|Carcinoma of Unknown Primary|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Adenocarcinoma|Esophageal Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|HER2-positive Breast Cancer|Hormone Receptor Positive / HER2-negative Breast Cancer|Kidney Clear Cell Carcinoma|Lung Adenocarcinoma|Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation|Lung Squamous Cell Carcinoma|Melanoma|Mesothelioma|MSI-H Colorectal Cancer|Other Histology|Ovarian Serous Cystadenocarcinoma|Pancreatic Adenocarcinoma|Prostate Adenocarcinoma|Sarcoma|Small Cell Lung Cancer|Squamous Esophageal Carcinoma|Stomach Adenocarcinoma|Thyroid Carcinoma|Triple Negative Breast Cancer|Uterine Carcinosarcoma|Uterine Endometrial Carcinoma|Uveal Melanoma,Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff,Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors,Anal Carcinoma|Bladder Carcinoma|Carcinoma of Unknown Primary|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Adenocarcinoma|Esophageal Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|HER2-positive Breast Cancer|Hormone Receptor Positive / HER2-negative Breast Cancer|Kidney Clear Cell Carcinoma|Lung Adenocarcinoma|Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation|Lung Squamous Cell Carcinoma|Melanoma|Mesothelioma|MSI-H Colorectal Cancer|Other Histology|Ovarian Serous Cystadenocarcinoma|Pancreatic Adenocarcinoma|Prostate Adenocarcinoma|Sarcoma|Small Cell Lung Cancer|Squamous Esophageal Carcinoma|Stomach Adenocarcinoma|Thyroid Carcinoma|Triple Negative Breast Cancer|Uterine Carcinosarcoma|Uterine Endometrial Carcinoma|Uveal Melanoma,2021-03-14,2023-12-31,2024-12-11,141.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,SOLTI Breast Cancer Research Group,Novartis|SOLTI Breast Cancer Research Group,Ico Badalona|Hospital Universitari Sant Joan de Reus|IOB - H. Quironsalud Barcelona|Hospital Vall Hebron|Hospital Clinic Barcelona|Complejo Asistencial Universitario de Len|Fundacin Jimnez Daz|Hospital Universitario 12 de Octubre|Instituto Valenciano de Oncologa (IVO)|Hospital Clnico Universitario de Valencia,Drug,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04802876
3073,NCT04806269,Hypothyroidism|Thyrotoxicosis,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Symptom Survey by Wearable Device in the Patients With Thyroid Dysfunction",Biosignals by Wearables in Thyroid Dysfunction,Hypothyroidism|Thyrotoxicosis,2021-01-26,2022-05-30,2022-12-31,120.0,Case-Control,,Prospective,Observational,Recruiting,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Device,"Korea, Republic of",18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04806269
3076,NCT04806672,Euthyroid Sick Syndromes in Traumatic Brain Injury Patient and GFAP Level,Euthyroid Sick Syndrome (ESS).. Can it Influence Morbidity and Mortality in Moderate to Severe Traumatic Brain Injury Patients or Correlate With Glial Fibrillary Acidic Protein (GFAP) Level.,Euthyroid Sick Syndrome (ESS) Effect on Traumatic Brain Injury Patients and Its Relation With GFAP Level,Euthyroid Sick Syndromes in Traumatic Brain Injury Patient and GFAP Level,2021-03-14,2021-12-31,2022-04-30,50.0,Cohort,,Prospective,Observational,Not yet recruiting,,Minia University,Minia University,,,,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04806672
3077,NCT04809454,Thyroid Dysfunction,Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt: A Cross Sectional Study,Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt,Thyroid Dysfunction,2021-03-16,2022-03-31,2022-03-31,100.0,Other,,Cross-Sectional,Observational,Not yet recruiting,,"Services Institute of Medical Sciences, Pakistan","Services Institute of Medical Sciences, Pakistan",Mehwish Iftikhar,,Pakistan,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04809454
3078,NCT04821336,Thyroid Cancer,"Cholesterol Metabolites (Dendrogenin A or DDA, 6-oxo-cholestane-3,5-diol or OCDO,...) Quantification in Malignant Versus Normal Human Thyroid Tissue Refractory to Iodine",Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance,Thyroid Cancer,2021-03-25,2022-06-30,2022-06-30,30.0,Other,,Retrospective,Observational,Not yet recruiting,,Institut Claudius Regaud,Cancer Research Center of Toulouse|Institut Claudius Regaud,Institut Claudius regaud IUCT Oncopole,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04821336
3079,NCT04823728,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis: Part II,HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2021-03-26,2024-12-31,2025-12-31,700.0,Case-Control,,Retrospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hpital Neurologique,Genetic,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04823728
3082,NCT04825964,Hyperthyroidism,Comparison of Exercise Capacity and Physical Activity Levels in Patients With Hyperthyroid and Healthy Controls,"Exercise Capacity, Physical Activity Levels in Patients With Hyperthyroid",Hyperthyroidism,2021-03-20,2021-11-30,2021-12-31,30.0,Case-Control,,Prospective,Observational,Completed,,Gazi University,Gazi University,"Gazi University Facutly of Health Sciences Department of Physiotheraphy and Rehabilitation, Cardiopulmonary Rehabilitation Unit",,Turkey,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04825964
3083,NCT04831957,Hypothyroidism|TAVI,Hypothyroidism After the TAVI Procedure in Elderly Patients,Hypothyroidism After the TAVI Procedure in Elderly Patients,Hypothyroidism|TAVI,2021-03-19,2023-12-31,2023-12-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,UZ brussel,Diagnostic Test,Belgium,70.0,120.0,[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04831957
3084,NCT04842994,Malignant Neoplasm of Thyroid Gland,"Phase III, Assessor Blinded, Randomised Controlled Trial of Use of Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery(ACTION)",Trial on Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery.,Malignant Neoplasm of Thyroid Gland,2020-10-06,2024-08-31,2024-08-31,448.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Tata Memorial Hospital,Tata Memorial Hospital,Tata Memorial Hospital,Device,India,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04842994
3085,NCT04844164,"Acromegaly|Diabetes Mellitus, Type 1|Pituitary ACTH Hypersecretion|Primary Hyperparathyroidism","Prospective Non-randomised Controlled Study of Vitamin D Metabolism in Patients With Endocrine Disorders (Acromegaly, Cushing's Disease, Primary Hyperparathyroidism, Diabetes Mellitus Type 1) Treated With Cholecalciferol Bolus Dose",Vitamin D Metabolism in Patients With Endocrine Disorders,"Acromegaly|Diabetes Mellitus, Type 1|Pituitary ACTH Hypersecretion|Primary Hyperparathyroidism",2021-04-09,2021-05-15,2021-06-01,240.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1,"Endocrinology Research Centre, Moscow","Endocrinology Research Centre, Moscow|Russian Science Foundation","Endocrinology Research Centre, Moscow",Drug,Russian Federation,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04844164
3088,NCT04846010,"Anxiety Disorders|Depression|Depression, Anxiety|Depression, Bipolar|Gastro Esophageal Reflux|GERD|Glomerulonephritis|Hepatitis|Insomnia|Post Infection Glomerulonephritis|Post-Infectious Arthritis|Post-Infectious Disorder (Disorder)|Post-Infectious Hypothyroidism|Post Infectious Osteoarthritis|Post-Infectious Parkinsonism|Post-Infectious Peripheral Neuralgia|Post-Infectious Polyneuritis|Sequelae of; Infection",Treating Sequalae Caused by Post-acute Sequelae of SARS (Severe Acute Respiratory Syndrome)-CoV-2 Infection,"Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2","Anxiety Disorders|Depression|Depression, Anxiety|Depression, Bipolar|Gastro Esophageal Reflux|GERD|Glomerulonephritis|Hepatitis|Insomnia|Post Infection Glomerulonephritis|Post-Infectious Arthritis|Post-Infectious Disorder (Disorder)|Post-Infectious Hypothyroidism|Post Infectious Osteoarthritis|Post-Infectious Parkinsonism|Post-Infectious Peripheral Neuralgia|Post-Infectious Polyneuritis|Sequelae of; Infection",2021-03-31,2022-05-01,2022-10-01,2000.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC","All Natural Medicine Clinic, LLC","All Natural Medicine Clinic, LLC",Combination Product|Combination Product|Combination Product|Combination Product|Combination Product|Combination Product|Combination Product,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04846010
3089,NCT04853680,Thyroid Cancer|Thyroid Nodule|Voice Disorders,A Prospective Randomized Controlled Study of Whether Anti-adhesion Barrier Can Prevent Voice Quality After Thyroidectomy.,Effect of Anti-adhesion Barrier on the Voice Quality After Thyroidectomy.,Thyroid Cancer|Thyroid Nodule|Voice Disorders,2021-04-11,2023-06-30,2023-07-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04853680
3091,NCT04856488,Hyperthyroidism,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,182.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04856488
3095,NCT04857086,Differentiated Thyroid Cancer,A Multi-center Study to Observe Five-year Outcomes of the Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China (The Second Stage of DTCC),The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China,Differentiated Thyroid Cancer,2021-04-20,2022-07-30,2023-03-28,1400.0,Cohort,,Retrospective,Observational,Recruiting,,Huazhong University of Science and Technology,"China-Japan Union Hospital, Jilin University|Chinese PLA General Hospital|First Hospital of China Medical University|Gansu Cancer Hospital|Huazhong University of Science and Technology|Sir Run Run Shaw Hospital|The First Affiliated Hospital of Kunming Medical College|Tongji Hospital|West China Hospital|Wuhan Union Hospital, China","Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04857086
3096,NCT04858867,Differentiated Thyroid Cancer,Reinducing Radioiodine-sensitivity in Radioiodine-refractory Differentiated Thyroid Cancer Using Lenvatinib (RESET),Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET),Differentiated Thyroid Cancer,2021-04-09,2024-01-01,2024-06-01,12.0,,Sequential Assignment,,Interventional,Recruiting,Not Applicable,Leiden University Medical Center,Leiden University Medical Center,Leiden University Medical Center,Radiation|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04858867
3097,NCT04860622,Dysfunction|Hypothyroidism|Iodine Deficiency|Pregnancy Related|Thyroid,Normal Range of TSH and FT4 in Pregnancy,Normal Range of TSH and FT4 in Pregnancy,Dysfunction|Hypothyroidism|Iodine Deficiency|Pregnancy Related|Thyroid,2021-04-22,2021-08-15,2021-09-01,528.0,Cohort,,Prospective,Observational [Patient Registry],Completed,,Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital,Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital,Sehit Prof Dr Ilhan Varank Sancaktepe Training and Research Hospital,Diagnostic Test,Turkey,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04860622
3098,NCT04868045,Thyroid Cancer,Evaluation of The Development of Central Resistance to Thyroid Hormone After Prolonged Exposure to Excess Thyroid Hormone in Thyroid Cancer Patients,Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer,Thyroid Cancer,2021-04-28,2023-04-30,2023-04-30,16.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04868045
3102,NCT04876287,Thyroid Cancer,Salivary dysfuncTion After Radioiodine Treatment,Salivary dysfuncTion After Radioiodine Treatment,Thyroid Cancer,2021-04-26,2021-04-26,2021-04-26,138.0,Cohort,,Prospective,Observational,Completed,,Institut de Radioprotection et de Surete Nucleaire,Institut de Radioprotection et de Surete Nucleaire,Piti-Salptrire hospital,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04876287
3103,NCT04876534,Graves Ophthalmopathy,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Tocilizumab in Active Moderate-severe Graves' Orbitopathy,Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,64.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04876534
3107,NCT04877613,Metastatic Medullary Thyroid Cancer,Phase I Trial of GFR4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer,GFR4 CAR T Cells in MTC Patients,Metastatic Medullary Thyroid Cancer,2021-05-03,2039-06-01,2039-06-01,18.0,,Sequential Assignment,,Interventional,Recruiting,Phase 1,University of Pennsylvania,University of Pennsylvania,University of Pennsylvania,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04877613
3108,NCT04877665,Hypothyroidism,Establishing Reference Intervals for Thyroid Stimulating Hormone in Children Under the Age of Two Years,Establishing RIs for TSH in Children Under the Age of Two Years,Hypothyroidism,2021-05-05,2019-03-30,2019-03-30,131.0,Other,,Prospective,Observational [Patient Registry],Completed,,"Aga Khan University Hospital, Pakistan","Aga Khan University Hospital, Pakistan",The Aga Khan University,,Pakistan,1.0,24.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04877665
3109,NCT04878614,Hypothyroidism,Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding,Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding,Hypothyroidism,2021-05-04,2022-04-30,2023-04-30,34.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",UCLA Center for Human Nutrition,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04878614
3110,NCT04879173,Hyperthyroidism/Thyrotoxicosis,The Clinical Value of Microvascular Ultrasonography in Real-time Differential Diagnosis of Thyrotoxic Patients Between Hyperthyroidism and Thyroiditis,Clinical Value of Microvascular Ultrasonography in Real-time Differential Diagnosis of Thyrotoxic Patients,Hyperthyroidism/Thyrotoxicosis,2021-05-04,2021-10-31,2022-10-31,50.0,Case-Only,,Prospective,Observational,Recruiting,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St. Mary hospital,Device,"Korea, Republic of",0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04879173
3112,NCT04879355,Thyroid Nodule,The Use of Spinal Needles for Ultrasound-guided Fine Needle Aspiration From Thyroid Nodules - a Protocol for a Multicentre Randomised Controlled Trial,Spinal Needles in Ultrasound-guided Fine Needle Aspirations From Thyroid Nodules,Thyroid Nodule,2021-03-07,2022-11-01,2023-12-01,350.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Zealand University Hospital,"Herlev Hospital|Preben Home|Rigshospitalet, Denmark",,Device|Device,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04879355
3114,NCT04880798,Differentiated Thyroid Cancer,Effect of Thyrotropin Level on Iodine Uptake: a Prospective 124I PET/CT Study in Metastatic Differentiated Thyroid Cancer,Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2021-05-06,2022-12-31,2022-12-31,10.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Peking Union Medical College Hospital,Beijing Cancer Hospital|Peking Union Medical College Hospital,Peking Union Medical College Hospital|Beijing Cancer Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04880798
3115,NCT04883294,Thyroid Neoplasm,Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer,Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer,Thyroid Neoplasm,2021-05-11,2024-01-01,2025-01-01,1500.0,Cohort,,Prospective,Observational,Not yet recruiting,,Maastricht University Medical Center,Maastricht University Medical Center,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04883294
3116,NCT04892303,Recurrent Thyroid Cancer,Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer,Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer,Recurrent Thyroid Cancer,2021-05-03,2025-03-31,2025-08-31,48.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,The Johns Hopkins SKCCC,Combination Product,United States,18.0,85.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04892303
3117,NCT04895631,"Hyperparathyroidism, Primary",18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2021-05-13,2026-06-30,2027-06-30,140.0,,Single Group Assignment,,Interventional,Recruiting,Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04895631
3121,NCT04904159,Thyroid Cancer|Thyroid Nodule,A New Scoring System in the Diagnosis of Thyroid Gland Pathologies,Scoring System for Thyroid Gland Pathologies,Thyroid Cancer|Thyroid Nodule,2021-05-17,2023-01-01,2023-05-01,300.0,Cohort,,Prospective,Observational [Patient Registry],Enrolling by invitation,,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Kartal Dr Lutfi Kirdar Tranining and Research Hospital,Procedure|Procedure,Turkey,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04904159
3123,NCT04905641,Parathyroid Adenoma|Thyroid Nodule,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy Under Moderate Sedation; Retrospective Study,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy,Parathyroid Adenoma|Thyroid Nodule,2021-05-26,2017-05-25,2017-07-31,19.0,Case-Only,,Retrospective,Observational,Completed,,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04905641
3127,NCT04916262,Differentiated Thyroid Carcinoma|TCM Syndrome Type,Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer,Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer,Differentiated Thyroid Carcinoma|TCM Syndrome Type,2021-05-24,2021-12-01,2022-01-01,160.0,Cohort,,Prospective,Observational,Not yet recruiting,,Qianfoshan Hospital,Qianfoshan Hospital,,,,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04916262
3128,NCT04919694,Thyroid Associated Ophthalmopathy,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04919694
3132,NCT04922801,Hyperthyroidism|Neuroendocrine Tumors|Thyroid Cancer|Thyroid Carcinoma,OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE),Optimising Molecular Radionuclide Therapy,Hyperthyroidism|Neuroendocrine Tumors|Thyroid Cancer|Thyroid Carcinoma,2021-05-17,2022-04-20,2022-06-30,60.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,King's College London,Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas Hospitals Foundation Trust,Diagnostic Test|Diagnostic Test|Diagnostic Test|Device|Diagnostic Test,United Kingdom,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04922801
3134,NCT04922892,Secondary Hyperparathyroidism;Parathyroidectomy,Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism,Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism,Secondary Hyperparathyroidism;Parathyroidectomy,2021-06-07,2023-05-31,2028-05-31,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,The Second Hospital of Nanjing Medical University,The Second Hospital of Nanjing Medical University,NanjingMU,Procedure,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04922892
3137,NCT04927416,Metastic Thyroid Cancer,The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer,The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer,Metastic Thyroid Cancer,2021-06-15,2030-11-30,2030-11-30,54.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04927416
3138,NCT04927468,"Graves Ophthalmopathy|Strabismus, Mechanical",The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04927468
3142,NCT04931576,Drainage|Thyroid Cancer,The Feasibility of no Drainage During Transoral Endoscopic Thyroidectomy Via the Vestibular Approach in Treatment of Papillary Thyroid Carcinoma,No Drainage During Transoral Endoscopic Thyroidectomy Vestibular Approach(TOETVA),Drainage|Thyroid Cancer,2021-06-14,2023-06-01,2023-10-01,600.0,,Crossover Assignment,,Interventional,Not yet recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",,Procedure,,18.0,55.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04931576
3143,NCT04932135,Graves Disease|Hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,40.0,Cohort,,Prospective,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04932135
3146,NCT04936854,Thyroid-Associated Ophthalmopathy,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04936854
3150,NCT04940052,Differentiated Thyroid Cancer,"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)","Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer",Differentiated Thyroid Cancer,2021-06-22,2024-02-19,2026-10-30,150.0,,Crossover Assignment,,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug|Drug|Drug,"China|India|Korea, Republic of|Malaysia|Taiwan|Turkey",18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04940052
3151,NCT04942769,Selenium,Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis,Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis,Selenium,2021-06-24,2021-07-30,2021-10-30,30.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,"Beijing Chao-Yang Hospital, Capital Medical University",Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04942769
3154,NCT04946123,Hyperthyroidism,Association of Methimazole With L-carnitine and Selenium in Patients With Hyperthyroidism,Hyperthyroidism: Methimazole Plus L-carnitine and Selenium,Hyperthyroidism,2021-06-15,2022-06-30,2022-07-31,60.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Lo.Li.Pharma s.r.l,Lo.Li.Pharma s.r.l,Azienda Ospedaliero-Universitaria Citt della scienza e degli studi di Torino,Dietary Supplement,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04946123
3155,NCT04948437,Follicular Thyroid Cancer|Papillary Thyroid Cancer|Thyroid Cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Well-differentiated Thyroid Cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer,Follicular Thyroid Cancer|Papillary Thyroid Cancer|Thyroid Cancer,2021-06-24,2024-10-31,2026-10-31,103.0,Cohort,,Prospective,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,"Chih-Yuan Wang, M.D",,Taiwan,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04948437
3158,NCT04948671,"Hyperparathyroidism, Primary",Primary Hyperparathyroidism and Gut Microbiota Unravelling an Unexpected Relationship: the HYPOGEUM Study,Primary Hyperparathyroidism and Gut Microbiota,"Hyperparathyroidism, Primary",2021-06-28,2023-02-28,2024-02-28,90.0,Case-Control,,Prospective,Observational,Recruiting,,Centre Hospitalier Universitaire Vaudois,Centre Hospitalier Universitaire Vaudois|The Novartis Foundation,Patrizia D'amelio,Other,Switzerland,30.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04948671
3161,NCT04952012,"Thyroiditis, Autoimmune",The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,"Thyroiditis, Autoimmune",2021-06-20,2021-11-30,2022-11-30,4000.0,Case-Control,,Retrospective,Observational,Recruiting,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Changxing People's Hospital|First People's Hospital of Yuhang|Second Affiliated Hospital, School of Medicine, Zhejiang University|Taizhou Women and Children's Hospital Affiliated to Wenzhou Medical University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Drug,China,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04952012
3163,NCT04952493,Thyroid Cancer,"The Efficacy and Safety of Anlotinib Hydrochloride or Penpulimab In Combination With RAI in Patients With Local Advanced or Metastatic Differentiated Thyroid Cancer: A Randomized, Open-label, Exploratory Clinical Trial",Anlotinib or Penpulimab in Combination With RAI for DTC,Thyroid Cancer,2021-06-27,2023-07-20,2024-07-20,42.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Peking Union Medical College Hospital",Peking Union Medical College Hospital,Drug|Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04952493
3164,NCT04953195,Subclinical Hypothyroidisms,Effect of Thyroid Replacement Therapy on Thyroid Structure in Patients With Subclinical Hypothyroidism,Thyroid Replacement Therapy in Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidisms,2021-06-25,2021-09-15,2021-10-30,30.0,,Single Group Assignment,,Interventional,Recruiting,Phase 4,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,"Beijing Chao-Yang Hospital, Capital Medical University",Drug,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04953195
3165,NCT04964284,Differentiated Thyroid Cancer,"A Randomized, Open-label, Multi-center, Controlled Phase  Study to Evaluate the Safety and Efficacy of Recombinant Human Thryoid Stimulating HormonerhTSH for Adjuvant Radioiodine Ablation Therapy in Postoperative Patients With Differentiated Thyroid Cancer",Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2021-07-06,2022-09-30,2022-12-31,328.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Biological|Radiation,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04964284
3166,NCT04969926,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",Natural History Study of Parathyroid Disorders,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,3000.0,Cohort,,Prospective,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04969926
3172,NCT04970134,Differentiated Thyroid Carcinoma|Medullary Thyroid Carcinoma,Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY Project,Spanish Study for Molecular Characterization of Thyroid Carcinoma,Differentiated Thyroid Carcinoma|Medullary Thyroid Carcinoma,2021-07-16,2023-03-31,2024-03-31,150.0,Other,,Retrospective,Observational,Recruiting,,Grupo Espaol de Tratamiento de Tumores de Cabeza y Cuello,Grupo Espaol de Tratamiento de Tumores de Cabeza y Cuello,Hospital Universitario Durn i Reinals|Fundaci Althaia|Consorci Corporaci Sanitria Parc Taul de Sabadell|Hospital Universitario Vall d'Hebron|Hospital Clnic de Barcelona|Institut Catal d'Oncologia Girona - ICO Girona|Hospital Universitario Ramn y Cajal|Hospital Universitario La Paz|Hospital universitario Marqus de Valdecilla|Hospital General Universitario de Valencia|Hospital Universitario y Politcnico La Fe|Hospital Universitario Miguel Servet,Other|Other|Other,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04970134
3173,NCT04971473,Differentiated Thyroid Cancer,"An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal",Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal,Differentiated Thyroid Cancer,2021-07-07,2023-06-30,2023-07-31,201.0,,Single Group Assignment,,Interventional,Recruiting,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Biological,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04971473
3174,NCT04976816,Thyroid Eye Disease,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,64.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04976816
3178,NCT04988802,Hypothyroidism Primary,The Effect of Dietary Supplements for Pregnant Women on Levothyroxine Absorption,The Effect of Dietary Supplements for Pregnant Women on Levothyroxine Absorption,Hypothyroidism Primary,2021-07-25,2022-07-30,2022-09-30,37.0,,Crossover Assignment,,Interventional,Recruiting,Not Applicable,University Hospital Dubrava,University Hospital Dubrava,Dubrava University Hospital,Dietary Supplement|Other,Croatia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04988802
3179,NCT04994080,Secondary Hyperparathyroidism,"A Multi-center, Randomized, Double-blind, Parallel Grouping, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Paricalcitol Soft Capsules in the Treatment of Secondary Hyperparathyroidism in Subjects With Stage 3 and Stage 4 Chronic Kidney Disease",A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2021-07-21,2023-03-31,2023-03-31,84.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,"Chengdu Suncadia Medicine Co., Ltd.","Chengdu Suncadia Medicine Co., Ltd.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04994080
3182,NCT04998968,Permanent Hypoparathyroidism,Quality of Life in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy in a Swedish Population Based Cohort,Quality in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy,Permanent Hypoparathyroidism,2021-08-09,2021-12-31,2022-05-31,1700.0,Cohort,,Prospective,Observational,Enrolling by invitation,,Uppsala University,Uppsala University,Uppsala University Hospital,,Sweden,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04998968
3184,NCT05002998,Thyroid Eye Disease,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",TEPEZZA (Teprotumumab-trbw) Post-Marketing Requirement Study,Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,300.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute|Mayo Clinic|Washington University in St. Louis|University of Nebraska Medical Center|Casey Eye Institute - OHSU|Hospital La Arruzafa|Hospital Universitario Ramon Y Cajal|Hospital Universitario Virgen Macarena,Drug|Drug,Spain|United States,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05002998
3188,NCT05003856,Benign Thyroid Gland Neoplasm|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|Thyroid Gland Nodule|Thyroid Gland Papillary Carcinoma,Radiofrequency Ablation Use in Thyroid Nodule,Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule,Benign Thyroid Gland Neoplasm|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|Thyroid Gland Nodule|Thyroid Gland Papillary Carcinoma,2021-08-05,2025-06-30,2025-06-30,100.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 4,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05003856
3191,NCT05007093,DTC - Differentiated Thyroid Cancer,An Exploratory Study on Efficacy of Anlotinib Hydrochloride in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer,Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib,DTC - Differentiated Thyroid Cancer,2021-08-09,2023-12-07,2023-12-07,10.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,Yansong Lin,Peking Union Medical College Hospital,Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05007093
3192,NCT05012033,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,120.0,Case-Only,,Cross-Sectional,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05012033
3196,NCT05014698,"Differentiated Thyroid Cancer|Thyroid Cancer, Nonmedullary",IDEntification of New Predisposition Genes in Differentiated THYroid Cancer,IDEntification of New Predisposition Genes in Differentiated THYroid Cancer,"Differentiated Thyroid Cancer|Thyroid Cancer, Nonmedullary",2021-08-05,2025-02-28,2025-02-28,95.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Nantes University Hospital,Nantes University Hospital,Vende Hospital|Nantes University Hospital,Genetic,France,8.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05014698
3197,NCT05015127,Thyroid Ophthalmopathy,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease,Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,36.0,,Parallel Assignment,,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05015127
3201,NCT05015725,Hypothyroidism,"A Single Center Cross-sectional Study to Evaluate the Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients","The Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients",Hypothyroidism,2021-06-30,2022-07-05,2022-07-05,350.0,Case-Only,,Cross-Sectional,Observational,Recruiting,,Semmelweis University,Semmelweis University,Semmelweis University - Departement Medicine and Oncology,Diagnostic Test,Hungary,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05015725
3202,NCT05017142,"Acute Disseminated Encephalomyelitis|Anti-AMPAR-1/2 Associated Autoimmune Encephalitis|Anti-CASPR-2 Associated Autoimmune Encephalitis|Anti-GABAR-1/2 Associated Autoimmune Encephalitis|Anti-GAD65 Associated Autoimmune Encephalitis|Anti-Lgi-1 Associated Autoimmune Encephalitis|Anti-NMDAR Encephalitis|CNS Lupus|CNS Sarcoidosis|CNS Vasculitis|Hashimoto Encephalitis|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis|Optic Neuritis|Rasmussen Encephalitis|Transverse Myelitis",Swiss Pediatric Inflammatory Bain Disease Cohort Study,Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD),"Acute Disseminated Encephalomyelitis|Anti-AMPAR-1/2 Associated Autoimmune Encephalitis|Anti-CASPR-2 Associated Autoimmune Encephalitis|Anti-GABAR-1/2 Associated Autoimmune Encephalitis|Anti-GAD65 Associated Autoimmune Encephalitis|Anti-Lgi-1 Associated Autoimmune Encephalitis|Anti-NMDAR Encephalitis|CNS Lupus|CNS Sarcoidosis|CNS Vasculitis|Hashimoto Encephalitis|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis|Optic Neuritis|Rasmussen Encephalitis|Transverse Myelitis",2021-08-04,2071-01-01,2071-01-01,500.0,Cohort,,Other,Observational [Patient Registry],Recruiting,,University of Bern,"Novartis|Roche Pharma (Switzerland) Ltd|Schweizerische Multiple Sklerose Gesellschaft|University Hospital Inselspital, Berne|University of Bern","Kantonsspital Aarau|Kantonsspital Graubnden|Children's Hospital of Eastern Switzerland|Pediatric Institute of Southern Switzerland, Ospedale San Giovanni|University Children's Hospital Lausanne (CHUV)|Kinderspital Winterthur|University Children's Hospital Basel, UKBB|University Children's Hospital, Inselspital Bern|Institute of Social and Preventive Medicine, University of Bern|University Hospitals of Geneva (HUG)|Luzerner Kantonsspital|University Children's Hospital Zurich",,Switzerland,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05017142
3205,NCT05019118,Subclinical Hypothyroidism,"Dietary Intervention With nicla Dairy Products, Naturally Enriched With Selenium and Omega-3 Fatty Acids, May Improve Thyroid-stimulating Hormone (TSH) Levels in Women With Subclinical Hypothyroidism",Dietary Intervention With nicla Dairy Products (DANTIAN),Subclinical Hypothyroidism,2021-08-13,2021-12-30,2022-05-30,90.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Cooperativas Lacteas Unidas,Cooperativas Lacteas Unidas|Galician South Health Research Institute,Nursing University School of Ourense,Other|Other|Other|Other|Other|Other,Spain,40.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05019118
3206,NCT05022641,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Neoplasms|Primary Hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Neoplasms|Primary Hyperparathyroidism,2021-08-22,2023-08-31,2023-08-31,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05022641
3210,NCT05022667,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,2021-08-22,2023-08-31,2023-08-31,160.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05022667
3213,NCT05024929,Papillary Thyroid Cancer|Pediatric Cancer,Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Papillary Thyroid Cancer,Targeted Therapy to Increase RAI Uptake in Metastatic PTC,Papillary Thyroid Cancer|Pediatric Cancer,2021-08-23,2031-02-01,2033-02-01,32.0,Cohort,,Prospective,Observational,Recruiting,,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Procedure,United States,0.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05024929
3215,NCT05025046,Thyroid Cancer|Thyroid Nodule,"Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules",NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2021-08-25,2022-06-30,2022-06-30,400.0,Cohort,,Prospective,Observational,Recruiting,,Rigen Biotech,"Guangdong Provincial People's Hospital|RenJi Hospital|Rigen Biotech|Shenzhen People's Hospital|The First People's Hospital of Changzhou|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Provincial People's Hospital|Zhongshan People's Hospital, Guangdong, China",Zhongshan City People's Hospital|The First Peple's Hospital of Changzhou|Guangdong Provincial People's Hospital|Zhejiang Provincial People's Hospital|Shanghai Jiaotong University School of Medicine|Shenzhen People's Hospital|Tianjin Medical University Center Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05025046
3217,NCT05033496,Hypothyroidism,The Yield of Postnatal Thyroid Function Test in Term Newborn Infants in the Well Baby Nursery in Addition to the National Screening Test Program,The Yield of Postnatal Thyroid Function Test in the Well Baby Nursery,Hypothyroidism,2021-08-25,2020-12-31,2021-10-03,40601.0,Case-Only,,Retrospective,Observational,Completed,,Hillel Yaffe Medical Center,Hillel Yaffe Medical Center,Hillel Yaffe medical center,Diagnostic Test,Israel,0.0,30.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05033496
3218,NCT05043233,Patient Acceptance of Health Care,The Observation Study of Graves' Disease Cohort,Observation in the Treatment of Graves' Disease,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,1000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05043233
3221,NCT05043584,Autofluorescence|Hypocalcemia|Hypoparathyroidism|Thyroidectomy,Prevention of Postoperative Hypoparathyroidism Following Thyroid Surgery by Using Intraoperative Autofluorescence,"Near-infrared Autofluorescence (NIRAF) in Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Centers",Autofluorescence|Hypocalcemia|Hypoparathyroidism|Thyroidectomy,2021-09-05,2023-09-30,2024-03-31,78.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Regional Hospital West Jutland,Hospital of South West Jutland|Regional Hospital West Jutland,"Department of Otorhinolaryngology, Hospital South West Jutland|Department of Otorhinolaryngology, Regional Hospital West Jutland",Device,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05043584
3223,NCT05049551,Hyperthyroidism,Quantitative Analysis of 99mTc-Pertechnetate Thyroid Uptake With a Large Field CZT Gamma Camera: Feasibility and Comparison Between SPECT/CT and Planar Acquisitions,Thyroid Uptake Quantification on a New Generation of Gamma Camera,Hyperthyroidism,2021-09-09,2020-06-22,2020-09-07,23.0,Other,,Retrospective,Observational,Completed,,Centre Hospitalier Princesse Grace,Centre Hospitalier Princesse Grace,Centre Hospitalier Princesse Grace,,Monaco,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05049551
3224,NCT05049603,Graves' Orbitopathy,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study,Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,102.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,University of Pisa,Universit degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05049603
3228,NCT05052359,Follicular Thyroid Cancer,Aberrant Helix Pomatia Agglutinin Binding Glycan Expression Changes With the Phenotype of Follicular Thyroid Tumours,Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours,Follicular Thyroid Cancer,2021-09-02,2021-08-01,2021-09-01,37.0,Cohort,,Retrospective,Observational,Completed,,"National University Health System, Singapore","National University Health System, Singapore",National University Hospital,Diagnostic Test,Singapore,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05052359
3230,NCT05054634,Thyroid Cancer,Psycho-oncological Intervention Through Counselling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine: A Non-randomized Controlled Study,Psycho-oncological Intervention Through Counselling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine,Thyroid Cancer,2021-09-03,2014-09-30,2015-03-31,75.0,Cohort,,Prospective,Observational,Completed,,Quironsalud,Quironsalud,Hospital Quironsalud Torrevieja,Behavioral,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05054634
3231,NCT05059470,Thyroid,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,Thyroid,2021-09-15,2023-10-01,2023-10-01,35.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05059470
3232,NCT05068687,Head and Neck Neoplasms|Skin Neoplasm|Thyroid Neoplasm,"Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Malignancies of the Head and Neck, a Pilot Study",Peroperative Assessment of Malignancies of the Head and Neck Using High-resolution 18F-FDG-PET/CT,Head and Neck Neoplasms|Skin Neoplasm|Thyroid Neoplasm,2021-09-24,2022-09-30,2022-09-30,40.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,"University Hospital, Ghent","University Hospital, Ghent|XEOS Medical",Ghent University Hospital,Diagnostic Test,Belgium,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05068687
3233,NCT05070091,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,180.0,Other,,Prospective,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05070091
3237,NCT05077865,Hashimoto Disease,"A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MYMD1 Capsules in Healthy Male and Female Adult Subjects","Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects",Hashimoto Disease,2021-10-01,2021-08-10,2021-08-10,32.0,,Parallel Assignment,,Interventional,Completed,Phase 1,"MyMD Pharmaceuticals, Inc.","MyMD Pharmaceuticals, Inc.","Clinical Research of West Florida, Inc",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05077865
3240,NCT05078853,Differentiated Thyroid Cancer|Lymph Node Metastases,Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma- A Multi-Center Validation Study,Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma,Differentiated Thyroid Cancer|Lymph Node Metastases,2021-09-27,2022-12-31,2022-12-31,250.0,Other,,Cross-Sectional,Observational,Recruiting,,Soroka University Medical Center,Soroka University Medical Center,Barzilai Medical Center|Soroka University Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05078853
3241,NCT05088187,"Cognitive Decline|Survivorship|Symptoms, Cognitive|Thyroid Cancer|Thyroid Nodule",Longitudinal Evaluation of Objective Cognitive Function and Quality of Life in Patients Undergoing Surgery for Malignant and Benign Thyroid Nodules,Cognition and QoL After Thyroid Surgery,"Cognitive Decline|Survivorship|Symptoms, Cognitive|Thyroid Cancer|Thyroid Nodule",2021-10-11,2023-11-01,2026-11-01,320.0,Cohort,,Prospective,Observational,Not yet recruiting,,Karolinska University Hospital,Karolinska University Hospital|The Netherlands Cancer Institute,,,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05088187
3243,NCT05096195,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis; Complications|Fragility Fracture|Kidney Diseases,"Denosumab for the Prevention of Fragility Fractures in Hemodialysis: a Pilot Study for an Innovative, Randomized-controlled Trial, Embedded in Routine Care",PREventing FracturEs in Renal Disease - 1,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis; Complications|Fragility Fracture|Kidney Diseases,2021-09-21,2023-12-31,2023-12-31,60.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,"Western University, Canada","Academic Medical Organization of Southwestern Ontario|ICES|The Kidney Foundation of Canada|Western University|Western University, Canada",,Drug|Other|Diagnostic Test,,40.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05096195
3246,NCT05098600,"Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo","The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,1000.0,Cohort,,Retrospective,Observational,Active not recruiting,,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05098600
3250,NCT05102292,Anaplastic Thyroid Cancer|ATC,"An Open Label, Multicenter Phase Ib/II Clinical Study to Evaluate Efficacy , Safety and PK of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation",The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation,Anaplastic Thyroid Cancer|ATC,2021-10-20,2023-05-30,2024-12-30,25.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1/Phase 2,Shanghai Henlius Biotech,Shanghai Henlius Biotech,Fudan University Affiliated Oncology Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05102292
3252,NCT05103956,Goiter,"Regular Treatment Versus Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Immediate Postoperative of the Thyroidectomy, Unicentric Study, Non-inferiority, Open and Randomized (Tiropatch Study)",Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Postoperative of the Thyroidectomy.,Goiter,2021-10-07,2022-04-01,2022-04-01,108.0,Case-Control,,Prospective,Observational,Recruiting,,Fundacin Pblica Andaluza para la gestin de la Investigacin en Sevilla,Fundacin Pblica Andaluza para la gestin de la Investigacin en Sevilla,Hospital Universitario Virgen del Roco,,Spain,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05103956
3253,NCT05108298,"Bone Cancer, NOS|Breast Cancer, NOS|Cervical Cancer, NOS|CNS Primary Tumor, NOS|Colorectal Cancer, NOS|Leukemia, NOS|Lymphoma, NOS|Melanoma|Miscellaneous Neoplasm, NOS|Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS|Testicular Nonseminomatous Germ Cell Tumor, NOS|Thyroid Cancer, NOS",Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,"Bone Cancer, NOS|Breast Cancer, NOS|Cervical Cancer, NOS|CNS Primary Tumor, NOS|Colorectal Cancer, NOS|Leukemia, NOS|Lymphoma, NOS|Melanoma|Miscellaneous Neoplasm, NOS|Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS|Testicular Nonseminomatous Germ Cell Tumor, NOS|Thyroid Cancer, NOS",2021-10-05,2023-03-31,2024-10-31,400.0,Cohort,,Prospective,Observational,Recruiting,,Eastern Cooperative Oncology Group,Eastern Cooperative Oncology Group,Wake Forest School of Medicine,Other,United States,18.0,39.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05108298
3254,NCT05110040,Thyroid Associated Ophthalmopathy,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Multi-model Image of Immunosuppressive Agents in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,12.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05110040
3258,NCT05112211,Thyroid Associated Ophthalmopathy,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Multi-model Image of Doxycycline in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05112211
3262,NCT05114980,Hypoparathyroidism,Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism,Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism,Hypoparathyroidism,2021-10-29,2024-01-31,2025-01-31,5.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,University of Alabama at Birmingham,University of Alabama at Birmingham,University of Alabama at Birmingham,Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05114980
3264,NCT05117853,Hypoparathyroidism Postprocedural|Thyroid Disease,The Use of Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Total Thyroidectomy: A Randomized Clinical Trial,Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Thyroidectomy,Hypoparathyroidism Postprocedural|Thyroid Disease,2021-10-21,2024-10-31,2025-05-31,300.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Drug|Procedure,Belgium,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05117853
3266,NCT05118542,Atherosclerosis of Artery|Graves Disease|Hyperthyroidism|Pathophysiology,"Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness",Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis,Atherosclerosis of Artery|Graves Disease|Hyperthyroidism|Pathophysiology,2021-10-06,2020-06-01,2020-08-01,36.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Indonesia University,Indonesia University,University of Indonesia,Drug|Drug,Indonesia,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05118542
3269,NCT05119296,Thyroid Cancer,Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Thyroid Cancer,2021-10-29,2024-11-30,2026-11-30,20.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,Stanford University,Merck Sharp & Dohme LLC|Stanford University,Stanford University,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05119296
3271,NCT05124938,Thyroid Cancer,Assessment of CA19-9 in Patients' With Thyroid Malignancies,Assessment of CA 19-9 in Patients' With Thyroid Malignancies,Thyroid Cancer,2021-10-26,2022-06-01,2022-12-01,120.0,Case-Control,,Retrospective,Observational,Not yet recruiting,,Sohag University,Sohag University,Sohag faculty of medicine,Diagnostic Test,Egypt,1.0,80.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05124938
3272,NCT05126147,Graves Ophthalmopathy,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,104.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05126147
3276,NCT05126706,"Weight Change, Body",Validating Efficacy for Digital Lifestyle Management for Weight Loss Control After Thyroidectomy in Thyroid Cancer Patients,Digital Lifestyle Management for Weight Loss Control After Thyroidectomy in Thyroid Cancer Patients,"Weight Change, Body",2021-09-26,2024-08-30,2024-08-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Behavioral,"Korea, Republic of",19.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05126706
3277,NCT05130476,Hypoparathyroidism Postprocedural,Intraoperative Near-infrared Imaging Techniques for Identifying and Preserving Viable Parathyroid Glands During Total and Completion Thyroidectomy: a Matched Cohort Study,Near-infrared Imaging Techniques for Identifying and Preserving Viable Parathyroid Glands During Thyroidectomy,Hypoparathyroidism Postprocedural,2021-11-08,2023-09-30,2025-03-31,139.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Odense University Hospital,Odense University Hospital,Odense University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05130476
3279,NCT05132205,Papillary Thyroid Cancer,Radiofrequency Ablation of Papillary Thyroid Microcarcinoma,Radiofrequency Ablation of Papillary Thyroid Microcarcinoma,Papillary Thyroid Cancer,2021-11-10,2024-09-28,2024-09-28,10.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Procedure,United States,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05132205
3281,NCT05132478,Benign Thyroid Nodule|Thyroid Cancer|Thyroid Nodule,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer: a Randomized Hypothetical Choice Experiment,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer,Benign Thyroid Nodule|Thyroid Cancer|Thyroid Nodule,2021-11-12,2023-11-30,2023-11-30,118.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Michigan|University of Wisconsin, Madison",University of Wisconsin Carbone Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05132478
3283,NCT05142904,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,232.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05142904
3286,NCT05143918,Hypothyroidism,Assessment of Quality of Life Among Hypothyroid Patients in Assiut University Hospitals,Quality of Life Among Egyptian Hypothyroid Patients,Hypothyroidism,2021-11-23,2022-12-30,2023-12-30,176.0,Case-Control,,Cross-Sectional,Observational,Not yet recruiting,,Assiut University,Assiut University,,Other,,18.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05143918
3287,NCT05149898,22Q Deletion Syndrome,"Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome",Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome,22Q Deletion Syndrome,2021-10-05,2022-11-30,2022-12-31,20.0,,Single Group Assignment,,Interventional,Active not recruiting,Phase 1/Phase 2,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",Greenwood Genetic Center|Lady Cilento Children's Hospital - South Brisbane|Genetics Clinics Australia,Drug,Australia|United States,4.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT05149898
3289,NCT05152927,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",2021-11-29,2025-01-31,2025-01-31,110.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco|Vanderbilt University Medical Center","University of California, San Francisco",Device,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05152927
3293,NCT05172921,Thyroid Cancer,The Role of Environmental Factors in Thyroid Cancer,Environmental Factors and Thyroid Cancer,Thyroid Cancer,2021-12-23,2030-01-31,2030-01-31,500.0,Case-Control,,Prospective,Observational [Patient Registry],Recruiting,,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05172921
3294,NCT05175404,Thyroid Cancer,Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers,Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers,Thyroid Cancer,2021-12-14,2022-12-31,2022-12-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"University Hospital, Ghent","University Hospital, Ghent",University hospital Ghent,Diagnostic Test,Belgium,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05175404
3295,NCT05176639,Thyroid Eye Disease,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)","A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,76.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05176639
3299,NCT05177939,Autoimmune Encephalitis,Phase III Study to Evaluate the Efficacy and Safety of NPB-01 in Patients With Autoimmune Encephalitis Refractory to Steroid Pulse Therapy,Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis,Autoimmune Encephalitis,2021-12-03,2024-05-31,2024-10-31,40.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 3,"Nihon Pharmaceutical Co., Ltd","Nihon Pharmaceutical Co., Ltd",,Drug|Drug,,15.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05177939
3302,NCT05178186,Thyroid Carcinoma,Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer: an International Multicenter Study,Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer,Thyroid Carcinoma,2021-12-30,2022-02-15,2022-03-30,1000.0,,Single Group Assignment,,Interventional,Enrolling by invitation,Not Applicable,University of Cagliari,University of Cagliari,AOU Cagliari,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05178186
3303,NCT05180214,Thyroid Goiter|Thyroid Nodule,The Effect of Adding Ketorolac to Bupivacaine in Superficial Cervical Plexus Block in Thyroid Surgery.,Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it.,Thyroid Goiter|Thyroid Nodule,2021-12-17,2021-08-19,2021-09-15,46.0,,Parallel Assignment,,Interventional,Completed,Phase 2,Sohag University,Sohag University,Sohag University Faculty of Medicine,Drug|Drug,Egypt,20.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05180214
3306,NCT05182931,Thyroid Cancer,"A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)","A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)",Thyroid Cancer,2021-11-23,2024-12-30,2025-12-30,80.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,Olivia Newton-John Cancer Research Institute,"Austin Health|Eastern Health|Monash Health|Olivia Newton-John Cancer Research Institute|Peter MacCallum Cancer Centre, Australia|Royal Brisbane and Women's Hospital|Royal North Shore Hospital|Sir Charles Gairdner Hospital|The Alfred",Royal North Shore Hospital|Royal Brisbane and Women's Hospital|Eastern Health|Monash Health|Austin Health|Alfred Hospital|Sir Charles Gairdner Hospital|Peter MacCallum Cancer Centre,Drug|Drug,Australia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05182931
3307,NCT05186883,Postoperative Hypoparathyroidism,Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells,Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells,Postoperative Hypoparathyroidism,2021-12-01,2023-12-31,2023-12-31,20.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 1/Phase 2,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,Belarusian State Medical University|Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,,Biological|Other,,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05186883
3309,NCT05189314,Thyroid Nodules,Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules,RFA of Benign Thyroid Nodules: Clinical Outcomes and Quality of Life Study,Thyroid Nodules,2021-12-28,2023-08-30,2024-08-30,100.0,Cohort,,Prospective,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05189314
3311,NCT05189808,Indeterminate Bethesda III Thyroid Nodules,Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules,Radiofrequency Ablation for BIII Thyroid Nodules,Indeterminate Bethesda III Thyroid Nodules,2021-12-28,2023-08-31,2024-08-31,50.0,Cohort,,Prospective,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05189808
3313,NCT05189821,Papillary Thyroid Microcarcinoma,RFA Treatment for Papillary Thyroid Microcarcinoma Cohort,RFA Treatment for Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2021-12-28,2025-11-30,2026-11-30,50.0,Cohort,,Prospective,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05189821
3314,NCT05191927,Thyroid Papillary Carcinoma,A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma Suitable for Primary Hospitals,A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma,Thyroid Papillary Carcinoma,2021-11-17,2021-01-01,2021-08-01,1200.0,Cohort,,Retrospective,Observational,Completed,,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|The First Affiliated Hospital of Zhengzhou University,Sun Yat-sen Memorial Hospital of Sun Yat-Sen University,Other,China,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05191927
3319,NCT05199103,Graves Orbitopathy,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy,Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,20.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05199103
3323,NCT05214274,Chronic Hypoparathyroidism,The Status of Diagnosis and Treatment of Chronic Hypoparathyroidism in Chinese Adults: a Multicenter Registry Study,Multicenter Registry Study of Chronic Hypoparathyroidism in Chinese Adults,Chronic Hypoparathyroidism,2021-12-24,2022-12-31,2022-12-31,500.0,Other,,Cross-Sectional,Observational,Recruiting,,Peking University,"Central South University|First Affiliated Hospital of Xinjiang Medical University|First Affiliated Hospital, Sun Yat-Sen University|First Hospital of China Medical University|Peking Union Medical College Hospital|Peking University|Shanghai 6th People's Hospital|West China Hospital","Peking Union Medical College Hospital|The First Hospital of China Medical University|The First Affiliated Hospital , Sun Yat-sen University|The Second Xiangya Hospital of Central South University|Shanghai Sixth People's Hospital|West China Hospital of Sichuan University|The First Affiliated Hospital of Xinjiang Medical University",Other,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05214274
3325,NCT05216718,Thyroid Nodule,Prospective Randomized Controlled Study on Mini-flap Bilateral Axillo-breast Approach Robotic Thyroidectomy : Effect on Postoperative Pain and Sensation,Mini-flap BABA (Bilateral Axillo-breast Approach) Robotic Thyroidectomy is Safe,Thyroid Nodule,2021-12-30,2022-12-31,2023-12-01,80.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Inje University,Inje University,Dong sik Bae,Procedure|Procedure,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05216718
3327,NCT05218395,Organic Pollutant|Thyroid Cancer|Type 2 Diabetes,Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer,Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer,Organic Pollutant|Thyroid Cancer|Type 2 Diabetes,2022-01-20,2024-12-29,2025-12-30,900.0,Case-Control,,Prospective,Observational,Recruiting,,Qianfoshan Hospital,Chinese Academy of Sciences|Qianfoshan Hospital,Xiaoling Guan,,China,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05218395
3328,NCT05221008,Secondary Hyperparathyroidism,"Study on Tolerability, Pharmacokinetics and Pharmacodynamics of SHR6508 in Chinese Patients With Secondary Hyperparathyroidism of Chronic Kidney Disease Treated by Maintenance Hemodialysis",A Trial of SHR6508 in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2022-01-07,2022-09-01,2022-09-30,55.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 1,"Shanghai Hengrui Pharmaceutical Co., Ltd.","Shanghai Hengrui Pharmaceutical Co., Ltd.",,Drug|Drug|Drug|Drug,,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05221008
3331,NCT05225883,Autoimmune Encephalitis,GEnome-wide Association Study in N-methyl-D-Aspartate Receptor and Other autoiMmune Encephalitis.,GWAS in NMDAR Encephalitis,Autoimmune Encephalitis,2022-01-25,2023-12-31,2025-12-31,2000.0,Case-Control,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de rfrence des syndromes neurologiques paranoplasiques et encphalites auto-immunes,Genetic,France,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05225883
3334,NCT05228184,Congenital Hypothyroidism,A Randomized Comparative Study Between Liquid (Tirosint-SOL) and Tablet Formulations of Levothyroxine in Neonates and Infants With Congenital Hypothyroidism,Use of Tirosint-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH),Congenital Hypothyroidism,2021-12-21,2023-06-15,2023-06-15,126.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,IBSA Institut Biochimique SA,Cromsource|IBSA Institut Biochimique SA,CHOC Children's Hospital|Ann & Robert H. Lurie Children's Hospital of Chicago|Children's Mercy Hospital and Clinics|Icahn School of Medicine at Mount Sinai|Cook Children's Health Care Systems,Drug|Drug,United States,0.0,9.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT05228184
3336,NCT05229341,Thyroid Gland Carcinoma,Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules,Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules,Thyroid Gland Carcinoma,2022-02-04,2026-10-22,2026-10-22,1450.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Procedure|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05229341
3338,NCT05239221,Chronic Hypoparathyroidism,"A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism",AZP-3601 SAD and MAD Study in Healthy Subjects and Subjects With Hypoparathyroidism,Chronic Hypoparathyroidism,2022-01-07,2022-12-31,2023-01-31,130.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 1,Amolyt Pharma,Amolyt Pharma,Amolyt Pharma Investigational Site Hungary|PRA-EDS,Drug|Drug,Hungary|Netherlands,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05239221
3340,NCT05240911,Hypothyroidism|Surgery|Thyroid Neoplasms,Compare a New Method to the Traditional One to Estimate Levothyroxine Dose for Patients Needing Replacement Therapy After Total or Completion Thyroidectomy,Individual Dosing of Levothyroxine After Thyroidectomy,Hypothyroidism|Surgery|Thyroid Neoplasms,2022-02-06,2023-02-10,2023-06-10,202.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Second Affiliated Hospital Zhejiang University School of Medicine,Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05240911
3342,NCT05241626,Thyroid Eye Disease,Anterior Segment Optical Coherence Tomography Study of the Tear Film and Cornea in Thyroid Eye Diseases.,AS-OCT of the Cornea in Thyroid Diseases,Thyroid Eye Disease,2022-02-04,2022-10-29,2022-10-29,70.0,Case-Control,,Prospective,Observational,Enrolling by invitation,,Minia University,Minia University,Minia Faculty of medicine|Minia University hospital,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05241626
3346,NCT05241834,"Carcinoma, Non-Small-Cell Lung|Thyroid Neoplasms","A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors",A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment,"Carcinoma, Non-Small-Cell Lung|Thyroid Neoplasms",2022-02-08,2026-04-30,2026-04-30,140.0,,Parallel Assignment,,Interventional,Recruiting,Phase 1,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Cleveland Clinic Foundation|Sarah Cannon Cancer Center,Drug,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05241834
3347,NCT05242055,Anemia|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases|Hyperglycemia|Hyperlipidemias|Hypertension|Malnutrition,"A Prospective, Cohort, and Observational Study of the Effect of Integrated Diagnosis and Treatment of Chronic Kidney Disease (CKD) on Clinical Outcomes in Real World Clinical Practice",Integrated Diagnosis and Treatment of CKD on Outcomes,Anemia|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases|Hyperglycemia|Hyperlipidemias|Hypertension|Malnutrition,2022-01-29,2026-12-31,2026-12-31,1000.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,Capital Medical University,Capital Medical University,Nephrology Department of Beijing Jishuitan Hospital,Other,China,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05242055
3350,NCT05243979,CKD|Parathyroid Diseases|Thyroid,"The Relation Between Thyroid , Parathyroid Hormones and Estimated Glomerular Filtration Rate in Chronic Kidney Disease Patients in Assiut","The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut",CKD|Parathyroid Diseases|Thyroid,2022-02-08,2023-03-01,2023-04-01,80.0,Other,,Prospective,Observational,Not yet recruiting,,Assiut University,Assiut University,,Radiation,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05243979
3351,NCT05247476,"Hypothyroidism|Thyroid Cancer, Papillary",Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused,Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.,"Hypothyroidism|Thyroid Cancer, Papillary",2022-02-09,2022-03-31,2022-09-30,50.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Zhongshan Hospital Xiamen University,Zhongshan Hospital Xiamen University,Yan Ling,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05247476
3354,NCT05252884,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,180.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05252884
3357,NCT05260255,Hyperparathyroidism|Hypocalcemia|Systemic Lupus Erythematosus (Disorder)|Vitamin D Deficiency,The Effect of Vitamin D Supplementation on Disease Activity of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial in Rajavithi Hospital,Effect of Vitamin D Supplement on Disease Activity in SLE,Hyperparathyroidism|Hypocalcemia|Systemic Lupus Erythematosus (Disorder)|Vitamin D Deficiency,2021-05-12,2022-05-01,2022-12-01,100.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Rajavithi Hospital,Rajavithi Hospital,Rajavithi Hospital,Drug|Drug,Thailand,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05260255
3359,NCT05263141,Papillary Thyroid Carcinoma,"Single-center, Prospective, Non-Randomized Control Clinical Trial of Retro-Auricular Single-Site Endoscopic Versus Open Surgery in Patients With Early Stage Papillary Thyroid Carcinoma",Retro-Auricular Single-Site Endoscopic to Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2022-02-20,2023-06-30,2023-06-30,80.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Sun Yat-Sen University Cancer Center,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05263141
3361,NCT05264857,Thyroid Nodule,Decision Aid for Management of Thyroid Nodules and Early Thyroid Cancer,Decision Aid and Thyroid Nodules Management,Thyroid Nodule,2022-02-17,2026-09-30,2026-09-30,134.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,Stony Brook University,Stony Brook University,Stony Brook University Cancer Center,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05264857
3363,NCT05265819,Thyroid Cancer,Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy,Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy,Thyroid Cancer,2022-02-23,2022-12-05,2022-12-05,80.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Cairo University,Nabil Mahmoud Ismail Abdel-Aal,,Device|Dietary Supplement|Drug,,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05265819
3364,NCT05270798,Euthyroid Sick Syndromes|Septic Shock,Triiodothyronine Hormone Replacement Therapy in Patients With Septic Shock With Euthyroid Sick Syndrome,Thyroid Hormone Replacement in Patients With Septic Shock,Euthyroid Sick Syndromes|Septic Shock,2022-02-26,2023-03-15,2023-03-15,108.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,Cantonal Hospital Zenica,Cantonal Hospital Zenica,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05270798
3365,NCT05275374,BRAF V600 Mutation|Cancer|Colorectal Cancer|Melanoma|Nonsmall Cell Lung Cancer|Thyroid Cancer,A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE),XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation,BRAF V600 Mutation|Cancer|Colorectal Cancer|Melanoma|Nonsmall Cell Lung Cancer|Thyroid Cancer,2022-02-20,2024-12-31,2026-12-31,221.0,,Sequential Assignment,,Interventional,Not yet recruiting,Phase 1/Phase 2,"Xynomic Pharmaceuticals, Inc.","Xynomic Pharmaceuticals, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05275374
3366,NCT05275946,Thyroid Cancer,"Phase I Investigator-initiated Clinical Trial in Patients With Differentiated Thyroid Cancer (Papillary Cancer, Follicular Cancer) by the Targeted Alpha Therapy Drug TAH-1005 ([211At] NaAt) (Alpha-T1 Study)",Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer,Thyroid Cancer,2022-01-22,2023-09-30,2024-03-31,11.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Osaka University,Osaka University,Osaka University Hospital,Drug,Japan,0.0,18.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05275946
3367,NCT05276063,Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,75.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05276063
3371,NCT05276856,Secondary Hypothyroidism,Rate of Recovery of Secondary Hypothyroidism in Patients With Pituitary Disorders.,Recovery Rate in Secondary Hypothyroidism,Secondary Hypothyroidism,2022-02-28,2022-11-01,2022-12-15,90.0,Cohort,,Prospective,Observational,Not yet recruiting,,Nova Scotia Health Authority,Nova Scotia Health Authority,,Drug,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05276856
3372,NCT05278364,Medullary Thyroid Cancer|Non-Small Cell Lung Cancer|Solid Tumor,"A Phase I, Open-Label, Single-arm , Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of SY-5007 in Patients With RET-altered Advanced Solid Tumor.","A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SY-5007 in Patients With Advanced Solid Tumors",Medullary Thyroid Cancer|Non-Small Cell Lung Cancer|Solid Tumor,2022-03-08,2023-03-01,2023-06-01,80.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,Shouyao Holdings (Beijing) Co. LTD,Shouyao Holdings (Beijing) Co. LTD,Shanghai Pulmonary Hospital|Tianjin People's Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05278364
3373,NCT05280379,"Colon Carcinoma|Thyroid Cancer, Nonmedullary",Trained Immunity of Myeloid Cells and Their Progenitors in Patients With Non-medullary Thyroid Carcinoma and Colon Carcinoma,Trained Immunity in Thyroid Carcinoma and Colon Carcinoma,"Colon Carcinoma|Thyroid Cancer, Nonmedullary",2022-02-24,2024-04-07,2025-04-07,60.0,Other,,Cross-Sectional,Observational,Not yet recruiting,,Radboud University Medical Center,Radboud University Medical Center,,Other,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05280379
3374,NCT05280600,Anti-N-Methyl-D-Aspartate Receptor Encephalitis|Autoimmune Encephalitis,Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis,Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis,Anti-N-Methyl-D-Aspartate Receptor Encephalitis|Autoimmune Encephalitis,2022-02-10,2024-02-28,2026-02-28,75.0,Cohort,,Prospective,Observational,Not yet recruiting,,King's College London,Action Medical Research|Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas' NHS Foundation Trust,Other,United Kingdom,8.0,24.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05280600
3377,NCT05286801,Atypical Teratoid/Rhabdoid Tumor|Epithelioid Sarcoma|Kidney Medullary Carcinoma|Malignant Solid Neoplasm|Poorly Differentiated Chordoma|Recurrent Atypical Teratoid/Rhabdoid Tumor|Recurrent Chordoma|Recurrent Epithelioid Sarcoma|Recurrent Kidney Medullary Carcinoma|Recurrent Rhabdoid Tumor|Refractory Atypical Teratoid/Rhabdoid Tumor|Refractory Chordoma|Refractory Epithelioid Sarcoma|Refractory Kidney Medullary Carcinoma|Refractory Rhabdoid Tumor|Rhabdoid Tumor,A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors,Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors,Atypical Teratoid/Rhabdoid Tumor|Epithelioid Sarcoma|Kidney Medullary Carcinoma|Malignant Solid Neoplasm|Poorly Differentiated Chordoma|Recurrent Atypical Teratoid/Rhabdoid Tumor|Recurrent Chordoma|Recurrent Epithelioid Sarcoma|Recurrent Kidney Medullary Carcinoma|Recurrent Rhabdoid Tumor|Refractory Atypical Teratoid/Rhabdoid Tumor|Refractory Chordoma|Refractory Epithelioid Sarcoma|Refractory Kidney Medullary Carcinoma|Refractory Rhabdoid Tumor|Rhabdoid Tumor,2022-03-15,2025-07-31,2025-07-31,78.0,,Single Group Assignment,,Interventional,Not yet recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),,Biological|Biological,,12.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05286801
3378,NCT05290493,22q11 Deletion Syndrome,"A Randomized, Placebo-Controlled Crossover Trial to Assess the Safety and Efficacy of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome",NB-001 in Children and Adolescents With 22q11 Deletion Syndrome,22q11 Deletion Syndrome,2022-01-26,2022-12-31,2023-01-30,34.0,,Crossover Assignment,,Interventional,Recruiting,Phase 2,"Nobias Therapeutics, Inc.","Nobias Therapeutics, Inc.",Children's Hospital of Philadelphia (CHOP)|Seattle Children's Hospital|The Hospital for Sick Children (SickKids),Drug|Other,Canada|United States,6.0,17.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT05290493
3380,NCT05294393,"Anesthesia, Local|Parathyroid Diseases|Postoperative Pain|Thyroid Diseases",Evaluation of Ropivacaine and Ropivacaine Plus Magnesium Sulphate Infiltration for Postoperative Analgesia in Patients Undergoing Thyroidectomy,Ropivacaine Plus Magnesium Sulphate Infiltration,"Anesthesia, Local|Parathyroid Diseases|Postoperative Pain|Thyroid Diseases",2022-03-01,2024-01-21,2024-01-21,64.0,,Parallel Assignment,,Interventional,Enrolling by invitation,Phase 4,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,Aristotle University,Drug|Drug|Drug,Greece,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05294393
3381,NCT05299437,Metastatic Differentiated Thyroid Cancer,Personalized Therapy of Metastatic Thyroid Cancer: Biological Characterization and Optimization With 124I PET Dosimetry,Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry,Metastatic Differentiated Thyroid Cancer,2022-03-07,2024-03-30,2024-09-30,50.0,,Single Group Assignment,,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Associazione Italiana per la Ricerca sul Cancro|Carlo Chiesa,"Nuclear Medicine, Ospedale Sacro Cuore - Don Calabria|Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori",Drug,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05299437
3382,NCT05299632,Hyperparathyroidism,Pre-operative Localization of Parathyroid Adenomas Using F-18 PSMA PET/CT: A Pilot Study,F-18 PSMA for Localization of Parathyroid Adenoma,Hyperparathyroidism,2022-03-09,2023-03-31,2023-12-31,10.0,Other,,Prospective,Observational,Recruiting,,Emory University,Emory University,Emory Saint Joseph's Hospital|Emory University Hospital (EUH)|Emory Johns Creek Hospital,Diagnostic Test|Diagnostic Test,United States,18.0,99.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05299632
3385,NCT05314790,Hypothyroidism,"Management of Patients With Diagnosis of Hypothyroidism, as Hospitalized and as Outpatients, in Internal Medicine Units: Observational Study Before & After Educational Programme","Management of Patients With Diagnosis of Hypothyroidism, as Hospitalized and as Outpatients, in Internal Medicine Units: Observational Study Before & After Educational Programme",Hypothyroidism,2022-01-20,2018-01-01,2019-01-01,1200.0,Cohort,,Retrospective,Observational,Completed,,"Fadoi Foundation, Italy","Fadoi Foundation, Italy","ULSS1 Belluno San Martino|Ospedale Versilia|Ospedale di Canicatt|Ospedale di Castiglione del Lago, Medicina del Trasimeno|Garibaldi Nesima|Ospedale G.B. Morgagni - P.L. Pierantoni|Ospedale G.P. Delogu|Ospedale Gubbio-Gualdo Tadino|Ospedale ""F. Veneziale""|ASL Latina|Ospedale S. Andrea|Ospedale S. Croce di Moncalieri - ASL TO5|Ospedale Del Mare|Ospedale Fatebenefratelli|Ospedale Maggiore di Novara|Ospedale Civico di Partinico|Ospedale ""Bianchi-Melacrino-Morelli""|Casa Sollievo della Sofferenza|AOU di Sassari|Ospedale San Paolo",Other,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05314790
3386,NCT05316922,Hypothyroidism; Irradiation,Protection From Iatrogenic Hypothyroidism Patients With MBL and Pediatric Patients With HL and Non-HL Needing Radiotherapy on Thyroid Site,TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients,Hypothyroidism; Irradiation,2021-09-14,2029-09-30,2029-09-30,68.0,,Parallel Assignment,,Interventional,Recruiting,Phase 3,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Fondazione IRCCS Istituto Nazionale dei Tumori,Drug,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05316922
3387,NCT05323669,Thyroid Cancer|Thyroid Nodule,Study of Molecular-genetic Profile of Thyroid Nodules,Molecular Profile of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2022-04-05,2023-12-29,2024-12-31,400.0,Cohort,,Retrospective,Observational,Not yet recruiting,,Belarusian State Medical University,Belarusian State Medical University|Minsk City Clinical Oncologic Centre|The Institute of Genetics and Cytology National Academy of Sciences of Belarus,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05323669
3389,NCT05328076,Hypoparathyroidism|Thyroid|Thyroid Cancer|Vascularization,Analysis of Parathyroid Vascularization During Total Thyroidectomy Using Quantitative Real-time Indocyanine Green Angiography,Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography,Hypoparathyroidism|Thyroid|Thyroid Cancer|Vascularization,2022-04-07,2023-04-30,2023-05-31,66.0,Cohort,,Prospective,Observational,Recruiting,,IRCCS San Raffaele,IRCCS San Raffaele,San Raffaele Hospital,Drug|Device,Italy,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05328076
3392,NCT05329935,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|Congenital Athymia,Congenital Athymia Patient Registry of RETHYMIC,Congenital Athymia Patient Registry,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|Congenital Athymia,2022-03-24,2026-04-30,2026-04-30,75.0,Cohort,,Other,Observational,Recruiting,,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH,Duke University School of Medicine,Biological,United States,0.0,21.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05329935
3394,NCT05334069,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Ann Arbor Stage III Lymphoma|Ann Arbor Stage II Lymphoma|Ann Arbor Stage I Lymphoma|Ann Arbor Stage IV Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Gastroesophageal Junction Adenocarcinoma|Head and Neck Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Invasive Breast Carcinoma|Kidney Carcinoma|Malignant Hepatobiliary Neoplasm|Malignant Solid Neoplasm|Melanoma|Muscle-Invasive Bladder Carcinoma|RISS Stage III Plasma Cell Myeloma|RISS Stage II Plasma Cell Myeloma|RISS Stage I Plasma Cell Myeloma|Sarcoma|Stage I Bladder Cancer AJCC v6 and v7|Stage I Breast Cancer AJCC v7|Stage I Colorectal Cancer AJCC v6 and v7|Stage I Esophageal Cancer AJCC V7|Stage I Gastric Cancer AJCC V7|Stage II Bladder Cancer AJCC v6 and v7|Stage II Breast Cancer AJCC v6 and v7|Stage II Colorectal Cancer AJCC v7|Stage II Esophageal Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage III Bladder Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Esophageal Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Uterine Corpus Cancer AJCC v7|Stage II Lung Cancer AJCC v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage II Prostate Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7|Stage I Lung Cancer AJCC v7|Stage I Ovarian Cancer AJCC v6 and v7|Stage I Pancreatic Cancer AJCC v6 and v7|Stage I Prostate Cancer AJCC v7|Stage I Uterine Corpus Cancer AJCC v7|Stage IV Bladder Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Thyroid Gland Carcinoma,Blinded Reference Set for Multicancer Early Detection Blood Tests,Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Ann Arbor Stage III Lymphoma|Ann Arbor Stage II Lymphoma|Ann Arbor Stage I Lymphoma|Ann Arbor Stage IV Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Gastroesophageal Junction Adenocarcinoma|Head and Neck Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Invasive Breast Carcinoma|Kidney Carcinoma|Malignant Hepatobiliary Neoplasm|Malignant Solid Neoplasm|Melanoma|Muscle-Invasive Bladder Carcinoma|RISS Stage III Plasma Cell Myeloma|RISS Stage II Plasma Cell Myeloma|RISS Stage I Plasma Cell Myeloma|Sarcoma|Stage I Bladder Cancer AJCC v6 and v7|Stage I Breast Cancer AJCC v7|Stage I Colorectal Cancer AJCC v6 and v7|Stage I Esophageal Cancer AJCC V7|Stage I Gastric Cancer AJCC V7|Stage II Bladder Cancer AJCC v6 and v7|Stage II Breast Cancer AJCC v6 and v7|Stage II Colorectal Cancer AJCC v7|Stage II Esophageal Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage III Bladder Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Esophageal Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Uterine Corpus Cancer AJCC v7|Stage II Lung Cancer AJCC v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage II Prostate Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7|Stage I Lung Cancer AJCC v7|Stage I Ovarian Cancer AJCC v6 and v7|Stage I Pancreatic Cancer AJCC v6 and v7|Stage I Prostate Cancer AJCC v7|Stage I Uterine Corpus Cancer AJCC v7|Stage IV Bladder Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Thyroid Gland Carcinoma,2022-04-12,2025-01-31,2025-02-28,2000.0,Case-Control,,Prospective,Observational,Not yet recruiting,,Alliance for Clinical Trials in Oncology,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),,Other|Procedure,,40.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05334069
3395,NCT05334771,Hypothyroidism,Early Detection of Endolymphatic Hydrops in Hypothyroid Patients,Early Detection of Endolymphatic Hydrops in Hypothyroid Patients,Hypothyroidism,2022-03-11,2024-03-31,2025-04-30,50.0,Cohort,,Prospective,Observational,Not yet recruiting,,Assiut University,Assiut University,,Device,,25.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05334771
3396,NCT05345119,Graves Ophthalmopathy,"An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus in Graves' Orbitopathy,Graves Ophthalmopathy,2022-04-19,2021-06-15,2021-06-15,30.0,Cohort,,Retrospective,Observational,Completed,,University of Pisa,University of Pisa,Endocrinologia II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05345119
3400,NCT05346419,Hyperparathyroidism|Hypovitaminosis D|Postmenopausal Osteoporosis,Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients,Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients,Hyperparathyroidism|Hypovitaminosis D|Postmenopausal Osteoporosis,2022-04-15,2022-02-03,2022-02-26,33.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospital Regional 1o de Octubre,"Hospital Regional 1o de Octubre|National Polytechnic Institute, Mexico|Universidad Nacional Autonoma de Mexico",Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE,Drug|Drug,Mexico,40.0,78.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05346419
3402,NCT05347082,"Hyperparathyroidism, Primary|Hyperparathyroidism, Secondary|Hypovitaminosis D|Postmenopausal Osteoporosis|Postmenopause",Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women,Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment,"Hyperparathyroidism, Primary|Hyperparathyroidism, Secondary|Hypovitaminosis D|Postmenopausal Osteoporosis|Postmenopause",2022-04-17,2021-12-29,2022-02-20,47.0,,Single Group Assignment,,Interventional,Completed,Not Applicable,Hospital Regional 1o de Octubre,"Hospital Regional 1o de Octubre|National Polytechnic Institute, Mexico|Universidad Nacional Autonoma de Mexico",Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE,Drug,Mexico,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05347082
3406,NCT05355701,Colorectal Cancer|Glioma|Melanoma|Non-Small-Cell Lung Cancer|Thyroid Cancer,"A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS",A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors.,Colorectal Cancer|Glioma|Melanoma|Non-Small-Cell Lung Cancer|Thyroid Cancer,2022-04-26,2026-02-23,2027-08-27,174.0,,Sequential Assignment,,Interventional,Not yet recruiting,Phase 1,Pfizer,Pfizer,,Drug|Drug|Biological,,16.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05355701
3407,NCT05371262,Congenital Hypothyroidism,"Evaluation of Long-term Benefit-risk Profile of Levothyroxine Treatment in Children With Congenital Hypothyroidism: Influence of Initial Levothyroxine Dose on Neurodevelopmental, Growth, Cardiovascular and Skeletal Outcomes",Influence of Initial Levothyroxine Dose on Neurodevelopmental and Growth Outcomes in Congenital Hypothyroidism,Congenital Hypothyroidism,2022-05-04,2018-05-31,2018-05-31,72.0,,Parallel Assignment,,Interventional,Completed,Phase 4,Federico II University,Federico II University,,Drug,,0.0,29.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05371262
3409,NCT05377736,Thyroid Cancer|Thyroid Nodule (Diagnosis),Thyroid Nodule Gene Sequencing in a Danish Population - A Pilot Study,Thyroid Nodule Gene Sequencing in a Danish Population,Thyroid Cancer|Thyroid Nodule (Diagnosis),2022-03-15,2022-12-31,2027-01-18,30.0,,Single Group Assignment,,Interventional,Enrolling by invitation,Not Applicable,University of Aarhus,Aarhus University Hospital|Odense University Hospital|University of Aarhus,Aarhus Universityhospital,Genetic,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05377736
3411,NCT05382988,"Hyperkalemia|Hyperparathyroidism, Secondary|Sodium Zirconium Cyclosilicate",Effect of Sodium Zirconium Cyclosilicate on Hyperkalemia After Parathyroidectomy in Secondary Hyperparathyroidism Patients With Maintenance Hemodialysis,Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy,"Hyperkalemia|Hyperparathyroidism, Secondary|Sodium Zirconium Cyclosilicate",2022-05-09,2021-12-31,2021-12-31,62.0,,Parallel Assignment,,Interventional,Completed,Phase 3,Guangdong Provincial People's Hospital,Guangdong Provincial People's Hospital,,Drug,,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05382988
3414,NCT05385029,Hyperthyroidism|Hypothyroidism|Thyroid Dysfunction,Thyroid Function Tests in Infants of COVID-19 Positive Pregnant Mothers,Fetal and Neonatal Thyroid in Pregnancies With Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS- COV2 ) COVID-19,Hyperthyroidism|Hypothyroidism|Thyroid Dysfunction,2022-05-10,2021-09-30,2021-09-30,95.0,Case-Control,,Prospective,Observational [Patient Registry],Completed,,Security Forces Hospital,OMER B ABDELBASIT,Security Forces Hospital,Drug,Saudi Arabia,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05385029
48,NCT02378233,Lactation|Thyroid Gland; Node,A Double-blinded Randomised Study of Iodine Supplementation to Lactating Women in an Iodine-sufficient Area in Sweden and Evaluation of Maternal and Neonatal Iodine Levels and Thyroid Function,Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant,Lactation|Thyroid Gland; Node,2015-01-19,2017-12-31,2023-12-31,221.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Gteborg University,"Gteborg University|Sahlgrenska University Hospital, Sweden",Health Care center,Dietary Supplement|Dietary Supplement,Sweden,18.0,40.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02378233
61,NCT02742597,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Multimorbidity|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Multimorbidity|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,2016-03-21,2019-04-07,2022-03-30,175.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Lawson Health Research Institute,"Canadian Institutes of Health Research (CIHR)|Lawson Health Research Institute|Michael Garron Hospital|Mount Sinai Hospital, Canada|Providence Healthcare|Sunnybrook Health Sciences Centre|Toronto Central Community Care Access Centre|Unity Health Toronto|Universit de Sherbrooke|University Health Network, Toronto|Western University, Canada|Women's College Hospital",Western University|Mount Sinai Hospital|Providence Healthcare|St. Michael's Hospital|Sunnybrook Health Sciences Centre|Toronto Central Community Care Access Centre|Toronto East General Hospital|University Hospital Network|Women's College Hospital,Behavioral,Canada,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02742597
64,NCT02789800,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,2016-03-16,2022-04-01,2022-04-02,1956.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Universit de Sherbrooke,"Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean|Canadian Institutes of Health Research (CIHR)|Universit de Sherbrooke|Western University, Canada",Universit de Sherbrooke|CIUSSS du Sageunay-Lac-Saint-Jean,Behavioral,Canada,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02789800
68,NCT02868476,Thyroid Diseases,Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases,Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases,Thyroid Diseases,2016-08-05,2017-05-26,2024-07-30,532.0,Cohort,,Prospective,Observational [Patient Registry],Active not recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,,,,20.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT02868476
73,NCT02966405,Diseases Pregnancy Thyroid,The Establish of Trimester-specific Reference Ranges for Thyroid Tests in Pregnant Women and the Influence of Thyroid Disorders on Pregnancy and Its Outcomes.,The Establish of Specific Reference Ranges for Thyroid Tests in Pregnant Women,Diseases Pregnancy Thyroid,2016-10-24,2020-12-31,2020-12-31,1000.0,Case-Only,,Prospective,Observational [Patient Registry],Recruiting,,Peking University International Hospital,Xiaomei Zhang,Peking University International Hospital|Peking University International Hospital,,China,19.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT02966405
89,NCT03149354,HIV Infections|Thyroid,Prevalence of Thyroid Function Abnormalities in HIV-infected Patients: State of Play in 2012,Prevalence of Thyroid Function Abnormalities in HIV-infected Patients,HIV Infections|Thyroid,2017-05-04,2022-12-19,2022-12-19,104.0,,Single Group Assignment,,Interventional,Recruiting,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03149354
95,NCT03191188,"Kidney Diseases, Chronic|Thyroid Disease",A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients,A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients,"Kidney Diseases, Chronic|Thyroid Disease",2017-06-13,2021-07-31,2021-07-31,96.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University of California, Irvine","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Irvine",University Dialysis Center of Orange,Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03191188
105,NCT03369405,Chronic Periodontitis|Thyroid Diseases,Thyroid Insufficiency as a Modifying Factor for Chronic Periodontitis,Thyroid Disease and Chronic Periodontitis,Chronic Periodontitis|Thyroid Diseases,2017-11-28,2022-08-01,2022-08-01,2000.0,Other,,Retrospective,Observational,Active not recruiting,,University at Buffalo,University at Buffalo,"School of Dental Medicine, University at Buffalo",Other,United States,35.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03369405
109,NCT03414021,Bone Diseases|Brain Diseases|Heart Diseases|Kidney Diseases|Thyroid Diseases,Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies,Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor,Bone Diseases|Brain Diseases|Heart Diseases|Kidney Diseases|Thyroid Diseases,2018-01-23,2023-01-30,2023-01-30,250.0,Cohort,,Prospective,Observational,Recruiting,,Lille Catholic University,Lille Catholic University,Humanitep|Hopital Priv Le Bois,Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT03414021
151,NCT03922087,"Allergic Disorder|Anemia in Pregnancy|Asthma|Complications, Pregnancy|Depression|Gestational Diabetes Mellitus in Pregnancy|Gestational Hypertension|Immune System Diseases|Neurodevelopmental Disorders|Obesity|Obstetric Labor Complications|Reproductive Disorder|Thyroid Disease Pregnancy",Huizhou Mother-infant Cohort,No-worry Baby Project,"Allergic Disorder|Anemia in Pregnancy|Asthma|Complications, Pregnancy|Depression|Gestational Diabetes Mellitus in Pregnancy|Gestational Hypertension|Immune System Diseases|Neurodevelopmental Disorders|Obesity|Obstetric Labor Complications|Reproductive Disorder|Thyroid Disease Pregnancy",2019-04-13,2022-04-01,2025-12-31,10000.0,Case-Control,,Prospective,Observational,Recruiting,,Sun Yat-sen University,Huizhou No.1 Maternal and Child Care Service Cencer|Sun Yat-sen University,School of Public Health of Sun Yat-sen University (North Campus),Other,China,18.0,49.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03922087
153,NCT03932487,The Effect of Iodine and BPA on AITD in Reproduction Women,"The Relationship Between Urine Iodine, Urine Bisphenol A and Autoimmune Thyroid Disease in Reproductive Women","The Relationship Between Urine Iodine, Urine Bisphenol A and Autoimmune Thyroid Disease in Reproductive Women",The Effect of Iodine and BPA on AITD in Reproduction Women,2019-04-24,2022-10-01,2022-10-01,142.0,Other,,Cross-Sectional,Observational,Recruiting,,Peking University International Hospital,Xiaomei Zhang,Peking University international hospital,Other,China,20.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT03932487
161,NCT04019509,Fertility Disorders|Thyroid Dysfunction,The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology,The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology,Fertility Disorders|Thyroid Dysfunction,2019-07-10,2022-01-01,2022-09-01,900.0,,Factorial Assignment,,Interventional,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,UZ Brussel,Diagnostic Test|Other,Belgium,18.0,36.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04019509
180,NCT04208503,Gland; Functional Disturbance|Thyroid,Ultrasound and Functional Thyroid Evaluation in Preterm Infants Born Between 24 and 32 Weeks of Gestation,Ultrasound and Functional Thyroid Evaluation,Gland; Functional Disturbance|Thyroid,2019-12-13,2021-12-30,2021-12-31,200.0,Cohort,,Prospective,Observational [Patient Registry],Recruiting,,"Princess Anna Mazowiecka Hospital, Warsaw, Poland","Princess Anna Mazowiecka Hospital, Warsaw, Poland",Department of Neonatology and Neonatal Intensive Care Warsaw Medical University|Department of Neonatology and Neonatal Intensive Care Warsaw Medical University,Diagnostic Test,Poland,0.0,12.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT04208503
188,NCT04279184,Diabetes|Thyroid Diseases|Urinary Incontinence,Urinary Incontinence and Endocrine Factors.,Urinary Incontinence and Endocrine Factors. A Part of Lolland-Falster Health Study (LOFUS).,Diabetes|Thyroid Diseases|Urinary Incontinence,2020-01-16,2020-02-29,2021-02-28,6000.0,Cohort,,Cross-Sectional,Observational,Recruiting,,Nykbing Falster County Hospital,Nykbing Falster County Hospital|Region Zealand|University of Southern Denmark|Zealand University Hospital,Randi Jepsen,,Denmark,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04279184
202,NCT04323007,Thyroid Dysfunction,Thyroid Dysfunction in Patients With Nephrotic Syndrome,Thyroid Dysfunction in Patients With Nephrotic Syndrome,Thyroid Dysfunction,2020-01-12,2021-10-01,2022-10-01,100.0,,Single Group Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University|Merna Makram,,Diagnostic Test,,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04323007
208,NCT04351945,Cortisol Deficiency|Diabetes Insipidus|Endocrine System Diseases|End-stage Heart Failure|End Stage Lung Disease|Thyroid Diseases,A Study of Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors,Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors,Cortisol Deficiency|Diabetes Insipidus|Endocrine System Diseases|End-stage Heart Failure|End Stage Lung Disease|Thyroid Diseases,2020-04-15,2022-05-15,2022-07-01,100.0,Cohort,,Prospective,Observational,Active not recruiting,,Semmelweis University Heart and Vascular Center,Semmelweis University|Semmelweis University Heart and Vascular Center,Heart and Vascular Center,Procedure,Hungary,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04351945
213,NCT04388956,Diagnoses Disease|Nodule|Thyroid,Diagnosis of Thyroid Tumors by Multiple Ultrasonic Factors.,Thyroid Disease Diagnosis by Mutiple Ultrasonic Factors.,Diagnoses Disease|Nodule|Thyroid,2020-05-12,2022-12-31,2022-12-31,300.0,Case-Only,,Prospective,Observational [Patient Registry],Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,0.0,120.0,[0-17]|[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04388956
217,NCT04427904,"Anesthesia, Local|Postoperative Pain|Thyroid Diseases",Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery: A Randomized Controlled Trial,Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery,"Anesthesia, Local|Postoperative Pain|Thyroid Diseases",2020-05-26,2023-12-31,2024-12-31,210.0,,Parallel Assignment,,Interventional,Not yet recruiting,Phase 2,St. Joseph's Healthcare Hamilton,St. Joseph's Healthcare Hamilton,St. Joeseph's Healthcare Hamilton,Drug|Drug,Canada,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04427904
224,NCT04471597,Thyroid Diseases,Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia In Patients Undergoing Elective Thyroidectomy. A Randomized Controlled Study,Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia,Thyroid Diseases,2020-07-12,2022-04-01,2022-05-01,48.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Zagazig University,Zagazig University,"Faculty of medicine, zagazig university",Drug|Drug,Egypt,21.0,60.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04471597
232,NCT04542278,Thyroid Diseases,Randomized Controlled Trial of Preoperative Steroids in Autoimmune Thyroid Disease,Preoperative Steroids in Autoimmune Thyroid Disease,Thyroid Diseases,2020-09-01,2022-10-31,2022-10-31,30.0,,Parallel Assignment,,Interventional,Active not recruiting,Phase 4,"University of Wisconsin, Madison","University of Wisconsin, Madison",University of Wisconsin Hospital and Clinics,Drug,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04542278
241,NCT04571736,Thyroid,Interest of Improving Preoperative Medical Information by Video Support and Personalized and Secure Web Platform: Pilot Study in Thyroid Surgery (AMEDOP),Pilot Study for Thyroid Surgery by Preoperative Video Support and Personalized and Secure Web Platform,Thyroid,2020-07-27,2022-11-30,2022-11-30,200.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University Hospital, Montpellier","EDOP|University Hospital, Montpellier",CHU Gui de Chauliac,Other,France,18.0,75.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04571736
247,NCT04585126,Thyroid Surgery,Effect of Ultrasound-guided Intermediate Cervical Block on Recurrent Laryngeal Nerve Monitoring During Thyroid Surgery : a Randomised Non-inferiority Study,Effect of Cervical Block on Recurrent Laryngeal Nerve Monitoring During Thyroid Surgery,Thyroid Surgery,2020-10-02,2021-11-30,2021-11-30,120.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,"University Hospital, Caen","Centre Francois Baclesse|University Hospital, Caen",Caen University Hospital,Drug,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04585126
254,NCT04615988,Cancer|PD-1|Thyroid,Correlation of Serum Vitamin D Level With the Development of Endocrine Autoimmune Complications During Treatment With Immune Checkpoint Inhibitors,Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors,Cancer|PD-1|Thyroid,2020-10-29,2022-12-31,2024-06-30,153.0,Cohort,,Prospective,Observational,Recruiting,,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Mount Sinai Hospital /Tisch Cancer Cancer/Ruttenberg Treatment Center,,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04615988
260,NCT04658524,Chronic Kidney Disease|Thyroid Dysfunction,Evaluation of Thyroid Function in Patients With Chronic Kidney Disease,Evaluation of Thyroid Function in Patients With Chronic Kidney Disease,Chronic Kidney Disease|Thyroid Dysfunction,2020-11-20,2019-11-30,2025-12-30,44.0,Cohort,,Cross-Sectional,Observational,Active not recruiting,,Rio de Janeiro State University,Rio de Janeiro State University,Ana Beatriz Winter Tavares,Diagnostic Test,Brazil,18.0,100.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04658524
268,NCT04684953,Thyroid,Implantation of Thyroid Gland After Total Thyroidectomy in Quadriceps Femoris Muscle,Thyroid Autotransplantation in Quadriceps Femoris Muscle,Thyroid,2020-12-22,2022-10-31,2022-12-31,40.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Drug,,15.0,40.0,[0-17]|[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04684953
274,NCT04708704,Thyroid; Functional Disturbance,Investigation of Photodegraded Edible Food Dyes in Drinking Water on Thyroid Function,Photodegraded Edible Food Dyes,Thyroid; Functional Disturbance,2020-12-21,2023-12-31,2024-12-31,10.0,,Sequential Assignment,,Interventional,Not yet recruiting,Not Applicable,Yale University,Yale University,Yale University,Dietary Supplement|Dietary Supplement|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04708704
295,NCT04794257,Recurrent Laryngeal Nerve Injuries|Surgery|Thyroid Diseases,Clinical Validation of NerveTrend vs. Conventional i-IONM Mode of NIM Vital in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.,NerveTrend vs. i-IONM in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.,Recurrent Laryngeal Nerve Injuries|Surgery|Thyroid Diseases,2021-03-07,2022-12-31,2023-03-31,264.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Jagiellonian University,Marcin Barczynski,"Department of Endocrine Surgery, Jagiellonian University College of Medicine",Device,Poland,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04794257
304,NCT04842942,Surgery|Thyroid Diseases,The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach,The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach,Surgery|Thyroid Diseases,2021-02-19,2021-12-31,2022-07-31,15.0,,Single Group Assignment,,Interventional,Recruiting,Phase 1,"University Health Network, Toronto","University Health Network, Toronto",Univeristy Health Network,Procedure,Canada,18.0,80.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04842942
306,NCT04845867,Thyroid,Thyroid HEmorrhage DetectOr Study,Thyroid HEmorrhage DetectOr Study,Thyroid,2021-04-13,2022-06-30,2022-08-31,1470.0,Cohort,,Prospective,Observational [Patient Registry],Not yet recruiting,,ISAR-M GmbH,CRI-The Clinical Research Institute GmbH|ISAR-M GmbH,,Device,,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04845867
329,NCT04936698,Thyroid Disease Pregnancy,The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan,The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan,Thyroid Disease Pregnancy,2021-06-17,2022-03-31,2022-03-31,2000.0,Cohort,,Prospective,Observational,Recruiting,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Chang Gung Memorial hospital,Drug|Drug,Taiwan,18.0,50.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04936698
333,NCT04943146,Thyroid Diseases,An Assessment of Aspirin Plus Prednisone Treatment for Euthyroid Women With Thyroid Autoimmunity Undergoing In Vitro Fertilization,An Assessment of Aspirin Plus Prednisone Treatment for Euthyroid Women With Thyroid Autoimmunity,Thyroid Diseases,2021-06-21,2021-06-30,2022-03-31,402.0,Case-Only,,Retrospective,Observational,Recruiting,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Ningbo Women and Children's Hospital|People's Hospital of Jinhua|Second Affiliated Hospital, School of Medicine, Zhejiang University",People's Hospital of Jinhua|Ningbo Women and Children's Hospital,Drug,China,18.0,40.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT04943146
344,NCT04991493,Intubation Intratracheal|Post-operative Sore Throat|Thyroid Surgery,Effect of Tramadol on Postoperative Sore Throat in Thyroid Surgery Under General Anesthesia With Endotracheal Intubation: A Randomized Controlled Trial,Effect of Tramadol on Postoperative Sore Throat After General Anesthesia,Intubation Intratracheal|Post-operative Sore Throat|Thyroid Surgery,2021-07-27,2023-07-31,2023-12-31,168.0,,Parallel Assignment,,Interventional,Recruiting,Phase 4,Affiliated Cancer Hospital of Shantou University Medical College,Affiliated Cancer Hospital of Shantou University Medical College,Affiliated Cancer Hospital of Shantou University Medical College Medical,Drug|Other,China,18.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT04991493
352,NCT05016518,Patients Undergoing Thyroid Surgery for Neoplasm,Comparison of Quality of Recovery (QoR)-15 Scores According to the Use of Anesthetics During Total Intravenous Anesthesia in Female Patients Undergoing Thyroid Surgery,Comparison of Quality of Recovery (QoR)-15 Scores Between Propofol and Remimazolam Anesthesia,Patients Undergoing Thyroid Surgery for Neoplasm,2021-08-10,2022-06-30,2022-07-04,140.0,,Parallel Assignment,,Interventional,Recruiting,Not Applicable,Gangnam Severance Hospital,Gangnam Severance Hospital,Gangnam Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05016518
358,NCT05036525,Adhesion|Thyroid Diseases,"Evaluation of the Efficacy and Safety of a High Molecular Weight Native Hyaluronic Acid Gel (HANBIO BarriGel) in Adhesion Prevention After Open Thyroidectomy: a Prospective, Randomized Controlled, Single Blind Study.",Evaluation of the Efficacy and Safety of a Hyaluronic Acid Gel in Adhesion Prevention After Open Thyroidectomy.,Adhesion|Thyroid Diseases,2021-09-02,2023-06-30,2023-06-30,100.0,,Parallel Assignment,,Interventional,Not yet recruiting,Not Applicable,HAN Biomedical Inc,HAN Biomedical Inc,,Device,,20.0,70.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05036525
367,NCT05103774,Value of Thyroid Functions in Children With Congenital Heart Diseases,Thyroid Functions in Children With Congenital Heart Diseases,Thyroid Functions in Children With Congenital Heart Diseases,Value of Thyroid Functions in Children With Congenital Heart Diseases,2021-10-18,2022-11-01,2022-11-15,100.0,Other,,Retrospective,Observational,Not yet recruiting,,Sohag University,Sohag University,Hospital of Sohag University,Diagnostic Test,Egypt,1.0,12.0,[0-17],,,https://clinicaltrials.gov/ct2/show/NCT05103774
375,NCT05126108,Equiring General Anesthesia With Intubation With a Nerve Integrity Monitor (NIM) Tube|Non-morbidly Obese Patients (BMI<35)|Thyroid and Parathyroid Surgery,Evaluation of the Decurarisation Kinetics of Rocuronium in Cervical Surgery,Decurarisation Kinetics of Rocuronium in Cervical Surgery,Equiring General Anesthesia With Intubation With a Nerve Integrity Monitor (NIM) Tube|Non-morbidly Obese Patients (BMI<35)|Thyroid and Parathyroid Surgery,2021-11-08,2022-05-31,2022-05-31,50.0,Cohort,,Prospective,Observational,Not yet recruiting,,Assistance Publique - Hpitaux de Paris,Assistance Publique - Hpitaux de Paris,Surgical anesthesia service - Cochin Hospital,Procedure|Other,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05126108
382,NCT05151120,"Thyroid Disorders|Thyroid Stimulating; Hormone, C",Harmonization of Thyroid-stimulating Hormone Immunoassays Reagents - Blood Collection From Patients With Thyroid Disorders,Harmonization of Thyroid-stimulating Hormone Immunoassays Reagents,"Thyroid Disorders|Thyroid Stimulating; Hormone, C",2021-10-21,2023-11-05,2023-11-05,100.0,Other,,Prospective,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Service D'endocrinologie - Hpital Louis Pradel - Hospices Civils de Lyon|Service de Mdecine Nuclaire - Hpital Louis Pradel - Hospices Civils de Lyon,Biological,France,18.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05151120
402,NCT05251194,Thyroid Surgery,The Effect of McGrath Video Laryngoscope on the Glottic View at Thyroid Surgery Position in Tracheal Intubation,The Effect of McGrath Video Laryngoscope on the Glottic View at Thyroid Surgery Position,Thyroid Surgery,2022-02-11,2022-06-30,2022-08-31,39.0,,Single Group Assignment,,Interventional,Not yet recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital|SMG-SNU Boramae Medical Center,Seoul Metropolitan Government Seoul National University Boramae Medical Center,Device,"Korea, Republic of",19.0,120.0,[18-65]|[65 and more],,,https://clinicaltrials.gov/ct2/show/NCT05251194
418,NCT05323539,Endometrioma|Thyroid,Comparison of Thyroid Volumes by Ultrasonography in Patients With and Without Endometrioma,Comparison of Thyroid Volumes in Patients With and Without Endometrioma,Endometrioma|Thyroid,2022-04-05,2022-05-31,2022-05-31,60.0,,Parallel Assignment,,Interventional,Active not recruiting,Not Applicable,Adana City Training and Research Hospital,Adana City Training and Research Hospital,Adana City Education and Research Hospital,Other,Turkey,18.0,45.0,[18-65],,,https://clinicaltrials.gov/ct2/show/NCT05323539
